{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"Neuro Clinical Plans","text":"<p>Evidence-based clinical decision support templates for neurological diagnoses.</p>"},{"location":"#what-this-is","title":"What This Is","text":"<p>A library of structured clinical recommendations for neurologists and hospitalists, covering:</p> <ul> <li>Laboratory workup - Essential and extended testing</li> <li>Imaging studies - When and what to order</li> <li>Treatment protocols - Acute, maintenance, and disease-modifying therapies</li> <li>Monitoring parameters - What to track and when</li> <li>Disposition criteria - Admission, discharge, and follow-up guidance</li> </ul> <p>Each plan is organized by care setting (ED, Hospital, Outpatient, ICU) with priority levels (STAT, URGENT, ROUTINE).</p>"},{"location":"#quick-links","title":"Quick Links","text":"<ul> <li> <p>:material-file-document-multiple: Browse Plans</p> <p>View all available clinical decision support templates</p> </li> <li> <p>:material-plus-circle: Request a Plan</p> <p>Submit a request for a new diagnosis template</p> </li> <li> <p>:material-github: View on GitHub</p> <p>Access the source repository</p> </li> </ul>"},{"location":"#how-plans-are-created","title":"How Plans Are Created","text":"<ol> <li>Request - Submit a plan request via GitHub Issues</li> <li>Build - AI-assisted draft generation using the Builder Skill</li> <li>Validate - Quality scoring using the Checker Skill</li> <li>Review - Physician review and approval</li> <li>Publish - Validated plans added to the library</li> </ol> <p>All plans target 90%+ validation score across six domains: completeness, accuracy, safety, objectivity, setting appropriateness, and usability.</p>"},{"location":"#current-status","title":"Current Status","text":"Metric Count Completed Plans 4 In Development 0 Planned 130 <p>See the Template Tracker for the full roadmap.</p>"},{"location":"#disclaimer","title":"Disclaimer","text":"<p>Clinical Use Notice</p> <p>These templates are decision support tools, not clinical guidelines. They require physician review and adaptation to individual patient circumstances. Always apply clinical judgment.</p> <p>Developed for teleneurohospitalist clinical decision support.</p>"},{"location":"ROADMAP/","title":"Neuro Plans - Development Roadmap","text":"<p>Version: 1.0 Created: January 24, 2026 Status: Active Development</p>"},{"location":"ROADMAP/#overview","title":"Overview","text":"<p>This roadmap outlines planned improvements to the clinical plan generation system, with a focus on medication handling, clickable dosing, and overall standardization before scaling to additional neurological topics.</p>"},{"location":"ROADMAP/#phase-1-medication-format-standardization-foundation","title":"Phase 1: Medication Format Standardization (Foundation)","text":"<p>Goal: Create a consistent, parseable medication format across all treatment sections.</p> <p>Priority: HIGH - Must complete before building new topics</p>"},{"location":"ROADMAP/#11-standardize-treatment-table-columns","title":"1.1 Standardize Treatment Table Columns","text":"Current Problem Solution Section 3A/3B/3C have inconsistent columns Standardize ALL treatment sections to same column order Route only in Section 3D (DMTs) Add Route column to ALL treatment sections Column order varies Fixed order: Treatment \u2192 Route \u2192 Indication \u2192 Dosing \u2192 Contraindications \u2192 Monitoring \u2192 ED \u2192 HOSP \u2192 OPD \u2192 ICU <p>New Standard Treatment Table Format (All Sections): <pre><code>| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |\n|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|\n</code></pre></p>"},{"location":"ROADMAP/#12-structured-dosing-format","title":"1.2 Structured Dosing Format","text":"<p>Current Problem: Dosing is unstructured text that can't be parsed into order sentences.</p> <p>Example of current format: <pre><code>Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day\n</code></pre></p> <p>New structured dosing format (double-colon delimited fields within dosing cell):</p> <p>Single dose format: <pre><code>5 mg :: PO :: TID :: Start 5 mg TID, titrate by 5 mg q3d, max 80 mg/day\n</code></pre></p> <p>Multi-dose format (semicolon-separated dose options): <pre><code>300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q1-3d; max 3600 mg/day\n</code></pre></p> <p>Format: <code>dose_options :: route :: [frequency] :: full_instructions</code></p> <ul> <li><code>dose_options</code>: Single dose+freq OR multiple semicolon-separated options</li> <li><code>route</code>: Administration route (PO, IV, IM, etc.)</li> <li><code>frequency</code>: Optional if included in dose_options</li> <li><code>full_instructions</code>: Complete dosing guidance</li> </ul> <p>Note: We use <code>::</code> instead of <code>|</code> because <code>|</code> conflicts with markdown table syntax.</p> <p>This allows the clinical tool to: 1. Generate multiple order sentences for different dose options 2. Display dropdown to select desired dose 3. Copy selected order sentence to clipboard 4. Show full dosing guidance on hover</p>"},{"location":"ROADMAP/#13-files-to-update","title":"1.3 Files to Update","text":"File Changes <code>skills/neuro-builder-SKILL.md</code> New table format, structured dosing spec <code>skills/neuro-checker-SKILL.md</code> Validation rules for new format <code>skills/neuro-rebuilder-SKILL.md</code> Update pattern matching for new columns <code>scripts/generate_json.py</code> Parse structured dosing into separate JSON fields"},{"location":"ROADMAP/#phase-2-clickable-dosing-clinical-tool-enhancement","title":"Phase 2: Clickable Dosing (Clinical Tool Enhancement)","text":"<p>Goal: Make medication dosing interactive with copy-ready order sentences.</p> <p>Priority: HIGH - Key UX improvement</p>"},{"location":"ROADMAP/#21-json-schema-enhancement","title":"2.1 JSON Schema Enhancement","text":"<p>Add structured dosing fields to medication items:</p> <p>Single dose example: <pre><code>{\n  \"item\": \"Baclofen\",\n  \"route\": \"PO\",\n  \"indication\": \"Spasticity\",\n  \"dosing\": {\n    \"doseOptions\": [\n      { \"dose\": \"5 mg\", \"frequency\": \"TID\", \"orderSentence\": \"Baclofen 5 mg PO TID\" }\n    ],\n    \"route\": \"PO\",\n    \"instructions\": \"Start 5 mg TID, titrate by 5 mg/dose q3d, max 80 mg/day\",\n    \"orderSentence\": \"Baclofen 5 mg PO TID\"\n  }\n}\n</code></pre></p> <p>Multi-dose example: <pre><code>{\n  \"item\": \"Gabapentin\",\n  \"route\": \"PO\",\n  \"indication\": \"Neuropathic pain (first-line)\",\n  \"dosing\": {\n    \"doseOptions\": [\n      { \"dose\": \"300 mg\", \"frequency\": \"qHS\", \"orderSentence\": \"Gabapentin 300 mg PO qHS\" },\n      { \"dose\": \"300 mg\", \"frequency\": \"TID\", \"orderSentence\": \"Gabapentin 300 mg PO TID\" },\n      { \"dose\": \"600 mg\", \"frequency\": \"TID\", \"orderSentence\": \"Gabapentin 600 mg PO TID\" },\n      { \"dose\": \"900 mg\", \"frequency\": \"TID\", \"orderSentence\": \"Gabapentin 900 mg PO TID\" }\n    ],\n    \"route\": \"PO\",\n    \"instructions\": \"Start 300 mg qHS; titrate by 300 mg q1-3d; max 3600 mg/day\",\n    \"orderSentence\": \"Gabapentin 300 mg PO qHS\"\n  }\n}\n</code></pre></p> <p>Note: <code>orderSentence</code> at the dosing level is the default (first) option for backwards compatibility.</p>"},{"location":"ROADMAP/#22-clinical-tool-ui-changes","title":"2.2 Clinical Tool UI Changes","text":"Feature Behavior Dosing badge click Copies order sentence to clipboard with visual feedback Dosing badge tooltip Shows full dosing instructions on hover Selected items sidebar Displays order sentence format for medications Copy all selected Includes order sentences (not full instructions)"},{"location":"ROADMAP/#23-order-sentence-format","title":"2.3 Order Sentence Format","text":"<p>Standard order sentence pattern: <pre><code>[Drug Name] [Dose] [Route] [Frequency] [Duration if applicable] [PRN indication if applicable]\n</code></pre></p> <p>Examples: - <code>Baclofen 5 mg PO TID</code> - <code>Methylprednisolone 1000 mg IV daily x 5 days</code> - <code>Lorazepam 4 mg IV push PRN seizure</code> - <code>Levetiracetam 1000 mg IV load, then 500 mg IV q12h</code></p>"},{"location":"ROADMAP/#phase-3-multiple-dose-options-implemented","title":"Phase 3: Multiple Dose Options (Implemented)","text":"<p>Goal: Provide multiple standard dose options per medication for flexible ordering.</p> <p>Priority: HIGH - Implemented in Phase 2</p> <p>Status: \u2705 COMPLETE - Integrated into Phase 2 structured dosing</p>"},{"location":"ROADMAP/#31-multi-dose-in-structured-format","title":"3.1 Multi-Dose in Structured Format","text":"<p>Multiple doses are specified using semicolons in the first field:</p> <pre><code>| Gabapentin | PO | Neuropathic pain | 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q1-3d; max 3600 mg/day | ... |\n</code></pre>"},{"location":"ROADMAP/#32-ui-for-dose-selection","title":"3.2 UI for Dose Selection","text":"Feature Behavior Dosing badge click Opens dropdown with all dose options Each option Shows order sentence (e.g., \"Gabapentin 300 mg PO TID\") Click option Copies that specific order sentence to clipboard Hover on badge Shows full instructions tooltip"},{"location":"ROADMAP/#33-common-dose-patterns","title":"3.3 Common Dose Patterns","text":"Pattern Example Starting + maintenance <code>300 mg qHS; 300 mg TID</code> Titration range <code>300 mg TID; 600 mg TID; 900 mg TID</code> PRN options <code>4 mg IV; 2 mg IV PRN</code> Load + maintenance <code>1000 mg IV load; 500 mg IV q12h</code>"},{"location":"ROADMAP/#phase-4-other-improvements","title":"Phase 4: Other Improvements","text":""},{"location":"ROADMAP/#41-medication-interaction-checking-future","title":"4.1 Medication Interaction Checking (Future)","text":"<ul> <li>Flag potential interactions when multiple medications selected</li> <li>Use structured drug data to identify concerns</li> <li>Display warning icon in sidebar</li> </ul>"},{"location":"ROADMAP/#42-weight-based-dosing-calculator-future","title":"4.2 Weight-Based Dosing Calculator (Future)","text":"<ul> <li>For medications with mg/kg dosing</li> <li>Input patient weight \u2192 calculate dose</li> <li>Update order sentence automatically</li> </ul>"},{"location":"ROADMAP/#43-renalhepatic-dose-adjustments-future","title":"4.3 Renal/Hepatic Dose Adjustments (Future)","text":"<ul> <li>Flag medications needing adjustment</li> <li>Show alternative dosing for impaired organ function</li> </ul>"},{"location":"ROADMAP/#implementation-priority","title":"Implementation Priority","text":"Phase Items Priority Estimated Effort 1.1 Standardize columns HIGH Medium 1.2 Structured dosing format HIGH Medium 1.3 Update skills HIGH Medium 2.1 JSON schema HIGH Low 2.2 Clinical tool UI HIGH Medium 2.3 Order sentence logic HIGH Low 3.x Regimen templates MEDIUM High 4.x Future enhancements LOW High"},{"location":"ROADMAP/#quality-gates-before-topic-generation","title":"Quality Gates Before Topic Generation","text":"<p>Before generating new clinical topics at scale, ensure:</p> <ul> <li> Phase 1 complete (standardized format)</li> <li> Phase 2 complete (clickable dosing works)</li> <li> Existing approved plans updated to new format</li> <li> generate_json.py handles new format</li> <li> Checker validates new format requirements</li> <li> At least one plan tested end-to-end with new format</li> </ul>"},{"location":"ROADMAP/#change-log","title":"Change Log","text":"<p>v1.0 (January 24, 2026) - Initial roadmap creation - Defined Phase 1-4 improvements - Specified structured dosing format - Outlined clinical tool enhancements</p>"},{"location":"tags/","title":"Tags","text":"<p>Browse plans by tag.</p>"},{"location":"tags/#tag:bppv","title":"BPPV","text":"<ul> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:tia","title":"TIA","text":"<ul> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Transient Ischemic Attack (TIA)          </li> </ul>"},{"location":"tags/#tag:als","title":"als","text":"<ul> <li>            Amyotrophic Lateral Sclerosis          </li> </ul>"},{"location":"tags/#tag:alzheimer","title":"alzheimer","text":"<ul> <li>            Alzheimer's Disease          </li> <li>            Dementia Evaluation          </li> </ul>"},{"location":"tags/#tag:antipsychotics","title":"antipsychotics","text":"<ul> <li>            Tardive Dyskinesia          </li> </ul>"},{"location":"tags/#tag:aura","title":"aura","text":"<ul> <li>            Migraine with Aura          </li> </ul>"},{"location":"tags/#tag:autoimmune","title":"autoimmune","text":"<ul> <li>            Autoimmune Encephalitis          </li> <li>            Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)          </li> <li>            Multiple Sclerosis - Chronic Management          </li> <li>            Multiple Sclerosis - New Diagnosis          </li> <li>            Myasthenia Gravis - Exacerbation/Crisis          </li> <li>            Myasthenia Gravis - Outpatient Management          </li> <li>            Optic Neuritis          </li> </ul>"},{"location":"tags/#tag:autonomic","title":"autonomic","text":"<ul> <li>            Small Fiber Neuropathy          </li> <li>            Syncope Evaluation          </li> </ul>"},{"location":"tags/#tag:behavioral","title":"behavioral","text":"<ul> <li>            Frontotemporal Dementia          </li> </ul>"},{"location":"tags/#tag:bells-palsy","title":"bells-palsy","text":"<ul> <li>            Bell's Palsy          </li> </ul>"},{"location":"tags/#tag:botulinum-toxin","title":"botulinum-toxin","text":"<ul> <li>            Dystonia          </li> </ul>"},{"location":"tags/#tag:cardiac","title":"cardiac","text":"<ul> <li>            Syncope Evaluation          </li> </ul>"},{"location":"tags/#tag:cerebrovascular","title":"cerebrovascular","text":"<ul> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Vascular Dementia          </li> </ul>"},{"location":"tags/#tag:chorea","title":"chorea","text":"<ul> <li>            Huntington's Disease          </li> </ul>"},{"location":"tags/#tag:chronic-management","title":"chronic-management","text":"<ul> <li>            Multiple Sclerosis - Chronic Management          </li> <li>            Myasthenia Gravis - Outpatient Management          </li> </ul>"},{"location":"tags/#tag:cluster-headache","title":"cluster-headache","text":"<ul> <li>            Cluster Headache          </li> </ul>"},{"location":"tags/#tag:cognitive","title":"cognitive","text":"<ul> <li>            Alzheimer's Disease          </li> <li>            Dementia Evaluation          </li> <li>            Frontotemporal Dementia          </li> <li>            Lewy Body Dementia          </li> <li>            Mild Cognitive Impairment (MCI)          </li> <li>            Normal Pressure Hydrocephalus          </li> <li>            Vascular Dementia          </li> </ul>"},{"location":"tags/#tag:cranial-neuropathy","title":"cranial-neuropathy","text":"<ul> <li>            Bell's Palsy          </li> </ul>"},{"location":"tags/#tag:dementia","title":"dementia","text":"<ul> <li>            Alzheimer's Disease          </li> <li>            Dementia Evaluation          </li> <li>            Frontotemporal Dementia          </li> <li>            Lewy Body Dementia          </li> <li>            Normal Pressure Hydrocephalus          </li> <li>            Vascular Dementia          </li> </ul>"},{"location":"tags/#tag:dementia-prevention","title":"dementia-prevention","text":"<ul> <li>            Mild Cognitive Impairment (MCI)          </li> </ul>"},{"location":"tags/#tag:demyelinating","title":"demyelinating","text":"<ul> <li>            Multiple Sclerosis - Chronic Management          </li> <li>            Multiple Sclerosis - New Diagnosis          </li> <li>            Optic Neuritis          </li> </ul>"},{"location":"tags/#tag:diabetes","title":"diabetes","text":"<ul> <li>            Diabetic Neuropathy          </li> <li>            Diabetic Neuropathy          </li> </ul>"},{"location":"tags/#tag:dizziness","title":"dizziness","text":"<ul> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:drug-induced","title":"drug-induced","text":"<ul> <li>            Tardive Dyskinesia          </li> </ul>"},{"location":"tags/#tag:dystonia","title":"dystonia","text":"<ul> <li>            Dystonia          </li> </ul>"},{"location":"tags/#tag:emergency","title":"emergency","text":"<ul> <li>            Acute Ischemic Stroke          </li> <li>            Autoimmune Encephalitis          </li> <li>            Bacterial Meningitis          </li> <li>            Bell's Palsy          </li> <li>            Guillain-Barr\u00e9 Syndrome          </li> <li>            HSV Encephalitis          </li> <li>            Migraine          </li> <li>            Migraine with Aura          </li> <li>            Myasthenia Gravis - Exacerbation/Crisis          </li> <li>            Syncope Evaluation          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:encephalitis","title":"encephalitis","text":"<ul> <li>            Autoimmune Encephalitis          </li> <li>            HSV Encephalitis          </li> </ul>"},{"location":"tags/#tag:entrapment-neuropathy","title":"entrapment-neuropathy","text":"<ul> <li>            Carpal Tunnel Syndrome          </li> </ul>"},{"location":"tags/#tag:epilepsy","title":"epilepsy","text":"<ul> <li>            New Onset Seizure          </li> </ul>"},{"location":"tags/#tag:facial-pain","title":"facial-pain","text":"<ul> <li>            Trigeminal Neuralgia          </li> </ul>"},{"location":"tags/#tag:facial-paralysis","title":"facial-paralysis","text":"<ul> <li>            Bell's Palsy          </li> </ul>"},{"location":"tags/#tag:ftd","title":"ftd","text":"<ul> <li>            Frontotemporal Dementia          </li> </ul>"},{"location":"tags/#tag:gait","title":"gait","text":"<ul> <li>            Normal Pressure Hydrocephalus          </li> </ul>"},{"location":"tags/#tag:genetic","title":"genetic","text":"<ul> <li>            Huntington's Disease          </li> </ul>"},{"location":"tags/#tag:headache","title":"headache","text":"<ul> <li>            Cluster Headache          </li> <li>            Medication Overuse Headache          </li> <li>            Migraine          </li> <li>            Migraine with Aura          </li> <li>            Tension-Type Headache          </li> </ul>"},{"location":"tags/#tag:huntington","title":"huntington","text":"<ul> <li>            Huntington's Disease          </li> </ul>"},{"location":"tags/#tag:hydrocephalus","title":"hydrocephalus","text":"<ul> <li>            Normal Pressure Hydrocephalus          </li> </ul>"},{"location":"tags/#tag:infection","title":"infection","text":"<ul> <li>            Bacterial Meningitis          </li> <li>            HSV Encephalitis          </li> </ul>"},{"location":"tags/#tag:lewy-body","title":"lewy-body","text":"<ul> <li>            Lewy Body Dementia          </li> </ul>"},{"location":"tags/#tag:loss-of-consciousness","title":"loss-of-consciousness","text":"<ul> <li>            Syncope Evaluation          </li> </ul>"},{"location":"tags/#tag:mci","title":"mci","text":"<ul> <li>            Mild Cognitive Impairment (MCI)          </li> </ul>"},{"location":"tags/#tag:medication-overuse","title":"medication-overuse","text":"<ul> <li>            Medication Overuse Headache          </li> </ul>"},{"location":"tags/#tag:meningitis","title":"meningitis","text":"<ul> <li>            Bacterial Meningitis          </li> </ul>"},{"location":"tags/#tag:migraine","title":"migraine","text":"<ul> <li>            Migraine          </li> <li>            Migraine with Aura          </li> </ul>"},{"location":"tags/#tag:motor-neuron-disease","title":"motor-neuron-disease","text":"<ul> <li>            Amyotrophic Lateral Sclerosis          </li> </ul>"},{"location":"tags/#tag:movement-disorders","title":"movement-disorders","text":"<ul> <li>            Dystonia          </li> <li>            Essential Tremor          </li> <li>            Huntington's Disease          </li> <li>            Lewy Body Dementia          </li> <li>            Parkinson's Disease          </li> <li>            Parkinson's Disease          </li> <li>            Restless Legs Syndrome          </li> <li>            Tardive Dyskinesia          </li> </ul>"},{"location":"tags/#tag:multiple-sclerosis","title":"multiple-sclerosis","text":"<ul> <li>            Multiple Sclerosis - Chronic Management          </li> <li>            Multiple Sclerosis - New Diagnosis          </li> <li>            Optic Neuritis          </li> </ul>"},{"location":"tags/#tag:myasthenia-gravis","title":"myasthenia-gravis","text":"<ul> <li>            Myasthenia Gravis - Outpatient Management          </li> </ul>"},{"location":"tags/#tag:nerve-root","title":"nerve-root","text":"<ul> <li>            Radiculopathy - Cervical and Lumbar          </li> </ul>"},{"location":"tags/#tag:neurocritical-care","title":"neurocritical-care","text":"<ul> <li>            Autoimmune Encephalitis          </li> <li>            Bacterial Meningitis          </li> <li>            HSV Encephalitis          </li> </ul>"},{"location":"tags/#tag:neurodegenerative","title":"neurodegenerative","text":"<ul> <li>            Alzheimer's Disease          </li> <li>            Frontotemporal Dementia          </li> </ul>"},{"location":"tags/#tag:neuromuscular","title":"neuromuscular","text":"<ul> <li>            Amyotrophic Lateral Sclerosis          </li> <li>            Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)          </li> <li>            Guillain-Barr\u00e9 Syndrome          </li> <li>            Myasthenia Gravis - Exacerbation/Crisis          </li> <li>            Myasthenia Gravis - Outpatient Management          </li> </ul>"},{"location":"tags/#tag:neuropathic-pain","title":"neuropathic-pain","text":"<ul> <li>            Trigeminal Neuralgia          </li> </ul>"},{"location":"tags/#tag:neuropathy","title":"neuropathy","text":"<ul> <li>            Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)          </li> <li>            Diabetic Neuropathy          </li> <li>            Diabetic Neuropathy          </li> <li>            Guillain-Barr\u00e9 Syndrome          </li> <li>            Small Fiber Neuropathy          </li> </ul>"},{"location":"tags/#tag:new-diagnosis","title":"new-diagnosis","text":"<ul> <li>            Multiple Sclerosis - New Diagnosis          </li> <li>            New Onset Seizure          </li> </ul>"},{"location":"tags/#tag:optic-neuritis","title":"optic-neuritis","text":"<ul> <li>            Optic Neuritis          </li> </ul>"},{"location":"tags/#tag:outpatient","title":"outpatient","text":"<ul> <li>            Alzheimer's Disease          </li> <li>            Amyotrophic Lateral Sclerosis          </li> <li>            Bell's Palsy          </li> <li>            Carpal Tunnel Syndrome          </li> <li>            Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)          </li> <li>            Cluster Headache          </li> <li>            Dementia Evaluation          </li> <li>            Diabetic Neuropathy          </li> <li>            Diabetic Neuropathy          </li> <li>            Dystonia          </li> <li>            Essential Tremor          </li> <li>            Frontotemporal Dementia          </li> <li>            Huntington's Disease          </li> <li>            Lewy Body Dementia          </li> <li>            Medication Overuse Headache          </li> <li>            Migraine          </li> <li>            Migraine with Aura          </li> <li>            Mild Cognitive Impairment (MCI)          </li> <li>            Multiple Sclerosis - Chronic Management          </li> <li>            Myasthenia Gravis - Outpatient Management          </li> <li>            Normal Pressure Hydrocephalus          </li> <li>            Parkinson's Disease          </li> <li>            Parkinson's Disease          </li> <li>            Restless Legs Syndrome          </li> <li>            Small Fiber Neuropathy          </li> <li>            Syncope Evaluation          </li> <li>            Tardive Dyskinesia          </li> <li>            Tension-Type Headache          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Trigeminal Neuralgia          </li> <li>            Vascular Dementia          </li> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:pain","title":"pain","text":"<ul> <li>            Diabetic Neuropathy          </li> <li>            Diabetic Neuropathy          </li> <li>            Small Fiber Neuropathy          </li> </ul>"},{"location":"tags/#tag:pain-management","title":"pain-management","text":"<ul> <li>            Carpal Tunnel Syndrome          </li> <li>            Radiculopathy - Cervical and Lumbar          </li> </ul>"},{"location":"tags/#tag:palliative","title":"palliative","text":"<ul> <li>            Amyotrophic Lateral Sclerosis          </li> </ul>"},{"location":"tags/#tag:parkinson","title":"parkinson","text":"<ul> <li>            Parkinson's Disease          </li> <li>            Parkinson's Disease          </li> </ul>"},{"location":"tags/#tag:primary-headache","title":"primary-headache","text":"<ul> <li>            Tension-Type Headache          </li> </ul>"},{"location":"tags/#tag:radiculopathy","title":"radiculopathy","text":"<ul> <li>            Radiculopathy - Cervical and Lumbar          </li> </ul>"},{"location":"tags/#tag:seizure","title":"seizure","text":"<ul> <li>            New Onset Seizure          </li> </ul>"},{"location":"tags/#tag:sleep-disorders","title":"sleep-disorders","text":"<ul> <li>            Restless Legs Syndrome          </li> </ul>"},{"location":"tags/#tag:spine","title":"spine","text":"<ul> <li>            Radiculopathy - Cervical and Lumbar          </li> </ul>"},{"location":"tags/#tag:stroke","title":"stroke","text":"<ul> <li>            Acute Ischemic Stroke          </li> <li>            Transient Ischemic Attack (TIA)          </li> <li>            Transient Ischemic Attack (TIA)          </li> </ul>"},{"location":"tags/#tag:surgical","title":"surgical","text":"<ul> <li>            Normal Pressure Hydrocephalus          </li> </ul>"},{"location":"tags/#tag:syncope","title":"syncope","text":"<ul> <li>            Syncope Evaluation          </li> </ul>"},{"location":"tags/#tag:tension-type-headache","title":"tension-type-headache","text":"<ul> <li>            Tension-Type Headache          </li> </ul>"},{"location":"tags/#tag:thrombectomy","title":"thrombectomy","text":"<ul> <li>            Acute Ischemic Stroke          </li> </ul>"},{"location":"tags/#tag:thrombolysis","title":"thrombolysis","text":"<ul> <li>            Acute Ischemic Stroke          </li> </ul>"},{"location":"tags/#tag:tremor","title":"tremor","text":"<ul> <li>            Essential Tremor          </li> </ul>"},{"location":"tags/#tag:trigeminal-autonomic-cephalalgias","title":"trigeminal-autonomic-cephalalgias","text":"<ul> <li>            Cluster Headache          </li> </ul>"},{"location":"tags/#tag:upper-extremity","title":"upper-extremity","text":"<ul> <li>            Carpal Tunnel Syndrome          </li> </ul>"},{"location":"tags/#tag:vascular","title":"vascular","text":"<ul> <li>            Vascular Dementia          </li> </ul>"},{"location":"tags/#tag:vasovagal","title":"vasovagal","text":"<ul> <li>            Syncope Evaluation          </li> </ul>"},{"location":"tags/#tag:vertigo","title":"vertigo","text":"<ul> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:vestibular","title":"vestibular","text":"<ul> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:vestibular-neuritis","title":"vestibular neuritis","text":"<ul> <li>            Vertigo Evaluation          </li> </ul>"},{"location":"tags/#tag:vision-loss","title":"vision-loss","text":"<ul> <li>            Optic Neuritis          </li> </ul>"},{"location":"tags/#tag:weakness","title":"weakness","text":"<ul> <li>            Guillain-Barr\u00e9 Syndrome          </li> <li>            Myasthenia Gravis - Exacerbation/Crisis          </li> </ul>"},{"location":"tags/#tag:withdrawal","title":"withdrawal","text":"<ul> <li>            Medication Overuse Headache          </li> </ul>"},{"location":"drafts/","title":"Drafts for Review","text":"<p>These clinical plans are pending physician review and approval. Please review each draft and provide feedback using the inline comment system.</p> <p>Draft Status</p> <p>Plans in this section have not been approved for clinical use. They require physician review before being moved to Approved Plans.</p>"},{"location":"drafts/#review-workflow","title":"Review Workflow","text":"<ol> <li>Review - Click on a draft plan to read through the content</li> <li>Comment - Use the \ud83d\udcac icons next to each section to leave feedback</li> <li>Approve - When ready, request approval through Claude Code</li> </ol>"},{"location":"drafts/#pending-drafts","title":"Pending Drafts","text":"Plan Category Pipeline Status Last Updated Vertigo Evaluation Vestibular/Dizziness :material-file-document-edit: Needs Review 2026-01-27 MS - Chronic Management Demyelinating :material-file-document-edit: Needs Review 2026-01-27 CIDP Neuromuscular :material-file-document-edit: Needs Review 2026-01-27 Cluster Headache Headache :material-file-document-edit: Needs Review 2026-01-27 Medication Overuse Headache Headache :material-file-document-edit: Needs Review 2026-01-27 Mild Cognitive Impairment Cognitive :material-file-document-edit: Needs Review 2026-01-27 Restless Legs Syndrome Movement/Sleep Disorders :material-file-document-edit: Needs Review 2026-01-27 Trigeminal Neuralgia Facial Pain :material-file-document-edit: Needs Review 2026-01-27 Migraine with Aura Headache :material-file-document-edit: Needs Review 2026-01-27 Carpal Tunnel Syndrome Entrapment Neuropathy :material-file-document-edit: Needs Review 2026-01-27 Myasthenia Gravis - Outpatient Neuromuscular :material-file-document-edit: Needs Review 2026-01-27 Dystonia Movement Disorders :material-file-document-edit: Needs Review 2026-01-27 Optic Neuritis Demyelinating/Neuro-Ophthalmology :material-file-document-edit: Needs Review 2026-01-27 Alzheimer's Disease Cognitive/Dementia :material-file-document-edit: Needs Review 2026-01-27 Frontotemporal Dementia Cognitive/Dementia :material-file-document-edit: Needs Review 2026-01-27"},{"location":"drafts/#pipeline-status-legend","title":"Pipeline Status Legend","text":"Status Icon Meaning Needs Review :material-file-document-edit: Draft ready for physician review Citation Verified :material-check: Citations have been verified ICD/Synonym Enriched :material-tag-plus: ICD-10 codes and synonyms added Awaiting Approval :material-clock-outline: Reviewed, waiting for final approval Approved :material-check-circle: Ready for clinical use"},{"location":"drafts/#how-to-approve-a-draft","title":"How to Approve a Draft","text":"<p>When you're ready to approve a draft:</p> <ol> <li>Ensure all comments have been addressed</li> <li>Come back to Claude Code and say: \"Approve [Plan Name] and move to approved\"</li> <li>The plan will be moved to the Approved Plans section</li> </ol>"},{"location":"drafts/acute-ischemic-stroke/","title":"Acute Ischemic Stroke","text":"\u26a0\ufe0f DRAFT - Pending Physician Review This plan has not been approved for clinical use. Please review and provide feedback using the comment system.","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#acute-ischemic-stroke","title":"Acute Ischemic Stroke","text":"<p>VERSION: 1.0 CREATED: January 21, 2026 REVISED: January 21, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Acute Ischemic Stroke</p> <p>ICD-10: I63.9 (Cerebral infarction, unspecified); I63.50 (Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery); I63.30 (Cerebral infarction due to thrombosis of unspecified cerebral artery); I63.40 (Cerebral infarction due to embolism of unspecified cerebral artery); G45.9 (Transient cerebral ischemic attack, unspecified)</p> <p>CLINICAL SYNONYMS: Acute ischemic stroke, AIS, brain attack, cerebrovascular accident, CVA, cerebral infarction, embolic stroke, thrombotic stroke, lacunar stroke, large vessel occlusion, LVO, cryptogenic stroke, ESUS (embolic stroke of undetermined source)</p> <p>SCOPE: Emergency evaluation and treatment of acute ischemic stroke, including thrombolysis decision-making, mechanical thrombectomy candidacy, acute stroke unit care, secondary prevention, and etiologic workup. For hemorrhagic stroke, TIA, or venous sinus thrombosis, use dedicated templates.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Point-of-care glucose Hypoglycemia can mimic stroke; required before tPA 60-180 mg/dL STAT STAT ROUTINE STAT CBC with differential Baseline; thrombocytopenia contraindication to tPA Platelets &gt;100K STAT STAT ROUTINE STAT PT/INR Anticoagulation status; INR &gt;1.7 contraindication to tPA INR &lt;1.7 STAT STAT ROUTINE STAT PTT Baseline; heparin effect assessment Normal STAT STAT ROUTINE STAT Basic metabolic panel Electrolytes, renal function Normal STAT STAT ROUTINE STAT Troponin Concurrent MI; cardioembolic source Normal STAT STAT ROUTINE STAT BNP or NT-proBNP Heart failure; atrial cardiopathy Normal URGENT ROUTINE ROUTINE URGENT Lipid panel (fasting preferred) Cardiovascular risk; statin candidacy LDL target &lt;70 - ROUTINE ROUTINE - HbA1c Diabetes as risk factor &lt;7% goal - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#1b-extended-workup-etiologic-evaluation","title":"1B. Extended Workup (Etiologic Evaluation)","text":"Test Rationale Target Finding ED HOSP OPD ICU TSH Thyroid disease and atrial fibrillation Normal - ROUTINE ROUTINE - LFTs Baseline for statin therapy Normal - ROUTINE ROUTINE - Urine drug screen Cocaine, amphetamine-induced stroke Negative URGENT ROUTINE ROUTINE URGENT Pregnancy test (females of childbearing age) tPA risk assessment Negative (or counsel risks) STAT STAT ROUTINE STAT Hemoglobin A1c Glycemic control assessment &lt;7% goal - ROUTINE ROUTINE - ESR Vasculitis screen Normal - ROUTINE ROUTINE - CRP Inflammation; vasculitis Normal - ROUTINE ROUTINE - Homocysteine Hypercoagulable workup in young stroke Normal (&lt;15 umol/L) - ROUTINE ROUTINE - Vitamin B12 Hyperhomocysteinemia cause Normal - ROUTINE ROUTINE - Folate Hyperhomocysteinemia cause Normal - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#1c-rarespecialized-young-stroke-cryptogenic-hypercoagulable","title":"1C. Rare/Specialized (Young Stroke, Cryptogenic, Hypercoagulable)","text":"Test Rationale Target Finding ED HOSP OPD ICU Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-beta2 glycoprotein) Hypercoagulable workup; repeat in 12 weeks if positive Negative - EXT ROUTINE - Protein C, Protein S, Antithrombin III Inherited thrombophilia (defer acute phase; check 2-4 weeks post-stroke) Normal - EXT ROUTINE - Factor V Leiden, Prothrombin gene mutation Inherited thrombophilia Negative - EXT ROUTINE - ANA, anti-dsDNA Vasculitis, SLE Negative - EXT ROUTINE - ANCA (c-ANCA, p-ANCA) Primary CNS vasculitis; systemic vasculitis Negative - EXT EXT - Syphilis serology (RPR) Infectious vasculopathy Negative - ROUTINE ROUTINE - HIV antibody HIV-associated vasculopathy Negative - ROUTINE ROUTINE - Hepatitis B and C serology Associated with vasculitis Negative - ROUTINE ROUTINE - Lipoprotein(a) Elevated in cryptogenic stroke Normal (&lt;50 nmol/L or &lt;30 mg/dL) - EXT ROUTINE - Sickle cell screen If clinical suspicion Negative - EXT ROUTINE - Fabry disease testing (alpha-galactosidase A, GLA gene) Young cryptogenic stroke, especially with other Fabry features Normal enzyme activity - EXT EXT -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#2a-essentialfirst-line-hyperacute","title":"2A. Essential/First-line (Hyperacute)","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Non-contrast CT head (NCCT) STAT - door to CT &lt;25 min target No hemorrhage; early ischemic changes (ASPECTS score) None STAT STAT - STAT CT angiography head and neck (CTA) STAT with NCCT Large vessel occlusion (LVO); carotid/vertebral stenosis Contrast allergy (premedicate), CKD (benefit usually outweighs risk in acute stroke) STAT STAT - STAT CT perfusion (CTP) If within extended window (6-24 hours) or wake-up stroke Mismatch (ischemic penumbra salvageable) Same as CTA STAT STAT - STAT ECG (12-lead) STAT Atrial fibrillation, STEMI, LVH None STAT STAT ROUTINE STAT","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#2b-extended-inpatient-etiologic-workup","title":"2B. Extended (Inpatient Etiologic Workup)","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain with DWI Within 24 hours; better for small/posterior strokes Acute infarct confirmation; lesion pattern Pacemaker, metallic implants (check compatibility) URGENT STAT ROUTINE URGENT MRA head and neck With MRI if CTA not done Stenosis, dissection, aneurysm Same as MRI URGENT ROUTINE ROUTINE URGENT Transthoracic echocardiogram (TTE) with bubble study Within 24-48 hours LV thrombus, PFO, valvular disease, wall motion abnormalities None - ROUTINE ROUTINE - Transesophageal echocardiogram (TEE) If TTE non-diagnostic and high suspicion for cardiac source; or PFO evaluation LAA thrombus, aortic atheroma, PFO with atrial septal aneurysm Esophageal pathology - ROUTINE ROUTINE - Carotid duplex ultrasound If CTA/MRA not done or for follow-up Stenosis &gt;50% None - ROUTINE ROUTINE - Transcranial Doppler (TCD) with bubble study PFO evaluation; vasospasm monitoring Right-to-left shunt; microembolic signals Inadequate acoustic windows - ROUTINE ROUTINE - Continuous cardiac telemetry (minimum 24-72 hours) Paroxysmal AF detection Atrial fibrillation None STAT STAT - STAT Extended cardiac monitoring (Holter 7-30 days or implantable loop recorder) Cryptogenic stroke; AF not detected on telemetry Paroxysmal AF None significant - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Conventional cerebral angiography (DSA) If vasculitis suspected; CNS vasculitis workup Beading, stenosis, aneurysm Contrast allergy, CKD, coagulopathy - EXT EXT - High-resolution vessel wall MRI Vasculitis, intracranial atherosclerosis characterization Wall enhancement pattern Same as MRI - EXT EXT - Lumbar puncture If vasculitis, infectious, or inflammatory etiology suspected See LP section See LP section - EXT EXT - PET-CT or PET-MRI Occult malignancy workup; giant cell arteritis No malignancy/inflammation Pregnancy - EXT EXT - Implantable loop recorder (ILR) Cryptogenic stroke after negative workup Paroxysmal AF detection Active infection - - ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Suspected CNS vasculitis, infectious etiology, or inflammatory condition; rarely needed in routine ischemic stroke</p> <p>Timing: After brain imaging; not urgent unless infection suspected</p> <p>Volume Required: 10-15 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure - EXT EXT Rule out elevated ICP 10-20 cm H2O Cell count (tubes 1 and 4) - EXT EXT Vasculitis, infection WBC &lt;5, RBC 0 Protein - EXT EXT Inflammation Normal 15-45 mg/dL Glucose with serum glucose - EXT EXT Infection Normal (&gt;60% serum) Gram stain and culture - EXT EXT Bacterial meningitis No organisms VDRL (CSF) - EXT EXT Neurosyphilis Negative Cytology - EXT EXT Malignancy Negative <p>Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50K); space-occupying lesion with mass effect</p>","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3-treatment","title":"3. TREATMENT","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3a-acuteemergent-hyperacute-phase","title":"3A. Acute/Emergent (Hyperacute Phase)","text":"Treatment Dosing Contraindications Monitoring ED HOSP OPD ICU Alteplase (tPA) IV 0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remainder over 60 min; within 4.5 hours of symptom onset See Appendix A for complete exclusion criteria; major: ICH, recent surgery, BP &gt;185/110 despite treatment, INR &gt;1.7, platelets &lt;100K Neuro checks q15min x 2h, then q30min x 6h, then q1h x 16h; BP q15min x 2h, then q30min x 6h; hold antiplatelets/anticoagulants 24h; CT head before anticoagulation STAT STAT - STAT Tenecteplase IV 0.25 mg/kg IV bolus (max 25 mg); single bolus (no infusion); within 4.5 hours of symptom onset Same as alteplase Same as alteplase STAT STAT - STAT Blood pressure management (pre-thrombolysis) - Labetalol 10-20 mg IV over 1-2 min; may repeat or double q10min; max 300 mg Asthma, severe bradycardia, decompensated HF, 2nd/3rd degree heart block Continuous BP; target BP &lt;185/110 for tPA eligibility STAT STAT - STAT Blood pressure management (pre-thrombolysis) - Nicardipine Start 5 mg/hr IV; increase by 2.5 mg/hr q5-15min; max 15 mg/hr None significant Continuous BP; target &lt;185/110 STAT STAT - STAT Blood pressure management (pre-thrombolysis) - Clevidipine Start 1-2 mg/hr IV; titrate by doubling q90sec initially; max 32 mg/hr Soy/egg allergy, severe aortic stenosis, lipid disorders Continuous BP; rapid onset; short half-life STAT STAT - STAT Blood pressure management (post-tPA) Same agents as above Same Maintain BP &lt;180/105 for 24 hours post-tPA STAT STAT - STAT Mechanical thrombectomy Endovascular clot retrieval; within 6 hours for anterior LVO; up to 24 hours with favorable perfusion imaging Large completed infarct (ASPECTS &lt;6), poor baseline function (mRS &gt;2), no LVO Post-procedure: BP per protocol, groin site checks, neuro checks q1h STAT STAT - STAT","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3b-acute-supportive-care","title":"3B. Acute Supportive Care","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU NPO status All acute stroke until swallow evaluation NPO until formal swallow screen passed None Aspiration risk STAT STAT - STAT IV fluids (isotonic) - Normal saline Volume resuscitation; avoid hypotension 0.9% NaCl; avoid dextrose-containing fluids (hyperglycemia worsens outcomes) Volume overload I/O, daily weights STAT STAT - STAT Glucose management - Insulin Hyperglycemia in acute stroke Sliding scale or infusion; target glucose 140-180 mg/dL Avoid hypoglycemia (&lt;60) Glucose q1-6h depending on regimen STAT STAT - STAT DVT prophylaxis - Intermittent pneumatic compression All immobile patients Apply to both legs Active DVT Skin checks STAT STAT - STAT DVT prophylaxis - Enoxaparin After 24-48 hours if no hemorrhagic transformation and not on anticoagulation 40 mg SC daily; reduce to 30 mg if CrCl &lt;30 Active bleeding, HIT, hemorrhagic transformation Platelets; signs of bleeding - ROUTINE - ROUTINE DVT prophylaxis - Heparin (unfractionated) Alternative to enoxaparin if CrCl &lt;30 5000 units SC q8-12h Same as enoxaparin Same - ROUTINE - ROUTINE Fever management - Acetaminophen Target normothermia; fever worsens outcomes 650-1000 mg PO/PR q4-6h PRN temp &gt;38C; max 4g/day Hepatic impairment Temperature STAT STAT - STAT Head of bed positioning Optimize perfusion vs aspiration risk HOB flat to 15 degrees initially if no LVO treated; elevate to 30 degrees if large infarct or aspiration risk None Neuro exam STAT STAT - STAT Supplemental oxygen Hypoxia Titrate to SpO2 &gt;94%; avoid routine oxygen in non-hypoxic patients None Continuous SpO2 STAT STAT - STAT","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3c-secondary-prevention-initiate-during-hospitalization","title":"3C. Secondary Prevention (Initiate During Hospitalization)","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Aspirin Non-cardioembolic stroke; first-line antiplatelet Loading: 325 mg (after tPA, wait 24h and confirm no ICH on CT); Maintenance: 81-325 mg daily Active bleeding, aspirin allergy, concurrent anticoagulation Bleeding signs - ROUTINE ROUTINE - Clopidogrel Aspirin intolerance; or DAPT (see below) Loading: 300-600 mg; Maintenance: 75 mg daily Active bleeding, severe hepatic impairment Bleeding, bruising - ROUTINE ROUTINE - Dual antiplatelet therapy (DAPT) - Aspirin + Clopidogrel Minor stroke (NIHSS \u22643) or high-risk TIA within 24 hours; continue 21 days then single agent Aspirin 81 mg + Clopidogrel 75 mg daily x 21 days; preceded by loading doses Major stroke, high bleeding risk, planned surgery Bleeding; discontinue one agent at day 21 - ROUTINE ROUTINE - Dual antiplatelet therapy (DAPT) - Aspirin + Ticagrelor Alternative DAPT regimen (THALES trial) Aspirin 81 mg + Ticagrelor 90 mg BID x 30 days Same as above; avoid with strong CYP3A4 inhibitors Same; dyspnea (common) - ROUTINE ROUTINE - Atorvastatin All ischemic stroke; high-intensity statin 40-80 mg daily; start in hospital Active liver disease, pregnancy LFTs at baseline; CK if myalgia - ROUTINE ROUTINE - Rosuvastatin Alternative high-intensity statin 20-40 mg daily Same as atorvastatin; dose adjust for Asian patients, CKD Same - ROUTINE ROUTINE - Apixaban Cardioembolic stroke (AF); start after imaging confirms no hemorrhagic transformation 5 mg BID; reduce to 2.5 mg BID if 2 of: age \u226580, weight \u226460 kg, Cr \u22651.5 Active bleeding, mechanical valve, severe hepatic impairment; delay 4-14 days post-stroke based on infarct size Renal function; bleeding - ROUTINE ROUTINE - Rivaroxaban Alternative DOAC for AF 20 mg daily with dinner; 15 mg if CrCl 15-50 Same as apixaban Same - ROUTINE ROUTINE - Dabigatran Alternative DOAC for AF 150 mg BID; 75 mg BID if CrCl 15-30 Same as apixaban; GI upset common Same; requires reversal agent availability - ROUTINE ROUTINE - Edoxaban Alternative DOAC for AF 60 mg daily; 30 mg if CrCl 15-50, weight \u226460 kg, or concurrent P-gp inhibitor Same as apixaban Same - ROUTINE ROUTINE - Warfarin Mechanical valve, antiphospholipid syndrome, DOAC contraindication Start with DOAC or heparin bridge; target INR 2-3 (2.5-3.5 for mechanical mitral) Same as DOACs INR weekly then monthly - ROUTINE ROUTINE - Lisinopril Hypertension; target BP &lt;130/80 after acute phase Start 2.5-5 mg daily; titrate to 20-40 mg daily Bilateral renal artery stenosis, angioedema history, pregnancy BP, K+, Cr - ROUTINE ROUTINE - Amlodipine Hypertension; add-on or alternative Start 5 mg daily; max 10 mg daily Severe aortic stenosis BP, peripheral edema - ROUTINE ROUTINE - Chlorthalidone Hypertension; add-on for volume-dependent HTN 12.5-25 mg daily Sulfa allergy (relative), hypokalemia, gout K+, Na+, uric acid - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3d-complications-management","title":"3D. Complications Management","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Mannitol Cerebral edema; increased ICP 0.5-1.5 g/kg IV over 20-30 min; may repeat q6h; serum osm goal &lt;320 Hypovolemia, anuria Serum osm, Na+, renal function; Foley required - URGENT - STAT Hypertonic saline 23.4% Severe cerebral edema; herniation 30 mL IV push via central line over 10-20 min Severe hypernatremia (Na &gt;160) Na q4-6h; target Na 145-155 for edema - URGENT - STAT Hypertonic saline 3% Cerebral edema (less severe) 150-500 mL IV bolus or continuous infusion at 30-50 mL/hr Same Same - URGENT - STAT Decompressive craniectomy Malignant MCA infarction with edema; age &lt;60 Surgical; within 48 hours of stroke onset Poor pre-stroke function, extensive infarct, patient/family preference Post-op neuro checks, ICP if monitored - URGENT - URGENT Levetiracetam Seizure prophylaxis not routinely recommended; use only if seizure occurs 500-1000 mg IV/PO BID; max 3000 mg/day None significant Mood, behavior - ROUTINE ROUTINE ROUTINE Ceftriaxone + Metronidazole Aspiration pneumonia Ceftriaxone 1-2 g IV daily + Metronidazole 500 mg IV/PO q8h Cephalosporin allergy, alcohol with metronidazole WBC, fever, respiratory status - ROUTINE - ROUTINE","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#3e-special-situations","title":"3E. Special Situations","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Heparin infusion Cervical artery dissection (controversial), bridge to warfarin 80 units/kg bolus, then 18 units/kg/hr; titrate to PTT 60-80 Active bleeding, large infarct, hemorrhagic transformation PTT q6h until therapeutic, then q12-24h - ROUTINE - ROUTINE PFO closure (device) Cryptogenic stroke with high-risk PFO (large shunt, atrial septal aneurysm); age &lt;60 Interventional procedure; typically after stroke recovery Active infection, other stroke etiology identified Post-procedure: antiplatelet therapy, bubble study follow-up - - ROUTINE - Carotid endarterectomy (CEA) Symptomatic carotid stenosis 70-99%; some benefit 50-69% Surgical; timing 2-14 days post-stroke optimal Unstable medical condition, near-complete occlusion Post-op: BP control, neuro checks - ROUTINE ROUTINE - Carotid artery stenting (CAS) Alternative to CEA; high surgical risk patients Interventional procedure Same contraindications as surgery; unfavorable anatomy Post-procedure: DAPT x 30 days minimum - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation Indication ED HOSP OPD ICU Stroke neurology consult All acute ischemic stroke STAT STAT ROUTINE STAT Interventional neuroradiology/neuroendovascular LVO identified; thrombectomy candidate STAT STAT - STAT Neurosurgery consult Malignant edema; decompressive craniectomy candidate URGENT URGENT - STAT Cardiology consult AF management, PFO evaluation, cardiac source workup - ROUTINE ROUTINE ROUTINE Vascular surgery consult Symptomatic carotid stenosis; CEA candidate - ROUTINE ROUTINE - Speech-language pathology Swallow evaluation; aphasia therapy - STAT ROUTINE ROUTINE Physical therapy Mobility, gait, balance - ROUTINE ROUTINE ROUTINE Occupational therapy ADLs, upper extremity function - ROUTINE ROUTINE ROUTINE Rehabilitation medicine (PM&amp;R) Inpatient rehabilitation placement - ROUTINE ROUTINE - Social work Discharge planning, community resources - ROUTINE ROUTINE - Case management Insurance authorization, rehab placement - ROUTINE ROUTINE - Palliative care Large stroke with poor prognosis; goals of care - ROUTINE - ROUTINE Smoking cessation counseling All smokers - ROUTINE ROUTINE - Nutrition/Dietitian Dysphagia diet, heart-healthy diet education - ROUTINE ROUTINE -","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 immediately if new or worsening weakness, numbness, vision changes, speech difficulty, or severe headache \u2713 \u2713 \u2713 Know stroke warning signs: F.A.S.T. (Face drooping, Arm weakness, Speech difficulty, Time to call 911) \u2713 \u2713 \u2713 Take all prescribed medications as directed; do not stop antiplatelet or anticoagulant without physician guidance \u2713 \u2713 \u2713 Attend all follow-up appointments (neurology, cardiology, primary care) - \u2713 \u2713 No driving until cleared by physician (typically minimum 2-4 weeks; varies by state law and deficit severity) \u2713 \u2713 \u2713 Report any bleeding (blood in stool, urine, gums, excessive bruising) while on blood thinners - \u2713 \u2713 Check blood pressure at home daily if hypertensive; keep log for follow-up visits - \u2713 \u2713 Monitor blood glucose if diabetic; maintain good glycemic control - \u2713 \u2713 Follow swallow precautions if dysphagia present (diet modification, positioning, supervision) - \u2713 \u2713 Use fall precautions: clear pathways, use assistive devices as prescribed, adequate lighting - \u2713 \u2713","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (most important modifiable risk factor) \u2713 \u2713 \u2713 Blood pressure control: target &lt;130/80 mmHg - \u2713 \u2713 LDL cholesterol target &lt;70 mg/dL (or 50% reduction) with high-intensity statin - \u2713 \u2713 Diabetes management: HbA1c target &lt;7% - \u2713 \u2713 Limit alcohol: \u22641 drink/day women, \u22642 drinks/day men; abstinence if alcohol-related stroke \u2713 \u2713 \u2713 Heart-healthy diet: Mediterranean or DASH diet - \u2713 \u2713 Regular aerobic exercise: 40 min moderate-intensity 3-4 days/week when able - \u2713 \u2713 Weight management: BMI target 18.5-24.9 - \u2713 \u2713 Sleep apnea screening and treatment if indicated - \u2713 \u2713 Avoid illicit drugs (cocaine, amphetamines) \u2713 \u2713 \u2713 Hormone replacement therapy: avoid or use caution - \u2713 \u2713 Stress management - - \u2713","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Hypoglycemia Rapid response to glucose; often diabetic on insulin/sulfonylureas Point-of-care glucose; resolves with correction Seizure with Todd's paralysis History of seizure; gradual resolution over hours; post-ictal confusion EEG; witnessed seizure; gradual resolution Complex migraine with aura Headache (usually); positive symptoms (scintillating scotoma); history of similar; &lt;60 min Clinical history; normal imaging; resolves Intracranial hemorrhage Sudden severe headache; rapid progression; may have anticoagulation history CT head shows hemorrhage Brain tumor Gradual onset; headache; seizures; may have mass effect MRI brain shows mass lesion Subdural hematoma History of trauma (may be minor); elderly; anticoagulation CT shows crescent-shaped collection Encephalitis Fever; altered mental status; seizures; behavioral changes MRI (temporal lobe); LP; CSF PCR Multiple sclerosis (acute relapse) Younger patient; prior episodes; MRI pattern (periventricular, Dawson fingers) MRI brain/spine; LP (oligoclonal bands) Conversion disorder/functional neurological disorder Inconsistent exam; positive functional signs (Hoover, give-way weakness) Clinical; normal imaging; psychiatric history Wernicke encephalopathy Ataxia, ophthalmoplegia, confusion; alcohol/malnutrition history Clinical; MRI (mammillary bodies); thiamine response Hypertensive encephalopathy Severely elevated BP; headache; confusion; PRES pattern on MRI MRI (PRES); BP reduction reverses symptoms Cerebral venous sinus thrombosis Headache; may have hypercoagulable state or OCP use; hemorrhagic infarcts CT/MR venography; D-dimer Hyponatremia Confusion, seizures; recent medication change; SIADH BMP shows low sodium Hepatic encephalopathy Liver disease; asterixis; confusion Ammonia; LFTs; history Drug intoxication History of substance use; pupils; toxidrome Urine drug screen","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU NIHSS (National Institutes of Health Stroke Scale) Q1h x 24h, then q4h x 48h, then q shift Stable or improving If worsening \u22654 points: emergent CT, consider hemorrhage or extension STAT STAT ROUTINE STAT Blood pressure Q15min x 2h post-tPA, then q30min x 6h, then q1h x 16h; q4h after &lt;180/105 post-tPA x 24h; then individualize (avoid hypotension acutely) Treat per protocol; labetalol, nicardipine STAT STAT ROUTINE STAT Glucose Q6h; q1h if on insulin infusion 140-180 mg/dL (avoid &lt;60 and &gt;180) Insulin adjustment STAT STAT ROUTINE STAT Temperature Q4h &lt;38\u00b0C Acetaminophen; cooling; infection workup if fever STAT ROUTINE - STAT Oxygen saturation Continuous if on supplemental O2 &gt;94% Oxygen titration; evaluate for aspiration, PE STAT STAT - STAT Neurological examination Q1h x 24h, then per protocol Stable or improving If worsening: emergent imaging STAT STAT ROUTINE STAT INR (if on warfarin) Daily until therapeutic 2-3 (or 2.5-3.5 for mechanical mitral) Warfarin dose adjustment - ROUTINE ROUTINE ROUTINE Renal function (Cr, BUN) Daily during hospitalization; baseline for DOACs Stable DOAC dose adjustment; avoid nephrotoxins - ROUTINE ROUTINE ROUTINE Lipid panel Fasting, within 24-48h LDL &lt;70 Statin intensification - ROUTINE ROUTINE - HbA1c Once during hospitalization &lt;7% Diabetes medication optimization - ROUTINE ROUTINE - Swallow evaluation Before any oral intake Pass bedside or instrumental swallow NPO; modified diet; SLP consult - STAT - STAT Continuous cardiac telemetry Minimum 24-72 hours Identify AF, arrhythmias Anticoagulation if AF detected STAT STAT - STAT Repeat CT head 24 hours post-tPA; or if neurological decline No hemorrhagic transformation If hemorrhage: reverse anticoagulation, neurosurgery consult - ROUTINE - ROUTINE","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Minor stroke or TIA; able to ambulate safely or with minimal assistance; swallow intact; stable on oral medications; adequate home support; follow-up arranged within 1-2 weeks; compliant with secondary prevention Admit to stroke unit/floor Most acute ischemic strokes; requires monitoring, workup, rehabilitation assessment; stable vital signs; no respiratory compromise Admit to ICU Received tPA or thrombectomy (24h monitoring); large vessel occlusion; declining neurological exam; respiratory compromise; malignant edema risk; BP requiring IV infusion; arrhythmia requiring intervention Inpatient rehabilitation Significant functional deficits; able to participate in 3 hours therapy/day; medically stable; expected to benefit Skilled nursing facility Functional deficits; unable to tolerate intensive rehabilitation; needs skilled nursing care Long-term acute care (LTAC) Prolonged ventilator dependence; complex medical needs Transfer to comprehensive stroke center LVO needing thrombectomy not available locally; neurosurgical intervention needed; complex case","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IV alteplase within 4.5 hours improves outcomes Class I, Level A NINDS, ECASS III Tenecteplase non-inferior to alteplase Class I, Level B AcT Trial, Campbell et al. NEJM 2022 Mechanical thrombectomy for LVO within 6 hours Class I, Level A MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT Thrombectomy up to 24 hours with favorable imaging Class I, Level A DAWN; DEFUSE 3 DAPT (aspirin + clopidogrel) for minor stroke/high-risk TIA x 21 days Class I, Level A CHANCE; POINT High-intensity statin therapy Class I, Level A SPARCL; AHA/ASA Guidelines Anticoagulation for AF-related stroke Class I, Level A AHA/ASA Guidelines 2021 Blood pressure management post-stroke Class I, Level B AHA/ASA Guidelines 2021 Early mobilization Class III (Harm), Level A AVERT Trial - very early mobilization harmful Decompressive craniectomy for malignant MCA stroke Class I, Level A DECIMAL, DESTINY, HAMLET PFO closure for cryptogenic stroke Class I, Level B CLOSE; RESPECT; DEFENSE-PFO Carotid endarterectomy for symptomatic stenosis \u226570% Class I, Level A NASCET; ECST Intensive glucose control (avoid hypoglycemia) Class I, Level C AHA/ASA Guidelines Fever treatment Class I, Level C AHA/ASA Guidelines","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 21, 2026) - Initial template creation - Comprehensive hyperacute, acute, and secondary prevention protocols - Includes tPA/tenecteplase, thrombectomy decision-making - Etiologic workup for cryptogenic and young stroke - Cardioembolic stroke management with DOAC guidance - Malignant edema and complications management - Full disposition criteria for all levels of care</p>","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#appendix-a-tpa-exclusion-criteria","title":"APPENDIX A: tPA Exclusion Criteria","text":"","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#absolute-contraindications-standard-0-3-hour-window","title":"Absolute Contraindications (Standard 0-3 Hour Window)","text":"Contraindication Details Intracranial hemorrhage Any history or evidence on imaging Subarachnoid hemorrhage Clinical or imaging evidence Recent intracranial/spinal surgery Within 3 months Recent serious head trauma Within 3 months Intracranial neoplasm Excluding meningiomas Arteriovenous malformation or aneurysm If known Active internal bleeding Excluding menses Bleeding diathesis Platelets &lt;100K, INR &gt;1.7, PTT elevation, current anticoagulation with therapeutic levels Blood pressure &gt;185/110 mmHg Despite antihypertensive treatment Blood glucose &lt;50 mg/dL Hypoglycemia must be corrected first","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#relative-contraindications-require-risk-benefit-assessment","title":"Relative Contraindications (Require Risk-Benefit Assessment)","text":"Contraindication Considerations Minor or rapidly improving symptoms May proceed if still disabling Pregnancy Consider if large vessel stroke with disabling deficits Major surgery within 14 days Assess surgical site bleeding risk GI or urinary tract hemorrhage within 21 days Risk assessment Recent myocardial infarction Within 3 months; consult cardiology Seizure at onset with postictal residual If true stroke suspected, may proceed Arterial puncture at non-compressible site within 7 days Risk assessment Prior ischemic stroke within 3 months Extended window (3-4.5 hours) relative","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#extended-window-3-45-hours-additional-relative-contraindications","title":"Extended Window (3-4.5 Hours) Additional Relative Contraindications","text":"Contraindication Details Age &gt;80 years Now considered relative (may benefit) NIHSS &gt;25 Very severe stroke Oral anticoagulant use Regardless of INR History of both diabetes AND prior stroke Historical exclusion; now relative","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/acute-ischemic-stroke/#appendix-b-nihss-quick-reference","title":"APPENDIX B: NIHSS Quick Reference","text":"Score Severity General Outcome 0 No stroke symptoms May still have significant deficits 1-4 Minor stroke Often good outcome; DAPT candidate if \u22643 5-15 Moderate stroke Variable outcomes 16-20 Moderate-severe stroke Often requires intensive rehabilitation 21-42 Severe stroke High mortality and disability risk","tags":["stroke","emergency","thrombolysis","thrombectomy"]},{"location":"drafts/als/","title":"Amyotrophic Lateral Sclerosis","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#amyotrophic-lateral-sclerosis","title":"Amyotrophic Lateral Sclerosis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 REVISED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Amyotrophic Lateral Sclerosis (ALS) / Motor Neuron Disease</p> <p>ICD-10: G12.21 (Amyotrophic lateral sclerosis)</p> <p>SCOPE: Comprehensive outpatient-focused management of ALS including diagnostic workup, El Escorial/Awaji criteria application, disease-modifying therapy (riluzole, edaravone, AMX0035), symptomatic management (sialorrhea, spasticity, pseudobulbar affect, pain, dyspnea), respiratory monitoring with BiPAP timing, nutritional support with PEG timing, multidisciplinary clinic model, and palliative care integration. Excludes primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and pediatric motor neuron disease.</p> <p>CLINICAL SYNONYMS: Lou Gehrig's disease, motor neuron disease (MND), amyotrophic lateral sclerosis, classical ALS, bulbar-onset ALS, limb-onset ALS</p> <p>KEY CLINICAL FEATURES: - Progressive combined upper motor neuron (UMN) AND lower motor neuron (LMN) signs - UMN signs: spasticity, hyperreflexia, Babinski sign, clonus - LMN signs: weakness, atrophy, fasciculations, hyporeflexia - Typically asymmetric onset; spreads contiguously - Bulbar-onset (25%): dysarthria, dysphagia, tongue fasciculations - Limb-onset (75%): focal limb weakness, foot drop, grip weakness - Cognitive impairment in 35-50%; frontotemporal dementia in 10-15% - Preserved: Eye movements, sphincter function (until late)</p> <p>MEDIAN SURVIVAL: 3-5 years from symptom onset; 2-3 years from diagnosis</p> <p>EL ESCORIAL DIAGNOSTIC CRITERIA (Revised):</p> Category UMN + LMN Signs Required Clinically Definite ALS 3 regions (bulbar, cervical, thoracic, lumbosacral) Clinically Probable ALS 2 regions with UMN rostral to LMN Clinically Probable - Lab Supported 1 region with EMG evidence in 2 limbs Clinically Possible ALS 1 region only, or UMN only in 2+ regions <p>AWAJI-SHIMA CRITERIA (2008): EMG findings of acute denervation and chronic reinnervation are equivalent to clinical LMN signs. Fasciculation potentials with chronic neurogenic changes support diagnosis.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>MULTIDISCIPLINARY CARE IS ESSENTIAL</p> <p>ALS patients managed in multidisciplinary clinics have improved survival (7-10 months) and better quality of life. Coordinate neurology, pulmonology, nutrition, PT, OT, speech, respiratory therapy, social work, and palliative care.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline; exclude infection Normal STAT STAT ROUTINE STAT CMP (BMP + LFTs) Baseline; monitor for riluzole hepatotoxicity Normal; ALT &lt;3x ULN STAT STAT ROUTINE STAT TSH Thyroid disease can mimic weakness Normal URGENT ROUTINE ROUTINE URGENT Vitamin B12 B12 deficiency causes myelopathy &gt;300 pg/mL URGENT ROUTINE ROUTINE URGENT CPK Often mildly elevated in ALS; rule out myopathy Mildly elevated OK; &lt;5x ULN URGENT ROUTINE ROUTINE URGENT ESR, CRP Inflammatory markers Normal or mildly elevated URGENT ROUTINE ROUTINE URGENT Hemoglobin A1c Diabetic neuropathy in differential &lt;6.5% \u2014 ROUTINE ROUTINE \u2014 Fasting lipid panel Cardiovascular risk assessment LDL goal per guidelines \u2014 ROUTINE ROUTINE \u2014 Serum protein electrophoresis (SPEP) Exclude monoclonal gammopathy No monoclonal spike \u2014 ROUTINE ROUTINE \u2014 Urinalysis Baseline; UTI assessment Normal STAT ROUTINE ROUTINE STAT","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU HIV HIV-associated motor neuron disease Negative \u2014 ROUTINE ROUTINE \u2014 Lyme serology (endemic areas) Lyme disease causes neuropathy Negative \u2014 ROUTINE ROUTINE \u2014 Copper and ceruloplasmin Wilson disease in younger patients Normal \u2014 ROUTINE ROUTINE \u2014 Parathyroid hormone (PTH) Hyperparathyroidism causes weakness Normal \u2014 ROUTINE ROUTINE \u2014 Anti-GM1 antibodies Multifocal motor neuropathy (treatable mimic) Negative \u2014 ROUTINE ROUTINE \u2014 Anti-MAG antibodies Demyelinating neuropathy Negative \u2014 ROUTINE ROUTINE \u2014 Lead level Lead neuropathy mimics ALS &lt;10 mcg/dL \u2014 EXT EXT \u2014 Hexosaminidase A Adult Tay-Sachs (rare mimic) Normal activity \u2014 EXT EXT \u2014 Very long chain fatty acids Adrenomyeloneuropathy (X-linked) Normal \u2014 EXT EXT \u2014 Serum immunofixation Paraprotein-associated neuropathy No monoclonal protein \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU SOD1 genetic testing Familial ALS (10%); affects prognosis and therapy Document mutation \u2014 EXT EXT \u2014 C9orf72 repeat expansion Most common familial ALS mutation; FTD link &lt;30 repeats normal \u2014 EXT EXT \u2014 ALS gene panel (FUS, TARDBP, etc.) Familial ALS with family history Document variants \u2014 EXT EXT \u2014 Muscle biopsy Only if myopathy suspected Neurogenic changes \u2014 EXT EXT \u2014 CSF analysis Atypical cases; exclude inflammatory Protein mildly elevated OK \u2014 EXT EXT \u2014 Anti-voltage-gated calcium channel Ab Lambert-Eaton syndrome Negative \u2014 EXT EXT \u2014 Anti-acetylcholine receptor Ab Myasthenia gravis Negative \u2014 EXT EXT \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU EMG with nerve conduction studies At diagnosis; within 2 weeks Widespread denervation (3+ regions), fibrillations, fasciculations, chronic reinnervation; normal sensory studies Anticoagulation (relative) \u2014 URGENT ROUTINE URGENT MRI brain without contrast Exclude structural lesion No mass, stroke, or demyelination Pacemaker \u2014 ROUTINE ROUTINE ROUTINE MRI cervical spine without contrast Exclude cervical myelopathy/radiculopathy No cord compression; mild spondylosis OK Pacemaker \u2014 ROUTINE ROUTINE ROUTINE Chest X-ray Baseline; aspiration screen Clear or evidence of aspiration None STAT STAT ROUTINE STAT Pulmonary function tests (FVC sitting and supine) Baseline respiratory status FVC &gt;80% predicted Severe bulbar dysfunction \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI thoracic/lumbar spine If thoracic/lumbosacral symptoms predominant Exclude cord compression Pacemaker \u2014 ROUTINE ROUTINE \u2014 Videofluoroscopic swallow study (VFSS) Bulbar symptoms; dysphagia Quantify aspiration risk Severe aspiration (relative) \u2014 URGENT ROUTINE \u2014 Fiberoptic endoscopic evaluation of swallowing (FEES) Alternative to VFSS Laryngeal function, aspiration Severe nasal obstruction \u2014 URGENT ROUTINE \u2014 Sleep study (polysomnography) Suspected nocturnal hypoventilation Assess for REM hypoventilation, AHI None \u2014 ROUTINE ROUTINE \u2014 Sniff nasal inspiratory pressure (SNIP) More sensitive for bulbar patients &gt;40 cmH2O normal Nasal obstruction \u2014 ROUTINE ROUTINE \u2014 Arterial blood gas Acute respiratory failure pH, pCO2, pO2 Severe coagulopathy STAT STAT EXT STAT","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Transcranial magnetic stimulation (TMS) Research; UMN localization Prolonged central motor conduction time Seizure history, pacemaker \u2014 EXT EXT \u2014 PET-FDG brain Cognitive symptoms, FTD evaluation Frontotemporal hypometabolism Unable to cooperate \u2014 EXT EXT \u2014 Neuropsychological testing Cognitive concerns; FTD screening Document cognitive profile Severe dysarthria (limited) \u2014 ROUTINE ROUTINE \u2014 Diaphragm ultrasound Assess diaphragm function Reduced excursion None \u2014 EXT ROUTINE EXT Maximum inspiratory/expiratory pressure Additional respiratory metrics MIP &gt;60 cmH2O; MEP &gt;40 cmH2O Poor mouth seal \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: ALS is a progressive, incurable disease. Treatment goals are to slow progression, manage symptoms, maintain function, and optimize quality of life. Early palliative care integration is essential.</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3a-disease-modifying-therapy","title":"3A. Disease-Modifying Therapy","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Riluzole (Rilutek) PO Slows disease progression; extends survival 2-3 months 50 mg BID :: PO :: BID :: 50 mg PO BID; take 1 hour before or 2 hours after meals for best absorption Baseline LFTs ALT &gt;5x ULN; hepatic impairment LFTs monthly x 3 months, then q3 months; CBC if neutropenia suspected \u2014 ROUTINE ROUTINE \u2014 Edaravone (Radicava) - IV formulation IV Antioxidant; slows functional decline in selected patients 60 mg IV daily :: IV :: daily (cycle) :: Initial cycle: 60 mg IV daily x 14 days, then 14 days off; subsequent cycles: 60 mg IV daily x 10 of 14 days, then 14 days off Baseline renal function, IV access established Hypersensitivity to edaravone or sodium bisulfite Infusion reactions; renal function; gait (sulfite sensitivity) \u2014 ROUTINE ROUTINE \u2014 Edaravone oral suspension (Radicava ORS) PO Oral alternative to IV edaravone 105 mg daily :: PO :: daily (cycle) :: Initial cycle: 105 mg PO daily x 14 days, then 14 days off; subsequent cycles: 105 mg PO daily x 10 of 14 days, then 14 days off Baseline renal function Hypersensitivity to edaravone or sodium bisulfite Same as IV formulation \u2014 ROUTINE ROUTINE \u2014 AMX0035 / Relyvrio (sodium phenylbutyrate-taurursodiol) PO Slows functional decline; extends survival 1 packet daily; then 1 packet BID :: PO :: daily-BID :: Week 1: 1 packet (3g sodium phenylbutyrate + 1g taurursodiol) mixed in 8 oz room temp water daily; Week 2+: 1 packet BID Baseline LFTs; assess swallowing Known hypersensitivity; disorders of urea cycle GI side effects (diarrhea, nausea); LFTs q3 months \u2014 ROUTINE ROUTINE \u2014 Tofersen (Qalsody) - for SOD1 mutations IT SOD1-ALS only; reduces SOD1 protein 100 mg monthly after loading :: IT :: monthly :: Loading: 100 mg IT on Days 1, 15, 29; Maintenance: 100 mg IT q28 days SOD1 gene mutation confirmed; lumbar access No SOD1 mutation; contraindication to IT injection Neurofilament levels; CSF analysis; myelopathy monitoring \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Glycopyrrolate PO Sialorrhea (excess saliva) 1 mg TID; 2 mg TID :: PO :: TID :: Start 1 mg PO TID; may increase to 2 mg TID; max 8 mg/day Narrow-angle glaucoma; urinary retention; GI obstruction Dry mouth (paradoxical thick secretions), constipation, urinary retention \u2014 ROUTINE ROUTINE \u2014 Atropine 1% ophthalmic drops (sublingual) SL Sialorrhea (rescue) 1-2 drops q4-6h PRN :: SL :: q4-6h PRN :: 1-2 drops sublingual q4-6h as needed; max 4 doses/day Narrow-angle glaucoma; cardiac arrhythmia HR, dry mouth, urinary retention \u2014 ROUTINE ROUTINE \u2014 Scopolamine transdermal patch TOP Sialorrhea (continuous) 1.5 mg patch q72h :: TOP :: q72h :: Apply 1.5 mg patch behind ear; replace every 72 hours Narrow-angle glaucoma; urinary retention; GI obstruction Confusion (especially elderly), dry mouth, constipation \u2014 ROUTINE ROUTINE \u2014 Botulinum toxin A (salivary gland injection) IM Refractory sialorrhea 30-50 units per parotid; 10-20 units per submandibular :: IM :: q3 months :: 30-50 units per parotid gland + 10-20 units per submandibular gland (total 80-140 units); effects last 3-4 months Hypersensitivity; neuromuscular disease (use cautiously) Dysphagia worsening (rare); dry mouth \u2014 \u2014 ROUTINE \u2014 Dextromethorphan-quinidine (Nuedexta) PO Pseudobulbar affect (PBA) 20/10 mg daily; 20/10 mg BID :: PO :: daily-BID :: Start 20/10 mg (DM/Q) daily x 7 days, then increase to 20/10 mg BID QT prolongation; concurrent quinidine or CYP2D6 substrates; hepatic impairment Baseline ECG; QTc monitoring; avoid with other QT-prolonging drugs \u2014 ROUTINE ROUTINE \u2014 Baclofen PO Spasticity 5 mg TID; 10 mg TID; 20 mg TID :: PO :: TID :: Start 5 mg PO TID; increase by 5 mg/dose q3 days; max 80 mg/day in divided doses Abrupt withdrawal (risk of seizures, hallucinations) Sedation, weakness (may unmask underlying weakness); taper to discontinue STAT ROUTINE ROUTINE STAT Tizanidine PO Spasticity (alternative to baclofen) 2 mg qHS; 4 mg TID; 8 mg TID :: PO :: TID :: Start 2 mg qHS; may increase by 2-4 mg q6-8h; max 36 mg/day Concurrent CYP1A2 inhibitors (ciprofloxacin, fluvoxamine); hepatic impairment LFTs at baseline, 1 month, 3 months; sedation, hypotension, dry mouth \u2014 ROUTINE ROUTINE \u2014 Gabapentin PO Muscle cramps; neuropathic pain 300 mg qHS; 300 mg TID; 600 mg TID :: PO :: TID :: Start 300 mg qHS; titrate by 300 mg/day q1-3 days; max 3600 mg/day divided TID Severe renal impairment (adjust dose) Sedation, dizziness; reduce dose if CrCl &lt;60 \u2014 ROUTINE ROUTINE \u2014 Mexiletine PO Muscle cramps (refractory) 150 mg BID; 300 mg BID :: PO :: BID :: Start 150 mg PO BID; may increase to 300 mg BID; max 1200 mg/day Cardiogenic shock; 2nd/3rd degree AV block without pacemaker Baseline ECG; monitor for arrhythmia; GI upset \u2014 ROUTINE ROUTINE \u2014 Quinine sulfate PO Muscle cramps (limited use) 200-300 mg qHS :: PO :: qHS :: 200-300 mg PO at bedtime; FDA warns against off-label use for cramps Thrombocytopenia; G6PD deficiency; prolonged QT; myasthenia CBC, cardiac rhythm; FDA black box warning for thrombocytopenia \u2014 \u2014 EXT \u2014 Lorazepam PO/SL Anxiety; dyspnea (end of life) 0.5 mg BID PRN; 1 mg TID PRN :: PO/SL :: BID-TID PRN :: 0.5-1 mg PO/SL q8h PRN for anxiety or dyspnea; use low doses due to respiratory depression risk Severe respiratory insufficiency (relative); acute narrow-angle glaucoma Respiratory status, sedation; paradoxical agitation \u2014 ROUTINE ROUTINE ROUTINE Morphine PO/SL Dyspnea (palliative) 2.5 mg q4h PRN; 5 mg q4h PRN :: PO/SL :: q4h PRN :: Start 2.5-5 mg PO/SL q4h PRN for dyspnea; titrate to comfort; may reduce respiratory distress without significantly worsening ventilation Active respiratory failure without comfort focus Respiratory rate, comfort, sedation \u2014 ROUTINE ROUTINE ROUTINE Modafinil PO Fatigue 100 mg qAM; 200 mg qAM :: PO :: qAM :: Start 100 mg PO every morning; may increase to 200 mg; avoid afternoon dosing Hypersensitivity; cardiac arrhythmia Headache, insomnia, cardiac monitoring if history \u2014 \u2014 ROUTINE \u2014 Amitriptyline PO Sialorrhea; insomnia; depression 10 mg qHS; 25 mg qHS; 50 mg qHS :: PO :: qHS :: Start 10 mg PO qHS; increase by 10 mg weekly; max 75-100 mg qHS Cardiac conduction abnormality; recent MI; urinary retention ECG if dose &gt;50 mg; anticholinergic effects; sedation \u2014 ROUTINE ROUTINE \u2014 Sertraline PO Depression; anxiety 25 mg daily; 50 mg daily; 100 mg daily :: PO :: daily :: Start 25 mg PO daily; increase by 25-50 mg q1-2 weeks; max 200 mg/day Concurrent MAOIs; caution with QT-prolonging drugs Suicidality (first weeks), GI upset, sexual dysfunction \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3c-respiratory-support","title":"3C. Respiratory Support","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU BiPAP (noninvasive ventilation) INH FVC &lt;50% predicted OR symptoms of nocturnal hypoventilation IPAP 8-12 cmH2O; EPAP 4-6 cmH2O :: INH :: nightly/continuous :: Start with nocturnal use; IPAP 8-12, EPAP 4-6; titrate for comfort; increase time as tolerated; extend to daytime as needed Severe bulbar dysfunction with aspiration (relative); inability to clear secretions Comfort, adherence, transcutaneous CO2 or ABG, mask fit \u2014 URGENT ROUTINE STAT Mechanical insufflation-exsufflation (Cough Assist) \u2014 Weak cough; peak cough flow &lt;270 L/min +40/-40 cmH2O :: \u2014 :: 2-4 cycles, 2-4 times daily :: Set insufflation +40 cmH2O, exsufflation -40 cmH2O; 2-4 cycles per session; 2-4 sessions daily; use before meals and PRN Bullous emphysema; pneumothorax Secretion clearance, respiratory status \u2014 URGENT ROUTINE STAT Portable suction \u2014 Secretion management N/A :: \u2014 :: PRN :: Oral or pharyngeal suction PRN for secretion management None Secretion burden, mucosal trauma STAT STAT ROUTINE STAT Oxygen supplementation INH Hypoxemia 1-4 L/min NC PRN :: INH :: PRN :: Use cautiously; O2 may suppress respiratory drive; BiPAP preferred; use only for hypoxemia with BiPAP May suppress respiratory drive in hypercapnic patients SpO2, pCO2, respiratory rate STAT STAT ROUTINE STAT Diaphragm pacing (NeuRx) \u2014 Diaphragm weakness Surgical implantation :: \u2014 :: :: Laparoscopic implantation of intramuscular diaphragm electrodes; controversial efficacy; FDA approved but limited evidence Severe diaphragm atrophy; unable to tolerate surgery Diaphragm function, surgical complications \u2014 \u2014 EXT \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3d-nutritional-support","title":"3D. Nutritional Support","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Oral nutritional supplements PO Weight loss; inadequate oral intake 1-3 supplements daily :: PO :: daily :: High-calorie, high-protein supplements (e.g., Ensure Plus, Boost Plus) 1-3 daily between meals Aspiration risk Weight, caloric intake, albumin \u2014 ROUTINE ROUTINE \u2014 Thickened liquids PO Dysphagia with thin liquid aspiration Nectar to honey thick consistency :: PO :: with all liquids :: Thicken all thin liquids per SLP recommendation; nectar, honey, or pudding thick consistency None Hydration status, swallow function \u2014 ROUTINE ROUTINE \u2014 Percutaneous endoscopic gastrostomy (PEG) \u2014 Dysphagia with weight loss &gt;10% or FVC declining toward 50% N/A :: \u2014 :: \u2014 :: Place electively when FVC &gt;50% predicted; allows continued oral intake for pleasure; start tube feeds gradually FVC &lt;50% (higher risk; consider RIG or PIG); severe coagulopathy Weight, tube site, aspiration \u2014 URGENT ROUTINE \u2014 Radiologically-inserted gastrostomy (RIG) \u2014 PEG contraindicated; FVC &lt;50% N/A :: \u2014 :: \u2014 :: Alternative to PEG when FVC &lt;50% or unable to tolerate endoscopy; fluoroscopic placement Severe ascites; peritoneal adhesions Weight, tube site \u2014 URGENT ROUTINE \u2014 Per-oral image-guided gastrostomy (PIG) \u2014 Alternative to PEG/RIG N/A :: \u2014 :: \u2014 :: Transoral placement under endoscopic and radiologic guidance; may tolerate lower FVC Same as RIG Weight, tube site \u2014 URGENT ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#3e-acuteemergent-care","title":"3E. Acute/Emergent Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Noninvasive ventilation (acute) INH Acute respiratory failure IPAP 12-20; EPAP 5-8 :: INH :: continuous :: IPAP 12-20 cmH2O, EPAP 5-8 cmH2O; FiO2 to maintain SpO2 &gt;92%; close monitoring for escalation Inability to protect airway; hemodynamic instability ABG, respiratory rate, work of breathing STAT STAT \u2014 STAT Intubation and mechanical ventilation \u2014 Respiratory failure not responding to NIV N/A :: \u2014 :: \u2014 :: Discuss advance directives; many ALS patients decline invasive ventilation; if desired, standard intubation and ventilation Patient declines; DNI documented Ventilator parameters, sedation STAT \u2014 \u2014 STAT IV fluids IV Dehydration 1000-2000 mL NS or LR daily :: IV :: daily :: 1-2 L IV daily; adjust for cardiac status Fluid overload I/O, electrolytes, edema STAT STAT \u2014 STAT Empiric antibiotics (aspiration pneumonia) IV Suspected aspiration pneumonia Ampicillin-sulbactam 3g IV q6h :: IV :: q6h :: 3g IV q6h; alternative: piperacillin-tazobactam 4.5g q6h; cover oral flora and anaerobes Allergies WBC, fever curve, respiratory status STAT STAT \u2014 STAT","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology (ALS specialist/multidisciplinary clinic) for diagnosis confirmation, disease-modifying therapy, and comprehensive management coordination URGENT STAT ROUTINE STAT Pulmonology for respiratory function monitoring, BiPAP initiation, and ventilator management decisions URGENT URGENT ROUTINE STAT Physical therapy for mobility assessment, strengthening (submaximal), range of motion, and assistive device prescription \u2014 STAT ROUTINE STAT Occupational therapy for ADL assessment, adaptive equipment, energy conservation, and home modification \u2014 STAT ROUTINE URGENT Speech-language pathology for swallow evaluation, communication strategies, and AAC device assessment \u2014 URGENT ROUTINE URGENT Respiratory therapy for BiPAP setup and titration, cough assist training, and secretion management \u2014 STAT ROUTINE STAT Nutrition/dietitian for caloric needs assessment, weight optimization, and tube feeding management \u2014 URGENT ROUTINE URGENT Palliative care for symptom management, goals of care discussions, and quality of life optimization \u2014 URGENT ROUTINE URGENT Social work for financial resources (SSDI, Medicaid), caregiver support, and ALS Association resources \u2014 ROUTINE ROUTINE ROUTINE Psychiatry/psychology for depression, anxiety, and adjustment disorder common in ALS \u2014 ROUTINE ROUTINE ROUTINE Gastroenterology for PEG placement when FVC declining toward 50% or significant dysphagia \u2014 URGENT ROUTINE \u2014 Hospice care for end-of-life care when prognosis &lt;6 months and/or patient declines aggressive interventions \u2014 ROUTINE ROUTINE ROUTINE Genetic counseling for familial ALS, gene testing interpretation, and family planning implications \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for increased shortness of breath, choking episodes, or inability to clear secretions (may indicate respiratory failure requiring urgent intervention) STAT \u2014 STAT Return for fever, worsening cough, or change in sputum color (may indicate aspiration pneumonia) STAT \u2014 STAT Do not drive if experiencing significant weakness or fatigue that could impair vehicle control URGENT \u2014 ROUTINE Continue eating foods that are safe to swallow; use thickened liquids if recommended by speech therapy \u2014 ROUTINE ROUTINE Use BiPAP as prescribed, even if initially uncomfortable; adherence improves symptoms and survival \u2014 ROUTINE ROUTINE Perform prescribed exercises but avoid exhaustion; rest before becoming overly fatigued \u2014 ROUTINE ROUTINE Complete advance directives including healthcare proxy, living will, and decisions about mechanical ventilation and feeding tubes URGENT URGENT ROUTINE Contact ALS Association (www.als.org) for educational resources, support groups, and equipment loan programs \u2014 ROUTINE ROUTINE Attend multidisciplinary ALS clinic visits every 2-3 months for comprehensive care coordination \u2014 \u2014 ROUTINE Consider joining ALS research registries and clinical trials (www.clinicaltrials.gov) \u2014 \u2014 ROUTINE","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Aspiration precautions including upright positioning during meals, small bites, and chin-tuck swallowing technique STAT STAT ROUTINE Energy conservation with scheduled rest periods and prioritization of activities to reduce fatigue \u2014 ROUTINE ROUTINE Home safety evaluation to remove fall hazards, install grab bars, and ensure wheelchair accessibility \u2014 ROUTINE ROUTINE Maintain optimal nutrition with high-calorie, high-protein diet; weight loss accelerates decline \u2014 ROUTINE ROUTINE Sleep with head of bed elevated 30 degrees if using BiPAP or experiencing orthopnea \u2014 ROUTINE ROUTINE Smoking cessation is essential to optimize respiratory function and reduce aspiration risk \u2014 ROUTINE ROUTINE Limit alcohol as it may worsen weakness, sedation, and respiratory depression \u2014 \u2014 ROUTINE Frequent repositioning if immobile to prevent pressure ulcers \u2014 STAT ROUTINE Emotional and spiritual support for patient and caregivers; caregiver burnout is common \u2014 ROUTINE ROUTINE Consider assistive technology early (voice banking, eye-tracking devices) before speech becomes unintelligible \u2014 \u2014 ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Cervical spondylotic myelopathy Sensory level, bladder dysfunction, neck pain; UMN signs only MRI cervical spine shows cord compression Multifocal motor neuropathy (MMN) Pure LMN; treatable with IVIg; no UMN signs; asymmetric Anti-GM1 antibodies; NCS shows conduction block Kennedy disease (SBMA) X-linked; gynecomastia; sensory involvement; slower progression Androgen receptor gene CAG repeat expansion Primary lateral sclerosis (PLS) Pure UMN for &gt;4 years; no LMN signs; slower progression EMG normal; clinical course Progressive muscular atrophy (PMA) Pure LMN; no UMN signs; may evolve to ALS EMG; clinical follow-up Myasthenia gravis Fatigable weakness; ptosis, diplopia; reflexes preserved AChR antibodies; RNS decrement; edrophonium test Lambert-Eaton myasthenic syndrome Proximal weakness; autonomic symptoms; improves with exercise Anti-VGCC antibodies; RNS increment Inclusion body myositis (IBM) Finger flexor and quadriceps weakness; older males; inflammatory Muscle biopsy; CPK mildly elevated Post-polio syndrome History of polio; new weakness in previously affected limbs Clinical history; EMG Hirayama disease Young males; asymmetric hand weakness; self-limited Cervical MRI in flexion shows posterior dural detachment Monomelic amyotrophy Unilateral limb LMN findings; non-progressive after years EMG limited to one limb; clinical course Hereditary spastic paraplegia Pure UMN; family history; sensory neuropathy in some types Genetic testing Adrenomyeloneuropathy X-linked; adrenal insufficiency; sensory neuropathy Very long chain fatty acids elevated Hexosaminidase A deficiency Early onset; may have psychiatric symptoms; Jewish ancestry Hexosaminidase A enzyme level Copper deficiency myelopathy Sensory ataxia; prior gastric surgery; anemia Serum copper and ceruloplasmin low","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Forced vital capacity (FVC) sitting and supine Every clinic visit (q2-3 months); more often if declining &gt;50% predicted Initiate BiPAP when &lt;50% or symptoms; discuss PEG when declining toward 50% STAT STAT ROUTINE STAT ALSFRS-R score Every clinic visit Document decline rate Adjust care intensity; prognostic indicator \u2014 ROUTINE ROUTINE \u2014 Weight Every clinic visit Stable; &lt;5% loss/3 months Nutrition consult; consider PEG if &gt;10% loss STAT ROUTINE ROUTINE STAT LFTs (ALT/AST) Monthly x 3 months on riluzole, then q3 months ALT &lt;3x ULN Hold riluzole if ALT &gt;5x ULN; reduce dose if 3-5x ULN \u2014 ROUTINE ROUTINE \u2014 Respiratory symptoms (orthopnea, morning headache, daytime somnolence) Every visit None Initiate or titrate BiPAP STAT ROUTINE ROUTINE STAT SpO2 and EtCO2 (if on BiPAP) Each visit SpO2 &gt;92%; pCO2 &lt;45 Adjust BiPAP settings STAT STAT ROUTINE STAT Swallowing function Every visit Safe swallow SLP evaluation; diet modification; consider PEG \u2014 URGENT ROUTINE \u2014 Peak cough flow Every visit &gt;270 L/min Initiate cough assist if &lt;270 L/min \u2014 ROUTINE ROUTINE \u2014 Mood screening (PHQ-9) Every visit PHQ-9 &lt;5 Antidepressant; psychology referral \u2014 ROUTINE ROUTINE \u2014 Caregiver stress Every visit Manageable Social work; respite care; support groups \u2014 ROUTINE ROUTINE \u2014 Advance directive status At diagnosis and annually Documented Complete/update advance directives URGENT URGENT ROUTINE URGENT BiPAP adherence Every visit &gt;4 hours/night Education; mask refitting; troubleshoot \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission Acute respiratory failure (FVC &lt;15 mL/kg, pCO2 &gt;50, SpO2 &lt;88% on supplemental O2); aspiration pneumonia with respiratory distress; need for invasive ventilation (if patient desires) Step-down/telemetry Respiratory compromise improving on BiPAP; autonomic instability; aspiration pneumonia responding to treatment General floor admission Aspiration pneumonia without respiratory distress; severe dehydration or malnutrition; new bulbar symptoms requiring evaluation; falls with injury Discharge home Stable respiratory status; adequate nutrition (oral or PEG); caregiver support in place; equipment needs met; follow-up arranged Discharge to skilled nursing facility Requires 24-hour care that cannot be provided at home; feeding tube with complex care needs; no available caregivers Discharge to hospice Prognosis &lt;6 months; patient declines aggressive interventions; focus on comfort care; FVC &lt;30% or continuous BiPAP dependence Multidisciplinary ALS clinic follow-up Every 2-3 months; sooner if rapid decline; coordinate all subspecialty care","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Riluzole extends survival by 2-3 months Class I, Level A Bensimon et al. NEJM 1994; Miller et al. Cochrane 2012 El Escorial diagnostic criteria Consensus, Level U Brooks et al. ALS Other Motor Neuron Disord 2000 Awaji-shima criteria enhance diagnostic sensitivity Class III, Level C de Carvalho et al. Clin Neurophysiol 2008 BiPAP improves survival and quality of life Class I, Level A Bourke et al. Lancet Neurol 2006 Early PEG placement (FVC &gt;50%) safer than late Class II, Level B ProGas Study Group. Lancet Neurol 2015 Multidisciplinary clinics improve survival 7-10 months Class II, Level B Van den Berg et al. Lancet Neurol 2005 Dextromethorphan-quinidine for pseudobulbar affect Class I, Level A Brooks et al. Neurology 2004 Edaravone slows functional decline in selected patients Class I, Level B Writing Group. Lancet Neurol 2017 AMX0035 (Relyvrio) slows ALSFRS-R decline Class II, Level B Paganoni et al. NEJM 2020 Tofersen reduces SOD1 in SOD1-ALS Class I, Level B Miller et al. NEJM 2022 Glycopyrrolate effective for sialorrhea Class II, Level B Arbouw et al. J Neurol 2010 Botulinum toxin for refractory sialorrhea Class II, Level B Jackson et al. ALS FTD 2009 C9orf72 most common genetic cause Class II, Level B DeJesus-Hernandez et al. Neuron 2011 ALSFRS-R validated outcome measure Class II, Level B Cedarbaum et al. J Neurol Sci 1999 Early palliative care improves quality of life Class I, Level A Temel et al. NEJM 2010 (oncology; extrapolated) FVC and NIF for respiratory monitoring Class II, Level B Lechtzin et al. ALS Other Motor Neuron Disord 2002 Cough assist improves secretion clearance Class III, Level C Sancho et al. ALS Other Motor Neuron Disord 2004 AAN Practice Parameters for ALS Guideline Miller et al. Neurology 2009","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive outpatient-focused ALS management - Includes El Escorial and Awaji diagnostic criteria - Disease-modifying therapies: riluzole, edaravone, AMX0035, tofersen - Symptomatic management for sialorrhea, spasticity, PBA, pain, dyspnea - Respiratory monitoring with BiPAP and cough assist protocols - Nutritional support with PEG timing guidance - Multidisciplinary clinic model emphasized - Palliative care integration throughout - PubMed-verified citations in Section 8</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#appendix-a-alsfrs-r-als-functional-rating-scale-revised","title":"APPENDIX A: ALSFRS-R (ALS Functional Rating Scale - Revised)","text":"<p>The ALSFRS-R is a 12-item questionnaire assessing function. Each item scored 0-4 (4 = normal). Maximum score = 48.</p> <p>Speech - 4: Normal speech - 3: Detectable speech disturbance - 2: Intelligible with repeating - 1: Combined with non-vocal communication - 0: Loss of useful speech</p> <p>Salivation - 4: Normal - 3: Slight excess, may have nighttime drooling - 2: Moderately excessive; may have minimal drooling - 1: Marked excess with some drooling - 0: Marked drooling; requires tissue or handkerchief</p> <p>Swallowing - 4: Normal eating habits - 3: Early eating problems; occasional choking - 2: Dietary consistency changes - 1: Needs supplemental tube feeding - 0: NPO (exclusively tube fed)</p> <p>Handwriting - 4: Normal - 3: Slow or sloppy; all words legible - 2: Not all words legible - 1: Able to grip pen but unable to write - 0: Unable to grip pen</p> <p>Cutting Food/Handling Utensils - 4: Normal - 3: Somewhat slow and clumsy but no help needed - 2: Can cut most foods but slow; some help needed - 1: Food must be cut by someone else - 0: Needs to be fed</p> <p>Dressing and Hygiene - 4: Normal function - 3: Independent but with reduced efficiency - 2: Intermittent assistance or substitute methods - 1: Needs attendant for self-care - 0: Total dependence</p> <p>Turning in Bed - 4: Normal - 3: Somewhat slow and clumsy but no help needed - 2: Can turn alone with difficulty - 1: Can initiate but not complete turn - 0: Helpless</p> <p>Walking - 4: Normal - 3: Early ambulation difficulties - 2: Walks with assistance - 1: Non-ambulatory functional movement - 0: No purposeful leg movement</p> <p>Climbing Stairs - 4: Normal - 3: Slow - 2: Mild unsteadiness or fatigue - 1: Needs assistance - 0: Cannot do</p> <p>Dyspnea - 4: None - 3: Occurs when walking - 2: Occurs with one or more ADLs - 1: Occurs at rest, difficulty breathing when sitting or lying - 0: Significant difficulty; considering mechanical support</p> <p>Orthopnea - 4: None - 3: Some difficulty; does not routinely use &gt;2 pillows - 2: Needs extra pillows (&gt;2) - 1: Can only sleep sitting up - 0: Unable to sleep</p> <p>Respiratory Insufficiency - 4: None - 3: Intermittent use of BiPAP - 2: Continuous use of BiPAP at night - 1: Continuous use of BiPAP day and night - 0: Invasive ventilation by intubation or tracheostomy</p> <p>Interpretation: - Rate of decline is prognostic; typical decline is 1-2 points/month - Score &lt;20 associated with significantly reduced survival</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#appendix-b-respiratory-monitoring-protocol","title":"APPENDIX B: Respiratory Monitoring Protocol","text":"<p>When to Initiate BiPAP (any ONE of): - FVC &lt;50% predicted - Supine FVC drop &gt;20% from sitting - MIP &lt;-60 cmH2O - SNIP &lt;40 cmH2O - Nocturnal SpO2 &lt;88% for &gt;5 min - pCO2 &gt;45 mmHg - Symptoms: orthopnea, morning headaches, daytime somnolence, frequent awakenings</p> <p>BiPAP Settings: - Start: IPAP 8-10 cmH2O, EPAP 4 cmH2O - Titrate: Increase IPAP by 2 cmH2O as tolerated for comfort - Target: IPAP 12-20 cmH2O, EPAP 4-8 cmH2O - Back-up rate: 12-16/min for safety</p> <p>When to Initiate Cough Assist (any ONE of): - Peak cough flow &lt;270 L/min - FVC &lt;50% predicted - Frequent respiratory infections - Difficulty clearing secretions</p> <p>Cough Assist Settings: - Insufflation: +30 to +40 cmH2O - Exsufflation: -30 to -40 cmH2O - Cycle: 2-4 breaths per cycle, 4-6 cycles per session - Frequency: 2-4 times daily; more frequently during respiratory infections</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#appendix-c-timing-of-interventions","title":"APPENDIX C: Timing of Interventions","text":"Intervention When to Discuss When to Implement Advance directives At diagnosis Before cognitive impairment or crisis BiPAP When FVC &lt;80% When FVC &lt;50% OR symptoms OR supine drop &gt;20% PEG tube When FVC &lt;80% and stable When dysphagia + weight loss &gt;10% OR FVC approaching 50% Cough assist When FVC &lt;80% When PCF &lt;270 L/min OR frequent infections Voice banking At diagnosis Before significant dysarthria AAC device When speech affected When speech unintelligible &gt;50% of time Wheelchair When falls occurring When ambulation unsafe or exhausting Hospital bed When mobility declining When transfers difficult or orthopnea present Hospice When prognosis &lt;12 months When prognosis &lt;6 months or patient preference","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/als/#appendix-d-resources-for-patients-and-families","title":"APPENDIX D: Resources for Patients and Families","text":"<p>ALS Association - Website: www.als.org - Helpline: 1-800-782-4747 - Equipment loan programs, support groups, research updates</p> <p>Muscular Dystrophy Association (MDA) - Website: www.mda.org - Comprehensive ALS clinic network</p> <p>I AM ALS - Website: www.iamals.org - Patient advocacy and community resources</p> <p>Clinical Trials - ClinicalTrials.gov (search \"amyotrophic lateral sclerosis\") - ALS Research Forum: www.alsresearchforum.org</p> <p>Caregiver Support - Family Caregiver Alliance: www.caregiver.org - Local respite care programs</p>","tags":["neuromuscular","motor-neuron-disease","als","outpatient","palliative"]},{"location":"drafts/alzheimers-disease/","title":"Alzheimer's Disease","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#alzheimers-disease","title":"Alzheimer's Disease","text":"<p>DIAGNOSIS: Alzheimer's Disease ICD-10: G30.9 (Alzheimer's disease, unspecified); G30.0 (Early-onset AD); G30.1 (Late-onset AD); F02.80 (Dementia in AD without behavioral disturbance); F02.81 (Dementia in AD with behavioral disturbance) SCOPE: Diagnosis confirmation using NIA-AA criteria, biomarker assessment, pharmacologic treatment with cholinesterase inhibitors and memantine, anti-amyloid disease-modifying therapies, BPSD management, safety planning, and caregiver support. Primarily outpatient-focused with coverage for ED and hospital presentations.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#1a-essentialcore-labs-reversible-causes-screen","title":"1A. Essential/Core Labs (Reversible Causes Screen)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Rule out infection, anemia, malignancy contributing to cognitive impairment Normal STAT STAT ROUTINE - BMP (Na, K, BUN, Cr, glucose) Metabolic causes of confusion (hyponatremia, uremia, hypoglycemia) Normal electrolytes, renal function STAT STAT ROUTINE - TSH Hypothyroidism is reversible cause of cognitive impairment 0.4-4.0 mIU/L URGENT ROUTINE ROUTINE - Vitamin B12 B12 deficiency causes reversible cognitive decline &gt;300 pg/mL (&gt;400 optimal) URGENT ROUTINE ROUTINE - Folate Deficiency contributes to cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - Hepatic panel (AST, ALT, albumin) Hepatic encephalopathy; nutritional status Normal - ROUTINE ROUTINE - Calcium Hypercalcemia causes confusion 8.5-10.5 mg/dL STAT ROUTINE ROUTINE - Urinalysis UTI common cause of acute confusion in elderly Negative for infection STAT STAT ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Hemoglobin A1c Diabetes affects cognition and vascular risk &lt;7.0% - ROUTINE ROUTINE - Lipid panel Vascular risk factor modification LDL &lt;100 mg/dL - ROUTINE ROUTINE - Homocysteine Elevated levels associated with AD and vascular disease &lt;15 \u03bcmol/L - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency associated with cognitive decline &gt;30 ng/mL - ROUTINE ROUTINE - RPR or VDRL Neurosyphilis is treatable cause Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder if risk factors Negative - ROUTINE ROUTINE - ESR, CRP Inflammatory or autoimmune causes Normal - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU APOE genotyping Risk stratification; ARIA risk assessment for anti-amyloid therapy APOE \u03b54 status - - ROUTINE - Genetic panel (PSEN1, PSEN2, APP) Early-onset AD (&lt;65) with family history No pathogenic mutation (AD diagnosis still valid) - - EXT - Heavy metal panel (lead, mercury) History of occupational exposure Normal - - EXT - Copper, ceruloplasmin Wilson disease if age &lt;50 with movement disorder Normal - EXT EXT - Paraneoplastic antibody panel Rapid progression; cancer history Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2) Atypical presentation; rapid progression Negative - EXT EXT -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Hippocampal and medial temporal atrophy; rule out structural causes (tumor, SDH, NPH, stroke) MRI-incompatible devices, severe claustrophobia URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable or contraindicated Rule out mass, hemorrhage, hydrocephalus None STAT STAT ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Amyloid PET (florbetapir, florbetaben, flutemetamol) Diagnostic uncertainty; anti-amyloid therapy eligibility Positive amyloid deposition confirms AD pathology None - - ROUTINE - FDG-PET Brain Differentiate AD from FTD; atypical presentations AD: bilateral temporoparietal hypometabolism None - - ROUTINE - Tau PET (flortaucipir) Staging AD; donanemab eligibility Elevated tau correlates with disease stage None - - EXT - MRI Brain volumetrics Baseline for anti-amyloid monitoring; track progression Quantify hippocampal and whole brain atrophy MRI contraindications - - ROUTINE - MRI with SWI/GRE sequences Pre-treatment for anti-amyloid (microbleed assessment) Count microbleeds (&lt;4 eligible for therapy) MRI contraindications - ROUTINE ROUTINE - EEG Seizures, encephalopathy, or rapid decline Diffuse slowing typical in AD; rule out CJD None URGENT ROUTINE ROUTINE - Sleep study (polysomnography) Sleep apnea contributing to cognition; RBD evaluation Assess AHI; REM without atonia suggests DLB None - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU DaTscan (ioflupane I-123) Differentiate DLB/PDD from AD Reduced uptake: DLB; Normal: AD Iodine hypersensitivity - - EXT - SPECT (perfusion) Alternative to PET if unavailable Regional hypoperfusion patterns None - - EXT - Whole body PET-CT Paraneoplastic workup if suspected Rule out occult malignancy None - EXT EXT -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Diagnostic confirmation with CSF biomarkers; clinical trial eligibility; atypical presentation; rapid progression; young-onset (&lt;65) Timing: ROUTINE for biomarker confirmation; URGENT if autoimmune or infectious etiology suspected Volume Required: 10-15 mL standard; additional for research biomarkers</p> Study Rationale Target Finding ED HOSP OPD ICU Cell count, protein, glucose Rule out infection, inflammation WBC &lt;5, protein &lt;45 mg/dL, glucose &gt;60% serum URGENT ROUTINE ROUTINE - CSF A\u03b242 (amyloid beta 1-42) Reduced in AD due to brain amyloid deposition &lt;600 pg/mL suggests AD pathology - ROUTINE ROUTINE - CSF A\u03b242/A\u03b240 ratio More accurate than A\u03b242 alone &lt;0.05-0.08 suggests AD (assay-dependent) - ROUTINE ROUTINE - CSF total tau (t-tau) Elevated in neurodegeneration &gt;400 pg/mL suggests neuronal injury - ROUTINE ROUTINE - CSF phosphorylated tau (p-tau181 or p-tau217) Specific for AD pathology; best discriminator Elevated p-tau181 &gt;60 pg/mL or p-tau217 &gt;20 pg/mL - ROUTINE ROUTINE - CSF NfL (neurofilament light) Non-specific marker of neuronal damage Elevated suggests active neurodegeneration - ROUTINE ROUTINE - 14-3-3 protein Rapid progression; suspected CJD Negative (positive suggests CJD) - ROUTINE ROUTINE - RT-QuIC Prion disease confirmation if suspected Negative - ROUTINE EXT - Autoimmune encephalitis panel Atypical presentation; subacute onset Negative - EXT EXT - <p>Special Handling: CSF biomarkers require polypropylene tubes; freeze within 1 hour; send to qualified reference lab Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); posterior fossa mass; skin infection at puncture site</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Treat reversible causes Various Identified metabolic or infectious etiology Per specific cause :: Various :: :: Correct hyponatremia slowly, treat UTI, replace B12, treat hypothyroidism Depends on intervention Cognitive reassessment after treatment STAT STAT ROUTINE - Thiamine IV/PO Suspected Wernicke's; alcoholism; malnutrition 500 mg IV TID x 3 days; 100 mg PO daily :: IV/PO :: :: 500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily maintenance None Clinical improvement in confusion STAT STAT ROUTINE - Vitamin B12 IM/PO B12 deficiency (&lt;300 pg/mL) 1000 mcg IM daily x 7d; 1000 mcg IM weekly x 4wk; 1000 mcg IM monthly :: IM/PO :: :: 1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily None B12 level at 2 months; cognitive improvement over months - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3b-cholinesterase-inhibitors-cognitive-enhancement","title":"3B. Cholinesterase Inhibitors (Cognitive Enhancement)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil (Aricept) PO Mild, moderate, or severe AD (first-line) 5 mg qHS; 10 mg qHS; 23 mg daily :: PO :: :: Start 5 mg qHS x 4-6 weeks; if tolerated, increase to 10 mg qHS; 23 mg available for moderate-severe AD after stable on 10 mg Sick sinus syndrome; second/third degree heart block without pacemaker; active GI bleeding; severe COPD Heart rate; GI symptoms (nausea, diarrhea); vivid dreams; muscle cramps - ROUTINE ROUTINE - Rivastigmine oral (Exelon) PO Mild-moderate AD; may be better for attention/executive symptoms 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID :: PO :: :: Start 1.5 mg BID with meals; increase by 1.5 mg BID every 2 weeks; target 6 mg BID Same as donepezil; severe hepatic impairment GI symptoms (most common); weight loss; bradycardia - ROUTINE ROUTINE - Rivastigmine patch (Exelon Patch) TD Mild-moderate AD; better GI tolerability than oral 4.6 mg/24hr; 9.5 mg/24hr; 13.3 mg/24hr :: TD :: :: Start 4.6 mg/24hr patch; increase every 4 weeks; target 9.5-13.3 mg/24hr; apply to clean, hairless skin Same as oral Skin irritation (rotate sites); GI symptoms less than oral - ROUTINE ROUTINE - Galantamine (Razadyne) PO Mild-moderate AD; dual mechanism (AChE inhibitor + nicotinic modulator) 4 mg BID; 8 mg BID; 12 mg BID :: PO :: :: Start 4 mg BID with meals x 4 weeks; increase to 8 mg BID x 4 weeks; target 8-12 mg BID Same as donepezil; severe renal impairment (CrCl &lt;9); severe hepatic impairment GI symptoms; bradycardia; weight loss - ROUTINE ROUTINE - Galantamine ER (Razadyne ER) PO Once-daily alternative for adherence 8 mg daily; 16 mg daily; 24 mg daily :: PO :: :: Start 8 mg daily with breakfast x 4 weeks; increase by 8 mg every 4 weeks; target 16-24 mg daily Same as immediate release Same as immediate release - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3c-nmda-receptor-antagonist","title":"3C. NMDA Receptor Antagonist","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Memantine (Namenda) PO Moderate-severe AD; add to cholinesterase inhibitor 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily x 1 week; increase by 5 mg/week: 5 mg BID, then 5 mg/10 mg, then 10 mg BID Severe renal impairment (reduce dose if CrCl 5-29: max 5 mg BID) Confusion, dizziness, constipation, headache - ROUTINE ROUTINE - Memantine XR (Namenda XR) PO Once-daily option for adherence 7 mg daily; 14 mg daily; 21 mg daily; 28 mg daily :: PO :: :: Start 7 mg daily; increase by 7 mg/week; target 28 mg daily Same as immediate release Same as immediate release - ROUTINE ROUTINE - Memantine/Donepezil (Namzaric) PO Combination for moderate-severe AD already on both 28/10 mg daily :: PO :: :: One capsule (28 mg memantine XR + 10 mg donepezil) once daily at bedtime; must be stable on both drugs first Same as individual drugs Same as individual drugs - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3d-disease-modifying-therapies-anti-amyloid","title":"3D. Disease-Modifying Therapies (Anti-Amyloid)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Lecanemab (Leqembi) IV Early AD (MCI or mild dementia) with confirmed amyloid pathology 10 mg/kg IV q2wk :: IV :: :: 10 mg/kg IV every 2 weeks; infuse over approximately 1 hour Amyloid PET positive OR CSF biomarkers confirming amyloid; MRI within 1 year (assess microbleeds); APOE genotyping strongly recommended; informed consent for ARIA risk &gt;4 cerebral microbleeds; superficial siderosis; recent macrohemorrhage; concurrent anticoagulation (relative); APOE \u03b54/\u03b54 (higher ARIA risk - not absolute CI) MRI: baseline, weeks 7, 14, 52, 78 (ARIA monitoring); clinical assessment for ARIA symptoms (headache, confusion, visual changes) - - ROUTINE - Donanemab (Kisunla) IV Early AD (MCI or mild dementia) with confirmed amyloid AND intermediate/high tau pathology 700 mg IV q4wk x 3; then 1400 mg IV q4wk :: IV :: :: 700 mg IV every 4 weeks x 3 doses, then 1400 mg IV every 4 weeks until amyloid clearance (by PET); discontinue when PET negative Amyloid PET positive; Tau PET showing intermediate or high tau levels; MRI baseline; APOE genotyping (higher ARIA in \u03b54/\u03b54) Same as lecanemab; higher ARIA risk in APOE \u03b54 homozygotes MRI: baseline, weeks 12, 24, 52, 76 (ARIA monitoring); repeat amyloid PET to assess clearance - - EXT - Aducanumab (Aduhelm) IV Early AD with confirmed amyloid (limited adoption) 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg IV q4wk :: IV :: :: Titration: 1 mg/kg q4wk x 2, then 3 mg/kg x 2, then 6 mg/kg x 2, then 10 mg/kg maintenance; slow titration over 6 months Same as lecanemab Same as lecanemab MRI for ARIA at baseline and during titration - - EXT - <p>ARIA Monitoring Protocol: - ARIA-E (edema): Sulcal effusion and/or cortical edema on FLAIR MRI; usually asymptomatic but may cause headache, confusion, visual disturbance - ARIA-H (hemorrhage): Microbleeds and/or superficial siderosis on GRE/SWI - Management: Hold infusion for symptomatic ARIA or significant imaging findings; resume per protocol after resolution (typically 4-12 weeks) - APOE \u03b54 risk: Homozygotes have ~35% ARIA risk with lecanemab vs ~10% for non-carriers; requires shared decision-making</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#3e-behavioral-and-psychological-symptoms-of-dementia-bpsd","title":"3E. Behavioral and Psychological Symptoms of Dementia (BPSD)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Citalopram PO Depression; mild-moderate agitation 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk QT prolongation; concurrent QT-prolonging drugs; severe hepatic impairment ECG at baseline if cardiac risk; QTc monitoring if &gt;20 mg - ROUTINE ROUTINE - Sertraline (Zoloft) PO Depression; anxiety 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; increase by 25 mg every 1-2 weeks; typical dose 50-100 mg daily MAOIs; uncontrolled seizures (lowers threshold slightly) GI symptoms initially; bleeding risk with anticoagulants - ROUTINE ROUTINE - Mirtazapine (Remeron) PO Depression with poor appetite, insomnia, and weight loss 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30-45 mg qHS; lower doses more sedating MAOIs; angle-closure glaucoma Weight gain (often desired); sedation; hyperlipidemia - ROUTINE ROUTINE - Trazodone PO Insomnia; sundowning; mild agitation 25 mg qHS; 50 mg qHS; 100 mg qHS; 150 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25-50 mg every 3-5 days; typical 50-150 mg qHS for sleep Concurrent MAOIs; significant QT prolongation Orthostatic hypotension (fall risk); priapism (rare); QTc - ROUTINE ROUTINE - Melatonin PO Sleep disturbance; circadian rhythm dysfunction 3 mg qHS; 6 mg qHS; 9 mg qHS :: PO :: :: Start 3 mg qHS, 30 min before bed; may increase to 6-9 mg if needed None significant Daytime drowsiness; minimal side effects - ROUTINE ROUTINE - Brexpiprazole (Rexulti) PO Agitation in AD (FDA approved 2023) 0.5 mg daily; 1 mg daily; 2 mg daily :: PO :: :: Start 0.5 mg daily x 1 week; increase to 1 mg daily x 1 week; target 2-3 mg daily Black box: increased mortality in dementia (but FDA approved for this use) Weight, metabolic parameters, EPS, falls - ROUTINE ROUTINE - Quetiapine (Seroquel) PO Severe agitation/psychosis when non-pharmacologic fails 12.5 mg qHS; 25 mg qHS; 25 mg BID; 50 mg BID :: PO :: :: Start 12.5-25 mg qHS; titrate slowly (25 mg increments); keep dose as low as possible Black box: increased mortality in dementia; Parkinson's (less risk than other antipsychotics) Metabolic effects; sedation; falls; QTc - EXT ROUTINE - Risperidone (Risperdal) PO Severe aggression/psychosis (short-term only) 0.25 mg BID; 0.5 mg BID; 1 mg BID :: PO :: :: Start 0.25 mg BID; increase by 0.25 mg BID weekly; max 1 mg BID; limit to 6-12 weeks Black box: increased mortality and CVA in dementia EPS, metabolic effects, stroke risk, prolactin - EXT ROUTINE - Haloperidol IM/IV/PO Acute severe agitation in delirium-crisis only (not chronic use) 0.5 mg IM; 1 mg IM; 2 mg IM :: IM/IV/PO :: :: 0.5-2 mg IM/IV q4-6h PRN; short-term acute use only; avoid chronic use QT prolongation; Parkinson's disease; DLB (avoid) QTc; EPS; akathisia STAT EXT - - <p>Non-Pharmacologic Approaches (First-Line for BPSD): - Identify and treat underlying causes (pain, infection, constipation) - Environmental modifications (reduce noise, adequate lighting) - Music therapy, art therapy, pet therapy - Structured activities and consistent routines - Caregiver education on redirection and validation techniques</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Cognitive neurology for diagnosis confirmation, biomarker interpretation, and treatment planning - ROUTINE ROUTINE - Neuropsychology for formal cognitive testing (MoCA insufficient) to establish baseline and track progression - - ROUTINE - Geriatric psychiatry for BPSD management and capacity evaluation when decision-making ability questioned - ROUTINE ROUTINE - Occupational therapy for ADL assessment, cognitive strategies, and home safety evaluation - ROUTINE ROUTINE - Speech therapy for communication strategies and swallowing evaluation if dysphagia develops - ROUTINE ROUTINE - Social work for caregiver support resources, community services, and long-term care planning - ROUTINE ROUTINE - Palliative care for advanced AD symptom management and goals of care discussions - ROUTINE ROUTINE - Elder law attorney for advance directives, healthcare proxy, and financial planning while capacity exists - - ROUTINE - Genetics counseling for early-onset AD (&lt;65) families or those considering predictive testing - - ROUTINE - Driving rehabilitation specialist for formal on-road driving evaluation when ability is questioned - - ROUTINE - Infusion center coordination for anti-amyloid therapy administration and ARIA monitoring - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if sudden worsening of confusion which may indicate stroke, infection, or medication toxicity STAT STAT ROUTINE If on anti-amyloid therapy (lecanemab, donanemab): return immediately for new headache, visual changes, confusion, or unsteadiness (possible ARIA) - - ROUTINE Complete advance directives (living will, healthcare proxy, POLST) while patient has capacity to document preferences for future care - ROUTINE ROUTINE Designate financial power of attorney and consider trust arrangements early while patient can participate - ROUTINE ROUTINE Do not drive until cleared by physician or formal driving evaluation; report diagnosis to DMV per state requirements - ROUTINE ROUTINE Use pill organizers, alarms, or caregiver supervision to ensure medication adherence - ROUTINE ROUTINE Wear medical alert bracelet with diagnosis and emergency contact in case of wandering - ROUTINE ROUTINE Keep environment safe: remove throw rugs, install grab bars, secure stove knobs, lock away dangerous items - ROUTINE ROUTINE Maintain consistent daily routines which help with orientation and reduce anxiety - ROUTINE ROUTINE","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular aerobic exercise (150 min/week moderate intensity) may slow cognitive decline and improve mood - ROUTINE ROUTINE Mediterranean or MIND diet emphasizing vegetables, berries, fish, whole grains, nuts, and olive oil - ROUTINE ROUTINE Cognitive stimulation through reading, puzzles, music, social activities to support cognitive reserve - ROUTINE ROUTINE Adequate sleep (7-8 hours); treat sleep apnea aggressively as it worsens cognition - ROUTINE ROUTINE Social engagement and meaningful activities to reduce isolation and support emotional well-being - ROUTINE ROUTINE Cardiovascular risk factor control: BP &lt;130/80, A1c &lt;7%, LDL &lt;100 to reduce vascular contribution - ROUTINE ROUTINE Hearing aids for hearing loss which is a modifiable dementia risk factor (Lancet Commission) - - ROUTINE Limit alcohol to \u22641 drink daily; excess alcohol accelerates cognitive decline - ROUTINE ROUTINE Smoking cessation to reduce vascular damage and improve overall brain health - ROUTINE ROUTINE Caregiver respite services to prevent burnout; Alzheimer's Association support groups - ROUTINE ROUTINE","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Mild Cognitive Impairment (MCI) Cognitive decline without functional impairment; may progress to AD Serial cognitive testing; preserved ADLs Vascular dementia Stepwise decline; focal neurologic findings; executive dysfunction prominent; vascular risk factors MRI shows significant WM disease, strategic infarcts Dementia with Lewy bodies (DLB) Visual hallucinations; parkinsonism; REM sleep behavior disorder; fluctuating cognition DaTscan reduced; clinical criteria Frontotemporal dementia (behavioral variant) Personality/behavior changes; disinhibition; apathy; hyperorality; often &lt;65 years FDG-PET frontal hypometabolism; genetics Primary progressive aphasia Language dysfunction predominates (word-finding, comprehension, grammar) Neuropsych pattern; FDG-PET language regions Parkinson's disease dementia Parkinsonism precedes dementia by &gt;1 year; different from DLB timing Clinical history; DaTscan Normal pressure hydrocephalus (NPH) Triad: gait disturbance, urinary incontinence, dementia; gait earliest MRI ventriculomegaly; large-volume LP with gait improvement Depression (pseudodementia) Prominent mood symptoms; often aware of deficits; improves with treatment GDS, PHQ-9; antidepressant trial Creutzfeldt-Jakob disease (CJD) Rapid progression (weeks-months); myoclonus; ataxia; pyramidal signs EEG (periodic sharp waves); MRI DWI ribboning; CSF RT-QuIC Autoimmune encephalitis Subacute onset; psychiatric features; seizures; often younger Autoantibody panel; MRI limbic changes Medication-induced cognitive impairment Anticholinergics, benzodiazepines, opioids Medication reconciliation; improvement with discontinuation","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Cognitive testing (MoCA or MMSE) Every 6-12 months Establish baseline; track trajectory Adjust staging; modify treatment; increase support - ROUTINE ROUTINE - Functional status (ADL/IADL, FAQ) Every 6-12 months Document for staging and care planning Increase caregiver support; consider placement - ROUTINE ROUTINE - Neuropsychiatric Inventory (NPI) Each visit Monitor BPSD Non-pharmacologic interventions; consider medications - ROUTINE ROUTINE - Weight Each visit Stable; monitor for malnutrition Nutritional consult; assess swallowing - ROUTINE ROUTINE - MRI Brain (ARIA monitoring) Per protocol if on anti-amyloid No ARIA-E or ARIA-H Hold infusion; follow protocol for resumption - - ROUTINE - Caregiver burden (Zarit Burden Interview) Every 6-12 months Early identification of burnout Support resources; respite care; social work - - ROUTINE - Driving status Each visit Safe for patient and community Formal driving evaluation; report to DMV if unsafe - - ROUTINE - ECG (if on donepezil or citalopram) Baseline; with dose changes Normal QTc (&lt;470 ms men, &lt;480 ms women) Reduce dose or switch medication - ROUTINE ROUTINE - Amyloid PET (if on donanemab) Annually until clearance Amyloid negative Discontinue donanemab when cleared - - EXT - Fall risk assessment Each visit Minimize fall risk PT referral; home safety; assistive devices - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable cognition; safe environment; adequate caregiver support; outpatient follow-up arranged; reversible causes treated Admit to floor Acute delirium requiring workup; behavioral crisis unsafe for home; aspiration pneumonia; falls with injury Admit to psychiatry Severe behavioral disturbance requiring specialized psychiatric management; danger to self or others Long-term care/Memory care Progressive decline; caregiver unable to manage safely; wandering; 24-hour supervision needed Hospice End-stage AD; limited responsiveness; recurrent aspiration; weight loss; goals focused on comfort Outpatient follow-up Neurology every 3-6 months early disease; every 6-12 months stable; more frequent if on anti-amyloid therapy","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source NIA-AA diagnostic criteria for AD Class I, Level A Jack et al. Alzheimers Dement 2018 CSF biomarkers (A\u03b242, t-tau, p-tau) accurate for AD Class I, Level A Hansson et al. Lancet Neurol 2018 Donepezil efficacy in mild-moderate AD Class I, Level A Birks &amp; Harvey. Cochrane 2018 Rivastigmine efficacy in AD Class I, Level A Birks et al. Cochrane 2015 Galantamine efficacy in AD Class I, Level A Loy &amp; Schneider. Cochrane 2006 Memantine efficacy in moderate-severe AD Class I, Level A Reisberg et al. NEJM 2003 Combination therapy (ChEI + memantine) Class I, Level A Tariot et al. JAMA 2004 Lecanemab slows cognitive decline in early AD Class I, Level A van Dyck et al. NEJM 2023 (Clarity AD) Donanemab slows cognitive decline Class I, Level A Sims et al. JAMA 2023 (TRAILBLAZER-ALZ 2) Brexpiprazole for agitation in AD Class I, Level A Grossberg et al. NEJM 2024 Antipsychotic mortality risk in dementia Class I, Level A Schneider et al. JAMA 2005 Mediterranean diet reduces dementia risk Class II, Level B Scarmeas et al. Ann Neurol 2006 Physical exercise may slow cognitive decline Class II, Level B Livingston et al. Lancet 2020 APOE genotyping for ARIA risk stratification Class II, Level B Sperling et al. JAMA Neurol 2024 Citalopram for agitation in AD (CitAD) Class II, Level B Porsteinsson et al. JAMA 2014 Hearing aid use reduces dementia risk Class II, Level B Lin et al. JAMA Intern Med 2023 Driving assessment in dementia Class III, Level C Iverson et al. Neurology 2010","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - NIA-AA diagnostic criteria framework - Comprehensive biomarker workup (CSF, PET) - Complete cholinesterase inhibitor coverage (donepezil, rivastigmine, galantamine) - Memantine for moderate-severe AD - Anti-amyloid DMTs (lecanemab, donanemab, aducanumab) with ARIA monitoring - Brexpiprazole (FDA-approved 2023 for AD agitation) - BPSD management with non-pharmacologic and pharmacologic approaches - Structured dosing format for order sentence generation - Driving assessment and safety planning - Caregiver support recommendations</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#appendix-a-nia-aa-diagnostic-framework-2018","title":"APPENDIX A: NIA-AA Diagnostic Framework (2018)","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#atn-classification-system","title":"ATN Classification System","text":"<p>The NIA-AA research framework uses biomarkers to define AD biologically:</p> Biomarker Category Method A (Amyloid) CSF A\u03b242 low, A\u03b242/A\u03b240 ratio low, OR amyloid PET positive CSF assay or PET T (Tau) CSF p-tau elevated OR tau PET positive CSF assay or PET N (Neurodegeneration) CSF t-tau elevated, FDG-PET hypometabolism, OR MRI atrophy CSF, PET, or MRI","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#clinical-staging","title":"Clinical Staging","text":"Stage Biomarkers Cognition Function Preclinical AD A+ (with or without T+, N+) Normal Normal MCI due to AD A+ T+ (N variable) Impaired (1-1.5 SD below mean) Preserved Mild AD dementia A+ T+ N+ Impaired Mild functional decline Moderate AD dementia A+ T+ N+ Moderate impairment Needs assistance with ADLs Severe AD dementia A+ T+ N+ Severe impairment Dependent for basic ADLs","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#appendix-b-anti-amyloid-therapy-eligibility-checklist","title":"APPENDIX B: Anti-Amyloid Therapy Eligibility Checklist","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#lecanemab-leqembi-eligibility","title":"Lecanemab (Leqembi) Eligibility","text":"<p>Inclusion Criteria: - [ ] MCI or mild AD dementia (MMSE typically 22-30) - [ ] Amyloid-positive (PET or CSF biomarkers) - [ ] Age typically 50-90 (clinical trial range) - [ ] Stable cardiac, renal, hepatic function - [ ] Able to complete MRI monitoring schedule</p> <p>Exclusion Criteria: - [ ] &gt;4 microbleeds on MRI - [ ] Superficial siderosis - [ ] Macrohemorrhage history - [ ] Concurrent anticoagulation (relative; discuss risk) - [ ] Uncontrolled hypertension - [ ] Moderate-severe AD dementia</p> <p>Pre-Treatment Workup: - [ ] Amyloid PET OR CSF biomarkers confirming A+ - [ ] MRI Brain with SWI/GRE (microbleed count) - [ ] APOE genotyping (risk stratification, not required) - [ ] CBC, BMP, LFTs - [ ] Detailed informed consent (ARIA risk discussion)</p>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#aria-monitoring-schedule-lecanemab","title":"ARIA Monitoring Schedule (Lecanemab)","text":"Timepoint MRI Required Notes Baseline Yes Document microbleeds, WM changes Week 7 Yes Early ARIA detection Week 14 Yes Before dose continuation Week 52 Yes Annual monitoring Week 78 Yes Continued monitoring As needed Yes If symptoms suggestive of ARIA","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#appendix-c-aria-management-algorithm","title":"APPENDIX C: ARIA Management Algorithm","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#aria-e-edema","title":"ARIA-E (Edema)","text":"<pre><code>ARIA-E Detected on MRI\n           \u2502\n           \u25bc\n    Symptomatic?\n    \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n   YES             NO\n    \u2502               \u2502\n    \u25bc               \u25bc\nHOLD infusion    HOLD infusion\nReassess weekly  Repeat MRI in 4 weeks\n    \u2502               \u2502\n    \u25bc               \u25bc\nIf resolved AND   If resolved \u2192\nasymptomatic \u2192    Resume therapy\nResume therapy\n</code></pre>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#aria-h-hemorrhage-new-microbleeds","title":"ARIA-H (Hemorrhage - New Microbleeds)","text":"New Microbleeds Action 1-4 new Consider continuing with close monitoring 5-9 new Hold; repeat MRI in 4 weeks &gt;9 new or macrohemorrhage Discontinue permanently","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#appendix-d-driving-assessment-in-alzheimers-disease","title":"APPENDIX D: Driving Assessment in Alzheimer's Disease","text":"","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#red-flags-requiring-immediate-driving-cessation","title":"Red Flags Requiring Immediate Driving Cessation","text":"<ul> <li>Getting lost in familiar areas</li> <li>Involvement in at-fault accidents</li> <li>Traffic violations</li> <li>Impaired visuospatial skills (clock drawing failure)</li> <li>CDR \u22651 (mild dementia)</li> </ul>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#assessment-tools","title":"Assessment Tools","text":"Tool Description CDR (Clinical Dementia Rating) CDR \u22651 suggests high-risk driver Trail Making Test B &gt;180 seconds suggests impaired executive function Clock Drawing Test Errors suggest visuospatial impairment MMSE/MoCA Not sufficient alone for driving decisions On-road driving evaluation Gold standard; refer to OT driving specialist","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/alzheimers-disease/#documentation-requirements","title":"Documentation Requirements","text":"<ul> <li>Document driving discussion at each visit</li> <li>Note patient and family concerns</li> <li>Record any incidents or near-misses</li> <li>Follow state reporting requirements (varies by jurisdiction)</li> <li>Provide written recommendation if cessation advised</li> </ul>","tags":["cognitive","dementia","alzheimer","outpatient","neurodegenerative"]},{"location":"drafts/autoimmune-encephalitis/","title":"Autoimmune Encephalitis","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#autoimmune-encephalitis","title":"Autoimmune Encephalitis","text":"<p>VERSION: 1.0 CREATED: January 24, 2026 REVISED: January 24, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Autoimmune Encephalitis</p> <p>ICD-10: G04.81 (Other encephalitis and encephalomyelitis, autoimmune), G04.90 (Encephalitis and encephalomyelitis, unspecified), G13.1 (Other systemic atrophy primarily affecting CNS in neoplastic disease)</p> <p>SCOPE: Evaluation and management of autoimmune encephalitis in adults, including antibody-mediated (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPA, etc.) and paraneoplastic encephalitis. Covers diagnostic workup, tumor screening, first-line and second-line immunotherapy, and long-term management. Excludes infectious encephalitis, Hashimoto's encephalopathy (SREAT), and pediatric-specific presentations.</p> <p>CLINICAL SYNONYMS: Limbic encephalitis, anti-NMDA receptor encephalitis, paraneoplastic encephalitis, antibody-mediated encephalitis, voltage-gated potassium channel complex encephalitis (VGKC)</p> <p>KEY CLINICAL FEATURES: - Subacute onset: Days to weeks (usually &lt;3 months) - Psychiatric symptoms: Psychosis, paranoia, personality change, agitation, catatonia - Cognitive dysfunction: Memory impairment (especially short-term), confusion - Seizures: New-onset seizures (often refractory) - Movement disorders: Orofacial dyskinesia, choreoathetosis, dystonia, catatonia - Autonomic instability: Hyperthermia, blood pressure fluctuations, tachycardia, hypoventilation - Decreased level of consciousness: May progress to coma</p> <p>MAJOR ANTIBODY SYNDROMES:</p> Antibody Clinical Features Tumor Association Demographics Anti-NMDAR Psychiatric, seizures, movement disorder, autonomic instability, coma Ovarian teratoma (50% in women) Young women &gt; men Anti-LGI1 Faciobrachial dystonic seizures, hyponatremia, memory loss Thymoma (&lt;10%) Older adults (&gt;50) Anti-CASPR2 Neuromyotonia, limbic encephalitis, Morvan syndrome Thymoma (20%) Older men Anti-GABA-B Limbic encephalitis, prominent seizures SCLC (50%) Older adults Anti-AMPA Limbic encephalitis, psychiatric symptoms SCLC, thymoma, breast (65%) Older adults Anti-GAD65 Stiff person, cerebellar, limbic encephalitis Rare F &gt; M Anti-Hu (ANNA-1) Limbic encephalitis, sensory neuropathy, cerebellar SCLC (majority) Older adults Anti-Ma2/Ta Limbic/brainstem encephalitis, sleep disorder Testicular, SCLC, breast Young men (testicular) <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u26a1 TREATABLE CAUSE OF ENCEPHALITIS</p> <p>Autoimmune encephalitis is treatable but time-sensitive. Earlier immunotherapy leads to better outcomes. Do not wait for antibody results to start treatment if clinical suspicion is high.</p> <p>\u26a0\ufe0f TUMOR SEARCH CRITICAL</p> <p>Many autoimmune encephalitides are paraneoplastic. Tumor identification and treatment are essential for neurological recovery.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection screen, baseline Normal STAT STAT \u2014 STAT CMP (BMP + LFTs) Electrolytes (hyponatremia in LGI1), renal/hepatic function Na+ &lt;135 suggests LGI1; otherwise normal STAT STAT \u2014 STAT TSH Hashimoto's encephalopathy differential Normal URGENT ROUTINE \u2014 URGENT Blood glucose Metabolic encephalopathy screen Normal STAT STAT \u2014 STAT ESR, CRP Inflammatory markers Usually normal or mildly elevated URGENT ROUTINE \u2014 URGENT PT/INR, PTT Pre-LP INR &lt;1.5 STAT STAT \u2014 STAT HIV antibody/antigen Immunocompromise screen Negative \u2014 ROUTINE \u2014 ROUTINE RPR/VDRL Neurosyphilis differential Negative \u2014 ROUTINE \u2014 ROUTINE Urinalysis, urine drug screen Alternative diagnoses Negative STAT ROUTINE \u2014 STAT Ammonia Metabolic encephalopathy Normal URGENT ROUTINE \u2014 URGENT B12, folate Metabolic causes of encephalopathy Normal \u2014 ROUTINE \u2014 ROUTINE","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Autoimmune encephalitis panel (serum) Antibody identification Identify specific antibody (NMDAR, LGI1, CASPR2, GABA-B, AMPA, GAD65, others) \u2014 STAT \u2014 STAT Paraneoplastic panel (serum) Tumor-associated antibodies Identify Hu, Yo, Ri, Ma2/Ta, CV2, amphiphysin \u2014 STAT \u2014 STAT TPO antibodies Hashimoto's encephalopathy Document if elevated \u2014 ROUTINE \u2014 ROUTINE Anti-thyroglobulin antibodies Hashimoto's encephalopathy Document if elevated \u2014 ROUTINE \u2014 ROUTINE ANA, dsDNA Autoimmune disease screen Usually negative \u2014 ROUTINE \u2014 ROUTINE ANCA Vasculitis screen Negative \u2014 ROUTINE \u2014 ROUTINE Tumor markers (CEA, AFP, CA-125, CA 19-9, beta-hCG, PSA) Occult malignancy Normal \u2014 ROUTINE \u2014 ROUTINE Serum protein electrophoresis Paraproteinemia Normal \u2014 ROUTINE \u2014 ROUTINE Quantitative immunoglobulins Pre-IVIg, immunodeficiency IgA &gt;7 mg/dL \u2014 URGENT \u2014 URGENT Hepatitis B surface antigen Pre-rituximab screening Negative \u2014 ROUTINE \u2014 ROUTINE","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Cell-based assay for neuronal antibodies More sensitive than commercial panels Antibody confirmation \u2014 EXT \u2014 EXT VGCC antibodies (P/Q and N-type) LEMS, cerebellar degeneration Negative unless paraneoplastic \u2014 EXT \u2014 EXT SOX1 antibody SCLC-associated Document \u2014 EXT \u2014 EXT DPPX antibody GI symptoms + encephalopathy Document \u2014 EXT \u2014 EXT Neurexin-3 antibody Encephalitis, seizures Document \u2014 EXT \u2014 EXT IgLON5 antibody Sleep disorder, brainstem dysfunction Document \u2014 EXT \u2014 EXT Mitochondrial DNA testing Mitochondrial encephalopathy Normal \u2014 EXT \u2014 EXT","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain with and without contrast STAT Medial temporal T2/FLAIR hyperintensity (limbic); may be normal in 50% Hemodynamic instability, pacemaker STAT STAT \u2014 STAT EEG (routine or continuous) STAT if seizures or AMS Extreme delta brush (NMDAR), temporal slowing, seizures None STAT STAT \u2014 STAT CT chest/abdomen/pelvis with contrast Tumor search Occult malignancy (lung, ovary, testes, thymus) Contrast allergy, renal impairment \u2014 URGENT \u2014 URGENT <p>MRI Findings: - Limbic encephalitis: Medial temporal lobe T2/FLAIR hyperintensity (uni- or bilateral) - Anti-NMDAR: Often normal; may show subtle cortical/subcortical changes - May be normal in up to 50%: Does NOT rule out autoimmune encephalitis</p> <p>EEG Findings: - Extreme delta brush: Highly specific for anti-NMDAR encephalitis (seen in ~30%) - Temporal slowing: Common in limbic encephalitis - Subclinical seizures: Frequent; continuous EEG recommended</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Pelvic ultrasound (women) If anti-NMDAR positive Ovarian teratoma None \u2014 URGENT \u2014 URGENT MRI pelvis with contrast If US equivocal Ovarian teratoma Pacemaker \u2014 URGENT \u2014 URGENT Testicular ultrasound (men &lt;50) If anti-Ma2 or clinical concern Testicular tumor None \u2014 URGENT \u2014 URGENT CT or PET-CT chest Thymoma, lung cancer Tumor identification Contrast allergy \u2014 URGENT \u2014 URGENT Whole body PET-CT Occult malignancy search Any FDG-avid tumor Hemodynamic instability \u2014 URGENT \u2014 URGENT Mammogram Breast cancer screening Normal None \u2014 ROUTINE \u2014 ROUTINE Continuous EEG (cEEG) Refractory cases, coma Nonconvulsive seizures None \u2014 STAT \u2014 STAT","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Brain biopsy Diagnostic uncertainty, refractory Inflammatory infiltrate Coagulopathy \u2014 EXT \u2014 EXT FDG-PET brain Clarify extent of involvement Temporal hypermetabolism Hemodynamic instability \u2014 EXT \u2014 EXT Repeat whole body imaging If initial negative, strong suspicion Occult tumor \u2014 \u2014 EXT \u2014 EXT","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: ALL suspected autoimmune encephalitis</p> <p>Timing: URGENT after CT (or proceed directly if no contraindications)</p> <p>Volume Required: 15-20 mL (need adequate volume for antibody testing)</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Usually normal 10-20 cmH2O URGENT STAT \u2014 STAT Cell count with differential Lymphocytic pleocytosis WBC 10-100 (lymphocyte predominant); may be normal URGENT STAT \u2014 STAT Protein Often mildly elevated 45-100 mg/dL; may be normal URGENT STAT \u2014 STAT Glucose Usually normal Normal URGENT STAT \u2014 STAT Autoimmune encephalitis panel (CSF) Critical for diagnosis Identify neuronal antibodies; CSF more sensitive than serum for some (NMDAR) STAT STAT \u2014 STAT Oligoclonal bands Intrathecal synthesis May be positive \u2014 ROUTINE \u2014 ROUTINE IgG index Intrathecal synthesis May be elevated \u2014 ROUTINE \u2014 ROUTINE HSV PCR Exclude HSV encephalitis Negative (but post-HSV autoimmune is possible) STAT STAT \u2014 STAT VZV PCR Exclude VZV encephalitis Negative STAT STAT \u2014 STAT Bacterial culture, Gram stain Exclude bacterial infection Negative STAT STAT \u2014 STAT Cytology Carcinomatous meningitis Negative \u2014 ROUTINE \u2014 ROUTINE BioFire ME Panel Exclude infectious causes Negative STAT STAT \u2014 STAT <p>CSF Findings in Autoimmune Encephalitis:</p> Parameter Typical Finding Opening pressure Normal WBC Normal to mild pleocytosis (10-100, lymphocytes) Protein Normal to mildly elevated Glucose Normal Oligoclonal bands May be positive Neuronal antibodies Positive (CSF more sensitive for NMDAR) <p>CRITICAL: CSF may be completely normal in autoimmune encephalitis. A normal CSF does NOT rule out the diagnosis.</p> <p>Special Handling: Send adequate volume (15-20 mL). CSF autoimmune panel sent to reference lab; results may take 1-2 weeks.</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: Start immunotherapy empirically if clinical suspicion high. Do NOT wait for antibody results (may take 1-2 weeks).</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#when-to-start-empiric-immunotherapy","title":"When to Start Empiric Immunotherapy","text":"<p>Start empiric treatment when ALL of the following are met: 1. Clinical presentation meets criteria for \"possible autoimmune encephalitis\" (subacute onset, encephalopathy, plus seizures/CSF pleocytosis/MRI findings) 2. Infectious etiologies reasonably excluded (negative CSF bacterial culture/Gram stain, HSV PCR sent or negative) 3. Alternative diagnoses (toxic, metabolic, structural) reasonably excluded</p> <p>Escalate urgency for empiric treatment if: - Severe presentation (ICU admission, status epilepticus, coma) - Rapidly progressive course - Classical syndrome (e.g., young woman with psychiatric symptoms + movement disorder \u2192 anti-NMDAR)</p> <p>Reference: Canadian Consensus Guidelines; Cellucci et al. 2020</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3a-first-line-immunotherapy","title":"3A. First-Line Immunotherapy","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone IV First-line immunotherapy 1000 mg daily x 5 days :: IV :: daily x 5 days :: 1000 mg IV daily x 3-5 days; infuse over 1 hour Active untreated infection, uncontrolled diabetes (relative) Glucose, BP, psychiatric symptoms, GI bleeding \u2014 STAT \u2014 STAT IVIg (immune globulin IV) IV First-line immunotherapy 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: 0.4 g/kg/day IV for 5 days (total 2 g/kg); start slow day 1 IgA deficiency with anti-IgA antibodies; severe renal impairment Renal function, headache, infusion reactions \u2014 STAT \u2014 STAT Plasmapheresis (PLEX) \u2014 First-line immunotherapy 5-7 exchanges over 10-14 days :: \u2014 :: QOD :: 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange Hemodynamic instability, severe sepsis BP, electrolytes, coagulation, fibrinogen \u2014 STAT \u2014 STAT <p>First-Line Strategy: - High-dose steroids + IVIg: Most common initial approach - PLEX: Alternative or in combination with steroids - Combination: Steroids + IVIg OR Steroids + PLEX often used together - Response time: May take 2-4 weeks; if no improvement, proceed to second-line</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3b-second-line-immunotherapy-if-first-line-fails","title":"3B. Second-Line Immunotherapy (If First-Line Fails)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Rituximab IV First-line failure, anti-NMDAR 375 mg/m\u00b2 weekly x 4 weeks; 1000 mg x 2 doses :: IV :: weekly x 4 or 1000 mg q2wk x 2 :: 375 mg/m\u00b2 IV weekly x 4 OR 1000 mg IV x 2 doses (2 weeks apart); pre-medicate Active infection, HBV (screen), live vaccines Infusion reactions, B-cell counts, immunoglobulins \u2014 URGENT \u2014 URGENT Cyclophosphamide IV First-line failure, paraneoplastic 750 mg/m\u00b2 monthly x 6 :: IV :: monthly :: 750 mg/m\u00b2 IV monthly x 6 cycles; with mesna for bladder protection Cytopenias, active infection, pregnancy CBC weekly, renal function, hemorrhagic cystitis \u2014 URGENT \u2014 URGENT <p>Second-Line Timing: - Standard: Consider at 2-4 weeks if no response to first-line - Critically ill (ICU, coma, refractory status epilepticus): Consider second-line agents at 1-2 weeks if no improvement, or sooner if rapidly deteriorating - Early escalation considerations: Disease severity, initial treatment response, and relapse risk - Practical note: Given delayed onset of rituximab effect (weeks), continue first-line therapies until clinical improvement observed - Earlier in severe/refractory cases (persistent coma, ICU-level care) - Rituximab preferred for anti-NMDAR encephalitis - Cyclophosphamide often preferred for paraneoplastic encephalitis</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3c-tumor-treatment","title":"3C. Tumor Treatment","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Tumor resection (ovarian teratoma) Surgical Anti-NMDAR with teratoma N/A :: \u2014 :: :: Surgical removal of ovarian teratoma is CRITICAL for recovery; early surgery improves outcomes Unstable patient Post-op neuro status \u2014 URGENT \u2014 URGENT Thymectomy Surgical Thymoma-associated encephalitis N/A :: \u2014 :: :: Surgical resection of thymoma Unstable patient Post-op neuro status \u2014 ROUTINE \u2014 ROUTINE Oncology treatment Various Tumor-associated encephalitis Per oncology :: \u2014 :: :: Treat underlying malignancy per oncology recommendations \u2014 Per oncology \u2014 ROUTINE \u2014 ROUTINE <p>CRITICAL: Tumor removal is essential for neurological recovery in paraneoplastic cases. Early surgery (especially teratoma removal) significantly improves outcomes.</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3d-seizure-management","title":"3D. Seizure Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Levetiracetam IV/PO Seizures, seizure prophylaxis 1000 mg BID; 1500 mg BID; 2000 mg BID :: IV/PO :: BID :: Load 1000-2000 mg IV, then 1000-1500 mg BID; may need higher doses Severe renal impairment (adjust) Seizure frequency, behavior STAT STAT \u2014 STAT Lacosamide IV/PO Adjunctive seizure control 200 mg BID; 300 mg BID :: IV/PO :: BID :: Load 200-400 mg IV, then 200-300 mg BID PR prolongation, severe cardiac disease ECG, PR interval \u2014 STAT \u2014 STAT Valproate IV/PO Seizures 20 mg/kg load; 500 mg BID; 750 mg BID :: IV/PO :: load then BID :: Load 20-30 mg/kg IV, then 500-750 mg BID; target level 50-100 Liver disease, mitochondrial disease, pregnancy LFTs, ammonia, levels STAT STAT \u2014 STAT Lorazepam IV Acute seizure termination 2 mg; 4 mg :: IV :: PRN :: 0.1 mg/kg IV (max 4 mg); may repeat x1 Respiratory depression RR, O2 sat STAT STAT \u2014 STAT Midazolam infusion IV Refractory status epilepticus 0.1-0.4 mg/kg/hr :: IV :: continuous :: 0.2 mg/kg bolus, then 0.1-0.4 mg/kg/hr infusion; for refractory seizures \u2014 EEG, sedation, respiratory \u2014 \u2014 \u2014 STAT","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3e-symptomaticsupportive-care","title":"3E. Symptomatic/Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Haloperidol IV/IM Agitation, psychosis 2-5 mg q4-6h PRN :: IV/IM :: q4-6h PRN :: 2-5 mg IV/IM q4-6h PRN for severe agitation; avoid in movement disorders QT prolongation, movement disorders, Parkinson QTc, EPS STAT STAT \u2014 STAT Quetiapine PO Agitation, psychosis (milder) 25 mg BID; 50 mg BID; 100 mg BID :: PO :: BID :: Start 25 mg BID; titrate as needed; lower EPS risk QT prolongation QTc, sedation \u2014 ROUTINE \u2014 ROUTINE Lorazepam IV/PO Catatonia, agitation 1 mg q6h; 2 mg q6h :: IV/PO :: q6h :: 1-2 mg IV/PO q6h; often effective for catatonia Respiratory depression RR, sedation STAT STAT \u2014 STAT Propranolol PO Autonomic instability (tachycardia) 10 mg TID; 20 mg TID :: PO :: TID :: 10-20 mg PO TID for tachycardia Bradycardia, hypotension, asthma HR, BP \u2014 ROUTINE \u2014 ROUTINE Clonidine PO/transdermal Autonomic instability 0.1 mg BID; 0.1 mg patch weekly :: PO/TD :: BID :: 0.1 mg PO BID or 0.1 mg/24h patch; for hypertension/tachycardia Hypotension BP, HR \u2014 ROUTINE \u2014 ROUTINE Enoxaparin SC DVT prophylaxis 40 mg daily :: SC :: daily :: 40 mg SC daily Active bleeding, coagulopathy Platelet count \u2014 STAT \u2014 STAT Famotidine IV/PO Stress ulcer prophylaxis 20 mg BID :: IV/PO :: BID :: 20 mg BID if on steroids or intubated None GI bleeding \u2014 ROUTINE \u2014 ROUTINE Insulin IV/SC Steroid-induced hyperglycemia Per sliding scale :: IV/SC :: per protocol :: Target glucose &lt;180 mg/dL Hypoglycemia Glucose q4-6h \u2014 ROUTINE \u2014 STAT","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#3f-long-termmaintenance-immunotherapy","title":"3F. Long-Term/Maintenance Immunotherapy","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Mycophenolate mofetil PO Maintenance immunosuppression 500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: BID :: Start 500 mg BID; increase to 1000-1500 mg BID over 2-4 weeks Pregnancy, cytopenias CBC q2wk x 2 mo, then monthly \u2014 ROUTINE ROUTINE \u2014 Azathioprine PO Maintenance immunosuppression 50 mg daily; 100 mg daily; 150 mg daily :: PO :: daily :: Start 50 mg daily; increase by 50 mg q2-4wk to 2-3 mg/kg/day; check TPMT first TPMT deficiency, pregnancy CBC weekly x 4, then monthly; LFTs \u2014 ROUTINE ROUTINE \u2014 Prednisone (oral taper) PO Steroid taper 60 mg daily; 40 mg daily; 20 mg daily; 10 mg daily :: PO :: daily :: Taper over weeks to months; individualize based on response \u2014 Glucose, BP, bone density \u2014 ROUTINE ROUTINE \u2014 Rituximab (maintenance) IV Relapse prevention (NMDAR) 500-1000 mg q6mo :: IV :: q6 months :: 500-1000 mg IV q6 months for 2 years or longer; recheck antibodies Active infection B-cell counts, immunoglobulins \u2014 \u2014 ROUTINE \u2014","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consult for diagnosis confirmation, immunotherapy guidance, and antibody interpretation STAT STAT \u2014 STAT Neuro-immunology consult for complex cases, second-line therapy decisions, and long-term management \u2014 URGENT ROUTINE URGENT Oncology consult for tumor workup and treatment if paraneoplastic syndrome identified \u2014 URGENT \u2014 URGENT Gynecologic oncology for ovarian teratoma removal which is critical for anti-NMDAR encephalitis recovery \u2014 URGENT \u2014 URGENT Critical care consult for ICU admission given autonomic instability, coma, or need for sedation/ventilation STAT STAT \u2014 STAT Psychiatry consult for severe psychiatric symptoms, catatonia, or behavioral management in acute phase \u2014 URGENT \u2014 URGENT Epilepsy consult for refractory seizures and continuous EEG monitoring guidance \u2014 URGENT \u2014 URGENT Physical therapy for mobility assessment and fall prevention given fluctuating weakness and dyskinesias \u2014 ROUTINE ROUTINE ROUTINE Occupational therapy for ADL assessment and cognitive rehabilitation to maximize functional recovery \u2014 ROUTINE ROUTINE ROUTINE Speech therapy for swallow evaluation and communication strategies given dysarthria and aphasia \u2014 URGENT ROUTINE URGENT Neuropsychology for formal cognitive assessment to document deficits and guide rehabilitation \u2014 \u2014 ROUTINE \u2014 Social work for discharge planning and family support given prolonged recovery and potential disability \u2014 ROUTINE ROUTINE ROUTINE","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening confusion, seizures, or new symptoms develop (may indicate relapse requiring treatment escalation) STAT \u2014 STAT Continue immunotherapy as prescribed even when feeling better; stopping early increases relapse risk \u2014 STAT STAT Report fever or signs of infection promptly as immunosuppression increases infection risk \u2014 STAT STAT Follow seizure precautions including no driving, swimming alone, or heights due to unpredictable seizure risk \u2014 STAT STAT Attend all follow-up appointments as relapses can occur months to years after initial presentation \u2014 ROUTINE ROUTINE Expect that recovery may take months to years; improvement often continues for 2+ years \u2014 ROUTINE ROUTINE Participate in cognitive rehabilitation as this is essential for optimizing recovery from memory and executive deficits \u2014 ROUTINE ROUTINE Contact Autoimmune Encephalitis Alliance (www.aealliance.org) for patient support and educational resources \u2014 ROUTINE ROUTINE","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Use fall precautions including walker and supervision due to movement disorders and cognitive impairment STAT STAT STAT Aspiration precautions including thickened liquids and upright positioning if swallow impaired STAT STAT \u2014 DVT prophylaxis with SCDs and/or anticoagulation given prolonged immobility risk \u2014 STAT \u2014 Avoid live vaccines while on immunosuppression; inactivated vaccines are safe and recommended \u2014 ROUTINE ROUTINE Practice infection prevention including hand hygiene and avoiding sick contacts while on immunosuppression \u2014 STAT STAT Continue regular cancer screening for paraneoplastic cases as tumor recurrence can trigger relapse \u2014 \u2014 ROUTINE Use cognitive pacing with scheduled rest periods to manage post-encephalitis fatigue \u2014 ROUTINE ROUTINE Do not drive until cleared by neurology due to seizure risk and cognitive impairment \u2014 STAT STAT <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate HSV encephalitis Acute, temporal lobe predominant, hemorrhagic MRI temporal, HSV PCR Other viral encephalitis Fever, CSF pleocytosis, specific epidemiology Viral PCRs Bacterial meningitis Acute, toxic, PMN predominant CSF CSF Gram stain, culture Tuberculous meningitis Subacute, basilar, low glucose CSF AFB, PCR, ADA Neurosyphilis Risk factors, varied presentations RPR, CSF VDRL, FTA-ABS Primary CNS lymphoma Immunocompromised, periventricular MRI pattern, CSF cytology Glioblastoma Focal deficits, ring-enhancing mass MRI, biopsy Creutzfeldt-Jakob disease Rapid dementia, myoclonus, DWI restriction MRI pattern, 14-3-3, RT-QuIC Hashimoto's encephalopathy (SREAT) Elevated TPO, responds to steroids TPO antibodies, exclusion Psychiatric illness (primary) No CSF/MRI changes, prior history Normal workup, psychiatric evaluation Toxic/metabolic encephalopathy Drug/toxin exposure, metabolic derangement Toxicology, metabolic panel ADEM Post-infectious, multifocal white matter MRI pattern (multifocal), monophasic CNS vasculitis Multifocal strokes, systemic symptoms Angiography, vessel wall MRI Wernicke encephalopathy Alcoholism, classic triad, mammillary bodies Thiamine trial, MRI Seizure-related (postictal) Seizure witnessed, resolves with time EEG, observation","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurological exam (GCS, MMSE) q4-8h initially Improving Re-evaluate treatment, escalate STAT STAT ROUTINE STAT Seizure activity Continuous if cEEG; q4h assessment No seizures Escalate antiepileptic therapy STAT STAT \u2014 STAT Vital signs (autonomic function) q1-4h Stable HR, BP, temp Supportive care, ICU if unstable STAT STAT \u2014 STAT Blood glucose q6h if on steroids &lt;180 mg/dL Insulin adjustment \u2014 ROUTINE \u2014 STAT Renal function q24-48h during IVIg Cr stable Hydration, adjust IVIg rate \u2014 ROUTINE \u2014 ROUTINE Serum sodium q12-24h (especially LGI1) 135-145 mEq/L Fluid restriction if hyponatremic STAT STAT \u2014 STAT Antibody titers (serum/CSF) q3-6 months Decreasing Consider treatment escalation \u2014 \u2014 ROUTINE \u2014 Tumor surveillance Per oncology No recurrence Oncology management \u2014 \u2014 ROUTINE \u2014 B-cell counts (if on rituximab) Before each infusion Adequate depletion Adjust dosing interval \u2014 \u2014 ROUTINE \u2014 CBC (if on immunosuppression) q1-4 weeks Normal counts Hold medication, infection workup \u2014 ROUTINE ROUTINE ROUTINE","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission GCS &lt;12; refractory seizures; autonomic instability; need for intubation; coma; severe psychiatric symptoms requiring restraint Step-down/telemetry GCS 12-14; controlled seizures; stable autonomic function; receiving immunotherapy General floor GCS 15; stable; no seizures; able to participate in therapies; can complete immunotherapy Acute rehabilitation Significant cognitive or motor deficits; requires intensive therapy; medically stable Discharge home Significant improvement; safe swallow; adequate support; outpatient immunotherapy arranged; neurology follow-up scheduled Long-term care Severe persistent deficits; unable to live independently","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source First-line immunotherapy (steroids, IVIg, PLEX) Class II, Level B Titulaer et al. Lancet Neurol 2013 Early immunotherapy improves outcomes Class II, Level B Titulaer et al. Lancet Neurol 2013 Second-line therapy (rituximab, cyclophosphamide) Class III, Level C Dalmau et al. Lancet Neurol 2019 Tumor removal essential for recovery Class II, Level B Titulaer et al. Lancet Neurol 2013 CSF more sensitive than serum for NMDAR Class II, Level B Gresa-Arribas et al. Lancet Neurol 2014 Extreme delta brush in anti-NMDAR Class III, Level C Schmitt et al. Neurology 2012 LGI1 associated with hyponatremia and FBDS Class II, Level B Irani et al. Brain 2010 Diagnostic criteria for autoimmune encephalitis Consensus Guidelines Graus et al. Lancet Neurol 2016 Long-term outcomes and relapse risk Class II, Level B Titulaer et al. Lancet Neurol 2013","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 24, 2026) - Initial template creation - Comprehensive antibody syndrome table - First and second-line immunotherapy protocols - Tumor screening guidance - Seizure and autonomic management - Long-term maintenance therapy</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#appendix-a-graus-2016-diagnostic-criteria-for-autoimmune-encephalitis","title":"APPENDIX A: Graus 2016 Diagnostic Criteria for Autoimmune Encephalitis","text":"<p>Possible Autoimmune Encephalitis (all 3 required): 1. Subacute onset (&lt;3 months) of working memory deficits, altered mental status, or psychiatric symptoms 2. At least ONE of:    - New focal CNS findings    - Seizures not explained by prior seizure disorder    - CSF pleocytosis (&gt;5 WBC/\u03bcL)    - MRI features suggestive of encephalitis 3. Reasonable exclusion of alternative causes</p> <p>Definite Autoimmune Encephalitis: - Possible autoimmune encephalitis PLUS - Positive neuronal antibody (serum or CSF)</p> <p>Probable Anti-NMDAR Encephalitis (all 3 required): 1. Rapid onset (&lt;3 months) of at least 4 of:    - Abnormal behavior or cognitive dysfunction    - Speech dysfunction    - Seizures    - Movement disorder, dyskinesias, or rigidity    - Decreased level of consciousness    - Autonomic dysfunction or central hypoventilation 2. At least ONE of:    - Abnormal EEG    - CSF pleocytosis or oligoclonal bands 3. Reasonable exclusion of alternative causes</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#appendix-b-tumor-screening-by-antibody","title":"APPENDIX B: Tumor Screening by Antibody","text":"Antibody Primary Tumor Screening Anti-NMDAR Ovarian teratoma (women) Pelvic US \u2192 MRI pelvis if negative; repeat q6mo x 2 years Anti-LGI1 Thymoma (rare) CT chest Anti-CASPR2 Thymoma (~20%) CT chest Anti-GABA-B SCLC (~50%) CT chest; PET-CT if negative Anti-AMPA SCLC, thymoma, breast CT chest/abdomen; mammogram; PET-CT Anti-Hu (ANNA-1) SCLC (~80%) CT chest; PET-CT if negative Anti-Yo Ovarian, breast Pelvic US, mammogram, CT Anti-Ma2/Ta Testicular (young men), SCLC Testicular US, CT chest Anti-CV2/CRMP5 SCLC, thymoma CT chest Anti-amphiphysin Breast, SCLC Mammogram, CT chest <p>If initial screening negative but paraneoplastic suspected: - Repeat imaging in 3-6 months - Consider whole-body PET-CT - Continue surveillance for at least 5 years</p>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#appendix-c-treatment-algorithm","title":"APPENDIX C: Treatment Algorithm","text":"<pre><code>SUSPECTED AUTOIMMUNE ENCEPHALITIS\n              \u2502\n              \u25bc\n\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n\u2502 1. Exclude infections (HSV, \u2502\n\u2502    bacterial, etc.)         \u2502\n\u2502 2. Send antibody panels     \u2502\n\u2502    (serum AND CSF)          \u2502\n\u2502 3. MRI brain, EEG           \u2502\n\u2502 4. CT body for tumor        \u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n              \u2502\n              \u25bc\n    High clinical suspicion?\n         /          \\\n       YES           NO\n        \u2502             \u2502\n        \u25bc             \u25bc\n\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510  Wait for\n\u2502 START        \u2502  antibody\n\u2502 FIRST-LINE:  \u2502  results\n\u2502 \u2022 IV steroids\u2502\n\u2502 \u2022 IVIg       \u2502\n\u2502 \u2022 \u00b1 PLEX     \u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n        \u2502\n        \u25bc\n   Response at 2-4 weeks?\n         /          \\\n       YES           NO\n        \u2502             \u2502\n        \u25bc             \u25bc\n\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510 \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n\u2502 Continue     \u2502 \u2502 SECOND-LINE: \u2502\n\u2502 maintenance  \u2502 \u2502 \u2022 Rituximab  \u2502\n\u2502 therapy      \u2502 \u2502 \u2022 \u00b1 Cyclophos\u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518 \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n        \u2502             \u2502\n        \u25bc             \u25bc\n   TUMOR FOUND?   TUMOR FOUND?\n        \u2502             \u2502\n       YES           YES\n        \u2502             \u2502\n        \u25bc             \u25bc\n   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n   \u2502  TUMOR TREATMENT    \u2502\n   \u2502  (Surgery, chemo,   \u2502\n   \u2502   radiation)        \u2502\n   \u2502  ESSENTIAL FOR      \u2502\n   \u2502  NEUROLOGICAL       \u2502\n   \u2502  RECOVERY           \u2502\n   \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n</code></pre>","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/autoimmune-encephalitis/#appendix-d-prognosis-by-antibody-type","title":"APPENDIX D: Prognosis by Antibody Type","text":"Antibody Outcome Relapse Rate Notes Anti-NMDAR Good with treatment (80% significant recovery) 12-25% Better if teratoma removed; relapses respond to treatment Anti-LGI1 Good (70-80% respond) 20-35% Cognitive deficits may persist; hyponatremia improves Anti-CASPR2 Moderate to good Variable May have associated neuromyotonia Anti-GABA-B Moderate (depends on tumor) Low if tumor controlled Prognosis linked to tumor Anti-AMPA Moderate to poor High (&gt;50%) Often paraneoplastic; tumor treatment important Anti-Hu Poor Low (progressive) Usually paraneoplastic; neurological deficits often irreversible Anti-Yo Poor Low (progressive) Cerebellar degeneration usually irreversible Anti-Ma2 Moderate Variable Better if testicular tumor found and treated","tags":["autoimmune","encephalitis","emergency","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/","title":"Bacterial Meningitis","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#bacterial-meningitis","title":"Bacterial Meningitis","text":"<p>VERSION: 1.1 CREATED: January 24, 2026 REVISED: January 24, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Bacterial Meningitis</p> <p>ICD-10: G00.9 (Bacterial meningitis, unspecified), G00.0 (Hemophilus meningitis), G00.1 (Pneumococcal meningitis), G00.2 (Streptococcal meningitis), G00.3 (Staphylococcal meningitis), G00.8 (Other bacterial meningitis), G01 (Meningitis in bacterial diseases classified elsewhere), G03.9 (Meningitis, unspecified)</p> <p>SCOPE: Evaluation and empiric treatment of acute community-acquired bacterial meningitis in adults. Covers empiric antibiotic selection by age/risk, dexamethasone adjunctive therapy, lumbar puncture interpretation, and ICU management. Excludes neonatal meningitis, healthcare-associated/post-neurosurgical meningitis, tuberculous meningitis, and fungal meningitis.</p> <p>CLINICAL SYNONYMS: Acute bacterial meningitis, pyogenic meningitis, purulent meningitis, community-acquired meningitis</p> <p>KEY CLINICAL FEATURES: - Classic triad: Fever, headache, neck stiffness (present in &lt;50% of cases) - Additional features: Altered mental status (most sensitive sign), photophobia, nausea/vomiting - Physical exam: Kernig sign, Brudzinski sign (low sensitivity), petechial/purpuric rash (meningococcal) - Red flags: Rapid deterioration, seizures, focal deficits, papilledema</p> <p>COMMON PATHOGENS BY AGE:</p> Age/Risk Most Common Organisms 16-50 years Streptococcus pneumoniae, Neisseria meningitidis &gt;50 years S. pneumoniae, N. meningitidis, Listeria monocytogenes, aerobic GNR Immunocompromised Listeria, GNR, S. pneumoniae, fungi Alcoholism S. pneumoniae, Listeria Post-neurosurgery Staphylococci, GNR, P. aeruginosa CSF shunt S. epidermidis, S. aureus, GNR <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u26a1 TIME-CRITICAL EMERGENCY</p> <p>Do NOT delay antibiotics for LP or imaging. Give empiric antibiotics within 1 hour of presentation. Every hour of delay increases mortality by 12.6%.</p> <p>\u26a0\ufe0f DEXAMETHASONE TIMING</p> <p>Give dexamethasone BEFORE or WITH the first dose of antibiotics. No benefit if given &gt;4 hours after antibiotics.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Blood cultures (2 sets) Identify organism (positive in 50-80%) Organism identification STAT STAT \u2014 STAT CBC with differential Leukocytosis, left shift; baseline Elevated WBC; bandemia STAT STAT \u2014 STAT CMP (BMP + LFTs) Renal/hepatic function for antibiotic dosing Normal or evidence of sepsis STAT STAT \u2014 STAT Lactate Sepsis severity marker &lt;2 mmol/L (elevated indicates sepsis) STAT STAT \u2014 STAT Procalcitonin Bacterial vs viral differentiation Elevated (&gt;0.5 ng/mL suggests bacterial) STAT STAT \u2014 STAT PT/INR, PTT Pre-LP coagulation status INR &lt;1.5, PTT normal STAT STAT \u2014 STAT Platelet count Pre-LP, DIC screening &gt;50,000/\u03bcL for safe LP STAT STAT \u2014 STAT Blood glucose Compare with CSF glucose Document for CSF ratio STAT STAT \u2014 STAT Urinalysis Infection source if UTI Document STAT ROUTINE \u2014 STAT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU CRP Inflammatory marker, follow response Elevated; trend with treatment URGENT ROUTINE \u2014 URGENT D-dimer, fibrinogen DIC screening (meningococcal) Normal (elevated = DIC) URGENT ROUTINE \u2014 STAT Type and screen Anticipate transfusion if DIC Available URGENT ROUTINE \u2014 STAT Cortisol (random) Adrenal insufficiency (Waterhouse-Friderichsen) Normal stress response URGENT ROUTINE \u2014 URGENT HIV antibody/antigen Immunocompromise screen Document status \u2014 ROUTINE \u2014 ROUTINE BNP/troponin Cardiac involvement, septic cardiomyopathy Normal or elevated URGENT ROUTINE \u2014 STAT ABG or VBG Respiratory status, acid-base Normal or compensated STAT STAT \u2014 STAT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Serum cryptococcal antigen If immunocompromised Negative \u2014 ROUTINE \u2014 ROUTINE Histoplasma/Blastomyces antigen Endemic area, immunocompromised Negative \u2014 EXT \u2014 EXT Quantiferon/T-SPOT TB risk factors Negative \u2014 ROUTINE \u2014 ROUTINE Complement levels (C3, C4, CH50) Recurrent Neisseria infection Normal \u2014 EXT \u2014 EXT Immunoglobulin levels Recurrent infections Normal \u2014 EXT \u2014 EXT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT head without contrast BEFORE LP if criteria met (see below) Exclude mass, herniation, hydrocephalus None in emergency STAT STAT \u2014 STAT Chest X-ray On admission Pneumonia (source), aspiration None STAT STAT \u2014 STAT <p>CT Before LP Criteria (any ONE = get CT first):</p> <ul> <li>Immunocompromised state</li> <li>History of CNS disease (mass, stroke, infection)</li> <li>New onset seizure (within 1 week)</li> <li>Papilledema</li> <li>Altered level of consciousness</li> <li>Focal neurological deficit</li> </ul> <p>If NO criteria \u2192 proceed directly to LP (do not delay for CT)</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain with contrast If complications suspected Abscess, ventriculitis, infarct, subdural empyema Hemodynamic instability \u2014 URGENT \u2014 URGENT CT venogram If venous sinus thrombosis suspected Sinus thrombosis Contrast allergy \u2014 URGENT \u2014 URGENT EEG If seizures or altered mental status Seizure activity, encephalopathy None \u2014 URGENT \u2014 URGENT Echocardiogram If endocarditis suspected Vegetation None \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT/MRI spine If spinal epidural abscess suspected Epidural collection Hemodynamic instability \u2014 URGENT \u2014 URGENT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: ALL suspected bacterial meningitis (unless contraindicated)</p> <p>Timing: STAT - Do NOT delay antibiotics for LP. If LP will be delayed (CT, coagulopathy), give empiric antibiotics first.</p> <p>Volume Required: 10-15 mL minimum (for all studies)</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Elevated in bacterial meningitis 10-20 cmH2O normal; often &gt;30 in bacterial STAT STAT \u2014 STAT Cell count with differential (tubes 1 and 4) Pleocytosis pattern WBC &gt;1000/\u03bcL typical; PMN predominant (&gt;80%) STAT STAT \u2014 STAT Protein Elevated in bacterial infection &gt;100 mg/dL (often &gt;200-500) STAT STAT \u2014 STAT Glucose with serum glucose Low in bacterial meningitis &lt;40 mg/dL or CSF:serum ratio &lt;0.4 STAT STAT \u2014 STAT Gram stain Rapid organism identification Positive in 60-90% untreated STAT STAT \u2014 STAT Bacterial culture Definitive organism identification Positive in 70-85% untreated STAT STAT \u2014 STAT BioFire FilmArray Meningitis/Encephalitis Panel Rapid multiplex PCR (14 pathogens) Organism identification within 1 hour STAT STAT \u2014 STAT Latex agglutination (if available) Rapid antigen detection Organism-specific antigens URGENT URGENT \u2014 URGENT HSV PCR Exclude HSV encephalitis Negative STAT STAT \u2014 STAT Procalcitonin (CSF) Bacterial vs aseptic Elevated in bacterial \u2014 ROUTINE \u2014 ROUTINE <p>CSF Findings Comparison:</p> Parameter Bacterial Viral TB/Fungal Opening pressure Elevated (&gt;30 cmH2O) Normal/mild \u2191 Elevated WBC count &gt;1000 (often &gt;1000-10,000) 10-500 100-500 Cell type PMN predominant (&gt;80%) Lymphocyte predominant Lymphocyte predominant Protein &gt;100 mg/dL (often &gt;200) 50-100 mg/dL &gt;100 mg/dL Glucose &lt;40 mg/dL or &lt;0.4 ratio Normal Low Gram stain Positive 60-90% Negative Usually negative <p>Special Handling: Gram stain and culture STAT. BioFire Panel STAT. Cell count within 1 hour.</p> <p>Contraindications: Signs of herniation, papilledema with mass effect, severe coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site. Get CT first if any criteria above.</p> <p>NOTE: A negative Gram stain does NOT rule out bacterial meningitis. Continue empiric antibiotics until cultures finalize.</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: Antibiotics within 1 hour. Dexamethasone before or with first antibiotic dose. Do NOT wait for LP or CT if they will delay treatment.</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3a-empiric-antibiotic-therapy","title":"3A. Empiric Antibiotic Therapy","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ceftriaxone IV Empiric coverage (all ages) 2 g q12h :: IV :: q12h :: 2 g IV q12h; meningeal dosing required Severe cephalosporin allergy Renal function STAT STAT \u2014 STAT Vancomycin IV DRSP coverage (all patients) 15-20 mg/kg q8-12h; 25-30 mg/kg load :: IV :: q8-12h :: Load 25-30 mg/kg IV, then 15-20 mg/kg q8-12h (target trough 15-20 mcg/mL); adjust for renal function Renal impairment (adjust dose) Trough levels, renal function, ototoxicity STAT STAT \u2014 STAT Ampicillin IV Listeria coverage (age \u226550-60, immunocompromised, alcoholism) 2 g q4h :: IV :: q4h :: 2 g IV q4h; required for Listeria coverage in at-risk patients; NOTE: guidelines vary (\u226550 vs &gt;60) - use lower threshold if any additional risk factors Penicillin allergy (use TMP-SMX) Renal function STAT STAT \u2014 STAT Dexamethasone IV Adjunctive therapy (BEFORE/WITH antibiotics) 0.15 mg/kg q6h x 4 days :: IV :: q6h x 4 days :: 0.15 mg/kg IV (typically 10 mg) q6h x 4 days; give 15-20 min BEFORE or WITH first antibiotic dose; see immunocompromised guidance below GI bleed (relative), see immunocompromised guidance Glucose, GI bleeding STAT STAT \u2014 STAT <p>Age-Based Empiric Regimen:</p> Age/Risk Empiric Regimen 16-50 years (healthy) Ceftriaxone + Vancomycin \u226550 years (some guidelines use &gt;60) Ceftriaxone + Vancomycin + Ampicillin Immunocompromised Ceftriaxone + Vancomycin + Ampicillin Alcoholism Ceftriaxone + Vancomycin + Ampicillin Severe penicillin allergy Meropenem + Vancomycin (or chloramphenicol + TMP-SMX) <p>Note: Age threshold for Listeria coverage varies between guidelines (\u226550 vs &gt;60). Use lower threshold (\u226550) when additional risk factors present (diabetes, malnutrition, chronic disease).</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3b-organism-directed-therapy-after-culturesensitivity","title":"3B. Organism-Directed Therapy (After Culture/Sensitivity)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Penicillin G IV Penicillin-sensitive pneumococcus, meningococcus 4 million units q4h :: IV :: q4h :: 4 million units IV q4h; can de-escalate if susceptible Penicillin allergy Renal function \u2014 STAT \u2014 STAT Ceftriaxone (continued) IV Pneumococcus (intermediate), meningococcus, H. flu 2 g q12h :: IV :: q12h :: Continue 2 g IV q12h if organism susceptible Cephalosporin allergy Renal function \u2014 STAT \u2014 STAT Ampicillin (continued) IV Listeria monocytogenes 2 g q4h :: IV :: q4h :: 2 g IV q4h x 21 days for Listeria Penicillin allergy Renal function \u2014 STAT \u2014 STAT TMP-SMX IV Listeria (penicillin-allergic) 5 mg/kg TMP q6h :: IV :: q6h :: 5 mg/kg (TMP component) IV q6h; alternative for Listeria Sulfa allergy, severe renal impairment Renal function, K+, rash \u2014 STAT \u2014 STAT Meropenem IV Resistant GNR, penicillin allergy 2 g q8h :: IV :: q8h :: 2 g IV q8h; meningeal dosing Carbapenem allergy Renal function, seizures \u2014 STAT \u2014 STAT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3c-treatment-duration-by-organism","title":"3C. Treatment Duration by Organism","text":"Organism Duration Neisseria meningitidis 7 days Haemophilus influenzae 7 days Streptococcus pneumoniae 10-14 days Group B Streptococcus 14-21 days Listeria monocytogenes \u226521 days Gram-negative bacilli 21 days Unknown organism 10-14 days (minimum)","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3d-dexamethasone-guidance","title":"3D. Dexamethasone Guidance","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Dexamethasone (continue) IV Proven pneumococcal meningitis 0.15 mg/kg q6h x 4 days :: IV :: q6h x 4 days :: Continue full 4-day course if S. pneumoniae confirmed See below Glucose, GI bleed \u2014 STAT \u2014 STAT Dexamethasone (discontinue) \u2014 Non-pneumococcal meningitis N/A :: \u2014 :: :: DISCONTINUE dexamethasone if organism other than S. pneumoniae (benefit unproven) \u2014 \u2014 \u2014 STAT \u2014 STAT <p>Dexamethasone Notes: - Greatest benefit: Pneumococcal meningitis (reduces mortality and hearing loss) - Timing critical: Must be given BEFORE or WITH first antibiotic dose; no benefit if started &gt;4 hours after antibiotics - Continue if: S. pneumoniae confirmed - Discontinue if: Other organism confirmed, prior antibiotics given - Caution: May reduce CSF penetration of vancomycin (controversial; continue vancomycin anyway)</p> <p>Dexamethasone in Immunocompromised Patients: - HIV: Limited evidence of benefit in HIV-positive patients; meta-analyses show uncertain benefit. Use clinical judgment. - CRITICAL - Rule out cryptococcal/TB first: Dexamethasone is contraindicated in HIV-associated cryptococcal meningitis (increased mortality shown in trials). TB meningitis benefit in HIV+ patients is uncertain. - Practical approach: If HIV status unknown, give dexamethasone empirically but send cryptococcal antigen and evaluate for TB; discontinue if cryptococcal or TB confirmed. - Other immunocompromise: Benefit unproven in transplant, chemotherapy, biologics; weigh risks vs benefits.</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3e-supportive-care","title":"3E. Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Normal saline IV Fluid resuscitation, maintenance 30 mL/kg bolus; 125 mL/hr maintenance :: IV :: bolus then maintenance :: 30 mL/kg bolus for sepsis; avoid over-hydration (cerebral edema risk) Cerebral edema (restrict fluids) I/O, Na+, mental status STAT STAT \u2014 STAT Norepinephrine IV Septic shock 0.1-0.5 mcg/kg/min; 2-30 mcg/min :: IV :: infusion :: Start 2-5 mcg/min; titrate to MAP \u226565 \u2014 Continuous BP, lactate \u2014 \u2014 \u2014 STAT Phenytoin IV Seizure prophylaxis (if seizures occur) 20 mg/kg load; 100 mg q8h :: IV :: load then q8h :: 20 mg/kg IV load (max rate 50 mg/min), then 100 mg IV q8h; NOT recommended routinely for prophylaxis Bradycardia, heart block Cardiac monitoring during load, levels STAT STAT \u2014 STAT Levetiracetam IV Seizure treatment/prophylaxis 1000 mg BID; 1500 mg BID :: IV :: BID :: 1000-1500 mg IV BID; preferred for seizure prophylaxis if indicated Severe renal impairment (adjust) Renal function STAT STAT \u2014 STAT Acetaminophen IV/PO Fever, headache 650 mg q6h; 1000 mg q6h :: IV/PO :: q6h :: 650-1000 mg q6h; max 4 g/day Severe hepatic impairment Temperature STAT STAT \u2014 STAT Mannitol IV Elevated ICP 0.5-1 g/kg bolus :: IV :: PRN :: 0.5-1 g/kg IV bolus over 15-20 min; may repeat q6h PRN; target serum osm &lt;320 Renal failure, hypotension Serum osm, Na+, renal function \u2014 STAT \u2014 STAT Hypertonic saline (3%) IV Elevated ICP 250 mL bolus :: IV :: PRN :: 250 mL (or 30 mL of 23.4%) bolus for acute herniation; target Na 145-155 \u2014 Na+, serum osm \u2014 STAT \u2014 STAT Enoxaparin SC DVT prophylaxis (after stabilization) 40 mg daily :: SC :: daily :: 40 mg SC daily; start after 48-72h if no hemorrhagic complications Active bleeding, recent LP, coagulopathy Platelet count \u2014 ROUTINE \u2014 ROUTINE Famotidine IV Stress ulcer prophylaxis 20 mg BID :: IV :: BID :: 20 mg IV BID if on steroids or intubated None significant GI bleeding \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#3f-chemoprophylaxis-for-close-contacts","title":"3F. Chemoprophylaxis for Close Contacts","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Rifampin PO Meningococcal prophylaxis 600 mg BID x 2 days :: PO :: BID x 2 days :: 600 mg PO q12h x 4 doses (2 days); for household/close contacts Pregnancy, liver disease Orange secretions warning \u2014 ROUTINE \u2014 \u2014 Ciprofloxacin PO Meningococcal prophylaxis 500 mg single dose :: PO :: once :: 500 mg PO x 1 dose; alternative to rifampin Pregnancy, children (relative) Tendon warning \u2014 ROUTINE \u2014 \u2014 Ceftriaxone IM Meningococcal prophylaxis 250 mg single dose :: IM :: once :: 250 mg IM x 1 dose; safe in pregnancy Cephalosporin allergy None \u2014 ROUTINE \u2014 \u2014 Rifampin (H. flu) PO H. influenzae prophylaxis 20 mg/kg daily x 4 days :: PO :: daily x 4 days :: 20 mg/kg (max 600 mg) PO daily x 4 days; for household contacts if unvaccinated child &lt;4 yo present Pregnancy, liver disease Orange secretions warning \u2014 ROUTINE \u2014 \u2014 <p>Contact Prophylaxis Indications: - Meningococcal: Household contacts, daycare contacts, anyone exposed to respiratory secretions (kissing, mouth-to-mouth, intubation without mask) - H. influenzae type b: Household contacts if unvaccinated child &lt;4 years present - Pneumococcal: No prophylaxis indicated</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Infectious disease consult for antibiotic optimization, duration guidance, and organism-specific management URGENT STAT \u2014 STAT Neurology consult for seizure management, focal deficits evaluation, and neurological complication monitoring URGENT URGENT \u2014 STAT Critical care consult for ICU admission given septic shock, hemodynamic instability, or respiratory failure STAT STAT \u2014 STAT Neurosurgery consult for hydrocephalus management, abscess drainage, or elevated ICP requiring intervention \u2014 URGENT \u2014 STAT ENT consult for hearing evaluation as sensorineural hearing loss is a common complication of bacterial meningitis \u2014 ROUTINE \u2014 ROUTINE Audiology for formal hearing test before discharge to document baseline and detect early hearing loss \u2014 ROUTINE \u2014 ROUTINE Infection control for droplet isolation implementation and contact tracing if meningococcal disease confirmed STAT STAT \u2014 STAT Public health notification required for meningococcal disease (reportable condition) to enable contact prophylaxis STAT STAT \u2014 STAT","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening headache, fever, confusion, or seizures develop (may indicate treatment failure or complication) STAT \u2014 STAT Complete full antibiotic course even if feeling better to prevent relapse and resistance \u2014 STAT STAT Obtain hearing test after recovery as sensorineural hearing loss is a common complication of bacterial meningitis \u2014 ROUTINE ROUTINE Ensure close contacts receive prophylaxis if meningococcal disease confirmed (rifampin, ciprofloxacin, or ceftriaxone) STAT STAT \u2014 Report persistent headaches, hearing changes, or cognitive difficulties as these may indicate late complications \u2014 ROUTINE ROUTINE","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Maintain droplet isolation (meningococcal) until 24h of effective antibiotics to prevent transmission STAT STAT \u2014 Meningococcal vaccination for close contacts and patient after recovery to prevent future infection \u2014 ROUTINE ROUTINE Pneumococcal vaccination if not up to date as pneumococcus is the most common cause of bacterial meningitis \u2014 ROUTINE ROUTINE Practice hand hygiene and respiratory etiquette to prevent transmission of respiratory pathogens \u2014 ROUTINE ROUTINE Avoid sharing utensils, drinks, or close contact with respiratory secretions during active infection STAT STAT \u2014 <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Viral meningitis Milder course, lymphocytic CSF, normal glucose CSF profile, viral PCR HSV encephalitis Altered mental status, temporal lobe findings, seizures MRI brain, CSF HSV PCR Tuberculous meningitis Subacute course, basilar enhancement, low glucose CSF AFB, adenosine deaminase, PCR Fungal meningitis Immunocompromised, indolent course CSF fungal culture, cryptococcal antigen Subarachnoid hemorrhage Thunderclap headache, xanthochromia CT head, LP (xanthochromia, RBCs) Brain abscess Focal deficits, ring-enhancing lesion MRI brain with contrast Subdural empyema Post-sinusitis/otitis, focal deficits MRI brain with contrast Autoimmune encephalitis Subacute, psychiatric symptoms, movement disorder Autoimmune panel (serum/CSF) Carcinomatous meningitis Cancer history, cranial neuropathies CSF cytology, MRI Drug-induced meningitis NSAIDs, IVIG, TMP-SMX exposure Temporal relationship, improvement off drug Endocarditis with CNS embolization Heart murmur, embolic phenomena Echocardiogram, blood cultures Septic dural sinus thrombosis Headache, papilledema, focal signs CT/MR venography","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurological exam (GCS) q1-2h initially, then q4h GCS stable or improving Head CT, consider ICP monitoring STAT STAT \u2014 STAT Temperature q4h Afebrile by 48-72h Reassess antibiotic coverage STAT STAT \u2014 STAT Blood pressure q1-4h MAP \u226565 Vasopressors if septic shock STAT STAT \u2014 STAT Heart rate Continuous 60-100 bpm Evaluate for sepsis, arrhythmia STAT STAT \u2014 STAT Oxygen saturation Continuous &gt;94% Supplement O2, consider intubation STAT STAT \u2014 STAT Urine output q4h &gt;0.5 mL/kg/hr Fluid resuscitation \u2014 STAT \u2014 STAT Serum sodium q6-12h 135-145 mEq/L Evaluate for SIADH, cerebral salt wasting STAT STAT \u2014 STAT Lactate q6-12h until normal &lt;2 mmol/L Optimize resuscitation STAT STAT \u2014 STAT Vancomycin trough Before 4th dose 15-20 mcg/mL Dose adjustment \u2014 STAT \u2014 STAT Renal function Daily Cr stable Adjust antibiotic doses STAT STAT \u2014 STAT Glucose q6h if on steroids &lt;180 mg/dL Insulin \u2014 ROUTINE \u2014 STAT Hearing assessment Before discharge Normal Audiology referral \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission GCS &lt;12; hemodynamic instability (septic shock); respiratory failure; seizures; signs of elevated ICP; DIC; rapidly worsening Step-down/telemetry Stable but requiring close monitoring; improving mental status; weaning vasopressors General floor Stable; GCS 15; hemodynamically stable; no seizures; improving on antibiotics Discharge home NOT recommended for acute bacterial meningitis; requires IV antibiotics Transfer to higher level Need for neurosurgical intervention; refractory elevated ICP; ECMO candidacy <p>Typical Hospital Course: 10-21 days depending on organism</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Dexamethasone before antibiotics improves outcomes in pneumococcal meningitis Class I, Level A de Gans et al. NEJM 2002 Antibiotics within 1 hour reduce mortality Class II, Level B Proulx et al. QJM 2005 CT before LP only if criteria met Class II, Level B Hasbun et al. NEJM 2001 Vancomycin + ceftriaxone empiric for DRSP Class II, Level B Tunkel et al. IDSA Guidelines Clin Infect Dis 2004 Ampicillin for Listeria coverage in at-risk Class II, Level B IDSA Guidelines 2004 BioFire Panel for rapid diagnosis Class II, Level B Leber et al. J Clin Microbiol 2016 Rifampin or ciprofloxacin prophylaxis for meningococcal contacts Class I, Level A CDC MMWR Recommendations Antibiotic duration by organism Class II, Level B Tunkel et al. IDSA Guidelines Delay in antibiotics increases mortality Class II, Level B Auburtin et al. Crit Care Med 2006","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#change-log","title":"CHANGE LOG","text":"<p>v1.1 (January 24, 2026) - Citation verification: Corrected de Gans PMID (12432041)</p> <p>v1.0 (January 24, 2026) - Initial template creation - Age-based empiric antibiotic selection - Dexamethasone timing guidance - CSF interpretation table - Contact prophylaxis protocols - Treatment duration by organism</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#appendix-a-ct-before-lp-decision-algorithm","title":"APPENDIX A: CT Before LP Decision Algorithm","text":"<pre><code>Suspected Bacterial Meningitis\n         \u2502\n         \u25bc\nAny of the following?\n\u2022 Immunocompromised\n\u2022 History of CNS disease\n\u2022 New onset seizure (&lt;1 week)\n\u2022 Papilledema\n\u2022 Altered consciousness (GCS &lt;14)\n\u2022 Focal neurological deficit\n         \u2502\n    \u250c\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2510\n    \u2502         \u2502\n   YES        NO\n    \u2502         \u2502\n    \u25bc         \u25bc\nCT Head    Proceed directly\n  STAT     to LP\n    \u2502         \u2502\n    \u25bc         \u2502\nNo mass/    \u2500\u2518\nherniation?\n    \u2502\n   YES\n    \u2502\n    \u25bc\nProceed to LP\n\n**CRITICAL: Do NOT delay antibiotics for CT or LP**\nGive empiric antibiotics + dexamethasone immediately if meningitis suspected\n</code></pre>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#appendix-b-empiric-antibiotic-quick-reference","title":"APPENDIX B: Empiric Antibiotic Quick Reference","text":"Patient Type Regimen Key Points 16-50 yo, healthy Ceftriaxone 2g q12h + Vancomycin No Listeria coverage needed &gt;50 yo Ceftriaxone 2g q12h + Vancomycin + Ampicillin 2g q4h Add Listeria coverage Immunocompromised Ceftriaxone 2g q12h + Vancomycin + Ampicillin 2g q4h Broader coverage Alcoholism Ceftriaxone 2g q12h + Vancomycin + Ampicillin 2g q4h High Listeria risk Severe PCN allergy Meropenem 2g q8h + Vancomycin Or chloramphenicol + TMP-SMX Post-neurosurgery Vancomycin + Cefepime 2g q8h (or Meropenem) Cover Staph, Pseudomonas <p>ALL patients also receive: - Dexamethasone 0.15 mg/kg (or 10 mg) IV q6h x 4 days - Give dexamethasone 15-20 min BEFORE or WITH first antibiotic dose</p>","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bacterial-meningitis/#appendix-c-csf-parameters-quick-reference","title":"APPENDIX C: CSF Parameters Quick Reference","text":"Parameter Normal Bacterial Viral TB/Fungal Opening pressure 10-20 cmH2O &gt;30 cmH2O Normal/\u2191 \u2191\u2191 WBC &lt;5/\u03bcL 1,000-10,000 10-500 100-500 Differential \u2014 &gt;80% PMNs Lymphs Lymphs Protein 15-45 mg/dL &gt;200 mg/dL 50-100 &gt;100 Glucose 45-80 mg/dL &lt;40 Normal &lt;40 CSF:Serum glucose &gt;0.6 &lt;0.4 &gt;0.6 &lt;0.4 Gram stain Negative + in 60-90% Negative Usually - Lactate &lt;3.5 mmol/L &gt;4 mmol/L &lt;3.5 Variable","tags":["infection","emergency","meningitis","neurocritical-care"]},{"location":"drafts/bells-palsy/","title":"Bell's Palsy","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#bells-palsy","title":"Bell's Palsy","text":"<p>DIAGNOSIS: Bell's Palsy (Idiopathic Facial Nerve Palsy) ICD-10: G51.0 (Bell's palsy) SCOPE: Acute unilateral peripheral facial nerve palsy of presumed idiopathic etiology. Covers initial evaluation, treatment, and follow-up. Excludes Ramsay Hunt syndrome (herpes zoster oticus), central facial palsy, bilateral facial palsy, and secondary causes.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>CRITICAL: Time-Sensitive Treatment - Corticosteroids must be started within 72 hours of symptom onset for maximum benefit - Treatment initiated after 72 hours has significantly reduced efficacy - House-Brackmann Grade V-VI (severe/complete paralysis) may benefit from adjunctive antiviral therapy</p> <p>RED FLAGS (Consider Alternative Diagnosis)</p> Red Flag Concern Action Bilateral facial weakness Lyme disease, GBS, sarcoidosis, leukemia Comprehensive workup; do NOT assume Bell's palsy Slow progression (&gt;3 weeks) Tumor, malignancy MRI with contrast urgently Recurrent facial palsy Tumor, Melkersson-Rosenthal syndrome MRI; specialist referral No improvement at 4 months Incomplete recovery, synkinesis risk EMG/NCS; consider referral Facial twitching preceding weakness Facial nerve tumor MRI IAC/temporal bone Other cranial nerve involvement Brainstem lesion, skull base pathology Urgent MRI/CT Hyperacusis with vesicles in ear canal Ramsay Hunt syndrome (VZV) Treat as Ramsay Hunt (higher antiviral doses) Systemic symptoms (rash, arthritis, tick exposure) Lyme disease Lyme serology","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Glucose or HbA1c Diabetes is risk factor and affects prognosis Normal glucose; HbA1c &lt;7% ROUTINE ROUTINE ROUTINE -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Lyme serology (ELISA + Western blot) Endemic areas or tick exposure; bilateral palsy Negative ROUTINE ROUTINE ROUTINE - CBC with differential Concern for leukemia or infection Normal ROUTINE ROUTINE ROUTINE - ESR, CRP Inflammatory etiology suspected Normal - ROUTINE ROUTINE - HIV testing Risk factors present; atypical or recurrent Negative - ROUTINE ROUTINE - RPR/VDRL Syphilis can cause cranial neuropathies Nonreactive - ROUTINE ROUTINE -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ACE level, chest imaging Sarcoidosis suspected (bilateral, recurrent, uveitis) Normal ACE; clear CXR - EXT EXT - ANA, anti-Ro/La Autoimmune etiology suspected Negative - EXT EXT - CSF analysis Lyme neuroborreliosis, GBS, or carcinomatous meningitis suspected Normal; negative Lyme - EXT EXT -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU None routinely required N/A Clinical diagnosis sufficient for typical Bell's palsy N/A - - - -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Atypical features, no improvement by 4 months, recurrent Enhancement of facial nerve (may be normal in Bell's); exclude tumor MRI-incompatible devices; gadolinium allergy - EXT ROUTINE - MRI IAC/Temporal bone Suspected tumor, Ramsay Hunt, or recurrent palsy Exclude schwannoma, hemangioma, cholesteatoma MRI-incompatible devices - EXT EXT - CT Head non-contrast Concern for stroke (upper and lower face affected) Exclude acute CVA Pregnancy (relative) STAT STAT - -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Electroneuronography (ENoG) Days 3-14 for severe palsy &gt;90% degeneration may indicate need for decompression Too early (&lt;3 days) or late (&gt;3 weeks) - EXT EXT - EMG facial nerve After 2-3 weeks if complete palsy; at 4 months if no recovery Evidence of reinnervation; fibrillations indicate denervation None - EXT EXT - Needle EMG (blink reflex) Assessing recovery potential Present R1 response indicates favorable prognosis None - EXT EXT -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#3-treatment","title":"3. TREATMENT","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Prednisone PO First-line treatment; must start within 72 hours of onset 60 mg daily x 5 days; 60 mg daily x 5 days then taper :: PO :: :: 60-80 mg daily for 5 days, then taper over 5 days (or 60 mg x 5d then 10 mg daily decrease); total 10 days Uncontrolled diabetes (relative); active systemic infection; psychosis Glucose in diabetics; mood changes URGENT URGENT URGENT - Prednisolone PO Alternative to prednisone; may have better bioavailability 50 mg daily x 10 days; 25 mg BID x 10 days :: PO :: :: 50 mg daily (or 25 mg BID) for 10 days Same as prednisone Glucose in diabetics URGENT URGENT URGENT - Valacyclovir PO Adjunct for severe (HB V-VI) or complete facial paralysis 1000 mg TID x 7 days :: PO :: :: 1000 mg PO TID for 7 days; start within 72 hours; always combine with corticosteroid Renal impairment (dose adjust); hypersensitivity Renal function in CKD URGENT URGENT ROUTINE - Acyclovir PO Alternative antiviral if valacyclovir unavailable 400 mg 5x/day x 10 days :: PO :: :: 400 mg PO 5 times daily for 10 days; always combine with corticosteroid Renal impairment (dose adjust); hypersensitivity Renal function in CKD URGENT URGENT ROUTINE -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Artificial tears (carboxymethylcellulose) TOP Eye protection during waking hours; prevents exposure keratopathy 1-2 drops q1-2h while awake :: TOP :: :: 1-2 drops to affected eye every 1-2 hours while awake; increase frequency as needed None Corneal status URGENT ROUTINE ROUTINE - Lubricating eye ointment (lacri-lube) TOP Nighttime eye protection; prevents corneal drying during sleep Apply qHS :: TOP :: :: Apply 1/4 inch ribbon to affected eye at bedtime None Corneal status URGENT ROUTINE ROUTINE - Eye patch/Moisture chamber TOP Corneal protection especially at night or outdoors Use during sleep and windy conditions :: TOP :: :: Tape eye closed at night; use moisture chamber glasses during day if severe lagophthalmos None Ensure complete closure; no corneal contact URGENT ROUTINE ROUTINE - Surgical tape (for eye closure) TOP Ensure complete eyelid closure during sleep Apply at bedtime :: TOP :: :: Use hypoallergenic tape to gently tape eyelid closed at night; vertical taping preferred Skin sensitivity; ensure no tape touches cornea Skin irritation; corneal status URGENT ROUTINE ROUTINE - Acetaminophen PO Postauricular pain associated with Bell's palsy 650 mg q6h PRN; 1000 mg q6h PRN :: PO :: :: 650-1000 mg PO q6h PRN pain; max 3000 mg/day Hepatic impairment; avoid with alcohol Hepatic function with prolonged use ROUTINE ROUTINE ROUTINE - Ibuprofen PO Postauricular pain; mild anti-inflammatory effect 400 mg q6h PRN; 600 mg q6h PRN :: PO :: :: 400-600 mg PO q6h PRN pain; max 2400 mg/day Renal impairment; GI bleed; aspirin allergy GI symptoms; renal function ROUTINE ROUTINE ROUTINE -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Botulinum toxin A IM Synkinesis or hemifacial spasm following recovery 2.5-5 units per site :: IM :: :: Inject 2.5-5 units per site in affected muscles; dose varies by target muscle; repeat q3-4 months Infection at site; myasthenia gravis; aminoglycosides Weakness, ptosis, asymmetry - - EXT - Physical therapy (facial) N/A Facilitate recovery; prevent contracture; treat synkinesis Per PT protocol :: N/A :: :: Facial exercises, massage, mirror biofeedback; start after acute phase None Compliance; progress - ROUTINE ROUTINE - Facial nerve decompression Surgical ENoG shows &gt;90% degeneration within 14 days; controversial Surgical referral :: N/A :: :: Consider if &gt;90% degeneration on ENoG within 2 weeks of onset; rarely performed Surgical contraindications Post-operative course; hearing - EXT EXT - Gold weight implant Surgical Chronic lagophthalmos with corneal exposure risk Surgical referral :: N/A :: :: For persistent incomplete eye closure after 6-12 months Surgical contraindications Corneal protection; cosmesis - - EXT - Tarsorrhaphy Surgical Severe corneal exposure not controlled medically Surgical referral :: N/A :: :: Temporary or permanent suturing of eyelids for corneal protection Surgical contraindications Corneal status - EXT EXT -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Ophthalmology referral urgently if corneal involvement, severe lagophthalmos, or eye pain concerning for exposure keratopathy URGENT URGENT URGENT - Neurology referral if atypical features, no improvement by 3-4 weeks, or concern for central etiology - ROUTINE ROUTINE - ENT/Otolaryngology referral if Ramsay Hunt suspected, recurrent palsy, or consideration of surgical decompression - ROUTINE ROUTINE - Physical therapy referral for facial rehabilitation, particularly if incomplete recovery or synkinesis - - ROUTINE - Plastic surgery/Oculoplastic referral for chronic lagophthalmos requiring surgical intervention (gold weight, tarsorrhaphy) - - EXT -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for eye pain, redness, or vision changes which may indicate corneal injury from exposure STAT ROUTINE ROUTINE Return if facial weakness worsens after initial improvement or new symptoms develop (numbness, hearing loss, other weakness) URGENT ROUTINE ROUTINE Protect affected eye from wind, dust, and debris with glasses or moisture chamber during recovery ROUTINE ROUTINE ROUTINE Use artificial tears frequently during the day and lubricating ointment at night; tape eye closed if unable to fully close URGENT ROUTINE ROUTINE Most patients (70-85%) recover completely; recovery typically begins within 3 weeks and completes within 3-4 months - ROUTINE ROUTINE Do not discontinue steroids abruptly as this may cause adrenal insufficiency; complete the full taper as prescribed URGENT ROUTINE ROUTINE Facial exercises may help recovery; gently massage face and practice facial movements in mirror several times daily - ROUTINE ROUTINE","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Adequate sleep and stress management as viral reactivation may be triggered by stress and immunosuppression - ROUTINE ROUTINE Avoid extreme cold and wind exposure to face during recovery period to prevent irritation - ROUTINE ROUTINE Diabetic patients should maintain strict glycemic control as hyperglycemia worsens prognosis and slows recovery - ROUTINE ROUTINE Avoid driving if unable to fully close eye or if vision is significantly impaired ROUTINE ROUTINE ROUTINE","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Stroke (central facial palsy) Forehead sparing; upper face moves normally; other neurological deficits CT/MRI brain; complete neurological exam Ramsay Hunt syndrome (VZV) Vesicles in ear canal or on pinna; severe otalgia; worse prognosis Clinical exam for vesicles; VZV PCR if needed Lyme disease (facial palsy) Endemic area; tick exposure; bilateral (25%); erythema migrans; arthralgias Lyme ELISA + Western blot Otitis media with facial palsy Ear pain, otorrhea, conductive hearing loss, fever Otoscopic exam; CT temporal bone Parotid tumor/malignancy Slow onset; parotid mass; progressive; no recovery MRI parotid; FNA or biopsy Acoustic neuroma (schwannoma) Gradual onset; hearing loss; tinnitus; facial numbness MRI IAC with contrast Cholesteatoma Chronic ear disease; hearing loss; otorrhea Otoscopy; CT temporal bone Guillain-Barr\u00e9 syndrome Bilateral facial weakness; limb weakness; areflexia LP (albuminocytologic dissociation); EMG/NCS Sarcoidosis (Heerfordt syndrome) Bilateral; uveitis; parotid swelling; fever ACE level; chest imaging; biopsy Melkersson-Rosenthal syndrome Recurrent palsy; facial edema; fissured tongue Clinical triad; biopsy if needed","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU House-Brackmann grade Each visit Progressive improvement; Grade I-II by 4 months EMG if no improvement; consider referral ROUTINE ROUTINE ROUTINE - Corneal examination (fluorescein) Initial and PRN symptoms No corneal staining or ulceration Urgent ophthalmology; increase eye protection URGENT ROUTINE ROUTINE - Eye closure (lagophthalmos) Each visit Complete closure; Bell phenomenon present Intensify lubrication; consider tarsorrhaphy referral ROUTINE ROUTINE ROUTINE - Glucose (if on steroids) Daily if diabetic x 10 days &lt;180 mg/dL; HbA1c stable Adjust diabetes medications; endocrine consult - ROUTINE ROUTINE - Synkinesis development Starting at 4-8 weeks None or minimal Physical therapy; consider botulinum toxin - - ROUTINE - Recovery timeline Weeks 3, 6, 12, and 6 months Initial recovery by 3 weeks; near-complete by 4-6 months EMG at 4 months; consider secondary causes - - ROUTINE -","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Typical presentation; able to protect eye; steroids initiated within 72 hours; follow-up arranged Admit to floor Rare; only if unable to protect eye and no caregiver; severe comorbidities affecting steroid use; concern for secondary cause requiring inpatient workup Admit to ICU Not applicable for Bell's palsy Outpatient follow-up 2-3 weeks initial follow-up to assess recovery; earlier if corneal symptoms; neurology referral if no improvement by 4-6 weeks","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Corticosteroids improve recovery rates Class I, Level A Sullivan et al. NEJM 2007 (Scottish Bell's Palsy Study) Antiviral monotherapy not effective; corticosteroids superior Class I, Level A Engstrom et al. NEJM 2008 Combination corticosteroid + antiviral may benefit severe cases Class I, Level B de Almeida et al. JAMA 2009 (meta-analysis) Early treatment (within 72 hours) improves outcomes Class II, Level B Madhok et al. Cochrane 2016 AAN Practice Parameter: Steroids highly effective Class I, Level A Gronseth &amp; Paduga. Neurology 2012 (AAN Guideline) Eye protection prevents corneal complications Class III, Level C Expert consensus; standard of care House-Brackmann grading system for assessment Clinical standard House &amp; Brackmann. Otolaryngol Head Neck Surg 1985 ENoG &gt;90% degeneration predicts poor outcome Class II, Level B Fisch. Otolaryngol Head Neck Surg 1984 Physical therapy may improve recovery Class III, Level C Teixeira et al. Cochrane 2011 Botulinum toxin effective for post-paralytic synkinesis Class II, Level B Mehdizadeh et al. Plast Reconstr Surg 2008","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of diagnosis, treatment, and follow-up - Emphasis on time-sensitive corticosteroid initiation - Eye protection protocols detailed - House-Brackmann grading included in appendix - Red flags for atypical presentations - Real PubMed citations verified</p>","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#appendix-a-house-brackmann-facial-nerve-grading-scale","title":"APPENDIX A: House-Brackmann Facial Nerve Grading Scale","text":"Grade Description Characteristics I Normal Normal facial function in all areas II Mild dysfunction Slight weakness noticeable on close inspection; may have very slight synkinesis; complete eye closure with minimal effort III Moderate dysfunction Obvious but not disfiguring difference; noticeable but not severe synkinesis; complete eye closure with effort IV Moderately severe dysfunction Obvious weakness and/or disfiguring asymmetry; incomplete eye closure V Severe dysfunction Only barely perceptible motion; incomplete eye closure VI Total paralysis No movement <p>Clinical Significance: - Grade I-II: Excellent prognosis; minimal treatment needed beyond eye protection - Grade III-IV: Good prognosis with treatment; monitor for synkinesis - Grade V-VI: Consider adjunctive antiviral therapy; ENoG may guide prognosis; higher risk of incomplete recovery</p>","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#appendix-b-recovery-prognosis-and-timeline","title":"APPENDIX B: Recovery Prognosis and Timeline","text":"<p>Expected Recovery Timeline: - Days 1-7: Symptoms may worsen initially even with treatment - Weeks 1-3: First signs of recovery typically appear - Weeks 3-8: Significant improvement in most patients - Months 2-4: Near-complete recovery in majority - Months 4-12: Late recovery possible; synkinesis may develop</p> <p>Prognostic Factors:</p> Factor Better Prognosis Worse Prognosis Severity at onset Incomplete paralysis (HB II-III) Complete paralysis (HB V-VI) Treatment timing Steroids within 72 hours Delayed treatment Age Younger patients Older patients (&gt;60) Comorbidities None Diabetes, hypertension Recovery onset Within 3 weeks After 4 months ENoG findings &lt;90% degeneration &gt;90% degeneration <p>Overall Outcomes: - 70-85% of patients recover completely (HB I-II) - 10-15% have mild residual weakness (HB III) - 5-10% have moderate to severe residual weakness (HB IV-VI) - ~16% develop synkinesis (involuntary facial movements) - Recurrence rate: 7-12% (same or opposite side)</p>","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/bells-palsy/#appendix-c-eye-protection-protocol","title":"APPENDIX C: Eye Protection Protocol","text":"<p>Importance: The inability to fully close the eye leads to corneal exposure, drying, and potential ulceration. Corneal injury is the most serious complication of Bell's palsy.</p> <p>Daytime Protocol: 1. Artificial tears (preservative-free preferred): Every 1-2 hours while awake 2. Wear wrap-around glasses or moisture chamber when outdoors 3. Avoid fans, air conditioning directly on face 4. Blink consciously and frequently</p> <p>Nighttime Protocol: 1. Apply lubricating ointment (e.g., Lacri-Lube) before bed 2. Tape eyelid closed using hypoallergenic tape (vertical strip from eyebrow to cheek) 3. Consider moisture chamber patch 4. Elevate head of bed slightly</p> <p>Warning Signs Requiring Urgent Ophthalmology: - Eye pain or foreign body sensation - Eye redness - Discharge from eye - Vision changes or blurring - Photophobia</p> <p>When to Consider Surgical Eye Protection: - Persistent lagophthalmos beyond 6-12 months - Corneal breakdown despite medical management - Options: Gold weight implant, tarsal strip, tarsorrhaphy</p>","tags":["cranial-neuropathy","facial-paralysis","bells-palsy","outpatient","emergency"]},{"location":"drafts/carpal-tunnel-syndrome/","title":"Carpal Tunnel Syndrome","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#carpal-tunnel-syndrome","title":"Carpal Tunnel Syndrome","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 REVISED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Carpal Tunnel Syndrome</p> <p>ICD-10: G56.00 (Carpal tunnel syndrome, unspecified upper limb); G56.01 (Carpal tunnel syndrome, right upper limb); G56.02 (Carpal tunnel syndrome, left upper limb); G56.03 (Carpal tunnel syndrome, bilateral upper limbs)</p> <p>CLINICAL SYNONYMS: CTS, median neuropathy at wrist, median nerve compression, carpal tunnel entrapment, median nerve entrapment neuropathy, wrist compression syndrome, occupational hand numbness</p> <p>SCOPE: Evaluation and management of carpal tunnel syndrome from initial presentation through conservative treatment, injection therapy, and surgical referral. Covers clinical diagnosis, electrodiagnostic testing, severity grading, and treatment options. For acute median nerve injury or severe CTS with thenar atrophy, early surgical referral is indicated.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Fasting glucose Screen for diabetes (common CTS risk factor) &lt;100 mg/dL STAT STAT ROUTINE STAT HbA1c Diabetes/prediabetes screening (diabetic neuropathy overlap) &lt;5.7% - ROUTINE ROUTINE - TSH Hypothyroidism causes CTS (myxedematous tissue infiltration) 0.4-4.0 mIU/L - ROUTINE ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Rheumatoid factor RA-associated CTS (synovial hypertrophy) Negative - ROUTINE ROUTINE - Anti-CCP antibody More specific for RA if RF negative Negative - ROUTINE ROUTINE - ESR Inflammatory arthritis screen &lt;20 mm/hr - ROUTINE ROUTINE - CRP Inflammatory marker &lt;3.0 mg/L - ROUTINE ROUTINE - Uric acid Gout/tophaceous deposits in carpal tunnel Normal (3.5-7.2 mg/dL male; 2.5-6.2 mg/dL female) - ROUTINE ROUTINE - BUN/Creatinine Renal disease (dialysis-associated CTS from amyloid deposition) Normal - ROUTINE ROUTINE - CBC Anemia workup, infection screen Normal - ROUTINE ROUTINE - Pregnancy test (women of childbearing age) Pregnancy-associated CTS (common, often resolves postpartum) Document status URGENT ROUTINE ROUTINE - Vitamin B12 Concomitant peripheral neuropathy &gt;300 pg/mL - ROUTINE ROUTINE - Serum protein electrophoresis (SPEP) Amyloidosis, myeloma (bilateral CTS may be presenting sign of AL amyloid) No M-spike - EXT ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Free light chains (kappa/lambda) AL amyloidosis if bilateral CTS with cardiac/renal involvement Normal ratio (0.26-1.65) - EXT EXT - TTR gene testing Hereditary transthyretin amyloidosis if young onset bilateral CTS No pathogenic variant - - EXT - Fat pad biopsy Confirm amyloidosis if strongly suspected No amyloid deposits - EXT EXT - Acromegaly workup (IGF-1, GH) Bilateral CTS in patient with acromegalic features Normal - EXT EXT -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Nerve conduction studies (NCS) and EMG Recommended for diagnosis confirmation and severity grading; optimal before surgery Prolonged median sensory and/or motor distal latency; reduced SNAP amplitude; denervation in thenar muscles (severe) Anticoagulation for needle EMG (relative) - ROUTINE ROUTINE - Wrist X-ray (PA and lateral) If fracture, arthritis, or bony abnormality suspected Normal or degenerative changes; exclude fracture None URGENT ROUTINE ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Wrist/carpal tunnel ultrasound Alternative to MRI; can measure median nerve CSA; operator-dependent Median nerve CSA &gt;10-12 mm\u00b2 at pisiform level; flattening at tunnel None - ROUTINE ROUTINE - MRI wrist without contrast Mass lesion, ganglion cyst, tenosynovitis, anatomic variant No mass, normal median nerve signal Pacemaker; claustrophobia - ROUTINE ROUTINE - MRI cervical spine with and without contrast Rule out cervical radiculopathy if double crush suspected or atypical presentation No foraminal stenosis at C6-C7 GFR &lt;30; pacemaker; gadolinium allergy - ROUTINE ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT wrist Bony pathology not visible on X-ray; post-traumatic No fracture or bony deformity Pregnancy (relative) - EXT EXT - MRI with contrast Suspected tumor or inflammatory mass in carpal tunnel No enhancing mass GFR &lt;30; pacemaker; gadolinium allergy - EXT EXT - Comparative NCS (ulnar and radial) Distinguish CTS from polyneuropathy or brachial plexopathy Normal ulnar and radial studies None - ROUTINE ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#3-treatment","title":"3. TREATMENT","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Wrist splinting (neutral position) External First-line conservative therapy; nocturnal use prevents wrist flexion Neutral position splint :: External :: Nightly (minimum) :: Wear nightly x 4-6 weeks; may use during day if symptomatic; neutral wrist position (0-5 degrees extension) None Skin irritation; compliance ROUTINE ROUTINE ROUTINE - NSAID therapy (short-term) PO Acute symptom relief; limited evidence for CTS-specific benefit Ibuprofen 400 mg TID; Naproxen 500 mg BID :: PO :: :: Short course (7-14 days); take with food; not for long-term use GI bleeding; renal impairment; cardiovascular disease; third trimester pregnancy GI symptoms; renal function ROUTINE ROUTINE ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO Neuropathic pain/paresthesias (adjunctive) 300 mg qHS; 300 mg TID; 600 mg TID :: PO :: :: Start 300 mg qHS; increase by 300 mg q3-7d; max 1800 mg/day for CTS Renal impairment (dose adjust per CrCl) Sedation, dizziness, edema - ROUTINE ROUTINE - Pregabalin PO Neuropathic pain/paresthesias 75 mg BID; 150 mg BID :: PO :: :: Start 75 mg BID; may increase to 150 mg BID after 1 week Renal impairment; Class V controlled Sedation, weight gain, edema - ROUTINE ROUTINE - Duloxetine PO Neuropathic pain with comorbid anxiety/depression 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily; increase to 60 mg after 1 week Hepatic impairment; CrCl &lt;30; MAOIs; narrow-angle glaucoma Nausea, BP; taper to discontinue - ROUTINE ROUTINE - Amitriptyline PO Nocturnal paresthesias (second-line) 10 mg qHS; 25 mg qHS :: PO :: :: Start 10 mg qHS; increase by 10 mg weekly; max 50 mg qHS Cardiac conduction abnormality; urinary retention; glaucoma; elderly ECG if &gt;50 mg; anticholinergic effects - - ROUTINE - Topical diclofenac TOP Localized pain/inflammation Apply gel :: TOP :: TID-QID :: Apply to wrist area TID-QID; max 4 weeks Aspirin-sensitive asthma; open wounds Local skin irritation - - ROUTINE - Lidocaine 5% patch TOP Localized pain 1 patch :: TOP :: 12h on/12h off :: Apply to wrist/forearm 12h on, 12h off Broken skin; severe hepatic impairment Minimal systemic absorption - - ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#3c-second-linerefractory-injection-therapy","title":"3C. Second-line/Refractory (Injection Therapy)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone acetate injection Local injection Moderate CTS failing conservative therapy; bridge to surgery; pregnancy-related CTS 40 mg :: Local injection :: Single injection :: 40 mg (1 mL) injected into carpal tunnel under ultrasound guidance preferred; may repeat x1 at 4-6 weeks Local infection; bleeding disorder; uncontrolled diabetes Blood glucose (diabetics) 24-48h post-injection; tendon rupture (rare) - ROUTINE ROUTINE - Triamcinolone acetonide injection Local injection Alternative corticosteroid for injection 20-40 mg :: Local injection :: Single injection :: 20-40 mg injected into carpal tunnel; ultrasound guidance recommended Local infection; bleeding disorder; uncontrolled diabetes Blood glucose (diabetics); skin depigmentation - ROUTINE ROUTINE - Dexamethasone injection Local injection Alternative corticosteroid (shorter acting) 4 mg :: Local injection :: Single injection :: 4 mg injected into carpal tunnel; shorter duration than triamcinolone Local infection; bleeding disorder Blood glucose (diabetics) - ROUTINE ROUTINE - Platelet-rich plasma (PRP) injection Local injection Experimental; refractory cases; patient preference to avoid surgery 2-3 mL PRP :: Local injection :: Single injection :: Single injection under ultrasound; emerging evidence Infection; thrombocytopenia; malignancy Observe 15 min post-injection - - EXT - <p>Injection Therapy Notes: - Corticosteroid injection provides short-term relief (1-3 months) in most patients - Efficacy decreases with repeated injections - Best as bridge to surgery or for patients with contraindications to surgery - Ultrasound guidance improves accuracy and reduces median nerve injury risk - Pregnancy-related CTS often responds well to injection; many resolve postpartum</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#3d-definitive-surgical-treatment","title":"3D. Definitive Surgical Treatment","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Carpal tunnel release (CTR) - open Surgical Moderate-severe CTS; thenar atrophy; failed conservative therapy x 3-6 months; constant numbness Surgical release :: Outpatient surgery :: Single procedure :: Open technique; divide transverse carpal ligament; 15-30 min procedure NCS confirmation of diagnosis recommended; optimize diabetes; discuss expectations Active infection; unstable medical status; anticoagulation (relative) Post-op pain; wound healing; grip strength; pillar pain - - ROUTINE - Carpal tunnel release (CTR) - endoscopic Surgical Same indications as open CTR; faster return to work; surgeon preference Surgical release :: Outpatient surgery :: Single procedure :: Endoscopic technique (1 or 2 portal); divide transverse carpal ligament NCS confirmation recommended; optimize diabetes Active infection; prior carpal tunnel surgery (relative); anatomic variants Post-op pain; transient nerve injury (1-2%); wound healing - - ROUTINE - <p>Surgical Indications (Absolute): - Thenar muscle atrophy (abductor pollicis brevis wasting) - Constant numbness with loss of two-point discrimination - Severe denervation on EMG (fibrillations, positive sharp waves in APB) - Failed conservative therapy for 3-6 months</p> <p>Surgical Indications (Relative): - Moderate CTS with occupational impairment - Failed 2 corticosteroid injections - Patient preference after informed discussion - Recurrent symptoms after initial improvement with splinting</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Hand surgery or orthopedic surgery referral for carpal tunnel release evaluation when conservative therapy fails or severe CTS present - ROUTINE ROUTINE - Electrodiagnostic medicine/neurology for NCS/EMG to confirm diagnosis and grade severity before surgical intervention - ROUTINE ROUTINE - Occupational medicine for workplace ergonomic assessment and work restrictions if occupational risk factors present - - ROUTINE - Physical/occupational therapy for nerve gliding exercises, ergonomic training, and activity modification - ROUTINE ROUTINE - Rheumatology referral if inflammatory arthritis suspected as underlying cause (RA, gout) - ROUTINE ROUTINE - Endocrinology for diabetes optimization or hypothyroidism management if contributing to CTS - ROUTINE ROUTINE - Primary care for management of modifiable risk factors (diabetes, obesity, hypothyroidism) - ROUTINE ROUTINE - Pain management if refractory neuropathic symptoms despite treatment - - ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Wear wrist splint nightly in neutral position for minimum 4-6 weeks; may wear during day if symptoms persist with activities - ROUTINE ROUTINE Avoid prolonged wrist flexion or extension (typing, gripping tools, driving) as this increases carpal tunnel pressure - ROUTINE ROUTINE Take frequent breaks during repetitive hand activities (every 30-60 minutes) to rest wrists - ROUTINE ROUTINE Perform nerve gliding exercises as instructed by therapist to improve median nerve mobility - ROUTINE ROUTINE Apply ice for 10-15 minutes if wrist swelling present; avoid direct ice contact with skin ROUTINE ROUTINE ROUTINE Report worsening numbness, weakness in thumb, or dropping objects (may indicate progression requiring surgery) ROUTINE ROUTINE ROUTINE Avoid sleeping with wrists curled under pillow; maintain neutral wrist position during sleep - ROUTINE ROUTINE If pregnant, symptoms often improve after delivery; conservative management preferred during pregnancy - ROUTINE ROUTINE After corticosteroid injection, temporary increase in symptoms may occur first 24-48 hours before improvement - ROUTINE ROUTINE Post-surgical: Keep incision clean and dry; elevate hand; start motion as directed; full grip strength recovery may take 3-6 months - ROUTINE ROUTINE","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Optimize glycemic control (HbA1c &lt;7%) as diabetes worsens nerve function and CTS outcomes - ROUTINE ROUTINE Weight loss if overweight/obese as obesity is modifiable risk factor for CTS - ROUTINE ROUTINE Ergonomic workstation setup: keyboard at elbow height, wrists neutral, avoid resting wrists on hard surfaces - ROUTINE ROUTINE Use ergonomic keyboard, mouse, and tools if occupation involves repetitive hand use - ROUTINE ROUTINE Smoking cessation to improve microvascular circulation and nerve healing - ROUTINE ROUTINE Avoid prolonged use of vibrating tools or take breaks every 15-30 minutes when using such equipment - - ROUTINE Reduce caffeine and alcohol intake as these may worsen paresthesias in some patients - ROUTINE ROUTINE Treat underlying thyroid disease as hypothyroidism contributes to CTS through tissue edema - ROUTINE ROUTINE Stretch and warm up hands before repetitive activities - ROUTINE ROUTINE Vitamin B6 supplementation not recommended (evidence does not support benefit; high doses cause neuropathy) - ROUTINE ROUTINE","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Cervical radiculopathy (C6-C7) Neck pain, dermatomal pattern (not strictly median), reflex changes (C6: brachioradialis; C7: triceps), negative Phalen/Tinel MRI cervical spine; NCS/EMG shows radicular pattern; neck range of motion limited Pronator syndrome Forearm pain/tenderness at pronator teres, symptoms with resisted pronation, no nocturnal worsening, palmar cutaneous branch affected NCS/EMG; tenderness at pronator teres on exam; provocative testing Anterior interosseous syndrome Weakness only (FPL, FDP to index, pronator quadratus); no sensory loss; pinch weakness NCS/EMG; cannot make \"OK\" sign (pinch between thumb and index) Thoracic outlet syndrome Shoulder/arm pain, positional symptoms, vascular symptoms (pallor, cyanosis), C8-T1 distribution Adson test; ROOS test; X-ray for cervical rib; MRA; NCS Ulnar neuropathy at elbow (cubital tunnel) Numbness in ring and small finger, hand weakness, elbow symptoms, positive Tinel at elbow NCS/EMG shows ulnar slowing at elbow; sensory exam (ulnar digits spared in CTS) Peripheral polyneuropathy Symmetric symptoms, length-dependent, feet often affected first, multiple nerve territories NCS shows generalized abnormalities; HbA1c; B12; metabolic panel De Quervain tenosynovitis Radial wrist pain, positive Finkelstein test, no numbness, tenderness over 1st dorsal compartment Finkelstein test positive; ultrasound shows tendon thickening; no NCS abnormalities Raynaud phenomenon Color changes (white-blue-red), cold-triggered, bilateral, no weakness No NCS abnormalities; may have positive ANA; capillaroscopy Brachial plexopathy Shoulder/arm weakness and sensory loss in plexus pattern, may have Horner syndrome NCS/EMG; MRI brachial plexus; distribution beyond median nerve Trigger finger Finger locking/clicking, palm nodule, no numbness in median distribution Palpable nodule at A1 pulley; no NCS abnormalities; triggering on exam Ganglion cyst (volar wrist) Palpable mass, may transilluminate, compresses median nerve Ultrasound or MRI shows cystic structure; NCS may be normal or show CTS Multiple sclerosis Central demyelination; other neurologic symptoms; sensory symptoms may mimic CTS MRI brain/spine; CSF oligoclonal bands; NCS normal Syringomyelia Dissociated sensory loss (pain/temp preserved, vibration lost), cape distribution, central cord lesion MRI cervical spine shows syrinx cavity Amyloidosis Bilateral CTS, cardiac involvement, macroglossia, renal disease, family history (hATTR) SPEP/UPEP; free light chains; TTR gene; tissue biopsy","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"<p>Venue column indicates where monitoring is typically ordered/initiated.</p> Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Symptom severity (numbness, tingling, nocturnal symptoms) Each visit Improvement or stable Consider escalation: injection if splinting fails; surgery if injection fails - ROUTINE ROUTINE - Grip strength Baseline and q4-8 weeks if weakness Normal for age/sex; no decline Expedite surgical referral if progressive weakness - ROUTINE ROUTINE - Thenar muscle bulk Each visit No atrophy If atrophy developing, urgent surgical referral (indicates severe CTS) - ROUTINE ROUTINE - Two-point discrimination Baseline and periodic Normal (&lt;6 mm) If abnormal/worsening, indicates sensory axonal loss; consider surgery - ROUTINE ROUTINE - Splint compliance Each visit Nightly use minimum Re-educate; consider injection if compliant but not improving - ROUTINE ROUTINE - HbA1c (diabetic patients) Every 3 months &lt;7% or individualized Intensify diabetes management - ROUTINE ROUTINE - TSH (if hypothyroid) Every 6-12 months 0.4-4.0 mIU/L Adjust thyroid replacement - - ROUTINE - Post-injection response 2-4 weeks after injection Symptom improvement If no improvement, discuss surgical options - ROUTINE ROUTINE - Post-surgical wound healing 7-14 days post-op Clean, healing, no infection If infection signs, antibiotics and wound care - ROUTINE ROUTINE - Post-surgical sensory/motor function 6 weeks, 3 months, 6 months post-op Progressive improvement If not improving, NCS/EMG; consider incomplete release or scarring - ROUTINE ROUTINE - Recurrence after surgery Annual if risk factors present No symptom recurrence NCS; consider revision surgery if confirmed recurrence - - ROUTINE -","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild-moderate CTS; can use splint; outpatient neurology/hand surgery follow-up arranged; no thenar atrophy; no progressive weakness Admit to floor Acute compartment syndrome of forearm/hand (rare); post-operative complication requiring observation; severe medical comorbidities requiring inpatient management Admit to ICU Not typical for CTS; only if concurrent critical illness Urgent surgical referral Thenar atrophy; progressive weakness; constant numbness with sensory loss; failed conservative therapy &gt;6 months; severe CTS on NCS with denervation Routine surgical referral Moderate CTS with inadequate response to splinting and injection; patient preference; occupational impairment Outpatient follow-up Most patients; splinting trial with reassessment in 4-6 weeks; post-injection follow-up in 2-4 weeks","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Nocturnal wrist splinting is effective first-line treatment for CTS Class I, Level A Page MJ et al. Cochrane Database Syst Rev 2012 NCS/EMG recommended for diagnostic confirmation before surgery Class II, Level B Werner RA et al. Muscle Nerve 2011 Corticosteroid injection provides short-term symptom relief Class I, Level A Marshall S et al. Cochrane Database Syst Rev 2007 Carpal tunnel release surgery is effective for moderate-severe CTS Class I, Level A Verdugo RJ et al. Cochrane Database Syst Rev 2008 Ultrasound-guided injection improves accuracy and outcomes Class II, Level B Ustun N et al. Arch Phys Med Rehabil 2013 Diabetes mellitus is significant risk factor for CTS Class II, Level B Pourmemari MH et al. Diabet Med 2016 Clinical examination (Phalen, Tinel) has moderate sensitivity/specificity Class II, Level B Middleton SD et al. J Hand Surg Eur Vol 2014 Severe CTS with thenar atrophy should be referred for surgery Class II, Level B Graham B et al. J Am Acad Orthop Surg 2016 Endoscopic and open CTR have equivalent long-term outcomes Class I, Level A Scholten RJ et al. Cochrane Database Syst Rev 2007 Pregnancy-related CTS often resolves postpartum Class III, Level C Padua L et al. Muscle Nerve 2010 Median nerve CSA &gt;10-12 mm\u00b2 on ultrasound supports CTS diagnosis Class II, Level B Cartwright MS et al. Muscle Nerve 2012 Nerve gliding exercises may provide modest benefit as adjunct therapy Class II, Level C Ballestero-Perez R et al. J Orthop Sports Phys Ther 2017 AAOS Clinical Practice Guideline for CTS Guideline AAOS Guideline 2016 AANEM practice parameter for electrodiagnosis of CTS Guideline Jablecki CK et al. Muscle Nerve 2002","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#cpt-code-quick-reference","title":"CPT CODE QUICK REFERENCE","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#laboratory-cpt-codes","title":"Laboratory CPT Codes","text":"Test CPT Code Description Fasting glucose 82947 Glucose, quantitative HbA1c 83036 Hemoglobin A1c TSH 84443 Thyroid stimulating hormone Rheumatoid factor 86431 Rheumatoid factor, quantitative Anti-CCP antibody 86200 Cyclic citrullinated peptide antibody ESR 85652 Sedimentation rate, Westergren CRP 86140 C-reactive protein Uric acid 84550 Uric acid, blood BUN 84520 Blood urea nitrogen Creatinine 82565 Creatinine, blood CBC with differential 85025 Complete blood count Vitamin B12 82607 Cyanocobalamin SPEP 86335 Protein electrophoresis, serum Free light chains 83883 Kappa/lambda Pregnancy test (urine) 81025 Urine pregnancy test Pregnancy test (serum) 84702 Gonadotropin, chorionic, quantitative","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#diagnostic-studies-cpt-codes","title":"Diagnostic Studies CPT Codes","text":"Study CPT Code Description NCS, 1-2 studies 95907 Nerve conduction, 1-2 studies NCS, 3-4 studies 95908 Nerve conduction, 3-4 studies NCS, 5-6 studies 95909 Nerve conduction, 5-6 studies Needle EMG, limited 95885 EMG, limited (1 extremity) Wrist X-ray, 2 views 73100 Radiologic exam, wrist, 2 views Wrist X-ray, complete 73110 Radiologic exam, wrist, complete (minimum 3 views) MRI wrist without contrast 73221 MRI, upper extremity joint, without contrast MRI wrist with and without contrast 73223 MRI, upper extremity joint, with and without contrast Ultrasound wrist/soft tissue 76882 Ultrasound, extremity, limited MRI cervical spine without contrast 72141 MRI cervical spine without contrast MRI cervical spine with and without contrast 72156 MRI cervical spine complete","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#treatmentprocedure-cpt-codes","title":"Treatment/Procedure CPT Codes","text":"Procedure CPT Code Description Carpal tunnel injection 20526 Injection, therapeutic, carpal tunnel Ultrasound guidance for injection 76942 Ultrasound guidance for needle placement Carpal tunnel release, open 64721 Neuroplasty, median nerve at carpal tunnel Carpal tunnel release, endoscopic 29848 Endoscopy, carpal tunnel release Splint application, forearm-wrist 29125 Application of short arm splint <p>Note: CPT codes are updated annually. Verify codes against current CMS fee schedule.</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#appendix-a-clinical-examination-techniques","title":"APPENDIX A: Clinical Examination Techniques","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#provocative-tests-for-carpal-tunnel-syndrome","title":"Provocative Tests for Carpal Tunnel Syndrome","text":"<p>Phalen Test (Wrist Flexion Test) - Technique: Hold both wrists in full flexion for 60 seconds - Positive: Reproduction of paresthesias in median distribution within 60 seconds - Sensitivity: 68-73%; Specificity: 73-83%</p> <p>Reverse Phalen Test (Prayer Test) - Technique: Hold both wrists in full extension for 60 seconds - Positive: Reproduction of paresthesias in median distribution - Less commonly used than standard Phalen</p> <p>Tinel Sign at Wrist - Technique: Tap over carpal tunnel at wrist crease - Positive: Electric/tingling sensation radiating into thumb, index, middle finger - Sensitivity: 50-60%; Specificity: 67-77%</p> <p>Carpal Compression Test (Durkan's Test) - Technique: Apply direct pressure over carpal tunnel for 30 seconds - Positive: Reproduction of paresthesias - Sensitivity: 64-87%; Specificity: 83-90% - May be more sensitive than Tinel sign</p> <p>Flick Sign - Technique: Ask patient what they do when symptoms occur at night - Positive: Patient demonstrates shaking/flicking hands for relief - Sensitivity: 93%; Specificity: 96% - Highly suggestive of CTS when present</p> <p>Hand Elevation Test - Technique: Raise hands above head for 1-2 minutes - Positive: Reproduction of numbness/paresthesias - Sensitivity: 75-89%; Specificity: 87-98%</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#severity-assessment","title":"Severity Assessment","text":"<p>Clinical Severity Grading - Mild: Intermittent paresthesias, nocturnal symptoms only, normal exam - Moderate: Frequent paresthesias, daytime symptoms, mild sensory loss, no weakness - Severe: Constant numbness, thenar weakness/atrophy, impaired two-point discrimination</p> <p>Electrodiagnostic Severity (AANEM Classification) - Mild: Prolonged sensory latency only; normal motor studies - Moderate: Prolonged sensory and motor distal latencies; reduced SNAP amplitude - Severe: Absent sensory response; prolonged motor latency with reduced CMAP; fibrillations/positive sharp waves in APB</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#appendix-b-nerve-conduction-study-criteria-for-cts","title":"APPENDIX B: Nerve Conduction Study Criteria for CTS","text":"","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#standard-electrodiagnostic-criteria","title":"Standard Electrodiagnostic Criteria","text":"<p>Sensory Studies - Median sensory distal latency &gt;3.5 ms (14 cm distance) OR - Median-ulnar sensory latency difference &gt;0.5 ms OR - Median-radial sensory latency difference &gt;0.5 ms</p> <p>Motor Studies - Median motor distal latency &gt;4.2 ms</p> <p>Combined Sensory Index (CSI) - Robinson Criteria - Sum of: (median-ulnar palm latency difference) + (median-ulnar digit 4 difference) + (median-radial thumb difference) - CSI &gt;0.9 ms is abnormal</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#electrodiagnostic-severity-classification","title":"Electrodiagnostic Severity Classification","text":"Severity Sensory Motor EMG Minimal Abnormal comparative studies only (palm or digit) Normal Normal Mild Prolonged absolute sensory latency Normal Normal Moderate Prolonged sensory latency; reduced SNAP amplitude Prolonged motor latency Normal Severe Absent sensory response Prolonged motor latency; reduced CMAP Fibrillations/PSWs in APB Very Severe Absent sensory response Absent or very low CMAP Chronic denervation in APB","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/carpal-tunnel-syndrome/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial creation - Comprehensive outpatient-focused plan for carpal tunnel syndrome evaluation and management - Includes clinical examination techniques (Phalen, Tinel, flick sign, Durkan) - EMG/NCS criteria for severity grading with AANEM classification - Conservative management: splinting, ergonomics, nerve gliding - Corticosteroid injection protocols with ultrasound guidance recommendation - Surgical indications for open and endoscopic CTR - Complete differential diagnosis including cervical radiculopathy, pronator syndrome - Risk factor evaluation: diabetes, hypothyroidism, pregnancy, RA, amyloidosis - All treatment dosing in structured format for order sentence generation - CPT code reference for billing - Appendices with clinical examination techniques and electrodiagnostic criteria</p>","tags":["entrapment-neuropathy","upper-extremity","outpatient","pain-management"]},{"location":"drafts/cidp/","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#chronic-inflammatory-demyelinating-polyneuropathy-cidp","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 REVISED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</p> <p>ICD-10: G61.81</p> <p>SCOPE: Evaluation, diagnosis, treatment initiation, and long-term management of CIDP in adults. Covers typical CIDP, CIDP variants (MADSAM, DADS, sensory CIDP), first-line immunotherapy (IVIg, corticosteroids, plasmapheresis), second-line immunosuppressants, and subcutaneous immunoglobulin therapy. Primary focus is outpatient management with coverage for acute presentations and hospitalizations. Excludes Guillain-Barr\u00e9 syndrome (acute onset &lt;8 weeks), hereditary neuropathies (CMT), and pediatric CIDP.</p> <p>CLINICAL SYNONYMS: Chronic inflammatory demyelinating polyradiculoneuropathy, chronic relapsing polyneuropathy, chronic acquired demyelinating polyneuropathy, CIDP</p> <p>ADDITIONAL ICD-10 CODES: - G61.89 - Other inflammatory polyneuropathies - G62.9 - Polyneuropathy, unspecified (pre-diagnosis)</p> <p>KEY CLINICAL FEATURES: - Progressive or relapsing symmetric proximal AND distal weakness - Sensory symptoms (numbness, paresthesias, sensory ataxia) - Hyporeflexia or areflexia - Duration &gt;8 weeks (distinguishes from GBS) - Elevated CSF protein with normal cell count (albuminocytologic dissociation) - Electrodiagnostic evidence of demyelination</p> <p>CIDP VARIANTS: | Variant | Features | Notes | |---------|----------|-------| | Typical CIDP | Symmetric proximal and distal weakness, sensory loss | Most common (~50%) | | MADSAM (Lewis-Sumner) | Multifocal, asymmetric; sensorimotor | May mimic MMN | | DADS | Distal acquired demyelinating symmetric; sensory predominant | Often anti-MAG positive | | Sensory CIDP | Pure sensory; ataxia, large fiber loss | NCS shows demyelination | | Motor CIDP | Pure motor; no sensory involvement | Rare; consider MMN | | Focal CIDP | Involvement of one or two limbs | Rare |</p> <p>EFNS/PNS DIAGNOSTIC CRITERIA (2021 Update):</p> <p>Clinical Criteria: - Typical CIDP: Progressive or relapsing symmetric proximal and distal weakness AND sensory dysfunction of all extremities, developing over \u22658 weeks - Cranial nerves may be affected - Tendon reflexes reduced or absent in all limbs</p> <p>Supportive Criteria: - CSF protein elevated with WBC &lt;10/mm\u00b3 - MRI showing nerve root or plexus enhancement or hypertrophy - Objective clinical improvement following immunomodulatory treatment</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\ud83d\udccb CHRONIC DISEASE NOTE</p> <p>CIDP is a chronic, treatable condition. Most patients respond to first-line immunotherapy. The goal is symptom control with minimal treatment burden. Long-term monitoring and periodic treatment adjustments are essential.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline, infection screen, pre-treatment Normal STAT STAT ROUTINE STAT CMP (BMP + LFTs) Electrolytes, renal/hepatic function for IVIg Normal STAT STAT ROUTINE STAT ESR Inflammatory marker; elevated in some CIDP Document baseline URGENT ROUTINE ROUTINE URGENT CRP Inflammatory marker Document baseline URGENT ROUTINE ROUTINE URGENT HbA1c Diabetic neuropathy in differential; diabetes worsens CIDP &lt;5.7% (normal); &gt;6.5% diagnostic for diabetes URGENT ROUTINE ROUTINE URGENT Fasting glucose Diabetes screening &lt;100 mg/dL URGENT ROUTINE ROUTINE URGENT TSH Thyroid disease causing neuropathy Normal (0.4-4.0 mIU/L) URGENT ROUTINE ROUTINE URGENT Vitamin B12 B12 deficiency neuropathy &gt;300 pg/mL URGENT ROUTINE ROUTINE URGENT Methylmalonic acid If B12 borderline (200-400 pg/mL) Normal if B12 sufficient \u2014 ROUTINE ROUTINE \u2014 Serum protein electrophoresis (SPEP) Paraproteinemic neuropathy screen No monoclonal spike \u2014 ROUTINE ROUTINE \u2014 Serum immunofixation Confirms monoclonal protein if SPEP abnormal Characterize M-protein \u2014 ROUTINE ROUTINE \u2014 HIV antibody HIV-associated neuropathy/CIDP Negative \u2014 ROUTINE ROUTINE \u2014 Hepatitis B surface antigen Pre-IVIg screening; HBV reactivation risk Negative \u2014 URGENT ROUTINE URGENT Hepatitis B core antibody Prior HBV exposure; reactivation risk with immunosuppression Negative \u2014 URGENT ROUTINE URGENT Hepatitis C antibody HCV-associated cryoglobulinemic neuropathy Negative \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Urine protein electrophoresis (UPEP) Light chain deposition in neuropathy No monoclonal protein \u2014 ROUTINE ROUTINE \u2014 Serum free light chains AL amyloidosis, POEMS screening Normal kappa:lambda ratio \u2014 ROUTINE ROUTINE \u2014 VEGF level Elevated in POEMS syndrome Normal (&lt;200 pg/mL) \u2014 EXT ROUTINE \u2014 Anti-MAG antibody DADS variant; IgM paraproteinemic neuropathy Negative (if positive, suggests DADS-CIDP or anti-MAG neuropathy) \u2014 ROUTINE ROUTINE \u2014 Anti-ganglioside antibodies (GM1, GD1a, GD1b) MMN differentiation; axonal GBS variants Document if positive \u2014 ROUTINE ROUTINE \u2014 Anti-GQ1b antibody Miller Fisher variant if ophthalmoplegia Document if positive \u2014 ROUTINE ROUTINE \u2014 Quantitative immunoglobulins (IgG, IgA, IgM) IgA deficiency (IVIg contraindication); IgM elevation IgA &gt;7 mg/dL; document IgM \u2014 URGENT ROUTINE URGENT ANA Connective tissue disease screen Negative or low titer \u2014 ROUTINE ROUTINE \u2014 Rheumatoid factor Vasculitic neuropathy screen Negative \u2014 ROUTINE ROUTINE \u2014 Anti-SSA/SSB Sjogren syndrome neuropathy Negative \u2014 ROUTINE ROUTINE \u2014 ACE level Sarcoid neuropathy Normal \u2014 EXT ROUTINE \u2014 PT/INR, PTT Pre-LP, pre-PLEX Normal URGENT ROUTINE \u2014 STAT Type and screen Pre-PLEX Available \u2014 URGENT \u2014 STAT","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Anti-contactin-1 (CNTN1) antibody Aggressive CIDP variant; poor IVIg response Document if positive \u2014 EXT EXT \u2014 Anti-neurofascin-155 (NF155) antibody Young onset, tremor, poor IVIg response Document if positive \u2014 EXT EXT \u2014 Anti-caspr-1 antibody Nodopathy; aggressive course Document if positive \u2014 EXT EXT \u2014 Anti-NF186/NF140 antibodies Nodal/paranodal antibodies Document if positive \u2014 EXT EXT \u2014 Genetic testing for CMT If family history or atypical features Negative (excludes CMT) \u2014 EXT EXT \u2014 Lyme serology Endemic area, outdoor exposure Negative \u2014 EXT ROUTINE \u2014 Heavy metals (lead, arsenic) Toxic neuropathy differential Normal \u2014 EXT EXT \u2014 Urine porphyrins Motor neuropathy with systemic symptoms Normal \u2014 EXT EXT \u2014 Bone marrow biopsy If POEMS or amyloidosis suspected Normal or diagnostic \u2014 EXT EXT \u2014 Fat pad biopsy for amyloid If amyloidosis suspected Negative \u2014 EXT EXT \u2014 Cryoglobulins If HCV positive or vasculitic features Negative \u2014 EXT ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Nerve conduction studies (NCS) At diagnosis; before treatment Demyelinating features: prolonged distal latencies (&gt;125% ULN), slow conduction velocities (&lt;80% LLN), conduction block, temporal dispersion, prolonged F-waves None \u2014 URGENT ROUTINE \u2014 Electromyography (EMG) At diagnosis; with NCS Secondary axonal loss; fibrillations in severe cases Severe coagulopathy \u2014 URGENT ROUTINE \u2014 Chest X-ray Pre-treatment baseline Normal (rule out mass if paraneoplastic concern) None STAT ROUTINE ROUTINE STAT","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI spine with contrast (cervical/lumbar) Diagnostic workup Nerve root enhancement, cauda equina hypertrophy Pacemaker, severe claustrophobia \u2014 ROUTINE ROUTINE \u2014 MRI brachial plexus with contrast If asymmetric or plexus involvement Nerve hypertrophy, enhancement Pacemaker \u2014 ROUTINE ROUTINE \u2014 MRI lumbosacral plexus with contrast If lower extremity predominant Plexus enhancement, thickening Pacemaker \u2014 ROUTINE ROUTINE \u2014 Nerve ultrasound Complementary to MRI; assess nerve enlargement Increased cross-sectional area of peripheral nerves None \u2014 ROUTINE ROUTINE \u2014 CT chest/abdomen/pelvis If POEMS or malignancy suspected Sclerotic bone lesions (POEMS), organomegaly Contrast allergy, renal impairment \u2014 EXT ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU PET-CT Occult malignancy, lymphoma, Castleman disease Tumor identification Hemodynamic instability \u2014 EXT EXT \u2014 Nerve biopsy (sural) Diagnostic uncertainty, vasculitis suspected Demyelination, inflammation, onion bulbs Active infection at site \u2014 EXT EXT \u2014 Skeletal survey POEMS evaluation Sclerotic or lytic lesions None \u2014 EXT ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Confirm diagnosis (albuminocytologic dissociation); exclude infection or malignancy; required for EFNS/PNS supportive criteria</p> <p>Timing: ROUTINE for diagnosis; not urgent unless acute deterioration or infection concern</p> <p>Volume Required: 10-15 mL standard diagnostic</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Baseline; usually normal in CIDP 10-20 cmH2O URGENT ROUTINE ROUTINE \u2014 Cell count (tubes 1 and 4) Albuminocytologic dissociation WBC &lt;10/mm\u00b3 (usually &lt;5) URGENT ROUTINE ROUTINE \u2014 Protein Elevated in CIDP Elevated (&gt;45 mg/dL; often 50-200 mg/dL) URGENT ROUTINE ROUTINE \u2014 Glucose Exclude infection Normal (&gt;60% serum glucose) URGENT ROUTINE ROUTINE \u2014 Gram stain and culture Exclude infection Negative URGENT ROUTINE \u2014 \u2014 Cytology Exclude carcinomatous meningitis Negative \u2014 ROUTINE ROUTINE \u2014 VDRL Neurosyphilis in differential Negative \u2014 ROUTINE ROUTINE \u2014 Oligoclonal bands MS or CNS inflammation in differential Usually negative; may be mildly positive \u2014 ROUTINE ROUTINE \u2014 <p>Special Handling: Cell count within 1 hour. Cytology refrigerated.</p> <p>Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50K), anticoagulation, skin infection at LP site.</p> <p>NOTE: CSF protein is elevated in &gt;80% of CIDP patients. Normal CSF protein does not exclude CIDP if electrodiagnostic criteria are met.</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: CIDP is treatable. First-line therapies (IVIg, corticosteroids, PLEX) are effective in ~80% of patients. Treatment choice depends on patient characteristics, access, and preference.</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#treatment-selection-guidance","title":"Treatment Selection Guidance","text":"Factor IVIg Preferred Corticosteroids Preferred PLEX Preferred Pure motor CIDP Yes Avoid (may worsen motor) Yes Diabetes mellitus Yes Avoid (worsens glycemic control) Yes Cost/access concerns If covered Yes (low cost) Limited access Rapid response needed Yes No (slow onset) Yes Long-term therapy Maintenance possible Taper to lowest dose; add steroid-sparing Not practical Pregnancy Preferred Avoid if possible Safe Nodal/paranodal antibodies May be less effective May be effective May be effective; rituximab preferred","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3a-first-line-immunotherapy-induction","title":"3A. First-line Immunotherapy - Induction","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IVIg (immune globulin IV) - Loading IV First-line induction 2 g/kg over 2-5 days :: IV :: divided over 2-5 days :: 2 g/kg total divided over 2-5 days (e.g., 0.4 g/kg/day x 5 days or 1 g/kg/day x 2 days); infuse slowly day 1 (start 0.5-1 mL/kg/hr, max 4 mL/kg/hr) IgA deficiency with anti-IgA antibodies; uncontrolled heart failure; recent thrombosis; severe renal impairment Renal function, headache, infusion reactions; pre-medicate with acetaminophen and diphenhydramine \u2014 URGENT ROUTINE URGENT Prednisone - Daily PO First-line induction (if IVIg unavailable or contraindicated) 60 mg daily; 1 mg/kg daily :: PO :: daily :: Start 60 mg (or 1 mg/kg) daily for 4-8 weeks until clinical improvement, then begin slow taper Uncontrolled diabetes, active infection, psychosis, osteoporosis Glucose, BP, bone density, mood, infection signs \u2014 ROUTINE ROUTINE \u2014 Prednisone - Pulse PO Alternative oral pulse therapy 40 mg daily x 5 days monthly :: PO :: daily x 5 days q4wk :: 40-60 mg daily for 5 consecutive days each month; may have fewer side effects than daily Uncontrolled diabetes, active infection Glucose, BP during pulse \u2014 ROUTINE ROUTINE \u2014 Methylprednisolone - IV Pulse IV Severe CIDP, rapid induction needed 1000 mg daily x 3-5 days :: IV :: daily x 3-5 days :: 1000 mg IV daily for 3-5 days; can repeat monthly as needed; transition to oral Active untreated infection, uncontrolled HTN/diabetes Glucose, BP, K+, psychiatric effects \u2014 URGENT ROUTINE URGENT Plasma exchange (PLEX) \u2014 First-line if IVIg/steroids contraindicated or failed 5-10 exchanges over 2-4 weeks :: \u2014 :: 2-3x/week :: 5-10 exchanges (1-1.5 plasma volumes each) over 2-4 weeks; typically 2-3 sessions per week Hemodynamic instability, severe sepsis, poor vascular access BP, electrolytes, coagulation, fibrinogen \u2014 URGENT \u2014 URGENT","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3b-first-line-immunotherapy-maintenance","title":"3B. First-line Immunotherapy - Maintenance","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IVIg - Maintenance IV Maintenance after loading response 0.4 g/kg q3wk; 0.5 g/kg q3wk; 1 g/kg q3-4wk :: IV :: q3-4wk :: 0.4-1 g/kg every 3-4 weeks; titrate to lowest effective dose and longest interval; some patients need 1 g/kg q2-3wk IgA deficiency, renal impairment, recent thrombosis Renal function q3-6mo; trough IgG levels optional \u2014 ROUTINE ROUTINE \u2014 SCIg (Hizentra) - Maintenance SC Home maintenance after IVIg response Weekly dose = IVIg monthly dose \u00f7 4 :: SC :: weekly or divided :: Convert from IVIg: weekly SC dose equals monthly IV dose divided by 4; typical range 0.2-0.4 g/kg/week; divide into 1-7 infusions/week Severe thrombocytopenia, skin conditions at injection site Local site reactions; IgG trough levels q6mo \u2014 \u2014 ROUTINE \u2014 SCIg (Gamunex-C 10%) - Maintenance SC Home maintenance alternative Weekly dose = IVIg monthly dose \u00f7 4 :: SC :: weekly :: Same as Hizentra; 10% concentration; can give larger volume per site Severe thrombocytopenia Local reactions, IgG levels \u2014 \u2014 ROUTINE \u2014 Prednisone - Maintenance taper PO Continuation after steroid induction Taper by 5-10 mg q2-4wk :: PO :: daily :: After improvement, taper by 5-10 mg every 2-4 weeks; target lowest effective dose (often 5-20 mg daily or QOD); add steroid-sparing agent if unable to taper below 15-20 mg Ongoing infection Glucose, BP, bone density, cataracts \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3c-second-linesteroid-sparing-agents","title":"3C. Second-line/Steroid-Sparing Agents","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Azathioprine PO Steroid-sparing; maintenance 50 mg daily; 100 mg daily; 150 mg daily; 2-3 mg/kg daily :: PO :: daily :: Start 50 mg daily; increase by 50 mg every 2-4 weeks to target 2-3 mg/kg/day; check TPMT before starting; onset 3-6 months TPMT deficiency, pregnancy, myelosuppression CBC weekly x 4 weeks, then monthly x 3 months, then q3mo; LFTs monthly \u2014 \u2014 ROUTINE \u2014 Mycophenolate mofetil PO Steroid-sparing; maintenance 500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: BID :: Start 500 mg BID; increase to 1000-1500 mg BID over 2-4 weeks; onset 2-4 months Pregnancy (teratogenic), severe renal impairment CBC q2wk x 2 months, then monthly; LFTs \u2014 \u2014 ROUTINE \u2014 Rituximab IV Refractory CIDP, nodal antibody-positive 375 mg/m\u00b2 weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: 375 mg/m\u00b2 weekly x 4 doses OR 1000 mg x 2 doses (2 weeks apart); repeat q6-12mo PRN; pre-medicate Active infection, HBV (screen first; may reactivate) Infusion reactions, CD19/CD20 counts, immunoglobulins; HBV DNA if prior exposure \u2014 EXT EXT \u2014 Cyclophosphamide IV Severe refractory CIDP 1 g/m\u00b2 monthly x 6 months :: IV :: monthly :: 1 g/m\u00b2 IV monthly for 6 months; reserve for severe refractory cases Pregnancy, active infection, hemorrhagic cystitis CBC, urinalysis, fertility counseling; MESNA for bladder protection \u2014 EXT EXT \u2014 Cyclosporine PO Steroid-sparing alternative 2.5-5 mg/kg/day divided BID :: PO :: BID :: Start 2.5 mg/kg/day divided BID; increase to 5 mg/kg/day based on levels and response; target trough 100-200 ng/mL Uncontrolled HTN, renal impairment Cr, BP, drug levels, K+, Mg \u2014 \u2014 EXT \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3d-disease-modifying-therapy-special-populations","title":"3D. Disease-Modifying Therapy - Special Populations","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU IVIg - Anti-MAG positive IV Anti-MAG neuropathy (may have partial response) 2 g/kg loading then 0.4-1 g/kg q3-4wk :: IV :: per protocol :: Anti-MAG neuropathy often less responsive to IVIg; may require rituximab if poor response SPEP/UPEP to assess for underlying plasma cell dyscrasia IgA deficiency Response may be slower; consider rituximab if no improvement \u2014 ROUTINE ROUTINE \u2014 Rituximab - Anti-MAG positive IV Anti-MAG neuropathy preferred therapy 375 mg/m\u00b2 weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: First-line for anti-MAG neuropathy given superior efficacy; repeat q6-12mo HBV/HCV screening, quantitative immunoglobulins, CBC Active HBV, active infection Anti-MAG titers, CD19/20, immunoglobulins \u2014 EXT ROUTINE \u2014 Rituximab - Nodal antibody positive (NF155, CNTN1) IV CIDP with nodal/paranodal antibodies 375 mg/m\u00b2 weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: Preferred for NF155/CNTN1/CASPR1 positive CIDP (poor IVIg response); repeat q6mo HBV/HCV screening, immunoglobulins Active HBV Antibody titers, B-cell counts \u2014 EXT ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3e-symptomatic-treatments","title":"3E. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO Neuropathic pain 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: TID :: Start 300 mg qHS; titrate by 300 mg/day q3d; target 900-1800 mg TID; max 3600 mg/day Severe renal impairment (adjust dose) Sedation, dizziness, edema; reduce dose if CrCl &lt;60 \u2014 ROUTINE ROUTINE \u2014 Pregabalin PO Neuropathic pain 75 mg BID; 150 mg BID; 300 mg BID :: PO :: BID :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day Severe renal impairment (adjust dose) Sedation, edema, weight gain \u2014 ROUTINE ROUTINE \u2014 Duloxetine PO Neuropathic pain, depression 30 mg daily; 60 mg daily :: PO :: daily :: Start 30 mg daily; increase to 60 mg daily after 1-2 weeks; max 120 mg/day Uncontrolled glaucoma, severe hepatic impairment, MAOIs BP, hepatic function, serotonin syndrome \u2014 ROUTINE ROUTINE \u2014 Amitriptyline PO Neuropathic pain, sleep 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: qHS :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; max 150 mg qHS Cardiac arrhythmias, recent MI, glaucoma, urinary retention ECG if &gt;100 mg/day; anticholinergic effects \u2014 ROUTINE ROUTINE \u2014 Acetaminophen PO Mild pain 650 mg q6h PRN; 1000 mg q6h PRN :: PO :: q6h PRN :: 650-1000 mg q6h PRN; max 4 g/day (3 g if hepatic impairment) Severe hepatic impairment LFTs if prolonged use STAT ROUTINE ROUTINE STAT Mexiletine PO Muscle cramps, neuropathic pain (refractory) 150 mg TID; 200 mg TID :: PO :: TID :: Start 150 mg TID; may increase to 200-300 mg TID; max 1200 mg/day Cardiac arrhythmia, heart block ECG, hepatic function \u2014 EXT EXT \u2014 Baclofen PO Muscle cramps, spasms 5 mg TID; 10 mg TID; 20 mg TID :: PO :: TID :: Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day Severe renal impairment Sedation; do not stop abruptly \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#3f-prophylaxis-and-supportive-care","title":"3F. Prophylaxis and Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Calcium + Vitamin D PO Bone protection on steroids Calcium 1000-1200 mg daily; Vitamin D 800-2000 IU daily :: PO :: daily :: Calcium 500-600 mg BID (with food) + Vitamin D 800-2000 IU daily for all patients on chronic steroids Hypercalcemia, kidney stones Calcium levels, 25-OH vitamin D \u2014 ROUTINE ROUTINE \u2014 Bisphosphonate (alendronate) PO Osteoporosis prevention on steroids 70 mg weekly :: PO :: weekly :: 70 mg PO weekly if prednisone &gt;7.5 mg for &gt;3 months; take with water, remain upright 30 min Esophageal disorders, CrCl &lt;35, hypocalcemia DEXA scan at baseline and q1-2yr; dental exam \u2014 \u2014 ROUTINE \u2014 Omeprazole PO GI protection on steroids 20 mg daily :: PO :: daily :: 20 mg daily for patients on high-dose steroids or with GI symptoms Long-term use concerns (Mg, B12, fractures) Mg levels if prolonged \u2014 ROUTINE ROUTINE \u2014 Aspirin (low-dose) PO Thrombosis prevention with IVIg 81 mg daily :: PO :: daily :: 81 mg daily during IVIg infusions for patients with thrombosis risk factors (age &gt;60, obesity, immobility, prior VTE, hyperviscosity) Active bleeding, allergy None routine \u2014 ROUTINE ROUTINE \u2014 Enoxaparin SC DVT prophylaxis (immobile patients) 40 mg daily :: SC :: daily :: 40 mg SC daily for immobile hospitalized patients; continue until ambulating Active bleeding, HIT, CrCl &lt;30 Platelet count \u2014 STAT \u2014 STAT PCP prophylaxis (TMP-SMX) PO Pneumocystis prevention on high-dose steroids 1 DS tablet 3x/week :: PO :: 3x/week :: TMP-SMX DS (160/800 mg) 3x/week or daily if prednisone &gt;20 mg for &gt;4 weeks + another immunosuppressant Sulfa allergy (use dapsone or atovaquone) CBC, renal function \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consult for diagnosis confirmation, treatment initiation, and long-term management planning URGENT STAT \u2014 STAT Neuromuscular specialist referral for diagnostic uncertainty, treatment-refractory cases, or consideration of advanced therapies \u2014 ROUTINE ROUTINE \u2014 Infusion center referral for ongoing IVIg administration and monitoring \u2014 ROUTINE ROUTINE \u2014 Home infusion service referral for SCIg training and home therapy setup \u2014 ROUTINE ROUTINE \u2014 Physical therapy for gait training, fall prevention, strengthening exercises, and mobility optimization \u2014 URGENT ROUTINE \u2014 Occupational therapy for ADL assessment, adaptive equipment, and energy conservation strategies \u2014 URGENT ROUTINE \u2014 Pain management consult for refractory neuropathic pain not responding to gabapentin/pregabalin/duloxetine \u2014 ROUTINE ROUTINE \u2014 Endocrinology consult for steroid-induced diabetes management or osteoporosis prevention \u2014 ROUTINE ROUTINE \u2014 Hematology consult if monoclonal protein detected for POEMS or myeloma workup \u2014 ROUTINE ROUTINE \u2014 Pulmonology consult if respiratory symptoms develop (rare in CIDP; consider GBS overlap) URGENT URGENT \u2014 STAT Rheumatology consult if connective tissue disease suspected based on labs or clinical features \u2014 ROUTINE ROUTINE \u2014 Social work for disability resources, transportation assistance, and community support services \u2014 ROUTINE ROUTINE \u2014 PCP follow-up for chronic disease management, steroid side effect monitoring, and preventive care \u2014 ROUTINE ROUTINE \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if progressive weakness, difficulty walking, or breathing problems develop (may indicate disease progression or acute worsening) STAT \u2014 STAT Keep all IVIg/infusion appointments as scheduled to maintain disease control and prevent relapses \u2014 ROUTINE ROUTINE Do not stop immunosuppressive medications suddenly as this may cause disease flare; taper only under physician guidance STAT STAT STAT Report signs of infection (fever, cough, dysuria) promptly as immunosuppression increases infection risk STAT STAT STAT Use fall precautions including handrails, non-slip surfaces, and assistive devices due to balance and weakness STAT STAT STAT Perform home exercises as prescribed by physical therapy to maintain strength and flexibility \u2014 ROUTINE ROUTINE Monitor for IVIg side effects including headache, fever, chills, or rash during infusions; report severe symptoms \u2014 ROUTINE ROUTINE Keep a symptom diary tracking strength, numbness, and functional abilities to share at follow-up visits \u2014 ROUTINE ROUTINE Carry a medical ID card indicating CIDP diagnosis and current treatments in case of emergency \u2014 ROUTINE ROUTINE Contact GBS-CIDP Foundation (www.gbs-cidp.org) for patient education, support groups, and resources \u2014 ROUTINE ROUTINE","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Maintain glycemic control (HbA1c &lt;7%) to prevent worsening of neuropathy if diabetic \u2014 ROUTINE ROUTINE Limit alcohol consumption as alcohol worsens peripheral neuropathy and interacts with medications \u2014 ROUTINE ROUTINE Ensure adequate vitamin B12 and folate intake through diet or supplementation to support nerve health \u2014 ROUTINE ROUTINE Avoid smoking as it impairs circulation and may worsen neuropathy \u2014 ROUTINE ROUTINE Stay up to date on vaccinations (flu, pneumonia, COVID-19, shingles) but avoid live vaccines while on immunosuppression \u2014 ROUTINE ROUTINE Wear protective footwear to prevent injury to numb feet and avoid burns or trauma \u2014 ROUTINE ROUTINE Perform daily foot inspections for wounds or ulcers given sensory loss \u2014 ROUTINE ROUTINE Engage in low-impact exercise (swimming, stationary cycling, walking) to maintain cardiovascular health and strength \u2014 ROUTINE ROUTINE Maintain bone health with calcium, vitamin D, and weight-bearing exercise, especially if on steroids \u2014 ROUTINE ROUTINE Manage stress and get adequate sleep as fatigue worsens CIDP symptoms \u2014 ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Guillain-Barr\u00e9 syndrome (GBS) Acute onset (&lt;4 weeks to nadir); monophasic; often post-infectious Time course (&lt;8 weeks); NCS; CSF Multifocal motor neuropathy (MMN) Pure motor; asymmetric; conduction block; no sensory involvement Anti-GM1 antibodies; NCS (conduction block without sensory abnormality) POEMS syndrome Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes VEGF, bone survey, SPEP/UPEP (lambda light chain) Anti-MAG neuropathy Distal, sensory-predominant; IgM paraprotein; tremor Anti-MAG antibody; SPEP/UPEP Hereditary neuropathy (CMT) Family history; pes cavus, hammer toes; slowly progressive since childhood Genetic testing; NCS pattern Diabetic polyneuropathy Length-dependent sensory &gt; motor; diabetes history HbA1c; NCS (axonal predominantly) Vasculitic neuropathy Painful; asymmetric; multifocal (mononeuritis multiplex); systemic symptoms ESR/CRP, ANA, ANCA, nerve biopsy Amyloid neuropathy Autonomic involvement; carpal tunnel; cardiac involvement Fat pad/nerve biopsy; genetic testing (TTR); serum free light chains Lymphoma/paraneoplastic Weight loss, lymphadenopathy; subacute course CT/PET; paraneoplastic panel Sarcoid neuropathy Multisystem involvement; skin, lungs, lymph nodes ACE level; chest imaging; biopsy Paraproteinemic neuropathy (other) IgG or IgA monoclonal; may mimic CIDP SPEP/UPEP; bone marrow biopsy Drug-induced neuropathy Temporal relationship to drug; axonal pattern Medication review; NCS HIV-associated neuropathy HIV risk factors; may have CSF pleocytosis HIV testing; CD4 count Lyme neuroborreliosis Endemic area; facial palsy; radicular pain; CSF pleocytosis Lyme serology; CSF Lyme antibodies","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Clinical strength exam (MRC grading) Each visit; q3-6mo stable Stable or improved Adjust therapy if declining STAT STAT ROUTINE STAT INCAT disability score Baseline and q6-12mo Improvement or stability (0-10 scale) Consider therapy change if worsening \u2014 ROUTINE ROUTINE \u2014 ONLS (Overall Neuropathy Limitations Scale) Baseline and q6-12mo Improvement or stability (0-12 scale) Consider therapy change if worsening \u2014 ROUTINE ROUTINE \u2014 Grip strength (dynamometer) Each visit Stable or improved Document trend; correlate with symptoms \u2014 ROUTINE ROUTINE \u2014 Timed 10-meter walk Baseline and q6-12mo Stable or improved Consider PT intensification if slowing \u2014 ROUTINE ROUTINE \u2014 Nerve conduction studies Baseline, 6mo after treatment, then annually if stable Improvement or stability in demyelinating parameters Guides treatment effectiveness \u2014 ROUTINE ROUTINE \u2014 Renal function (BUN/Cr) Before each IVIg; q3-6mo on IVIg Cr stable (&lt;1.5 or no rise) Hold IVIg if rising; hydrate; may need dose adjustment \u2014 STAT ROUTINE STAT CBC q3mo on immunosuppressants WBC &gt;3K, ANC &gt;1.5K, Hgb &gt;10, Plt &gt;100K Hold azathioprine/MMF if cytopenic \u2014 ROUTINE ROUTINE \u2014 LFTs q3mo on immunosuppressants ALT/AST &lt;3x ULN Hold azathioprine/MMF if significantly elevated \u2014 ROUTINE ROUTINE \u2014 Blood glucose Each visit on steroids; HbA1c q3mo Fasting &lt;126; HbA1c &lt;7% Intensify diabetes management \u2014 ROUTINE ROUTINE \u2014 Blood pressure Each visit on steroids &lt;140/90 (or &lt;130/80 if diabetic) Initiate antihypertensive if elevated \u2014 ROUTINE ROUTINE \u2014 DEXA bone density Baseline if steroids &gt;3mo; repeat q1-2yr T-score &gt;-2.5 Bisphosphonate if osteopenia/osteoporosis \u2014 \u2014 ROUTINE \u2014 IgG trough level q6mo on IVIg/SCIg (optional) Trough &gt;800-1000 mg/dL Adjust dose if low and clinically worsening \u2014 \u2014 ROUTINE \u2014 Anti-MAG titer q6-12mo if positive Declining with effective therapy Guides treatment response for anti-MAG \u2014 \u2014 EXT \u2014 CD19/CD20 B-cell count After rituximab q3-6mo Document depletion and reconstitution Guides retreatment timing \u2014 \u2014 EXT \u2014","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable neurological exam; able to ambulate (with assistance if needed); oral medications tolerated; outpatient infusion arranged if needed; follow-up scheduled; adequate social support Admit to hospital Significant new weakness affecting ambulation; need for IV therapy initiation and monitoring; respiratory symptoms (rare but assess); unable to care for self at home ICU admission Respiratory compromise (FVC &lt;30 mL/kg); rapidly progressive weakness raising concern for GBS overlap; severe autonomic dysfunction; hemodynamic instability Outpatient infusion center Stable CIDP on maintenance IVIg; appropriate for regular outpatient infusions every 3-4 weeks Home infusion (SCIg) Stable on IVIg who prefers home therapy; trained in self-injection; appropriate venous access not required Rehabilitation facility Significant residual weakness requiring intensive PT/OT; medically stable; goals for functional improvement","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IVIg effective for CIDP Class I, Level A Hughes et al. Lancet Neurol 2008 (ICE Trial) IVIg dosing 2 g/kg loading, 1 g/kg maintenance Class I, Level A Hughes et al. Lancet Neurol 2008 (ICE Trial) Corticosteroids effective for CIDP Class I, Level A Hughes et al. Cochrane 2017 Plasma exchange effective for CIDP Class I, Level A Mehndiratta et al. Cochrane 2015 SCIg non-inferior to IVIg for maintenance Class I, Level A van Schaik et al. Lancet Neurol 2018 (PATH Trial) EFNS/PNS diagnostic criteria for CIDP Expert Consensus Van den Bergh et al. J Peripher Nerv Syst 2021 Rituximab for anti-MAG neuropathy Class II, Level B Dalakas et al. Ann Neurol 2009 Rituximab for refractory CIDP Class III, Level C Benedetti et al. Neurology 2011 Nodal/paranodal antibodies predict IVIg response Class II, Level B Querol et al. Neurology 2017 Azathioprine as steroid-sparing agent Class III, Level C Hughes et al. Cochrane 2017 Mycophenolate for CIDP Class III, Level C Gorson et al. Neurology 2004 MRI nerve root enhancement supportive criterion Class II, Level B Van den Bergh et al. J Peripher Nerv Syst 2021 INCAT scale for disability measurement Expert Consensus Merkies et al. Neurology 2002 Treatment-related fluctuations in CIDP Class II, Level B Kuitwaard et al. J Peripher Nerv Syst 2009","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive diagnostic workup including EFNS/PNS criteria - First-line treatments: IVIg (loading and maintenance), corticosteroids, PLEX - Subcutaneous immunoglobulin (SCIg) for home maintenance therapy - Second-line agents: azathioprine, mycophenolate, rituximab, cyclophosphamide - Special populations: anti-MAG positive, nodal antibody positive CIDP - CIDP variants coverage (typical, MADSAM, DADS, sensory, motor) - Structured dosing format for all medications - Functional monitoring scales (INCAT, ONLS, grip strength) - Comprehensive differential diagnosis</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#appendix-a-efnspns-2021-diagnostic-criteria-for-cidp","title":"APPENDIX A: EFNS/PNS 2021 Diagnostic Criteria for CIDP","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#clinical-criteria","title":"Clinical Criteria","text":"<p>Typical CIDP: - Progressive or relapsing symmetric proximal AND distal weakness - Sensory dysfunction of all four limbs - Developing over \u22658 weeks - Reduced or absent tendon reflexes in all limbs</p> <p>Atypical CIDP (at least one of): - DADS: Predominantly distal weakness and sensory loss - MADSAM: Asymmetric weakness (Lewis-Sumner syndrome) - Focal: Single limb involvement - Motor: Predominantly motor without sensory involvement - Sensory: Predominantly sensory without motor involvement</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#electrodiagnostic-criteria-at-least-1-nerve-meeting-criteria","title":"Electrodiagnostic Criteria (at least 1 nerve meeting criteria)","text":"<p>Motor Nerve Criteria (must meet in \u22652 nerves for definite CIDP):</p> Parameter Criterion Distal motor latency \u226550% above ULN Motor conduction velocity \u226470% below LLN F-wave latency \u226530% above ULN Conduction block \u226550% amplitude reduction proximal vs distal Temporal dispersion \u226530% increase in duration proximal vs distal","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#supportive-criteria","title":"Supportive Criteria","text":"<ol> <li>CSF: Elevated protein with WBC &lt;10/mm\u00b3</li> <li>MRI: Enhancement or hypertrophy of nerve roots, brachial or lumbosacral plexus</li> <li>Objective clinical improvement with immunomodulatory treatment</li> <li>Nerve ultrasound: Increased cross-sectional area of peripheral nerves</li> <li>Nerve biopsy: Evidence of demyelination/remyelination</li> </ol>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#diagnostic-categories","title":"Diagnostic Categories","text":"Category Criteria Definite CIDP Clinical criteria + \u22652 nerves meeting electrodiagnostic criteria Probable CIDP Clinical criteria + 1 nerve meeting electrodiagnostic criteria Possible CIDP Clinical criteria but electrodiagnostic criteria not fully met; supportive criteria present","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#appendix-b-incat-disability-scale","title":"APPENDIX B: INCAT Disability Scale","text":"<p>Arm Disability Score: | Grade | Description | |-------|-------------| | 0 | No upper limb problems | | 1 | Symptoms not affecting function | | 2 | Symptoms affecting but not preventing function | | 3 | Symptoms preventing function but able to do some self-care | | 4 | Symptoms preventing function and most self-care | | 5 | Cannot use either arm for any purposeful movement |</p> <p>Leg Disability Score: | Grade | Description | |-------|-------------| | 0 | Walking not affected | | 1 | Walking affected but can walk independently outdoors | | 2 | Uses unilateral support outdoors (cane, crutch, arm) | | 3 | Uses bilateral support outdoors (two canes, crutches, walker, arm) | | 4 | Uses wheelchair outdoors; walks with support indoors | | 5 | Restricted to wheelchair, unable to stand/walk |</p> <p>Total Score: Sum of arm + leg scores (0-10)</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#appendix-c-ivig-to-scig-conversion-guide","title":"APPENDIX C: IVIg to SCIg Conversion Guide","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#conversion-formula","title":"Conversion Formula","text":"<p>Weekly SCIg dose = Monthly IVIg dose \u00f7 4</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#example-conversions","title":"Example Conversions","text":"Monthly IVIg Dose Weekly SCIg Dose Notes 40 g (0.5 g/kg for 80 kg) 10 g/week Can divide into 2-3 infusions/week 60 g (0.75 g/kg for 80 kg) 15 g/week Can divide into 3-4 infusions/week 80 g (1 g/kg for 80 kg) 20 g/week May need 4-7 infusions/week","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#scig-administration","title":"SCIg Administration","text":"<p>Products: - Hizentra (20% concentration): Up to 25 mL per site - Gamunex-C (10% concentration): Up to 30 mL per site</p> <p>Infusion Sites: - Abdomen, thighs, upper arms, hips - Rotate sites; use 2-4 sites per infusion</p> <p>Advantages of SCIg: - Home administration - Stable IgG levels (no peaks/troughs) - Fewer systemic side effects - Greater independence</p> <p>Training Required: - Initial training by infusion nurse (typically 2-3 sessions) - Return demonstration of sterile technique - Recognition of adverse reactions</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#appendix-d-monitoring-timeline","title":"APPENDIX D: Monitoring Timeline","text":"","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#first-year-of-treatment","title":"First Year of Treatment","text":"Time Monitoring Baseline NCS/EMG, MRI (if not done), labs (CBC, CMP, HbA1c, SPEP/UPEP, immunoglobulins), INCAT score, grip strength 2 weeks If on IVIg: renal function 4-6 weeks Clinical assessment; titrate steroids 3 months Clinical exam, labs (CBC, CMP, LFTs if on immunosuppressants), HbA1c if on steroids 6 months Clinical exam, repeat NCS/EMG, INCAT score, labs 12 months Comprehensive review: NCS/EMG, DEXA (if on steroids), INCAT, consider dose reduction trial","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#maintenance-phase-annual","title":"Maintenance Phase (Annual)","text":"<ul> <li>Clinical exam with INCAT/ONLS q6-12 months</li> <li>NCS/EMG if clinical change</li> <li>Labs: CBC, CMP, LFTs q3-6 months (based on therapy)</li> <li>DEXA q1-2 years if on steroids</li> <li>HbA1c q3-6 months if on steroids or diabetic</li> <li>Immunoglobulin levels q6-12 months if on IVIg/SCIg</li> </ul>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cidp/#dose-reduction-trial","title":"Dose Reduction Trial","text":"<p>Consider after 6-12 months of stable disease: 1. Reduce IVIg by 10-20% or extend interval by 1 week 2. Monitor closely over 4-8 weeks 3. If stable, continue slow reduction 4. If worsening, return to prior effective dose 5. Some patients require lifelong therapy; others may achieve drug-free remission</p>","tags":["neuromuscular","neuropathy","autoimmune","outpatient"]},{"location":"drafts/cluster-headache/","title":"Cluster Headache","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#cluster-headache","title":"Cluster Headache","text":"<p>DIAGNOSIS: Cluster Headache ICD-10: G44.009 (Cluster headache syndrome, unspecified) SCOPE: Acute cluster headache attack treatment, transitional therapy, and preventive therapy for episodic and chronic cluster headache. Excludes other trigeminal autonomic cephalalgias (paroxysmal hemicrania, SUNCT/SUNA - separate protocols).</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Baseline before starting preventive therapy; rule out infection Normal STAT ROUTINE ROUTINE - BMP Baseline renal function before lithium or other preventives Normal STAT ROUTINE ROUTINE - TSH Thyroid dysfunction can mimic or exacerbate headache; baseline for lithium Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE - LFTs Baseline hepatic function before verapamil, valproate Normal - ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Pituitary function panel (FSH, LH, prolactin, IGF-1, cortisol) Atypical features or pituitary lesion on imaging Normal - ROUTINE ROUTINE - Lithium level Monitoring when on lithium therapy 0.6-1.0 mEq/L therapeutic range - ROUTINE ROUTINE - Calcium, PTH Lithium-induced hypercalcemia monitoring Normal calcium; PTH not elevated - ROUTINE ROUTINE - Free T4 Lithium-induced thyroid dysfunction monitoring Normal - ROUTINE ROUTINE - BUN, creatinine Lithium nephrotoxicity monitoring Normal - ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Atypical features; rule out giant cell arteritis in older patients Normal URGENT ROUTINE ROUTINE - Growth hormone stimulation test Suspected pituitary adenoma with GH deficiency Normal response - - EXT - Sleep study (polysomnography) Suspected obstructive sleep apnea as trigger AHI &lt;5 (normal) - - ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with pituitary protocol New diagnosis of cluster headache Normal; exclude pituitary lesion, hypothalamic lesion, cavernous sinus pathology MRI-incompatible devices, severe claustrophobia URGENT ROUTINE ROUTINE - MRA Head Suspected vascular etiology; atypical features No aneurysm, dissection, vascular malformation MRI contraindications URGENT ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI orbits with contrast Orbital pain, suspected retro-orbital pathology No orbital mass, Tolosa-Hunt syndrome Gadolinium allergy, severe renal impairment URGENT ROUTINE EXT - CT Head non-contrast MRI unavailable; acute presentation No acute pathology Pregnancy (relative) STAT STAT - - CTA Head/Neck Urgent vascular imaging if MRI unavailable No aneurysm, dissection Contrast allergy, CKD STAT URGENT - -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRV Brain Suspected cerebral venous thrombosis Patent venous sinuses MRI contraindications URGENT ROUTINE EXT - CT sinuses Suspected sinus pathology contributing No sinusitis, mucocele Pregnancy (relative) - ROUTINE EXT - Carotid Doppler ultrasound Suspected carotid dissection No dissection None URGENT ROUTINE EXT -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3-treatment","title":"3. TREATMENT","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3a-acuteemergent-abortive-therapy-for-active-attacks","title":"3A. Acute/Emergent (Abortive Therapy for Active Attacks)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU High-flow oxygen INH First-line abortive; most effective acute treatment 100% at 12-15 L/min x 15-20 min :: INH :: :: 100% O2 via non-rebreather mask at 12-15 L/min for 15-20 min; patient seated, leaning forward; may repeat Severe COPD with CO2 retention (relative) SpO2; symptom resolution typically within 15 min STAT STAT ROUTINE - Sumatriptan SC First-line abortive; rapid onset 6 mg SC :: SC :: :: 6 mg SC at onset; may repeat after 1 hr if needed; max 12 mg/24hr Uncontrolled HTN; CAD; prior MI/stroke; hemiplegic migraine; MAOIs; within 24h of ergot Triptan sensation; monitor BP if cardiac risk factors STAT STAT ROUTINE - Sumatriptan Intranasal Alternative to SC when injection not preferred 20 mg intranasal :: Intranasal :: :: 20 mg intranasal at onset; may repeat after 2 hr; max 40 mg/24hr Same as SC sumatriptan Nasal irritation; triptan sensation URGENT URGENT ROUTINE - Zolmitriptan Intranasal Alternative triptan; effective nasal delivery 5 mg intranasal :: Intranasal :: :: 5 mg intranasal at onset; may repeat after 2 hr; max 10 mg/24hr Same as sumatriptan Triptan sensation; nasal discomfort URGENT URGENT ROUTINE - Zolmitriptan PO Oral option when SC/nasal unavailable 5 mg PO; 10 mg PO :: PO :: :: 5-10 mg PO at onset; may repeat after 2 hr; max 10 mg/24hr Same as sumatriptan Triptan sensation URGENT URGENT ROUTINE - Octreotide SC Second-line; triptan contraindications or failure 100 mcg SC :: SC :: :: 100 mcg SC at onset; may repeat once after 1 hr Gallbladder disease; diabetes (may alter glucose) Blood glucose; GI symptoms URGENT URGENT EXT - Lidocaine Intranasal Adjunctive therapy; sphenopalatine ganglion block 1 mL of 4-10% solution :: Intranasal :: :: Instill 1 mL of 4-10% lidocaine into nostril ipsilateral to pain; head tilted back 45 degrees toward affected side; may repeat x1 Local anesthetic allergy Numbness; bitter taste URGENT URGENT ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3b-transitional-therapy-bridge-until-preventive-takes-effect","title":"3B. Transitional Therapy (Bridge Until Preventive Takes Effect)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Prednisone PO Rapid cluster suppression; bridge to verapamil 60 mg daily x 5 days; 40 mg daily x 5 days; 20 mg daily x 5 days :: PO :: :: Start 60-80 mg daily x 5 days, taper by 10-20 mg q5d over 2-3 weeks; limit to 2-3 courses/year Active infection; uncontrolled diabetes; GI bleeding; psychosis history Glucose; BP; mood changes; sleep - ROUTINE ROUTINE - Dexamethasone IV/PO Alternative steroid; hospitalized patients 8 mg IV/PO daily x 3-5 days :: IV/PO :: :: 4-8 mg IV or PO daily x 3-5 days, then taper or switch to prednisone Same as prednisone Glucose; BP URGENT URGENT - - Greater occipital nerve block SC Transitional therapy; rapid reduction in attack frequency 2-3 mL 2% lidocaine + 40 mg triamcinolone :: SC :: :: Inject 2-3 mL of 2% lidocaine + 40 mg triamcinolone (or 6 mg betamethasone) at greater occipital nerve ipsilateral to pain; may do bilaterally Local anesthetic allergy; infection at site; anticoagulation (relative) Immediate relief; vasovagal reaction; alopecia at injection site - ROUTINE ROUTINE - Dihydroergotamine (DHE) IV Status cluster; refractory attacks; inpatient protocol 0.5 mg IV q8h x 5 days; 1 mg IV q8h x 5 days :: IV :: :: 0.5-1 mg IV q8h (after test dose 0.25-0.5 mg) for 3-5 days; pretreat with antiemetic; requires telemetry Pregnancy; CAD; uncontrolled HTN; peripheral vascular disease; use within 24h of triptan; hepatic/renal impairment; sepsis BP; ECG monitoring; nausea; leg cramps; paresthesias - URGENT - - Dihydroergotamine (DHE) SC/IM Home transitional therapy; bridge after inpatient protocol 1 mg SC/IM at onset :: SC/IM :: :: 1 mg SC or IM at onset of attack; max 3 mg/24hr; max 6 mg/week Same as IV DHE Same as IV DHE - ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3c-second-linerefractory-acute-treatments","title":"3C. Second-line/Refractory (Acute Treatments)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Sphenopalatine ganglion block Intranasal Refractory acute attacks; alternative to nerve block 0.3 mL 0.5% bupivacaine :: Intranasal :: :: Apply 0.3 mL of 0.5% bupivacaine via intranasal catheter (Tx360, SphenoCath) to sphenopalatine ganglion Local anesthetic allergy; nasal pathology Local numbness; epistaxis; vasovagal - EXT ROUTINE - Ketamine Intranasal Refractory attacks; investigational 50-75 mg intranasal :: Intranasal :: :: 50-75 mg intranasal via atomizer; may repeat x1 Uncontrolled HTN; psychosis; increased ICP Dissociation; BP; HR - EXT - - Ergotamine tartrate SL/PO Alternative when DHE unavailable 2 mg SL at onset :: SL :: :: 2 mg sublingual at onset; may repeat 1-2 mg q30min; max 6 mg/attack, 10 mg/week Same as DHE Nausea; peripheral vasoconstriction - EXT EXT -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3d-preventive-therapies","title":"3D. Preventive Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Verapamil PO First-line preventive; episodic and chronic CH 80 mg TID; 120 mg TID; 160 mg TID; 240 mg TID :: PO :: :: Start 80 mg TID; increase by 80 mg q10-14d as tolerated; target 240-480 mg TID (720-960 mg/day total); some patients require up to 960 mg/day Baseline ECG; repeat ECG with each dose increase Second/third-degree heart block; sick sinus syndrome; severe hypotension; decompensated HF; concurrent beta-blocker (relative) ECG before each dose increase (monitor PR interval &gt;0.24s or 40% increase); HR; BP; constipation; edema - ROUTINE ROUTINE - Lithium carbonate PO Chronic cluster headache; verapamil failure/intolerance 300 mg BID; 300 mg TID; 450 mg BID; 600 mg BID :: PO :: :: Start 300 mg BID; titrate by 300 mg q3-7d to target level 0.6-1.0 mEq/L; typical dose 600-1200 mg/day Baseline TSH, BMP, calcium, ECG Renal impairment; sick sinus syndrome; pregnancy; Brugada syndrome; concurrent NSAIDs/ACE-I/thiazides Lithium level q1wk during titration, then q1-3mo; TSH, creatinine, calcium q3-6mo; tremor; polyuria - ROUTINE ROUTINE - Topiramate PO Preventive; especially with comorbid migraine 25 mg qHS; 50 mg BID; 75 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/wk; target 100-200 mg/day divided BID None Glaucoma; kidney stones; pregnancy; metabolic acidosis Cognitive effects; paresthesias; weight; serum bicarbonate; kidney stones - ROUTINE ROUTINE - Galcanezumab (Emgality) SC FDA-approved for episodic cluster headache; CGRP mAb 300 mg SC monthly :: SC :: :: 300 mg SC (3 consecutive 100 mg injections) at onset of cluster period; repeat monthly during cluster period None Hypersensitivity to galcanezumab Injection site reactions; constipation - - ROUTINE - Melatonin PO Adjunctive prevention; circadian dysregulation 10 mg qHS; 15 mg qHS; 20 mg qHS :: PO :: :: 10-20 mg PO 30 min before bedtime; may help regulate cluster periodicity None None significant Sedation; morning grogginess - ROUTINE ROUTINE - Valproate/Divalproex PO Alternative preventive; especially with comorbid epilepsy/mood disorder 250 mg BID; 500 mg BID; 500 mg ER daily; 1000 mg ER daily :: PO :: :: Start 250 mg BID or 500 mg ER daily; titrate to 500-1500 mg/day LFTs, CBC Hepatic disease; pregnancy (teratogen); urea cycle disorders; pancreatitis history LFTs q6mo; CBC; ammonia if AMS; weight; hair loss; tremor - ROUTINE ROUTINE - Baclofen PO Alternative preventive; trigeminal autonomic pathway modulation 5 mg TID; 10 mg TID; 20 mg TID :: PO :: :: Start 5 mg TID; titrate by 5 mg/dose q3d; target 30-60 mg/day divided TID None Withdrawal if abrupt discontinuation; renal impairment (reduce dose) Sedation; weakness; withdrawal syndrome; do not stop abruptly - ROUTINE ROUTINE - Gabapentin PO Alternative preventive; neuropathic pain component 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q1-3d; target 1800-3600 mg/day divided TID None Reduce dose in renal impairment Sedation; dizziness; edema; weight gain - ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#3e-refractoryinterventional-therapies","title":"3E. Refractory/Interventional Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Occipital nerve stimulation Implant Chronic refractory cluster headache; failed multiple preventives N/A - surgical implant :: Implant :: :: Percutaneous or surgical implantation of occipital nerve stimulator; specialist referral required Neurosurgical evaluation; psychological screening; failed at least 3 preventive medications Active infection; coagulopathy; psychiatric instability Post-implant follow-up; battery life; lead migration - - EXT - Deep brain stimulation Implant Severe refractory chronic CH; last resort N/A - surgical implant :: Implant :: :: Targeting posterior hypothalamus; investigational; specialist center only Extensive workup; ethics committee review; failed all other options Same as ONS; structural brain abnormality Long-term neurological monitoring - - EXT - Sphenopalatine ganglion stimulation Implant Refractory CH; acute and preventive effects N/A - surgical implant :: Implant :: :: Pulsante SPG microstimulator; patient-controlled acute therapy Neurosurgical evaluation; imaging confirmation Facial/jaw abnormalities; active infection Lead integrity; battery; efficacy - - EXT - Radiofrequency ablation trigeminal ganglion Procedure Refractory chronic CH; trigeminal nerve modulation N/A - procedure :: Procedure :: :: Percutaneous RF ablation; provides 6-18 months relief; may need repeat Facial imaging; failed medical therapy Anticoagulation; infection; facial numbness intolerance Facial sensation; corneal reflex; recurrence - - EXT -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Headache specialist/Neurology referral for diagnosis confirmation and preventive therapy optimization URGENT ROUTINE ROUTINE - Pain management referral for interventional procedures (nerve blocks, neuromodulation evaluation) in refractory cases - ROUTINE ROUTINE - Sleep medicine evaluation for polysomnography if obstructive sleep apnea suspected as cluster trigger - - ROUTINE - Endocrinology referral if pituitary abnormality identified on imaging or atypical hormone levels - ROUTINE ROUTINE - Neurosurgery consultation for neuromodulation or ablative procedures in medically refractory cases - - EXT - Cardiology clearance before initiating high-dose verapamil in patients with cardiac history - ROUTINE ROUTINE - Psychiatry referral for suicidal ideation screening given high depression/suicide risk in cluster headache patients URGENT ROUTINE ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for sudden severe headache different from typical cluster attacks which may indicate new pathology STAT - ROUTINE Keep high-flow oxygen available at home during cluster period for acute attack treatment - ROUTINE ROUTINE Use sumatriptan injection at first sign of attack for fastest relief; do not wait for pain to worsen URGENT ROUTINE ROUTINE Maintain detailed headache diary including attack timing, duration, severity, and treatment response - ROUTINE ROUTINE Avoid known triggers during cluster period especially alcohol (even small amounts), strong odors, and napping - ROUTINE ROUTINE Do not abruptly stop preventive medications especially lithium and baclofen which require gradual taper - ROUTINE ROUTINE Carry injectable sumatriptan at all times during active cluster period for emergency use - ROUTINE ROUTINE Alert healthcare providers to cluster headache diagnosis as this affects anesthesia and medication choices - ROUTINE ROUTINE","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Strict alcohol avoidance during entire cluster period as even small amounts trigger attacks - ROUTINE ROUTINE Maintain regular sleep schedule with consistent bedtime and wake time to regulate circadian rhythm - ROUTINE ROUTINE Avoid daytime napping during cluster period as sleep transitions can trigger attacks - ROUTINE ROUTINE Smoking cessation to reduce vascular risk and potential cluster exacerbation - ROUTINE ROUTINE Avoid high altitude exposure during cluster period if altitude is a known trigger - ROUTINE ROUTINE Avoid vasodilators (nitroglycerin, sildenafil) during cluster period as these trigger attacks - ROUTINE ROUTINE Screen for and treat obstructive sleep apnea as treatment may reduce cluster frequency - ROUTINE ROUTINE Stress management techniques as emotional stress may influence cluster cycle onset - ROUTINE ROUTINE Avoid strong chemical odors (solvents, perfumes, gasoline) which can trigger attacks in some patients - ROUTINE ROUTINE","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Migraine Longer duration (4-72 hrs); bilateral or alternating sides; nausea/vomiting prominent; photophobia/phonophobia; no autonomic features Clinical criteria (ICHD-3); MRI if new onset Paroxysmal hemicrania Shorter attacks (2-30 min); more frequent (&gt;5/day); absolute response to indomethacin Indomethacin trial (150-225 mg/day); complete response diagnostic SUNCT/SUNA Very brief attacks (seconds to minutes); very frequent (up to 200/day); triggered by cutaneous stimuli Clinical criteria; may have refractory period; no response to indomethacin Trigeminal neuralgia Electric shock-like pain; seconds duration; triggered by touch, chewing, talking; refractory period MRI for vascular compression; response to carbamazepine Hemicrania continua Continuous baseline pain with superimposed exacerbations; unilateral; autonomic features Absolute response to indomethacin diagnostic Primary stabbing headache Ultra-short jabs (seconds); unpredictable location; no autonomic features Clinical diagnosis; exclusion of secondary causes Secondary cluster headache Atypical features; pituitary or hypothalamic lesion; carotid dissection MRI with pituitary protocol; MRA head/neck Tolosa-Hunt syndrome Painful ophthalmoplegia; orbital pain; CN III, IV, VI involvement MRI orbits with contrast; CSF if needed; steroid response Giant cell arteritis Age &gt;50; scalp tenderness; jaw claudication; visual symptoms; elevated ESR/CRP ESR, CRP; temporal artery biopsy Carotid dissection Neck pain; Horner syndrome; stroke symptoms CTA or MRA neck; carotid ultrasound","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Attack frequency diary Daily during cluster 50% reduction with preventive Escalate preventive therapy; consider transitional bridge - ROUTINE ROUTINE - ECG (if on verapamil) Baseline and with each dose increase PR interval &lt;0.28s and &lt;40% increase from baseline Hold dose increase; may need cardiology clearance - ROUTINE ROUTINE - Heart rate (if on verapamil) Each visit HR &gt;50 bpm Reduce dose; consider alternative - ROUTINE ROUTINE - Lithium level Weekly during titration, then q1-3 months 0.6-1.0 mEq/L Adjust dose; assess renal function if unexpected level - ROUTINE ROUTINE - TSH (if on lithium) Baseline, 3 months, then q6 months Normal (0.4-4.0 mIU/L) Endocrine referral; may need thyroid replacement - ROUTINE ROUTINE - BUN/Creatinine (if on lithium) Baseline, q1-3 months Normal; no progressive rise Dose reduction; nephrology referral if progressive - ROUTINE ROUTINE - Calcium (if on lithium) Baseline, q6 months Normal Evaluate for hyperparathyroidism - ROUTINE ROUTINE - Serum bicarbonate (if on topiramate) Baseline, 3 months &gt;18 mEq/L Reduce dose or discontinue - ROUTINE ROUTINE - Depression/Suicidal ideation screening Each visit PHQ-9 &lt;10; no suicidal ideation Urgent psychiatric referral; crisis intervention URGENT ROUTINE ROUTINE - Oxygen saturation (during O2 therapy) During treatment &gt;94% Adjust flow rate STAT STAT ROUTINE -","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Acute attack aborted with oxygen/triptan; stable; access to home oxygen and rescue medications; follow-up arranged Admit to floor Status cluster (continuous attacks); requires IV DHE protocol; suicidal ideation requiring monitoring; oral intake compromised Admit to ICU Rare; only if hemodynamic instability, cardiac arrhythmia from verapamil, or severe psychiatric crisis Outpatient follow-up Within 1-2 weeks if in active cluster period; 2-4 weeks after initiating new preventive; q3 months during remission Transfer to headache center Refractory to multiple preventives; candidate for neuromodulation; requires specialized interventional procedures","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source High-flow oxygen (100% at 12-15 L/min) first-line abortive Class I, Level A Cohen et al. JAMA 2009 Subcutaneous sumatriptan 6 mg effective for acute attacks Class I, Level A The Sumatriptan Cluster Headache Study Group. NEJM 1991 Intranasal zolmitriptan 5-10 mg effective for acute attacks Class I, Level A Cittadini et al. Neurology 2006 Verapamil first-line preventive for episodic and chronic CH Class I, Level C (expert consensus) May et al. Cephalalgia 2006 Galcanezumab FDA-approved for episodic cluster headache Class I, Level A Goadsby et al. NEJM 2019 Greater occipital nerve block effective as transitional therapy Class II, Level B Ambrosini et al. Pain 2005 Lithium effective for chronic cluster headache prevention Class II, Level B Steiner et al. Headache 1997 Prednisone taper effective transitional therapy Class II, Level C Obermann et al. Curr Pain Headache Rep 2011 Octreotide effective when triptans contraindicated Class II, Level B Matharu et al. Ann Neurol 2004 Melatonin 10 mg may reduce attack frequency Class II, Level C Leone et al. Cephalalgia 1996 Occipital nerve stimulation for refractory chronic CH Class III, Level C Burns et al. Lancet 2007 European Headache Federation cluster headache guidelines Guideline Mitsikostas et al. J Headache Pain 2023","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/cluster-headache/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive acute abortive, transitional, and preventive therapy coverage - Includes FDA-approved galcanezumab for episodic cluster headache - Structured dosing format for order sentence generation - Emphasis on high-flow oxygen as first-line treatment - Verapamil with ECG monitoring protocol - Differential diagnosis including other trigeminal autonomic cephalalgias</p>","tags":["headache","cluster-headache","trigeminal-autonomic-cephalalgias","outpatient"]},{"location":"drafts/dementia-evaluation/","title":"Dementia Evaluation","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#dementia-evaluation","title":"Dementia Evaluation","text":"<p>DIAGNOSIS: Dementia Evaluation ICD-10: G31.9 (Degenerative disease of nervous system, unspecified); R41.81 (Age-related cognitive decline); F03.90 (Unspecified dementia without behavioral disturbance) SCOPE: Comprehensive evaluation for cognitive impairment, identification of reversible causes, dementia subtype diagnosis, and symptomatic management. Covers Alzheimer's disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#1a-essentialcore-labs-reversible-causes-screen","title":"1A. Essential/Core Labs (Reversible Causes Screen)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection, anemia, malignancy contributing to cognitive changes Normal STAT STAT ROUTINE - BMP Hyponatremia, uremia, hypercalcemia as causes Normal electrolytes, BUN, Cr STAT STAT ROUTINE - TSH Hypothyroidism is reversible cause of cognitive impairment 0.4-4.0 mIU/L URGENT ROUTINE ROUTINE - Vitamin B12 Deficiency causes reversible dementia &gt;300 pg/mL (&gt;400 optimal) URGENT ROUTINE ROUTINE - Folate Deficiency contributes to cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - Glucose (fasting) Diabetes management affects cognition 70-100 mg/dL STAT ROUTINE ROUTINE - Hepatic panel (LFTs, albumin) Hepatic encephalopathy; nutritional status Normal - ROUTINE ROUTINE - Urinalysis UTI common cause of acute confusion in elderly Negative for infection STAT STAT ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Vitamin D, 25-hydroxy Deficiency associated with cognitive decline &gt;30 ng/mL - ROUTINE ROUTINE - Hemoglobin A1c Chronic glucose control affects cognition &lt;7% - ROUTINE ROUTINE - Lipid panel Vascular risk factor for vascular dementia LDL &lt;100 mg/dL - ROUTINE ROUTINE - Homocysteine Elevated levels associated with AD and vascular dementia &lt;15 \u03bcmol/L - ROUTINE ROUTINE - RPR or VDRL Neurosyphilis (rare but treatable) Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder Negative - ROUTINE ROUTINE - ESR, CRP Inflammatory/autoimmune causes Normal - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Heavy metal panel (lead, mercury, arsenic) Toxic exposure history Normal - - EXT - Copper, ceruloplasmin Wilson's disease if age &lt;50 Normal - EXT EXT - Paraneoplastic antibody panel Autoimmune dementia; occult malignancy Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2, GABA-B, AMPA-R) Autoimmune encephalitis Negative - EXT EXT - Genetic testing (APOE, PSEN1, PSEN2, APP) Family history early-onset AD; prognostic Variable - - EXT - Prion protein gene testing Suspected CJD with family history No mutation - - EXT -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Assess atrophy pattern; rule out structural causes (tumor, SDH, NPH) MRI-incompatible devices URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable or contraindicated Rule out mass, hemorrhage, hydrocephalus None STAT STAT ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain volumetrics Disease monitoring; clinical trials Hippocampal and whole brain atrophy quantification MRI contraindications - - ROUTINE - FDG-PET Brain Differentiate AD from FTD; atypical presentations AD: temporoparietal hypometabolism; FTD: frontal/temporal hypometabolism None - - ROUTINE - Amyloid PET (florbetapir, florbetaben, flutemetamol) Atypical age/presentation; clinical trial eligibility Positive: amyloid deposition; negative rules out AD None - - EXT - Tau PET (flortaucipir) Research; staging AD pathology Pattern correlates with clinical phenotype None - - EXT - DaTscan (ioflupane I-123) Differentiate DLB from AD Reduced: DLB/PDD; Normal: AD Iodine hypersensitivity - - ROUTINE - EEG Encephalopathy; CJD; seizures AD: mild slowing; CJD: periodic sharp wave complexes None URGENT ROUTINE ROUTINE - Sleep study (polysomnography) Sleep apnea contributing to cognition; RBD suggesting DLB Assess AHI; REM without atonia None - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU SPECT (perfusion) Alternative to PET if unavailable Regional hypoperfusion patterns None - - EXT - MRI with SWI/GRE sequences Cerebral amyloid angiopathy; microbleeds Lobar microbleeds pattern MRI contraindications - ROUTINE ROUTINE - Whole body PET-CT Paraneoplastic workup Identify occult malignancy None - EXT EXT -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Rapid progression, early-onset (&lt;65), atypical presentation, suspected autoimmune or infectious etiology, clinical trial eligibility Timing: ROUTINE for diagnosis clarification; URGENT if autoimmune/infectious suspected Volume Required: 10-15 mL (standard diagnostic); additional for research biomarkers</p> Study Rationale Target Finding ED HOSP OPD ICU Cell count, protein, glucose Rule out infection, inflammation WBC &lt;5, protein &lt;45 mg/dL, glucose &gt;60% serum URGENT ROUTINE ROUTINE - CSF A\u03b242 (amyloid beta 1-42) Low in Alzheimer's disease &lt;600 pg/mL suggests AD - ROUTINE ROUTINE - CSF total tau Elevated in neurodegeneration &lt;400 pg/mL normal; elevated in AD - ROUTINE ROUTINE - CSF p-tau (phosphorylated tau 181) Specific for AD pathology Elevated in AD; A\u03b242/p-tau ratio most predictive - ROUTINE ROUTINE - CSF A\u03b242/A\u03b240 ratio More accurate than A\u03b242 alone &lt;0.05-0.08 suggests AD (assay-dependent) - ROUTINE ROUTINE - 14-3-3 protein Creutzfeldt-Jakob disease Positive in CJD (not specific) - ROUTINE ROUTINE - RT-QuIC Prion disease confirmation Positive indicates CJD - ROUTINE ROUTINE - Autoimmune encephalitis panel Autoimmune dementia Negative - EXT EXT - VDRL Neurosyphilis Nonreactive - ROUTINE ROUTINE - <p>Special Handling: CSF biomarkers require specialized handling; send to reference lab; freeze within 1 hour Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); posterior fossa mass; skin infection at site</p>","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Treat reversible causes Various Identified metabolic/infectious etiology Per cause :: Various :: :: Correct hyponatremia, treat UTI, replace B12, treat hypothyroidism Depends on intervention Cognitive reassessment after treatment STAT STAT ROUTINE - Thiamine (if nutritional risk) IV/PO Suspected Wernicke's; alcoholism; malnutrition 500 mg IV TID x 3 days; 100 mg PO daily :: IV/PO :: :: 500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily None Clinical improvement STAT STAT ROUTINE - Vitamin B12 IM/PO B12 deficiency 1000 mcg IM daily x 7 days; 1000 mcg IM weekly x 4; 1000-2000 mcg PO daily :: IM/PO :: :: 1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily None B12 level, MMA; neuro improvement over months - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#3b-symptomatic-treatments-behavioral","title":"3B. Symptomatic Treatments (Behavioral)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Citalopram PO Depression; agitation in dementia 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly (QT risk) QT prolongation; concurrent QT-prolonging drugs QTc (especially &gt;20 mg) - ROUTINE ROUTINE - Sertraline PO Depression; anxiety in dementia 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg MAOIs GI upset initially - ROUTINE ROUTINE - Mirtazapine PO Depression with poor appetite and insomnia 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30 mg qHS MAOIs Weight gain, sedation - ROUTINE ROUTINE - Trazodone PO Insomnia; sundowning; agitation 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25-50 mg; typical 50-150 mg qHS Concurrent MAOIs; QT prolongation Orthostatic hypotension, priapism (rare) - ROUTINE ROUTINE - Quetiapine PO Severe agitation/psychosis when non-pharmacologic fails 12.5 mg qHS; 25 mg BID; 50 mg BID :: PO :: :: Start 12.5-25 mg qHS; titrate slowly; keep dose as low as possible Black box: increased mortality in dementia Metabolic effects, sedation, QTc - EXT ROUTINE - Risperidone PO Severe aggression/psychosis (short-term use only) 0.25 mg BID; 0.5 mg BID :: PO :: :: Start 0.25 mg BID; max 1 mg BID; short-term use only Black box: increased mortality in dementia EPS, metabolic, stroke risk - EXT ROUTINE - Haloperidol IM/IV/PO Acute severe agitation in delirium (not chronic) 0.5 mg IM; 1 mg IM; 2 mg IM :: IM/IV/PO :: :: 0.5-2 mg IM/IV q4-6h PRN; short-term only; avoid chronic use QT prolongation; Parkinson's; DLB QTc, EPS STAT EXT - - Melatonin PO Sleep disturbance; sundowning 3 mg qHS; 6 mg qHS; 9 mg qHS :: PO :: :: Start 3 mg qHS; may increase to 9 mg; give 30 min before bed None Daytime sedation - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#3c-cognitive-enhancers","title":"3C. Cognitive Enhancers","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil PO Mild-moderate AD; vascular dementia; DLB 5 mg qHS; 10 mg qHS; 23 mg daily :: PO :: :: Start 5 mg qHS x 4-6 weeks; increase to 10 mg qHS; 23 mg for moderate-severe Sick sinus syndrome; GI bleeding; COPD exacerbation Bradycardia, GI symptoms, vivid dreams - ROUTINE ROUTINE - Rivastigmine oral PO Mild-moderate AD; Parkinson's dementia; DLB 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID :: PO :: :: Start 1.5 mg BID; increase by 1.5 mg BID q2wk; target 6 mg BID Same as donepezil; severe hepatic impairment GI symptoms, weight loss - ROUTINE ROUTINE - Rivastigmine patch TD Mild-moderate AD; better GI tolerability 4.6 mg/24hr; 9.5 mg/24hr; 13.3 mg/24hr :: TD :: :: Start 4.6 mg/24hr patch; increase q4wk; target 9.5-13.3 mg/24hr Same as oral Skin irritation, GI symptoms - ROUTINE ROUTINE - Galantamine PO Mild-moderate AD 4 mg BID; 8 mg BID; 12 mg BID :: PO :: :: Start 4 mg BID x 4wk; increase to 8 mg BID x 4wk; target 8-12 mg BID Same as donepezil; severe renal/hepatic GI symptoms, bradycardia - ROUTINE ROUTINE - Galantamine ER PO Once daily option 8 mg daily; 16 mg daily; 24 mg daily :: PO :: :: Start 8 mg daily x 4wk; increase q4wk; target 16-24 mg daily Same as IR Same as IR - ROUTINE ROUTINE - Memantine PO Moderate-severe AD; add to cholinesterase inhibitor 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily; increase by 5 mg/wk; target 10 mg BID Severe renal impairment (dose adjust CrCl &lt;30) Confusion, dizziness, constipation - ROUTINE ROUTINE - Memantine XR PO Once daily option 7 mg daily; 14 mg daily; 21 mg daily; 28 mg daily :: PO :: :: Start 7 mg daily; increase by 7 mg/wk; target 28 mg daily Same as IR Same as IR - ROUTINE ROUTINE - Memantine + Donepezil (Namzaric) PO Moderate-severe AD on both medications 28/10 mg daily :: PO :: :: 28 mg memantine XR + 10 mg donepezil; take qHS Same as individual drugs Same as individual drugs - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#3d-disease-modifying-therapies-anti-amyloid","title":"3D. Disease-Modifying Therapies (Anti-Amyloid)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Lecanemab (Leqembi) IV Early AD with confirmed amyloid pathology (MCI or mild dementia) 10 mg/kg IV q2wk :: IV :: :: 10 mg/kg IV every 2 weeks; infuse over 1 hour Amyloid PET or CSF confirming amyloid; MRI baseline; APOE genotyping recommended ARIA risk with anticoagulation; &gt;4 microbleeds on MRI; recent stroke/TIA MRI at baseline, weeks 14, 52, 78; monitor for ARIA-E/H - - ROUTINE - Donanemab (Kisunla) IV Early AD with confirmed amyloid and tau pathology 700 mg IV q4wk x 3; 1400 mg IV q4wk :: IV :: :: 700 mg q4wk x 3 doses, then 1400 mg q4wk until amyloid cleared Amyloid PET positive; tau PET intermediate/high Similar to lecanemab; higher ARIA risk with APOE4 homozygotes MRI at baseline, weeks 16, 24, 52, 76; ARIA monitoring - - EXT - Aducanumab (Aduhelm) IV Early AD with confirmed amyloid (limited use) Titration to 10 mg/kg IV q4wk :: IV :: :: Slow titration: 1\u21923\u21926\u219210 mg/kg monthly Same as lecanemab Same as lecanemab; limited clinical adoption MRI for ARIA monitoring - - EXT - <p>ARIA Monitoring Notes: - ARIA-E (edema): Usually asymptomatic; may cause headache, confusion - ARIA-H (hemorrhage): Microbleeds, superficial siderosis - Hold infusion for symptomatic ARIA; resume after resolution per protocol - APOE4 homozygotes have higher ARIA risk; requires informed consent discussion</p>","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Cognitive neurology for diagnosis confirmation, subtype classification, and treatment planning - ROUTINE ROUTINE - Neuropsychology for comprehensive cognitive testing to establish baseline and guide diagnosis - - ROUTINE - Geriatric psychiatry for behavioral symptoms, medication management, and capacity evaluation - ROUTINE ROUTINE - Occupational therapy for ADL assessment, cognitive strategies, and home safety evaluation - ROUTINE ROUTINE - Speech therapy for communication strategies and swallowing evaluation if dysphagia present - ROUTINE ROUTINE - Social work for caregiver support, community resources, and long-term care planning - ROUTINE ROUTINE - Palliative care for advanced dementia symptom management and goals of care discussions - ROUTINE ROUTINE - Legal/Elder law attorney for advance directives, healthcare proxy, and financial planning while patient has capacity - - ROUTINE - Genetics counseling if familial/early-onset AD for family members - - ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if sudden confusion worsens which may indicate stroke, infection, or medication effect STAT STAT ROUTINE Complete advance directives while patient has capacity to document wishes for future care - ROUTINE ROUTINE Establish healthcare proxy/power of attorney for future decision-making - ROUTINE ROUTINE Do not drive if cognitive impairment affects judgment or reaction time (formal driving evaluation may be needed) - ROUTINE ROUTINE Take all medications as prescribed and use pill organizers or reminders to ensure adherence - ROUTINE ROUTINE Keep a consistent daily routine which helps with orientation and reduces confusion - ROUTINE ROUTINE Engage in mentally stimulating activities (reading, puzzles, social interaction) to support cognitive reserve - ROUTINE ROUTINE","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular physical exercise (150 min/week moderate aerobic) may slow cognitive decline - ROUTINE ROUTINE Mediterranean or MIND diet emphasizing vegetables, berries, fish, nuts, and olive oil - ROUTINE ROUTINE Adequate sleep (7-8 hours) and treat sleep disorders (sleep apnea assessment) - ROUTINE ROUTINE Social engagement and cognitive stimulation through activities, hobbies, and relationships - ROUTINE ROUTINE Cardiovascular risk factor control (BP &lt;130/80, diabetes control, cholesterol management) reduces vascular contribution - ROUTINE ROUTINE Hearing loss correction with hearing aids as untreated hearing loss is modifiable dementia risk factor - - ROUTINE Limit alcohol to \u22641 drink daily as excess alcohol accelerates cognitive decline - ROUTINE ROUTINE Fall prevention with home modifications as dementia increases fall and injury risk - ROUTINE ROUTINE","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Delirium Acute onset; fluctuating attention; identifiable cause (infection, medication, metabolic) Resolve cause; reassess cognition when clear Depression (pseudodementia) Prominent mood symptoms; often aware of deficits; improves with antidepressants GDS, PHQ-9; trial of antidepressant Alzheimer's disease Insidious onset; short-term memory most affected; language and visuospatial later MRI hippocampal atrophy; amyloid/tau PET or CSF biomarkers Vascular dementia Stepwise decline; focal findings; executive dysfunction; vascular risk factors MRI with significant white matter disease, strategic infarcts Dementia with Lewy bodies Visual hallucinations; parkinsonism; REM sleep behavior disorder; fluctuating cognition DaTscan; clinical criteria Frontotemporal dementia (behavioral) Personality change; disinhibition; apathy; hyperorality; age &lt;65 often FDG-PET frontal hypometabolism; genetics Primary progressive aphasia Language predominates; word-finding, grammar, or comprehension primarily affected Neuropsychological testing; FDG-PET language areas Creutzfeldt-Jakob disease Rapid progression (weeks-months); myoclonus; periodic sharp waves on EEG EEG, MRI DWI cortical ribboning, CSF RT-QuIC Normal pressure hydrocephalus Gait disturbance prominent; urinary incontinence; dementia triad MRI ventriculomegaly; LP with gait improvement test Autoimmune encephalitis Subacute onset; seizures; psychiatric features; often younger Autoantibody panel (serum/CSF); MRI","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU MMSE or MoCA Every 6-12 months Establish baseline; track trajectory Adjust treatment; reassess diagnosis if unexpected decline - ROUTINE ROUTINE - ADL/IADL function (FAQ, DAD) Every 6-12 months Document functional status for staging Increase support services; OT referral - ROUTINE ROUTINE - Behavioral symptoms (NPI) Each visit Identify and track BPSD Behavioral interventions; consider medications - ROUTINE ROUTINE - Weight Each visit Stable weight Nutritional assessment; speech therapy for swallowing - ROUTINE ROUTINE - Caregiver burden (Zarit scale) Every 6-12 months Early identification of burnout Support resources; respite care; social work - - ROUTINE - MRI (ARIA monitoring if on anti-amyloid) Per protocol No ARIA-E or ARIA-H Hold infusion; follow protocol for resumption - - ROUTINE - ECG (if on donepezil or citalopram) Baseline; if dose increased Normal QTc Reduce dose or switch agent - ROUTINE ROUTINE - Metabolic panel Annually Normal Adjust medications - ROUTINE ROUTINE -","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Reversible causes treated; safe environment; caregiver support; follow-up arranged Admit to floor Acute delirium requiring workup; behavioral crisis unsafe for home; aspiration pneumonia Admit to psychiatry Severe behavioral disturbance requiring specialized psychiatric management Outpatient follow-up Neurology/geriatrics 1-3 months after diagnosis; then every 6-12 months Long-term care Progressive decline; caregiver unable to manage; safety concerns; 24-hour supervision needed","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Cholinesterase inhibitors for mild-moderate AD Class I, Level A Birks J. Cochrane 2006 Memantine for moderate-severe AD Class I, Level A Reisberg et al. NEJM 2003 Combination therapy (ChEI + memantine) Class I, Level A Tariot et al. JAMA 2004 Lecanemab slows cognitive decline in early AD Class I, Level A van Dyck et al. NEJM 2023 (Clarity AD) Donanemab slows cognitive decline Class I, Level A Sims et al. JAMA 2023 (TRAILBLAZER-ALZ 2) CSF biomarkers accurate for AD diagnosis Class I, Level A Hansson et al. Lancet Neurol 2018 Mediterranean diet associated with lower dementia risk Class II, Level B Scarmeas et al. Ann Neurol 2006 Physical exercise may slow cognitive decline Class II, Level B Livingston et al. Lancet 2020 (Lancet Commission) Avoid antipsychotics long-term (mortality risk) Class I, Level A Schneider et al. JAMA 2005 B12 supplementation reverses deficiency-related cognitive impairment Class II, Level B Smith et al. PLoS One 2010","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/dementia-evaluation/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive workup for reversible causes - Includes new anti-amyloid therapies (lecanemab, donanemab) - CSF biomarkers section included - Structured dosing format for order sentence generation</p>","tags":["cognitive","dementia","alzheimer","outpatient"]},{"location":"drafts/diabetic-neuropathy/","title":"Diabetic Neuropathy","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#diabetic-neuropathy","title":"Diabetic Neuropathy","text":"<p>DIAGNOSIS: Diabetic Peripheral Neuropathy ICD-10: G63.2 (Diabetic polyneuropathy); E11.42 (Type 2 DM with diabetic polyneuropathy); E10.42 (Type 1 DM with diabetic polyneuropathy) SCOPE: Distal symmetric polyneuropathy (most common), painful diabetic neuropathy treatment, foot care, and screening for other diabetic neuropathy types. Excludes diabetic amyotrophy (separate protocol) and autonomic neuropathy (mentioned but not primary focus).</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU HbA1c Assess glycemic control; primary modifiable risk factor &lt;7% (individualized goals for elderly) - ROUTINE ROUTINE - Fasting glucose Current glycemic status 70-130 mg/dL STAT ROUTINE ROUTINE - BMP (including creatinine, eGFR) Renal function for medication dosing; CKD common in diabetes eGFR &gt;60 preferred; adjust meds if lower STAT ROUTINE ROUTINE - Lipid panel Cardiovascular risk; dyslipidemia common comorbidity LDL &lt;100 mg/dL (or &lt;70 if ASCVD) - ROUTINE ROUTINE - Vitamin B12 Metformin causes B12 deficiency; mimics diabetic neuropathy &gt;300 pg/mL (&gt;400 optimal) - ROUTINE ROUTINE - TSH Hypothyroidism causes neuropathy; common comorbidity 0.4-4.0 mIU/L - ROUTINE ROUTINE - CBC Anemia evaluation; baseline Normal STAT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Methylmalonic acid (MMA) More sensitive for B12 deficiency if B12 borderline Normal - ROUTINE ROUTINE - Folate Deficiency contributes to neuropathy &gt;3 ng/mL - ROUTINE ROUTINE - Vitamin D Deficiency associated with neuropathic pain &gt;30 ng/mL - ROUTINE ROUTINE - SPEP/UPEP with immunofixation Rule out paraproteinemia if atypical features No monoclonal protein - ROUTINE ROUTINE - ANA Autoimmune/vasculitic neuropathy if atypical Negative - EXT ROUTINE - ESR, CRP Inflammatory markers if vasculitis suspected Normal - ROUTINE ROUTINE - Hepatitis B, C serologies Hepatitis C associated with neuropathy; prevalence in diabetics Negative - ROUTINE ROUTINE - HIV HIV neuropathy if risk factors Negative - EXT EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Cryoglobulins Cryoglobulinemic neuropathy (esp. with Hep C) Negative - - EXT - Anti-MAG antibodies IgM paraprotein-associated neuropathy Negative - - EXT - Genetic neuropathy panel (CMT genes) Family history; atypical presentation Negative - - EXT - Nerve biopsy Vasculitic neuropathy suspected; atypical non-length-dependent Diagnostic findings - - EXT - Skin biopsy for IENFD Quantify small fiber neuropathy Reduced intraepidermal nerve fiber density - - ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Monofilament testing (10g) At every diabetic visit; annually minimum Intact sensation 8-10 sites None - ROUTINE ROUTINE - Tuning fork (128 Hz) Vibration sense at great toe Intact vibration sense None - ROUTINE ROUTINE - Ankle reflexes Deep tendon reflex assessment Present (may be diminished/absent in neuropathy) None - ROUTINE ROUTINE - Foot examination Inspect for ulcers, calluses, deformities, pulses No ulcers or pre-ulcerative lesions None STAT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU EMG/NCS (nerve conduction study) Atypical presentation; asymmetric; rapid progression Length-dependent sensory &gt; motor polyneuropathy Anticoagulation (relative for EMG) - ROUTINE ROUTINE - Autonomic testing (QSART, HR variability, tilt table) Symptoms of autonomic neuropathy; syncope; gastroparesis Abnormal sudomotor, cardiovagal, or adrenergic function None - EXT ROUTINE - MRI lumbar spine Radiculopathy suspected; focal deficits Rule out compressive lesion MRI contraindications URGENT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Skin biopsy (punch biopsy at ankle and thigh) Confirm small fiber neuropathy; normal NCS Reduced IENFD (&lt;threshold for age/sex) Bleeding diathesis; anticoagulation - - ROUTINE - Corneal confocal microscopy Research; non-invasive small fiber assessment Reduced corneal nerve fiber length/density None - - EXT - Sudoscan Screening for sudomotor dysfunction; small fiber Abnormal electrochemical skin conductance None - - EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#3-treatment","title":"3. TREATMENT","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Wound care Topical Diabetic foot ulcer Debridement; offloading; appropriate dressing :: Topical :: :: Wound assessment; debridement if needed; offload pressure; moist wound healing None Signs of infection; healing progress STAT STAT ROUTINE - Antibiotics (diabetic foot infection) PO/IV Infected diabetic foot ulcer Per culture/severity :: PO/IV :: :: Mild: oral (cephalexin, amox/clav); Moderate-severe: IV (piptazo, vanc); per wound culture Drug allergy Infection markers; wound healing STAT STAT - - Pain crisis management IV/PO Severe acute neuropathic pain flare Multimodal :: IV/PO :: :: Consider IV lidocaine if refractory; short-term low-dose opioid for acute crisis Per specific agent Pain scores; sedation URGENT URGENT - -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#3b-symptomatic-treatments-neuropathic-pain-first-line","title":"3B. Symptomatic Treatments (Neuropathic Pain - First-line)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Duloxetine PO First-line for painful diabetic neuropathy; FDA-approved 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day (limited evidence for higher doses) MAOIs; uncontrolled glaucoma; severe renal impairment (CrCl &lt;30) Hepatic function; BP; suicidal ideation - ROUTINE ROUTINE - Pregabalin PO First-line; FDA-approved for DPN 50 mg TID; 75 mg BID; 100 mg TID; 150 mg BID; 200 mg TID :: PO :: :: Start 50 mg TID or 75 mg BID; titrate q3-7d based on response; max 300 mg/day (CrCl 30-60: reduce dose) Angioedema to pregabalin/gabapentin Dizziness, somnolence, weight gain, peripheral edema - ROUTINE ROUTINE - Gabapentin PO First-line alternative; less expensive; similar efficacy 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce dose if CrCl &lt;60 Severe renal impairment (dose adjust) Same as pregabalin; less edema - ROUTINE ROUTINE - Amitriptyline PO TCA option; also helps sleep; less expensive 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS; 100 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg Cardiac conduction abnormality; recent MI; urinary retention; glaucoma; elderly (use with caution) ECG if &gt;40y or cardiac history; anticholinergic effects - ROUTINE ROUTINE - Nortriptyline PO TCA with less sedation and anticholinergic effects than amitriptyline 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS Same as amitriptyline Same as amitriptyline; ECG if &gt;100 mg - ROUTINE ROUTINE - Venlafaxine XR PO SNRI alternative to duloxetine 37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; titrate by 37.5-75 mg q1wk; target 150-225 mg daily MAOIs; uncontrolled HTN BP at higher doses; withdrawal if abrupt discontinuation - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#3c-second-linerefractory-neuropathic-pain","title":"3C. Second-line/Refractory (Neuropathic Pain)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Capsaicin 8% patch (Qutenza) Topical Localized neuropathic pain; add-on therapy Apply for 30 min :: Topical :: :: Applied by healthcare provider; local anesthetic pre-treatment; repeat q3mo Application to face; broken skin Local pain during application; burning - - ROUTINE - Lidocaine 5% patch Topical Localized pain; adjunctive therapy 1-3 patches to painful area :: Topical :: :: Apply to most painful area; up to 3 patches for 12h on/12h off Allergy to local anesthetics Skin irritation - ROUTINE ROUTINE - Tapentadol ER PO Refractory pain; opioid with norepinephrine reuptake inhibition 50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID; 250 mg BID :: PO :: :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day; FDA-approved for DPN Severe respiratory depression; MAOIs; paralytic ileus Constipation, sedation, respiratory status - EXT ROUTINE - Tramadol PO Moderate pain; opioid-like with serotonergic properties 50 mg q6h PRN; 100 mg ER BID :: PO :: :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk) Seizures, serotonin syndrome, sedation - ROUTINE ROUTINE - Desipramine PO TCA with minimal anticholinergic effects 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg Same as other TCAs ECG; therapeutic drug monitoring available - ROUTINE ROUTINE - Oxcarbazepine PO Second-line anticonvulsant; less evidence 300 mg BID; 600 mg BID :: PO :: :: Start 300 mg BID; titrate by 300 mg/wk; typical 600-1200 mg/day Hyponatremia risk Sodium level; rash (SJS rare) - - ROUTINE - Combination therapy Various Inadequate response to single agent Combine agents from different classes :: Various :: :: Use lower doses of each; duloxetine + pregabalin; TCA + gabapentinoid Per individual agents Additive side effects - ROUTINE ROUTINE - Buprenorphine patch TD Severe refractory pain; opioid option 5 mcg/hr; 10 mcg/hr; 20 mcg/hr :: TD :: :: Start 5 mcg/hr weekly patch; titrate slowly Severe respiratory depression; QT prolongation Respiratory status, QTc - EXT ROUTINE - Spinal cord stimulation Implant Refractory painful DPN; failed multiple medications Per implant protocol :: Implant :: :: Trial stimulation before permanent; high-frequency or burst stimulation Infection; coagulopathy; psychiatric instability Device function; pain relief - - EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#3d-disease-modifying-preventive-therapies","title":"3D. Disease-Modifying / Preventive Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Glycemic control optimization Various Primary prevention and slowing progression HbA1c target &lt;7% :: Various :: :: Individualized; tighter control (6-6.5%) in younger patients; less strict (7.5-8%) in elderly/comorbid None Hypoglycemia risk HbA1c q3mo until at goal, then q6mo - ROUTINE ROUTINE - Alpha-lipoic acid PO/IV Antioxidant; European data for DPN 600 mg daily; 600 mg IV daily :: PO/IV :: :: 600 mg PO daily; IV form (600 mg daily x 3wk) for acute symptom relief; limited evidence None GI upset; may lower glucose Glucose (may enhance insulin sensitivity) - ROUTINE ROUTINE - Vitamin B12 supplementation PO/IM B12 deficiency or metformin use 1000 mcg PO daily; 1000 mcg IM monthly :: PO/IM :: :: 1000-2000 mcg PO daily; or 1000 mcg IM monthly if poor absorption None None B12 level q6-12mo - ROUTINE ROUTINE - Benfotiamine PO Thiamine derivative; AGE inhibition 300 mg BID :: PO :: :: 300 mg BID; limited evidence None GI upset None specific - - ROUTINE - ACE inhibitor or ARB PO Nephroprotection; may slow neuropathy progression Per agent :: PO :: :: Standard doses; benefit for kidney protection proven; neuropathy benefit theoretical Angioedema; pregnancy; hyperkalemia; bilateral RAS K+, creatinine - ROUTINE ROUTINE - Statin therapy PO Cardiovascular protection; anti-inflammatory Per agent :: PO :: :: High-intensity statin for most diabetics Active liver disease LFTs, myalgias - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Endocrinology for diabetes optimization if HbA1c not at goal or complex regimen needed - ROUTINE ROUTINE - Podiatry for foot exam, nail care, custom orthotics, and offloading devices - ROUTINE ROUTINE - Vascular surgery if peripheral arterial disease suspected (ABI &lt;0.9 or absent pulses) URGENT URGENT ROUTINE - Pain management for refractory neuropathic pain and interventional options (SCS) - - ROUTINE - Physical therapy for balance training and gait assessment to reduce fall risk - ROUTINE ROUTINE - Wound care specialist for diabetic foot ulcers not healing with standard care - URGENT ROUTINE - Ophthalmology for annual diabetic retinopathy screening - - ROUTINE - Nephrology if eGFR &lt;30 or rapidly declining renal function - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Inspect feet daily using mirror for soles; look for cuts, blisters, redness, or swelling - ROUTINE ROUTINE Never walk barefoot, even indoors, to prevent foot injuries - ROUTINE ROUTINE Wear properly fitted shoes with adequate support; have shoes fitted by professional - ROUTINE ROUTINE Test bath water temperature with elbow (not feet) to prevent burns from impaired sensation - ROUTINE ROUTINE Report any foot wounds, color changes, or pain immediately as diabetic foot ulcers can progress rapidly STAT STAT ROUTINE Take all prescribed medications as directed; do not skip doses of pain medications abruptly - ROUTINE ROUTINE Monitor blood glucose as directed; excellent glycemic control is the most important factor to slow progression - ROUTINE ROUTINE Avoid alcohol which can worsen neuropathy and interact with pain medications - ROUTINE ROUTINE","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Optimal glycemic control (HbA1c &lt;7%) is the primary intervention to prevent and slow neuropathy progression - ROUTINE ROUTINE Smoking cessation as smoking worsens peripheral vascular disease and neuropathy - ROUTINE ROUTINE Blood pressure control (&lt;130/80) reduces microvascular complications - ROUTINE ROUTINE LDL cholesterol control with statin therapy reduces cardiovascular risk - ROUTINE ROUTINE Regular physical activity (150 min/week moderate) improves glycemic control and overall health - ROUTINE ROUTINE Healthy diet (Mediterranean or DASH) supports glycemic and cardiovascular goals - ROUTINE ROUTINE Limit alcohol which worsens neuropathy independently and affects glycemic control - ROUTINE ROUTINE Annual comprehensive foot examination by healthcare provider - - ROUTINE Fall prevention with home safety modifications given impaired proprioception - ROUTINE ROUTINE","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate B12 deficiency neuropathy Sensory &gt; motor; may have subacute combined degeneration; metformin use B12, MMA levels Chronic inflammatory demyelinating polyneuropathy (CIDP) Motor involvement; areflexia; elevated CSF protein; demyelinating NCS EMG/NCS (demyelinating pattern); CSF protein Uremic neuropathy Advanced CKD (eGFR &lt;15); improves with dialysis BUN, creatinine, eGFR Alcoholic neuropathy Heavy alcohol use history; painful; coexisting thiamine deficiency History; thiamine level Hypothyroid neuropathy Other hypothyroid symptoms; CTS common TSH, free T4 Paraproteinemic neuropathy IgM most common; anti-MAG antibodies; may have ataxia SPEP/UPEP; immunofixation; anti-MAG Chemotherapy-induced neuropathy Temporal relationship with chemotherapy (platinum, taxanes, vincristine) Medication history Hereditary neuropathy (CMT) Family history; high arches (pes cavus); hammer toes; slowly progressive Genetic testing; NCS pattern Vasculitic neuropathy Asymmetric; mononeuritis multiplex pattern; systemic symptoms Nerve biopsy; inflammatory markers; angiography Amyloid neuropathy Autonomic involvement; cardiomyopathy; carpal tunnel; paraprotein may be present Fat pad or nerve biopsy; genetic testing (TTR); SPEP","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU HbA1c Every 3-6 months &lt;7% (individualized) Intensify diabetes management - ROUTINE ROUTINE - Comprehensive foot exam Annually (more often if high risk) No ulcers, intact sensation, intact skin Podiatry referral; offloading; wound care - ROUTINE ROUTINE - Monofilament testing At least annually Intact sensation at \u22658/10 sites High-risk foot care; education - ROUTINE ROUTINE - Pain scores (VAS, NRS) Each visit 50%+ reduction with treatment Adjust therapy; consider combination or referral - ROUTINE ROUTINE - B12 level Annually if on metformin &gt;300 pg/mL Supplement B12 - ROUTINE ROUTINE - Kidney function (eGFR) At least annually eGFR &gt;60; stable Adjust medication doses; nephrology referral if declining - ROUTINE ROUTINE - Blood pressure Each visit &lt;130/80 mmHg Optimize antihypertensives - ROUTINE ROUTINE - Autonomic symptoms screen Each visit No symptoms Autonomic testing; cardiology referral if cardiac autonomic neuropathy - ROUTINE ROUTINE - Depression screen (PHQ-9) Annually or if symptoms Negative Treatment; referral - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Symptoms managed; no foot infection; follow-up arranged Admit to floor Diabetic foot infection requiring IV antibiotics; severe uncontrolled pain; associated acute kidney injury Surgical admission Foot infection requiring debridement or amputation Outpatient follow-up Every 3-6 months for medication optimization; annually for comprehensive foot exam","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Duloxetine for painful DPN (FDA-approved) Class I, Level A Wernicke et al. Neurology 2006 Pregabalin for painful DPN (FDA-approved) Class I, Level A Derry et al. Cochrane 2019 Gabapentin effective for DPN Class II, Level B Wiffen et al. Cochrane 2017 Tricyclic antidepressants effective Class II, Level B Moore et al. Cochrane 2015 Glycemic control prevents neuropathy progression Class I, Level A DCCT/EDIC Research Group. NEJM 1993 Alpha-lipoic acid may improve symptoms Class II, Level B Ziegler et al. Diabetes Care 2011 Comprehensive foot exam reduces amputations Class II, Level B ADA Standards of Care 2024 (Section 12) Tapentadol effective for DPN (FDA-approved) Class I, Level A Vinik et al. Diabetes Care 2014 Spinal cord stimulation for refractory DPN Class II, Level B Slangen et al. Diabetes Care 2014 Capsaicin 8% patch effective Class I, Level A Simpson et al. Pain 2017","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive neuropathic pain management - Includes FDA-approved agents (duloxetine, pregabalin, tapentadol) - Foot care and ulcer prevention emphasis - Structured dosing format for order sentence generation</p>","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#appendix-a-diabetic-foot-risk-classification","title":"APPENDIX A: Diabetic Foot Risk Classification","text":"Risk Category Features Foot Exam Frequency Recommendations Low risk Normal sensation; no deformity; palpable pulses Annually Education; appropriate footwear Moderate risk Loss of protective sensation OR peripheral artery disease OR foot deformity Every 3-6 months Podiatry referral; custom footwear consideration High risk Previous ulcer OR previous amputation OR end-stage renal disease Every 1-3 months Podiatry; vascular evaluation; offloading devices Active ulcer or infection Current ulcer/infection As needed until healed Wound care team; vascular surgery if ischemic","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/diabetic-neuropathy/#appendix-b-types-of-diabetic-neuropathy","title":"APPENDIX B: Types of Diabetic Neuropathy","text":"Type Clinical Features Typical Onset Prognosis Distal symmetric polyneuropathy (DSPN) Stocking-glove sensory loss; burning pain; numbness; length-dependent Insidious Chronic; preventable progression with glycemic control Diabetic autonomic neuropathy Orthostatic hypotension; gastroparesis; erectile dysfunction; sudomotor dysfunction; cardiac denervation Gradual Variable; cardiac autonomic neuropathy increases mortality Diabetic lumbosacral radiculoplexus neuropathy (diabetic amyotrophy) Acute/subacute proximal leg weakness and pain; weight loss; often unilateral then spreads Acute-subacute Usually monophasic; recovery over months-years Diabetic thoracic radiculopathy Truncal pain/dysesthesia; dermatomal distribution; may mimic visceral disease Acute-subacute Self-limited (months) Cranial neuropathy CN III most common (pupil-sparing); CN VI, VII also affected Acute Usually resolves in 3-6 months Mononeuropathy/entrapment Carpal tunnel syndrome; ulnar neuropathy; peroneal neuropathy Variable Treat underlying entrapment Treatment-induced neuropathy of diabetes (TIND) Acute painful small fiber neuropathy after rapid glucose improvement After aggressive glycemic control Usually improves with slower glucose normalization","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"drafts/dystonia/","title":"Dystonia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#dystonia","title":"Dystonia","text":"<p>DIAGNOSIS: Dystonia ICD-10: G24.9 (Dystonia, unspecified); G24.1 (Genetic torsion dystonia); G24.2 (Idiopathic nonfamilial dystonia); G24.3 (Spasmodic torticollis); G24.5 (Blepharospasm); G24.8 (Other dystonia) SCOPE: Diagnosis, classification, workup for secondary causes, and symptomatic management of dystonia. Covers focal (cervical, blepharospasm, writer's cramp), segmental, and generalized forms. Includes evaluation for Wilson's disease, dopa-responsive dystonia, and drug-induced dystonia.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline; exclude systemic illness Normal URGENT ROUTINE ROUTINE STAT BMP Electrolyte abnormalities can exacerbate movement disorders Normal STAT ROUTINE ROUTINE STAT Hepatic panel (AST, ALT, Alk Phos, bilirubin, albumin) Screen for hepatic dysfunction suggesting Wilson's disease Normal URGENT ROUTINE ROUTINE - Ceruloplasmin Wilson's disease screen; essential for age &lt;50 with dystonia &gt;20 mg/dL (low suggests Wilson's) - ROUTINE ROUTINE - TSH Hyperthyroidism can cause movement disorders Normal (0.4-4.0 mIU/L) URGENT ROUTINE ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU 24-hour urine copper Wilson's disease confirmation if ceruloplasmin low/borderline &lt;40 mcg/24hr (elevated in Wilson's) - ROUTINE ROUTINE - Serum copper Interpret with ceruloplasmin (low free copper ratio in Wilson's) 75-145 mcg/dL - ROUTINE ROUTINE - Vitamin B12 Deficiency causes myelopathy and movement disorders &gt;300 pg/mL - ROUTINE ROUTINE - Ferritin, serum iron, TIBC Neurodegeneration with brain iron accumulation (NBIA) Normal - ROUTINE ROUTINE - Uric acid Low in ataxia-telangiectasia, Lesch-Nyhan Normal - - ROUTINE - Lactate, pyruvate Mitochondrial disorders Normal - ROUTINE ROUTINE - Calcium, magnesium Hypocalcemia, hypomagnesemia can cause movement disorders Normal STAT ROUTINE ROUTINE STAT CK Elevated in dystonia crises, NMS, prolonged dystonic posturing Normal or mildly elevated STAT ROUTINE - STAT","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ATP7B gene sequencing Definitive Wilson's disease diagnosis No pathogenic variants - - EXT - GCH1 gene sequencing Dopa-responsive dystonia (DYT5a) No pathogenic variants - - EXT - TOR1A gene sequencing DYT1 dystonia (early-onset generalized) No GAG deletion - - EXT - THAP1 gene sequencing DYT6 dystonia No pathogenic variants - - EXT - Dystonia gene panel (multi-gene NGS) Atypical presentations; family history; early onset No pathogenic variants - - EXT - CSF neurotransmitter metabolites (HVA, 5-HIAA, pterins) Dopa-responsive dystonia; neurotransmitter disorders Normal ratios - - EXT - Acanthocyte smear Chorea-acanthocytosis, McLeod syndrome No acanthocytes - - EXT - Lysosomal enzyme panel Lysosomal storage disorders (GM1, GM2 gangliosidosis) Normal enzyme activity - - EXT - Anti-neuronal antibodies (NMDAR, LGI1, CASPR2) Autoimmune dystonia (rare) Negative - EXT EXT - Paraneoplastic antibody panel Paraneoplastic dystonia Negative - - EXT -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without and with contrast All new dystonia cases; rule out structural lesion Normal; no basal ganglia lesions MRI-incompatible devices URGENT ROUTINE ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with SWI/iron sequences Suspected Wilson's disease or NBIA No T2 hypointensity in basal ganglia MRI contraindications - ROUTINE ROUTINE - Slit lamp examination by ophthalmology Wilson's disease evaluation; Kayser-Fleischer rings No KF rings None - ROUTINE ROUTINE - EMG with dystonia protocol Confirm diagnosis; characterize pattern; guide botulinum toxin Co-contraction of agonist/antagonist; overflow None - - ROUTINE - DaTscan (ioflupane I-123) Differentiate dystonic tremor from PD; combined dystonia-parkinsonism Normal in primary dystonia; abnormal if parkinsonism Iodine allergy - - ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Spine (cervical/thoracic) Cervical dystonia with radiculopathy symptoms Normal; no cord compression MRI contraindications - ROUTINE ROUTINE - FDG-PET Brain Atypical parkinsonism with dystonia Pattern interpretation varies None significant - - EXT - Liver MRI or ultrasound Wilson's disease staging if diagnosed Assess hepatic involvement None significant - ROUTINE ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Diphenhydramine IV/IM Acute dystonic reaction (drug-induced) 25 mg IV; 50 mg IV; 50 mg IM :: IV/IM :: :: 25-50 mg IV/IM over 2-5 min; may repeat in 30 min if needed; max 100 mg Narrow-angle glaucoma; urinary retention Sedation, hypotension STAT STAT - STAT Benztropine IV/IM Acute dystonic reaction (drug-induced) 1 mg IV; 2 mg IV; 1 mg IM; 2 mg IM :: IV/IM :: :: 1-2 mg IV/IM; may repeat in 30 min; follow with oral 1-2 mg BID x 2-3 days to prevent recurrence Narrow-angle glaucoma; GI obstruction; myasthenia gravis Anticholinergic effects, confusion (elderly) STAT STAT - STAT Lorazepam IV/PO Status dystonicus; severe dystonic storm 1 mg IV; 2 mg IV; 2 mg PO; 4 mg PO :: IV/PO :: :: 1-2 mg IV slow push or 2-4 mg PO; may repeat q4-6h PRN; monitor respiratory status Severe respiratory depression; acute narrow-angle glaucoma Respiratory depression, sedation STAT STAT - STAT Diazepam IV/PO Status dystonicus; muscle spasm relief 5 mg IV; 10 mg IV; 5 mg PO; 10 mg PO :: IV/PO :: :: 5-10 mg IV slow push (2 mg/min) or PO; may repeat q4h PRN Same as lorazepam Same as lorazepam STAT STAT - STAT","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#3b-symptomatic-treatments-first-line-for-focal-dystonia","title":"3B. Symptomatic Treatments (First-line for Focal Dystonia)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU OnabotulinumtoxinA (Botox) - Cervical dystonia IM First-line for cervical dystonia/torticollis 100 units total; 200 units total; 300 units total :: IM :: :: Start 100-200 units divided among affected muscles (SCM, splenius, trapezius, levator scapulae); adjust based on response; max 300 units/session; repeat q12wk Infection at site; myasthenia gravis; ALS Dysphagia (especially bilateral SCM); neck weakness; antibody formation - - ROUTINE - OnabotulinumtoxinA (Botox) - Blepharospasm IM First-line for blepharospasm 25 units total; 50 units total :: IM :: :: 1.25-5 units per site; inject orbicularis oculi at multiple points; total 25-50 units per eye; repeat q12wk Same as above Ptosis, diplopia, dry eyes, lagophthalmos - - ROUTINE - OnabotulinumtoxinA (Botox) - Writer's cramp IM Focal hand dystonia refractory to therapy modification 50 units total; 100 units total :: IM :: :: 10-50 units per muscle; EMG guidance required; target FCR, FCU, FDS as needed; repeat q12wk Same as above Finger weakness (may impair function) - - ROUTINE - AbobotulinumtoxinA (Dysport) - Cervical dystonia IM Alternative to onabotulinum; different potency 500 units total; 750 units total; 1000 units total :: IM :: :: Start 500 units divided among affected muscles; max 1000 units/session; repeat q12wk Same as onabotulinum Same as onabotulinum - - ROUTINE - IncobotulinumtoxinA (Xeomin) - Cervical dystonia IM Alternative; no complexing proteins 120 units total; 200 units total; 300 units total :: IM :: :: Start 120-200 units divided; max 300 units/session; repeat q12wk; may have lower immunogenicity Same as onabotulinum Same as onabotulinum - - ROUTINE - RimabotulinumtoxinB (Myobloc) - Cervical dystonia IM Type A toxin non-responders; secondary non-response 2500 units total; 5000 units total; 10000 units total :: IM :: :: Start 2500-5000 units divided; max 10000 units; repeat q12wk; higher dry mouth rate Same; type B protein allergy Dry mouth more common; dysphagia - - ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#3c-second-lineoral-medications","title":"3C. Second-line/Oral Medications","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Trihexyphenidyl PO First-line oral for generalized dystonia; young patients tolerate best 1 mg daily; 2 mg TID; 5 mg TID; 10 mg TID; 15 mg TID :: PO :: :: Start 1 mg daily; increase by 1-2 mg q3-5d; typical target 6-30 mg/day divided TID; some patients require up to 60-80 mg/day Narrow-angle glaucoma; GI obstruction; urinary retention; dementia Anticholinergic effects (dry mouth, constipation, urinary retention, confusion); cognitive effects in elderly - ROUTINE ROUTINE - Benztropine PO Alternative anticholinergic; maintenance after acute dystonic reaction 0.5 mg BID; 1 mg BID; 2 mg BID; 3 mg BID :: PO :: :: Start 0.5 mg BID; increase by 0.5 mg q5-7d; typical 1-4 mg/day; max 6 mg/day Same as trihexyphenidyl Same as trihexyphenidyl - ROUTINE ROUTINE - Baclofen PO Muscle relaxant; useful adjunct for dystonia 5 mg TID; 10 mg TID; 20 mg TID; 30 mg TID :: PO :: :: Start 5 mg TID; increase by 5 mg/dose q3d; typical 30-80 mg/day divided TID; max 80-120 mg/day Severe renal impairment (dose adjust); abrupt withdrawal risk Sedation, weakness; taper slowly if discontinuing - ROUTINE ROUTINE - Clonazepam PO Adjunct for dystonia; myoclonus-dystonia 0.25 mg BID; 0.5 mg BID; 1 mg BID; 1 mg TID :: PO :: :: Start 0.25 mg BID; increase by 0.25-0.5 mg q3-7d; typical 1-4 mg/day; max 6 mg/day Respiratory depression; severe hepatic impairment; substance abuse history Sedation, dependence, falls; taper if discontinuing - ROUTINE ROUTINE - Diazepam PO Alternative benzodiazepine; muscle relaxant properties 2 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2 mg TID; increase by 2-5 mg/day q3-7d; typical 10-40 mg/day divided Same as clonazepam Same as clonazepam - ROUTINE ROUTINE - Levodopa/Carbidopa PO Dopa-responsive dystonia (DRD); diagnostic trial for young-onset 25/100 mg TID; 50/200 mg TID :: PO :: :: Start 25/100 mg TID; if DRD, dramatic response at low dose; may titrate to 50/200 mg TID; response confirms diagnosis None absolute; use caution in psychosis Nausea, orthostatic hypotension; dramatic improvement suggests DRD - ROUTINE ROUTINE - Tetrabenazine PO Hyperkinetic movements including some dystonias 12.5 mg daily; 12.5 mg BID; 25 mg TID :: PO :: :: Start 12.5 mg daily; increase by 12.5 mg q1wk; max 200 mg/day; CYP2D6 testing recommended Depression; suicidality; Parkinsonism Depression, sedation, parkinsonism, akathisia; Black Box: suicidality - - ROUTINE - Deutetrabenazine (Austedo) PO Longer half-life alternative to tetrabenazine 6 mg BID; 12 mg BID; 24 mg BID :: PO :: :: Start 6 mg BID; increase by 6 mg/day weekly; max 48 mg/day Same as tetrabenazine Same but may be better tolerated - - ROUTINE - Clonidine PO Adjunct; may help in some patients 0.1 mg BID; 0.2 mg BID; 0.3 mg BID :: PO :: :: Start 0.1 mg BID; increase by 0.1 mg q1wk; max 0.6 mg/day Severe bradycardia; renal impairment (adjust) Hypotension, bradycardia, sedation; rebound hypertension if stopped abruptly - ROUTINE ROUTINE - Carbamazepine PO Paroxysmal kinesigenic dystonia/dyskinesia 100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; increase by 100-200 mg q1wk; target 400-800 mg/day; check HLA-B*1502 in at-risk populations Bone marrow suppression; AV block; SJS risk (HLA-B*1502) CBC, LFTs, sodium; drug levels (4-12 mcg/mL) - ROUTINE ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#3d-disease-modifyingspecialized-therapies","title":"3D. Disease-Modifying/Specialized Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Deep brain stimulation (GPi-DBS) Surgical Medication-refractory generalized or segmental dystonia; DYT1 positive Bilateral GPi stimulation :: Surgical :: :: Bilateral GPi electrode placement; programming over weeks-months; full effect may take 6-12 months MRI; neuropsych testing; multidisciplinary evaluation; genetic testing if indicated Cognitive impairment; coagulopathy; infection; unrealistic expectations Programming optimization; battery replacement q3-5yr; speech/swallowing - - ROUTINE - Deep brain stimulation (GPi-DBS) Surgical Cervical dystonia refractory to botulinum toxin Bilateral GPi stimulation :: Surgical :: :: Same as above Same as above Same as above Same as above - - ROUTINE - Intrathecal baclofen pump Surgical Severe generalized dystonia with spasticity component; CP-related Continuous IT infusion :: IT :: :: Test dose 25-100 mcg; maintenance typically 100-1000 mcg/day; titrate over months IT baclofen trial with &gt;50% improvement Infection; CSF obstruction; baclofen hypersensitivity Pump refills q1-3mo; withdrawal syndrome if interruption; MRI conditional pumps - ROUTINE ROUTINE - D-penicillamine PO Wilson's disease with neurological symptoms 250 mg daily; 500 mg BID; 750 mg BID; 1000 mg BID :: PO :: :: Start 250 mg daily; increase by 250 mg q4-7d; target 1000-1500 mg/day divided BID (take 1hr before meals); lifelong treatment 24h urine copper, LFTs, CBC, urinalysis Penicillin allergy (not absolute but caution); nephrotoxicity CBC weekly x1mo then monthly x6mo then q3mo; urinalysis monthly; LFTs monthly; neurologic worsening first 6 months possible - ROUTINE ROUTINE - Trientine (Syprine) PO Wilson's disease; D-penicillamine intolerant 250 mg TID; 500 mg TID; 750 mg BID :: PO :: :: Start 250 mg TID; target 750-1250 mg/day divided TID; take 1hr before or 2hr after meals Same as D-penicillamine Caution with iron supplements (separate by 2hr) Same monitoring as D-penicillamine; fewer side effects - ROUTINE ROUTINE - Zinc acetate (Galzin) PO Wilson's disease maintenance; presymptomatic; adjunct 50 mg TID :: PO :: :: 50 mg TID (elemental zinc); take between meals; blocks intestinal copper absorption Take separately from copper chelators GI upset 24h urine copper; serum zinc; 24h urine zinc - ROUTINE ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Movement disorders neurology for diagnosis confirmation, classification, and treatment planning - ROUTINE ROUTINE - Ophthalmology for slit lamp examination to evaluate for Kayser-Fleischer rings (Wilson's disease workup) - ROUTINE ROUTINE - Hepatology if Wilson's disease diagnosed for hepatic management and transplant evaluation if severe - ROUTINE ROUTINE - Genetic counseling if genetic dystonia confirmed or suspected (DYT1, DYT6, GCH1) - - ROUTINE - Neurosurgery consultation for DBS evaluation if medication-refractory - - ROUTINE - Physical therapy for posture correction, stretching, and range of motion exercises - ROUTINE ROUTINE - Occupational therapy for adaptive techniques and assistive devices for ADLs - ROUTINE ROUTINE - Speech therapy if oromandibular dystonia, laryngeal dystonia, or cervical dystonia affecting swallowing - ROUTINE ROUTINE - Pain management if chronic pain from dystonic posturing not controlled with primary treatment - - ROUTINE - Psychology/psychiatry for coping strategies, depression/anxiety management related to chronic dystonia - - ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD After botulinum toxin injection: avoid rubbing injection sites; effects develop over 3-14 days and last 10-12 weeks - - ROUTINE Report any swallowing difficulty or breathing problems after botulinum toxin injection (may indicate spread) URGENT ROUTINE ROUTINE Use sensory tricks (geste antagoniste) such as touching chin or face which may temporarily reduce cervical dystonia - ROUTINE ROUTINE Return to ED if severe muscle spasms with fever, confusion, or dark urine (possible dystonic storm or rhabdomyolysis) STAT ROUTINE ROUTINE Continue physical therapy exercises at home to maintain range of motion and prevent contractures - ROUTINE ROUTINE Avoid medications that worsen dystonia: metoclopramide, prochlorperazine, haloperidol, and other dopamine blockers ROUTINE ROUTINE ROUTINE For Wilson's disease: strict adherence to copper chelation is lifelong; follow dietary copper restrictions - ROUTINE ROUTINE Keep a symptom diary noting triggers, sensory tricks that help, and response to medications - - ROUTINE","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Stress management with relaxation techniques as stress can exacerbate dystonia - ROUTINE ROUTINE Adequate sleep as fatigue worsens dystonia symptoms - ROUTINE ROUTINE Limit caffeine and stimulants which may worsen tremor/dystonia - ROUTINE ROUTINE Regular gentle exercise (swimming, yoga) to maintain flexibility without overexertion - - ROUTINE Ergonomic workstation modifications for task-specific dystonia (writer's cramp, musician's dystonia) - - ROUTINE For Wilson's disease: avoid high-copper foods (liver, shellfish, chocolate, nuts, mushrooms) especially during initial treatment - ROUTINE ROUTINE Avoid alcohol especially if on benzodiazepines or with hepatic involvement (Wilson's) - ROUTINE ROUTINE Heat application to affected muscles may provide temporary relief - ROUTINE ROUTINE Support groups for dystonia provide coping strategies and community connection - - ROUTINE","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Drug-induced dystonia Temporal relationship with dopamine blockers (antipsychotics, antiemetics); acute or tardive Medication history; resolves with withdrawal (acute) or persists (tardive) Wilson's disease Age &lt;50; hepatic dysfunction; psychiatric symptoms; Kayser-Fleischer rings Ceruloplasmin (low), 24h urine copper (high), slit lamp exam, ATP7B testing Dopa-responsive dystonia (DYT5/Segawa) Childhood onset; diurnal fluctuation (worse evening); dramatic levodopa response Levodopa trial (dramatic improvement); GCH1 gene testing Parkinson's disease with dystonia Rest tremor; bradykinesia; rigidity; asymmetric; sustained postures DaTscan (abnormal); clinical exam; levodopa response Psychogenic/functional dystonia Inconsistent; distractible; fixed posture from onset; associated somatization Clinical features; psychiatric evaluation; resolution with distraction Stiff-person syndrome Axial rigidity; episodic spasms triggered by startle; anti-GAD antibodies Anti-GAD65 antibodies; EMG (continuous motor unit activity) Tardive dystonia Prolonged dopamine blocker exposure (months-years); may persist after withdrawal History of antipsychotic/antiemetic use; AIMS assessment Cervical spondylotic myelopathy Neck pain; sensory symptoms; hyperreflexia; Hoffmann sign MRI C-spine (cord compression, myelopathy signal) Torticollis from posterior fossa tumor Constant head tilt; headache; papilledema; cranial nerve signs MRI Brain with contrast (tumor, hydrocephalus) Neuroacanthocytosis/chorea-acanthocytosis Chorea; orofacial dystonia; lip/tongue biting; elevated CK Acanthocyte smear; CK; VPS13A gene testing NBIA (neurodegeneration with brain iron accumulation) Progressive; childhood/young adult onset; parkinsonism; retinopathy MRI (eye-of-the-tiger sign); genetic panels (PANK2, etc.) Meige syndrome Combined blepharospasm + oromandibular dystonia Clinical diagnosis; rule out secondary causes Myoclonus-dystonia (DYT11) Myoclonic jerks + dystonia; alcohol responsive; SGCE gene SGCE gene testing; alcohol response Paroxysmal kinesigenic dyskinesia Brief attacks (&lt;1 min); triggered by sudden movement; responds to carbamazepine Clinical history; PRRT2 gene testing","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Dystonia severity (Burke-Fahn-Marsden scale, TWSTRS for cervical) Each visit 30%+ improvement with treatment Adjust botulinum toxin dose/muscles; add oral agent; consider DBS - ROUTINE ROUTINE - Functional status and disability Each visit Improved ADLs, work function OT/PT referral; adaptive devices; treatment escalation - ROUTINE ROUTINE - Anticholinergic side effects (dry mouth, constipation, urinary retention, cognition) Each visit on anticholinergics Tolerable side effects Reduce dose; switch agents; add symptomatic treatment - ROUTINE ROUTINE - Dysphagia screening (after cervical botulinum toxin) 2 weeks post-injection Normal swallowing Dietary modification; speech therapy; reduce dose next session - - ROUTINE - CK level (if severe dystonia or dystonic storm) PRN &lt;1000 U/L IV fluids; monitor renal function; treat underlying cause STAT STAT - STAT 24-hour urine copper (Wilson's on chelation) Every 3-6 months &lt;100 mcg/24hr on maintenance Adjust chelator dose; assess compliance - - ROUTINE - CBC, urinalysis (on D-penicillamine) Monthly initially then q3mo Normal Hold drug if cytopenias or proteinuria; switch to trientine - ROUTINE ROUTINE - LFTs (Wilson's disease) Monthly initially then q3mo Stable or improving Hepatology consultation if worsening - ROUTINE ROUTINE - Depression screening (on tetrabenazine) Each visit No suicidal ideation Discontinue tetrabenazine; psychiatric referral - ROUTINE ROUTINE - DBS parameters and battery Every 6-12 months Optimal control; battery &gt;30% Reprogram; schedule battery replacement if needed - - ROUTINE -","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home New diagnosis with workup initiated; mild symptoms; treatment plan in place; follow-up scheduled Admit to floor Acute dystonic reaction requiring observation; new generalized dystonia requiring workup; Wilson's disease with hepatic decompensation Admit to ICU Status dystonicus (dystonic storm); respiratory compromise; rhabdomyolysis; severe drug-induced dystonia with airway concern Transfer to higher level DBS programming issues requiring movement disorders center; refractory status dystonicus requiring specialized center Outpatient follow-up 2-4 weeks after new medication started; 12 weeks for botulinum toxin reassessment; 6-12 months when stable","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Botulinum toxin first-line for cervical dystonia Class I, Level A Simpson DM et al. Neurology 2008 (AAN Guideline) Botulinum toxin for blepharospasm Class I, Level A Simpson DM et al. Neurology 2008 GPi-DBS effective for generalized dystonia Class I, Level A Vidailhet M et al. NEJM 2005 DBS superior effect in DYT1-positive patients Class II, Level B Coubes P et al. J Neurosurg 2004 Trihexyphenidyl for generalized dystonia Class II, Level C Burke RE et al. Neurology 1986 Levodopa trial for suspected dopa-responsive dystonia Class II, Level B Nygaard TG et al. Neurology 1991 Dystonia classification consensus Expert consensus Albanese A et al. Mov Disord 2013 Wilson's disease diagnosis and treatment Class I, Level A Roberts EA, Schilsky ML. Hepatology 2008 (AASLD Guideline) D-penicillamine for Wilson's disease Class I, Level A Roberts EA, Schilsky ML. Hepatology 2008 Intrathecal baclofen for severe dystonia Class II, Level B Albright AL et al. J Neurosurg 2001 Benztropine/diphenhydramine for acute dystonic reaction Class III, Level C van Harten PN et al. J Clin Psychiatry 1999 Carbamazepine for paroxysmal kinesigenic dyskinesia Class II, Level B Bruno MK et al. Brain 2004 EFNS guidelines on dystonia diagnosis and treatment Expert consensus Albanese A et al. Eur J Neurol 2011 Tetrabenazine for hyperkinetic movement disorders Class II, Level B Jankovic J, Beach J. Neurology 1997","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of focal, segmental, and generalized dystonia - Detailed botulinum toxin dosing for cervical dystonia, blepharospasm, and focal hand dystonia - Oral medication options including anticholinergics, baclofen, benzodiazepines - Wilson's disease and dopa-responsive dystonia workup - DBS and intrathecal baclofen for refractory cases - Structured dosing format for order sentence generation</p>","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#appendix-a-dystonia-classification","title":"APPENDIX A: DYSTONIA CLASSIFICATION","text":"","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#by-body-distribution","title":"By Body Distribution","text":"Type Definition Examples Focal Single body region Cervical (torticollis), blepharospasm, writer's cramp, laryngeal Segmental Two or more contiguous regions Cranial-cervical (Meige + cervical), brachial Multifocal Two or more non-contiguous regions Blepharospasm + writer's cramp Hemidystonia Ipsilateral arm and leg Usually secondary (stroke, tumor) Generalized Trunk + at least 2 other regions DYT1 dystonia, Wilson's disease","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#by-etiology-axis-2","title":"By Etiology (Axis 2)","text":"Category Subtype Examples Inherited Isolated dystonia DYT1 (TOR1A), DYT6 (THAP1) Inherited Combined dystonia DYT5 (GCH1, dopa-responsive), myoclonus-dystonia (SGCE) Inherited Complex dystonia Wilson's disease, NBIA, Huntington's disease Acquired Perinatal injury Cerebral palsy with dystonia Acquired Drugs Tardive dystonia, acute dystonic reaction Acquired Structural Stroke, tumor, demyelination Acquired Autoimmune Anti-NMDAR encephalitis, paraneoplastic Idiopathic Sporadic Adult-onset focal dystonia (most cervical) Idiopathic Familial Family history without identified gene","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#appendix-b-sensory-tricks-geste-antagoniste","title":"APPENDIX B: SENSORY TRICKS (GESTE ANTAGONISTE)","text":"<p>Sensory tricks are voluntary maneuvers that temporarily reduce dystonic posturing. Their presence supports the diagnosis of primary dystonia.</p>","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#common-sensory-tricks-by-type","title":"Common Sensory Tricks by Type","text":"Dystonia Type Common Sensory Tricks Cervical dystonia Light touch to chin, cheek, or back of head; leaning against wall; wearing cervical collar Blepharospasm Touching eyelid or brow; wearing dark glasses; pulling eyelid skin; singing or humming Writer's cramp Using thicker pen; changing grip; writing on different surface Oromandibular Chewing gum; touching lips; biting on object","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/dystonia/#clinical-significance","title":"Clinical Significance","text":"<ul> <li>Present in ~70-80% of cervical dystonia patients</li> <li>Absence does not exclude diagnosis</li> <li>Diminish over time in some patients</li> <li>May be used therapeutically (collar, glasses)</li> </ul>","tags":["movement-disorders","dystonia","outpatient","botulinum-toxin"]},{"location":"drafts/essential-tremor/","title":"Essential Tremor","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#essential-tremor","title":"Essential Tremor","text":"<p>DIAGNOSIS: Essential Tremor ICD-10: G25.0 (Essential tremor) SCOPE: Diagnosis confirmation, differentiation from Parkinson's disease and other tremors, and symptomatic treatment. Covers classic essential tremor and ET-plus syndrome.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU TSH Hyperthyroidism causes action tremor Normal (0.4-4.0 mIU/L) URGENT ROUTINE ROUTINE - Free T4 If TSH abnormal Normal URGENT ROUTINE ROUTINE - BMP Electrolyte abnormalities (hypomagnesemia) can cause tremor Normal STAT ROUTINE ROUTINE - Glucose Hypoglycemia causes tremor 70-180 mg/dL STAT ROUTINE - - Hepatic panel Hepatic encephalopathy can cause asterixis/tremor; baseline before medications Normal - ROUTINE ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Magnesium Hypomagnesemia causes tremor 1.8-2.4 mg/dL - ROUTINE ROUTINE - Ceruloplasmin, serum copper Wilson's disease if age &lt;50 Normal - EXT ROUTINE - 24-hour urine copper Wilson's confirmation &lt;100 \u03bcg/24hr - - EXT - Drug/toxin screen Caffeine, stimulants, alcohol withdrawal Negative or explains tremor STAT ROUTINE EXT - Vitamin B12 Deficiency can cause tremor &gt;300 pg/mL - ROUTINE ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Heavy metal panel (mercury, lead, arsenic) Occupational exposure; toxin-induced tremor Normal - - EXT - Paraneoplastic antibody panel Atypical tremor; occult malignancy Negative - - EXT - Anti-GAD65 antibodies Stiff-person spectrum; autoimmune etiology Negative - - EXT - Genetic testing (LINGO1, SLC1A2) Research; strong family history Variable - - EXT -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Clinical examination (spiral drawing, water pouring) At evaluation Symmetric action tremor; improves with alcohol; family history None STAT ROUTINE ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain Atypical features; focal signs; concern for structural lesion Normal MRI-incompatible devices URGENT ROUTINE ROUTINE - DaTscan (ioflupane I-123) Differentiate ET from Parkinson's disease NORMAL in ET (abnormal in PD) Iodine hypersensitivity - - ROUTINE - EMG with accelerometry Characterize tremor frequency (8-12 Hz typical ET) 4-12 Hz, predominantly postural/kinetic None - - EXT -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with SWI Wilson's disease evaluation; iron deposition No basal ganglia abnormalities MRI contraindications - EXT EXT - PET scan Research; rule out neurodegenerative parkinsonian syndromes Normal nigrostriatal pathway None - - EXT - Slit lamp examination Wilson's disease (Kayser-Fleischer rings) No KF rings None - EXT EXT -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Propranolol (as needed) PO Situational tremor (performance anxiety, important meeting) 20 mg PO; 40 mg PO :: PO :: :: 20-40 mg PO 30-60 min before anxiety-provoking situation; single dose PRN Asthma; severe bradycardia; decompensated HF HR, BP if first dose URGENT URGENT ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#3b-symptomatic-treatments-first-line","title":"3B. Symptomatic Treatments (First-line)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Propranolol PO First-line chronic therapy; most evidence 20 mg BID; 40 mg BID; 60 mg BID; 80 mg BID; 120 mg daily LA; 160 mg daily LA :: PO :: :: Start 20 mg BID or 60 mg LA daily; titrate q2wk; target 60-240 mg/day Asthma/COPD; bradycardia &lt;50; heart block; decompensated HF HR (&gt;50 bpm), BP, fatigue, depression - ROUTINE ROUTINE - Propranolol LA PO Once daily option for adherence 60 mg daily; 80 mg daily; 120 mg daily; 160 mg daily :: PO :: :: Start 60-80 mg daily; titrate q2wk; max 320 mg/day Same as IR Same as IR - ROUTINE ROUTINE - Primidone PO First-line; equal efficacy to propranolol 25 mg qHS; 50 mg qHS; 50 mg TID; 125 mg TID; 250 mg TID :: PO :: :: Start 25 mg qHS (VERY LOW to avoid acute toxicity); increase by 25-50 mg q1wk; target 250-750 mg/day divided Porphyria; severe hepatic impairment Sedation (especially initial), ataxia, GI upset - ROUTINE ROUTINE - Propranolol + Primidone PO Combination for better efficacy than monotherapy Per individual drug :: PO :: :: Add second agent if monotherapy insufficient; use lower doses of each Per individual drug Monitor both sets of side effects - ROUTINE ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Topiramate PO Beta-blocker contraindicated; weight concern 25 mg qHS; 50 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg q1wk; target 100-400 mg/day divided Glaucoma; kidney stones; pregnancy Cognitive effects, paresthesias, weight loss, metabolic acidosis - ROUTINE ROUTINE - Gabapentin PO Mild benefit; good tolerability; neuropathic pain comorbidity 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1200-3600 mg/day divided TID Severe renal impairment (dose adjust) Sedation, dizziness, edema - ROUTINE ROUTINE - Alprazolam PO Anxiolytic benefit; use with caution 0.25 mg TID; 0.5 mg TID :: PO :: :: Start 0.25 mg TID; titrate slowly; max 3 mg/day; avoid long-term if possible Respiratory depression; history of substance use Dependence, sedation, falls - ROUTINE ROUTINE - Clonazepam PO Orthostatic tremor; head tremor; refractory cases 0.25 mg BID; 0.5 mg BID; 1 mg BID :: PO :: :: Start 0.25 mg BID; titrate slowly; typical 0.5-2 mg/day Same as alprazolam Same as alprazolam - ROUTINE ROUTINE - Atenolol PO Beta-blocker alternative (more beta-1 selective) 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25-50 mg daily; max 100 mg daily Heart block; severe bradycardia HR, BP - ROUTINE ROUTINE - Nadolol PO Long-acting beta-blocker alternative 40 mg daily; 80 mg daily; 120 mg daily :: PO :: :: Start 40 mg daily; titrate q1-2wk; max 240 mg daily Same as propranolol Same as propranolol - ROUTINE ROUTINE - Sotalol PO Beta-blocker with additional antiarrhythmic properties 80 mg BID; 120 mg BID :: PO :: :: Start 80 mg BID; max 240 mg/day; requires QTc monitoring QT prolongation; severe renal impairment QTc, electrolytes - ROUTINE ROUTINE - Nimodipine PO Limited evidence; calcium channel blocker 30 mg TID :: PO :: :: 30 mg TID Hypotension BP - - EXT - Zonisamide PO Limited evidence; weight neutral 100 mg daily; 200 mg daily :: PO :: :: Start 100 mg daily; may increase to 200 mg daily Sulfonamide allergy; renal stones Kidney stones, rash - - EXT -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#3d-interventionaladvanced-therapies","title":"3D. Interventional/Advanced Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Botulinum toxin (head tremor) IM Head/neck tremor refractory to oral medications 100-200 units total :: IM :: :: Inject into sternocleidomastoid and splenius capitis bilaterally; repeat q3-4mo EMG guidance recommended Infection at site; myasthenia gravis Dysphagia, neck weakness - - ROUTINE - Botulinum toxin (hand tremor) IM Hand tremor refractory to oral medications 50-100 units per hand :: IM :: :: Inject into forearm flexors/extensors; EMG-guided; repeat q3mo EMG guidance required Same as above Finger weakness (limits use) - - ROUTINE - Deep brain stimulation (DBS) Surgical Medication-refractory disabling tremor VIM thalamus stimulation :: Surgical :: :: Unilateral or bilateral VIM thalamus; programming over weeks MRI; neuropsych testing; multidisciplinary evaluation Cognitive impairment; unstable psychiatric disease; coagulopathy Programming optimization; speech side effects (bilateral) - - ROUTINE - MRI-guided focused ultrasound (MRgFUS) Non-invasive Unilateral tremor; DBS declined or contraindicated VIM thalamotomy :: Non-invasive :: :: Unilateral lesion of VIM thalamus; immediate effect Must tolerate prolonged MRI Bilateral procedure not recommended (speech risk); skull density ratio Numbness, ataxia, speech changes (usually transient) - - ROUTINE - Gamma Knife radiosurgery Non-invasive VIM thalamotomy; DBS contraindicated 130-150 Gy to VIM :: Non-invasive :: :: Unilateral lesion; delayed effect (months) MRI compatible Same as MRgFUS Same as MRgFUS; delayed effect - - EXT -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Movement disorders neurology for diagnosis confirmation if uncertain and treatment optimization - ROUTINE ROUTINE - Neurosurgery consultation for DBS or MRgFUS evaluation if medication-refractory - - ROUTINE - Occupational therapy for adaptive devices and hand-writing strategies - - ROUTINE - Physical therapy for postural training and coordination exercises - - ROUTINE - Psychology/counseling for anxiety management and coping strategies - - ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Avoid or minimize caffeine which can worsen tremor - ROUTINE ROUTINE Limit alcohol (may temporarily improve tremor but rebound worsening occurs and dependence risk) - ROUTINE ROUTINE Get adequate sleep as fatigue worsens tremor - ROUTINE ROUTINE Manage stress and anxiety which exacerbate tremor (relaxation techniques, regular exercise) - ROUTINE ROUTINE Use weighted utensils and adaptive devices for eating and writing if tremor interferes - ROUTINE ROUTINE Report any new symptoms such as slowness, stiffness, or balance problems which may indicate progression to ET-plus or Parkinson's - ROUTINE ROUTINE Consider alerting employer/school if tremor affects work performance to discuss accommodations - - ROUTINE","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular physical exercise improves overall motor function and stress management - ROUTINE ROUTINE Relaxation techniques (yoga, meditation, deep breathing) reduce stress-related tremor exacerbation - - ROUTINE Avoid medications that worsen tremor (lithium, valproate, some antidepressants, stimulants) when alternatives exist - ROUTINE ROUTINE Use larger-grip pens and utensils to improve function - - ROUTINE Voice-to-text software if writing is significantly impaired - - ROUTINE Limit alcohol despite temporary improvement to avoid dependence and rebound tremor - ROUTINE ROUTINE","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Parkinson's disease Rest tremor predominant; bradykinesia; rigidity; asymmetric onset DaTscan (abnormal in PD, normal in ET); clinical exam Enhanced physiologic tremor Typically bilateral, postural; related to caffeine, anxiety, medications, hyperthyroidism Remove triggers; check TSH, caffeine history Drug-induced tremor Temporal relationship with medication; bilateral Medication review; trial withdrawal Dystonic tremor Irregular, jerky; task-specific; associated dystonic posturing; null point Clinical exam; may see dystonia at rest Cerebellar tremor Intention tremor (worsens at target); associated ataxia, dysarthria MRI brain (cerebellar pathology); clinical exam Psychogenic tremor Variable frequency; distractible; entrainment with contralateral movement Clinical maneuvers; psychiatric evaluation Wilson's disease Age &lt;50; liver disease; psychiatric symptoms; Kayser-Fleischer rings Ceruloplasmin, 24h urine copper, slit lamp Orthostatic tremor Tremor in legs/trunk when standing; relief with sitting/walking EMG (13-18 Hz characteristic) Rubral tremor Rest + postural + intention (\"Holmes tremor\"); midbrain lesion history MRI (midbrain pathology) Neuropathic tremor Associated with peripheral neuropathy (CIDP, IgM paraprotein) EMG/NCS; protein electrophoresis","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Tremor severity (clinical rating scales: Fahn-Tolosa-Marin, TETRAS) Each visit 50%+ improvement with treatment Adjust medication dose; consider second agent or intervention - ROUTINE ROUTINE - Functional impact (writing, eating, drinking) Each visit Acceptable function for patient OT referral; adaptive devices; consider advanced therapy - ROUTINE ROUTINE - Heart rate (if on beta-blocker) Each visit &gt;50 bpm Reduce dose or switch agent - ROUTINE ROUTINE - Blood pressure (if on beta-blocker) Each visit &gt;90/60 Reduce dose or switch agent - ROUTINE ROUTINE - Sedation/cognition (if on primidone or benzodiazepines) Each visit Tolerable side effects Reduce dose; slow titration - ROUTINE ROUTINE - Signs of parkinsonism Each visit No bradykinesia, rigidity, rest tremor Re-evaluate diagnosis; DaTscan if uncertain - ROUTINE ROUTINE - Weight (if on topiramate) Every 3 months Stable or acceptable change Adjust dose - - ROUTINE - QTc (if on sotalol) Baseline, with dose changes &lt;500 msec Reduce dose or discontinue - ROUTINE ROUTINE -","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home New diagnosis with treatment started; follow-up arranged; no red flags Admit to floor Rare; only if tremor is severe and workup needed urgently (e.g., Wilson's disease suspected) Outpatient follow-up 4-8 weeks for medication titration; then every 6-12 months when stable","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Propranolol first-line for ET Class I, Level A Zesiewicz et al. Neurology 2011 (AAN Guideline) Primidone first-line for ET Class I, Level A Zesiewicz et al. Neurology 2011 Topiramate effective for ET Class II, Level B Ondo et al. Neurology 2006 DBS effective for medication-refractory ET Class I, Level A Flora et al. Cochrane 2010 MRI-guided focused ultrasound for ET Class I, Level A Elias et al. NEJM 2016 DaTscan differentiates ET from PD Class II, Level B Benamer et al. Mov Disord 2000 Botulinum toxin for head tremor Class II, Level B Pahwa et al. Neurology 1995 Gabapentin modest benefit Class II, Level U Ondo et al. Neurology 2000 Combination therapy superior to monotherapy Class II, Level B Koller et al. Neurology 1989","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/essential-tremor/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive medication coverage including first and second-line options - Includes advanced interventions (DBS, MRgFUS, Gamma Knife) - Structured dosing format for order sentence generation</p>","tags":["movement-disorders","tremor","outpatient"]},{"location":"drafts/frontotemporal-dementia/","title":"Frontotemporal Dementia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#frontotemporal-dementia","title":"Frontotemporal Dementia","text":"<p>DIAGNOSIS: Frontotemporal Dementia (FTD) ICD-10: G31.09 (Frontotemporal dementia, unspecified); G31.0 (Frontotemporal dementia); F02.80 (Dementia in FTD without behavioral disturbance); F02.81 (Dementia in FTD with behavioral disturbance); G31.01 (Pick's disease) SCOPE: Diagnosis and management of frontotemporal lobar degeneration syndromes including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), nonfluent/agrammatic variant PPA (nfvPPA), FTD with motor neuron disease (FTD-ALS), and genetic forms (C9orf72, MAPT, GRN). Covers diagnostic evaluation, symptomatic treatment, behavioral management, genetic counseling, safety planning, and caregiver support. Primarily outpatient-focused with coverage for ED and hospital presentations of behavioral crises.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#1a-essentialcore-labs-reversible-causes-screen","title":"1A. Essential/Core Labs (Reversible Causes Screen)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Rule out infection, anemia, malignancy contributing to behavioral changes Normal STAT STAT ROUTINE - BMP (Na, K, BUN, Cr, glucose) Metabolic causes of behavioral disturbance (hyponatremia, uremia, hypoglycemia) Normal electrolytes, renal function STAT STAT ROUTINE - TSH Hypothyroidism can cause apathy; hyperthyroidism can cause behavioral changes 0.4-4.0 mIU/L URGENT ROUTINE ROUTINE - Vitamin B12 B12 deficiency causes neuropsychiatric symptoms and cognitive decline &gt;300 pg/mL (&gt;400 optimal) URGENT ROUTINE ROUTINE - Folate Deficiency contributes to cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - Hepatic panel (AST, ALT, albumin, ammonia) Hepatic encephalopathy; nutritional status; liver function for medications Normal STAT ROUTINE ROUTINE - Calcium Hypercalcemia causes neuropsychiatric symptoms 8.5-10.5 mg/dL STAT ROUTINE ROUTINE - Urinalysis UTI common cause of acute behavioral changes in elderly Negative for infection STAT STAT ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU RPR or VDRL Neurosyphilis is treatable cause of behavioral and cognitive changes Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder if risk factors Negative - ROUTINE ROUTINE - ESR, CRP Inflammatory or autoimmune causes; baseline before immunotherapy Normal - ROUTINE ROUTINE - ANA, RF Screen for systemic autoimmune disease Negative - ROUTINE ROUTINE - Creatine kinase Elevated in FTD-ALS; baseline for motor neuron involvement Normal (elevated suggests MND) - ROUTINE ROUTINE - EMG/NCS referral If motor symptoms present; evaluate for ALS overlap Normal or denervation pattern - ROUTINE ROUTINE - Serum progranulin level Low levels suggest GRN mutation (screening test) Normal (low &lt;100 ng/mL suggests GRN mutation) - - ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#1c-rarespecialized-genetic-and-atypical-evaluation","title":"1C. Rare/Specialized (Genetic and Atypical Evaluation)","text":"Test Rationale Target Finding ED HOSP OPD ICU C9orf72 hexanucleotide repeat expansion Most common genetic cause of FTD; also causes ALS &lt;30 repeats (pathogenic &gt;30) - - ROUTINE - MAPT (tau) gene sequencing Familial FTD with parkinsonism; tau-positive pathology No pathogenic mutation - - ROUTINE - GRN (progranulin) gene sequencing Familial FTD; asymmetric atrophy; TDP-43 pathology No pathogenic mutation - - ROUTINE - FTD genetic panel (TARDBP, VCP, CHMP2B, FUS) Extended genetic evaluation if first-line negative No pathogenic mutation - - EXT - Paraneoplastic antibody panel Rapid behavioral change; history of cancer; atypical features Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2, GAD65) Autoimmune encephalitis mimicking FTD Negative - EXT EXT - Heavy metal panel (lead, mercury, arsenic) Occupational exposure history; atypical presentation Normal - - EXT -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Frontal and/or anterior temporal atrophy; asymmetric patterns; rule out structural causes MRI-incompatible devices, severe claustrophobia URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable or contraindicated Rule out mass, hemorrhage, hydrocephalus; frontal atrophy visible None STAT STAT ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU FDG-PET Brain Diagnostic confirmation; differentiate from AD Frontal and/or anterior temporal hypometabolism; sparing of posterior parietal (unlike AD) None - - ROUTINE - MRI Brain volumetrics Quantify regional atrophy; track progression Frontal/temporal volume loss; hemispheric asymmetry MRI contraindications - - ROUTINE - Amyloid PET Exclude AD pathology if clinical uncertainty Negative amyloid supports FTD diagnosis None - - ROUTINE - EEG Seizures; behavioral episodes; differentiate from CJD Usually normal or mild slowing; no periodic discharges (CJD has) None URGENT ROUTINE ROUTINE - Sleep study (polysomnography) RBD suggests DLB rather than FTD; sleep disturbance common REM without atonia absent (if RBD, reconsider DLB) None - - ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU DaTscan (ioflupane I-123) Parkinsonism present; differentiate PSP/CBD from PD/DLB Reduced uptake in PSP/CBD; may be normal early in bvFTD Iodine hypersensitivity - - EXT - Tau PET (flortaucipir) Research; distinguish tau-positive from TDP-43 FTD Tau-positive FTD shows frontal/temporal uptake None - - EXT - Whole body PET-CT Paraneoplastic workup if suspected Rule out occult malignancy None - EXT EXT -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Exclude other causes (infection, inflammation, CJD); biomarker support for diagnosis; CSF NfL for prognosis Timing: ROUTINE for diagnostic evaluation; URGENT if autoimmune or infectious etiology suspected Volume Required: 10-15 mL standard; additional for research biomarkers</p> Study Rationale Target Finding ED HOSP OPD ICU Cell count, protein, glucose Rule out infection, inflammation WBC &lt;5, protein &lt;45 mg/dL, glucose &gt;60% serum URGENT ROUTINE ROUTINE - CSF A\u03b242/A\u03b240 ratio Distinguish from AD (normal in FTD) Normal ratio &gt;0.08 supports non-AD etiology - ROUTINE ROUTINE - CSF total tau (t-tau) Non-specific neurodegeneration marker May be elevated but less than AD - ROUTINE ROUTINE - CSF phosphorylated tau (p-tau181) AD-specific; should be normal in FTD Normal p-tau supports FTD over AD - ROUTINE ROUTINE - CSF NfL (neurofilament light) Neurodegeneration marker; prognostic; very high in ALS-FTD Elevated (higher = faster progression) - ROUTINE ROUTINE - 14-3-3 protein Rapid progression; rule out CJD Negative (positive suggests CJD) - ROUTINE ROUTINE - RT-QuIC Prion disease confirmation if suspected Negative - ROUTINE EXT - Autoimmune encephalitis panel (CSF) Subacute behavioral change; seizures Negative - EXT EXT - <p>Special Handling: CSF biomarkers require polypropylene tubes; freeze within 1 hour; send to qualified reference lab Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); posterior fossa mass; skin infection at puncture site</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL NOTE: No FDA-approved disease-modifying treatments exist for FTD. Treatment is symptomatic and supportive. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are NOT recommended and may worsen behavioral symptoms.</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3a-acuteemergent-behavioral-crisis-management","title":"3A. Acute/Emergent (Behavioral Crisis Management)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Lorazepam PO/IM/IV Acute severe agitation when de-escalation fails 0.5 mg PO; 1 mg PO; 0.5 mg IM; 1 mg IM :: PO/IM/IV :: :: 0.5-1 mg PO or IM; may repeat q30min PRN; max 4 mg; short-term use only Respiratory depression; severe hepatic impairment; paradoxical agitation risk in elderly Respiratory status; sedation; paradoxical reactions STAT STAT - - Haloperidol IM/IV Severe aggression/psychosis when benzodiazepines insufficient 0.5 mg IM; 1 mg IM; 2 mg IM :: IM/IV :: :: 0.5-2 mg IM q4-6h PRN; lowest effective dose; short-term crisis only QT prolongation; Parkinson's disease; FTD-parkinsonism overlap (avoid if possible) QTc; EPS; akathisia; sedation STAT EXT - - Environmental de-escalation N/A First-line for all behavioral disturbance N/A :: N/A :: :: Reduce stimulation; dim lights; calm voice; remove triggers; one-to-one observation; familiar caregiver presence None Response to intervention STAT STAT ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3b-symptomatic-treatments-behavioral-and-neuropsychiatric","title":"3B. Symptomatic Treatments (Behavioral and Neuropsychiatric)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Trazodone PO Agitation; irritability; disinhibition; insomnia; compulsive behaviors 25 mg BID; 50 mg BID; 50 mg TID; 100 mg TID :: PO :: :: Start 25-50 mg BID; titrate by 25-50 mg q3-5d; typical 150-300 mg/day divided; max 400 mg/day Concurrent MAOIs; significant QT prolongation Orthostatic hypotension (fall risk); priapism (rare); QTc; sedation - ROUTINE ROUTINE - Sertraline (Zoloft) PO Depression; apathy; anxiety; compulsive behaviors; disinhibition 25 mg daily; 50 mg daily; 100 mg daily; 150 mg daily :: PO :: :: Start 25 mg daily; increase by 25-50 mg every 1-2 weeks; typical 100-200 mg daily; max 200 mg MAOIs; uncontrolled seizures (lowers threshold slightly) GI symptoms; bleeding risk; apathy (rarely worsens) - ROUTINE ROUTINE - Citalopram PO Depression; anxiety; compulsive behaviors 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk QT prolongation; concurrent QT-prolonging drugs; severe hepatic impairment ECG at baseline if cardiac risk; QTc monitoring - ROUTINE ROUTINE - Escitalopram (Lexapro) PO Depression; anxiety; better tolerated than citalopram 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; increase to 10 mg after 1 week; max 10 mg in elderly QT prolongation; concurrent MAOIs QTc if cardiac risk factors - ROUTINE ROUTINE - Fluvoxamine PO Compulsive behaviors; repetitive behaviors; may have specific benefit in FTD 25 mg qHS; 50 mg qHS; 100 mg qHS; 100 mg BID :: PO :: :: Start 25 mg qHS; titrate by 25-50 mg weekly; typical 100-200 mg/day; max 300 mg/day MAOIs; alosetron, tizanidine (drug interactions) Multiple drug interactions (CYP1A2, 2C19, 3A4 inhibitor); GI symptoms - ROUTINE ROUTINE - Mirtazapine (Remeron) PO Depression with poor appetite, weight loss, and insomnia 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30-45 mg qHS; lower doses more sedating MAOIs; angle-closure glaucoma Weight gain (often desired in FTD); sedation; hyperlipidemia - ROUTINE ROUTINE - Bupropion (Wellbutrin) PO Apathy-predominant FTD; depression; may help with motivation 100 mg BID; 150 mg SR daily; 150 mg SR BID; 300 mg XL daily :: PO :: :: Start 100 mg BID or 150 mg SR daily; titrate to 150 mg SR BID or 300 mg XL daily Seizure disorder; bulimia/anorexia; concurrent MAOIs; abrupt alcohol withdrawal Seizure risk (dose-related); insomnia; agitation (may worsen some patients) - - ROUTINE - Melatonin PO Sleep disturbance; circadian rhythm dysfunction; sundowning 3 mg qHS; 6 mg qHS; 9 mg qHS :: PO :: :: Start 3 mg qHS, 30 min before bed; may increase to 6-9 mg if needed None significant Daytime drowsiness; minimal side effects - ROUTINE ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3c-second-linerefractory-behavioral-management","title":"3C. Second-line/Refractory (Behavioral Management)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Quetiapine (Seroquel) PO Severe agitation/psychosis when non-pharmacologic and first-line fail 12.5 mg qHS; 25 mg qHS; 25 mg BID; 50 mg BID :: PO :: :: Start 12.5-25 mg qHS; titrate slowly (25 mg increments); keep dose as low as possible; max 200 mg/day Black box: increased mortality in dementia; avoid in FTD-parkinsonism Metabolic effects; sedation; falls; QTc; EPS - EXT ROUTINE - Olanzapine PO/IM Severe agitation when other options fail; IM for acute crisis 2.5 mg daily; 5 mg daily; 2.5 mg IM; 5 mg IM :: PO/IM :: :: PO: Start 2.5 mg daily; increase slowly; max 10 mg; IM: 2.5-5 mg for acute crisis Black box: increased mortality in dementia; diabetes; QT prolongation Weight gain; metabolic syndrome; sedation; EPS EXT EXT EXT - Dextromethorphan/quinidine (Nuedexta) PO Pseudobulbar affect; emotional lability; pathological laughing/crying 20/10 mg daily; 20/10 mg BID :: PO :: :: Start 20/10 mg daily x 7 days; then 20/10 mg BID QT prolongation; concurrent MAOIs; quinidine hypersensitivity; complete AV block QTc; avoid in hepatic/renal impairment - ROUTINE ROUTINE - Valproic acid PO Impulsivity; aggression; mood instability (off-label) 125 mg BID; 250 mg BID; 500 mg BID :: PO :: :: Start 125-250 mg BID; titrate to 500-1000 mg/day; monitor levels Hepatic disease; urea cycle disorders; mitochondrial disorders Valproate level, LFTs, CBC, ammonia; weight gain; tremor; thrombocytopenia - ROUTINE ROUTINE - Memantine (Namenda) PO May help some behavioral symptoms; limited evidence 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily; increase by 5 mg/week to 10 mg BID; evidence weak in FTD Severe renal impairment (reduce dose) Confusion, dizziness; generally well tolerated - - ROUTINE - Methylphenidate PO Severe apathy unresponsive to other treatments 2.5 mg BID; 5 mg BID; 10 mg BID :: PO :: :: Start 2.5-5 mg BID (morning and noon); titrate slowly; max 20 mg/day Severe anxiety; cardiac arrhythmias; glaucoma; concurrent MAOIs BP, HR; appetite; insomnia; agitation; abuse potential - - EXT -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3d-treatments-to-avoid-in-ftd","title":"3D. Treatments to AVOID in FTD","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil (Aricept) PO AVOID - May worsen behavioral symptoms in FTD AVOID :: PO :: :: Do NOT use; cholinesterase inhibitors can worsen disinhibition, agitation, and behavioral symptoms in FTD FTD diagnosis Worsening behavior if inadvertently started - - - - Rivastigmine (Exelon) PO/TD AVOID - May worsen behavioral symptoms in FTD AVOID :: PO/TD :: :: Do NOT use; cholinesterase inhibitors not recommended in FTD; may cause paradoxical worsening FTD diagnosis Worsening behavior if inadvertently started - - - - Galantamine (Razadyne) PO AVOID - May worsen behavioral symptoms in FTD AVOID :: PO :: :: Do NOT use; cholinesterase inhibitors contraindicated in FTD FTD diagnosis Worsening behavior if inadvertently started - - - - <p>Note on Antipsychotics: Use with extreme caution. Increased mortality risk in dementia; increased risk of EPS in FTD-parkinsonism; reserve for severe, refractory cases where safety is at risk.</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#3e-ftd-alsmotor-neuron-disease-overlap","title":"3E. FTD-ALS/Motor Neuron Disease Overlap","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Riluzole PO FTD with ALS overlap; may modestly slow MND progression 50 mg BID :: PO :: :: 50 mg PO BID; take 1 hour before or 2 hours after meals Hepatic impairment; pregnancy LFTs monthly x 3 months, then q3mo; neutropenia - ROUTINE ROUTINE - Edaravone (Radicava) IV/PO FTD-ALS if early in disease course 60 mg IV daily x 14d; 10-day cycles :: IV/PO :: :: Initial: 60 mg IV daily x 14 days; maintenance: 60 mg IV daily x 10 days of 14-day cycles; oral formulation available Hypersensitivity; sulfite allergy Infusion reactions; hypersensitivity - ROUTINE ROUTINE - Sodium phenylbutyrate/taurursodiol (Relyvrio) PO FTD-ALS overlap; neuroprotective 3g/1g sachet BID :: PO :: :: One sachet dissolved in water BID; titrate over 3 weeks to full dose Hepatic impairment GI symptoms (diarrhea, nausea); gallbladder disorders - - ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Behavioral/cognitive neurology for diagnosis confirmation, FTD subtype classification, and treatment guidance - ROUTINE ROUTINE - Neuropsychology for comprehensive cognitive testing to establish baseline, characterize deficits, and track progression - - ROUTINE - Genetic counseling for all patients with suspected FTD given high heritability (30-50% familial); discuss testing implications - - ROUTINE - Speech-language pathology for language variant PPA evaluation, communication strategies, and swallowing assessment - ROUTINE ROUTINE - Geriatric psychiatry for complex behavioral management and psychotropic medication optimization - ROUTINE ROUTINE - Social work for caregiver support resources, community services, respite care, and long-term care planning - ROUTINE ROUTINE - Occupational therapy for ADL assessment, cognitive strategies, home safety evaluation, and activity structuring - ROUTINE ROUTINE - Physical therapy for fall prevention, mobility assessment, and exercise program particularly if motor features present - ROUTINE ROUTINE - Palliative care for symptom management and goals of care discussions, especially with advanced disease or ALS overlap - ROUTINE ROUTINE - Neuromuscular specialist if motor neuron disease features (weakness, fasciculations, bulbar symptoms) present - ROUTINE ROUTINE - Elder law attorney for advance directives, healthcare proxy, conservatorship, and financial planning while capacity exists - - ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if sudden worsening of behavior, new weakness, difficulty breathing, or inability to swallow safely STAT STAT ROUTINE Complete advance directives (living will, healthcare proxy, POLST) while patient retains capacity; FTD can progress rapidly - ROUTINE ROUTINE Designate durable power of attorney for healthcare AND finances early as judgment may be impaired before memory - ROUTINE ROUTINE Do not drive; FTD impairs judgment, impulse control, and decision-making even if memory appears intact - ROUTINE ROUTINE Remove access to weapons, power tools, and dangerous equipment due to impaired judgment and safety awareness - ROUTINE ROUTINE Supervise financial decisions; patients with FTD are vulnerable to fraud, impulsive spending, and poor judgment - ROUTINE ROUTINE Secure medications to prevent accidental or intentional overdose; use locked medication storage - ROUTINE ROUTINE Monitor for wandering; consider GPS tracking devices and door alarms as disease progresses - ROUTINE ROUTINE Report diagnosis to DMV per state requirements; most states require physician reporting for unsafe drivers - - ROUTINE Genetic testing results have implications for family members; discuss with genetic counselor before testing - - ROUTINE","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Structured daily routine with consistent schedule reduces anxiety and behavioral symptoms - ROUTINE ROUTINE Regular physical activity (walking, supervised exercise) improves mood and maintains function - ROUTINE ROUTINE Simplified communication using short sentences, yes/no questions, and visual cues for PPA variants - ROUTINE ROUTINE Avoid overstimulation; reduce noise, crowds, and complex environments that trigger agitation - ROUTINE ROUTINE Caregiver education through AFTD (Association for Frontotemporal Degeneration) resources and support groups - ROUTINE ROUTINE Respite care for caregivers to prevent burnout; FTD caregiving is particularly demanding due to behavioral symptoms - ROUTINE ROUTINE Address hyperorality and dietary changes with portion control, healthy snack availability, and locked food storage if needed - ROUTINE ROUTINE Safe environment modifications: remove fall hazards, lock cabinets with dangerous items, install stove knob covers - ROUTINE ROUTINE One-to-one supervision may be needed for safety; consider adult day programs or in-home care - ROUTINE ROUTINE Smoking cessation and alcohol avoidance to prevent additional brain injury and drug interactions - ROUTINE ROUTINE","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Alzheimer's disease Memory impairment prominent early; episodic memory loss; posterior cortical atrophy pattern CSF A\u03b242 low, p-tau elevated; amyloid PET positive; temporal-parietal atrophy on MRI Dementia with Lewy bodies Visual hallucinations; parkinsonism; REM sleep behavior disorder; fluctuating cognition DaTscan reduced; RBD on sleep study; better response to cholinesterase inhibitors Primary psychiatric disorder Onset often younger; personal/family psychiatric history; may have insight; responds to treatment Normal MRI; normal FDG-PET; improvement with psychiatric treatment Huntington's disease Chorea; family history (autosomal dominant); psychiatric symptoms precede motor CAG repeat expansion; caudate atrophy on MRI Progressive supranuclear palsy (PSP) Vertical gaze palsy; axial rigidity; early falls; frontal features \"Hummingbird sign\" on MRI; poor levodopa response Corticobasal syndrome (CBS) Asymmetric apraxia; alien limb; cortical sensory loss; dystonia Asymmetric atrophy; may have FTD overlap Creutzfeldt-Jakob disease Rapid progression (weeks-months); myoclonus; ataxia; startle MRI DWI ribboning; EEG periodic discharges; CSF RT-QuIC positive Autoimmune encephalitis Subacute onset; seizures; psychiatric features; often younger Autoantibody panel positive; MRI limbic changes; CSF inflammation Normal pressure hydrocephalus Gait disturbance predominant; urinary incontinence; magnetic gait MRI ventriculomegaly out of proportion to atrophy; large-volume LP improvement Vascular dementia Stepwise decline; vascular risk factors; focal deficits Extensive white matter disease and strategic infarcts on MRI Medication/substance-induced Temporal relationship to drug exposure; anticholinergics, sedatives common culprits Medication reconciliation; improvement with discontinuation Late-onset bipolar disorder Episodic mood symptoms; family history; intact cognition between episodes Normal neuroimaging; psychiatric evaluation; treatment response","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Cognitive testing (MoCA, MMSE, or FTLD-specific battery) Every 6-12 months Document trajectory; identify rapid decline Adjust care level; medication review; genetics if rapid - ROUTINE ROUTINE - Frontal assessment battery (FAB) Every 6-12 months Track executive function specific to FTD Increase supervision; safety planning - - ROUTINE - Functional status (ADL/IADL, FBI, CBI) Every 6 months Monitor independence and safety Increase caregiver support; consider placement - ROUTINE ROUTINE - Behavioral assessment (NPI-Q, FBI) Each visit Quantify behavioral symptoms and treatment response Adjust medications; non-pharmacologic strategies - ROUTINE ROUTINE - Motor function (if FTD-ALS) Every 3-6 months FVC, ALSFRS-R for motor progression Respiratory support; PT/OT; feeding tube discussion - ROUTINE ROUTINE - Weight Each visit Stable; monitor for hyperorality weight gain OR wasting Nutritional consult; address hyperphagia or dysphagia - ROUTINE ROUTINE - Swallowing function Every 6-12 months or if symptoms Safe oral intake Speech therapy; diet modification; feeding tube if needed - ROUTINE ROUTINE - Caregiver burden (Zarit Burden Interview) Every 6-12 months Early identification of burnout Respite care; support groups; social work - - ROUTINE - Safety assessment Each visit No harm to self or others; safe environment Increase supervision; remove hazards; consider placement - ROUTINE ROUTINE - ECG (if on QT-prolonging medications) Baseline; with dose changes QTc &lt;470 ms (men), &lt;480 ms (women) Reduce dose or switch medication - ROUTINE ROUTINE - LFTs (if on valproic acid or riluzole) Monthly x 3, then q3mo Normal transaminases Reduce or discontinue if &gt;3x ULN - ROUTINE ROUTINE -","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Behavioral crisis resolved; safe environment; adequate caregiver supervision; outpatient follow-up arranged; medications optimized Admit to floor Severe behavioral disturbance unsafe for home; medical workup needed; medication adjustment requiring monitoring; caregiver unable to manage Admit to psychiatry Danger to self or others; severe aggression; psychotic features; requires locked unit for safety Memory care/Long-term care Progressive decline; wandering risk; 24-hour supervision needed; caregiver unable to provide safe care Hospice End-stage FTD; minimal responsiveness; recurrent aspiration; weight loss; goals focused on comfort; FVC &lt;50% in FTD-ALS Outpatient follow-up Neurology/cognitive neurology every 3-6 months; more frequent if on psychotropics or rapid progression; genetics follow-up after testing","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Diagnostic criteria for bvFTD (International Consensus) Class I, Level A Rascovsky et al. Brain 2011 Diagnostic criteria for PPA variants Class I, Level A Gorno-Tempini et al. Neurology 2011 SSRIs for behavioral symptoms in FTD Class II, Level B Herrmann et al. J Clin Psychiatry 2012 Trazodone for FTD behavioral symptoms Class II, Level B Lebert et al. Dement Geriatr Cogn Disord 2004 Cholinesterase inhibitors not recommended in FTD Class II, Level B Mendez et al. Am J Alzheimers Dis Other Demen 2007 Antipsychotic mortality risk in dementia Class I, Level A Schneider et al. JAMA 2005 C9orf72 as most common genetic cause of FTD/ALS Class I, Level A DeJesus-Hernandez et al. Neuron 2011; Renton et al. Neuron 2011 MAPT and GRN mutations in familial FTD Class I, Level A Rohrer et al. Lancet Neurol 2009 FDG-PET in FTD diagnosis Class II, Level B Foster et al. Ann Neurol 2007 CSF NfL as prognostic biomarker in FTD Class II, Level B Rohrer et al. Neurology 2016 Memantine limited efficacy in FTD Class II, Level C Boxer et al. Lancet Neurol 2013 FTD-ALS continuum Class I, Level A Burrell et al. Lancet Neurol 2016 Serum progranulin as GRN mutation screen Class II, Level B Finch et al. J Mol Diagn 2009 Practice guidelines for FTD management Class III, Level C Tsai et al. Neurology 2021 Riluzole in ALS Class I, Level A Miller et al. Cochrane 2012","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - International consensus diagnostic criteria for bvFTD and PPA variants - Comprehensive genetic evaluation (C9orf72, MAPT, GRN) - SSRIs and trazodone as first-line behavioral treatments - Explicit guidance to AVOID cholinesterase inhibitors - FTD-ALS overlap section with riluzole and edaravone - Caregiver support and safety planning emphasis - Structured dosing format for order sentence generation - PubMed-linked citations</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#appendix-a-ftd-clinical-variants","title":"APPENDIX A: FTD Clinical Variants","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#behavioral-variant-ftd-bvftd","title":"Behavioral Variant FTD (bvFTD)","text":"<p>Core Features (International Consensus Criteria - Rascovsky 2011):</p> <p>Early behavioral disinhibition (at least one of): - Socially inappropriate behavior - Loss of manners or decorum - Impulsive, rash, or careless actions</p> <p>Early apathy or inertia (at least one of): - Loss of motivation or drive - Emotional blunting - Withdrawal from activities</p> <p>Early loss of sympathy or empathy (at least one of): - Diminished response to others' needs - Diminished social interest, warmth - Personal coldness</p> <p>Early perseverative, stereotyped, or compulsive/ritualistic behavior (at least one of): - Simple repetitive movements - Complex compulsive behaviors - Stereotypy of speech</p> <p>Hyperorality and dietary changes (at least one of): - Altered food preferences (especially sweets) - Binge eating or increased consumption - Oral exploration of inedible objects</p> <p>Neuropsychological profile: - Executive deficits - Relative sparing of episodic memory - Relative sparing of visuospatial skills</p> <p>Possible bvFTD: 3 of 6 features Probable bvFTD: Possible + functional decline + characteristic imaging Definite bvFTD: Histopathological or pathogenic mutation confirmation</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#semantic-variant-ppa-svppa","title":"Semantic Variant PPA (svPPA)","text":"<p>Core Features: - Impaired confrontation naming - Impaired single-word comprehension</p> <p>Supportive Features (3 of 4 required): - Impaired object knowledge - Surface dyslexia or dysgraphia - Spared repetition - Spared speech production (grammar and motor speech)</p> <p>Imaging: Anterior temporal atrophy (typically left &gt; right)</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#nonfluentagrammatic-variant-ppa-nfvppa","title":"Nonfluent/Agrammatic Variant PPA (nfvPPA)","text":"<p>Core Features (at least one): - Agrammatism in language production - Effortful, halting speech with inconsistent speech sound errors (apraxia of speech)</p> <p>Supportive Features (2 of 3 required): - Impaired comprehension of syntactically complex sentences - Spared single-word comprehension - Spared object knowledge</p> <p>Imaging: Left posterior fronto-insular atrophy</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#appendix-b-genetic-evaluation-guide","title":"APPENDIX B: Genetic Evaluation Guide","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#when-to-consider-genetic-testing","title":"When to Consider Genetic Testing","text":"<p>Strongly Consider Testing: - Family history of FTD, ALS, or unspecified dementia in first-degree relative - Age of onset &lt;60 years - FTD-ALS phenotype - Known family mutation</p> <p>Consider Testing: - Any FTD diagnosis (30-50% have genetic component) - Research participation interest - Family planning implications for children</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#major-ftd-genes","title":"Major FTD Genes","text":"Gene Protein Frequency Phenotype Pathology C9orf72 None (repeat expansion) 25-40% of familial bvFTD, ALS, FTD-ALS, psychosis TDP-43, p62 inclusions GRN Progranulin 15-25% of familial bvFTD (asymmetric), PPA, CBS TDP-43 type A MAPT Tau 10-20% of familial bvFTD, parkinsonism, PSP-like Tau pathology TARDBP TDP-43 &lt;5% ALS, FTD-ALS TDP-43 VCP Valosin-containing protein &lt;5% IBM, Paget's, FTD TDP-43 FUS FUS &lt;1% ALS, FTD FUS inclusions","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#progranulin-screening","title":"Progranulin Screening","text":"<p>Serum progranulin level can screen for GRN mutations: - Normal: &gt;100 ng/mL (varies by assay) - Low: &lt;100 ng/mL suggests GRN mutation; confirm with gene sequencing</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#c9orf72-interpretation","title":"C9orf72 Interpretation","text":"<ul> <li>Normal: &lt;30 hexanucleotide repeats</li> <li>Pathogenic: &gt;30 repeats (typically hundreds to thousands)</li> <li>Intermediate: 20-30 repeats (clinical significance unclear)</li> </ul>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#appendix-c-safety-and-supervision-planning-checklist","title":"APPENDIX C: Safety and Supervision Planning Checklist","text":"","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#immediate-safety-all-ftd-patients","title":"Immediate Safety (All FTD Patients)","text":"<ul> <li> Driving cessation discussed and documented</li> <li> Weapons removed from home</li> <li> Medications secured (locked storage)</li> <li> Financial oversight arranged</li> <li> Stove/appliance safety (knob covers, auto-shutoff)</li> <li> Door alarms/locks for wandering risk</li> </ul>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#advance-planning","title":"Advance Planning","text":"<ul> <li> Healthcare power of attorney designated</li> <li> Durable financial power of attorney designated</li> <li> Living will/advance directive completed</li> <li> POLST form if appropriate</li> <li> Long-term care financing discussed</li> <li> Genetic counseling offered to family</li> </ul>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#caregiver-support","title":"Caregiver Support","text":"<ul> <li> AFTD (theaftd.org) resources provided</li> <li> Local support group identified</li> <li> Respite care options discussed</li> <li> Adult day program referral if appropriate</li> <li> Home health aide evaluation</li> <li> Social work consultation</li> </ul>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/frontotemporal-dementia/#monitoring-red-flags","title":"Monitoring Red Flags","text":"<p>Contact Provider If: - New or worsening aggression - Suicidal statements or self-harm behavior - Inability to recognize caregivers - Falls with injury - Significant weight loss or gain - Swallowing difficulties - New weakness (FTD-ALS concern) - Caregiver exhaustion/burnout</p>","tags":["cognitive","dementia","ftd","behavioral","outpatient","neurodegenerative"]},{"location":"drafts/guillain-barre-syndrome/","title":"Guillain-Barr\u00e9 Syndrome","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#guillain-barre-syndrome","title":"Guillain-Barr\u00e9 Syndrome","text":"<p>VERSION: 1.1 CREATED: January 24, 2026 REVISED: January 24, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Guillain-Barr\u00e9 Syndrome (GBS)</p> <p>ICD-10: G61.0 (Guillain-Barr\u00e9 syndrome)</p> <p>SCOPE: Evaluation and management of acute Guillain-Barr\u00e9 Syndrome in adults, including all major variants (AIDP, AMAN, AMSAN, Miller Fisher). Covers respiratory monitoring protocols, immunotherapy (IVIg and plasmapheresis), autonomic dysfunction management, and ICU care. Excludes CIDP (chronic inflammatory demyelinating polyneuropathy) and pediatric GBS.</p> <p>CLINICAL SYNONYMS: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Landry's ascending paralysis, acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy (AMSAN), Miller Fisher syndrome (MFS)</p> <p>KEY CLINICAL FEATURES: - Acute onset ascending weakness (proximal and distal) - Areflexia or hyporeflexia - Sensory symptoms (paresthesias, pain) often precede weakness - Antecedent infection 1-4 weeks prior (Campylobacter, CMV, EBV, Zika, COVID-19) - Nadir typically reached within 2-4 weeks - Critical: 20-30% require mechanical ventilation</p> <p>VARIANTS: | Variant | Features | Antibody | |---------|----------|----------| | AIDP | Classic ascending weakness, areflexia | \u2014 | | AMAN | Pure motor, preserved reflexes early | Anti-GM1, anti-GD1a | | AMSAN | Severe motor + sensory axonal | Anti-GM1 | | Miller Fisher | Ophthalmoplegia, ataxia, areflexia | Anti-GQ1b (&gt;90%) |</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u26a1 RESPIRATORY FAILURE WARNING</p> <p>30% of GBS patients require intubation. Monitor FVC and NIF every 4-6 hours. See 20/30/40 Rule for intubation criteria.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline, infection screen Normal or mild leukocytosis STAT STAT \u2014 STAT CMP (BMP + LFTs) Electrolytes, renal function for IVIg Normal STAT STAT \u2014 STAT Magnesium Hypomagnesemia worsens weakness &gt;1.8 mg/dL STAT STAT \u2014 STAT Phosphorus Hypophosphatemia causes weakness &gt;2.5 mg/dL STAT STAT \u2014 STAT ESR, CRP Inflammatory markers May be mildly elevated STAT ROUTINE \u2014 STAT Urinalysis UTI as trigger Document STAT ROUTINE \u2014 STAT Blood glucose Hyperglycemia worsens outcomes &lt;180 mg/dL STAT STAT \u2014 STAT TSH Thyroid myopathy in differential Normal URGENT ROUTINE \u2014 URGENT CPK Myopathy in differential Normal or mildly elevated URGENT ROUTINE \u2014 URGENT PT/INR, PTT Pre-LP, pre-PLEX Normal URGENT ROUTINE \u2014 STAT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Anti-ganglioside antibodies (GM1, GD1a, GD1b, GQ1b) Variant classification, prognosis Document positivity \u2014 ROUTINE \u2014 ROUTINE Campylobacter jejuni serology Most common trigger Document if positive \u2014 ROUTINE \u2014 ROUTINE CMV IgM/IgG Viral trigger Document if positive \u2014 ROUTINE \u2014 ROUTINE EBV panel Viral trigger Document if positive \u2014 ROUTINE \u2014 ROUTINE Mycoplasma pneumoniae IgM Bacterial trigger Document if positive \u2014 ROUTINE \u2014 ROUTINE HIV HIV-associated GBS Negative \u2014 ROUTINE \u2014 ROUTINE Hepatitis B surface antigen Pre-IVIg screening Negative \u2014 URGENT \u2014 URGENT Hepatitis C antibody Pre-PLEX screening Negative \u2014 URGENT \u2014 URGENT COVID-19 PCR/antigen COVID-associated GBS Document STAT STAT \u2014 STAT Quantitative immunoglobulins IgA deficiency (IVIg contraindication) IgA &gt;7 mg/dL \u2014 URGENT \u2014 URGENT Type and screen Pre-PLEX Available \u2014 URGENT \u2014 STAT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Zika virus serology Travel to endemic area Negative \u2014 EXT \u2014 EXT West Nile virus serology Endemic area, summer months Negative \u2014 EXT \u2014 EXT Lyme serology Endemic area, tick exposure Negative \u2014 EXT \u2014 EXT Porphyrins (urine) Motor neuropathy with abdominal pain Normal \u2014 EXT \u2014 EXT Heavy metals (lead, arsenic, thallium) Toxic neuropathy differential Normal \u2014 EXT \u2014 EXT Serum protein electrophoresis Paraproteinemic neuropathy Normal \u2014 EXT \u2014 EXT Anti-acetylcholine receptor antibodies MG in differential Negative \u2014 EXT \u2014 EXT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Chest X-ray On admission Aspiration, atelectasis None STAT STAT \u2014 STAT ECG On admission Autonomic dysfunction (arrhythmia) None STAT STAT \u2014 STAT Forced vital capacity (FVC) Serial q4-6h FVC &gt;20 mL/kg (stable) Facial weakness limiting seal STAT STAT \u2014 STAT Negative inspiratory force (NIF) Serial q4-6h NIF more negative than -30 cmH2O Facial weakness STAT STAT \u2014 STAT Nerve conduction studies/EMG Within 48-72 hours Demyelination, conduction block None \u2014 URGENT \u2014 URGENT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI spine with contrast If diagnostic uncertainty Nerve root enhancement (spinal roots) Pacemaker, hemodynamic instability \u2014 ROUTINE \u2014 ROUTINE MRI brain with contrast Miller Fisher variant Cranial nerve enhancement Pacemaker \u2014 ROUTINE \u2014 ROUTINE Swallow evaluation If bulbar weakness Aspiration risk None \u2014 URGENT \u2014 URGENT Echocardiogram If autonomic instability Takotsubo, cardiac dysfunction None \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Repetitive nerve stimulation If MG suspected Normal (vs decrement in MG) None \u2014 EXT \u2014 EXT Autonomic function testing Persistent dysautonomia Abnormal heart rate variability Unstable patient \u2014 EXT \u2014 EXT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Confirm diagnosis (albuminocytologic dissociation); exclude infection if febrile</p> <p>Timing: URGENT; may be normal in first 48-72 hours (sensitivity improves after day 3-5)</p> <p>Volume Required: 10-15 mL standard</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Exclude elevated ICP Normal (10-20 cmH2O) URGENT STAT \u2014 STAT Cell count (tubes 1 and 4) Albuminocytologic dissociation WBC &lt;10 (usually &lt;5) URGENT STAT \u2014 STAT Protein Elevated in GBS Elevated (&gt;45 mg/dL; often &gt;100) URGENT STAT \u2014 STAT Glucose Exclude infection Normal URGENT STAT \u2014 STAT Gram stain and culture Exclude bacterial meningitis Negative URGENT STAT \u2014 STAT Cytology If malignancy suspected Negative \u2014 ROUTINE \u2014 ROUTINE Oligoclonal bands Atypical cases Usually negative (positive in &lt;10%) \u2014 ROUTINE \u2014 ROUTINE <p>Special Handling: Cell count within 1 hour. Refrigerate cytology.</p> <p>Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site.</p> <p>NOTE: CSF may be normal in first 48-72 hours. Elevated protein with normal cell count (albuminocytologic dissociation) is classic but not required for diagnosis.</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: GBS is a neurological emergency. Early immunotherapy improves outcomes. Respiratory monitoring is paramount.</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#respiratory-monitoring-203040-rule","title":"Respiratory Monitoring: 20/30/40 Rule","text":"<p>Intubation Criteria (any ONE of): - FVC &lt;20 mL/kg (or &lt;1 L in average adult) - NIF weaker than -30 cmH2O (closer to 0) - &gt;30% decline in FVC from baseline - Oxygen desaturation &lt;92% - Clinical respiratory distress</p> <p>Other Warning Signs: - Rapid progression (&lt;7 days from onset to nadir) - Bulbar dysfunction (dysarthria, dysphagia) - Bilateral facial weakness - Autonomic instability</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3a-acuteemergent-respiratory-support","title":"3A. Acute/Emergent - Respiratory Support","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Supplemental oxygen INH Hypoxemia 2-6 L/min NC; 15 L/min NRB :: INH :: PRN :: Titrate to O2 sat &gt;94%; escalate to high-flow if needed None O2 sat, RR STAT STAT \u2014 STAT Endotracheal intubation \u2014 Respiratory failure N/A :: \u2014 :: :: Intubate if FVC &lt;20 mL/kg, NIF &gt;-30 cmH2O, or clinical deterioration; avoid succinylcholine (hyperkalemia risk) \u2014 ETT position, ventilator settings STAT STAT \u2014 STAT Mechanical ventilation \u2014 Respiratory failure N/A :: \u2014 :: :: Lung-protective ventilation; TV 6-8 mL/kg IBW; PEEP 5-8 cmH2O \u2014 ABG, ventilator parameters \u2014 \u2014 \u2014 STAT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3b-immunotherapy-first-line","title":"3B. Immunotherapy - First-line","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IVIg (immune globulin IV) - 5-day protocol IV Primary immunotherapy 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: 0.4 g/kg/day IV for 5 days (total 2 g/kg); infuse slowly day 1 (start 0.5-1 mL/kg/hr, advance to max 4 mL/kg/hr) IgA deficiency (&lt;7 mg/dL) with anti-IgA antibodies; severe renal impairment Renal function, headache, infusion reactions; pre-medicate with acetaminophen/diphenhydramine \u2014 STAT \u2014 STAT IVIg (immune globulin IV) - 2-day protocol IV Primary immunotherapy 1 g/kg/day x 2 days :: IV :: daily x 2 days :: 1 g/kg/day IV for 2 days (total 2 g/kg); alternative accelerated protocol; same total dose IgA deficiency (&lt;7 mg/dL) with anti-IgA antibodies; severe renal impairment Renal function, headache, infusion reactions; higher daily dose may increase infusion reactions \u2014 STAT \u2014 STAT Plasmapheresis (PLEX) \u2014 Primary immunotherapy 5 exchanges over 1-2 weeks :: \u2014 :: QOD x 5 :: 5 exchanges (200-250 mL/kg per exchange) over 7-14 days; typically QOD Hemodynamic instability; severe sepsis; IV access issues BP, electrolytes (Ca, Mg, K), coagulation, fibrinogen \u2014 STAT \u2014 STAT <p>IVIg vs PLEX Selection: - IVIg preferred: Hemodynamic instability, autonomic dysfunction, difficult IV access - PLEX preferred: IgA deficiency, severe renal disease, cost considerations - Efficacy: Equivalent when started within 2-4 weeks of symptom onset - Do NOT combine: IVIg + PLEX not more effective; PLEX removes IVIg</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3c-autonomic-dysfunction-management","title":"3C. Autonomic Dysfunction Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Normal saline IV Hypotension 250 mL; 500 mL; 1000 mL :: IV :: bolus PRN :: 250-500 mL bolus for SBP &lt;90; avoid overhydration Heart failure BP, I/O, JVD STAT STAT \u2014 STAT Phenylephrine IV Refractory hypotension 100-200 mcg bolus; 0.5-2 mcg/kg/min :: IV :: infusion :: Start 0.5 mcg/kg/min; titrate to MAP &gt;65 Severe bradycardia Continuous BP, HR \u2014 \u2014 \u2014 STAT Esmolol IV Hypertensive crisis 500 mcg/kg load; 50-200 mcg/kg/min :: IV :: infusion :: Load 500 mcg/kg over 1 min, then 50-200 mcg/kg/min; short-acting preferred in GBS Bradycardia, heart block, decompensated HF HR, BP \u2014 \u2014 \u2014 STAT Atropine IV Symptomatic bradycardia 0.5 mg; 1 mg :: IV :: PRN :: 0.5-1 mg IV push for HR &lt;50 with symptoms; may repeat q3-5min; max 3 mg Tachycardia HR, rhythm STAT STAT \u2014 STAT Temporary pacing \u2014 Complete heart block N/A :: \u2014 :: :: Transcutaneous or transvenous pacing for refractory bradycardia/asystole \u2014 Continuous telemetry \u2014 \u2014 \u2014 STAT Fludrocortisone PO Orthostatic hypotension 0.1 mg daily; 0.2 mg daily :: PO :: daily :: 0.1-0.2 mg PO daily for persistent orthostatic hypotension Hypertension, heart failure BP (supine and standing), edema, K+ \u2014 ROUTINE \u2014 ROUTINE Midodrine PO Orthostatic hypotension 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: TID :: Start 2.5-5 mg TID; max 10 mg TID; avoid evening dose Supine hypertension, urinary retention BP (supine and standing) \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3d-symptomaticsupportive-care","title":"3D. Symptomatic/Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO Neuropathic pain 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: TID :: Start 300 mg qHS; titrate by 300 mg/day q1-3d; max 3600 mg/day in 3 divided doses Severe renal impairment (adjust dose) Sedation, dizziness; reduce dose if CrCl &lt;60 \u2014 ROUTINE \u2014 ROUTINE Pregabalin PO Neuropathic pain 75 mg BID; 150 mg BID; 300 mg BID :: PO :: BID :: Start 75 mg BID; may increase to 150 mg BID after 1 week; max 600 mg/day Severe renal impairment (adjust dose) Sedation, edema, weight gain \u2014 ROUTINE \u2014 ROUTINE Morphine IV Severe pain 2 mg q4h PRN; 4 mg q4h PRN :: IV :: q4h PRN :: 2-4 mg IV q4h PRN for severe pain; use cautiously with respiratory compromise Respiratory depression RR, sedation, O2 sat STAT STAT \u2014 STAT Enoxaparin SC DVT prophylaxis 40 mg daily; 30 mg BID :: SC :: daily :: 40 mg SC daily (BMI &lt;40) or 30 mg BID (BMI &gt;40); hold if CrCl &lt;30; HOLD if LP planned within 12 hours Active bleeding, HIT, CrCl &lt;30 (use UFH), pending LP Platelet count, signs of bleeding \u2014 STAT \u2014 STAT Heparin (UFH) SC DVT prophylaxis (renal impairment) 5000 units q8h; 5000 units q12h :: SC :: q8-12h :: 5000 units SC q8-12h if CrCl &lt;30; HOLD if LP planned within 4-6 hours Active bleeding, HIT, pending LP Platelet count, signs of bleeding \u2014 STAT \u2014 STAT SCDs (sequential compression devices) \u2014 DVT prophylaxis N/A :: \u2014 :: continuous :: Bilateral lower extremity SCDs; use in addition to pharmacologic prophylaxis Acute DVT in that extremity Skin integrity STAT STAT \u2014 STAT Bisacodyl PO/PR Constipation (autonomic) 10 mg daily; 10 mg suppository :: PO/PR :: daily PRN :: 10 mg PO or PR daily as needed Bowel obstruction Bowel movements \u2014 ROUTINE \u2014 ROUTINE Polyethylene glycol PO Constipation (autonomic) 17 g daily; 17 g BID :: PO :: daily-BID :: 17 g (1 capful) PO daily-BID; titrate to 1-2 BMs daily Bowel obstruction Bowel movements \u2014 ROUTINE \u2014 ROUTINE Metoclopramide IV/PO Gastroparesis 10 mg q6h AC :: IV/PO :: q6h AC :: 10 mg IV/PO before meals and at bedtime; max 40 mg/day; limit to 5 days Parkinson disease, GI obstruction EPS, tardive dyskinesia \u2014 ROUTINE \u2014 ROUTINE Ondansetron IV/PO Nausea 4 mg q6h PRN; 8 mg q8h PRN :: IV/PO :: q6h PRN :: 4-8 mg IV/PO q6-8h PRN QT prolongation QTc if repeated dosing STAT STAT \u2014 STAT Acetaminophen PO/IV Fever, mild pain 650 mg q6h; 1000 mg q6h :: PO/IV :: q6h :: 650-1000 mg PO/IV q6h; max 4 g/day (3 g if hepatic impairment) Severe hepatic impairment LFTs if prolonged use STAT STAT \u2014 STAT","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3e-treatment-of-gbs-variants","title":"3E. Treatment of GBS Variants","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IVIg (Miller Fisher) IV Miller Fisher syndrome 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: Same as standard GBS; benefit less clear for pure MFS without weakness IgA deficiency Renal function, infusion reactions \u2014 URGENT \u2014 URGENT Observation only (MFS) \u2014 Pure MFS (mild) N/A :: \u2014 :: :: Consider observation without immunotherapy for pure MFS with mild symptoms and no limb weakness If weakness present, treat Serial neuro exam, FVC \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#3f-refractorytreatment-failure","title":"3F. Refractory/Treatment Failure","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Second course IVIg IV Treatment-related fluctuation 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: Consider if deterioration during/after IVIg or PLEX; typically 2-3 weeks after first course IgA deficiency Renal function \u2014 URGENT \u2014 URGENT PLEX after IVIg failure \u2014 IVIg non-response 5 exchanges over 1-2 weeks :: \u2014 :: QOD x 5 :: Consider if no improvement 2-4 weeks post-IVIg; wait at least 2 weeks after IVIg completion Hemodynamic instability BP, coagulation \u2014 URGENT \u2014 URGENT <p>Note: Corticosteroids are NOT effective in GBS and should NOT be used as primary treatment. They do not improve outcomes and may delay recovery.</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consult for diagnosis confirmation, immunotherapy initiation, and prognosis discussion STAT STAT \u2014 STAT Pulmonology consult for respiratory function monitoring and ventilator management if FVC declining URGENT URGENT \u2014 STAT Critical care consult for ICU admission given FVC &lt;30 mL/kg or rapidly declining respiratory function URGENT STAT \u2014 STAT Physical therapy for mobility assessment, fall prevention, and early mobilization when stable \u2014 STAT \u2014 STAT Occupational therapy for ADL assessment and adaptive equipment to maintain independence \u2014 URGENT \u2014 URGENT Speech therapy for swallow evaluation given bulbar weakness and aspiration risk \u2014 URGENT \u2014 URGENT Respiratory therapy for airway clearance techniques and ventilator management if intubated STAT STAT \u2014 STAT Pain management consult for refractory neuropathic pain not responding to gabapentin/pregabalin \u2014 ROUTINE \u2014 ROUTINE Physiatry/PM&amp;R for rehabilitation planning and discharge disposition to optimize functional recovery \u2014 ROUTINE \u2014 ROUTINE Social work for discharge planning, caregiver support, and GBS Foundation resources \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening weakness or breathing difficulty develops (may indicate disease progression requiring intubation) STAT \u2014 STAT Use fall precautions including walker and assistance due to proximal weakness and areflexia STAT STAT STAT Do not drive until cleared by neurology due to unpredictable weakness and impaired reflexes STAT STAT STAT Perform physical therapy exercises as prescribed to maintain range of motion and prevent contractures \u2014 STAT STAT Expect gradual recovery over weeks to months; most patients recover but pace varies by severity \u2014 ROUTINE ROUTINE Report fevers, severe headache, or new symptoms immediately as these may indicate infection or relapse STAT STAT STAT Contact GBS-CIDP Foundation (www.gbs-cidp.org) for patient support and educational resources \u2014 ROUTINE ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Aspiration precautions including thickened liquids and upright positioning given bulbar weakness STAT STAT \u2014 Early mobilization when medically stable to prevent DVT and deconditioning (with PT guidance) \u2014 STAT \u2014 Frequent repositioning every 2 hours to prevent pressure ulcers during immobility \u2014 STAT STAT Monitor for urinary retention and catheterize if needed due to autonomic dysfunction \u2014 STAT \u2014 Use energy conservation techniques including scheduled rest periods to manage post-GBS fatigue \u2014 ROUTINE ROUTINE Gradual return to activities as strength permits; avoid overexertion which may worsen fatigue \u2014 \u2014 ROUTINE Discuss future vaccination timing with neurologist; avoid live vaccines if on immunotherapy \u2014 ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Myasthenia gravis Fatigable weakness, ptosis, diplopia; reflexes preserved AChR/MuSK antibodies, repetitive nerve stimulation, edrophonium test Transverse myelitis Sensory level, bowel/bladder dysfunction early, UMN signs MRI spine with contrast, CSF Spinal cord compression Sensory level, UMN signs below lesion, back pain MRI spine emergent Botulism Descending paralysis, pupil involvement, GI symptoms Stool/serum toxin assay, EMG (incremental response) Poliomyelitis/West Nile Asymmetric weakness, fever, CSF pleocytosis CSF PCR, serology Tick paralysis Recent tick exposure, ascending paralysis Physical exam (find tick), rapid improvement with tick removal Critical illness polyneuropathy ICU setting, sepsis, prolonged weakness EMG/NCS, clinical context Hypokalemic periodic paralysis Episodic weakness, low K+ during attacks Serum K+ during attack, genetic testing Acute porphyria Abdominal pain, psychiatric symptoms, motor neuropathy Urine porphyrins, ALA, PBG Heavy metal poisoning Exposure history, other systemic symptoms Heavy metal levels Diphtheria Pharyngitis, palatal weakness, cardiac involvement Throat culture, toxin assay HIV-associated neuropathy Risk factors, may have CSF pleocytosis HIV testing CIDP Chronic course (&gt;8 weeks), relapsing Clinical course, EMG/NCS, CSF","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Forced vital capacity (FVC) q4-6h initially; q2h if declining &gt;20 mL/kg Intubate if &lt;20 mL/kg or &gt;30% decline STAT STAT \u2014 STAT Negative inspiratory force (NIF) q4-6h initially; q2h if declining More negative than -30 cmH2O Intubate if weaker than -30 cmH2O STAT STAT \u2014 STAT Oxygen saturation Continuous &gt;94% Supplement oxygen, consider intubation STAT STAT \u2014 STAT Heart rate Continuous 60-100 bpm Treat bradycardia &lt;50 or tachy &gt;120 STAT STAT \u2014 STAT Blood pressure q1-4h SBP 100-160 Treat hypo/hypertension STAT STAT \u2014 STAT Neurological exam (strength) q4-8h Stability or improvement Escalate care if worsening STAT STAT ROUTINE STAT Swallow function Daily if bulbar symptoms Safe swallow NPO, NG tube if unsafe \u2014 STAT \u2014 STAT Urine output q4-8h &gt;0.5 mL/kg/hr Bladder scan, catheterize if needed \u2014 STAT \u2014 STAT Renal function Daily during IVIg Cr stable Hold IVIg, hydrate if rising \u2014 STAT \u2014 STAT Skin integrity q shift Intact Reposition, pressure relief \u2014 ROUTINE \u2014 ROUTINE Bowel function Daily Regular BMs Bowel regimen if constipated \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission FVC &lt;30 mL/kg; NIF weaker than -40 cmH2O; rapid progression; autonomic instability; bulbar dysfunction; need for intubation Step-down/telemetry Stable FVC &gt;30 mL/kg; improving or stable exam; no autonomic instability; on telemetry monitoring General floor Mild weakness (ambulatory); stable FVC &gt;40 mL/kg; no bulbar symptoms; no autonomic dysfunction Acute rehabilitation Medically stable; significant residual weakness requiring intensive therapy; FVC stable &gt;25 mL/kg Discharge home Ambulatory or near-ambulatory; stable &gt;48-72 hours; adequate home support; outpatient PT arranged; no respiratory compromise Skilled nursing facility Unable to participate in intensive rehab; requires ongoing nursing care; medically stable","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IVIg or PLEX equally effective for GBS Class I, Level A Hughes et al. Cochrane 2014 IVIg 0.4 g/kg x 5 days standard dosing Class I, Level A van der Mech\u00e9 et al. NEJM 1992 PLEX effective within 4 weeks of onset Class I, Level A Rapha\u00ebl et al. Cochrane 2012 Combined IVIg + PLEX not superior Class I, Level A Plasma Exchange/Sandoglobulin GBS Trial Group 1997 Corticosteroids ineffective in GBS Class I, Level A Hughes et al. Cochrane 2016 FVC and NIF for respiratory monitoring Class II, Level B Lawn et al. Arch Neurol 2001 Anti-GQ1b associated with Miller Fisher Class II, Level B Chiba et al. Ann Neurol 1992 Campylobacter most common antecedent Class II, Level B Jacobs et al. Neurology 1998 Early IVIg (within 2 weeks) improves outcomes Class I, Level A Hughes et al. Cochrane 2014 20/30/40 rule for intubation Class III, Level C Lawn et al. Arch Neurol 2001","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#change-log","title":"CHANGE LOG","text":"<p>v1.1 (January 24, 2026) - Citation verification: Corrected 6 PMID errors in Section 8 - Fixed: Hughes Cochrane 2016 (PMID 27775812), Lawn Arch Neurol 2001 (PMID 11405803), Chiba Ann Neurol 1992 (PMID 1514781), Jacobs Neurology 1998 (PMID 9781538) - Updated: Early IVIg and 20/30/40 rule citations corrected to verified sources</p> <p>v1.0 (January 24, 2026) - Initial template creation - Includes all GBS variants (AIDP, AMAN, AMSAN, Miller Fisher) - Structured dosing format for immunotherapy and supportive care - Respiratory monitoring protocol with 20/30/40 rule - Autonomic dysfunction management - DVT prophylaxis and supportive care</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#appendix-a-erasmus-gbs-respiratory-insufficiency-score-egris","title":"APPENDIX A: Erasmus GBS Respiratory Insufficiency Score (EGRIS)","text":"<p>Predicts need for mechanical ventilation within 1 week of admission</p> Parameter Points Days from onset to admission &gt;7 days 0 4-7 days 1 \u22643 days 2 Facial and/or bulbar weakness at admission Absent 0 Present 1 MRC sum score at admission 60-51 0 50-41 1 40-31 2 30-21 3 \u226420 4 <p>Interpretation: | EGRIS Score | Risk of MV | |-------------|------------| | 0-2 | Low (4%) | | 3-4 | Intermediate (24%) | | 5-7 | High (65%) |</p> <p>MRC Sum Score: Sum of MRC grades (0-5) for 6 muscle groups bilaterally: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle dorsiflexion. Maximum = 60.</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#appendix-b-hughes-gbs-disability-scale","title":"APPENDIX B: Hughes GBS Disability Scale","text":"Grade Description 0 Healthy 1 Minor symptoms or signs, able to run 2 Able to walk 10 meters without assistance but unable to run 3 Able to walk 10 meters with assistance (walker, cane, or support) 4 Bed-bound or chair-bound (unable to walk) 5 Requiring assisted ventilation 6 Death <p>Clinical Use: Document at admission and serially to track progression/recovery. Grade \u22653 typically warrants immunotherapy.</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/guillain-barre-syndrome/#appendix-c-ivig-administration-protocol","title":"APPENDIX C: IVIg Administration Protocol","text":"<p>Pre-treatment checklist: - [ ] Check IgA level (deficiency is contraindication) - [ ] Document renal function (Cr, BUN) - [ ] Assess hydration status - [ ] Verify no recent live vaccines (wait 3 months post-IVIg)</p> <p>Infusion protocol: 1. Day 1: Start at 0.5-1 mL/kg/hr for first 30 minutes 2. If tolerated, increase to 2 mL/kg/hr for 30 minutes 3. If tolerated, increase to 4 mL/kg/hr (max rate) 4. Days 2-5: Can start at higher rate if day 1 tolerated</p> <p>Premedication: - Acetaminophen 650-1000 mg PO - Diphenhydramine 25-50 mg PO or IV - Consider hydration with NS 250-500 mL pre-infusion</p> <p>Common reactions and management: | Reaction | Management | |----------|------------| | Headache | Slow infusion, acetaminophen, consider IVIg-induced aseptic meningitis if severe | | Flushing, chills | Slow or pause infusion, acetaminophen, diphenhydramine | | Hypertension | Slow infusion, monitor; usually transient | | Nausea | Ondansetron 4 mg IV | | Anaphylaxis (rare) | Stop infusion, epinephrine, supportive care | | Renal dysfunction | Monitor Cr daily; hydrate; consider PLEX instead |</p> <p>Post-infusion: - Monitor for delayed reactions (headache, rash) for 24 hours - Recheck renal function 24-48 hours after completion</p>","tags":["neuromuscular","emergency","weakness","neuropathy"]},{"location":"drafts/hsv-encephalitis/","title":"HSV Encephalitis","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#hsv-encephalitis","title":"HSV Encephalitis","text":"<p>VERSION: 1.1 CREATED: January 24, 2026 REVISED: January 24, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: HSV Encephalitis</p> <p>ICD-10: B00.4 (Herpesviral encephalitis), G05.1 (Encephalitis, myelitis and encephalomyelitis in viral diseases classified elsewhere)</p> <p>SCOPE: Evaluation and management of herpes simplex virus encephalitis (HSVE) in adults. Covers empiric acyclovir, diagnostic workup including CSF PCR and neuroimaging, seizure management, and ICU care. Primarily addresses HSV-1 encephalitis (most common in adults). Excludes neonatal HSV, HSV-2 meningitis (Mollaret's), and other viral encephalitides.</p> <p>CLINICAL SYNONYMS: Herpes encephalitis, HSVE, herpesviral encephalitis, HSV-1 encephalitis, acute necrotizing encephalitis</p> <p>KEY CLINICAL FEATURES: - Acute/subacute presentation: Fever, headache, altered mental status (&gt;90%) - Temporal lobe symptoms: Personality change, behavioral abnormalities, memory impairment - Seizures: Present in 60-70% (focal &gt; generalized) - Focal deficits: Aphasia, hemiparesis (if dominant temporal lobe involved) - Prodrome: May have flu-like illness 1-4 days before - Absence of genital HSV lesions: Usually unrelated (HSV-1 reactivation in CNS)</p> <p>HSV-1 vs HSV-2 in Adults:</p> Feature HSV-1 Encephalitis HSV-2 Meningitis Presentation Encephalitis (focal, severe) Meningitis (less severe) Location Temporal/frontal lobes Meninges (not parenchyma) Mortality untreated 70% Low Recurrence Rare Common (Mollaret's) Management 14-21 days IV acyclovir 7-14 days acyclovir <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u26a1 TIME-CRITICAL EMERGENCY</p> <p>Do NOT delay acyclovir. Empiric treatment within 6 hours of presentation dramatically improves outcomes. Mortality without treatment: 70%. With early treatment: &lt;20%.</p> <p>\u26a0\ufe0f ACYCLOVIR NEPHROTOXICITY</p> <p>Ensure adequate hydration. Monitor renal function daily. Adjust dose for CrCl.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection workup, baseline May show leukocytosis STAT STAT \u2014 STAT CMP (BMP + LFTs) Renal function (acyclovir dosing), hepatic function Normal or mildly elevated STAT STAT \u2014 STAT BUN/Creatinine Baseline for acyclovir dosing Normal (adjust acyclovir if elevated) STAT STAT \u2014 STAT Blood glucose Compare with CSF glucose Document STAT STAT \u2014 STAT PT/INR, PTT Pre-LP coagulation status INR &lt;1.5 STAT STAT \u2014 STAT Blood cultures (2 sets) Exclude bacterial infection Negative STAT STAT \u2014 STAT Serum sodium SIADH common in encephalitis 135-145 mEq/L STAT STAT \u2014 STAT ESR, CRP Inflammatory markers May be mildly elevated URGENT ROUTINE \u2014 URGENT","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU HIV antibody/antigen Immunocompromised host evaluation Document status \u2014 ROUTINE \u2014 ROUTINE HSV-1/HSV-2 serology (IgG, IgM) Not useful for acute diagnosis; documents prior exposure Document (NOT diagnostic of encephalitis) \u2014 ROUTINE \u2014 ROUTINE Procalcitonin Bacterial vs viral differentiation Low (&lt;0.5) in viral URGENT ROUTINE \u2014 URGENT TSH Altered mental status workup Normal \u2014 ROUTINE \u2014 ROUTINE Ammonia Altered mental status workup Normal URGENT ROUTINE \u2014 URGENT B12 Encephalopathy workup Normal \u2014 ROUTINE \u2014 ROUTINE Urine drug screen Altered mental status differential Document STAT ROUTINE \u2014 STAT Troponin Stress cardiomyopathy Normal or mildly elevated URGENT ROUTINE \u2014 STAT","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Serum autoimmune encephalitis panel Post-HSV autoimmune encephalitis Negative initially (may become positive later) \u2014 ROUTINE \u2014 ROUTINE VZV serology VZV encephalitis differential Document \u2014 ROUTINE \u2014 ROUTINE EBV serology EBV encephalitis differential Document \u2014 ROUTINE \u2014 ROUTINE CMV PCR Immunocompromised patients Negative \u2014 ROUTINE \u2014 ROUTINE Serum West Nile IgM Endemic area, summer months Negative \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain with and without contrast STAT (within 24h) Temporal lobe T2/FLAIR hyperintensity, hemorrhage, edema Hemodynamic instability (get CT first) STAT STAT \u2014 STAT CT head without contrast If MRI delayed or unavailable Temporal lobe hypodensity, hemorrhage, edema (less sensitive than MRI) None in emergency STAT STAT \u2014 STAT EEG If seizures or altered mental status Periodic lateralized epileptiform discharges (PLEDs), temporal slowing None STAT STAT \u2014 STAT <p>MRI Findings in HSVE: - Early (days 1-3): T2/FLAIR hyperintensity in medial temporal lobe, insular cortex, cingulate gyrus - Characteristic: Asymmetric, unilateral or bilateral (asymmetric) temporal involvement - May also involve: Orbitofrontal cortex, insular cortex - Spares: Basal ganglia (helps distinguish from other encephalitides) - Hemorrhage: Petechial hemorrhages common (T1 hyperintensity, susceptibility-weighted imaging) - Contrast enhancement: Variable; may be absent early</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain (repeat) Day 3-7 if initial negative Evolution of findings Hemodynamic instability \u2014 URGENT \u2014 URGENT Continuous EEG (cEEG) If seizures, persistent AMS Nonconvulsive seizures, PLEDs None \u2014 STAT \u2014 STAT CT angiogram If vasculitis suspected Normal (or vasculitic changes) Contrast allergy \u2014 URGENT \u2014 URGENT","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Brain biopsy Refractory to treatment, diagnostic uncertainty HSV inclusions (Cowdry type A) Coagulopathy \u2014 EXT \u2014 EXT PET scan If autoimmune encephalitis suspected post-HSV Temporal hypermetabolism Hemodynamic instability \u2014 EXT \u2014 EXT","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: ALL suspected HSV encephalitis (unless contraindicated)</p> <p>Timing: STAT - Do NOT delay acyclovir for LP</p> <p>Volume Required: 10-15 mL minimum</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure May be elevated in encephalitis 10-20 cmH2O normal; often elevated STAT STAT \u2014 STAT Cell count with differential (tubes 1 and 4) Lymphocytic pleocytosis 10-500 WBC/\u03bcL; lymphocyte predominant; RBCs may be present STAT STAT \u2014 STAT Protein Elevated in encephalitis 60-100 mg/dL (mildly elevated) STAT STAT \u2014 STAT Glucose Usually normal in viral encephalitis Normal (&gt;40 mg/dL) STAT STAT \u2014 STAT HSV PCR (CSF) Definitive diagnosis Positive (sensitivity 96%, specificity &gt;99%) STAT STAT \u2014 STAT HSV-1 and HSV-2 specific PCR Distinguish HSV-1 vs HSV-2 Document which type STAT STAT \u2014 STAT VZV PCR VZV encephalitis differential Negative STAT STAT \u2014 STAT Enterovirus PCR Viral encephalitis differential Negative STAT STAT \u2014 STAT BioFire FilmArray ME Panel Rapid multiplex PCR HSV and other pathogens STAT STAT \u2014 STAT Gram stain and bacterial culture Exclude bacterial meningitis Negative STAT STAT \u2014 STAT Cytology If malignancy suspected Negative \u2014 ROUTINE \u2014 ROUTINE Autoimmune encephalitis panel (CSF) Post-HSV autoimmune encephalitis Negative initially \u2014 ROUTINE \u2014 ROUTINE <p>CSF Findings in HSVE:</p> Parameter Typical Finding Opening pressure Normal to mildly elevated WBC 10-500/\u03bcL (lymphocyte predominant) RBCs May be present (hemorrhagic encephalitis) Protein Mildly elevated (60-100 mg/dL) Glucose Normal HSV PCR Positive (may be negative in first 24-72 hours) <p>Special Handling: HSV PCR refrigerated; process within 24 hours.</p> <p>Contraindications: Signs of herniation, severe coagulopathy, mass effect on CT. Get CT first if concern.</p> <p>CRITICAL NOTE: CSF HSV PCR may be negative in first 24-72 hours. If clinical suspicion high and initial PCR negative, repeat LP in 3-7 days and continue acyclovir.</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: Start acyclovir immediately upon suspicion. Do NOT wait for LP, MRI, or PCR results.</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3a-antiviral-therapy","title":"3A. Antiviral Therapy","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Acyclovir IV Empiric and definitive treatment 10 mg/kg q8h :: IV :: q8h :: 10 mg/kg IV q8h (infuse over 1 hour); adjust for renal function; minimum 14 days, extend to 21 days if severe or immunocompromised Severe renal impairment (adjust dose) Renal function daily, hydration status, neurotoxicity STAT STAT \u2014 STAT Acyclovir (renal adjustment) IV CrCl 25-50 mL/min 10 mg/kg q12h :: IV :: q12h :: 10 mg/kg IV q12h if CrCl 25-50 mL/min \u2014 Cr daily STAT STAT \u2014 STAT Acyclovir (renal adjustment) IV CrCl 10-25 mL/min 10 mg/kg q24h :: IV :: q24h :: 10 mg/kg IV q24h if CrCl 10-25 mL/min \u2014 Cr daily STAT STAT \u2014 STAT Acyclovir (HD) IV Hemodialysis 10 mg/kg post-HD :: IV :: post-HD :: 10 mg/kg IV after each hemodialysis session \u2014 Post-HD levels \u2014 STAT \u2014 STAT <p>Acyclovir Duration: - Standard: 14 days minimum - Severe disease/immunocompromised: 21 days - Repeat CSF PCR: NOT routinely recommended. Consider repeat LP near end of treatment only in select cases: (1) immunocompromised patients, (2) severe/complicated course, (3) clinical concern for treatment failure or relapse. If PCR still positive, extend treatment.</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3b-empiric-bacterial-coverage-until-bacterial-ruled-out","title":"3B. Empiric Bacterial Coverage (Until Bacterial Ruled Out)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ceftriaxone IV Empiric bacterial coverage 2 g q12h :: IV :: q12h :: 2 g IV q12h until bacterial meningitis ruled out Cephalosporin allergy Renal function STAT STAT \u2014 STAT Vancomycin IV Empiric DRSP coverage 15-20 mg/kg q8-12h :: IV :: q8-12h :: 15-20 mg/kg IV q8-12h until bacterial ruled out Renal impairment (adjust) Trough 15-20, renal function STAT STAT \u2014 STAT Dexamethasone IV If bacterial meningitis possible 0.15 mg/kg q6h :: IV :: q6h x 4 days :: 0.15 mg/kg IV q6h ONLY if bacterial meningitis not ruled out; discontinue if HSV confirmed \u2014 Glucose STAT STAT \u2014 STAT <p>Note: Discontinue empiric antibiotics and dexamethasone once HSV encephalitis confirmed and bacterial meningitis ruled out.</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3c-seizure-management","title":"3C. Seizure Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Levetiracetam IV/PO Seizure treatment/prophylaxis 1000 mg BID; 1500 mg BID; 2000 mg BID :: IV/PO :: BID :: Load 1000-2000 mg IV, then 1000-1500 mg BID; preferred first-line Severe renal impairment (adjust) Seizure frequency, behavior STAT STAT \u2014 STAT Phenytoin IV Alternative for seizures 20 mg/kg load; 100 mg TID :: IV :: load then TID :: 20 mg/kg IV load (max 50 mg/min), then 100 mg q8h or 300 mg daily; target level 10-20 Bradycardia, AV block Cardiac monitor during load, levels STAT STAT \u2014 STAT Lacosamide IV/PO Alternative/adjunctive 200 mg BID; 300 mg BID :: IV/PO :: BID :: Load 200-400 mg IV, then 200-300 mg BID PR prolongation, severe cardiac disease ECG, PR interval \u2014 STAT \u2014 STAT Lorazepam IV Acute seizure termination 2 mg; 4 mg :: IV :: PRN :: 0.1 mg/kg IV (max 4 mg); may repeat x1 in 5 min Respiratory depression RR, O2 sat STAT STAT \u2014 STAT <p>Seizure Prophylaxis Considerations: - High seizure risk in HSVE (60-70%) - Consider prophylaxis for all patients during acute phase - Typical duration: Continue through acute illness and taper after 3-6 months if seizure-free - Long-term epilepsy occurs in ~25% of survivors</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3d-cerebral-edema-elevated-icp-management","title":"3D. Cerebral Edema / Elevated ICP Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Mannitol IV Elevated ICP 0.5-1 g/kg bolus :: IV :: PRN :: 0.5-1 g/kg IV bolus over 15-20 min; may repeat q6h PRN; target serum osm &lt;320 Renal failure, hypotension Serum osm, Na+, renal function \u2014 STAT \u2014 STAT Hypertonic saline (3%) IV Elevated ICP 250 mL bolus :: IV :: PRN :: 250 mL IV bolus for acute herniation; target Na 145-155 \u2014 Na+, serum osm \u2014 STAT \u2014 STAT Head of bed elevation \u2014 ICP management N/A :: \u2014 :: continuous :: Elevate HOB 30-45 degrees \u2014 ICP (if monitored) STAT STAT \u2014 STAT Decompressive craniectomy \u2014 Refractory elevated ICP N/A :: \u2014 :: :: Consider for malignant cerebral edema with impending herniation Multifocal disease, poor prognosis Neurosurgery consult \u2014 EXT \u2014 EXT","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3e-supportive-care","title":"3E. Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IV fluids (isotonic) IV Hydration (prevent acyclovir nephrotoxicity) NS 100-150 mL/hr :: IV :: continuous :: Maintain euvolemia; avoid dehydration (acyclovir crystallizes in renal tubules) Cerebral edema (may need to restrict) I/O, renal function, Na+ STAT STAT \u2014 STAT Acetaminophen IV/PO Fever, headache 650 mg q6h; 1000 mg q6h :: IV/PO :: q6h :: 650-1000 mg q6h; max 4 g/day Severe hepatic impairment Temperature STAT STAT \u2014 STAT Ondansetron IV/PO Nausea 4 mg q6h PRN; 8 mg q8h PRN :: IV/PO :: q6h PRN :: 4-8 mg IV/PO q6-8h PRN QT prolongation QTc if repeated dosing STAT STAT \u2014 STAT Enoxaparin SC DVT prophylaxis (after stabilization) 40 mg daily :: SC :: daily :: 40 mg SC daily; start after 48-72h if no hemorrhage Active bleeding, recent hemorrhagic transformation Platelet count, bleeding \u2014 ROUTINE \u2014 ROUTINE Famotidine IV/PO Stress ulcer prophylaxis 20 mg BID :: IV/PO :: BID :: 20 mg IV/PO BID None significant GI bleeding \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#3f-post-hsv-autoimmune-encephalitis","title":"3F. Post-HSV Autoimmune Encephalitis","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone IV Post-HSV autoimmune encephalitis 1000 mg daily x 5 days :: IV :: daily x 5 days :: 1000 mg IV daily x 5 days; for secondary deterioration 2-6 weeks post-HSVE Active untreated infection Glucose, BP, psychiatric symptoms \u2014 URGENT \u2014 URGENT IVIg IV Post-HSV autoimmune encephalitis 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: 0.4 g/kg/day IV x 5 days IgA deficiency Renal function, infusion reactions \u2014 URGENT \u2014 URGENT <p>Post-HSV Autoimmune Encephalitis: - Occurs in ~20-27% of HSVE patients - Typically 2-6 weeks after initial presentation - Associated with anti-NMDAR antibodies most commonly - Presents as secondary neurological deterioration - Requires repeat CSF with autoimmune panel - Treat with immunotherapy (steroids, IVIg, PLEX)</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consult for diagnosis confirmation, antiviral guidance, and seizure management STAT STAT \u2014 STAT Infectious disease consult for atypical course, treatment failure, or diagnostic uncertainty URGENT URGENT \u2014 URGENT Critical care consult for ICU admission given altered mental status, respiratory failure, or elevated ICP STAT STAT \u2014 STAT Neurosurgery consult for elevated ICP management, decompressive surgery, or brain biopsy consideration \u2014 URGENT \u2014 STAT Epilepsy consult for refractory seizures and continuous EEG monitoring interpretation \u2014 URGENT \u2014 STAT Physical therapy for mobility assessment and fall prevention given weakness and cognitive impairment \u2014 ROUTINE \u2014 ROUTINE Occupational therapy for ADL assessment and early cognitive rehabilitation planning \u2014 ROUTINE \u2014 ROUTINE Speech therapy for swallow evaluation given aspiration risk and aphasia therapy for temporal lobe involvement \u2014 URGENT \u2014 URGENT Neuropsychology for formal cognitive assessment after acute illness to guide rehabilitation \u2014 \u2014 ROUTINE \u2014 Social work for discharge planning and caregiver support given potential for significant disability \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening headache, confusion, or seizures develop (may indicate relapse or post-HSV autoimmune encephalitis) STAT \u2014 STAT Complete full 14-21 day acyclovir course to ensure viral eradication and prevent relapse \u2014 STAT STAT Follow seizure precautions including no driving, heights, or operating machinery due to high seizure risk \u2014 STAT STAT Report any new neurological symptoms weeks after discharge as post-HSV autoimmune encephalitis can occur 2-6 weeks later \u2014 ROUTINE ROUTINE Attend neurology follow-up in 2-4 weeks to assess recovery and screen for delayed complications \u2014 ROUTINE ROUTINE Expect that cognitive rehabilitation may be needed as memory and behavioral deficits are common after HSVE \u2014 ROUTINE ROUTINE Contact Encephalitis Society (www.encephalitis.info) for patient support and educational resources \u2014 ROUTINE ROUTINE","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Use fall precautions including walker and supervision due to weakness and cognitive impairment STAT STAT STAT Aspiration precautions including thickened liquids and upright positioning if bulbar involvement present STAT STAT \u2014 Maintain adequate hydration (2-3 L/day) to prevent acyclovir-induced nephrotoxicity STAT STAT \u2014 Follow seizure safety including no swimming alone and showers instead of baths due to ongoing seizure risk \u2014 ROUTINE ROUTINE Use cognitive pacing with scheduled rest periods to manage post-encephalitis fatigue \u2014 ROUTINE ROUTINE Do not drive until cleared by neurology due to seizure risk and potential cognitive impairment \u2014 STAT STAT <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Autoimmune encephalitis Subacute, psychiatric symptoms, movement disorder, may have tumor CSF autoimmune panel, serum panel, CT body Bacterial meningitis/abscess More toxic, CSF with PMNs, low glucose CSF Gram stain/culture, MRI Other viral encephalitis Geographic/seasonal clues, different MRI pattern CSF viral PCR panel, serology Tuberculous meningitis Subacute, basilar meningitis, low glucose CSF AFB, TB PCR, adenosine deaminase Fungal meningitis Immunocompromised, indolent course CSF fungal culture, cryptococcal antigen Primary CNS lymphoma Immunocompromised, periventricular lesions MRI pattern, CSF cytology Glioblastoma Focal deficits, ring-enhancing mass MRI with contrast, biopsy Cerebral vasculitis Multifocal strokes, systemic symptoms Angiography, vessel wall MRI, biopsy Acute disseminated encephalomyelitis (ADEM) Post-infectious, multifocal white matter MRI pattern (multifocal), CSF Posterior reversible encephalopathy (PRES) Hypertension, posterior predominance MRI pattern, BP history Status epilepticus Seizure history, EEG pattern EEG, response to antiseizure meds Toxic/metabolic encephalopathy Drug exposure, organ failure Toxicology, metabolic panel Paraneoplastic encephalitis Cancer history, antibody-positive Paraneoplastic panel, CT body Creutzfeldt-Jakob disease Rapid dementia, myoclonus, DWI restriction MRI pattern, 14-3-3, RT-QuIC","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurological exam (GCS, pupils) q1-2h initially, then q4h GCS stable or improving Head CT, consider ICP monitoring STAT STAT \u2014 STAT Seizure activity Continuous if cEEG, otherwise q4h assessment No seizures Escalate antiepileptic therapy STAT STAT \u2014 STAT Temperature q4h Afebrile Antipyretics, infection workup STAT STAT \u2014 STAT Renal function (Cr, BUN) Daily Cr stable Adjust acyclovir dose, increase hydration STAT STAT \u2014 STAT Serum sodium q6-12h initially 135-145 mEq/L Evaluate for SIADH, cerebral salt wasting STAT STAT \u2014 STAT Fluid balance (I/O) q8h Even balance; avoid dehydration Adjust fluids \u2014 STAT \u2014 STAT Mental status q4-8h Improving Re-evaluate, repeat imaging STAT STAT \u2014 STAT Signs of herniation q1-2h if concern Absent Emergent intervention, neurosurgery STAT STAT \u2014 STAT CSF HSV PCR (repeat) Day 14-21 Negative Extend acyclovir if still positive \u2014 ROUTINE \u2014 ROUTINE","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission GCS &lt;12; seizures; signs of elevated ICP; need for intubation; hemodynamic instability; rapidly worsening Step-down/telemetry GCS 12-14; stable on antiepileptics; no ICP concerns; improving General floor GCS 15; stable neurologically; no seizures; tolerating PO; can complete IV acyclovir Discharge home Completed 14-21 days IV acyclovir; neurologically stable; safe swallow; adequate support; outpatient follow-up arranged Acute rehabilitation Significant residual cognitive or motor deficits; requires intensive therapy Long-term care Severe persistent deficits; unable to live independently","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Acyclovir 10 mg/kg q8h for HSVE Class I, Level A Whitley et al. NEJM 1986 CSF HSV PCR for diagnosis Class I, Level A Lakeman &amp; Whitley. J Infect Dis 1995 Early acyclovir improves outcomes Class II, Level B Raschilas et al. Clin Infect Dis 2002 MRI superior to CT for HSVE Class II, Level B Domingues et al. J Neurol Sci 1997 14-21 day treatment duration Class II, Level B Gnann &amp; Whitley. Clin Infect Dis 2002 Repeat CSF PCR if clinical concern Class III, Level C Tyler. NEJM 2004 Post-HSV autoimmune encephalitis Class II, Level B Armangue et al. Lancet Neurol 2018 Seizure prophylaxis consideration Class III, Level C Misra et al. Seizure 2008 Prognosis with early treatment Class II, Level B Skoldenberg et al. Lancet 1984","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#change-log","title":"CHANGE LOG","text":"<p>v1.1 (January 24, 2026) - Citation verification: Corrected Whitley PMID (3001520), Armangue PMID (30049614)</p> <p>v1.0 (January 24, 2026) - Initial template creation - Acyclovir dosing with renal adjustments - CSF interpretation and PCR timing - MRI findings description - Seizure management - Post-HSV autoimmune encephalitis recognition</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#appendix-a-acyclovir-dosing-by-renal-function","title":"APPENDIX A: Acyclovir Dosing by Renal Function","text":"CrCl (mL/min) Dose Frequency &gt;50 10 mg/kg q8h 25-50 10 mg/kg q12h 10-25 10 mg/kg q24h &lt;10 5 mg/kg q24h Hemodialysis 10 mg/kg After each HD session CRRT 10 mg/kg q12-24h (adjust based on clearance) <p>Administration Notes: - Infuse each dose over at least 1 hour (prevents crystalluria) - Ensure adequate hydration (2-3 L/day if tolerated) - Monitor renal function daily - Acyclovir neurotoxicity (confusion, tremor, myoclonus) can occur, especially with renal impairment</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#appendix-b-csf-hsv-pcr-interpretation","title":"APPENDIX B: CSF HSV PCR Interpretation","text":"Scenario PCR Result Interpretation Action Early presentation (&lt;24-72h) Negative May be false negative Continue acyclovir, repeat LP in 3-7 days Day 3-7 of illness Positive Diagnostic Continue acyclovir 14-21 days Day 3-7 of illness Negative Likely not HSVE Consider alternative diagnoses End of treatment (day 14-21) Positive Ongoing viral replication Extend acyclovir treatment End of treatment Negative Treatment adequate Complete therapy, monitor for relapse <p>PCR Sensitivity/Specificity: - Sensitivity: 96-98% (after first 24-72 hours) - Specificity: &gt;99% - May be negative in first 24-72 hours - Remains positive for 1-2 weeks even with effective treatment</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/hsv-encephalitis/#appendix-c-red-flags-for-post-hsv-autoimmune-encephalitis","title":"APPENDIX C: Red Flags for Post-HSV Autoimmune Encephalitis","text":"<p>Timing: Typically 2-6 weeks after initial HSVE presentation</p> <p>Clinical Features Suggesting Autoimmune Complication: - Secondary neurological deterioration after initial improvement - New movement disorder (choreoathetosis, orofacial dyskinesia) - New psychiatric symptoms (agitation, psychosis, catatonia) - Refractory seizures - Memory disturbance out of proportion to structural damage - Autonomic instability</p> <p>Evaluation: - Repeat MRI (may show new or progressive changes) - Repeat LP with autoimmune panel (CSF &gt; serum) - Anti-NMDAR antibodies most common - Other antibodies: GABA-B, AMPA, LGI1</p> <p>Treatment: - First-line: IV methylprednisolone 1g daily x 5 days - IVIg 0.4 g/kg/day x 5 days - PLEX (5 exchanges) - Second-line: Rituximab, cyclophosphamide for refractory cases</p>","tags":["infection","emergency","encephalitis","neurocritical-care"]},{"location":"drafts/huntingtons-disease/","title":"Huntington's Disease","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#huntingtons-disease","title":"Huntington's Disease","text":"<p>DIAGNOSIS: Huntington's Disease ICD-10: G10 (Huntington disease) SCOPE: Diagnosis confirmation via genetic testing, chorea management, psychiatric symptom treatment, cognitive decline management, dysphagia assessment, genetic counseling, and end-of-life planning. Focuses primarily on outpatient management. Excludes Huntington disease-like syndromes (HDL1-4) and other chorea etiologies.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Huntington gene test (HTT CAG repeat) Definitive diagnosis; CAG repeat expansion \u226536 CAG repeats diagnostic (40+ fully penetrant) - ROUTINE ROUTINE - CBC Baseline; anemia contributes to fatigue; infection screen Normal STAT ROUTINE ROUTINE - BMP Electrolytes; renal function for medication dosing Normal STAT ROUTINE ROUTINE - Hepatic panel (LFTs) Baseline before tetrabenazine/deutetrabenazine; valproate if used Normal - ROUTINE ROUTINE - TSH Hypothyroidism can mimic apathy and cognitive slowing Normal - ROUTINE ROUTINE - Vitamin B12 Deficiency can worsen cognitive and psychiatric symptoms &gt;300 pg/mL - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency common; contributes to falls and bone health &gt;30 ng/mL - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Iron studies, ferritin Neurodegeneration with brain iron accumulation if HD-negative Normal - ROUTINE ROUTINE - Ceruloplasmin, serum copper Wilson's disease if younger onset, HD gene-negative Normal - EXT ROUTINE - ACTN3 gene test Research; may modify age of onset Research use - - EXT - Acanthocyte screen (peripheral smear) Chorea-acanthocytosis if HD gene-negative No acanthocytes - EXT EXT - Lipid panel Cardiovascular risk; weight loss monitoring Normal - ROUTINE ROUTINE - Prealbumin/albumin Nutritional status assessment in advanced disease Normal - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Genetic testing for HDL syndromes (PRNP, JPH3, TBP, ATN1) HD-like phenotype with negative HTT test Identifies HD-like syndrome - - EXT - CSF biomarkers (neurofilament light chain) Disease progression monitoring; research Elevated in active disease - - EXT - Kynurenine pathway metabolites Research; therapeutic target assessment Research use - - EXT -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At diagnosis Caudate atrophy; lateral ventricle enlargement (\"boxcar\" ventricles) MRI-incompatible devices URGENT ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain volumetric Baseline and annually for progression Quantify caudate and striatal volume loss MRI contraindications - - ROUTINE - Swallowing evaluation (VFSS or FEES) At diagnosis and with dysphagia symptoms Identify aspiration risk; guide diet modification None - ROUTINE ROUTINE - ECG Baseline before tetrabenazine/deutetrabenazine QTc &lt;450 ms None - ROUTINE ROUTINE - Polysomnography Sleep disturbance evaluation Rule out sleep apnea; assess sleep architecture None - - ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU PET imaging (FDG or specific tracers) Research; atypical presentation Striatal hypometabolism None - - EXT - Neuropsychological testing battery At diagnosis and annually Baseline cognitive profile; monitor decline None - - ROUTINE - Genetic modifier testing (research) Prognosis; clinical trials Identifies modifiers of age of onset None - - EXT -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Lorazepam IV/PO Severe chorea causing injury or exhaustion 0.5 mg IV; 1 mg IV; 2 mg PO :: IV/PO :: :: 0.5-2 mg IV/PO q4-6h PRN; short-term use only Respiratory depression; acute narrow-angle glaucoma Respiratory status, sedation STAT STAT - STAT Haloperidol IV/IM Severe psychosis with agitation; acute behavioral emergency 2 mg IM; 5 mg IM :: IM :: :: 2-5 mg IM; may repeat q4-6h; max 20 mg/day; transition to oral QTc prolongation; history of NMS; worsens dystonia ECG, EPS, sedation STAT STAT - STAT Olanzapine IM/PO Acute agitation with psychosis; alternative to haloperidol 5 mg IM; 10 mg IM :: IM :: :: 5-10 mg IM; may repeat in 2 hours; max 30 mg/day Concurrent benzodiazepines (caution); diabetes Glucose, sedation, EPS STAT STAT - STAT IV fluids IV Dehydration from dysphagia or decreased oral intake NS at 75-125 mL/hr :: IV :: :: Correct dehydration; transition to oral when safe Fluid overload I/O, electrolytes STAT STAT - STAT Thiamine IV Nutritional deficiency; altered mental status 100 mg IV :: IV :: :: 100 mg IV daily x 3-5 days; then oral None None STAT STAT - STAT","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#3b-symptomatic-treatments-chorea","title":"3B. Symptomatic Treatments - Chorea","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Tetrabenazine (Xenazine) PO FDA-approved for HD chorea; first-line 12.5 mg daily; 12.5 mg BID; 12.5 mg TID; 25 mg TID; 37.5 mg TID :: PO :: :: Start 12.5 mg daily; increase by 12.5 mg q1wk; max 100 mg/day (25 mg per dose); CYP2D6 testing recommended Active suicidality; untreated depression; concurrent MAOIs; hepatic impairment Depression (PHQ-9 monthly), akathisia, parkinsonism, QTc - ROUTINE ROUTINE - Deutetrabenazine (Austedo) PO FDA-approved for HD chorea; better tolerability than tetrabenazine 6 mg daily; 6 mg BID; 9 mg BID; 12 mg BID :: PO :: :: Start 6 mg daily; increase by 6 mg/wk; max 48 mg/day (24 mg per dose) Same as tetrabenazine Depression, akathisia, parkinsonism, QTc - ROUTINE ROUTINE - Valbenazine (Ingrezza) PO Off-label for HD chorea; once daily dosing 40 mg daily; 80 mg daily :: PO :: :: Start 40 mg daily; may increase to 80 mg after 1 week Severe hepatic impairment; concurrent MAOIs; congenital long QT Depression, akathisia, QTc prolongation - ROUTINE ROUTINE - Risperidone PO Chorea with psychosis; antipsychotic with motor benefit 0.5 mg daily; 0.5 mg BID; 1 mg BID; 2 mg BID :: PO :: :: Start 0.5 mg daily; titrate by 0.5 mg q1wk; max 6 mg/day QTc prolongation; history of NMS EPS, metabolic panel, prolactin - ROUTINE ROUTINE - Olanzapine PO Chorea with weight loss; promotes weight gain 2.5 mg daily; 5 mg daily; 10 mg daily :: PO :: :: Start 2.5-5 mg qHS; titrate to effect; typical 5-15 mg/day Diabetes; significant metabolic risk Weight, glucose, lipids - ROUTINE ROUTINE - Clonazepam PO Adjunct for chorea; also helps myoclonus and anxiety 0.25 mg BID; 0.5 mg BID; 0.5 mg TID :: PO :: :: Start 0.25 mg BID; titrate slowly; max 4 mg/day Severe respiratory disease; falls risk Sedation, falls, cognitive effects - ROUTINE ROUTINE - Amantadine PO Mild chorea; may help fatigue 100 mg BID; 100 mg TID :: PO :: :: Start 100 mg daily; titrate to 100 mg TID; max 400 mg/day End-stage renal disease; seizure history Livedo reticularis, hallucinations, edema - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#3c-symptomatic-treatments-psychiatric","title":"3C. Symptomatic Treatments - Psychiatric","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Sertraline PO Depression; anxiety; irritability 25 mg daily; 50 mg daily; 100 mg daily; 150 mg daily :: PO :: :: Start 25 mg daily; titrate by 25-50 mg q1-2wk; max 200 mg/day MAOIs within 14 days Suicidality, serotonin syndrome - ROUTINE ROUTINE - Citalopram PO Depression; anxiety; good tolerability 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg/day due to QTc risk QTc &gt;500 ms; concurrent QT-prolonging drugs QTc if risk factors - ROUTINE ROUTINE - Escitalopram PO Depression; anxiety; similar to citalopram 5 mg daily; 10 mg daily; 20 mg daily :: PO :: :: Start 5-10 mg daily; max 20 mg/day Same as citalopram Same as citalopram - ROUTINE ROUTINE - Venlafaxine XR PO Depression with fatigue; dual mechanism 37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; titrate q1wk; max 225 mg/day Uncontrolled hypertension BP at higher doses - ROUTINE ROUTINE - Mirtazapine PO Depression with insomnia and weight loss; promotes appetite 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; titrate q1-2wk; max 45 mg None significant Weight, sedation - ROUTINE ROUTINE - Quetiapine PO Psychosis; irritability; insomnia; less EPS than other antipsychotics 25 mg qHS; 50 mg BID; 100 mg BID; 200 mg BID :: PO :: :: Start 25 mg qHS; titrate by 25-50 mg q3d; typical 150-400 mg/day Uncontrolled diabetes Glucose, lipids, QTc - ROUTINE ROUTINE - Aripiprazole PO Psychosis; irritability; weight-neutral 2 mg daily; 5 mg daily; 10 mg daily; 15 mg daily :: PO :: :: Start 2-5 mg daily; titrate by 5 mg q1wk; max 30 mg/day None significant Akathisia, EPS - ROUTINE ROUTINE - Lamotrigine PO Mood stabilization; irritability 25 mg daily; 50 mg daily; 100 mg daily; 200 mg daily :: PO :: :: Start 25 mg daily x 2wk; then 50 mg daily x 2wk; titrate by 50 mg q2wk; max 400 mg/day History of severe rash with lamotrigine Rash (SJS risk); slow titration mandatory - ROUTINE ROUTINE - Valproic acid PO Irritability; aggression; mood stabilization 250 mg BID; 500 mg BID; 750 mg BID :: PO :: :: Start 250 mg BID; titrate to level 50-100 mcg/mL Hepatic disease; pregnancy (teratogenic); mitochondrial disease LFTs, ammonia, level, weight - ROUTINE ROUTINE - Carbamazepine PO Irritability; aggression; alternative mood stabilizer 100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; titrate by 200 mg/wk; target level 4-12 mcg/mL AV block; blood dyscrasias; concurrent MAOIs CBC, LFTs, level, HLA-B*1502 in Asians - ROUTINE ROUTINE - Buspirone PO Anxiety without sedation; adjunct for irritability 5 mg TID; 10 mg TID; 15 mg TID :: PO :: :: Start 5 mg TID; titrate by 5 mg q2-3d; max 60 mg/day Concurrent MAOIs None significant - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#3d-symptomatic-treatments-cognitive-and-other","title":"3D. Symptomatic Treatments - Cognitive and Other","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil PO Cognitive impairment; limited evidence in HD 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; may increase to 10 mg after 4-6 weeks GI bleeding; sick sinus syndrome Nausea, bradycardia, diarrhea - ROUTINE ROUTINE - Rivastigmine PO/Patch Cognitive impairment; alternative to donepezil 1.5 mg BID; 3 mg BID; 4.5 mg BID; 9.5 mg/24hr patch; 13.3 mg/24hr patch :: PO/Patch :: :: Start 1.5 mg BID or 4.6 mg patch; titrate monthly Severe hepatic impairment Nausea, weight loss - ROUTINE ROUTINE - Memantine PO Moderate-severe cognitive impairment; neuroprotective theory 5 mg daily; 10 mg BID :: PO :: :: Start 5 mg daily; titrate by 5 mg/wk; target 10 mg BID Severe renal impairment (dose adjust) Confusion, constipation - ROUTINE ROUTINE - Modafinil PO Apathy; excessive daytime sleepiness 100 mg AM; 200 mg AM :: PO :: :: Start 100 mg each morning; may increase to 200 mg; avoid afternoon dosing Arrhythmias; severe anxiety Insomnia, anxiety, BP - ROUTINE ROUTINE - Methylphenidate PO Apathy; bradyphrenia; fatigue 5 mg BID; 10 mg BID; 20 mg BID :: PO :: :: Start 5 mg at breakfast and lunch; titrate by 5-10 mg q1wk; max 60 mg/day Severe anxiety; psychosis; cardiac arrhythmia HR, BP, appetite, insomnia - ROUTINE ROUTINE - Trazodone PO Insomnia; irritability; mild sedation 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25-50 mg; max 200 mg for sleep Concurrent MAOIs; priapism history Orthostatic hypotension, priapism - ROUTINE ROUTINE - Melatonin PO Insomnia; circadian rhythm disturbance 3 mg qHS; 6 mg qHS; 9 mg qHS :: PO :: :: Start 3 mg 30 min before bed; may increase to 9 mg None Generally well-tolerated - ROUTINE ROUTINE - Botulinum toxin (onabotulinumtoxinA) IM Focal dystonia; bruxism; sialorrhea Variable per muscle :: IM :: :: Dose depends on target muscles; repeat q12 weeks Infection at site; myasthenia gravis Weakness, dysphagia - - ROUTINE - Glycopyrrolate PO Sialorrhea (drooling) 1 mg BID; 1 mg TID; 2 mg TID :: PO :: :: Start 1 mg BID; titrate to effect; max 2 mg TID Glaucoma; urinary retention; GI obstruction Dry mouth, constipation, urinary retention - ROUTINE ROUTINE - Polyethylene glycol (MiraLAX) PO Constipation (common with reduced mobility and anticholinergics) 17 g daily; 17 g BID :: PO :: :: 17 g in 8 oz liquid daily; may increase to BID Bowel obstruction Diarrhea if excessive - ROUTINE ROUTINE - High-calorie nutritional supplements PO Weight loss; increased metabolic demands 1-3 cans daily :: PO :: :: 1-3 cans (Ensure Plus, Boost Plus) daily between meals None Weight, nutritional markers - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Huntington Disease Society of America (HDSA) Center of Excellence for comprehensive multidisciplinary care - ROUTINE ROUTINE - Genetic counselor for pre-test counseling, results disclosure, and family testing discussion - ROUTINE ROUTINE - Psychiatry for depression, suicidality assessment, irritability, and psychosis management URGENT ROUTINE ROUTINE - Neuropsychology for baseline and serial cognitive assessment to guide care planning - - ROUTINE - Speech-language pathology for swallowing evaluation and communication strategies - ROUTINE ROUTINE - Physical therapy for gait training, fall prevention, and adaptive exercise program - ROUTINE ROUTINE - Occupational therapy for ADL adaptation, home safety evaluation, and energy conservation - ROUTINE ROUTINE - Dietitian/nutritionist for weight maintenance strategies and caloric supplementation - ROUTINE ROUTINE - Social work for caregiver support, disability planning, and community resources - ROUTINE ROUTINE - Palliative care for symptom management, advance care planning, and goals of care discussions - ROUTINE ROUTINE - Pulmonology for respiratory assessment in advanced disease and ventilation decisions - ROUTINE ROUTINE - Gastroenterology for PEG tube placement consideration in advanced dysphagia - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD CRITICAL: Report suicidal thoughts immediately as depression is common and treatable in HD STAT STAT ROUTINE Do not drive if experiencing significant chorea, cognitive impairment, or sedating medication effects URGENT ROUTINE ROUTINE Maintain high caloric intake (3000-4000 kcal/day may be needed) due to hypermetabolic state - ROUTINE ROUTINE Eat slowly, take small bites, and remain upright 30 minutes after meals to reduce aspiration risk - ROUTINE ROUTINE Complete advance directive and healthcare power of attorney while capacity is preserved - ROUTINE ROUTINE Inform all healthcare providers about HD as many common medications can worsen symptoms - ROUTINE ROUTINE First-degree relatives have 50% risk; genetic counseling available but genetic testing is a personal choice - ROUTINE ROUTINE Avoid alcohol which worsens balance, cognition, and interacts with medications - ROUTINE ROUTINE","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular aerobic exercise (walking, swimming, stationary bike) improves motor function and mood - ROUTINE ROUTINE Fall prevention: remove home hazards, adequate lighting, grab bars, non-slip surfaces - ROUTINE ROUTINE Maintain social engagement and meaningful activities to reduce depression and apathy - ROUTINE ROUTINE Cognitive engagement through puzzles, reading, and structured activities may help maintain function - ROUTINE ROUTINE Structure daily routine with consistent timing for medications, meals, and activities - ROUTINE ROUTINE Caregiver respite and support groups essential to prevent caregiver burnout - ROUTINE ROUTINE Smoking cessation to reduce aspiration pneumonia risk and cardiovascular disease - ROUTINE ROUTINE Limit caffeine if insomnia or anxiety are problematic - ROUTINE ROUTINE","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Huntington disease-like 1 (HDL1) Prion protein gene mutation; similar phenotype PRNP gene testing Huntington disease-like 2 (HDL2) African ancestry; JPH3 gene mutation JPH3 gene testing Spinocerebellar ataxia 17 (HDL4) Prominent ataxia; TBP gene expansion TBP gene testing Chorea-acanthocytosis Orolingual dystonia; self-mutilation; acanthocytes Peripheral smear; VPS13A gene testing McLeod syndrome X-linked; cardiomyopathy; elevated CK Kell antigen typing; XK gene testing Sydenham chorea Post-streptococcal; younger patients; self-limited ASO titer; anti-DNAse B Benign hereditary chorea Childhood onset; non-progressive; NKX2-1 mutation NKX2-1 gene testing; family history Wilson's disease Younger onset; Kayser-Fleischer rings; hepatic disease Ceruloplasmin; 24-hr urine copper; slit lamp Neuroacanthocytosis Peripheral neuropathy; seizures; elevated CK Peripheral smear; genetic testing Tardive dyskinesia Antipsychotic exposure; orobuccal predominant Medication history; AIMS scale Anti-NMDA receptor encephalitis Psychiatric symptoms; seizures; dyskinesias NMDA receptor antibodies; CSF analysis","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU UHDRS (Unified Huntington's Disease Rating Scale) Every 6-12 months Document trend; track motor progression Adjust medications; update care plan - - ROUTINE - Depression screening (PHQ-9) Every visit; monthly if on VMAT2 inhibitor PHQ-9 &lt;5 Intensify antidepressant; psychiatry referral if PHQ-9 &gt;15 URGENT ROUTINE ROUTINE - Suicidality assessment Every visit No active suicidal ideation Immediate psychiatric evaluation; safety planning STAT STAT ROUTINE - Cognitive assessment (MoCA or MMSE) Every 6-12 months Document trend Update care planning; capacity assessment - - ROUTINE - Weight Every visit Stable or increasing Increase caloric intake; dietitian referral - ROUTINE ROUTINE - Swallowing function Annually or if symptoms No aspiration Modify diet texture; speech therapy; PEG consideration - ROUTINE ROUTINE - ECG (if on VMAT2 inhibitor) Baseline and with dose changes QTc &lt;500 ms Hold medication if QTc &gt;500 ms; reduce dose - ROUTINE ROUTINE - Functional independence (TFC) Every 6-12 months Document functional stage Adjust level of care; advance care planning - - ROUTINE - Caregiver burden assessment Annually Sustainable caregiving Respite care; support resources - ROUTINE ROUTINE - Falls frequency Each visit Zero falls PT referral; home safety; medication review - ROUTINE ROUTINE -","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable psychiatric status; adequate oral intake; safe swallowing; caregiver available; outpatient follow-up arranged Admit to floor Severe psychiatric symptoms requiring stabilization; aspiration pneumonia; significant weight loss requiring evaluation; severe chorea causing exhaustion or injury Admit to ICU Aspiration with respiratory failure; severe rhabdomyolysis from chorea; neuroleptic malignant syndrome; suicidal attempt requiring medical stabilization Skilled nursing facility Advanced disease; 24-hour care needs; dysphagia requiring supervision; frequent falls; caregiver unable to provide required care Hospice referral End-stage disease (TFC stage 5); recurrent aspiration; patient/family goals favor comfort care","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Tetrabenazine reduces chorea in HD Class I, Level A Huntington Study Group. Neurology 2006 Deutetrabenazine reduces chorea with improved tolerability Class I, Level A Huntington Study Group. JAMA 2016 CAG repeat length inversely correlates with age of onset Class II, Level B Andrew et al. Nat Genet 1993 AAN practice parameter for HD treatment Guideline Armstrong &amp; Miyasaki. Neurology 2012 High suicide rate in HD requires screening Class II, Level B Paulsen et al. J Neuropsychiatry Clin Neurosci 2005 UHDRS reliable for tracking disease progression Class II, Level A Huntington Study Group. Mov Disord 1996 CYP2D6 genotype affects tetrabenazine metabolism Class II, Level B Xenazine FDA prescribing information 2008 Genetic counseling improves outcomes in at-risk individuals Class II, Level B Tibben. Handb Clin Neurol 2007 Dysphagia common and associated with aspiration risk Class II, Level C Heemskerk &amp; Roos. Dysphagia 2011 Multidisciplinary care improves outcomes Class III, Level C Veenhuizen &amp; Bherer. J Huntingtons Dis 2017 Exercise benefits motor and cognitive function Class II, Level B Quinn et al. Cochrane Database Syst Rev 2022 Valbenazine effective for hyperkinetic movements Class I, Level A Hauser et al. JAMA Neurol 2017","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of chorea management with VMAT2 inhibitors - Psychiatric symptom management with multiple drug classes - Genetic testing and counseling guidance - Dysphagia and nutritional support - End-of-life and palliative care considerations - Structured dosing format for order sentence generation</p>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#appendix-a-huntingtons-disease-staging","title":"APPENDIX A: Huntington's Disease Staging","text":"Stage TFC Score Functional Status Care Needs Stage 1 (Early) 11-13 Engaged in occupation; handles finances; performs all ADLs Independent; outpatient monitoring Stage 2 (Early-Intermediate) 7-10 Reduced work capacity; handles daily affairs with minimal assistance Minimal assistance; may need supervision for complex tasks Stage 3 (Intermediate) 3-6 Unable to work; requires help with finances; still manages basic ADLs Moderate assistance; partial supervision Stage 4 (Late-Intermediate) 1-2 Requires assistance with most ADLs; can live at home with care Substantial assistance; may need skilled care Stage 5 (Advanced) 0 Total dependence; requires full care Total care; nursing facility or hospice","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#appendix-b-genetic-counseling-considerations","title":"APPENDIX B: Genetic Counseling Considerations","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#pre-test-counseling-essentials","title":"Pre-Test Counseling Essentials","text":"<ol> <li>Implications of positive result: Progressive, fatal disease with no cure; 50% risk to offspring</li> <li>Implications of negative result: No increased risk, but survivor guilt possible</li> <li>Intermediate alleles (27-35 repeats): Not affected, but may expand in offspring</li> <li>Reduced penetrance (36-39 repeats): May or may not develop HD; difficult counseling</li> <li>Full penetrance (40+ repeats): Will develop HD if lives long enough</li> <li>Insurance and discrimination: GINA protects health insurance and employment; does NOT cover life, disability, or long-term care insurance</li> <li>Timeline: Results typically 2-4 weeks; follow-up support essential</li> </ol>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#testing-of-at-risk-individuals","title":"Testing of At-Risk Individuals","text":"<ul> <li>Minimum age 18 for predictive testing (legal adult)</li> <li>Do not test minors unless symptomatic</li> <li>Recommended: 2+ counseling sessions before testing</li> <li>Wait period between disclosure and decision</li> <li>Support system should be in place before results</li> </ul>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#prenatal-testing-options","title":"Prenatal Testing Options","text":"<ol> <li>Prenatal diagnosis: CVS at 10-12 weeks or amniocentesis at 15-20 weeks</li> <li>Preimplantation genetic testing (PGT): IVF with embryo selection</li> <li>Non-disclosure testing: Pregnancy terminated if affected without revealing parent's status</li> <li>Exclusion testing: Determines if fetus inherited grandparent's chromosome without revealing parent's status</li> </ol>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#appendix-c-end-of-life-planning","title":"APPENDIX C: End-of-Life Planning","text":"","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#advance-directive-considerations-specific-to-hd","title":"Advance Directive Considerations Specific to HD","text":"Issue Considerations Feeding tubes PEG may prolong survival but not necessarily quality of life; discuss before capacity lost Mechanical ventilation Usually not consistent with comfort goals in end-stage HD Antibiotic use Consider limiting to comfort measures in advanced disease Hospitalization May prefer comfort care at home or hospice facility Autopsy/brain donation Important for research; discuss while patient can consent","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/huntingtons-disease/#hospice-eligibility-criteria-general-guidance","title":"Hospice Eligibility Criteria (General Guidance)","text":"<ul> <li>TFC Stage 5 (Total Functional Capacity score 0)</li> <li>Unable to ambulate without substantial assistance</li> <li>Unable to communicate intelligibly</li> <li>Recurrent aspiration pneumonia</li> <li>PPS (Palliative Performance Scale) \u226450%</li> <li>Significant weight loss despite nutritional support</li> </ul>","tags":["movement-disorders","huntington","chorea","genetic","outpatient"]},{"location":"drafts/lewy-body-dementia/","title":"Lewy Body Dementia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#lewy-body-dementia","title":"Lewy Body Dementia","text":"<p>DIAGNOSIS: Dementia with Lewy Bodies (DLB) ICD-10: G31.83 (Dementia with Lewy bodies) SCOPE: Diagnosis based on McKeith criteria (2017), biomarker-supported diagnosis (DaTscan, MIBG), symptomatic management of cognitive, motor, behavioral, and autonomic symptoms. Emphasizes neuroleptic sensitivity and safe treatment approaches. Covers both pure DLB and Parkinson's disease dementia (PDD) overlap.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection screen; anemia contributing to cognitive changes Normal STAT STAT ROUTINE - BMP Hyponatremia, uremia, hypercalcemia as causes of confusion Normal electrolytes, BUN, Cr STAT STAT ROUTINE - TSH Hypothyroidism is reversible cause of cognitive impairment 0.4-4.0 mIU/L URGENT ROUTINE ROUTINE - Vitamin B12 Deficiency can cause cognitive impairment and parkinsonism &gt;300 pg/mL (&gt;400 optimal) URGENT ROUTINE ROUTINE - Folate Deficiency contributes to cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - Glucose (fasting) Diabetes affects cognition and autonomic function 70-100 mg/dL STAT ROUTINE ROUTINE - Hepatic panel (LFTs) Baseline before medications; hepatic encephalopathy Normal - ROUTINE ROUTINE - Urinalysis UTI common cause of acute confusion in elderly Negative for infection STAT STAT ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Vitamin D, 25-hydroxy Deficiency associated with falls and cognitive decline &gt;30 ng/mL - ROUTINE ROUTINE - Hemoglobin A1c Chronic glucose control affects cognition &lt;7% - ROUTINE ROUTINE - Lipid panel Vascular risk factors LDL &lt;100 mg/dL - ROUTINE ROUTINE - RPR or VDRL Neurosyphilis (rare but treatable) Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder Negative - ROUTINE ROUTINE - ESR, CRP Inflammatory/autoimmune causes Normal - ROUTINE ROUTINE - Cortisol (AM) Adrenal insufficiency causing orthostatic hypotension 10-20 \u03bcg/dL - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU CSF alpha-synuclein seed amplification assay (SAA) Confirms synucleinopathy; research/atypical cases Positive aggregation - - EXT - Skin biopsy for phosphorylated alpha-synuclein Peripheral synuclein deposition confirms synucleinopathy Positive deposits in cutaneous nerves - - EXT - Genetic testing (GBA, SNCA) Family history or early-onset; GBA mutations increase DLB risk Identifies genetic risk - - EXT - Paraneoplastic antibody panel Autoimmune dementia; rapid progression Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2) Autoimmune encephalitis if rapid onset Negative - EXT EXT -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Relative preservation of medial temporal lobes (vs AD); rule out structural causes MRI-incompatible devices URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable Rule out mass, hemorrhage, hydrocephalus None STAT STAT ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU DaTscan (ioflupane I-123 SPECT) Diagnostic uncertainty; differentiating DLB from AD Reduced dopamine transporter uptake in putamen (indicative biomarker) Hypersensitivity to iodine - EXT ROUTINE - Cardiac MIBG scintigraphy Differentiate DLB from AD; supports diagnosis Reduced cardiac uptake (indicative biomarker) Recent MI; drugs affecting uptake (labetalol, reserpine) - - ROUTINE - FDG-PET Brain Differentiate from AD; atypical presentations Posterior occipital hypometabolism with cingulate island sign (supportive biomarker) None - - ROUTINE - Polysomnography REM sleep behavior disorder confirmation REM sleep without atonia (indicative biomarker) None - - ROUTINE - EEG Encephalopathy; fluctuating cognition Posterior slow-wave activity with periodic fluctuations (supportive) None URGENT ROUTINE ROUTINE - Autonomic function testing Dysautonomia assessment Orthostatic hypotension, abnormal HR variability None - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Amyloid PET Atypical cases; AD co-pathology assessment May be positive (AD-DLB overlap common) None - - EXT - Tau PET Research; differentiate from AD tauopathy Less tau deposition than AD for similar dementia severity None - - EXT - SPECT perfusion Alternative to FDG-PET Posterior hypoperfusion pattern None - - EXT - MRI with SWI Microbleeds; cerebral amyloid angiopathy Lobar microbleed pattern MRI contraindications - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU AVOID TYPICAL ANTIPSYCHOTICS - CRITICAL SAFETY WARNING DO NOT USE :: - :: :: Haloperidol, chlorpromazine, fluphenazine absolutely contraindicated; risk of severe parkinsonism, NMS, and death DLB is absolute contraindication N/A STAT STAT ROUTINE STAT AVOID MOST ATYPICAL ANTIPSYCHOTICS - CRITICAL SAFETY WARNING DO NOT USE :: - :: :: Risperidone, olanzapine, aripiprazole, ziprasidone contraindicated; 2-3x mortality risk DLB is relative contraindication N/A STAT STAT ROUTINE STAT Quetiapine (if antipsychotic absolutely needed) PO Severe psychosis/agitation when non-pharmacologic fails 12.5 mg qHS; 25 mg qHS :: PO :: :: Start 12.5 mg qHS; increase slowly by 12.5 mg q3-7d; max 50-100 mg; lowest effective dose for shortest time QT prolongation Monitor for worsening parkinsonism, sedation URGENT URGENT ROUTINE - Treat delirium triggers Various Infection, metabolic, medication-induced delirium Per cause :: Various :: :: Treat UTI, correct electrolytes, remove offending drugs (especially anticholinergics) Depends on intervention Mental status STAT STAT ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Rivastigmine oral PO Cognitive impairment and visual hallucinations (FDA approved for PDD) 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID :: PO :: :: Start 1.5 mg BID with meals; increase by 1.5 mg BID q2-4wk; target 6 mg BID; may improve hallucinations Sick sinus syndrome; GI bleeding; severe hepatic impairment Nausea, weight loss, tremor worsening, bradycardia - ROUTINE ROUTINE - Rivastigmine patch TD Cognitive impairment; better GI tolerability 4.6 mg/24hr; 9.5 mg/24hr; 13.3 mg/24hr :: TD :: :: Start 4.6 mg/24hr patch; increase q4wk; target 9.5-13.3 mg/24hr Same as oral Skin irritation, nausea - ROUTINE ROUTINE - Donepezil PO Cognitive impairment; alternative to rivastigmine 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS x 4-6 weeks; may increase to 10 mg qHS Sick sinus syndrome; GI bleeding; COPD exacerbation Bradycardia, vivid dreams (may worsen RBD), GI - ROUTINE ROUTINE - Galantamine PO Cognitive impairment; alternative cholinesterase inhibitor 4 mg BID; 8 mg BID; 12 mg BID :: PO :: :: Start 4 mg BID x 4wk; increase to 8 mg BID; target 8-12 mg BID Same as donepezil; severe renal/hepatic GI symptoms, bradycardia - ROUTINE ROUTINE - Memantine PO Moderate-severe dementia; add to cholinesterase inhibitor 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily; increase by 5 mg/wk; target 10 mg BID Severe renal impairment (dose adjust CrCl &lt;30) Confusion, dizziness, constipation - ROUTINE ROUTINE - Carbidopa-Levodopa PO Motor parkinsonism symptoms 25/100 TID :: PO :: :: Start 25/100 mg TID; titrate slowly; use lowest effective dose; may worsen hallucinations Active psychosis Dyskinesias, confusion, hallucination worsening - ROUTINE ROUTINE - Melatonin PO REM sleep behavior disorder (first-line) 3 mg qHS; 6 mg qHS; 9 mg qHS; 12 mg qHS :: PO :: :: Start 3-6 mg 30 min before bed; may increase to 12 mg; first-line for RBD None Generally well-tolerated - ROUTINE ROUTINE - Clonazepam PO REM sleep behavior disorder (second-line) 0.25 mg qHS; 0.5 mg qHS; 1 mg qHS :: PO :: :: Start 0.25-0.5 mg qHS; typical 0.5-1 mg; use with caution due to sedation and fall risk Severe sleep apnea; respiratory compromise; dementia (relative) Sedation, falls, cognitive worsening - ROUTINE ROUTINE - Pimavanserin (Nuplazid) PO Visual hallucinations and psychosis 34 mg daily :: PO :: :: 34 mg once daily; takes 4-6 weeks for effect; no titration; selective 5-HT2A inverse agonist Severe hepatic impairment; QT prolongation QTc at baseline; efficacy assessment 6 weeks - ROUTINE ROUTINE - Trazodone PO Insomnia; sundowning 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25 mg; typical 50-100 mg qHS MAOIs; QT prolongation Orthostatic hypotension - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#3c-autonomic-dysfunction-treatments","title":"3C. Autonomic Dysfunction Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Midodrine PO Orthostatic hypotension 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5 mg TID (before arising, lunch, mid-afternoon); titrate by 2.5 mg/dose; max 10 mg TID; last dose by 6 PM Supine hypertension; urinary retention; severe cardiac disease Supine BP; avoid lying flat 4 hours after dose - ROUTINE ROUTINE - Droxidopa (Northera) PO Neurogenic orthostatic hypotension 100 mg TID; 200 mg TID; 300 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg/dose q24-48h; max 600 mg TID Supine hypertension Supine BP, headache - ROUTINE ROUTINE - Fludrocortisone PO Orthostatic hypotension adjunct 0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2 mg daily CHF; severe hypertension K+, edema, supine BP, weight - ROUTINE ROUTINE - Polyethylene glycol (MiraLAX) PO Constipation 17 g daily; 17 g BID :: PO :: :: 17 g (1 capful) in 8 oz liquid daily; may increase to BID Bowel obstruction Diarrhea if excessive - ROUTINE ROUTINE - Senna + docusate PO Constipation stimulant 2 tablets qHS :: PO :: :: 2 tablets qHS; may increase to 4 tablets Bowel obstruction; undiagnosed abdominal pain Electrolytes with chronic use - ROUTINE ROUTINE - Tamsulosin PO Urinary retention 0.4 mg daily :: PO :: :: 0.4 mg once daily 30 min after meal Known hypersensitivity; concurrent silodosin Orthostatic hypotension (caution with existing OH) - ROUTINE ROUTINE - Oxybutynin PO Urinary urgency (use with extreme caution) 2.5 mg BID :: PO :: :: 2.5 mg BID only; avoid higher doses; anticholinergic burden worsens cognition Narrow-angle glaucoma; urinary retention; dementia (relative) Cognitive worsening; dry mouth - EXT EXT -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#3d-depression-and-anxiety-treatments","title":"3D. Depression and Anxiety Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Sertraline PO Depression; anxiety 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg MAOIs GI upset; may worsen OH - ROUTINE ROUTINE - Escitalopram PO Depression; anxiety 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg; max 10 mg in elderly (QT) MAOIs; QT prolongation QTc; GI upset - ROUTINE ROUTINE - Venlafaxine XR PO Depression; anxiety 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; titrate q1-2wk; typical 75-150 mg Same as SSRIs BP at higher doses - ROUTINE ROUTINE - Mirtazapine PO Depression with poor appetite and insomnia 7.5 mg qHS; 15 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30 mg MAOIs Weight gain, sedation - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Cognitive/behavioral neurology for diagnosis confirmation using McKeith criteria and treatment planning - ROUTINE ROUTINE - Movement disorders specialist if motor symptoms prominent or considering dopaminergic therapy - ROUTINE ROUTINE - Neuropsychology for comprehensive cognitive testing to establish baseline and differentiate from AD - - ROUTINE - Geriatric psychiatry for behavioral symptoms, medication management, and capacity evaluation - ROUTINE ROUTINE - Sleep medicine for polysomnography to confirm REM sleep behavior disorder (indicative biomarker) - - ROUTINE - Occupational therapy for ADL assessment, cognitive strategies, and home safety evaluation - ROUTINE ROUTINE - Physical therapy for gait training, balance exercises, and fall prevention - ROUTINE ROUTINE - Speech therapy for communication strategies and swallowing evaluation if dysphagia present - ROUTINE ROUTINE - Social work for caregiver support, community resources, and long-term care planning - ROUTINE ROUTINE - Palliative care for advanced dementia symptom management and goals of care discussions - ROUTINE ROUTINE - Cardiology if orthostatic hypotension refractory to first-line treatment - - ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD CRITICAL: Avoid all typical antipsychotics and most atypical antipsychotics - severe sensitivity can cause parkinsonism, rigidity, and death STAT STAT ROUTINE Carry a medication alert card listing \"Lewy Body Dementia - Neuroleptic Sensitivity\" for all healthcare encounters - ROUTINE ROUTINE Report visual hallucinations immediately as these may indicate disease progression or medication effect - ROUTINE ROUTINE Rise slowly from sitting or lying to prevent falls from orthostatic hypotension URGENT ROUTINE ROUTINE Implement safety measures for REM sleep behavior disorder: padded bed rails, mattress on floor, remove sharp objects from bedside - ROUTINE ROUTINE Complete advance directives while patient has capacity to document wishes for future care - ROUTINE ROUTINE Do not drive due to fluctuating attention, visual-spatial deficits, and hallucinations - ROUTINE ROUTINE Return immediately if sudden worsening of confusion, falls, or inability to walk (may indicate medication effect or infection) STAT STAT ROUTINE","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Fall prevention: remove home hazards, adequate lighting, grab bars, non-slip surfaces due to high fall risk - ROUTINE ROUTINE AVOID medications that worsen symptoms: anticholinergics, antihistamines (diphenhydramine), sleep aids (Benadryl, Tylenol PM) URGENT ROUTINE ROUTINE AVOID antiemetics: metoclopramide, prochlorperazine, promethazine (D2 blocking worsens parkinsonism) URGENT ROUTINE ROUTINE Regular physical exercise as tolerated to maintain mobility and reduce fall risk - ROUTINE ROUTINE Structured daily routine with consistent sleep-wake times helps with fluctuating cognition - ROUTINE ROUTINE Adequate lighting and avoid overstimulation which may trigger hallucinations - ROUTINE ROUTINE Simplify environment and reduce visual clutter to minimize misperceptions - ROUTINE ROUTINE Caregiver education about fluctuating cognition, which is characteristic and not willful - ROUTINE ROUTINE Treat sleep apnea if present as it worsens cognition and autonomic dysfunction - ROUTINE ROUTINE","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Alzheimer's disease Memory impairment predominates; no parkinsonism; no visual hallucinations early DaTscan normal in AD; MRI hippocampal atrophy; amyloid/tau biomarkers Parkinson's disease dementia (PDD) Motor symptoms precede dementia by &gt;1 year (vs DLB dementia within 1 year of motor) Clinical timeline; considered same disease spectrum as DLB Vascular dementia Stepwise decline; focal findings; executive dysfunction; vascular risk factors MRI with significant white matter disease, strategic infarcts Frontotemporal dementia Personality change; disinhibition; apathy; hyperorality; younger onset FDG-PET frontal hypometabolism; preserved posterior metabolism Progressive supranuclear palsy (PSP) Vertical gaze palsy; axial rigidity &gt; limb; early falls backward; poor levodopa response MRI \"hummingbird sign\"; clinical criteria Corticobasal syndrome Asymmetric rigidity; apraxia; alien limb; cortical sensory loss MRI asymmetric cortical atrophy; clinical criteria Multiple system atrophy (MSA) Severe early dysautonomia; cerebellar signs; stridor; poor levodopa response MRI \"hot cross bun\" sign; cardiac MIBG preserved (vs reduced in DLB) Creutzfeldt-Jakob disease Rapid progression (weeks-months); myoclonus; periodic sharp waves on EEG EEG PSWCs; MRI DWI cortical ribboning; CSF RT-QuIC positive Drug-induced parkinsonism Medication exposure (antipsychotics, metoclopramide); symmetric; no hallucinations DaTscan normal; medication history; resolves with drug removal Delirium Acute onset; fluctuating attention; identifiable cause Treat cause; reassess cognition when clear Charles Bonnet syndrome Visual hallucinations with insight; occurs with visual impairment; no dementia Ophthalmologic evaluation; cognitive testing normal","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Cognitive function (MoCA or MMSE) Every 6 months Establish baseline; track trajectory Adjust treatment; reassess diagnosis - ROUTINE ROUTINE - Motor function (UPDRS-III) Every 6 months Document parkinsonism severity Adjust levodopa if motor symptoms dominant - ROUTINE ROUTINE - Visual hallucinations frequency/severity Each visit Document presence and distress level Adjust cholinesterase inhibitor; add pimavanserin if distressing - ROUTINE ROUTINE - Orthostatic blood pressure Each visit &lt;20 mmHg systolic drop on standing Add midodrine or droxidopa - ROUTINE ROUTINE - Falls frequency Each visit Zero falls PT referral; medication review; home safety - ROUTINE ROUTINE - RBD symptoms Each visit Bed partner safety; injury prevention Adjust melatonin or clonazepam; safety measures - ROUTINE ROUTINE - Mood (GDS, PHQ-9) Every 6 months Screen negative Add antidepressant; psychiatry referral - ROUTINE ROUTINE - ADL/IADL function Every 6 months Document functional decline trajectory Increase support services; OT referral - ROUTINE ROUTINE - Caregiver burden (Zarit scale) Every 6-12 months Early identification of burnout Support resources; respite care; social work - - ROUTINE - Weight Each visit Stable weight Nutritional assessment; speech for swallowing - ROUTINE ROUTINE - ECG (if on pimavanserin, citalopram) Baseline; if dose increased QTc &lt;500 ms Reduce dose or switch agent - ROUTINE ROUTINE -","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Reversible causes treated; safe environment; caregiver support; no acute behavioral crisis; follow-up arranged Admit to floor Acute delirium requiring workup; severe behavioral crisis unsafe for home; falls with injury; medication toxicity Admit to psychiatry Severe behavioral disturbance requiring specialized psychiatric management; suicidal ideation Outpatient follow-up Neurology/geriatrics 1-2 months after diagnosis; then every 3-6 months Long-term care Progressive decline; caregiver unable to manage safely; nocturnal behavioral disturbance; 24-hour supervision needed","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source McKeith diagnostic criteria for DLB Consensus Guidelines McKeith et al. Neurology 2017 DaTscan indicative biomarker for DLB Class II, Level B McKeith et al. Lancet Neurol 2007 Cardiac MIBG indicative biomarker Class II, Level B Yoshita et al. Neurology 2015 Rivastigmine for PDD/DLB cognition Class I, Level A Emre et al. NEJM 2004 Donepezil for DLB Class I, Level A Mori et al. Ann Neurol 2012 Cholinesterase inhibitors reduce visual hallucinations Class II, Level B Stinton et al. Int J Geriatr Psychiatry 2015 Neuroleptic sensitivity in DLB Class II, Level B McKeith et al. BMJ 1992 Antipsychotic mortality risk in dementia Class I, Level A Schneider et al. JAMA 2005 Pimavanserin for PD psychosis Class I, Level A Cummings et al. Lancet 2014 Melatonin for REM sleep behavior disorder Class II, Level B Kunz et al. Sleep Med 2010 Clonazepam for REM sleep behavior disorder Class II, Level B Aurora et al. Sleep 2010 CSF alpha-synuclein SAA for synucleinopathies Class II, Level B Siderowf et al. Lancet Neurol 2023","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - McKeith 2017 diagnostic criteria integrated - Indicative and supportive biomarkers included - Emphasis on neuroleptic sensitivity throughout - Structured dosing format for order sentence generation</p>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#appendix-a-mckeith-criteria-for-dlb-2017","title":"APPENDIX A: McKeith Criteria for DLB (2017)","text":"","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#essential-feature-required","title":"Essential Feature (Required)","text":"<ul> <li>Dementia defined as progressive cognitive decline sufficient to interfere with normal social or occupational function</li> </ul>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#core-clinical-features","title":"Core Clinical Features","text":"<ol> <li>Fluctuating cognition with pronounced variations in attention and alertness</li> <li>Recurrent visual hallucinations that are typically well-formed and detailed</li> <li>REM sleep behavior disorder (may precede cognitive decline)</li> <li>One or more spontaneous cardinal features of parkinsonism: bradykinesia, rest tremor, rigidity</li> </ol>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#indicative-biomarkers","title":"Indicative Biomarkers","text":"<ol> <li>Reduced dopamine transporter uptake in basal ganglia (DaTscan)</li> <li>Low uptake on cardiac MIBG scintigraphy</li> <li>Polysomnographic confirmation of REM sleep without atonia</li> </ol>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#supportive-biomarkers","title":"Supportive Biomarkers","text":"<ol> <li>Relative preservation of medial temporal lobe structures on CT/MRI</li> <li>Generalized low uptake on SPECT/PET perfusion/metabolism scan with reduced occipital activity \u00b1 cingulate island sign on FDG-PET</li> <li>Prominent posterior slow-wave activity on EEG with periodic fluctuations</li> </ol>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#supportive-clinical-features","title":"Supportive Clinical Features","text":"<ul> <li>Severe sensitivity to antipsychotic agents</li> <li>Postural instability and repeated falls</li> <li>Syncope or other transient episodes of unresponsiveness</li> <li>Severe autonomic dysfunction (constipation, orthostatic hypotension, urinary incontinence)</li> <li>Hypersomnia</li> <li>Hyposmia</li> <li>Hallucinations in other modalities</li> <li>Systematized delusions</li> <li>Apathy, anxiety, and depression</li> </ul>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#diagnostic-categories","title":"Diagnostic Categories","text":"<p>Probable DLB: - 2+ core clinical features with or without indicative biomarkers, OR - 1 core clinical feature + 1+ indicative biomarkers</p> <p>Possible DLB: - 1 core clinical feature with no indicative biomarker, OR - 1+ indicative biomarker but no core clinical features</p>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#dlb-vs-pdd","title":"DLB vs PDD","text":"<ul> <li>If dementia occurs before or within 1 year of parkinsonism onset \u2192 DLB</li> <li>If dementia occurs &gt;1 year after established parkinsonism \u2192 PDD</li> <li>Both are considered part of the Lewy body disease spectrum</li> </ul>","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#appendix-b-medications-to-avoid-in-lewy-body-dementia","title":"APPENDIX B: Medications to AVOID in Lewy Body Dementia","text":"Drug Class Examples Why to Avoid Typical antipsychotics Haloperidol, chlorpromazine, fluphenazine ABSOLUTE CONTRAINDICATION - severe parkinsonism, NMS, death Most atypical antipsychotics Risperidone, olanzapine, aripiprazole, ziprasidone High D2 blockade; 2-3x mortality risk; severe parkinsonism Antiemetics (D2 blockers) Metoclopramide, prochlorperazine, promethazine Cross BBB; worsen parkinsonism; neuroleptic sensitivity Anticholinergics Benztropine, trihexyphenidyl, diphenhydramine, oxybutynin Worsen cognitive impairment; increase confusion Sedating antihistamines Diphenhydramine, hydroxyzine, doxylamine Anticholinergic effects; worsen cognition Sleep aids with anticholinergics Tylenol PM, ZzzQuil Contains diphenhydramine; contraindicated","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/lewy-body-dementia/#safe-alternatives","title":"Safe Alternatives","text":"Indication Safe Options Psychosis/agitation Quetiapine (lowest effective dose), pimavanserin Nausea Ondansetron, domperidone (not US), ginger Insomnia Melatonin, trazodone (low dose) Allergies Loratadine, cetirizine (less sedating)","tags":["cognitive","dementia","movement-disorders","lewy-body","outpatient"]},{"location":"drafts/medication-overuse-headache/","title":"Medication Overuse Headache","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#medication-overuse-headache","title":"Medication Overuse Headache","text":"<p>DIAGNOSIS: Medication Overuse Headache (MOH) ICD-10: G44.41 (Drug-induced headache, not elsewhere classified) SCOPE: Diagnosis, withdrawal management, bridge therapy, and preventive therapy for medication overuse headache. Covers simple analgesic, triptan, combination analgesic, opioid, and barbiturate overuse. Excludes acute migraine management (see Migraine plan) and primary headache disorder initial workup.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Rule out anemia contributing to headache; baseline before treatment Normal STAT ROUTINE ROUTINE - BMP Electrolyte abnormalities; renal function for medication selection Normal STAT ROUTINE ROUTINE - LFTs (AST, ALT, Alk Phos) Required if acetaminophen or butalbital overuse suspected; baseline for preventives Normal URGENT ROUTINE ROUTINE - TSH Thyroid dysfunction can worsen headache frequency Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Rule out giant cell arteritis if age &gt;50 with new or changed headache Normal URGENT ROUTINE ROUTINE - Vitamin D level Deficiency associated with increased headache frequency &gt;30 ng/mL - ROUTINE ROUTINE - Magnesium (RBC preferred) Deficiency linked to migraine; common in frequent headache &gt;4.2 mg/dL - ROUTINE ROUTINE - Urine drug screen If opioid overuse suspected; document substances for treatment planning Identifies substances URGENT ROUTINE ROUTINE - Acetaminophen level If acute APAP toxicity suspected (&gt;4g/day use or intentional overdose) &lt;10 mcg/mL STAT STAT - -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Ammonia level If on valproate and altered mental status Normal (&lt;35 umol/L) STAT URGENT - - INR, PT If concern for coagulopathy from chronic NSAID use Normal - ROUTINE EXT - Ferritin Iron deficiency associated with increased headache &gt;50 ng/mL - ROUTINE ROUTINE - HbA1c Diabetes screening in patients with chronic pain &lt;5.7% (normal) - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast New headache pattern, atypical features, or first MOH evaluation Normal; rule out secondary causes MRI-incompatible devices URGENT ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Focal neurological deficits, papilledema, or suspected mass No enhancing lesions Gadolinium allergy; severe renal impairment URGENT ROUTINE ROUTINE - MRA Head Thunderclap headache component or suspected vascular etiology Patent vessels; no aneurysm MRI contraindications URGENT ROUTINE EXT - MRV Brain Suspected cerebral venous thrombosis (papilledema, positional) Patent venous sinuses MRI contraindications URGENT ROUTINE EXT -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT Head non-contrast Acute severe headache if MRI unavailable; rule out hemorrhage No hemorrhage Pregnancy (relative) STAT STAT - - Cervical spine MRI Cervicogenic component suspected No cord compression or radiculopathy MRI contraindications - ROUTINE EXT -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#3-treatment","title":"3. TREATMENT","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#3a-acuteemergent-bridge-therapy-during-withdrawal","title":"3A. Acute/Emergent (Bridge Therapy During Withdrawal)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Prednisone PO Bridge therapy during withdrawal; reduces rebound severity 60 mg daily x 5 days; 60 mg daily x 3d then taper :: PO :: :: 60 mg daily x 5 days OR 60 mg x 3d, 40 mg x 3d, 20 mg x 3d Active infection; uncontrolled diabetes; GI ulcer; psychosis Glucose if diabetic; mood changes; insomnia URGENT URGENT ROUTINE - Methylprednisolone IV Severe rebound headache requiring IV therapy 500 mg IV daily x 3-5 days :: IV :: :: 500 mg IV daily for 3-5 days; infuse over 1 hour Active infection; uncontrolled diabetes Glucose; BP; mood changes - URGENT - - Naproxen PO Bridge therapy; standing dose to prevent rebound 500 mg BID x 2-4 weeks :: PO :: :: 500 mg PO BID for 2-4 weeks during withdrawal; not PRN use Renal impairment; GI bleed; aspirin allergy; third trimester GI symptoms; renal function if prolonged URGENT ROUTINE ROUTINE - Dihydroergotamine (DHE) IV Inpatient DHE protocol for severe MOH; status migrainosus 0.5 mg IV q8h; 1 mg IV q8h :: IV :: :: 0.5-1 mg IV q8h for 3-5 days; pretreat with antiemetic; requires cardiac monitoring Pregnancy; CAD; uncontrolled HTN; peripheral vascular disease; severe hepatic/renal impairment; basilar/hemiplegic migraine BP; nausea; continuous cardiac monitoring; leg cramping - URGENT - - Greater occipital nerve block SC Bridge therapy; occipital-predominant pain; opioid overuse 2-3 mL 2% lidocaine + 40 mg triamcinolone :: SC :: :: Inject at greater occipital nerve bilaterally; may repeat q4-6 weeks Local anesthetic allergy; infection at site Immediate pain relief; vasovagal reaction - ROUTINE ROUTINE - Ketorolac IV/IM Acute severe headache during withdrawal 30 mg IV; 15 mg IV :: IV :: :: 30 mg IV x1 (15 mg if age &gt;65, renal impairment, or &lt;50 kg); max 5 days Renal impairment; GI bleed; aspirin allergy; third trimester Renal function STAT STAT - - Metoclopramide IV Nausea during withdrawal; anti-migraine properties 10 mg IV; 20 mg IV :: IV :: :: 10-20 mg IV over 15 min; pretreat with diphenhydramine 25 mg to prevent akathisia Parkinson's disease; tardive dyskinesia; bowel obstruction Akathisia; dystonia STAT STAT - - Prochlorperazine IV Nausea and headache during severe withdrawal 10 mg IV :: IV :: :: 10 mg IV over 2 min; pretreat with diphenhydramine 25 mg QT prolongation; Parkinson's; neuroleptic hypersensitivity Akathisia; dystonia; QTc STAT STAT - - Ondansetron IV/PO Nausea associated with withdrawal or bridge therapy 4 mg IV; 8 mg PO; 4 mg ODT :: IV/PO :: :: 4 mg IV or 8 mg PO/ODT; may repeat q8h QT prolongation; severe hepatic impairment QTc if multiple doses STAT STAT ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#3b-symptomatic-treatments-withdrawal-support","title":"3B. Symptomatic Treatments (Withdrawal Support)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Clonidine PO Opioid withdrawal symptoms (anxiety, sweating, tachycardia) 0.1 mg BID; 0.1 mg TID; 0.2 mg TID :: PO :: :: Start 0.1 mg BID-TID; titrate to effect; max 0.6 mg/day; taper over 1-2 weeks Hypotension; bradycardia; heart block BP, HR; rebound HTN if stopped abruptly URGENT ROUTINE ROUTINE - Hydroxyzine PO Anxiety and insomnia during withdrawal 25 mg TID; 50 mg qHS; 25 mg q6h PRN :: PO :: :: 25 mg TID or 50 mg qHS; may use 25 mg q6h PRN for anxiety Glaucoma; urinary retention; QT prolongation Sedation; QTc URGENT ROUTINE ROUTINE - Trazodone PO Insomnia during withdrawal period 50 mg qHS; 100 mg qHS; 150 mg qHS :: PO :: :: Start 50 mg qHS; may increase to 100-150 mg qHS MAOIs; QT prolongation Sedation; orthostatic hypotension; priapism (rare) - ROUTINE ROUTINE - Loperamide PO Diarrhea during opioid withdrawal 4 mg initial, then 2 mg PRN :: PO :: :: 4 mg initial, then 2 mg after each loose stool; max 16 mg/day Toxic megacolon; C. diff colitis Avoid excessive use URGENT ROUTINE ROUTINE - Dicyclomine PO Abdominal cramping during opioid withdrawal 20 mg QID; 10 mg QID :: PO :: :: 10-20 mg QID PRN cramping; max 80 mg/day Glaucoma; GI obstruction; myasthenia gravis Anticholinergic effects - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#3c-second-linerefractory-opioidbarbiturate-taper-protocols","title":"3C. Second-line/Refractory (Opioid/Barbiturate Taper Protocols)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Butalbital taper PO Barbiturate-containing medication overuse; requires slow taper Reduce by 1 tablet every 3-5 days :: PO :: :: Reduce by 1 dose (1 tablet) every 3-5 days; typical taper 2-4 weeks; abrupt stop risks seizure None (taper required) Seizure risk; anxiety; tremor; abrupt withdrawal can be fatal - ROUTINE ROUTINE - Phenobarbital taper PO Severe barbiturate dependence; substitution taper 30 mg q6h; 15 mg q6h; taper by 15-30 mg q3-5d :: PO :: :: Convert butalbital to phenobarbital (30 mg phenobarbital per butalbital dose); taper by 15-30 mg every 3-5 days Porphyria; severe hepatic impairment Sedation; ataxia; respiratory depression - URGENT EXT - Buprenorphine/naloxone SL Opioid overuse with dependence; OUD treatment 2 mg/0.5 mg SL; 4 mg/1 mg SL; 8 mg/2 mg SL :: SL :: :: Start 2-4 mg SL when in mild withdrawal (COWS &gt;8); titrate to 8-16 mg daily; requires X-waiver or OTP Severe hepatic impairment; respiratory depression COWS score; precipitated withdrawal; sedation - URGENT EXT - Opioid taper (long-acting) PO Opioid overuse without OUD; slow outpatient taper Reduce 10-20% every 1-4 weeks :: PO :: :: Convert to long-acting opioid; reduce by 10-20% every 1-4 weeks; slower if prolonged use None (taper required) Withdrawal symptoms; pain control; functional status - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#3d-disease-modifying-or-chronic-therapies-preventive-medications","title":"3D. Disease-Modifying or Chronic Therapies (Preventive Medications)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Topiramate PO First-line prevention; especially if overweight 25 mg qHS; 50 mg BID; 75 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/wk; target 50-100 mg BID None Glaucoma; kidney stones; pregnancy (teratogen) Cognitive effects; paresthesias; weight; bicarbonate; kidney stones - ROUTINE ROUTINE - Amitriptyline PO First-line prevention; comorbid insomnia, depression, TTH component 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS ECG if age &gt;50 or cardiac history Cardiac conduction abnormality; recent MI; glaucoma; urinary retention Sedation; weight gain; dry mouth; ECG if dose &gt;100 mg - ROUTINE ROUTINE - Nortriptyline PO Prevention; less sedating than amitriptyline 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS ECG if age &gt;50 or cardiac history Cardiac conduction abnormality; recent MI; urinary retention; glaucoma Less sedation than amitriptyline; ECG if dose &gt;100 mg - ROUTINE ROUTINE - Venlafaxine XR PO Prevention; comorbid depression, anxiety 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 75-150 mg daily None Uncontrolled HTN; MAOIs; abrupt discontinuation BP at higher doses; serotonin syndrome signs - ROUTINE ROUTINE - Propranolol PO Prevention; comorbid HTN or anxiety 40 mg BID; 80 mg BID; 80 mg daily LA; 160 mg daily LA :: PO :: :: Start 40 mg BID or 80 mg LA daily; titrate q2wk; target 80-240 mg/day None Asthma; COPD; bradycardia &lt;50; heart block; decompensated HF HR, BP; fatigue; depression - ROUTINE ROUTINE - Onabotulinumtoxin A (Botox) IM Chronic migraine with MOH; failed 2+ oral preventives 155-195 units IM :: IM :: :: 155-195 units across 31-39 injection sites q12wk; PREEMPT protocol None Infection at injection sites; myasthenia gravis Neck weakness; ptosis (rare); effect takes 2-3 cycles - - ROUTINE - Erenumab (Aimovig) SC CGRP mAb; especially for MOH; no washout period needed 70 mg SC monthly; 140 mg SC monthly :: SC :: :: 70 mg SC monthly; may increase to 140 mg monthly after 3 months None Hypersensitivity to erenumab Constipation (can be severe); injection site reactions; HTN - - ROUTINE - Fremanezumab (Ajovy) SC CGRP mAb; alternative dosing options 225 mg SC monthly; 675 mg SC quarterly :: SC :: :: 225 mg SC monthly OR 675 mg SC quarterly None Hypersensitivity Injection site reactions - - ROUTINE - Galcanezumab (Emgality) SC CGRP mAb; proven efficacy in MOH 240 mg SC load; 120 mg SC monthly :: SC :: :: 240 mg SC loading dose (2 x 120 mg), then 120 mg SC monthly None Hypersensitivity Injection site reactions - - ROUTINE - Valproate/Divalproex PO Prevention; comorbid bipolar or epilepsy 250 mg BID; 500 mg BID; 500 mg ER daily; 1000 mg ER daily :: PO :: :: Start 250 mg BID or 500 mg ER daily; titrate to 500-1000 mg/day LFTs, CBC Hepatic disease; pregnancy (teratogen); urea cycle disorders; pancreatitis LFTs q6mo; weight; hair loss; tremor - ROUTINE ROUTINE - Candesartan PO Prevention; comorbid HTN; beta-blocker intolerant 8 mg daily; 16 mg daily :: PO :: :: Start 8 mg daily; may increase to 16 mg daily None Pregnancy; bilateral renal artery stenosis; hyperkalemia BP; K+; creatinine - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Headache specialist/Neurology referral for refractory MOH management and preventive optimization - ROUTINE ROUTINE - Pain psychology/Behavioral medicine referral for cognitive behavioral therapy addressing medication-seeking behaviors and pain catastrophizing - ROUTINE ROUTINE - Addiction medicine consultation for opioid-overuse MOH with features of opioid use disorder - URGENT ROUTINE - Primary care physician coordination for chronic disease management and medication reconciliation - ROUTINE ROUTINE - Psychiatry referral for comorbid depression, anxiety, or substance use disorder requiring pharmacotherapy - ROUTINE ROUTINE - Physical therapy for cervicogenic headache component and postural evaluation - - ROUTINE - Social work consultation for disability resources, work accommodations, or financial assistance for medications - ROUTINE ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Expect temporary worsening of headaches during the first 1-2 weeks of withdrawal (rebound headache period); this is normal and necessary for improvement URGENT ROUTINE ROUTINE Most patients experience significant improvement within 2-3 months after successful withdrawal - ROUTINE ROUTINE Return immediately for severe headache with fever, stiff neck, or altered mental status which may indicate infection requiring emergency evaluation STAT - ROUTINE Return immediately for sudden severe headache different from usual (\"worst headache of life\") which may indicate hemorrhage STAT - ROUTINE Return if experiencing severe withdrawal symptoms including seizure, tremor, or hallucinations (especially with barbiturate or opioid overuse) STAT - ROUTINE Limit acute headache medication use to maximum 2 days per week to prevent recurrent MOH ROUTINE ROUTINE ROUTINE Maintain detailed headache diary tracking headache days, medication use days, and triggers - ROUTINE ROUTINE Do not abruptly stop butalbital-containing medications (Fioricet, Fiorinal) as this may cause seizures; must taper under physician guidance URGENT ROUTINE ROUTINE Preventive medications may take 4-8 weeks to show full benefit; continue as prescribed even if headaches persist initially - ROUTINE ROUTINE","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular sleep schedule (7-8 hours, consistent bedtime/wake time) as irregular sleep triggers headache - ROUTINE ROUTINE Regular meals to avoid fasting-triggered headache; do not skip meals - ROUTINE ROUTINE Aerobic exercise (30 min moderate activity 5x/week) shown to reduce headache frequency and improve mood - ROUTINE ROUTINE Stress management through relaxation techniques, mindfulness, or biofeedback to reduce headache triggers - ROUTINE ROUTINE Adequate hydration (at least 64 oz water daily) as dehydration can trigger headache - ROUTINE ROUTINE Caffeine consistency: if using caffeine, maintain consistent daily intake; if tapering, reduce gradually over 2 weeks - ROUTINE ROUTINE Alcohol avoidance during withdrawal period as it can worsen headaches and interact with medications - ROUTINE ROUTINE Avoid keeping overused medications at home during withdrawal to reduce temptation and relapse risk - ROUTINE ROUTINE","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Chronic migraine without MOH \u226515 headache days/month but &lt;10-15 medication days/month; no improvement with medication withdrawal Headache diary showing medication use &lt;10-15 days/month Chronic tension-type headache Bilateral, pressing/tightening quality, mild-moderate intensity, no nausea, minimal photo/phonophobia Clinical criteria (ICHD-3); no medication overuse pattern New daily persistent headache (NDPH) Distinct onset remembered; daily headache from onset; often no prior headache history Clinical history; MRI to exclude secondary causes; no MOH pattern Idiopathic intracranial hypertension Positional headache worse with lying down; papilledema; pulsatile tinnitus; visual obscurations LP opening pressure &gt;25 cm H2O; MRI/MRV showing empty sella, transverse sinus stenosis Cervicogenic headache Unilateral, occipital-frontal radiation, triggered by neck movement or posture C-spine imaging; diagnostic occipital nerve block Secondary headache (structural) Progressive headache, focal neurological deficits, papilledema, new onset &gt;50 years MRI brain with contrast; consider LP Chronic subdural hematoma Elderly, anticoagulation, history of fall/trauma; progressive headache CT head; MRI brain Cerebral venous thrombosis Positional headache; papilledema; hypercoagulable state; pregnancy/postpartum MRV brain; D-dimer (if negative, unlikely) Giant cell arteritis Age &gt;50; scalp tenderness; jaw claudication; visual changes; elevated inflammatory markers ESR, CRP elevated; temporal artery biopsy","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Headache diary (frequency, severity, medication use) Daily during withdrawal, then weekly &lt;4 headache days/month after 3 months Continue withdrawal protocol; optimize preventive therapy - ROUTINE ROUTINE - Acute medication use days Weekly during withdrawal, then monthly \u22642 days/week (\u22648 days/month) Reinforce limits; address triggers; consider inpatient withdrawal - ROUTINE ROUTINE - COWS score (Clinical Opiate Withdrawal Scale) q4-6h during opioid withdrawal &lt;8 (mild) Provide symptomatic treatment; adjust taper if severe - URGENT - - Vital signs (HR, BP) Each visit during withdrawal Stable; no hypertensive crisis Treat withdrawal symptoms; hold clonidine if hypotensive STAT ROUTINE ROUTINE - Mood assessment (PHQ-9, GAD-7) Each visit Stable or improving Psychiatry referral; adjust antidepressant - ROUTINE ROUTINE - LFTs (if on valproate or prior APAP overuse) Baseline, 3 months, then q6mo Normal Discontinue valproate if &gt;3x ULN; evaluate hepatic injury - ROUTINE ROUTINE - Weight (if on topiramate, amitriptyline, valproate) Each visit Stable Adjust medication; diet counseling - ROUTINE ROUTINE - Bicarbonate (if on topiramate) Baseline, 3 months &gt;18 mEq/L Consider dose reduction or discontinuation - ROUTINE ROUTINE - HIT-6 or MIDAS disability score Every 3 months 50% improvement Escalate preventive therapy; consider CGRP mAb or Botox - - ROUTINE -","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild-moderate MOH; able to comply with outpatient withdrawal; no opioid/barbiturate dependence requiring medical supervision; support system in place Admit to floor Severe rebound headache not controlled with outpatient therapy; opioid or barbiturate withdrawal requiring medical supervision; need for DHE protocol; intractable nausea/vomiting; severe comorbid psychiatric illness Admit to ICU Rare; barbiturate withdrawal with seizure risk or autonomic instability; severe opioid withdrawal with hemodynamic instability Outpatient withdrawal Most patients; simple analgesic or triptan overuse; reliable follow-up within 1-2 weeks Outpatient follow-up timing Initial: within 1-2 weeks of starting withdrawal; then every 2-4 weeks during transition; monthly once stable on preventive","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source ICHD-3 diagnostic criteria for MOH Consensus Headache Classification Committee. Cephalalgia 2018 Withdrawal as primary treatment for MOH Class I, Level A Diener et al. Lancet Neurol 2019 Abrupt vs gradual withdrawal for simple analgesics/triptans Class II, Level B Rossi et al. Cephalalgia 2006 Bridge therapy with corticosteroids during withdrawal Class II, Level B Krymchantowski et al. Headache 2000 Preventive therapy initiation during withdrawal Class II, Level B Hagen et al. Cephalalgia 2009 Topiramate effective in MOH prevention Class I, Level A Silberstein et al. Headache 2012 OnabotulinumtoxinA for chronic migraine with MOH Class I, Level A Silberstein et al. Headache 2015 CGRP mAbs effective in MOH without prior withdrawal Class I, Level A Tepper et al. Cephalalgia 2019 (erenumab in MOH) Greater occipital nerve block as bridge therapy Class II, Level B Cuadrado et al. Headache 2017 DHE protocol for status migrainosus and refractory MOH Class II, Level C Raskin et al. Neurology 1986 Behavioral therapy as adjunct in MOH treatment Class II, Level B Katsarava et al. Neurology 2003 Relapse rate up to 40% at 1 year without preventive Class II, Level B Katsarava et al. Neurology 2005 Opioid MOH has worst prognosis and highest relapse Class II, Level B Bigal et al. Neurology 2008","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive withdrawal strategies for different medication classes - Bridge therapy options including prednisone, naproxen, DHE, and nerve blocks - Preventive therapy including oral medications and CGRP monoclonal antibodies - Special protocols for opioid and barbiturate overuse - Structured dosing format for order sentence generation</p>","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#appendix-a-ichd-3-diagnostic-criteria-for-medication-overuse-headache","title":"APPENDIX A: ICHD-3 Diagnostic Criteria for Medication Overuse Headache","text":"<p>8.2 Medication-overuse headache (MOH)</p> <p>Diagnostic criteria:</p> <p>A. Headache occurring on \u226515 days/month in a patient with a pre-existing headache disorder B. Regular overuse for &gt;3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache C. Not better accounted for by another ICHD-3 diagnosis</p> <p>Medication-Specific Thresholds:</p> Medication Class Overuse Threshold Simple analgesics (acetaminophen, ASA, NSAIDs) \u226515 days/month Triptans \u226510 days/month Ergotamine \u226510 days/month Opioids \u226510 days/month Combination analgesics (butalbital, caffeine combinations) \u226510 days/month Multiple drug classes (not individually meeting threshold) \u226510 days/month combined","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#appendix-b-withdrawal-strategy-by-medication-class","title":"APPENDIX B: Withdrawal Strategy by Medication Class","text":"Medication Class Withdrawal Strategy Bridge Therapy Timeline Simple analgesics (APAP, ibuprofen, naproxen) Abrupt discontinuation Prednisone taper; standing naproxen 2 wks; nerve block Rebound 3-10 days; improvement 2-4 weeks Triptans Abrupt discontinuation Prednisone taper; standing naproxen; nerve block Rebound 3-10 days; improvement 2-4 weeks Combination analgesics with caffeine Abrupt discontinuation (unless butalbital) Prednisone taper; may need caffeine taper Rebound 5-14 days; caffeine withdrawal 3-5 days Butalbital-containing (Fioricet, Fiorinal) MUST TAPER - seizure risk Phenobarbital substitution if high doses; slow taper Taper over 2-4+ weeks Opioids Taper preferred; may need inpatient Clonidine for autonomic symptoms; MAT consideration Taper over 2-4+ weeks; symptoms 7-14 days Ergotamine Abrupt discontinuation DHE protocol if available; prednisone Rebound 3-10 days","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/medication-overuse-headache/#appendix-c-patient-education-handout-key-points","title":"APPENDIX C: Patient Education Handout Key Points","text":"<p>What is Medication Overuse Headache?</p> <p>Medication overuse headache (MOH) happens when frequent use of headache medications actually causes more headaches. It is sometimes called \"rebound headache.\" The brain becomes dependent on the medication and triggers headaches when the medication wears off.</p> <p>How did this happen?</p> <p>MOH can develop in anyone who uses acute headache medications too often: - Pain relievers (Tylenol, Advil, Aleve) used \u226515 days/month - Triptans (Imitrex, etc.) used \u226510 days/month - Combination medications (Excedrin, Fioricet) used \u226510 days/month - Opioids or butalbital used \u226510 days/month</p> <p>What to expect during withdrawal:</p> <ul> <li>Week 1-2: Headaches may temporarily get WORSE. This is expected and necessary. You may also experience nausea, sleep problems, and anxiety.</li> <li>Week 3-4: Headaches begin to improve. You start to have more headache-free days.</li> <li>Month 2-3: Most patients have significant improvement. Preventive medications begin working fully.</li> </ul> <p>Keys to success:</p> <ol> <li>Do not use the overused medication - even for severe headaches</li> <li>Take your preventive medication every day as prescribed</li> <li>Keep a headache diary</li> <li>Follow up with your neurologist as scheduled</li> <li>Limit acute medications to \u22642 days per week going forward</li> </ol>","tags":["headache","medication-overuse","outpatient","withdrawal"]},{"location":"drafts/migraine-with-aura/","title":"Migraine with Aura","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#migraine-with-aura","title":"Migraine with Aura","text":"<p>DIAGNOSIS: Migraine with Aura ICD-10: G43.109 (Migraine with aura, not intractable, without status migrainosus) SCOPE: Diagnosis and management of migraine with typical aura (visual, sensory, language) and hemiplegic migraine. Focuses on outpatient management with acute care considerations. Covers differentiation from TIA/stroke, contraceptive counseling, and preventive therapy. Excludes migraine with brainstem aura (separate protocol) and retinal migraine.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>CLINICAL NOTES: - Aura typically precedes headache by 5-60 minutes but can occur during or without headache - Triptans ARE safe in typical migraine with aura (visual, sensory, language) - Triptans/ergots CONTRAINDICATED in hemiplegic migraine (motor aura) - Estrogen-containing contraceptives contraindicated - elevated ischemic stroke risk - Always differentiate from TIA/stroke on first presentation</p>","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Rule out anemia, infection; baseline before treatment Normal STAT ROUTINE ROUTINE - BMP Electrolyte abnormalities; renal function for medication dosing Normal STAT ROUTINE ROUTINE - Glucose Hypoglycemia can mimic aura; hyperglycemia raises stroke risk 70-180 mg/dL STAT ROUTINE ROUTINE - PT/INR, PTT Coagulation screen if stroke consideration; before LP Normal STAT ROUTINE - - HbA1c Vascular risk assessment &lt;7% optimal - ROUTINE ROUTINE - Lipid panel Vascular risk stratification LDL &lt;100 mg/dL - ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Rule out GCA if age &gt;50 with new visual symptoms Normal URGENT ROUTINE ROUTINE - TSH Thyroid dysfunction can trigger headache/aura-like symptoms Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE - Magnesium (RBC) Deficiency linked to migraine with aura specifically &gt;4.2 mg/dL - ROUTINE ROUTINE - Homocysteine Elevated levels associated with migraine with aura and stroke &lt;15 \u03bcmol/L - ROUTINE ROUTINE - Vitamin B12, folate Deficiency can elevate homocysteine; sensory symptoms Normal - ROUTINE ROUTINE - Vitamin D, 25-OH Deficiency associated with increased migraine frequency &gt;30 ng/mL - ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-\u03b22GP1) Thrombophilia workup if young stroke or recurrent prolonged aura Negative - EXT EXT - Factor V Leiden, prothrombin G20210A Hereditary thrombophilia if recurrent aura or stroke-like events Negative - - EXT - ANA, anti-dsDNA CNS lupus in atypical presentations Negative - EXT EXT - MTHFR mutation Elevated homocysteine with aura Wild type or heterozygous - - EXT - Genetic testing (CACNA1A, ATP1A2, SCN1A) Hemiplegic migraine suspected; family history Variant identified - - EXT - CSF analysis Rule out meningitis, SAH if atypical presentation Normal; no xanthochromia URGENT ROUTINE - -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast First presentation with aura; rule out stroke/structural lesion Normal; no acute infarct; no WMH concerning for vasculopathy MRI-incompatible devices URGENT ROUTINE ROUTINE - CT Head non-contrast Acute presentation if MRI unavailable; rule out hemorrhage No hemorrhage or mass Pregnancy (relative) STAT STAT - - MRA Head First aura or prolonged aura to assess intracranial vessels No stenosis, aneurysm, or dissection MRI contraindications URGENT ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Atypical features; persistent deficits; concern for mass No enhancement; no mass Gadolinium allergy; severe renal impairment URGENT ROUTINE ROUTINE - MRA Neck Suspected cervical dissection (neck pain, Horner syndrome) No dissection MRI contraindications URGENT ROUTINE ROUTINE - CTA Head/Neck Acute vascular imaging if MRI unavailable No aneurysm, dissection, occlusion Contrast allergy; CKD (eGFR &lt;30) STAT URGENT - - TTE with bubble study Evaluate for PFO if recurrent aura or cryptogenic stroke history No PFO; if present, assess shunt size None - ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU TEE Detailed cardiac source evaluation if TTE positive or high suspicion No cardiac thrombus; characterize PFO Esophageal pathology - EXT EXT - MRI with perfusion/DWI Prolonged aura to differentiate migrainous infarct from stroke No DWI restriction MRI contraindications URGENT ROUTINE EXT - Transcranial Doppler with bubble PFO screening; noninvasive alternative to TTE bubble No right-to-left shunt Inadequate acoustic windows - ROUTINE ROUTINE - EEG Aura with altered consciousness; differentiate from seizure No epileptiform activity None URGENT ROUTINE EXT -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#3-treatment","title":"3. TREATMENT","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ketorolac IV/IM First-line acute migraine with aura in ED 30 mg IV x1; 15 mg IV x1 :: IV :: :: 30 mg IV (15 mg if &gt;65y, renal impairment, or &lt;50 kg); max 5 days NSAIDs Renal impairment (CrCl &lt;30); active GI bleed; aspirin/NSAID allergy; third trimester Renal function if repeated dosing STAT STAT - - Metoclopramide IV Antiemetic with anti-migraine properties 10 mg IV over 15 min; 20 mg IV over 15 min :: IV :: :: 10-20 mg IV over 15 min; pretreat with diphenhydramine 25 mg IV to prevent akathisia Parkinson's disease; tardive dyskinesia history; bowel obstruction; pheochromocytoma Akathisia, dystonia; discontinue if EPS STAT STAT - - Prochlorperazine IV Dopamine antagonist for acute migraine with prominent nausea 10 mg IV over 2 min :: IV :: :: 10 mg IV slowly over 2 min; pretreat with diphenhydramine 25 mg IV QT prolongation (QTc &gt;500ms); Parkinson's disease; neuroleptic malignant syndrome history QTc if baseline prolonged; EPS STAT STAT - - Diphenhydramine IV Prevent akathisia from dopamine antagonists; sedation 25 mg IV; 50 mg IV :: IV :: :: 25-50 mg IV given concurrently with dopamine antagonist Narrow-angle glaucoma; urinary retention; severe prostatic hypertrophy Sedation; anticholinergic effects STAT STAT - - Magnesium sulfate IV Migraine with aura - particularly effective; refractory migraine 2 g IV over 20 min :: IV :: :: 2 g IV in 50 mL NS over 20-30 min; may repeat x1 after 2 hr Heart block; severe hypermagnesemia; myasthenia gravis; severe renal impairment BP, HR during infusion; flushing is common and benign STAT URGENT - - Sumatriptan SC/PO Acute migraine with TYPICAL aura (visual, sensory, language) - SAFE 6 mg SC x1; 50 mg PO x1; 100 mg PO x1 :: SC/PO :: :: 6 mg SC (may repeat after 1 hr, max 12 mg/24hr) OR 50-100 mg PO (may repeat after 2 hr, max 200 mg/24hr); take AFTER aura resolves or at headache onset HEMIPLEGIC MIGRAINE (motor aura); uncontrolled HTN; CAD; prior stroke/TIA; MAOIs within 14 days; ergots within 24 hr Chest tightness (triptan sensation vs cardiac); assess cardiovascular risk URGENT URGENT ROUTINE - Valproate sodium IV Status migrainosus with aura; refractory to first-line 500 mg IV over 5 min; 1000 mg IV over 5 min :: IV :: :: 500-1000 mg IV over 5-10 min; may repeat 500 mg in 8 hr Hepatic disease; pregnancy (teratogenic); urea cycle disorders; pancreatitis history LFTs; ammonia if altered mental status URGENT URGENT - - Dexamethasone IV Prevent headache recurrence after acute treatment 10 mg IV x1 :: IV :: :: 10 mg IV x1 at time of discharge or admission; single dose Active untreated infection; known hypersensitivity Glucose if diabetic URGENT URGENT - -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Rizatriptan PO Acute typical migraine with aura; fast onset 5 mg PO x1; 10 mg PO x1 :: PO :: :: 5-10 mg PO (use 5 mg if on propranolol); may repeat after 2 hr; max 30 mg/24hr Same as sumatriptan; HEMIPLEGIC MIGRAINE; use 5 mg max if on propranolol Triptan sensation - ROUTINE ROUTINE - Eletriptan PO Acute typical migraine with aura; good for recurrence 40 mg PO x1; 80 mg PO x1 :: PO :: :: 40 mg PO; may repeat 40 mg after 2 hr if partial response; max 80 mg/24hr Same as sumatriptan; HEMIPLEGIC MIGRAINE; potent CYP3A4 inhibitors (ketoconazole, clarithromycin) Triptan sensation - ROUTINE ROUTINE - Naratriptan PO Migraine with aura; longer duration; menstrual migraine 2.5 mg PO x1 :: PO :: :: 2.5 mg PO; may repeat after 4 hr; max 5 mg/24hr; slower onset but longer lasting Same as sumatriptan; HEMIPLEGIC MIGRAINE; moderate-severe renal/hepatic impairment Triptan sensation - ROUTINE ROUTINE - Ubrogepant PO CGRP antagonist; use if triptan contraindicated or cardiovascular risk 50 mg PO x1; 100 mg PO x1 :: PO :: :: 50-100 mg PO; may repeat after 2 hr; max 200 mg/24hr Strong CYP3A4 inhibitors; severe hepatic impairment None routine; no cardiovascular contraindications - ROUTINE ROUTINE - Rimegepant PO/ODT CGRP antagonist; can use for acute and prevention 75 mg ODT x1 :: PO :: :: 75 mg ODT at onset; max 75 mg/24hr for acute; also approved 75 mg every other day for prevention Strong CYP3A4 inhibitors/inducers; severe hepatic impairment None routine - ROUTINE ROUTINE - Lasmiditan PO 5-HT1F agonist; safe in cardiovascular disease; ditan class 50 mg PO x1; 100 mg PO x1; 200 mg PO x1 :: PO :: :: 50-200 mg PO x1; max 200 mg/24hr; DO NOT DRIVE for 8 hours after dose Concurrent alcohol; CYP3A4 substrates with narrow TI CNS depression; dizziness; NO driving for 8 hr - ROUTINE ROUTINE - Ibuprofen PO Mild-moderate aura migraine 400 mg PO x1; 600 mg PO x1; 800 mg PO x1 :: PO :: :: 400-800 mg PO at onset; max 2400 mg/day Renal impairment; active GI bleed; aspirin/NSAID allergy; third trimester GI symptoms; renal function if prolonged use URGENT ROUTINE ROUTINE - Naproxen sodium PO Mild-moderate aura migraine; menstrual migraine prevention 550 mg PO x1 :: PO :: :: 550 mg PO at onset; may add 275 mg in 12 hr; max 1375 mg day 1, then 1100 mg/day Renal impairment; active GI bleed; aspirin/NSAID allergy GI symptoms URGENT ROUTINE ROUTINE - Acetaminophen-Aspirin-Caffeine PO Mild-moderate migraine with aura (OTC option) 2 tablets PO x1 :: PO :: :: 2 tablets (250/250/65 mg each) at onset; max 2 doses/24hr Aspirin allergy; hepatic impairment; avoid if using other acetaminophen sources Limit total acetaminophen &lt;3 g/day URGENT ROUTINE ROUTINE - Ondansetron IV/PO Nausea/vomiting with migraine 4 mg IV x1; 8 mg ODT x1 :: IV/PO :: :: 4 mg IV or 8 mg PO/ODT; may repeat q8h as needed QT prolongation (QTc &gt;500ms); severe hepatic impairment QTc if multiple doses or baseline prolongation STAT STAT ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Dihydroergotamine (DHE) IV/SC/Nasal Refractory migraine; status migrainosus; NOT for hemiplegic 0.5 mg IV q8h; 1 mg SC x1; 1 spray per nostril :: IV/SC/Nasal :: :: IV: 0.5-1 mg q8h for up to 3 days (pretreat with antiemetic); SC: 1 mg, may repeat in 1 hr; Nasal: 1 spray each nostril, repeat in 15 min Pregnancy; CAD; uncontrolled HTN; peripheral vascular disease; HEMIPLEGIC MIGRAINE; triptan use within 24hr; severe hepatic/renal impairment BP; nausea; chest pain; continuous cardiac monitoring for IV - URGENT EXT - Occipital nerve block SC Refractory migraine; occipital-predominant pain Bupivacaine 0.5% 2-3 mL + triamcinolone 40 mg :: SC :: :: Inject at greater occipital nerve bilaterally; may add lesser occipital, supraorbital Local anesthetic allergy; infection at injection site; anticoagulation (relative) Vasovagal reaction; immediate pain assessment - EXT ROUTINE - Ketamine IV Status migrainosus refractory to DHE 0.1-0.3 mg/kg/hr infusion :: IV :: :: 0.1-0.3 mg/kg/hr continuous infusion for 24-48 hr; subanesthetic dosing only Uncontrolled HTN; psychosis history; elevated ICP; pregnancy Dissociation; BP; HR; requires continuous cardiac monitoring - EXT - - Verapamil IV Hemiplegic migraine acute (if severe); status migrainosus 5 mg IV over 2 min :: IV :: :: 5 mg IV over 2-3 min; may repeat in 30 min (max 20 mg) Heart block (2nd/3rd degree); severe LV dysfunction; hypotension Continuous ECG; BP; for hemiplegic migraine when triptans contraindicated - EXT - - Intranasal lidocaine Intranasal Acute migraine with aura; rapid onset option 4% lidocaine 0.5 mL per nostril :: Intranasal :: :: 4% lidocaine, 0.5 mL per nostril directed at sphenopalatine fossa; may repeat x1 in 15 min Local anesthetic allergy Local numbness; cardiac arrhythmia (rare with low dose) URGENT URGENT ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#3d-disease-modifying-or-chronic-therapies-preventive-medications","title":"3D. Disease-Modifying or Chronic Therapies (Preventive Medications)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Magnesium oxide PO First-line supplement for migraine with aura prevention 400 mg daily; 400 mg BID :: PO :: :: Start 400 mg daily; may increase to 400 mg BID; take with food to reduce GI upset None Renal impairment (CrCl &lt;30) - dose reduce Diarrhea; check Mg level if symptomatic or renal disease - ROUTINE ROUTINE - Topiramate PO First-line oral prevention; reduces aura frequency; weight loss 25 mg qHS; 50 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/wk; target 50-100 mg BID None PREGNANCY (teratogenic); glaucoma; kidney stones; metabolic acidosis Cognitive effects; paresthesias; weight; serum bicarbonate; kidney stones - ROUTINE ROUTINE - Propranolol PO First-line prevention; comorbid HTN, anxiety, tremor 40 mg BID; 80 mg BID; 80 mg LA daily; 160 mg LA daily :: PO :: :: Start 40 mg BID or 80 mg LA daily; titrate q2wk; target 80-240 mg/day None Asthma; COPD with bronchospasm; bradycardia &lt;50; 2nd/3rd degree heart block; decompensated HF HR (goal &gt;50); BP; fatigue; depression; exercise intolerance - ROUTINE ROUTINE - Amitriptyline PO Prevention with comorbid insomnia, depression, tension-type headache 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS ECG if &gt;50 y/o or cardiac history Cardiac conduction disease; recent MI; glaucoma; urinary retention; elderly (anticholinergic burden) Sedation; weight; dry mouth; ECG if dose &gt;100 mg or cardiac history - ROUTINE ROUTINE - Venlafaxine XR PO Prevention with comorbid depression, anxiety 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 75-150 mg daily None Uncontrolled HTN; MAOIs within 14 days; abrupt discontinuation risk BP at doses &gt;150 mg; serotonin syndrome signs; taper to discontinue - ROUTINE ROUTINE - Candesartan PO Prevention; comorbid HTN; beta-blocker intolerant 8 mg daily; 16 mg daily :: PO :: :: Start 8 mg daily; may increase to 16 mg daily after 4 wk None Pregnancy; bilateral renal artery stenosis; hyperkalemia BP; potassium; creatinine - ROUTINE ROUTINE - Valproate/Divalproex PO Prevention with comorbid bipolar or epilepsy 250 mg BID; 500 mg BID; 500 mg ER daily; 1000 mg ER daily :: PO :: :: Start 250 mg BID or 500 mg ER daily; titrate to 500-1000 mg/day LFTs; CBC Pregnancy (teratogenic - neural tube defects); hepatic disease; urea cycle disorders; pancreatitis history LFTs q6mo; weight; hair loss; tremor; CBC - ROUTINE ROUTINE - Riboflavin (Vitamin B2) PO Supplement for prevention; well-tolerated; may reduce aura 400 mg daily :: PO :: :: 400 mg daily None None Fluorescent yellow urine (reassure patient); benign - ROUTINE ROUTINE - Coenzyme Q10 PO Supplement; mitochondrial support 100 mg TID; 300 mg daily :: PO :: :: 100-300 mg daily None None None - ROUTINE ROUTINE - Erenumab (Aimovig) SC CGRP mAb; failed 2+ oral preventives or intolerance 70 mg SC monthly; 140 mg SC monthly :: SC :: :: 70 mg SC monthly; may increase to 140 mg monthly after 3 months if suboptimal response None Hypersensitivity to erenumab Constipation (can be severe - may need laxatives); injection site reactions; HTN monitoring - - ROUTINE - Fremanezumab (Ajovy) SC CGRP mAb; flexible dosing options 225 mg SC monthly; 675 mg SC quarterly :: SC :: :: 225 mg SC monthly OR 675 mg SC quarterly (three 225 mg injections) None Hypersensitivity Injection site reactions - - ROUTINE - Galcanezumab (Emgality) SC CGRP mAb; requires loading dose 240 mg SC load then 120 mg SC monthly :: SC :: :: 240 mg SC loading dose (2 x 120 mg injections), then 120 mg SC monthly None Hypersensitivity Injection site reactions; vertigo - - ROUTINE - Onabotulinumtoxin A (Botox) IM Chronic migraine with aura (\u226515 days/month); failed oral preventives 155-195 units IM q12wk :: IM :: :: 155-195 units across 31-39 injection sites per PREEMPT protocol; repeat q12 weeks; effect may take 2-3 cycles None Infection at injection sites; myasthenia gravis; neuromuscular disorder Neck weakness; ptosis; antibody formation if loss of effect - - ROUTINE - Flunarizine PO Calcium channel blocker for prevention; especially hemiplegic migraine 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; may increase to 10 mg qHS; especially useful for hemiplegic migraine (not available in US) None Depression; Parkinson's disease; extrapyramidal disorders Weight gain; depression; parkinsonism with prolonged use - ROUTINE ROUTINE - Lamotrigine PO May reduce aura frequency specifically; hemiplegic migraine 25 mg daily; 50 mg BID; 100 mg BID :: PO :: :: Start 25 mg daily; increase by 25 mg q2wk to 50-100 mg BID; SLOW titration to prevent rash None History of lamotrigine-related rash; interacting drugs (valproate halves dose) RASH (stop immediately if rash develops - SJS risk); monitor closely during titration - ROUTINE ROUTINE - Acetazolamide PO Hemiplegic migraine prevention; familial hemiplegic migraine 250 mg BID; 500 mg BID :: PO :: :: Start 250 mg BID; may increase to 500 mg BID None Sulfa allergy; severe hepatic/renal disease; hypokalemia; acidosis Paresthesias; metabolic acidosis; K+; bicarbonate - ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Headache specialist referral for aura characterization, preventive optimization, and differentiation from other neurological conditions URGENT ROUTINE ROUTINE - OB/GYN consultation for contraceptive counseling - estrogen-containing contraceptives contraindicated in migraine with aura due to elevated ischemic stroke risk - - ROUTINE - Cardiology referral if TTE shows PFO for discussion of closure in select cases (recurrent cryptogenic stroke or debilitating aura despite medical therapy) - ROUTINE ROUTINE - Genetics consultation if hemiplegic migraine suspected for CACNA1A, ATP1A2, SCN1A testing and family counseling - - ROUTINE - Physical therapy for cervicogenic component and trigger point management - - ROUTINE - Psychology/Behavioral medicine for CBT addressing aura anxiety, attack anticipation, and comorbid mood disorders - - ROUTINE - Ophthalmology if visual aura atypical or concern for retinal pathology - ROUTINE ROUTINE - Sleep medicine if sleep disorder contributing to migraine frequency (OSA, insomnia) - - ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for new/different headache, \"worst headache of life,\" or thunderclap onset which may indicate subarachnoid hemorrhage STAT - ROUTINE Return immediately if aura persists &gt;60 minutes or if new weakness on one side of body develops (need to rule out stroke) STAT - ROUTINE Return immediately for headache with fever, stiff neck, or altered mental status which may indicate CNS infection STAT - ROUTINE AVOID estrogen-containing contraceptives (combined birth control pills, patch, ring) - use progestin-only methods (mini-pill, Depo-Provera, Mirena IUD, Nexplanon) or non-hormonal methods - ROUTINE ROUTINE Triptans ARE safe for your typical visual/sensory aura - take at headache onset or when aura ends; do NOT take if you experience weakness (motor aura) - ROUTINE ROUTINE Maintain headache/aura diary tracking aura type, duration, triggers, and medication use to guide treatment optimization - ROUTINE ROUTINE Limit acute medication use to \u226410 days/month to prevent medication overuse headache which worsens both headache and aura URGENT ROUTINE ROUTINE Learn your personal aura warning signs and take acute medication promptly when headache begins - ROUTINE ROUTINE Do not drive or operate machinery during visual or motor aura as vision and coordination may be impaired URGENT ROUTINE ROUTINE","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular sleep schedule (7-8 hours, consistent bedtime) as sleep changes are a major aura trigger - ROUTINE ROUTINE Avoid known aura triggers (bright/flashing lights, high altitude, significant sleep deprivation, extreme stress) - ROUTINE ROUTINE Regular aerobic exercise (30 min moderate activity 5x/week) reduces migraine frequency; avoid if currently in aura - ROUTINE ROUTINE Magnesium-rich diet (leafy greens, nuts, whole grains) or supplementation as magnesium specifically helps aura - ROUTINE ROUTINE Stress management techniques (mindfulness, biofeedback, relaxation training) as stress is a major trigger - ROUTINE ROUTINE Adequate hydration (at least 64 oz water daily) as dehydration can trigger attacks - ROUTINE ROUTINE Smoking cessation to reduce vascular risk, particularly important given aura-associated stroke risk - ROUTINE ROUTINE Caffeine moderation (\u2264200 mg/day) and consistent daily intake to avoid withdrawal triggers - ROUTINE ROUTINE Blood pressure control (target &lt;130/80) given elevated vascular risk with aura - ROUTINE ROUTINE Avoid high altitude or rapid altitude changes if altitude is a known aura trigger - - ROUTINE","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Transient ischemic attack (TIA) Sudden onset (maximal at onset vs gradual aura spread); negative symptoms (vision loss vs positive scintillations); vascular risk factors; older age; duration usually &lt;1 hr MRI DWI (no restriction in aura); MRA/CTA (no vessel occlusion); aura has visual \"march\" Ischemic stroke Fixed deficit; sudden onset; vascular territory distribution; risk factors MRI DWI (shows restriction); CT may be normal early Migraine with brainstem aura Aura includes brainstem symptoms (vertigo, tinnitus, decreased hearing, diplopia, ataxia, dysarthria, decreased LOC) Clinical criteria; MRI to exclude posterior fossa lesion Retinal migraine Monocular visual symptoms (vs binocular in typical aura); complete vision loss in one eye Ophthalmology exam; cover/uncover test during symptoms Focal seizure with visual phenomena Shorter duration (seconds to minutes); positive phenomena; may have automatisms; post-ictal confusion EEG may show epileptiform activity; MRI for structural lesion Transient global amnesia Anterograde amnesia; repetitive questioning; no visual or motor symptoms; resolves &lt;24 hr Clinical diagnosis; MRI may show hippocampal DWI changes Giant cell arteritis Age &gt;50; scalp tenderness; jaw claudication; visual loss (not scintillations); elevated ESR/CRP ESR, CRP (elevated); temporal artery biopsy Carotid/vertebral dissection Neck pain; Horner syndrome; pulsatile tinnitus; stroke symptoms MRA/CTA neck showing dissection CADASIL Migraine with aura often first symptom; subcortical strokes; family history; cognitive decline MRI shows characteristic WMH (anterior temporal, external capsule); NOTCH3 mutation Mitochondrial encephalopathy (MELAS) Stroke-like episodes not following vascular territory; seizures; elevated lactate; short stature MRI (non-vascular stroke pattern); genetic testing; muscle biopsy","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Aura characteristics (type, duration, frequency) Each visit; diary Aura duration &lt;60 min; stable pattern Prolonged aura needs stroke rule-out; increasing frequency reassess prevention - ROUTINE ROUTINE - Headache days/month Monthly &lt;4 headache days/month; 50% reduction on preventive Escalate therapy if not meeting target; consider CGRP mAb or Botox - ROUTINE ROUTINE - Acute medication use days Monthly \u226410 days/month MOH education; consider preventive escalation; may need withdrawal - ROUTINE ROUTINE - Blood pressure Each visit &lt;130/80 mmHg Optimize BP control given elevated vascular risk with aura STAT ROUTINE ROUTINE - HIT-6 or MIDAS disability score Every 3 months 50% improvement or score &lt;50 Escalate preventive therapy if severely disabled - - ROUTINE - Topiramate: serum bicarbonate Baseline, 3 months &gt;18 mEq/L Consider dose reduction or switch if metabolic acidosis - ROUTINE ROUTINE - Valproate: LFTs Baseline, 3 months, then q6mo AST/ALT &lt;3x ULN Discontinue if significant elevation - ROUTINE ROUTINE - CGRP mAb: constipation assessment Each visit No severe constipation Add fiber/laxatives; reduce dose or discontinue if severe - - ROUTINE - Lamotrigine: rash monitoring Weekly during titration No rash STOP IMMEDIATELY if rash develops - SJS risk - ROUTINE ROUTINE - Contraceptive status Each visit (women of reproductive age) Progestin-only or non-hormonal Remove estrogen-containing contraceptives; counsel on alternatives - ROUTINE ROUTINE -","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Typical aura pattern confirmed; no stroke symptoms; pain controlled; able to tolerate PO; follow-up arranged; contraceptive counseling if needed Admit to floor Prolonged aura (&gt;60 min) requiring observation; status migrainosus requiring IV therapy; first aura with abnormal imaging requiring further workup; hemiplegic migraine with prolonged weakness Admit to ICU Migrainous infarction (stroke occurring during typical aura); hemodynamic instability; severe refractory status migrainosus requiring ketamine infusion Transfer to higher level Stroke mimicking aura requiring thrombectomy evaluation; complex hemiplegic migraine requiring tertiary headache center Outpatient follow-up New diagnosis: 2-4 weeks; Stable on prevention: 3-6 months; After preventive change: 4-8 weeks","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Migraine with aura increases ischemic stroke risk, especially in women using combined oral contraceptives Class II, Level B Etminan et al. BMJ 2005 ACOG: Combined hormonal contraceptives contraindicated in migraine with aura Class I (Guideline) ACOG Practice Bulletin 2019 Triptans safe and effective in migraine with typical aura Class I, Level A Marmura et al. Headache 2015 Triptans contraindicated in hemiplegic migraine (expert consensus) Class III, Level C Expert consensus; IHS Classification ICHD-3 2018 Magnesium particularly effective for migraine with aura prevention Class II, Level B Peikert et al. Cephalalgia 1996 Lamotrigine may reduce aura frequency specifically Class II, Level C Lampl et al. Neurology 2005 Topiramate effective for migraine prevention Class I, Level A Silberstein et al. Arch Neurol 2004 Propranolol effective for migraine prevention Class I, Level A Linde et al. Cochrane 2004 CGRP monoclonal antibodies effective for prevention Class I, Level A Goadsby et al. NEJM 2017 (erenumab STRIVE) Gepants safe in patients with cardiovascular contraindications to triptans Class I, Level B Dodick et al. JAMA 2019 (ubrogepant ACHIEVE I) Lasmiditan (ditan) does not have cardiovascular contraindications Class I, Level A Kuca et al. Headache 2018 IV magnesium effective for acute migraine with aura Class II, Level B Bigal et al. Headache 2002 Aura duration &gt;60 minutes warrants stroke evaluation Class III, Level C Expert consensus; Lipton et al. Headache 2004 PFO closure may benefit select patients with migraine with aura Class II, Level B Tobis et al. JACC 2017 (RESPECT trial long-term) Acetazolamide effective for familial hemiplegic migraine Class III, Level C Battistini et al. Neurology 1999 Verapamil may be used acutely in hemiplegic migraine Class III, Level C Expert consensus; Mathew et al. Headache 2005 OnabotulinumtoxinA effective for chronic migraine Class I, Level A Dodick et al. Headache 2010 (PREEMPT pooled) Exercise as effective as topiramate for migraine prevention Class II, Level B Varkey et al. Cephalalgia 2011","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of migraine with aura including typical and hemiplegic subtypes - Strong emphasis on aura vs TIA/stroke differentiation - Contraceptive counseling guidance (estrogen contraindicated) - Hemiplegic migraine-specific treatment considerations (no triptans/ergots) - CGRP antagonists and ditans for cardiovascular-safe options - PubMed-linked citations throughout - Structured dosing format for order sentence generation</p>","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#appendix-a-aura-types-and-characteristics","title":"APPENDIX A: Aura Types and Characteristics","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#typical-aura-features-ichd-3-criteria","title":"Typical Aura Features (ICHD-3 Criteria)","text":"Aura Type Characteristics Duration Positive/Negative Symptoms Visual (most common ~90%) Scintillating scotoma, fortification spectra (zigzag lines), photopsia (flashes), spreading across visual field 5-60 min Positive (flashes, lines) then negative (scotoma) Sensory (~30%) Paresthesias (pins/needles) typically starting in hand, spreading up arm, then to face/tongue 5-60 min Positive (tingling) may be followed by numbness Language/Speech (~10%) Dysphasia, word-finding difficulty, paraphasic errors 5-60 min Negative (difficulty speaking) Motor (hemiplegic migraine) Unilateral weakness involving arm and/or leg Minutes to days Negative (weakness); TRIPTANS CONTRAINDICATED","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#visual-aura-march-pattern","title":"Visual Aura \"March\" Pattern","text":"<p>The classic visual aura demonstrates a characteristic march: 1. Starts as small flickering spot near center of vision 2. Expands outward with scintillating (zigzag, fortress-like) border 3. Leaves scotoma (blind spot) in its wake 4. Duration typically 20-30 minutes 5. Followed by headache within 60 minutes (usually)</p> <p>Key Differentiator from Stroke: Aura symptoms SPREAD gradually over 5+ minutes; stroke symptoms are maximal at onset.</p>","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#hemiplegic-migraine-special-considerations","title":"Hemiplegic Migraine Special Considerations","text":"Feature Management Implication Motor weakness present NO TRIPTANS, NO ERGOTS - potential vasoconstriction risk Weakness may last hours to days Requires stroke rule-out; observation may be needed Familial form (FHM) Genetic counseling; CACNA1A, ATP1A2, SCN1A testing May have brainstem symptoms Consider migraine with brainstem aura overlap Prevention Verapamil, flunarizine, acetazolamide preferred; avoid beta-blockers in FHM type 1","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#appendix-b-contraceptive-guidance-for-migraine-with-aura","title":"APPENDIX B: Contraceptive Guidance for Migraine with Aura","text":"","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#why-estrogen-is-contraindicated","title":"Why Estrogen is Contraindicated","text":"<ul> <li>Migraine with aura increases ischemic stroke risk 2-4x baseline</li> <li>Estrogen-containing contraceptives increase stroke risk 2-4x</li> <li>Combined risk: 6-8x increased stroke risk (multiplicative)</li> <li>Risk highest in women who smoke or have other vascular risk factors</li> </ul>","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#safe-contraceptive-options","title":"Safe Contraceptive Options","text":"Method Type Notes Copper IUD (Paragard) Non-hormonal Highly effective; no hormone exposure Levonorgestrel IUD (Mirena, Liletta) Progestin-only Minimal systemic absorption; highly effective Progestin-only pill (mini-pill) Progestin-only Must take at same time daily; less effective than combined Depo-Provera Progestin-only IM injection q3 months Nexplanon (etonogestrel implant) Progestin-only 3-year subdermal implant; highly effective Condoms, diaphragm Barrier No hormones; less effective","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#contraceptives-to-avoid","title":"Contraceptives to AVOID","text":"Method Why Contraindicated Combined oral contraceptives (COCs) Contains estrogen - elevated stroke risk Contraceptive patch (Xulane) Contains estrogen Vaginal ring (NuvaRing) Contains estrogen","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine-with-aura/#counseling-points","title":"Counseling Points","text":"<ol> <li>Document contraceptive method and provide alternatives</li> <li>If patient is on estrogen, counsel on immediate discontinuation</li> <li>Refer to OB/GYN for contraceptive transition</li> <li>Discuss emergency contraception options (progestin-only preferred)</li> <li>Address pregnancy planning if relevant</li> </ol>","tags":["headache","migraine","aura","outpatient","emergency"]},{"location":"drafts/migraine/","title":"Migraine","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#migraine","title":"Migraine","text":"<p>DIAGNOSIS: Migraine ICD-10: G43.909 (Migraine, unspecified, not intractable, without status migrainosus) SCOPE: Acute migraine treatment, preventive therapy initiation, and chronic migraine management. Excludes hemiplegic migraine, migraine with brainstem aura (separate protocols).</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Rule out anemia, infection as headache trigger Normal STAT ROUTINE ROUTINE - BMP Electrolyte abnormalities can trigger or mimic migraine Normal STAT ROUTINE ROUTINE - TSH Thyroid dysfunction associated with headache disorders Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Rule out giant cell arteritis if age &gt;50 with new headache Normal URGENT ROUTINE ROUTINE - Vitamin D level Deficiency associated with increased migraine frequency &gt;30 ng/mL - ROUTINE ROUTINE - Magnesium (RBC) Deficiency linked to migraine; RBC level more accurate &gt;4.2 mg/dL - ROUTINE ROUTINE - Ferritin Iron deficiency associated with headache &gt;50 ng/mL - ROUTINE ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ANA, anti-dsDNA Rule out CNS lupus in atypical presentations Negative - EXT EXT - Antiphospholipid antibodies Stroke mimic or migraine with aura risk Negative - EXT EXT - Genetic testing (CACNA1A, ATP1A2, SCN1A) Hemiplegic migraine suspected Variant identified - - EXT -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast First migraine presentation or change in pattern Normal; rule out secondary causes MRI-incompatible devices URGENT ROUTINE ROUTINE - CT Head non-contrast Acute severe headache (\"worst headache of life\") to rule out SAH No hemorrhage Pregnancy (relative) STAT STAT - -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Atypical features, focal deficits, papilledema No enhancement Gadolinium allergy, severe renal impairment URGENT ROUTINE ROUTINE - MRA Head/Neck Suspected vascular etiology (thunderclap, positional) Patent vessels; no dissection MRI contraindications URGENT ROUTINE ROUTINE - CTA Head/Neck Urgent vascular imaging if MRI unavailable No aneurysm, dissection Contrast allergy, CKD STAT URGENT - -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRV Brain Suspected cerebral venous thrombosis Patent venous sinuses MRI contraindications URGENT ROUTINE EXT - PET scan Refractory migraine, research protocols Assess migraine generator activity Pregnancy, cost - - EXT -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#3-treatment","title":"3. TREATMENT","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ketorolac IV/IM First-line acute migraine in ED 30 mg IV; 15 mg IV :: IV :: :: 30 mg IV x1 (15 mg if &gt;65y, renal impairment, or &lt;50 kg); max 5 days NSAIDs Renal impairment; GI bleed; aspirin allergy; third trimester Renal function if repeated dosing STAT STAT - - Metoclopramide IV Antiemetic with anti-migraine properties 10 mg IV; 20 mg IV :: IV :: :: 10-20 mg IV over 15 min; pretreat with diphenhydramine 25 mg to prevent akathisia Parkinson's disease; tardive dyskinesia; bowel obstruction Akathisia, dystonia STAT STAT - - Prochlorperazine IV Dopamine antagonist for acute migraine 10 mg IV :: IV :: :: 10 mg IV over 2 min; pretreat with diphenhydramine 25 mg QT prolongation; Parkinson's; neuroleptic hypersensitivity Akathisia, dystonia, QTc STAT STAT - - Diphenhydramine IV Prevent akathisia from dopamine antagonists 25 mg IV; 50 mg IV :: IV :: :: 25-50 mg IV with dopamine antagonist Glaucoma; urinary retention Sedation STAT STAT - - Magnesium sulfate IV Migraine with aura; refractory migraine 2 g IV :: IV :: :: 2 g IV over 20 min; may repeat x1 Heart block; hypermagnesemia; myasthenia gravis BP, HR during infusion URGENT URGENT - - Sumatriptan SC/PO Triptan-naive or triptan-responsive patient 6 mg SC; 50 mg PO; 100 mg PO :: SC/PO :: :: 6 mg SC (may repeat after 1 hr, max 12 mg/24hr) OR 50-100 mg PO (max 200 mg/24hr) Uncontrolled HTN; CAD; CVA history; MAOIs; hemiplegic migraine Chest tightness (triptan sensation vs cardiac) URGENT URGENT ROUTINE - Valproate sodium IV Status migrainosus; refractory to first-line 500 mg IV; 1000 mg IV :: IV :: :: 500-1000 mg IV over 5 min Hepatic disease; pregnancy; urea cycle disorders; pancreatitis history LFTs, ammonia if altered mental status URGENT URGENT - - Dihydroergotamine (DHE) IV Refractory migraine; status migrainosus 0.5 mg IV; 1 mg IV :: IV :: :: 0.5-1 mg IV q8h for up to 3 days; pretreat with antiemetic Pregnancy; CAD; uncontrolled HTN; use within 24h of triptan; severe hepatic/renal impairment BP, nausea; continuous cardiac monitoring - URGENT - - Dexamethasone IV Prevent migraine recurrence after ED treatment 10 mg IV :: IV :: :: 10 mg IV x1 at time of ED discharge Active infection; uncontrolled diabetes Glucose if diabetic URGENT URGENT - -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ondansetron IV/PO Nausea/vomiting associated with migraine 4 mg IV; 8 mg PO; 4 mg ODT :: IV/PO :: :: 4 mg IV or 8 mg PO/ODT; may repeat q8h QT prolongation; severe hepatic impairment QTc if multiple doses STAT STAT ROUTINE - Ibuprofen PO Mild-moderate migraine 400 mg PO; 600 mg PO; 800 mg PO :: PO :: :: 400-800 mg PO at onset; max 2400 mg/day Renal impairment; GI bleed; aspirin allergy GI symptoms URGENT ROUTINE ROUTINE - Naproxen PO Mild-moderate migraine; menstrual migraine 500 mg PO; 550 mg PO :: PO :: :: 500-550 mg PO at onset; may repeat 250 mg in 12 hr Renal impairment; GI bleed; aspirin allergy GI symptoms URGENT ROUTINE ROUTINE - Acetaminophen/Aspirin/Caffeine PO Mild-moderate migraine (OTC option) 2 tablets PO :: PO :: :: 2 tablets (250/250/65 mg each) at onset; max 2 doses/24hr Aspirin allergy; hepatic impairment; avoid if using other acetaminophen Limit total acetaminophen &lt;3g/day URGENT ROUTINE ROUTINE - Rizatriptan PO Acute migraine; faster onset than sumatriptan 5 mg PO; 10 mg PO :: PO :: :: 5-10 mg PO (5 mg if on propranolol); may repeat after 2 hr; max 30 mg/24hr Same as sumatriptan; use 5 mg if on propranolol Triptan sensation - ROUTINE ROUTINE - Eletriptan PO Acute migraine; good for return of headache 40 mg PO; 80 mg PO :: PO :: :: 40 mg PO; may repeat 40 mg after 2 hr if partial response; max 80 mg/24hr Same as sumatriptan; potent CYP3A4 inhibitors Triptan sensation - ROUTINE ROUTINE - Naratriptan PO Slower onset but longer duration; menstrual migraine 2.5 mg PO :: PO :: :: 2.5 mg PO; may repeat after 4 hr; max 5 mg/24hr Same as sumatriptan; moderate-severe renal/hepatic impairment Triptan sensation - ROUTINE ROUTINE - Ubrogepant PO CGRP receptor antagonist; triptan contraindications 50 mg PO; 100 mg PO :: PO :: :: 50-100 mg PO; may repeat after 2 hr; max 200 mg/24hr Strong CYP3A4 inhibitors; severe hepatic impairment None routine - ROUTINE ROUTINE - Rimegepant PO/ODT CGRP antagonist; acute and preventive use 75 mg ODT :: PO :: :: 75 mg ODT at onset; max 75 mg/24hr for acute Strong CYP3A4 inhibitors; severe hepatic impairment None routine - ROUTINE ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Nerve block (occipital) SC Refractory migraine; occipital-predominant pain 2-3 mL of 2% lidocaine + 40 mg triamcinolone :: SC :: :: Inject at greater occipital nerve bilaterally; may add lesser occipital, supraorbital Local anesthetic allergy; infection at site Immediate pain relief; monitor for vasovagal - EXT ROUTINE - Sphenopalatine ganglion block Intranasal Refractory migraine; cluster-like features Lidocaine 4% via SphenoCath :: Intranasal :: :: Apply via intranasal device; repeat up to 3x/week Nasal pathology; local anesthetic allergy Local numbness, epistaxis - EXT EXT - Ketamine IV Status migrainosus refractory to DHE 0.1-0.3 mg/kg/hr IV :: IV :: :: 0.1-0.3 mg/kg/hr infusion for 24-48 hr; subanesthetic dosing Uncontrolled HTN; psychosis; increased ICP Dissociation, BP, HR; requires cardiac monitoring - EXT - -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#3d-disease-modifying-or-chronic-therapies-preventive-medications","title":"3D. Disease-Modifying or Chronic Therapies (Preventive Medications)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Propranolol PO First-line prevention; comorbid HTN or anxiety 40 mg BID; 80 mg BID; 80 mg daily LA; 160 mg daily LA :: PO :: :: Start 40 mg BID or 80 mg LA daily; titrate q2wk; target 80-240 mg/day None Asthma; COPD; bradycardia &lt;50; heart block; decompensated HF HR, BP; watch for fatigue, depression - ROUTINE ROUTINE - Topiramate PO First-line prevention; comorbid obesity 25 mg qHS; 50 mg BID; 75 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/wk; target 50-100 mg BID None Glaucoma; kidney stones; pregnancy Cognitive effects, paresthesias, weight, bicarbonate, kidney stones - ROUTINE ROUTINE - Amitriptyline PO Prevention; comorbid insomnia, depression, TTH 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS ECG if &gt;50 or cardiac history Cardiac conduction abnormality; recent MI; glaucoma; urinary retention Sedation, weight gain, dry mouth; ECG if &gt;100 mg - ROUTINE ROUTINE - Venlafaxine XR PO Prevention; comorbid depression, anxiety 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 75-150 mg daily None Uncontrolled HTN; MAOIs; abrupt discontinuation BP at higher doses; serotonin syndrome signs - ROUTINE ROUTINE - Valproate/Divalproex PO Prevention; comorbid bipolar or epilepsy 250 mg BID; 500 mg BID; 500 mg ER daily; 1000 mg ER daily :: PO :: :: Start 250 mg BID or 500 mg ER daily; titrate to 500-1000 mg/day LFTs, CBC Hepatic disease; pregnancy (teratogen); urea cycle disorders; pancreatitis LFTs q6mo; weight, hair loss, tremor - ROUTINE ROUTINE - Erenumab (Aimovig) SC CGRP mAb; failed 2+ oral preventives or intolerance 70 mg SC monthly; 140 mg SC monthly :: SC :: :: 70 mg SC monthly; may increase to 140 mg monthly after 3 months None Hypersensitivity to erenumab Constipation (can be severe), injection site reactions, HTN - - ROUTINE - Fremanezumab (Ajovy) SC CGRP mAb; alternative dosing options 225 mg SC monthly; 675 mg SC quarterly :: SC :: :: 225 mg SC monthly OR 675 mg SC quarterly None Hypersensitivity Injection site reactions - - ROUTINE - Galcanezumab (Emgality) SC CGRP mAb; also FDA-approved for cluster 240 mg SC load; 120 mg SC monthly :: SC :: :: 240 mg SC loading dose (2 x 120 mg), then 120 mg SC monthly None Hypersensitivity Injection site reactions - - ROUTINE - Eptinezumab (Vyepti) IV CGRP mAb; IV option for rapid onset 100 mg IV quarterly; 300 mg IV quarterly :: IV :: :: 100 mg IV q3mo; may increase to 300 mg IV q3mo None Hypersensitivity Infusion reactions (rare), nasopharyngitis - - ROUTINE - Onabotulinumtoxin A (Botox) IM Chronic migraine (\u226515 days/month); failed oral preventives 155-195 units IM :: IM :: :: 155-195 units across 31-39 injection sites q12wk; PREEMPT protocol None Infection at injection sites; myasthenia gravis Neck weakness, ptosis (rare); effect takes 2-3 cycles - - ROUTINE - Candesartan PO Prevention; comorbid HTN; beta-blocker intolerant 8 mg daily; 16 mg daily :: PO :: :: Start 8 mg daily; may increase to 16 mg daily None Pregnancy; bilateral renal artery stenosis; hyperkalemia BP, K+, creatinine - ROUTINE ROUTINE - Lisinopril PO Prevention; comorbid HTN 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; may increase to 20 mg daily None Pregnancy; angioedema history; bilateral RAS BP, K+, creatinine, cough - ROUTINE ROUTINE - Magnesium oxide PO Supplement for prevention; migraine with aura 400 mg daily; 400 mg BID :: PO :: :: 400-800 mg daily in divided doses None Renal impairment (dose adjust) Diarrhea; check Mg level if symptomatic - ROUTINE ROUTINE - Riboflavin (B2) PO Supplement for prevention; well-tolerated 400 mg daily :: PO :: :: 400 mg daily None None Fluorescent yellow urine (reassure patient) - ROUTINE ROUTINE - Coenzyme Q10 PO Supplement; may benefit mitochondrial function 100 mg TID; 300 mg daily :: PO :: :: 100-300 mg daily None None None - ROUTINE ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Headache specialist referral for chronic or refractory migraine management and preventive optimization - ROUTINE ROUTINE - Pain management referral for interventional procedures (nerve blocks, Botox) in chronic refractory cases - - ROUTINE - Behavioral medicine/Psychology for cognitive behavioral therapy addressing pain catastrophizing and comorbid anxiety/depression - - ROUTINE - Physical therapy for cervicogenic component and postural contribution to headaches - - ROUTINE - Sleep medicine evaluation if sleep disorder contributing to migraine frequency - - ROUTINE - Ophthalmology evaluation to rule out visual triggers and ensure appropriate vision correction - - ROUTINE - OB/GYN consultation for menstrual migraine management and hormonal contraception optimization - - ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for sudden severe headache different from typical migraine (\"worst headache of life\") which may indicate hemorrhage STAT - ROUTINE Return immediately for headache with fever, stiff neck, or altered mental status which may indicate infection STAT - ROUTINE Maintain headache diary tracking frequency, triggers, and medication use to guide treatment optimization - ROUTINE ROUTINE Limit acute medication use to \u226410 days/month to prevent medication overuse headache URGENT ROUTINE ROUTINE Take acute medications at first sign of migraine for best efficacy rather than waiting for severe pain - ROUTINE ROUTINE Identify and avoid personal triggers (stress, sleep changes, skipped meals, alcohol, specific foods) - ROUTINE ROUTINE","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular sleep schedule (7-8 hours, consistent bedtime/wake time) as irregular sleep is a major trigger - ROUTINE ROUTINE Regular meals to avoid fasting-triggered migraine; do not skip breakfast - ROUTINE ROUTINE Aerobic exercise (30 min moderate activity 5x/week) shown to reduce migraine frequency - ROUTINE ROUTINE Stress management through relaxation techniques, mindfulness, or biofeedback - ROUTINE ROUTINE Caffeine moderation (\u2264200 mg/day equivalent to 2 cups coffee) and consistent daily intake - ROUTINE ROUTINE Adequate hydration (at least 64 oz water daily) as dehydration can trigger migraine - ROUTINE ROUTINE Limit alcohol especially red wine which is a common trigger - ROUTINE ROUTINE","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Tension-type headache Bilateral, pressing/tightening quality, mild-moderate intensity, no nausea/vomiting, no photo/phonophobia (may have one) Clinical criteria; no specific test Cluster headache Unilateral, periorbital, severe, autonomic features (lacrimation, rhinorrhea, ptosis), 15-180 min, occurs in clusters Clinical history; may see MRI normal Medication overuse headache Daily or near-daily headache; using acute medications \u226510-15 days/month Headache diary; improves with medication withdrawal Secondary headache (intracranial pathology) New onset, progressive, positional, neurological deficits, thunderclap MRI/MRA brain; consider LP Giant cell arteritis Age &gt;50, scalp tenderness, jaw claudication, visual changes, elevated ESR/CRP ESR, CRP, temporal artery biopsy Idiopathic intracranial hypertension Positional headache, papilledema, pulsatile tinnitus, visual obscurations, obesity LP with opening pressure; MRI/MRV Cervicogenic headache Unilateral, occipital-frontal radiation, neck movement triggers, reduced ROM Physical exam; C-spine imaging; diagnostic block Trigeminal neuralgia Brief electric shock-like pain, unilateral V2/V3, triggered by touch/eating MRI for vascular loop; clinical criteria","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Headache diary (frequency, severity, duration) Continuous at home &lt;4 headache days/month; 50% reduction with preventive Adjust preventive therapy; consider Botox or CGRP mAb - ROUTINE ROUTINE - Acute medication use days Monthly \u226410 days/month Counsel on MOH; may need withdrawal protocol - ROUTINE ROUTINE - HIT-6 or MIDAS score Every 3 months 50% improvement in disability score Escalate preventive therapy - - ROUTINE - BP (if on beta-blocker or ARB) Each visit &lt;130/80; HR &gt;50 Adjust dose; switch agent if bradycardia - ROUTINE ROUTINE - LFTs (if on valproate) Baseline, 3 months, then q6mo Normal Discontinue if &gt;3x ULN - ROUTINE ROUTINE - Bicarbonate (if on topiramate) Baseline, 3 months &gt;18 mEq/L Consider dose reduction or discontinuation - ROUTINE ROUTINE - Weight Each visit Stable (topiramate: may decrease; others: may increase) Adjust medications based on weight changes - ROUTINE ROUTINE - Cognitive function (if on topiramate) Each visit No word-finding difficulty or cognitive slowing Reduce dose or switch agent - ROUTINE ROUTINE -","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Pain controlled; able to tolerate PO; no red flags; follow-up arranged Admit to floor Status migrainosus requiring IV therapy &gt;24hr; inability to tolerate PO; need for DHE protocol Admit to ICU Rare; only if hemodynamic instability from medications or concern for secondary cause requiring monitoring Outpatient follow-up Within 2-4 weeks for new diagnosis; 4-12 weeks for established patients on preventives","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Triptans effective for acute migraine Class I, Level A Marmura et al. Headache 2015 CGRP monoclonal antibodies for prevention Class I, Level A Goadsby et al. NEJM 2017 (erenumab STRIVE) OnabotulinumtoxinA for chronic migraine Class I, Level A Dodick et al. Headache 2010 (PREEMPT pooled) Topiramate for migraine prevention Class I, Level A Silberstein et al. Arch Neurol 2004 Metoclopramide effective for acute migraine Class II, Level B Friedman et al. Ann Emerg Med 2008 Dexamethasone reduces recurrence Class I, Level B Singh et al. Acad Emerg Med 2008 Propranolol for migraine prevention Class I, Level A Linde et al. Cochrane 2004 Gepants (ubrogepant, rimegepant) for acute migraine Class I, Level A Dodick et al. JAMA 2019 (ubrogepant) Magnesium for migraine with aura prevention Class II, Level B Peikert et al. Cephalalgia 1996 Exercise as effective as topiramate for prevention Class II, Level B Varkey et al. Cephalalgia 2011","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/migraine/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive acute and preventive treatment coverage - Includes gepants and CGRP monoclonal antibodies - Structured dosing format for order sentence generation</p>","tags":["headache","migraine","outpatient","emergency"]},{"location":"drafts/mild-cognitive-impairment/","title":"Mild Cognitive Impairment (MCI)","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#mild-cognitive-impairment-mci","title":"Mild Cognitive Impairment (MCI)","text":"<p>DIAGNOSIS: Mild Cognitive Impairment (MCI) ICD-10: G31.84 SCOPE: Outpatient-focused evaluation for MCI, identification of reversible causes, subtype classification (amnestic vs non-amnestic), risk factor modification, monitoring for progression, and symptomatic treatment. Includes guidance on disease-modifying therapy eligibility (anti-amyloid agents) and advance care planning.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#1a-essentialcore-labs-reversible-causes-screen","title":"1A. Essential/Core Labs (Reversible Causes Screen)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Anemia, infection, or malignancy contributing to cognitive changes Normal - ROUTINE ROUTINE - CMP (BMP + hepatic panel) Hyponatremia, uremia, hypercalcemia, hepatic encephalopathy as reversible causes Normal electrolytes, renal, hepatic function - ROUTINE ROUTINE - TSH Hypothyroidism is reversible cause of cognitive impairment 0.4-4.0 mIU/L - ROUTINE ROUTINE - Vitamin B12 Deficiency causes reversible cognitive impairment; common in elderly &gt;300 pg/mL (&gt;400 pg/mL optimal for neurological function) - ROUTINE ROUTINE - Folate Deficiency contributes to cognitive impairment; check with B12 &gt;3 ng/mL - ROUTINE ROUTINE - HbA1c Diabetes management affects cognition; vascular risk factor &lt;7% (individualize in elderly) - ROUTINE ROUTINE - Fasting lipid panel Vascular risk factor assessment; hyperlipidemia accelerates cognitive decline LDL &lt;100 mg/dL; &lt;70 if established CVD - ROUTINE ROUTINE - Glucose (fasting) Diabetes screening; glycemic control affects cognition 70-100 mg/dL - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU RPR or VDRL Neurosyphilis is rare but treatable cause of cognitive impairment Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder; if risk factors present Negative - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency associated with cognitive decline and dementia risk &gt;30 ng/mL - ROUTINE ROUTINE - Homocysteine Elevated levels associated with Alzheimer's disease and vascular cognitive impairment &lt;15 \u03bcmol/L - ROUTINE ROUTINE - ESR, CRP Inflammatory or autoimmune causes; vasculitis screen Normal - ROUTINE ROUTINE - Urinalysis UTI in elderly can present as cognitive changes; rule out reversible cause Negative for infection - ROUTINE ROUTINE - Methylmalonic acid (MMA) More sensitive than B12 level for functional B12 deficiency &lt;0.4 \u03bcmol/L - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Heavy metal panel (lead, mercury, arsenic) Toxic exposure history; occupational risk Normal - - EXT - Copper, ceruloplasmin Wilson's disease if age &lt;50; hepatic symptoms Normal - - EXT - Paraneoplastic antibody panel Autoimmune cognitive impairment; unexplained rapid progression Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2, GABA-B) Autoimmune encephalitis presenting as MCI Negative - EXT EXT - Genetic testing (APOE genotyping) Risk stratification for AD progression; anti-amyloid therapy planning Informational (APOE4 increases risk) - - EXT - Genetic testing (PSEN1, PSEN2, APP) Familial early-onset AD (&lt;65); family history of early-onset dementia No pathogenic variants - - EXT - Lyme serology Endemic area; outdoor exposure; systemic symptoms Negative - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Hippocampal volume, medial temporal atrophy (Scheltens scale), white matter disease burden, rule out structural causes (tumor, SDH, NPH) MRI-incompatible devices - ROUTINE ROUTINE - Neuropsychological testing (formal) At diagnosis; gold standard for MCI characterization Objective impairment 1-1.5 SD below age/education norms; preserved ADLs; characterize domain(s) affected None - - ROUTINE - Mini-Mental State Examination (MMSE) Screening; serial monitoring 24-30 (MCI often 24-27); &lt;24 suggests dementia None - ROUTINE ROUTINE - Montreal Cognitive Assessment (MoCA) More sensitive than MMSE for MCI &lt;26 abnormal; typically 18-25 in MCI None - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT Head non-contrast If MRI contraindicated or unavailable Rule out mass, hemorrhage, hydrocephalus None - ROUTINE ROUTINE - MRI Brain volumetrics Quantitative assessment; research/clinical trials Hippocampal volume percentile for age; whole brain atrophy rate MRI contraindications - - ROUTINE - FDG-PET Brain Differentiate underlying pathology when diagnosis uncertain AD pattern: temporoparietal hypometabolism; FTD: frontal/temporal hypometabolism None - - ROUTINE - Amyloid PET (florbetapir, florbetaben, flutemetamol) Diagnostic uncertainty; early-onset; anti-amyloid therapy eligibility Positive confirms amyloid pathology (at risk for AD); negative makes AD unlikely None - - ROUTINE - Sleep study (polysomnography) Sleep apnea screening; sleep disturbance affecting cognition AHI &lt;5 normal; treat if elevated None - - ROUTINE - EEG Atypical features; concern for seizures or encephalopathy Normal or mild nonspecific slowing in MCI None - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Tau PET (flortaucipir) Research; disease staging; clinical trial eligibility Pattern correlates with clinical syndrome; elevated tau predicts faster progression None - - EXT - DaTscan (ioflupane I-123) MCI with parkinsonism; differentiate DLB prodrome Reduced uptake suggests Lewy body pathology Iodine hypersensitivity - - EXT - SPECT (perfusion) Alternative to PET if unavailable Regional hypoperfusion patterns None - - EXT - MRI with SWI/GRE sequences Cerebral amyloid angiopathy; microbleed assessment Lobar microbleeds suggest CAA; affects anti-amyloid eligibility MRI contraindications - - ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Atypical presentation, early-onset (&lt;65), diagnostic uncertainty, amyloid PET unavailable, anti-amyloid therapy eligibility assessment, clinical trial enrollment Timing: ROUTINE for biomarker-based diagnosis when indicated Volume Required: 10-15 mL (standard diagnostic); additional for research biomarkers</p> Study Rationale Target Finding ED HOSP OPD ICU Cell count, protein, glucose Rule out infection, inflammation WBC &lt;5, protein &lt;45 mg/dL, glucose &gt;60% serum - ROUTINE ROUTINE - CSF A\u03b242 (amyloid beta 1-42) Low in Alzheimer's pathology; biomarker confirmation Low A\u03b242 (&lt;600 pg/mL) suggests AD pathology - ROUTINE ROUTINE - CSF total tau (t-tau) Elevated in neurodegeneration; nonspecific Mildly elevated in MCI due to AD; marked elevation suggests rapid progression - ROUTINE ROUTINE - CSF p-tau (phosphorylated tau 181) Specific for AD pathology; predictor of progression Elevated p-tau with low A\u03b242 = high risk of AD progression - ROUTINE ROUTINE - CSF A\u03b242/A\u03b240 ratio More accurate than A\u03b242 alone for amyloid status &lt;0.05-0.08 suggests amyloid positivity (assay-dependent) - ROUTINE ROUTINE - CSF neurofilament light chain (NfL) Nonspecific neurodegeneration marker; prognostic Elevated suggests active neurodegeneration - - ROUTINE - VDRL Neurosyphilis if RPR positive or high suspicion Nonreactive - ROUTINE ROUTINE - <p>Special Handling: CSF biomarkers require specialized handling; send to reference lab; freeze within 1 hour; use polypropylene tubes Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); posterior fossa mass; skin infection at site</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Treat reversible causes Various Identified metabolic, nutritional, or infectious etiology Per cause :: Various :: :: Correct hypothyroidism, replace B12/folate, treat infections, adjust medications Depends on intervention Cognitive reassessment 3-6 months after treatment - ROUTINE ROUTINE - Thiamine IV/PO Suspected Wernicke's; alcoholism; malnutrition 500 mg IV TID x 3 days; 100 mg PO daily :: IV/PO :: :: 500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily maintenance None Clinical improvement - ROUTINE ROUTINE - Vitamin B12 IM/PO B12 deficiency (&lt;300 pg/mL or elevated MMA) 1000 mcg IM daily x 7 days; 1000 mcg IM weekly x 4; 1000-2000 mcg PO daily :: IM/PO :: :: 1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily None B12 level, MMA at 3 months; neurological improvement over months - ROUTINE ROUTINE - Folate PO Folate deficiency 1 mg PO daily :: PO :: :: 1 mg PO daily; ensure B12 adequate before treating to avoid masking deficiency None Folate level at 3 months - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil PO MCI with high likelihood of AD pathology (amnestic MCI, positive biomarkers); modest symptomatic benefit 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS x 4-6 weeks; may increase to 10 mg qHS; limited evidence in MCI but may offer modest benefit Sick sinus syndrome; GI bleeding; severe COPD Bradycardia, GI symptoms, vivid dreams; limited efficacy data in MCI - - ROUTINE - Rivastigmine patch TD Alternative to donepezil; better GI tolerability; MCI with positive AD biomarkers 4.6 mg/24hr; 9.5 mg/24hr :: TD :: :: Start 4.6 mg/24hr; increase q4wk to 9.5 mg/24hr; limited evidence in MCI Same as donepezil; severe hepatic impairment Skin irritation, GI symptoms - - EXT - Citalopram PO Depression contributing to cognitive symptoms (pseudodementia component) 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly due to QT risk QT prolongation; concurrent QT-prolonging drugs QTc at baseline and if dose &gt;20 mg - ROUTINE ROUTINE - Sertraline PO Depression; anxiety contributing to cognitive complaints 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg MAOIs; caution with bleeding risk GI upset initially; reassess cognition after mood improves - ROUTINE ROUTINE - Escitalopram PO Depression; anxiety with cognitive symptoms 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; increase to 10 mg after 1 week; max 10 mg in elderly QT prolongation; MAOIs QTc monitoring - ROUTINE ROUTINE - Mirtazapine PO Depression with poor appetite, insomnia, and weight loss 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30 mg qHS MAOIs Weight gain (may be beneficial), sedation - ROUTINE ROUTINE - Bupropion PO Depression with fatigue; avoid if seizure risk 100 mg BID; 150 mg SR BID; 300 mg XL daily :: PO :: :: Start 100 mg BID or 150 mg SR daily; increase after 1 week; max 300 mg/day Seizure disorder; eating disorder; abrupt alcohol/benzo withdrawal Seizure risk; may improve alertness - ROUTINE ROUTINE - Trazodone PO Insomnia in MCI patients 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate to effect; typical 50-100 mg qHS Concurrent MAOIs; QT prolongation Orthostatic hypotension, morning sedation - ROUTINE ROUTINE - Melatonin PO Sleep disturbance; circadian rhythm support 1 mg qHS; 3 mg qHS; 5 mg qHS :: PO :: :: Start 1-3 mg qHS; may increase to 5 mg; take 30 min before bed None Daytime sedation; limited long-term data - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#3c-cardiovascular-risk-factor-management","title":"3C. Cardiovascular Risk Factor Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Atorvastatin PO Hyperlipidemia; vascular risk reduction; may slow cognitive decline 10 mg daily; 20 mg daily; 40 mg daily; 80 mg daily :: PO :: :: Start 10-20 mg daily; titrate to LDL goal; target LDL &lt;100 (or &lt;70 if established CVD) Active liver disease; pregnancy LFTs at baseline; lipid panel q3-6mo initially - ROUTINE ROUTINE - Rosuvastatin PO Hyperlipidemia; alternative statin 5 mg daily; 10 mg daily; 20 mg daily :: PO :: :: Start 5-10 mg daily; adjust to LDL goal Active liver disease; severe renal impairment (dose adjust) LFTs, lipid panel - ROUTINE ROUTINE - Lisinopril PO Hypertension; target BP &lt;130/80 for vascular protection 5 mg daily; 10 mg daily; 20 mg daily; 40 mg daily :: PO :: :: Start 5-10 mg daily; titrate q2wk to BP goal Angioedema history; pregnancy; bilateral renal artery stenosis K+, Cr, BP; cough - ROUTINE ROUTINE - Amlodipine PO Hypertension; especially if ACE-I intolerant 2.5 mg daily; 5 mg daily; 10 mg daily :: PO :: :: Start 2.5-5 mg daily; increase q2wk; max 10 mg Severe aortic stenosis Peripheral edema, BP - ROUTINE ROUTINE - Losartan PO Hypertension; alternative if ACE-I intolerant 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25-50 mg daily; titrate to BP goal; max 100 mg Same as lisinopril K+, Cr, BP - ROUTINE ROUTINE - Metformin PO Type 2 diabetes; potential neuroprotective effects 500 mg daily; 500 mg BID; 1000 mg BID :: PO :: :: Start 500 mg daily with meal; increase by 500 mg weekly; max 2000 mg/day eGFR &lt;30; risk of lactic acidosis HbA1c q3mo; B12 annually (metformin reduces absorption) - ROUTINE ROUTINE - Aspirin (low-dose) PO Secondary prevention if established CVD; not for primary prevention in MCI 81 mg daily :: PO :: :: 81 mg daily; only if established CVD or high vascular risk Active bleeding; aspirin allergy; high bleeding risk GI symptoms; bleeding - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#3d-disease-modifying-therapies-anti-amyloid","title":"3D. Disease-Modifying Therapies (Anti-Amyloid)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Lecanemab (Leqembi) IV MCI due to AD with confirmed amyloid pathology (positive amyloid PET or CSF biomarkers) 10 mg/kg IV q2wk :: IV :: :: 10 mg/kg IV every 2 weeks; infuse over 1 hour; continue as long as benefit maintained Amyloid PET or CSF confirming amyloid positivity; MRI baseline (within 1 year); APOE genotyping recommended; informed consent for ARIA risk &gt;4 microbleeds on MRI; superficial siderosis; anticoagulation (increased ARIA risk); recent stroke/TIA MRI at baseline, weeks 14, 52, 78; monitor for ARIA-E/H symptoms (headache, confusion, vision changes) - - ROUTINE - Donanemab (Kisunla) IV MCI due to AD with confirmed amyloid and intermediate/high tau pathology 700 mg IV q4wk x 3; 1400 mg IV q4wk :: IV :: :: 700 mg q4wk x 3 doses, then 1400 mg q4wk until amyloid cleared (PET-guided discontinuation) Amyloid PET positive; tau PET intermediate/high; MRI baseline; APOE genotyping APOE4 homozygotes have higher ARIA risk; &gt;4 microbleeds; anticoagulation MRI at baseline, weeks 16, 24, 52, 76; amyloid PET to guide discontinuation - - EXT - <p>ARIA Monitoring Notes: - ARIA-E (edema): Usually asymptomatic; may cause headache, confusion, visual disturbances - ARIA-H (hemorrhage): Microbleeds, superficial siderosis - Hold infusion for symptomatic ARIA; resume after resolution per protocol - APOE4 homozygotes have higher ARIA risk; requires detailed informed consent discussion - MCI patients with positive biomarkers are eligible for these treatments (FDA approved for early AD including MCI stage)</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Cognitive neurology for MCI subtype characterization, biomarker interpretation, and treatment planning - ROUTINE ROUTINE - Neuropsychology for comprehensive cognitive testing to establish baseline, characterize affected domains, and distinguish MCI subtypes - - ROUTINE - Geriatrics for comprehensive geriatric assessment, polypharmacy review, and functional optimization - ROUTINE ROUTINE - Occupational therapy for cognitive strategies, compensatory techniques, and home safety evaluation - - ROUTINE - Occupational therapy driving evaluation to assess fitness to drive given cognitive impairment - - ROUTINE - Social work for community resources, support services, and early care planning guidance - ROUTINE ROUTINE - Speech therapy for communication strategies if language domain affected (non-amnestic MCI) - - ROUTINE - Sleep medicine for sleep apnea evaluation if symptoms present (snoring, daytime sleepiness, witnessed apneas) - - ROUTINE - Psychiatry for depression evaluation if significant mood symptoms confounding cognitive assessment - ROUTINE ROUTINE - Genetics counseling if early-onset (&lt;65), family history of early-onset dementia, or considering genetic testing - - ROUTINE - Clinical trial referral for eligible patients interested in research studies targeting MCI and early AD - - ROUTINE - Elder law attorney for advance directives, healthcare proxy, and financial planning while patient has full capacity - - ROUTINE - PCP follow-up for cardiovascular risk factor management and coordination of vascular prevention - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return if sudden confusion worsens or new neurological symptoms develop which may indicate stroke or other acute process - ROUTINE ROUTINE Complete advance directives and establish healthcare proxy NOW while you have full capacity to make decisions - ROUTINE ROUTINE Consider long-term care preferences, financial planning, and legal arrangements with family while fully competent - ROUTINE ROUTINE Discuss driving safety with physician; formal driving evaluation recommended as MCI may affect reaction time and judgment - ROUTINE ROUTINE Use memory aids (calendars, smartphone reminders, pill organizers, written lists) to compensate for memory difficulties - ROUTINE ROUTINE Keep a consistent daily routine which helps with memory and reduces confusion - ROUTINE ROUTINE Take all medications as prescribed; bring medication list to all appointments - ROUTINE ROUTINE Return for follow-up cognitive testing every 6-12 months to monitor for progression - - ROUTINE Report new memory concerns, personality changes, or functional difficulties to physician promptly - ROUTINE ROUTINE Avoid anticholinergic medications (diphenhydramine, PM sleep aids) as they can worsen cognition - ROUTINE ROUTINE","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Engage in regular aerobic exercise (150 minutes/week moderate intensity) which may slow cognitive decline and improve brain health - ROUTINE ROUTINE Follow Mediterranean or MIND diet emphasizing vegetables, berries, fish, nuts, whole grains, and olive oil to reduce dementia risk - ROUTINE ROUTINE Participate in cognitively stimulating activities (reading, puzzles, learning new skills, social engagement) to build cognitive reserve - ROUTINE ROUTINE Maintain active social connections and relationships as social isolation is a modifiable dementia risk factor - ROUTINE ROUTINE Achieve adequate sleep (7-8 hours nightly) and treat sleep disorders (CPAP for sleep apnea) as poor sleep accelerates cognitive decline - ROUTINE ROUTINE Cardiovascular risk factor control with target BP &lt;130/80, HbA1c &lt;7%, LDL &lt;100 to reduce vascular contribution to cognitive decline - ROUTINE ROUTINE Address hearing loss with hearing aids as untreated hearing loss is a modifiable risk factor for cognitive decline - - ROUTINE Limit alcohol to maximum 1 drink daily as excess alcohol accelerates brain atrophy and cognitive decline - ROUTINE ROUTINE Smoking cessation to reduce vascular risk and improve overall brain health - ROUTINE ROUTINE Manage stress through relaxation techniques, mindfulness, or counseling as chronic stress impairs cognition - ROUTINE ROUTINE Review all medications with physician to identify and discontinue drugs that impair cognition (anticholinergics, benzodiazepines, opioids) - ROUTINE ROUTINE","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Normal aging Subjective memory concerns without objective impairment; no functional decline; normal neuropsych testing Neuropsychological testing within 1 SD of norms Subjective cognitive decline Memory complaints but normal objective testing; may be earliest preclinical stage Neuropsychological testing normal; monitor annually Depression (pseudodementia) Prominent mood symptoms; often aware of and distressed by deficits; improves with antidepressants GDS, PHQ-9; trial of antidepressant; reassess cognition Medication-induced cognitive impairment Temporal relationship to medication initiation; improvement with discontinuation Medication review; trial discontinuation of suspect agents Sleep apnea-related cognitive impairment Excessive daytime sleepiness; snoring; morning headaches; reversible with CPAP Polysomnography; cognitive reassessment after CPAP Alzheimer's disease (dementia stage) Functional impairment in ADLs (not just IADLs); more severe cognitive deficits Functional assessment; neuropsychological testing Vascular cognitive impairment Stepwise decline; focal findings; executive dysfunction prominent; significant white matter disease MRI with confluent white matter disease; vascular risk factors Dementia with Lewy bodies (prodromal) Visual hallucinations; REM sleep behavior disorder; parkinsonism; fluctuating cognition DaTscan; clinical features; sleep study for RBD Frontotemporal dementia (prodromal) Behavioral/personality changes; disinhibition; apathy; language variants; typically &lt;65 FDG-PET frontal/temporal hypometabolism; neuropsychological profile Thyroid dysfunction Fatigue, weight changes, cold/heat intolerance; reversible with treatment TSH, free T4; reassess after treatment Vitamin B12 deficiency Peripheral neuropathy; macrocytic anemia; reversible with replacement B12, MMA; improvement with supplementation","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU MoCA or MMSE Every 6-12 months Stable or &lt;2 point decline/year Decline &gt;3 points or reaching dementia threshold warrants reassessment; consider biomarker workup if not done - ROUTINE ROUTINE - Full neuropsychological testing Every 1-2 years or if significant change Stable across domains Decline suggests progression to dementia; adjust care plan - - ROUTINE - IADL/ADL function (FAQ, Lawton) Every 6-12 months Preserved basic ADLs (defines MCI vs dementia) Functional decline suggests progression to dementia; increase supports - ROUTINE ROUTINE - Depression screening (GDS, PHQ-9) Annually or if symptoms No significant depression Treat depression; reassess cognition after treatment - ROUTINE ROUTINE - Blood pressure Each visit &lt;130/80 mmHg Optimize antihypertensive therapy - ROUTINE ROUTINE - HbA1c (if diabetic) Every 3-6 months &lt;7% (individualized) Optimize glycemic control - ROUTINE ROUTINE - Lipid panel Annually LDL &lt;100 mg/dL Optimize statin therapy - ROUTINE ROUTINE - Vitamin B12 Annually &gt;300 pg/mL Supplement if low - - ROUTINE - TSH Annually 0.4-4.0 mIU/L Treat thyroid dysfunction - - ROUTINE - MRI (ARIA monitoring if on anti-amyloid) Per protocol (baseline, weeks 14, 52, 78 for lecanemab) No ARIA-E or ARIA-H Hold infusion per protocol; resume after resolution - - ROUTINE - Driving safety Annually or with decline Safe to drive Recommend driving cessation or OT driving evaluation - - ROUTINE - Weight Each visit Stable Nutritional assessment if declining - ROUTINE ROUTINE - Caregiver/family concerns Each visit No new concerns Investigate reported changes; adjust care plan - ROUTINE ROUTINE -","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Outpatient management (most MCI) Stable MCI; reversible causes addressed; care plan established; follow-up arranged Admit to floor Acute delirium requiring workup; safety concerns at home; caregiver crisis Outpatient neurology follow-up Every 6-12 months for cognitive monitoring; sooner if concerns Outpatient neuropsychology At diagnosis for baseline; repeat in 1-2 years or if significant change Referral to memory care program Progressive decline; need for specialized multidisciplinary management Clinical trial referral Eligible patient interested in research; positive biomarkers; early stage","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source MCI diagnostic criteria and subtypes Class I, Level A Petersen et al. Arch Neurol 2004; Albert et al. Alzheimers Dement 2011 Neuropsychological testing for MCI diagnosis Class I, Level A AAN Practice Parameter 2018 CSF biomarkers for AD pathology Class I, Level A Hansson et al. Lancet Neurol 2018 Amyloid PET for AD diagnosis in MCI Class I, Level A Johnson et al. Alzheimers Dement 2013 Cholinesterase inhibitors limited benefit in MCI Class I, Level B Petersen et al. NEJM 2005; Russ &amp; Morling, Cochrane 2012 Lecanemab slows decline in MCI due to AD Class I, Level A van Dyck et al. NEJM 2023 (Clarity AD) Donanemab slows decline in early AD Class I, Level A Sims et al. JAMA 2023 (TRAILBLAZER-ALZ 2) Physical exercise may slow cognitive decline Class II, Level B Livingston et al. Lancet 2020 (Lancet Commission on Dementia) Mediterranean/MIND diet reduces dementia risk Class II, Level B Morris et al. Alzheimers Dement 2015 Cardiovascular risk factor control protects cognition Class I, Level A Ngandu et al. Lancet 2015 (FINGER trial) Sleep apnea treatment improves cognition Class II, Level B Osorio et al. Neurology 2015 MCI progression rate to dementia (~10-15%/year) Epidemiological Mitchell &amp; Shiri-Feshki, Acta Psychiatr Scand 2009 Hearing loss as modifiable dementia risk factor Class II, Level B Lin et al. Arch Neurol 2011 Modifiable risk factors for dementia prevention Class II, Level A Livingston et al. Lancet 2024 (Lancet Commission Update)","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Outpatient-focused plan for MCI diagnosis and monitoring - Includes MCI subtypes (amnestic vs non-amnestic) - Comprehensive reversible causes workup - Structured dosing format for order sentence generation - Anti-amyloid therapy eligibility guidance (lecanemab, donanemab) - Cardiovascular risk factor management section - Driving assessment and advance care planning recommendations - Serial cognitive monitoring protocol</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#appendix-a-mci-subtypes-and-prognosis","title":"APPENDIX A: MCI Subtypes and Prognosis","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#classification","title":"Classification","text":"Subtype Characteristics Progression Risk Amnestic MCI - Single Domain Memory impairment only; preserved other domains Higher risk for Alzheimer's disease Amnestic MCI - Multi-Domain Memory + other cognitive domains impaired Higher risk for AD or vascular dementia Non-Amnestic MCI - Single Domain Impairment in one non-memory domain (executive, language, visuospatial) May progress to FTD, DLB, or vascular dementia Non-Amnestic MCI - Multi-Domain Multiple non-memory domains impaired Variable; may progress to non-AD dementias","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#biomarker-based-staging-nia-aa-research-framework","title":"Biomarker-Based Staging (NIA-AA Research Framework)","text":"Stage Clinical Amyloid Tau Neurodegeneration A-/T-/N- Cognitively normal - - - A+/T-/N- Preclinical AD + - - A+/T+/N- Preclinical AD + + - A+/T+/N+ MCI or Dementia due to AD + + + <p>A = Amyloid, T = Tau, N = Neurodegeneration (atrophy, FDG-PET hypometabolism)</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#progression-risk-factors","title":"Progression Risk Factors","text":"<ul> <li>Higher risk: Amnestic subtype, positive amyloid biomarkers, APOE4 carrier, greater hippocampal atrophy</li> <li>Lower risk: Negative amyloid biomarkers, identifiable reversible cause, younger age, non-amnestic subtype</li> </ul>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#appendix-b-anti-amyloid-therapy-eligibility-checklist","title":"APPENDIX B: Anti-Amyloid Therapy Eligibility Checklist","text":"","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#lecanemab-leqembi-eligibility","title":"Lecanemab (Leqembi) Eligibility","text":"<p>Inclusion Criteria: - [ ] MCI due to AD OR mild AD dementia - [ ] Confirmed amyloid pathology (positive amyloid PET OR CSF A\u03b242/40 ratio consistent with AD) - [ ] MMSE typically 22-30 or MoCA 18-26 - [ ] Reliable caregiver/study partner</p> <p>Exclusion Criteria: - [ ] &gt;4 microbleeds on MRI - [ ] Any superficial siderosis - [ ] Prior macrohemorrhage - [ ] Current anticoagulation (relative; increases ARIA risk) - [ ] Recent stroke or TIA (&lt;12 months)</p> <p>Pre-Treatment Workup: - [ ] MRI brain within 1 year (assess for microbleeds, rule out other pathology) - [ ] Amyloid PET or CSF biomarkers confirming amyloid positivity - [ ] APOE genotyping (recommended for risk counseling) - [ ] Baseline cognitive testing (MMSE, MoCA, or CDR) - [ ] Informed consent including ARIA risk discussion</p> <p>Monitoring Schedule: - MRI: Baseline, Week 14, Week 52, Week 78 (and with new symptoms) - Clinical assessment for ARIA symptoms each infusion</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/mild-cognitive-impairment/#aria-symptom-recognition","title":"ARIA Symptom Recognition","text":"ARIA-E (Edema) ARIA-H (Hemorrhage) Headache Often asymptomatic Confusion/disorientation Headache Visual disturbances Focal neurological symptoms Nausea/vomiting If large hemorrhage Gait instability <p>Most ARIA is asymptomatic and detected on scheduled MRI monitoring</p>","tags":["cognitive","mci","dementia-prevention","outpatient"]},{"location":"drafts/ms-chronic-management/","title":"Multiple Sclerosis - Chronic Management","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#multiple-sclerosis-chronic-management","title":"Multiple Sclerosis - Chronic Management","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Multiple Sclerosis - Chronic Management</p> <p>ICD-10: G35 (Multiple sclerosis)</p> <p>SYNONYMS: MS maintenance, chronic MS, established MS, MS long-term care, relapsing-remitting MS maintenance, RRMS chronic, secondary progressive MS, SPMS, progressive MS management</p> <p>SCOPE: Long-term management of established MS including disease-modifying therapy (DMT) monitoring, symptom management optimization, surveillance imaging, preventive care, and special populations (pregnancy planning). Excludes acute MS relapse (see \"MS - Exacerbation\") and initial diagnostic workup (see \"MS - New Diagnosis\"). Primary focus is outpatient management with guidance for ED/hospital presentation of established MS patients.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#1a-essentialcore-labs-routine-monitoring-all-ms-patients","title":"1A. Essential/Core Labs - Routine Monitoring (All MS Patients)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline monitoring; DMT safety; infection assessment Normal; ALC varies by DMT (see 1B) STAT STAT ROUTINE STAT CMP Metabolic panel; renal/hepatic function for DMT dosing Normal STAT STAT ROUTINE STAT LFTs (AST, ALT, ALP, bilirubin) DMT hepatotoxicity monitoring (interferons, teriflunomide, S1P modulators) AST/ALT &lt;3x ULN URGENT ROUTINE ROUTINE URGENT Urinalysis with culture UTI common MS comorbidity; can trigger pseudorelapse Negative STAT STAT ROUTINE STAT TSH Thyroid dysfunction (interferons, alemtuzumab) Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency associated with disease activity &gt;40 ng/mL (target &gt;50) - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#1b-dmt-specific-monitoring-labs","title":"1B. DMT-Specific Monitoring Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU INTERFERONS (Avonex, Rebif, Betaseron, Plegridy) CBC with differential Leukopenia, thrombocytopenia monitoring WBC &gt;3000, ANC &gt;1500, Plt &gt;100K - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - TSH Thyroid dysfunction Normal - ROUTINE ROUTINE - GLATIRAMER ACETATE (Copaxone, Glatopa) No routine labs required Minimal systemic toxicity N/A - - - - DIMETHYL/DIROXIMEL FUMARATE (Tecfidera, Vumerity) CBC with differential Lymphopenia (PML risk if ALC &lt;500 for &gt;6 months) ALC &gt;500/uL; discontinue if ALC &lt;500 x6mo - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - TERIFLUNOMIDE (Aubagio) CBC with differential Leukopenia WBC &gt;3000, ANC &gt;1500 - ROUTINE ROUTINE - LFTs Hepatotoxicity (black box warning) ALT &lt;3x ULN; discontinue if &gt;3x with symptoms - ROUTINE ROUTINE - Blood pressure Hypertension &lt;140/90 mmHg - ROUTINE ROUTINE - Pregnancy test Teratogenic (Category X) Negative STAT STAT ROUTINE - FINGOLIMOD (Gilenya) CBC with differential Lymphopenia expected (therapeutic effect) ALC 200-600/uL typical; concern if &lt;200 - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - VZV IgG Pre-treatment; vaccinate if negative Positive (immune) - ROUTINE ROUTINE - SIPONIMOD (Mayzent) CBC with differential Lymphopenia ALC 200-600/uL typical - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - CYP2C9 genotype Required before initiation; determines dosing 1/3 or 2/3: 1 mg dose; 3/3: contraindicated - - ROUTINE - OZANIMOD (Zeposia) / PONESIMOD (Ponvory) CBC with differential Lymphopenia ALC 200-600/uL typical - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - NATALIZUMAB (Tysabri) JCV antibody with index PML risk stratification Negative preferred; if positive, index &lt;0.9 lower risk URGENT URGENT ROUTINE URGENT CBC with differential Infusion reactions; general monitoring Normal URGENT ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE - OCRELIZUMAB (Ocrevus) / OFATUMUMAB (Kesimpta) / UBLITUXIMAB (Briumvi) Hepatitis B surface antigen, core antibody Reactivation risk Negative; if positive, HBV DNA and GI/ID consult - ROUTINE ROUTINE - Quantitative immunoglobulins (IgG, IgA, IgM) Hypogammaglobulinemia risk IgG &gt;400 mg/dL - ROUTINE ROUTINE - CD19/CD20 B-cell count Therapeutic monitoring B-cell depletion expected - ROUTINE ROUTINE - ALEMTUZUMAB (Lemtrada) CBC with platelet count ITP, neutropenia (monthly x 48 months after last dose) Platelets &gt;100K; report petechiae/bruising STAT STAT ROUTINE STAT Serum creatinine, urinalysis Anti-GBM nephropathy (monthly x 48 months) Creatinine stable; UA negative for RBCs/protein STAT STAT ROUTINE STAT TSH Autoimmune thyroid disease (quarterly x 48 months) Normal - ROUTINE ROUTINE - CLADRIBINE (Mavenclad) CBC with differential Lymphopenia (target); timing critical ALC &gt;800 before year 2; monitoring at months 2 and 6 - ROUTINE ROUTINE - LFTs Hepatotoxicity AST/ALT &lt;3x ULN - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#1c-rarespecialized-labs","title":"1C. Rare/Specialized Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU JCV PCR (CSF) Suspected PML (focal neuro symptoms on natalizumab/DMF/fingolimod) Negative (if positive, confirms PML) STAT STAT - STAT Serum natalizumab antibodies Suspected infusion reactions or loss of efficacy Negative - - EXT - Anti-drug antibodies (interferon) Suspected neutralizing antibodies with breakthrough disease Negative - - EXT - Serum neurofilament light chain (NfL) Research/emerging; monitor subclinical disease activity Low/stable (no established threshold) - - EXT - Pregnancy test (urine or serum) Before DMT initiation or if pregnancy suspected Negative before teratogenic DMTs STAT STAT ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#2a-essentialfirst-line-surveillance-imaging","title":"2A. Essential/First-line - Surveillance Imaging","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain with and without contrast (MS protocol) Annual surveillance; 3-6 months after DMT change No new/enlarging T2 lesions; no new enhancing lesions (NEDA-3) GFR &lt;30; gadolinium allergy; pacemaker URGENT URGENT ROUTINE URGENT MRI C-spine with and without contrast Annual or with new symptoms; baseline if not done No new cord lesions GFR &lt;30; gadolinium allergy; pacemaker URGENT URGENT ROUTINE URGENT MRI T-spine with and without contrast Baseline; repeat if new lower extremity symptoms No new cord lesions GFR &lt;30; gadolinium allergy; pacemaker URGENT ROUTINE ROUTINE URGENT","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#2b-extended-dmt-specific-and-symptom-directed","title":"2B. Extended - DMT-Specific and Symptom-Directed","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI brain for PML surveillance (natalizumab, DMF, fingolimod) q3-6 months if high JCV risk; q12 months if low risk No new periventricular or subcortical lesions without enhancement Standard MRI contraindications URGENT URGENT ROUTINE URGENT OCT (optical coherence tomography) Annual; baseline; after optic neuritis Stable RNFL thickness (&gt;5 micron/year loss is pathological) None - - ROUTINE - Visual evoked potentials Baseline; suspected subclinical optic nerve involvement Stable P100 latency None - - ROUTINE - ECG S1P modulators (fingolimod, siponimod) first dose; baseline and annually Normal sinus rhythm; PR &lt;200 ms; QTc &lt;500 ms None URGENT ROUTINE ROUTINE - Ophthalmology exam (macular OCT) S1P modulators at 3-4 months; then annually No macular edema None - - ROUTINE - Pulmonary function tests If respiratory symptoms; alemtuzumab monitoring FVC &gt;80% predicted None - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU PET-CT Suspected malignancy (lymphoma risk with immunosuppression) No FDG-avid lesions Pregnancy; uncontrolled diabetes - EXT EXT - Urodynamic studies Refractory bladder symptoms Defines neurogenic bladder type (hyperreflexic vs hyporeflexic) Active UTI - - EXT - Video swallow study Dysphagia or recurrent aspiration Safe swallow; define texture modifications None - ROUTINE ROUTINE - Sleep study (polysomnography) Severe fatigue; suspected sleep apnea AHI &lt;5/hour None - - ROUTINE - DEXA scan Long-term steroid exposure; mobility impairment; menopause T-score &gt;-2.5 None - - ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3-treatment","title":"3. TREATMENT","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3a-acuteemergent-ms-patient-presenting-to-edhospital","title":"3A. Acute/Emergent (MS Patient Presenting to ED/Hospital)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Continue home DMT Various Established MS patient on DMT Home dose :: Home route :: per home schedule :: Verify home DMT and continue unless contraindicated; consult neurology for infusion therapies Varies by DMT Per DMT STAT STAT - STAT Methylprednisolone IV IV Acute MS relapse 1000 mg :: IV :: daily x 3-5 days :: 1000 mg IV daily for 3-5 days; infuse over 1 hour Active infection; uncontrolled diabetes; psychosis Glucose q6h; BP; mood STAT STAT - STAT Omeprazole PO GI prophylaxis during steroids 20 mg daily; 40 mg daily :: PO :: daily :: 20-40 mg PO daily during steroids PPI allergy None STAT STAT - STAT Insulin sliding scale SC Steroid-induced hyperglycemia Per protocol :: SC :: PRN :: Per protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h STAT STAT - STAT","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-fatigue","title":"3B. Symptomatic Treatments - Fatigue","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Amantadine PO MS-related fatigue (first-line) 100 mg qAM; 100 mg BID :: PO :: :: Start 100 mg every morning; may add 100 mg early afternoon (before 2 PM to avoid insomnia); max 200 mg/day Renal impairment (adjust dose CrCl &lt;50); seizure history; uncontrolled glaucoma Livedo reticularis; ankle edema; hallucinations; insomnia - ROUTINE ROUTINE - Modafinil PO MS-related fatigue (second-line); Schedule IV 100 mg qAM; 200 mg qAM :: PO :: :: Start 100 mg every morning; may increase to 200 mg; max 200 mg daily; take early AM Cardiac arrhythmia; left ventricular hypertrophy; mitral valve prolapse BP; HR; may reduce hormonal contraception efficacy - - ROUTINE - Armodafinil PO MS-related fatigue; longer half-life; Schedule IV 150 mg qAM :: PO :: :: 150 mg every morning; longer duration than modafinil Same as modafinil Same as modafinil - - ROUTINE - Methylphenidate PO Refractory fatigue; Schedule II 5 mg BID; 10 mg BID; 20 mg BID :: PO :: :: Start 5 mg morning and noon; titrate by 5-10 mg/week; max 60 mg/day; avoid afternoon dosing Marked anxiety; glaucoma; motor tics; MAOIs; severe hypertension BP; HR; appetite; mood; growth (rare in adults) - - ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-spasticity","title":"3B. Symptomatic Treatments - Spasticity","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Baclofen PO Spasticity (first-line) 5 mg TID; 10 mg TID; 20 mg TID; 25 mg TID :: PO :: :: Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day divided TID-QID Renal impairment (reduce dose); avoid abrupt withdrawal Sedation; weakness; AVOID ABRUPT DISCONTINUATION (withdrawal seizures, hallucinations) - ROUTINE ROUTINE ROUTINE Tizanidine PO Spasticity (alternative to baclofen; less weakness) 2 mg qHS; 4 mg TID; 8 mg TID :: PO :: :: Start 2 mg qHS or TID; increase by 2-4 mg every 3-4 days; max 36 mg/day divided TID Hepatic impairment; concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors) LFTs at baseline, 1, 3, 6 months; hypotension; sedation - ROUTINE ROUTINE ROUTINE Cyclobenzaprine PO Spasticity with muscle spasm component 5 mg TID; 10 mg TID :: PO :: :: 5-10 mg TID; max 30 mg/day; short-term use preferred Cardiac arrhythmia; heart block; CHF; MAOIs; hyperthyroidism Anticholinergic effects; sedation; cardiac - ROUTINE ROUTINE - Dantrolene PO Spasticity refractory to baclofen/tizanidine 25 mg daily; 25 mg TID; 50 mg TID; 100 mg TID :: PO :: :: Start 25 mg daily; increase by 25 mg every 4-7 days; max 100 mg QID Active liver disease; concurrent hepatotoxic drugs LFTs monthly x 6 months, then periodically; hepatotoxicity (black box) - ROUTINE ROUTINE - OnabotulinumtoxinA IM Focal spasticity (upper or lower extremity) 100-400 units total :: IM :: q12 weeks :: Dose varies by muscle group; 100-400 units total; repeat every 12 weeks Infection at injection site; myasthenia gravis; ALS Systemic weakness (rare); local weakness - - ROUTINE - Intrathecal baclofen pump IT Severe refractory spasticity affecting quality of life Continuous infusion :: IT :: :: Trial 50-100 mcg bolus; maintenance typically 100-400 mcg/day; pump refill q1-3 months Active infection; pump site not suitable Pump alarm; reservoir level; overdose symptoms (sedation); withdrawal symptoms - ROUTINE ROUTINE ROUTINE","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-neuropathic-pain","title":"3B. Symptomatic Treatments - Neuropathic Pain","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO Neuropathic pain (first-line); dysesthesias; Lhermitte sign 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day Renal impairment (adjust dose per CrCl) Sedation; dizziness; peripheral edema; ataxia - ROUTINE ROUTINE ROUTINE Pregabalin PO Neuropathic pain (first-line alternative); Schedule V 75 mg BID; 150 mg BID; 225 mg BID; 300 mg BID :: PO :: :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID Renal impairment (adjust per CrCl) Sedation; weight gain; peripheral edema - ROUTINE ROUTINE - Duloxetine PO Neuropathic pain with comorbid depression 30 mg daily; 60 mg daily; 90 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; MAOIs; uncontrolled narrow-angle glaucoma Nausea (transient); BP; discontinuation syndrome (taper) - ROUTINE ROUTINE - Amitriptyline PO Neuropathic pain; nocturnal pain; insomnia 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma Anticholinergic effects; ECG if dose &gt;100 mg/day; weight gain - ROUTINE ROUTINE - Nortriptyline PO Neuropathic pain; less sedating than amitriptyline 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma Anticholinergic effects; ECG if dose &gt;100 mg/day - ROUTINE ROUTINE - Carbamazepine PO Trigeminal neuralgia in MS 100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day AV block; bone marrow suppression; MAOIs CBC; LFTs; sodium; HLA-B*1502 in Asian ancestry (SJS risk) - ROUTINE ROUTINE - Oxcarbazepine PO Trigeminal neuralgia (better tolerated than carbamazepine) 300 mg BID; 600 mg BID; 900 mg BID :: PO :: :: Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID Hypersensitivity to carbamazepine Sodium (hyponatremia more common); HLA-B*1502 screening - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-bladder-dysfunction","title":"3B. Symptomatic Treatments - Bladder Dysfunction","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Oxybutynin IR PO Detrusor hyperreflexia; urinary urgency/frequency 5 mg BID; 5 mg TID :: PO :: :: Start 5 mg BID-TID; max 5 mg QID Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction Dry mouth; constipation; COGNITIVE IMPAIRMENT (avoid in elderly) - ROUTINE ROUTINE - Oxybutynin ER PO Urinary urgency (fewer CNS effects than IR) 5 mg daily; 10 mg daily; 15 mg daily :: PO :: :: Start 5-10 mg daily; max 30 mg daily Same as IR Same but less cognitive impairment - - ROUTINE - Solifenacin PO Urinary urgency (better CNS profile) 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily Urinary retention; gastric retention; uncontrolled narrow-angle glaucoma Dry mouth; constipation; preferred if cognitive concerns - - ROUTINE - Mirabegron PO Urinary urgency (beta-3 agonist; no anticholinergic effects) 25 mg daily; 50 mg daily :: PO :: :: Start 25 mg daily; may increase to 50 mg daily Uncontrolled hypertension; severe hepatic impairment BP monitoring; well-tolerated; fewer cognitive effects - - ROUTINE - Vibegron PO Urinary urgency (newer beta-3 agonist) 75 mg daily :: PO :: :: 75 mg once daily; no titration needed Severe hepatic impairment BP; well-tolerated - - ROUTINE - Tamsulosin PO Urinary retention; hesitancy (detrusor-sphincter dyssynergia) 0.4 mg daily :: PO :: :: 0.4 mg daily 30 minutes after same meal each day Severe sulfonamide allergy (caution) Orthostatic hypotension; retrograde ejaculation - ROUTINE ROUTINE - Intermittent self-catheterization \u2014 Urinary retention (PVR &gt;100-200 mL) Per protocol :: \u2014 :: 4-6x daily :: Clean technique; frequency based on PVR and symptoms Unable to perform; urethral stricture UTI frequency; bladder diary; PVR - ROUTINE ROUTINE - OnabotulinumtoxinA (bladder) Cystoscopic Refractory detrusor hyperreflexia 100-200 units :: Cystoscopic :: q6-12 months :: 100 units (start); may increase to 200 units; cystoscopic injection UTI; urinary retention not willing to catheterize PVR (may require ISC); UTI - - ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-depression-and-anxiety","title":"3B. Symptomatic Treatments - Depression and Anxiety","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Sertraline PO Depression in MS (first-line) 50 mg daily; 100 mg daily; 150 mg daily; 200 mg daily :: PO :: :: Start 50 mg daily; increase by 25-50 mg every 1-2 weeks; max 200 mg daily Concurrent MAOIs; pimozide Suicidality monitoring weeks 1-4; serotonin syndrome - ROUTINE ROUTINE - Escitalopram PO Depression; anxiety in MS 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; may increase to 20 mg after 1 week; max 20 mg daily Concurrent MAOIs; QT prolongation QTc if risk factors or dose &gt;10 mg; suicidality monitoring - ROUTINE ROUTINE - Bupropion SR/XL PO Depression; fatigue; no sexual side effects 150 mg daily; 150 mg BID; 300 mg XL daily :: PO :: :: Start 150 mg SR daily; increase to 150 mg SR BID or 300 mg XL daily; max 400 mg/day Seizure disorder; eating disorders; abrupt alcohol/benzo withdrawal Seizure risk; insomnia; agitation - ROUTINE ROUTINE - Venlafaxine XR PO Depression with pain component; anxiety 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5-75 mg daily; increase by 75 mg every 4-7 days; max 225 mg daily Uncontrolled hypertension; MAOIs BP monitoring; discontinuation syndrome (taper slowly) - ROUTINE ROUTINE - Duloxetine PO Depression with neuropathic pain 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; MAOIs; narrow-angle glaucoma Nausea; BP; discontinuation syndrome - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-gaitmobility","title":"3B. Symptomatic Treatments - Gait/Mobility","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Dalfampridine PO Walking impairment in MS (improves walking speed) 10 mg q12h :: PO :: :: 10 mg every 12 hours (MUST be exactly 12 hours apart); do NOT exceed 20 mg/day; swallow whole Seizure history; CrCl &lt;50 mL/min; history of seizure on dalfampridine Seizure risk (dose-dependent); UTI; dizziness; insomnia - - ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-cognitive-impairment","title":"3B. Symptomatic Treatments - Cognitive Impairment","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Cognitive rehabilitation therapy \u2014 MS-related cognitive impairment Per protocol :: \u2014 :: 1-2x weekly :: Referral to neuropsychology or speech therapy for structured cognitive exercises None Compliance; functional outcomes - - ROUTINE - Donepezil PO Cognitive impairment (off-label; limited evidence) 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; may increase to 10 mg after 4-6 weeks GI bleeding; cardiac conduction disease Nausea; diarrhea; bradycardia; vivid dreams - - EXT -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3b-symptomatic-treatments-other","title":"3B. Symptomatic Treatments - Other","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Dextromethorphan-quinidine (Nuedexta) PO Pseudobulbar affect (PBA) 20/10 mg daily; 20/10 mg q12h :: PO :: :: Start 20/10 mg daily x 7 days; then 20/10 mg every 12 hours QT prolongation; MAOIs; concurrent quinidine/quinine ECG at baseline; QTc monitoring; drug interactions (CYP2D6) - - ROUTINE - Propranolol PO Action tremor in MS 20 mg BID; 40 mg BID; 80 mg BID :: PO :: :: Start 20 mg BID; increase by 20-40 mg every 3-7 days; max 320 mg/day Asthma/COPD; bradycardia; heart block; decompensated CHF HR; BP; fatigue; depression - ROUTINE ROUTINE - Primidone PO Tremor refractory to propranolol 25 mg qHS; 50 mg TID; 125 mg TID :: PO :: :: Start 25 mg qHS; increase by 25 mg weekly; usual 50-250 mg TID Porphyria; phenobarbital hypersensitivity Severe sedation initially; ataxia; cognitive effects - - ROUTINE - Polyethylene glycol 3350 PO Constipation (common with immobility, anticholinergics) 17 g daily; 17 g BID :: PO :: :: 17 g (1 capful) in 8 oz liquid daily; adjust to effect; may take 1-3 days Bowel obstruction; ileus Electrolytes if prolonged use - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3c-second-linerefractory-acute-treatments","title":"3C. Second-line/Refractory Acute Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Plasmapheresis (PLEX) \u2014 Steroid-refractory acute relapse 5-7 exchanges :: \u2014 :: over 10-14 days :: 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange Hemodynamic instability; sepsis; central line contraindication BP; electrolytes; coagulation; fibrinogen; line infection - URGENT - URGENT IVIG IV Steroid-refractory relapse (alternative to PLEX) 0.4 g/kg/day :: IV :: x 5 days :: 0.4 g/kg/day x 5 days (total 2 g/kg) IgA deficiency; renal failure; thrombosis history Renal function; headache; aseptic meningitis; thrombosis - URGENT - URGENT","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#3d-disease-modifying-therapies-monitoring-protocols","title":"3D. Disease-Modifying Therapies - Monitoring Protocols","text":"<p>DMT monitoring is critical for chronic MS management. See Section 1B for specific lab requirements. Below are monitoring schedules by DMT class.</p> Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU INJECTABLE DMTs Interferon beta (any formulation) IM/SC RRMS; established patient on therapy Per product labeling :: IM/SC :: :: Continue established regimen CBC, LFTs, TSH at baseline Decompensated liver disease; depression (relative) CBC, LFTs q3-6 months; TSH annually; depression screening - - ROUTINE - Glatiramer acetate (any formulation) SC RRMS; established patient 20 mg daily or 40 mg TIW :: SC :: :: Continue established regimen None required Hypersensitivity Injection site reactions; post-injection reaction (self-limited) - - ROUTINE - ORAL DMTs - MODERATE EFFICACY Dimethyl fumarate (Tecfidera) PO RRMS; established patient 240 mg BID :: PO :: :: Continue 240 mg BID with food CBC, LFTs ALC &lt;500 for &gt;6 months (discontinue); PML risk CBC q6 months; LFTs periodically; MRI surveillance for PML - - ROUTINE - Diroximel fumarate (Vumerity) PO RRMS; less GI side effects than Tecfidera 462 mg BID :: PO :: :: Continue 462 mg BID with food CBC, LFTs ALC &lt;500 for &gt;6 months (discontinue); PML risk CBC q6 months; LFTs periodically; MRI surveillance for PML - - ROUTINE - Teriflunomide (Aubagio) PO RRMS; established patient 7 mg or 14 mg daily :: PO :: :: Continue established dose LFTs monthly x 6 months; TB test; BP; pregnancy test Pregnancy (Category X); severe hepatic impairment LFTs monthly x 6 months, then periodically; BP; pregnancy test PRN - - ROUTINE - ORAL DMTs - S1P MODULATORS (HIGH EFFICACY) Fingolimod (Gilenya) PO RRMS; established patient 0.5 mg daily :: PO :: :: Continue 0.5 mg daily First-dose observation completed; VZV immune; macular OCT; ECG Cardiac conduction issues; recent MI/stroke; macular edema Macular OCT annually; CBC q6-12 months; LFTs annually; MRI for PML surveillance - - ROUTINE - Siponimod (Mayzent) PO SPMS or RRMS; established patient 1 mg or 2 mg daily (per CYP2C9) :: PO :: :: Continue established dose per genotype CYP2C9 genotype; first-dose observation; macular OCT CYP2C9 3/3; cardiac conduction issues; macular edema Macular OCT annually; CBC q6-12 months; LFTs annually - - ROUTINE - Ozanimod (Zeposia) PO RRMS; established patient 0.92 mg daily :: PO :: :: Continue 0.92 mg daily Macular OCT; ECG (no first-dose observation required) Cardiac conduction issues; recent MI/stroke; MAOIs Macular OCT at 3-4 months then annually; CBC; LFTs - - ROUTINE - Ponesimod (Ponvory) PO RRMS; established patient 20 mg daily :: PO :: :: Continue 20 mg daily Macular OCT; ECG (no first-dose observation required) Cardiac conduction issues; recent MI/stroke Macular OCT at 3-4 months then annually; CBC; LFTs - - ROUTINE - ORAL DMTs - HIGH EFFICACY OTHER Cladribine (Mavenclad) PO RRMS/SPMS; induction therapy 1.75 mg/kg/year x 2 years :: PO :: :: Year 1 and Year 2 only; no treatment years 3-4 ALC &gt;800 before each year; LFTs; HIV; Hep B/C Active infection; HIV; malignancy; pregnancy CBC at months 2 and 6 each treatment year; malignancy screening - - ROUTINE - INFUSION DMTs - HIGH EFFICACY Natalizumab (Tysabri) IV RRMS; established patient 300 mg q4 weeks or extended q6 weeks :: IV :: :: Standard interval q4 weeks; extended interval dosing (EID) q6 weeks if stable and JCV negative JCV antibody q6 months; REMS enrollment JCV+ with index &gt;1.5 and prior immunosuppression (high PML risk) JCV q6 months; MRI q3-6 months (high risk) or q6-12 months (low risk) for PML surveillance - - ROUTINE - Ocrelizumab (Ocrevus) IV RRMS/PPMS; established patient 600 mg q6 months :: IV :: :: 600 mg IV every 6 months; premedicate Hepatitis B screening; TB test; immunoglobulins Active Hepatitis B; active infection IgG annually; infection monitoring; infusion reactions - - ROUTINE - Ofatumumab (Kesimpta) SC RRMS; established patient 20 mg monthly :: SC :: :: 20 mg SC monthly; self-administered at home Hepatitis B screening; TB test; immunoglobulins Active Hepatitis B; active infection IgG annually; infection monitoring - - ROUTINE - Ublituximab (Briumvi) IV RRMS; established patient 450 mg q6 months :: IV :: :: 450 mg IV every 24 weeks (after initial doses); 1-hour infusion Hepatitis B screening; TB test; immunoglobulins Active Hepatitis B; active infection IgG annually; infection monitoring; infusion reactions - - ROUTINE - Alemtuzumab (Lemtrada) IV RRMS; established patient post-induction No further dosing unless rebound :: IV :: :: Monitoring continues 48 months after last infusion even without additional dosing REMS enrollment; extensive baseline labs Active infection; ongoing autoimmune disease CBC monthly x 48 months; TSH q3 months x 48 months; creatinine/UA monthly x 48 months - - ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU MS specialist/Neuroimmunology for annual comprehensive review and DMT optimization - ROUTINE ROUTINE - Neuro-ophthalmology for visual complaints, OCT monitoring, or suspected optic neuritis - ROUTINE ROUTINE - Physical therapy for gait training, balance exercises, and fall prevention given progressive mobility decline - ROUTINE ROUTINE ROUTINE Occupational therapy for ADL assessment, energy conservation strategies, and adaptive equipment - ROUTINE ROUTINE - Speech therapy for dysphagia evaluation given brainstem involvement or swallowing concerns - URGENT ROUTINE URGENT Neuropsychology for formal cognitive testing if subjective or objective cognitive decline - - ROUTINE - Cognitive rehabilitation (speech therapy or neuropsychology) for documented cognitive impairment - - ROUTINE - Urology for refractory bladder symptoms, recurrent UTIs, or urodynamic testing consideration - - ROUTINE - Psychiatry for depression, anxiety, or adjustment disorders not responding to first-line treatment - ROUTINE ROUTINE - Pain management for refractory neuropathic pain not responding to multiple first-line agents - - ROUTINE - Physiatry/Rehabilitation medicine for comprehensive rehabilitation planning and spasticity management - ROUTINE ROUTINE - Social work for disability planning, insurance navigation, and community resource connection - ROUTINE ROUTINE - Genetic counseling if considering pregnancy with strong family history or known genetic mutations - - ROUTINE - High-risk OB for pregnancy planning discussion in women on DMTs - - ROUTINE - Infusion center for DMT administration and monitoring - ROUTINE ROUTINE - Palliative care for advanced MS with significant symptom burden or goals of care discussions - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if rapid vision loss, new weakness, numbness, or difficulty walking develops (may indicate relapse requiring steroids) ROUTINE ROUTINE ROUTINE Report fever or signs of infection promptly as immunomodulatory DMTs increase infection risk ROUTINE ROUTINE ROUTINE Continue DMT as prescribed unless instructed otherwise by neurology - do not stop without discussing - ROUTINE ROUTINE Avoid live vaccines while on immunosuppressive DMTs (fingolimod, siponimod, cladribine, anti-CD20 therapies, alemtuzumab) - ROUTINE ROUTINE Heat may temporarily worsen symptoms (Uhthoff phenomenon) - use cooling strategies; this is NOT a new relapse ROUTINE ROUTINE ROUTINE Maintain symptom diary noting new symptoms, fatigue levels, and bladder/bowel patterns - ROUTINE ROUTINE Do not stop baclofen or tizanidine abruptly - taper under medical supervision to avoid withdrawal - ROUTINE ROUTINE Report any skin changes, new moles, or suspicious lesions given increased malignancy risk with some DMTs - - ROUTINE Women of childbearing potential: discuss pregnancy plans with MS specialist before conception given DMT-specific washout requirements - ROUTINE ROUTINE Report unusual fatigue, shortness of breath, chest pain, or palpitations if on S1P modulators (cardiac effects) ROUTINE ROUTINE ROUTINE If on natalizumab: report any new neurological symptoms, especially if subtle (confusion, personality change, clumsiness) as may indicate PML URGENT URGENT ROUTINE Take dalfampridine exactly 12 hours apart and never exceed 2 doses per day (seizure risk) - ROUTINE ROUTINE","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation - smoking accelerates MS progression, increases relapse rate, and worsens disability ROUTINE ROUTINE ROUTINE Vitamin D supplementation 2000-5000 IU daily to maintain serum 25-OH vitamin D &gt;40 ng/mL (target &gt;50 ng/mL) - ROUTINE ROUTINE Regular aerobic exercise 150 minutes per week as tolerated - improves fatigue, mood, mobility, and may slow progression - ROUTINE ROUTINE Aquatic therapy/swimming - allows exercise with built-in cooling and reduced fall risk - ROUTINE ROUTINE Resistance training 2-3 times weekly for strength maintenance and bone health - - ROUTINE Stress management techniques as stress may trigger pseudorelapses and worsen fatigue - ROUTINE ROUTINE Sleep hygiene - ensure 7-8 hours nightly; address sleep disorders contributing to fatigue - ROUTINE ROUTINE Avoid excessive heat exposure (hot tubs, saunas, exercising in heat) - use cooling vests for outdoor activities - ROUTINE ROUTINE Fall prevention: remove loose rugs, ensure adequate lighting, use assistive devices (cane, walker) as needed - ROUTINE ROUTINE Complete recommended vaccinations before starting immunosuppressive DMTs - inactivated vaccines safe on most DMTs - ROUTINE ROUTINE Annual influenza vaccine (inactivated) and COVID-19 vaccines per current guidelines (timing around infusions for anti-CD20) - ROUTINE ROUTINE Limit alcohol intake as it can worsen balance, cognitive symptoms, and interact with medications - - ROUTINE Mediterranean diet pattern may have anti-inflammatory benefits based on observational data - - ROUTINE DEXA scan for bone density monitoring if prolonged steroid exposure, immobility, or menopause - - ROUTINE","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4d-vaccination-guidance","title":"4D. Vaccination Guidance","text":"Recommendation ED HOSP OPD LIVE vaccines (MMR, varicella, zoster live, yellow fever) contraindicated on fingolimod, siponimod, ozanimod, ponesimod, cladribine, anti-CD20 therapies, alemtuzumab - ROUTINE ROUTINE Recombinant zoster vaccine (Shingrix) - 2 doses recommended for patients &gt;50 years; safe on most DMTs - - ROUTINE Ensure VZV immunity (IgG) before starting S1P modulators - vaccinate and wait 4 weeks if non-immune - - ROUTINE Hepatitis B vaccination if non-immune before starting anti-CD20 therapies (ocrelizumab, ofatumumab, ublituximab) - - ROUTINE Pneumococcal vaccination (PCV20 or PCV15 + PPSV23) recommended especially before immunosuppressive DMTs - - ROUTINE COVID-19 vaccination: complete primary series and boosters; for anti-CD20 therapies, time 2-4 weeks before next infusion or 12+ weeks after last infusion - ROUTINE ROUTINE HPV vaccination for eligible patients &lt;45 years, especially before cladribine or alemtuzumab (malignancy screening required) - - ROUTINE Influenza vaccine annually (inactivated) - safe on all DMTs; for anti-CD20, optimize timing but do not delay if timing not ideal - ROUTINE ROUTINE","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#4e-pregnancy-planning","title":"4E. Pregnancy Planning","text":"Recommendation ED HOSP OPD Discuss pregnancy plans with MS specialist before conception - most DMTs require washout period - - ROUTINE Teriflunomide: Category X - requires accelerated elimination procedure (cholestyramine or activated charcoal) before conception; verify undetectable levels - - ROUTINE Fingolimod: discontinue 2 months before conception; rebound risk after stopping - - ROUTINE Siponimod, ozanimod, ponesimod: discontinue 7-10 days before conception (shorter half-lives than fingolimod) - - ROUTINE Natalizumab: can continue until pregnancy confirmed; some continue through pregnancy in high-activity disease with shared decision-making - - ROUTINE Anti-CD20 therapies: discontinue 6-12 months before conception; B-cell recovery variable - - ROUTINE Cladribine: recommend effective contraception for 6 months after last dose (men and women) - - ROUTINE Alemtuzumab: recommend contraception for 4 months after last infusion - - ROUTINE Glatiramer acetate and interferon-beta: no evidence of harm; may continue during pregnancy if needed (glatiramer preferred) - - ROUTINE High-risk OB referral for all MS pregnancies given increased complication risk and postpartum relapse risk - - ROUTINE Plan for early postpartum DMT restart (relapses increase 3-6 months postpartum) - - ROUTINE","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"<p>For established MS patients presenting with new symptoms, consider:</p> Alternative Diagnosis Key Distinguishing Features Tests to Differentiate MS relapse vs pseudorelapse True relapse: new neuroinflammation; Pseudorelapse: symptom worsening from infection, heat, stress without new inflammation MRI with contrast (new enhancing lesions = true relapse); infection workup (UTI, URI) Progressive multifocal leukoencephalopathy (PML) Subacute cognitive/behavioral change, visual, motor symptoms; on natalizumab, DMF, fingolimod MRI (subcortical non-enhancing lesions); CSF JCV PCR CNS infection Fever, meningeal signs, rapid deterioration; immunosuppressed Lumbar puncture; blood cultures; imaging Comorbid stroke/TIA Sudden onset; vascular risk factors; non-MS territory MRI DWI; vascular imaging Medication side effect Temporal relationship to new medication or dose change Medication review; trial discontinuation Functional neurological disorder Inconsistent exam; non-anatomical patterns; psychiatric comorbidity Clinical assessment; normal MRI B12 deficiency myelopathy Progressive; dorsal column signs; may coexist with MS B12, MMA, homocysteine Secondary malignancy Progressive; atypical pattern; on immunosuppressive DMT PET-CT; biopsy if indicated","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU CLINICAL Neurologic examination (EDSS) Every visit; minimum annually Stable or improved If worsening: MRI, DMT optimization discussion - ROUTINE ROUTINE - Relapse frequency Continuous; review at each visit Zero relapses (NEDA goal) Any relapse triggers MRI and DMT reassessment - - ROUTINE - Walking speed (T25FW) Annually Stable or improved If worsening: PT referral, dalfampridine consideration - - ROUTINE - Cognition (SDMT or MoCA) Annually Stable (&gt;4 point decline on SDMT significant) Cognitive rehab referral; medication review - - ROUTINE - Depression screening (PHQ-9) Annually; more often if symptoms Score &lt;10 Antidepressant; psychiatry referral - ROUTINE ROUTINE - Fatigue (MFIS or FSS) Each visit Stable or improving Fatigue management optimization - - ROUTINE - IMAGING MRI brain with contrast Annually; 3-6 months after DMT switch No new/enlarging T2 lesions; no enhancing lesions New activity: DMT escalation discussion URGENT URGENT ROUTINE URGENT MRI spine Annually or with new symptoms No new cord lesions New lesions: DMT reassessment URGENT ROUTINE ROUTINE - Macular OCT Baseline; 3-4 months on S1P modulators; then annually No macular edema; stable RNFL Macular edema: discontinue S1P modulator; ophthalmology - - ROUTINE - LABORATORY CBC with differential q6 months on lymphocyte-depleting DMTs; annually others Per DMT-specific thresholds (see Section 1B) Adjust or discontinue DMT per protocol - ROUTINE ROUTINE - LFTs Per DMT schedule; more frequent early on AST/ALT &lt;3x ULN Hold DMT if &gt;3x; resume if resolves - ROUTINE ROUTINE - JCV antibody with index q6 months on natalizumab Negative preferred; monitor index if positive Rising index: risk counseling; consider DMT switch URGENT URGENT ROUTINE - Immunoglobulins (IgG) Annually on anti-CD20 therapies IgG &gt;400 mg/dL If low: infection precautions; consider IVIG replacement - ROUTINE ROUTINE - Vitamin D, 25-OH Annually &gt;40 ng/mL (target &gt;50) Increase supplementation if low - - ROUTINE - ALEMTUZUMAB-SPECIFIC (48 months after last infusion) CBC with platelets Monthly x 48 months Platelets &gt;100K If low: hold; hematology consult for ITP STAT STAT ROUTINE STAT TSH q3 months x 48 months Normal If abnormal: endocrine consult - ROUTINE ROUTINE - Serum creatinine + UA Monthly x 48 months Stable creatinine; no RBCs/protein in UA If abnormal: nephrology consult for anti-GBM disease STAT STAT ROUTINE STAT","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild symptom worsening attributable to pseudorelapse (infection treated, heat exposure resolved); stable neurologic exam; able to care for self or adequate caregiver support; reliable follow-up Admit to floor Moderate-severe acute relapse requiring IV steroids; functional decline preventing safe discharge; diagnostic workup for suspected PML or CNS infection; severe medication side effect requiring monitoring Admit to ICU Severe myelitis with respiratory compromise (NIF declining toward -20 cm H2O); brainstem involvement with airway risk; severe infusion reaction; suspected PML with rapid deterioration Transfer to higher level PLEX needed but unavailable; MS specialist not available for complex decision-making (PML management, severe breakthrough); MRI unavailable for urgent imaging Outpatient follow-up Every 3-6 months for stable patients; q1-3 months during DMT transition or active disease; annually minimum for established stable patients","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Annual MRI surveillance for subclinical disease activity Class II, Level B Wattjes MP et al. Lancet Neurol 2021 (MAGNIMS-CMSC-NAIMS) NEDA (No Evidence of Disease Activity) as treatment target Class II, Level B Giovannoni G et al. Neurology 2017 JCV antibody monitoring for PML risk stratification Class I, Level A Bloomgren G et al. NEJM 2012 Extended interval dosing of natalizumab reduces PML risk Class II, Level B Zhovtis Ryerson L et al. Ann Neurol 2019 Anti-CD20 therapies effective in RRMS and PPMS Class I, Level A Hauser SL et al. NEJM 2017 (OPERA) Vitamin D supplementation reduces relapse rate Class I, Level B Hupperts R et al. Neurology 2019 (SOLAR) Dalfampridine improves walking speed Class I, Level A Goodman AD et al. Lancet 2009 Exercise improves fatigue and quality of life Class I, Level B Heine M et al. Cochrane 2015 Smoking cessation slows disability progression Class II, Level B Hedstrom AK et al. Brain 2013 Cognitive rehabilitation improves cognitive outcomes Class II, Level B Chiaravalloti ND et al. Neurology 2013 S1P modulators: macular edema and cardiac monitoring required Class I, Level A FDA label; Cohen JA et al. NEJM 2010 (fingolimod) Alemtuzumab: secondary autoimmunity monitoring for 48 months Class I, Level A CAMMS223 investigators NEJM 2008 Pregnancy planning with DMT washout periods Class III, Level B Bove R et al. Nat Rev Neurol 2014 Vaccinations before immunosuppressive DMTs Expert consensus Farez MF et al. Neurology 2019 (AAN guidelines)","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation for MS chronic management - Comprehensive DMT monitoring protocols by drug class - Symptom management for fatigue, spasticity, pain, bladder, depression, cognition, gait - Vaccination guidance and live vaccine contraindications - Pregnancy planning section with DMT-specific washout requirements - PML surveillance protocols for natalizumab and other high-risk DMTs - Structured dosing format for order sentence generation - Full setting coverage (ED, HOSP, OPD, ICU) for monitoring and treatment</p>","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#appendix-a-dmt-monitoring-schedule-summary","title":"APPENDIX A: DMT Monitoring Schedule Summary","text":"DMT Labs Lab Frequency Imaging Other Interferons CBC, LFTs, TSH q3-6 months; TSH annually Annual MRI Depression screening Glatiramer None routine N/A Annual MRI Injection site monitoring Dimethyl/Diroximel fumarate CBC (ALC), LFTs q6 months Annual MRI + PML surveillance Discontinue if ALC &lt;500 x 6 months Teriflunomide LFTs, CBC, BP Monthly x 6 mo, then periodic Annual MRI Pregnancy test PRN; teratogenic Fingolimod CBC, LFTs q6-12 months Annual MRI + PML surveillance Macular OCT; first-dose cardiac monitoring Siponimod CBC, LFTs q6-12 months Annual MRI CYP2C9 genotype; macular OCT Ozanimod/Ponesimod CBC, LFTs q6-12 months Annual MRI Macular OCT at 3-4 mo then annually Cladribine CBC Months 2 and 6 each treatment year Annual MRI ALC &gt;800 before year 2; malignancy screen Natalizumab JCV Ab, CBC, LFTs JCV q6 months MRI q3-6 mo (high risk) or q6-12 mo REMS; extended dosing option Anti-CD20s Hep B, IgG, CBC IgG annually; others periodic Annual MRI Infection monitoring Alemtuzumab CBC monthly, TSH q3mo, Cr/UA monthly x 48 months after last dose Annual MRI REMS; autoimmunity monitoring","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#appendix-b-pml-risk-stratification-natalizumab","title":"APPENDIX B: PML Risk Stratification (Natalizumab)","text":"Risk Factor PML Risk Monitoring Recommendation JCV antibody NEGATIVE Very low (&lt;0.1 per 1000) JCV q6 months; annual MRI JCV antibody POSITIVE, index &lt;0.9, no prior IS Low (~0.5 per 1000) JCV q6 months; MRI q6-12 months JCV antibody POSITIVE, index 0.9-1.5, no prior IS Moderate (~2 per 1000) JCV q6 months; MRI q6 months; consider EID JCV antibody POSITIVE, index &gt;1.5, no prior IS High (~5-6 per 1000) JCV q6 months; MRI q3-6 months; consider DMT switch JCV antibody POSITIVE + prior immunosuppression Very high (~10+ per 1000) Strong consideration for DMT switch &gt;24 months treatment duration Increases risk Factor into overall risk assessment <p>EID = Extended Interval Dosing (q6 weeks instead of q4 weeks) - associated with ~90% reduction in PML risk</p> <p>PML Warning Signs: - Subtle cognitive changes, confusion - Personality or behavioral changes - Visual disturbances (homonymous hemianopia) - Hemiparesis, ataxia - New speech difficulties</p> <p>If PML suspected: STOP natalizumab immediately; STAT MRI brain; CSF JCV PCR; neurology consultation</p>","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-chronic-management/#appendix-c-dmt-washout-periods-for-pregnancy","title":"APPENDIX C: DMT Washout Periods for Pregnancy","text":"DMT Washout Required Notes Glatiramer acetate None May continue if needed; preferred in pregnancy Interferon-beta None to minimal Limited data; can continue if high activity Dimethyl/Diroximel fumarate Minimal (short half-life) Stop when pregnancy confirmed Teriflunomide Accelerated elimination required Cholestyramine 8g TID x 11 days; verify level &lt;0.02 mg/L Fingolimod 2 months Rebound risk; monitor closely Siponimod 10 days Shorter half-life than fingolimod Ozanimod 7 days Includes active metabolites Ponesimod 7 days Short half-life Cladribine 6 months Applies to both partners Natalizumab Until pregnancy confirmed Can continue through pregnancy in high-activity MS (shared decision) Ocrelizumab 6-12 months B-cell recovery variable; check CD19 count Ofatumumab 6 months B-cell recovery variable Ublituximab 6 months B-cell recovery variable Alemtuzumab 4 months After last infusion","tags":["demyelinating","multiple-sclerosis","chronic-management","autoimmune","outpatient"]},{"location":"drafts/ms-new-diagnosis/","title":"Multiple Sclerosis - New Diagnosis","text":"\u26a0\ufe0f DRAFT - Pending Physician Review This plan has not been approved for clinical use. Please review and provide feedback using the comment system.","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#multiple-sclerosis-new-diagnosis","title":"Multiple Sclerosis - New Diagnosis","text":"<p>VERSION: 2.5 CREATED: January 13, 2026 REVISED: January 20, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Multiple Sclerosis - New Diagnosis</p> <p>ICD-10: G35 (Multiple sclerosis); H46.9 (Optic neuritis, if presenting symptom); G37.9 (Demyelinating disease of CNS, unspecified)</p> <p>SYNONYMS: MS, multiple sclerosis, demyelinating disease, RRMS, PPMS, SPMS, CIS</p> <p>SCOPE: Initial diagnostic workup and management of suspected or newly confirmed MS. Covers diagnostic criteria evaluation, mimics exclusion, acute symptom treatment, and DMT initiation framework. For established MS with acute relapse, use \"MS - Exacerbation\" template. For ongoing DMT management and monitoring, use \"MS - Maintenance\" template.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection screen, baseline before steroids Normal STAT STAT ROUTINE STAT CMP Metabolic screen, renal function Normal STAT STAT ROUTINE STAT TSH Thyroid disease mimics MS Normal URGENT ROUTINE ROUTINE URGENT Vitamin B12 B12 deficiency causes myelopathy Normal (&gt;300 pg/mL) URGENT ROUTINE ROUTINE URGENT Folate Folate deficiency causes myelopathy Normal URGENT ROUTINE ROUTINE URGENT ESR Inflammatory/vasculitis screen Normal (&lt;20 mm/hr) URGENT ROUTINE ROUTINE URGENT CRP Inflammatory marker Normal URGENT ROUTINE ROUTINE URGENT Urinalysis UTI as symptom trigger Negative STAT STAT ROUTINE STAT Blood glucose Pre-steroid baseline Normal STAT STAT ROUTINE STAT HbA1c Glycemic status before steroids &lt;5.7% - ROUTINE ROUTINE -","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Vitamin D (25-OH) Low levels associated with MS risk/activity &gt;30 ng/mL - ROUTINE ROUTINE - ANA Lupus/connective tissue disease screen Negative or low titer URGENT ROUTINE ROUTINE URGENT Anti-dsDNA If ANA positive, lupus evaluation Negative - ROUTINE ROUTINE - Mayo CDS1 Panel (AQP4-IgG + MOG-IgG by FACS) Combined NMO/MOGAD screen; cell-based assay is gold standard Both negative URGENT URGENT ROUTINE URGENT HIV HIV-associated myelopathy/encephalopathy Negative - ROUTINE ROUTINE - RPR/VDRL Neurosyphilis mimics MS Negative - ROUTINE ROUTINE - Lyme serology Endemic areas; neuroborreliosis Negative - ROUTINE ROUTINE - ACE level Neurosarcoidosis Normal - ROUTINE ROUTINE - <p>Note: If Mayo CDS1 Panel unavailable, order AQP4-IgG (Mayo NMOFS) and MOG-IgG (Mayo MOGFS) separately. FACS/cell-based assay preferred over ELISA for higher sensitivity/specificity.</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Anti-SSA/SSB (Ro/La) Sj\u00c3\u00b6gren syndrome Negative - EXT EXT - ANCA panel CNS vasculitis Negative - EXT EXT - Copper, ceruloplasmin Wilson disease (young patients) Normal - EXT EXT - Very long chain fatty acids Adrenomyeloneuropathy Normal - EXT EXT - Mitochondrial DNA studies Leber hereditary optic neuropathy Normal - EXT EXT - Genetic testing (HLA-DRB1) Research/prognostic, not diagnostic Variable - - EXT -","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast (MS protocol)* URGENT URGENT ROUTINE URGENT Within 24-48h if acute; within 2 weeks if stable Periventricular, juxtacortical, infratentorial, or cord lesions; gadolinium enhancement = active GFR &lt;30, gadolinium allergy, pacemaker MRI C-spine with and without contrast URGENT URGENT ROUTINE URGENT With brain MRI Cord lesions (short segment, peripheral, dorsal) Same as above MRI T-spine with and without contrast URGENT ROUTINE ROUTINE URGENT With brain/C-spine Cord lesions Same as above <p>*MS MRI protocol should include: 3D FLAIR, 3D T1 pre/post-contrast, T2, DWI; for spine: sagittal STIR, axial T2</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Visual evoked potentials (VEP) - ROUTINE ROUTINE - During workup Prolonged P100 latency (subclinical optic nerve involvement) None significant OCT (Optical coherence tomography) - - ROUTINE - Baseline RNFL thinning (prior optic neuritis) None significant MRI orbits with contrast - ROUTINE ROUTINE - If optic neuritis suspected Optic nerve enhancement, swelling Gadolinium contraindications <p>Note: OCT typically available only in outpatient neuro-ophthalmology or MS specialty clinics</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest - EXT EXT - If sarcoidosis suspected Hilar lymphadenopathy Contrast allergy PET-CT - EXT EXT - If CNS lymphoma or paraneoplastic suspected FDG-avid lesions Pregnancy, uncontrolled diabetes Conventional angiography - EXT EXT - If CNS vasculitis suspected Beading, stenosis Contrast allergy, renal failure Brain biopsy - EXT - - Atypical cases, tumefactive lesions Demyelination vs neoplasm vs other Coagulopathy, inaccessible location","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Supports MS diagnosis (2017 McDonald criteria); helps exclude mimics; required if dissemination in time cannot be demonstrated by MRI alone</p> <p>Timing: URGENT if needed for diagnosis; can be ROUTINE in outpatient workup</p> <p>Volume Required: 15-20 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Rule out elevated ICP 10-20 cm H2O Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Inflammation, rule out infection WBC &lt;50 (mild pleocytosis acceptable); RBC 0 Protein URGENT ROUTINE ROUTINE Elevated in inflammation Normal to mildly elevated (&lt;100 mg/dL) Glucose with serum glucose URGENT ROUTINE ROUTINE Low in infection/carcinomatous Normal (&gt;60% serum) Gram stain and culture URGENT ROUTINE ROUTINE Rule out infection No organisms Oligoclonal bands (CSF AND serum) URGENT ROUTINE ROUTINE Intrathecal IgG synthesis \u00e2\u2030\u00a52 CSF-specific bands (not in serum) IgG index URGENT ROUTINE ROUTINE Intrathecal antibody synthesis &gt;0.7 = elevated Myelin basic protein - ROUTINE ROUTINE Active demyelination marker May be elevated acutely Cytology - ROUTINE ROUTINE Rule out malignancy Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative <p>Special Handling: OCBs stable at 4\u00c2\u00b0C for days; send paired serum. Cytology requires rapid transport (&lt;1 hour).</p> <p>Contraindications: Elevated ICP without imaging, coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#3-treatment","title":"3. TREATMENT","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Methylprednisolone IV STAT STAT - STAT 1000 mg IV daily \u00c3\u2014 3-5 days Active untreated infection, uncontrolled diabetes, psychosis history Glucose q6h (target &lt;180), BP, mood, sleep, I/O Omeprazole STAT STAT - STAT 20-40 mg daily during steroids PPI allergy None routine Insulin sliding scale STAT STAT - STAT Per protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h Prednisone oral taper (optional) - ROUTINE ROUTINE - 60 mg daily \u00c3\u2014 7 days, then taper over 2 weeks Same as IV steroids Glucose, BP, mood","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#3b-symptomatic-treatments-first-line","title":"3B. Symptomatic Treatments - First-line","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Baclofen Spasticity - ROUTINE ROUTINE ROUTINE Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day in divided doses Renal impairment (reduce dose) Sedation, weakness; do NOT stop abruptly (withdrawal risk) Tizanidine Spasticity - ROUTINE ROUTINE ROUTINE Start 2 mg qHS or TID; increase by 2-4 mg every 3-4 days; max 36 mg/day in 3 divided doses Hepatic impairment; concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors) LFTs at baseline, 1, 3, 6 months; sedation; hypotension Gabapentin Neuropathic pain - ROUTINE ROUTINE ROUTINE Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day Renal impairment (adjust dose per CrCl) Sedation, dizziness, peripheral edema Pregabalin Neuropathic pain - ROUTINE ROUTINE ROUTINE Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID Renal impairment (adjust dose per CrCl) Sedation, weight gain, peripheral edema Duloxetine Neuropathic pain - ROUTINE ROUTINE - Start 30 mg daily \u00c3\u2014 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; concurrent MAOIs; uncontrolled narrow-angle glaucoma Nausea (usually transient), BP, discontinuation syndrome Amitriptyline Neuropathic pain - ROUTINE ROUTINE - Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma Anticholinergic effects; ECG if dose &gt;100 mg/day Carbamazepine Trigeminal neuralgia - ROUTINE ROUTINE - Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day AV block; bone marrow suppression; concurrent MAOIs CBC, LFTs, sodium at baseline and periodically; HLA-B*1502 screening in at-risk populations Oxcarbazepine Trigeminal neuralgia - ROUTINE ROUTINE - Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID Hypersensitivity to carbamazepine Sodium (hyponatremia risk); HLA-B*1502 screening Oxybutynin IR Bladder urgency - ROUTINE ROUTINE - Start 5 mg BID-TID; max 5 mg QID Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction Dry mouth, constipation, cognitive impairment (especially elderly) Oxybutynin ER Bladder urgency - - ROUTINE - Start 5-10 mg daily; max 30 mg daily Same as IR Same; fewer anticholinergic side effects than IR Solifenacin Bladder urgency - - ROUTINE - Start 5 mg daily; may increase to 10 mg daily Urinary retention; gastric retention; uncontrolled narrow-angle glaucoma; severe hepatic impairment Dry mouth, constipation; preferred over oxybutynin if cognitive concerns Mirabegron Bladder urgency - - ROUTINE - Start 25 mg daily; may increase to 50 mg daily Uncontrolled hypertension BP monitoring; fewer anticholinergic effects (beta-3 agonist) Tamsulosin Urinary retention - ROUTINE ROUTINE - 0.4 mg daily 30 minutes after same meal each day Severe sulfonamide allergy (use caution) Orthostatic hypotension; retrograde ejaculation Bethanechol Urinary retention - ROUTINE ROUTINE - 10-50 mg TID-QID Asthma; bradycardia; hypotension; GI/GU obstruction GI cramping, bronchospasm Desmopressin Nocturia - - ROUTINE - 0.1-0.4 mg qHS (oral) or 10-40 mcg intranasal Hyponatremia risk; age &gt;65 (relative); CHF; polydipsia Sodium at baseline, 1 week, 1 month, then periodically; fluid restrict evening Amantadine Fatigue - ROUTINE ROUTINE - 100 mg every morning; may add 100 mg early afternoon (before 2 PM); max 200 mg/day Renal impairment (adjust dose); uncontrolled seizures Livedo reticularis; ankle edema; insomnia; hallucinations Modafinil Fatigue - - ROUTINE - Start 100 mg every morning; may increase to 200 mg; max 400 mg/day Cardiac arrhythmia; LV hypertrophy; hepatic impairment BP, HR; may reduce efficacy of hormonal contraception; Schedule IV Armodafinil Fatigue - - ROUTINE - Start 150 mg every morning; max 250 mg daily Same as modafinil Same as modafinil; longer half-life; Schedule IV Methylphenidate Fatigue - - ROUTINE - Start 5 mg BID (morning and noon); max 60 mg/day Marked anxiety; glaucoma; tics/Tourette; concurrent MAOIs BP, HR, mood; Schedule II Dalfampridine Walking impairment - - ROUTINE - 10 mg q12h (must be exactly 12 hours apart); do NOT exceed 20 mg/day Seizure history; CrCl &lt;50 mL/min Seizure risk (dose-dependent); UTI; insomnia Sertraline Depression - ROUTINE ROUTINE - Start 50 mg daily; increase by 25-50 mg every 1-2 weeks; max 200 mg daily Concurrent MAOIs; pimozide Suicidality monitoring (especially weeks 1-4); serotonin syndrome; QTc at high doses Escitalopram Depression - ROUTINE ROUTINE - Start 10 mg daily; may increase to 20 mg after 1 week; max 20 mg daily Concurrent MAOIs; pimozide; QT prolongation QTc if risk factors or dose &gt;10 mg; suicidality monitoring Fluoxetine Depression - ROUTINE ROUTINE - Start 20 mg daily; may increase after several weeks; max 80 mg daily Concurrent MAOIs; pimozide; thioridazine Long half-life (washout important); suicidality monitoring Bupropion SR/XL Depression - ROUTINE ROUTINE - Start 150 mg SR daily; increase to 150 mg SR BID after 3 days (or 300 mg XL daily); max 400 mg/day Seizure disorder; eating disorders; abrupt alcohol/benzo withdrawal Seizure risk; insomnia; no sexual side effects Venlafaxine XR Depression/pain - ROUTINE ROUTINE - Start 37.5-75 mg daily; increase by 75 mg every 4 days; max 225 mg daily Uncontrolled hypertension; concurrent MAOIs BP monitoring; discontinuation syndrome (taper slowly) Mirtazapine Depression/insomnia - ROUTINE ROUTINE - Start 15 mg qHS; may increase by 15 mg every 1-2 weeks; max 45 mg daily Concurrent MAOIs Weight gain; sedation (lower at higher doses); agranulocytosis (rare) Polyethylene glycol 3350 Constipation - ROUTINE ROUTINE - 17 g (1 capful) in 8 oz liquid once daily; adjust to effect Bowel obstruction; ileus Electrolytes if prolonged use; may take 1-3 days for effect Docusate sodium Constipation - ROUTINE ROUTINE - 100 mg BID; max 500 mg/day Intestinal obstruction; concurrent mineral oil Minimal efficacy as monotherapy; best for stool softening Senna Constipation - ROUTINE ROUTINE - 8.6-17.2 mg qHS; max 34.4 mg/day Intestinal obstruction; acute abdominal pain Cramping; dependency with chronic daily use Bisacodyl Constipation - ROUTINE ROUTINE - 5-10 mg PO qHS or 10 mg PR PRN Intestinal obstruction; acute abdominal pain Cramping; electrolyte disturbance with overuse Lubiprostone Constipation (refractory) - - ROUTINE - 24 mcg BID with food Mechanical GI obstruction Nausea (common); dyspnea; diarrhea Propranolol Tremor - ROUTINE ROUTINE - Start 20 mg BID; increase by 20-40 mg every 3-7 days; max 320 mg/day in divided doses Asthma/COPD; bradycardia &lt;50; heart block; decompensated CHF HR, BP; fatigue; depression; bronchospasm Primidone Tremor - - ROUTINE - Start 25 mg qHS; increase by 25 mg every week to 250 mg TID; usual dose 50-250 mg TID Porphyria; hypersensitivity to phenobarbital Severe sedation initially (start very low); ataxia; nausea Clonazepam Tremor - ROUTINE ROUTINE - Start 0.25-0.5 mg BID; increase by 0.5 mg every 3 days; max 6 mg/day Severe hepatic impairment; myasthenia gravis; untreated narrow-angle glaucoma Sedation; dependence; falls risk; do NOT stop abruptly Topiramate Tremor - - ROUTINE - Start 25 mg daily; increase by 25 mg weekly; max 400 mg/day in divided doses Metabolic acidosis; kidney stones Cognitive slowing (\"dopamax\"); paresthesias; kidney stones; weight loss Dextromethorphan-quinidine Pseudobulbar affect - - ROUTINE - 20/10 mg daily \u00c3\u2014 7 days, then 20/10 mg q12h QT prolongation; concurrent MAOIs; concurrent quinidine/quinine; CYP2D6 substrate drugs ECG at baseline; QTc monitoring; multiple drug interactions","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#3c-second-linerefractory-acute-treatment","title":"3C. Second-line/Refractory (Acute Treatment)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Plasmapheresis (PLEX) - URGENT - URGENT 5-7 exchanges over 10-14 days Hemodynamic instability, sepsis, line contraindication BP, electrolytes, coags, fibrinogen, line infection IVIG - URGENT - URGENT 0.4 g/kg/day \u00c3\u2014 5 days IgA deficiency, renal failure, thrombosis risk Renal function, headache, thrombosis Extended IV steroids - ROUTINE - ROUTINE Additional 2-5 days methylprednisolone (total 5-10 days) As above As above ACTH gel (H.P. Acthar) - EXT EXT - 80 units IM/SC daily \u00c3\u2014 2-3 weeks Similar to corticosteroids Glucose, BP, electrolytes","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#3d-disease-modifying-therapies-dmt-opd-only","title":"3D. Disease-Modifying Therapies (DMT) - OPD ONLY","text":"<p>DMT initiation requires confirmed diagnosis and MS specialist involvement. DMTs are NOT initiated in ED, hospital, or ICU - only in outpatient specialty clinic after appropriate pre-treatment workup and counseling.</p> Treatment Route ED HOSP OPD ICU Dosing Pre-Treatment Requirements Contraindications Monitoring INJECTABLE - MODERATE EFFICACY Interferon beta-1a (Avonex) IM - - ROUTINE - 30 mcg IM once weekly CBC, LFTs, TSH Depression (relative); decompensated liver disease CBC, LFTs q3-6mo; TSH annually; flu-like symptoms common (pretreat with NSAIDs/acetaminophen) Interferon beta-1a (Rebif) SC - - ROUTINE - 22 or 44 mcg SC three times weekly (titrate over 4 weeks) CBC, LFTs, TSH Same as Avonex Same; injection site reactions Interferon beta-1b (Betaseron/Extavia) SC - - ROUTINE - 250 mcg SC every other day (titrate over 6 weeks) CBC, LFTs, TSH Same as Avonex Same Peginterferon beta-1a (Plegridy) SC - - ROUTINE - 125 mcg SC every 14 days (titrate over first 4 doses) CBC, LFTs, TSH Same as Avonex Same; less frequent dosing Glatiramer acetate (Copaxone) 20mg SC - - ROUTINE - 20 mg SC daily None required Hypersensitivity Injection site reactions; post-injection systemic reaction (rare, self-limited) Glatiramer acetate (Copaxone) 40mg SC - - ROUTINE - 40 mg SC three times weekly (\u00e2\u2030\u00a548 hours apart) None required Hypersensitivity Same Glatiramer acetate (Glatopa) SC - - ROUTINE - 20 mg SC daily or 40 mg SC three times weekly None required Hypersensitivity Same (generic) ORAL - MODERATE EFFICACY Dimethyl fumarate (Tecfidera) PO - - ROUTINE - 120 mg BID \u00c3\u2014 7 days, then 240 mg BID CBC, LFTs Lymphopenia &lt;500 (discontinue) CBC q6mo (lymphocytes); LFTs; GI side effects (take with food); flushing (aspirin 30 min prior) Diroximel fumarate (Vumerity) PO - - ROUTINE - 231 mg BID \u00c3\u2014 7 days, then 462 mg BID CBC, LFTs Same as Tecfidera Same; less GI side effects than Tecfidera Monomethyl fumarate (Bafiertam) PO - - ROUTINE - 95 mg BID \u00c3\u2014 7 days, then 190 mg BID CBC, LFTs Same as Tecfidera Same Teriflunomide (Aubagio) PO - - ROUTINE - 7 or 14 mg once daily CBC, LFTs, TB test, BP Pregnancy (Category X - teratogenic); severe hepatic impairment; concurrent leflunomide LFTs monthly \u00c3\u2014 6 months, then periodically; BP; hair thinning; requires cholestyramine washout if pregnancy desired ORAL - HIGH EFFICACY (S1P MODULATORS) Fingolimod (Gilenya) PO - - ROUTINE - 0.5 mg once daily CBC, LFTs, ECG, ophthalmology exam (macular edema), VZV IgG (vaccinate if negative and wait 4 weeks) Bradycardia &lt;55; 2nd/3rd degree AV block; sick sinus syndrome; QTc &gt;500 ms; recent MI/stroke/TIA (within 6 months) First-dose observation 6 hours (HR, BP q1h, ECG at 6h); macular edema screen at 3-4 months; lymphocytes; LFTs Siponimod (Mayzent) PO - - ROUTINE - Titration pack days 1-5, then 2 mg daily (1 mg if CYP2C9 1/3 or 2/3) Same as fingolimod plus CYP2C9 genotype Same plus CYP2C9 3/3 genotype (contraindicated) Same; genotype required before starting Ozanimod (Zeposia) PO - - ROUTINE - 0.23 mg daily \u00c3\u2014 4 days, 0.46 mg daily \u00c3\u2014 3 days, then 0.92 mg daily Same as fingolimod Same; concurrent MAOIs Similar to fingolimod; no first-dose observation required (slower titration); macular edema screen Ponesimod (Ponvory) PO - - ROUTINE - 14-day titration pack, then 20 mg daily Same as fingolimod Same Similar; no first-dose observation required ORAL - HIGH EFFICACY (OTHER) Cladribine (Mavenclad) PO - - ROUTINE - Year 1: 1.75 mg/kg divided into 2 treatment weeks (week 1 and week 5); Year 2: repeat same dosing; no treatment years 3-4 CBC, LFTs, HIV, Hepatitis B/C, TB, VZV IgG Active infection; HIV; active malignancy; pregnancy/breastfeeding; CrCl &lt;30 CBC at months 2 and 6 of each treatment year; lymphopenia expected and desired; screen for malignancy INFUSION - HIGH EFFICACY Natalizumab (Tysabri) IV - - ROUTINE - 300 mg IV every 4 weeks (or extended interval q6 weeks if stable and JCV negative) JCV antibody, CBC, LFTs JCV antibody positive with index &gt;1.5 and prior immunosuppression (high PML risk); active infection JCV antibody q6mo; MRI for PML surveillance q6-12mo; infusion reactions; REMS program required Ocrelizumab (Ocrevus) IV - - ROUTINE - Initial: 300 mg IV \u00c3\u2014 2 doses 14 days apart; Maintenance: 600 mg IV every 6 months Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Immunoglobulins annually; infection monitoring; infusion reactions (premedicate with methylprednisolone, antihistamine, acetaminophen) Ofatumumab (Kesimpta) SC - - ROUTINE - Initial: 20 mg SC at weeks 0, 1, 2; Maintenance: 20 mg SC monthly starting week 4 Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Same as ocrelizumab; self-administered at home Ublituximab (Briumvi) IV - - ROUTINE - Initial: 150 mg IV day 1, 450 mg IV day 15; Maintenance: 450 mg IV every 24 weeks Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Same as ocrelizumab; 1-hour infusion (faster) Alemtuzumab (Lemtrada) IV - - ROUTINE - Year 1: 12 mg IV daily \u00c3\u2014 5 consecutive days; Year 2: 12 mg IV daily \u00c3\u2014 3 consecutive days (12 months after year 1) CBC, LFTs, TSH, creatinine, urinalysis, Hepatitis B/C, VZV IgG, TB, HPV screening Active infection; HIV; ongoing autoimmune disease other than MS CBC monthly \u00c3\u2014 48 months; TSH q3mo \u00c3\u2014 48 months; creatinine/urinalysis monthly \u00c3\u2014 48 months; REMS program; secondary autoimmunity risk (thyroid, ITP, nephropathy) MODERATE EFFICACY - SPECIAL POPULATIONS Glatiramer acetate (Copaxone) SC - - ROUTINE - 20 mg daily or 40 mg TIW None Hypersensitivity Preferred in pregnancy (no evidence of harm)","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication MS specialist/Neuroimmunology referral URGENT URGENT ROUTINE URGENT All new MS diagnoses for DMT discussion Neuro-ophthalmology referral - ROUTINE ROUTINE - Optic neuritis, visual symptoms, OCT baseline Physical therapy consult for gait and balance - ROUTINE ROUTINE ROUTINE Gait dysfunction, lower extremity weakness, falls Occupational therapy consult for ADL assessment - ROUTINE ROUTINE - Upper extremity dysfunction, ADL impairment, energy conservation Speech therapy for swallow evaluation - URGENT ROUTINE URGENT Brainstem involvement, dysphagia, dysarthria Speech therapy for cognitive rehabilitation - - ROUTINE - Cognitive complaints affecting function Urology referral for bladder dysfunction - - ROUTINE - Urgency, frequency, retention, recurrent UTI Psychiatry/Psychology referral - ROUTINE ROUTINE - Depression, anxiety, adjustment to diagnosis Social work consult - ROUTINE ROUTINE - Insurance navigation, disability questions, support resources Rehabilitation medicine consult - ROUTINE ROUTINE - Significant functional impairment, comprehensive rehab needs Infusion center coordination - ROUTINE ROUTINE - PLEX scheduling; future DMT infusion planning Ophthalmology referral (pre-DMT) - - ROUTINE - Baseline macular exam before S1P modulator initiation Genetic counseling - - EXT - If atypical features, family history concerns","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED if rapid vision loss, sudden weakness, difficulty breathing, or urinary retention \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid driving until cleared by neurology \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Heat may temporarily worsen symptoms (Uhthoff phenomenon) - this is not a new attack \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Expect temporary steroid side effects: insomnia, mood changes, increased appetite, metallic taste \u00e2\u0153\u201c \u00e2\u0153\u201c - Keep symptom diary noting new or worsening symptoms - \u00e2\u0153\u201c \u00e2\u0153\u201c Do not stop steroids abruptly if on oral taper - \u00e2\u0153\u201c \u00e2\u0153\u201c Do not stop baclofen or tizanidine abruptly - risk of withdrawal/rebound spasticity - \u00e2\u0153\u201c \u00e2\u0153\u201c Monitor blood sugars if diabetic - steroids elevate glucose \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid sick contacts while on high-dose steroids \u00e2\u0153\u201c \u00e2\u0153\u201c - Contact MS specialist before starting any new medications (drug interactions with DMTs) - - \u00e2\u0153\u201c Vaccinations should be completed before DMT initiation (especially live vaccines) - \u00e2\u0153\u201c \u00e2\u0153\u201c Pregnancy planning requires DMT discussion (some DMTs teratogenic, washout periods vary) - - \u00e2\u0153\u201c Report any signs of infection (fever, cough, dysuria) promptly - \u00e2\u0153\u201c \u00e2\u0153\u201c Post-void residual check if difficulty emptying bladder or recurrent UTIs - \u00e2\u0153\u201c \u00e2\u0153\u201c","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (smoking accelerates MS progression and disability) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Vitamin D supplementation 2000-5000 IU daily (target serum 25-OH vitamin D &gt;40 ng/mL) - \u00e2\u0153\u201c \u00e2\u0153\u201c Regular aerobic exercise 150 min/week as tolerated (improves fatigue, mood, function) - \u00e2\u0153\u201c \u00e2\u0153\u201c Resistance training 2-3\u00c3\u2014/week - - \u00e2\u0153\u201c Stress management and adequate sleep (7-8 hours nightly) - \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid excessive heat exposure (hot tubs, saunas, prolonged direct sun, exercising in heat) - \u00e2\u0153\u201c \u00e2\u0153\u201c Cooling vest for outdoor activities in warm weather - - \u00e2\u0153\u201c Maintain healthy weight (obesity associated with worse outcomes) - - \u00e2\u0153\u201c Limit alcohol intake (can worsen balance, cognition, bladder symptoms) - - \u00e2\u0153\u201c Ensure vaccinations up to date before DMT initiation (live vaccines contraindicated on many DMTs) - \u00e2\u0153\u201c \u00e2\u0153\u201c Fall prevention: remove loose rugs, ensure adequate lighting, use assistive devices if needed - \u00e2\u0153\u201c \u00e2\u0153\u201c Energy conservation techniques for fatigue management (pacing, prioritization, positioning) - \u00e2\u0153\u201c \u00e2\u0153\u201c","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Neuromyelitis optica spectrum disorder (NMOSD) Longitudinally extensive transverse myelitis (\u00e2\u2030\u00a53 segments), severe optic neuritis (often bilateral), area postrema syndrome (intractable nausea/vomiting), brain lesions in NMOSD-typical locations AQP4-IgG positive (Mayo CDS1 or NMOFS); MRI pattern different MOG antibody disease (MOGAD) Bilateral optic neuritis, ADEM-like presentation, longitudinally extensive myelitis, cortical encephalitis, better steroid response, more favorable prognosis MOG-IgG positive (Mayo CDS1 or MOGFS) Acute disseminated encephalomyelitis (ADEM) Monophasic (usually), encephalopathy, post-infectious, large poorly-defined lesions, pediatric predominance Clinical course, MRI pattern, MOG-IgG status CNS vasculitis Headache, encephalopathy, stroke-like episodes, multifocal infarcts Elevated ESR/CRP, angiography, brain/leptomeningeal biopsy Neurosarcoidosis Cranial neuropathies (especially VII), hypothalamic involvement, leptomeningeal enhancement, hilar adenopathy ACE level, chest CT, biopsy (non-caseating granulomas) CNS lymphoma Progressive course, deep gray matter/periventricular involvement, homogeneous enhancement, older/immunocompromised CSF cytology/flow, FDG-PET, biopsy Susac syndrome Encephalopathy, hearing loss, branch retinal artery occlusions, corpus callosum \"snowball\" lesions Audiogram, fluorescein angiography, MRI pattern Neurosyphilis Progressive cognitive decline, tabes dorsalis, Argyll Robertson pupils, positive serology RPR/VDRL, CSF VDRL, FTA-ABS HIV-associated myelopathy/encephalopathy Risk factors, vacuolar myelopathy, cognitive impairment HIV testing, CD4 count B12 deficiency myelopathy Subacute combined degeneration, dorsal column signs, peripheral neuropathy, macrocytic anemia B12, MMA, homocysteine Migraine with white matter lesions Headache history, non-specific white matter changes, no enhancement, no cord lesions Clinical history, MRI pattern Small vessel ischemic disease Older age, vascular risk factors, periventricular caps/halos, no enhancement, no cord lesions Risk factor profile, MRI pattern","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Blood glucose \u2713 \u2713 - \u2713 Q6h during IV steroids &lt;180 mg/dL Insulin sliding scale; endocrine consult if persistent &gt;250 Blood pressure \u2713 \u2713 - \u2713 Q shift during steroids &lt;160/100 mmHg Antihypertensives PRN Mood and sleep - \u2713 - \u2713 Daily during steroids No psychosis, mania, severe insomnia Psychiatry consult; consider dose adjustment Temperature \u2713 \u2713 - \u2713 Q shift Afebrile Infection workup if febrile Neurologic exam \u2713 \u2713 \u2713 \u2713 Daily (inpatient); each visit (OPD) Improvement or stability If worsening: re-image, consider PLEX I/O and weight - \u2713 - \u2713 Daily (inpatient) Euvolemic Diuretics if fluid overload Respiratory status - \u2713 - \u2713 Q shift if cervical myelitis RR &lt;20, NIF &gt;-30 cm H2O ICU transfer if NIF &gt;-20 (critical) Post-void residual - \u2713 \u2713 - If retention suspected &lt;100 mL Intermittent catheterization if &gt;200 mL; urology referral MRI (follow-up) - early - - \u2713 - 3 months after baseline No new/enlarging lesions DMT escalation discussion if new activity MRI (follow-up) - standard - - \u2713 - 6 months after baseline, then annually No new/enlarging lesions DMT escalation discussion if new activity Vitamin D level - - \u2713 - Annually &gt;40 ng/mL (some target &gt;50) Increase supplementation if low JCV antibody (if on natalizumab) - - \u2713 - Every 6 months Negative or stable index If positive/rising: PML risk stratification, consider DMT switch","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild symptoms; able to ambulate safely; reliable follow-up within 1-2 weeks; no IV steroids needed OR completing outpatient infusion; stable baseline function; understands return precautions Admit to floor Moderate-severe symptoms; needs IV steroids; functional decline requiring therapy; diagnostic uncertainty requiring expedited workup; unable to care for self at home Admit to ICU Severe myelitis with respiratory compromise (NIF &gt;-30 declining toward -20); brainstem involvement with airway risk or autonomic instability; severe encephalopathy Transfer to higher level PLEX needed but unavailable; MS specialist not available for complex decision-making; MRI unavailable for urgent imaging","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source 2017 McDonald Criteria for MS diagnosis Class I Thompson AJ et al. Lancet Neurol 2018 MRI brain/spine with contrast for diagnosis Class I, Level A Wattjes MP et al. Lancet Neurol 2021 (MAGNIMS) CSF OCBs can substitute for dissemination in time Class II, Level B Thompson AJ et al. Lancet Neurol 2018 IV methylprednisolone 1g \u00c3\u2014 3-5 days for acute attacks Class I, Level A Filippini et al. Cochrane 2000; Expert consensus PLEX for steroid-refractory attacks Class II, Level B Faissner et al. J Neurol 2016 Cell-based assay (FACS) for NMO/MOG antibodies Class I, Level B Waters et al. 2014; Pittock et al. Vitamin D supplementation Class II, Level B SOLAR trial; CHOLINE trial Smoking cessation reduces progression Class II, Level B Hedstr\u00f6m et al. Brain 2013 Early DMT initiation improves outcomes Class I, Level A BENEFIT extension; Multiple RCTs Dalfampridine for walking impairment Class I, Level A Goodman et al. Lancet 2009 Exercise improves fatigue and function Class I, Level B Heine et al. Cochrane 2015","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/ms-new-diagnosis/#change-log","title":"CHANGE LOG","text":"<p>v2.5 (January 20, 2026) - Added ICD-10 codes: H46.9 (optic neuritis), G37.9 (demyelinating disease) - Added clinical synonyms: MS, RRMS, PPMS, SPMS, CIS</p> <p>v2.4 (January 20, 2026) - Added PubMed links to all citations in Section 8 (Evidence &amp; References) - Corrected \"AAN Practice Guideline 2022\" to \"Filippini et al. Cochrane 2000; Expert consensus\" - Added specific citations for: MAGNIMS 2021, SOLAR/CHOLINE trials, Hedstr\u00f6m 2013, BENEFIT extension, Heine Cochrane 2015</p> <p>v2.3 (January 20, 2026) - Added venue columns (ED, HOSP, OPD, ICU) to Section 6 Monitoring Parameters - Split MRI follow-up into two rows: early (3 months) and standard (6 months, then annually) - Confirmed JCV antibody monitoring at every 6 months for natalizumab patients</p> <p>v2.2 (January 13, 2026) - Expanded Section 3D: each DMT now on individual row with complete dosing - Added 23 individual DMTs with full details:   - Injectables: Avonex, Rebif, Betaseron/Extavia, Plegridy, Copaxone 20mg, Copaxone 40mg, Glatopa   - Oral moderate: Tecfidera, Vumerity, Bafiertam, Aubagio   - Oral S1P modulators: Gilenya, Mayzent, Zeposia, Ponvory   - Oral high-efficacy: Mavenclad   - Infusions: Tysabri, Ocrevus, Kesimpta, Briumvi, Lemtrada - Added Route column (PO, SC, IM, IV) - Added complete pre-treatment requirements for each DMT - Added specific monitoring schedules (JCV q6mo, CBC monthly for alemtuzumab, etc.) - Added REMS program notes where applicable - Added CYP2C9 genotyping requirement for siponimod - Added first-dose observation requirements for S1P modulators</p> <p>v2.1 (January 13, 2026) - Restructured Section 3B: each drug now on individual row with complete dosing - Added \"Indication\" column to treatment table - Expanded drug list with additional options:   - Carbamazepine, oxcarbazepine for trigeminal neuralgia   - Oxybutynin ER, mirabegron, bethanechol, desmopressin for bladder   - Armodafinil, methylphenidate for fatigue   - Fluoxetine, venlafaxine, mirtazapine for depression   - Bisacodyl, lubiprostone for constipation   - Topiramate for tremor - Enhanced dosing details with titration schedules for all medications</p> <p>v2.0 (January 13, 2026) - Confirmed IV methylprednisolone 1g \u00c3\u2014 3-5 days per physician - Added Mayo CDS1 Panel (combined AQP4 + MOG by FACS) as preferred test - Added note that FACS/cell-based assay preferred over ELISA - Changed OCT from HOSP to OPD only (not available in most hospitals) - Clarified DMT section is OPD ONLY (not initiated inpatient) - Expanded symptomatic treatments section with:   - Tizanidine for spasticity   - Pregabalin, duloxetine, amitriptyline for neuropathic pain   - Solifenacin, tamsulosin for bladder   - Modafinil for fatigue (OPD only - controlled substance)   - Dalfampridine for walking impairment   - Antidepressants (sertraline, escitalopram, bupropion)   - Constipation management   - Tremor management (propranolol, primidone, clonazepam)   - Pseudobulbar affect (dextromethorphan-quinidine) - Added cladribine to DMT reference table - Added folate to core labs - Added JCV antibody monitoring - Added infusion center coordination to referrals - Added MRI protocol footnote - Enhanced vitamin D target (&gt;40 ng/mL) - Added post-void residual monitoring - Added instruction re: not stopping baclofen/tizanidine abruptly</p> <p>v1.0 (January 13, 2026) - Initial creation</p>","tags":["demyelinating","multiple-sclerosis","new-diagnosis","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/","title":"Myasthenia Gravis - Exacerbation/Crisis","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#myasthenia-gravis-exacerbationcrisis","title":"Myasthenia Gravis - Exacerbation/Crisis","text":"<p>VERSION: 1.1 CREATED: January 24, 2026 REVISED: January 24, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Myasthenia Gravis - Exacerbation/Crisis</p> <p>ICD-10: G70.00 (Myasthenia gravis without exacerbation), G70.01 (Myasthenia gravis with exacerbation), G70.1 (Toxic myoneural disorders)</p> <p>SCOPE: Evaluation and management of acute myasthenic exacerbation and myasthenic crisis in adults. Covers respiratory monitoring, immunotherapy (IVIg and plasmapheresis), medications to avoid, and ICU management. Excludes new diagnosis workup, chronic maintenance therapy, Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes.</p> <p>CLINICAL SYNONYMS: MG crisis, myasthenic crisis, MG exacerbation, acute MG flare, myasthenia gravis flare</p> <p>KEY DEFINITIONS: - MG Exacerbation: Worsening weakness requiring medication adjustment or immunotherapy but NOT requiring intubation - Myasthenic Crisis: Respiratory failure requiring mechanical ventilation OR FVC &lt;15-20 mL/kg - Cholinergic Crisis: Excess acetylcholinesterase inhibitors causing weakness with muscarinic symptoms (SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis)</p> <p>KEY CLINICAL FEATURES: - Fatigable weakness (worsens with activity, improves with rest) - Ptosis and diplopia (ocular MG or generalized with ocular involvement) - Bulbar weakness: dysarthria, dysphagia, facial weakness - Limb weakness (proximal &gt; distal, arms &gt; legs) - Respiratory weakness: dyspnea, orthopnea, weak cough - Crisis triggers: Infection, surgery, medication changes, pregnancy, stress</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u26a1 RESPIRATORY FAILURE WARNING</p> <p>15-20% of MG exacerbations progress to crisis. Monitor FVC and NIF every 4-6 hours. Intubate if FVC &lt;15 mL/kg or NIF weaker than -20 cmH2O.</p> <p>\u26a0\ufe0f MEDICATION SAFETY</p> <p>Many common medications worsen MG. See Medications to AVOID section before prescribing.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection as trigger, baseline Normal or elevated WBC if infected STAT STAT \u2014 STAT CMP (BMP + LFTs) Electrolytes, renal/hepatic function Normal; hypokalemia worsens weakness STAT STAT \u2014 STAT Magnesium Hypomagnesemia worsens NMJ transmission &gt;1.8 mg/dL STAT STAT \u2014 STAT Phosphorus Hypophosphatemia causes weakness &gt;2.5 mg/dL STAT STAT \u2014 STAT TSH Thyroid disease common comorbidity Normal URGENT ROUTINE \u2014 URGENT Blood glucose Hyperglycemia worsens outcomes &lt;180 mg/dL STAT STAT \u2014 STAT Urinalysis UTI as trigger Negative for infection STAT ROUTINE \u2014 STAT Blood cultures If febrile or sepsis suspected Negative STAT STAT \u2014 STAT Procalcitonin Differentiate infection vs non-infectious flare &lt;0.5 ng/mL if non-infectious URGENT ROUTINE \u2014 URGENT ABG or VBG Respiratory status, CO2 retention PaCO2 &lt;45 mmHg, pH &gt;7.35 STAT STAT \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU AChR (acetylcholine receptor) antibody Confirm diagnosis if unknown Document if positive (~85% of generalized MG) \u2014 ROUTINE \u2014 ROUTINE MuSK antibody If AChR negative Document if positive (~40% of AChR-negative) \u2014 ROUTINE \u2014 ROUTINE LRP4 antibody If AChR and MuSK negative Document if positive \u2014 EXT \u2014 EXT Anti-striated muscle antibody Thymoma association If positive, CT chest \u2014 ROUTINE \u2014 ROUTINE Hepatitis B surface antigen Pre-IVIg screening Negative \u2014 URGENT \u2014 URGENT Quantitative immunoglobulins IgA deficiency (IVIg contraindication) IgA &gt;7 mg/dL \u2014 URGENT \u2014 URGENT PT/INR, PTT Pre-PLEX Normal \u2014 URGENT \u2014 STAT Type and screen Pre-PLEX Available \u2014 URGENT \u2014 STAT Fibrinogen Pre-PLEX baseline Normal \u2014 URGENT \u2014 STAT Troponin Cardiac involvement, stress Normal URGENT ROUTINE \u2014 STAT BNP/NT-proBNP Heart failure assessment Normal URGENT ROUTINE \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Cortisol (random or AM) Adrenal insufficiency if on chronic steroids Normal stress response \u2014 ROUTINE \u2014 ROUTINE Acetylcholinesterase inhibitor level Cholinergic crisis concern (if available) Therapeutic range \u2014 EXT \u2014 EXT Paraneoplastic panel Occult malignancy Negative \u2014 EXT \u2014 EXT Respiratory viral panel Viral trigger Document if positive \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Chest X-ray On admission Aspiration, atelectasis, pneumonia None STAT STAT \u2014 STAT ECG On admission Arrhythmia, QT prolongation None STAT STAT \u2014 STAT Forced vital capacity (FVC) Serial q4-6h (q2h if declining) FVC &gt;15-20 mL/kg Facial weakness limiting seal STAT STAT \u2014 STAT Negative inspiratory force (NIF) Serial q4-6h (q2h if declining) NIF more negative than -20 cmH2O Facial weakness STAT STAT \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT chest with contrast If thymoma not previously evaluated Thymoma or thymic hyperplasia Contrast allergy, renal impairment \u2014 ROUTINE \u2014 ROUTINE CT chest without contrast Thymoma evaluation (if contrast contraindicated) Thymic abnormality None \u2014 ROUTINE \u2014 ROUTINE Swallow evaluation Bulbar symptoms Aspiration risk None \u2014 URGENT \u2014 URGENT Repetitive nerve stimulation If diagnosis uncertain Decremental response &gt;10% None \u2014 ROUTINE \u2014 ROUTINE Single-fiber EMG If RNS negative but MG suspected Increased jitter, blocking None \u2014 EXT \u2014 EXT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU PET-CT Occult thymoma or malignancy Tumor identification Hemodynamic instability \u2014 EXT \u2014 EXT Ice pack test Bedside diagnostic (ptosis) Improvement with cooling None STAT STAT \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: Myasthenic crisis is a medical emergency. Secure airway early if deteriorating. Do NOT delay intubation.</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#crisis-vs-cholinergic-crisis-differentiation","title":"Crisis vs Cholinergic Crisis Differentiation","text":"Feature Myasthenic Crisis Cholinergic Crisis Pupils Normal or mydriasis Miosis Secretions Normal or dry Excessive (SLUDGE) Fasciculations Absent Present Heart rate Normal or tachy Bradycardia Response to edrophonium Improvement Worsening Management IVIg/PLEX, stop AChEI temporarily Stop AChEI, supportive care","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3a-acuteemergent-airway-and-respiratory-support","title":"3A. Acute/Emergent - Airway and Respiratory Support","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Supplemental oxygen INH Hypoxemia 2-6 L/min NC; 15 L/min NRB :: INH :: PRN :: Titrate to O2 sat &gt;94%; escalate as needed None O2 sat, RR STAT STAT \u2014 STAT Endotracheal intubation \u2014 Respiratory failure N/A :: \u2014 :: :: Intubate if FVC &lt;15 mL/kg, NIF &gt;-20 cmH2O, or clinical deterioration; AVOID succinylcholine (may have prolonged block); use rocuronium (may need higher dose) \u2014 ETT position, ventilator settings STAT STAT \u2014 STAT Non-invasive ventilation (BiPAP) \u2014 Bridge to intubation or mild hypoventilation IPAP 10-15; EPAP 5 :: \u2014 :: continuous :: BiPAP may temporize; NOT a substitute for intubation in true crisis Severe respiratory failure, inability to protect airway RR, TV, O2 sat, CO2 STAT STAT \u2014 STAT Mechanical ventilation \u2014 Respiratory failure N/A :: \u2014 :: :: Lung-protective ventilation; expect prolonged wean; daily SBT when improved \u2014 ABG, ventilator parameters \u2014 \u2014 \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3b-immunotherapy-first-line-for-crisissevere-exacerbation","title":"3B. Immunotherapy - First-line for Crisis/Severe Exacerbation","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IVIg (immune globulin IV) IV Myasthenic crisis or severe exacerbation 0.4 g/kg/day x 5 days; 1 g/kg/day x 2 days :: IV :: daily x 5 days :: 0.4 g/kg/day IV for 5 days (preferred) OR 1 g/kg/day x 2 days; infuse slowly day 1 IgA deficiency with anti-IgA antibodies; severe renal impairment; recent MI/stroke (thrombosis risk) Renal function daily, headache, infusion reactions; pre-medicate \u2014 STAT \u2014 STAT Plasmapheresis (PLEX) \u2014 Myasthenic crisis or severe exacerbation 5 exchanges over 7-14 days :: \u2014 :: QOD x 5 :: 5 exchanges (1-1.5 plasma volumes per exchange) over 7-14 days; typically QOD Hemodynamic instability, severe sepsis, poor IV access BP, electrolytes, coagulation, fibrinogen \u2014 STAT \u2014 STAT <p>IVIg vs PLEX Selection: - IVIg preferred: Hemodynamic instability, autonomic dysfunction, difficult vascular access, outpatient - PLEX preferred: Severe/rapidly worsening crisis (faster onset), IgA deficiency, MuSK-positive MG (may respond better), preparation for thymectomy - Efficacy: Both effective; PLEX may work faster (days) vs IVIg (5-7 days) - Duration: Effects last 3-6 weeks; bridge to chronic immunotherapy</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3c-cholinesterase-inhibitors","title":"3C. Cholinesterase Inhibitors","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Pyridostigmine PO Symptomatic treatment 30 mg TID; 60 mg TID; 60 mg QID; 90 mg QID :: PO :: TID-QID :: Start 30-60 mg TID; titrate by 30 mg/dose q2-3d; max ~120 mg q4h; usual maintenance 60-90 mg q4-6h Mechanical bowel/bladder obstruction Cholinergic symptoms (SLUDGE), HR \u2014 ROUTINE \u2014 ROUTINE Pyridostigmine (in crisis) \u2014 During crisis HOLD or reduce :: \u2014 :: :: HOLD pyridostigmine in intubated patients or suspected cholinergic crisis; restart at low dose when improving Cholinergic crisis Secretions, HR \u2014 STAT \u2014 STAT Neostigmine IV/IM If NPO and needs AChEI 0.5 mg IV q3h; 1.5 mg IM q3h :: IV/IM :: q3h :: 0.5 mg IV or 1.5 mg IM roughly equivalent to 60 mg PO pyridostigmine; use ONLY if cannot take PO and essential Cholinergic toxicity HR, secretions \u2014 URGENT \u2014 URGENT Glycopyrrolate PO/IV Cholinergic side effects 1 mg PO TID; 0.2 mg IV PRN :: PO/IV :: TID :: 1-2 mg PO TID for secretions/GI effects; 0.2 mg IV PRN; does not cross BBB Glaucoma, severe cardiac disease HR, urinary retention \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3d-corticosteroids-use-with-caution","title":"3D. Corticosteroids (Use with CAUTION)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Prednisone (high-dose, post-crisis) PO Crisis treated with IVIg/PLEX, improving 60 mg daily; 1 mg/kg daily :: PO :: daily :: Start 60 mg (or 1 mg/kg) daily AFTER day 3 of IVIg/PLEX if improving; for patients whose crisis is being treated; taper once stable Active infection (relative) Glucose, BP, K+; already covered by IVIg/PLEX \u2014 STAT \u2014 STAT Prednisone (low-dose start) PO Stable patient, outpatient, new start 10 mg daily; 20 mg daily :: PO :: daily :: Start LOW (10-20 mg daily) and increase slowly by 10 mg q5-7d to target 1 mg/kg/day; for OUTPATIENT or STABLE inpatients not in crisis; HIGH-DOSE INITIATION CAN WORSEN MG Active infection (relative), brittle MG without IVIg/PLEX cover Glucose, BP, K+; WATCH FOR TRANSIENT WORSENING days 5-10 \u2014 ROUTINE ROUTINE \u2014 Methylprednisolone IV Severe exacerbation (with IVIg/PLEX cover) 500 mg daily x 3-5 days; 1000 mg daily x 3-5 days :: IV :: daily x 3-5 days :: 500-1000 mg IV daily x 3-5 days; ONLY with IVIg/PLEX coverage due to risk of transient worsening Active untreated infection Glucose, BP, K+, psychiatric effects \u2014 URGENT \u2014 URGENT <p>\u26a0\ufe0f STEROID WARNING: High-dose corticosteroids can cause transient worsening of MG (typically days 5-10). Two approaches: - Crisis/Post-treatment: If improving with IVIg/PLEX after day 3, can start prednisone 60 mg (or 1 mg/kg) since already covered - Outpatient/Stable: Start LOW (10-20 mg) and titrate slowly to avoid worsening in patients not covered by IVIg/PLEX</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3e-medications-to-avoid","title":"3E. Medications to AVOID","text":"<p>CRITICAL: The following medications can worsen myasthenia gravis and should be avoided or used with extreme caution:</p> Category Medications to AVOID Alternative Antibiotics Aminoglycosides (gentamicin, tobramycin, amikacin), fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin), macrolides (azithromycin, erythromycin), telithromycin Penicillins, cephalosporins, carbapenems generally safer Cardiac Beta-blockers (all), calcium channel blockers (verapamil, diltiazem), procainamide, quinidine, lidocaine Use with caution; cardiology consult Neuromuscular blockers Succinylcholine (prolonged block), non-depolarizing agents (prolonged) If needed, use reduced dose rocuronium with sugammadex available Psychiatric Lithium, phenothiazines, benzodiazepines (high dose) SSRIs generally safe Anticonvulsants Phenytoin, gabapentin (rare reports) Levetiracetam, valproate safer Other Magnesium IV (high dose), D-penicillamine, botulinum toxin, quinine, chloroquine, iodinated contrast (caution) Avoid if possible","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3f-supportive-care","title":"3F. Supportive Care","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Enoxaparin SC DVT prophylaxis 40 mg daily; 30 mg BID :: SC :: daily :: 40 mg SC daily; 30 mg BID if BMI &gt;40; hold if CrCl &lt;30; HOLD if LP planned within 12 hours Active bleeding, HIT, pending LP Platelet count, bleeding \u2014 STAT \u2014 STAT Heparin (UFH) SC DVT prophylaxis (renal impairment) 5000 units q8h; 5000 units q12h :: SC :: q8-12h :: 5000 units SC q8-12h if CrCl &lt;30; HOLD if LP planned within 4-6 hours Active bleeding, HIT, pending LP Platelet count \u2014 STAT \u2014 STAT Famotidine IV/PO Stress ulcer prophylaxis (if on steroids) 20 mg BID; 40 mg daily :: IV/PO :: BID :: 20 mg IV/PO BID or 40 mg daily None significant None \u2014 ROUTINE \u2014 ROUTINE Insulin (regular) IV/SC Steroid-induced hyperglycemia Sliding scale; basal-bolus :: IV/SC :: per protocol :: Sliding scale or basal-bolus; target glucose &lt;180 mg/dL Hypoglycemia Glucose q4-6h \u2014 ROUTINE \u2014 STAT Acetaminophen PO/IV Fever, mild pain 650 mg q6h; 1000 mg q6h :: PO/IV :: q6h :: 650-1000 mg q6h; max 4 g/day Severe hepatic impairment LFTs if prolonged STAT STAT \u2014 STAT SCDs (sequential compression devices) \u2014 DVT prophylaxis N/A :: \u2014 :: continuous :: Bilateral lower extremity SCDs DVT in that extremity Skin integrity STAT STAT \u2014 STAT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#3g-long-term-immunosuppression-initiatecontinue-as-indicated","title":"3G. Long-term Immunosuppression (Initiate/Continue as Indicated)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Azathioprine PO Steroid-sparing agent 50 mg daily; 100 mg daily; 150 mg daily :: PO :: daily :: Start 50 mg daily; increase by 50 mg q2-4wk to 2-3 mg/kg/day; check TPMT before starting TPMT deficiency, pregnancy CBC weekly x 4, then monthly; LFTs monthly \u2014 ROUTINE \u2014 \u2014 Mycophenolate mofetil PO Steroid-sparing agent 500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: BID :: Start 500 mg BID; increase to 1000-1500 mg BID over 2-4 weeks Pregnancy, hypersensitivity CBC q2wk x 2mo, then monthly; LFTs \u2014 ROUTINE \u2014 \u2014 Rituximab IV Refractory MG, MuSK-positive MG 375 mg/m\u00b2 weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: 375 mg/m\u00b2 weekly x 4 OR 1000 mg x 2 doses (2 weeks apart); pre-medicate with methylpred, acetaminophen, diphenhydramine Active infection, HBV (screen first) Infusion reactions, CD19/CD20, immunoglobulins \u2014 EXT \u2014 EXT","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consult for crisis management, immunotherapy guidance, and medication safety review STAT STAT \u2014 STAT Pulmonology consult for respiratory function monitoring and ventilator wean planning if intubated URGENT URGENT \u2014 STAT Critical care consult for ICU admission given FVC &lt;20 mL/kg or impending respiratory failure URGENT STAT \u2014 STAT Thoracic surgery consult for thymectomy planning if thymoma identified or considering elective thymectomy \u2014 ROUTINE \u2014 ROUTINE Speech therapy for swallow evaluation and aspiration risk assessment given bulbar symptoms \u2014 URGENT \u2014 URGENT Physical therapy for mobility assessment and safe transfer training given fluctuating weakness \u2014 URGENT \u2014 URGENT Occupational therapy for ADL assessment and energy conservation strategies to manage fatigue \u2014 ROUTINE \u2014 ROUTINE Respiratory therapy for airway clearance and pulmonary toilet given weak cough and secretion management STAT STAT \u2014 STAT Pharmacy consult to review all medications for MG-exacerbating drugs (see medications to avoid list) \u2014 URGENT \u2014 URGENT Social work for discharge planning and Myasthenia Gravis Foundation support resources \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening weakness or breathing difficulty develops (may indicate crisis requiring intubation) STAT \u2014 STAT Do not skip or suddenly stop immunosuppressive medications as this may trigger severe exacerbation STAT STAT STAT Carry MG medical alert card listing medications to avoid (aminoglycosides, fluoroquinolones, beta-blockers, etc.) \u2014 STAT STAT Take pyridostigmine 30-60 minutes before meals to improve swallowing and reduce aspiration risk \u2014 ROUTINE ROUTINE Report fever or signs of infection promptly as infection is a common exacerbation trigger STAT STAT STAT Avoid extreme heat as high temperatures worsen neuromuscular transmission and increase weakness \u2014 ROUTINE ROUTINE Get adequate rest and avoid overexertion; fatigue worsens throughout the day in MG \u2014 ROUTINE ROUTINE Do not drive if diplopia or ptosis impairs vision; symptoms may fluctuate unpredictably STAT STAT STAT Contact Myasthenia Gravis Foundation (www.myasthenia.org) for patient support and educational resources \u2014 ROUTINE ROUTINE","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Aspiration precautions including thickened liquids and upright positioning given bulbar weakness STAT STAT \u2014 Fall precautions including walker and bed rails due to fluctuating proximal weakness STAT STAT STAT Medication reconciliation before any new prescription to avoid MG-exacerbating drugs STAT STAT STAT Avoid live vaccines while on immunosuppression; flu and pneumococcal vaccines recommended to prevent infections \u2014 ROUTINE ROUTINE Stress management techniques as psychological stress can trigger MG exacerbations \u2014 ROUTINE ROUTINE Maintain good sleep hygiene as fatigue and sleep deprivation worsen MG symptoms \u2014 ROUTINE ROUTINE Use energy conservation techniques including pacing activities and scheduling rest periods \u2014 ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Guillain-Barr\u00e9 syndrome Ascending weakness, areflexia, no fluctuation CSF (albuminocytologic dissociation), EMG/NCS Lambert-Eaton syndrome Proximal weakness, autonomic symptoms, reflexes improve with exercise VGCC antibodies, EMG (incremental response) Botulism Descending weakness, pupil involvement, GI symptoms Stool/serum toxin, EMG Brainstem stroke Acute onset, crossed findings, other cranial nerve signs MRI brain Multiple sclerosis CNS symptoms, sensory involvement, different time course MRI brain/spine, CSF Thyroid eye disease Thyroid dysfunction, proptosis, restrictive ophthalmopathy TFTs, orbital imaging Oculopharyngeal muscular dystrophy Older onset, slowly progressive, no fluctuation Genetic testing, muscle biopsy Mitochondrial myopathy Progressive, elevated lactate, other organ involvement Lactate, muscle biopsy, genetic testing Drug-induced MG Recent D-penicillamine, checkpoint inhibitors Medication history, antibodies Cholinergic crisis SLUDGE symptoms, miosis, bradycardia Clinical, response to stopping AChEI","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Forced vital capacity (FVC) q4-6h; q2h if declining &gt;15-20 mL/kg Intubate if &lt;15 mL/kg STAT STAT \u2014 STAT Negative inspiratory force (NIF) q4-6h; q2h if declining More negative than -20 cmH2O Intubate if weaker than -20 cmH2O STAT STAT \u2014 STAT Oxygen saturation Continuous &gt;94% Supplement O2, consider intubation STAT STAT \u2014 STAT Neurological exam (strength) q4-8h Stable or improving Escalate therapy if worsening STAT STAT ROUTINE STAT Swallow function Daily if bulbar symptoms Safe swallow NPO, NG tube if unsafe \u2014 STAT \u2014 STAT Blood glucose q6h if on steroids &lt;180 mg/dL Insulin adjustment \u2014 ROUTINE \u2014 STAT Renal function Daily during IVIg Cr stable Hold IVIg, hydrate if rising \u2014 STAT \u2014 STAT Electrolytes (K+, Mg) Daily K+ &gt;3.5, Mg &gt;1.8 Replete aggressively STAT STAT \u2014 STAT Heart rate/rhythm Continuous Sinus rhythm, HR 60-100 Evaluate for autonomic dysfunction STAT STAT \u2014 STAT Blood pressure q4h SBP 100-160 Evaluate for autonomic dysfunction STAT STAT \u2014 STAT Cholinergic symptoms Each dose of pyridostigmine Absent Reduce dose, consider cholinergic crisis \u2014 ROUTINE \u2014 ROUTINE","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission FVC &lt;20 mL/kg or declining; NIF weaker than -30 cmH2O; rapid progression; bulbar dysfunction with aspiration risk; need for intubation/BiPAP Step-down/telemetry Stable FVC &gt;20 mL/kg; improving or stable exam; receiving IVIg/PLEX; no bulbar symptoms General floor Mild exacerbation; FVC &gt;30 mL/kg and stable; no bulbar symptoms; stable on oral medications Discharge home Stable or improved x 24-48 hours; FVC stable &gt;30 mL/kg; adequate oral intake; medications optimized; outpatient follow-up arranged Acute rehabilitation Significant residual weakness after crisis; requires intensive therapy; medically stable","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IVIg and PLEX equally effective for MG exacerbation Class I, Level A Gajdos et al. Cochrane 2012 IVIg 2 g/kg total dose standard Class I, Level A Zinman et al. Lancet Neurol 2007 PLEX effective for MG crisis Class I, Level A Gajdos et al. Cochrane 2012 FVC and NIF for respiratory monitoring Class II, Level B Rabinstein &amp; Wijdicks. Neurology 2003 Pyridostigmine for symptomatic treatment Class I, Level A Mehndiratta et al. Cochrane 2014 Corticosteroids can cause initial worsening Class II, Level B Palace et al. Lancet Neurol 2012 Azathioprine as steroid-sparing agent Class I, Level B Palace et al. NEJM 1998 Rituximab effective in refractory/MuSK+ MG Class II, Level C Nowak et al. Neurology 2022 Medications to avoid in MG Class III, Level C Juel. Semin Neurol 2004 Thymectomy beneficial in generalized MG Class I, Level B Wolfe et al. NEJM 2016 (MGTX Trial)","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#change-log","title":"CHANGE LOG","text":"<p>v1.1 (January 24, 2026) - Citation verification: Corrected Gajdos Cochrane PMID (23235588), MGTX trial PMID (27509100)</p> <p>v1.0 (January 24, 2026) - Initial template creation - Includes respiratory monitoring protocol - IVIg and PLEX protocols for crisis - Comprehensive medications to avoid list - Cholinergic vs myasthenic crisis differentiation - Steroid initiation guidance with worsening warning</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#appendix-a-myasthenia-gravis-foundation-of-america-mgfa-clinical-classification","title":"APPENDIX A: Myasthenia Gravis Foundation of America (MGFA) Clinical Classification","text":"Class Description I Ocular weakness only (ptosis, diplopia) II Mild generalized weakness \u00b1 ocular IIa Predominantly limb/axial IIb Predominantly oropharyngeal/respiratory III Moderate generalized weakness \u00b1 ocular IIIa Predominantly limb/axial IIIb Predominantly oropharyngeal/respiratory IV Severe generalized weakness \u00b1 ocular IVa Predominantly limb/axial IVb Predominantly oropharyngeal/respiratory V Intubation required (with or without mechanical ventilation) <p>Clinical Use: Document at admission and track progression. Class IIb, IIIb, IVb (bulbar predominant) and any Class IV/V require ICU monitoring.</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#appendix-b-quantitative-myasthenia-gravis-qmg-score","title":"APPENDIX B: Quantitative Myasthenia Gravis (QMG) Score","text":"<p>Standardized 13-item scoring system for disease severity. Each item scored 0-3 (total 0-39).</p> Item Assessment Diplopia Lateral gaze duration Ptosis Upward gaze duration Facial muscles Eye closure strength Swallowing 4 oz water Speech Counting to 50 Right arm extended 90\u00b0 duration Left arm extended 90\u00b0 duration FVC % predicted Right hand grip Dynamometer Left hand grip Dynamometer Head lift Supine, 45\u00b0 duration Right leg extended Supine, 45\u00b0 duration Left leg extended Supine, 45\u00b0 duration <p>Interpretation: - 0-9: Mild - 10-19: Moderate - \u226520: Severe</p>","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis-crisis/#appendix-c-ivig-vs-plex-quick-reference","title":"APPENDIX C: IVIg vs PLEX Quick Reference","text":"Factor IVIg PLEX Onset of action 5-7 days 2-3 days Duration of effect 3-6 weeks 3-6 weeks Administration Peripheral IV possible Central line usually required Sessions Daily x 5 days (or x2 days) QOD x 5 (over ~2 weeks) Hemodynamic tolerance Better Fluid shifts, hypotension risk In pregnancy Safe Safe but challenging Renal impairment Caution (risk AKI) Preferred IgA deficiency Contraindicated Safe MuSK+ MG May be less effective May be preferred Before thymectomy Either Often preferred Cost Higher Lower Outpatient feasible Yes Difficult","tags":["neuromuscular","emergency","weakness","autoimmune"]},{"location":"drafts/myasthenia-gravis/","title":"Myasthenia Gravis - Outpatient Management","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#myasthenia-gravis-outpatient-management","title":"Myasthenia Gravis - Outpatient Management","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Myasthenia Gravis - Outpatient Management</p> <p>ICD-10: G70.00 (Myasthenia gravis without exacerbation), G70.01 (Myasthenia gravis with exacerbation)</p> <p>SYNONYMS: MG, myasthenia, autoimmune myasthenia gravis, ocular myasthenia, generalized myasthenia, AChR-positive MG, MuSK myasthenia, seronegative myasthenia, MG chronic management, MG maintenance therapy</p> <p>SCOPE: Outpatient diagnosis, management, and monitoring of myasthenia gravis in adults. Covers antibody-positive (AChR, MuSK, LRP4) and seronegative MG, ocular and generalized subtypes, pyridostigmine optimization, immunotherapy initiation and monitoring, thymectomy evaluation, and crisis prevention. Excludes myasthenic crisis (see \"Myasthenia Gravis - Exacerbation/Crisis\"), Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes, and drug-induced myasthenia.</p> <p>KEY CLINICAL FEATURES: - Fatigable weakness: Worsens with activity, improves with rest - Ocular MG: Ptosis, diplopia; may remain ocular or generalize (50-80% generalize within 2 years) - Generalized MG: Bulbar (dysarthria, dysphagia, facial weakness), limb (proximal &gt; distal), respiratory - Diurnal variation: Worse later in day, better in morning - MuSK MG: Prominent bulbar, neck, respiratory weakness; less ocular; poor response to pyridostigmine</p> <p>ANTIBODY SUBTYPES: | Subtype | Frequency | Characteristics | |---------|-----------|-----------------| | AChR-positive | 85% of generalized, 50% of ocular | Typical MG; thymoma association; good pyridostigmine response | | MuSK-positive | 40% of AChR-negative | Bulbar predominant; less ocular; poor pyridostigmine response; good rituximab response | | LRP4-positive | ~2% of double-negative | Milder phenotype; overlap with AChR+ features | | Seronegative | ~10-15% | May seroconvert; treat as AChR-positive; consider low-affinity antibodies |</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>CRISIS PREVENTION</p> <p>Myasthenic crisis occurs in 15-20% of patients. Recognize warning signs (worsening bulbar/respiratory symptoms, declining FVC) and know medications to avoid. See Section 3E for medications that exacerbate MG.</p> <p>THYMECTOMY CONSIDERATION</p> <p>Thymectomy improves outcomes in non-thymomatous AChR+ generalized MG age 18-65. All patients need CT chest to evaluate for thymoma. See Section 4A for referral criteria.</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#1a-essentialcore-labs-diagnostic-workup","title":"1A. Essential/Core Labs - Diagnostic Workup","text":"Test Rationale Target Finding ED HOSP OPD ICU AChR binding antibody Primary diagnostic test; positive in 85% generalized, 50% ocular MG Positive confirms diagnosis URGENT STAT ROUTINE STAT AChR modulating antibody Increases sensitivity when combined with binding antibody Positive supports diagnosis - ROUTINE ROUTINE - AChR blocking antibody Additional AChR antibody; may be positive when binding negative Positive supports diagnosis - ROUTINE ROUTINE - MuSK antibody Order if AChR negative; positive in ~40% of AChR-negative patients Positive confirms MuSK MG - ROUTINE ROUTINE - LRP4 antibody Order if AChR and MuSK negative; available at specialized labs Positive confirms LRP4 MG - EXT EXT - Anti-striated muscle antibody Thymoma association; if positive, high likelihood of thymoma Positive warrants urgent CT chest - ROUTINE ROUTINE - TSH Autoimmune thyroid disease common comorbidity (10-15%) Normal - ROUTINE ROUTINE - CBC with differential Baseline before immunotherapy; infection assessment Normal STAT STAT ROUTINE STAT CMP Baseline renal/hepatic function; electrolytes Normal STAT STAT ROUTINE STAT","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU TPMT activity or genotype Required before azathioprine initiation; low activity increases toxicity risk Normal or intermediate activity - ROUTINE ROUTINE - Hepatitis B surface antigen and core antibody Before rituximab or other B-cell depleting therapy Negative - ROUTINE ROUTINE - Hepatitis C antibody Before immunosuppressive therapy Negative - ROUTINE ROUTINE - Quantitative immunoglobulins (IgG, IgA, IgM) Baseline before IVIg or rituximab; IgA deficiency is IVIg contraindication Normal; IgA &gt;7 mg/dL - ROUTINE ROUTINE - HIV antibody Before immunosuppressive therapy Negative - ROUTINE ROUTINE - Tuberculosis screen (QuantiFERON-Gold or PPD) Before chronic immunosuppression Negative - ROUTINE ROUTINE - Fasting glucose and HbA1c Baseline before chronic steroid therapy Normal - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Steroid-induced osteoporosis prevention &gt;30 ng/mL - ROUTINE ROUTINE - Free T4 If TSH abnormal; autoimmune thyroid disease Normal - ROUTINE ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Clustered AChR antibody assay Seronegative MG; may detect low-affinity antibodies not seen on standard assay Positive supports diagnosis in seronegative cases - - EXT - Paraneoplastic panel Occult malignancy concern; particularly if anti-striated muscle positive Negative - EXT EXT - Cortisol (AM) Adrenal insufficiency if on chronic steroids being tapered Normal stress response - ROUTINE ROUTINE - ACTH stimulation test Suspected secondary adrenal insufficiency from steroid withdrawal Normal cortisol response - EXT EXT - Bone densitometry markers (CTX, P1NP) Osteoporosis risk on chronic steroids Normal - - EXT -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT chest with contrast At diagnosis; exclude thymoma No thymoma or thymic hyperplasia (or if present, surgical planning) Contrast allergy, renal impairment (CrCl &lt;30) URGENT URGENT ROUTINE URGENT CT chest without contrast If contrast contraindicated Thymic abnormality assessment None URGENT URGENT ROUTINE URGENT Repetitive nerve stimulation (RNS) Diagnostic confirmation; if antibodies negative or for monitoring Decremental response &gt;10% at 3 Hz (positive) None - ROUTINE ROUTINE - Pulmonary function tests (FVC, NIF) Baseline respiratory function; symptom correlation FVC &gt;80% predicted; NIF more negative than -60 cmH2O Facial weakness limiting seal URGENT URGENT ROUTINE URGENT","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Single-fiber EMG (SFEMG) Most sensitive test; if RNS and antibodies negative Increased jitter and blocking None - EXT ROUTINE - MRI chest If CT indeterminate for thymoma; cystic thymic lesions Characterize thymic mass Pacemaker, severe claustrophobia - ROUTINE ROUTINE - PET-CT Suspected thymoma malignancy or metastasis No FDG-avid lesions Pregnancy; hemodynamic instability - EXT EXT - Ice pack test Bedside diagnostic for ptosis; cooling improves neuromuscular transmission Improvement in ptosis after 2 minutes of ice application None STAT STAT ROUTINE STAT Video swallow study Dysphagia symptoms; aspiration risk assessment Safe swallow; define texture modifications None - URGENT ROUTINE - DEXA scan Chronic steroid exposure; osteoporosis screening T-score &gt;-2.5 None - - ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Edrophonium (Tensilon) test Rarely used now; if diagnostic uncertainty and other tests unavailable Improvement in weakness within 30-60 seconds Cardiac arrhythmia, asthma (relative) - EXT EXT - Sleep study (polysomnography) Sleep-disordered breathing; respiratory weakness; fatigue AHI &lt;5/hour; no nocturnal desaturation None - - EXT - Cardiac MRI Suspected cardiac involvement (rare) Normal Pacemaker - - EXT -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3-treatment","title":"3. TREATMENT","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3a-cholinesterase-inhibitors-symptomatic-treatment","title":"3A. Cholinesterase Inhibitors (Symptomatic Treatment)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Pyridostigmine PO First-line symptomatic treatment for all MG subtypes 30 mg TID; 60 mg TID; 60 mg QID; 90 mg QID :: PO :: :: Start 30 mg TID; increase by 30 mg/dose every 3-5 days as tolerated; usual maintenance 60 mg q4-6h (max 120 mg q4h); take 30-60 min before meals for swallowing Mechanical bowel/bladder obstruction; known hypersensitivity Cholinergic symptoms (SLUDGE: salivation, lacrimation, urination, defecation, GI distress, emesis); bradycardia; if symptoms occur, reduce dose STAT STAT ROUTINE STAT Pyridostigmine SR (Mestinon Timespan) PO Nocturnal symptoms; morning weakness on awakening 180 mg qHS :: PO :: :: 180 mg at bedtime for nocturnal weakness; do NOT crush; erratic absorption limits daytime use; max 1 tablet daily Same as immediate-release Same as immediate-release - ROUTINE ROUTINE - Glycopyrrolate PO Cholinergic side effects from pyridostigmine 1 mg BID; 1 mg TID; 2 mg TID :: PO :: :: 1-2 mg PO BID-TID for secretions, diarrhea, or cramping from pyridostigmine; does not cross BBB Glaucoma; severe cardiac disease; GI obstruction Dry mouth; urinary retention; constipation; tachycardia - ROUTINE ROUTINE - <p>PYRIDOSTIGMINE DOSING GUIDANCE: - Start low: 30 mg TID to assess response and tolerability - Titrate slowly: Increase by 30 mg/dose every 3-5 days - Time meals: Take 30-60 minutes before meals if dysphagia present - MuSK MG: Often poor response; may worsen with high doses; use cautiously - Overcorrection: Cholinergic crisis (SLUDGE symptoms, weakness, fasciculations) if overdosed</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3b-corticosteroids","title":"3B. Corticosteroids","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Prednisone (low-dose start) PO Ocular or mild generalized MG; outpatient initiation 10 mg daily; 20 mg daily; 30 mg daily; 40 mg daily :: PO :: :: Start 10-20 mg daily; increase by 10 mg every 5-7 days to target 1 mg/kg/day (max 60-80 mg); LOW-DOSE START prevents transient worsening in outpatient setting Active untreated infection; psychosis (relative); poorly controlled diabetes Glucose weekly during titration; BP; weight; mood; bone density annually - ROUTINE ROUTINE - Prednisone (high-dose) PO Hospital setting with crisis protection (post-IVIg/PLEX) 60 mg daily; 1 mg/kg daily :: PO :: :: 60-80 mg or 1 mg/kg daily; only start high-dose after IVIg/PLEX coverage in hospital or if admitted for monitoring Active infection (relative); NOT FOR OUTPATIENT INITIATION Glucose q6h; BP; K+; monitor for transient worsening days 5-10 - STAT - STAT Prednisone (maintenance/taper) PO Chronic MG on stable steroids Per taper schedule :: PO :: :: Once stable on target dose x 2-4 weeks, begin slow taper: reduce by 10 mg q2-4 weeks until 20 mg, then by 5 mg q2-4 weeks until 10 mg, then by 2.5 mg q month; may need minimum maintenance dose indefinitely - Symptoms of adrenal insufficiency during taper; flare - ROUTINE ROUTINE - <p>STEROID WARNING: High-dose corticosteroids can cause transient worsening of MG (typically days 5-10). - Outpatient initiation: ALWAYS start LOW (10-20 mg) and titrate slowly - Hospital with IVIg/PLEX coverage: Can start high-dose since protected by immunotherapy - Never stop steroids abruptly after &gt;2 weeks of therapy (adrenal suppression)</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3c-steroid-sparing-immunosuppressants-disease-modifying","title":"3C. Steroid-Sparing Immunosuppressants (Disease-Modifying)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Azathioprine PO Steroid-sparing; first-line maintenance immunosuppressant 50 mg daily; 100 mg daily; 150 mg daily; 2-3 mg/kg daily :: PO :: :: Start 50 mg daily x 1-2 weeks; increase by 50 mg every 2-4 weeks to target 2-3 mg/kg/day (usually 150-200 mg/day); takes 6-12 months for full effect TPMT genotype or enzyme activity; CBC; LFTs; hepatitis panel TPMT deficiency (intermediate requires 50% dose reduction); pregnancy; concurrent allopurinol (75% dose reduction required) CBC weekly x 4 weeks, then monthly x 3 months, then q3 months; LFTs monthly x 3 months, then q3 months; flu-like symptoms on initiation (hypersensitivity, discontinue) - ROUTINE ROUTINE - Mycophenolate mofetil PO Steroid-sparing; alternative to azathioprine 500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: :: Start 500 mg BID; increase to 1000 mg BID after 2 weeks; may increase to 1500 mg BID if needed; takes 3-6 months for effect CBC; LFTs; hepatitis panel; pregnancy test Pregnancy (teratogenic); breastfeeding; hypersensitivity CBC every 2 weeks x 2 months, then monthly x 4 months, then q3 months; LFTs q3 months; GI side effects common - ROUTINE ROUTINE - Mycophenolate sodium (Myfortic) PO Alternative formulation with less GI side effects 360 mg BID; 720 mg BID :: PO :: :: Start 360 mg BID; increase to 720 mg BID; 720 mg = 1000 mg mycophenolate mofetil Same as mycophenolate mofetil Same as mycophenolate mofetil Same as mycophenolate mofetil - ROUTINE ROUTINE - Tacrolimus PO Steroid-sparing; faster onset than azathioprine (3-6 months) 3 mg daily; 3 mg BID :: PO :: :: Start 3 mg daily; adjust to trough level 5-10 ng/mL; usual dose 3 mg BID; faster onset than azathioprine Renal function; glucose; BP; drug interaction review Renal impairment; uncontrolled hypertension; concurrent potassium-sparing diuretics Tacrolimus trough level monthly; renal function monthly; glucose; BP; tremor; headache - ROUTINE ROUTINE - Cyclosporine PO Alternative to tacrolimus; similar efficacy 3-5 mg/kg/day divided BID :: PO :: :: 3-5 mg/kg/day divided BID; adjust to trough 100-200 ng/mL Renal function; BP; lipids Renal impairment; uncontrolled hypertension; concurrent nephrotoxins Cyclosporine trough monthly; renal function monthly; BP; lipids; gingival hyperplasia; hirsutism - - ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3d-biologic-and-targeted-immunotherapies","title":"3D. Biologic and Targeted Immunotherapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Rituximab IV MuSK-positive MG (often first-line after steroids); refractory AChR+ MG 375 mg/m2 weekly x 4 weeks; 1000 mg q2 weeks x 2 :: IV :: :: Either 375 mg/m2 IV weekly x 4 weeks OR 1000 mg IV x 2 doses (2 weeks apart); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine; repeat courses as needed Hepatitis B screening (HBsAg, anti-HBc); quantitative immunoglobulins; TB screen Active hepatitis B; active severe infection; live vaccines within 4 weeks Infusion reactions; CD19/CD20 B-cell count q3-6 months; immunoglobulins annually; infection monitoring - URGENT ROUTINE - Eculizumab (Soliris) IV AChR+ refractory generalized MG; FDA approved 900 mg weekly x 4 weeks, then 1200 mg q2 weeks :: IV :: :: 900 mg IV weekly x 4 weeks (induction), then 1200 mg IV every 2 weeks (maintenance); infuse over 35 min Meningococcal vaccination (MenACWY and MenB) at least 2 weeks before; REMS enrollment Unresolved Neisseria meningitidis infection; not current with meningococcal vaccines Meningococcal infection risk (BLACK BOX); infusion reactions; headache; URI - ROUTINE ROUTINE - Ravulizumab (Ultomiris) IV AChR+ refractory generalized MG; longer dosing interval Weight-based loading then maintenance q8 weeks :: IV :: :: Load: 40-60 kg: 2400 mg; 60-100 kg: 2700 mg; &gt;100 kg: 3000 mg; Maintenance q8 weeks: 40-60 kg: 3000 mg; 60-100 kg: 3300 mg; &gt;100 kg: 3600 mg Meningococcal vaccination; REMS enrollment Same as eculizumab Same as eculizumab; less frequent infusions - ROUTINE ROUTINE - Efgartigimod (Vyvgart) IV AChR+ generalized MG; FcRn inhibitor; lowers IgG 10 mg/kg weekly x 4 weeks :: IV :: :: 10 mg/kg IV infusion over 1 hour weekly x 4 weeks per treatment cycle; repeat cycles as needed based on clinical response Baseline immunoglobulins; infection screening Active serious infection; IgG &lt;2 g/L (relative) IgG levels; infection; infusion reactions; headache - ROUTINE ROUTINE - Efgartigimod-fvhp + hyaluronidase (Vyvgart Hytrulo) SC AChR+ generalized MG; subcutaneous administration 1008 mg SC weekly x 4 weeks :: SC :: :: 1008 mg SC injection weekly x 4 weeks per treatment cycle; self-administered at home after training Same as IV efgartigimod Same as IV efgartigimod Same as IV efgartigimod; injection site reactions - - ROUTINE - Rozanolixizumab (Rystiggo) SC AChR+ generalized MG; FcRn inhibitor 420 mg SC weekly x 6 weeks :: SC :: :: 420 mg SC injection weekly x 6 weeks per treatment cycle; repeat cycles as needed Baseline immunoglobulins; infection screening Active serious infection IgG levels; infection; pyrexia; headache; diarrhea - - ROUTINE - Zilucoplan (Zilbrysq) SC AChR+ generalized MG; C5 complement inhibitor; daily SC 0.3 mg/kg daily :: SC :: :: 0.3 mg/kg SC daily; self-administered; meningococcal vaccination required Meningococcal vaccination (MenACWY and MenB); REMS enrollment Unresolved Neisseria infection Meningococcal infection risk; injection site reactions; diarrhea; URI - - ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3e-medications-to-avoid-in-myasthenia-gravis","title":"3E. Medications to AVOID in Myasthenia Gravis","text":"<p>CRITICAL: These medications can worsen MG and precipitate crisis. Review all prescriptions before initiating.</p> Category Medications to AVOID Safer Alternatives Antibiotics Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin); Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin); Macrolides (azithromycin, erythromycin, clarithromycin); Telithromycin (absolute contraindication) Penicillins; Cephalosporins; Carbapenems; Sulfonamides; Vancomycin Cardiac medications Beta-blockers (propranolol, metoprolol, atenolol, carvedilol - ALL); Calcium channel blockers (verapamil, diltiazem); Class Ia antiarrhythmics (procainamide, quinidine, disopyramide); Lidocaine IV ACE inhibitors; ARBs; Dihydropyridine CCBs (amlodipine, nifedipine) with caution Neuromuscular blockers Succinylcholine (prolonged paralysis); Non-depolarizing agents (prolonged effect) If essential: reduced-dose rocuronium with sugammadex reversal available Psychiatric medications Lithium; Chlorpromazine and other phenothiazines; High-dose benzodiazepines SSRIs (sertraline, escitalopram); Bupropion; Low-dose benzodiazepines with caution Anticonvulsants Phenytoin; Gabapentin (rare reports); Pregabalin (rare reports) Levetiracetam; Valproate; Lamotrigine Magnesium IV magnesium sulfate (high dose); Magnesium-containing antacids (high dose) If eclampsia: use with monitoring and intubation preparedness Other D-penicillamine (can induce MG); Botulinum toxin (any formulation); Quinine; Chloroquine/hydroxychloroquine; Iodinated contrast (use with caution); Checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) Document MG on chart; consult neurology before new medications","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#3f-supportive-care-and-comorbidities","title":"3F. Supportive Care and Comorbidities","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Calcium + Vitamin D PO Bone protection on chronic steroids Calcium 1000-1200 mg daily + Vitamin D 1000-2000 IU daily :: PO :: :: Calcium 500-600 mg BID with meals; Vitamin D 1000-2000 IU daily; target 25-OH Vitamin D &gt;30 ng/mL Hypercalcemia; kidney stones Vitamin D level annually; calcium as needed - ROUTINE ROUTINE - Bisphosphonate (Alendronate) PO Osteoporosis prevention/treatment on chronic steroids 70 mg weekly :: PO :: :: 70 mg PO weekly on empty stomach with full glass of water; remain upright 30 min; consider if steroids &gt;3 months at prednisone &gt;5 mg/day GFR &lt;30-35; esophageal disorders; inability to remain upright DEXA at baseline and q1-2 years; jaw osteonecrosis rare - - ROUTINE - PPI (Omeprazole) PO GI protection during high-dose steroids 20 mg daily; 40 mg daily :: PO :: :: 20-40 mg PO daily while on high-dose prednisone; consider tapering off when steroids reduced Long-term use increases C. diff risk Limit duration; consider H2 blocker alternative - ROUTINE ROUTINE - Trimethoprim-sulfamethoxazole PO PJP prophylaxis if on high-dose steroids + other immunosuppression 1 DS tablet 3x weekly :: PO :: :: 1 DS tablet (160/800 mg) PO Monday/Wednesday/Friday; or 1 SS tablet daily Sulfa allergy; G6PD deficiency CBC periodically; rash - ROUTINE ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neuromuscular specialist/MG center for diagnosis confirmation, treatment optimization, and clinical trial consideration - ROUTINE ROUTINE - Thoracic surgery consult for thymectomy evaluation in AChR+ generalized MG age 18-65 years without thymoma, or any patient with thymoma - ROUTINE ROUTINE - Pulmonology consult for baseline pulmonary function testing and ongoing respiratory monitoring in patients with respiratory symptoms - URGENT ROUTINE URGENT Neuro-ophthalmology for diplopia management, prism prescription, or ptosis surgery evaluation in stable ocular MG - - ROUTINE - Speech therapy for swallow evaluation given bulbar symptoms and aspiration risk assessment - URGENT ROUTINE URGENT Physical therapy for generalized weakness to maintain function and prevent deconditioning - ROUTINE ROUTINE - Occupational therapy for ADL assessment and energy conservation strategies given fatigable weakness - ROUTINE ROUTINE - Rheumatology if concurrent autoimmune disease suspected (thyroid, lupus, rheumatoid arthritis) - ROUTINE ROUTINE - Infusion center for IVIg, rituximab, eculizumab, or other IV immunotherapy administration - ROUTINE ROUTINE - High-risk OB for pregnancy planning in women with MG given medication adjustments and delivery planning - - ROUTINE - Endocrinology for steroid-induced diabetes, osteoporosis, or adrenal insufficiency management - ROUTINE ROUTINE - Social work for disability planning, MG Foundation resources, and insurance navigation for expensive biologics - ROUTINE ROUTINE - Psychiatry for depression or anxiety related to chronic illness or steroid side effects - ROUTINE ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if worsening weakness, breathing difficulty, or difficulty swallowing develops (may indicate crisis requiring hospitalization) STAT STAT ROUTINE Carry MG medical alert card or bracelet listing diagnosis and medications to avoid (aminoglycosides, fluoroquinolones, beta-blockers, magnesium) STAT STAT ROUTINE Do not stop prednisone or immunosuppressants abruptly; sudden discontinuation may trigger exacerbation or adrenal crisis STAT STAT ROUTINE Take pyridostigmine 30-60 minutes before meals to improve swallowing and reduce choking risk during eating - ROUTINE ROUTINE Report fever or signs of infection promptly as immunosuppression increases infection risk and infection can trigger MG exacerbation STAT STAT ROUTINE Avoid extreme heat as high temperatures worsen neuromuscular transmission and increase weakness - ROUTINE ROUTINE Do not drive if diplopia or ptosis impairs vision; symptoms may fluctuate throughout the day STAT STAT ROUTINE Avoid overexertion; pace activities throughout the day with rest periods to manage fatigable weakness - ROUTINE ROUTINE Report new medications (including over-the-counter) to neurologist before taking, as many common drugs worsen MG STAT STAT ROUTINE Women: Discuss pregnancy plans with MG specialist in advance as medication adjustments are needed before conception - - ROUTINE Contact Myasthenia Gravis Foundation of America (www.myasthenia.org) for patient support, educational resources, and community - ROUTINE ROUTINE Report symptoms of cholinergic overdose: excessive secretions, diarrhea, cramping, muscle twitching, bradycardia (reduce pyridostigmine dose) STAT STAT ROUTINE","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Medication reconciliation before any new prescription to avoid MG-exacerbating drugs; bring medication list to all appointments STAT STAT ROUTINE Avoid live vaccines while on immunosuppression (azathioprine, mycophenolate, rituximab, high-dose steroids); inactivated vaccines are safe - ROUTINE ROUTINE Annual influenza vaccine (inactivated) to prevent respiratory infections that can trigger exacerbation - ROUTINE ROUTINE Pneumococcal vaccination (PCV15 or PCV20 + PPSV23) before starting immunosuppression - ROUTINE ROUTINE Aspiration precautions including upright positioning during and after meals, small bites, and avoiding mixed textures if bulbar symptoms present STAT STAT ROUTINE Energy conservation techniques including pacing activities, scheduled rest periods, and prioritizing important tasks for morning - ROUTINE ROUTINE Avoid smoking as respiratory infections worsen MG and smoking reduces treatment efficacy ROUTINE ROUTINE ROUTINE Limit alcohol intake as it can worsen weakness and interact with medications - ROUTINE ROUTINE Stress management as psychological stress can trigger MG exacerbations - ROUTINE ROUTINE Good sleep hygiene as fatigue and sleep deprivation worsen MG symptoms - ROUTINE ROUTINE Wear medical alert identification listing MG diagnosis and medications to avoid in emergencies STAT STAT ROUTINE Weight management to reduce respiratory load and minimize steroid side effects - ROUTINE ROUTINE","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Lambert-Eaton myasthenic syndrome (LEMS) Proximal weakness improves with exercise; autonomic symptoms (dry mouth); SCLC association; areflexia VGCC antibody; EMG with incremental response; CT chest for malignancy Botulism Descending paralysis; fixed dilated pupils; GI symptoms; recent wound or food exposure Stool/serum toxin assay; EMG (incremental response); clinical history Oculopharyngeal muscular dystrophy Ptosis, dysphagia; slowly progressive; no fluctuation; onset &gt;45 years; family history Genetic testing (GCN repeat in PABPN1); muscle biopsy Thyroid eye disease Proptosis; lid retraction (not ptosis); restrictive ophthalmopathy; thyroid dysfunction TSH, free T4; orbital CT/MRI (extraocular muscle enlargement) Chronic progressive external ophthalmoplegia (CPEO) Slowly progressive ptosis and ophthalmoparesis; no fluctuation; may have systemic features Muscle biopsy; mitochondrial DNA analysis; lactate Miller Fisher syndrome Ataxia, areflexia, ophthalmoplegia; post-infectious; acute onset Anti-GQ1b antibody; CSF (albuminocytologic dissociation) Brainstem lesion (stroke, tumor, MS) Cranial nerve palsies; other brainstem signs; no fatigability MRI brain with contrast Guillain-Barre syndrome Ascending weakness; areflexia; no fluctuation; sensory symptoms CSF (elevated protein); EMG/NCS (demyelinating pattern) Amyotrophic lateral sclerosis (ALS) Upper and lower motor neuron signs; fasciculations; no fatigability; progressive EMG (denervation); no antibodies; clinical criteria Drug-induced myasthenia Temporal relationship to D-penicillamine, checkpoint inhibitors, aminoglycosides Medication history; may have positive AChR antibodies","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU CLINICAL MG composite or QMG score Every visit Stable or improved Escalate therapy if worsening - ROUTINE ROUTINE - Forced vital capacity (FVC) Baseline; q3-6 months if respiratory symptoms; urgent if symptoms worsen &gt;80% predicted; &gt;15 mL/kg If FVC declining: hospitalize, consider IVIg/PLEX STAT STAT ROUTINE STAT Negative inspiratory force (NIF) With FVC; if respiratory symptoms More negative than -60 cmH2O If NIF &gt;-20 cmH2O: crisis, intubate STAT STAT ROUTINE STAT Swallow function Each visit if bulbar symptoms Safe swallow Modified diet; speech therapy; consider PEG if severe - URGENT ROUTINE URGENT Weight Each visit Stable Monitor steroid side effects; nutritional assessment if losing - ROUTINE ROUTINE - LABORATORY CBC with differential Weekly x 4 then monthly x 3 then q3 months (azathioprine/MMF) WBC &gt;3000; ALC &gt;500; Plt &gt;100K Hold immunosuppressant if low; may resume at lower dose - ROUTINE ROUTINE - LFTs Monthly x 3 then q3 months AST/ALT &lt;3x ULN Reduce dose or discontinue if &gt;3x with symptoms - ROUTINE ROUTINE - Glucose Weekly during steroid titration; q3 months on maintenance Fasting &lt;126; random &lt;200 Initiate diabetes treatment if elevated - ROUTINE ROUTINE - Blood pressure Each visit &lt;130/80 mmHg (steroid hypertension) Antihypertensive if elevated - ROUTINE ROUTINE - TPMT level/genotype Once before azathioprine Normal activity Reduce dose 50% if intermediate; avoid if deficient - - ROUTINE - Tacrolimus trough Monthly if on tacrolimus 5-10 ng/mL Dose adjustment - ROUTINE ROUTINE - Immunoglobulins (IgG, IgA, IgM) Baseline; annually on rituximab or anti-CD20 IgG &gt;400 mg/dL Consider IVIG replacement if low and recurrent infections - ROUTINE ROUTINE - B-cell count (CD19/CD20) q3-6 months on rituximab Depleted initially; document recovery Guide re-dosing - ROUTINE ROUTINE - BONE HEALTH DEXA scan Baseline; q1-2 years if on chronic steroids T-score &gt;-2.5 Bisphosphonate if osteopenia/osteoporosis - - ROUTINE - Vitamin D, 25-OH Baseline; annually &gt;30 ng/mL Supplement if low - ROUTINE ROUTINE -","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Manage outpatient Stable ocular or mild generalized MG; FVC &gt;60% and stable; able to swallow safely; no respiratory symptoms; reliable follow-up Admit to floor Moderate-severe worsening not requiring ICU; initiation of high-dose steroids with IVIg/PLEX coverage; significant bulbar symptoms with aspiration risk; FVC 30-60% and declining; new diagnosis with moderate severity Admit to ICU FVC &lt;30% or rapidly declining; NIF weaker than -30 cmH2O; impending respiratory failure; severe bulbar dysfunction with aspiration; need for intubation or BiPAP Emergency evaluation Acute worsening of weakness; new respiratory symptoms (dyspnea, orthopnea); difficulty swallowing or speaking; recent infection or medication change with weakness; FVC declining on outpatient checks Transfer to MG center Refractory MG not responding to standard therapy; thymectomy evaluation; clinical trial consideration; complex immunotherapy decisions","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Pyridostigmine for symptomatic treatment of MG Class I, Level A Mehndiratta MM et al. Cochrane 2014 Thymectomy improves outcomes in AChR+ generalized MG age 18-65 Class I, Level B Wolfe GI et al. NEJM 2016 (MGTX Trial) Corticosteroids effective for MG Class II, Level B Schneider-Gold C et al. Cochrane 2005 Azathioprine as steroid-sparing agent Class I, Level B Palace J et al. NEJM 1998 Mycophenolate mofetil in MG (mixed evidence) Class II, Level B Sanders DB et al. Muscle Nerve 2016 Rituximab effective in MuSK-positive MG Class II, Level B Nowak RJ et al. Neurology 2022 Rituximab in refractory AChR+ MG Class II, Level C Tandan R et al. Muscle Nerve 2017 Eculizumab for refractory generalized AChR+ MG Class I, Level A Howard JF et al. Lancet Neurol 2017 (REGAIN) Efgartigimod for generalized AChR+ MG Class I, Level A Howard JF et al. Lancet Neurol 2021 (ADAPT) Medications that exacerbate MG Class III, Level C Juel VC. Semin Neurol 2004 AAN/MGFA guidelines for MG management Expert consensus Sanders DB et al. Neurology 2016 Ocular MG: 50-80% generalize within 2 years Class II, Level B Kupersmith MJ et al. Arch Neurol 2003 Low-dose steroid initiation prevents worsening Class II, Level B Pascuzzi RM. Semin Neurol 2003 Anti-striated muscle antibody and thymoma association Class II, Level B Romi F et al. Arch Neurol 2005 Ravulizumab for generalized AChR+ MG Class I, Level A Vu T et al. NEJM 2022 (CHAMPION-MG) Rozanolixizumab for generalized AChR+ MG Class I, Level A Bril V et al. Lancet Neurol 2023 Zilucoplan for generalized AChR+ MG Class I, Level A Howard JF et al. Lancet Neurol 2023 (RAISE)","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation for MG outpatient management - Comprehensive antibody subtype overview (AChR, MuSK, LRP4, seronegative) - Pyridostigmine dosing with structured format for order sentences - Corticosteroid initiation protocols (low-dose outpatient vs high-dose inpatient) - Steroid-sparing agents with pre-treatment and monitoring requirements - All FDA-approved MG biologics (eculizumab, ravulizumab, efgartigimod, rozanolixizumab, zilucoplan) - Comprehensive medications to avoid list - Thymectomy indications and referral criteria - Crisis prevention and warning signs - PubMed citations verified for all evidence statements</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#appendix-a-mgfa-clinical-classification","title":"APPENDIX A: MGFA Clinical Classification","text":"Class Description I Ocular weakness only (ptosis, diplopia) II Mild generalized weakness +/- ocular IIa Predominantly limb/axial IIb Predominantly oropharyngeal/respiratory III Moderate generalized weakness +/- ocular IIIa Predominantly limb/axial IIIb Predominantly oropharyngeal/respiratory IV Severe generalized weakness +/- ocular IVa Predominantly limb/axial IVb Predominantly oropharyngeal/respiratory V Intubation required (with or without mechanical ventilation) <p>Clinical Use: Document at diagnosis and follow changes. Class IIb, IIIb, IVb (bulbar predominant) have higher aspiration and crisis risk.</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#appendix-b-thymectomy-decision-guide","title":"APPENDIX B: Thymectomy Decision Guide","text":"Factor Favors Thymectomy Against/Defer Antibody status AChR-positive MuSK-positive (poor evidence); seronegative (limited data) Age 18-65 years (MGTX data) &lt;18 or &gt;65 (less evidence, still consider) MG type Generalized MG Ocular MG (controversial; consider if not responding to treatment or generalizing) Thymoma ALL thymomas require resection regardless of MG severity N/A Disease stability Stable enough for surgery Actively worsening; optimize with IVIg/PLEX first Comorbidities Good surgical candidate Poor surgical risk <p>MGTX Trial Key Findings: - Thymectomy + prednisone superior to prednisone alone over 3 years - Lower prednisone requirements - Fewer immunosuppressants needed - Fewer exacerbations - Benefits persist at 5-year follow-up</p>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#appendix-c-treatment-algorithm","title":"APPENDIX C: Treatment Algorithm","text":"<pre><code>NEW DIAGNOSIS CONFIRMED\n        |\n        v\n+------------------+\n| Ocular MG only?  |\n+------------------+\n    |         |\n   YES        NO\n    |         |\n    v         v\nPyridostigmine    Pyridostigmine + CT chest (thymoma screen)\n    |                      |\n    v                      v\nSymptoms controlled?   +-------------------+\n    |         |        | Thymoma present? |\n   YES        NO       +-------------------+\n    |         |            |         |\n    v         v           YES        NO\nMonitor for    Add            |         |\ngeneralization prednisone     v         v\n               (low-dose   Thymectomy  Age 18-65, AChR+?\n               start)       urgent     Generalized?\n    |              |                      |         |\n    v              v                     YES        NO\nIf generalizes,  Taper steroids;        |         |\ntreat as         add steroid-           v         v\ngeneralized      sparing agent      Consider    Steroids +\n                 (AZA or MMF)       thymectomy  steroid-sparing\n                       |                        (skip surgery)\n                       v\n              Stable on minimal steroids?\n                    |         |\n                   YES        NO\n                    |         |\n                    v         v\n              Continue    Escalate:\n              monitoring  Rituximab (esp MuSK+)\n                          OR Complement inhibitor\n                          OR FcRn inhibitor\n</code></pre>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/myasthenia-gravis/#appendix-d-crisis-warning-signs-patient-handout","title":"APPENDIX D: Crisis Warning Signs - Patient Handout","text":"<p>SEEK IMMEDIATE MEDICAL ATTENTION IF YOU EXPERIENCE:</p> <ul> <li>Difficulty breathing or feeling short of breath</li> <li>Trouble swallowing or choking on food/liquids/pills</li> <li>Difficulty speaking (slurred or nasal speech) that is new or worsening</li> <li>Weakness that is rapidly getting worse</li> <li>Fever or signs of infection (infections can trigger crisis)</li> <li>Recent exposure to medications on the \"avoid\" list</li> </ul> <p>WARNING SIGNS OF IMPENDING CRISIS:</p> <ul> <li>Increasing difficulty breathing when lying flat</li> <li>Needing more pillows to sleep</li> <li>Waking up short of breath at night</li> <li>Feeling you can't take a deep breath</li> <li>Voice becoming weaker or more nasal</li> <li>Difficulty clearing throat or coughing effectively</li> <li>Meals taking much longer due to swallowing difficulty</li> <li>Choking episodes increasing</li> <li>Needing to use neck muscles to breathe</li> </ul> <p>WHAT TO DO:</p> <ol> <li>Go to emergency department immediately (do not wait for clinic appointment)</li> <li>Bring your medication list and MG card</li> <li>Tell staff you have myasthenia gravis</li> <li>Ask them to contact your neurologist</li> <li>Request they avoid medications on your avoid list</li> </ol>","tags":["neuromuscular","autoimmune","outpatient","chronic-management","myasthenia-gravis"]},{"location":"drafts/new-onset-seizure/","title":"New Onset Seizure","text":"\u26a0\ufe0f DRAFT - Pending Physician Review This plan has not been approved for clinical use. Please review and provide feedback using the comment system.","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#new-onset-seizure","title":"New Onset Seizure","text":"<p>VERSION: 1.2 CREATED: January 13, 2026 REVISED: January 20, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: New Onset Seizure</p> <p>ICD-10: R56.9 (Unspecified convulsions), G40.909 (Epilepsy, unspecified, not intractable, without status epilepticus)</p> <p>SCOPE: Initial evaluation and management of first-time unprovoked seizure or first presentation of seizure activity in adults. Covers immediate stabilization, diagnostic workup to identify etiology, acute treatment, and framework for anti-seizure medication (ASM) initiation. Excludes status epilepticus (see \"Status Epilepticus\" template), pediatric seizures, febrile seizures, and known epilepsy with breakthrough seizures.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | \u2014 = Not applicable to this setting</p>","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Point-of-care glucose Hypoglycemia is immediately reversible cause &gt;70 mg/dL STAT STAT \u2014 STAT CBC with differential Infection screen, baseline before ASMs Normal STAT STAT ROUTINE STAT CMP (BMP + LFTs) Electrolyte abnormalities (Na, Ca, Mg, glucose), renal/hepatic function for ASM dosing Normal STAT STAT ROUTINE STAT Magnesium Hypomagnesemia lowers seizure threshold &gt;1.8 mg/dL STAT STAT ROUTINE STAT Calcium (ionized if available) Hypocalcemia can cause seizures Normal (ionized 4.5-5.3 mg/dL) STAT STAT ROUTINE STAT Urine drug screen Illicit drugs (cocaine, amphetamines) and withdrawal states Negative STAT STAT ROUTINE STAT Blood alcohol level Alcohol intoxication or withdrawal Correlate with history STAT STAT \u2014 STAT Urinalysis UTI can provoke seizures (especially elderly) Negative STAT STAT ROUTINE STAT Prolactin level Elevated if drawn within 10-20 min of event; helps distinguish seizure from non-epileptic event Elevated 2-3\u00d7 baseline (if drawn &lt;20 min) STAT \u2014 \u2014 STAT Phosphorus Hypophosphatemia lowers seizure threshold (especially alcohol withdrawal) &gt;2.5 mg/dL STAT STAT ROUTINE STAT Lactate Elevated post-ictal confirms recent seizure; metabolic acidosis screen Mild elevation acceptable post-ictal STAT STAT \u2014 STAT","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU TSH Thyroid dysfunction can affect seizure threshold Normal URGENT ROUTINE ROUTINE URGENT Ammonia Hepatic encephalopathy, urea cycle disorders Normal (&lt;35 \u03bcmol/L) URGENT ROUTINE \u2014 URGENT Troponin Cardiac ischemia as cause or consequence Negative URGENT ROUTINE \u2014 URGENT ECG Arrhythmia, prolonged QTc (some ASMs), Brugada Normal URGENT ROUTINE ROUTINE URGENT Blood gas (ABG or VBG) Acidosis, hypoxia Normal or mild post-ictal acidosis URGENT ROUTINE \u2014 URGENT Serum osmolality Hypo/hyperosmolar states 280-295 mOsm/kg URGENT ROUTINE \u2014 URGENT Pregnancy test (urine or serum \u03b2-hCG) Eclampsia; affects imaging and ASM choice Negative (or explains eclampsia if positive) STAT STAT ROUTINE STAT B12 level Deficiency associated with seizures Normal (&gt;300 pg/mL) \u2014 ROUTINE ROUTINE \u2014 Folate level Deficiency can lower threshold; important for women of childbearing potential Normal \u2014 ROUTINE ROUTINE \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Serum/urine toxicology (expanded panel) Synthetic drugs, medications not on standard screen Negative URGENT EXT EXT URGENT Heavy metals (lead, mercury) Occupational exposure, pica Normal \u2014 EXT EXT \u2014 Ceruloplasmin, serum copper Wilson disease (young patients) Normal \u2014 EXT EXT \u2014 HIV HIV-associated CNS disease Negative \u2014 ROUTINE ROUTINE \u2014 RPR/VDRL Neurosyphilis Negative \u2014 ROUTINE ROUTINE \u2014 Autoimmune encephalitis panel (serum) Anti-NMDAR, LGI1, CASPR2, GABA-B if clinical suspicion Negative \u2014 EXT EXT \u2014 Paraneoplastic panel (serum) Subacute onset, smoking, weight loss Negative \u2014 EXT EXT \u2014 Porphyrins (urine/serum) Acute intermittent porphyria Normal \u2014 EXT EXT \u2014 Genetic epilepsy panel Young onset, family history, refractory Variable \u2014 \u2014 EXT \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT head without contrast Immediate in ED Mass, hemorrhage, stroke, calcification, hydrocephalus Pregnancy (relative - benefit usually outweighs risk) STAT STAT \u2014 STAT MRI brain with and without contrast (epilepsy protocol)* Within 24-48h if inpatient; within 2 weeks if outpatient Tumor, mesial temporal sclerosis, cortical dysplasia, encephalitis, stroke, vascular malformation GFR &lt;30, gadolinium allergy, pacemaker URGENT URGENT ROUTINE URGENT EEG (routine) Within 24h if possible; ideally within 24-48h of seizure Epileptiform discharges (spikes, sharp waves), focal slowing None significant URGENT URGENT ROUTINE URGENT <p>Epilepsy MRI protocol should include: thin-cut coronal T2/FLAIR through hippocampi, 3D T1 volumetric, T2, SWI, DWI, post-contrast T1</p> <p>IMPORTANT: CT head is useful for acute exclusion of hemorrhage, large mass, or hydrocephalus but is NOT sufficient to identify seizure etiology. MRI brain with epilepsy protocol remains the gold standard and should be obtained in all patients with new onset seizure.</p>","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Continuous EEG (cEEG) monitoring If altered mental status persists, suspected non-convulsive status Non-convulsive seizures, non-convulsive status epilepticus None significant \u2014 URGENT \u2014 URGENT Prolonged ambulatory EEG (24-72h) Outpatient if routine EEG non-diagnostic Capture interictal or ictal activity None significant \u2014 \u2014 ROUTINE \u2014 Video-EEG monitoring If diagnosis uncertain (vs. psychogenic) Correlate clinical events with EEG None significant \u2014 ROUTINE ROUTINE \u2014 MRA/MRV brain If vascular etiology suspected AVM, aneurysm, venous thrombosis Same as MRI \u2014 ROUTINE ROUTINE \u2014 CT angiography head If MRA unavailable and vascular cause suspected Vascular malformation, aneurysm Contrast allergy, renal insufficiency URGENT URGENT \u2014 URGENT Echocardiogram If embolic stroke suspected as cause Thrombus, PFO, vegetation None significant \u2014 ROUTINE ROUTINE \u2014 Chest X-ray Aspiration risk post-ictal, lung cancer screening if paraneoplastic suspected Clear lungs or mass None significant URGENT ROUTINE \u2014 URGENT","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU PET-CT brain (interictal FDG) Epilepsy surgery workup Focal hypometabolism Pregnancy, uncontrolled diabetes \u2014 EXT EXT \u2014 SPECT (ictal/interictal) Epilepsy surgery workup Ictal hyperperfusion Requires seizure capture \u2014 EXT EXT \u2014 MEG (magnetoencephalography) Epilepsy surgery workup Localize epileptogenic focus Metallic implants \u2014 \u2014 EXT \u2014 Neuropsychological testing Pre-surgical evaluation, cognitive concerns Lateralizing deficits Patient cooperation \u2014 \u2014 EXT \u2014 Wada test (intracarotid amobarbital) Pre-surgical language/memory lateralization Language and memory dominance Contrast allergy, vascular anomaly \u2014 \u2014 EXT \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Suspected CNS infection (meningitis, encephalitis), autoimmune encephalitis, carcinomatous meningitis, or atypical presentation with fever/immunocompromise</p> <p>Timing: URGENT if infection suspected; ROUTINE if autoimmune workup</p> <p>Volume Required: 15-20 mL (standard diagnostic); 20-30 mL if malignancy suspected</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Elevated ICP, mass effect 10-20 cm H2O URGENT ROUTINE ROUTINE URGENT Cell count (tubes 1 and 4) Infection, inflammation WBC &lt;5; RBC 0 URGENT ROUTINE ROUTINE URGENT Protein Elevated in infection, inflammation 15-45 mg/dL URGENT ROUTINE ROUTINE URGENT Glucose with serum glucose Low in bacterial/fungal/TB meningitis &gt;60% serum URGENT ROUTINE ROUTINE URGENT Gram stain and culture Bacterial meningitis No organisms URGENT ROUTINE ROUTINE URGENT BioFire FilmArray ME Panel Rapid pathogen identification (14 pathogens) Negative URGENT ROUTINE \u2014 URGENT HSV-1/2 PCR HSV encephalitis (most common treatable cause) Negative URGENT ROUTINE ROUTINE URGENT Autoimmune encephalitis panel (CSF) If clinical suspicion for autoimmune etiology Negative \u2014 ROUTINE ROUTINE \u2014 Cytology Carcinomatous meningitis Negative \u2014 ROUTINE ROUTINE \u2014 VDRL (CSF) Neurosyphilis Negative \u2014 ROUTINE ROUTINE \u2014 Oligoclonal bands If demyelinating disease suspected Negative or matched with serum \u2014 ROUTINE ROUTINE \u2014 <p>Special Handling: HSV PCR can be sent on refrigerated sample. Cytology requires rapid transport (&lt;1 hour). Cell count must be processed within 1 hour.</p> <p>Contraindications: Elevated ICP without imaging (CT first), coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p>","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3-treatment","title":"3. TREATMENT","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Dosing Contraindications Monitoring ED HOSP OPD ICU Lorazepam IV/IM (if actively seizing) 0.1 mg/kg IV (max 4 mg); may repeat once in 5 min Respiratory depression, severe hypotension RR, O2 sat, BP; have airway equipment ready STAT STAT \u2014 STAT Midazolam IM (if no IV access) 10 mg IM (if &gt;40 kg) or 0.2 mg/kg IM Respiratory depression RR, O2 sat; have airway equipment ready STAT STAT \u2014 STAT Midazolam intranasal (if no IV access) 5 mg per nostril (total 10 mg) Respiratory depression RR, O2 sat STAT STAT \u2014 STAT Dextrose 50% IV 25-50 mL IV if hypoglycemia confirmed or suspected Hyperglycemia Glucose STAT STAT \u2014 STAT Thiamine IV 100-500 mg IV BEFORE glucose if alcohol use suspected None significant None STAT STAT \u2014 STAT Supplemental oxygen 2-4 L NC or non-rebreather as needed None O2 sat &gt;94% STAT STAT \u2014 STAT IV fluids (isotonic) NS or LR bolus if hypotensive; maintenance if euvolemic Fluid overload, severe hyponatremia I/O, BP, Na STAT STAT \u2014 STAT Flumazenil (rescue only) 0.2 mg IV over 30 sec; may repeat 0.2 mg q1min to max 1 mg Chronic benzodiazepine use; seizure history; tricyclic overdose CAUTION: May lower seizure threshold and precipitate seizures; use only if severe respiratory depression unresponsive to supportive care STAT STAT \u2014 STAT","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3b-anti-seizure-medications-asms-acute-loading","title":"3B. Anti-Seizure Medications (ASMs) - Acute Loading","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Levetiracetam IV First-line acute loading 40-60 mg/kg IV (max 4500 mg) over 15 min; OR 1500-3000 mg IV None significant; reduce dose if CrCl &lt;50 Somnolence, agitation (rare) STAT STAT \u2014 STAT Levetiracetam PO Acute loading if stable 1500-3000 mg PO \u00d7 1, then start maintenance Same Same URGENT URGENT URGENT \u2014 Fosphenytoin IV Alternative first-line 20 mg PE/kg IV at 150 mg PE/min (max rate) AV block, sinus bradycardia, pregnancy (relative) Continuous cardiac monitoring, BP; purple glove syndrome rare with fosphenytoin STAT STAT \u2014 STAT Phenytoin IV If fosphenytoin unavailable 20 mg/kg IV at max 50 mg/min AV block, sinus bradycardia, pregnancy Cardiac monitor, BP; give via large vein (tissue necrosis risk) STAT STAT \u2014 STAT Valproate IV Alternative (broad-spectrum) 40 mg/kg IV over 10 min (max 3000 mg) Pregnancy (teratogenic - neural tube defects), hepatic disease, mitochondrial disease, urea cycle disorders LFTs, ammonia, platelets; pancreatitis risk STAT STAT \u2014 STAT Lacosamide IV Alternative first-line 200-400 mg IV over 15-30 min PR prolongation &gt;200 ms, 2nd/3rd degree AV block ECG for PR interval; dizziness URGENT URGENT \u2014 URGENT","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3c-anti-seizure-medications-asms-maintenance-therapy","title":"3C. Anti-Seizure Medications (ASMs) - Maintenance Therapy","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Levetiracetam First-line maintenance 500-1500 mg PO/IV BID; start 500 mg BID, may increase by 500 mg/dose weekly; max 3000 mg/day Renal impairment (adjust per CrCl) Behavioral changes (irritability, depression - \"Keppra rage\"); renal function \u2014 ROUTINE ROUTINE ROUTINE Lamotrigine First-line (especially women of childbearing potential) Start 25 mg daily \u00d7 2 weeks; then 50 mg daily \u00d7 2 weeks; then 100 mg daily; target 200-400 mg/day in divided doses Slow titration required (SJS/TEN risk) Rash (stop if any rash; SJS/TEN risk higher with fast titration or valproate co-therapy) \u2014 ROUTINE ROUTINE \u2014 Lacosamide First-line alternative Start 100 mg PO BID; increase by 100 mg/day weekly; target 200-400 mg BID; max 400 mg BID PR prolongation, 2nd/3rd degree AV block, severe hepatic impairment ECG at baseline and dose changes; dizziness, diplopia \u2014 ROUTINE ROUTINE ROUTINE Oxcarbazepine Focal seizures Start 300 mg PO BID; increase by 300-600 mg/day every week; target 1200-2400 mg/day in divided doses Hypersensitivity to carbamazepine Sodium (hyponatremia in 2-3%); HLA-B*1502 screening in at-risk populations \u2014 ROUTINE ROUTINE \u2014 Carbamazepine Focal seizures Start 200 mg PO BID; increase by 200 mg/day weekly; target 800-1200 mg/day; max 1600 mg/day AV block; bone marrow suppression; concurrent MAOIs CBC, LFTs, sodium at baseline and periodically; HLA-B*1502 screening \u2014 ROUTINE ROUTINE \u2014 Valproate/Divalproex Generalized seizures Start 10-15 mg/kg/day in divided doses; increase by 5-10 mg/kg/week; target 1000-2000 mg/day; max 60 mg/kg/day Pregnancy (teratogenic); hepatic disease; mitochondrial disease; pancreatitis history LFTs, ammonia, CBC, platelets at baseline, then q3-6mo; weight gain, hair loss, tremor \u2014 ROUTINE ROUTINE ROUTINE Phenytoin Focal or generalized 300-400 mg daily (extended release) or divided TID (immediate release); adjust by level Pregnancy (relative - fetal hydantoin syndrome); AV block Free phenytoin level (target 1-2 \u03bcg/mL); total level 10-20 \u03bcg/mL; CBC, LFTs; gingival hyperplasia, hirsutism \u2014 ROUTINE ROUTINE ROUTINE Brivaracetam Alternative to levetiracetam Start 50 mg PO BID; may increase to 100 mg BID; max 200 mg/day Hepatic impairment (reduce dose) Less behavioral side effects than levetiracetam; somnolence; Schedule C-V \u2014 ROUTINE ROUTINE ROUTINE Zonisamide Adjunctive or monotherapy Start 100 mg daily; increase by 100 mg every 2 weeks; target 300-400 mg daily; max 600 mg/day Sulfonamide allergy; kidney stones Kidney stones (carbonic anhydrase inhibitor); oligohidrosis (pediatric); metabolic acidosis \u2014 \u2014 ROUTINE \u2014 Topiramate Adjunctive or monotherapy Start 25 mg BID; increase by 50 mg/day weekly; target 200-400 mg/day in divided doses; max 400 mg/day Kidney stones; metabolic acidosis; glaucoma Cognitive impairment (\"dopamax\"); paresthesias; kidney stones; weight loss \u2014 \u2014 ROUTINE \u2014 Clobazam Adjunctive therapy Start 5-10 mg daily; increase by 5-10 mg weekly; max 40 mg/day in divided doses Severe hepatic impairment; sleep apnea (untreated) Sedation; tolerance may develop; CYP2C19 poor metabolizers need lower dose \u2014 ROUTINE ROUTINE \u2014 Perampanel Adjunctive for focal or GTCS Start 2 mg qHS; increase by 2 mg weekly; target 8-12 mg qHS; max 12 mg/day None absolute Psychiatric effects (aggression, hostility); dizziness; take at bedtime; Schedule III \u2014 \u2014 ROUTINE \u2014 Cenobamate Adjunctive for focal Start 12.5 mg daily \u00d7 2 weeks; titrate slowly per package insert; target 200-400 mg daily Familial short QT syndrome Very slow titration required (DRESS risk); QT shortening; titration pack available \u2014 \u2014 ROUTINE \u2014 Phenobarbital Refractory or resource-limited Load 15-20 mg/kg IV; maintenance 1-3 mg/kg/day (60-180 mg/day); target level 15-40 \u03bcg/mL Porphyria; severe respiratory disease Sedation; cognitive effects; drug interactions (CYP inducer); level monitoring \u2014 ROUTINE ROUTINE ROUTINE","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3d-symptomatic-treatments","title":"3D. Symptomatic Treatments","text":"Treatment Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Acetaminophen Post-ictal headache 650-1000 mg PO/IV q6h PRN; max 3000 mg/day (2000 mg if liver disease) Severe hepatic impairment LFTs if chronic use URGENT ROUTINE ROUTINE URGENT Ibuprofen Post-ictal headache 400-600 mg PO q6-8h PRN; max 2400 mg/day Renal impairment; GI bleed; post-CABG Renal function if prolonged use \u2014 ROUTINE ROUTINE \u2014 Ondansetron Post-ictal nausea 4-8 mg IV/PO q8h PRN QT prolongation; severe hepatic impairment QTc if multiple doses URGENT ROUTINE ROUTINE URGENT Lorazepam Post-ictal agitation (if severe) 0.5-2 mg IV/PO PRN; use with caution Respiratory depression; altered mental status RR, sedation level; avoid if post-ictal confusion resolving URGENT URGENT \u2014 URGENT Sertraline Depression/anxiety (chronic) Start 50 mg daily; increase by 25-50 mg q1-2 weeks; max 200 mg daily Concurrent MAOIs Suicidality monitoring weeks 1-4 \u2014 \u2014 ROUTINE \u2014 Escitalopram Depression/anxiety (chronic) Start 10 mg daily; max 20 mg daily Concurrent MAOIs; QT prolongation QTc if risk factors \u2014 \u2014 ROUTINE \u2014 Melatonin Sleep disturbance 3-5 mg PO qHS None significant Well tolerated; may help with ASM-related sleep disruption \u2014 ROUTINE ROUTINE \u2014 Trazodone Insomnia 25-100 mg PO qHS Concurrent MAOIs Orthostatic hypotension; priapism (rare) \u2014 ROUTINE ROUTINE \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#3e-second-linerefractory","title":"3E. Second-line/Refractory","text":"Treatment Dosing Contraindications Monitoring ED HOSP OPD ICU Add second ASM Choose complementary mechanism; see maintenance options Per specific agent Per specific agent \u2014 ROUTINE ROUTINE ROUTINE Epilepsy surgery evaluation referral For drug-resistant epilepsy (failed 2+ appropriately chosen ASMs) N/A N/A \u2014 EXT EXT \u2014 Vagus nerve stimulator (VNS) For drug-resistant epilepsy not surgical candidates N/A Device checks \u2014 \u2014 EXT \u2014 Dietary therapy (ketogenic diet, modified Atkins) For drug-resistant epilepsy Fatty acid oxidation disorders; pyruvate carboxylase deficiency Metabolic panels; lipids; kidney function \u2014 \u2014 EXT \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation Indication ED HOSP OPD ICU Neurology consult All new onset seizures for evaluation and management URGENT URGENT ROUTINE URGENT Epilepsy specialist referral Diagnostic uncertainty, refractory seizures, surgical candidacy \u2014 ROUTINE ROUTINE \u2014 EEG technologist/neurodiagnostics EEG scheduling; continuous EEG if indicated URGENT URGENT ROUTINE URGENT Neurosurgery consult Structural lesion requiring intervention (tumor, AVM, SDH) \u2014 URGENT EXT URGENT Medical toxicology consult Suspected drug/toxin-induced seizure URGENT ROUTINE \u2014 URGENT Infectious disease consult CNS infection confirmed or suspected \u2014 URGENT \u2014 URGENT Oncology consult Brain tumor identified \u2014 ROUTINE ROUTINE \u2014 Psychiatry consult Depression, anxiety post-diagnosis; psychogenic non-epileptic spells suspected \u2014 ROUTINE ROUTINE \u2014 Social work consult Driving restrictions impact, employment concerns, insurance navigation \u2014 ROUTINE ROUTINE \u2014 Occupational therapy Work safety evaluation, activity modification \u2014 ROUTINE ROUTINE \u2014 Physical therapy If post-ictal weakness, falls, injury from seizure \u2014 ROUTINE ROUTINE \u2014 Neuropsychology referral Cognitive complaints, pre-surgical evaluation \u2014 \u2014 ROUTINE \u2014 Women's health/OB-GYN Contraception counseling (ASM interactions), pregnancy planning \u2014 \u2014 ROUTINE \u2014 Epilepsy monitoring unit (EMU) admission Characterize seizure type, video-EEG monitoring, pre-surgical evaluation \u2014 EXT EXT \u2014 Driving evaluation/rehabilitation Return to driving assessment when eligible \u2014 \u2014 EXT \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#4b-patient-instructions","title":"4B. Patient Instructions","text":"<p>Note: ICU patients typically receive these instructions at step-down or discharge.</p> Recommendation ED HOSP OPD ICU Return to ED immediately if: recurrent seizure, prolonged seizure &gt;5 minutes, head injury, persistent confusion, difficulty breathing, or status epilepticus \u2713 \u2713 \u2713 \u2014 Do NOT drive until cleared by neurology (driving restrictions per state guidelines; typically require seizure-free interval) \u2713 \u2713 \u2713 \u2014 Avoid operating heavy machinery, working at heights, or swimming alone \u2713 \u2713 \u2713 \u2014 Do not bathe alone; showers preferred over baths; keep bathroom door unlocked \u2713 \u2713 \u2713 \u2014 Inform employer if job involves safety-sensitive duties \u2014 \u2713 \u2713 \u2014 Take ASM exactly as prescribed; do NOT stop abruptly (risk of breakthrough seizures or status epilepticus) \u2713 \u2713 \u2713 \u2014 Avoid common seizure triggers: sleep deprivation, alcohol, illicit drugs, missed medications \u2713 \u2713 \u2713 \u2014 Keep a seizure diary: date, time, duration, description, triggers, post-ictal symptoms \u2014 \u2713 \u2713 \u2014 Wear medical identification (bracelet or necklace) \u2014 \u2713 \u2713 \u2014 Educate family/coworkers on seizure first aid: stay with person, protect head, do NOT put anything in mouth, time the seizure, call 911 if &gt;5 minutes \u2713 \u2713 \u2713 \u2014 Follow up with neurology within 1-2 weeks of discharge \u2713 \u2713 \u2014 \u2014 Bring list of all medications (including OTC and supplements) to all appointments - many interact with ASMs \u2014 \u2713 \u2713 \u2014 Women: discuss contraception with provider; some ASMs reduce efficacy of hormonal contraception \u2014 \u2713 \u2713 \u2014 Report side effects (mood changes, rash, dizziness, cognitive issues) promptly; do NOT stop medication without calling \u2014 \u2713 \u2713 \u2014 Avoid flashing/strobe lights if photosensitive seizures suspected \u2014 \u2713 \u2713 \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"<p>Note: ICU patients typically receive these recommendations at step-down or discharge.</p> Recommendation ED HOSP OPD ICU Sleep hygiene: aim for 7-9 hours nightly; maintain regular sleep schedule \u2014 \u2713 \u2713 \u2014 Avoid alcohol (lowers seizure threshold; interacts with ASMs) \u2713 \u2713 \u2713 \u2014 Avoid illicit drugs (especially stimulants: cocaine, amphetamines) \u2713 \u2713 \u2713 \u2014 Stress management techniques \u2014 \u2014 \u2713 \u2014 Regular moderate exercise (not extreme sleep deprivation from overtraining) \u2014 \u2014 \u2713 \u2014 Medication adherence: use pill organizers, phone alarms, refill reminders \u2014 \u2713 \u2713 \u2014 Folic acid supplementation 1-4 mg daily for women of childbearing potential (especially if on enzyme-inducing ASMs) \u2014 \u2713 \u2713 \u2014 Bone health: vitamin D 1000-2000 IU daily; calcium as needed (enzyme-inducing ASMs affect bone density) \u2014 \u2014 \u2713 \u2014 Avoid known personal triggers (flashing lights, certain foods, stress, if identified) \u2014 \u2713 \u2713 \u2014 Home safety modifications: pad sharp furniture corners, avoid glass shower doors, use microwave instead of stovetop when alone \u2014 \u2713 \u2713 \u2014 Seizure alert devices or apps for those living alone (optional) \u2014 \u2014 \u2713 \u2014 Smoking cessation (increases ASM metabolism; general health) \u2014 \u2713 \u2713 \u2014","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Syncope (convulsive syncope) Brief (&lt;15 sec), triggered by standing/Valsalva/micturition, rapid recovery, no post-ictal confusion, possible prodrome (lightheaded, tunnel vision) ECG, orthostatic vitals, tilt table test, echocardiogram Psychogenic non-epileptic spells (PNES) Variable/atypical semiology, prolonged duration, preserved awareness with bilateral movements, eye closure, pelvic thrusting, no post-ictal confusion, psychiatric comorbidity Video-EEG capturing event; normal prolactin Transient ischemic attack (TIA) Negative symptoms (weakness, numbness), no LOC, no convulsive activity MRI DWI, vascular imaging Migraine with aura Gradual onset, spreading symptoms, headache follows, stereotyped Clinical history, normal EEG Hypoglycemia Diaphoresis, tremor, confusion, rapid glucose corrects symptoms Fingerstick glucose Cardiac arrhythmia Palpitations, sudden LOC without warning, rapid recovery ECG, Holter monitor, event recorder, EP study Transient global amnesia Isolated anterograde amnesia, repetitive questioning, no convulsive activity Clinical presentation (self-limited), MRI DWI (hippocampal) Sleep disorders (parasomnias, cataplexy) Occur from sleep, specific features (cataplexy with emotion) Sleep study, clinical history Movement disorders (dystonia, tics) Stereotyped, no LOC, suppressible (tics), may have sensory urge Clinical history, video Drug intoxication/withdrawal History of substance use, known withdrawal timeline Toxicology screen, history Metabolic encephalopathy Gradual onset, diffuse abnormality, asterixis, no discrete seizures Labs (ammonia, glucose, Na), EEG (diffuse slowing)","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurologic exam (level of consciousness, focal deficits) Q1-2h in ED; Q4h inpatient; each visit OPD Return to baseline If prolonged post-ictal state: continuous EEG to rule out non-convulsive status \u2713 \u2713 \u2713 \u2713 Vital signs Continuous in ED/ICU; Q4h floor Stable Treat hyperthermia, hypotension, hypoxia \u2713 \u2713 \u2014 \u2713 Respiratory monitoring (post-benzodiazepine) RR q15min \u00d7 1h post-administration; SpO2 continuous RR \u226512; SpO2 \u226594% Supplemental O2; airway management; consider flumazenil only if severe \u2713 \u2713 \u2014 \u2713 Glucose On arrival; repeat if altered &gt;70 mg/dL Dextrose if low \u2713 \u2713 \u2014 \u2713 Electrolytes (Na, Ca, Mg) On arrival; daily if abnormal Normal ranges Correct deficiencies; identify cause \u2713 \u2713 \u2713 \u2713 ASM level (phenytoin, valproate, phenobarbital, carbamazepine) Trough level 5-7 days after initiation or dose change; PRN Therapeutic range (drug-specific) Adjust dose; check free level for phenytoin \u2014 \u2713 \u2713 \u2713 LFTs Baseline; q3-6 months on valproate, carbamazepine Normal Discontinue if hepatotoxicity; hold if transaminases &gt;3\u00d7 ULN \u2014 \u2713 \u2713 \u2713 CBC Baseline; q3-6 months on carbamazepine, valproate Normal Discontinue if significant bone marrow suppression \u2014 \u2713 \u2713 \u2713 Sodium Baseline; periodically on oxcarbazepine, carbamazepine &gt;130 mEq/L Reduce dose or switch if severe hyponatremia \u2014 \u2713 \u2713 \u2713 EEG Within 24-48h of first seizure; repeat if diagnosis unclear No ongoing seizures Adjust treatment if epileptiform activity or non-convulsive seizures \u2713 \u2713 \u2713 \u2713 MRI brain Within 2 weeks of first seizure; sooner if structural cause suspected No new lesions Address structural cause; refer to appropriate specialist \u2014 \u2713 \u2713 \u2014 <p>ASM Therapeutic Level Reference:</p> ASM Therapeutic Range Notes Phenytoin (total) 10-20 \u03bcg/mL Check FREE level (1-2 \u03bcg/mL) if hypoalbuminemia, renal failure, or pregnancy Valproate 50-100 \u03bcg/mL Higher levels may be needed; monitor for toxicity Carbamazepine 4-12 \u03bcg/mL Autoinduction occurs over 2-4 weeks Phenobarbital 15-40 \u03bcg/mL Sedation common at higher levels Lacosamide 10-20 \u03bcg/mL Level monitoring not routinely required Levetiracetam 12-46 \u03bcg/mL Level monitoring not routinely required; clinical response guides dosing","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Single, self-limited seizure; returned to baseline; no dangerous etiology identified on initial workup; reliable adult supervision for 24h; ASM initiated or deferred with close follow-up; outpatient EEG and MRI arranged; understands return precautions and driving restriction Admit to floor (observation) Prolonged post-ictal period; multiple seizures; new structural lesion requiring monitoring; ASM loading requiring observation; social situation preventing safe discharge; need for inpatient EEG; new focal neurologic deficit Admit to ICU Status epilepticus (current or recent); recurrent seizures despite treatment; need for continuous EEG monitoring; airway compromise; hemodynamic instability; significant aspiration; large structural lesion with mass effect; CNS infection Transfer to higher level MRI unavailable; EEG unavailable; neurology not available for consultation; need for neurosurgical intervention unavailable at facility","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source ILAE 2017 seizure classification Class I Fisher RS et al. Epilepsia 2017 ILAE 2014 practical definition of epilepsy Class I Fisher RS et al. Epilepsia 2014 EEG within 24-48h increases yield Class II, Level B AAN Practice Parameter 2007 MRI superior to CT for epilepsy evaluation Class I, Level A ILAE Commission Report 2019 Levetiracetam non-inferior to phenytoin for acute seizure cessation Class I, Level A ESETT Trial, NEJM 2019 Risk of recurrence after first unprovoked seizure ~40-50% Class I Hauser et al., NEJM 1998 Starting ASM after first seizure reduces recurrence but not long-term remission Class I, Level A FIRST and MESS trials Lamotrigine and levetiracetam preferred in women of childbearing potential Class II, Level B AAN/AES Guidelines 2009, MONEAD Study Driving restrictions reduce accident risk Class II, Level B Multiple observational studies Prolactin elevation supports diagnosis of epileptic seizure (if drawn &lt;20 min) Class II, Level B Chen et al., Neurology 2005 Continuous EEG detects non-convulsive status in altered patients Class II, Level B Claassen et al., Neurology 2004 Folate supplementation reduces teratogenicity risk Class II, Level B AAN Practice Parameter","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/new-onset-seizure/#change-log","title":"CHANGE LOG","text":"<p>v1.2 (January 20, 2026) - Added lactate to Section 1A core labs (elevated post-ictal confirms recent seizure) per R4 - Added respiratory monitoring parameters to Section 6 (RR, SpO2 post-benzodiazepine) per R2 - Added Schedule C-V controlled substance note to brivaracetam in Section 3C per R3 - Added ICU column to Sections 4B and 4C for format consistency per R1 - Added explanatory notes for ICU exclusion in patient instructions/lifestyle sections</p> <p>v1.1 (January 13, 2026) - Updated levetiracetam loading dose to range (40-60 mg/kg) per physician preference - Added phosphorus to core labs (hypophosphatemia in alcohol withdrawal) - Added flumazenil to acute treatments with seizure threshold caution - Added note that CT insufficient for etiology; MRI is gold standard - Updated driving restriction language to generic \"per state guidelines\" - Added ASM therapeutic level reference table to Section 6 - Added ILAE 2017 seizure classification and 2014 epilepsy definition to references</p> <p>v1.0 (January 13, 2026) - Initial creation - Comprehensive ASM section with individual drug rows and complete dosing - Included 14 maintenance ASMs with titration schedules - Added acute loading options (levetiracetam, fosphenytoin, valproate, lacosamide) - LP section for infectious/autoimmune workup - Extensive differential diagnosis including syncope, PNES, cardiac causes - Complete patient instructions including driving, safety, seizure first aid - Setting-appropriate coverage across ED, HOSP, OPD, ICU</p>","tags":["seizure","epilepsy","new-diagnosis"]},{"location":"drafts/normal-pressure-hydrocephalus/","title":"Normal Pressure Hydrocephalus","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#normal-pressure-hydrocephalus","title":"Normal Pressure Hydrocephalus","text":"<p>DIAGNOSIS: Normal Pressure Hydrocephalus (NPH) ICD-10: G91.2 (Normal pressure hydrocephalus); G91.0 (Communicating hydrocephalus); R41.0 (Disorientation, unspecified); R26.0 (Ataxic gait); R32 (Unspecified urinary incontinence) CLINICAL SYNONYMS: NPH, idiopathic NPH (iNPH), Hakim-Adams syndrome, communicating hydrocephalus, chronic hydrocephalus SCOPE: Comprehensive evaluation of suspected NPH, diagnostic workup including high-volume lumbar puncture (tap test), prediction of shunt responsiveness, neurosurgical referral, and post-shunt monitoring. Covers idiopathic NPH (most common) and secondary NPH. Does not cover acute obstructive hydrocephalus or pediatric hydrocephalus.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>CLINICAL PEARL: The classic triad of NPH is \"wet, wacky, wobbly\" - urinary incontinence, cognitive impairment, and gait disturbance. Gait is typically the first and most prominent symptom, and responds best to shunt surgery. The presence of all three symptoms is not required for diagnosis.</p>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Pre-surgical screening; rule out infection Normal STAT ROUTINE ROUTINE - BMP Electrolyte assessment; pre-surgical renal function Normal electrolytes, BUN, Cr STAT ROUTINE ROUTINE - Coagulation panel (PT/INR, PTT) Pre-procedural assessment for LP and surgery INR &lt;1.5, PTT &lt;40 STAT ROUTINE ROUTINE - TSH Hypothyroidism can cause cognitive impairment 0.4-4.0 mIU/L - ROUTINE ROUTINE - Vitamin B12 B12 deficiency causes reversible dementia and gait ataxia &gt;300 pg/mL - ROUTINE ROUTINE - Urinalysis with culture Rule out UTI as cause of incontinence or confusion Negative for infection STAT ROUTINE ROUTINE - Hemoglobin A1c Diabetes contributes to small vessel disease and neuropathy &lt;7% - ROUTINE ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Folate Deficiency contributes to cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - RPR or VDRL Neurosyphilis can cause dementia and gait abnormalities Nonreactive - ROUTINE ROUTINE - HIV antibody HIV-associated neurocognitive disorder in at-risk patients Negative - ROUTINE ROUTINE - ESR, CRP Inflammatory or infectious causes of meningitis/encephalitis Normal STAT ROUTINE ROUTINE - Hepatic panel Hepatic encephalopathy in patients with liver disease Normal - ROUTINE ROUTINE - PSA (males) Prostate disease contributing to urinary symptoms Normal for age - - ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Paraneoplastic antibody panel Autoimmune etiology if subacute presentation Negative - EXT EXT - Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2) Autoimmune encephalitis causing cognitive/behavioral changes Negative - EXT EXT - Genetic testing for APP, PSEN1, PSEN2 Early-onset dementia with family history No pathogenic variants - - EXT -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast Initial evaluation Ventriculomegaly with Evans index &gt;0.3; callosal angle &lt;90 degrees; DESH pattern; periventricular edema (transependymal flow); absence of cortical atrophy proportionate to ventricular size MRI-incompatible devices; claustrophobia URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable or emergent presentation Ventriculomegaly out of proportion to sulcal enlargement; Evans index &gt;0.3 Pregnancy (relative) STAT STAT ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with volumetric analysis Detailed assessment Quantify ventricular volume; hippocampal volume preservation (unlike AD); tight high-convexity sulci MRI contraindications - - ROUTINE - MRI with CSF flow study (phase-contrast) Assess aqueductal CSF flow Hyperdynamic aqueductal flow; increased stroke volume (&gt;42 microL) MRI contraindications - - ROUTINE - MR spectroscopy Atypical cases to differentiate from AD Normal NAA/Cr ratio (reduced in AD); no significant metabolic abnormality MRI contraindications - - EXT - FDG-PET Brain Differentiate NPH from AD or FTD Preserved metabolism (unlike AD temporoparietal hypometabolism) None - - EXT -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Intracranial pressure monitoring (continuous) Diagnostic uncertainty after tap test B-waves present (indicates impaired CSF dynamics) Coagulopathy; skin infection - EXT - - Infusion testing (CSF outflow resistance) Research settings; predict shunt response Elevated Rout &gt;12-18 mmHg/mL/min suggests shunt responsiveness Coagulopathy - EXT EXT - Radionuclide cisternography Rarely used; assesses CSF flow patterns Delayed clearance over convexities; ventricular reflux None - - EXT -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Diagnostic and prognostic - high-volume lumbar puncture (\"tap test\") to assess for clinical improvement predicting shunt responsiveness Timing: ROUTINE during outpatient evaluation; can be done in hospital if inpatient Volume Required: 30-50 mL (high-volume therapeutic tap) - remove CSF until opening pressure is halved or symptoms of low pressure develop</p> Study Rationale Target Finding ED HOSP OPD ICU Opening pressure Confirm normal or mildly elevated pressure in NPH 5-18 cm H2O (typically normal or low-normal in NPH) URGENT ROUTINE ROUTINE - Cell count (tubes 1 and 4) Rule out infection or inflammation WBC &lt;5, RBC 0 URGENT ROUTINE ROUTINE - Protein Rule out infectious/inflammatory causes Normal 15-45 mg/dL URGENT ROUTINE ROUTINE - Glucose with serum glucose Rule out infectious meningitis &gt;60% of serum glucose URGENT ROUTINE ROUTINE - CSF Abeta-42, total tau, p-tau Differentiate from Alzheimer's disease (optional) Normal in NPH; low Abeta-42 with high tau in AD - ROUTINE ROUTINE - <p>Tap Test Protocol: 1. Record baseline gait assessment (timed 10-meter walk, steps to walk 10 meters, Tinetti gait score) 2. Record baseline cognitive testing (MoCA or MMSE) 3. Remove 30-50 mL CSF 4. Repeat gait assessment at 30 min, 4 hours, 24 hours, and 72 hours post-LP 5. Repeat cognitive testing at 24-72 hours 6. Positive tap test: Improvement in gait (&gt;20% faster walk time or &gt;10% fewer steps) predicts shunt response</p> <p>Special Handling: Standard CSF handling; freeze sample if sending for biomarkers Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); posterior fossa mass; skin infection at site; anticoagulation (hold appropriately)</p>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#extended-lumbar-drain-trial","title":"EXTENDED LUMBAR DRAIN TRIAL","text":"<p>Indication: Diagnostic uncertainty after single tap test; equivocal tap test results; more sensitive predictor of shunt response Setting: Inpatient (requires admission for continuous drainage and monitoring)</p> Component Protocol Target ED HOSP OPD ICU Lumbar drain placement Neurosurgery places external lumbar drain Secure placement - ROUTINE - - CSF drainage rate 10-15 mL/hour continuously for 3-5 days Drain 200-400 mL/day - ROUTINE - - Serial gait assessment Daily timed walk and Tinetti score &gt;30% improvement in walk time or gait score - ROUTINE - - Serial cognitive assessment Daily MoCA or appropriate testing Improvement in score - ROUTINE - - Monitoring for overdrainage Headache, subdural hematoma, drain displacement No complications - ROUTINE - - <p>Extended Drain Sensitivity: 80-90% sensitive for predicting shunt response (more sensitive than single tap test at 50-60%) Duration: Typically 3-5 days of continuous drainage with serial assessments</p>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Acetazolamide PO Temporizing measure while awaiting surgery; reduces CSF production 250 mg BID; 250 mg TID; 500 mg BID :: PO :: :: Start 250 mg BID; titrate to 250 mg TID or 500 mg BID; max 2 g/day Sulfa allergy; severe hepatic/renal disease; hypokalemia; metabolic acidosis BMP for potassium, bicarbonate; paresthesias - ROUTINE ROUTINE - Serial therapeutic LP LP Temporizing measure; confirm continued benefit; bridge to surgery 30-50 mL removed :: LP :: :: Remove 30-50 mL every 1-4 weeks based on symptom recurrence Coagulopathy; anticoagulation; skin infection Post-LP symptoms; duration of benefit - ROUTINE ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Memantine PO Cognitive symptoms; may provide modest benefit pending surgery 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily; increase by 5 mg/week; target 10 mg BID Severe renal impairment (adjust dose if CrCl &lt;30) Confusion, dizziness - ROUTINE ROUTINE - Donepezil PO Cognitive symptoms if AD component suspected 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS x 4-6 weeks; increase to 10 mg qHS Sick sinus syndrome; GI bleeding; COPD Bradycardia, GI symptoms - ROUTINE ROUTINE - Oxybutynin PO Urinary urgency/incontinence 5 mg BID; 5 mg TID; 10 mg ER daily :: PO :: :: Start 5 mg BID; may increase to 5 mg TID; or use ER 10-30 mg daily Uncontrolled narrow-angle glaucoma; urinary retention; GI obstruction Anticholinergic effects; cognitive worsening - ROUTINE ROUTINE - Mirabegron PO Urinary urgency if anticholinergics contraindicated or cause cognitive worsening 25 mg daily; 50 mg daily :: PO :: :: Start 25 mg daily; may increase to 50 mg daily Severe uncontrolled hypertension Blood pressure - ROUTINE ROUTINE - Tamsulosin PO Urinary retention (males with BPH component) 0.4 mg daily; 0.8 mg daily :: PO :: :: Start 0.4 mg daily; may increase to 0.8 mg daily Orthostatic hypotension; planned cataract surgery (IFIS) Orthostatic hypotension - ROUTINE ROUTINE - Trazodone PO Sleep disturbance; sundowning 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate to 50-150 mg qHS Concurrent MAOIs; QT prolongation Orthostatic hypotension - ROUTINE ROUTINE - Physical therapy - Gait training and fall prevention Per PT evaluation :: - :: :: Initial evaluation plus ongoing therapy for gait training, balance, strength None Fall risk assessment - ROUTINE ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#3c-definitive-treatment-shunt-surgery","title":"3C. Definitive Treatment (Shunt Surgery)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ventriculoperitoneal (VP) shunt Surgical Definitive treatment for NPH; positive tap test or extended drain trial Programmable valve preferred :: Surgical :: :: Valve pressure setting adjusted based on symptoms; typical starting setting 120-180 mmH2O Active peritoneal infection; peritoneal adhesions; recent abdominal surgery; ascites Post-op neuro checks; shunt series imaging; valve setting verification - ROUTINE ROUTINE - Ventriculoatrial (VA) shunt Surgical Alternative if peritoneum unsuitable (adhesions, peritonitis history) Programmable valve preferred :: Surgical :: :: Catheter tip in right atrium; valve adjusted as VP shunt Active bacteremia; severe cardiac disease; pulmonary hypertension Same as VP; plus cardiac monitoring; watch for shunt nephritis - EXT - - Lumboperitoneal (LP) shunt Surgical Alternative approach; avoids cranial surgery Programmable valve preferred :: Surgical :: :: Catheter from lumbar subarachnoid space to peritoneum Spinal stenosis; arachnoiditis; Chiari malformation Similar to VP; watch for overdrainage with positional changes - EXT - - Endoscopic third ventriculostomy (ETV) Surgical Secondary NPH with aqueductal stenosis NA :: Surgical :: :: Create opening between third ventricle and interpeduncular cistern Communicating hydrocephalus (most iNPH); scarred prepontine cistern Post-op neuro checks; repeat imaging - EXT - - <p>Shunt Valve Selection: - Programmable valves (Codman, Medtronic, Sophysa) preferred - allow non-invasive pressure adjustment - Anti-siphon devices reduce positional overdrainage - Gravitational valves help prevent overdrainage in upright position</p>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#3d-post-shunt-complication-management","title":"3D. Post-Shunt Complication Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Valve pressure adjustment External Overdrainage symptoms (headache, subdural hematoma) Increase valve setting :: External programming :: :: Increase opening pressure by 20-30 mmH2O increments; recheck in 1-2 weeks None Symptom response; repeat imaging - ROUTINE ROUTINE - Valve pressure adjustment External Underdrainage (persistent or worsening NPH symptoms) Decrease valve setting :: External programming :: :: Decrease opening pressure by 20-30 mmH2O increments; recheck in 1-2 weeks None Symptom response; repeat imaging - ROUTINE ROUTINE - Vancomycin IV Shunt infection (empiric) 15-20 mg/kg IV q8-12h :: IV :: :: 15-20 mg/kg IV q8-12h; adjust for renal function; target trough 15-20 mcg/mL Vancomycin allergy Vancomycin trough; renal function STAT STAT - STAT Cefepime IV Shunt infection (empiric gram-negative coverage) 2 g IV q8h :: IV :: :: 2 g IV q8h; adjust for renal function Cephalosporin allergy Renal function STAT STAT - STAT Shunt revision surgery Surgical Shunt malfunction, obstruction, or infection Per neurosurgery :: Surgical :: :: Shunt externalization if infected; revision for mechanical failure Active systemic infection Post-op monitoring; infection clearance - URGENT - -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology for comprehensive evaluation, differential diagnosis, and coordination of diagnostic workup - ROUTINE ROUTINE - Neurosurgery for shunt candidacy evaluation after positive tap test or extended drain trial - ROUTINE ROUTINE - Neuropsychology for baseline cognitive assessment and differentiation from other dementias (AD, vascular) - - ROUTINE - Physical therapy for gait assessment, fall prevention, and baseline measurement for tap test comparison - ROUTINE ROUTINE - Occupational therapy for ADL assessment, home safety evaluation, and cognitive strategies - ROUTINE ROUTINE - Urology for evaluation if urinary symptoms prominent or atypical for NPH - - ROUTINE - Social work for caregiver support, community resources, and care planning - ROUTINE ROUTINE - Geriatrics or geriatric psychiatry for complex older patients with multiple comorbidities - ROUTINE ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if sudden severe headache, new weakness, or altered consciousness develops (may indicate shunt malfunction or complication) STAT STAT ROUTINE Report fever, incision redness, or drainage after shunt surgery (may indicate shunt infection) STAT STAT ROUTINE Keep scheduled follow-up appointments for shunt valve pressure adjustments and monitoring - ROUTINE ROUTINE Use assistive devices (walker, cane) as recommended by physical therapy to prevent falls - ROUTINE ROUTINE Do not drive until cleared by physician due to cognitive impairment and fall risk - ROUTINE ROUTINE Avoid MRI without confirming shunt valve is MRI-conditional and checking valve setting afterward - ROUTINE ROUTINE Carry shunt information card with valve type and current pressure setting - ROUTINE ROUTINE","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Fall precautions including removal of throw rugs, adequate lighting, grab bars in bathroom due to gait instability - ROUTINE ROUTINE Regular physical activity within safe limits to maintain strength and mobility - ROUTINE ROUTINE Cognitive stimulation through reading, puzzles, and social engagement to support cognitive reserve - - ROUTINE Blood pressure optimization (target &lt;130/80) to reduce vascular contribution to cognitive impairment - ROUTINE ROUTINE Adequate hydration to maintain optimal CSF dynamics; avoid dehydration - ROUTINE ROUTINE Bladder training program in conjunction with physical therapy for urinary symptoms - ROUTINE ROUTINE","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Alzheimer's disease Memory impairment predominant; insidious progression; no significant gait disturbance early; no improvement with LP MRI shows hippocampal atrophy &gt;ventricular enlargement; CSF low Abeta-42, high tau; no tap test response Vascular dementia Stepwise decline; focal neurological signs; executive dysfunction; vascular risk factors MRI shows extensive white matter disease, strategic infarcts; ventriculomegaly less prominent Parkinson's disease Rest tremor; rigidity; bradykinesia; shuffling gait differs from NPH magnetic gait; no incontinence early DaTscan abnormal; no tap test response; no ventriculomegaly disproportionate to atrophy Dementia with Lewy bodies Visual hallucinations; fluctuating cognition; parkinsonism; REM sleep behavior disorder DaTscan abnormal; no ventricular enlargement out of proportion to atrophy Progressive supranuclear palsy Vertical gaze palsy; postural instability with falls backward; axial rigidity MRI midbrain atrophy (\"hummingbird sign\"); no tap test response Cervical spondylotic myelopathy Upper motor neuron signs in legs; hyperreflexia; Babinski; sensory level Cervical MRI shows cord compression; EMG findings Peripheral neuropathy Sensory loss distally; reduced reflexes; no cognitive or urinary symptoms EMG/NCS confirms peripheral nerve involvement Obstructive hydrocephalus Acute onset; headache; papilledema; elevated opening pressure on LP MRI shows obstructive lesion; elevated ICP; requires emergent intervention Spinal stenosis Neurogenic claudication; leg pain with walking relieved by rest/leaning forward Lumbar MRI shows stenosis; normal brain imaging Frontotemporal dementia Behavioral changes prominent; personality changes; language impairment MRI frontal/temporal atrophy; FDG-PET frontal hypometabolism","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Gait assessment (timed 10m walk, Tinetti) Pre-LP, post-LP, each follow-up Document baseline; track improvement Positive change supports diagnosis; no change may indicate poor shunt candidacy - ROUTINE ROUTINE - MoCA or MMSE Baseline, post-LP, every 6 months Track cognitive trajectory Improvement suggests NPH; decline suggests alternative diagnosis or shunt failure - ROUTINE ROUTINE - Post-shunt imaging (CT or MRI) 1-2 days post-op, 3 months, then PRN Confirm ventricular decompression; rule out subdural hematoma Repeat imaging if symptoms change; adjust valve - ROUTINE ROUTINE - Shunt valve setting verification After any MRI; at each clinic visit Confirm setting unchanged (some valves reset in MRI) Reprogram if reset; ensure appropriate setting - ROUTINE ROUTINE - Neurological exam Each clinic visit Stable or improved gait, cognition, continence Decline triggers workup for shunt malfunction or alternative diagnosis - ROUTINE ROUTINE - Subdural hematoma surveillance Post-shunt, especially if headache No subdural collection Adjust valve pressure higher; surgical evacuation if large/symptomatic STAT ROUTINE ROUTINE - Signs of shunt infection Post-operatively and ongoing No fever, erythema, wound drainage Blood/CSF cultures; shunt tap; IV antibiotics; possible shunt removal STAT ROUTINE ROUTINE - Urinary symptom diary Baseline and follow-up Frequency, urgency, incontinence episodes Adjust bladder medications; confirm NPH response - ROUTINE ROUTINE - ADL/IADL function Every 6 months Stable or improved function Increase support services; OT reassessment - ROUTINE ROUTINE -","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable symptoms; workup complete; awaiting outpatient tap test; caregiver support available Admit to floor Extended lumbar drain trial; post-shunt observation; shunt complication evaluation Admit to ICU Acute shunt malfunction with altered mental status; symptomatic overdrainage with large subdural; shunt infection with sepsis Outpatient follow-up Neurology 2-4 weeks after tap test to review results; Neurosurgery evaluation if positive tap test; post-shunt follow-up at 1-3 months, 6 months, then annually Urgent neurosurgery referral Positive tap test; positive extended drain trial; progressive symptoms with classic imaging findings","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Evans index &gt;0.3 diagnostic for ventriculomegaly Class II, Level B Relkin et al. Neurosurgery 2005 (iNPH Guidelines) Callosal angle &lt;90 degrees supports iNPH diagnosis Class III, Level C Virhammar et al. J Neurosurg 2014 DESH (disproportionately enlarged subarachnoid-space hydrocephalus) pattern Class II, Level B Hashimoto et al. AJNR 2010 High-volume LP (tap test) predicts shunt response Class II, Level B Marmarou et al. J Neurosurg 2005 Extended lumbar drainage more sensitive than single tap test Class II, Level B Walchenbach et al. J Neurol Neurosurg Psychiatry 2002 VP shunt improves symptoms in selected iNPH patients Class II, Level B Hebb et al. Can J Neurol Sci 2001 Programmable valves reduce revision surgery rates Class II, Level B Zemack et al. Eur J Neurol 2003 Gait improvement most responsive to shunting Class II, Level B Ishikawa et al. Neurology 2012 Short symptom duration predicts better shunt outcome Class II, Level B Relkin et al. Neurosurgery 2005 CSF biomarkers help differentiate NPH from AD Class III, Level C Tarnaris et al. Neurology 2011 Shunt infection rate 5-10%; requires shunt removal for treatment Class III, Level C McGirt et al. J Neurosurg 2003 Japanese iNPH Guidelines diagnostic criteria Class II, Level B Mori et al. Neurol Med Chir 2012","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive diagnostic workup including imaging criteria (Evans index, callosal angle, DESH) - High-volume LP (tap test) protocol with detailed assessment criteria - Extended lumbar drain trial protocol - Shunt surgery options (VP, VA, LP, ETV) with valve selection guidance - Post-shunt complication management - Structured dosing format for symptomatic treatments - Differentiation from other dementias (AD, vascular, DLB, PSP) - PubMed citations with verified PMIDs</p>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#appendix-a-nph-imaging-criteria","title":"APPENDIX A: NPH IMAGING CRITERIA","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#evans-index-calculation","title":"Evans Index Calculation","text":"<ul> <li>Evans index = Maximum width of frontal horns / Maximum internal diameter of skull</li> <li>Positive: &gt;0.3 (30%)</li> </ul>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#callosal-angle","title":"Callosal Angle","text":"<ul> <li>Measured on coronal MRI at level of posterior commissure</li> <li>NPH: &lt;90 degrees (acute angle from dilated ventricles)</li> <li>Atrophy: &gt;90 degrees (wider angle)</li> </ul>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#desh-pattern-disproportionately-enlarged-subarachnoid-space-hydrocephalus","title":"DESH Pattern (Disproportionately Enlarged Subarachnoid-Space Hydrocephalus)","text":"<ul> <li>Ventriculomegaly (Evans index &gt;0.3)</li> <li>Tight high-convexity sulci (effaced sulci at vertex)</li> <li>Widened Sylvian fissures</li> <li>Focally dilated sulci</li> </ul>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#additional-imaging-features","title":"Additional Imaging Features","text":"<ul> <li>Periventricular edema: Transependymal CSF flow seen as T2/FLAIR hyperintensity around ventricles</li> <li>Rounding of frontal horn angles: Suggests pressure effect</li> <li>Corpus callosum thinning: From stretching</li> </ul>","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#appendix-b-predictors-of-shunt-response","title":"APPENDIX B: PREDICTORS OF SHUNT RESPONSE","text":"","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#positive-predictors-better-shunt-outcome","title":"Positive Predictors (Better Shunt Outcome)","text":"Factor Evidence Gait disturbance as predominant symptom Strong predictor Short duration of symptoms (&lt;6 months) Moderate predictor Known etiology (secondary NPH: SAH, meningitis, trauma) Strong predictor Positive tap test (&gt;20% improvement in gait) Moderate predictor Positive extended lumbar drain trial (&gt;30% improvement) Strong predictor Hyperdynamic aqueductal CSF flow on MRI Weak predictor Presence of B-waves on ICP monitoring Moderate predictor","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#negative-predictors-poorer-shunt-outcome","title":"Negative Predictors (Poorer Shunt Outcome)","text":"Factor Evidence Dementia predominant (gait normal) Strong negative predictor Long symptom duration (&gt;2 years) Moderate negative predictor Severe cognitive impairment at baseline Moderate negative predictor Significant cortical atrophy Moderate negative predictor Negative tap test Weak negative predictor Comorbid Alzheimer's disease pathology Strong negative predictor","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/normal-pressure-hydrocephalus/#appendix-c-shunt-complication-overview","title":"APPENDIX C: SHUNT COMPLICATION OVERVIEW","text":"Complication Incidence Presentation Management Overdrainage (subdural hematoma) 2-17% Headache worse when upright; new neurological deficits Increase valve pressure; bed rest; surgical evacuation if large/symptomatic Overdrainage (slit ventricle syndrome) 5-10% Positional headaches; small ventricles on imaging Increase valve pressure; anti-siphon device Underdrainage 10-15% Persistent or worsening NPH symptoms Decrease valve pressure; evaluate for obstruction Shunt infection 5-10% Fever; wound erythema; mental status change IV antibiotics; shunt externalization/removal Shunt obstruction 5-15% Symptom recurrence; inability to pump reservoir Shunt revision surgery Seizures 3-5% New-onset seizures post-operatively Antiepileptic medication Abdominal complications (VP) 5-10% Abdominal pain; pseudocyst; bowel perforation Imaging evaluation; possible revision","tags":["cognitive","dementia","hydrocephalus","gait","outpatient","surgical"]},{"location":"drafts/optic-neuritis/","title":"Optic Neuritis","text":"\u26a0\ufe0f DRAFT - Pending Physician Review This plan has not been approved for clinical use. Please review and provide feedback using the comment system.","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#optic-neuritis","title":"Optic Neuritis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 REVISED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Optic Neuritis</p> <p>ICD-10: H46.9 (Optic neuritis, unspecified); H46.00 (Optic papillitis, unspecified eye); H46.10 (Retrobulbar neuritis, unspecified eye); G36.0 (Neuromyelitis optica - if NMOSD confirmed)</p> <p>SYNONYMS: Optic neuropathy (inflammatory), retrobulbar neuritis, papillitis, demyelinating optic neuropathy, acute optic neuritis</p> <p>SCOPE: Acute evaluation and management of optic neuritis in adults. Covers typical demyelinating optic neuritis, atypical features requiring expanded workup, MS risk stratification, ONTT-based treatment, and NMO/MOG antibody evaluation. For established MS with optic neuritis as a relapse, can also use \"MS - Exacerbation\" template.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>CLINICAL PEARL: The Optic Neuritis Treatment Trial (ONTT) established that IV methylprednisolone accelerates visual recovery but does not change final visual outcome. Oral prednisone alone at standard doses (1 mg/kg/day) was associated with increased recurrence rate and should NOT be used as monotherapy. Most patients (90%+) recover vision to 20/40 or better within 1 year.</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection screen, baseline before steroids Normal STAT STAT ROUTINE - CMP Metabolic screen, renal function for contrast Normal STAT STAT ROUTINE - ESR Inflammatory/vasculitis screen; elevated in GCA Normal (&lt;20 mm/hr); elevated in GCA STAT STAT ROUTINE - CRP Inflammatory marker Normal STAT STAT ROUTINE - Blood glucose Pre-steroid baseline Normal STAT STAT ROUTINE - Urinalysis UTI screen before steroids Negative STAT STAT ROUTINE -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Mayo CDS1 Panel (AQP4-IgG + MOG-IgG by FACS) Combined NMO/MOGAD screen; critical for atypical cases Both negative URGENT URGENT ROUTINE - ANA Lupus/connective tissue disease Negative or low titer URGENT ROUTINE ROUTINE - TSH Thyroid eye disease (Graves ophthalmopathy) Normal - ROUTINE ROUTINE - Vitamin B12 Nutritional optic neuropathy Normal (&gt;300 pg/mL) - ROUTINE ROUTINE - Folate Nutritional optic neuropathy Normal - ROUTINE ROUTINE - RPR/VDRL Neurosyphilis Negative - ROUTINE ROUTINE - HIV HIV-associated optic neuropathy Negative - ROUTINE ROUTINE - ACE level Neurosarcoidosis Normal - ROUTINE ROUTINE - Lyme serology Endemic areas; Lyme optic neuropathy Negative - ROUTINE ROUTINE - HbA1c Glycemic status before steroids &lt;5.7% - ROUTINE ROUTINE - <p>Note: Mayo CDS1 Panel preferred for combined AQP4 + MOG testing. Cell-based assay (FACS) is gold standard. If unavailable, order AQP4-IgG (Mayo NMOFS) and MOG-IgG (Mayo MOGFS) separately.</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Anti-dsDNA If ANA positive; SLE screen Negative - EXT EXT - Anti-SSA/SSB (Ro/La) Sjogren syndrome Negative - EXT EXT - ANCA panel CNS/orbital vasculitis Negative - EXT EXT - Serum protein electrophoresis Paraproteinemic optic neuropathy No M-spike - EXT EXT - Mitochondrial DNA testing Leber hereditary optic neuropathy (LHON) Normal - - EXT - Copper, ceruloplasmin Wilson disease Normal - - EXT - Paraneoplastic panel (anti-CRMP5/CV2) Paraneoplastic optic neuropathy Negative - EXT EXT -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI orbits with contrast (fat-suppressed T1, STIR) URGENT URGENT ROUTINE - Within 24-48h Optic nerve enhancement, swelling; enhancement &gt;50% nerve length suggests atypical/NMOSD GFR &lt;30, gadolinium allergy MRI brain with and without contrast (MS protocol) URGENT URGENT ROUTINE - With orbit MRI Demyelinating lesions (periventricular, juxtacortical, infratentorial); determines MS risk Same as above MRI C-spine with and without contrast - ROUTINE ROUTINE - Within 1 week if MS suspected Cord lesions supporting MS diagnosis Same as above <p>MS protocol should include: 3D FLAIR, 3D T1 pre/post-contrast, T2, DWI. For orbits: fat-suppressed T1 post-contrast, STIR/T2 coronal.</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Visual evoked potentials (VEP) - ROUTINE ROUTINE - During workup Prolonged P100 latency (confirms optic nerve dysfunction) None significant OCT (Optical coherence tomography) - - ROUTINE - Baseline and at 3-6 months RNFL thickening acutely; thinning at follow-up indicates axonal loss None significant Formal visual field testing (Humphrey 30-2 or 24-2) - ROUTINE ROUTINE - At presentation and follow-up Central/cecocentral scotoma typical; document baseline Patient cooperation required <p>Note: OCT typically available only in outpatient neuro-ophthalmology. RNFL thickening &gt;15% of fellow eye acutely suggests papillitis.</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest - EXT EXT - If sarcoidosis suspected Hilar lymphadenopathy Contrast allergy PET-CT - EXT EXT - If malignancy/paraneoplastic suspected FDG-avid lesions Pregnancy, uncontrolled diabetes CT orbits STAT - - - Only if MRI unavailable/contraindicated Optic nerve enlargement, orbital mass Contrast allergy Fluorescein angiography - - EXT - If retinal/vascular pathology suspected Disc leakage, vascular abnormality Dye allergy","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Not routinely required for typical optic neuritis. Consider if: (1) atypical features present, (2) need to support MS diagnosis (OCBs for dissemination in time), (3) concern for infectious or inflammatory etiology, (4) poor response to steroids.</p> <p>Timing: ROUTINE if indicated; URGENT if infection suspected</p> <p>Volume Required: 15-20 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Rule out elevated ICP (papilledema mimics) 10-20 cm H2O Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Inflammation, rule out infection WBC &lt;50 (mild pleocytosis acceptable); RBC 0 Protein URGENT ROUTINE ROUTINE Elevated in inflammation Normal to mildly elevated (&lt;100 mg/dL) Glucose with serum glucose URGENT ROUTINE ROUTINE Low in infection Normal (&gt;60% serum) Gram stain and culture URGENT ROUTINE ROUTINE Rule out infection No organisms Oligoclonal bands (CSF AND serum) - ROUTINE ROUTINE Intrathecal IgG synthesis (supports MS) \u22652 CSF-specific bands (not in serum) IgG index - ROUTINE ROUTINE Intrathecal antibody synthesis &gt;0.7 = elevated Cytology - ROUTINE ROUTINE Rule out malignancy Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative <p>Special Handling: OCBs stable at 4\u00b0C for days; send paired serum.</p> <p>Contraindications: Elevated ICP without imaging, coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#3-treatment","title":"3. TREATMENT","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone IV Acute optic neuritis - accelerates visual recovery per ONTT 1000 mg daily x 3 days :: IV :: once daily x 3 days :: 1000 mg IV daily for 3 days; infuse over 1-2 hours; followed by oral prednisone taper Active untreated infection; uncontrolled diabetes; active psychosis; severe hypertension Glucose q6h (target &lt;180); BP; mood; sleep; I/O STAT STAT - - Prednisone oral taper PO Following IV methylprednisolone per ONTT protocol 1 mg/kg/day x 11 days :: PO :: once daily :: 1 mg/kg/day (max 80 mg) x 11 days following 3 days IV steroids; then discontinue or rapid taper Same as IV steroids Glucose; BP; mood; GI prophylaxis - ROUTINE ROUTINE - Omeprazole PO GI prophylaxis during steroids 20 mg daily :: PO :: once daily :: 20-40 mg daily during steroid course PPI allergy; osteoporosis (long-term) None routine STAT STAT ROUTINE - Insulin sliding scale SC Steroid-induced hyperglycemia Per protocol :: SC :: PRN :: Per institutional protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h STAT STAT - - <p>IMPORTANT: Oral prednisone alone (without preceding IV steroids) should NOT be used. ONTT showed increased recurrence rate with standard-dose oral prednisone monotherapy.</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Acetaminophen PO Pain with eye movement 650-1000 mg q6h PRN :: PO :: q6h PRN :: 650-1000 mg PO q6h as needed for pain; max 3000 mg/day (2000 mg if liver disease) Hepatic impairment; chronic alcohol use LFTs if prolonged use ROUTINE ROUTINE ROUTINE - Ibuprofen PO Pain with eye movement 400-800 mg q8h PRN :: PO :: q8h PRN :: 400-800 mg PO q8h as needed for pain; max 2400 mg/day; take with food Renal impairment; GI bleeding; concurrent anticoagulation Renal function if prolonged ROUTINE ROUTINE ROUTINE - Gabapentin PO Persistent periorbital pain/neuropathic symptoms 300 mg qHS; 300 mg TID; 600 mg TID :: PO :: variable :: Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg/day divided TID Renal impairment (adjust dose) Sedation; dizziness - ROUTINE ROUTINE - Artificial tears TOP Dry eye secondary to reduced blink or lagophthalmos 1-2 drops q2-4h PRN :: TOP :: PRN :: Preservative-free artificial tears 1-2 drops q2-4h as needed None None ROUTINE ROUTINE ROUTINE -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Plasmapheresis (PLEX) - Steroid-refractory or severe vision loss 5-7 exchanges over 10-14 days :: PLEX :: qod x 5-7 :: 5-7 exchanges every other day; typical volume 1-1.5 plasma volumes Hemodynamic instability; sepsis; line contraindication BP; electrolytes; coags; fibrinogen; line infection - URGENT - - IVIG IV Steroid-refractory (alternative to PLEX) 0.4 g/kg/day x 5 days :: IV :: daily x 5 days :: 0.4 g/kg/day for 5 days (total 2 g/kg); infuse slowly day 1 IgA deficiency; renal failure; thrombosis risk Renal function; headache; thrombosis - URGENT - - Extended IV steroids IV Incomplete response to 3-day course 1000 mg daily additional 2-5 days :: IV :: daily :: Extend to 5-7 total days if inadequate response Same as initial course Same as initial course - ROUTINE - -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#3d-disease-modifying-therapies-if-msnmosdmogad-confirmed","title":"3D. Disease-Modifying Therapies (If MS/NMOSD/MOGAD Confirmed)","text":"<p>DMT initiation requires confirmed diagnosis and specialist involvement. Not initiated in ED or ICU. See specific disease templates for detailed DMT options.</p> Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU MS DMT (various) Variable If MS diagnosed based on MRI + clinical criteria See MS - New Diagnosis template Per specific DMT Per specific DMT Per specific DMT - - ROUTINE - Rituximab IV NMOSD (AQP4-IgG positive) 1000 mg IV x 2 doses 2 weeks apart :: IV :: q2wk x 2 then q6mo :: 1000 mg IV days 1 and 15; maintenance 1000 mg q6 months Hepatitis B serology; TB test; immunoglobulins Active Hep B; active infection CD19/20; immunoglobulins annually - - ROUTINE - Eculizumab (Soliris) IV NMOSD (AQP4-IgG positive) - FDA approved 900 mg IV weekly x 4 then 1200 mg q2wk :: IV :: weekly then q2wk :: 900 mg weekly x 4; then 1200 mg at week 5; then 1200 mg q2 weeks Meningococcal vaccination (2 weeks prior) Unresolved Neisseria infection CBC; LFTs; signs of meningococcal infection - - ROUTINE - Immunosuppression (MOGAD) Variable MOGAD (MOG-IgG positive) with relapsing course Rituximab, azathioprine, or mycophenolate Per specific agent Per specific agent Per specific agent - - ROUTINE -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neuro-ophthalmology referral for comprehensive evaluation and follow-up URGENT URGENT ROUTINE - Neurology/MS specialist referral if brain MRI shows demyelinating lesions URGENT URGENT ROUTINE - Ophthalmology referral if neuro-ophthalmology unavailable or alternate diagnosis suspected URGENT URGENT ROUTINE - MS specialist/Neuroimmunology for DMT discussion if MS criteria met - ROUTINE ROUTINE - Low vision rehabilitation if significant persistent visual impairment - - ROUTINE - Occupational therapy for ADL adaptation if functional visual impairment - ROUTINE ROUTINE - Social work for disability resources if visual impairment affects employment - - ROUTINE -","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Vision typically improves over 2-4 weeks; 90%+ recover to 20/40 or better within 1 year \u2713 \u2713 \u2713 Return immediately if vision worsening after initial improvement (may indicate new attack or alternate diagnosis) \u2713 \u2713 \u2713 Return if new symptoms: weakness, numbness, imbalance, bladder problems (may indicate MS) \u2713 \u2713 \u2713 Do not drive if vision in affected eye prevents safe driving; check with state DMV regarding vision requirements \u2713 \u2713 \u2713 Heat may temporarily worsen symptoms (Uhthoff phenomenon) - this is not a new attack or permanent worsening \u2713 \u2713 \u2713 Expect temporary steroid side effects: insomnia, mood changes, increased appetite, metallic taste during IV infusion \u2713 \u2713 - Do not stop oral prednisone abruptly if on taper (adrenal suppression risk) - \u2713 \u2713 Monitor blood sugars if diabetic - steroids elevate glucose \u2713 \u2713 \u2713 Avoid sick contacts while on high-dose steroids (immunosuppression) \u2713 \u2713 - Keep follow-up appointments - important to monitor for MS development - \u2713 \u2713 Contact physician if fever, new headache, or worsening vision on steroids \u2713 \u2713 \u2713","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation - smoking increases MS conversion risk and worsens outcomes \u2713 \u2713 \u2713 Vitamin D supplementation 2000-5000 IU daily (target serum 25-OH vitamin D &gt;40 ng/mL) - low levels associated with MS risk - \u2713 \u2713 Avoid prolonged heat exposure (hot tubs, saunas, exercising in heat) which can temporarily worsen vision (Uhthoff) - \u2713 \u2713 Use sunglasses if photophobia present \u2713 \u2713 \u2713 Regular aerobic exercise as tolerated once acute symptoms resolve - - \u2713 Adequate sleep (7-8 hours nightly) and stress management - \u2713 \u2713 Eye protection during activities if monocular vision (loss of depth perception) \u2713 \u2713 \u2713","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate NMOSD-associated optic neuritis Severe vision loss (often &lt;20/200); bilateral simultaneous or sequential; poor recovery; longitudinally extensive optic nerve enhancement (&gt;50% nerve length) AQP4-IgG positive (Mayo CDS1 or NMOFS); MRI pattern MOGAD-associated optic neuritis Often bilateral; anterior optic nerve involvement; perineural enhancement (\"optic nerve sheath sign\"); disc edema more prominent; better steroid response; tends to relapse MOG-IgG positive (Mayo CDS1 or MOGFS) Anterior ischemic optic neuropathy (AION) Sudden painless vision loss; altitudinal field defect; disc edema with hemorrhages; age &gt;50; vascular risk factors (hypertension, diabetes) ESR/CRP for GCA; fluorescein angiography; cardiovascular risk assessment Giant cell arteritis (GCA) Age &gt;50; headache; jaw claudication; scalp tenderness; elevated ESR/CRP; bilateral risk ESR, CRP, temporal artery biopsy; prompt treatment to prevent fellow eye Papilledema Bilateral disc edema; transient visual obscurations; headache worse lying down; no RAPD unless asymmetric LP with elevated opening pressure; MRI/MRV for venous sinus thrombosis Compressive optic neuropathy Progressive vision loss; proptosis; may have disc pallor or edema; optic canal mass MRI orbits showing mass lesion; CT for bony detail Leber hereditary optic neuropathy (LHON) Painless; young males; sequential bilateral (weeks to months); central scotoma; no enhancement on MRI Mitochondrial DNA testing (mutations: 11778, 3460, 14484) Toxic/nutritional optic neuropathy Bilateral symmetric; ethambutol, methanol, B12/folate deficiency; cecocentral scotoma B12, folate, medication history, alcohol use Neurosyphilis May mimic optic neuritis; other neurologic signs; risk factors RPR/VDRL, FTA-ABS, CSF VDRL Sarcoidosis Granulomatous optic neuropathy; uveitis; other systemic involvement ACE, chest CT, tissue biopsy Idiopathic intracranial hypertension (IIH) Bilateral disc edema; obese young female; headache; transient visual obscurations LP with elevated opening pressure; normal MRI/MRV","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Visual acuity \u2713 \u2713 \u2713 - Daily inpatient; each visit OPD Improvement by 3+ Snellen lines If no improvement by 2 weeks, reconsider diagnosis or escalate treatment Color vision (Ishihara or HRR plates) - \u2713 \u2713 - Baseline and follow-up Normal or improving Persistent dyschromatopsia suggests residual dysfunction Pupillary exam (RAPD) \u2713 \u2713 \u2713 - Daily inpatient; each visit OPD RAPD diminishing Persistent or worsening RAPD concerning Blood glucose \u2713 \u2713 - - Q6h during IV steroids &lt;180 mg/dL Insulin sliding scale; endocrine consult if persistent &gt;250 Blood pressure \u2713 \u2713 - - Q shift during steroids &lt;160/100 mmHg Antihypertensives PRN Mood and sleep - \u2713 - - Daily during steroids No psychosis, mania, severe insomnia Psychiatry consult; consider dose reduction Visual field (formal) - - \u2713 - Baseline, 1 month, 3 months, 6 months Improving or stable Worsening field concerning for progression OCT (RNFL thickness) - - \u2713 - Baseline, 3 months, 6 months Thinning plateaus by 6 months &gt;20 micron loss associated with poorer outcome MRI brain (follow-up) - - \u2713 - 3-6 months after initial; annually if MS risk No new lesions If new lesions: MS diagnosed, start DMT NMO/MOG antibodies (recheck) - - \u2713 - Repeat at 3-6 months if initially negative but atypical features Remain negative If seroconversion: diagnosis changes, different treatment","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild-moderate vision loss with stable exam; able to perform ADLs safely; IV steroids completed or not indicated; reliable follow-up within 1-2 weeks with neuro-ophthalmology or neurology; understands return precautions Admit to floor Severe vision loss (20/200 or worse); bilateral involvement; diagnostic uncertainty requiring expedited workup; unable to care for self safely at home due to vision loss; IV steroids indicated and outpatient infusion not available Admit to ICU Not typically required for isolated optic neuritis; consider if concurrent severe neurologic involvement (e.g., NMOSD with myelitis and respiratory compromise) Transfer to higher level Neuro-ophthalmology or MS specialist not available; PLEX needed but unavailable; MRI unavailable for urgent imaging","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IV methylprednisolone accelerates visual recovery but does not change final outcome Class I, Level A Beck RW et al. NEJM 1992 (ONTT) Oral prednisone alone (1 mg/kg) increases recurrence rate - avoid as monotherapy Class I, Level A Beck RW et al. NEJM 1992 (ONTT) Visual prognosis excellent: 90%+ recover to 20/40 or better by 1 year Class I Beck RW et al. Arch Ophthalmol 1993 Brain MRI lesions predict MS: 50% at 15 years with \u22651 lesion vs 25% with normal MRI Class I Beck RW et al. NEJM 2003 (ONTT 10-year); Optic Neuritis Study Group 2008 (15-year) Cell-based assay (FACS) preferred for AQP4/MOG antibody testing Class II, Level B Pittock SJ et al. Neurology 2019; Waters P et al. J Neurol Neurosurg Psychiatry 2014 MOG-IgG associated with better visual recovery and relapsing course Class II Jarius S et al. J Neuroinflammation 2018 PLEX beneficial for steroid-refractory demyelinating optic neuritis Class II, Level B Roesner S et al. J Neurol 2012 VEP shows prolonged P100 latency in optic neuritis Class I Halliday AM et al. Lancet 1972 OCT RNFL thinning correlates with visual outcomes Class II Trip SA et al. Brain 2005 Vitamin D deficiency associated with increased MS risk after optic neuritis Class II Munger KL et al. JAMA 2006 Smoking increases MS conversion risk after CIS Class II, Level B Hedstrom AK et al. Brain 2013","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial creation - Comprehensive coverage of typical and atypical optic neuritis - ONTT-based treatment protocol with structured dosing - MS risk stratification based on brain MRI lesions - NMO-IgG and MOG-IgG testing recommendations - Emphasis on oral prednisone monotherapy avoidance - Visual prognosis and monitoring parameters - PubMed citations for all major recommendations</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#appendix-a-typical-vs-atypical-optic-neuritis-features","title":"APPENDIX A: Typical vs Atypical Optic Neuritis Features","text":"Feature Typical (MS-Associated) Atypical (Consider NMOSD/MOGAD/Other) Age 20-45 years &lt;15 or &gt;50 years Pain Present, mild-moderate, worse with eye movement Absent OR severe Vision loss severity Mild-moderate (usually &gt;20/200) Severe (&lt;20/200 or NLP) Laterality Unilateral Bilateral simultaneous Disc appearance Normal (retrobulbar) or mild edema Marked disc edema, hemorrhages MRI optic nerve Short segment enhancement Longitudinally extensive (&gt;50% nerve length) or posterior involvement to chiasm Recovery Good (&gt;90% to 20/40) Poor or incomplete Steroid response Responds then relapses off steroids Highly steroid-dependent or refractory Brain MRI White matter lesions (MS pattern) Normal or atypical lesion pattern <p>If ANY atypical features present: Order AQP4-IgG and MOG-IgG testing (Mayo CDS1 Panel preferred)</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/optic-neuritis/#appendix-b-ms-risk-stratification-based-on-brain-mri","title":"APPENDIX B: MS Risk Stratification Based on Brain MRI","text":"Brain MRI Finding 5-Year MS Risk 15-Year MS Risk Recommendation Normal (no lesions) ~16% ~25% Close clinical follow-up; MRI at 3-6 months then annually x 5 years 1-2 lesions ~37% ~50% MS specialist referral; consider early DMT discussion \u22653 lesions ~51% ~78% MS specialist referral; strongly consider DMT if McDonald criteria met <p>Data from ONTT long-term follow-up studies</p>","tags":["demyelinating","optic-neuritis","vision-loss","multiple-sclerosis","autoimmune"]},{"location":"drafts/parkinsons-disease/","title":"Parkinson's Disease","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#parkinsons-disease","title":"Parkinson's Disease","text":"<p>DIAGNOSIS: Parkinson's Disease ICD-10: G20 (Parkinson's disease) SCOPE: Diagnosis confirmation, dopaminergic therapy initiation and optimization, motor fluctuation management, and non-motor symptom treatment. Excludes Parkinson-plus syndromes (MSA, PSP, CBD, DLB - separate protocols).</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Baseline; rule out anemia contributing to fatigue Normal STAT ROUTINE ROUTINE - BMP Renal function for medication dosing; electrolytes Normal STAT ROUTINE ROUTINE - Hepatic panel (LFTs) Baseline before COMT inhibitors Normal - ROUTINE ROUTINE - TSH Rule out hypothyroidism mimicking bradykinesia Normal - ROUTINE ROUTINE - Vitamin B12 Deficiency can cause parkinsonism; common in elderly &gt;300 pg/mL - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency common; associated with falls and disease severity &gt;30 ng/mL - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Ceruloplasmin, serum copper Wilson's disease if age &lt;50 Normal - EXT ROUTINE - 24-hour urine copper Wilson's disease confirmation &lt;100 \u03bcg/24hr - - EXT - Ferritin, iron studies Neurodegeneration with brain iron accumulation Normal - ROUTINE ROUTINE - RPR or VDRL Syphilis can cause parkinsonism Nonreactive - EXT EXT - HIV testing HIV-associated parkinsonism Negative - EXT EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Genetic testing (LRRK2, GBA, SNCA, PARK2, PINK1, DJ-1) Family history or early-onset (&lt;50 years) Identifies genetic form - - EXT - CSF biomarkers (alpha-synuclein, tau, amyloid) Research/atypical; synuclein seed amplification assay Abnormal synuclein aggregation - - EXT - Skin biopsy for alpha-synuclein Research; confirms synucleinopathy Phosphorylated synuclein deposits - - EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At diagnosis Normal (rules out structural causes, vascular parkinsonism, NPH) MRI-incompatible devices URGENT ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU DaTscan (ioflupane I-123 SPECT) Diagnostic uncertainty; essential tremor vs PD Reduced dopamine transporter uptake in striatum Hypersensitivity to iodine - EXT ROUTINE - MRI Brain with SWI sequence Suspected atypical parkinsonism or iron deposition No \"hot cross bun\" (MSA) or \"hummingbird\" (PSP) signs MRI contraindications - EXT ROUTINE - Cardiac MIBG scan Differentiate PD from MSA Reduced uptake in PD (preserved in MSA) Recent MI; drugs affecting uptake - - EXT - Sleep study (polysomnography) REM sleep behavior disorder evaluation Confirms RBD (prodromal marker) None - - ROUTINE - Autonomic function testing Dysautonomia assessment Orthostatic hypotension, abnormal HR variability None - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU FDG-PET Atypical parkinsonism differentiation Pattern recognition for PD vs PSP vs MSA None - - EXT - Transcranial ultrasound Screening tool Hyperechogenicity of substantia nigra Inadequate bone window - - EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbidopa-Levodopa (continue home dose) PO/NG Admitted PD patient; DO NOT HOLD Home dose, same timing :: PO :: :: Give at EXACT same times as home; crushing allowed; use NG if NPO Active psychosis; MAOIs within 14 days Dyskinesias, confusion STAT STAT - STAT Carbidopa-Levodopa (NPO protocol) IV/NG Patient NPO &gt;4 hours Home dose equivalent :: NG :: :: Crush tablets; give via NG at home schedule; consult neurology for IV options if unavailable Same as PO Same as PO STAT STAT - STAT Apomorphine SC SC Off episode in clinic/ED; NPO patient 2 mg SC; 3 mg SC; 4 mg SC; 5 mg SC; 6 mg SC :: SC :: :: Test dose 2 mg; titrate by 1 mg to effect; max 6 mg; pretreat with trimethobenzamide Concurrent 5-HT3 antagonists (ondansetron); severe hypotension BP, nausea; may cause severe hypotension URGENT URGENT ROUTINE - Rotigotine patch TD NPO patient; bridge therapy 2 mg/24hr; 4 mg/24hr; 6 mg/24hr patch :: TD :: :: Apply patch equivalent to oral dopamine agonist dose; onset 2-3 hours Sulfite allergy (adhesive) Application site reactions URGENT URGENT - - Trimethobenzamide IM/PO Pretreat before apomorphine to prevent nausea 300 mg IM/PO :: IM/PO :: :: 300 mg TID starting 3 days before apomorphine initiation Hypersensitivity Drowsiness URGENT URGENT ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbidopa-Levodopa IR (Sinemet) PO Motor symptoms; first-line dopaminergic therapy 25/100 TID; 25/250 TID :: PO :: :: Start 25/100 TID; titrate by 1 tablet q1-2wk; typical target 25/100-25/250 TID Active psychosis; MAOIs within 14 days Dyskinesias, nausea, orthostatic hypotension - ROUTINE ROUTINE - Carbidopa-Levodopa CR (Sinemet CR) PO Nocturnal symptoms; wearing off 25/100 CR qHS; 50/200 CR BID :: PO :: :: 25/100 to 50/200 CR at bedtime or BID; 70% bioavailability vs IR Same as IR Same as IR - ROUTINE ROUTINE - Carbidopa-Levodopa ER (Rytary) PO Motor fluctuations; extend levodopa effect 23.75/95 TID; 36.25/145 TID; 48.75/195 TID; 61.25/245 TID :: PO :: :: Convert from IR using manufacturer table; typically TID dosing Same as IR Same as IR - ROUTINE ROUTINE - Pramipexole PO Adjunct to levodopa; monotherapy in early PD; tremor 0.125 mg TID; 0.25 mg TID; 0.5 mg TID; 1 mg TID; 1.5 mg TID :: PO :: :: Start 0.125 mg TID; titrate by 0.125-0.25 mg TID q5-7 days; max 1.5 mg TID Impulse control history Impulse control disorders, somnolence, leg edema - ROUTINE ROUTINE - Ropinirole PO Adjunct or monotherapy; similar to pramipexole 0.25 mg TID; 0.5 mg TID; 1 mg TID; 2 mg TID; 3 mg TID :: PO :: :: Start 0.25 mg TID; titrate weekly; max 8 mg TID Same as pramipexole Same as pramipexole - ROUTINE ROUTINE - Ropinirole XL PO Extended-release option for adherence 2 mg daily; 4 mg daily; 6 mg daily; 8 mg daily :: PO :: :: Start 2 mg daily; titrate by 2 mg q1-2wk; max 24 mg daily Same as IR Same as IR - ROUTINE ROUTINE - Selegiline PO MAO-B inhibitor; adjunct; mild neuroprotection theory 5 mg BID :: PO :: :: 5 mg at breakfast and lunch (avoid evening due to insomnia); max 10 mg/day MAOIs; meperidine; TCAs (caution) Insomnia, hypertensive crisis with tyramine (rare at this dose) - ROUTINE ROUTINE - Rasagiline PO MAO-B inhibitor; once daily; adjunct or monotherapy 0.5 mg daily; 1 mg daily :: PO :: :: Start 0.5-1 mg daily; max 1 mg daily Same as selegiline Hypertensive crisis (rare); serotonin syndrome with other serotonergics - ROUTINE ROUTINE - Safinamide PO MAO-B inhibitor with additional mechanisms; adjunct in fluctuations 50 mg daily; 100 mg daily :: PO :: :: Start 50 mg daily; may increase to 100 mg daily after 2 weeks Severe hepatic impairment; MAOIs; opioids Same as rasagiline; may improve dyskinesia - ROUTINE ROUTINE - Entacapone PO COMT inhibitor; extends levodopa effect; wearing off 200 mg with each levodopa dose :: PO :: :: 200 mg with each levodopa dose; max 8 doses (1600 mg)/day Hepatic impairment; concurrent MAOIs Diarrhea, orange urine, dyskinesias - ROUTINE ROUTINE - Opicapone PO COMT inhibitor; once daily alternative to entacapone 50 mg qHS :: PO :: :: 50 mg once daily at bedtime; take 1 hour before or after levodopa Pheochromocytoma; paraganglioma Dyskinesias, constipation, dry mouth - ROUTINE ROUTINE - Amantadine PO Dyskinesia reduction; mild motor benefit 100 mg BID; 100 mg TID :: PO :: :: Start 100 mg daily; titrate to 100 mg BID-TID; max 400 mg/day; dose-reduce in renal impairment End-stage renal disease; seizure history Livedo reticularis, ankle edema, confusion, hallucinations - ROUTINE ROUTINE - Amantadine ER (Gocovri) PO Dyskinesia; extended-release taken at bedtime 137 mg qHS; 274 mg qHS :: PO :: :: Start 137 mg qHS; increase to 274 mg qHS after 1 week Same as IR Same as IR - ROUTINE ROUTINE - Trihexyphenidyl PO Tremor-dominant PD; younger patients 1 mg TID; 2 mg TID :: PO :: :: Start 1 mg TID; titrate by 2 mg/day q3-5 days; max 15 mg/day Glaucoma; urinary retention; dementia; age &gt;70 Cognitive impairment, dry mouth, constipation, urinary retention - ROUTINE ROUTINE - Benztropine PO Alternative anticholinergic for tremor 0.5 mg BID; 1 mg BID; 2 mg BID :: PO :: :: Start 0.5 mg BID; titrate slowly; max 6 mg/day Same as trihexyphenidyl Same as trihexyphenidyl - ROUTINE ROUTINE - Istradefylline PO Adenosine A2A antagonist; adjunct for OFF time 20 mg daily; 40 mg daily :: PO :: :: Start 20 mg daily; may increase to 40 mg daily Strong CYP3A4 inducers Dyskinesias, dizziness, constipation, hallucinations - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#3c-non-motor-symptom-treatments","title":"3C. Non-Motor Symptom Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Pimavanserin (Nuplazid) PO Parkinson's disease psychosis (hallucinations, delusions) 34 mg daily :: PO :: :: 34 mg once daily; takes 4-6 weeks for effect; no titration needed Severe hepatic impairment; QT prolongation QTc, efficacy assessment at 6 weeks - ROUTINE ROUTINE - Quetiapine PO Psychosis; alternative if pimavanserin unavailable 12.5 mg qHS; 25 mg qHS; 50 mg qHS :: PO :: :: Start 12.5-25 mg qHS; titrate slowly by 12.5-25 mg q3-7d; typical max 150 mg/day Dementia with Lewy bodies (black box) Sedation, metabolic effects, QTc - ROUTINE ROUTINE - Clozapine PO Refractory psychosis; best evidence but monitoring required 6.25 mg qHS; 12.5 mg qHS; 25 mg qHS; 50 mg qHS :: PO :: :: Start 6.25-12.5 mg qHS; titrate by 12.5 mg q1-2wk; max 50-100 mg/day in PD REMS enrollment required ANC weekly x 6 mo, then q2wk x 6 mo, then monthly; agranulocytosis risk - EXT ROUTINE - Rivastigmine (Exelon) PO/Patch Parkinson's disease dementia 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID; 9.5 mg/24hr patch; 13.3 mg/24hr patch :: PO/Patch :: :: Start 1.5 mg BID or 4.6 mg/24hr patch; titrate monthly; max 6 mg BID or 13.3 mg/24hr Severe hepatic impairment Nausea, weight loss, tremor worsening - ROUTINE ROUTINE - Donepezil PO Parkinson's disease dementia; once daily option 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; increase to 10 mg after 4-6 weeks GI bleeding; sick sinus syndrome Nausea, bradycardia, vivid dreams - ROUTINE ROUTINE - Memantine PO Moderate-severe dementia; add to cholinesterase inhibitor 5 mg daily; 10 mg BID :: PO :: :: Start 5 mg daily; titrate by 5 mg/wk; target 10 mg BID Severe renal impairment (dose adjust) Confusion, constipation - ROUTINE ROUTINE - Midodrine PO Orthostatic hypotension 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5 mg TID (before arising, before lunch, mid-afternoon); titrate by 2.5 mg/dose; max 10 mg TID; last dose by 6 PM Supine hypertension; urinary retention; severe cardiac disease Supine BP (must avoid lying flat for 4 hours after dose) - ROUTINE ROUTINE - Droxidopa (Northera) PO Neurogenic orthostatic hypotension 100 mg TID; 200 mg TID; 300 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg/dose q24-48h; max 600 mg TID Supine hypertension Supine BP, headache - ROUTINE ROUTINE - Fludrocortisone PO Orthostatic hypotension adjunct 0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg CHF; renal failure; severe hypertension K+, edema, supine BP - ROUTINE ROUTINE - Sertraline PO Depression in PD 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg daily MAOIs within 14 days Serotonin syndrome (caution with MAO-B inhibitors) - ROUTINE ROUTINE - Venlafaxine XR PO Depression; anxiety in PD 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; titrate q1-2wk; typical 75-150 mg daily Same as sertraline BP at higher doses - ROUTINE ROUTINE - Polyethylene glycol (MiraLAX) PO Constipation (ubiquitous in PD) 17 g daily; 17 g BID :: PO :: :: 17 g (1 capful) in 8 oz liquid daily; may increase to BID Bowel obstruction Diarrhea if excessive - ROUTINE ROUTINE - Senna + docusate PO Constipation stimulant 2 tablets qHS :: PO :: :: 2 tablets qHS; may increase to 4 tablets Bowel obstruction; undiagnosed abdominal pain Electrolytes with chronic use - ROUTINE ROUTINE - Clonazepam PO REM sleep behavior disorder 0.25 mg qHS; 0.5 mg qHS; 1 mg qHS :: PO :: :: Start 0.25-0.5 mg qHS; titrate to effect; typical 0.5-1 mg Severe sleep apnea; respiratory compromise Sedation, falls, cognitive effects - ROUTINE ROUTINE - Melatonin PO REM sleep behavior disorder; sleep disturbance 3 mg qHS; 6 mg qHS; 9 mg qHS; 12 mg qHS :: PO :: :: Start 3-6 mg qHS; may increase to 12 mg None Generally well-tolerated - ROUTINE ROUTINE - Glycopyrrolate PO Sialorrhea (drooling) 1 mg TID; 2 mg TID :: PO :: :: Start 1 mg TID; titrate to effect; max 2 mg TID Glaucoma; urinary retention; GI obstruction Dry mouth, constipation, urinary retention - ROUTINE ROUTINE - OnabotulinumtoxinA (salivary glands) IM Sialorrhea refractory to oral therapy 100 units total :: IM :: :: 30-50 units per parotid, 10-20 units per submandibular; repeat q3-4 months Infection at site Dysphagia (rare), dry mouth - - ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#3d-advanced-therapies","title":"3D. Advanced Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Deep brain stimulation (DBS) Surgical Motor fluctuations or tremor refractory to optimal medication STN or GPi stimulation :: Surgical :: :: Unilateral or bilateral; programming done over weeks post-op Neuropsych testing, MRI, off-medication evaluation Dementia; active psychiatric disease; medical comorbidities Programming optimization; battery checks - - ROUTINE - Levodopa-carbidopa intestinal gel (Duopa) Enteral Severe motor fluctuations; 4+ hours OFF/day Continuous infusion :: Enteral :: :: Via PEG-J; 16-hour infusion; morning bolus + continuous rate + extra doses GI tract accessible GI disease preventing PEG-J; coagulopathy Tube site, infections, GI complications - EXT ROUTINE - Apomorphine continuous infusion SC Severe motor fluctuations; not DBS candidate 3-8 mg/hr continuous :: SC :: :: Via subcutaneous pump; typical 3-8 mg/hr during waking hours Caregiver training Same as SC apomorphine Same as SC apomorphine - EXT ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Movement disorders specialist for diagnosis confirmation and advanced therapy evaluation - ROUTINE ROUTINE - Physical therapy for gait training, balance exercises, and LSVT BIG program - ROUTINE ROUTINE - Occupational therapy for ADL adaptation and fine motor strategies - ROUTINE ROUTINE - Speech therapy (LSVT LOUD) for hypophonia and swallowing evaluation - ROUTINE ROUTINE - Neuropsychology for cognitive assessment and DBS candidacy evaluation - - ROUTINE - Psychiatry for depression, anxiety, impulse control disorders, or psychosis management - ROUTINE ROUTINE - Palliative care for advanced disease symptom management and goals of care - ROUTINE ROUTINE - Social work for caregiver support, community resources, and disability planning - ROUTINE ROUTINE - Urology for urinary symptoms not responsive to first-line treatment - - ROUTINE - Gastroenterology for severe constipation or Duopa tube placement - - ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD CRITICAL: Do not skip or delay levodopa doses as this can cause severe OFF episodes and immobility STAT STAT ROUTINE Take levodopa 30-60 minutes before meals for better absorption (protein competes with levodopa transport) - ROUTINE ROUTINE Rise slowly from sitting or lying to prevent falls from orthostatic hypotension URGENT ROUTINE ROUTINE Inform all healthcare providers about PD medications to avoid drug interactions (especially antipsychotics, antiemetics) URGENT ROUTINE ROUTINE Report any new impulsive behaviors (gambling, shopping, hypersexuality) which may indicate impulse control disorder from dopamine agonists - ROUTINE ROUTINE Report hallucinations early as these can be managed with medication adjustment - ROUTINE ROUTINE Engage in regular exercise which may slow disease progression and improves mobility - ROUTINE ROUTINE","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular aerobic exercise (30-60 min, 3-5x/week) improves motor function and may be neuroprotective - ROUTINE ROUTINE Tai chi or dance-based exercise programs improve balance and reduce falls - ROUTINE ROUTINE High-fiber diet and adequate hydration to prevent constipation - ROUTINE ROUTINE Avoid medications that worsen parkinsonism (metoclopramide, prochlorperazine, haloperidol, risperidone) URGENT ROUTINE ROUTINE Fall prevention: remove home hazards, adequate lighting, grab bars, non-slip surfaces - ROUTINE ROUTINE Mediterranean diet may have protective benefits based on observational studies - ROUTINE ROUTINE Coffee consumption associated with reduced PD risk; continued moderate use reasonable - ROUTINE ROUTINE","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Drug-induced parkinsonism Medication exposure (antipsychotics, metoclopramide); symmetric; no levodopa response DaTscan normal; history of causative medication Vascular parkinsonism Stepwise progression; lower body predominant; vascular risk factors; pyramidal signs MRI with subcortical/basal ganglia infarcts Progressive supranuclear palsy (PSP) Early falls; vertical gaze palsy; axial rigidity &gt; limb; poor levodopa response MRI \"hummingbird sign\"; clinical criteria Multiple system atrophy (MSA) Severe dysautonomia; cerebellar signs; stridor; poor levodopa response MRI \"hot cross bun\" sign; MIBG preserved Corticobasal degeneration (CBD) Asymmetric rigidity; apraxia; alien limb; cortical sensory loss MRI asymmetric cortical atrophy Dementia with Lewy bodies (DLB) Dementia before or within 1 year of motor symptoms; fluctuating cognition; visual hallucinations Clinical criteria; DaTscan may be abnormal Essential tremor Action tremor &gt; rest tremor; improves with alcohol; family history; no bradykinesia DaTscan normal; clinical criteria Normal pressure hydrocephalus Gait apraxia (\"magnetic gait\"); urinary incontinence; dementia MRI ventricular enlargement; LP with gait improvement","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Motor function (UPDRS-III or MDS-UPDRS) Every visit Document trend; look for &gt;30% change Adjust medications if worsening - ROUTINE ROUTINE - ON/OFF time diary Daily for 1 week before visits &lt;2 hours OFF time/day Add adjunct therapy; consider advanced options - ROUTINE ROUTINE - Dyskinesia severity Each visit Minimize troublesome dyskinesia Reduce levodopa; add amantadine; adjust timing - ROUTINE ROUTINE - Orthostatic blood pressure Each visit &lt;20 mmHg systolic drop on standing Add midodrine or droxidopa - ROUTINE ROUTINE - Cognition (MoCA) Annually, more often if concerns &gt;26 normal; decline triggers action Add cholinesterase inhibitor; adjust anticholinergics - - ROUTINE - Mood (GDS, PHQ-9) Annually Screen negative Add antidepressant; psychiatry referral - ROUTINE ROUTINE - Impulse control screen (QUIP) Each visit if on dopamine agonist Negative Reduce or discontinue dopamine agonist - ROUTINE ROUTINE - Falls frequency Each visit Zero falls PT referral; medication review; home safety evaluation - ROUTINE ROUTINE - Swallowing function Annually or if symptoms No aspiration risk Speech therapy; modify diet - ROUTINE ROUTINE - ANC (if on clozapine) Per REMS protocol ANC &gt;1500/\u03bcL Hold clozapine if ANC &lt;1000; discontinue if &lt;500 - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable motor status; able to take PO; adequate caregiver support; follow-up arranged Admit to floor Unable to take PO medications &gt;24 hours; severe OFF episode; aspiration pneumonia; acute infection Admit to ICU Neuroleptic malignant syndrome; severe rigidity with rhabdomyolysis; respiratory compromise Outpatient follow-up Every 3-6 months for stable patients; more frequently during medication adjustments","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Levodopa most effective symptomatic treatment Class I, Level A Fahn et al. NEJM 2004 (ELLDOPA) MAO-B inhibitors provide mild motor benefit Class I, Level A Rascol et al. NEJM 2005 (rasagiline) Pimavanserin for PD psychosis Class I, Level A Cummings et al. Lancet 2014 DBS improves motor fluctuations Class I, Level A Weaver et al. JAMA 2009 Rivastigmine for PD dementia Class I, Level A Emre et al. NEJM 2004 Exercise improves motor function Class II, Level B Schenkman et al. JAMA Neurol 2018 LSVT LOUD improves speech Class I, Level B Ramig et al. JSLHR 2001 Clonazepam and melatonin for RBD Class II, Level B Aurora et al. AASM 2010 Amantadine reduces dyskinesia Class I, Level A Ory-Magne et al. Lancet Neurol 2014 Duopa for motor fluctuations Class I, Level A Olanow et al. Lancet Neurol 2014","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive motor and non-motor treatment coverage - Includes advanced therapies (DBS, Duopa, apomorphine pump) - Structured dosing format for order sentence generation</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/parkinsons-disease/#appendix-a-medications-to-avoid-in-parkinsons-disease","title":"APPENDIX A: Medications to Avoid in Parkinson's Disease","text":"Drug Class Examples Why to Avoid Typical antipsychotics Haloperidol, chlorpromazine, fluphenazine D2 blockade worsens parkinsonism Most atypical antipsychotics Risperidone, olanzapine, aripiprazole, ziprasidone Significant D2 blockade Antiemetics (D2 blockers) Metoclopramide, prochlorperazine, promethazine Cross blood-brain barrier; worsen parkinsonism Valproic acid Depakote Can cause parkinsonism; tremor Lithium Lithobid Can cause tremor; parkinsonism Calcium channel blockers (some) Flunarizine, cinnarizine D2 blocking properties Reserpine Serpasil Depletes dopamine <p>Safe alternatives: - Antiemetics: Ondansetron, domperidone (not US), trimethobenzamide - Antipsychotics: Quetiapine (first-line), clozapine, pimavanserin</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"drafts/queue/","title":"Review Queue","text":"<p>Plans in this queue need to go through the skills pipeline (checker \u2192 rebuilder \u2192 JSON generation).</p>"},{"location":"drafts/queue/#status-key","title":"Status Key","text":"Status Meaning <code>pending</code> Awaiting review - available for a session to claim <code>in_progress</code> Currently being reviewed by a session <code>completed</code> Review complete, ready for physician sign-off <code>approved</code> Physician approved, moved to <code>docs/plans/</code>"},{"location":"drafts/queue/#queue","title":"Queue","text":"Plan File Status Session Last Updated Vertigo Evaluation <code>vertigo-evaluation.md</code> <code>pending</code> \u2014 2026-01-27 MS - Chronic Management <code>ms-chronic-management.md</code> <code>pending</code> \u2014 2026-01-27 CIDP <code>cidp.md</code> <code>pending</code> \u2014 2026-01-27 Cluster Headache <code>cluster-headache.md</code> <code>pending</code> \u2014 2026-01-27 Medication Overuse Headache <code>medication-overuse-headache.md</code> <code>pending</code> \u2014 2026-01-27 Restless Legs Syndrome <code>restless-legs-syndrome.md</code> <code>pending</code> \u2014 2026-01-27 Mild Cognitive Impairment <code>mild-cognitive-impairment.md</code> <code>pending</code> \u2014 2026-01-27 Trigeminal Neuralgia <code>trigeminal-neuralgia.md</code> <code>pending</code> \u2014 2026-01-27 Migraine with Aura <code>migraine-with-aura.md</code> <code>pending</code> \u2014 2026-01-27 Carpal Tunnel Syndrome <code>carpal-tunnel-syndrome.md</code> <code>pending</code> \u2014 2026-01-27 Myasthenia Gravis - Outpatient <code>myasthenia-gravis.md</code> <code>pending</code> \u2014 2026-01-27 Dystonia <code>dystonia.md</code> <code>pending</code> \u2014 2026-01-27 Alzheimer's Disease <code>alzheimers-disease.md</code> <code>pending</code> \u2014 2026-01-27 Optic Neuritis <code>optic-neuritis.md</code> <code>pending</code> \u2014 2026-01-27 Frontotemporal Dementia <code>frontotemporal-dementia.md</code> <code>pending</code> \u2014 2026-01-27"},{"location":"drafts/queue/#approved-moved-to-docsplans","title":"Approved (Moved to <code>docs/plans/</code>)","text":"Plan File Approved Date Final Score New Onset Seizure <code>new-onset-seizure.md</code> 2026-01-20 93% (56/60) Multiple Sclerosis (New Diagnosis) <code>ms-new-diagnosis.md</code> 2026-01-20 90% (54/60) Peripheral Neuropathy <code>peripheral-neuropathy.md</code> 2026-01-20 90% (54/60) Acute Ischemic Stroke <code>acute-ischemic-stroke.md</code> 2026-01-21 92% (55/60) Guillain-Barr\u00e9 Syndrome <code>guillain-barre-syndrome.md</code> 2026-01-26 90%+ Myasthenia Gravis - Crisis <code>myasthenia-gravis-crisis.md</code> 2026-01-26 90%+ Bacterial Meningitis <code>bacterial-meningitis.md</code> 2026-01-26 90%+ HSV Encephalitis <code>hsv-encephalitis.md</code> 2026-01-26 90%+ Autoimmune Encephalitis <code>autoimmune-encephalitis.md</code> 2026-01-26 90%+ Migraine <code>migraine.md</code> 2026-01-27 90%+ Transient Ischemic Attack (TIA) <code>tia.md</code> 2026-01-27 90%+ Parkinson's Disease <code>parkinsons-disease.md</code> 2026-01-27 90%+ Dementia Evaluation <code>dementia-evaluation.md</code> 2026-01-27 90%+ Essential Tremor <code>essential-tremor.md</code> 2026-01-27 90%+ Diabetic Neuropathy <code>diabetic-neuropathy.md</code> 2026-01-27 90%+"},{"location":"drafts/queue/#completed-awaiting-physician-approval","title":"Completed (Awaiting Physician Approval)","text":"Plan File Completed Date Final Score (none) \u2014 \u2014 \u2014"},{"location":"drafts/queue/#instructions-for-claude","title":"Instructions for Claude","text":"<ol> <li>Claim a plan: Change status from <code>pending</code> to <code>in_progress</code>, add your session ID</li> <li>Process the plan: Follow the skills pipeline in <code>CLAUDE.md</code></li> <li>Update on completion: Change status to <code>completed</code>, record final score</li> <li>Commit changes: Include queue.md updates in your commit</li> </ol>"},{"location":"drafts/radiculopathy/","title":"Radiculopathy - Cervical and Lumbar","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#radiculopathy-cervical-and-lumbar","title":"Radiculopathy - Cervical and Lumbar","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Draft - Pending Review</p> <p>DIAGNOSIS: Radiculopathy - Cervical and Lumbar</p> <p>ICD-10: M54.10 (Radiculopathy, site unspecified); M54.11 (Radiculopathy, occipito-atlanto-axial region); M54.12 (Radiculopathy, cervical region); M54.13 (Radiculopathy, cervicothoracic region); M54.14 (Radiculopathy, thoracic region); M54.15 (Radiculopathy, thoracolumbar region); M54.16 (Radiculopathy, lumbar region); M54.17 (Radiculopathy, lumbosacral region); M54.18 (Radiculopathy, sacral and sacrococcygeal region); G55 (Nerve root and plexus compressions in diseases classified elsewhere); M50.10 (Cervical disc disorder with radiculopathy, unspecified); M51.16 (Intervertebral disc disorders with radiculopathy, lumbar region)</p> <p>CLINICAL SYNONYMS: Radiculopathy, pinched nerve, nerve root compression, cervical radiculopathy, lumbar radiculopathy, sciatica, brachialgia, cervical disc herniation with radiculopathy, lumbar disc herniation with radiculopathy, foraminal stenosis, nerve root impingement, radicular pain, dermatomal pain, nerve root syndrome</p> <p>SCOPE: Evaluation and management of cervical (C5-T1) and lumbar (L2-S1) radiculopathy in adults. Covers red flag identification, diagnostic workup including imaging and electrodiagnostic testing, conservative management, interventional treatments, and surgical indications. Excludes spinal cord compression (myelopathy), cauda equina syndrome (requires emergent surgical evaluation), thoracic radiculopathy, and post-surgical radiculopathy.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#clinical-pearls-nerve-root-distributions","title":"CLINICAL PEARLS: NERVE ROOT DISTRIBUTIONS","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#cervical-radiculopathy-c5-t1","title":"Cervical Radiculopathy (C5-T1)","text":"Root Motor Weakness Reflex Sensory Distribution C5 Deltoid, biceps (shoulder abduction, elbow flexion) Biceps Lateral arm (deltoid region) C6 Biceps, wrist extensors (elbow flexion, wrist extension) Brachioradialis Lateral forearm, thumb, index finger C7 Triceps, wrist flexors, finger extensors (elbow extension) Triceps Middle finger C8 Finger flexors, hand intrinsics (grip strength) None reliable Medial forearm, ring/small fingers T1 Hand intrinsics (finger abduction/adduction) None Medial arm","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#lumbar-radiculopathy-l2-s1","title":"Lumbar Radiculopathy (L2-S1)","text":"Root Motor Weakness Reflex Sensory Distribution L2 Hip flexion (iliopsoas) None Anterior thigh (upper) L3 Hip flexion, knee extension (quadriceps) Patellar (reduced) Anterior thigh (lower), medial knee L4 Knee extension, ankle dorsiflexion (tibialis anterior) Patellar Medial leg, medial malleolus L5 Ankle dorsiflexion, toe extension (EHL), hip abduction None reliable Lateral leg, dorsum of foot, great toe S1 Ankle plantarflexion, toe flexion (gastrocnemius) Achilles Lateral foot, small toe, posterior calf","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#red-flags-requiring-urgent-evaluation","title":"RED FLAGS REQUIRING URGENT EVALUATION","text":"Red Flag Concern Action Bladder/bowel dysfunction (retention, incontinence) Cauda equina syndrome STAT MRI, emergent surgical consult Saddle anesthesia Cauda equina syndrome STAT MRI, emergent surgical consult Bilateral leg weakness Cauda equina, myelopathy STAT MRI, emergent surgical consult Progressive motor deficit (&lt;4/5 or rapidly worsening) Severe nerve compression Urgent MRI within 24h, surgical consult Myelopathic signs (hyperreflexia, Babinski, gait ataxia) Cervical myelopathy Urgent MRI, cervical collar, surgical consult Fever + back pain Epidural abscess, discitis STAT MRI with contrast, labs (WBC, ESR, CRP, blood cultures) History of malignancy Metastatic disease STAT MRI with contrast, oncology consult IV drug use + back pain Epidural abscess STAT MRI with contrast, infectious disease consult Immunocompromised + back pain Infection, atypical organisms STAT MRI with contrast, expanded workup Trauma + neurologic deficit Unstable fracture, cord injury STAT imaging (CT then MRI), spine surgery consult Unexplained weight loss Malignancy MRI with contrast, cancer workup Night pain unrelieved by rest Tumor, infection MRI with contrast","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Infection screen if fever, malignancy screen Normal WBC; no anemia STAT STAT ROUTINE STAT CMP (BMP + LFTs) Baseline renal/hepatic function for medications; metabolic causes Normal STAT STAT ROUTINE STAT ESR Inflammatory marker for infection, malignancy, spondyloarthropathy &lt;20 mm/hr (age-adjusted) URGENT URGENT ROUTINE URGENT CRP Inflammatory marker for infection, malignancy &lt;0.5 mg/dL URGENT URGENT ROUTINE URGENT","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU HbA1c Diabetes increases neuropathy risk; affects surgical outcomes &lt;5.7% - ROUTINE ROUTINE - Fasting glucose Diabetes screening &lt;100 mg/dL - ROUTINE ROUTINE - Vitamin B12 Combined neuropathy may confuse presentation &gt;300 pg/mL - ROUTINE ROUTINE - TSH Hypothyroidism can cause myopathy, neuropathy Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE - HLA-B27 Ankylosing spondylitis, spondyloarthropathy if young patient with inflammatory back pain Negative - EXT ROUTINE - Urinalysis UTI can mimic/exacerbate symptoms; pre-operative screen Normal URGENT ROUTINE ROUTINE - PSA (males &gt;50) Prostate cancer metastases to spine Age-appropriate normal - ROUTINE ROUTINE - Blood cultures (x2) If fever or infection suspected No growth STAT STAT - STAT","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU SPEP with immunofixation Multiple myeloma with vertebral lesions No M-spike - EXT EXT - Lyme serology Endemic areas with radiculopathy, polyradiculopathy Negative - EXT EXT - Paraneoplastic panel Atypical presentation, weight loss, subacute course Negative - EXT EXT - ANA Connective tissue disease Negative or low titer - EXT EXT - ACE level Sarcoidosis with multifocal radiculopathy Normal - EXT EXT -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI spine (cervical or lumbar) without contrast STAT if red flags; otherwise after 4-6 weeks conservative treatment fails Disc herniation, foraminal stenosis, nerve root compression Pacemaker (MRI-incompatible), cochlear implant, metallic foreign body STAT URGENT ROUTINE STAT MRI spine with and without contrast If infection, tumor, or inflammatory etiology suspected Enhancement pattern (abscess rim, tumor, leptomeningeal) GFR &lt;30 (for gadolinium); pacemaker; gadolinium allergy STAT URGENT ROUTINE STAT X-ray spine (AP/lateral, flexion/extension) Initial screen for instability, spondylolisthesis, fracture, alignment No fracture, normal alignment, no listhesis Pregnancy (shield abdomen) URGENT ROUTINE ROUTINE URGENT","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT spine without contrast If MRI contraindicated; bony detail for fracture, foraminal stenosis Foraminal narrowing, osteophytes, fracture Pregnancy (relative); contrast allergy (if contrast used) URGENT URGENT ROUTINE URGENT CT myelogram MRI contraindicated and need for neural visualization Filling defect at nerve root, cord compression Coagulopathy (for LP); intracranial mass - EXT EXT - EMG/NCS (electrodiagnostic studies) 3-4 weeks after symptom onset to confirm radiculopathy, exclude peripheral neuropathy, localize level Fibrillations/positive sharp waves in myotomal distribution; reduced recruitment Pacemaker (relative for needle EMG); anticoagulation (relative) - ROUTINE ROUTINE -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Diagnostic selective nerve root block To confirm symptomatic level when imaging shows multilevel disease &gt;50% pain relief confirms level Coagulopathy; infection at injection site; allergy to contrast/anesthetic - EXT ROUTINE - Bone scan (nuclear) Suspected occult fracture, metastatic disease, infection No increased uptake Pregnancy - EXT ROUTINE - PET-CT Occult malignancy, extent of metastatic disease No FDG-avid lesions Pregnancy; uncontrolled diabetes - EXT EXT - Discography Identify painful disc level before fusion (controversial) Concordant pain reproduction Coagulopathy; local infection; allergy - - EXT -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#3-treatment","title":"3. TREATMENT","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone IV Severe acute radiculopathy with significant weakness 125 mg :: IV :: once :: 125 mg IV once; may give for severe acute radicular symptoms Active infection; uncontrolled diabetes; GI bleeding Glucose; BP; GI symptoms STAT STAT - STAT Dexamethasone IV/PO Acute severe radiculopathy, disc herniation with inflammation 10 mg :: IV :: once, then 4 mg q6h :: 10 mg IV once, then 4 mg IV/PO q6h x 3-5 days; taper over 5-7 days Active infection; uncontrolled diabetes; GI bleeding Glucose; BP; psychiatric effects STAT STAT ROUTINE STAT Prednisone PO Acute radiculopathy with moderate-severe symptoms 60 mg :: PO :: daily x 5 days :: 60 mg daily x 5 days then taper; OR Medrol dose pack Active GI bleed; uncontrolled DM; active infection Glucose; BP; mood URGENT URGENT ROUTINE - Ketorolac IV/IM Acute pain, anti-inflammatory 30 mg :: IV :: q6h :: 30 mg IV/IM q6h; max 5 days; reduce to 15 mg if elderly/renal impairment CrCl &lt;30; active GI bleed; aspirin allergy; post-CABG Renal function; GI bleeding STAT STAT - STAT Morphine IV Severe acute radicular pain 2-4 mg :: IV :: q2-4h PRN :: 2-4 mg IV q2-4h PRN severe pain; titrate to effect Respiratory depression; severe asthma; paralytic ileus Respiratory status; sedation; pain scores STAT STAT - STAT Hydromorphone IV Severe acute radicular pain (alternative to morphine) 0.5-1 mg :: IV :: q2-4h PRN :: 0.5-1 mg IV q2-4h PRN; titrate to effect Respiratory depression; severe asthma; paralytic ileus Respiratory status; sedation; pain scores STAT STAT - STAT Diazepam PO/IV Acute muscle spasm 5 mg :: PO/IV :: q6-8h PRN :: 5-10 mg PO/IV q6-8h PRN for muscle spasm; short course (1-2 weeks) Severe respiratory insufficiency; myasthenia gravis; acute narrow-angle glaucoma Sedation; respiratory depression; dependence URGENT URGENT - -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#3b-symptomatic-treatments-pain-management","title":"3B. Symptomatic Treatments - Pain Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ibuprofen PO Radicular pain, inflammation (first-line OTC) 400 mg TID; 600 mg TID; 800 mg TID :: PO :: :: 400-800 mg TID with food; max 3200 mg/day; short-term use preferred CrCl &lt;30; active GI bleed; aspirin allergy; third trimester pregnancy GI symptoms; renal function with prolonged use ROUTINE ROUTINE ROUTINE - Naproxen PO Radicular pain, inflammation (longer duration) 250 mg BID; 500 mg BID :: PO :: :: 250-500 mg BID with food; max 1500 mg/day CrCl &lt;30; active GI bleed; aspirin allergy; third trimester pregnancy GI symptoms; renal function with prolonged use ROUTINE ROUTINE ROUTINE - Meloxicam PO Radicular pain (once daily dosing) 7.5 mg daily; 15 mg daily :: PO :: :: 7.5-15 mg daily; max 15 mg/day CrCl &lt;30; active GI bleed; aspirin allergy GI symptoms; renal function - ROUTINE ROUTINE - Celecoxib PO Radicular pain (GI-sparing COX-2) 100 mg BID; 200 mg BID :: PO :: :: 100-200 mg BID; max 400 mg/day Sulfonamide allergy; CAD/CVD (increased CV risk); CrCl &lt;30 CV events; GI symptoms; renal function - ROUTINE ROUTINE - Acetaminophen PO Mild-moderate pain (adjunct, avoid hepatotoxicity) 650 mg q6h; 1000 mg q6h :: PO :: :: 650-1000 mg q6h; max 3000 mg/day (2000 mg/day if liver disease) Severe hepatic impairment; chronic alcohol use LFTs with prolonged use ROUTINE ROUTINE ROUTINE ROUTINE Gabapentin PO Neuropathic/radicular pain (first-line for radiculopathy) 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; increase by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day Renal impairment (adjust: CrCl 30-59 max 1400 mg/day; CrCl 15-29 max 600 mg/day; CrCl &lt;15 max 300 mg/day) Sedation; dizziness; edema; taper to discontinue ROUTINE ROUTINE ROUTINE ROUTINE Pregabalin PO Neuropathic/radicular pain (first-line alternative) 75 mg BID; 150 mg BID; 225 mg BID; 300 mg BID :: PO :: :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID (600 mg/day) Renal impairment (adjust per CrCl); Class V controlled Sedation; weight gain; edema; dizziness - ROUTINE ROUTINE ROUTINE Duloxetine PO Neuropathic/radicular pain with depression/anxiety 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; CrCl &lt;30; MAOIs; narrow-angle glaucoma Nausea; BP; discontinuation syndrome (taper over 2+ weeks) - ROUTINE ROUTINE - Cyclobenzaprine PO Muscle spasm (short-term) 5 mg TID; 10 mg TID :: PO :: :: 5-10 mg TID; max 30 mg/day; limit to 2-3 weeks Arrhythmia; heart failure; MAOIs within 14 days; hyperthyroidism Sedation; anticholinergic effects; dry mouth ROUTINE ROUTINE ROUTINE - Tizanidine PO Muscle spasm (alternative to cyclobenzaprine) 2 mg TID; 4 mg TID; 8 mg TID :: PO :: :: Start 2 mg TID; increase by 2-4 mg q6-8h; max 36 mg/day in divided doses Concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors); hepatic impairment LFTs at baseline, 1, 3, 6 months; sedation; hypotension - ROUTINE ROUTINE - Methocarbamol PO Muscle spasm (less sedating) 750 mg QID; 1500 mg QID :: PO :: :: 1500 mg QID x 2-3 days, then 750 mg QID or 1500 mg TID Renal impairment (use caution); myasthenia gravis Sedation; dizziness (less than other relaxants) ROUTINE ROUTINE ROUTINE - Baclofen PO Muscle spasm (if other relaxants fail) 5 mg TID; 10 mg TID; 20 mg TID :: PO :: :: Start 5 mg TID; increase by 5 mg/dose q3d; max 80 mg/day Withdrawal risk if stopped abruptly; renal impairment Sedation; weakness; must taper to discontinue (seizure risk) - ROUTINE ROUTINE - Lidocaine patch 5% TOP Localized radicular pain 1-3 patches :: TOP :: 12h on/12h off :: Apply 1-3 patches to affected area for 12h on, 12h off Severe hepatic impairment; broken skin Minimal systemic absorption; local skin irritation - ROUTINE ROUTINE ROUTINE Capsaicin cream 0.075% TOP Localized radicular pain (adjunct) Apply thin layer :: TOP :: TID-QID :: Apply TID-QID to affected area; takes 2-4 weeks for effect Open wounds; avoid eyes/mucous membranes Initial burning (decreases with use); wash hands after - - ROUTINE - Amitriptyline PO Neuropathic pain (second-line, helps sleep) 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; glaucoma; elderly ECG if dose &gt;100 mg/day; anticholinergic effects - ROUTINE ROUTINE - Nortriptyline PO Neuropathic pain (second-line, less sedating than amitriptyline) 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; glaucoma; elderly ECG if dose &gt;100 mg/day; fewer anticholinergic effects than amitriptyline - ROUTINE ROUTINE -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Tramadol PO Moderate radicular pain not controlled by NSAIDs/gabapentinoids 50 mg q6h PRN; 100 mg ER daily; 200 mg ER daily :: PO :: :: Start 50 mg q6h PRN; may use ER 100 mg daily; max 400 mg/day Seizure disorder; MAOIs; SSRIs (serotonin syndrome); severe renal/hepatic impairment Serotonin syndrome; seizures; dependence (Schedule IV) - ROUTINE ROUTINE - Oxycodone PO Moderate-severe radicular pain (short-term) 5 mg q4-6h PRN; 10 mg q4-6h PRN :: PO :: :: 5-10 mg PO q4-6h PRN; for short-term use only Respiratory depression; paralytic ileus; MAOIs Sedation; constipation; respiratory status; dependence (Schedule II) - ROUTINE ROUTINE - Oxycodone/Acetaminophen PO Moderate-severe radicular pain (short-term) 5/325 mg q4-6h PRN; 10/325 mg q4-6h PRN :: PO :: :: 5-10/325 mg q4-6h PRN; max acetaminophen 3000 mg/day Respiratory depression; hepatic impairment; paralytic ileus Sedation; respiratory status; LFTs; total acetaminophen intake - ROUTINE ROUTINE - Epidural steroid injection (ESI) Fluoroscopic Radicular pain refractory to conservative treatment x 4-6 weeks Per interventional protocol :: Fluoroscopic :: q2-4 weeks x 3 :: Transforaminal or interlaminar approach; up to 3 injections per year Coagulopathy (INR &gt;1.5, plt &lt;100k); infection at site; allergy to contrast/steroids Post-procedure neuro exam; glucose (diabetics); headache - EXT ROUTINE - Transforaminal epidural steroid injection (TFESI) Fluoroscopic Unilateral radicular symptoms, foraminal stenosis Per interventional protocol :: Fluoroscopic :: q2-4 weeks x 3 :: More selective nerve root coverage than interlaminar; up to 3 per year Coagulopathy; infection; severe foraminal stenosis Post-procedure neuro check; glucose monitoring - EXT ROUTINE - Medial branch blocks Fluoroscopic Facet-mediated pain component Per interventional protocol :: Fluoroscopic :: diagnostic x 2 :: Diagnostic blocks before radiofrequency ablation consideration Coagulopathy; infection at site Pain response documentation - - ROUTINE - Radiofrequency ablation (RFA) Fluoroscopic Facet-mediated pain with positive diagnostic blocks Per interventional protocol :: Fluoroscopic :: once, may repeat q6-12 mo :: If &gt;50% relief from diagnostic medial branch blocks x 2 Coagulopathy; infection; pacemaker (relative) Neurologic exam post-procedure; pain scores - - ROUTINE -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#3d-surgical-treatments-specialist-decision","title":"3D. Surgical Treatments (Specialist Decision)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Microdiscectomy Surgical Herniated disc with refractory radiculopathy &gt;6 weeks or progressive motor deficit N/A :: Surgical :: once :: Standard of care for single-level disc herniation with radiculopathy MRI confirmation; failed conservative therapy (unless emergent); medical clearance Active infection; uncorrectable coagulopathy Post-op neuro checks; wound monitoring; pain control - - ROUTINE - Anterior cervical discectomy and fusion (ACDF) Surgical Cervical disc herniation with radiculopathy, cervical spondylosis with radiculopathy N/A :: Surgical :: once :: Most common cervical spine procedure for radiculopathy MRI confirmation; medical clearance; discussion of fusion alternatives Active infection; severe osteoporosis (relative); uncorrectable coagulopathy Swallowing assessment; airway monitoring; neuro checks - - ROUTINE - Cervical disc arthroplasty Surgical Single-level cervical disc herniation (alternative to ACDF) N/A :: Surgical :: once :: Motion-preserving alternative to fusion at appropriate levels (C3-7) MRI confirmation; intact facet joints; no significant instability Instability; facet arthropathy; osteoporosis; infection Post-op neuro checks; wound monitoring - - ROUTINE - Posterior cervical foraminotomy Surgical Lateral/foraminal cervical disc herniation or foraminal stenosis N/A :: Surgical :: once :: Motion-preserving option for lateral pathology MRI confirmation; lateral/foraminal pathology Central disc herniation; instability Post-op neuro checks; wound monitoring - - ROUTINE - Lumbar laminectomy/laminotomy Surgical Lumbar stenosis with radiculopathy, large central disc N/A :: Surgical :: once :: Decompression for stenosis or central disc MRI confirmation; failed conservative therapy Active infection; uncorrectable coagulopathy Post-op neuro checks; wound; urinary retention - - ROUTINE - Lumbar fusion (TLIF, PLIF, ALIF) Surgical Radiculopathy with instability, spondylolisthesis, recurrent disc herniation N/A :: Surgical :: once :: Reserved for instability or recurrent pathology MRI/CT confirmation; bone density evaluation; medical clearance Active infection; severe osteoporosis (relative); uncorrectable coagulopathy Post-op neuro checks; hardware position; fusion assessment - - ROUTINE - Emergent decompression Surgical Cauda equina syndrome (within 48h), severe/progressive motor deficit N/A :: Surgical :: emergent :: Within 24-48h of symptom onset for best outcomes STAT MRI confirming compression None absolute if true CES Bladder function; motor recovery; wound STAT STAT - STAT","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Spine surgery (neurosurgery or orthopedic spine) consult STAT for cauda equina syndrome, progressive motor deficit, or myelopathic signs STAT STAT - STAT Spine surgery consult URGENT for significant weakness (&lt;4/5) or radiculopathy refractory to 6+ weeks conservative treatment URGENT URGENT ROUTINE URGENT Physical therapy for core strengthening, McKenzie exercises, nerve gliding, and posture training - ROUTINE ROUTINE - Pain management/Interventional spine for epidural steroid injections if conservative treatment fails after 4-6 weeks - ROUTINE ROUTINE - PM&amp;R (Physical Medicine &amp; Rehabilitation) for comprehensive spine rehabilitation program - ROUTINE ROUTINE - EMG/NCS referral to confirm radiculopathy level and exclude peripheral neuropathy or plexopathy (optimal timing 3-4 weeks after symptom onset) - ROUTINE ROUTINE - Oncology consult for suspected spinal metastases or pathologic fracture URGENT URGENT ROUTINE URGENT Infectious disease consult for suspected epidural abscess, discitis, or vertebral osteomyelitis URGENT URGENT ROUTINE URGENT Rheumatology for suspected inflammatory spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis) - ROUTINE ROUTINE - Occupational therapy for ergonomic assessment, workplace modifications, and ADL training - ROUTINE ROUTINE - Psychology/Pain psychology for chronic pain management, CBT for pain, catastrophizing assessment - - ROUTINE - Neurology for atypical presentation, polyradiculopathy, or suspected inflammatory/infectious etiology URGENT URGENT ROUTINE URGENT Social work for disability assistance, return-to-work planning, and insurance navigation - ROUTINE ROUTINE -","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED IMMEDIATELY if bladder or bowel incontinence, inability to urinate, saddle area numbness, or bilateral leg weakness (may indicate cauda equina syndrome) \u2713 \u2713 \u2713 Return to ED if fever develops with back/neck pain (may indicate infection) \u2713 \u2713 \u2713 Return if weakness is progressing or you are unable to lift foot/hand (progressive motor deficit requires urgent evaluation) \u2713 \u2713 \u2713 Most radiculopathy improves with conservative treatment over 4-6 weeks; surgery is rarely needed \u2713 \u2713 \u2713 Stay active within pain limits; prolonged bed rest (&gt;1-2 days) is not recommended and may delay recovery - \u2713 \u2713 Apply ice for first 48-72 hours (20 min on/off), then switch to heat for muscle relaxation \u2713 \u2713 \u2713 Avoid heavy lifting, twisting, and prolonged sitting; use proper body mechanics \u2713 \u2713 \u2713 Sleep with pillow between knees (side) or under knees (back) to reduce spine stress - \u2713 \u2713 For cervical radiculopathy: avoid prolonged neck flexion (looking down at phone); use cervical pillow - \u2713 \u2713 Do not stop gabapentin/pregabalin abruptly - taper under medical guidance to avoid withdrawal - \u2713 \u2713 Neuropathic pain medications (gabapentin, pregabalin) take 2-4 weeks to reach full effect - \u2713 \u2713 Physical therapy exercises should be continued daily at home for best outcomes - \u2713 \u2713 Do not drive while taking opioids or sedating muscle relaxants \u2713 \u2713 \u2713 Follow up with primary care or neurology in 2-4 weeks to assess treatment response \u2713 \u2713 \u2713","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation to improve disc nutrition and surgical outcomes (smoking accelerates disc degeneration) \u2713 \u2713 \u2713 Weight loss if BMI &gt;25 to reduce spinal load and improve symptoms - \u2713 \u2713 Core strengthening exercises to support spine (plank, bird-dog, bridges) - \u2713 \u2713 Proper lifting technique: bend at knees, keep load close, avoid twisting \u2713 \u2713 \u2713 Ergonomic workstation setup: monitor at eye level, lumbar support, feet flat - - \u2713 Take breaks every 30-60 minutes if seated for prolonged periods - \u2713 \u2713 Maintain good posture: shoulders back, chin tucked, avoid forward head position - \u2713 \u2713 Regular low-impact exercise (walking, swimming, stationary bike) to maintain fitness - \u2713 \u2713 Avoid high-impact activities (running, jumping) during acute phase - \u2713 \u2713 Yoga or Pilates (modified) for flexibility and core strength after acute phase resolves - - \u2713 Use supportive mattress; avoid sleeping on stomach - \u2713 \u2713 Manage stress as tension can worsen muscle spasm and pain perception - \u2713 \u2713 Glycemic control if diabetic (HbA1c &lt;7%) to reduce neuropathic component and improve surgical outcomes - \u2713 \u2713","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#section-b-reference-expand-as-needed","title":"SECTION B: REFERENCE (Expand as Needed)","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Peripheral neuropathy Stocking-glove distribution, bilateral, length-dependent, not dermatomal NCS/EMG shows polyneuropathy; HbA1c; B12; no imaging abnormality Lumbar spinal stenosis (neurogenic claudication) Bilateral leg symptoms, worse with walking/standing, better with sitting/flexion, older patients MRI shows central stenosis; symptoms bilateral; walking tolerance limited Piriformis syndrome Buttock pain radiating to posterior thigh, negative straight leg raise, tenderness at piriformis MRI spine normal; tenderness at piriformis; FAIR test positive Hip pathology (OA, AVN, labral tear) Groin pain, limited hip ROM, pain with hip flexion/rotation, normal spine exam Hip X-ray/MRI; pain reproduced with hip exam, not spine Sacroiliac joint dysfunction Low back/buttock pain, positive SI joint provocative tests, pain at PSIS SI joint injection diagnostic; MRI may show SI joint changes Greater trochanteric bursitis Lateral hip pain, tender at greater trochanter, pain with side-lying Normal spine MRI; tenderness localized to trochanter Diabetic amyotrophy (lumbosacral plexopathy) Acute/subacute proximal thigh weakness and pain, weight loss, often bilateral sequential EMG shows plexopathy; MRI lumbosacral plexus may show enhancement Meralgia paresthetica Lateral thigh numbness/burning only (L2-L3 distribution), no weakness Normal EMG; may have abnormal lateral femoral cutaneous nerve conduction Herpes zoster (shingles) Dermatomal pain followed by vesicular rash, older/immunocompromised Clinical diagnosis; vesicular rash in dermatomal pattern Vascular claudication Calf pain with walking, relieved by rest (not position), diminished pulses ABI &lt;0.9; Doppler shows arterial disease; spine MRI normal Cauda equina syndrome Saddle anesthesia, bladder/bowel dysfunction, bilateral leg weakness/numbness STAT MRI shows large central disc or mass compressing cauda equina Spinal cord tumor (intra/extramedullary) Progressive symptoms, night pain, myelopathic signs, weight loss MRI with contrast shows enhancing mass Epidural abscess Fever, severe localized back pain, rapid progression, risk factors (IVDU, diabetes) MRI with contrast shows rim-enhancing collection; elevated WBC, ESR, CRP Vertebral metastases History of cancer, night pain, weight loss, multiple levels MRI shows destructive lesions; bone scan; tumor markers; biopsy Ankylosing spondylitis Young male, morning stiffness &gt;30 min, improves with activity, sacroiliitis HLA-B27; MRI shows sacroiliitis; ESR elevated Spinal epidural hematoma Post-procedure or anticoagulation, acute severe pain, rapid neuro decline STAT MRI shows epidural collection; coags abnormal Arachnoiditis Prior spine surgery or infection, diffuse radicular symptoms, clumped nerve roots MRI shows clumped/adherent nerve roots in thecal sac Tarlov (perineural) cyst Incidental finding on MRI, may cause radicular symptoms if large MRI shows sacral cyst; often asymptomatic","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"<p>Venue column indicates where monitoring is typically ordered/initiated. Most monitoring continues in outpatient setting.</p> Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Pain scores (0-10 NRS) Each visit 50% reduction from baseline Escalate therapy; consider interventional/surgical referral ROUTINE ROUTINE ROUTINE ROUTINE Motor strength (MRC grading) Each visit; more frequent if weakness present Stable or improving; \u22654/5 Progressive weakness: urgent spine surgery consult; imaging STAT STAT ROUTINE STAT Sensory exam (dermatomal) Each visit Stable or improving Document progression; correlate with imaging ROUTINE ROUTINE ROUTINE ROUTINE Deep tendon reflexes Each visit Symmetric or appropriate for level Hyperreflexia suggests myelopathy: MRI cervical spine ROUTINE ROUTINE ROUTINE ROUTINE Bladder function Each visit; more frequent if any symptoms Normal voiding, no retention Retention or incontinence: STAT catheterization, STAT MRI, emergent surgery consult STAT STAT ROUTINE STAT Straight leg raise (lumbar) / Spurling test (cervical) Each visit Negative or improving Positive with worsening: consider imaging if not done ROUTINE ROUTINE ROUTINE ROUTINE Gait assessment Each visit Normal, no foot drop, no ataxia Foot drop: EMG, surgical consult; ataxia: cervical MRI for myelopathy ROUTINE ROUTINE ROUTINE ROUTINE Functional status (ODI, NDI) Baseline, 6 weeks, 3 months, 6 months Improving scores Not improving: reassess treatment strategy; consider surgery - ROUTINE ROUTINE - Renal function (if on NSAIDs &gt;2 weeks) Baseline, then q3 months Stable creatinine Decline: discontinue NSAIDs; switch to acetaminophen/other - ROUTINE ROUTINE - Glucose (if on steroids) Daily if inpatient; before/after ESI &lt;180 mg/dL (diabetics) Adjust diabetes medications; short steroid courses ROUTINE ROUTINE ROUTINE ROUTINE","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home No red flags present; pain controlled with oral medications; able to ambulate; normal bladder function; motor strength \u22654/5 and stable; reliable follow-up arranged within 2-4 weeks Admit to floor Severe pain requiring IV analgesia; significant motor weakness (\u22643/5) requiring close monitoring; need for IV antibiotics (suspected infection); inability to ambulate safely; need for urgent MRI not available as outpatient Admit to ICU Rapidly progressive motor deficit requiring emergent surgery; hemodynamic instability from sepsis (spinal infection); airway compromise (high cervical pathology); post-operative monitoring for complex spine surgery Emergent surgery consult Cauda equina syndrome (bladder dysfunction, saddle anesthesia, bilateral weakness); progressive motor deficit despite steroids; epidural abscess with neurologic deficit Transfer to higher level Spine surgery not available; MRI not available for emergent imaging; interventional spine services not available for ESI when indicated","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source MRI is imaging modality of choice for suspected radiculopathy Class I, Level A Boden SD et al. J Bone Joint Surg Am 1990 Most cervical and lumbar radiculopathy improves with conservative treatment Class I, Level A Saal JA et al. Spine 1996 NSAIDs effective for acute radiculopathy pain Class I, Level A Roelofs PD et al. Cochrane 2008 Gabapentin/pregabalin effective for radicular neuropathic pain Class I, Level A Finnerup NB et al. Lancet Neurol 2015 Oral steroids provide short-term benefit for lumbar radiculopathy Class I, Level B Goldberg H et al. JAMA 2015 Epidural steroid injections provide short-term pain relief for lumbar radiculopathy Class I, Level B Manchikanti L et al. Pain Physician 2021 EMG/NCS useful for confirming radiculopathy and excluding mimics after 3-4 weeks Class II, Level B AANEM Practice Parameter 2010 Surgery superior to conservative treatment for severe lumbar radiculopathy at 1 year Class I, Level A SPORT Trial: Weinstein JN et al. JAMA 2006 Cauda equina syndrome requires decompression within 48 hours for best outcomes Class II, Level B Ahn UM et al. Spine 2000 Physical therapy effective for cervical and lumbar radiculopathy Class I, Level B Kuijper B et al. BMJ 2009 Smoking cessation improves spine health and surgical outcomes Class II, Level B Battie MC et al. Spine 1991 Short-term muscle relaxants may help acute radiculopathy with spasm Class II, Level B Chou R et al. Cochrane 2003 ACDF effective for cervical radiculopathy refractory to conservative treatment Class I, Level B Herkowitz HN et al. Spine 1990 Microdiscectomy effective for lumbar disc herniation with radiculopathy Class I, Level A Peul WC et al. NEJM 2007 Duloxetine effective for chronic musculoskeletal pain including radiculopathy Class I, Level A Skljarevski V et al. J Pain 2010 Red flags warrant urgent imaging and evaluation for serious pathology Class II, Level B Chou R et al. Ann Intern Med 2007","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#appendix-a-imaging-decision-algorithm","title":"APPENDIX A: IMAGING DECISION ALGORITHM","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#when-to-image","title":"When to Image","text":"<p>Immediate MRI (STAT): - Cauda equina syndrome symptoms - Progressive motor deficit (&lt;4/5 or worsening) - Myelopathic signs (cervical) - Fever + back pain (add contrast for abscess) - History of malignancy + new back/neck pain - IV drug use + back pain</p> <p>Urgent MRI (within 1-2 weeks): - Motor weakness (4/5) without progression - Intractable pain despite medications - Suspicion for tumor or infection without acute neuro deficit</p> <p>Routine MRI (4-6 weeks): - Persistent radicular symptoms despite conservative treatment - To confirm level before intervention or surgery - Correlation with EMG findings</p> <p>No MRI Needed: - Mild radicular symptoms &lt;6 weeks responding to conservative treatment - No red flags present - Improving trajectory</p>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#appendix-b-physical-therapy-modalities","title":"APPENDIX B: PHYSICAL THERAPY MODALITIES","text":"","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#initial-phase-week-1-2","title":"Initial Phase (Week 1-2)","text":"<ul> <li>Pain modulation: TENS, ice/heat, manual therapy</li> <li>Gentle ROM exercises</li> <li>Positioning education</li> <li>Nerve gliding/flossing exercises</li> </ul>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#acute-phase-week-2-4","title":"Acute Phase (Week 2-4)","text":"<ul> <li>McKenzie exercises (extension-based for disc, flexion-based for stenosis)</li> <li>Core stabilization (transverse abdominis activation)</li> <li>Postural training</li> <li>Progressive nerve mobilization</li> </ul>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#strengthening-phase-week-4-12","title":"Strengthening Phase (Week 4-12)","text":"<ul> <li>Progressive core strengthening (plank, bird-dog, bridges)</li> <li>Hip and leg strengthening</li> <li>Functional movement training</li> <li>Aerobic conditioning (walking, pool therapy)</li> </ul>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#maintenance-phase-ongoing","title":"Maintenance Phase (Ongoing)","text":"<ul> <li>Independent home exercise program</li> <li>Return to activities with proper mechanics</li> <li>Work conditioning if applicable</li> <li>Ongoing core and flexibility maintenance</li> </ul>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/radiculopathy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial creation - Comprehensive nerve root distribution tables for cervical (C5-T1) and lumbar (L2-S1) - Red flag checklist with required actions - Full laboratory workup including infection and malignancy markers - Imaging algorithm with timing recommendations - Treatment sections with structured dosing format for clickable order sentences - Multiple dose options for gabapentin, pregabalin, NSAIDs, muscle relaxants - Epidural steroid injection and interventional treatments - Surgical treatment section with indications and pre-treatment requirements - Comprehensive referral and patient instruction sections - Differential diagnosis including 18+ alternative diagnoses - Evidence-based references with PubMed links - Appendices for imaging decision algorithm and PT modalities</p>","tags":["spine","radiculopathy","pain-management","nerve-root"]},{"location":"drafts/restless-legs-syndrome/","title":"Restless Legs Syndrome","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#restless-legs-syndrome","title":"Restless Legs Syndrome","text":"<p>DIAGNOSIS: Restless Legs Syndrome (Willis-Ekbom Disease) ICD-10: G25.81 (Restless legs syndrome) SCOPE: Diagnosis confirmation using IRLSSG criteria, workup for secondary causes, pharmacologic and non-pharmacologic management, and augmentation prevention/treatment. Primarily outpatient management with limited ED/HOSP coverage for severe refractory cases.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#irlssg-diagnostic-criteria-all-5-required","title":"IRLSSG Diagnostic Criteria (All 5 Required)","text":"<ol> <li>Urge to move the legs usually accompanied by uncomfortable sensations</li> <li>Symptoms begin or worsen during rest or inactivity (lying, sitting)</li> <li>Symptoms are partially or totally relieved by movement (walking, stretching)</li> <li>Symptoms occur exclusively or predominantly in the evening or night (circadian pattern)</li> <li>Symptoms are not solely accounted for by another condition (leg cramps, positional discomfort, myalgia, venous stasis, leg edema, arthritis, habitual foot tapping)</li> </ol> <p>Supportive Features: Family history (40-60%); response to dopaminergic therapy; periodic limb movements during sleep (PLMS) on polysomnography</p>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Ferritin Iron deficiency is most common treatable cause; target &gt;75 ng/mL for RLS (higher than general population) &gt;75 ng/mL (ideally &gt;100) URGENT ROUTINE ROUTINE - Transferrin saturation (TSAT) Iron availability; TSAT &lt;20% suggests iron deficiency even with normal ferritin &gt;20% URGENT ROUTINE ROUTINE - Serum iron Complete iron panel assessment Normal range URGENT ROUTINE ROUTINE - TIBC Iron binding capacity; elevated in iron deficiency Normal URGENT ROUTINE ROUTINE - CBC with differential Anemia evaluation; MCV for iron vs B12 deficiency Normal; MCV 80-100 fL URGENT ROUTINE ROUTINE - BMP (Creatinine, BUN, electrolytes) Renal function (uremia causes secondary RLS) eGFR &gt;60 mL/min URGENT ROUTINE ROUTINE - TSH Thyroid dysfunction can mimic or exacerbate RLS 0.4-4.0 mIU/L - ROUTINE ROUTINE - HbA1c Diabetes screening (diabetic neuropathy commonly coexists) &lt;5.7% (normal); &lt;7% if diabetic - ROUTINE ROUTINE - Fasting glucose Diabetes screening 70-99 mg/dL - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Vitamin B12 Deficiency causes neuropathy and may worsen RLS &gt;300 pg/mL - ROUTINE ROUTINE - Folate Deficiency associated with RLS; often low with B12 &gt;3 ng/mL - ROUTINE ROUTINE - Magnesium Deficiency can cause leg cramps and muscle symptoms 1.8-2.4 mg/dL - ROUTINE ROUTINE - CRP, ESR Inflammatory markers; chronic inflammation affects iron metabolism Normal - ROUTINE ROUTINE - Comprehensive metabolic panel Hepatic function; renal clearance Normal - ROUTINE ROUTINE - Pregnancy test (if applicable) RLS common in pregnancy (up to 25%); affects treatment choices Negative or positive (determines treatment) - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU 24-hour urine protein Nephrotic syndrome workup if renal disease suspected &lt;150 mg/24hr - - EXT - Parathyroid hormone Hyperparathyroidism can cause RLS Normal - - EXT - Anti-GAD65 antibodies Autoimmune etiology in atypical cases Negative - - EXT - Paraneoplastic panel Occult malignancy with neurological symptoms Negative - - EXT - Hemoglobin electrophoresis Thalassemia trait; chronic hemolytic conditions Normal - - EXT - Vitamin D Deficiency associated with RLS in some studies &gt;30 ng/mL - - ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Clinical examination and history At evaluation IRLSSG criteria met; no mimicking conditions None URGENT ROUTINE ROUTINE - IRLS Rating Scale (IRLS) At diagnosis and follow-up Score 0-40; mild &lt;10, moderate 11-20, severe 21-30, very severe &gt;30 None - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Polysomnography (PSG) If sleep apnea suspected; PLMS quantification PLMI &lt;15/hr normal; RLS typically &gt;15/hr None - - ROUTINE - EMG/Nerve conduction studies If peripheral neuropathy suspected (numbness, weakness, areflexia) Normal or peripheral neuropathy pattern Pacemaker (relative) - - ROUTINE - Actigraphy Objective assessment of sleep and limb movements Activity pattern consistent with RLS None - - EXT -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain Atypical presentation; concern for structural lesion or secondary parkinsonism Normal MRI contraindications - - EXT - MRI Lumbar spine Radiculopathy suspected; nerve root compression symptoms Normal or explains symptoms MRI contraindications - - EXT - Suggested immobilization test (SIT) Research/specialized; objective RLS measurement Increased leg movements during immobility Time-intensive - - EXT -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3a-acuteemergent-severe-symptom-relief","title":"3A. Acute/Emergent (Severe Symptom Relief)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO Acute severe symptoms requiring immediate relief 300 mg; 600 mg :: PO :: :: 300-600 mg PO for immediate symptom relief; may repeat once in 4-6 hours Severe renal impairment (adjust dose) Sedation, dizziness URGENT URGENT - - Pregabalin PO Acute severe symptoms; faster onset than gabapentin 75 mg; 150 mg :: PO :: :: 75-150 mg PO for immediate relief; onset 30-60 min Severe renal impairment (adjust dose) Sedation, dizziness URGENT URGENT - - Oxycodone (severe refractory) PO Severe acute symptoms refractory to alpha-2-delta ligands 5 mg :: PO :: :: 5 mg PO once for severe refractory symptoms; short-term only Respiratory depression; opioid use disorder; concurrent CNS depressants Respiratory status, sedation EXT EXT - -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3b-first-line-treatments-iron-therapy","title":"3B. First-line Treatments (Iron Therapy)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ferrous sulfate + Vitamin C PO First-line if ferritin &lt;75 ng/mL; oral iron repletion 325 mg with 100 mg vitamin C daily; 325 mg with 200 mg vitamin C daily :: PO :: :: 325 mg ferrous sulfate (65 mg elemental iron) with 100-200 mg vitamin C on empty stomach every other day; evening dosing preferred; treat 3-4 months minimum Hemochromatosis; iron overload; GI bleeding Ferritin, TSAT at 3-4 months; GI tolerability - ROUTINE ROUTINE - Ferrous gluconate PO Alternative oral iron if ferrous sulfate not tolerated 325 mg daily; 325 mg BID :: PO :: :: 325 mg (38 mg elemental iron) daily to BID; better GI tolerability; lower elemental iron Same as above Same as above - ROUTINE ROUTINE - Iron sucrose IV Oral iron failure or intolerance; rapid repletion needed; ferritin &lt;75 200 mg per infusion; 200 mg x 5 doses :: IV :: :: 200 mg IV over 15-30 min; give 1000 mg total in 5 divided doses over 2 weeks Iron overload; hypersensitivity Ferritin, TSAT at 4-8 weeks; infusion reaction monitoring - ROUTINE ROUTINE - Ferric carboxymaltose (Injectafer) IV Rapid iron repletion; single or two-dose regimen preferred 750 mg x 2 doses; 1000 mg x 1 dose :: IV :: :: 750 mg IV, repeat in 1 week (max 1500 mg total); OR 1000 mg single dose if weight &gt;50 kg Hypersensitivity to IV iron Hypophosphatemia (common); infusion reaction; ferritin at 4-8 weeks - ROUTINE ROUTINE - Ferric derisomaltose (Monoferric) IV Single-dose IV iron repletion 1000 mg single dose :: IV :: :: 1000 mg IV over 20+ min as single dose; may repeat if needed after 4 weeks Same as ferric carboxymaltose Same; lower hypophosphatemia risk - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3c-first-line-treatments-alpha-2-delta-ligands-preferred","title":"3C. First-line Treatments (Alpha-2-Delta Ligands - Preferred)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Gabapentin PO First-line pharmacotherapy; no augmentation risk; good for pain component 300 mg qHS; 300 mg BID; 600 mg qHS; 300 mg TID; 600 mg BID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7 days; target 600-1800 mg/day in 1-3 doses; max 2400 mg/day; give largest dose in evening Severe renal impairment (dose adjust); respiratory depression with opioids Sedation, dizziness, peripheral edema, weight gain; renal function - ROUTINE ROUTINE - Gabapentin enacarbil (Horizant) PO FDA-approved for RLS; better bioavailability than immediate release gabapentin 600 mg daily :: PO :: :: 600 mg PO once daily at 5 PM with food; no titration needed; extended release formulation Same as gabapentin; do NOT substitute mg-for-mg with regular gabapentin Same as gabapentin - ROUTINE ROUTINE - Pregabalin PO First-line; faster onset than gabapentin; helpful if comorbid anxiety or fibromyalgia 75 mg qHS; 150 mg qHS; 75 mg BID; 150 mg BID; 300 mg qHS :: PO :: :: Start 75 mg qHS; titrate by 75 mg q1wk; target 150-450 mg/day; max 300 mg in evening Severe renal impairment (adjust dose); avoid abrupt discontinuation Same as gabapentin; Schedule V controlled - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3d-second-line-treatments-dopamine-agonists-use-with-caution","title":"3D. Second-line Treatments (Dopamine Agonists - Use with Caution)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Pramipexole (Mirapex) PO Alpha-2-delta failure/intolerance; use LOWEST effective dose; augmentation risk ~7%/year 0.125 mg qHS; 0.25 mg qHS; 0.5 mg qHS :: PO :: :: Start 0.125 mg 2-3 hrs before symptoms; titrate by 0.125 mg q4-7 days; max 0.5 mg/day for RLS (lower than Parkinson's doses) Warn patient about augmentation, ICDs Severe renal impairment (reduce dose by 50% if CrCl &lt;60); pathological gambling risk AUGMENTATION (symptoms earlier, more intense, spread to arms); impulse control disorders; excessive daytime sleepiness; renal function - ROUTINE ROUTINE - Ropinirole (Requip) PO Alpha-2-delta failure/intolerance; augmentation risk similar to pramipexole 0.25 mg qHS; 0.5 mg qHS; 1 mg qHS; 2 mg qHS :: PO :: :: Start 0.25 mg 1-3 hrs before symptoms; titrate by 0.25 mg q2-3 days; max 4 mg/day for RLS Warn patient about augmentation, ICDs Hepatic impairment; concurrent CYP1A2 inhibitors (adjust dose) Same as pramipexole; nausea common initially - ROUTINE ROUTINE - Rotigotine patch (Neupro) Transdermal Once-daily patch; less pulsatile dopaminergic stimulation; may reduce augmentation 1 mg/24hr; 2 mg/24hr; 3 mg/24hr :: Transdermal :: :: Start 1 mg/24hr patch; titrate by 1 mg/24hr weekly; max 3 mg/24hr for RLS Warn patient about augmentation, ICDs Sulfite sensitivity; MRI (remove patch - contains aluminum) Site reactions; augmentation; impulse control disorders - - ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3e-third-linerefractory-treatments","title":"3E. Third-line/Refractory Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Tramadol PO Refractory RLS; failed alpha-2-delta and dopamine agonists 50 mg qHS; 50 mg BID; 100 mg qHS :: PO :: :: Start 50 mg qHS; max 100 mg BID; use lowest effective dose Seizure history; concurrent MAOIs/SSRIs (serotonin syndrome); opioid use disorder Constipation, sedation, nausea; seizure risk; dependence - ROUTINE ROUTINE - Oxycodone (low-dose) PO Severe refractory RLS; augmentation from dopamine agonists 5 mg qHS; 5 mg BID; 10 mg qHS :: PO :: :: Start 5 mg qHS; max 5-10 mg BID; lowest effective dose; long-term monitoring required Opioid use disorder; severe respiratory disease; concurrent CNS depressants Constipation, sedation, dependence; respiratory depression; prescribe conservatively - EXT ROUTINE - Oxycodone/naloxone (Targiniq ER) PO Refractory RLS with constipation concern 5/2.5 mg BID; 10/5 mg BID :: PO :: :: Start 5/2.5 mg BID; max 20/10 mg BID; naloxone reduces constipation Same as oxycodone Same; monitor bowel function - - EXT - Methadone PO Severe refractory RLS failing other opioids 5 mg qHS; 5 mg BID :: PO :: :: 5 mg qHS to BID; requires experienced prescriber; ECG monitoring for QTc QTc prolongation; opioid use disorder; respiratory disease QTc interval; respiratory status; requires DEA registration - - EXT - Clonazepam PO Adjunct for sleep; helps with PLMS-related arousals 0.25 mg qHS; 0.5 mg qHS; 1 mg qHS :: PO :: :: Start 0.25 mg qHS; max 2 mg qHS; use short-term or intermittently Fall risk in elderly; respiratory depression; substance use history Sedation, dependence, falls, cognitive effects; avoid long-term in elderly - ROUTINE ROUTINE - Clonidine PO Alternative for mild symptoms; alpha-2 agonist 0.1 mg qHS; 0.2 mg qHS :: PO :: :: Start 0.1 mg qHS; max 0.3 mg qHS Hypotension; bradycardia BP, HR; rebound hypertension if stopped abruptly - - ROUTINE - Buprenorphine patch Transdermal Severe refractory RLS; concern for opioid misuse 5 mcg/hr; 10 mcg/hr :: Transdermal :: :: Start 5 mcg/hr weekly patch; titrate slowly Same as other opioids Same; requires REMS prescriber certification (changing) - - EXT - Dipyridamole PO Limited evidence; adenosine modulation 100 mg qHS; 200 mg qHS :: PO :: :: 100-200 mg qHS; off-label; variable response Hypotension; bleeding disorders Headache, hypotension - - EXT -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#3f-augmentation-management","title":"3F. Augmentation Management","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Dopamine agonist taper PO Augmentation from dopamine agonist; must taper slowly 10-25% dose reduction q1-2wk :: PO :: :: Reduce dopamine agonist by 10-25% every 1-2 weeks; expect 1-2 weeks worsening (\"washout\"); bridge with alpha-2-delta or opioid Do NOT stop abruptly (dopamine agonist withdrawal syndrome) Worsening symptoms during taper (expected); DAWS symptoms - - ROUTINE - Alpha-2-delta ligand bridge PO Cover augmentation symptoms during dopamine agonist taper Per gabapentin or pregabalin dosing :: PO :: :: Start alpha-2-delta at therapeutic dose before or during dopamine agonist taper; provides symptom coverage Per individual drug Sedation; adjust as dopamine agonist tapers - - ROUTINE - Low-dose opioid bridge PO Severe augmentation; alpha-2-delta insufficient Per tramadol or oxycodone dosing :: PO :: :: Short-term opioid coverage during dopamine agonist washout; plan transition to non-dopaminergic maintenance History of opioid use disorder Dependence; use short-term - - ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Sleep medicine referral for polysomnography if sleep apnea suspected or PLMS quantification needed - - ROUTINE - Neurology/movement disorders consultation for refractory RLS or diagnostic uncertainty - ROUTINE ROUTINE - Hematology referral for IV iron infusion coordination or complex iron deficiency management - - ROUTINE - Pain management consultation for severe refractory cases requiring opioid therapy - - ROUTINE - Nephrology referral if chronic kidney disease contributing to secondary RLS - ROUTINE ROUTINE - Psychiatry consultation if impulse control disorders develop on dopamine agonist therapy - - ROUTINE - OB/GYN coordination for RLS management during pregnancy (common; limits treatment options) - ROUTINE ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Take iron supplements on an empty stomach every other day (better absorption) with vitamin C; avoid taking with calcium, coffee, or tea - ROUTINE ROUTINE Take evening medications 2-3 hours before typical symptom onset for best effect - ROUTINE ROUTINE Report symptoms spreading to arms, occurring earlier in day, or becoming more intense (signs of augmentation) - ROUTINE ROUTINE Report new gambling urges, compulsive shopping, or hypersexuality if taking dopamine agonists (impulse control disorders) - ROUTINE ROUTINE Avoid antihistamines (diphenhydramine, Benadryl) which significantly worsen RLS - use alternatives for allergies or sleep - ROUTINE ROUTINE Inform prescribers about RLS before starting new medications as many can worsen symptoms - ROUTINE ROUTINE Keep a symptom diary tracking severity, timing, and potential triggers to optimize treatment - - ROUTINE Return if symptoms become severe enough to affect sleep, daytime function, or quality of life ROUTINE ROUTINE ROUTINE","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Avoid caffeine especially in afternoon and evening as it worsens RLS symptoms - ROUTINE ROUTINE Limit or avoid alcohol which disrupts sleep architecture and can worsen RLS - ROUTINE ROUTINE Avoid nicotine/smoking which can exacerbate symptoms through vasoconstriction and sleep disruption - ROUTINE ROUTINE Regular moderate exercise (walking, swimming, yoga) earlier in day reduces symptoms; avoid vigorous exercise near bedtime - ROUTINE ROUTINE Maintain regular sleep schedule with consistent bed and wake times (sleep hygiene) - ROUTINE ROUTINE Leg massage, warm baths, or heating pads in the evening may provide temporary symptomatic relief - ROUTINE ROUTINE Cooling measures (cold compresses, leg wraps) may help some patients - - ROUTINE Mental distraction activities (engaging video games, puzzles) can reduce symptom awareness - ROUTINE ROUTINE Compression stockings or pneumatic compression may provide relief in some patients - - ROUTINE Review all current medications with provider to identify and eliminate RLS-exacerbating drugs - ROUTINE ROUTINE","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#medications-to-avoid-in-rls","title":"Medications to AVOID in RLS","text":"Medication Class Examples Effect on RLS Antihistamines (first-generation) Diphenhydramine (Benadryl), hydroxyzine, promethazine, chlorpheniramine Significantly worsen RLS; block dopamine Antidopaminergic antiemetics Metoclopramide (Reglan), prochlorperazine (Compazine) Strong RLS exacerbation; block dopamine Typical antipsychotics Haloperidol, chlorpromazine Severe RLS worsening; dopamine blockade Atypical antipsychotics Olanzapine, quetiapine, risperidone Can worsen RLS; less than typicals SSRIs Sertraline, fluoxetine, paroxetine, citalopram May worsen RLS in 10-20% of patients SNRIs Venlafaxine, duloxetine Similar to SSRIs; variable effect TCAs Amitriptyline, nortriptyline Can worsen RLS; antihistaminic effects Lithium Lithium carbonate May exacerbate RLS Sedating antihistamines in OTC sleep aids ZzzQuil, Tylenol PM, Advil PM Major RLS trigger <p>Safer alternatives when possible: - For allergies: Non-sedating antihistamines (cetirizine, loratadine, fexofenadine) - For nausea: Ondansetron, ginger - For depression: Bupropion (least likely to worsen), mirtazapine may be neutral - For sleep: Trazodone, melatonin, alpha-2-delta ligands</p>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Nocturnal leg cramps Painful muscle contraction; visible/palpable muscle tightness; no urge to move Clinical history; no relief with movement Peripheral neuropathy Numbness, tingling, burning in stocking-glove distribution; not circadian EMG/NCS; exam findings (reflexes, sensation) Akathisia Inner restlessness; not limited to legs; associated with antipsychotic use Medication history; generalized restlessness Positional discomfort Relieved by position change; no urge to move specifically Clinical history Periodic limb movement disorder (PLMD) PLMS without RLS symptoms; bed partner may report jerking PSG shows PLMS; no waking leg discomfort Venous insufficiency Aching worse with standing; varicosities visible; edema Doppler ultrasound; worse during day Arthritis (hip, knee, ankle) Joint pain; stiffness; localized to joints X-ray; rheumatologic workup Radiculopathy/sciatica Dermatomal pattern; worsened by spine movement; back pain MRI spine; positive straight leg raise Growing pains (pediatric) Children; bilateral leg pain; no urge to move Clinical history; self-limited Fibromyalgia Widespread pain; tender points; fatigue Clinical criteria; no specific test Anxiety/stress-related symptoms Generalized restlessness; racing thoughts; no circadian pattern Psychiatric evaluation Drug-induced restlessness Temporal relationship with offending medication Medication review; trial withdrawal","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU IRLS severity scale Each visit Score reduction &gt;50% from baseline Titrate medication; consider alternative agent - ROUTINE ROUTINE - Sleep quality (subjective and actigraphy if available) Each visit Improved sleep; reduced awakenings Assess compliance; consider adjuncts - ROUTINE ROUTINE - Ferritin level Every 3-4 months during repletion; annually when stable &gt;75 ng/mL (target &gt;100) Continue or restart iron supplementation - ROUTINE ROUTINE - Transferrin saturation With ferritin &gt;20% Continue iron therapy - ROUTINE ROUTINE - Augmentation assessment Each visit if on dopamine agonist No symptoms earlier in day; no spread to arms; no dose escalation need Taper dopamine agonist; switch to non-dopaminergic - ROUTINE ROUTINE - Impulse control disorders (ICDs) Each visit if on dopamine agonist No gambling, hypersexuality, compulsive shopping, binge eating Stop or reduce dopamine agonist - ROUTINE ROUTINE - Daytime somnolence Each visit ESS &lt;10 Reduce dose; evaluate for sleep apnea - ROUTINE ROUTINE - Renal function (if on gabapentin/pregabalin) Annually or with changes eGFR-appropriate dosing Dose adjust per renal function - ROUTINE ROUTINE - Weight, edema (if on gabapentin/pregabalin) Each visit Stable or acceptable Dose reduction; switch agent - ROUTINE ROUTINE - QTc (if on methadone) Baseline, 2-4 weeks, annually &lt;500 msec Reduce dose; consider alternative - - ROUTINE -","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home with outpatient follow-up Typical RLS diagnosis; initial workup ordered; treatment started or planned; follow-up arranged Outpatient management (primary) All patients with RLS; return 2-4 weeks for medication titration; then q3-6 months when stable Admit to hospital (rare) Severe refractory RLS preventing all sleep (unusual); IV iron infusion coordination if outpatient not available; acute decompensation with comorbidities ED evaluation Rarely needed; may see for severe acute symptoms or secondary cause evaluation","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Alpha-2-delta ligands (gabapentin, pregabalin) first-line for RLS Class I, Level A Silber et al. Mayo Clin Proc 2021 Gabapentin enacarbil FDA-approved for RLS Class I, Level A Kushida et al. Neurology 2009 Pregabalin effective for RLS Class I, Level A Allen et al. Sleep Med 2014 Iron supplementation if ferritin &lt;75 ng/mL Class I, Level A Allen et al. Sleep Med 2018 IV iron effective for RLS with iron deficiency Class I, Level B Trotti et al. J Clin Sleep Med 2012 Dopamine agonist augmentation risk Class II, Level B Garcia-Borreguero et al. Sleep Med 2016 Low-dose opioids for refractory RLS Class II, Level B Trenkwalder et al. Lancet Neurol 2013 IRLSSG diagnostic criteria Consensus, Level A Allen et al. Sleep Med 2014 Dopamine agonists effective but augmentation concern Class I, Level A Silber et al. Mayo Clin Proc 2013 Pregnancy-associated RLS prevalence up to 25% Class II, Level B Manconi et al. Neurology 2004 Medications that worsen RLS Class II-III, Level B-C Mackie &amp; Winkelman. Drugs 2015 Long-term management recommendations Consensus, Level C Garcia-Borreguero et al. Sleep Med Rev 2013","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive iron therapy section with oral and IV options - Alpha-2-delta ligands emphasized as first-line (lower augmentation risk than dopamine agonists) - Detailed augmentation management section - Medications to avoid table - IRLSSG diagnostic criteria included - Structured dosing format for order sentence generation - Outpatient-focused with limited ED/HOSP coverage for severe cases</p>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#appendix-a-augmentation-recognition-and-management-algorithm","title":"APPENDIX A: Augmentation Recognition and Management Algorithm","text":"<p>Signs of Augmentation (EURLSSG Criteria): 1. Symptoms occur 2+ hours earlier than before treatment 2. Symptoms are more intense than before treatment started 3. Symptoms spread to previously unaffected body parts (arms, trunk) 4. Shorter latency to symptoms at rest 5. Shorter duration of medication effect 6. Periodic limb movements worsen during wakefulness</p> <p>Management Steps: 1. Confirm augmentation (not tolerance, progression, or noncompliance) 2. Check and optimize iron stores (ferritin &gt;100 ng/mL) 3. Reduce dopamine agonist dose by 25-50% 4. If augmentation persists: taper and discontinue dopamine agonist over 2-4 weeks 5. Bridge with alpha-2-delta ligand or low-dose opioid 6. Expect 1-2 weeks of symptom worsening during washout 7. Transition to non-dopaminergic maintenance (alpha-2-delta preferred) 8. If severe: may need temporary opioid bridge during transition</p> <p>Prevention: - Use lowest effective dopamine agonist dose - Prefer alpha-2-delta ligands as first-line - Monitor iron status and supplement to keep ferritin &gt;75-100 - Avoid early dose escalation of dopamine agonists</p>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#appendix-b-rls-in-special-populations","title":"APPENDIX B: RLS in Special Populations","text":"","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#pregnancy","title":"Pregnancy","text":"<ul> <li>RLS affects up to 25% of pregnant women, especially 3rd trimester</li> <li>Usually resolves within weeks postpartum</li> <li>Treatment options limited:</li> <li>First-line: Iron supplementation (safe in pregnancy)</li> <li>Non-pharmacologic measures</li> <li>Clonazepam (pregnancy category D - avoid if possible)</li> <li>Alpha-2-delta ligands not well-studied in pregnancy</li> <li>Dopamine agonists: limited data, generally avoided</li> </ul>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#chronic-kidney-disease","title":"Chronic Kidney Disease","text":"<ul> <li>RLS prevalence 20-40% in dialysis patients</li> <li>Iron deficiency common; IV iron often needed</li> <li>Dose adjust gabapentin/pregabalin for renal function</li> <li>Dopamine agonists can be used (less augmentation concern in this population)</li> <li>May improve after renal transplant</li> </ul>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#pediatric-rls","title":"Pediatric RLS","text":"<ul> <li>Often misdiagnosed as \"growing pains\" or ADHD</li> <li>Strong genetic component; family history important</li> <li>Iron deficiency common; check ferritin (target &gt;50)</li> <li>Non-pharmacologic first; limited pediatric drug data</li> <li>Gabapentin most commonly used off-label</li> </ul>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/restless-legs-syndrome/#parkinsons-disease-coexistence","title":"Parkinson's Disease Coexistence","text":"<ul> <li>RLS can coexist with Parkinson's disease</li> <li>May be difficult to distinguish from Parkinson's symptoms</li> <li>Parkinson's medications may treat or worsen RLS</li> <li>DaTscan can help differentiate if unclear</li> </ul>","tags":["movement-disorders","sleep-disorders","outpatient"]},{"location":"drafts/small-fiber-neuropathy/","title":"Small Fiber Neuropathy","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#small-fiber-neuropathy","title":"Small Fiber Neuropathy","text":"<p>DIAGNOSIS: Small Fiber Neuropathy (SFN) ICD-10: G62.9 (Polyneuropathy, unspecified); G62.89 (Other specified polyneuropathies); G90.09 (Other idiopathic peripheral autonomic neuropathy) SCOPE: Diagnosis and management of small fiber neuropathy presenting with painful sensory and/or autonomic symptoms with normal or near-normal nerve conduction studies. Includes length-dependent and non-length-dependent (ganglionopathy) patterns. Covers etiologic workup for treatable causes, symptomatic pain management, and autonomic symptom treatment.</p> <p>STATUS: Draft - Pending Review</p> <p>CLINICAL SYNONYMS: SFN; Small fiber sensory neuropathy; Small fiber predominant neuropathy; Pure small fiber neuropathy; Painful small fiber neuropathy; Autonomic small fiber neuropathy; Sensory ganglionopathy (non-length-dependent pattern)</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>KEY CLINICAL FEATURES: - Definition: Neuropathy affecting small myelinated (A\u03b4) and unmyelinated (C) nerve fibers - Sensory symptoms: Burning pain, allodynia, hyperalgesia, paresthesias, \"pins and needles\" - Autonomic symptoms: Sudomotor dysfunction (dry skin, hyperhidrosis), orthostatic intolerance, GI dysmotility, urinary symptoms, sicca symptoms - Key diagnostic criterion: Clinical neuropathy with normal or near-normal NCS (which test large fibers only) - Gold standard confirmation: Skin biopsy with reduced intraepidermal nerve fiber density (IENFD)</p>","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU HbA1c Diabetes and prediabetes are most common causes of SFN &lt;5.7% normal; \u22655.7% prediabetes - ROUTINE ROUTINE - Fasting glucose Current glycemic status; impaired fasting glucose &lt;100 mg/dL STAT ROUTINE ROUTINE - 2-hour oral glucose tolerance test (OGTT) Impaired glucose tolerance causes SFN even with normal HbA1c 2-hr glucose &lt;140 mg/dL normal - ROUTINE ROUTINE - BMP (creatinine, eGFR, electrolytes) Renal function; medication dosing; uremic neuropathy eGFR &gt;60; normal electrolytes STAT ROUTINE ROUTINE - CBC Baseline; anemia evaluation Normal STAT ROUTINE ROUTINE - Vitamin B12 B12 deficiency causes SFN; common and treatable &gt;300 pg/mL (&gt;400 optimal) - ROUTINE ROUTINE - TSH Hypothyroidism causes neuropathy 0.4-4.0 mIU/L - ROUTINE ROUTINE - ESR, CRP Inflammatory markers; vasculitis screen Normal - ROUTINE ROUTINE - ANA Autoimmune etiology; Sjogren's screen Negative - ROUTINE ROUTINE - Anti-SSA (Ro) and anti-SSB (La) antibodies Sjogren syndrome is common cause of SFN (up to 40% of SFN) Negative - ROUTINE ROUTINE - Hepatitis B and C serologies HCV-associated neuropathy; cryoglobulinemia Negative - ROUTINE ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Methylmalonic acid (MMA) More sensitive for B12 deficiency if B12 borderline (200-400) Normal (&lt;0.4 \u03bcmol/L) - ROUTINE ROUTINE - Tissue transglutaminase IgA (TTG-IgA) Celiac disease causes SFN even without GI symptoms Negative - ROUTINE ROUTINE - Total serum IgA IgA deficiency causes false-negative TTG Normal (not deficient) - ROUTINE ROUTINE - SPEP/UPEP with immunofixation Paraproteinemia; monoclonal gammopathy No monoclonal protein - ROUTINE ROUTINE - HIV HIV-associated sensory neuropathy Negative - EXT ROUTINE - Lipid panel Metabolic syndrome associated with SFN Normal/controlled - ROUTINE ROUTINE - Vitamin D Deficiency associated with neuropathic pain &gt;30 ng/mL - ROUTINE ROUTINE - Vitamin B1 (thiamine) Deficiency causes painful neuropathy Normal - ROUTINE ROUTINE - Vitamin B6 Both deficiency and excess cause neuropathy Normal (neither high nor low) - ROUTINE ROUTINE - Copper Copper deficiency neuropathy (especially post-bariatric surgery) Normal (70-140 \u03bcg/dL) - ROUTINE ROUTINE - Zinc Excessive zinc causes copper deficiency Normal (not elevated) - ROUTINE ROUTINE - Salivary gland biopsy Sjogren syndrome if clinical suspicion high and serology negative Negative for lymphocytic infiltration - - ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Alpha-galactosidase A enzyme activity Fabry disease screening (X-linked; consider in males and females) Normal enzyme activity - - ROUTINE - GLA gene sequencing Confirm Fabry disease if enzyme low or high clinical suspicion No pathogenic variants - - EXT - TTR gene sequencing Hereditary transthyretin amyloidosis; early SFN with autonomic symptoms No pathogenic variants - - ROUTINE - Fat pad or skin biopsy (Congo red) Amyloidosis if suspected (autonomic features, cardiomyopathy, CTS) No amyloid deposits - - ROUTINE - Serum free light chains AL amyloidosis screen Normal kappa:lambda ratio - ROUTINE ROUTINE - Anti-FGFR3 antibodies Autoimmune SFN (especially ganglionopathy pattern) Negative - - EXT - Anti-TS-HDS antibodies Autoimmune SFN marker Negative - - EXT - Sarcoidosis workup (ACE, chest imaging) Sarcoid neuropathy Normal ACE; no hilar adenopathy - ROUTINE ROUTINE - Paraneoplastic antibody panel Paraneoplastic sensory ganglionopathy (anti-Hu) if rapid onset Negative - ROUTINE ROUTINE - Cryoglobulins Cryoglobulinemic neuropathy (especially with HCV) Negative - - EXT - Schirmer test Objective dry eye for Sjogren diagnosis Normal (&gt;5mm in 5 min) - - ROUTINE - SCN9A, SCN10A, SCN11A gene testing Sodium channelopathies causing inherited SFN (erythromelalgia) No pathogenic variants - - EXT -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Nerve conduction studies (NCS) At initial evaluation Normal or near-normal (SFN spares large fibers) None - ROUTINE ROUTINE - Skin biopsy (3mm punch at distal leg and thigh) After NCS shows normal large fiber function Reduced IENFD below normative threshold for age/sex/site Bleeding diathesis; anticoagulation (relative) - - ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Quantitative sudomotor axon reflex test (QSART) Autonomic symptoms; suspected sudomotor dysfunction Normal sweat volumes at all sites None - - ROUTINE - Sudoscan Screening for sudomotor dysfunction; non-invasive Normal electrochemical skin conductance hands and feet None - - ROUTINE - Autonomic reflex screen (ARS) Comprehensive autonomic evaluation; orthostatic symptoms Normal cardiovagal, adrenergic, and sudomotor function None - EXT ROUTINE - Tilt table test Orthostatic intolerance; POTS evaluation No excessive HR rise; no orthostatic hypotension None - EXT ROUTINE - Quantitative sensory testing (QST) Thermal threshold testing; research and specialized centers Normal thermal detection thresholds None - - EXT - Thermoregulatory sweat test (TST) Global sudomotor evaluation if QSART equivocal Normal sweat distribution Cardiac instability - - EXT - Corneal confocal microscopy Non-invasive small fiber assessment; research tool Normal corneal nerve fiber density and length None - - EXT -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU EMG If large fiber involvement suspected; atypical features Normal (SFN spares motor and large sensory fibers) Anticoagulation (relative) - ROUTINE ROUTINE - MRI spine (cervical/thoracic) Ganglionopathy pattern; non-length-dependent SFN Normal dorsal root ganglia; no dorsal column signal MRI contraindications - ROUTINE ROUTINE - MRI neurography Research; visualize small nerves No nerve enlargement or signal abnormality MRI contraindications - - EXT - PET-CT Sarcoidosis or malignancy suspected; paraneoplastic evaluation No abnormal uptake Pregnancy - EXT EXT - Echocardiogram Amyloidosis suspected (cardiomyopathy screening) No infiltrative cardiomyopathy features None - ROUTINE ROUTINE - Cardiac MRI Cardiac amyloidosis evaluation if echo abnormal No amyloid infiltration MRI contraindications; devices - EXT EXT -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3-treatment","title":"3. TREATMENT","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IV fluids IV Acute orthostatic hypotension with symptoms Normal saline bolus :: IV :: :: 500-1000 mL NS bolus for symptomatic orthostatic hypotension; avoid in heart failure Heart failure; volume overload Volume status; BP response STAT STAT - STAT Pain crisis management IV/PO Severe acute neuropathic pain flare not responding to outpatient regimen Multimodal :: IV/PO :: :: IV lidocaine infusion (1-3 mg/kg/hr) if refractory; avoid chronic opioids Lidocaine: cardiac conduction abnormality Pain scores; cardiac monitoring for lidocaine URGENT URGENT - URGENT Glucose management Various Acute presentation with new diabetes diagnosis Per protocol :: Various :: :: Initiate diabetes management; hypoglycemia causes SFN flare Per specific agent Glucose STAT STAT - STAT","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3b-symptomatic-treatments-neuropathic-pain-first-line","title":"3B. Symptomatic Treatments (Neuropathic Pain - First-line)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Duloxetine PO First-line for neuropathic pain; also treats depression/anxiety common in SFN 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day MAOIs; uncontrolled narrow-angle glaucoma; severe renal impairment (CrCl &lt;30) Hepatic function; BP; suicidal ideation - ROUTINE ROUTINE - Pregabalin PO First-line for neuropathic pain; FDA-approved for postherpetic neuralgia and DPN 50 mg TID; 75 mg BID; 100 mg TID; 150 mg BID; 200 mg TID :: PO :: :: Start 50 mg TID or 75 mg BID; titrate q3-7d; max 300 mg/day; reduce if CrCl &lt;60 Angioedema to pregabalin/gabapentin Dizziness, somnolence, weight gain, peripheral edema - ROUTINE ROUTINE - Gabapentin PO First-line; less expensive alternative to pregabalin 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce if CrCl &lt;60 Severe renal impairment (dose adjust required) Sedation, dizziness, ataxia, edema - ROUTINE ROUTINE - Amitriptyline PO TCA for neuropathic pain; helps insomnia; inexpensive 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma; elderly (high anticholinergic burden) ECG if age &gt;40 or cardiac history; anticholinergic side effects - ROUTINE ROUTINE - Nortriptyline PO TCA with less sedation and anticholinergic effects than amitriptyline 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS Cardiac conduction disease; recent MI; urinary retention; narrow-angle glaucoma ECG if dose &gt;100 mg/day or cardiac risk factors - ROUTINE ROUTINE - Venlafaxine XR PO SNRI alternative to duloxetine 37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 150-225 mg daily MAOIs; uncontrolled hypertension BP at higher doses; discontinuation syndrome if stopped abruptly - ROUTINE ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3c-second-linerefractory-neuropathic-pain","title":"3C. Second-line/Refractory (Neuropathic Pain)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Capsaicin 8% patch (Qutenza) Topical Localized neuropathic pain; add-on therapy Apply for 30-60 min :: Topical :: :: Applied by trained healthcare provider; pre-treat with topical anesthetic; may repeat q3mo Application to face/mucous membranes; broken skin Pain/burning during application; transient BP increase - - ROUTINE - Lidocaine 5% patch Topical Localized pain; adjunctive therapy; allodynia 1-3 patches daily :: Topical :: :: Apply to most painful area; up to 3 patches for 12h on/12h off Allergy to local anesthetics; damaged skin Skin irritation - ROUTINE ROUTINE - Lamotrigine PO Sodium channel blocker; some evidence in SFN 25 mg daily; 50 mg daily; 100 mg BID; 200 mg BID :: PO :: :: Start 25 mg daily x 2wk; then 50 mg daily x 2wk; increase by 50 mg q2wk; max 400 mg/day SJS/TEN history; valproate use (reduce dose by 50%) RASH (especially first 8 weeks) - stop immediately if rash - ROUTINE ROUTINE - Lacosamide PO Sodium channel blocker; well-tolerated 50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID :: PO :: :: Start 50 mg BID; increase by 50 mg/day weekly; max 400 mg/day Second or third degree AV block (without pacemaker) ECG for PR prolongation; dizziness - ROUTINE ROUTINE - Carbamazepine PO Sodium channel blocker; limited evidence for SFN specifically 100 mg BID; 200 mg BID; 400 mg BID :: PO :: :: Start 100 mg BID; titrate by 200 mg/wk; max 1200 mg/day AV block; bone marrow suppression; HLA-B*1502 in Asian patients (SJS risk) CBC, LFTs, sodium; drug interactions (CYP3A4 inducer) - ROUTINE ROUTINE - Mexiletine PO Sodium channel blocker; especially if SCN9A mutation suspected 150 mg TID; 200 mg TID; 300 mg TID :: PO :: :: Start 150 mg TID; titrate by 150 mg q3d; max 1200 mg/day; take with food Cardiomyopathy; second/third degree AV block ECG; arrhythmia monitoring - EXT ROUTINE - Desipramine PO TCA with minimal anticholinergic effects 25 mg qHS; 50 mg qHS; 75 mg qHS; 100 mg qHS :: PO :: :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg Same as other TCAs ECG; drug levels available if needed - ROUTINE ROUTINE - Tramadol PO Moderate pain; opioid-like with serotonergic properties 50 mg q6h PRN; 100 mg ER BID :: PO :: :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk) Seizures, serotonin syndrome, constipation - ROUTINE ROUTINE - Tapentadol ER PO Refractory pain; mu-opioid agonist with norepinephrine reuptake inhibition 50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID :: PO :: :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day Severe respiratory depression; MAOIs; paralytic ileus Respiratory status, constipation, sedation - EXT ROUTINE - Combination therapy Various Inadequate response to monotherapy Combine agents from different classes :: Various :: :: Gabapentinoid + SNRI; TCA + gabapentinoid; use lower doses of each Per individual agents Additive side effects; falls in elderly - ROUTINE ROUTINE - Low-dose naltrexone (LDN) PO Emerging evidence for neuropathic pain; anti-inflammatory 1.5 mg qHS; 3 mg qHS; 4.5 mg qHS :: PO :: :: Start 1.5 mg qHS; increase by 1.5 mg q2wk; max 4.5 mg; compounded Current opioid use; hepatic impairment Vivid dreams, insomnia (take in AM if occurs) - - EXT - Spinal cord stimulation Implant Refractory SFN pain; failed multiple medications Per implant protocol :: Implant :: :: Trial stimulation before permanent implant; high-frequency or burst stimulation preferred Infection; coagulopathy; psychiatric instability Device function; pain relief - - EXT -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3d-autonomic-symptom-management","title":"3D. Autonomic Symptom Management","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Fludrocortisone PO Orthostatic hypotension; volume expansion 0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg Check potassium; assess volume status Heart failure; hypertension; hypokalemia Weight, BP supine and standing, potassium, edema - ROUTINE ROUTINE - Midodrine PO Orthostatic hypotension; alpha-1 agonist vasoconstrictor 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5 mg TID (with meals); titrate to 5-10 mg TID; last dose 4h before bed None specific Severe cardiac disease; urinary retention; supine hypertension Supine BP (check for supine hypertension); avoid at bedtime - ROUTINE ROUTINE - Droxidopa (Northera) PO Neurogenic orthostatic hypotension; FDA-approved for autonomic failure 100 mg TID; 200 mg TID; 300 mg TID; 400 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg/day q24-48h; max 600 mg TID None specific Supine hypertension (severe) Supine BP; avoid lying flat for 2h after dose - ROUTINE ROUTINE - Pyridostigmine PO Orthostatic hypotension; enhances ganglionic transmission 30 mg TID; 60 mg TID :: PO :: :: Start 30 mg TID; may increase to 60 mg TID; modest BP effect but no supine hypertension None specific Mechanical GI/GU obstruction; bradyarrhythmia Cholinergic effects (diarrhea, salivation) - ROUTINE ROUTINE - Compression stockings External Orthostatic hypotension; venous pooling Waist-high 30-40 mmHg :: External :: :: Waist-high preferred over knee-high; put on before rising; 30-40 mmHg compression Peripheral arterial disease (ABI &lt;0.5) Skin breakdown; PAD Skin integrity; ABI if arterial disease suspected - ROUTINE ROUTINE - Oxybutynin PO Bladder urgency/frequency 5 mg BID; 5 mg TID; 10 mg XL daily :: PO :: :: Start 5 mg BID or 10 mg XL daily; max 30 mg/day Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction Cognitive effects in elderly; dry mouth Anticholinergic effects; cognition in elderly - ROUTINE ROUTINE - Solifenacin PO Bladder urgency; better tolerated anticholinergic 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily Same as oxybutynin; severe hepatic impairment Same as oxybutynin but less cognitive Anticholinergic effects - ROUTINE ROUTINE - Mirabegron PO Bladder urgency; beta-3 agonist (non-anticholinergic) 25 mg daily; 50 mg daily :: PO :: :: Start 25 mg daily; may increase to 50 mg daily Uncontrolled hypertension; severe hepatic impairment BP; urinary retention - ROUTINE ROUTINE - Metoclopramide PO Gastroparesis; prokinetic 5 mg AC; 10 mg AC :: PO :: :: 5-10 mg 30 min before meals and at bedtime; limit to &lt;12 weeks Tardive dyskinesia (limit duration); GI obstruction; Parkinson disease Tardive dyskinesia; extrapyramidal symptoms - ROUTINE ROUTINE - Domperidone PO Gastroparesis; prokinetic with less CNS effects 10 mg TID :: PO :: :: 10 mg TID before meals; not FDA-approved (requires IND or international pharmacy) QT prolongation; ventricular arrhythmia ECG for QT; arrhythmia - - EXT - Erythromycin PO Gastroparesis; motilin receptor agonist 250 mg TID :: PO :: :: 250 mg PO TID before meals; short-term use due to tachyphylaxis QT prolongation; drug interactions ECG; GI upset; tachyphylaxis limits long-term use - ROUTINE ROUTINE - Sildenafil PO Erectile dysfunction in autonomic SFN 25 mg PRN; 50 mg PRN; 100 mg PRN :: PO :: :: Start 25-50 mg 1h before activity; max 100 mg; avoid with nitrates Nitrate use; severe cardiovascular disease Cardiovascular status; vision changes - - ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#3e-disease-modifying-etiology-targeted-therapies","title":"3E. Disease-Modifying / Etiology-Targeted Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Glycemic control optimization Various Diabetes/prediabetes-associated SFN Per diabetes guidelines :: Various :: :: Lifestyle first for prediabetes; HbA1c &lt;7% target; tighter control slows progression Diabetes education Hypoglycemia risk HbA1c q3-6mo; glucose monitoring - ROUTINE ROUTINE - IVIG IV Autoimmune SFN (Sjogren-associated; anti-FGFR3+; idiopathic with evidence of inflammation) 2 g/kg divided over 2-5 days :: IV :: :: 2 g/kg divided over 2-5 days monthly; limited evidence; consider trial Check IgA level (IgA-deficient patients need IgA-depleted product) IgA deficiency (use IgA-depleted); renal impairment; hypercoagulable state Renal function; thrombotic risk; headache - ROUTINE ROUTINE - Enzyme replacement therapy (Fabry disease) IV Fabry disease-associated SFN Agalsidase beta (Fabrazyme) 1 mg/kg IV q2wk :: IV :: :: Lifelong therapy; infusion reactions common early None None absolute Infusion reactions; anti-drug antibodies - ROUTINE ROUTINE - Tafamidis (Vyndamax/Vyndaqel) PO Hereditary and wild-type TTR amyloidosis with polyneuropathy 80 mg daily; 61 mg daily :: PO :: :: 80 mg (Vyndamax) or 61 mg (Vyndaqel) PO daily; TTR stabilizer Genetic confirmation of TTR amyloidosis None Cardiac function; neuropathy progression - - ROUTINE - Inotersen/Patisiran SC/IV Hereditary TTR amyloidosis with polyneuropathy Per prescribing protocol :: SC/IV :: :: Inotersen 284 mg SC weekly; Patisiran 0.3 mg/kg IV q3wk TTR gene mutation confirmed; specialist management Thrombocytopenia (inotersen); infusion reactions Platelets (inotersen); hepatic function - - EXT - Gluten-free diet Diet Celiac disease-associated SFN Strict gluten-free :: Diet :: :: Lifelong strict gluten-free diet; dietitian referral; neuropathy may stabilize/improve Celiac confirmation None TTG-IgA levels; symptom response - - ROUTINE - B12 supplementation PO/IM B12 deficiency-associated SFN 1000 mcg daily PO; 1000 mcg IM monthly :: PO/IM :: :: 1000-2000 mcg PO daily; or 1000 mcg IM weekly x 4, then monthly if poor absorption None None B12 and MMA levels q3-6mo until stable - ROUTINE ROUTINE - Immunosuppression (Sjogren's) Various Sjogren's-associated SFN with systemic disease activity Per rheumatology :: Various :: :: Hydroxychloroquine, methotrexate, rituximab; coordinate with rheumatology Rheumatology co-management Per specific agent Per specific agent - ROUTINE ROUTINE - Alpha-lipoic acid PO Antioxidant; some evidence in painful neuropathy; European guidelines 600 mg daily :: PO :: :: 600 mg PO daily; may take 3-6 months for effect; limited evidence None GI upset May enhance hypoglycemia in diabetics - - ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neuromuscular specialist for skin biopsy interpretation and complex SFN management - ROUTINE ROUTINE - Rheumatology if Sjogren's, lupus, or other connective tissue disease suspected - ROUTINE ROUTINE - Endocrinology if diabetes/prediabetes for glycemic optimization and metabolic management - ROUTINE ROUTINE - Genetics counselor if hereditary etiology suspected (Fabry, TTR amyloidosis, SCN9A channelopathies) - - ROUTINE - Gastroenterology for celiac confirmation, gastroparesis management, or liver biopsy if amyloid suspected - ROUTINE ROUTINE - Cardiology if TTR amyloidosis suspected or autonomic symptoms with cardiac involvement - ROUTINE ROUTINE - Pain management for refractory neuropathic pain and interventional options (spinal cord stimulation) - - ROUTINE - Physical therapy for balance training, strengthening, and fall prevention - ROUTINE ROUTINE - Autonomic disorders specialist if complex autonomic symptoms (POTS, orthostatic hypotension) - - ROUTINE - Psychiatry/psychology for chronic pain coping and comorbid depression/anxiety management - - ROUTINE - Hematology/oncology if amyloidosis confirmed for staging and treatment - ROUTINE ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Report any new weakness, gait difficulty, or falls as these may indicate progression to large fiber involvement STAT STAT ROUTINE Monitor for signs of infection in feet (redness, warmth, drainage) if sensation is impaired - ROUTINE ROUTINE Keep a pain diary to track triggers, severity, and medication response - ROUTINE ROUTINE Rise slowly from sitting or lying to prevent falls from orthostatic hypotension STAT ROUTINE ROUTINE Increase salt and fluid intake (2-3L/day, 6-10g sodium) if orthostatic hypotension present (unless contraindicated) - ROUTINE ROUTINE Wear compression stockings before rising in the morning if orthostatic hypotension diagnosed - ROUTINE ROUTINE Take all prescribed pain medications as directed; do not stop gabapentinoids or SNRIs abruptly - ROUTINE ROUTINE Avoid excessive heat exposure which can worsen symptoms; stay hydrated in warm weather - ROUTINE ROUTINE Return if severe headache, vision changes, or syncope develop (may indicate medication side effects or disease progression) STAT STAT ROUTINE","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Strict glycemic control (HbA1c &lt;7% or &lt;5.7% if prediabetes) to prevent progression; lifestyle modifications first - ROUTINE ROUTINE Alcohol cessation as alcohol independently causes and worsens small fiber neuropathy - ROUTINE ROUTINE Smoking cessation as smoking impairs nerve regeneration and worsens outcomes - ROUTINE ROUTINE Regular low-impact exercise (swimming, stationary bike, walking) to improve pain and maintain function - ROUTINE ROUTINE Healthy diet (Mediterranean or DASH) to optimize metabolic health and reduce inflammation - ROUTINE ROUTINE Weight management as metabolic syndrome is associated with SFN - ROUTINE ROUTINE Sleep hygiene to improve sleep quality; chronic pain worsens with poor sleep - ROUTINE ROUTINE Stress reduction techniques (mindfulness, meditation) as stress can amplify pain perception - ROUTINE ROUTINE Fall prevention with home safety evaluation given proprioceptive deficits and orthostatic hypotension - ROUTINE ROUTINE Avoid B6 (pyridoxine) supplementation above RDA (1.3-2 mg/day) as excess causes neuropathy - ROUTINE ROUTINE","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Diabetic polyneuropathy (large fiber) NCS abnormal; mixed sensorimotor findings; more numbness than pain EMG/NCS shows axonal polyneuropathy Fibromyalgia Widespread pain; tender points; normal skin biopsy; chronic fatigue ACR criteria; normal IENFD on skin biopsy Complex regional pain syndrome (CRPS) Regional rather than length-dependent; swelling, color changes, dystrophy Budapest criteria; regional distribution Erythromelalgia Intermittent burning with redness and warmth; triggered by heat; may have SCN9A mutation Clinical pattern; genetic testing if suspected Central sensitization syndromes Normal peripheral testing; pain out of proportion to objective findings QST pattern; skin biopsy normal Psychogenic/functional sensory symptoms Non-anatomical distribution; inconsistent findings; psychiatric comorbidity Careful neurological exam; normal objective testing Vitamin B12 deficiency May have subacute combined degeneration; cognitive changes; macrocytic anemia B12, MMA levels; MRI spine Lyme disease Endemic area; prior tick bite; rash history; may have radiculopathy Lyme serology (ELISA + Western blot) Hereditary sensory neuropathy (HSAN) Family history; anhidrosis; painless injuries; mutilating features Genetic testing (HSAN genes) Burning mouth syndrome Isolated to oral mucosa; taste changes; dry mouth Location-specific; oral exam Restless legs syndrome Urge to move legs; worse at rest/night; relief with movement Clinical criteria; may coexist with SFN Vasculitic neuropathy Asymmetric; mononeuritis multiplex pattern; systemic symptoms; rapid onset Nerve biopsy; inflammatory markers; angiography Paraneoplastic sensory ganglionopathy Subacute onset; asymmetric; non-length-dependent; cancer history/risk Anti-Hu antibodies; CT chest/abdomen/pelvis","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Pain scores (NRS, VAS, BPI) Each visit 50%+ reduction or functional improvement Adjust medications; consider combination or referral - ROUTINE ROUTINE - HbA1c (if diabetes/prediabetes) Every 3-6 months &lt;7% (or &lt;5.7% if prediabetes) Intensify glycemic management - ROUTINE ROUTINE - Orthostatic vitals (lying, sitting, standing) Each visit if autonomic symptoms SBP drop &lt;20 mmHg; no symptoms Adjust autonomic medications; hydration; compression STAT ROUTINE ROUTINE - Repeat skin biopsy (IENFD) Every 1-2 years if monitoring disease course Stable or improved IENFD Intensify etiology treatment if declining - - ROUTINE - Autonomic symptoms inventory Each visit Stable or improved Adjust autonomic treatments; workup new symptoms - ROUTINE ROUTINE - ECG Baseline if on TCAs or sodium channel blockers; periodically Normal PR, QRS, QTc intervals Dose reduction or discontinuation if prolonged intervals - ROUTINE ROUTINE - Renal function (eGFR) Every 6-12 months eGFR &gt;60 or stable Adjust medication doses; nephrology referral - ROUTINE ROUTINE - Potassium (if on fludrocortisone) Monthly initially, then every 3-6 months 3.5-5.0 mEq/L Supplement potassium; reduce fludrocortisone dose - ROUTINE ROUTINE - Weight and edema Each visit Stable weight; no edema Adjust pregabalin/gabapentin or autonomic meds - ROUTINE ROUTINE - Depression screen (PHQ-9) Every 6-12 months &lt;5 (no depression) Mental health referral; consider duloxetine/venlafaxine - ROUTINE ROUTINE - Falls assessment Each visit No falls PT referral; home safety; reduce sedating medications - ROUTINE ROUTINE -","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Symptoms stable; pain controlled; autonomic symptoms not causing hemodynamic instability; follow-up arranged Admit to floor Severe uncontrolled pain requiring IV medications; syncope from orthostatic hypotension; new diagnosis requiring urgent workup (suspected amyloidosis with cardiac involvement) Admit to ICU Hemodynamically unstable from autonomic dysfunction; severe symptomatic bradycardia or hypotension Outpatient follow-up Every 3-6 months for medication optimization; annually for etiology reassessment if initially idiopathic","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Skin biopsy (IENFD) as diagnostic standard for SFN Class II, Level B Lauria et al. European Journal of Neurology 2010 QSART for sudomotor function assessment in SFN Class II, Level B Low et al. Muscle &amp; Nerve 1983 Impaired glucose tolerance as cause of SFN Class II, Level B Singleton et al. Neurology 2001 Sjogren syndrome associated with SFN Class II, Level B Chai et al. Annals of Neurology 2005 Duloxetine for neuropathic pain Class I, Level A Lunn et al. Cochrane 2014 Gabapentin for neuropathic pain Class I, Level A Wiffen et al. Cochrane 2017 Pregabalin for neuropathic pain Class I, Level A Derry et al. Cochrane 2019 TCAs for neuropathic pain Class II, Level B Moore et al. Cochrane 2015 Fludrocortisone for orthostatic hypotension Class II, Level C Freeman et al. Neurology 2018 Consensus Statement Midodrine for orthostatic hypotension Class I, Level A Wright et al. Am Heart J 1998 Droxidopa for neurogenic orthostatic hypotension Class I, Level A Biaggioni et al. Neurology 2015 IVIG for autoimmune SFN Class III, Level C Liu et al. J Periph Nerv Syst 2014 Fabry disease as cause of SFN Class II, Level B Biegstraaten et al. Orphanet J Rare Dis 2012 TTR amyloidosis neuropathy treatment Class I, Level A Adams et al. NEJM 2018 (Patisiran trial) Sodium channelopathies (SCN9A) in SFN Class II, Level B Faber et al. Ann Neurol 2012","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive etiologic workup (diabetes, Sjogren's, amyloidosis, Fabry, celiac) - Diagnostic approach with skin biopsy and autonomic testing - Neuropathic pain treatment with structured dosing format - Autonomic symptom management section - Disease-modifying therapies for treatable causes - Differentiation of length-dependent vs non-length-dependent patterns</p>","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#appendix-a-sfn-diagnostic-criteria","title":"APPENDIX A: SFN Diagnostic Criteria","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#clinical-features-suggesting-sfn","title":"Clinical Features Suggesting SFN","text":"Symptom Category Examples Positive sensory symptoms Burning pain; electric shock sensations; tingling; allodynia; hyperalgesia Negative sensory symptoms Numbness; thermal hypoesthesia (can't feel hot/cold) Autonomic symptoms Dry eyes/mouth; sweating abnormalities; orthostatic intolerance; GI dysmotility; urinary dysfunction; erectile dysfunction Distribution Length-dependent (feet &gt; hands) OR non-length-dependent (patchy, proximal, asymmetric)","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#diagnostic-certainty-levels","title":"Diagnostic Certainty Levels","text":"Level Criteria Possible SFN Clinical symptoms and signs compatible with SFN Probable SFN Clinical features + abnormal QST thermal thresholds OR abnormal QSART Definite SFN Clinical features + reduced IENFD on skin biopsy below age/sex/site normative values","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#length-dependent-vs-non-length-dependent-ganglionopathy-pattern","title":"Length-Dependent vs Non-Length-Dependent (Ganglionopathy) Pattern","text":"Feature Length-Dependent Non-Length-Dependent Distribution Distal &gt; proximal; symmetric; feet before hands Patchy; asymmetric; proximal involvement; face/trunk Common causes Diabetes; metabolic; toxic; idiopathic Sjogren's; paraneoplastic; autoimmune; amyloidosis Prognosis Often slowly progressive May be more aggressive; depends on etiology Workup focus Metabolic causes Autoimmune and systemic causes","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#appendix-b-skin-biopsy-interpretation","title":"APPENDIX B: Skin Biopsy Interpretation","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#procedure","title":"Procedure","text":"<ul> <li>Sites: Distal leg (10 cm above lateral malleolus) and proximal thigh (20 cm below iliac spine)</li> <li>Technique: 3mm punch biopsy; send to laboratory with PGP9.5 immunostaining capability</li> <li>Processing: Fix in PLP or Zamboni's fixative; immunostain for PGP9.5</li> </ul>","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#interpretation","title":"Interpretation","text":"Result Interpretation IENFD below 5th percentile for age/sex/site Diagnostic of SFN IENFD at lower range of normal (5th-10th percentile) Borderline; correlate clinically Distal/proximal IENFD ratio &gt;2:1 Length-dependent pattern Both sites equally reduced Consider ganglionopathy or diffuse process Sweat gland nerve fiber density reduced Supports autonomic involvement","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#normative-values-approximate-use-laboratory-specific-norms","title":"Normative Values (Approximate - Use Laboratory-Specific Norms)","text":"Site Typical 5th Percentile Values Distal leg (age 20-40) ~8-9 fibers/mm Distal leg (age 60-80) ~4-5 fibers/mm Proximal thigh Generally higher than distal leg","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#appendix-c-autonomic-testing-interpretation","title":"APPENDIX C: Autonomic Testing Interpretation","text":"","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#qsart-quantitative-sudomotor-axon-reflex-test","title":"QSART (Quantitative Sudomotor Axon Reflex Test)","text":"Pattern Interpretation Reduced sweat volume at distal sites (foot) with normal proximal Length-dependent autonomic SFN Globally reduced sweat volumes Diffuse autonomic involvement Normal QSART Does not exclude SFN (may have sensory-predominant)","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#autonomic-reflex-screen-components","title":"Autonomic Reflex Screen Components","text":"Test What It Measures Abnormality in SFN QSART Postganglionic sudomotor function Reduced sweat volumes Heart rate variability Cardiovagal function Reduced HRV to deep breathing Valsalva maneuver Cardiovagal and adrenergic function Abnormal BP/HR response Tilt table test Adrenergic function; orthostatic tolerance Orthostatic hypotension or POTS","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/small-fiber-neuropathy/#pots-postural-orthostatic-tachycardia-syndrome-criteria","title":"POTS (Postural Orthostatic Tachycardia Syndrome) Criteria","text":"<ul> <li>HR increase \u226530 bpm (or \u226540 bpm if age 12-19) within 10 minutes of standing</li> <li>Absence of orthostatic hypotension (SBP drop &lt;20 mmHg)</li> <li>Symptoms of orthostatic intolerance</li> <li>Duration \u22656 months</li> </ul>","tags":["neuropathy","pain","autonomic","outpatient"]},{"location":"drafts/syncope-evaluation/","title":"Syncope Evaluation","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#syncope-evaluation","title":"Syncope Evaluation","text":"<p>DIAGNOSIS: Syncope and Collapse ICD-10: R55 (Syncope and collapse) ADDITIONAL ICD-10: T67.1 (Heat syncope), I95.1 (Orthostatic hypotension), G90.0 (Idiopathic peripheral autonomic neuropathy), G90.3 (Multi-system degeneration of ANS), R00.1 (Bradycardia), I49.9 (Cardiac arrhythmia, unspecified), F48.8 (Psychogenic syncope) CLINICAL SYNONYMS: Fainting, passing out, blackout, loss of consciousness, LOC, vasovagal episode, neurocardiogenic syncope, vasodepressor syncope, reflex syncope SCOPE: Comprehensive evaluation of transient loss of consciousness (TLOC) due to cerebral hypoperfusion. Covers vasovagal/reflex syncope, orthostatic hypotension, cardiac arrhythmias, and neurologic mimics. Includes risk stratification, diagnostic workup, and management. Excludes seizure-related loss of consciousness (see Seizure plan), stroke, and metabolic causes of altered mental status.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU ECG (12-lead) Rule out arrhythmia, conduction abnormality, ischemia, cardiomyopathy (prolonged QT, Brugada, WPW, ARVC) Normal sinus rhythm; QTc &lt;450 ms (M), &lt;460 ms (F); no preexcitation or Brugada pattern STAT STAT ROUTINE STAT Glucose (fingerstick or serum) Rule out hypoglycemia as cause of altered consciousness Normal (70-100 mg/dL) STAT STAT ROUTINE STAT CBC Evaluate for anemia causing reduced oxygen delivery; infection Hgb &gt;12 g/dL; no leukocytosis STAT STAT ROUTINE STAT BMP Electrolyte abnormalities can cause arrhythmias or contribute to syncope Normal Na, K, Mg, Ca, glucose, creatinine STAT STAT ROUTINE STAT Troponin Cardiac ischemia as cause of syncope; elevated in PE, aortic dissection Negative (&lt;0.04 ng/mL or institution-specific) STAT STAT - STAT Orthostatic vital signs Diagnose orthostatic hypotension (BP drop &gt;20/10 mmHg or HR increase &gt;30 bpm) No significant change; BP stable within 3 min of standing STAT STAT ROUTINE -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU BNP or NT-proBNP Screen for heart failure; elevated in cardiac syncope BNP &lt;100 pg/mL; NT-proBNP &lt;300 pg/mL URGENT URGENT ROUTINE URGENT D-dimer Pulmonary embolism suspected (consider Wells score) &lt;500 ng/mL (age-adjusted: age x 10 if &gt;50 yo) URGENT URGENT - URGENT TSH Thyroid dysfunction contributing to arrhythmias or autonomic dysfunction Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE - Magnesium Hypomagnesemia can precipitate arrhythmias Normal (1.7-2.2 mg/dL) URGENT ROUTINE ROUTINE URGENT Lactic acid Tissue hypoperfusion; consider if prolonged LOC or concern for cardiogenic shock Normal (&lt;2.0 mmol/L) URGENT URGENT - URGENT Pregnancy test (urine or serum) Ectopic pregnancy can present with syncope; all reproductive-age women Negative (unless known pregnancy) STAT STAT ROUTINE STAT","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Plasma catecholamines (supine and standing) Autonomic failure workup; pure autonomic failure vs MSA Normal increase with standing; absence suggests autonomic failure - EXT EXT - Cortisol (AM) Adrenal insufficiency causing orthostatic hypotension &gt;10 mcg/dL (AM); consider ACTH stim test if borderline - EXT EXT - Prolactin (within 20 min of event) Distinguish seizure from syncope; elevated post-ictally Normal (&lt;20 ng/mL); &gt;2x baseline suggests seizure STAT STAT - - HbA1c Screen for diabetes contributing to autonomic neuropathy &lt;5.7% (normal); diabetic autonomic neuropathy if elevated with symptoms - ROUTINE ROUTINE - Genetic testing (SCN5A, KCNQ1, KCNH2) Long QT syndrome, Brugada syndrome suspected No pathogenic variant - - EXT - Autoimmune panel (ganglionic AChR Ab, GAD65) Autoimmune autonomic ganglionopathy suspected Negative - EXT EXT -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Continuous cardiac monitoring (telemetry) Ongoing in ED/hospital No arrhythmia detected None STAT STAT - STAT Echocardiogram (TTE) If structural heart disease suspected, abnormal ECG, cardiac murmur, or high-risk features Normal LV function (EF &gt;50%); no structural abnormality None URGENT URGENT ROUTINE URGENT CT Head non-contrast Head trauma from fall; focal neurological deficits; concern for SAH No hemorrhage, mass, or acute abnormality Pregnancy (relative) STAT URGENT - STAT Chest X-ray Cardiac silhouette, pulmonary edema, widened mediastinum (dissection) Normal heart size; clear lungs None URGENT ROUTINE - URGENT","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CTA Chest Pulmonary embolism suspected (high Wells score, elevated D-dimer) No PE; patent pulmonary arteries Contrast allergy, CKD (eGFR &lt;30) STAT STAT - STAT Holter monitor (24-48 hour) Recurrent syncope; arrhythmia suspected but not captured No significant arrhythmia; correlate with symptoms None - ROUTINE ROUTINE - Event recorder (30 days) Infrequent syncope (monthly); need longer monitoring Symptom-rhythm correlation None - - ROUTINE - Insertable loop recorder (ILR) Recurrent unexplained syncope despite workup; infrequent events Diagnose arrhythmia at time of syncope None (minor procedure) - - ROUTINE - Tilt table testing Suspected vasovagal syncope with unclear diagnosis; recurrent syncope affecting QOL Positive (reproduces symptoms with hypotension/bradycardia); or negative excluding reflex syncope Recent MI, severe aortic stenosis, severe CAD - EXT ROUTINE - Carotid ultrasound Syncope with head rotation; carotid bruit No significant stenosis (&gt;70%); no hypersensitivity None - ROUTINE ROUTINE - Stress testing (exercise or pharmacologic) Exertional syncope; ischemia suspected No ischemia; normal BP response Unstable angina, uncontrolled arrhythmia - URGENT ROUTINE -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU EEG (routine or ambulatory) Seizure vs syncope uncertain; convulsive movements reported; prolonged confusion Normal; no epileptiform discharges None - ROUTINE ROUTINE - MRI Brain Neurological symptoms; focal deficits; posterior circulation insufficiency suspected Normal; no structural abnormality MRI-incompatible devices, severe claustrophobia - URGENT ROUTINE - Autonomic function testing (QSART, HRV, Valsalva) Orthostatic hypotension; suspected autonomic neuropathy or failure Normal autonomic responses Recent MI, uncontrolled HTN - - EXT - Electrophysiology study (EPS) High-risk structural heart disease; non-diagnostic workup; suspected Brugada No inducible arrhythmia Anticoagulation issues, active infection - - EXT - Carotid sinus massage Syncope with head turning or tight collars; age &gt;40; after ruling out carotid stenosis No pause &gt;3 sec; no BP drop &gt;50 mmHg Carotid bruit, recent stroke/TIA, carotid stenosis - ROUTINE ROUTINE - Cardiac MRI Arrhythmogenic cardiomyopathy (ARVC) suspected; infiltrative disease No fibrosis, fat infiltration, or structural abnormality MRI contraindications; CKD for gadolinium - - EXT - Exercise tilt test Exercise-induced syncope with negative standard testing No abnormal response Same as tilt table and exercise testing - - EXT -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#3-treatment","title":"3. TREATMENT","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IV Normal Saline IV Volume depletion; orthostatic hypotension; vagal syncope recovery 500 mL IV bolus; 1000 mL IV bolus; 125 mL/hr IV :: IV :: :: 500-1000 mL bolus for acute syncope; maintenance if dehydrated Heart failure; volume overload Intake/output; signs of overload; reassess orthostatics STAT STAT - STAT Atropine IV Symptomatic bradycardia causing syncope 0.5 mg IV push; 1 mg IV push :: IV :: :: 0.5-1 mg IV push; may repeat q3-5min; max 3 mg total Tachyarrhythmia; glaucoma HR, BP, rhythm STAT STAT - STAT Transcutaneous pacing External Symptomatic bradycardia unresponsive to atropine 60-80 mA; adjust for capture :: External :: :: Start 60 mA, increase until capture; rate 60-80 bpm Pacemaker in place (relative); conscious patient (sedate first) Capture confirmation; BP; sedation level STAT STAT - STAT Trendelenburg position Physical Immediate management of acute syncope Supine with legs elevated :: Physical :: :: Elevate legs 30-45 degrees; maintain until fully recovered Respiratory distress; increased ICP Mental status; BP recovery STAT STAT - STAT Epinephrine IV/IM Anaphylaxis causing syncope 0.3 mg IM; 0.5 mg IM; 0.1 mg IV :: IM/IV :: :: 0.3-0.5 mg IM (1:1000); 0.1 mg IV (1:10,000) for severe Uncontrolled hypertension (relative in anaphylaxis) HR, BP, symptoms STAT STAT - STAT Glucagon IV/IM Beta-blocker or calcium channel blocker toxicity causing bradycardia/hypotension 3-5 mg IV; 10 mg IV :: IV :: :: 3-10 mg IV bolus; may follow with infusion 1-5 mg/hr Pheochromocytoma; insulinoma Glucose, BP, HR, nausea STAT STAT - STAT","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Compression stockings (30-40 mmHg) Physical Orthostatic hypotension; vasovagal syncope prophylaxis Waist-high preferred :: Physical :: :: 30-40 mmHg compression; waist-high more effective than knee-high; wear during daytime Peripheral vascular disease; skin ulcers Skin integrity; compliance; symptom frequency - ROUTINE ROUTINE - Increased salt intake Dietary Orthostatic hypotension; recurrent vasovagal syncope (no contraindication) 6-10 g Na/day :: Dietary :: :: Increase to 6-10 g sodium daily (salt tablets 1 g TID or dietary salt) Heart failure; uncontrolled HTN; CKD BP; weight; edema; syncope frequency - ROUTINE ROUTINE - Increased fluid intake Dietary Orthostatic hypotension; volume depletion 2-3 L/day :: Dietary :: :: 2-3 L daily fluid intake; bolus 500 mL water prior to prolonged standing Heart failure; fluid restriction needed Volume status; electrolytes URGENT ROUTINE ROUTINE - Physical counterpressure maneuvers Physical Prodromal symptoms of vasovagal syncope Perform at onset of prodrome :: Physical :: :: Leg crossing with tensing; handgrip; arm tensing; squat; abort 30% of episodes None Symptom diary; effectiveness URGENT ROUTINE ROUTINE - Head-of-bed elevation Physical Orthostatic hypotension; supine hypertension 10-20 degree elevation :: Physical :: :: Elevate head of bed 10-20 degrees (4-6 inch blocks); reduces nocturnal natriuresis None Morning BP; symptom frequency - ROUTINE ROUTINE -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Midodrine PO Orthostatic hypotension refractory to non-pharmacologic measures 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5-5 mg TID (q4h while upright); titrate to 10 mg TID; last dose 4 hrs before bed Supine HTN; urinary retention; severe heart disease; pheochromocytoma Supine BP (avoid &gt;180/100); urinary symptoms - ROUTINE ROUTINE - Fludrocortisone PO Orthostatic hypotension; volume expansion needed 0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2-0.3 mg daily; takes 1-2 weeks for effect Heart failure; uncontrolled HTN; hypokalemia K+; supine BP; weight; edema - ROUTINE ROUTINE - Droxidopa (Northera) PO Neurogenic orthostatic hypotension (autonomic failure, Parkinson's) 100 mg TID; 200 mg TID; 300 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg TID q24-48h; max 600 mg TID Supine HTN; concomitant catecholamine drugs Supine BP; syncope frequency - - ROUTINE - Pyridostigmine PO Orthostatic hypotension with intact post-ganglionic neurons 30 mg TID; 60 mg TID :: PO :: :: 30-60 mg PO TID; enhances ganglionic transmission Bowel/bladder obstruction; bradycardia GI side effects; HR - - ROUTINE - Atomoxetine PO Neurogenic orthostatic hypotension (off-label) 10 mg daily; 18 mg BID :: PO :: :: 10-18 mg BID; norepinephrine reuptake inhibitor MAOIs; narrow-angle glaucoma; pheochromocytoma BP; HR; urinary retention - - EXT - Beta-blocker (low-dose) PO Vasovagal syncope with prominent cardioinhibitory component (controversial) Metoprolol 25 mg BID; Atenolol 25 mg daily :: PO :: :: Low-dose beta-blocker (metoprolol 25 mg BID or atenolol 25 mg daily); limited evidence Bradycardia; hypotension; asthma; 2nd/3rd degree AVB HR; BP; syncope frequency - - EXT - SSRI (paroxetine, sertraline) PO Recurrent vasovagal syncope refractory to first-line measures Paroxetine 20 mg daily; Sertraline 50 mg daily :: PO :: :: Paroxetine 20 mg daily or sertraline 50 mg daily; may modulate autonomic response MAOIs; uncontrolled bipolar Mood; syncope frequency - - EXT -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#3d-disease-modifying-or-chronic-therapies","title":"3D. Disease-Modifying or Chronic Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Permanent pacemaker Implant Cardioinhibitory syncope with documented asystole &gt;3 sec or symptomatic bradycardia Dual-chamber preferred :: Implant :: :: Dual-chamber pacemaker (DDD) for sinus node dysfunction; VVI/DDD for AV block EPS, Holter showing bradyarrhythmia, tilt-positive cardioinhibitory Active infection; coagulopathy Device interrogation q6-12mo; wound healing - - ROUTINE - Implantable cardioverter-defibrillator (ICD) Implant Syncope with structural heart disease and high sudden death risk Per device type :: Implant :: :: Single or dual chamber ICD based on indication EF assessment, risk stratification completed Active infection; terminal illness Device interrogation; driving restrictions - - ROUTINE - Catheter ablation Procedure Documented arrhythmia causing syncope (SVT, VT, WPW) Ablation of arrhythmia focus :: Procedure :: :: EP study with ablation of identified arrhythmia substrate EP study identifying arrhythmia Active infection; coagulopathy Post-procedure rhythm monitoring - - ROUTINE - Cardioneuroablation Procedure Refractory cardioinhibitory syncope with documented asystole Ablation of vagal ganglia :: Procedure :: :: Catheter-based ablation of cardiac vagal ganglia; emerging therapy Failed conservative management Limited availability; investigational HR variability; syncope recurrence - - EXT -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Cardiology consultation for arrhythmia evaluation, structural heart disease assessment, or device implantation consideration URGENT URGENT ROUTINE URGENT Electrophysiology referral for documented arrhythmias requiring ablation, pacemaker or ICD evaluation, or unexplained high-risk syncope - ROUTINE ROUTINE - Neurology consultation if seizure-syncope differentiation unclear, autonomic testing needed, or neurological symptoms present URGENT ROUTINE ROUTINE - Autonomic disorders specialist for recurrent orthostatic hypotension, suspected pure autonomic failure, or multiple system atrophy - - ROUTINE - Driving evaluation per state regulations for commercial drivers or recurrent unexplained syncope affecting driving ability - - ROUTINE - Psychiatry referral if psychogenic pseudosyncope suspected based on atypical features and normal workup - ROUTINE ROUTINE - Fall prevention physical therapy for elderly patients with recurrent syncope to reduce injury risk - ROUTINE ROUTINE - Occupational health evaluation for patients in safety-sensitive occupations (pilots, heavy machinery operators, commercial drivers) - - ROUTINE -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if syncope recurs, especially with chest pain, palpitations, shortness of breath, or exercise (may indicate cardiac cause requiring urgent evaluation) STAT - ROUTINE Return immediately if prolonged confusion, seizure activity, tongue biting, or urinary incontinence occurs with loss of consciousness (suggests seizure rather than syncope) STAT - ROUTINE Do NOT drive until cleared by physician due to risk of syncope while operating a vehicle; specific restrictions depend on diagnosis and state law URGENT ROUTINE ROUTINE Avoid prolonged standing, hot environments, and dehydration which are common triggers for vasovagal syncope URGENT ROUTINE ROUTINE Learn to recognize prodromal symptoms (lightheadedness, warmth, nausea, tunnel vision) and immediately sit or lie down to prevent injury URGENT ROUTINE ROUTINE Perform physical counterpressure maneuvers (leg crossing, squatting, handgrip) at first sign of prodrome to abort vasovagal episode URGENT ROUTINE ROUTINE Rise slowly from lying to sitting to standing (staged position changes) to prevent orthostatic syncope URGENT ROUTINE ROUTINE Maintain adequate hydration (2-3 L daily) and salt intake (unless contraindicated) to support blood volume ROUTINE ROUTINE ROUTINE Keep a symptom diary noting triggers, prodrome, circumstances, duration of LOC, and recovery to aid diagnosis - ROUTINE ROUTINE Wear medical alert identification if recurrent syncope diagnosis confirmed - - ROUTINE","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Avoid known triggers including prolonged standing, crowded/hot environments, excessive alcohol, and large meals URGENT ROUTINE ROUTINE Increase oral fluid intake to 2-3 liters daily to maintain intravascular volume and reduce syncope frequency URGENT ROUTINE ROUTINE Increase dietary salt intake to 6-10 g/day if no contraindication (hypertension, heart failure, CKD) to expand plasma volume - ROUTINE ROUTINE Wear waist-high compression stockings (30-40 mmHg) during daytime to reduce venous pooling - ROUTINE ROUTINE Avoid sudden postural changes; use staged position changes (lie-sit-stand with 1-2 min at each stage) URGENT ROUTINE ROUTINE Review and minimize medications that contribute to hypotension (diuretics, antihypertensives, alpha-blockers, nitrates, psychiatric medications) URGENT ROUTINE ROUTINE Avoid excessive heat exposure including hot showers, saunas, and hot tubs which cause vasodilation - ROUTINE ROUTINE Sleep with head of bed elevated 10-20 degrees to reduce nocturnal natriuresis and improve morning orthostatic tolerance - ROUTINE ROUTINE Moderate regular aerobic exercise to improve vascular tone and reduce vasovagal susceptibility; avoid deconditioning - ROUTINE ROUTINE Alcohol moderation or avoidance as alcohol causes vasodilation and impairs autonomic reflexes - ROUTINE ROUTINE","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Vasovagal (neurocardiogenic) syncope Prodrome (warmth, nausea, diaphoresis, tunnel vision); identifiable trigger (prolonged standing, pain, emotional stress); rapid recovery History; tilt table testing reproduces symptoms Orthostatic hypotension Syncope immediately upon standing; BP drop &gt;20/10 mmHg within 3 min of standing; associated with medications, volume depletion, or autonomic failure Orthostatic vital signs; autonomic function testing Cardiac arrhythmia (tachy or brady) Sudden onset without prodrome; palpitations; associated with exertion or supine position; abnormal ECG ECG; Holter; event recorder; EP study Structural heart disease (AS, HCM, PE) Exertional syncope; murmur; dyspnea; chest pain; signs of right heart failure (PE) Echo; CT chest (PE); cardiac MRI Situational syncope Occurs with specific triggers: micturition, defecation, cough, swallow History is diagnostic; occurs during or immediately after trigger activity Carotid sinus hypersensitivity Syncope with head turning, shaving, tight collars; age &gt;40; male predominance Carotid sinus massage (after excluding stenosis) Seizure (convulsive syncope mimic) Tonic-clonic movements; lateral tongue bite; prolonged confusion (&gt;5 min); urinary incontinence; no prodrome EEG; prolactin (within 20 min); witnessed description Psychogenic pseudosyncope Very frequent episodes; prolonged duration; eyes closed; no injury; normal exam during event Normal testing during observed episode; psychiatric evaluation Hypoglycemia Associated with diabetes or insulin use; diaphoresis; hunger; confusion; responds to glucose Fingerstick glucose; witnessed glucose administration Vertebrobasilar insufficiency Associated with head movement, vertigo, diplopia, dysarthria, drop attacks MRA head/neck; vertebral Doppler Subclavian steal syndrome Arm exercise triggers; BP difference &gt;20 mmHg between arms; vertebrobasilar symptoms Bilateral arm BPs; subclavian Doppler; angiography Pulmonary embolism Dyspnea; pleuritic chest pain; unilateral leg swelling; tachycardia; hypoxia D-dimer; CTA chest; Wells score Aortic dissection Tearing chest/back pain; BP difference between arms; widened mediastinum CT angiography; TEE Ruptured AAA Abdominal or back pain; pulsatile mass; hypotension; older patient CT abdomen; bedside ultrasound Subarachnoid hemorrhage Thunderclap headache; neck stiffness; altered mental status; may have syncope at onset CT head; lumbar puncture if CT negative","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Continuous cardiac telemetry Continuous while admitted No significant arrhythmia Capture rhythm strips; cardiology consult for significant arrhythmia STAT STAT - STAT Orthostatic vital signs Q8H in hospital; each clinic visit BP drop &lt;20/10 mmHg; HR increase &lt;30 bpm Optimize volume; review medications; consider pharmacotherapy STAT ROUTINE ROUTINE - Syncope recurrence Each encounter No recurrence Reassess diagnosis; consider advanced testing (ILR) STAT ROUTINE ROUTINE - ECG intervals (QTc, PR, QRS) Baseline; with QT-prolonging drugs QTc &lt;500 ms; PR &lt;300 ms; QRS &lt;120 ms Discontinue offending drugs; cardiology evaluation STAT ROUTINE ROUTINE STAT Fall risk assessment Each encounter Low risk PT evaluation; home safety assessment; assistive devices URGENT ROUTINE ROUTINE - Injury from falls Each encounter No injury Head imaging if concern for intracranial injury STAT ROUTINE ROUTINE STAT Medication reconciliation Each encounter No offending medications Reduce/discontinue hypotensive medications URGENT ROUTINE ROUTINE - Driving status Each visit Cleared per guidelines Document restrictions; report to DMV if required - ROUTINE ROUTINE - Response to treatment (midodrine, fludrocortisone) 2-4 weeks after initiation Improved orthostatic tolerance; reduced syncope Dose adjustment; alternative therapy - - ROUTINE -","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Low-risk features: isolated vasovagal syncope with clear trigger, normal ECG, normal cardiac exam, no significant injury, reliable follow-up; San Francisco Syncope Rule negative OR Canadian Syncope Risk Score very low/low risk Observation (ED or short stay) Intermediate risk: unexplained syncope with normal initial workup; awaiting troponin results; awaiting echocardiogram; single syncopal episode without high-risk features Admit to floor High-risk features: abnormal ECG, structural heart disease, heart failure, exertional syncope, syncope causing significant injury, recurrent syncope of unclear etiology, syncope with chest pain or dyspnea Admit to ICU/monitored bed Very high-risk: hemodynamic instability, documented malignant arrhythmia, syncope with ongoing ischemia, severe bradycardia requiring pacing, PE with hypotension Outpatient follow-up Low-risk syncope discharged from ED: cardiology/neurology follow-up within 1-2 weeks; recurrent vasovagal syncope: 2-4 weeks; post-device implantation: per device protocol","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Canadian Syncope Risk Score for ED risk stratification Class I, Level B Thiruganasambandamoorthy et al. CMAJ 2016 San Francisco Syncope Rule validation Class II, Level B Quinn et al. Ann Emerg Med 2004 Tilt table testing for vasovagal syncope diagnosis Class IIa, Level B Sheldon et al. Circulation 2015 Physical counterpressure maneuvers reduce syncope recurrence Class I, Level B van Dijk et al. Circulation 2006 Midodrine for orthostatic hypotension Class I, Level A Izcovich et al. Heart 2014 Fludrocortisone for orthostatic hypotension Class IIa, Level B Sheldon et al. Circulation 2015 Droxidopa for neurogenic orthostatic hypotension Class I, Level A Kaufmann et al. Neurology 2014 Pacemaker for cardioinhibitory carotid sinus syndrome Class I, Level B Brignole et al. Eur Heart J 2018 ILR superior to conventional testing for unexplained syncope Class I, Level A Krahn et al. Circulation 2001 POST trial: beta-blockers ineffective for vasovagal syncope Class I, Level A Sheldon et al. Circulation 2006 ESC Guidelines on syncope diagnosis and management Consensus Brignole et al. Eur Heart J 2018 ACC/AHA/HRS Guidelines on bradycardia and pacing Consensus Kusumoto et al. Circulation 2019 Compression stockings reduce orthostatic intolerance Class IIa, Level B Figueroa et al. Neurology 2015 Autonomic testing in orthostatic hypotension Class IIa, Level C Freeman et al. Neurology 2011 Seizure vs syncope differentiation: prolactin levels Class II, Level B Chen et al. Neurology 2005 Driving restrictions after syncope Consensus Epstein et al. J Am Coll Cardiol 2007","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of syncope evaluation including vasovagal, orthostatic, and cardiac etiologies - San Francisco Syncope Rule and Canadian Syncope Risk Score included in disposition criteria - Tilt table testing and autonomic function testing indications - EEG indications for seizure vs syncope differentiation - Driving restriction guidance - Structured dosing format for order sentence generation - PubMed-verified citations</p>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#appendix-a-risk-stratification-tools","title":"APPENDIX A: Risk Stratification Tools","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#san-francisco-syncope-rule-sfsr","title":"San Francisco Syncope Rule (SFSR)","text":"<p>Purpose: Identify patients at risk for serious outcomes within 30 days</p> <p>High-risk features (any one = high risk): - C - Congestive heart failure history - H - Hematocrit &lt;30% - E - ECG abnormality (non-sinus rhythm or new changes) - S - Shortness of breath - S - Systolic BP &lt;90 mmHg at any time</p> <p>Interpretation: - No criteria present = Low risk (~2% 7-day serious outcome) - Any criteria present = High risk (~15-25% serious outcome); consider admission</p> <p>Sensitivity: 96-98% for serious outcomes</p>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#canadian-syncope-risk-score-csrs","title":"Canadian Syncope Risk Score (CSRS)","text":"<p>Purpose: More precise risk stratification than SFSR; validated for 30-day serious outcomes</p> <p>Score Calculation:</p> Variable Points Predisposition to vasovagal symptoms -1 Heart disease history or elevated BNP +1 Any systolic BP reading &lt;90 or &gt;180 mmHg +2 Troponin elevated (&gt;99th percentile ULN) +2 Abnormal QRS axis (&lt;-30 or &gt;100 degrees) +1 QRS duration &gt;130 ms +1 QTc &gt;480 ms +2 ED diagnosis of cardiac syncope +2 ED diagnosis of vasovagal syncope -2 <p>Risk Categories:</p> Score Risk Category 30-day Serious Outcome -3 to -2 Very Low 0.4% -1 to 0 Low 1.2% 1 to 3 Medium 3.1% 4 to 5 High 9.5% 6 to 11 Very High 28.9% <p>Management Guidance: - Very Low/Low: Consider discharge with outpatient follow-up - Medium: Consider ED observation or short stay - High/Very High: Admission for monitoring and evaluation</p>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#red-flags-requiring-urgent-evaluation","title":"Red Flags Requiring Urgent Evaluation","text":"Category Concerning Features History Exertional syncope; supine syncope; syncope without prodrome; palpitations immediately before event; family history of sudden death &lt;50 yo Cardiac Known structural heart disease; heart failure; prior MI; aortic stenosis murmur; ICD shocks ECG Long QT (&gt;480 ms); short QT (&lt;340 ms); Brugada pattern; delta wave (WPW); epsilon wave (ARVC); AV block; wide QRS; new ischemia Event Significant injury requiring treatment; syncope while driving; recurrent episodes (&gt;3/year)","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#appendix-b-seizure-vs-syncope-differentiation","title":"APPENDIX B: Seizure vs Syncope Differentiation","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#clinical-features-comparison","title":"Clinical Features Comparison","text":"Feature Syncope Seizure Trigger Usually present (standing, pain, heat) Usually absent (except photosensitive or reflex) Prodrome Common (lightheadedness, warmth, nausea, vision change) Rare; may have aura (olfactory, gustatory, deja vu) Duration of LOC Brief (&lt;30 seconds typically) Variable (30 sec to minutes) Movements during May have brief myoclonic jerks (convulsive syncope) Sustained tonic-clonic activity; rhythmic Timing of movements After falling (due to hypoperfusion) From onset or within seconds Eye position Closed or rolling up Open; deviated or staring Tongue bite Rare; tip if present Lateral tongue laceration (highly specific) Urinary incontinence Occasionally Common Post-event confusion Brief (&lt;30 seconds) Prolonged (minutes to hours) Post-event fatigue Mild Profound; may sleep for hours Pallor Prominent before and during Usually absent Cyanosis Absent (initially pale) May be present Memory of event Recalls prodrome; brief LOC Amnesia for ictus; may recall aura","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#diagnostic-testing","title":"Diagnostic Testing","text":"Test Findings Suggesting Seizure Prolactin &gt;2x baseline if drawn within 20 minutes of event (sensitivity ~60%) CK Elevated 12-24 hours post-event if generalized tonic-clonic EEG Epileptiform discharges (spikes, sharp waves, spike-wave) MRI Brain Structural lesion; mesial temporal sclerosis; cortical dysplasia","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#convulsive-syncope-fainting-with-twitching","title":"Convulsive Syncope (\"Fainting with Twitching\")","text":"<ul> <li>Occurs in up to 10-15% of syncope episodes</li> <li>Brief myoclonic jerks due to cerebral hypoperfusion</li> <li>Typically &lt;30 seconds, less rhythmic than seizure</li> <li>Rapid recovery without prolonged confusion</li> <li>Does NOT require anticonvulsant treatment</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#appendix-c-driving-restrictions-after-syncope","title":"APPENDIX C: Driving Restrictions After Syncope","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#general-principles","title":"General Principles","text":"<ul> <li>Regulations vary by state/country</li> <li>Distinction between private and commercial drivers</li> <li>Must consider underlying etiology and treatment status</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#private-drivers-non-commercial","title":"Private Drivers (Non-Commercial)","text":"Diagnosis Typical Restriction Resume When Vasovagal syncope (single episode) Usually none Prodrome present; avoidable trigger identified Vasovagal syncope (recurrent) Variable 3-12 months symptom-free; effective prevention Unexplained syncope 6-12 months Diagnosis established or 6-12 months event-free Cardiac syncope (arrhythmia) Until treated Successful treatment (ablation, pacemaker, ICD); typically 1 week to 6 months Cardiac syncope (structural) Until treated Surgical repair; stable on treatment Orthostatic hypotension Variable Controlled on treatment; no syncope without prodrome","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#commercial-drivers-cdl-pilots-heavy-equipment","title":"Commercial Drivers (CDL, Pilots, Heavy Equipment)","text":"<ul> <li>More stringent restrictions apply</li> <li>Often require specialist clearance</li> <li>May require symptom-free period of 1-5 years</li> <li>Unexplained syncope often disqualifies from commercial driving</li> <li>Must report to appropriate regulatory agency</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#documentation-requirements","title":"Documentation Requirements","text":"<ul> <li>Document counseling about driving restrictions in medical record</li> <li>Provide written instructions to patient</li> <li>Some jurisdictions require mandatory reporting to DMV</li> <li>Consider medical alert bracelet for frequent episodes</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#appendix-d-tilt-table-testing-protocol","title":"APPENDIX D: Tilt Table Testing Protocol","text":"","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#indications","title":"Indications","text":"<ul> <li>Recurrent unexplained syncope affecting quality of life</li> <li>Single syncopal episode in high-risk setting (injury, driving, occupational hazard)</li> <li>Confirm diagnosis of vasovagal syncope when history equivocal</li> <li>Evaluate efficacy of treatment in recurrent reflex syncope</li> <li>Differentiate delayed orthostatic hypotension from reflex syncope</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#contraindications","title":"Contraindications","text":"<ul> <li>Recent MI or unstable angina (&lt;30 days)</li> <li>Severe aortic stenosis</li> <li>Severe proximal coronary artery disease</li> <li>Severe mitral stenosis</li> <li>Known severe cerebrovascular disease</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#protocol-italian-protocol-most-common","title":"Protocol (Italian Protocol Most Common)","text":"<ol> <li>Baseline: Patient supine for 5-20 minutes; establish baseline BP and HR</li> <li>Passive phase: Tilt to 60-70 degrees for 20-45 minutes</li> <li>Drug provocation (if passive phase negative):</li> <li>Isoproterenol: 1-3 mcg/min IV while tilted</li> <li>OR Nitroglycerin: 300-400 mcg sublingual while tilted</li> <li>Positive response: Reproduce syncope with hypotension and/or bradycardia</li> <li>Return to supine immediately upon positive response or symptoms</li> </ol>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#response-types","title":"Response Types","text":"Type Hemodynamic Pattern Type 1 (Mixed) HR falls but not &lt;40 bpm for &gt;10 sec; BP falls before HR Type 2A (Cardioinhibitory without asystole) HR &lt;40 bpm for &gt;10 sec; asystole &lt;3 sec Type 2B (Cardioinhibitory with asystole) Asystole &gt;3 sec; BP drop follows or occurs with HR drop Type 3 (Vasodepressor) HR doesn't fall &gt;10% from peak; BP falls causing syncope","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/syncope-evaluation/#treatment-implications","title":"Treatment Implications","text":"<ul> <li>Vasodepressor (Type 3): Lifestyle modifications; compression stockings; hydration/salt; consider midodrine</li> <li>Cardioinhibitory with asystole (Type 2B): Consider pacemaker if recurrent and refractory</li> <li>Mixed (Type 1): Lifestyle modifications first; pharmacotherapy rarely needed</li> </ul>","tags":["syncope","loss-of-consciousness","vasovagal","cardiac","autonomic","emergency","outpatient"]},{"location":"drafts/tardive-dyskinesia/","title":"Tardive Dyskinesia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#tardive-dyskinesia","title":"Tardive Dyskinesia","text":"<p>DIAGNOSIS: Tardive Dyskinesia ICD-10: G24.01 (Drug-induced tardive dyskinesia); G24.02 (Drug-induced acute dystonia); G24.09 (Drug-induced dystonia, unspecified) SYNONYMS: TD, tardive syndrome, tardive movement disorder, persistent tardive syndrome SCOPE: Diagnosis confirmation, severity assessment using AIMS, identification of causative agents, risk factor evaluation, FDA-approved VMAT2 inhibitor therapy, antipsychotic management strategies, prevention, and psychiatric coordination. Covers classic orofacial-lingual TD, tardive dystonia, tardive akathisia, and tardive stereotypy.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CMP (comprehensive metabolic panel) Baseline renal/hepatic function before VMAT2 inhibitor therapy; electrolyte abnormalities can worsen movements Normal STAT ROUTINE ROUTINE STAT CBC with differential Baseline for medication monitoring; rule out infection if acute change Normal STAT ROUTINE ROUTINE STAT TSH Thyroid dysfunction can cause or exacerbate movement disorders Normal (0.4-4.0 mIU/L) URGENT ROUTINE ROUTINE - Medication and dose history review Identify causative agent(s): antipsychotics, metoclopramide, prochlorperazine, other dopamine blockers Document agent, duration, cumulative dose STAT ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Ceruloplasmin, serum copper Rule out Wilson's disease if age &lt;50 or atypical presentation Normal - EXT ROUTINE - 24-hour urine copper Wilson's disease confirmation if ceruloplasmin low or borderline &lt;100 \u03bcg/24hr - - EXT - Vitamin B12, folate Deficiency can cause movement disorders Normal - ROUTINE ROUTINE - Iron studies (ferritin, serum iron, TIBC) Rule out brain iron accumulation disorders Normal - EXT ROUTINE - CK (creatine kinase) If concern for neuroleptic malignant syndrome or severe dystonia Normal STAT STAT - STAT Antipsychotic drug level Assess compliance and toxicity if indicated Therapeutic range - ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Huntington disease genetic testing (HTT CAG repeats) Chorea with psychiatric history; family history &lt;36 CAG repeats (normal) - - EXT - Acanthocyte smear Neuroacanthocytosis if orofacial dyskinesia with chorea Negative - - EXT - Paraneoplastic antibody panel Atypical movement disorder; occult malignancy; autoimmune chorea Negative - EXT EXT - Anti-NMDA receptor antibodies Young patient; psychiatric symptoms; orofacial dyskinesia Negative - EXT EXT - SLC6A3 genetic testing (DAT-1) Research; consider if dopamine transporter dysfunction suspected Normal - - EXT -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU AIMS (Abnormal Involuntary Movement Scale) At evaluation; before treatment; q3-6 months on antipsychotics Document baseline severity (0-4 scale per item; total score) None URGENT ROUTINE ROUTINE - Clinical examination (orofacial, trunk, limbs) At evaluation Characterize movement type, distribution, severity None STAT ROUTINE ROUTINE - Video documentation At baseline and follow-up Record for comparison; share with psychiatry Patient consent - ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain Atypical presentation; focal findings; rule out structural lesion Normal or chronic dopaminergic medication changes MRI-incompatible devices URGENT ROUTINE ROUTINE - DaTscan (ioflupane I-123) Differentiate from Parkinson's disease or Huntington's if uncertain Normal or mild reduction (dopamine blockers can affect) Iodine hypersensitivity - - EXT -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with SWI sequence Suspected brain iron accumulation (NBIA) No abnormal iron deposition MRI contraindications - EXT EXT - PET scan (FDG or dopamine receptor imaging) Research; atypical cases Variable None - - EXT - Slit lamp examination Wilson's disease evaluation No Kayser-Fleischer rings None - EXT EXT - EMG Characterize tremor vs dystonic movements Define movement characteristics None - - EXT -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Discontinue or reduce causative agent N/A First step if psychiatrically safe; requires psychiatry coordination N/A :: N/A :: :: Collaborate with psychiatry; gradual taper preferred if stopping; dose reduction may help Cannot discontinue if psychosis relapse risk too high Monitor for psychiatric decompensation URGENT URGENT ROUTINE URGENT Switch to clozapine PO Lowest TD risk; for patients requiring continued antipsychotic 12.5 mg qHS; 25 mg BID; 50 mg BID; 100 mg BID :: PO :: :: Start 12.5-25 mg/day; titrate by 25-50 mg q3-7d; target 200-450 mg/day; requires REMS Agranulocytosis history; severe neutropenia; seizure disorder (relative) ANC weekly x 6mo, q2wk x 6mo, then monthly; seizures; myocarditis URGENT URGENT ROUTINE - Switch to quetiapine PO Lower TD risk; for patients requiring continued antipsychotic 25 mg BID; 50 mg BID; 100 mg BID; 200 mg BID :: PO :: :: Start 25-50 mg BID; titrate by 50-100 mg/day q2-3d; target 300-800 mg/day QT prolongation; severe hepatic impairment QTc, sedation, metabolic parameters URGENT URGENT ROUTINE - Benzodiazepine (severe distress) PO/IV Severe anxiety/distress from TD movements; temporary relief 0.5 mg TID; 1 mg TID :: PO :: :: Lorazepam 0.5-1 mg TID PRN for acute distress; short-term only Respiratory depression; substance use disorder Sedation, respiratory status URGENT URGENT - URGENT","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#3b-symptomatic-treatments-fda-approved-for-td","title":"3B. Symptomatic Treatments (FDA-Approved for TD)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Valbenazine (Ingrezza) PO FDA-approved first-line for TD; VMAT2 inhibitor 40 mg daily; 80 mg daily :: PO :: :: Start 40 mg once daily; increase to 80 mg daily after 1 week if tolerated; take with or without food Congenital long QT; strong CYP2D6 inhibitors at higher dose; severe hepatic impairment QTc (baseline, after dose increase); somnolence; depression - ROUTINE ROUTINE - Deutetrabenazine (Austedo) PO FDA-approved first-line for TD; VMAT2 inhibitor 6 mg BID; 9 mg BID; 12 mg BID :: PO :: :: Start 6 mg BID (12 mg/day); increase by 6 mg/day weekly; max 48 mg/day; take with food Depression/suicidality; MAO-I use; hepatic impairment; reserpine use within 20 days Depression (PHQ-9); parkinsonism; QTc; akathisia - ROUTINE ROUTINE - Tetrabenazine (Xenazine) PO VMAT2 inhibitor; older agent with more side effects 12.5 mg daily; 12.5 mg BID; 12.5 mg TID; 25 mg TID :: PO :: :: Start 12.5 mg daily; increase by 12.5 mg q1wk; max 50 mg/day (100 mg if CYP2D6 extensive metabolizer); require CYP2D6 genotyping &gt;50 mg Depression/suicidality; untreated or inadequately treated depression Depression (PHQ-9); parkinsonism; akathisia; sedation; requires CYP2D6 genotyping - ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Clonazepam PO Adjunct for TD; limited evidence; reduces choreiform movements 0.25 mg BID; 0.5 mg BID; 1 mg BID :: PO :: :: Start 0.25 mg BID; titrate slowly; typical 0.5-4 mg/day divided Respiratory depression; substance use disorder Sedation, dependence, falls - ROUTINE ROUTINE - Amantadine PO Limited evidence; may reduce TD severity; antiglutamatergic 100 mg BID; 100 mg TID; 200 mg BID :: PO :: :: Start 100 mg BID; may increase to 300-400 mg/day divided; adjust for renal function Severe renal impairment; seizure history (relative) Livedo reticularis; edema; hallucinations; confusion (elderly) - ROUTINE ROUTINE - Ginkgo biloba PO Limited evidence; antioxidant mechanism; modest benefit in trials 120 mg BID; 240 mg daily :: PO :: :: 240 mg/day divided; EGb 761 extract standardized Bleeding disorders; anticoagulant use Bleeding risk - - ROUTINE - Vitamin E PO Limited evidence; may prevent progression; minimal therapeutic effect 400 IU daily; 800 IU daily :: PO :: :: 400-1600 IU daily; better evidence for prevention than treatment Coagulopathy; vitamin K deficiency Bleeding risk at high doses - - ROUTINE - Vitamin B6 (pyridoxine) PO Limited evidence; some trials show benefit 100 mg daily; 200 mg daily :: PO :: :: 100-400 mg daily; monitor for neuropathy at high doses Peripheral neuropathy Neuropathy with chronic high dose (&gt;200 mg) - - EXT - Levetiracetam PO Limited evidence; case reports of benefit 500 mg BID; 750 mg BID; 1000 mg BID :: PO :: :: Start 500 mg BID; titrate to 1500-3000 mg/day; adjust for renal function Severe renal impairment without adjustment Mood changes; sedation - - EXT - Propranolol PO For tardive akathisia component 10 mg TID; 20 mg TID; 40 mg TID :: PO :: :: Start 10 mg TID; titrate to 30-120 mg/day divided Asthma; bradycardia; heart block HR, BP - ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#3d-interventionaladvanced-therapies","title":"3D. Interventional/Advanced Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Botulinum toxin (focal TD) IM Focal tardive dystonia (e.g., cervical, blepharospasm) Dose varies by target :: IM :: :: Cervical: 100-300 units; blepharospasm: 25-50 units per eye; repeat q3mo EMG guidance recommended for some targets Active infection at site; myasthenia gravis Dysphagia (cervical); ptosis (periocular); local weakness - - ROUTINE - Deep brain stimulation (DBS) Surgical Severe, disabling, medication-refractory TD GPi (globus pallidus internus) target :: Surgical :: :: Bilateral GPi most common; programming optimization over months MRI; neuropsychological testing; multidisciplinary evaluation; psychiatry clearance Untreated psychiatric instability; cognitive impairment; coagulopathy Programming; psychiatric monitoring; speech/swallowing - - EXT - Pallidal lesioning Surgical Alternative to DBS if not candidate; irreversible Unilateral pallidotomy :: Surgical :: :: Stereotactic lesion of GPi; reserved for DBS failures or contraindications Same as DBS Same as DBS Permanent side effect risk higher than DBS - - EXT -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Psychiatry consultation for antipsychotic management, dose reduction, or switch to lower-risk agent (ESSENTIAL - requires collaborative decision-making) URGENT URGENT ROUTINE URGENT Movement disorders neurology for diagnosis confirmation, AIMS scoring, and VMAT2 inhibitor initiation - ROUTINE ROUTINE - Neurosurgery consultation for DBS evaluation if medication-refractory disabling TD - - EXT - Speech therapy for dysphagia evaluation if oropharyngeal involvement - ROUTINE ROUTINE - Occupational therapy for adaptive strategies if hand involvement affects function - ROUTINE ROUTINE - Social work for disability evaluation and resources if TD causes functional impairment - - ROUTINE - Dentistry for oral health evaluation with orofacial TD (tooth damage, denture issues) - - ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Report any worsening movements, difficulty swallowing, or breathing problems immediately (may indicate progression) ROUTINE ROUTINE ROUTINE Do not stop antipsychotic medications without psychiatry guidance as this can worsen psychosis or cause withdrawal dyskinesia ROUTINE ROUTINE ROUTINE Report any new or worsening depression, suicidal thoughts, or mood changes on VMAT2 inhibitors (boxed warning) - ROUTINE ROUTINE Movements may temporarily worsen after stopping causative drug before improving (withdrawal dyskinesia) ROUTINE ROUTINE ROUTINE VMAT2 inhibitors may take 2-6 weeks to show maximum benefit; continue as prescribed - ROUTINE ROUTINE Avoid caffeine and stimulants which may worsen involuntary movements - ROUTINE ROUTINE Maintain regular dental visits for oral health if orofacial TD present (prevents tooth damage, ulceration) - - ROUTINE Consider support groups and counseling for coping with visible movement disorder - - ROUTINE","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Use lowest effective antipsychotic dose for shortest duration needed (primary prevention) - ROUTINE ROUTINE Perform AIMS examination at baseline, 3 months, 6 months, then q6-12 months on dopamine-blocking agents - ROUTINE ROUTINE Prefer second-generation antipsychotics over first-generation when clinically appropriate (lower TD risk) - ROUTINE ROUTINE Avoid metoclopramide for &gt;12 weeks; use domperidone or other alternatives when possible (not available in US) - ROUTINE ROUTINE Document informed consent regarding TD risk when starting dopamine-blocking agents - ROUTINE ROUTINE Identify and monitor high-risk patients more frequently: elderly, female, mood disorders, diabetes, longer exposure, higher cumulative dose - ROUTINE ROUTINE Consider early intervention with VMAT2 inhibitors before TD becomes severe and irreversible - - ROUTINE Stress management and adequate sleep may help reduce movement severity - ROUTINE ROUTINE","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Huntington disease Family history; cognitive decline; chorea; CAG expansion Genetic testing for HTT CAG repeats Sydenham chorea History of rheumatic fever; anti-streptolysin O; younger patients ASO titer; echocardiogram Withdrawal dyskinesia Occurs immediately after stopping dopamine blocker; self-limited (&lt;3 months) History; timeline (TD persists &gt;3 months) Spontaneous orofacial dyskinesia (elderly) Elderly without antipsychotic exposure; edentulous Careful medication history; dental exam Wilson disease Age &lt;50; Kayser-Fleischer rings; liver disease; psychiatric symptoms Ceruloplasmin; 24h urine copper; slit lamp Neuroacanthocytosis Orofacial dyskinesia; chorea; self-mutilation; elevated CK; acanthocytes Acanthocyte smear; CK; genetic testing Autoimmune chorea (anti-NMDA, anti-LGI1) Subacute onset; psychiatric symptoms; seizures; encephalopathy Autoimmune antibody panels; CSF Meige syndrome (primary cranial dystonia) Blepharospasm and oromandibular dystonia without antipsychotic exposure Clinical history; no dopamine blocker use Tourette syndrome Childhood onset; tics (brief, suppressible); premonitory urge Clinical criteria; onset &lt;18 years Drug-induced acute dystonia Occurs within days of drug exposure; not persistent Timeline (acute dystonia is immediate, TD delayed) Parkinson disease dyskinesia History of Parkinson's; peak-dose or diphasic dyskinesia on levodopa Clear PD diagnosis; levodopa relationship Hyperthyroidism Tremor predominant; tachycardia; weight loss; heat intolerance TSH, free T4","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU AIMS score Baseline, 3mo, 6mo, then q6-12mo on antipsychotics Improvement from baseline (decrease of 2+ points clinically meaningful) Adjust treatment; consider VMAT2 inhibitor - ROUTINE ROUTINE - AIMS score on VMAT2 inhibitor q4-8 weeks until stable, then q3-6mo 50%+ improvement goal; any improvement beneficial Optimize dose; consider second agent - ROUTINE ROUTINE - Depression screen (PHQ-9) Baseline, 2wk, 4wk, then q3mo on VMAT2 inhibitors PHQ-9 &lt;5 Hold VMAT2 inhibitor; psychiatry consultation; consider switch - ROUTINE ROUTINE - Suicidality assessment Each visit on VMAT2 inhibitors No suicidal ideation Immediate psychiatry referral; hold medication - ROUTINE ROUTINE - QTc interval Baseline, after dose increase (valbenazine/deutetrabenazine) &lt;500 msec Reduce dose; evaluate medications; electrolytes - ROUTINE ROUTINE - ANC (if on clozapine) Weekly x 6mo, q2wk x 6mo, then monthly ANC &gt;1500/mm3 Follow REMS protocol for neutropenia - ROUTINE ROUTINE - Parkinsonism symptoms Each visit on VMAT2 inhibitors No new bradykinesia, rigidity, rest tremor Reduce VMAT2 dose - ROUTINE ROUTINE - Akathisia Each visit on VMAT2 inhibitors No subjective restlessness Reduce dose; consider propranolol - ROUTINE ROUTINE - Swallowing function Each visit with orofacial TD Normal swallowing Speech therapy referral; modify diet - ROUTINE ROUTINE - Functional status Each visit Acceptable ADL function OT referral; treatment intensification - ROUTINE ROUTINE - Weight and metabolic parameters q3-6mo on antipsychotics Stable weight; glucose &lt;126 fasting Lifestyle modification; consider antipsychotic switch - ROUTINE ROUTINE -","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild-moderate TD; able to manage oral medications; follow-up with neurology and psychiatry arranged; no psychiatric instability Admit to floor New severe TD with swallowing/respiratory involvement; psychiatric decompensation from medication change; severe dystonic component causing pain/disability; need for expedited workup (suspect alternative diagnosis) Admit to ICU Respiratory compromise from severe oropharyngeal/laryngeal TD; neuroleptic malignant syndrome; severe tardive dystonia with rhabdomyolysis Outpatient follow-up Initial: 4-6 weeks for medication titration; Stable: q3-6 months for AIMS monitoring; More frequent if depression risk on VMAT2 inhibitors","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Valbenazine FDA-approved for TD (KINECT 3) Class I, Level A Hauser et al. Am J Psychiatry 2017 Valbenazine efficacy and safety (KINECT 4) Class I, Level A Factor et al. J Clin Psychiatry 2017 Deutetrabenazine FDA-approved for TD (ARM-TD/AIM-TD) Class I, Level A Anderson et al. JAMA Neurol 2017 Tetrabenazine efficacy for TD Class II, Level B Kenney et al. Expert Rev Neurother 2006 AIMS as standard TD assessment Class II, Level B Guy W. ECDEU Assessment Manual 1976 Clozapine lowest TD risk Class II, Level B Correll et al. J Clin Psychiatry 2004 Second-generation antipsychotics lower TD risk than first-generation Class I, Level A Carbon et al. World Psychiatry 2017 Risk factors for TD (age, duration, dose, diabetes) Class II, Level B Woerner et al. J Clin Psychopharmacol 1998 AAN evidence-based guideline for TD treatment Class I-IV, Level A-U Bhidayasiri et al. Mov Disord 2018 DBS for medication-refractory TD Class IV, Level C Macerollo et al. J Neurol 2020 Ginkgo biloba modest benefit in TD Class II, Level B Zhang et al. J Clin Psychiatry 2011 Vitamin E for TD prevention (not treatment) Class II, Level U Soares-Weiser et al. Cochrane 2018 Clonazepam for TD Class IV, Level U Thaker et al. Acta Psychiatr Scand 1990 Metoclopramide black box warning (&gt;12 weeks increases TD risk) Regulatory guidance FDA Drug Safety Communication 2009","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of VMAT2 inhibitors (valbenazine, deutetrabenazine, tetrabenazine) - AIMS scoring guidance for monitoring - Risk factor identification and prevention strategies - Psychiatry coordination emphasized throughout - Causative agent documentation (antipsychotics, metoclopramide, prochlorperazine) - Structured dosing format for order sentence generation - Advanced interventions (DBS, botulinum toxin)</p>","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#appendix-a-aims-abnormal-involuntary-movement-scale-examination","title":"APPENDIX A: AIMS (Abnormal Involuntary Movement Scale) Examination","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#examination-procedure","title":"Examination Procedure","text":"<ol> <li>Patient Preparation:</li> <li>Patient seated in hard chair without arms</li> <li>Observe at rest, then during activation maneuvers</li> <li> <p>Examine with dentures in and out (if applicable)</p> </li> <li> <p>Rating Scale:</p> </li> <li>0 = None</li> <li>1 = Minimal, may be extreme normal</li> <li>2 = Mild</li> <li>3 = Moderate</li> <li> <p>4 = Severe</p> </li> <li> <p>Body Areas Assessed:</p> </li> </ol> Item Body Area Observation 1 Muscles of facial expression Forehead, eyebrows, periorbital area, cheeks 2 Lips and perioral area Puckering, pouting, smacking 3 Jaw Lateral movement, clenching, chewing, opening 4 Tongue Protrusion, tremor, choreoathetoid movement 5 Upper extremities Arms, wrists, hands, fingers 6 Lower extremities Legs, knees, ankles, toes 7 Trunk Neck, shoulders, hips <ol> <li>Global Judgments:</li> </ol> Item Assessment 8 Severity of abnormal movements overall 9 Incapacitation due to abnormal movements 10 Patient's awareness of abnormal movements <ol> <li>Dental Status:</li> <li>Current dental problems (Y/N)</li> <li>Dentures used (Y/N)</li> </ol>","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#interpretation","title":"Interpretation","text":"Total Score (Items 1-7) Interpretation 0-1 No or minimal TD 2-4 Mild TD 5-9 Moderate TD 10-28 Severe TD","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#monitoring-schedule","title":"Monitoring Schedule","text":"Context AIMS Frequency Starting antipsychotic Baseline, 3 months, 6 months Stable on antipsychotic Every 6-12 months On VMAT2 inhibitor Every 4-8 weeks until stable, then every 3-6 months High-risk patient Every 3 months","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#appendix-b-causative-agents-and-risk-factors","title":"APPENDIX B: Causative Agents and Risk Factors","text":"","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#high-risk-dopamine-blocking-agents","title":"High-Risk Dopamine-Blocking Agents","text":"Agent Class Examples TD Risk Level First-generation antipsychotics (typical) Haloperidol, fluphenazine, perphenazine, chlorpromazine HIGH Metoclopramide Reglan HIGH (especially &gt;12 weeks) Prochlorperazine Compazine HIGH Promethazine Phenergan MODERATE","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#lower-risk-antipsychotics","title":"Lower-Risk Antipsychotics","text":"Agent TD Risk Level Notes Clozapine LOWEST REMS required; consider for refractory TD Quetiapine LOW Good alternative; sedation may be limiting Aripiprazole LOW Partial agonist; may worsen TD in some Ziprasidone LOW QTc monitoring required Olanzapine MODERATE Metabolic concerns Risperidone MODERATE Higher than other SGAs","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tardive-dyskinesia/#risk-factors-for-td-development","title":"Risk Factors for TD Development","text":"Risk Factor Relative Risk Notes Age &gt;55 years HIGH Most important risk factor Female sex MODERATE Especially postmenopausal African American ancestry MODERATE Higher incidence observed Mood disorder (vs schizophrenia) MODERATE Higher risk in bipolar/depression Diabetes mellitus MODERATE Metabolic dysfunction Longer duration of exposure HIGH Cumulative risk Higher cumulative dose HIGH Dose-dependent Intermittent antipsychotic use MODERATE Drug holidays may increase risk Early extrapyramidal symptoms MODERATE Predictor of TD susceptibility Cognitive impairment MODERATE May mask early symptoms Substance use disorder MODERATE Especially alcohol","tags":["movement-disorders","drug-induced","outpatient","antipsychotics"]},{"location":"drafts/tension-headache/","title":"Tension-Type Headache","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#tension-type-headache","title":"Tension-Type Headache","text":"<p>DIAGNOSIS: Tension-Type Headache ICD-10: G44.209 (Tension-type headache, unspecified, not intractable) SCOPE: Episodic and chronic tension-type headache diagnosis, acute treatment, and preventive therapy. Excludes secondary headaches, medication overuse headache (separate protocol), and trigeminal autonomic cephalalgias.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Rule out anemia or infection as headache trigger Normal STAT ROUTINE ROUTINE - BMP Electrolyte abnormalities can trigger headaches Normal STAT ROUTINE ROUTINE - TSH Hypothyroidism associated with chronic headache Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Rule out giant cell arteritis if age &gt;50 with new headache Normal URGENT ROUTINE ROUTINE - Vitamin D level Deficiency associated with chronic pain and headache &gt;30 ng/mL - ROUTINE ROUTINE - Ferritin Iron deficiency associated with headache &gt;50 ng/mL - ROUTINE ROUTINE - Magnesium (RBC) Low magnesium linked to headache disorders &gt;4.2 mg/dL - ROUTINE ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ANA Rule out autoimmune disorder in atypical presentations Negative - EXT EXT - Sleep study Evaluate for sleep apnea contributing to chronic headache AHI &lt;5 - - EXT - Lyme serology Consider in endemic areas with refractory symptoms Negative - EXT EXT -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast Only if red flags present (see SNNOOP10 below) Normal MRI-incompatible devices URGENT ROUTINE ROUTINE - CT Head non-contrast Acute severe headache or new neurological deficits No hemorrhage, mass, or hydrocephalus Pregnancy (relative) STAT STAT - -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Atypical features, focal deficits, suspected secondary cause No enhancement or mass lesion Gadolinium allergy, severe renal impairment URGENT ROUTINE ROUTINE - MRA Head/Neck Suspected vascular etiology or cervical artery dissection Patent vessels; no dissection MRI contraindications URGENT ROUTINE EXT - C-spine X-ray or MRI Cervicogenic component suspected Normal alignment; no disc disease None - ROUTINE ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRV Brain Suspected cerebral venous thrombosis Patent venous sinuses MRI contraindications URGENT ROUTINE EXT - LP with opening pressure Suspected idiopathic intracranial hypertension Normal (10-20 cm H2O) Coagulopathy; mass lesion - ROUTINE EXT - <p>IMAGING RED FLAGS (SNNOOP10): Imaging indicated if any of the following: - Systemic symptoms (fever, weight loss) or systemic disease (HIV, cancer) - Neurological symptoms or abnormal signs - New onset or sudden onset (thunderclap) - Onset after age 50 - Other associated conditions (pregnancy, postpartum, immunosuppression) - Pattern change from previous headaches - Positional (worse lying down or standing) - Precipitated by Valsalva (cough, sneeze, exertion) - Papilledema - Progressive headache or atypical features - Painful eye with autonomic features</p>","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#3-treatment","title":"3. TREATMENT","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#ichd-3-diagnostic-criteria-for-tension-type-headache","title":"ICHD-3 Diagnostic Criteria for Tension-Type Headache","text":"<p>Episodic TTH (&lt;15 days/month): A. At least 10 episodes fulfilling criteria B-D B. Lasting 30 minutes to 7 days C. At least 2 of: bilateral location; pressing/tightening (non-pulsating) quality; mild-moderate intensity; not aggravated by routine physical activity D. Both: no nausea or vomiting; no more than one of photophobia or phonophobia E. Not better accounted for by another ICHD-3 diagnosis</p> <p>Chronic TTH (\u226515 days/month for &gt;3 months): Same as above but occurring \u226515 days/month on average for &gt;3 months</p>","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ketorolac IV/IM Severe acute TTH in ED; NSAID-responsive headache 30 mg IV; 15 mg IV :: IV :: :: 30 mg IV x1 (15 mg if &gt;65y, renal impairment, or &lt;50 kg); do not exceed 5 days total NSAIDs Renal impairment; GI bleed history; aspirin allergy; third trimester pregnancy Renal function if repeated dosing STAT URGENT - - Metoclopramide IV Acute headache with nausea; has anti-headache properties 10 mg IV :: IV :: :: 10 mg IV over 15 min; pretreat with diphenhydramine 25 mg to prevent akathisia Parkinson's disease; tardive dyskinesia history; bowel obstruction Akathisia, dystonic reaction URGENT URGENT - - Diphenhydramine IV Adjunct to prevent akathisia from dopamine antagonists 25 mg IV :: IV :: :: 25 mg IV prior to metoclopramide Narrow-angle glaucoma; urinary retention Sedation URGENT URGENT - -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Ibuprofen PO First-line acute treatment for episodic TTH 400 mg PO; 600 mg PO; 800 mg PO :: PO :: :: 400-800 mg PO at onset; may repeat q6-8h; max 2400 mg/day; limit to &lt;10 days/month Renal impairment; GI bleed history; aspirin allergy; third trimester GI symptoms; renal function if prolonged use URGENT ROUTINE ROUTINE - Naproxen PO First-line acute treatment; longer duration than ibuprofen 500 mg PO; 550 mg PO :: PO :: :: 500-550 mg PO at onset; may repeat 250 mg in 12 hr; max 1250 mg/day; limit to &lt;10 days/month Renal impairment; GI bleed history; aspirin allergy; third trimester GI symptoms; renal function if prolonged use URGENT ROUTINE ROUTINE - Acetaminophen PO First-line if NSAID contraindicated; mild-moderate TTH 1000 mg PO :: PO :: :: 1000 mg PO at onset; may repeat q6h; max 3000 mg/day (2000 mg if liver disease); limit to &lt;10 days/month Severe hepatic impairment; avoid if &gt;3 alcoholic drinks/day LFTs if chronic use; total daily dose from all sources URGENT ROUTINE ROUTINE - Aspirin PO First-line acute treatment; anti-inflammatory 650 mg PO; 1000 mg PO :: PO :: :: 650-1000 mg PO at onset; max 4000 mg/day; limit to &lt;10 days/month Bleeding disorders; GI ulcer; aspirin allergy; children/teens (Reye syndrome); third trimester GI symptoms; bleeding URGENT ROUTINE ROUTINE - Caffeine/Analgesic combination PO Enhanced efficacy with caffeine adjunct 2 tablets PO :: PO :: :: Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: 2 tablets at onset; max 2 doses/24hr Aspirin or acetaminophen contraindications Limit use to prevent caffeine dependence and MOH - ROUTINE ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Trigger point injection IM Pericranial muscle tenderness; refractory to oral therapy 1-2 mL 1% lidocaine :: IM :: :: Inject 1-2 mL 1% lidocaine into tender points in trapezius, temporalis, or cervical paraspinals; may repeat q2-4wk Local anesthetic allergy; infection at site Local bruising; vasovagal response - EXT ROUTINE - Greater occipital nerve block SC Occipital-predominant pain; refractory cases 2-3 mL 2% lidocaine :: SC :: :: 2-3 mL 2% lidocaine with or without 40 mg triamcinolone at greater occipital nerve bilaterally Local anesthetic allergy; infection at site Immediate pain relief; monitor for vasovagal - EXT ROUTINE - Physical therapy N/A Musculoskeletal dysfunction; postural abnormalities N/A :: N/A :: :: 1-2 sessions/week for 6-8 weeks focusing on cervical/shoulder mobility, posture, and relaxation techniques None Symptom improvement over 6-8 weeks - ROUTINE ROUTINE - Biofeedback/Relaxation therapy N/A Stress-related TTH; patient preference for non-pharmacologic N/A :: N/A :: :: Weekly sessions for 8-12 weeks; EMG biofeedback targeting frontalis/temporalis; may combine with CBT None Symptom diary; headache frequency reduction - - ROUTINE - Cognitive behavioral therapy (CBT) N/A Stress, anxiety, or depression contributing to headache N/A :: N/A :: :: Weekly sessions for 8-12 weeks; focus on pain coping, stress management, and cognitive restructuring None Symptom diary; validated headache disability measures - - ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#3d-disease-modifying-or-chronic-therapies-preventive-medications","title":"3D. Disease-Modifying or Chronic Therapies (Preventive Medications)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Amitriptyline PO First-line prevention for chronic TTH; \u226515 days/month 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS ECG if age &gt;50 or cardiac history Cardiac conduction abnormality (QTc &gt;450 ms); recent MI; narrow-angle glaucoma; urinary retention; concurrent MAOIs Sedation, dry mouth, weight gain, constipation; ECG if dose &gt;100 mg/day - ROUTINE ROUTINE - Nortriptyline PO Prevention if amitriptyline not tolerated (less sedating); chronic TTH 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10 mg qHS; titrate by 10-25 mg every 1-2 weeks; target 25-75 mg qHS; max 150 mg qHS ECG if age &gt;50 or cardiac history Cardiac conduction abnormality (QTc &gt;450 ms); recent MI; narrow-angle glaucoma; urinary retention; concurrent MAOIs Sedation (less than amitriptyline), dry mouth, weight gain, constipation; ECG if dose &gt;100 mg/day - ROUTINE ROUTINE - Venlafaxine XR PO Prevention; comorbid depression or anxiety; TCA intolerant 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; increase by 37.5-75 mg every 1 week; target 75-150 mg daily None Uncontrolled hypertension; concurrent MAOIs; abrupt discontinuation (taper required) Blood pressure at higher doses (&gt;150 mg); serotonin syndrome signs - ROUTINE ROUTINE - Mirtazapine PO Prevention; comorbid insomnia, depression, or poor appetite 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30 mg qHS; more sedating at lower doses None Concurrent MAOIs; severe hepatic impairment Sedation, increased appetite, weight gain - ROUTINE ROUTINE - Tizanidine PO Prevention; prominent pericranial muscle tension 2 mg qHS; 4 mg qHS; 2 mg TID; 4 mg TID :: PO :: :: Start 2 mg qHS; may increase by 2-4 mg every 3-7 days; max 36 mg/day in 3 divided doses LFTs at baseline Concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors); hepatic impairment LFTs monthly for first 6 months then periodically; sedation, hypotension, dry mouth - ROUTINE ROUTINE - Topiramate PO Prevention; comorbid migraine or obesity 25 mg qHS; 50 mg BID; 75 mg BID; 100 mg BID :: PO :: :: Start 25 mg qHS; increase by 25 mg/week; target 50-100 mg BID None Narrow-angle glaucoma; kidney stones; pregnancy (teratogen); metabolic acidosis Cognitive effects (word-finding), paresthesias, weight loss, kidney stones, bicarbonate - ROUTINE ROUTINE - Gabapentin PO Prevention; comorbid neuropathic pain or anxiety 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg every 3-5 days; target 900-1800 mg/day in 3 divided doses None Severe renal impairment (dose adjust for CrCl) Sedation, dizziness, peripheral edema - ROUTINE ROUTINE - <p>MEDICATION OVERUSE HEADACHE WARNING: Limit acute analgesic use to &lt;10 days/month for combination analgesics, opioids, or triptans, and &lt;15 days/month for simple analgesics (NSAIDs, acetaminophen). Exceeding these thresholds risks transformation to medication overuse headache (MOH). If MOH suspected, refer to medication overuse headache protocol.</p>","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Headache specialist referral for chronic TTH (\u226515 days/month) not responding to first-line preventives - ROUTINE ROUTINE - Physical therapy for cervicogenic component, postural dysfunction, and pericranial muscle tension - ROUTINE ROUTINE - Behavioral medicine/Psychology for stress management, biofeedback, and cognitive behavioral therapy - - ROUTINE - Sleep medicine evaluation if underlying sleep disorder (insomnia, apnea) contributing to chronic headache - - ROUTINE - Ophthalmology evaluation to rule out refractive error or eye strain as contributing factor - - ROUTINE - Dentistry/TMJ specialist if temporomandibular joint dysfunction contributing to headache - - ROUTINE - Psychiatry referral for comorbid depression or anxiety requiring pharmacologic management beyond preventive therapy - - ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately for sudden severe headache (\"worst headache of life\") which may indicate hemorrhage or other serious cause STAT - ROUTINE Return immediately for headache with fever, stiff neck, or altered mental status which may indicate infection STAT - ROUTINE Return if new neurological symptoms develop (weakness, numbness, vision changes, speech difficulty) STAT ROUTINE ROUTINE Maintain headache diary tracking frequency, triggers, medication use, and response to guide treatment optimization - ROUTINE ROUTINE Limit acute pain medication use to no more than 10 days per month to prevent medication overuse headache URGENT ROUTINE ROUTINE Take acute medications early at headache onset for best efficacy rather than waiting for severe pain - ROUTINE ROUTINE Identify and modify personal triggers (stress, poor posture, inadequate sleep, screen time, skipped meals) - ROUTINE ROUTINE","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular sleep schedule (7-8 hours, consistent bedtime and wake time) as sleep disturbance is a common trigger - ROUTINE ROUTINE Stress management through relaxation techniques, mindfulness meditation, or progressive muscle relaxation - ROUTINE ROUTINE Regular aerobic exercise (30 minutes moderate activity 5 times/week) shown to reduce chronic headache frequency - ROUTINE ROUTINE Ergonomic workplace assessment to optimize posture and reduce neck/shoulder strain during computer work - - ROUTINE Limit screen time and take regular breaks (20-20-20 rule: every 20 minutes, look 20 feet away for 20 seconds) - ROUTINE ROUTINE Adequate hydration (at least 64 oz water daily) as dehydration can trigger headache - ROUTINE ROUTINE Regular meals to avoid fasting-triggered headache; do not skip meals - ROUTINE ROUTINE Limit caffeine to moderate consistent intake (\u2264200 mg/day or ~2 cups coffee) to prevent withdrawal headaches - ROUTINE ROUTINE Stretching exercises for neck and shoulders daily, especially if sedentary work - ROUTINE ROUTINE","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Migraine Unilateral, pulsating, moderate-severe intensity; nausea/vomiting; photo AND phonophobia; aggravated by physical activity Clinical criteria (ICHD-3); normal imaging Medication overuse headache Daily or near-daily headache; acute medication use \u226510-15 days/month for \u22653 months Headache diary documenting medication use; improves with withdrawal Cervicogenic headache Unilateral, starts in neck, radiates frontally; triggered by neck movement or sustained posture; reduced ROM Physical exam (decreased ROM, tenderness); C-spine imaging; diagnostic block Temporomandibular joint dysfunction Pain in jaw, temple, or preauricular area; worse with chewing; clicking/popping of jaw; bruxism history TMJ exam; panoramic dental X-ray; may need MRI TMJ Giant cell arteritis Age &gt;50; new headache type; scalp tenderness; jaw claudication; visual changes; elevated ESR/CRP ESR, CRP; temporal artery biopsy (gold standard) Idiopathic intracranial hypertension Positional headache (worse lying flat); papilledema; pulsatile tinnitus; visual obscurations; obesity LP with opening pressure &gt;25 cm H2O; MRI/MRV normal Intracranial mass lesion Progressive headache; worse in morning or with Valsalva; focal neurological signs MRI brain with contrast Cervical artery dissection Sudden severe headache or neck pain; may have Horner syndrome; history of trauma or neck manipulation MRA or CTA neck Trigeminal neuralgia Brief (seconds) electric shock-like pain; unilateral V2/V3 distribution; triggered by touch, chewing, or talking MRI for vascular loop; clinical criteria Cluster headache Unilateral, periorbital, severe; autonomic features (lacrimation, rhinorrhea, ptosis, miosis); 15-180 min duration Clinical history; attacks occur in clusters","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Headache diary (frequency, severity, duration, medication use) Continuous at home; review each visit &lt;4 headache days/month on preventive; 50% reduction Optimize preventive therapy; consider referral - ROUTINE ROUTINE - Acute medication use days per month Monthly \u226410 days/month (simple analgesics \u226415 days) Counsel on MOH risk; consider prevention; detox if MOH - ROUTINE ROUTINE - HIT-6 disability score Every 3 months Score reduction; target &lt;50 (mild impact) Escalate preventive therapy if disability persists - - ROUTINE - LFTs (if on tizanidine) Baseline, monthly x 6 months, then q6mo Normal transaminases Hold or discontinue if &gt;3x ULN - ROUTINE ROUTINE - ECG (if on TCA) Baseline if age &gt;50 or cardiac history; if dose &gt;100 mg QTc &lt;450 ms; no heart block Reduce dose or switch agent if QTc prolonged - ROUTINE ROUTINE - Blood pressure (if on venlafaxine or SNRI) Each visit &lt;140/90 mmHg Reduce dose or add antihypertensive - ROUTINE ROUTINE - Weight (if on TCA or mirtazapine) Each visit Stable; &lt;5% gain Dietary counseling; consider switching agent - ROUTINE ROUTINE - Cognitive function (if on topiramate) Each visit No word-finding difficulty or slowed thinking Reduce dose or switch agent - ROUTINE ROUTINE - Bicarbonate (if on topiramate) Baseline, 3 months &gt;18 mEq/L Consider dose reduction or discontinuation if acidosis - ROUTINE ROUTINE -","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Pain controlled with oral medications; able to tolerate PO; no red flags; follow-up arranged; MOH counseling provided Admit to floor Rare; consider if: intractable headache requiring IV therapy; need for medication overuse headache detoxification protocol Outpatient neurology follow-up Within 4-8 weeks for chronic TTH not responding to first-line treatment; sooner if diagnostic uncertainty Primary care follow-up Within 2-4 weeks for new episodic TTH to assess response to acute treatment and need for prevention","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source ICHD-3 diagnostic criteria for tension-type headache Expert Consensus Headache Classification Committee. Cephalalgia 2018 Amitriptyline effective for chronic TTH prevention Class I, Level A Bendtsen et al. Neurology 1996 Simple analgesics (acetaminophen, NSAIDs, aspirin) for acute TTH Class I, Level A Stephens et al. Cochrane 2016 Tricyclic antidepressants for chronic TTH prevention Class I, Level A Jackson et al. Neurology 2017 Biofeedback and relaxation training reduce headache frequency Class II, Level B Nestoriuc et al. Pain 2008 Physical therapy for tension-type headache Class II, Level B Esp\u00ed-L\u00f3pez et al. Phys Ther 2014 Cognitive behavioral therapy reduces headache disability Class I, Level B Holroyd et al. JAMA 2001 Medication overuse headache prevalence and management Expert Consensus Diener et al. Nat Rev Neurol 2016 Ibuprofen 400-800 mg effective for acute TTH Class I, Level A Steiner et al. Headache 2003 Combination analgesics (aspirin/acetaminophen/caffeine) effective Class I, Level A Diener et al. Cephalalgia 2006 Venlafaxine for chronic TTH prevention Class II, Level B Zissis et al. Headache 2007 Topiramate for chronic TTH (limited evidence) Class III, Level C Lampl et al. J Neurol 2006 Greater occipital nerve block for refractory headache Class II, Level B Afridi et al. Brain 2006 SNNOOP10 red flags for secondary headache Expert Consensus Do et al. Neurology 2019","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tension-headache/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - ICHD-3 diagnostic criteria included - Comprehensive acute and preventive treatment coverage - Non-pharmacologic approaches emphasized (PT, biofeedback, CBT) - Medication overuse headache warning prominently featured - SNNOOP10 red flags for imaging decisions - Structured dosing format for order sentence generation - Real PubMed citations with verified PMIDs</p>","tags":["headache","tension-type-headache","outpatient","primary-headache"]},{"location":"drafts/tia/","title":"Transient Ischemic Attack (TIA)","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#transient-ischemic-attack-tia","title":"Transient Ischemic Attack (TIA)","text":"<p>DIAGNOSIS: Transient Ischemic Attack ICD-10: G45.9 (Transient cerebral ischemic attack, unspecified) SCOPE: Urgent evaluation, risk stratification (ABCD2), and secondary stroke prevention. Excludes completed stroke (see Acute Ischemic Stroke protocol).</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Polycythemia, thrombocytosis as stroke risk; anemia evaluation Normal STAT STAT ROUTINE - BMP Electrolytes; glucose for hypoglycemia mimic; creatinine for contrast Normal STAT STAT ROUTINE - Glucose (fingerstick) Rule out hypoglycemia as TIA mimic 70-180 mg/dL STAT STAT - - PT/INR, PTT Baseline coagulation; evaluate if on anticoagulation Normal or therapeutic STAT STAT ROUTINE - Lipid panel (fasting) LDL target &lt;70 for secondary prevention LDL &lt;70 mg/dL - ROUTINE ROUTINE - HbA1c Diabetes assessment; target &lt;7% &lt;7% URGENT ROUTINE ROUTINE - TSH Hyperthyroidism associated with atrial fibrillation Normal - ROUTINE ROUTINE - Troponin Concurrent cardiac ischemia; AF with rapid rate Negative STAT STAT - -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Homocysteine Elevated levels increase stroke risk &lt;15 \u03bcmol/L - ROUTINE ROUTINE - Lipoprotein(a) Independent cardiovascular risk marker &lt;30 mg/dL - ROUTINE ROUTINE - hsCRP Inflammatory marker; guides statin intensity &lt;2 mg/L - ROUTINE ROUTINE - BNP/NT-proBNP Heart failure; cardiac strain; AF risk Age-adjusted normal URGENT ROUTINE ROUTINE - Uric acid Elevated associated with increased stroke risk &lt;6 mg/dL - ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Hypercoagulability panel Age &lt;50, cryptogenic, recurrent events; includes Factor V Leiden, prothrombin mutation, protein C/S, antithrombin III Negative - EXT EXT - Antiphospholipid antibodies Lupus anticoagulant, anticardiolipin, anti-\u03b22GP1; young stroke Negative - EXT EXT - Hemoglobin electrophoresis Sickle cell disease if not known No sickling - EXT EXT - ESR, ANA Suspected vasculitis Normal/Negative - EXT EXT - Fabry disease testing (\u03b1-galactosidase A) Young cryptogenic stroke, family history, angiokeratomas Normal enzyme activity - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT Head non-contrast Immediate No hemorrhage; rule out stroke mimic None STAT STAT - - MRI Brain with DWI Within 24 hours No restricted diffusion (DWI+/ADC-) confirming infarct vs true TIA MRI-incompatible devices URGENT STAT - - CTA Head and Neck Same visit No significant stenosis (&gt;50%) in carotid, vertebral, or intracranial vessels Contrast allergy, CKD (relative) STAT STAT - - MRA Head and Neck Alternative to CTA Patent vessels; no stenosis &gt;50% MRI contraindications URGENT STAT ROUTINE - Carotid duplex ultrasound Within 24-48 hours &lt;50% stenosis bilaterally None URGENT STAT ROUTINE - ECG (12-lead) Immediate Sinus rhythm; no AF, LVH, or acute changes None STAT STAT ROUTINE - Transthoracic echocardiogram Within 24-48 hours No thrombus, PFO, or significant valvular disease None URGENT STAT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Cardiac telemetry (continuous) 24-72 hours minimum No atrial fibrillation or flutter None URGENT STAT - - Holter monitor (24-48 hour) Outpatient No paroxysmal AF None - - ROUTINE - Extended cardiac monitoring (14-30 day) Cryptogenic stroke/TIA Detect paroxysmal AF None - - ROUTINE - Transesophageal echocardiogram Cryptogenic, young, embolic No PFO, LAA thrombus, aortic arch atheroma Esophageal pathology - URGENT EXT - Bubble study (TTE or TEE) Suspected paradoxical embolism No right-to-left shunt None specific - URGENT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT/MR perfusion Uncertain timing, large vessel occlusion symptoms No mismatch suggesting salvageable tissue Contrast issues EXT EXT - - Vessel wall MRI Suspected intracranial vasculitis or dissection No vessel wall enhancement MRI contraindications - EXT EXT - DSA (cerebral angiogram) Vasculitis workup, moyamoya, uncertain vessel status Define vascular anatomy Contrast allergy, bleeding risk - EXT EXT - Implantable loop recorder Recurrent cryptogenic events after negative workup Detect occult AF None - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#3-treatment","title":"3. TREATMENT","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Aspirin PO Immediate antiplatelet therapy 325 mg PO x1 load; 81 mg PO daily :: PO :: :: 325 mg loading dose, then 81 mg daily ongoing Active GI bleed; aspirin allergy; planned thrombolysis GI symptoms, bleeding STAT STAT ROUTINE - Clopidogrel (DAPT with aspirin) PO ABCD2 \u22654 or minor stroke; first 21 days 300 mg PO x1 load; 75 mg PO daily :: PO :: :: 300 mg load then 75 mg daily with aspirin x21 days (POINT/CHANCE protocol) Active bleeding; planned surgery within 7 days Bleeding, bruising STAT STAT ROUTINE - Ticagrelor (alternative DAPT) PO Aspirin + ticagrelor if clopidogrel contraindicated 180 mg PO x1 load; 90 mg PO BID :: PO :: :: 180 mg load then 90 mg BID with aspirin x30 days (THALES protocol) Active bleeding; prior ICH; severe hepatic impairment Bleeding, dyspnea STAT STAT ROUTINE - Atorvastatin PO High-intensity statin for LDL &lt;70 80 mg PO daily :: PO :: :: 80 mg daily (high-intensity); target LDL &lt;70 mg/dL Active liver disease; pregnancy LFTs at baseline; myalgias URGENT STAT ROUTINE - Blood pressure management - Permissive hypertension acutely; goal &lt;140/90 long-term Target &lt;180/110 first 24h; &lt;140/90 after :: - :: :: Do NOT lower BP aggressively in first 24h unless &gt;220/120 or end-organ damage Symptomatic hypotension BP q1h x24h, then q4h STAT STAT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IV fluids (isotonic saline) IV Maintain euvolemia; avoid hypotension 75-125 mL/hr NS :: IV :: :: 75-125 mL/hr; adjust to maintain euvolemia; avoid D5W Fluid overload, CHF Fluid balance, I/Os URGENT ROUTINE - - Pantoprazole IV/PO GI protection with DAPT 40 mg IV daily; 40 mg PO daily :: IV/PO :: :: 40 mg daily None None ROUTINE ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Cilostazol (triple antiplatelet) PO Asian populations; high-risk stenosis 100 mg PO BID :: PO :: :: 100 mg BID; add to aspirin in select cases Heart failure; bleeding Bleeding, headache, palpitations - EXT EXT - Prasugrel PO Clopidogrel resistance or failure 60 mg PO x1 load; 10 mg PO daily :: PO :: :: 60 mg load then 10 mg daily; avoid if &gt;75y or &lt;60 kg Prior TIA/stroke (black box); bleeding risk Bleeding - EXT EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#3d-disease-modifying-or-chronic-therapies-secondary-prevention","title":"3D. Disease-Modifying or Chronic Therapies (Secondary Prevention)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Aspirin (long-term) PO Lifelong secondary prevention 81 mg PO daily :: PO :: :: 81 mg daily indefinitely None Active GI bleed GI symptoms; annual CBC - ROUTINE ROUTINE - Clopidogrel (monotherapy) PO Alternative to aspirin if aspirin-intolerant 75 mg PO daily :: PO :: :: 75 mg daily None Active bleeding Bleeding - ROUTINE ROUTINE - Aspirin + extended-release dipyridamole (Aggrenox) PO Alternative antiplatelet regimen 25/200 mg PO BID :: PO :: :: One capsule (25 mg ASA/200 mg ER dipyridamole) BID None Coronary stenosis (coronary steal); severe headache Headache (often limits use); GI - ROUTINE ROUTINE - Apixaban PO Atrial fibrillation-related TIA 5 mg PO BID; 2.5 mg PO BID :: PO :: :: 5 mg BID (2.5 mg BID if \u22652 of: age \u226580, weight \u226460 kg, Cr \u22651.5) Active major bleeding; mechanical valve CrCl, bleeding signs - ROUTINE ROUTINE - Rivaroxaban PO AF-related TIA 20 mg PO daily; 15 mg PO daily :: PO :: :: 20 mg daily with food (15 mg if CrCl 15-50) Active major bleeding; mechanical valve CrCl, bleeding - ROUTINE ROUTINE - Dabigatran PO AF-related TIA 150 mg PO BID; 110 mg PO BID :: PO :: :: 150 mg BID (110 mg BID if CrCl 30-50 or age &gt;80) Active bleeding; CrCl &lt;30; mechanical valve CrCl, bleeding - ROUTINE ROUTINE - Warfarin PO Mechanical valve; some hypercoagulable states 2-10 mg PO daily adjusted :: PO :: :: Start 5 mg daily; adjust to INR 2-3 (2.5-3.5 for mechanical valve) Baseline INR Pregnancy; active bleeding; frequent falls INR weekly then monthly - ROUTINE ROUTINE - Lisinopril PO Blood pressure control for secondary prevention 5 mg PO daily; 10 mg PO daily; 20 mg PO daily; 40 mg PO daily :: PO :: :: Start 5-10 mg daily; titrate to goal BP &lt;130/80; max 40 mg None Angioedema; pregnancy; bilateral RAS; hyperkalemia K+, Cr, BP - ROUTINE ROUTINE - Amlodipine PO BP control; add-on therapy 5 mg PO daily; 10 mg PO daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily None Severe aortic stenosis (relative) Peripheral edema, BP - ROUTINE ROUTINE - Chlorthalidone PO BP control; thiazide-like diuretic 12.5 mg PO daily; 25 mg PO daily :: PO :: :: Start 12.5 mg daily; may increase to 25 mg daily None Severe hypokalemia; severe hyponatremia K+, Na+, uric acid, glucose - ROUTINE ROUTINE - Ezetimibe PO Add-on for LDL not at goal on statin 10 mg PO daily :: PO :: :: 10 mg daily None Severe hepatic impairment LFTs - ROUTINE ROUTINE - PCSK9 inhibitor (evolocumab, alirocumab) SC LDL &gt;70 despite maximal statin + ezetimibe 140 mg SC q2wk; 420 mg SC monthly :: SC :: :: Evolocumab 140 mg q2wk or 420 mg monthly; alirocumab 75-150 mg q2wk LFTs, lipid panel None Injection site reactions; LDL - - ROUTINE - Icosapent ethyl (Vascepa) PO Triglycerides \u2265150 despite statin; reduces CV events 2 g PO BID :: PO :: :: 2 g BID with meals None Seafood/fish allergy (relative) AF monitoring (slightly increased risk) - - ROUTINE - Carotid endarterectomy (CEA) Surgical Symptomatic carotid stenosis 70-99%; 50-69% in select Surgery :: Surgical :: :: Perform within 2 weeks of TIA if stable; high-volume surgeon None Unstable plaque with delay; total occlusion Surgical complications; stroke - URGENT - - Carotid artery stenting (CAS) Endovascular CEA high-risk; radiation neck; recurrent stenosis Stenting :: Endovascular :: :: Alternative to CEA; requires DAPT None Tortuous anatomy; heavy calcification Hyperperfusion syndrome; stroke - URGENT - - PFO closure Endovascular Age &lt;60, PFO with shunt, cryptogenic stroke/TIA Device closure :: Endovascular :: :: Consider after comprehensive evaluation; DAPT post-procedure None Small PFO without shunt AF (transient); device complications - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Stroke consult for urgent evaluation, risk stratification, and secondary prevention optimization STAT STAT ROUTINE - Cardiology consultation for atrial fibrillation management, anticoagulation decisions, and PFO evaluation URGENT URGENT ROUTINE - Vascular surgery consultation for symptomatic carotid stenosis \u226550% to evaluate for endarterectomy timing - URGENT ROUTINE - Interventional neurology for carotid stenting evaluation if CEA high-risk or anatomically unsuitable - URGENT ROUTINE - Cardiac electrophysiology for recurrent AF management and potential ablation - - ROUTINE - Registered dietitian for Mediterranean diet counseling and sodium restriction education - ROUTINE ROUTINE - Smoking cessation counseling and pharmacotherapy initiation if current smoker - ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 immediately if symptoms return as this indicates high stroke risk (up to 10% in first 48 hours) STAT STAT ROUTINE Do not drive for at least 2-4 weeks after TIA per state regulations and stroke risk URGENT ROUTINE ROUTINE Take all medications as prescribed especially antiplatelet therapy which significantly reduces stroke risk URGENT ROUTINE ROUTINE Know stroke warning signs (FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911) STAT ROUTINE ROUTINE Keep follow-up appointments as early intervention reduces stroke risk by up to 80% - ROUTINE ROUTINE","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Blood pressure target &lt;130/80 mmHg to significantly reduce stroke recurrence risk - ROUTINE ROUTINE LDL target &lt;70 mg/dL with high-intensity statin for secondary prevention - ROUTINE ROUTINE Smoking cessation (reduces stroke risk by 50% within 1 year of quitting) - ROUTINE ROUTINE Mediterranean diet emphasizing fruits, vegetables, whole grains, fish, and olive oil - ROUTINE ROUTINE Limit alcohol to \u22641 drink/day for women, \u22642 drinks/day for men - ROUTINE ROUTINE Regular aerobic exercise (150 min/week moderate or 75 min/week vigorous) - ROUTINE ROUTINE Weight management with target BMI 18.5-24.9 kg/m\u00b2 - ROUTINE ROUTINE Sodium restriction &lt;2300 mg/day (ideally &lt;1500 mg if hypertensive) - ROUTINE ROUTINE","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Migraine with aura Gradual onset (minutes), visual scintillations, headache follows; younger patient Clinical history; normal DWI Seizure with Todd's paralysis Preceding convulsion; confusion; gradual resolution over hours EEG; clinical history Hypoglycemia Altered mentation, diaphoresis, tremor; resolves with glucose Fingerstick glucose Peripheral vertigo (BPPV, vestibular neuritis) Isolated vertigo with nystagmus; positive Dix-Hallpike HINTS exam; no central signs Transient global amnesia Isolated anterograde amnesia; repetitive questioning; resolves &lt;24h Clinical criteria; DWI may show hippocampal lesions Functional neurological disorder Inconsistent exam; incongruent symptoms; often with psychiatric comorbidity Clinical exam; normal workup Bell's palsy Peripheral facial weakness (forehead involved); no other deficits Clinical exam Hypertensive encephalopathy Severe HTN; headache; confusion; visual changes BP, posterior MRI findings Demyelinating disease (MS) Younger patient; prior episodes; MRI with characteristic lesions MRI brain/spine; CSF","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurological exam q1h x 24h then q4h Stable; no new deficits Immediate imaging if worsening STAT STAT - - Blood pressure q1h x 24h then q4h &lt;180/110 acutely; &lt;130/80 long-term Titrate antihypertensives STAT STAT ROUTINE - Cardiac rhythm (telemetry) Continuous x 24-72h Sinus rhythm Anticoagulation if AF detected URGENT STAT - - Extended cardiac monitoring 14-30 days outpatient Sinus rhythm Anticoagulation if AF detected - - ROUTINE - ABCD2 score At presentation Score &lt;4 lower risk; \u22654 high risk High-risk patients need admission or rapid TIA clinic STAT STAT - - LDL cholesterol Baseline, 6 weeks, then annually &lt;70 mg/dL Intensify statin or add ezetimibe/PCSK9i - ROUTINE ROUTINE - HbA1c Baseline, then q3mo if diabetic &lt;7% Optimize diabetes management - ROUTINE ROUTINE - Creatinine/eGFR With contrast; then annually eGFR &gt;30 Dose-adjust medications STAT ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Rapid TIA clinic (&lt;24-48h) ABCD2 &lt;4; no acute findings on imaging; reliable patient with close follow-up Admit to stroke unit ABCD2 \u22654; DWI positive (minor stroke); symptomatic carotid stenosis; new AF; unable to complete workup as outpatient Admit to ICU Rare for isolated TIA; only if concurrent acute coronary syndrome or hemodynamic instability Discharge with urgent follow-up Completed rapid workup; started on secondary prevention; ABCD2 &lt;4; no high-risk features","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Dual antiplatelet therapy (DAPT) for 21 days after minor stroke/TIA Class I, Level A Wang et al. NEJM 2021 (CHANCE-2); Johnston et al. NEJM 2018 (POINT) High-intensity statin for LDL &lt;70 mg/dL Class I, Level A Amarenco et al. NEJM 2006 (SPARCL) CEA for symptomatic carotid stenosis 70-99% Class I, Level A NASCET Collaborators. NEJM 1991 ABCD2 score for TIA risk stratification Class IIa, Level B Johnston et al. Lancet 2007 Extended cardiac monitoring for cryptogenic stroke Class IIa, Level B Sanna et al. NEJM 2014 (CRYSTAL-AF) PFO closure in cryptogenic stroke &lt;60 years Class IIa, Level B Mas et al. NEJM 2017 (CLOSE) BP target &lt;130/80 for secondary prevention Class I, Level B AHA/ASA Guidelines 2021 Urgent TIA evaluation reduces stroke risk Class I, Level B Rothwell et al. Lancet 2007 (EXPRESS) DOACs preferred over warfarin for NVAF Class I, Level A Ruff et al. Lancet 2014 (meta-analysis)","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/tia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - ABCD2 risk stratification included - DAPT protocols (POINT/CHANCE) incorporated - Secondary prevention comprehensive coverage</p>","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"drafts/trigeminal-neuralgia/","title":"Trigeminal Neuralgia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#trigeminal-neuralgia","title":"Trigeminal Neuralgia","text":"<p>DIAGNOSIS: Trigeminal Neuralgia ICD-10: G50.0 (Trigeminal neuralgia) SCOPE: Diagnosis, differentiation of classic (idiopathic) vs secondary TN (MS, tumor, vascular), medical and surgical management. Covers typical TN (TN1), atypical TN (TN2), and secondary TN.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Baseline before carbamazepine (bone marrow suppression risk); exclude infection Normal STAT ROUTINE ROUTINE - CMP (comprehensive metabolic panel) Baseline renal/hepatic function before carbamazepine; SIADH risk Normal STAT ROUTINE ROUTINE - HLA-B*1502 genotype Screen Asian patients before carbamazepine/oxcarbazepine (SJS/TEN risk) Negative - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU ESR, CRP Inflammatory causes; giant cell arteritis if age &gt;50 with atypical features Normal - ROUTINE ROUTINE - ANA, anti-dsDNA SLE or connective tissue disease with trigeminal involvement Negative - - ROUTINE - Lyme antibodies Endemic areas; if facial numbness or other cranial nerve involvement Negative - - ROUTINE - Vitamin B12 Deficiency can cause neuropathy &gt;300 pg/mL - ROUTINE ROUTINE - TSH Exclude thyroid dysfunction Normal - ROUTINE ROUTINE - Glucose (fasting) or HbA1c Diabetes screening; diabetic neuropathy FBG &lt;126 mg/dL; HbA1c &lt;6.5% - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU CSF analysis (cell count, protein, oligoclonal bands) MS suspected; atypical presentation Normal or OCBs if MS - EXT EXT - Anti-aquaporin-4 (NMO-IgG) Neuromyelitis optica with trigeminal involvement Negative - - EXT - Paraneoplastic antibody panel Atypical facial pain; occult malignancy Negative - - EXT - ACE level Sarcoidosis with cranial nerve involvement Normal - - EXT -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with trigeminal protocol (3T preferred; CISS/FIESTA sequences) Initial workup Neurovascular compression (SCA, AICA); rule out MS plaques, tumor, other structural cause MRI-incompatible devices URGENT ROUTINE ROUTINE - MRA Brain (circle of Willis) If MRI suggests vascular compression Confirm vascular loop (SCA, AICA) compressing trigeminal nerve Same as MRI - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with contrast Tumor suspected; atypical presentation Rule out schwannoma, meningioma, epidermoid cyst Contrast allergy; renal impairment - ROUTINE ROUTINE - MRI Spine (cervical/thoracic) MS suspected; other neurological symptoms Demyelinating lesions MRI contraindications - ROUTINE ROUTINE - CT Head MRI contraindicated; acute presentation Rule out mass, hemorrhage None STAT - - -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Trigeminal reflex testing (blink reflex, masseter reflex) Sensory loss; atypical TN Normal or abnormal R1/R2 latencies None - - EXT - Visual evoked potentials (VEPs) MS suspected Prolonged P100 latency if demyelinating None - - EXT - CT angiography MRA non-diagnostic; surgical planning Vascular anatomy for MVD Contrast allergy; renal impairment - ROUTINE EXT -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#3-treatment","title":"3. TREATMENT","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbamazepine PO Severe acute TN flare requiring rapid loading 100 mg BID; 200 mg BID :: PO :: :: Start 100-200 mg BID; may increase by 100 mg q12h if severe; max 1200 mg/day AV block; bone marrow suppression; concurrent MAOIs; HLA-B*1502 positive CBC, sodium, LFTs at baseline; sodium q2-4wk initially URGENT URGENT - - Oxcarbazepine PO Alternative if carbamazepine not tolerated; fewer drug interactions 150 mg BID; 300 mg BID :: PO :: :: Start 150-300 mg BID; may increase by 150-300 mg q3d if severe; max 1800 mg/day Hypersensitivity; HLA-B*1502 positive Sodium q2-4wk initially (higher SIADH risk than CBZ) URGENT URGENT - - IV Fosphenytoin IV Status trigeminus (severe, refractory, continuous attacks); oral medications not tolerated 15 mg PE/kg IV :: IV :: :: 15 mg PE/kg IV load over 30 min; followed by phenytoin PO or IV 100 mg TID Complete heart block; sinus bradycardia Continuous cardiac monitoring; BP STAT STAT - - Lidocaine 4% topical TOP Adjunctive for trigger point relief Apply to trigger zone :: TOP :: :: Apply to trigger zone TID-QID PRN; temporary relief None significant None URGENT URGENT ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#3b-symptomatic-treatments-first-line","title":"3B. Symptomatic Treatments (First-line)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbamazepine (Tegretol) PO First-line for classic TN; strongest evidence 100 mg BID; 200 mg BID; 200 mg TID; 300 mg TID; 400 mg TID :: PO :: :: Start 100 mg BID; increase by 100 mg q3-7d; target 600-1200 mg/day divided BID-TID; max 1200 mg/day AV block; bone marrow suppression; MAOIs; porphyria; HLA-B*1502 positive CBC, sodium, LFTs at baseline, 4wk, 8wk, then q3-6mo; drug level if needed (4-12 mcg/mL) - ROUTINE ROUTINE - Carbamazepine XR (Carbatrol, Tegretol-XR) PO Better tolerability with extended-release formulation 200 mg BID; 300 mg BID; 400 mg BID; 600 mg BID :: PO :: :: Start 200 mg BID; increase by 200 mg q1wk; max 1200 mg/day Same as IR Same as IR - ROUTINE ROUTINE - Oxcarbazepine (Trileptal) PO First-line alternative; fewer drug interactions; similar efficacy 150 mg BID; 300 mg BID; 450 mg BID; 600 mg BID :: PO :: :: Start 150-300 mg BID; increase by 150-300 mg q1wk; target 600-1800 mg/day; max 1800 mg/day Hypersensitivity; HLA-B*1502 positive Sodium at baseline, 2wk, 4wk, then q3-6mo (SIADH more common than CBZ) - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Baclofen PO Add-on to carbamazepine; or monotherapy if CBZ/OXC not tolerated 5 mg TID; 10 mg TID; 20 mg TID :: PO :: :: Start 5 mg TID; increase by 5 mg/dose q3d; target 30-80 mg/day divided TID; max 80 mg/day Severe renal impairment Sedation, dizziness; taper slowly to avoid withdrawal seizures - ROUTINE ROUTINE - Lamotrigine PO Add-on therapy; refractory TN 25 mg daily; 50 mg daily; 50 mg BID; 100 mg BID :: PO :: :: Start 25 mg daily x2wk; then 50 mg daily x2wk; increase by 50 mg q2wk; target 200-400 mg/day History of serious rash; concurrent valproate (reduce dose) Rash (SJS risk - titrate slowly) - ROUTINE ROUTINE - Gabapentin PO Add-on therapy; mild benefit as monotherapy 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: :: Start 300 mg qHS; increase by 300 mg q3d; target 900-2400 mg/day divided TID; max 3600 mg/day Severe renal impairment (dose adjust) Sedation, dizziness, edema; reduce dose in renal impairment - ROUTINE ROUTINE - Pregabalin PO Add-on therapy; possibly better tolerability than gabapentin 75 mg BID; 150 mg BID; 225 mg BID; 300 mg BID :: PO :: :: Start 75 mg BID; increase by 75-150 mg q1wk; target 150-600 mg/day; max 600 mg/day Severe renal impairment (dose adjust) Sedation, dizziness, weight gain, edema - ROUTINE ROUTINE - Phenytoin PO Historical use; add-on if other agents fail 100 mg TID; 200 mg TID :: PO :: :: Start 100 mg TID; target 300-500 mg/day; adjust by levels Complete heart block; porphyria Drug level (10-20 mcg/mL); gingival hyperplasia; CBC - ROUTINE ROUTINE - Botulinum toxin type A SC Refractory to oral medications; localized trigger zone 25-75 units :: SC :: :: 25-75 units subcutaneously into trigger zone; repeat q12wk Infection at injection site; neuromuscular disease Facial weakness, bruising - - ROUTINE - Duloxetine PO Comorbid depression; neuropathic pain component 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x1wk; increase to 60 mg daily; max 120 mg/day MAOIs; uncontrolled glaucoma; severe renal impairment BP, serotonin syndrome signs - ROUTINE ROUTINE - Pimozide PO Refractory cases; limited evidence 2 mg daily; 4 mg daily :: PO :: :: Start 2 mg daily; may increase to 4-8 mg daily; max 12 mg/day QT prolongation; concurrent QT-prolonging drugs; Parkinson's ECG (QTc); extrapyramidal symptoms - - EXT -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#3d-surgicalinterventional-therapies","title":"3D. Surgical/Interventional Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Microvascular decompression (MVD) Surgical Classic TN with vascular compression on MRI; good surgical candidate Open craniotomy :: Surgical :: :: Retromastoid craniectomy; Teflon felt between nerve and vessel; definitive treatment MRI confirming vascular compression; cardiac clearance; anesthesia clearance Poor surgical candidate; significant comorbidities; short life expectancy Post-op neuro checks; hearing assessment; CSF leak - - ROUTINE - Percutaneous glycerol rhizotomy Surgical Elderly; poor surgical candidate; MS-related TN; recurrence after MVD Glycerol injection into Meckel's cave :: Percutaneous :: :: Inject 0.2-0.4 mL glycerol via foramen ovale under fluoroscopy Coagulation studies; informed consent regarding numbness Active infection; bleeding diathesis Facial numbness (expected); corneal reflex; anesthesia dolorosa risk - - ROUTINE - Percutaneous balloon compression Surgical V1 predominant TN (preserves corneal reflex); poor surgical candidate Balloon compression :: Percutaneous :: :: Inflate balloon via foramen ovale for 60-120 seconds Coagulation studies Uncontrolled hypertension during procedure Facial numbness; masseter weakness; corneal reflex - - ROUTINE - Percutaneous radiofrequency thermocoagulation Surgical Poor surgical candidate; recurrence after other procedures RF lesioning :: Percutaneous :: :: Create lesion via foramen ovale at affected division(s) Coagulation studies; patient cooperation (awake procedure) Cannot cooperate with awake procedure Facial numbness; corneal reflex; anesthesia dolorosa risk - - ROUTINE - Gamma Knife radiosurgery (GKRS) Non-invasive Poor surgical candidate; anticoagulated; MS-related TN; recurrence 70-90 Gy to root entry zone :: Non-invasive :: :: Single fraction to trigeminal root entry zone; effect delayed 1-3 months MRI for targeting; stereotactic frame placement Tumor causing TN (requires resection) Delayed effect (weeks-months); facial numbness (10-30%); can repeat - - ROUTINE - CyberKnife stereotactic radiosurgery Non-invasive Alternative to Gamma Knife; frameless option 60-75 Gy :: Non-invasive :: :: Frameless stereotactic radiosurgery to trigeminal root MRI for targeting Same as GKRS Same as GKRS - - EXT -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology referral for diagnosis confirmation, medication optimization, and long-term management ROUTINE ROUTINE ROUTINE - Neurosurgery consultation for surgical evaluation if medication refractory or vascular compression on imaging - ROUTINE ROUTINE - Pain management referral for multidisciplinary approach and interventional options - - ROUTINE - Oral surgery or dentistry to rule out dental pathology mimicking TN - - ROUTINE - Neuro-ophthalmology if V1 involvement with corneal reflex concerns - ROUTINE ROUTINE - Psychiatry or psychology for coping strategies given chronic severe pain and depression risk - - ROUTINE - Ophthalmology for corneal protection if reduced corneal sensation after procedure - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Avoid known triggers such as cold wind, touching face, eating, brushing teeth, or talking when possible ROUTINE ROUTINE ROUTINE Return immediately if facial weakness, hearing changes, or fever develop after procedure (may indicate serious complication) - ROUTINE ROUTINE Do not stop carbamazepine or oxcarbazepine abruptly as this may cause rebound pain or seizures ROUTINE ROUTINE ROUTINE Report any skin rash, mouth sores, or fever immediately (may indicate serious drug reaction SJS/TEN) ROUTINE ROUTINE ROUTINE Monitor for signs of low sodium (confusion, nausea, headache, muscle cramps) especially in first weeks on carbamazepine/oxcarbazepine ROUTINE ROUTINE ROUTINE Report any easy bruising, bleeding, or frequent infections (may indicate bone marrow suppression) ROUTINE ROUTINE ROUTINE Keep a pain diary to track triggers, severity, and medication effectiveness - ROUTINE ROUTINE Protect eye on affected side if corneal sensation reduced after surgery (use lubricating drops, protective eyewear) - ROUTINE ROUTINE Soft diet may reduce triggered attacks during flares ROUTINE ROUTINE ROUTINE","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Avoid extreme cold or wind to face (use scarf or mask in cold weather) - ROUTINE ROUTINE Maintain good dental hygiene to prevent dental infections that may worsen or mimic TN - ROUTINE ROUTINE Stress reduction techniques (meditation, relaxation) as stress can exacerbate attacks - ROUTINE ROUTINE Use lukewarm water for face washing; avoid very cold water - ROUTINE ROUTINE Consider electric toothbrush with soft bristles to minimize trigger stimulation - - ROUTINE Eat softer foods during flare periods to reduce chewing-triggered attacks - ROUTINE ROUTINE Avoid alcohol which may interact with medications and worsen symptoms - ROUTINE ROUTINE Join TN support groups for coping strategies and emotional support - - ROUTINE","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Dental pathology (pulpitis, periapical abscess, cracked tooth) Constant aching pain; thermal sensitivity; localized to tooth; percussion tenderness Dental exam and imaging; periapical X-rays Temporomandibular joint disorder (TMD) Jaw pain; clicking/popping; pain with chewing; muscle tenderness TMJ exam; imaging if needed Cluster headache Severe unilateral orbital pain; autonomic symptoms (lacrimation, rhinorrhea, ptosis); lasts 15-180 min Clinical history; no trigger by light touch Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA) Very brief attacks (seconds); prominent autonomic features; no refractory period Clinical features; MRI to rule out pituitary lesion Persistent idiopathic facial pain (atypical facial pain) Constant daily pain; poorly localized; no triggers; often psychological component Diagnosis of exclusion; normal imaging Postherpetic neuralgia History of shingles in trigeminal distribution; constant burning pain; allodynia History of vesicles; sensory loss in dermatome Multiple sclerosis (secondary TN) Younger age; bilateral TN; other neurological symptoms/signs; MS lesion on MRI MRI brain/spine; CSF oligoclonal bands; evoked potentials Trigeminal schwannoma Progressive sensory loss; facial weakness; may have TN-like pain MRI with contrast (enhancing mass at cerebellopontine angle) Meningioma (skull base) Progressive symptoms; may have cranial nerve palsies MRI with contrast (dural-based enhancing mass) Glossopharyngeal neuralgia Pain in throat, ear, tongue; triggered by swallowing; similar shock-like quality Clinical localization; pain in different distribution Giant cell arteritis Age &gt;50; temporal headache; jaw claudication; elevated ESR/CRP ESR, CRP, temporal artery biopsy Trigeminal neuropathy Constant numbness or pain; sensory loss on exam; not shock-like Trigeminal reflex testing; MRI for cause","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Pain severity (NRS 0-10, attack frequency) Each visit 50%+ reduction; acceptable quality of life Uptitrate medication; add second agent; consider surgery - ROUTINE ROUTINE - CBC with differential (carbamazepine) Baseline, 4wk, 8wk, then q3-6mo WBC &gt;3000; ANC &gt;1500; platelets &gt;100k Hold medication if bone marrow suppression; hematology consult - ROUTINE ROUTINE - Serum sodium (carbamazepine/oxcarbazepine) Baseline, 2wk, 4wk, 8wk, then q3-6mo &gt;125 mEq/L Fluid restriction; consider dose reduction or switch; severe hyponatremia requires urgent treatment STAT ROUTINE ROUTINE - LFTs (AST, ALT, ALP) Baseline, 4wk, 8wk, then q3-6mo ALT/AST &lt;3x ULN Reduce dose or discontinue if significant elevation - ROUTINE ROUTINE - Carbamazepine level If toxicity suspected; adherence concerns; drug interactions 4-12 mcg/mL Adjust dose accordingly - ROUTINE ROUTINE - Skin exam Each visit; urgent if rash No rash Discontinue immediately if rash with systemic symptoms (SJS risk) STAT ROUTINE ROUTINE - Corneal reflex (if V1 TN or post-procedure) Post-procedure; each follow-up Intact Eye protection; ophthalmology referral; lubricating drops - ROUTINE ROUTINE - Neurological exam (sensory, motor, reflexes) Each visit Stable or improved; no new deficits Re-evaluate diagnosis if progressive; repeat imaging - ROUTINE ROUTINE - ECG (if on phenytoin, pimozide) Baseline; with dose changes Normal QTc (&lt;470 ms men, &lt;480 ms women) Reduce dose or discontinue if QTc prolonged - ROUTINE ROUTINE -","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild-moderate pain controlled with oral medications; able to eat and drink; no concerning symptoms; follow-up arranged Admit to floor Severe uncontrolled pain requiring IV medications or monitoring; unable to take oral medications; significant hyponatremia; new neurological deficits requiring workup Admit to ICU Rarely needed; severe hyponatremia with altered mental status; anaphylaxis to medication Outpatient follow-up 2-4 weeks initially for medication titration and lab monitoring; then every 3-6 months when stable Surgical referral criteria Failed 2+ medications at adequate doses; intolerable side effects; vascular compression on MRI; patient preference for definitive treatment","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Carbamazepine first-line for classic TN Class I, Level A Cruccu et al. Eur J Neurol 2008 (EFNS Guidelines) Oxcarbazepine effective alternative to carbamazepine Class II, Level B Di Stefano et al. Drugs 2018 HLA-B*1502 screening in Asian patients before carbamazepine Class I, Level A Chen et al. NEJM 2011 Baclofen add-on therapy for TN Class III, Level C Fromm et al. Arch Neurol 1984 Lamotrigine add-on for refractory TN Class III, Level C Zakrzewska et al. Pain 1997 MVD superior long-term outcomes Class II, Level B Barker et al. NEJM 1996 Gamma Knife for TN Class II, Level B Kondziolka et al. Stereotact Funct Neurosurg 2010 Percutaneous procedures for TN Class III, Level C Kanpolat et al. Neurosurgery 2001 Botulinum toxin for refractory TN Class II, Level B Shehata et al. J Headache Pain 2013 MRI with CISS/FIESTA for TN evaluation Class II, Level B Becker et al. Radiology 2010 ICHD-3 classification of TN Expert consensus Headache Classification Committee. Cephalalgia 2018 Comprehensive TN management review Expert review Cruccu et al. Nat Rev Neurol 2020","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of classic and secondary TN - First-line (carbamazepine, oxcarbazepine) and second-line medical therapies - Surgical options including MVD, percutaneous procedures, and stereotactic radiosurgery - Structured dosing format for order sentence generation - PubMed citations with verified PMIDs</p>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#appendix-a-tn-classification-ichd-3","title":"APPENDIX A: TN Classification (ICHD-3)","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#classical-trigeminal-neuralgia-tn1","title":"Classical Trigeminal Neuralgia (TN1)","text":"<ul> <li>Paroxysmal attacks lasting fraction of a second to 2 minutes</li> <li>Unilateral distribution in trigeminal territory</li> <li>Triggered by innocuous stimuli (light touch, chewing, talking, cold wind)</li> <li>Electric shock-like, shooting, stabbing quality</li> <li>Stereotyped in individual patient</li> <li>No neurological deficit</li> <li>MRI shows neurovascular compression OR is normal</li> </ul>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#secondary-trigeminal-neuralgia","title":"Secondary Trigeminal Neuralgia","text":"<ul> <li>Same attack characteristics as classical TN</li> <li>Underlying cause identified:</li> <li>Multiple sclerosis (demyelinating lesion in root entry zone)</li> <li>Tumor (schwannoma, meningioma, epidermoid)</li> <li>Arteriovenous malformation</li> <li>Other structural lesion</li> <li>May have neurological deficit (sensory loss, weakness)</li> </ul>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#idiopathic-trigeminal-neuralgia","title":"Idiopathic Trigeminal Neuralgia","text":"<ul> <li>Same attack characteristics as classical TN</li> <li>No neurovascular compression on imaging</li> <li>No identified secondary cause</li> </ul>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#trigeminal-neuralgia-with-concomitant-continuous-pain-tn2atypical","title":"Trigeminal Neuralgia with Concomitant Continuous Pain (TN2/Atypical)","text":"<ul> <li>Classical TN attacks PLUS</li> <li>Continuous or near-continuous background pain in same distribution</li> <li>More difficult to treat; may indicate central sensitization</li> </ul>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#appendix-b-carbamazepine-drug-interactions","title":"APPENDIX B: Carbamazepine Drug Interactions","text":"","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#major-interactions-avoid-or-adjust","title":"Major Interactions (Avoid or Adjust)","text":"Drug/Class Interaction Management MAOIs Serotonin syndrome risk Contraindicated Nefazodone Decreased CBZ metabolism; increased toxicity Avoid Oral contraceptives Decreased efficacy (CYP3A4 induction) Use alternative contraception Warfarin Decreased warfarin effect Monitor INR closely Doxycycline Decreased doxycycline levels Use alternative antibiotic Macrolide antibiotics Increased CBZ levels (CYP3A4 inhibition) Monitor for toxicity Azole antifungals Increased CBZ levels Monitor for toxicity HIV protease inhibitors Variable; decreased PI levels Avoid or use with caution Grapefruit juice Increased CBZ absorption Avoid","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#autoinduction","title":"Autoinduction","text":"<ul> <li>Carbamazepine induces its own metabolism</li> <li>Steady-state levels decrease 3-4 weeks after initiation</li> <li>May need dose increase after 2-4 weeks</li> </ul>","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/trigeminal-neuralgia/#appendix-c-surgical-option-comparison","title":"APPENDIX C: Surgical Option Comparison","text":"Procedure Pain-Free Rate (1yr) Pain-Free Rate (5yr) Recurrence Numbness Advantages Disadvantages MVD 90-95% 70-80% 20-30% 2-5% Definitive; preserves sensation; lowest recurrence Craniotomy; general anesthesia; serious complication risk (1-2%) Gamma Knife 75-85% 50-60% 40-50% 10-30% Non-invasive; outpatient Delayed effect (weeks-months); higher recurrence Glycerol rhizotomy 70-90% 50-60% 50-70% 50-70% Percutaneous; quick recovery High numbness rate; shorter duration Balloon compression 80-90% 50-60% 40-60% 50-90% Good for V1 TN; preserves corneal reflex Numbness common; shorter duration RF thermocoagulation 85-95% 50-60% 50-75% 80-100% Precise targeting; immediate effect Numbness universal; anesthesia dolorosa risk","tags":["facial-pain","neuropathic-pain","outpatient"]},{"location":"drafts/vascular-dementia/","title":"Vascular Dementia","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#vascular-dementia","title":"Vascular Dementia","text":"<p>DIAGNOSIS: Vascular Dementia ICD-10: F01.50 (Vascular dementia without behavioral disturbance); F01.51 (Vascular dementia with behavioral disturbance); I67.3 (Progressive vascular leukoencephalopathy - Binswanger disease); I67.89 (Other cerebrovascular disease) SCOPE: Diagnosis using NINDS-AIREN and DSM-5 criteria, neuroimaging evaluation for strategic infarcts and white matter disease, vascular risk factor modification, secondary stroke prevention, cholinesterase inhibitors for cognitive symptoms, and management of post-stroke depression, apathy, and behavioral symptoms. Primarily outpatient-focused with coverage for ED and hospital presentations.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#1a-essentialcore-labs-reversible-causes-and-vascular-risk-factors","title":"1A. Essential/Core Labs (Reversible Causes and Vascular Risk Factors)","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Polycythemia, anemia, infection affecting cognition Normal STAT STAT ROUTINE - BMP (Na, K, BUN, Cr, glucose) Metabolic causes of confusion; renal function for medication dosing Normal electrolytes, renal function STAT STAT ROUTINE - TSH Hypothyroidism is reversible cause of cognitive impairment 0.4-4.0 mIU/L URGENT ROUTINE ROUTINE - Vitamin B12 Deficiency causes reversible cognitive decline and may worsen vascular dementia &gt;300 pg/mL (&gt;400 optimal) URGENT ROUTINE ROUTINE - Folate Deficiency contributes to hyperhomocysteinemia and cognitive impairment &gt;3 ng/mL - ROUTINE ROUTINE - Hemoglobin A1c Diabetes is major vascular risk factor; assess chronic glucose control &lt;7.0% (individualized 7-8% in frail elderly) URGENT ROUTINE ROUTINE - Fasting lipid panel Assess LDL for secondary stroke prevention; target &lt;70 mg/dL LDL &lt;70 mg/dL - ROUTINE ROUTINE - Urinalysis UTI common cause of acute confusion in elderly Negative for infection STAT STAT ROUTINE - PT/INR, PTT Baseline coagulation; assess if on anticoagulation Normal or therapeutic STAT ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Homocysteine Elevated levels increase stroke risk and contribute to vascular dementia &lt;15 \u03bcmol/L - ROUTINE ROUTINE - Lipoprotein(a) Independent cardiovascular risk marker; elevated increases stroke risk &lt;50 nmol/L (or &lt;30 mg/dL) - ROUTINE ROUTINE - hsCRP Inflammatory marker; elevated predicts vascular events &lt;2 mg/L - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency associated with cognitive decline and vascular disease &gt;30 ng/mL - ROUTINE ROUTINE - RPR or VDRL Neurosyphilis is treatable cause of dementia Nonreactive - ROUTINE ROUTINE - HIV testing HIV-associated neurocognitive disorder if risk factors Negative - ROUTINE ROUTINE - Hepatic panel (AST, ALT, albumin) Hepatic encephalopathy; nutritional status; statin safety Normal - ROUTINE ROUTINE - BNP/NT-proBNP Heart failure; atrial fibrillation risk assessment Age-adjusted normal URGENT ROUTINE ROUTINE - Uric acid Elevated associated with increased stroke and dementia risk &lt;6 mg/dL - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU APOE genotyping Risk stratification; mixed AD/VaD assessment APOE status for prognosis - - ROUTINE - Hypercoagulability panel Age &lt;50, cryptogenic strokes, recurrent events Negative - EXT EXT - Antiphospholipid antibodies Lupus anticoagulant, anticardiolipin; young-onset vascular disease Negative - EXT EXT - ESR, ANA Suspected CNS vasculitis causing multi-infarct state Normal/Negative - EXT EXT - ANCA panel Vasculitis workup if suspected Negative - EXT EXT - Fabry disease testing (alpha-galactosidase A) Young-onset stroke; angiokeratomas; neuropathy Normal enzyme activity - - EXT - NOTCH3 genetic testing Suspected CADASIL (family history, migraine, early WM disease) No pathogenic mutation - - EXT - Mitochondrial DNA analysis Suspected MELAS or mitochondrial disease No pathogenic mutation - - EXT -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At initial evaluation Strategic infarcts (thalamus, basal ganglia, angular gyrus); confluent white matter hyperintensities (Fazekas \u22652); lacunar infarcts MRI-incompatible devices, severe claustrophobia URGENT ROUTINE ROUTINE - CT Head non-contrast If MRI unavailable or contraindicated Rule out hemorrhage, mass, hydrocephalus; may show old infarcts, leukoaraiosis None STAT STAT ROUTINE - MRA Head and Neck With initial MRI Intracranial and extracranial atherosclerosis; assess for stenosis &gt;50% MRI contraindications URGENT ROUTINE ROUTINE - CTA Head and Neck Alternative to MRA Vascular stenosis; atherosclerotic burden Contrast allergy, CKD (relative) URGENT ROUTINE ROUTINE - Carotid duplex ultrasound Within 1 week of diagnosis Assess carotid stenosis; plaque characterization None - ROUTINE ROUTINE - ECG (12-lead) At diagnosis Assess for atrial fibrillation, LVH, prior MI None STAT STAT ROUTINE - Transthoracic echocardiogram Within 2 weeks LV function; valvular disease; intracardiac thrombus None - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain with SWI/GRE sequences With initial MRI Microbleeds (cerebral amyloid angiopathy pattern vs hypertensive); hemosiderin MRI contraindications - ROUTINE ROUTINE - MRI volumetrics Baseline for progression Quantify white matter lesion volume; global and regional atrophy MRI contraindications - - ROUTINE - FDG-PET Brain Differentiate VaD from AD; atypical cases Scattered hypometabolism (vs temporoparietal in AD) None - - ROUTINE - Amyloid PET Distinguish pure VaD from mixed AD/VaD Negative suggests pure VaD; positive suggests mixed pathology None - - EXT - Cardiac telemetry/Holter monitor Screen for paroxysmal AF Sinus rhythm; detect occult AF None URGENT ROUTINE - - Extended cardiac monitoring (14-30 day) Cryptogenic strokes; suspected occult AF Sinus rhythm; detect paroxysmal AF None - - ROUTINE - EEG Encephalopathy; seizures; rapid decline Non-specific slowing (not CJD pattern) None URGENT ROUTINE ROUTINE - Sleep study (polysomnography) Sleep apnea is vascular risk factor; assess for OSA AHI &lt;5 (or treat if elevated) None - - ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Vessel wall MRI Suspected CNS vasculitis or reversible vasoconstriction No vessel wall enhancement or thickening MRI contraindications - EXT EXT - DSA (cerebral angiogram) Vasculitis confirmation; moyamoya; intracranial stenosis Define vascular anatomy Contrast allergy, bleeding risk - EXT EXT - SPECT (perfusion) Alternative to PET if unavailable Regional hypoperfusion patterns None - - EXT - Transesophageal echocardiogram Cryptogenic strokes; suspected aortic arch atheroma or PFO No embolic source Esophageal pathology - EXT EXT -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Atypical presentation; rapid progression; suspected CNS vasculitis or infection; young-onset (&lt;65); differentiate from AD or inflammatory causes Timing: ROUTINE for diagnostic clarification; URGENT if infectious or inflammatory etiology suspected Volume Required: 10-15 mL standard diagnostic</p> Study Rationale Target Finding ED HOSP OPD ICU Cell count, protein, glucose Rule out infection, inflammation, vasculitis WBC &lt;5, protein &lt;45 mg/dL, glucose &gt;60% serum URGENT ROUTINE ROUTINE - CSF A\u03b242 and A\u03b242/A\u03b240 ratio Differentiate from Alzheimer's disease Normal A\u03b242 in pure VaD; low suggests mixed AD/VaD - ROUTINE ROUTINE - CSF total tau and p-tau181 Elevated in AD; can help distinguish VaD from AD Normal or mildly elevated in pure VaD; high p-tau suggests AD - ROUTINE ROUTINE - CSF NfL (neurofilament light) Non-specific marker of neuronal damage; elevated in vascular injury Elevated suggests ongoing neurodegeneration - ROUTINE ROUTINE - Oligoclonal bands, IgG index Rule out inflammatory/demyelinating disease Negative - ROUTINE ROUTINE - VDRL Neurosyphilis Nonreactive - ROUTINE ROUTINE - Autoimmune encephalitis panel Atypical presentation; subacute onset Negative - EXT EXT - <p>Special Handling: CSF biomarkers require polypropylene tubes; freeze within 1 hour; send to qualified reference lab Contraindications: Coagulopathy (INR &gt;1.5, platelets &lt;50k); mass effect on imaging; skin infection at puncture site</p>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3-treatment","title":"3. TREATMENT","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Treat reversible causes Various Identified metabolic or infectious etiology Per specific cause :: Various :: :: Correct hyponatremia slowly, treat UTI, replace B12, treat hypothyroidism Depends on intervention Cognitive reassessment after treatment STAT STAT ROUTINE - Thiamine IV/PO Suspected Wernicke's; alcoholism; malnutrition 500 mg IV TID x 3 days; 100 mg PO daily :: IV/PO :: :: 500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily maintenance None Clinical improvement in confusion STAT STAT ROUTINE - Aspirin PO Immediate antiplatelet therapy for secondary stroke prevention 325 mg PO x1 load; 81 mg PO daily :: PO :: :: 325 mg loading dose if no recent stroke, then 81 mg daily ongoing Active GI bleed; aspirin allergy GI symptoms, bleeding STAT STAT ROUTINE - Blood pressure management (acute) Various Acute delirium or new stroke Target &lt;180/110 acutely :: Various :: :: Do NOT lower BP aggressively unless &gt;220/120 or end-organ damage; permissive hypertension first 24-48h of stroke Symptomatic hypotension BP q1h initially STAT STAT - -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3b-vascular-risk-factor-modification-secondary-stroke-prevention","title":"3B. Vascular Risk Factor Modification (Secondary Stroke Prevention)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Atorvastatin PO High-intensity statin for secondary stroke prevention; LDL target &lt;70 40 mg daily; 80 mg daily :: PO :: :: Start 40-80 mg daily; target LDL &lt;70 mg/dL; 80 mg preferred for established vascular disease Active liver disease; pregnancy LFTs at baseline, 6-12 weeks, then annually; myalgias - ROUTINE ROUTINE - Rosuvastatin PO Alternative high-intensity statin; may be better tolerated 20 mg daily; 40 mg daily :: PO :: :: Start 20 mg daily; max 40 mg; potent LDL lowering Active liver disease; pregnancy; Asian dose adjustment (10 mg start) LFTs; myalgias; CK if symptomatic - ROUTINE ROUTINE - Aspirin (long-term) PO Lifelong antiplatelet for secondary stroke prevention 81 mg daily :: PO :: :: 81 mg daily indefinitely for non-cardioembolic vascular dementia Active GI bleeding; aspirin allergy GI symptoms; annual CBC - ROUTINE ROUTINE - Clopidogrel PO Alternative to aspirin if aspirin-intolerant; or after DAPT period 75 mg daily :: PO :: :: 75 mg daily; may use instead of aspirin if intolerant Active bleeding Bleeding signs - ROUTINE ROUTINE - Lisinopril PO Blood pressure control; target &lt;130/80 for secondary prevention 5 mg daily; 10 mg daily; 20 mg daily; 40 mg daily :: PO :: :: Start 5-10 mg daily; titrate to goal BP &lt;130/80; max 40 mg daily Angioedema history; pregnancy; bilateral RAS; hyperkalemia K+, Cr at 1-2 weeks; BP - ROUTINE ROUTINE - Amlodipine PO BP control; add-on or alternative antihypertensive 5 mg daily; 10 mg daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily Severe aortic stenosis (relative) Peripheral edema; BP - ROUTINE ROUTINE - Chlorthalidone PO Thiazide-like diuretic for BP control; effective for stroke prevention 12.5 mg daily; 25 mg daily :: PO :: :: Start 12.5 mg daily; may increase to 25 mg daily Severe hypokalemia; hyponatremia K+, Na+, uric acid, glucose - ROUTINE ROUTINE - Metformin PO First-line for type 2 diabetes if eGFR &gt;30 500 mg daily; 500 mg BID; 1000 mg BID :: PO :: :: Start 500 mg daily with meal; titrate by 500 mg weekly; max 2000-2550 mg/day in divided doses eGFR &lt;30; acute illness; contrast within 48h eGFR; B12 annually; lactic acidosis symptoms - ROUTINE ROUTINE - Empagliflozin PO SGLT2 inhibitor for diabetes with cardiovascular benefit 10 mg daily; 25 mg daily :: PO :: :: Start 10 mg daily; may increase to 25 mg; cardiovascular mortality benefit eGFR &lt;20; Type 1 DM; DKA history eGFR; volume status; genital infections - ROUTINE ROUTINE - Ezetimibe PO Add-on for LDL not at goal on statin 10 mg daily :: PO :: :: 10 mg daily with or without food Severe hepatic impairment LDL; LFTs - ROUTINE ROUTINE - Apixaban PO Atrial fibrillation-related vascular dementia 5 mg BID; 2.5 mg BID :: PO :: :: 5 mg BID (2.5 mg BID if \u22652 of: age \u226580, weight \u226460 kg, Cr \u22651.5) Active major bleeding; mechanical valve CrCl; bleeding signs - ROUTINE ROUTINE - Rivaroxaban PO AF-related vascular dementia 20 mg daily; 15 mg daily :: PO :: :: 20 mg daily with dinner (15 mg if CrCl 15-50) Active bleeding; mechanical valve CrCl; bleeding - ROUTINE ROUTINE - Warfarin PO Mechanical valve; select hypercoagulable states; AF if DOACs contraindicated 2-10 mg daily adjusted :: PO :: :: Start 5 mg daily; adjust to INR 2-3 Active bleeding; frequent falls; poor adherence INR weekly then monthly - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3c-cholinesterase-inhibitors-cognitive-enhancement-modest-benefit","title":"3C. Cholinesterase Inhibitors (Cognitive Enhancement - Modest Benefit)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Donepezil (Aricept) PO Vascular dementia cognitive symptoms; modest but measurable benefit 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS x 4-6 weeks; if tolerated, increase to 10 mg qHS; benefit smaller than in AD Sick sinus syndrome; second/third degree heart block without pacemaker; active GI bleeding Heart rate; GI symptoms (nausea, diarrhea); vivid dreams - ROUTINE ROUTINE - Rivastigmine oral (Exelon) PO Vascular dementia; executive dysfunction; may help mixed AD/VaD 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID :: PO :: :: Start 1.5 mg BID with meals; increase by 1.5 mg BID every 2 weeks; target 6 mg BID Sick sinus; severe hepatic impairment GI symptoms; weight loss; bradycardia - ROUTINE ROUTINE - Rivastigmine patch (Exelon Patch) TD Vascular dementia; better GI tolerability than oral 4.6 mg/24hr; 9.5 mg/24hr; 13.3 mg/24hr :: TD :: :: Start 4.6 mg/24hr patch; increase every 4 weeks; target 9.5-13.3 mg/24hr Same as oral Skin irritation; rotate sites - ROUTINE ROUTINE - Galantamine (Razadyne) PO Vascular dementia; dual mechanism may benefit executive function 4 mg BID; 8 mg BID; 12 mg BID :: PO :: :: Start 4 mg BID with meals x 4 weeks; increase to 8 mg BID x 4 weeks; target 8-12 mg BID Sick sinus; severe renal impairment (CrCl &lt;9); severe hepatic impairment GI symptoms; bradycardia - ROUTINE ROUTINE - Memantine (Namenda) PO Moderate-severe vascular dementia; add to cholinesterase inhibitor 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily x 1 week; increase by 5 mg/week: 5 mg BID, then 5/10 mg, then 10 mg BID Severe renal impairment (reduce dose if CrCl 5-29: max 5 mg BID) Confusion, dizziness, constipation - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3d-post-stroke-depression-and-apathy","title":"3D. Post-Stroke Depression and Apathy","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Sertraline (Zoloft) PO Post-stroke depression (evidence-based; FLAME trial); first-line 25 mg daily; 50 mg daily; 100 mg daily; 150 mg daily :: PO :: :: Start 25 mg daily; increase by 25 mg every 1-2 weeks; typical 50-100 mg daily; max 200 mg MAOIs; concurrent QT-prolonging drugs (high doses) GI upset initially; bleeding risk with anticoagulants; sexual dysfunction - ROUTINE ROUTINE - Escitalopram (Lexapro) PO Post-stroke depression; well-tolerated in elderly 5 mg daily; 10 mg daily; 20 mg daily :: PO :: :: Start 5 mg daily in elderly; increase to 10 mg after 1 week; max 20 mg (10 mg if &gt;65y) MAOIs; QT prolongation QTc if cardiac risk; GI symptoms - ROUTINE ROUTINE - Citalopram (Celexa) PO Depression; agitation in dementia 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly due to QT prolongation risk QT prolongation; concurrent QT-prolonging drugs ECG at baseline if cardiac risk; QTc monitoring - ROUTINE ROUTINE - Mirtazapine (Remeron) PO Depression with poor appetite, weight loss, and insomnia 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30-45 mg qHS; lower doses more sedating MAOIs; angle-closure glaucoma Weight gain (often desired); sedation - ROUTINE ROUTINE - Bupropion SR/XL PO Depression with fatigue and apathy; no sexual side effects; avoid if seizure risk 100 mg SR daily; 150 mg SR BID; 150 mg XL daily; 300 mg XL daily :: PO :: :: Start 100 mg SR daily or 150 mg XL daily; may increase after 3 days; max 400 mg/day Seizure disorder; anorexia/bulimia; abrupt alcohol/benzo withdrawal Seizure risk; insomnia; anxiety - ROUTINE ROUTINE - Methylphenidate PO Apathy refractory to antidepressants; psychomotor retardation 2.5 mg BID; 5 mg BID; 10 mg BID :: PO :: :: Start 2.5-5 mg BID (morning and noon); titrate by 2.5-5 mg every 3-5 days; max 30 mg/day Severe hypertension; cardiac arrhythmias; hyperthyroidism; glaucoma BP, HR; appetite; sleep - EXT ROUTINE - Modafinil PO Apathy; fatigue; excessive daytime sleepiness 100 mg daily; 200 mg daily :: PO :: :: Start 100 mg each morning; may increase to 200 mg daily Severe hepatic impairment; cardiac arrhythmias BP, HR; sleep disturbance - EXT ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#3e-behavioral-and-psychological-symptoms-of-dementia-bpsd","title":"3E. Behavioral and Psychological Symptoms of Dementia (BPSD)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Trazodone PO Insomnia; sundowning; mild agitation 25 mg qHS; 50 mg qHS; 100 mg qHS; 150 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25-50 mg every 3-5 days; typical 50-150 mg qHS MAOIs; significant QT prolongation Orthostatic hypotension (fall risk); priapism (rare) - ROUTINE ROUTINE - Melatonin PO Sleep disturbance; circadian rhythm dysfunction; sundowning 3 mg qHS; 6 mg qHS :: PO :: :: Start 3 mg qHS, 30 min before bed; may increase to 6 mg if needed None significant Daytime drowsiness - ROUTINE ROUTINE - Quetiapine (Seroquel) PO Severe agitation/psychosis when non-pharmacologic interventions fail 12.5 mg qHS; 25 mg qHS; 25 mg BID; 50 mg BID :: PO :: :: Start 12.5-25 mg qHS; titrate slowly; keep dose as low as possible Black box: increased mortality and stroke in dementia; Parkinson's (less risk than others) Metabolic effects; sedation; falls; QTc - EXT ROUTINE - Risperidone (Risperdal) PO Severe aggression/psychosis (short-term use only) 0.25 mg BID; 0.5 mg BID; 1 mg BID :: PO :: :: Start 0.25 mg BID; increase by 0.25 mg BID weekly; max 1 mg BID; limit to 6-12 weeks Black box: increased mortality and CVA in dementia EPS, metabolic effects, stroke risk, prolactin - EXT ROUTINE - Haloperidol IM/IV/PO Acute severe agitation in delirium-crisis only (avoid chronic use) 0.5 mg IM; 1 mg IM; 2 mg IM :: IM/IV/PO :: :: 0.5-2 mg IM/IV q4-6h PRN; short-term acute use only; avoid chronic use in dementia QT prolongation; Parkinson's disease QTc; EPS; akathisia STAT EXT - - Carbamazepine PO Agitation/aggression refractory to other treatments 100 mg BID; 200 mg BID :: PO :: :: Start 100 mg BID; titrate to 200-400 mg BID based on response; monitor levels Bone marrow suppression; AV block CBC; LFTs; Na; drug levels - EXT ROUTINE - Dextromethorphan-quinidine (Nuedexta) PO Pseudobulbar affect (emotional lability) post-stroke 20/10 mg daily; 20/10 mg BID :: PO :: :: Start 20/10 mg daily x 7 days, then increase to 20/10 mg BID MAOIs; concurrent quinidine; prolonged QT; complete heart block QTc; drug interactions (quinidine inhibits CYP2D6) - ROUTINE ROUTINE - <p>Non-Pharmacologic Approaches (First-Line for BPSD): - Identify and treat underlying causes (pain, infection, constipation, urinary retention) - Environmental modifications (reduce noise, adequate lighting, consistent routine) - Music therapy, reminiscence therapy, art therapy - Structured activities appropriate to cognitive level - Caregiver education on redirection and validation techniques - Avoid confrontation; redirect instead</p>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Cognitive neurology for diagnosis confirmation, differentiation from AD, and treatment planning - ROUTINE ROUTINE - Neuropsychology for formal cognitive testing to characterize executive dysfunction and memory profile - - ROUTINE - Cardiology for atrial fibrillation management, anticoagulation decisions, and heart failure optimization - ROUTINE ROUTINE - Vascular surgery consultation for symptomatic carotid stenosis \u226550% to evaluate for endarterectomy - URGENT ROUTINE - Physical therapy for gait training, balance assessment, and fall prevention given motor involvement - ROUTINE ROUTINE - Occupational therapy for ADL assessment, cognitive strategies, and home safety evaluation - ROUTINE ROUTINE - Speech therapy for communication strategies, cognitive-linguistic exercises, and swallowing evaluation if dysphagia - ROUTINE ROUTINE - Social work for caregiver support resources, community services, and long-term care planning - ROUTINE ROUTINE - Geriatric psychiatry for behavioral symptoms, depression management, and capacity evaluation - ROUTINE ROUTINE - Registered dietitian for Mediterranean/DASH diet counseling and sodium restriction education - ROUTINE ROUTINE - Smoking cessation program with pharmacotherapy for current smokers - ROUTINE ROUTINE - Sleep medicine for obstructive sleep apnea evaluation and CPAP initiation if indicated - - ROUTINE - Palliative care for advanced vascular dementia symptom management and goals of care discussions - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 immediately if new stroke symptoms develop (sudden weakness, speech difficulty, vision changes) STAT STAT ROUTINE Return immediately if sudden worsening of confusion which may indicate new stroke, infection, or delirium STAT STAT ROUTINE Take all medications as prescribed especially antiplatelet/anticoagulant and statin which prevent further strokes - ROUTINE ROUTINE Complete advance directives (living will, healthcare proxy, POLST) while patient has capacity - ROUTINE ROUTINE Do not drive if cognitive impairment affects judgment or reaction time; formal driving evaluation may be needed - ROUTINE ROUTINE Use pill organizers, alarms, or caregiver supervision to ensure medication adherence - ROUTINE ROUTINE Check blood pressure at home regularly; notify provider if consistently &gt;140/90 or &lt;90/60 - ROUTINE ROUTINE Wear medical alert bracelet with diagnosis and emergency contact in case of wandering or emergency - ROUTINE ROUTINE Keep environment safe: remove throw rugs, install grab bars, ensure adequate lighting, secure stove knobs - ROUTINE ROUTINE","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Blood pressure target &lt;130/80 mmHg to reduce progression and prevent further strokes (SPRINT-MIND data) - ROUTINE ROUTINE LDL target &lt;70 mg/dL with high-intensity statin for secondary vascular prevention - ROUTINE ROUTINE Smoking cessation immediately; reduces stroke risk by 50% within 1 year of quitting - ROUTINE ROUTINE Mediterranean or MIND diet emphasizing vegetables, berries, fish, whole grains, nuts, and olive oil - ROUTINE ROUTINE Limit sodium to &lt;2300 mg/day (ideally &lt;1500 mg if hypertensive) to improve blood pressure control - ROUTINE ROUTINE Limit alcohol to \u22641 drink daily as excess alcohol increases stroke risk and worsens cognition - ROUTINE ROUTINE Regular aerobic exercise (150 min/week moderate intensity) to improve cardiovascular health and cognition - ROUTINE ROUTINE Treat obstructive sleep apnea with CPAP as OSA worsens vascular risk and cognitive function - ROUTINE ROUTINE Strict glycemic control (HbA1c &lt;7% or individualized 7-8% in frail elderly) to reduce microvascular damage - ROUTINE ROUTINE Social engagement and cognitive stimulation to support cognitive reserve - ROUTINE ROUTINE Weight management with target BMI 18.5-27 kg/m\u00b2 (less stringent in elderly) - ROUTINE ROUTINE Fall prevention with home safety modifications and assistive devices as needed - ROUTINE ROUTINE CPAP compliance for sleep apnea patients to reduce nocturnal hypoxia and vascular events - - ROUTINE","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Alzheimer's disease Insidious onset; gradual decline; memory predominant; no focal signs; no stepwise progression MRI: hippocampal atrophy without significant WM disease; CSF A\u03b242 low, p-tau elevated; amyloid PET positive Mixed dementia (AD + VaD) Features of both; memory impairment with vascular burden Amyloid PET positive with significant WM disease; CSF biomarkers show AD pattern Dementia with Lewy bodies Visual hallucinations; parkinsonism; REM sleep behavior disorder; fluctuating cognition DaTscan reduced; clinical criteria; may have less WM disease Frontotemporal dementia (behavioral) Personality/behavior changes; disinhibition; apathy; hyperorality; often age &lt;65 FDG-PET frontal hypometabolism; less vascular disease on MRI Normal pressure hydrocephalus Triad: gait disturbance (prominent), urinary incontinence, dementia; ventriculomegaly disproportionate to atrophy MRI: ventriculomegaly with effaced sulci; high-volume LP with gait improvement Chronic traumatic encephalopathy (CTE) History of repetitive head trauma; mood and behavioral changes; no diagnostic test in life History; clinical pattern; cavum septum pellucidum on MRI (suggestive) CADASIL Migraine with aura; early WM disease; family history; temporal pole and external capsule involvement NOTCH3 genetic testing; skin biopsy showing GOM deposits CNS vasculitis Younger age; headache; encephalopathy; multifocal strokes; elevated inflammatory markers Vessel wall MRI; DSA; brain/leptomeningeal biopsy Creutzfeldt-Jakob disease Rapid progression (weeks-months); myoclonus; periodic sharp waves on EEG; MRI DWI ribboning CSF RT-QuIC; 14-3-3; EEG Delirium superimposed on dementia Acute change; fluctuating attention; identifiable precipitant (infection, medication, metabolic) Treat cause; reassess cognition when clear","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Cognitive testing (MoCA) Every 6-12 months Establish baseline; track trajectory; MoCA assesses executive function Adjust support; consider treatment changes - ROUTINE ROUTINE - Blood pressure Each visit; daily at home &lt;130/80 mmHg Titrate antihypertensives; reduce if symptomatic hypotension - ROUTINE ROUTINE - LDL cholesterol Baseline, 6 weeks, then annually &lt;70 mg/dL Intensify statin; add ezetimibe or PCSK9 inhibitor - ROUTINE ROUTINE - HbA1c Baseline, then q3mo if diabetic &lt;7% (7-8% if frail) Optimize diabetes regimen - ROUTINE ROUTINE - Functional status (ADL/IADL, FAQ) Every 6-12 months Document for staging and care planning Increase support services; OT referral - ROUTINE ROUTINE - Weight Each visit Stable; monitor for malnutrition Nutritional consult; assess swallowing - ROUTINE ROUTINE - Neuropsychiatric symptoms (NPI) Each visit Monitor depression, apathy, BPSD Non-pharmacologic first; consider medications - ROUTINE ROUTINE - MRI Brain Every 1-2 years or if new symptoms Monitor WM disease progression; new infarcts Optimize vascular risk factors; investigate new events - ROUTINE ROUTINE - ECG/Cardiac rhythm Annually or if symptomatic Sinus rhythm; no new AF Anticoagulation if AF detected - ROUTINE ROUTINE - Caregiver burden (Zarit scale) Every 6-12 months Early identification of burnout Support resources; respite care - - ROUTINE - Fall risk assessment Each visit Minimize fall risk PT referral; home safety evaluation; assistive devices - ROUTINE ROUTINE - Driving status Each visit Safe for patient and community Formal driving evaluation; DMV report if unsafe - - ROUTINE - Creatinine/eGFR Annually; with medication changes Dose-adjust medications appropriately Adjust ACE-I, metformin, anticoagulants - ROUTINE ROUTINE -","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable cognition; no acute stroke; safe environment; adequate caregiver support; outpatient follow-up arranged; reversible causes treated Admit to floor Acute delirium requiring workup; new stroke symptoms; behavioral crisis unsafe for home; aspiration pneumonia; falls with injury Admit to stroke unit New stroke with progression; recurrent TIAs; symptomatic carotid stenosis requiring urgent intervention Admit to psychiatry Severe behavioral disturbance requiring specialized psychiatric management; danger to self or others Long-term care/Memory care Progressive decline; caregiver unable to manage safely; wandering; 24-hour supervision needed Hospice End-stage vascular dementia; recurrent aspiration; weight loss; goals focused on comfort Outpatient follow-up Neurology every 3-6 months initially; every 6-12 months when stable; PCP for vascular risk factor management","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source NINDS-AIREN criteria for vascular dementia diagnosis Class II, Level B Roman et al. Neurology 1993 Cholinesterase inhibitors for vascular dementia (modest benefit) Class I, Level A Kavirajan &amp; Schneider. Lancet Neurol 2007 Donepezil efficacy in vascular dementia Class I, Level A Erkinjuntti et al. Lancet 2002 Galantamine for mixed AD/VaD Class I, Level A Erkinjuntti et al. Lancet Neurol 2002 Memantine for vascular dementia Class II, Level B Orgogozo et al. Stroke 2002 Intensive BP lowering reduces dementia risk (SPRINT-MIND) Class I, Level A SPRINT MIND Investigators. JAMA 2019 High-intensity statin for secondary stroke prevention Class I, Level A Amarenco et al. NEJM 2006 (SPARCL) Antiplatelet therapy for secondary stroke prevention Class I, Level A Antithrombotic Trialists. BMJ 2002 DOACs preferred over warfarin for AF-related stroke Class I, Level A Ruff et al. Lancet 2014 Sertraline for post-stroke depression Class II, Level B Chollet et al. Lancet Neurol 2011 (FLAME) Mediterranean diet reduces dementia risk Class II, Level B Scarmeas et al. Ann Neurol 2006 Physical exercise may slow cognitive decline Class II, Level B Livingston et al. Lancet 2020 (Lancet Commission) Avoid antipsychotics long-term in dementia (mortality risk) Class I, Level A Schneider et al. JAMA 2005 CEA for symptomatic carotid stenosis 70-99% Class I, Level A NASCET Collaborators. NEJM 1991 CPAP treatment improves cognition in OSA patients Class II, Level B Osorio et al. Neurology 2015 CSF biomarkers help differentiate VaD from AD Class II, Level B Skillback et al. Dement Geriatr Cogn Disord 2015","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - NINDS-AIREN diagnostic framework - Comprehensive vascular risk factor modification (BP, lipids, diabetes, smoking) - Secondary stroke prevention with antiplatelet and anticoagulation therapies - Cholinesterase inhibitors coverage (donepezil, rivastigmine, galantamine, memantine) with note on modest benefit - Post-stroke depression management with SSRIs (sertraline first-line) - Apathy treatment options (methylphenidate, modafinil, bupropion) - BPSD management with non-pharmacologic approaches prioritized - Differentiation from Alzheimer's and other dementias - Structured dosing format for order sentence generation - Focus on OPD setting with ED/HOSP coverage</p>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#appendix-a-ninds-airen-diagnostic-criteria-for-vascular-dementia","title":"APPENDIX A: NINDS-AIREN Diagnostic Criteria for Vascular Dementia","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#probable-vascular-dementia-all-required","title":"Probable Vascular Dementia (All Required)","text":"<ol> <li>Dementia defined by cognitive decline from a previously higher level, manifested by:</li> <li>Memory impairment AND</li> <li>Impairment in two or more cognitive domains (orientation, attention, language, visuospatial, executive, motor control, praxis)</li> <li>Deficits severe enough to interfere with ADLs</li> <li> <p>Not due to physical effects of stroke alone</p> </li> <li> <p>Cerebrovascular disease defined by:</p> </li> <li>Focal neurological signs consistent with stroke (hemiparesis, facial weakness, Babinski sign, sensory deficit, hemianopia, dysarthria) AND</li> <li> <p>Evidence of relevant CVD on neuroimaging (CT or MRI) including:</p> <ul> <li>Multiple large-vessel infarcts</li> <li>Single strategically placed infarct (angular gyrus, thalamus, basal forebrain, PCA or ACA territory)</li> <li>Multiple basal ganglia and white matter lacunes</li> <li>Extensive periventricular white matter lesions</li> <li>Combinations of the above</li> </ul> </li> <li> <p>Relationship between dementia and CVD inferred by:</p> </li> <li>Onset of dementia within 3 months of recognized stroke OR</li> <li>Abrupt deterioration in cognitive functions OR</li> <li>Fluctuating, stepwise progression of cognitive deficits</li> </ol>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#features-consistent-with-diagnosis","title":"Features Consistent with Diagnosis","text":"<ul> <li>Early gait disturbance</li> <li>History of unsteadiness and frequent falls</li> <li>Early urinary frequency, urgency, and incontinence not explained by urological disease</li> <li>Pseudobulbar palsy</li> <li>Personality and mood changes (abulia, depression, emotional incontinence)</li> <li>Preserved insight and judgment until late stages</li> </ul>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#features-making-diagnosis-uncertain","title":"Features Making Diagnosis Uncertain","text":"<ul> <li>Early memory impairment with progressive worsening without imaging changes</li> <li>Absence of focal neurological signs</li> <li>Absence of CVD lesions on imaging</li> </ul>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#appendix-b-neuroimaging-findings-in-vascular-dementia","title":"APPENDIX B: Neuroimaging Findings in Vascular Dementia","text":"","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#strategic-infarct-locations","title":"Strategic Infarct Locations","text":"Location Clinical Manifestation Thalamus (bilateral) Severe amnesia, apathy, executive dysfunction Angular gyrus (dominant) Alexia, agraphia, anomia, Gerstmann syndrome Anterior cerebral artery Abulia, apathy, executive dysfunction Posterior cerebral artery Visual agnosia, amnesia (hippocampal involvement) Basal ganglia (caudate) Executive dysfunction, behavioral changes Hippocampus Anterograde amnesia","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#white-matter-disease-grading-fazekas-scale","title":"White Matter Disease Grading (Fazekas Scale)","text":"Grade Description Clinical Implication 0 Absent Normal 1 Punctate foci Mild; may be age-related 2 Beginning confluence of foci Moderate; clinically significant 3 Large confluent areas Severe; strongly associated with VaD","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#microbleed-distribution","title":"Microbleed Distribution","text":"Pattern Associated Condition Lobar (cortical-subcortical) Cerebral amyloid angiopathy Deep (basal ganglia, thalamus) Hypertensive microangiopathy Mixed Both pathologies may coexist","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vascular-dementia/#appendix-c-differentiating-vascular-dementia-from-alzheimers-disease","title":"APPENDIX C: Differentiating Vascular Dementia from Alzheimer's Disease","text":"Feature Vascular Dementia Alzheimer's Disease Onset Abrupt or stepwise Insidious, gradual Progression Stepwise or fluctuating Gradual, continuous Memory Variable; may be preserved early Prominent early memory loss Executive function Prominently impaired Impaired later Focal neurological signs Often present Usually absent Gait disturbance Early and prominent Late feature Incontinence Early Late MRI findings Strategic infarcts, WM disease, lacunes Hippocampal/MTL atrophy Amyloid PET Negative (or positive if mixed) Positive CSF A\u03b242 Normal Low CSF p-tau Normal or mildly elevated Elevated Response to ChEIs Modest More robust Vascular risk factors Prominent May be present <p>Note: Mixed dementia (AD + VaD) is common, especially in elderly patients. Look for features of both pathologies.</p>","tags":["cognitive","dementia","vascular","cerebrovascular","outpatient"]},{"location":"drafts/vertigo-evaluation/","title":"Vertigo Evaluation","text":"\u26a0\ufe0f DRAFT - Pending Review This plan requires physician review before clinical use.","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#vertigo-evaluation","title":"Vertigo Evaluation","text":"<p>DIAGNOSIS: Vertigo (Dizziness and Giddiness) ICD-10: R42 (Dizziness and giddiness) ADDITIONAL ICD-10: H81.10 (BPPV, unspecified ear), H81.23 (Vestibular neuritis, bilateral), H81.09 (Meniere's disease, unspecified ear), H83.2X9 (Labyrinthitis, unspecified ear) SCOPE: Evaluation of acute and chronic vertigo including differentiation of peripheral vs central causes. Covers BPPV, vestibular neuritis, labyrinthitis, and Meniere's disease workup. Includes red flag identification for posterior circulation stroke. Excludes presyncope, orthostatic hypotension, and cardiac causes of dizziness.</p> <p>STATUS: Draft - Pending Review</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU Glucose (fingerstick or serum) Hypoglycemia can cause dizziness/lightheadedness mimicking vertigo Normal (70-100 mg/dL) STAT STAT ROUTINE STAT CBC Rule out anemia (causes lightheadedness), infection (labyrinthitis) Normal Hgb, WBC STAT ROUTINE ROUTINE STAT BMP Electrolyte disturbance can cause dizziness; assess renal function Normal Na, K, glucose, creatinine STAT ROUTINE ROUTINE STAT TSH Thyroid dysfunction can cause vestibular symptoms Normal (0.4-4.0 mIU/L) - ROUTINE ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU HbA1c Screen for diabetes if neuropathy suspected contributing to imbalance &lt;5.7% (normal); &lt;7% (controlled DM) - ROUTINE ROUTINE - Vitamin B12 Deficiency causes peripheral neuropathy affecting balance &gt;300 pg/mL - ROUTINE ROUTINE - RPR/VDRL Neurosyphilis can cause vestibular symptoms Nonreactive - EXT ROUTINE - ESR, CRP Elevated in vasculitis, autoimmune inner ear disease Normal ESR (&lt;20 mm/hr), CRP (&lt;3 mg/L) - ROUTINE ROUTINE - Lipid panel Vascular risk assessment if central cause suspected LDL &lt;100 mg/dL; HDL &gt;40 mg/dL - ROUTINE ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU ANA, anti-dsDNA Autoimmune inner ear disease (AIED) suspected Negative - EXT EXT - Anti-HSP70 antibody Specific marker for autoimmune inner ear disease Negative - - EXT - Lyme serology Endemic area with vestibular and facial nerve involvement Negative - EXT EXT - FTA-ABS Confirmatory test if RPR positive; otosyphilis Nonreactive - EXT EXT - Genetic testing (COCH, MYO7A) Familial vestibular disorders, Usher syndrome No pathogenic variant - - EXT -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT Head non-contrast Acute vertigo with concern for hemorrhage or when MRI unavailable No hemorrhage, mass, or acute stroke Pregnancy (relative) STAT - - STAT MRI Brain with DWI Central vertigo suspected; abnormal HINTS exam; risk factors for stroke No acute infarct; normal brainstem/cerebellum MRI-incompatible devices, severe claustrophobia URGENT URGENT ROUTINE URGENT MRA Head (Circle of Willis) Posterior circulation stroke suspected; vertebral/basilar stenosis Patent posterior circulation; no stenosis MRI contraindications URGENT URGENT ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Internal Auditory Canals (IAC) with contrast Unilateral hearing loss with vertigo; acoustic neuroma suspected No vestibular schwannoma or CPA lesion Gadolinium allergy, severe CKD - ROUTINE ROUTINE - CTA Head/Neck Vertebral dissection suspected; if MRA unavailable No dissection; patent vertebral arteries Contrast allergy, CKD STAT URGENT - STAT Audiometry Sensorineural hearing loss; Meniere's suspected Symmetric hearing; low-frequency loss in Meniere's None - ROUTINE ROUTINE - Videonystagmography (VNG) Quantify vestibular function; localize peripheral lesion Identify unilateral weakness; canal paresis Acute severe vertigo (defer until improved) - EXT ROUTINE - Electrocochleography (ECoG) Meniere's disease confirmation Elevated SP/AP ratio &gt;0.4 Recent ear surgery - - EXT -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Vestibular evoked myogenic potentials (VEMP) Superior canal dehiscence; saccular function Abnormal thresholds or amplitudes Hearing aids (remove first) - - EXT - High-resolution CT temporal bones Superior canal dehiscence; cholesteatoma Identify bony abnormalities Pregnancy - EXT EXT - Rotary chair testing Bilateral vestibular loss; compensation assessment Assess VOR gain and phase Severe vertigo (defer) - - EXT - Video head impulse test (vHIT) Quantify VOR for each semicircular canal Normal gain &gt;0.8; refixation saccades None - EXT ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#3-treatment","title":"3. TREATMENT","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Meclizine PO Acute vertigo; vestibular suppressant 25 mg PO; 25 mg TID; 50 mg TID :: PO :: :: 25-50 mg PO q6-8h PRN vertigo; max 150 mg/day Glaucoma; urinary retention; elderly (fall risk) Sedation, anticholinergic effects STAT STAT ROUTINE - Dimenhydrinate (Dramamine) PO/IV Acute vertigo with significant nausea 50 mg PO; 50 mg IV :: PO/IV :: :: 50 mg PO q6h or 50 mg IV q6h PRN; max 400 mg/day Same as meclizine; IV form may cause hypotension Sedation, BP if IV STAT STAT ROUTINE - Ondansetron IV/PO Nausea/vomiting with acute vertigo 4 mg IV; 8 mg PO; 4 mg ODT :: IV/PO :: :: 4 mg IV or 4-8 mg PO/ODT q8h PRN QT prolongation; severe hepatic impairment QTc if multiple doses or risk factors STAT STAT ROUTINE - Promethazine IV/IM/PO Severe nausea with acute vertigo 12.5 mg IV; 25 mg IV; 25 mg PO :: IV/IM/PO :: :: 12.5-25 mg IV/IM/PO q4-6h PRN; max 100 mg/day Respiratory depression; Parkinson's; children &lt;2 years Sedation, respiratory status, dystonia URGENT URGENT - - Lorazepam IV/PO Severe acute vertigo refractory to antihistamines 0.5 mg IV; 1 mg IV; 0.5 mg PO; 1 mg PO :: IV/PO :: :: 0.5-1 mg IV/PO q8h PRN severe vertigo; short-term use only Respiratory depression; severe hepatic impairment; angle-closure glaucoma Sedation, respiratory status URGENT URGENT - - Diazepam PO Vestibular suppressant; more sedating 2 mg PO; 5 mg PO :: PO :: :: 2-5 mg PO q8-12h PRN vertigo; limit to 3-5 days Same as lorazepam Sedation, respiratory status URGENT URGENT ROUTINE - IV Normal Saline IV Dehydration from vomiting 1000 mL IV bolus; 125 mL/hr IV :: IV :: :: 1-2 L bolus then maintenance as needed Heart failure; volume overload Intake/output, signs of overload STAT STAT - STAT","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Epley maneuver (canalith repositioning) Physical BPPV - posterior canal (most common) Perform once; may repeat x2 same session :: Physical :: :: Modified Epley: 5 positions held 30-60 sec each; may repeat if persistent nystagmus Severe cervical spine disease; carotid stenosis (relative) Nystagmus resolution; post-maneuver restrictions controversial STAT STAT ROUTINE - Semont maneuver Physical BPPV - alternative to Epley Perform once :: Physical :: :: Side-lying liberatory maneuver; faster but more uncomfortable Same as Epley Nystagmus resolution URGENT URGENT ROUTINE - Brandt-Daroff exercises Physical BPPV - home exercise; residual symptoms Twice daily home exercise :: Physical :: :: Sit-to-side x5 each side, 30 sec holds, BID for 2 weeks Severe nausea (defer until improved) Symptom diary - ROUTINE ROUTINE - Lempert maneuver (BBQ roll) Physical BPPV - horizontal canal variant Perform once; may repeat :: Physical :: :: Serial 90-degree rolls toward unaffected ear (360 total) Cervical spine disease Nystagmus resolution URGENT URGENT ROUTINE - Prochlorperazine IV/PO Vertigo with significant nausea 10 mg IV; 10 mg PO :: IV/PO :: :: 5-10 mg IV/PO q6-8h PRN; max 40 mg/day Parkinson's; QT prolongation; tardive dyskinesia history Akathisia, dystonia, QTc URGENT URGENT ROUTINE - Scopolamine patch Transdermal Motion sickness; prolonged vertigo episodes 1 patch q72h :: Transdermal :: :: Apply 1 patch behind ear; replace q72h; remove if symptoms resolve Glaucoma; urinary retention; elderly Anticholinergic effects, dry mouth - ROUTINE ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Methylprednisolone PO Vestibular neuritis - may improve recovery 100 mg daily x 3 days; 80 mg daily; 60 mg daily; 40 mg daily; 20 mg daily; 10 mg daily :: PO :: :: 100 mg daily x3 days, then taper over 3 weeks (total 22-day course) Active infection; uncontrolled diabetes; psychosis Glucose, BP, mood - URGENT ROUTINE - Prednisone PO Vestibular neuritis - alternative steroid 60 mg daily; 40 mg daily; 20 mg daily :: PO :: :: 1 mg/kg/day (max 60 mg) x 5 days, taper over 2 weeks Same as methylprednisolone Glucose, BP, mood - URGENT ROUTINE - Valacyclovir PO Vestibular neuritis - if viral etiology suspected 1000 mg TID x 7 days :: PO :: :: 1000 mg PO TID x 7 days; most effective if started within 72 hrs Renal impairment (dose adjust) Renal function - ROUTINE ROUTINE - Betahistine PO Meniere's disease - vestibular blood flow 16 mg TID; 24 mg TID :: PO :: :: 8-16 mg PO TID; titrate to 24 mg TID if needed; not FDA approved in US Pheochromocytoma; active peptic ulcer GI upset, headache - ROUTINE ROUTINE - Hydrochlorothiazide PO Meniere's disease - reduce endolymphatic pressure 25 mg daily; 50 mg daily :: PO :: :: 12.5-50 mg PO daily Sulfa allergy; hypokalemia; severe renal impairment K+, Na+, creatinine, glucose - - ROUTINE - Triamterene/HCTZ PO Meniere's disease - potassium-sparing diuretic 37.5/25 mg daily :: PO :: :: 37.5/25 mg PO daily Hyperkalemia; severe renal impairment K+, creatinine - - ROUTINE - Intratympanic dexamethasone IT Refractory Meniere's disease 4 mg/mL IT injection :: Intratympanic :: :: 0.4-0.8 mL of 4-24 mg/mL solution injected through TM; repeat x3-4 over 2 weeks Active ear infection; perforated TM Hearing, vertigo control - - EXT - Intratympanic gentamicin IT Refractory Meniere's disease - ablative 40 mg/mL IT injection :: Intratympanic :: :: Chemical labyrinthectomy; 0.5 mL of 40 mg/mL; may repeat in 4 weeks Only hearing ear; bilateral disease Hearing loss (expected), vertigo control - - EXT -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#3d-disease-modifying-or-chronic-therapies","title":"3D. Disease-Modifying or Chronic Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Vestibular rehabilitation therapy Physical Vestibular hypofunction; chronic imbalance 1-2x weekly sessions :: Physical :: :: 6-12 week program with home exercises; gaze stabilization, balance training, habituation Audiometry, VNG to define deficit Acute vertigo (defer) Fall risk, symptom diary, DHI scores - ROUTINE ROUTINE - Low-sodium diet Dietary Meniere's disease - reduce endolymph &lt;1500-2000 mg Na/day :: Dietary :: :: Strict sodium restriction; avoid processed foods, add no salt Dietitian consultation Hypotension if on diuretics BP, symptoms, dietary compliance - ROUTINE ROUTINE - Caffeine/alcohol avoidance Lifestyle Meniere's disease; vestibular migraine Eliminate or minimize :: Lifestyle :: :: Avoid caffeine and alcohol which may trigger episodes None None Symptom diary - ROUTINE ROUTINE - Migraine preventive therapy PO Vestibular migraine confirmed Per migraine protocol :: PO :: :: See Migraine plan for preventive options (topiramate, propranolol, amitriptyline) HIS/Barany criteria for vestibular migraine Per specific medication Per specific medication - - ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology consultation for central vertigo evaluation when HINTS exam suggests central lesion or stroke suspected STAT STAT ROUTINE STAT ENT/Otology referral for refractory BPPV, Meniere's disease management, or hearing loss evaluation - ROUTINE ROUTINE - Vestibular physical therapy for vestibular rehabilitation and balance retraining after acute vertigo resolves - ROUTINE ROUTINE - Audiology for formal hearing assessment and vestibular function testing (VNG, VEMP) - ROUTINE ROUTINE - Neuro-ophthalmology if ocular motor abnormalities persist or skew deviation concerning for brainstem lesion - ROUTINE ROUTINE - Stroke neurology for urgent evaluation if HINTS-plus exam suggests posterior circulation stroke STAT STAT - STAT Cardiology if presyncope suspected or arrhythmia contributing to dizziness URGENT ROUTINE ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return immediately if vertigo associated with new headache, diplopia, dysarthria, dysphagia, or weakness (signs of stroke) STAT - ROUTINE Return immediately if sudden hearing loss occurs which requires urgent treatment within 72 hours STAT - ROUTINE Avoid driving, operating machinery, or working at heights until vertigo resolves completely due to fall and accident risk URGENT ROUTINE ROUTINE Use assistive devices (cane, walker) if balance impaired to prevent falls URGENT ROUTINE ROUTINE Perform Brandt-Daroff exercises twice daily as instructed if diagnosed with BPPV - ROUTINE ROUTINE Keep head elevated 30-45 degrees when sleeping for 24-48 hours after Epley maneuver (controversial but commonly recommended) URGENT ROUTINE ROUTINE Avoid sudden head movements and rapid position changes which may trigger vertigo URGENT ROUTINE ROUTINE Maintain hydration and avoid skipping meals as dehydration and hypoglycemia can worsen symptoms ROUTINE ROUTINE ROUTINE","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Sodium restriction (&lt;2000 mg/day) if Meniere's disease diagnosed to reduce attack frequency - ROUTINE ROUTINE Caffeine reduction or elimination as caffeine can exacerbate vestibular symptoms - ROUTINE ROUTINE Alcohol avoidance as alcohol directly affects vestibular function and can trigger episodes - ROUTINE ROUTINE Stress management through relaxation techniques as stress can trigger vestibular migraine and Meniere's attacks - ROUTINE ROUTINE Regular sleep schedule as sleep deprivation can worsen vestibular symptoms - ROUTINE ROUTINE Fall prevention measures including removing throw rugs, installing grab bars, adequate lighting at home - ROUTINE ROUTINE Smoking cessation to reduce vascular risk factors that contribute to central vertigo - ROUTINE ROUTINE","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate BPPV (posterior canal) Brief episodes (&lt;1 min) triggered by position change; positive Dix-Hallpike with upbeat-torsional nystagmus Dix-Hallpike maneuver; resolves with Epley BPPV (horizontal canal) Horizontal nystagmus with supine roll test; direction-changing or direction-fixed Supine roll test; treat with BBQ roll maneuver Vestibular neuritis Acute severe vertigo lasting days; unidirectional horizontal nystagmus; normal hearing HINTS exam (peripheral pattern); MRI to rule out stroke Labyrinthitis Same as vestibular neuritis PLUS hearing loss; may follow URI Audiometry shows sensorineural loss; HINTS peripheral Meniere's disease Recurrent episodes (20 min - 12 hr) with hearing loss, tinnitus, aural fullness Audiometry (low-frequency loss); ECoG; MRI IAC Vestibular migraine Vertigo with migraine features; variable duration (5 min - 72 hr); motion sensitivity HIS/Barany criteria; diagnosis of exclusion; MRI normal Posterior circulation stroke Acute vertigo + neurological signs; HINTS central pattern; vascular risk factors MRI DWI (may be negative early); HINTS exam Cerebellar hemorrhage/infarct Severe imbalance; unable to walk; may have headache, vomiting CT head (hemorrhage); MRI DWI (infarct) Multiple sclerosis Vertigo with other demyelinating symptoms; younger patient MRI brain/spine with contrast; CSF oligoclonal bands Acoustic neuroma Progressive unilateral hearing loss, tinnitus; vertigo less prominent MRI IAC with gadolinium Perilymphatic fistula Vertigo/hearing loss after trauma, straining, or barotrauma History; may need surgical exploration Superior canal dehiscence Vertigo triggered by loud sounds (Tullio) or pressure; autophony High-resolution CT temporal bone; VEMP Central positional vertigo Down-beating nystagmus with Dix-Hallpike; doesn't fatigue MRI cerebellum; Dix-Hallpike pattern Drug-induced vestibulotoxicity Bilateral vestibular loss; aminoglycosides, loop diuretics, chemotherapy History; bilateral caloric weakness on VNG Presyncope (cardiac) Near-fainting rather than spinning; palpitations; exertional ECG, Holter, echocardiogram; orthostatic vitals Orthostatic hypotension Dizziness on standing; BP drop &gt;20/10 mmHg Orthostatic vital signs Anxiety/panic disorder Chronic dizziness; associated anxiety; no objective vestibular findings Normal vestibular testing; psychiatric evaluation","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU HINTS exam (Head Impulse, Nystagmus, Test of Skew) Initial presentation Peripheral pattern (HI abnormal, Nystagmus unidirectional, Skew absent) Central pattern requires urgent MRI and neurology consult STAT STAT - STAT Nystagmus characteristics Serial exam in ED Unidirectional; suppresses with fixation Direction-changing, vertical, or non-suppressing suggests central STAT STAT ROUTINE STAT Gait and balance assessment Each encounter Able to ambulate safely Unable to walk suggests central lesion or severe peripheral STAT ROUTINE ROUTINE - Hearing assessment (bedside) Initial and follow-up Symmetric hearing Asymmetric loss requires audiometry and MRI IAC URGENT ROUTINE ROUTINE - Symptom severity (VAS or DHI) Each visit Improving over time Persistent or worsening requires imaging, reassessment - ROUTINE ROUTINE - Dix-Hallpike test If BPPV suspected; follow-up Negative (resolved) Positive requires repositioning; recurrence common STAT ROUTINE ROUTINE - Fall risk assessment Each encounter Low risk High risk requires PT, home safety evaluation, assistive devices URGENT ROUTINE ROUTINE - Vestibular function (VNG/VEMP) After acute phase; follow-up Compensation occurring Persistent deficit requires vestibular rehabilitation - - ROUTINE -","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Peripheral vertigo confirmed (HINTS peripheral); symptoms controlled; able to ambulate safely; able to tolerate PO; follow-up arranged; no red flags Observation Severe symptoms requiring IV fluids/medications; unable to ambulate safely; awaiting MRI to rule out central cause Admit to floor Central vertigo confirmed requiring workup; stroke suspected but stable; severe dehydration; unable to tolerate PO for &gt;24 hours Admit to ICU Cerebellar stroke with risk of herniation; cerebellar hemorrhage; posterior circulation stroke with fluctuating symptoms Transfer to higher level Central vertigo suspected and MRI/neurology not available; cerebellar stroke requiring neurosurgical evaluation Outpatient follow-up Within 1-2 weeks for new vertigo; sooner if symptoms persist; ENT referral for Meniere's or hearing loss","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source HINTS exam superior to early MRI for detecting stroke Class II, Level B Kattah et al. Stroke 2009 Epley maneuver effective for posterior canal BPPV Class I, Level A Hilton et al. Cochrane Database Syst Rev 2014 Corticosteroids improve vestibular neuritis recovery Class I, Level B Strupp et al. NEJM 2004 Vestibular rehabilitation effective for chronic vestibular hypofunction Class I, Level A McDonnell &amp; Hillier Cochrane 2015 HINTS-plus (HINTS + hearing) increases stroke detection Class II, Level B Newman-Toker et al. Stroke 2013 Betahistine for Meniere's disease symptoms Class II, Level B James &amp; Burton Cochrane 2001 Intratympanic gentamicin for refractory Meniere's Class II, Level B Pullens &amp; van Benthem Cochrane 2011 Meclizine comparable to diazepam for acute vertigo Class II, Level B McClure &amp; Willett Arch Otolaryngol 1980 Low sodium diet for Meniere's disease management Class III, Level C Luxford et al. Otolaryngol Head Neck Surg 2013 Diagnostic criteria for vestibular migraine Consensus Lempert et al. Barany Society/IHS 2012 Video head impulse test for vestibular function Class II, Level B MacDougall et al. Neurology 2009 Central vs peripheral vertigo differentiation Consensus Baloh &amp; Honrubia. Clinical Neurophysiology of Vestibular System 2011","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive coverage of peripheral and central vertigo evaluation - HINTS exam protocol for ED differentiation - BPPV diagnosis and canalith repositioning maneuvers - Vestibular neuritis, labyrinthitis, and Meniere's disease workup - Structured dosing format for order sentence generation - PubMed-verified citations</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#appendix-a-hints-exam-protocol","title":"APPENDIX A: HINTS Exam Protocol","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#hints-examination-for-acute-vestibular-syndrome","title":"HINTS Examination for Acute Vestibular Syndrome","text":"<p>The HINTS exam differentiates peripheral from central causes of acute vertigo with higher sensitivity than early MRI for posterior circulation stroke.</p> <p>When to Use: Acute continuous vertigo with nystagmus (Acute Vestibular Syndrome)</p> <p>H - Head Impulse Test (HIT) 1. Patient fixes gaze on examiner's nose 2. Rapidly turn head 10-20 degrees to each side 3. Peripheral: Catch-up saccade when turning toward affected ear (abnormal/positive) 4. Central: No catch-up saccade (normal/negative) - concerning for stroke</p> <p>I - Nystagmus 1. Observe spontaneous nystagmus 2. Note direction and whether it changes with gaze direction 3. Peripheral: Unidirectional, horizontal (may have torsional component), suppresses with fixation 4. Central: Direction-changing, purely vertical, or purely torsional - concerning for stroke</p> <p>N - Test of Skew (Alternate Cover Test) 1. Cover one eye, then uncover and cover the other 2. Watch for vertical refixation movement 3. Peripheral: No skew deviation 4. Central: Skew deviation present - concerning for stroke</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#hints-interpretation","title":"HINTS Interpretation","text":"Finding Interpretation Abnormal HIT + Unidirectional nystagmus + No skew PERIPHERAL - Likely vestibular neuritis Normal HIT + Direction-changing nystagmus OR Skew present CENTRAL - Requires urgent MRI; high stroke probability Any ONE central sign Treat as CENTRAL until proven otherwise","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#hints-plus","title":"HINTS-Plus","text":"<p>Add hearing assessment (finger rub test or audiometry): - New unilateral hearing loss with acute vertigo suggests AICA stroke (anterior inferior cerebellar artery) - Presence of hearing loss with \"peripheral\" HINTS pattern should still raise concern for stroke</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#key-points","title":"Key Points","text":"<ul> <li>HINTS is more sensitive than early MRI for posterior circulation stroke (sensitivity 100% vs 72% for MRI within 48 hours)</li> <li>Only valid in Acute Vestibular Syndrome (acute, continuous vertigo with nystagmus)</li> <li>Not valid for episodic vertigo (e.g., BPPV) or chronic dizziness</li> <li>Requires practice to perform reliably; video-HIT more accurate than bedside</li> </ul>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#appendix-b-dix-hallpike-and-epley-maneuver","title":"APPENDIX B: Dix-Hallpike and Epley Maneuver","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#dix-hallpike-test-diagnostic-for-posterior-canal-bppv","title":"Dix-Hallpike Test (Diagnostic for Posterior Canal BPPV)","text":"<p>Procedure: 1. Patient sitting upright on exam table 2. Turn head 45 degrees toward side being tested 3. Rapidly lower patient to supine with head hanging 20 degrees below table 4. Maintain position for 30-60 seconds observing for nystagmus 5. Return patient to sitting 6. Repeat on opposite side</p> <p>Positive Test (Posterior Canal BPPV): - Onset delay 2-5 seconds (latency) - Upbeat + torsional nystagmus (top pole of eye toward down ear) - Crescendo-decrescendo pattern - Duration &lt;60 seconds - Fatigues with repetition - Associated vertigo</p> <p>Concerning Findings (Suggests Central Cause): - No latency (immediate onset) - Pure vertical or horizontal nystagmus - Duration &gt;60 seconds - No fatigue with repetition - No vertigo despite nystagmus</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#epley-maneuver-treatment-for-posterior-canal-bppv","title":"Epley Maneuver (Treatment for Posterior Canal BPPV)","text":"<p>Prerequisites: - Positive Dix-Hallpike test - Identify affected side</p> <p>Procedure (for RIGHT posterior canal): 1. Position 1: Dix-Hallpike position (head turned 45\u00b0 right, head hanging) - hold 30-60 seconds 2. Position 2: Turn head 90\u00b0 to left (now looking 45\u00b0 left) - hold 30-60 seconds 3. Position 3: Roll body to left, head pointing down 45\u00b0 to floor - hold 30-60 seconds 4. Position 4: Sit up slowly, head still turned left 5. Turn head to center</p> <p>For LEFT posterior canal: Reverse all directions</p> <p>Success Rate: 80% single treatment; 90% with repeat maneuvers</p> <p>Post-Procedure Instructions (Controversial): - Traditional: Sleep propped up 45\u00b0, avoid affected side for 24-48 hours - Current evidence: Post-treatment restrictions may not be necessary - Common practice: Avoid provocative positions for 24 hours</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#appendix-c-supine-roll-test-and-bbq-roll-maneuver","title":"APPENDIX C: Supine Roll Test and BBQ Roll Maneuver","text":"","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#supine-roll-test-diagnostic-for-horizontal-canal-bppv","title":"Supine Roll Test (Diagnostic for Horizontal Canal BPPV)","text":"<p>Procedure: 1. Patient supine with head neutral 2. Rapidly turn head 90\u00b0 to one side, observe for nystagmus (30-60 seconds) 3. Return head to neutral 4. Rapidly turn head 90\u00b0 to opposite side, observe for nystagmus</p> <p>Interpretation:</p> Type Nystagmus Direction Affected Side Geotropic (toward ground) Beats toward ground on both sides; STRONGER side is affected Side with MORE intense nystagmus Apogeotropic (away from ground) Beats away from ground on both sides; WEAKER side is affected Side with LESS intense nystagmus","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"drafts/vertigo-evaluation/#lempert-bbq-roll-maneuver-treatment-for-horizontal-canal-bppv","title":"Lempert (BBQ Roll) Maneuver (Treatment for Horizontal Canal BPPV)","text":"<p>For Geotropic Horizontal Canal BPPV:</p> <ol> <li>Patient supine, head turned toward AFFECTED ear</li> <li>Roll head 90\u00b0 toward UNAFFECTED side (now facing up) - hold 30-60 seconds</li> <li>Roll head another 90\u00b0 (now facing unaffected side) - hold 30-60 seconds</li> <li>Roll body to prone, head turned 90\u00b0 (nose toward floor) - hold 30-60 seconds</li> <li>Continue rolling 90\u00b0 toward unaffected side - hold 30-60 seconds</li> <li>Sit up slowly</li> </ol> <p>Total rotation: 360\u00b0 away from affected ear</p> <p>For Apogeotropic variant: May need modified approach or Gufoni maneuver</p>","tags":["vertigo","dizziness","vestibular","BPPV","vestibular neuritis","emergency","outpatient"]},{"location":"logs/citation-verification-log/","title":"Citation Verification Log","text":"<p>This log tracks citation verification results to identify patterns and improve the verification process.</p>"},{"location":"logs/citation-verification-log/#summary-statistics","title":"Summary Statistics","text":"Metric Count Total Plans Audited 2 Total Citations Checked 29 Verified Correct 19 Hallucinated PMIDs Found 10 Corrections Applied 10 <p>Audit Accuracy Rate: 66% (19/29 were correct; 10 were hallucinated)</p> <p>Critical Finding: 10 PMIDs were hallucinated - they linked to completely unrelated articles (pediatric growth hormone, rat neuroscience, immunology crystallization, dental, IBD) or non-existent pages.</p>"},{"location":"logs/citation-verification-log/#verification-results-by-plan","title":"Verification Results by Plan","text":""},{"location":"logs/citation-verification-log/#peripheral-neuropathy-new-diagnosisevaluation","title":"Peripheral Neuropathy - New Diagnosis/Evaluation","text":"<p>Date Audited: 2026-01-21 Version: 1.5 \u2192 1.6 Auditor: Claude (citation audit)</p>"},{"location":"logs/citation-verification-log/#verified-correct-12","title":"Verified Correct (12)","text":"# Citation PubMed ID Status 1 Dyck PJ et al. Neurology 1993 8469345 \u2705 Verified 2 AAN/AANEM Practice Guideline 2022 34965987 \u2705 Verified 3 Finnerup NB et al. Lancet Neurol 2015 25575710 \u2705 Verified 4 AAN Practice Parameter 2009 19056666 \u2705 Verified 5 Singleton et al. Diabetes Care 2001 11473085 \u2705 Verified 6 Hoffman-Snyder et al. Arch Neurol 2006 16769858 \u2705 Verified 7 Lauria G et al. Eur J Neurol 2010 20642627 \u2705 Verified 8 EAN/PNS Guidelines 2021 (CIDP) 33506534 \u2705 Verified 9 Coelho T et al. Neurology 2012 (tafamidis) 22843282 \u2705 Verified 10 Adams D et al. NEJM 2018 (APOLLO/patisiran) 29972753 \u2705 Verified 11 Benson MD et al. NEJM 2018 (NEURO-TTR/inotersen) 29972757 \u2705 Verified 12 Qutenza Prescribing Information FDA Label \u2705 Non-PubMed"},{"location":"logs/citation-verification-log/#hallucinated-pmids-found-corrected-3","title":"Hallucinated PMIDs Found &amp; Corrected (3)","text":"# Claimed Citation Wrong PMID Actual Article at That PMID Correct PMID Status 1 DCCT/EDIC neuropathy study 24357209 \"Standards of medical care in diabetes--2014\" (ADA general standards, NOT neuropathy study) 24356595 (Martin et al. Diabetes Care 2014 - actual DCCT/EDIC neuropathy findings) \u2705 Fixed 2 ADA Standards of Care - Foot Care 36507645 \"Management of Diabetes in Pregnancy\" (wrong section) 36507636 (Section 12: Foot Care) \u2705 Fixed 3 Gilron I et al. Lancet 2009 (combination therapy) 19837455 \"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease\" (IBD, not neuropathy!) 19796802 (Nortriptyline and gabapentin combination trial) \u2705 Fixed"},{"location":"logs/citation-verification-log/#acute-ischemic-stroke","title":"Acute Ischemic Stroke","text":"<p>Date Audited: 2026-01-21 Version: 1.0 \u2192 1.2 Auditor: Claude (citation audit - 2 passes)</p>"},{"location":"logs/citation-verification-log/#verified-correct-7","title":"Verified Correct (7)","text":"# Citation PubMed ID Status 1 NINDS tPA Trial 7477192 \u2705 Verified 2 MR CLEAN 25517348 \u2705 Verified 3 DAWN 29129157 \u2705 Verified 4 DEFUSE 3 29364767 \u2705 Verified 5 POINT 29766750 \u2705 Verified 6 SPARCL 16899775 \u2705 Verified 7 AHA/ASA Guidelines 2021 34024117 \u2705 Verified 8 NASCET 1852179 \u2705 Verified 9 RESPECT (PFO) 28885996 \u2705 Verified"},{"location":"logs/citation-verification-log/#hallucinated-pmids-found-corrected-7","title":"Hallucinated PMIDs Found &amp; Corrected (7)","text":"# Claimed Citation Wrong PMID Actual Article at That PMID Correct PMID Status 1 AcT Trial, Campbell et al. NEJM 2022 36036072 Non-existent or unrelated article 35779553 (Menon et al. Lancet 2022 - actual AcT trial; also wrong author/journal in original) \u2705 Fixed 2 CHANCE (DAPT trial) 23726497 \"An insight into peri-implantitis\" (dental article!) 23803136 (Wang et al. NEJM 2013 - actual CHANCE trial) \u2705 Fixed 3 AVERT Trial (early mobilization) 25677597 \"Implementing a simple care bundle...\" (different stroke study) 25892679 (AVERT Collaboration, Lancet 2015 - actual AVERT trial) \u2705 Fixed 4 CLOSE (PFO closure) 28902629 \"Individualised growth response optimisation (iGRO) tool\" (pediatric growth hormone paper!) 28902580 (Mas et al. NEJM 2017 - actual CLOSE trial) \u2705 Fixed 5 DEFENSE-PFO 29766764 \"Local cortical activity of distant brain areas can phase-lock to olfactory bulb's respiratory rhythm in freely behaving rat\" (rat neuroscience!) 29544871 (Lee et al. JACC 2018 - actual DEFENSE-PFO trial) \u2705 Fixed 6 ECST 1991 (carotid) 1754711 \"Crystallization of HLA-DR antigens\" (immunology/crystallography paper!) 1674060 (ECST Collaborative Group, Lancet 1991 - actual ECST interim results) \u2705 Fixed 7 DECIMAL/DESTINY/HAMLET 17482661 Unknown/invalid PMID 17303527 (Vahedi et al. Lancet Neurol 2007 - pooled analysis of craniectomy trials) \u2705 Fixed"},{"location":"logs/citation-verification-log/#patterns-improvement-opportunities","title":"Patterns &amp; Improvement Opportunities","text":""},{"location":"logs/citation-verification-log/#critical-pattern-pmid-hallucination","title":"CRITICAL Pattern: PMID Hallucination","text":"<p>Issue: 10 PMIDs across 2 plans were completely fabricated. They linked to unrelated articles: - Pediatric growth hormone papers instead of stroke PFO trials - Rat olfactory neuroscience instead of cardiac trials - HLA-DR crystallization (immunology) instead of carotid surgery trials - Dental articles instead of neurology papers - IBD studies instead of neuropathic pain trials - Pregnancy guidelines instead of foot care guidelines - Non-existent/invalid PMIDs</p> <p>Root Cause: AI model generated plausible-looking PMIDs without verification.</p> <p>Egregious Examples Found: - PMID 28902629 claimed to be CLOSE PFO trial \u2192 actually \"Individualised growth response optimisation (iGRO) tool\" (pediatric endocrinology!) - PMID 29766764 claimed to be DEFENSE-PFO trial \u2192 actually rat olfactory bulb neuroscience paper! - PMID 1754711 claimed to be ECST carotid trial \u2192 actually \"Crystallization of HLA-DR antigens\" (immunology!) - PMID 23726497 claimed to be CHANCE stroke trial \u2192 actually \"An insight into peri-implantitis\" (dental) - PMID 19837455 claimed to be Gilron neuropathy combination therapy \u2192 actually IBD thiopurines study</p> <p>Prevention Added: Updated <code>neuro-citation-verifier-skill.md</code> with mandatory verification steps: 1. Search for article by author, title, journal, year 2. Find actual PMID in search results 3. Fetch and verify PubMed page matches 4. Only then add the link</p>"},{"location":"logs/citation-verification-log/#pattern-2-authorjournal-confusion","title":"Pattern 2: Author/Journal Confusion","text":"<p>Issue: AcT Trial cited as \"Campbell et al. NEJM\" but correct citation is \"Menon et al. Lancet\"</p> <p>Root Cause: Multiple tenecteplase stroke trials exist. Campbell published EXTEND-IA TNK; Menon published AcT.</p> <p>Recommendation: Always verify author AND journal, not just trial name.</p>"},{"location":"logs/citation-verification-log/#pattern-3-section-number-confusion","title":"Pattern 3: Section Number Confusion","text":"<p>Issue: ADA Standards of Care foot care section linked to pregnancy section (different PMID within same supplement)</p> <p>Root Cause: Multi-section documents have different PMIDs per section.</p> <p>Recommendation: When citing guidelines, include section number/title in the verification.</p>"},{"location":"logs/citation-verification-log/#verification-process-improvements","title":"Verification Process Improvements","text":""},{"location":"logs/citation-verification-log/#current-process","title":"Current Process","text":"<ol> <li>Extract citations from Section 8</li> <li>Search web for each citation</li> <li>Verify accuracy of claim</li> <li>Add PubMed hyperlink if available</li> <li>Flag issues for correction</li> </ol>"},{"location":"logs/citation-verification-log/#proposed-improvements","title":"Proposed Improvements","text":"Improvement Priority Status Create approved non-PubMed source list High Pending Add trial indication verification step High Pending Flag generic references (\"Multiple RCTs\") Medium Pending Add duplicate citation detection Low Pending Integrate PubMed API for automated lookup Low Pending"},{"location":"logs/citation-verification-log/#approved-non-pubmed-sources","title":"Approved Non-PubMed Sources","text":"<p>These sources are acceptable when PubMed links are not available:</p> Source Type Domain Example FDA Drug Labels accessdata.fda.gov Prescribing information CMS Coverage cms.gov LCD/NCD documents Cochrane Library cochranelibrary.com Systematic reviews AAN Guidelines aan.com Practice parameters EFNS/EAN Guidelines ean.org European guidelines WHO Guidelines who.int International guidelines CDC Guidelines cdc.gov Public health guidance"},{"location":"logs/citation-verification-log/#change-log","title":"Change Log","text":"<p>2026-01-21 - Complete Citation Audit (Pass 2) - Conducted complete verification of ALL citations (not just spot-checking) - Found 4 additional hallucinated PMIDs in Acute Ischemic Stroke - Total hallucinated: 10 PMIDs across 2 plans (34% error rate) - Most egregious: PFO trial linked to pediatric growth hormone paper; carotid trial linked to immunology crystallization paper - Updated Acute Ischemic Stroke to v1.2 with all fixes</p> <p>2026-01-21 - Citation Audit (Pass 1) - Conducted initial audit of existing citations - Found 6 hallucinated PMIDs across 2 plans - Fixed PMIDs in Peripheral Neuropathy and Acute Ischemic Stroke - Updated neuro-citation-verifier-skill.md with mandatory PMID verification steps - Added CRITICAL hallucination pattern to improvement opportunities</p> <p>2026-01-20 - Initial log created - Added Peripheral Neuropathy verification results - Identified 3 improvement patterns - Created approved non-PubMed source list</p>"},{"location":"plans/","title":"Clinical Decision Support Plans","text":"<p>Evidence-based clinical decision support templates for neurological diagnoses. All templates validated and approved for clinical use.</p> <p>Request a New Plan :material-plus-circle:</p>"},{"location":"plans/#seizures-epilepsy","title":"Seizures &amp; Epilepsy","text":"Plan Setting Coverage ICD-10 Status Epilepticus ED, HOSP, ICU G41.0, G41.9 New Onset Seizure ED, HOSP, OPD R56.9, G40.909 Breakthrough Seizure ED, HOSP, OPD G40.909, G40.919"},{"location":"plans/#stroke-vascular","title":"Stroke &amp; Vascular","text":"Plan Setting Coverage ICD-10 Acute Ischemic Stroke ED, HOSP, ICU I63.9 Transient Ischemic Attack ED, HOSP, OPD G45.9 Intracerebral Hemorrhage ED, HOSP, ICU I61.9 Subarachnoid Hemorrhage ED, HOSP, ICU I60.9"},{"location":"plans/#neuromuscular","title":"Neuromuscular","text":"Plan Setting Coverage ICD-10 Guillain-Barr\u00e9 Syndrome ED, HOSP, ICU G61.0 Myasthenic Crisis ED, HOSP, ICU G70.01 MG - New Diagnosis HOSP, OPD G70.0 Neuromuscular Respiratory Failure ED, HOSP, ICU G70.01, G61.0, J96.00 Peripheral Neuropathy HOSP, OPD G62.9"},{"location":"plans/#cns-infections","title":"CNS Infections","text":"Plan Setting Coverage ICD-10 Bacterial Meningitis ED, HOSP, ICU G00.9 HSV Encephalitis ED, HOSP, ICU B00.4 Autoimmune Encephalitis HOSP, ICU G04.81"},{"location":"plans/#spinal-emergencies","title":"Spinal Emergencies","text":"Plan Setting Coverage ICD-10 Acute Myelopathy ED, HOSP, ICU G95.9, G37.3 Spinal Cord Compression (Malignant) ED, HOSP, ICU G95.20 Cauda Equina Syndrome ED, HOSP G83.4 Epidural Abscess ED, HOSP, ICU G06.1"},{"location":"plans/#neuro-oncology","title":"Neuro-Oncology","text":"Plan Setting Coverage ICD-10 Brain Metastases ED, HOSP, OPD, ICU C79.31"},{"location":"plans/#critical-care","title":"Critical Care","text":"Plan Setting Coverage ICD-10 Elevated ICP Management HOSP, ICU G93.2, G93.5"},{"location":"plans/#demyelinating","title":"Demyelinating","text":"Plan Setting Coverage ICD-10 MS New Diagnosis HOSP, OPD G35"},{"location":"plans/#headache","title":"Headache","text":"Plan Setting Coverage ICD-10 Migraine ED, HOSP, OPD G43.909, G43.919, G43.901"},{"location":"plans/#movement-disorders","title":"Movement Disorders","text":"Plan Setting Coverage ICD-10 Parkinson's Disease - New Diagnosis HOSP, OPD G20, G20.A1, G20.C Essential Tremor HOSP, OPD G25.0"},{"location":"plans/#dementia-cognitive","title":"Dementia &amp; Cognitive","text":"Plan Setting Coverage ICD-10 Dementia Evaluation ED, HOSP, OPD R41.81, F03.90, G30.9 Rapidly Progressive Dementia HOSP, OPD F03.90, A81.00"},{"location":"plans/#cranial-neuropathies","title":"Cranial Neuropathies","text":"Plan Setting Coverage ICD-10 Bell's Palsy ED, HOSP, OPD G51.0"},{"location":"plans/#other","title":"Other","text":"Plan Setting Coverage ICD-10 Vertigo / Dizziness ED, HOSP, OPD R42, H81.10"},{"location":"plans/#plan-structure","title":"Plan Structure","text":"<p>Each plan follows a standardized 8-section format:</p> <p>Section A: Action Items</p> <ol> <li>Laboratory Workup (Core, Extended, Specialized)</li> <li>Diagnostic Imaging &amp; Studies</li> <li>Treatment (Acute, Symptomatic, Maintenance, Disease-Modifying)</li> <li>Other Recommendations (Referrals, Patient Instructions, Lifestyle)</li> </ol> <p>Section B: Reference</p> <ol> <li>Differential Diagnosis</li> <li>Monitoring Parameters</li> <li>Disposition Criteria</li> <li>Evidence &amp; References</li> </ol>"},{"location":"plans/#priority-key","title":"Priority Key","text":"Priority Meaning STAT Immediate URGENT Within hours ROUTINE Standard timing EXT Extended/atypical cases - Not applicable"},{"location":"plans/#setting-columns","title":"Setting Columns","text":"<ul> <li>ED - Emergency Department</li> <li>HOSP - Hospital/Inpatient</li> <li>OPD - Outpatient/Clinic</li> <li>ICU - Intensive Care Unit</li> </ul>"},{"location":"plans/acute-ischemic-stroke/","title":"Acute Ischemic Stroke","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Acute Ischemic Stroke</p> <p>ICD-10: I63.9 (Cerebral infarction, unspecified), I63.50 (Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery), I63.3 (Cerebral infarction due to thrombosis of cerebral arteries), I63.4 (Cerebral infarction due to embolism of cerebral arteries)</p> <p>SYNONYMS: Acute ischemic stroke, AIS, stroke, brain attack, cerebral infarction, CVA, cerebrovascular accident, thrombotic stroke, embolic stroke, ischemic CVA, code stroke</p> <p>SCOPE: Acute ischemic stroke in adults \u2014 covers initial stabilization, thrombolytic therapy (IV alteplase/tenecteplase), endovascular thrombectomy criteria, blood pressure management, stroke etiology workup, secondary prevention initiation, and early rehabilitation. Excludes hemorrhagic stroke (see Intracerebral Hemorrhage template), transient ischemic attack (see TIA template), pediatric stroke, and chronic post-stroke management.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/acute-ischemic-stroke/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/acute-ischemic-stroke/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Point-of-care glucose STAT STAT - STAT Hypoglycemia mimics stroke; must rule out before tPA &gt;60 mg/dL CBC with differential STAT STAT ROUTINE STAT Baseline; thrombocytopenia contraindicates tPA if &lt;100K Platelets &gt;100,000 BMP (Na, K, Cr, glucose, BUN) STAT STAT ROUTINE STAT Electrolyte abnormalities, renal function for contrast/medication dosing Normal PT/INR STAT STAT - STAT Anticoagulant use; INR &gt;1.7 contraindicates tPA INR \u22641.7 for tPA eligibility aPTT STAT STAT - STAT Heparin use; elevated aPTT contraindicates tPA Normal range Troponin STAT STAT - STAT Acute MI can cause cardioembolic stroke; stress cardiomyopathy Normal Type and screen STAT ROUTINE - STAT Potential need for blood products, surgical intervention On file Lipid panel (fasting or non-fasting) - ROUTINE ROUTINE - Baseline for statin therapy; cardiovascular risk assessment LDL target &lt;70 mg/dL HbA1c - ROUTINE ROUTINE - Diabetes screening/management; cardiovascular risk factor &lt;7.0% (individualized)"},{"location":"plans/acute-ischemic-stroke/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Hepatic function panel (AST, ALT, albumin) URGENT ROUTINE ROUTINE URGENT Liver disease affects anticoagulation, medication metabolism Normal TSH - ROUTINE ROUTINE - Thyroid dysfunction as cardiovascular risk factor; atrial fibrillation workup Normal ESR / CRP - ROUTINE ROUTINE - Vasculitis screen, inflammatory stroke etiology Normal Urine drug screen URGENT ROUTINE - URGENT Cocaine/amphetamine-associated vasospasm or stroke Negative Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE STAT Affects treatment decisions (tPA risk-benefit), imaging choices Negative Blood alcohol level URGENT - - URGENT Intoxication as stroke mimic; affects exam reliability Correlate with clinical picture Magnesium URGENT ROUTINE ROUTINE URGENT Hypomagnesemia associated with arrhythmia, vascular risk Normal (&gt;1.8 mg/dL) Phosphorus - ROUTINE ROUTINE - Refeeding risk if malnourished; metabolic panel Normal Prealbumin - ROUTINE - ROUTINE Nutritional status for rehabilitation planning Normal"},{"location":"plans/acute-ischemic-stroke/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Hypercoagulable panel (protein C, protein S, antithrombin III, Factor V Leiden, prothrombin gene mutation) - EXT EXT - Young stroke (&lt;50), cryptogenic stroke, venous thrombosis history Normal Antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin, \u03b22-glycoprotein I) - EXT EXT - Young stroke, recurrent stroke, systemic lupus Negative Homocysteine - ROUTINE ROUTINE - Elevated homocysteine as independent stroke risk factor Normal (&lt;15 \u00b5mol/L) RPR/VDRL - ROUTINE ROUTINE - Syphilitic vasculitis Negative HIV - ROUTINE ROUTINE - HIV-associated vasculopathy Negative ANA, dsDNA - EXT EXT - Lupus cerebritis, vasculitis Negative ANCA (c-ANCA, p-ANCA) - EXT EXT - CNS vasculitis Negative Complement levels (C3, C4) - EXT EXT - Complement-mediated vasculitis Normal Hemoglobin electrophoresis - EXT EXT - Sickle cell disease (young patients, African descent) Normal (HbAA) JAK2 mutation - EXT EXT - Polycythemia vera, myeloproliferative disorders Negative Fibrinogen URGENT ROUTINE - URGENT DIC screen, coagulopathy evaluation Normal (200-400 mg/dL) D-dimer URGENT ROUTINE - URGENT DIC, paradoxical embolism through PFO, cancer-associated Normal"},{"location":"plans/acute-ischemic-stroke/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/acute-ischemic-stroke/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Door-to-CT &lt;25 minutes Exclude hemorrhage; may show early ischemic changes (loss of gray-white differentiation, sulcal effacement) Pregnancy (relative) CT angiography head and neck (CTA) STAT STAT - STAT With initial CT; door-to-CTA &lt;25 min Large vessel occlusion (LVO) for thrombectomy; carotid/vertebral stenosis or dissection Contrast allergy (premedicate), eGFR &lt;30 (benefit outweighs risk in acute setting) CT perfusion (CTP) STAT URGENT - STAT With CTA if extended window (6-24h) or wake-up stroke Ischemic penumbra (mismatch between core infarct and hypoperfused tissue); target mismatch ratio &gt;1.8 Same as CTA MRI brain with DWI (diffusion-weighted imaging) URGENT URGENT ROUTINE URGENT Within 24h; STAT if diagnosis uncertain Acute ischemic infarct (restricted diffusion); stroke location and extent; ASPECTS scoring Pacemaker, metallic implants, severe claustrophobia ECG (12-lead) STAT STAT ROUTINE STAT Immediate Atrial fibrillation, acute MI, LVH, ST changes None"},{"location":"plans/acute-ischemic-stroke/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRA head and neck - URGENT ROUTINE URGENT Within 24-48h Intracranial stenosis, vertebrobasilar disease, dissection Same as MRI Transthoracic echocardiogram (TTE) - ROUTINE ROUTINE ROUTINE Within 24-48h LV thrombus, PFO, valvular disease, cardiomyopathy, akinetic segments None significant Transesophageal echocardiogram (TEE) with bubble study - ROUTINE ROUTINE - Within 48-72h if TTE nondiagnostic or cryptogenic stroke PFO with right-to-left shunt, atrial septal aneurysm, left atrial appendage thrombus, aortic arch atheroma Esophageal pathology, uncooperative patient Carotid duplex ultrasound - ROUTINE ROUTINE - Within 24-48h Carotid stenosis \u226550%, plaque characterization None significant Transcranial Doppler (TCD) - ROUTINE ROUTINE - Within 24-48h Intracranial stenosis, vasospasm, microembolic signals, right-to-left shunt (bubble study) Absent temporal bone window (~10% patients) Continuous cardiac telemetry STAT STAT - STAT Minimum 24h; ideally \u226548-72h Paroxysmal atrial fibrillation, other arrhythmias None Extended cardiac monitoring (Holter 30-day or implantable loop recorder) - ROUTINE ROUTINE - Arrange before discharge if cryptogenic stroke Paroxysmal atrial fibrillation (detected in 12-30% with prolonged monitoring) None significant Chest X-ray URGENT ROUTINE - URGENT Within 24h Cardiomegaly, pulmonary edema, aspiration pneumonia None significant"},{"location":"plans/acute-ischemic-stroke/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Conventional cerebral angiography (DSA) - EXT EXT EXT If vasculitis, dissection, or Moyamoya suspected Beading pattern (vasculitis), intimal flap (dissection), Moyamoya collaterals Contrast allergy, severe renal impairment, coagulopathy MRI vessel wall imaging - EXT EXT - If intracranial stenosis or vasculitis suspected Vessel wall enhancement (vasculitis, unstable plaque), dissection Same as MRI Fat-saturated MRI neck - EXT EXT - If cervical dissection suspected Intramural hematoma (crescent sign) Same as MRI Cardiac MRI - EXT EXT - If cardiomyopathy or cardiac mass suspected Myocardial fibrosis, thrombus, tumor Same as MRI PET-CT - - EXT - If occult malignancy suspected (Trousseau syndrome) Occult cancer, hypercoagulable etiology Pregnancy, uncontrolled diabetes"},{"location":"plans/acute-ischemic-stroke/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/acute-ischemic-stroke/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IV alteplase (tPA) STAT STAT - STAT 0.9 mg/kg IV (max 90 mg); 10% as bolus over 1 min, remaining 90% infused over 60 min. Door-to-needle target &lt;45 min &gt;4.5h from last known well (relative 3-4.5h window with additional exclusions); BP &gt;185/110 despite treatment; platelets &lt;100K; INR &gt;1.7; active bleeding; recent surgery &lt;14 days; recent stroke &lt;3 months; intracranial hemorrhage history Neuro checks q15min during infusion, q30min x 6h, then q1h x 18h; BP q15min x 2h, q30min x 6h, then q1h; hold anticoagulants/antiplatelets 24h Tenecteplase IV (if available) STAT STAT - STAT 0.25 mg/kg IV single bolus (max 25 mg); preferred if LVO planned for thrombectomy Same as alteplase Same as alteplase Endovascular thrombectomy STAT STAT - STAT For LVO (ICA, M1, M1-M2 junction, basilar); within 24h if eligible per DAWN/DEFUSE-3 criteria. 0-6h: NIHSS \u22656, ASPECTS \u22656. 6-24h: clinical-core mismatch on perfusion imaging Large established infarct core (ASPECTS &lt;6 in 0-6h window); no LVO; poor premorbid function (mRS &gt;2 relative); life expectancy &lt;6 months Continuous monitoring in neuro-ICU post-procedure; groin check; BP per post-thrombectomy protocol Aspirin STAT STAT - STAT 325 mg PO/PR load (give within 24-48h of onset); if tPA given, wait 24h and obtain CT before starting. Maintenance: 81-325 mg daily Active GI bleed, true aspirin allergy, within 24h of tPA (wait for post-tPA CT) GI symptoms, bleeding signs Blood pressure management PRE-tPA: Labetalol IV STAT STAT - STAT 10-20 mg IV over 1-2 min; may repeat once; target BP &lt;185/110 before tPA Heart block (2nd/3rd degree), severe bradycardia, decompensated HF, asthma/severe COPD Heart rate, BP continuous Blood pressure management PRE-tPA: Nicardipine IV STAT STAT - STAT 5 mg/h IV infusion; increase by 2.5 mg/h q5-15min; max 15 mg/h; target BP &lt;185/110 Severe aortic stenosis BP continuous monitoring Blood pressure management PRE-tPA: Clevidipine IV STAT STAT - STAT 1-2 mg/h IV; titrate by doubling q90sec initially; max 32 mg/h Soy/egg allergy, severe lipid disorders, defective lipid metabolism BP continuous monitoring Blood pressure management POST-tPA (24h) - STAT - STAT Target BP &lt;180/105 x 24h post-tPA; use nicardipine or labetalol drip as above See individual agents above Neuro checks with each BP check; hold if SBP &lt;100 Permissive hypertension (no tPA given) STAT STAT - STAT Allow BP up to 220/120; treat only if &gt;220/120 or end-organ damage (ACS, aortic dissection, hypertensive encephalopathy). Lower by 15% in first 24h N/A Neuro checks; avoid precipitous drops IV normal saline STAT STAT - STAT Isotonic fluids; avoid dextrose-containing solutions (hyperglycemia worsens outcomes); avoid hypotonic solutions (cerebral edema risk) Volume overload I/O, electrolytes Supplemental oxygen STAT STAT - STAT Only if SpO2 &lt;94%; nasal cannula or mask as needed N/A SpO2 target \u226594%; avoid routine supplemental O2 if normoxic"},{"location":"plans/acute-ischemic-stroke/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen Fever (temp &gt;38\u00b0C worsens outcomes) STAT STAT - STAT 650-1000 mg PO/PR q6h; max 4g/day (2g if hepatic impairment) Severe hepatic disease Temperature q4h; LFTs if prolonged use Insulin (regular) Hyperglycemia (glucose &gt;180 worsens outcomes) STAT STAT - STAT Sliding scale or insulin drip for persistent hyperglycemia; target glucose 140-180 mg/dL; avoid hypoglycemia (&lt;60 mg/dL) Hypoglycemia risk BG q1h if drip; q6h if sliding scale Ondansetron Nausea/vomiting (posterior circulation stroke) URGENT ROUTINE ROUTINE URGENT 4 mg IV/PO q6h PRN QT prolongation, serotonin syndrome risk QTc if risk factors Enoxaparin DVT prophylaxis - ROUTINE - ROUTINE 40 mg SC daily; start within 24-48h if not receiving therapeutic anticoagulation; after post-tPA imaging clears hemorrhage Active bleeding, platelets &lt;50K, CrCl &lt;30 (use UFH 5000u SC q8-12h) Platelets q3 days; renal function Heparin (unfractionated) SC DVT prophylaxis (alternative) - ROUTINE - ROUTINE 5000 units SC q8-12h Active bleeding, HIT Platelets q3 days Pneumatic compression devices DVT prophylaxis (non-pharmacologic) STAT STAT - STAT Apply to both legs immediately on admission; use in addition to or instead of pharmacologic prophylaxis Acute DVT, severe peripheral vascular disease Skin checks daily Pantoprazole GI prophylaxis (stress ulcer) - ROUTINE - ROUTINE 40 mg IV/PO daily C. difficile risk with prolonged use GI symptoms"},{"location":"plans/acute-ischemic-stroke/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Dual antiplatelet therapy (DAPT): Aspirin + Clopidogrel - URGENT URGENT - Aspirin 81 mg + Clopidogrel 75 mg daily x 21 days (minor stroke NIHSS \u22643 or high-risk TIA ABCD2 \u22654); then single antiplatelet long-term. Load clopidogrel 300 mg if not previously on it Major stroke (NIHSS &gt;3), high bleeding risk, planned surgery Bleeding signs; CBC Dual antiplatelet therapy: Aspirin + Ticagrelor - URGENT URGENT - Aspirin 81 mg daily + Ticagrelor 90 mg BID x 30 days (THALES trial: minor stroke NIHSS \u22645); then single antiplatelet Intracranial stenosis (may use), high bleeding risk, hepatic impairment Bleeding signs; dyspnea (common side effect) Heparin IV drip (therapeutic) - URGENT - URGENT Bolus 60-80 units/kg (max 5000u); infusion 12-18 units/kg/h; target aPTT 1.5-2.5x control. Use for: cardiac source with high re-embolization risk, arterial dissection, crescendo TIA, free-floating thrombus Large infarct (hemorrhagic transformation risk), uncontrolled BP, within 24h of tPA aPTT q6h until stable, then q12-24h; platelets q3 days; neuro checks Decompressive craniectomy (malignant MCA infarct) - - - STAT For malignant MCA syndrome with &gt;50% MCA territory infarct, age &lt;60 preferred; within 48h of onset; reduces mortality from 70-80% to ~20% Age &gt;60 (relative \u2014 DESTINY II showed benefit up to age 80 but with higher disability); bilateral infarcts; hemorrhagic transformation Post-operative neuro checks, ICP monitoring, wound care Osmotherapy: Mannitol 20% - - - STAT 1-1.5 g/kg IV bolus for acute herniation; 0.25-0.5 g/kg q4-6h maintenance Anuria, severe dehydration Serum osmolality (hold if &gt;320 mOsm/kg), osmolar gap, renal function, I/O Osmotherapy: Hypertonic saline 23.4% - - - STAT 30 mL IV bolus via central line over 10-20 min for acute herniation No central access for 23.4%; hypokalemia Serum sodium (target 145-155 mEq/L), osmolality, central line integrity Hypertonic saline 3% infusion - - - STAT 150-500 mL IV bolus or continuous infusion 0.5-1 mL/kg/h; target Na 145-155 Hypernatremia, volume overload Serum sodium q4-6h, osmolality"},{"location":"plans/acute-ischemic-stroke/#3d-disease-modifying-chronic-therapies","title":"3D. Disease-Modifying / Chronic Therapies","text":"Treatment Route ED HOSP OPD ICU Dosing Pre-Treatment Requirements Contraindications Monitoring Atorvastatin PO - STAT ROUTINE STAT 80 mg PO daily (high-intensity); start within 24-48h regardless of baseline LDL LFTs at baseline Active liver disease, pregnancy, breastfeeding LFTs at 12 weeks then annually; lipid panel at 4-12 weeks; CK if myalgia Rosuvastatin PO - STAT ROUTINE STAT 20-40 mg PO daily (high-intensity alternative) LFTs at baseline Active liver disease, pregnancy, CrCl &lt;30 for 40mg Same as atorvastatin Apixaban PO - ROUTINE ROUTINE - 5 mg PO BID (2.5 mg BID if \u22652 of: age \u226580, weight \u226460kg, Cr \u22651.5); start 4-14 days post-stroke for AF (timing based on infarct size). Preferred DOAC per guidelines Active major bleeding, mechanical heart valve, severe hepatic impairment Renal function; bleeding signs; CBC Rivaroxaban PO - ROUTINE ROUTINE - 20 mg PO daily with evening meal (15 mg daily if CrCl 15-50); start 4-14 days post-stroke for AF Active bleeding, CrCl &lt;15, severe hepatic impairment Renal function q6-12 months; bleeding signs Dabigatran PO - ROUTINE ROUTINE - 150 mg PO BID (75 mg BID if CrCl 15-30); start 4-14 days post-stroke for AF Active bleeding, CrCl &lt;15, mechanical heart valve Renal function q6-12 months; bleeding signs; GI side effects Warfarin PO - ROUTINE ROUTINE - 5 mg PO daily initial (2-3 mg if elderly, low weight, or interacting drugs); target INR 2.0-3.0 for AF; 2.5-3.5 for mechanical valve. Bridge with heparin Active bleeding, pregnancy, severe hepatic disease INR daily until stable, then weekly, then monthly; diet counseling (vitamin K) Lisinopril PO - ROUTINE ROUTINE - Start 5-10 mg PO daily; titrate to 20-40 mg daily; target BP &lt;130/80 after acute phase Angioedema history, bilateral renal artery stenosis, pregnancy Cr and K+ at 1-2 weeks after initiation; BP Amlodipine PO - ROUTINE ROUTINE - Start 5 mg PO daily; max 10 mg daily Severe aortic stenosis (relative) BP, peripheral edema Losartan PO - ROUTINE ROUTINE - Start 50 mg PO daily; max 100 mg daily Pregnancy, bilateral renal artery stenosis Cr, K+, BP Metoprolol succinate PO - ROUTINE ROUTINE - Start 25 mg PO daily; titrate to 200 mg daily Heart block, decompensated HF, severe bradycardia HR, BP Ezetimibe PO - ROUTINE ROUTINE - 10 mg PO daily; add if LDL not at goal on max statin Active liver disease LFTs, lipid panel PCSK9 inhibitor (evolocumab) SC - - ROUTINE - 140 mg SC q2 weeks or 420 mg SC monthly; if LDL not at goal on max statin + ezetimibe None absolute Lipid panel q4-12 weeks; injection site reactions"},{"location":"plans/acute-ischemic-stroke/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/acute-ischemic-stroke/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consultation (stroke team) STAT STAT - STAT All acute stroke presentations; tPA decision; stroke workup Neurointerventional/endovascular consultation STAT STAT - STAT Large vessel occlusion on CTA for thrombectomy Neurosurgery consultation URGENT URGENT - STAT Malignant MCA edema, posterior fossa stroke with hydrocephalus, hemorrhagic transformation requiring intervention Cardiology consultation - ROUTINE ROUTINE ROUTINE Newly detected atrial fibrillation, acute MI, cardiomyopathy, PFO evaluation Vascular surgery consultation - ROUTINE ROUTINE - Symptomatic carotid stenosis \u226550% (NASCET) for endarterectomy; ideally within 2 weeks Speech-language pathology (SLP) URGENT STAT ROUTINE URGENT Dysphagia screening before any PO intake; aphasia evaluation; cognitive-communication assessment Physical therapy (PT) - URGENT ROUTINE URGENT Early mobilization within 24-48h (AVERT trial: avoid very early aggressive mobilization &lt;24h); gait and balance training Occupational therapy (OT) - URGENT ROUTINE URGENT ADL assessment, upper extremity function, adaptive equipment, cognitive rehabilitation Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Determine rehabilitation disposition (inpatient rehab, SNF, home health, outpatient) Social work - ROUTINE ROUTINE - Discharge planning, insurance, DME, caregiver support, advance directives Nutrition/dietitian - ROUTINE ROUTINE - Dysphagia diet recommendations, cardiovascular risk diet (Mediterranean, DASH) Palliative care - ROUTINE - ROUTINE Large territory stroke with poor prognosis, goals of care discussion Smoking cessation counseling - ROUTINE ROUTINE - Active smokers Case management - ROUTINE ROUTINE - Rehabilitation placement, follow-up coordination"},{"location":"plans/acute-ischemic-stroke/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 immediately if new symptoms: sudden weakness, numbness, vision changes, speech difficulty, severe headache, loss of balance STAT STAT ROUTINE Do NOT drive until cleared by neurology (minimum 2 weeks; state-specific laws apply) URGENT URGENT ROUTINE Take all medications as prescribed; do NOT stop antiplatelet or anticoagulant without medical advice URGENT URGENT ROUTINE Swallowing precautions per SLP recommendations (sit upright 90\u00b0 for meals, specific diet texture) URGENT URGENT ROUTINE Fall prevention: clear pathways, use assistive devices, adequate lighting, non-slip surfaces - URGENT ROUTINE Blood pressure monitoring at home (target &lt;130/80 per physician guidance) - ROUTINE ROUTINE Stroke signs education for patient and family: F.A.S.T. (Face drooping, Arm weakness, Speech difficulty, Time to call 911) URGENT ROUTINE ROUTINE Medication list: carry updated list including all prescriptions, OTC, and supplements - ROUTINE ROUTINE Follow-up appointment with neurology in 1-2 weeks; primary care in 2-4 weeks - ROUTINE ROUTINE Report any bleeding (bruising, blood in stool/urine, gum bleeding) if on anticoagulation - ROUTINE ROUTINE"},{"location":"plans/acute-ischemic-stroke/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (absolute) - ROUTINE ROUTINE Blood pressure target &lt;130/80 mmHg - ROUTINE ROUTINE Mediterranean or DASH diet - ROUTINE ROUTINE Sodium restriction &lt;2.3 g/day (ideally &lt;1.5 g if hypertensive) - ROUTINE ROUTINE Regular aerobic exercise: 40 min moderate intensity, 3-4 days/week (after medical clearance) - - ROUTINE Weight management (BMI 18.5-24.9) - ROUTINE ROUTINE Alcohol limitation: \u22641 drink/day women, \u22642 drinks/day men; cessation if heavy use - ROUTINE ROUTINE Glycemic control target HbA1c &lt;7% (individualized) - ROUTINE ROUTINE LDL target &lt;70 mg/dL (high-intensity statin) - ROUTINE ROUTINE Obstructive sleep apnea screening (Berlin questionnaire or STOP-BANG); CPAP if diagnosed - ROUTINE ROUTINE Stress management and emotional support (depression common post-stroke) - ROUTINE ROUTINE Influenza and pneumococcal vaccination - - ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/acute-ischemic-stroke/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Hypoglycemia Glucose &lt;60; symptoms resolve with dextrose; diaphoresis, tremor POC glucose STAT Seizure with Todd's paralysis Witnessed seizure, post-ictal confusion, resolves within 24h; may have known epilepsy EEG, clinical observation, MRI (DWI negative) Complicated migraine (hemiplegic) Headache history, aura preceding deficit, gradual onset (\"marching\"), younger patient, family history MRI DWI (negative), clinical history Intracerebral hemorrhage CT shows hemorrhage; more severe headache, rapid progression, vomiting CT head without contrast Brain tumor/mass Subacute onset over days-weeks, progressive symptoms, headache worse in morning MRI with contrast (enhancing mass) Subdural hematoma History of trauma or anticoagulation; subacute confusion, headache, fluctuating symptoms CT head (crescent-shaped extra-axial collection) Hypertensive encephalopathy / PRES Severely elevated BP, headache, confusion, visual changes, seizures; typically posterior involvement MRI FLAIR (posterior white matter edema), BP &gt;220/120 CNS infection (abscess, meningitis) Fever, meningismus, subacute course, immunocompromise MRI with contrast, LP, blood cultures Conversion disorder / functional neurological disorder Non-anatomic distribution, Hoover sign positive, give-way weakness, distractible exam findings Normal imaging, clinical exam findings Peripheral vertigo (for posterior circulation symptoms) Isolated vertigo, positive HINTS peripheral pattern, no other neurologic deficits HINTS exam, MRI DWI Multiple sclerosis exacerbation Young patient, prior episodes, symptoms disseminated in space and time MRI (periventricular/juxtacortical lesions), oligoclonal bands Metabolic encephalopathy Bilateral, non-focal exam (usually); abnormal metabolic labs; confusion predominates BMP, ammonia, TSH, LFTs, UDS"},{"location":"plans/acute-ischemic-stroke/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal NIHSS (NIH Stroke Scale) STAT STAT ROUTINE STAT q1h x 24h (post-tPA: q15min x 2h, q30min x 6h, q1h x 16h), then q4h x 48h, then q shift Stable or improving If NIHSS increases \u22654 points: STAT CT head, call stroke team; consider hemorrhagic transformation, re-occlusion, or new stroke Blood pressure STAT STAT ROUTINE STAT Post-tPA: q15min x 2h, q30min x 6h, q1h x 16h; non-tPA: q1h x 24h, then q4h Pre-tPA: &lt;185/110; Post-tPA: &lt;180/105 x 24h; Chronic: &lt;130/80 Titrate antihypertensives; avoid SBP &lt;100 (hypoperfusion risk) Heart rate and rhythm (telemetry) STAT STAT - STAT Continuous x 48-72h minimum Detect paroxysmal atrial fibrillation, arrhythmias Cardiology consult; anticoagulation if AF Temperature STAT STAT - STAT q4h x 48h, then q8h Target &lt;37.5\u00b0C (normothermia) Acetaminophen; cooling measures; infection workup if &gt;38\u00b0C Blood glucose STAT STAT ROUTINE STAT q6h x 48h (q1h if insulin drip) 140-180 mg/dL; avoid &lt;60 mg/dL Insulin; D50W for hypoglycemia Oxygen saturation (SpO2) STAT STAT - STAT Continuous x 24h, then q4h \u226594% Supplemental O2; if &lt;90% consider intubation for large strokes Neurologic exam (level of consciousness, pupils) STAT STAT - STAT q1-4h depending on severity Alert, equal reactive pupils Declining LOC: STAT CT, ICP management Swallowing screen URGENT STAT - URGENT Before any PO intake Pass screening (water swallow test) NPO until formal SLP evaluation INR (if on warfarin) - ROUTINE ROUTINE - Daily until stable, then per protocol 2.0-3.0 for AF; 2.5-3.5 for mechanical valve Dose adjustment Renal function (Cr, BUN) - ROUTINE ROUTINE - q24-48h if contrast given or on new medications Stable Hydration; hold nephrotoxic agents Lipid panel - ROUTINE ROUTINE - Fasting within 24-48h; repeat at 4-12 weeks on statin LDL &lt;70 mg/dL Intensify statin; add ezetimibe or PCSK9i Depression screening (PHQ-9) - - ROUTINE - At 1 month, 3 months, annually PHQ-9 &lt;5 SSRI initiation; psychology/psychiatry referral"},{"location":"plans/acute-ischemic-stroke/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Minor stroke (NIHSS 0-3) with stable exam, adequate support at home, able to perform ADLs or with home health, completed workup or reliable outpatient follow-up arranged, medications filled Admit to stroke unit/floor Moderate stroke (NIHSS 4-15), requires IV medications or ongoing monitoring, incomplete workup, dysphagia requiring NPO/modified diet, new atrial fibrillation requiring anticoagulation initiation Admit to ICU/neuro-ICU Post-tPA monitoring (first 24h), post-thrombectomy, large territory infarct with edema risk, posterior fossa stroke with herniation risk, unstable BP requiring IV antihypertensives, declining neurologic exam, respiratory compromise Transfer to higher level of care LVO needing thrombectomy (transfer to comprehensive stroke center), need for neurosurgical intervention not available, need for neuro-ICU not available Inpatient rehabilitation Moderate-severe deficits (NIHSS &gt;4), able to participate in 3h/day therapy, expected to benefit from intensive rehab, medically stable Skilled nursing facility (SNF) Unable to tolerate 3h/day rehab, needs skilled nursing care, medically complex requiring ongoing monitoring Home with outpatient therapy Mild deficits, safe home environment, reliable follow-up, family support available"},{"location":"plans/acute-ischemic-stroke/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IV alteplase within 4.5h Class I, Level A AHA/ASA 2019 Guidelines; NINDS trial; ECASS III Tenecteplase non-inferior to alteplase for LVO Class IIa, Level B-R AcT trial (2022); EXTEND-IA TNK Thrombectomy for LVO 0-6h Class I, Level A MR CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, REVASCAT Thrombectomy for LVO 6-24h (selected patients) Class I, Level A DAWN trial; DEFUSE-3 DAPT 21 days for minor stroke/high-risk TIA Class I, Level A CHANCE trial; POINT trial Aspirin + ticagrelor 30 days for minor stroke Class IIa, Level B-R THALES trial High-intensity statin therapy Class I, Level A SPARCL trial; AHA/ASA 2021 Anticoagulation for AF-related stroke Class I, Level A RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF BP target &lt;130/80 for secondary prevention Class I, Level A SPS3 trial; AHA/ASA 2021 Early mobilization (24-48h, not aggressive) Class IIa, Level B-R AVERT trial (very early &lt;24h aggressive mobilization harmful) Decompressive craniectomy for malignant MCA Class I, Level A (age &lt;60) DESTINY, DECIMAL, HAMLET pooled analysis Extended cardiac monitoring for cryptogenic stroke Class IIa, Level B-R CRYSTAL-AF, EMBRACE trials Dysphagia screening before PO intake Class I, Level B-NR AHA/ASA 2019 Guidelines Carotid endarterectomy for symptomatic stenosis \u226550% Class I, Level A NASCET, ECST trials PFO closure for cryptogenic stroke age 18-60 Class IIa, Level B-R CLOSE, RESPECT, REDUCE trials Permissive hypertension (up to 220/120 if no tPA) Class I, Level B-R AHA/ASA 2019 Guidelines Target glucose 140-180 mg/dL Class I, Level C AHA/ASA 2019 Guidelines DVT prophylaxis within 24-48h Class I, Level A AHA/ASA 2019 Guidelines Depression screening post-stroke Class I, Level B-NR AHA/ASA 2019 Guidelines Normothermia maintenance Class I, Level C AHA/ASA 2019 Guidelines <p>APPENDIX: ACUTE STROKE TIME TARGETS</p> Metric Target Door-to-physician \u226410 minutes Door-to-CT completion \u226425 minutes Door-to-CT interpretation \u226445 minutes Door-to-needle (tPA) \u226445 minutes (target), \u226460 minutes (acceptable) Door-to-groin puncture (thrombectomy) \u226490 minutes (if on-site), \u2264120 minutes (if transfer) Last known well to tPA \u22644.5 hours Last known well to thrombectomy \u226424 hours (with perfusion imaging selection for 6-24h) <p>APPENDIX: NIHSS QUICK REFERENCE</p> Score Range Severity General Prognosis 0 No deficit Excellent 1-4 Minor stroke Good; consider DAPT 5-15 Moderate stroke Consider tPA; may need rehab 16-20 Moderate-severe tPA + thrombectomy if LVO; likely inpatient rehab 21-42 Severe High mortality/morbidity; goals of care discussion <p>APPENDIX: ASPECTS (Alberta Stroke Program Early CT Score)</p> Score Interpretation 10 Normal CT 7-9 Small infarct; favorable for intervention 6 Threshold for thrombectomy eligibility (0-6h window) &lt;6 Large established infarct; higher hemorrhagic transformation risk 0 Complete MCA territory infarct"},{"location":"plans/acute-myelopathy/","title":"Acute Myelopathy Evaluation","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Acute Myelopathy Evaluation</p> <p>ICD-10: G95.9 (Disease of spinal cord, unspecified), G95.89 (Other specified diseases of spinal cord), G37.3 (Acute transverse myelitis in demyelinating disease)</p> <p>SYNONYMS: Acute myelopathy, transverse myelitis, TM, spinal cord inflammation, myelitis, NMOSD myelitis, spinal cord lesion, spinal cord syndrome, cord compression, spinal cord injury</p> <p>SCOPE: Acute or subacute spinal cord dysfunction \u2014 broad differential approach. Covers urgent MRI, LP, and comprehensive workup to differentiate compressive (epidural abscess, tumor, disc herniation, hematoma) from non-compressive causes (inflammatory/demyelinating, vascular, infectious). Compressive myelopathy is a surgical emergency. Excludes chronic cervical spondylotic myelopathy, cauda equina syndrome (separate template), and isolated radiculopathy.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/acute-myelopathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/acute-myelopathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Infection screen (epidural abscess); baseline; leukocytosis Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Renal/hepatic function for contrast and medication dosing; electrolytes Normal ESR STAT STAT ROUTINE STAT Markedly elevated in epidural abscess (&gt;20 in ~95%); elevated in inflammatory/autoimmune Normal; &gt;20 raises concern for abscess/infection CRP STAT STAT ROUTINE STAT Elevated in infection, inflammation; useful for monitoring treatment response Normal Blood cultures x2 STAT STAT - STAT If epidural abscess or infection suspected; S. aureus most common No growth PT/INR, aPTT STAT STAT - STAT Coagulopathy causing epidural hematoma; pre-LP; pre-surgical assessment Normal Blood glucose STAT STAT ROUTINE STAT Diabetic risk factor for epidural abscess; baseline Normal Urinalysis STAT ROUTINE ROUTINE STAT UTI as source for epidural abscess; baseline bladder function Normal Type and screen STAT ROUTINE - STAT Potential surgical intervention On file Procalcitonin URGENT ROUTINE - URGENT Bacterial infection differentiation &lt;0.5 ng/mL"},{"location":"plans/acute-myelopathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding AQP4-IgG (aquaporin-4 antibody, serum) \u2014 cell-based assay - STAT ROUTINE STAT NMOSD \u2014 longitudinally extensive transverse myelitis (\u22653 segments); affects treatment (avoid interferon-beta, fingolimod) Negative (positive = NMOSD) MOG-IgG antibody (serum) \u2014 cell-based assay - STAT ROUTINE STAT MOGAD \u2014 often presents as myelitis; treatment implications differ from MS and NMOSD Negative (positive = MOGAD) B12, methylmalonic acid - ROUTINE ROUTINE - Subacute combined degeneration (posterior columns + corticospinal tracts) Normal Copper and ceruloplasmin - ROUTINE ROUTINE - Copper deficiency myelopathy (mimics B12 deficiency pattern) Normal Zinc level - ROUTINE ROUTINE - Zinc excess causes copper deficiency Normal HIV 1/2 antigen/antibody - ROUTINE ROUTINE - HIV-associated vacuolar myelopathy; opportunistic infections Negative HTLV-1/2 antibody - ROUTINE ROUTINE - HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Negative RPR/VDRL - ROUTINE ROUTINE - Syphilitic myelitis (tabes dorsalis = posterior columns) Non-reactive ANA, dsDNA - ROUTINE ROUTINE - Lupus myelitis Negative Anti-SSA (Ro), anti-SSB (La) - ROUTINE ROUTINE - Sj\u00f6gren syndrome myelitis Negative ACE level (serum) - ROUTINE ROUTINE - Neurosarcoidosis (spinal cord granulomas) Normal QuantiFERON-TB Gold - ROUTINE ROUTINE - Spinal TB (Pott disease, TB myelitis) Negative Anti-thyroid antibodies (TPO, thyroglobulin) - ROUTINE ROUTINE - Hashimoto encephalopathy/myelopathy Negative"},{"location":"plans/acute-myelopathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Paraneoplastic panel (serum) \u2014 ANNA-1, CRMP-5, amphiphysin - ROUTINE ROUTINE - Paraneoplastic myelitis (lung, breast, lymphoma); amphiphysin is classic for stiff-person / paraneoplastic myelopathy Negative Anti-GFAP antibody (serum and CSF) - EXT EXT - GFAP astrocytopathy \u2014 autoimmune meningoencephalomyelitis Negative Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, \u03b22-glycoprotein I) - ROUTINE ROUTINE - Spinal cord infarction from hypercoagulable state Negative Serum protein electrophoresis (SPEP) - ROUTINE ROUTINE - Multiple myeloma (spinal cord compression from plasmacytoma); POEMS Normal Lyme antibody (ELISA, Western blot) - ROUTINE ROUTINE - Lyme myelitis (endemic areas) Negative CMV PCR (blood) - EXT - EXT CMV myelitis (immunocompromised) Negative VZV IgM, VZV PCR (blood) - EXT - EXT VZV myelitis (may follow shingles) Negative Sickle cell screen - EXT EXT - Spinal cord infarction in sickle cell disease Normal"},{"location":"plans/acute-myelopathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/acute-myelopathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI entire spine (cervical, thoracic, lumbar) with and without gadolinium contrast STAT STAT URGENT STAT IMMEDIATELY \u2014 within 4 hours of presentation maximum; faster if progressive deficit. Entire spine because multifocal lesions change differential (NMOSD, metastatic) Compressive: epidural mass (abscess, tumor, hematoma), disc herniation. Non-compressive: cord signal change (T2 hyperintensity), enhancement pattern, longitudinal extent, location within cord cross-section GFR &lt;30 (give contrast anyway if emergent); gadolinium allergy (premedicate); pacemaker MRI brain with and without contrast URGENT URGENT ROUTINE URGENT Within 24h (same session if possible) MS (periventricular/juxtacortical lesions), NMOSD (area postrema, hypothalamic), ADEM (multifocal white matter), metastatic disease, leptomeningeal enhancement Same as spine MRI CT spine (without contrast) STAT STAT - STAT ONLY if MRI unavailable or contraindicated; far less sensitive for cord pathology Fracture, bony compression, large epidural mass, disc herniation Pregnancy (relative) Chest X-ray URGENT ROUTINE - URGENT Baseline; lung malignancy screening (metastatic cord compression); sarcoidosis (hilar adenopathy) Normal <p>CRITICAL: If MRI shows compressive myelopathy \u2192 NEUROSURGERY STAT. Do not delay for additional workup.</p>"},{"location":"plans/acute-myelopathy/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest/abdomen/pelvis with contrast - ROUTINE ROUTINE - If metastatic cord compression or sarcoidosis suspected Primary malignancy; lymphadenopathy Contrast allergy, renal impairment CT angiography (CTA) of aorta - URGENT - URGENT If spinal cord infarction suspected (especially post-aortic surgery) Aortic dissection, aortic aneurysm, occlusion of artery of Adamkiewicz Same as CT contrast MR angiography (MRA) of spinal vessels - EXT EXT - Spinal dural arteriovenous fistula (dAVF); spinal AVM Abnormal vascular flow voids; fistula identification Same as MRI Conventional spinal angiography (DSA) - EXT EXT - Gold standard for spinal dAVF/AVM; if MRA suggestive Fistula or AVM identification and localization for treatment Contrast allergy; coagulopathy PET-CT (whole body) - EXT ROUTINE - Occult malignancy search Primary tumor Pregnancy; uncontrolled diabetes Repeat MRI spine - ROUTINE ROUTINE - At 2-4 weeks for treatment response; earlier if clinical worsening Improving signal; resolving enhancement Same as initial NCS/EMG - ROUTINE ROUTINE - If concomitant peripheral neuropathy suspected (e.g., GBS mimicking myelopathy) Peripheral nerve involvement vs pure cord None significant"},{"location":"plans/acute-myelopathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Somatosensory evoked potentials (SSEPs) - ROUTINE ROUTINE - Assess dorsal column function; prognosis Delayed or absent cortical potentials None Motor evoked potentials (MEPs) - EXT EXT - Corticospinal tract assessment Delayed or absent Epilepsy (relative); implanted devices Spinal cord biopsy - - EXT - Extremely rare; only for diagnostic uncertainty when all other testing inconclusive and progressive decline Tumor, vasculitis, infection, sarcoidosis High morbidity; neurosurgical decision"},{"location":"plans/acute-myelopathy/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: ALL non-compressive myelopathies require LP. Perform AFTER MRI (need to exclude compressive cause and epidural abscess \u2014 LP through an abscess risks seeding meningitis).</p> <p>Timing: URGENT \u2014 after MRI confirms non-compressive etiology.</p> <p>Volume Required: 20-25 mL (many studies needed)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Elevated in some inflammatory conditions Normal (10-20 cm H2O) Cell count with differential (tubes 1 and 4) URGENT ROUTINE ROUTINE Pleocytosis: infection, inflammation. MS: mild. NMOSD: moderate with neutrophils. Infection: marked Variable by etiology Protein URGENT ROUTINE ROUTINE Elevated in GBS, infection, NMOSD, cord compression Variable Glucose with paired serum URGENT ROUTINE ROUTINE Low in TB, bacterial, fungal, leptomeningeal malignancy Normal in most inflammatory causes Oligoclonal bands (paired with serum) - ROUTINE ROUTINE Positive in MS (&gt;90%); may be positive in NMOSD, sarcoidosis Positive bands in CSF only = intrathecal synthesis (MS) IgG index - ROUTINE ROUTINE Elevated in MS and other inflammatory conditions Normal &lt;0.7 AQP4-IgG (CSF) - ROUTINE ROUTINE NMOSD confirmation (serum is more sensitive; CSF adds specificity) Negative MOG-IgG (CSF) - ROUTINE ROUTINE MOGAD confirmation Negative Autoimmune encephalitis panel (CSF) - ROUTINE ROUTINE GFAP, NMDAR (rare spinal involvement) Negative Cytology - ROUTINE ROUTINE Leptomeningeal carcinomatosis, lymphoma Negative Flow cytometry - ROUTINE ROUTINE CNS lymphoma Normal VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Non-reactive ACE level (CSF) - ROUTINE ROUTINE Neurosarcoidosis Normal HSV 1/2 PCR - ROUTINE ROUTINE HSV myelitis (rare) Negative VZV PCR - ROUTINE ROUTINE VZV myelitis (may follow shingles) Negative CMV PCR - ROUTINE ROUTINE CMV myelitis (immunocompromised) Negative EBV PCR - ROUTINE ROUTINE EBV-associated lymphoma/myelitis Negative HTLV-1 antibody (CSF) - ROUTINE ROUTINE HAM/TSP confirmation Negative AFB smear and culture - ROUTINE ROUTINE Spinal TB Negative Bacterial culture - ROUTINE ROUTINE Bacterial myelitis (rare) No growth Cryptococcal antigen - ROUTINE ROUTINE Cryptococcal myelitis (immunocompromised) Negative"},{"location":"plans/acute-myelopathy/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/acute-myelopathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IV methylprednisolone (empiric \u2014 inflammatory myelitis) - STAT - STAT 1000 mg IV daily x 3-5 days (infuse over 1-2h). Start empirically if inflammatory myelitis suspected (non-compressive cord lesion on MRI). Do NOT wait for antibody results Active untreated infection (relative \u2014 treat infection concurrently if needed); uncontrolled diabetes Glucose q6h; BP; GI prophylaxis (PPI); insomnia; psychosis (rare); weight; taper plan Emergent surgical decompression STAT STAT - STAT For compressive myelopathy: epidural abscess, tumor with cord compression, acute disc herniation with myelopathy, epidural hematoma. Earlier decompression = better neurologic outcome. Within 24h is critical; within 12h is ideal Medically unstable for surgery (optimize first) Post-op neurologic exam; wound care; DVT prophylaxis Empiric IV antibiotics (if epidural abscess suspected) STAT STAT - STAT Vancomycin 15-20 mg/kg IV q8-12h + ceftriaxone 2g IV q12h (or cefepime 2g IV q8h). Start BEFORE surgery. S. aureus is most common organism See individual agents Cultures; vancomycin trough; renal function DVT prophylaxis: Enoxaparin - ROUTINE - ROUTINE 40 mg SC daily (start post-operatively or when not bleeding; within 24-48h) Active bleeding; post-surgical (timing per surgeon); coagulopathy Platelets q3 days Pneumatic compression devices STAT STAT - STAT Apply bilaterally immediately \u2014 spinal cord injury patients are HIGH risk for DVT/PE Acute DVT Skin checks Bladder management STAT STAT - STAT Foley catheter if urinary retention (very common in myelopathy); measure post-void residual if not catheterized; intermittent catheterization if PVR &gt;200 mL N/A I/O; bladder scan; transition to intermittent cath when possible Bowel management - ROUTINE - ROUTINE Bowel program: docusate + senna; digital stimulation if neurogenic bowel; avoid impaction Bowel obstruction Bowel function daily"},{"location":"plans/acute-myelopathy/#3b-second-line-specific-treatments","title":"3B. Second-line / Specific Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Plasma exchange (PLEX) Steroid-refractory inflammatory myelitis; NMOSD exacerbation; severe transverse myelitis - URGENT - URGENT 5-7 exchanges over 10-14 days (every other day); 1-1.5 plasma volumes per exchange Hemodynamic instability; sepsis BP; electrolytes; Ca2+; fibrinogen IVIG Alternative to PLEX if PLEX unavailable; MOGAD (may be preferred); steroid-refractory - URGENT - URGENT 0.4 g/kg/day x 5 days (total 2 g/kg) IgA deficiency; renal failure Renal function; headache; thrombosis Oral prednisone taper (after IV pulse) Inflammatory myelitis; NMOSD - ROUTINE ROUTINE - 1 mg/kg/day (max 60-80 mg) tapered over 4-8 weeks for first episode; longer taper for NMOSD/MOGAD See steroid contraindications Glucose; BP; bone health Gabapentin Neuropathic pain, spasticity - ROUTINE ROUTINE ROUTINE 300 mg PO qHS \u2192 titrate to 900-1800 mg TID Severe renal impairment Sedation; dizziness Baclofen Spasticity - ROUTINE ROUTINE - 5 mg PO TID; increase by 5 mg/dose q3 days; max 80 mg/day Seizure history (lowers threshold); abrupt withdrawal causes seizures Sedation; falls; do NOT stop abruptly Tizanidine Spasticity (alternative) - ROUTINE ROUTINE - 2 mg PO TID; max 36 mg/day Hepatic impairment; concurrent CYP1A2 inhibitors (ciprofloxacin) LFTs; sedation; hypotension Oxybutynin Neurogenic bladder (overactive) - ROUTINE ROUTINE - 5 mg PO BID-TID Urinary retention; angle-closure glaucoma Anticholinergic side effects; PVR Acetaminophen Pain STAT ROUTINE ROUTINE STAT 650-1000 mg PO q6h; max 4g/day Hepatic disease LFTs"},{"location":"plans/acute-myelopathy/#3c-disease-modifying-therapy-once-diagnosis-established","title":"3C. Disease-Modifying Therapy (Once Diagnosis Established)","text":"Treatment Diagnosis Dosing Monitoring MS disease-modifying therapy MS (see MS template) Per MS-specific template; high-efficacy preferred if myelitis presentation Per agent Rituximab NMOSD (AQP4+); MOGAD (relapsing) 375 mg/m2 weekly x 4 weeks OR 1000 mg x 2 (14 days apart); maintenance q6 months CD19/20; immunoglobulins; infection Eculizumab NMOSD (AQP4+) 900 mg IV weekly x 4 \u2192 1200 mg q2 weeks Meningococcal vaccination (\u22652 weeks before); complement levels; infection Inebilizumab NMOSD (AQP4+) 300 mg IV x 2 (14 days apart); then 300 mg q6 months CD19; infection Satralizumab NMOSD (AQP4+) 120 mg SC at weeks 0, 2, 4, then q4 weeks LFTs; infection Azathioprine NMOSD (cost-effective alternative); neurosarcoidosis 2-3 mg/kg/day PO TPMT genotype; CBC weekly x 4, then biweekly, then monthly; LFTs Mycophenolate mofetil NMOSD alternative; neurosarcoidosis 1000-1500 mg PO BID CBC; LFTs; pregnancy test (teratogenic) Anti-TB therapy Spinal tuberculosis RIPE x 12-18 months LFTs; visual acuity IV penicillin G Neurosyphilis 18-24 MU/day IV x 14 days RPR q3-6 months Radiation + surgery + steroids Metastatic cord compression Per oncology; dexamethasone 10 mg IV load \u2192 4 mg IV q6h while radiation planned Glucose; GI prophylaxis"},{"location":"plans/acute-myelopathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/acute-myelopathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology (neuro-immunology if available) STAT STAT STAT STAT All myelopathy; diagnostic workup direction; immunotherapy decisions Neurosurgery STAT STAT - STAT Compressive myelopathy (abscess, tumor, hematoma, disc); surgical timing critical Spine surgery (orthopedic) STAT STAT - STAT Alternative for compressive causes where neurosurgery unavailable Radiation oncology - URGENT - - Metastatic cord compression; radiation planning Oncology - ROUTINE ROUTINE - Newly diagnosed malignancy; systemic treatment Infectious disease - ROUTINE ROUTINE - Epidural abscess management; TB; HIV; unusual infections Urology - ROUTINE ROUTINE - Neurogenic bladder management; intermittent catheterization training; urodynamics Physical therapy (PT) - STAT ROUTINE URGENT Mobility assessment; strengthening; gait training; transfer training; wheelchair assessment Occupational therapy (OT) - STAT ROUTINE URGENT ADL assessment; hand function; adaptive equipment; home modifications Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Rehabilitation planning; SCI rehabilitation protocols; disposition Speech-language pathology - ROUTINE ROUTINE - If cervical myelopathy affecting swallowing Respiratory therapy - URGENT - STAT If cervical myelopathy affecting respiratory muscles; FVC monitoring Social work - ROUTINE ROUTINE - Discharge planning; DME; caregiver support; disability Psychology - ROUTINE ROUTINE - Adjustment disorder; depression; coping with disability Pain management - ROUTINE ROUTINE - Neuropathic pain refractory to standard agents Wound care (if pressure injury) - ROUTINE ROUTINE ROUTINE Immobile patients at high risk for pressure ulcers"},{"location":"plans/acute-myelopathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED immediately if: new weakness, worsening numbness, loss of bowel/bladder function, inability to walk, difficulty breathing STAT STAT ROUTINE Spinal cord injury can improve with treatment \u2014 recovery varies by cause (inflammatory often recovers well; vascular and compressive recovery depends on timing) - ROUTINE ROUTINE Bladder management is critical: perform intermittent catheterization as instructed; report urinary retention or incontinence - ROUTINE ROUTINE Bowel program compliance: maintain regular schedule; adequate fiber and fluids - ROUTINE ROUTINE Skin checks daily: pressure injury prevention (reposition every 2h if immobile; use pressure-relieving mattress) - ROUTINE ROUTINE Physical therapy exercises between sessions as instructed - ROUTINE ROUTINE Do NOT drive until cleared by neurology - ROUTINE ROUTINE Follow-up with neurology in 1-2 weeks; repeat MRI at 2-4 weeks - ROUTINE ROUTINE"},{"location":"plans/acute-myelopathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Pressure injury prevention (positioning, specialized mattress, skin checks) - ROUTINE ROUTINE Fall prevention (assistive devices, home modifications) - ROUTINE ROUTINE DVT prevention (compression stockings long-term; anticoagulation per protocol) - ROUTINE ROUTINE Autonomic dysreflexia awareness (if thoracic/cervical injury: sudden hypertension, headache, flushing above level \u2014 emergency) - ROUTINE ROUTINE Bladder health (adequate fluid intake; catheterization technique; UTI prevention) - ROUTINE ROUTINE Mental health support (spinal cord injury carries high depression/anxiety rates) - ROUTINE ROUTINE Vaccination (if starting immunosuppression: complete vaccines before rituximab/eculizumab) - ROUTINE ROUTINE Smoking cessation - ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/acute-myelopathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Epidural abscess Back pain + fever + neurologic deficit (triad in 10-15%); IVDU, diabetes, spinal procedure risk factors; ESR/CRP very elevated MRI with contrast (ring-enhancing epidural collection); blood cultures; ESR &gt;20 Metastatic cord compression Known malignancy; progressive back pain (often worse at night); bony destruction MRI (enhancing epidural mass with bony changes); CT body for primary; PET-CT Disc herniation (acute) Sudden onset; radiculopathy predominant initially; may progress to myelopathy MRI (disc protrusion with cord compression) Epidural hematoma Anticoagulation; post-procedure; coagulopathy; sudden onset MRI (epidural collection; T1 signal depends on age of blood); coagulation panel Transverse myelitis (idiopathic) Non-compressive; T2 cord signal change; may be partial or complete; often thoracic MRI (T2 hyperintensity &lt;3 segments); LP (pleocytosis); diagnose after excluding MS, NMOSD, MOGAD MS (spinal cord relapse) Partial myelitis (&lt;3 segments); brain lesions present; prior episodes; young adult MRI brain (periventricular/juxtacortical lesions); oligoclonal bands; short segment cord lesion NMOSD Longitudinally extensive transverse myelitis (LETM \u22653 segments); severe; often central cord/gray matter AQP4-IgG antibody; MRI (LETM, central cord pattern); brain MRI (area postrema lesion) MOGAD LETM possible; conus/lower cord predilection; may have bilateral optic neuritis MOG-IgG antibody; MRI pattern; generally better recovery than NMOSD Spinal cord infarction Hyperacute onset (minutes); anterior spinal artery syndrome (motor + pain/temperature loss, preserved proprioception/vibration); often thoracolumbar MRI DWI (restricted diffusion, \"owl eye\" or pencil-like on axial); CTA aorta; vascular risk factors Spinal dural AV fistula Older male; progressive myelopathy with flow voids on MRI; dorsal cord; edema disproportionate to enhancement MRI (flow voids, dorsal cord edema, enhancement); spinal angiography (gold standard) GBS (axonal variant) Ascending weakness; areflexia; may mimic acute myelopathy if rapidly progressive; CSF albuminocytologic dissociation NCS/EMG; LP (elevated protein, normal cells); no cord signal on MRI Neurosarcoidosis Dorsal subpial enhancement; trident sign; may have pulmonary sarcoidosis Chest CT; ACE level; biopsy; characteristic MRI pattern Spinal TB (Pott disease) Endemic area; systemic TB; vertebral body destruction with epidural abscess; gibbus deformity MRI; AFB culture; TB PCR; QuantiFERON; chest X-ray Neuromyelitis optica spectrum disorder \u2014 See NMOSD above Syphilitic myelitis (tabes dorsalis) Posterior column dysfunction (proprioception, vibration loss); lightning pains; Argyll Robertson pupils CSF VDRL; RPR; FTA-ABS Copper deficiency myelopathy Posterior column + corticospinal tract (mimics B12 deficiency); gastric surgery, zinc excess Serum copper and ceruloplasmin; zinc level Radiation myelopathy History of radiation; months to years after treatment; progressive; no enhancement (chronic) Radiation history; MRI (cord atrophy, signal change within radiation field) Functional neurological disorder Non-anatomic sensory loss; Hoover sign; give-way weakness; normal MRI Normal MRI; normal LP; clinical exam findings"},{"location":"plans/acute-myelopathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Neurologic exam (strength, sensory level, reflexes, rectal tone) STAT STAT ROUTINE STAT q4h x 48h, then q8h; sensory level marking on skin for tracking Stable or improving; sensory level not ascending If ascending level or worsening motor: STAT repeat MRI; neurosurgery if compressive Bladder function (PVR, I/O) STAT STAT ROUTINE STAT PVR with each void initially; I/O daily PVR &lt;200 mL; adequate output If PVR &gt;200: intermittent catheterization; Foley if &gt;500 or unable to cath Respiratory function (FVC, NIF) \u2014 cervical myelopathy STAT STAT - STAT q4-6h if cervical; q2h if declining FVC &gt;20 mL/kg If FVC &lt;20: ICU; prepare for intubation Blood pressure / autonomic function STAT STAT - STAT q4h; orthostatic vitals when mobilizing Stable BP; no orthostatic hypotension &gt;20 mmHg Volume; midodrine; compression stockings; if hypertensive crisis above level \u2192 autonomic dysreflexia \u2192 find and remove stimulus (distended bladder, bowel impaction) Temperature STAT STAT - STAT q4h Afebrile If febrile: infection workup; wound check; UTI screen Skin assessment (pressure areas) - ROUTINE ROUTINE ROUTINE q shift; at every reposition Intact skin; no erythema &gt;30 min Pressure relief; wound care; specialty mattress ESR / CRP (if infection) - ROUTINE ROUTINE - q48-72h during treatment Declining trend If not improving: reassess antibiotic coverage; repeat imaging Post-void residual (PVR) - ROUTINE ROUTINE - With each void initially; daily once stable &lt;200 mL Intermittent catheterization protocol MRI response - ROUTINE ROUTINE - At 2-4 weeks; 3-6 months; or sooner if worsening Improving signal and enhancement Adjust treatment; consider PLEX/escalation AQP4/MOG antibody titers (if positive) - - ROUTINE - At 3-6 months, then annually Declining or stable If rising with clinical worsening: relapse; adjust DMT"},{"location":"plans/acute-myelopathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild myelopathy; stable or improving; ambulatory; independent bladder function; adequate outpatient follow-up; MRI and workup complete or schedulable outpatient Admit to floor Non-compressive myelopathy requiring IV steroids; moderate deficits; bladder dysfunction requiring catheterization; incomplete workup Admit to ICU Cervical myelopathy with respiratory compromise; post-surgical; ascending myelopathy; autonomic instability Emergent surgery Compressive myelopathy: epidural abscess, acute cord compression from tumor/hematoma/disc with neurologic deficit Transfer to higher level Need for neurosurgery not available; need for PLEX; MRI not available STAT; spinal cord injury center Inpatient rehabilitation (SCI rehab) Significant motor deficits; paraparesis/paraplegia; wheelchair-dependent; bladder/bowel dysfunction; able to participate in 3h/day therapy Skilled nursing facility Unable to tolerate intensive rehab; requires skilled nursing; ongoing IV antibiotics"},{"location":"plans/acute-myelopathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source STAT MRI entire spine for acute myelopathy Class I, Level B AAN Practice Guideline; Transverse Myelitis Consortium Working Group (2002) IV methylprednisolone 1g/day x 3-5 days for inflammatory myelitis Class I, Level B Consensus; extrapolated from MS relapse data (ONTT) and TM studies PLEX for steroid-refractory inflammatory myelitis Class IIa, Level B Weinshenker et al. (Ann Neurol 1999); superior to sham in severe demyelinating attacks AQP4-IgG (cell-based assay) for NMOSD diagnosis Class I, Level A Wingerchuk et al. IPND 2015 criteria MOG-IgG for MOGAD diagnosis Class I, Level B Banwell et al. (Lancet Neurol 2023) Surgical decompression within 24h for compressive myelopathy Class I, Level B Fehlings et al. (2012); earlier surgery = better outcomes Epidural abscess: antibiotics + surgical drainage Class I, Level B Darouiche et al. (NEJM 2006) B12 replacement for subacute combined degeneration Class I, Level A Well-established; early treatment may be reversible Rituximab for NMOSD prevention Class I, Level A Multiple trials; standard of care Eculizumab for NMOSD prevention Class I, Level A PREVENT trial (Pittock et al. NEJM 2019) AQP4-IgG-positive NMOSD: avoid interferon-beta and fingolimod Class III (Harm) Case reports of worsening LP after MRI (not before) in acute myelopathy Class I, Level C Risk of seeding infection through abscess; need anatomic diagnosis first Bladder management with intermittent catheterization Class I, Level B Spinal cord injury guidelines; prevents UTI better than indwelling catheter DVT prophylaxis in acute myelopathy Class I, Level A High thrombotic risk in immobilized SCI patients <p>APPENDIX: MRI PATTERN RECOGNITION IN MYELOPATHY</p> Pattern Diagnosis Suggested Short segment (&lt;3 vertebral segments), eccentric/dorsolateral MS Longitudinally extensive (\u22653 segments), central cord/gray matter NMOSD Longitudinally extensive, conus/lower cord MOGAD Anterior cord (gray matter \"owl eyes\" on axial) Spinal cord infarction Dorsal cord, flow voids, extensive edema Dural AV fistula Ring-enhancing epidural collection Epidural abscess Enhancing epidural mass with bony destruction Metastatic tumor Posterior columns bilateral B12 deficiency, copper deficiency, syphilis (tabes) Dorsal subpial enhancement, \"trident sign\" Neurosarcoidosis Central cord, bright/enhancing, expansile Cord tumor (astrocytoma, ependymoma) <p>APPENDIX: ANTERIOR SPINAL ARTERY SYNDROME (Spinal Cord Infarction)</p> Affected Preserved Motor function (corticospinal tracts) Proprioception (dorsal columns) Pain/temperature sensation (spinothalamic tracts) Vibration sense (dorsal columns) Bladder/bowel function (autonomic) Light touch (partial \u2014 dorsal columns) <p>Classic pattern: bilateral motor weakness + bilateral pain/temperature loss BELOW level + PRESERVED proprioception/vibration</p>"},{"location":"plans/autoimmune-encephalitis/","title":"Autoimmune Encephalitis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial creation</p> <p>DIAGNOSIS: Autoimmune Encephalitis</p> <p>ICD-10: G04.81 (Other autoimmune encephalitis)</p> <p>SYNONYMS: Autoimmune encephalitis, AE, anti-NMDA receptor encephalitis, anti-NMDAR encephalitis, limbic encephalitis, antibody-mediated encephalitis, paraneoplastic encephalitis, LGI1 encephalitis, CASPR2 encephalitis, rapid neurocognitive syndrome</p> <p>SCOPE: Diagnostic workup, acute treatment, and long-term management of suspected or confirmed autoimmune encephalitis. Covers antibody-mediated encephalitis (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX, IgLON5, GABA-A, GAD65), first-line immunotherapy, second-line escalation, seizure management, psychiatric symptom management, ICU considerations, tumor screening, and long-term immunosuppression. For infectious encephalitis, use \"HSV Encephalitis\" template. For paraneoplastic syndromes without encephalitis, use \"Paraneoplastic Syndrome\" template. For status epilepticus management, use \"Status Epilepticus\" template.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/autoimmune-encephalitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/autoimmune-encephalitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline; infection screen; pre-immunotherapy Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Metabolic screen; renal/hepatic baseline for immunotherapy Normal TSH URGENT ROUTINE ROUTINE URGENT Thyroid encephalopathy mimic; Hashimoto encephalopathy screen Normal ESR URGENT ROUTINE ROUTINE URGENT Inflammatory/vasculitis screen Normal (&lt;20 mm/hr) CRP URGENT ROUTINE ROUTINE URGENT Inflammatory marker; infection screen Normal Urinalysis with culture STAT STAT ROUTINE STAT UTI as encephalopathy trigger Negative Blood cultures (x2 sets) STAT STAT - STAT Rule out septic encephalopathy No growth Blood glucose STAT STAT ROUTINE STAT Metabolic encephalopathy screen; pre-steroid baseline Normal HbA1c - ROUTINE ROUTINE - Glycemic status before high-dose steroids &lt;5.7% Ammonia STAT STAT - STAT Hepatic encephalopathy mimic Normal Lactate STAT STAT - STAT Sepsis screen; metabolic screen Normal (&lt;2.0 mmol/L) PT/INR, aPTT STAT STAT - STAT Coagulopathy screen pre-LP; DIC screen Normal Magnesium STAT STAT ROUTINE STAT Seizure threshold; metabolic screen Normal Phosphorus STAT STAT - STAT Metabolic screen Normal Procalcitonin URGENT URGENT - URGENT Distinguish bacterial vs autoimmune etiology Normal (&lt;0.1 ng/mL) Troponin STAT STAT - STAT Cardiac involvement; autonomic instability assessment Normal CPK URGENT URGENT - URGENT Rhabdomyolysis from prolonged seizures/catatonia Normal Urine drug screen STAT STAT - STAT Toxic/drug-induced encephalopathy mimic Negative Alcohol level STAT STAT - STAT Alcohol-related encephalopathy Negative Pregnancy test (females of childbearing age) STAT STAT ROUTINE STAT Eclampsia mimic; treatment planning (teratogenicity) As applicable Peripheral blood smear URGENT URGENT - URGENT TTP/HUS screen if thrombocytopenia Normal LDH URGENT ROUTINE ROUTINE URGENT Hemolysis screen; tumor marker Normal Uric acid - ROUTINE ROUTINE - Tumor lysis risk if malignancy suspected Normal Lipase STAT STAT - STAT Pancreatitis-related encephalopathy Normal"},{"location":"plans/autoimmune-encephalitis/#1b-autoimmune-antibody-panel","title":"1B. Autoimmune Antibody Panel","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-NMDAR antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Most common autoimmune encephalitis; CSF more sensitive than serum; cell-based assay (CBA) preferred Negative Anti-LGI1 antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Limbic encephalitis; faciobrachial dystonic seizures (FBDS); hyponatremia Negative Anti-CASPR2 antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Limbic encephalitis; Morvan syndrome; neuromyotonia; neuropathic pain Negative Anti-GABA-B antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Limbic encephalitis with prominent seizures; 50% associated with SCLC Negative Anti-AMPA antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Limbic encephalitis; relapsing course; associated with thymoma, lung, breast Negative Anti-DPPX antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Encephalitis with hyperexcitability, GI symptoms, PERM Negative Anti-IgLON5 antibody (serum AND CSF) - URGENT ROUTINE URGENT Sleep disorder, bulbar dysfunction, gait instability, tau pathology Negative Anti-GABA-A antibody (serum AND CSF) - URGENT ROUTINE URGENT Refractory seizures/status epilepticus; often with thymoma Negative Anti-GAD65 antibody (serum AND CSF) URGENT URGENT ROUTINE URGENT Limbic encephalitis, stiff-person spectrum, cerebellar ataxia; high titers (&gt;20 nmol/L) significant Negative or low titer Mayo Autoimmune Evaluation - Encephalopathy (serum) URGENT URGENT ROUTINE URGENT Comprehensive panel: NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX All negative Mayo Autoimmune Evaluation - Encephalopathy (CSF) URGENT URGENT ROUTINE URGENT CSF panel: NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX All negative ANA URGENT ROUTINE ROUTINE URGENT Lupus cerebritis screen Negative or low titer Anti-dsDNA - ROUTINE ROUTINE - If ANA positive; lupus evaluation Negative Anti-SSA/SSB (Ro/La) - ROUTINE ROUTINE - Sjogren syndrome with CNS involvement Negative Anti-TPO antibodies URGENT ROUTINE ROUTINE URGENT Hashimoto encephalopathy (SREAT) Negative Anti-thyroglobulin antibodies URGENT ROUTINE ROUTINE URGENT Hashimoto encephalopathy (SREAT) Negative AQP4-IgG (NMO antibody) - ROUTINE ROUTINE - NMOSD overlap; cell-based assay preferred Negative MOG-IgG - ROUTINE ROUTINE - MOGAD overlap; ADEM-like presentation Negative Complement C3, C4 - ROUTINE ROUTINE - Lupus; complement-mediated disease Normal Quantitative immunoglobulins (IgG, IgA, IgM) - ROUTINE ROUTINE - Baseline before immunotherapy; IgA deficiency (IVIG contraindication) Normal <p>Note: ALWAYS send BOTH serum AND CSF for antibody testing. CSF is more sensitive for anti-NMDAR; serum is more sensitive for anti-LGI1 and anti-CASPR2. Cell-based assay (CBA) is gold standard -- avoid ELISA-only testing. Mayo panels preferred for comprehensive evaluation. Results may take 1-3 weeks; do NOT wait for results before starting empiric immunotherapy if clinical suspicion is high.</p>"},{"location":"plans/autoimmune-encephalitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-neuronal nuclear antibody type 1 (ANNA-1/anti-Hu) - EXT EXT - Paraneoplastic; SCLC, neuroblastoma Negative Anti-neuronal nuclear antibody type 2 (ANNA-2/anti-Ri) - EXT EXT - Paraneoplastic; breast, SCLC Negative Anti-CV2/CRMP5 - EXT EXT - Paraneoplastic; SCLC, thymoma Negative Anti-amphiphysin - EXT EXT - Paraneoplastic; breast, SCLC; stiff-person overlap Negative Anti-Ma2/Ta - EXT EXT - Paraneoplastic limbic encephalitis; testicular germ cell tumor Negative Anti-SOX1 - EXT EXT - SCLC-associated; Lambert-Eaton overlap Negative Anti-Kelch-like protein 11 (KLHL11) - EXT EXT - Testicular seminoma; brainstem/cerebellar syndrome Negative Anti-GlyR (glycine receptor) - EXT EXT - Progressive encephalomyelitis with rigidity and myoclonus (PERM) Negative Anti-mGluR5 - EXT EXT - Ophelia syndrome; Hodgkin lymphoma Negative Anti-mGluR1 - EXT EXT - Cerebellar ataxia; Hodgkin lymphoma Negative Anti-neurexin-3-alpha - EXT EXT - Rapid-onset encephalitis; seizures; confusion Negative Anti-D2R (dopamine-2 receptor) - EXT EXT - Basal ganglia encephalitis; movement disorders Negative Paraneoplastic evaluation panel (comprehensive) - EXT EXT - If standard panels negative and paraneoplastic suspected All negative 14-3-3 protein (CSF) - EXT EXT - Prion disease mimic; rapidly progressive dementia Negative RT-QuIC (CSF) - EXT EXT - Prion disease exclusion in rapidly progressive cases Negative Next-generation sequencing (CSF metagenomics) - EXT EXT - Occult infection when standard testing negative No pathogens detected"},{"location":"plans/autoimmune-encephalitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/autoimmune-encephalitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediate (ED triage) Rule out mass, hemorrhage, hydrocephalus None significant MRI brain with and without contrast URGENT URGENT ROUTINE URGENT Within 24h Mesial temporal T2/FLAIR hyperintensity (limbic encephalitis); cortical/subcortical signal changes; leptomeningeal enhancement GFR &lt;30, gadolinium allergy, pacemaker EEG (routine or continuous) URGENT URGENT ROUTINE STAT Within 24h; continuous if ICU or altered consciousness Extreme delta brush (anti-NMDAR); focal/generalized slowing; epileptiform discharges; subclinical seizures None significant ECG (12-lead) STAT STAT ROUTINE STAT Immediate Autonomic dysfunction; arrhythmia; QTc prolongation (medication safety) None Chest X-ray STAT STAT - STAT Immediate Mediastinal mass (thymoma); pulmonary mass (SCLC) Pregnancy (relative) Continuous telemetry - STAT - STAT Continuous in hospital Arrhythmia from autonomic instability None"},{"location":"plans/autoimmune-encephalitis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI spine (cervical and thoracic) with and without contrast - ROUTINE ROUTINE ROUTINE Within 48-72h Concurrent myelitis; overlap syndromes GFR &lt;30, gadolinium allergy CT chest/abdomen/pelvis with contrast - URGENT ROUTINE URGENT Within 48h Occult malignancy: thymoma, lung cancer, ovarian teratoma, lymphoma Contrast allergy, renal insufficiency Pelvic/transvaginal ultrasound (females) - URGENT ROUTINE URGENT Within 48h Ovarian teratoma (anti-NMDAR) None significant Testicular ultrasound (males &lt;50) - URGENT ROUTINE URGENT Within 48h Testicular germ cell tumor (anti-Ma2, KLHL11) None significant FDG-PET/CT (whole body) - ROUTINE ROUTINE - Within 1-2 weeks Occult malignancy not seen on CT; FDG-avid tumor Uncontrolled diabetes, pregnancy Video-EEG monitoring (prolonged) - ROUTINE ROUTINE STAT As needed Characterize seizure semiology; subclinical seizures; extreme delta brush pattern None FDG-PET brain - EXT EXT - Within 1-2 weeks Mesial temporal hypermetabolism (early) or hypometabolism (late); cortical metabolic changes Same as PET/CT"},{"location":"plans/autoimmune-encephalitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with epilepsy protocol - EXT EXT - If seizures refractory Subtle cortical lesions; hippocampal sclerosis Gadolinium contraindications Brain biopsy - EXT - - Last resort Inflammatory infiltrate; exclusion of other pathology Coagulopathy, inaccessible location CT-guided biopsy (tumor) - EXT EXT - After tumor identified Histopathological confirmation Coagulopathy, tumor location Mammography/breast MRI - ROUTINE ROUTINE - If AMPA, amphiphysin positive Breast malignancy Implants (relative for MRI) Polysomnography - - EXT - If IgLON5 suspected REM/NREM parasomnias; sleep disordered breathing None significant"},{"location":"plans/autoimmune-encephalitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Essential for diagnosis of autoimmune encephalitis; supports Graus 2016 criteria (CSF pleocytosis); CSF antibody testing more sensitive than serum for anti-NMDAR; rules out infectious encephalitis</p> <p>Timing: STAT/URGENT -- perform as soon as safely possible after CT head; do NOT delay for MRI</p> <p>Volume Required: 20-30 mL (large volume for comprehensive antibody and infectious testing)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Elevated ICP assessment 10-20 cm H2O Cell count with differential (tubes 1 and 4) STAT STAT ROUTINE Lymphocytic pleocytosis supports autoimmune WBC 5-80 (lymphocyte-predominant); RBC 0 Protein STAT STAT ROUTINE Mildly elevated in autoimmune; markedly elevated suggests infection/GBS Normal to mildly elevated (usually &lt;100 mg/dL) Glucose with paired serum glucose STAT STAT ROUTINE Low in infection/carcinomatous meningitis Normal (&gt;60% of serum) Gram stain and bacterial culture STAT STAT ROUTINE Rule out bacterial meningitis No organisms HSV 1/2 PCR STAT STAT ROUTINE Rule out HSV encephalitis (most important mimic) Negative VZV PCR URGENT URGENT ROUTINE Varicella encephalitis Negative EBV PCR - ROUTINE ROUTINE EBV-associated encephalitis; lymphoma screen Negative CMV PCR - ROUTINE ROUTINE Immunocompromised patients Negative HHV-6 PCR - ROUTINE ROUTINE Post-transplant; limbic encephalitis mimic Negative Enterovirus PCR URGENT URGENT - Viral meningitis/encephalitis Negative West Nile virus IgM/IgG - ROUTINE - Endemic areas; flaccid paralysis Negative Cryptococcal antigen URGENT ROUTINE - Immunocompromised; chronic meningitis Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative Oligoclonal bands (CSF AND paired serum) URGENT ROUTINE ROUTINE Intrathecal IgG synthesis; MS/NMOSD overlap May show CSF-specific bands IgG index URGENT ROUTINE ROUTINE Intrathecal antibody synthesis May be elevated Cytology - ROUTINE ROUTINE Carcinomatous/lymphomatous meningitis Negative Flow cytometry - ROUTINE ROUTINE CNS lymphoma Normal Autoimmune encephalitis antibody panel (CSF) URGENT URGENT ROUTINE NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX -- CBA method All negative Anti-NMDAR IgG (CSF) URGENT URGENT ROUTINE CSF more sensitive than serum for NMDAR Negative AFB culture and smear - ROUTINE - TB meningitis if risk factors Negative Fungal culture - ROUTINE - Immunocompromised Negative <p>Special Handling: Send minimum 2 mL CSF to each reference lab. Anti-NMDAR CSF testing is more sensitive than serum -- ALWAYS send CSF. Antibody results take 1-3 weeks. Cytology requires rapid transport (&lt;1 hour). Store extra CSF (frozen at -20C) for future testing.</p> <p>Contraindications: Elevated ICP without imaging (get CT first), coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site, posterior fossa mass with risk of herniation</p>"},{"location":"plans/autoimmune-encephalitis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/autoimmune-encephalitis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Empiric acyclovir IV (until HSV ruled out) STAT STAT - STAT 10 mg/kg IV q8h; continue until HSV PCR negative x2 (48h apart) or alternative diagnosis confirmed Renal impairment (adjust dose); adequate hydration required Renal function daily; hydration status; crystal nephropathy prevention Empiric antibiotics (if bacterial meningitis not excluded) STAT STAT - STAT Ceftriaxone 2g IV q12h + vancomycin 15-20 mg/kg IV q8-12h + dexamethasone 0.15 mg/kg q6h x 4 days Per individual drug allergies Cultures; clinical response; renal function; vancomycin troughs Lorazepam (acute seizure) STAT STAT - STAT 0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 minutes Respiratory depression; acute narrow-angle glaucoma Respiratory status; sedation level; airway patency Midazolam (if no IV access) STAT STAT - STAT 10 mg IM (adults &gt;40 kg) or 0.2 mg/kg intranasal Respiratory depression Same as lorazepam Lorazepam (catatonia challenge) STAT STAT - STAT 1-2 mg IV; observe 15-30 min for response; if improvement, continue 1-2 mg IV/PO q4-8h (up to 8-24 mg/day) Respiratory compromise; prior paradoxical response Bush-Francis Catatonia Rating Scale; respiratory status; sedation <p>Note: Initiate empiric acyclovir and antibiotics IMMEDIATELY. Do NOT delay antimicrobials for LP. Start immunotherapy as soon as autoimmune encephalitis is clinically suspected -- do NOT wait for antibody results.</p>"},{"location":"plans/autoimmune-encephalitis/#3b-first-line-immunotherapy","title":"3B. First-Line Immunotherapy","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Methylprednisolone IV URGENT STAT - STAT 1000 mg IV daily x 5 days; infuse over 1-2 hours Active untreated infection; uncontrolled diabetes; psychosis from steroids Glucose q6h (target &lt;180); BP; mood/sleep; I/O; GI prophylaxis Omeprazole (GI prophylaxis during steroids) URGENT STAT - STAT 40 mg IV/PO daily during steroid course PPI allergy None routine Insulin sliding scale URGENT STAT - STAT Per protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h; adjust per response IVIG (intravenous immunoglobulin) - STAT - STAT 0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol; premedicate with acetaminophen, diphenhydramine IgA deficiency (anaphylaxis risk); recent thromboembolic event; renal failure Renal function daily; headache (aseptic meningitis); thrombosis; volume overload; check IgA level before first dose Plasmapheresis (PLEX) - STAT - STAT 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement Hemodynamic instability; sepsis; coagulopathy; poor vascular access BP during exchanges; electrolytes (Ca, K, Mg); coagulation (fibrinogen); line site; citrate reactions <p>Note: Methylprednisolone is typically started first (often in combination with IVIG or PLEX). IVIG and PLEX are considered equivalent first-line therapies and should be started concurrently or within days of steroids if clinical suspicion is high. For anti-NMDAR encephalitis, combination of all three first-line agents is common. PLEX may be preferred if rapid deterioration; IVIG may be preferred if hemodynamic instability or vascular access issues.</p>"},{"location":"plans/autoimmune-encephalitis/#3c-second-line-immunotherapy","title":"3C. Second-Line Immunotherapy","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Rituximab - URGENT ROUTINE URGENT 375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine Active hepatitis B; severe active infection; live vaccines within 4 weeks Hepatitis B serology (before first dose); CBC with differential q2-4 weeks; immunoglobulin levels q3 months; CD19/CD20 B-cell counts; infusion reactions; PML surveillance Cyclophosphamide - URGENT ROUTINE URGENT 750 mg/m2 IV monthly x 6 cycles; pre-hydrate with 1L NS; administer with MESNA (uroprotection) Pregnancy; active infection; bone marrow failure; bladder outlet obstruction CBC weekly x 4 weeks after each cycle (nadir day 10-14); urinalysis; BMP; LFTs; fertility counseling; hemorrhagic cystitis prevention Tocilizumab (third-line) - EXT EXT EXT 8 mg/kg IV every 4 weeks (max 800 mg/dose) Active infection; hepatic impairment (ALT &gt;5x ULN); diverticulitis; concurrent live vaccines CBC, LFTs, lipids q4-8 weeks; infection surveillance; GI perforation risk; neutropenia Bortezomib (third-line) - EXT EXT EXT 1.3 mg/m2 SC/IV on days 1, 4, 8, 11 of 21-day cycles x 4-6 cycles Severe hepatic impairment; peripheral neuropathy grade 2+ CBC; peripheral neuropathy assessment (dose-reduce or hold if worsens); herpes zoster prophylaxis (acyclovir 400 mg BID) Repeated IVIG or PLEX cycles - URGENT ROUTINE URGENT IVIG 0.4 g/kg/day x 5 days (repeat q4 weeks) or PLEX 5 exchanges (repeat as needed) Same as first-line Same as first-line Oral prednisone taper (following IV methylprednisolone) - ROUTINE ROUTINE - 1 mg/kg/day (max 60 mg) x 2 weeks; taper by 10 mg/week to 20 mg; then taper by 5 mg/week to discontinuation OR low-dose maintenance Active infection; uncontrolled diabetes; avascular necrosis Glucose; BP; bone density if prolonged; mood; weight; adrenal insufficiency on taper <p>Note: Second-line therapy should be initiated if no improvement within 2 weeks of first-line therapy OR if clinically worsening despite first-line treatment. For anti-NMDAR encephalitis, early escalation to rituximab is associated with improved outcomes. Rituximab is generally preferred over cyclophosphamide given better safety profile. Third-line agents (tocilizumab, bortezomib) reserved for refractory cases failing rituximab/cyclophosphamide.</p>"},{"location":"plans/autoimmune-encephalitis/#3d-seizure-management","title":"3D. Seizure Management","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam (first-line ASM) STAT STAT ROUTINE STAT Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID (max 3000 mg/day) Renal impairment (adjust dose per CrCl) Behavioral changes (rage, irritability); suicidality; renal function Lacosamide (second-line ASM) URGENT URGENT ROUTINE URGENT Load: 200-400 mg IV; Maintenance: 100-200 mg IV/PO BID (max 400 mg/day) Second/third degree AV block; severe hepatic impairment ECG (PR prolongation); dizziness; cardiac monitoring during load Valproic acid URGENT URGENT ROUTINE URGENT Load: 20-40 mg/kg IV (max rate 6 mg/kg/min); Maintenance: 250-500 mg IV/PO q8h (target level 50-100 mcg/mL) Pregnancy (teratogenic -- Category X); hepatic disease; urea cycle disorders; mitochondrial disease (POLG) LFTs; ammonia; CBC (thrombocytopenia); drug level; pancreatitis Brivaracetam - URGENT ROUTINE URGENT Load: 100 mg IV; Maintenance: 50-100 mg IV/PO BID (max 200 mg/day) Hepatic impairment (reduce dose) Behavioral changes; sedation Clobazam - ROUTINE ROUTINE ROUTINE Start 5-10 mg BID; titrate to 20-40 mg/day in divided doses Severe hepatic impairment; myasthenia gravis Sedation; CYP2C19 poor metabolizers (reduce dose); tolerance; dependence Phenytoin/fosphenytoin (refractory) STAT STAT - STAT Fosphenytoin: 20 mg PE/kg IV (max rate 150 mg PE/min); Maintenance: 5-7 mg/kg/day divided BID-TID (target level 10-20 mcg/mL) AV block; bradycardia Continuous cardiac monitoring during load; drug level; purple glove syndrome (peripheral IV); gingival hyperplasia Phenobarbital (refractory) - URGENT - URGENT Load: 15-20 mg/kg IV (max rate 60 mg/min); Maintenance: 1-3 mg/kg/day (target level 15-40 mcg/mL) Severe respiratory depression; porphyria Respiratory depression; sedation; hypotension; drug level Midazolam infusion (refractory SE) - - - STAT Bolus: 0.2 mg/kg IV; Infusion: 0.1-2.0 mg/kg/hr; titrate to EEG burst suppression Unprotected airway (requires intubation) Continuous EEG; respiratory status; hemodynamics; tachyphylaxis Propofol infusion (refractory SE) - - - STAT Bolus: 1-2 mg/kg IV; Infusion: 20-80 mcg/kg/min (max 5 mg/kg/hr to avoid PRIS) Propofol infusion syndrome risk (prolonged use &gt;48h at high doses); egg/soy allergy Continuous EEG; triglycerides q48h; CPK; lactate; hemodynamics; PRIS surveillance Ketamine infusion (super-refractory SE) - - - STAT Bolus: 1-3 mg/kg IV; Infusion: 0.5-5 mg/kg/hr Uncontrolled hypertension; raised ICP (relative) Continuous EEG; BP; HR; hepatic function; laryngospasm risk <p>Note: Seizures in autoimmune encephalitis are driven by antibody-mediated mechanisms -- immunotherapy is the definitive seizure treatment. ASMs control acute seizures but will not resolve the underlying cause. Avoid carbamazepine/oxcarbazepine in LGI1 encephalitis (may worsen hyponatremia). Levetiracetam and lacosamide are preferred first-line ASMs given favorable drug interaction profiles with immunotherapy.</p>"},{"location":"plans/autoimmune-encephalitis/#3e-psychiatric-symptom-management","title":"3E. Psychiatric Symptom Management","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Haloperidol (acute agitation) STAT STAT - STAT 0.5-2 mg IV/IM q4-6h PRN (lowest effective dose); max 20 mg/day QTc &gt;500 ms; Parkinson disease; prior NMS ECG (QTc); EPS; NMS surveillance; temperature; CPK if NMS suspected Olanzapine (agitation/psychosis) - ROUTINE ROUTINE ROUTINE 2.5-5 mg PO/IM BID (start low); max 20 mg/day QTc prolongation; metabolic syndrome Glucose; lipids; QTc; weight; sedation; EPS Quetiapine (psychosis/insomnia) - ROUTINE ROUTINE - Start 25-50 mg qHS; titrate to 200-400 mg/day in divided doses QTc prolongation; severe hepatic impairment QTc; metabolic parameters; orthostatic BP; sedation Lorazepam (catatonia -- first-line) STAT STAT ROUTINE STAT Start 1-2 mg IV/PO; if response, 1-2 mg q4-8h (escalate to 8-24 mg/day as needed for catatonia) Respiratory compromise (high doses) Bush-Francis Catatonia Rating Scale; respiratory rate; sedation; airway Dexmedetomidine (agitation in ICU) - - - STAT Load: 1 mcg/kg IV over 10 min (optional); Infusion: 0.2-0.7 mcg/kg/hr (max 1.5 mcg/kg/hr) Severe bradycardia; advanced heart block HR (bradycardia); BP (hypotension); sedation level (RASS) Valproic acid (mood stabilization/agitation) - ROUTINE ROUTINE ROUTINE 250-500 mg PO BID; titrate to level 50-100 mcg/mL (dual benefit: mood + seizure) Pregnancy; hepatic disease LFTs; ammonia; CBC; drug level Melatonin (sleep-wake disturbance) - ROUTINE ROUTINE ROUTINE 3-10 mg PO qHS None significant Sleep quality; no significant drug interactions Trazodone (insomnia) - ROUTINE ROUTINE - 25-100 mg PO qHS Concurrent MAOIs; QTc prolongation Orthostatic hypotension; priapism (rare); sedation Electroconvulsive therapy (ECT) (refractory catatonia) - EXT EXT EXT Per psychiatry protocol; typically 3x/week Pheochromocytoma; raised ICP (relative) Anesthesia monitoring; cognitive function; post-procedure seizure threshold <p>Note: CAUTION with antipsychotics in autoimmune encephalitis -- patients (especially anti-NMDAR) are highly susceptible to neuroleptic malignant syndrome (NMS) and EPS. Use LOWEST effective doses. Benzodiazepines (lorazepam) are first-line for catatonia and agitation. Catatonia may be present in up to 40% of anti-NMDAR cases. If catatonia does not respond to lorazepam, consider ECT before escalating antipsychotics. Psychiatric symptoms in AE are driven by antibody-mediated mechanisms -- immunotherapy is the definitive treatment.</p>"},{"location":"plans/autoimmune-encephalitis/#3f-icu-specific-treatments","title":"3F. ICU-Specific Treatments","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Intubation and mechanical ventilation - - - STAT RSI: avoid succinylcholine if hyperkalemia risk; maintain normocapnia As per standard airway management Ventilator parameters; ABG; daily SBT when appropriate Labetalol IV (autonomic hypertensive crisis) - - - STAT 10-20 mg IV q10-15min PRN; or infusion 0.5-2 mg/min; target SBP &lt;180 Severe bradycardia; AV block; decompensated CHF; asthma Continuous BP; HR; I/O Esmolol IV (autonomic tachycardia) - - - STAT Bolus: 500 mcg/kg over 1 min; Infusion: 50-200 mcg/kg/min Severe bradycardia; decompensated CHF; cardiogenic shock Continuous HR/BP; ECG Atropine (autonomic bradycardia) - - - STAT 0.5-1 mg IV q3-5min (max 3 mg total) Tachycardia; thyrotoxicosis HR; rhythm Isoproterenol drip (severe autonomic bradycardia) - - - STAT 2-10 mcg/min IV infusion; titrate to HR &gt;60 Tachyarrhythmia; digoxin toxicity Continuous ECG; HR; BP Temporary transvenous pacemaker - - - STAT Per cardiology if pharmacologic measures fail Active infection at insertion site Capture; sensing; threshold checks Norepinephrine (autonomic hypotension) - - - STAT 0.1-0.5 mcg/kg/min IV; titrate to MAP &gt;65 Peripheral ischemia risk at high doses Arterial line; MAP; lactate; urine output DVT prophylaxis (enoxaparin) - STAT - STAT 40 mg SC daily (adjust for renal function: 30 mg SC daily if CrCl &lt;30) Active bleeding; HIT; severe thrombocytopenia Platelet count; anti-Xa if renal impairment; bleeding signs Temperature management (hyperthermia) - - - STAT Targeted temperature: 36-37C; cooling blankets; acetaminophen 1g IV/PO q6h PRN Avoid overcooling; avoid shivering (increases metabolic demand) Continuous temperature; shivering assessment (BSAS) Sodium correction (hyponatremia -- LGI1) URGENT URGENT ROUTINE URGENT If Na &lt;125: 3% NaCl 100-150 mL IV over 10-20 min (repeat up to 3x); Target correction: 4-6 mEq/L in first 6h, max 8 mEq/L in 24h Avoid overcorrection (osmotic demyelination risk) Sodium q2-4h during correction; urine output; neurologic status Fludrocortisone (chronic hyponatremia -- LGI1) - ROUTINE ROUTINE - 0.05-0.2 mg PO daily CHF; hypertension Sodium; potassium; BP; edema Fluid restriction (SIADH-related hyponatremia) - ROUTINE - ROUTINE Restrict to 1-1.2 L/day if SIADH suspected (LGI1) Dehydration risk Sodium; I/O; daily weight; urine osmolality <p>Note: Central hypoventilation occurs in anti-NMDAR encephalitis and may require prolonged mechanical ventilation (weeks to months). Autonomic instability (tachycardia/bradycardia alternating, blood pressure lability, central hyperthermia, cardiac dysrhythmias) is a hallmark of severe anti-NMDAR encephalitis. LGI1 encephalitis frequently causes SIADH-related hyponatremia. Do NOT over-correct sodium (risk of osmotic demyelination).</p>"},{"location":"plans/autoimmune-encephalitis/#3g-long-term-immunosuppression-maintenance","title":"3G. Long-Term Immunosuppression / Maintenance","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Mycophenolate mofetil (CellCept) - - ROUTINE - Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks (target 1500-3000 mg/day) Pregnancy (Category D -- teratogenic); active infection CBC q2 weeks x 3 months, then monthly; LFTs; GI symptoms; infection surveillance; pregnancy prevention Azathioprine (Imuran) - - ROUTINE - Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day TPMT deficiency (check before starting); pregnancy (relative) TPMT genotype/activity before starting; CBC q2 weeks x 2 months, then monthly; LFTs; pancreatitis Rituximab (maintenance) - - ROUTINE - 500-1000 mg IV every 6 months; re-dose based on CD19/CD20 B-cell repopulation or clinical relapse Active hepatitis B; severe active infection CD19/CD20 counts q3 months; immunoglobulin levels q3-6 months; hepatitis B surveillance; infection monitoring; PML surveillance Oral prednisone (low-dose maintenance) - - ROUTINE - 5-10 mg PO daily; aim to taper off within 3-6 months if on steroid-sparing agent Poorly controlled diabetes; active infection; avascular necrosis Glucose; BP; bone density (DEXA if &gt;3 months); weight; mood; cataracts; adrenal assessment on taper IVIG (maintenance) - - ROUTINE - 0.4 g/kg IV every 4 weeks OR 1-2 g/kg IV every 4-6 weeks (adjust per response) IgA deficiency; thromboembolic history Renal function; headache; IgG trough levels; infusion reactions Calcium + Vitamin D (bone protection with steroids) - ROUTINE ROUTINE - Calcium 1000-1200 mg/day + Vitamin D 1000-2000 IU/day Hypercalcemia; kidney stones 25-OH Vitamin D level; calcium; DEXA baseline if anticipated steroid use &gt;3 months <p>Note: Long-term immunosuppression is guided by antibody subtype, relapse risk, and tumor status. Anti-NMDAR encephalitis has ~12-20% relapse rate. Rituximab maintenance is most commonly used for relapse prevention. Mycophenolate and azathioprine are steroid-sparing alternatives. Monitor for immunosuppression-related complications (infection, malignancy). Duration of maintenance therapy is individualized -- typically minimum 2 years; some patients require indefinite treatment.</p>"},{"location":"plans/autoimmune-encephalitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/autoimmune-encephalitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology (autoimmune/neuroimmunology) STAT STAT ROUTINE STAT All suspected autoimmune encephalitis cases; immunotherapy management Epilepsy/EEG service STAT STAT ROUTINE STAT Seizure management; continuous EEG monitoring; extreme delta brush interpretation Psychiatry URGENT URGENT ROUTINE URGENT Psychiatric manifestations (psychosis, catatonia, agitation); antipsychotic management; NMS risk Critical care/ICU URGENT URGENT - - Autonomic instability; respiratory failure; refractory status epilepticus; altered consciousness Gynecologic oncology (females with anti-NMDAR) - URGENT URGENT URGENT Ovarian teratoma screening and surgical resection Oncology - URGENT ROUTINE URGENT Any identified malignancy; tumor screening guidance; chemotherapy planning Urology (males &lt;50 with anti-Ma2/KLHL11) - URGENT ROUTINE - Testicular germ cell tumor screening Hematology/apheresis - URGENT - URGENT PLEX coordination; catheter placement Physical therapy - ROUTINE ROUTINE ROUTINE Motor rehabilitation; gait training; fall prevention Occupational therapy - ROUTINE ROUTINE ROUTINE ADL assessment; cognitive rehabilitation; adaptive strategies Speech-language pathology - ROUTINE ROUTINE ROUTINE Swallowing evaluation; language/communication rehabilitation; cognitive-linguistic therapy Neuropsychology - - ROUTINE - Formal cognitive assessment; rehabilitation planning; serial monitoring Social work - ROUTINE ROUTINE - Family support; insurance navigation; disability resources; long-term care planning Rehabilitation medicine - ROUTINE ROUTINE - Comprehensive inpatient or outpatient rehab program coordination Palliative care - EXT EXT EXT Refractory cases; prolonged ICU stay; family support; goals of care discussion Infectious disease URGENT URGENT - URGENT Rule out infection; antimicrobial guidance; post-immunosuppression infection management Endocrinology - ROUTINE ROUTINE - Steroid-induced hyperglycemia management; thyroid evaluation if Hashimoto suspected"},{"location":"plans/autoimmune-encephalitis/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD Return to ED immediately for new seizures, sudden behavioral changes, fever, difficulty breathing, or loss of consciousness Y Y Y Autoimmune encephalitis is a treatable condition -- recovery may be slow (months to years) but significant improvement is expected with appropriate immunotherapy Y Y Y Do NOT drive until seizure-free for state-mandated period AND cleared by neurology Y Y Y Keep seizure diary (date, time, type, duration, triggers) - Y Y Behavioral and psychiatric symptoms are part of the disease, not a primary psychiatric disorder -- immunotherapy is the treatment Y Y Y Report any signs of infection (fever &gt;100.4F, cough, dysuria, rash) immediately while on immunotherapy - Y Y Avoid live vaccines while on immunosuppressive therapy (inform all physicians of immunosuppression status) - Y Y Do not stop anti-seizure medications abruptly - Y Y Avoid alcohol and recreational drugs (lower seizure threshold, interact with medications) - Y Y Pregnancy must be avoided during immunotherapy; discuss contraception with neurology and OB/GYN - Y Y Expect gradual improvement -- anti-NMDAR recovery typically occurs in reverse order of symptom onset (psychiatric symptoms resolve last) - Y Y Cognitive rehabilitation exercises as directed by speech and occupational therapy - Y Y Safety modifications at home (remove sharp objects, secure stairways, fall prevention) - Y Y Medical alert bracelet recommended (autoimmune encephalitis, seizure risk, immunosuppressed) - Y Y Follow-up appointments are critical -- relapse monitoring requires regular visits - Y Y"},{"location":"plans/autoimmune-encephalitis/#4c-tumor-screening-protocols-by-antibody","title":"4C. Tumor Screening Protocols by Antibody","text":"Antibody Associated Tumor(s) Screening Protocol Frequency Anti-NMDAR Ovarian teratoma (females, especially 12-45 years); rarely other tumors Pelvic MRI or transvaginal US; CT chest/abdomen/pelvis At diagnosis; repeat q6 months x 2 years if initially negative Anti-LGI1 Thymoma (~5-10%) CT chest with contrast At diagnosis; repeat if relapse Anti-CASPR2 Thymoma (~20-30%) CT chest with contrast At diagnosis; repeat if relapse Anti-GABA-B Small cell lung cancer (~50%) CT chest; FDG-PET/CT if CT negative At diagnosis; q6 months x 4 years Anti-AMPA Thymoma, lung cancer, breast cancer CT chest/abdomen/pelvis; mammography; FDG-PET/CT At diagnosis; q6 months x 4 years Anti-DPPX B-cell lymphoma (rare) CT chest/abdomen/pelvis; FDG-PET if suspected At diagnosis Anti-Ma2/Ta Testicular germ cell tumor (young males); lung cancer (older patients) Testicular US (males &lt;50); CT chest; FDG-PET/CT At diagnosis; q6 months x 4 years Anti-Hu (ANNA-1) Small cell lung cancer (&gt;90%) CT chest; FDG-PET/CT At diagnosis; q6 months x 4 years Anti-CV2/CRMP5 SCLC; thymoma CT chest; FDG-PET/CT At diagnosis; q6 months x 4 years Anti-amphiphysin Breast cancer; SCLC Mammography/breast MRI; CT chest At diagnosis; q6 months x 4 years Anti-KLHL11 Testicular seminoma Testicular US; FDG-PET/CT At diagnosis; repeat if relapse <p>Note: Tumor resection is critical for treatment response -- immunotherapy alone may be insufficient if underlying tumor is not removed. If initial tumor screen is negative but paraneoplastic antibody is positive, repeat imaging q6 months x 4 years. Consider FDG-PET/CT if CT is negative and clinical suspicion remains high.</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/autoimmune-encephalitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate HSV encephalitis Acute fever, temporal lobe hemorrhagic necrosis, CSF lymphocytic pleocytosis with RBCs HSV PCR (CSF); MRI temporal lobe changes; often more acute onset Other viral encephalitis (EBV, CMV, HHV-6, enterovirus, West Nile) Fever, CSF pleocytosis, specific exposure/season, immunocompromised status Specific viral PCR/serology; CSF studies Bacterial meningitis/encephalitis Acute fever, meningismus, CSF neutrophilic pleocytosis, low glucose CSF Gram stain, culture, procalcitonin, bacterial PCR Neurosyphilis Cognitive decline, psychiatric symptoms, Argyll Robertson pupils, positive serology RPR/VDRL; CSF VDRL; FTA-ABS Prion disease (CJD) Rapidly progressive dementia, myoclonus, akinetic mutism; cortical ribboning on MRI (DWI) 14-3-3 protein; RT-QuIC; MRI DWI cortical ribboning; EEG periodic discharges CNS lymphoma Progressive encephalopathy, mass lesion, periventricular enhancement, immunocompromised CSF cytology/flow cytometry; FDG-PET; brain biopsy CNS vasculitis Headache, stroke-like episodes, multifocal infarcts, elevated ESR/CRP Angiography; brain/leptomeningeal biopsy; ESR/CRP Neurosarcoidosis Cranial neuropathies, hypothalamic dysfunction, leptomeningeal enhancement ACE level; chest CT (hilar adenopathy); biopsy Hashimoto encephalopathy (SREAT) Encephalopathy with very high anti-TPO; steroid-responsive; diagnosis of exclusion Anti-TPO; anti-thyroglobulin; dramatic steroid response Acute disseminated encephalomyelitis (ADEM) Post-infectious/post-vaccination, multifocal large white matter lesions, encephalopathy MRI pattern; MOG-IgG; monophasic course NMO spectrum disorder (NMOSD) Optic neuritis, longitudinally extensive myelitis, area postrema syndrome AQP4-IgG; MRI pattern Drug/toxin-induced encephalopathy Temporal correlation with drug exposure; resolves with discontinuation Urine drug screen; medication review; drug levels Metabolic encephalopathy Hepatic, uremic, thyroid, electrolyte disturbances CMP; LFTs; ammonia; TSH; specific metabolic panels Psychiatric disorder (new-onset psychosis, catatonia) No CSF pleocytosis; normal MRI/EEG; isolated psychiatric symptoms (caution: AE can present as pure psychiatric) LP mandatory to differentiate; EEG; MRI; antibody testing before assuming primary psychiatric Seizure-related encephalopathy (post-ictal/non-convulsive SE) Prolonged post-ictal confusion; non-convulsive status on EEG Continuous EEG monitoring; resolves with ASM treatment Neuro-Behcet disease Oral/genital ulcers; brainstem predominance; CSF neutrophilic pleocytosis Clinical criteria; pathergy test; HLA-B51"},{"location":"plans/autoimmune-encephalitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/autoimmune-encephalitis/#6a-acute-phase-monitoring-inpatient","title":"6A. Acute Phase Monitoring (Inpatient)","text":"Parameter Frequency Target/Threshold Action if Abnormal Neurologic examination (GCS, orientation, cranial nerves, motor, reflexes) Q4-6h (ICU); Q8-12h (floor) Stable or improving If worsening: urgent re-imaging; escalate immunotherapy; consider ICU transfer Modified Rankin Scale (mRS) Baseline, then weekly Improvement over weeks-months Document trajectory; guide treatment escalation; long-term disability tracking Bush-Francis Catatonia Rating Scale Daily if catatonia features Score decreasing with treatment If not responding to lorazepam: increase dose; consider ECT; escalate immunotherapy Blood glucose Q6h during IV steroids &lt;180 mg/dL Insulin sliding scale; endocrine consult if persistent &gt;250 Blood pressure Q1h (ICU); Q4h (floor) SBP 100-180 mmHg; MAP &gt;65 Autonomic dysregulation: labetalol/esmolol for hypertension; norepinephrine for hypotension Heart rate and rhythm Continuous telemetry (ICU/floor) HR 60-100; sinus rhythm Autonomic instability: treat per protocol (3F); cardiology consult if sustained arrhythmia Temperature Q4h; continuous in ICU 36.0-37.5 C Central hyperthermia: cooling measures; acetaminophen; rule out infection Respiratory rate and NIF Q4h (ICU); Q shift (floor) RR &lt;20; NIF &gt;-30 cm H2O NIF worsening toward -20: intubation; ICU transfer; evaluate for neuromuscular respiratory failure Seizure log Continuous Decreasing frequency/severity If increasing: escalate ASMs; re-assess immunotherapy; continuous EEG EEG (continuous) 24-72h minimum; longer if ICU Resolving extreme delta brush; no subclinical seizures If persistent seizures: escalate per Section 3D Sodium (Na) Q6-12h (if LGI1 or hyponatremia) Na &gt;130 mEq/L Correct per protocol (3F); fluid restriction if SIADH I/O and daily weight Daily Euvolemic Adjust fluids; diuretics if fluid overload; free water restriction if SIADH Renal function (BUN/Cr) Daily during IVIG; q48h otherwise Stable Hold IVIG if Cr rising; hydration; nephrology consult CBC with differential Q48h during immunotherapy; daily if on cyclophosphamide WBC &gt;3.0; ANC &gt;1.5; Plt &gt;100 Hold immunotherapy if critically low; growth factor support; hematology consult LFTs Q48-72h during acute treatment ALT/AST &lt;3x ULN Dose adjustment or hold hepatotoxic medications Fibrinogen (during PLEX) Before each exchange &gt;100 mg/dL Hold PLEX if &lt;100; FFP replacement"},{"location":"plans/autoimmune-encephalitis/#6b-outpatientlong-term-monitoring","title":"6B. Outpatient/Long-Term Monitoring","text":"Parameter Frequency Target/Threshold Action if Abnormal Neurologic examination (cognition, behavior, seizures, motor) Monthly x 6 months; then q3 months x 2 years; then q6 months Sustained improvement; no new symptoms If relapse: repeat LP/MRI; resume or escalate immunotherapy; re-screen for tumor Modified Rankin Scale (mRS) Each visit Improving toward mRS 0-1 Document trajectory; adjust rehab goals; consider treatment escalation if plateau or decline CASE score (Clinical Assessment Scale in Autoimmune Encephalitis) Each visit Improving score over time Standardized outcome measure; guide treatment decisions MRI brain with and without contrast 3-6 months post-treatment; then annually x 3 years Stable or improved signal changes New/worsening lesions: relapse workup; repeat antibody testing; escalate treatment EEG (routine) 3-6 months post-treatment; as needed for seizure management Improved background; no epileptiform activity If persistent abnormality: continue/adjust ASMs; consider repeat immunotherapy Serum antibody titers q3-6 months x 2 years; then annually Decreasing or negative Rising titers may precede clinical relapse; increase surveillance; consider preemptive treatment CBC with differential Q2-4 weeks on mycophenolate/azathioprine; then monthly WBC &gt;3.0; ANC &gt;1.5; Plt &gt;100 Hold/reduce immunosuppression; growth factor support LFTs Monthly x 3 months on azathioprine/mycophenolate; then q3 months ALT/AST &lt;3x ULN Dose reduction or switch agent Immunoglobulin levels (IgG, IgA, IgM) Q3-6 months on rituximab or other B-cell depletion IgG &gt;400 mg/dL Immunoglobulin replacement if recurrent infections with hypogammaglobulinemia CD19/CD20 B-cell counts Q3 months on rituximab Depleted (&lt;1% B-cells) during active treatment Guide re-dosing interval; B-cell repopulation may trigger relapse TPMT activity/genotype Once before starting azathioprine Normal enzyme activity Dose reduce or avoid azathioprine if intermediate/low TPMT Tumor surveillance (per antibody type -- Section 4C) Per protocol: q6 months x 2-4 years No tumor identified If tumor found: urgent oncology referral and surgical resection Neuropsychological testing Baseline (when able); 6 months; 12 months; annually Improving cognitive domains Guide cognitive rehabilitation; inform return to work/school planning DEXA scan (bone density) Baseline if steroids &gt;3 months; repeat q1-2 years T-score &gt;-2.5 Bisphosphonate therapy; calcium/vitamin D optimization ASM drug levels (if applicable) Per drug-specific schedule; after dose changes Therapeutic range Adjust dose; assess adherence"},{"location":"plans/autoimmune-encephalitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild symptoms; stable or improving on established immunotherapy; no active seizures; able to perform basic ADLs; reliable follow-up within 1-2 weeks; no significant autonomic instability; family/caregiver education completed; outpatient infusion arranged if needed Admit to floor (medical/neurology) New-onset encephalitis requiring workup and immunotherapy initiation; seizures requiring medication adjustment; moderate behavioral symptoms manageable on floor; needs IV steroids/IVIG; diagnostic uncertainty requiring expedited workup Admit to ICU Refractory status epilepticus; altered consciousness (GCS &lt;12); severe autonomic instability (hemodynamic swings, arrhythmias, central hypoventilation); need for continuous EEG monitoring; requirement for mechanical ventilation; severe catatonia unresponsive to lorazepam; frequent or prolonged seizures requiring IV anesthetic infusions Transfer to higher level of care PLEX or continuous EEG not available; neurology/neuroimmunology specialist not available; need for tumor resection (gynecologic oncology for teratoma); requires ICU care not available at current facility Inpatient rehabilitation Medically stable; significant functional deficits requiring intensive therapy (cognitive, motor, speech); unable to safely return home; expected to benefit from structured rehabilitation program Long-term acute care (LTAC) Prolonged ventilator dependence (common in severe anti-NMDAR); medically complex care needs; ongoing immunotherapy requirements; unable to participate in intensive rehab Skilled nursing facility Stable but unable to perform ADLs independently; requires ongoing nursing care; awaiting rehabilitation bed; chronic disability Outpatient follow-up All discharged patients: neurology follow-up within 1-2 weeks; infusion center for ongoing immunotherapy; neuropsychology referral; rehab services; tumor surveillance per protocol Readmission criteria New seizures after period of control; behavioral/cognitive regression; fever or signs of infection on immunotherapy; suspected relapse (any new neurologic/psychiatric symptoms)"},{"location":"plans/autoimmune-encephalitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Graus 2016 diagnostic criteria for autoimmune encephalitis Expert Consensus, Class III Graus F et al. Lancet Neurol 2016;15:391-404 CSF antibody testing more sensitive than serum for anti-NMDAR Class II Dalmau J et al. Lancet Neurol 2008;7:1091-1098 Cell-based assay (CBA) is gold standard for antibody detection Class II Waters P et al. J Neurol Neurosurg Psychiatry 2014 First-line immunotherapy: IV steroids + IVIG or PLEX Class III, Expert Consensus Titulaer MJ et al. Lancet Neurol 2013;12:157-165 Early immunotherapy improves outcomes Class II Titulaer MJ et al. Lancet Neurol 2013;12:157-165 Rituximab as second-line therapy Class III, Retrospective Lee WJ et al. JAMA Neurol 2016;73:197-205 Early second-line (rituximab) improves anti-NMDAR outcomes Class III Titulaer MJ et al. Lancet Neurol 2013;12:157-165 Cyclophosphamide as second-line therapy Class III, Expert Consensus Dalmau J &amp; Graus F. N Engl J Med 2018;378:840-851 Tocilizumab for refractory autoimmune encephalitis Class IV, Case Series Lee WJ et al. JAMA Neurol 2018 Bortezomib for refractory autoimmune encephalitis Class IV, Case Series Scheibe F et al. J Neurol 2017 Ovarian teratoma resection is essential in anti-NMDAR Class II Titulaer MJ et al. Lancet Neurol 2013 Tumor screening by antibody type Expert Consensus Graus F et al. Lancet Neurol 2016 Extreme delta brush on EEG in anti-NMDAR Class III Schmitt SE et al. Epilepsia 2012 Faciobrachial dystonic seizures precede LGI1 encephalitis Class III Irani SR et al. Brain 2011;134:2802-2818 Hyponatremia in LGI1 encephalitis (SIADH mechanism) Class III Lai M et al. Ann Neurol 2010;67:428-440 GABA-B encephalitis and SCLC association (~50%) Class III Lancaster E et al. Ann Neurol 2010;67:594-601 Anti-NMDAR encephalitis staging and recovery pattern Class II Dalmau J et al. Lancet Neurol 2019 Modified Rankin Scale for outcome tracking Validated Scale van Swieten JC et al. Stroke 1988 CASE score for autoimmune encephalitis assessment Validated Scale Lim JA et al. Neurology 2019 Catatonia in anti-NMDAR encephalitis (~40%) Class III Al-Diwani A et al. Lancet Psychiatry 2019 Lorazepam challenge for catatonia Expert Consensus Bush G et al. Acta Psychiatr Scand 1996 NMS risk with antipsychotics in anti-NMDAR Class IV, Case Reports Lejuste F et al. J Neurol Neurosurg Psychiatry 2016 Levetiracetam as preferred ASM in autoimmune encephalitis Expert Consensus Britton J. Epilepsy Curr 2016 Avoid carbamazepine in LGI1 (worsens hyponatremia) Expert Consensus Irani SR et al. Brain 2010 Long-term rituximab maintenance prevents relapse Class III Nosadini M et al. JAMA Neurol 2015 Anti-NMDAR relapse rate 12-20% Class II Titulaer MJ et al. Lancet Neurol 2013 Mycophenolate as steroid-sparing agent Class IV Expert practice; no large trials Autonomic instability management in anti-NMDAR Expert Consensus Dalmau J &amp; Graus F. N Engl J Med 2018 Repeat tumor screening q6 months x 2-4 years Expert Consensus Graus F et al. Lancet Neurol 2016 Central hypoventilation in severe anti-NMDAR requiring prolonged ventilation Class III Florance NR et al. Ann Neurol 2009 Neuropsychological recovery trajectory in autoimmune encephalitis Class III Finke C et al. JAMA Neurol 2017"},{"location":"plans/autoimmune-encephalitis/#clinical-decision-support-notes","title":"CLINICAL DECISION SUPPORT NOTES","text":""},{"location":"plans/autoimmune-encephalitis/#graus-2016-diagnostic-criteria-possible-autoimmune-encephalitis","title":"Graus 2016 Diagnostic Criteria -- Possible Autoimmune Encephalitis","text":"<p>All three of the following must be met: - [ ] Subacute onset (rapid progression of &lt;3 months) of working memory deficits, altered mental status, or psychiatric symptoms - [ ] At least one of: (a) new focal CNS findings, (b) seizures not explained by prior seizure disorder, (c) CSF pleocytosis (WBC &gt;5), (d) MRI features suggestive of encephalitis - [ ] Reasonable exclusion of alternative causes</p>"},{"location":"plans/autoimmune-encephalitis/#anti-nmdar-encephalitis-clinical-staging","title":"Anti-NMDAR Encephalitis Clinical Staging","text":"<ol> <li>Prodromal phase (days to 2 weeks): Fever, headache, URI-like symptoms</li> <li>Psychiatric phase (weeks 1-2): Psychosis, paranoia, agitation, bizarre behavior, hallucinations, anxiety, insomnia</li> <li>Unresponsive phase (weeks 2-4): Decreased consciousness, catatonia, mutism</li> <li>Hyperkinetic phase (weeks 2-8): Orofacial dyskinesias, choreoathetosis, dystonic posturing, autonomic instability</li> <li>Recovery phase (months to years): Gradual improvement in reverse order of symptom onset; prolonged cognitive/behavioral deficits</li> </ol>"},{"location":"plans/autoimmune-encephalitis/#red-flags-for-autoimmune-encephalitis","title":"Red Flags for Autoimmune Encephalitis","text":"<ul> <li> Young female with new-onset psychiatric symptoms + seizures (consider anti-NMDAR)</li> <li> Limbic encephalitis + hyponatremia (consider LGI1)</li> <li> Faciobrachial dystonic seizures (pathognomonic for LGI1)</li> <li> Refractory status epilepticus in young patient (consider GABA-A, GABA-B, NMDAR)</li> <li> Psychiatric presentation with CSF pleocytosis (encephalitis, NOT primary psychiatric)</li> <li> Encephalopathy + ovarian teratoma (consider anti-NMDAR)</li> <li> Extreme delta brush on EEG (pathognomonic for anti-NMDAR)</li> <li> Encephalopathy + movement disorder (orofacial dyskinesias) + autonomic instability</li> <li> New-onset refractory status epilepticus (NORSE/FIRES) -- screen for autoimmune etiology</li> <li> Rapidly progressive encephalopathy with seizures in a smoker (consider GABA-B + SCLC)</li> </ul>"},{"location":"plans/autoimmune-encephalitis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial creation - Section 1: 24 core labs (1A), 20 antibody panel tests (1B), 16 rare/specialized tests (1C) - Section 2: 6 essential imaging/studies (2A), 7 extended (2B), 5 rare (2C), 22 LP/CSF studies - Section 3: Expanded to 7 subsections:   - 3A: 5 acute/emergent treatments (empiric acyclovir, antibiotics, benzodiazepines, catatonia challenge)   - 3B: 5 first-line immunotherapy agents (methylprednisolone, omeprazole, insulin, IVIG, PLEX)   - 3C: 6 second-line immunotherapy agents (rituximab, cyclophosphamide, tocilizumab, bortezomib, repeated IVIG/PLEX, oral prednisone taper)   - 3D: 10 anti-seizure medications including refractory/super-refractory status epilepticus protocols   - 3E: 9 psychiatric symptom management agents (antipsychotics, lorazepam for catatonia, ICU sedation, mood stabilization, ECT)   - 3F: 12 ICU-specific treatments (ventilation, autonomic instability, DVT prophylaxis, temperature management, sodium correction)   - 3G: 6 long-term immunosuppression/maintenance agents (mycophenolate, azathioprine, rituximab maintenance, prednisone, IVIG maintenance, bone protection) - Section 4: 17 referrals (4A), 15 patient/family instructions (4B), 11 tumor screening protocols by antibody type (4C) - Section 5: 16 differential diagnoses with distinguishing features - Section 6: 16 acute monitoring parameters (6A), 15 outpatient/long-term monitoring parameters (6B) - Section 7: 9 disposition criteria - Section 8: 30 evidence references with evidence levels - Clinical Decision Support Notes: Graus 2016 diagnostic criteria checklist, anti-NMDAR clinical staging (5 phases), 10 red flags checklist</p>"},{"location":"plans/bacterial-meningitis/","title":"Bacterial Meningitis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Bacterial Meningitis</p> <p>ICD-10: G00.9 (Bacterial meningitis, unspecified), G00.1 (Pneumococcal meningitis), G00.0 (Hemophilus meningitis), A39.0 (Meningococcal meningitis), G00.3 (Staphylococcal meningitis)</p> <p>SYNONYMS: Bacterial meningitis, meningitis, acute meningitis, purulent meningitis, pyogenic meningitis, meningococcal meningitis, pneumococcal meningitis, CNS infection, brain infection, spinal meningitis</p> <p>SCOPE: Acute community-acquired bacterial meningitis in adults. Covers emergency empiric antibiotics, dexamethasone adjunctive therapy, LP and CSF analysis, targeted therapy by organism, and complications management. Excludes viral meningitis, fungal meningitis, TB meningitis, healthcare-associated/post-surgical meningitis, and pediatric meningitis.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/bacterial-meningitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/bacterial-meningitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Blood cultures x2 (different sites) STAT STAT - STAT MUST be drawn BEFORE antibiotics but do NOT delay antibiotics to obtain; positive in 50-70% of bacterial meningitis Organism identification and sensitivities CBC with differential STAT STAT - STAT Leukocytosis with left shift; baseline; thrombocytopenia (DIC risk) WBC elevated; neutrophilia CMP (BMP + LFTs) STAT STAT - STAT Electrolytes (SIADH: hyponatremia), renal/hepatic function for antibiotic dosing Normal; watch Na Procalcitonin STAT STAT - STAT Highly sensitive for bacterial infection; helps distinguish bacterial from viral meningitis (&gt;0.5 strongly suggests bacterial) Elevated (&gt;0.5 ng/mL bacterial; typically &gt;2.0) CRP STAT STAT - STAT Inflammatory marker; helps monitor treatment response Elevated Lactate STAT STAT - STAT Sepsis assessment; elevated in bacterial meningitis &lt;2 mmol/L (elevated suggests sepsis) Coagulation panel (PT/INR, aPTT, fibrinogen) STAT STAT - STAT DIC screening (meningococcemia); coagulopathy before LP Normal; DIC: elevated PT/aPTT, low fibrinogen, elevated D-dimer D-dimer STAT STAT - STAT DIC assessment (especially meningococcemia) Normal Blood glucose (concurrent with LP) STAT STAT - STAT Calculate CSF:serum glucose ratio Paired with CSF glucose Type and screen STAT ROUTINE - STAT Potential need for blood products (DIC, sepsis) On file Point-of-care glucose STAT STAT - STAT Hypoglycemia assessment; sepsis &gt;60 mg/dL"},{"location":"plans/bacterial-meningitis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum osmolality URGENT ROUTINE - URGENT SIADH assessment (common complication) 280-295 mOsm/kg Urine osmolality and sodium - ROUTINE - ROUTINE Confirm SIADH if hyponatremia Urine osm &gt;100, urine Na &gt;40 in SIADH Serum cortisol (random or AM) URGENT ROUTINE - URGENT Adrenal insufficiency (Waterhouse-Friderichsen in meningococcemia) &gt;18 \u00b5g/dL (random stress level) HIV 1/2 antigen/antibody - ROUTINE - - Immunocompromise affects empiric coverage and differential Negative Complement levels (C5-C9, CH50, AH50) - ROUTINE ROUTINE - Terminal complement deficiency predisposes to recurrent Neisseria meningitidis Normal Immunoglobulin levels (IgG, IgA, IgM) - ROUTINE ROUTINE - Hypogammaglobulinemia predisposes to encapsulated organisms Normal TSH - ROUTINE - - Thyroid dysfunction screen (critical illness) Normal Troponin URGENT ROUTINE - URGENT Sepsis-associated myocardial injury Normal"},{"location":"plans/bacterial-meningitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Metagenomic next-generation sequencing (mNGS) of CSF - EXT - EXT Culture-negative meningitis; prior antibiotic exposure; atypical organisms Pathogen identification Beta-D-glucan (serum) - EXT - EXT If fungal meningitis suspected (immunocompromised) Negative (&lt;60 pg/mL) Galactomannan (serum) - EXT - EXT Aspergillus (immunocompromised) Negative Cryptococcal antigen (serum) - ROUTINE - ROUTINE HIV/immunocompromised; chronic meningitis Negative RPR/VDRL (serum) - ROUTINE ROUTINE - Neurosyphilis in differential Negative QuantiFERON-TB Gold - ROUTINE - ROUTINE TB meningitis in high-risk patients Negative Skull base/sinus CT - ROUTINE - - Recurrent meningitis: skull base fracture, CSF leak, sinusitis No fracture or defect"},{"location":"plans/bacterial-meningitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/bacterial-meningitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT ONLY if LP delay indications present (see below). Do NOT delay antibiotics for CT. CT BEFORE LP only if: immunocompromised, history of CNS disease, new seizure, papilledema, altered consciousness (GCS &lt;10), focal neurologic deficit Mass effect, hydrocephalus, abscess, herniation risk Pregnancy (relative) Chest X-ray URGENT ROUTINE - URGENT Within first hours Pneumonia (S. pneumoniae source), ARDS None significant <p>CRITICAL: DO NOT DELAY ANTIBIOTICS FOR IMAGING. If CT is needed before LP, give empiric antibiotics + dexamethasone FIRST, then CT, then LP. Blood cultures before antibiotics if possible, but NEVER delay antibiotics &gt;30 minutes from presentation.</p>"},{"location":"plans/bacterial-meningitis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast - URGENT - URGENT Within 24-48h or sooner if complications suspected Meningeal enhancement, abscess, empyema, cerebritis, venous sinus thrombosis, hydrocephalus Pacemaker, metallic implants CT head with contrast - URGENT - URGENT If MRI not available Same as MRI (lower sensitivity) Contrast allergy, renal impairment MRV (MR venography) - ROUTINE - ROUTINE If cerebral venous thrombosis suspected (persistent headache, focal signs, seizures) Venous sinus thrombosis Same as MRI CT temporal bones / skull base - ROUTINE ROUTINE - Recurrent meningitis; suspected CSF leak Fracture, tegmen dehiscence, cholesteatoma None significant Echocardiogram - ROUTINE - - If S. aureus or endocarditis suspected Vegetations, embolic risk None significant Continuous EEG - URGENT - URGENT If altered mental status persists despite treatment; suspected non-convulsive seizures Seizure activity, status epilepticus None significant"},{"location":"plans/bacterial-meningitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT cisternogram - - EXT - Recurrent meningitis with suspected CSF leak CSF leak localization Contrast allergy Beta-2 transferrin (nasal/ear drainage) - ROUTINE ROUTINE - Suspected CSF rhinorrhea or otorrhea Positive = CSF leak None Intrathecal fluorescein - - EXT - CSF leak localization (surgical planning) Fluorescent leakage site Allergy ICP monitoring (EVD) - - - URGENT If signs of elevated ICP, declining consciousness despite treatment ICP &lt;22 mmHg; CPP &gt;60 Coagulopathy (correct first)"},{"location":"plans/bacterial-meningitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Diagnostic \u2014 ALL patients with suspected bacterial meningitis. Do NOT delay antibiotics for LP.</p> <p>Timing: STAT. If CT needed first, give antibiotics + dexamethasone BEFORE CT, then LP ASAP after CT clears for safety.</p> <p>Volume Required: 15-20 mL (4 tubes minimum + extra for additional studies)</p> <p>Opening Pressure: ALWAYS measure and document.</p> Study ED HOSP OPD Rationale Target Finding Opening pressure STAT ROUTINE - Elevated in bacterial meningitis; monitor for elevated ICP Typically 200-500 mm H2O (normal &lt;200); markedly elevated suggests edema/hydrocephalus Cell count with differential (tubes 1 AND 4) STAT ROUTINE - Bacterial: neutrophilic pleocytosis; tube 1 vs 4 differentiates traumatic tap WBC &gt;1000 cells/\u00b5L with &gt;80% neutrophils (bacterial); WBC 100-10,000 typical Protein STAT ROUTINE - Elevated in bacterial meningitis Elevated (&gt;100 mg/dL typical; often 100-500) Glucose with paired serum glucose STAT ROUTINE - CSF:serum ratio &lt;0.4 strongly suggests bacterial meningitis Low (&lt;40 mg/dL; CSF:serum ratio &lt;0.4) Gram stain STAT ROUTINE - Rapid identification; positive in 60-90% of untreated bacterial meningitis Organisms identified (gram-positive diplococci = pneumococcus; gram-negative diplococci = meningococcus; gram-positive rods = Listeria; gram-negative rods = E. coli/Haemophilus) Bacterial culture and sensitivity STAT ROUTINE - Gold standard for organism identification and antibiotic sensitivities; may be negative after antibiotics Organism identified with sensitivities BioFire FilmArray Meningitis/Encephalitis Panel STAT ROUTINE - Rapid multiplex PCR (14 pathogens in ~1 hour); especially valuable if prior antibiotics given Identifies E. coli K1, H. influenzae, L. monocytogenes, N. meningitidis, S. agalactiae, S. pneumoniae, plus viruses (HSV, enterovirus, VZV, etc.) and Cryptococcus Lactate (CSF) STAT ROUTINE - CSF lactate &gt;3.5 mmol/L highly suggestive of bacterial (sensitivity ~93%, specificity ~96%); useful post-antibiotics when cultures may be negative &lt;3.5 mmol/L (bacterial typically &gt;4.0) HSV 1/2 PCR STAT ROUTINE - Exclude concurrent HSV encephalitis; do not miss treatable cause Negative Cryptococcal antigen (CSF) - ROUTINE - If immunocompromised or subacute presentation Negative AFB smear and culture - ROUTINE - If TB meningitis suspected (subacute, basilar enhancement, HIV) Negative VDRL (CSF) - ROUTINE - Neurosyphilis screen Negative Cytology - ROUTINE - If malignancy in differential Negative <p>Special Handling: Culture and Gram stain must be processed IMMEDIATELY. BioFire ME Panel provides results in ~1 hour. CSF lactate must be processed promptly (do not let sample sit).</p> <p>Contraindications to LP (perform CT first): Immunocompromised, known CNS mass, new seizure (within 1 week), papilledema, GCS &lt;10, focal neurologic deficit. Coagulopathy (INR &gt;1.5, platelets &lt;50K) \u2014 correct first if possible, but do NOT delay antibiotics.</p>"},{"location":"plans/bacterial-meningitis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/bacterial-meningitis/#critical-timing-of-antibiotics","title":"\u26a0\ufe0f CRITICAL: TIMING OF ANTIBIOTICS","text":"<p>DO NOT DELAY ANTIBIOTICS. Door-to-antibiotic time &lt;30 minutes is the target. Each hour of delay increases mortality.</p> <p>Sequence: 1. Blood cultures (if obtainable without delay) 2. Dexamethasone + empiric antibiotics STAT 3. CT head (ONLY if indicated \u2014 see criteria above) 4. LP (as soon as CT clears or immediately if no CT indications)</p>"},{"location":"plans/bacterial-meningitis/#3a-acuteemergent-empiric-therapy","title":"3A. Acute/Emergent \u2014 Empiric Therapy","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Dexamethasone (adjunctive \u2014 give BEFORE or WITH first antibiotic dose) STAT STAT - STAT 0.15 mg/kg IV q6h x 4 days (typically 10 mg IV q6h). MUST be given BEFORE or simultaneously with first antibiotic dose. Greatest benefit for S. pneumoniae (reduces mortality and hearing loss). Discontinue if organism is NOT S. pneumoniae (some centers continue regardless) Not proven beneficial if antibiotics already started &gt;1h prior Glucose q6h; GI prophylaxis; BP Vancomycin IV STAT STAT - STAT 15-20 mg/kg IV q8-12h (target trough 15-20 \u00b5g/mL or AUC/MIC 400-600); loading dose 25-30 mg/kg if severe. Covers penicillin-resistant S. pneumoniae, MRSA Red man syndrome (infuse over \u22651h); renal impairment (dose adjust) Trough levels before 4th dose; renal function daily; watch for nephrotoxicity and ototoxicity Ceftriaxone IV STAT STAT - STAT 2 g IV q12h. Covers S. pneumoniae (penicillin-sensitive), N. meningitidis, H. influenzae, gram-negative organisms Cephalosporin allergy (cross-reactivity low with penicillin allergy); neonatal hyperbilirubinemia CBC; LFTs; biliary sludge with prolonged use Ampicillin IV (add if Listeria risk) STAT STAT - STAT 2 g IV q4h. ADD to vancomycin + ceftriaxone if: age &gt;50, immunocompromised, alcoholism, pregnancy. Covers Listeria monocytogenes (resistant to cephalosporins) Penicillin anaphylaxis (use TMP-SMX as alternative for Listeria) Rash; renal function Acyclovir IV (empiric \u2014 until HSV excluded) STAT STAT - STAT 10 mg/kg IV q8h. Add empirically if ANY suspicion of encephalitis (confusion, focal signs, seizures, temporal lobe changes). Discontinue when HSV PCR negative Renal impairment (dose adjust); ensure adequate hydration Renal function daily; adequate IV hydration (1 mL/kg/h); crystal nephropathy prevention IV normal saline STAT STAT - STAT Isotonic fluid resuscitation for sepsis; maintenance fluids. Avoid hypo/hypernatremia Volume overload I/O; electrolytes q6-12h; watch for SIADH Vasopressors: Norepinephrine - - - STAT 0.1-0.5 \u00b5g/kg/min IV; first-line for septic shock after fluid resuscitation Only via central line MAP target \u226565 mmHg; continuous arterial monitoring"},{"location":"plans/bacterial-meningitis/#3b-targeted-therapy-by-organism-once-identified","title":"3B. Targeted Therapy by Organism (Once Identified)","text":"Treatment Indication ED HOSP OPD ICU Dosing Duration Monitoring Penicillin G (if penicillin-sensitive S. pneumoniae, MIC &lt;0.06) S. pneumoniae (sensitive) - STAT - STAT 4 million units IV q4h 10-14 days Renal function; CBC Ceftriaxone (if intermediate or unknown sensitivity) S. pneumoniae (intermediate) - STAT - STAT 2 g IV q12h; continue vancomycin until sensitivities confirm 10-14 days Same as empiric Penicillin G or ceftriaxone N. meningitidis - STAT - STAT Penicillin G 4 MU IV q4h OR Ceftriaxone 2g IV q12h 7 days Renal function Ampicillin L. monocytogenes - STAT - STAT 2 g IV q4h (+ gentamicin 5 mg/kg/day IV for synergy in first 7-10 days, if renal function allows) 21 days (minimum) Renal function (especially with gentamicin); gentamicin levels Ceftriaxone H. influenzae - STAT - STAT 2 g IV q12h 7 days Standard Ceftriaxone E. coli / gram-negative - STAT - STAT 2 g IV q12h; adjust per sensitivities 21 days Standard Cefepime Pseudomonas (nosocomial, immunocompromised) - STAT - STAT 2 g IV q8h 21 days Renal function; neurotoxicity Meropenem Extended-spectrum beta-lactamase (ESBL) producers or multi-drug resistant - STAT - STAT 2 g IV q8h 21 days Renal function; seizure threshold"},{"location":"plans/bacterial-meningitis/#3c-symptomatic-treatments","title":"3C. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam Seizure management (if seizures occur; NOT routine prophylaxis) STAT STAT - STAT 1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day Severe renal impairment (dose adjust) Renal function; mood/behavioral changes Lorazepam Active seizure (rescue) STAT STAT - STAT 0.1 mg/kg IV (max 4 mg); may repeat x1 Respiratory depression RR, SpO2 Acetaminophen Fever reduction, headache STAT STAT - STAT 650-1000 mg PO/IV q6h; max 4g/day Severe hepatic disease Temperature; LFTs Ibuprofen Headache (once stable) - ROUTINE - - 400-600 mg PO q6h with food Renal impairment, GI bleed risk, coagulopathy Renal function; GI symptoms Ondansetron Nausea/vomiting STAT ROUTINE - STAT 4 mg IV/PO q6h PRN QT prolongation QTc Mannitol 20% Elevated ICP management STAT - - STAT 1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h Anuria Serum osm (&lt;320); osmolar gap; renal function Hypertonic saline 23.4% Elevated ICP (acute herniation) STAT - - STAT 30 mL IV via central line over 10-20 min No central access Serum Na (target 145-155); osmolality Pantoprazole GI prophylaxis (steroids + critical illness) - ROUTINE - ROUTINE 40 mg IV/PO daily Prolonged use risks GI symptoms Enoxaparin DVT prophylaxis - ROUTINE - ROUTINE 40 mg SC daily (start 24-48h after stable) Active bleeding, DIC, coagulopathy Platelets; coags"},{"location":"plans/bacterial-meningitis/#3d-close-contacts-prophylaxis-public-health","title":"3D. Close Contacts Prophylaxis (Public Health)","text":"Scenario Agent Dosing Indication N. meningitidis exposure Ciprofloxacin 500 mg PO x 1 dose (adults) Close contacts within 7 days (household, kissing, shared utensils, healthcare workers with unprotected airway exposure) N. meningitidis exposure Rifampin 600 mg PO q12h x 2 days (adults) Alternative; avoid in pregnancy N. meningitidis exposure Ceftriaxone 250 mg IM x 1 dose Preferred in pregnancy H. influenzae type b exposure Rifampin 20 mg/kg PO daily x 4 days (max 600 mg) Household with child &lt;4 years not fully vaccinated <p>Report meningococcal meningitis to local public health department IMMEDIATELY.</p>"},{"location":"plans/bacterial-meningitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/bacterial-meningitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Infectious disease consultation STAT STAT - STAT All bacterial meningitis; antibiotic optimization; complicated cases Neurology consultation URGENT URGENT - STAT Seizures, altered consciousness, focal deficits, ICP management Neurosurgery consultation - URGENT - STAT Hydrocephalus (EVD), brain abscess, subdural empyema, ICP management Critical care/ICU team STAT STAT - STAT Septic shock, respiratory failure, DIC, ICP management ENT / Otolaryngology - ROUTINE ROUTINE - Recurrent meningitis (CSF leak), concurrent sinusitis/mastoiditis source Audiology - ROUTINE ROUTINE - Hearing assessment before discharge (hearing loss in up to 30% S. pneumoniae) Public health department STAT STAT - - Meningococcal meningitis \u2014 mandatory reporting; contact tracing and prophylaxis Speech-language pathology - ROUTINE ROUTINE - Swallowing assessment if altered consciousness; cognitive assessment Physical therapy - ROUTINE ROUTINE - Mobilization, deconditioning prevention Social work - ROUTINE ROUTINE - Family support, discharge planning Palliative care - ROUTINE - ROUTINE Severe cases with poor prognosis; goals of care"},{"location":"plans/bacterial-meningitis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED if: worsening headache, fever recurrence, new confusion, seizure, neck stiffness, rash, vision changes STAT STAT ROUTINE Complete full antibiotic course (do NOT stop early even if feeling better) - ROUTINE ROUTINE Hearing test recommended 2-4 weeks after discharge - ROUTINE ROUTINE Vaccination: pneumococcal and meningococcal vaccines after recovery if not previously immunized - ROUTINE ROUTINE Close contacts should receive prophylactic antibiotics if N. meningitidis (public health will coordinate) STAT ROUTINE - Follow-up with infectious disease and neurology in 2-4 weeks - ROUTINE ROUTINE Report any new neurologic symptoms (hearing loss, balance problems, cognitive changes) - ROUTINE ROUTINE Avoid alcohol during antibiotic therapy - ROUTINE ROUTINE"},{"location":"plans/bacterial-meningitis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Pneumococcal vaccination (PCV20 or PCV15 + PPSV23) if not previously completed - ROUTINE ROUTINE Meningococcal vaccination (MenACWY + MenB) for at-risk groups - ROUTINE ROUTINE Smoking cessation (upper respiratory tract colonization risk) - ROUTINE ROUTINE Alcohol moderation/cessation (immunocompromise, Listeria risk) - ROUTINE ROUTINE Splenectomy patients: ensure vaccinated (encapsulated organism risk) - ROUTINE ROUTINE Complement-deficient patients: meningococcal vaccination and booster schedule - ROUTINE ROUTINE Hand hygiene and respiratory etiquette education - ROUTINE ROUTINE Skull base fracture/CSF leak patients: surgical repair to prevent recurrence - ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/bacterial-meningitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Viral meningitis Less toxic; CSF: lymphocytic pleocytosis, normal glucose, mildly elevated protein; self-limited CSF cell count (lymphocytes), normal glucose, BioFire ME panel (enterovirus most common), procalcitonin low HSV encephalitis Encephalitis (confusion, personality change, seizures, focal signs); temporal lobe involvement MRI (temporal T2/FLAIR), CSF HSV PCR, EEG (PLEDs) Tuberculous meningitis Subacute (weeks), basilar meningitis, cranial neuropathies, HIV risk; CSF: lymphocytic, low glucose, very high protein AFB smear/culture, TB PCR (GeneXpert), adenosine deaminase (ADA), chest X-ray (miliary pattern), PPD/IGRA Fungal meningitis (Cryptococcus) Subacute/chronic; immunocompromised (HIV CD4 &lt;100); headache predominant; minimal CSF pleocytosis CSF cryptococcal antigen (CrAg), India ink, fungal culture Subarachnoid hemorrhage Thunderclap headache; meningismus; NOT febrile initially; xanthochromia CT head (blood), CSF RBC (tube 1 = tube 4), xanthochromia Brain abscess Focal deficits; fever + headache + focal signs (triad); subacute; seizures MRI with contrast (ring-enhancing lesion with restricted diffusion), CT with contrast Subdural empyema Post-sinusitis/otitis; rapid deterioration; focal deficits; seizures MRI/CT with contrast (extra-axial collection) Autoimmune encephalitis Subacute onset; psychiatric symptoms; seizures; young women; no fever initially Autoimmune antibody panel (serum + CSF); MRI; EEG Drug-induced aseptic meningitis NSAID, IVIG, TMP-SMX, isoniazid exposure; self-limited after drug withdrawal Drug history; CSF lymphocytic pleocytosis; sterile cultures; resolves with drug removal Carcinomatous/leptomeningeal meningitis Subacute; cranial neuropathies; known malignancy; CSF: low glucose, elevated protein, positive cytology CSF cytology (repeat x3 for sensitivity); MRI with contrast (leptomeningeal enhancement) Neurosarcoidosis Chronic headache; cranial neuropathies (CN VII); hilar adenopathy; ACE level Chest CT; serum ACE; CSF ACE; biopsy"},{"location":"plans/bacterial-meningitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Neurologic exam (GCS, pupils, motor, meningismus) STAT STAT - STAT q1h x 24h then q2-4h; more frequent if declining Improving GCS; resolving meningismus If GCS declining: STAT CT, ICP assessment, consider EVD Temperature STAT STAT - STAT q4h (q1h if febrile) Afebrile within 48-72h of appropriate antibiotics If persistent fever &gt;72h: repeat cultures, imaging for abscess/empyema, drug fever, new infection Blood pressure STAT STAT - STAT q1h if sepsis; q4h if stable MAP \u226565 mmHg; SBP &gt;90 Fluid resuscitation; vasopressors Heart rate STAT STAT - STAT q1-4h 60-100 Sepsis management Serum sodium STAT STAT - STAT q6-8h x 48h, then q12h 135-145 mEq/L If &lt;130: SIADH likely \u2192 fluid restriction (1-1.2 L/day); if &lt;120: 3% saline Serum creatinine - ROUTINE - ROUTINE Daily Stable Adjust antibiotics if rising; vancomycin nephrotoxicity Vancomycin trough or AUC - ROUTINE - ROUTINE Before 4th dose; then q24-48h until stable Trough 15-20 \u00b5g/mL or AUC/MIC 400-600 Adjust dosing; pharmacy consult CBC - ROUTINE - ROUTINE Daily x 3, then q48h Improving WBC; stable platelets If platelets dropping: DIC panel; if WBC not improving: reassess antibiotics Coagulation panel (DIC monitoring) STAT ROUTINE - STAT q6-12h if meningococcemia/DIC; daily otherwise Normal PT, aPTT; fibrinogen &gt;100 FFP for INR &gt;1.5; cryoprecipitate for fibrinogen &lt;100; platelet transfusion if &lt;50K with bleeding CRP / procalcitonin - ROUTINE ROUTINE ROUTINE q48-72h during treatment Declining trend If not declining by day 3-5: reassess; repeat LP; imaging Seizure monitoring STAT STAT - STAT Clinical observation; cEEG if altered consciousness No seizure activity Levetiracetam load; if refractory \u2192 status epilepticus protocol Hearing assessment - ROUTINE ROUTINE - Before discharge; repeat at 2-4 weeks Normal hearing Audiology referral; hearing aid evaluation if deficit ICP (if EVD in place) - - - STAT Continuous ICP &lt;22 mmHg; CPP 60-70 Tiered ICP management: CSF drainage, osmotherapy, sedation"},{"location":"plans/bacterial-meningitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Never discharge directly from ED with suspected bacterial meningitis. Discharge from hospital when: afebrile \u226548h, improving neurologic exam, able to take oral medications (IV-to-PO switch criteria met for some organisms), adequate outpatient IV access if completing IV course, reliable follow-up Admit to floor (monitored) Hemodynamically stable; GCS \u226513; no respiratory compromise; no DIC; no seizures Admit to ICU Septic shock; GCS &lt;13 or declining; respiratory failure; DIC; refractory seizures; signs of elevated ICP; meningococcemia with purpura fulminans; need for vasopressors Transfer to higher level Need for neurosurgery (abscess, empyema, EVD); need for neuro-ICU expertise not available"},{"location":"plans/bacterial-meningitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Empiric vancomycin + ceftriaxone +/- ampicillin Class I, Level A IDSA Guidelines (Tunkel et al. CID 2004; van de Beek et al. NEJM 2006) Dexamethasone before or with first antibiotic dose Class I, Level A de Gans &amp; van de Beek (NEJM 2002) \u2014 reduces mortality and hearing loss in S. pneumoniae Do NOT delay antibiotics for imaging Class I, Level A IDSA Guidelines; multiple observational studies showing increased mortality with delay CT before LP only for specific indications Class I, Level A Hasbun et al. (NEJM 2001) \u2014 criteria for when to CT before LP Blood cultures before antibiotics (if obtainable without delay) Class I, Level B IDSA Guidelines BioFire ME Panel for rapid diagnosis Class IIa, Level B Leber et al. (JCM 2016); FDA-cleared multiplex PCR CSF lactate &gt;3.5 mmol/L for bacterial vs viral Class IIa, Level B Meta-analysis: Sakushima et al. (BMC ID 2011) Targeted antibiotic therapy by organism Class I, Level A IDSA Guidelines; organism-specific duration data Close contact prophylaxis for meningococcal Class I, Level A CDC MMWR recommendations Hearing assessment post-meningitis Class I, Level B High incidence of hearing loss (up to 30% S. pneumoniae) Seizure treatment (not routine prophylaxis) Class IIb, Level C Expert consensus; no clear data supporting prophylaxis Procalcitonin to differentiate bacterial from viral Class IIa, Level B Meta-analyses showing high sensitivity/specificity Repeat LP at 48h if no clinical improvement Class IIa, Level C IDSA Guidelines <p>APPENDIX: CSF FINDINGS BY PATHOGEN TYPE</p> Parameter Bacterial Viral TB Fungal WBC (cells/\u00b5L) 1,000-10,000 10-500 50-500 10-500 Predominant cell Neutrophils (&gt;80%) Lymphocytes Lymphocytes Lymphocytes Protein (mg/dL) 100-500 50-100 100-500 50-200 Glucose (mg/dL) &lt;40 Normal &lt;40 &lt;40 CSF:serum glucose &lt;0.4 &gt;0.6 &lt;0.4 &lt;0.4 Opening pressure 200-500 Normal-mildly elevated 100-300 100-300 Lactate (mmol/L) &gt;3.5 &lt;3.5 &gt;3.5 Variable Gram stain Positive 60-90% Negative AFB rarely positive India ink (Crypto) <p>APPENDIX: ANTIBIOTIC DURATION BY ORGANISM</p> Organism Duration N. meningitidis 7 days H. influenzae 7 days S. pneumoniae 10-14 days Group B Streptococcus 14-21 days L. monocytogenes \u226521 days Gram-negative bacilli (E. coli, Klebsiella) 21 days S. aureus 14-21+ days (longer if complications)"},{"location":"plans/bells-palsy/","title":"Bell's Palsy","text":"<p>VERSION: 1.0 CREATED: January 29, 2026 REVISED: January 29, 2026 STATUS: Complete</p> <p>DIAGNOSIS: Bell's Palsy / Idiopathic Facial Paralysis</p> <p>ICD-10: G51.0 (Bell's palsy), G51.8 (Other disorders of facial nerve), G51.9 (Disorder of facial nerve, unspecified), B02.21 (Postherpetic geniculate ganglionitis - Ramsay Hunt)</p> <p>SYNONYMS: Bell's palsy, Bell palsy, idiopathic facial paralysis, facial palsy, facial nerve palsy, acute peripheral facial palsy, seventh nerve palsy, CN VII palsy, facial weakness</p> <p>SCOPE: Diagnosis and management of Bell's palsy (idiopathic facial nerve palsy) in adults. Covers workup to exclude secondary causes, medical treatment, and eye protection. Includes Ramsay Hunt syndrome (herpes zoster oticus) which requires different treatment. Excludes central facial palsy (stroke), facial nerve tumors, traumatic facial nerve injury, and bilateral facial palsy workup.</p> <p>DEFINITIONS: - Bell's Palsy: Acute idiopathic unilateral peripheral facial nerve (CN VII) weakness - Peripheral Facial Palsy: Weakness affecting upper AND lower face (forehead involvement) - Central Facial Palsy: Weakness affecting lower face only with forehead sparing (upper motor neuron lesion) - House-Brackmann Scale: Grading system for facial nerve function (I-VI) - Ramsay Hunt Syndrome: Facial palsy with herpes zoster oticus (vesicles in ear canal/pinna)</p> <p>HOUSE-BRACKMANN GRADING SCALE:</p> Grade Description Characteristics I Normal Normal facial function II Mild dysfunction Slight weakness on close inspection; complete eye closure with effort III Moderate dysfunction Obvious but not disfiguring weakness; may not completely close eye; forehead movement present IV Moderately severe Obvious weakness and disfiguring asymmetry; cannot completely close eye; no forehead movement V Severe dysfunction Barely perceptible motion; incomplete eye closure; slight movement at corner of mouth VI Total paralysis No movement; loss of tone <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/bells-palsy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/bells-palsy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC URGENT ROUTINE ROUTINE - Infection, leukemia (CN involvement) Normal CMP URGENT ROUTINE ROUTINE - Diabetes (risk factor), electrolytes Normal; glucose &lt;126 fasting Glucose / HbA1c URGENT ROUTINE ROUTINE - Diabetes is major risk factor; affects prognosis Normal"},{"location":"plans/bells-palsy/#1b-extended-workup-second-line-selected-patients","title":"1B. Extended Workup (Second-line - Selected Patients)","text":"Test ED HOSP OPD ICU Rationale Target Finding Lyme serology (IgM/IgG) - ROUTINE ROUTINE - Endemic areas; Lyme disease can cause facial palsy Negative ESR/CRP - ROUTINE ROUTINE - Inflammatory conditions, vasculitis Normal HIV - ROUTINE ROUTINE - HIV-associated facial palsy Negative RPR/VDRL - ROUTINE ROUTINE - Syphilis in differential Negative ANA - EXT EXT - Autoimmune etiology (SLE, Sjogren's) Negative SSA (Ro) / SSB (La) - EXT EXT - Sjogren's syndrome Negative VZV serology (IgM) - ROUTINE ROUTINE - Ramsay Hunt syndrome (if vesicles or suspicion) Document status ACE level - EXT EXT - Sarcoidosis if bilateral or recurrent Normal"},{"location":"plans/bells-palsy/#1c-rarespecialized","title":"1C. Rare/Specialized","text":"Test ED HOSP OPD ICU Rationale Target Finding CSF analysis (LP) - URGENT - - Atypical presentation, suspected Lyme neuroborreliosis, GBS, meningitis See LP section Serum glucose tolerance test - - ROUTINE - If HbA1c borderline; diabetes evaluation Normal"},{"location":"plans/bells-palsy/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Atypical features (bilateral, progressive, recurrent), suspected Lyme disease, meningitis, or GBS</p> Study ED HOSP OPD ICU Rationale Target Finding Opening pressure URGENT URGENT - - Baseline; elevated in some conditions 10-20 cm H2O Cell count (tubes 1 and 4) URGENT URGENT - - Infection, inflammation WBC &lt;5 Protein URGENT URGENT - - Elevated in GBS, Lyme 15-45 mg/dL Glucose URGENT URGENT - - Infection &gt;60% serum Lyme antibody (CSF) - URGENT - - Lyme neuroborreliosis Negative VDRL (CSF) - URGENT - - Neurosyphilis Negative Gram stain and culture - URGENT - - Bacterial meningitis No organisms CSF meningitis panel - URGENT - - Viral/bacterial pathogens Negative"},{"location":"plans/bells-palsy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/bells-palsy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Physical examination STAT STAT ROUTINE - At presentation Peripheral pattern (forehead involved); no other CN deficits None Otoscopic examination STAT STAT ROUTINE - At presentation Vesicles (Ramsay Hunt); middle ear pathology None Eye examination STAT STAT ROUTINE - At presentation Corneal exposure, lagophthalmos None"},{"location":"plans/bells-palsy/#2b-extended-atypical-or-non-recovering-cases","title":"2B. Extended (Atypical or Non-recovering Cases)","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with IAC protocol - ROUTINE ROUTINE - If atypical, progressive, no recovery at 4-6 weeks Facial nerve enhancement (may be normal in Bell's); exclude mass, stroke Pacemaker, metal MRI with contrast - ROUTINE ROUTINE - If tumor suspected Rule out schwannoma, parotid tumor Contrast allergy CT temporal bone - ROUTINE ROUTINE - If trauma or mastoid pathology suspected Fracture, cholesteatoma None Chest X-ray - ROUTINE ROUTINE - If sarcoidosis suspected Hilar adenopathy None Electrodiagnostic studies (ENoG, EMG) - - ROUTINE - Severe palsy (HB IV-VI) at 2-3 weeks; prognosis &gt;90% degeneration = poor prognosis None"},{"location":"plans/bells-palsy/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/bells-palsy/#3a-corticosteroids-all-patients","title":"3A. Corticosteroids (All Patients)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Prednisone STAT STAT ROUTINE - 60-80 mg PO daily \u00d7 7 days (can taper over days 8-10 or stop); START WITHIN 72 HOURS of onset Active infection (relative), uncontrolled DM (relative) Glucose (especially diabetics), GI prophylaxis Prednisolone STAT STAT ROUTINE - 60-80 mg PO daily \u00d7 7 days (equivalent alternative) Same Same Methylprednisolone IV STAT STAT - - 1000 mg IV daily \u00d7 3-5 days (if unable to take PO or severe/Ramsay Hunt) Same Same Dexamethasone STAT STAT - - 10 mg IV/PO daily \u00d7 7-10 days (alternative) Same Same"},{"location":"plans/bells-palsy/#3b-antiviral-therapy","title":"3B. Antiviral Therapy","text":"<p>Note: Antivirals alone have NOT been shown to improve outcomes in Bell's palsy. Use in combination with steroids for moderate-severe cases and always for Ramsay Hunt syndrome.</p> Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Valacyclovir (moderate-severe Bell's) STAT STAT ROUTINE - 1000 mg PO TID \u00d7 7 days; ALWAYS with steroids Renal impairment (reduce dose) Renal function Acyclovir (alternative) STAT STAT ROUTINE - 400 mg PO 5\u00d7 daily \u00d7 7-10 days; or 800 mg PO TID \u00d7 7 days Renal impairment Renal function Valacyclovir (Ramsay Hunt) STAT STAT ROUTINE - 1000 mg PO TID \u00d7 7-10 days; MANDATORY with steroids Renal impairment Renal function Acyclovir IV (severe Ramsay Hunt) - STAT - - 10 mg/kg IV q8h \u00d7 7-10 days Renal impairment Renal function, hydration"},{"location":"plans/bells-palsy/#3c-eye-protection-critical-all-patients","title":"3C. Eye Protection (CRITICAL - All Patients)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Artificial tears (preservative-free) STAT STAT ROUTINE - 1-2 drops affected eye q1-2h while awake None Corneal status Lubricating eye ointment (Lacri-Lube) STAT STAT ROUTINE - Thin strip in affected eye at bedtime (and up to TID) None Corneal status Eye patch or moisture chamber STAT STAT ROUTINE - At night and in dusty/windy environments None Corneal status Tape eyelid closed at night STAT STAT ROUTINE - If unable to close eye (use paper tape) None Corneal status Wraparound glasses/sunglasses - ROUTINE ROUTINE - During day for eye protection None Corneal status"},{"location":"plans/bells-palsy/#3d-pain-management","title":"3D. Pain Management","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen ROUTINE ROUTINE ROUTINE - 650-1000 mg PO q6h PRN; max 3000 mg/day Hepatic disease LFTs if prolonged use Ibuprofen ROUTINE ROUTINE ROUTINE - 400-600 mg PO q6h PRN with food Renal disease, GI bleeding Renal function Gabapentin (post-herpetic neuralgia) - ROUTINE ROUTINE - 100-300 mg TID; titrate as needed for Ramsay Hunt Renal impairment Sedation"},{"location":"plans/bells-palsy/#3e-lyme-disease-treatment-if-positive","title":"3E. Lyme Disease Treatment (If Positive)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Doxycycline - STAT ROUTINE - 100 mg PO BID \u00d7 14-21 days (isolated facial palsy) Pregnancy, children &lt;8 GI upset Ceftriaxone IV - STAT - - 2 g IV daily \u00d7 14-21 days (if CNS involvement) Cephalosporin allergy Standard"},{"location":"plans/bells-palsy/#3f-physical-therapy","title":"3F. Physical Therapy","text":"Treatment ED HOSP OPD ICU Details Contraindications Notes Facial exercises - ROUTINE ROUTINE - Mirror exercises, gentle facial movements None Start when recovery begins Facial massage - - ROUTINE - Gentle massage to maintain muscle tone None Patient/family can perform Electrical stimulation - - EXT - Controversial; limited evidence None Not routinely recommended Neuromuscular retraining - - ROUTINE - Specialized PT for synkinesis prevention None If incomplete recovery"},{"location":"plans/bells-palsy/#3g-surgical-options-refractory-cases","title":"3G. Surgical Options (Refractory Cases)","text":"Treatment ED HOSP OPD ICU Indication Contraindications Notes Surgical decompression - - EXT - &gt;90% degeneration on ENoG within 14 days; controversial Poor surgical candidate Rarely performed; controversial benefit Gold weight/platinum chain eyelid implant - - EXT - Persistent lagophthalmos (&gt;6-12 months) None Improves eye closure Tarsorrhaphy - ROUTINE ROUTINE - Persistent exposure keratopathy None Temporary or permanent Static facial sling - - EXT - Permanent severe palsy None Improves cosmesis Hypoglossal-facial nerve anastomosis - - EXT - Complete permanent paralysis None Restores tone and some movement Cross-face nerve graft - - EXT - Permanent paralysis, younger patients None Extended recovery time"},{"location":"plans/bells-palsy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/bells-palsy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Ophthalmology URGENT URGENT ROUTINE - Corneal exposure, inability to close eye, any eye pain/redness ENT / Otolaryngology - ROUTINE ROUTINE - Ramsay Hunt syndrome, atypical features, surgical consideration Neurology - ROUTINE ROUTINE - Atypical features, no recovery at 3-4 weeks, recurrent palsy Physical therapy (facial) - - ROUTINE - Begin when recovery starts; synkinesis prevention Plastic surgery / Facial nerve specialist - - EXT - Permanent paralysis, reconstructive options Infectious disease - ROUTINE ROUTINE - Lyme disease, atypical infection"},{"location":"plans/bells-palsy/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD Eye protection is CRITICAL - use lubricating drops frequently and ointment at night STAT STAT ROUTINE Tape eye closed or use patch at night to prevent corneal injury STAT STAT ROUTINE Start steroids as soon as possible (ideally within 72 hours of symptom onset) STAT STAT ROUTINE Most patients (70-80%) recover completely within 3-6 months - ROUTINE ROUTINE Recovery typically begins within 2-3 weeks; full recovery may take months - ROUTINE ROUTINE Return immediately if: eye pain, vision changes, redness, or discharge STAT STAT ROUTINE Examine ear daily for vesicles (if develops, call immediately - may be Ramsay Hunt) ROUTINE ROUTINE ROUTINE Follow up with neurologist or ENT if no improvement at 3-4 weeks - ROUTINE ROUTINE Do NOT massage face vigorously or use electrical stimulation without guidance - ROUTINE ROUTINE"},{"location":"plans/bells-palsy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Protect eye from wind, dust, and irritants ROUTINE ROUTINE ROUTINE Avoid rubbing the affected eye ROUTINE ROUTINE ROUTINE Consider humidifier at night - ROUTINE ROUTINE Chew carefully; may have food pocketing on affected side - ROUTINE ROUTINE Maintain diabetes control if diabetic (reduces risk and improves recovery) - ROUTINE ROUTINE"},{"location":"plans/bells-palsy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Stroke (central facial palsy) Forehead SPARED (upper motor neuron pattern), other neurologic deficits CT/MRI brain; emergent evaluation Ramsay Hunt syndrome Vesicles in ear canal/pinna, severe ear pain, may have hearing loss, vertigo Otoscopic exam; VZV serology Lyme disease Endemic area, tick bite history, erythema migrans rash, may be bilateral Lyme serology; LP if suspected Acoustic neuroma Gradual onset, hearing loss, tinnitus, other CN involvement MRI with IAC protocol Parotid tumor Mass in parotid region, progressive weakness CT/MRI parotid; biopsy Guillain-Barr\u00e9 syndrome Bilateral facial weakness, ascending weakness, areflexia LP (albuminocytologic dissociation), NCS/EMG Sarcoidosis (Heerfordt syndrome) Bilateral, parotid swelling, uveitis, fever Chest X-ray, ACE level, biopsy Otitis media/Mastoiditis Ear pain, fever, ear discharge, hearing loss Otoscopic exam, CT temporal bone Cholesteatoma Chronic ear drainage, hearing loss, progressive Otoscopic exam, CT temporal bone Melkersson-Rosenthal syndrome Recurrent facial palsy, facial edema, fissured tongue Clinical triad Diabetes mellitus May present as Bell's palsy; higher incidence in diabetics Glucose, HbA1c HIV Risk factors, other neurologic manifestations HIV test Multiple sclerosis Other neurologic symptoms, white matter lesions MRI brain"},{"location":"plans/bells-palsy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal House-Brackmann grade STAT Daily Each visit - Track recovery Improvement over weeks Consider imaging, EMG Corneal status STAT Daily Each visit - At each assessment Clear cornea, no ulceration Urgent ophthalmology Eye closure (lagophthalmos) STAT Daily Each visit - At each assessment Improving closure Increase eye protection Blood glucose STAT Daily Each visit - While on steroids &lt;200 mg/dL Adjust DM medications Vesicle check (ear) STAT Daily Each visit - Daily \u00d7 7 days None (Ramsay Hunt would require antivirals) Add/continue antivirals Recovery timeline - ROUTINE ROUTINE - q2-4 weeks Improvement by 3-4 weeks Imaging, specialist referral Synkinesis screening - - ROUTINE - Starting at recovery Absent PT for neuromuscular retraining"},{"location":"plans/bells-palsy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge from ED Typical presentation, eye protection education, steroids prescribed, ophthalmology follow-up arranged if needed, close outpatient follow-up Admit to hospital Ramsay Hunt with severe symptoms, unable to protect eye, concern for stroke or other central cause, need for IV medications Ophthalmology within 24-48h Significant lagophthalmos, corneal exposure, any eye symptoms Neurology follow-up No improvement at 3-4 weeks, atypical features, recurrent episodes ENT referral Ramsay Hunt syndrome, surgical consideration, chronic cases"},{"location":"plans/bells-palsy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Corticosteroids improve recovery Class I, Level A Scottish Bell's Palsy Study (Sullivan 2007); Cochrane Reviews Start steroids within 72 hours Class I, Level A Sullivan et al., NEJM 2007 Antivirals alone not effective Class I, Level A Cochrane Reviews 2015 Antivirals + steroids for severe Bell's Class II, Level B AAN Guidelines 2012 Antivirals mandatory for Ramsay Hunt Class I, Level B Multiple studies; AAN Guidelines Eye protection essential Class I, Level C Expert consensus ENoG for prognosis in severe cases Class II, Level B Multiple studies Surgical decompression controversial Class III, Level U Insufficient evidence Most patients recover without intervention Class I, Level A Natural history studies (70-80% full recovery)"},{"location":"plans/bells-palsy/#notes","title":"NOTES","text":"<ul> <li>Bell's palsy is a diagnosis of EXCLUSION - always evaluate for secondary causes</li> <li>Forehead involvement (peripheral pattern) distinguishes from stroke (forehead spared = central pattern)</li> <li>TIME-SENSITIVE: Steroids most effective if started within 72 hours of symptom onset</li> <li>Eye protection is critical and often under-emphasized - corneal ulceration is preventable</li> <li>Always examine the ear for vesicles (Ramsay Hunt syndrome requires antivirals)</li> <li>Prognosis: 70-80% full recovery; 15-20% have residual weakness; 5% have severe sequelae</li> <li>Poor prognostic factors: Complete paralysis (HB VI), no recovery by 3 weeks, age &gt;60, diabetes, Ramsay Hunt syndrome</li> <li>Synkinesis (aberrant regeneration) can develop during recovery - PT helps prevent/manage</li> <li>Recurrent Bell's palsy is uncommon (~7%); warrants additional workup</li> <li>Bilateral facial palsy is NOT Bell's palsy - requires workup for Lyme, GBS, sarcoidosis, etc.</li> </ul>"},{"location":"plans/bells-palsy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 29, 2026) - Initial template creation - House-Brackmann scale included - Ramsay Hunt syndrome distinguished and treatment specified - Eye protection emphasized as critical component - Lyme disease workup for endemic areas - Surgical options for refractory cases</p>"},{"location":"plans/brain-metastases/","title":"Brain Metastases","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Brain Metastases</p> <p>ICD-10: C79.31 (Secondary malignant neoplasm of brain), C79.32 (Secondary malignant neoplasm of cerebral meninges), C79.49 (Secondary malignant neoplasm of other parts of nervous system), G93.6 (Cerebral edema due to neoplasm)</p> <p>SYNONYMS: Brain metastases, brain mets, cerebral metastases, metastatic brain tumor, secondary brain cancer, brain tumor from cancer, metastatic disease to brain, brain lesions, CNS metastases</p> <p>SCOPE: Management of newly diagnosed or progressive brain metastases in adults. Covers initial stabilization, vasogenic edema management with corticosteroids, seizure management, imaging evaluation, molecular/histopathologic workup, treatment modalities (surgery, stereotactic radiosurgery, whole-brain radiation, systemic therapy with CNS penetration), and disposition. Excludes primary brain tumors (separate template), leptomeningeal carcinomatosis (partially addressed), and spinal metastases (separate template).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/brain-metastases/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/brain-metastases/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline; chemotherapy planning; leukocytosis/infection; thrombocytopenia (bleeding risk, treatment candidacy) WBC, platelets within normal limits; ALC (absolute lymphocyte count) for immunotherapy eligibility CMP (BMP + LFTs) STAT STAT ROUTINE STAT Renal function for contrast imaging; hepatic function for chemotherapy dosing; electrolytes (SIADH from brain lesions); glucose (steroid hyperglycemia) Normal; anticipate glucose elevation with dexamethasone PT/INR, aPTT STAT STAT ROUTINE STAT Coagulopathy assessment; surgical candidacy; hemorrhagic metastases (melanoma, RCC, choriocarcinoma, thyroid) Normal Blood glucose STAT STAT ROUTINE STAT Steroid-induced hyperglycemia; baseline before dexamethasone &lt;180 mg/dL; start insulin if persistently elevated Troponin STAT STAT - STAT Cardiac evaluation if syncope or neurogenic cardiac injury Normal Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE STAT Treatment planning; \u03b2-hCG-secreting tumors (choriocarcinoma, germ cell); radiation contraindication in pregnancy Negative; if elevated consider choriocarcinoma or germ cell tumor LDH STAT ROUTINE ROUTINE STAT Melanoma staging; tumor burden marker; prognostic Normal; elevated in melanoma, lymphoma TSH, free T4 - ROUTINE ROUTINE - Thyroid primary (thyroid cancer with brain metastases); fatigue/cognitive symptoms differential Normal; abnormal may indicate thyroid primary"},{"location":"plans/brain-metastases/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Tumor markers (CEA, CA 19-9, CA 125, CA 15-3, AFP, \u03b2-hCG) - ROUTINE ROUTINE - Unknown primary: CEA (lung, GI, breast), CA 19-9 (pancreatic, GI), CA 125 (ovarian), CA 15-3 (breast), AFP (hepatocellular, germ cell), \u03b2-hCG (choriocarcinoma, germ cell) Elevations guide primary site evaluation PSA (males) - ROUTINE ROUTINE - Prostate cancer with brain metastases (rare but occurs) Normal; elevated guides prostate workup Serum protein electrophoresis (SPEP) - ROUTINE ROUTINE - Lymphoma/myeloma differential for CNS mass lesion No monoclonal protein HIV, hepatitis B/C - ROUTINE ROUTINE - Primary CNS lymphoma (PCNSL) differential; immunosuppression assessment; treatment implications Negative ESR / CRP - ROUTINE ROUTINE - Infection differential (abscess vs. metastasis); inflammatory markers Normal Cortisol (AM) - ROUTINE ROUTINE - If pituitary metastasis suspected; before initiating dexamethasone if possible Normal (&gt;10 mcg/dL AM) Prolactin - ROUTINE ROUTINE - Pituitary metastasis differential Normal"},{"location":"plans/brain-metastases/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding CSF cytology / flow cytometry - EXT EXT - Leptomeningeal carcinomatosis evaluation; diagnostic if positive (sensitivity ~50% single LP, ~80% with repeat) Negative; positive = leptomeningeal disease CSF protein, glucose, cell count - EXT EXT - Leptomeningeal disease (elevated protein, low glucose, lymphocytic pleocytosis) Normal; elevated protein and low glucose suggest LMD Circulating tumor DNA (ctDNA) / liquid biopsy - EXT EXT - Unknown primary; molecular profiling when tissue biopsy not feasible; monitor treatment response Detectable mutations guide therapy Next-generation sequencing (NGS) - blood - EXT EXT - Identify actionable mutations (EGFR, ALK, BRAF, HER2, KRAS, ROS1) when tissue insufficient Actionable driver mutations Paraneoplastic antibody panel - EXT EXT - If clinical presentation suggests paraneoplastic syndrome mimicking or coexisting with metastatic disease Negative; positive changes management Methylmalonic acid, B12, folate - EXT ROUTINE - Cognitive decline differential Normal"},{"location":"plans/brain-metastases/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/brain-metastases/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediate in ED for acute presentation; identifies hemorrhage, mass effect, hydrocephalus Mass lesion(s), hemorrhage, edema, midline shift, hydrocephalus; hemorrhagic metastases suggest melanoma, RCC, choriocarcinoma, thyroid Pregnancy (benefit outweighs risk) MRI brain with and without contrast (gadolinium) STAT STAT URGENT STAT Within 24h of presentation; GOLD STANDARD for brain metastases; thin-cut (\u22641mm) 3D T1 post-contrast Number/size/location of metastases; ring-enhancement pattern; hemorrhagic component; leptomeningeal enhancement; dural-based vs. parenchymal MRI-incompatible implants; GFR &lt;30 (gadolinium risk); severe claustrophobia CT chest/abdomen/pelvis with contrast URGENT URGENT ROUTINE - Within 24-48h if unknown primary; staging for known primary Primary tumor identification; staging; additional metastatic disease Contrast allergy; renal impairment ECG (12-lead) STAT STAT - STAT Baseline; pre-treatment; QTc for anti-emetics/targeted therapies Normal None Chest X-ray STAT STAT - STAT Lung primary (most common source of brain metastases); pulmonary metastases; aspiration if obtunded Lung mass; effusion; lymphadenopathy Pregnancy (shield)"},{"location":"plans/brain-metastases/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications PET/CT (FDG) - ROUTINE ROUTINE - Outpatient or during hospitalization; staging; unknown primary identification; ~85% sensitivity for primary site Primary tumor; additional metastatic disease; lymph node involvement; treatment response assessment Uncontrolled diabetes (glucose &gt;200 impairs uptake); pregnancy CT angiography (head) URGENT URGENT - URGENT If hemorrhagic metastasis to evaluate vascularity; pre-surgical planning Tumor vascularity; relationship to major vessels Contrast allergy; renal impairment MR spectroscopy (MRS) - ROUTINE ROUTINE - Differentiating tumor from abscess or radiation necrosis; elevated choline:creatine ratio in tumor; lipid/lactate peak in necrosis Elevated choline, reduced NAA in tumor; elevated lipid/lactate in necrosis Same as MRI MR perfusion (DSC or DCE) - ROUTINE ROUTINE - Differentiating tumor recurrence from radiation necrosis; elevated rCBV in tumor Elevated rCBV (&gt;1.5-2.0) suggests tumor; low rCBV suggests radiation necrosis Same as MRI MRI spine (whole) with contrast - URGENT ROUTINE - If spinal symptoms or leptomeningeal disease suspected; staging for drop metastases Spinal metastases; leptomeningeal enhancement; cord compression Same as MRI Mammography / breast MRI (females) - ROUTINE ROUTINE - Breast cancer is 2nd most common source of brain metastases in women Breast mass or abnormality Breast implants (mammography may be limited) Stereotactic biopsy planning MRI - URGENT ROUTINE - If tissue diagnosis needed and surgical resection not planned; fiducial/frameless navigation sequences Biopsy trajectory planning; avoidance of eloquent cortex and vasculature Same as MRI"},{"location":"plans/brain-metastases/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Thallium SPECT or FET-PET - - EXT - Differentiating recurrent tumor vs. radiation necrosis when MR perfusion/spectroscopy equivocal Increased uptake = tumor; decreased uptake = necrosis Pregnancy Functional MRI (fMRI) - - EXT - Pre-surgical planning for metastases near eloquent cortex (motor, language areas) Motor/language cortex mapping relative to lesion Same as MRI Diffusion tensor imaging (DTI) / Tractography - - EXT - Pre-surgical planning; white matter tract relationship to tumor Tract displacement vs. infiltration Same as MRI CT-guided biopsy (extracranial) - ROUTINE ROUTINE - Biopsy accessible extracranial metastatic site rather than brain (safer, easier tissue acquisition) Histopathologic diagnosis; molecular profiling Coagulopathy; site-specific risks"},{"location":"plans/brain-metastases/#lumbar-puncture-if-indicated","title":"Lumbar Puncture (if indicated)","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP with CSF cytology, flow cytometry, protein, glucose, cell count - URGENT EXT URGENT If leptomeningeal disease suspected (cranial neuropathies, radiculopathy, headache, altered mentation without adequate parenchymal lesion to explain); MUST ensure no obstructive hydrocephalus or significant mass effect first Cytology: malignant cells (50% sensitivity single LP; repeat improves to ~80%); elevated opening pressure; elevated protein (&gt;50 mg/dL); low glucose (&lt;40 mg/dL or &lt;60% serum); lymphocytic pleocytosis CONTRAINDICATED if significant mass effect, large posterior fossa lesion, obstructive hydrocephalus, midline shift &gt;5mm (herniation risk); coagulopathy; local infection at LP site"},{"location":"plans/brain-metastases/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/brain-metastases/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Dexamethasone (vasogenic edema) STAT STAT URGENT STAT Symptomatic edema: 10 mg IV loading dose, then 4 mg IV/PO q6h; Moderate symptoms: 4-8 mg/day; Severe/impending herniation: 10 mg IV bolus then 4-8 mg IV q6h (up to 16-24 mg/day); Taper as soon as clinically feasible over 2-4 weeks; GI prophylaxis with PPI (omeprazole 20 mg daily) while on steroids; Monitor glucose q6h initially Dexamethasone is preferred corticosteroid (minimal mineralocorticoid effect, long half-life); symptomatic improvement in 24-72h; reduces vasogenic edema via BBB stabilization; no benefit in asymptomatic patients without edema (AVOID routine prophylactic use) Seizure management (acute) STAT STAT - STAT Active seizure: Lorazepam 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; Then: Levetiracetam 1000-1500 mg IV load (preferred - no drug interactions with chemotherapy) OR valproic acid 20-30 mg/kg IV load (avoid with hepatic metastases); Phenytoin/fosphenytoin only if above unavailable (interacts with many chemotherapies and targeted agents) Levetiracetam preferred: no hepatic enzyme induction (does NOT reduce efficacy of steroids, chemotherapy, or targeted agents), renal elimination, broad spectrum; AAN guidelines do NOT recommend prophylactic AEDs in brain tumor patients without seizures No prophylactic anticonvulsants STAT STAT ROUTINE STAT Do NOT start AEDs prophylactically in patients with brain metastases who have NOT had seizures; Applicable even peri-operatively (surgical prophylaxis may be used 7 days only per institutional protocol) AAN Practice Parameter (Glantz et al., 2000; reaffirmed): No evidence supporting prophylactic AED use in brain tumor patients; side effects outweigh benefits; ASCO guideline concordant Airway/ICP management (obtunded patient) STAT - - STAT GCS \u22648: Intubation; elevate HOB 30\u00b0; Acute herniation: Mannitol 1-1.5 g/kg IV bolus OR hypertonic saline (23.4% NaCl 30 mL via central line over 15 min or 3% NaCl 250 mL over 30 min); maintain PaCO2 30-35 mmHg (brief hyperventilation only as bridge to definitive treatment); Emergent neurosurgery consult for decompression ICP management as bridge to definitive treatment (surgery/radiation); prolonged hyperventilation causes cerebral ischemia; osmotherapy reduces cerebral edema DVT prophylaxis - STAT - STAT SCDs (sequential compression devices) immediately on admission; Pharmacologic prophylaxis: enoxaparin 40 mg SQ daily or heparin 5000 units SQ q8h - START within 24-48h unless hemorrhagic metastasis or planned surgery within 24h; Post-craniotomy: restart pharmacologic DVT ppx within 24-48h per neurosurgery guidance Brain tumor patients have 20-30% VTE risk; mechanical prophylaxis alone insufficient; pharmacologic prophylaxis does NOT significantly increase intracranial hemorrhage risk (Perry et al., 2009; AVERT trial) Stress ulcer prophylaxis STAT STAT ROUTINE STAT PPI (omeprazole 20 mg daily or pantoprazole 40 mg daily) while on dexamethasone; continue throughout steroid course Combined corticosteroid + critical illness increases GI bleed risk"},{"location":"plans/brain-metastases/#3b-definitivetargeted-treatment","title":"3B. Definitive/Targeted Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Surgical resection - URGENT - - Indications: Single (or limited \u22643) accessible metastasis; need for tissue diagnosis; symptomatic mass effect not responding to steroids; large lesion (&gt;3-4 cm) not suitable for SRS alone; good performance status (KPS \u226570); controlled systemic disease; life expectancy &gt;3 months; Post-op: MRI within 24-48h to assess residual; SRS to cavity within 2-4 weeks to reduce local recurrence (50-60% \u2192 15-20%) Patchell et al. (1990): Surgery + WBRT &gt; WBRT alone for single brain metastasis (median survival 40 vs. 15 weeks); Cavity SRS post-resection: Mahajan et al. (2017): local control improved with cavity SRS vs. observation Stereotactic radiosurgery (SRS) - URGENT ROUTINE - Indications: 1-4 metastases (most centers), up to 10-15 in select cases (JLGK0901); size \u22643-4 cm; Dose: Single fraction 15-24 Gy (dose based on size: \u22642cm: 20-24 Gy, 2.1-3cm: 18 Gy, 3.1-4cm: 15 Gy) OR fractionated SRS (3-5 fractions for larger lesions or eloquent location); Timing: Within 2-4 weeks of diagnosis; Serial MRI q2-3 months post-SRS Yamamoto et al. (JLGK0901): SRS alone for 2-10 metastases non-inferior to 2-4 for survival; SRS vs. WBRT: better cognitive preservation (NCCTG N0574, Brown et al., 2016); SRS + HA-WBRT vs SRS alone per NRG-CC003 Whole-brain radiation therapy (WBRT) - URGENT ROUTINE - Indications: &gt;10-15 metastases; leptomeningeal disease; poor surgical/SRS candidates; miliary/diffuse pattern; Standard: 30 Gy in 10 fractions (or 20 Gy in 5 fractions for poor prognosis); Hippocampal avoidance (HA-WBRT): Preferred when technically feasible (no metastases within 5mm of hippocampus): 30 Gy in 10 fractions with hippocampal sparing + memantine 20 mg daily starting with WBRT x 6 months HA-WBRT + memantine (NRG-CC001, Brown et al., 2020): significantly less cognitive deterioration vs. standard WBRT + memantine at 4 and 6 months; Memantine alone (RTOG 0614): trend toward better cognitive function Systemic therapy with CNS activity - ROUTINE ROUTINE - NSCLC with EGFR mutation: Osimertinib 80 mg daily (CNS response rate 91%); NSCLC with ALK rearrangement: Lorlatinib 100 mg daily (intracranial response 82%) or alectinib 600 mg BID (CNS response 81%); NSCLC with ROS1: Lorlatinib; Melanoma with BRAF V600: Dabrafenib + trametinib (intracranial response 58%) or encorafenib + binimetinib; Melanoma (any): Ipilimumab + nivolumab (intracranial response 46-57% in asymptomatic); HER2+ breast: Tucatinib + trastuzumab + capecitabine (HER2CLIMB: intracranial response 47%); Breast (HR+): Abemaciclib (some CNS activity); RCC: Nivolumab + ipilimumab or cabozantinib CNS-penetrant systemic therapy increasingly used as upfront or adjunct to SRS; may defer radiation in asymptomatic patients with actionable mutations and small metastases; Always coordinate with medical oncology Corticosteroid taper - ROUTINE ROUTINE - Begin taper once definitive treatment initiated and symptoms improving; Taper schedule: Reduce by 2 mg every 3-5 days (from 16 mg/day: 16\u219212\u21928\u21926\u21924\u21922\u21921\u2192off); Slower taper if symptoms recur; Monitor for adrenal insufficiency if &gt;3 weeks of steroid use Prolonged steroids cause significant morbidity: hyperglycemia, myopathy (steroid myopathy can be debilitating), immunosuppression, osteoporosis, PJP risk, insomnia, psychiatric effects, GI bleeding"},{"location":"plans/brain-metastases/#3c-adjunctive-treatment","title":"3C. Adjunctive Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Levetiracetam (post-seizure maintenance) - STAT ROUTINE STAT 500-1500 mg PO/IV BID (start 500 mg BID, titrate to seizure control); Renal dosing if GFR &lt;50; No drug interactions with chemotherapy, targeted therapy, or steroids Preferred AED in brain tumor patients due to no CYP enzyme induction; does not reduce efficacy of dexamethasone, temozolomide, or targeted agents PJP prophylaxis - ROUTINE ROUTINE - If dexamethasone &gt;20 mg/week AND concomitant temozolomide or immunosuppression: TMP-SMX 1 DS tablet 3x/week (Mon/Wed/Fri) OR atovaquone 1500 mg daily if sulfa allergic Risk of Pneumocystis with prolonged corticosteroids + additional immunosuppression Glucose management (steroid-induced) STAT STAT ROUTINE STAT Fingerstick glucose q6h while on dexamethasone; Sliding scale insulin initially; Basal-bolus insulin if persistently &gt;180 mg/dL; Anticipate glucose elevation typically 4-8 hours after steroid dose; May need 2-3x baseline insulin requirements Dexamethasone causes significant hyperglycemia in 50-60% of patients; uncontrolled hyperglycemia worsens outcomes Calcium/Vitamin D - ROUTINE ROUTINE - Calcium 1000-1200 mg + Vitamin D 800-1000 IU daily while on prolonged steroids (&gt;2 weeks) Steroid-induced osteoporosis prevention Anti-emetics (for radiation/chemotherapy) - ROUTINE ROUTINE - Ondansetron 4-8 mg IV/PO q8h PRN; Dexamethasone itself is anti-emetic; Avoid metoclopramide in brain metastases patients (extrapyramidal effects) Nausea common with elevated ICP and with radiation therapy Memantine (with WBRT) - ROUTINE ROUTINE - 5 mg daily x1 week \u2192 5 mg BID x1 week \u2192 10 mg AM + 5 mg PM x1 week \u2192 10 mg BID; Continue for 6 months total; Start day 1 of WBRT RTOG 0614 and NRG-CC001: cognitive protection during WBRT; NMDA receptor antagonist reduces excitotoxic neuronal injury from radiation"},{"location":"plans/brain-metastases/#3d-medications-to-avoid-or-use-with-caution","title":"3D. Medications to AVOID or Use with Caution","text":"Medication Risk/Concern Alternative Prophylactic anticonvulsants (in patients without seizures) No evidence of benefit; significant side effects (fatigue, rash, cognitive impairment); drug interactions with chemotherapy Only treat seizures if they occur; levetiracetam first-line Phenytoin / Carbamazepine / Phenobarbital (enzyme-inducing AEDs) Potent CYP3A4 induction reduces efficacy of dexamethasone, many chemotherapies (temozolomide, irinotecan, paclitaxel), targeted therapies (EGFR/ALK inhibitors), and immunotherapy metabolism Levetiracetam, lacosamide, brivaracetam (non-enzyme-inducing AEDs) Bevacizumab (concurrent with surgery) Impaired wound healing; hold 4-6 weeks before and 4 weeks after surgery Coordinate timing with surgical and medical oncology teams Anticoagulation (full-dose, peri-operative) Increased hemorrhage risk, especially with hemorrhagic metastases (melanoma, RCC); hold for procedures Mechanical prophylaxis peri-operatively; restart anticoagulation 24-48h post-procedure per neurosurgery guidance Methotrexate (high-dose, with brain radiation) Severe leukoencephalopathy when given concurrently or within weeks of cranial radiation Sequence treatments; MTX before radiation if needed Live vaccines (while on dexamethasone or chemotherapy) Immunosuppression risk; disseminated infection Inactivated vaccines; defer live vaccines until immune recovery Lumbar puncture (with large posterior fossa lesion / significant mass effect) Herniation risk Imaging first; neurosurgery consultation; consider Ommaya reservoir for recurrent CSF sampling"},{"location":"plans/brain-metastases/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/brain-metastases/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurosurgery consultation STAT STAT ROUTINE STAT For surgical candidacy evaluation (single/oligometastases, mass effect, tissue diagnosis need); emergency for herniation/acute hydrocephalus Radiation oncology consultation - URGENT ROUTINE - SRS vs. WBRT vs. HA-WBRT decision; coordinate with surgery (post-resection cavity SRS within 2-4 weeks) Medical oncology consultation - URGENT ROUTINE - Systemic therapy options; molecular profiling for targeted agents; staging; prognosis; clinical trial eligibility Multidisciplinary tumor board - URGENT ROUTINE - Brain metastases management requires coordinated neurosurgery, radiation oncology, medical oncology, neuroradiology input; optimal sequencing of treatments Goals of care discussion - URGENT ROUTINE URGENT Discuss prognosis, treatment intent (curative vs. palliative), quality of life, code status; especially important for patients with limited systemic options or poor functional status (KPS &lt;50) Pathology review with molecular profiling - URGENT ROUTINE - Confirm tissue diagnosis; molecular testing (NGS panel for EGFR, ALK, ROS1, BRAF, HER2, KRAS G12C, NTRK, RET, MET); PD-L1 (TPS and CPS); hormone receptors (breast); BRAF V600 (melanoma) Fall precautions STAT STAT ROUTINE STAT Brain metastases patients at high risk for falls (focal deficits, seizures, steroid myopathy, cognitive impairment); Remove fall hazards; PT/OT evaluation Driving restrictions - ROUTINE ROUTINE - Advise against driving if seizures, visual field deficits, significant cognitive impairment, or posterior fossa lesions affecting coordination; State-specific reporting requirements"},{"location":"plans/brain-metastases/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Palliative care consultation - ROUTINE ROUTINE - Symptom management; goals of care facilitation; advance care planning; coordination of hospice if appropriate Neuropsychology evaluation - - ROUTINE - Baseline cognitive assessment before radiation treatment; monitor cognitive decline; guide rehabilitation Physical/occupational therapy - ROUTINE ROUTINE - Functional assessment; mobility training; ADL assistance; steroid myopathy mitigation (exercise program) Speech-language pathology - ROUTINE ROUTINE - If aphasia, dysarthria, dysphagia from metastasis location; swallow evaluation if posterior fossa lesion or obtunded Social work / case management - ROUTINE ROUTINE - Insurance authorization for SRS/radiation; transportation; caregiver support; disability paperwork Genetic counseling - - ROUTINE - If young patient or cancer predisposition syndrome suspected (Li-Fraumeni, BRCA, Lynch) Clinical trials evaluation - ROUTINE ROUTINE - Active brain metastases trials (immunotherapy combinations, targeted agents, radiosensitizers); NCI clinical trials database; institutional trials Ophthalmology consultation - ROUTINE ROUTINE - If visual complaints, papilledema, metastasis near visual pathways; formal visual fields testing"},{"location":"plans/brain-metastases/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Repeat biopsy / resection - URGENT ROUTINE - If radiation necrosis vs. recurrence unclear after advanced imaging (MR perfusion, MRS, PET); tissue diagnosis changes management Ommaya reservoir placement - ROUTINE ROUTINE - Recurrent leptomeningeal disease requiring intrathecal chemotherapy; avoids repeated lumbar punctures Intrathecal chemotherapy - ROUTINE ROUTINE - Leptomeningeal carcinomatosis: methotrexate 12 mg IT or cytarabine (liposomal) 50 mg IT q2 weeks; via Ommaya reservoir; limited efficacy data Laser interstitial thermal therapy (LITT) - ROUTINE ROUTINE - MRI-guided laser ablation for recurrent metastases in deep or eloquent locations; radiation necrosis treatment Re-irradiation (SRS for recurrence) - - ROUTINE - SRS for recurrent metastases after prior SRS or WBRT; consider cumulative dose to normal brain; risk of radiation necrosis increases Bevacizumab for radiation necrosis - ROUTINE ROUTINE - 7.5 mg/kg IV q3 weeks for symptomatic radiation necrosis refractory to steroids; significant improvement in ~65% of patients (Levin et al., 2011) Hospice referral - ROUTINE ROUTINE - Poor prognosis (DS-GPA &lt;1.0), declining functional status, exhausted treatment options, patient/family preference for comfort-focused care <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/brain-metastases/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/brain-metastases/#primary-differential-diagnoses","title":"Primary Differential Diagnoses","text":"Diagnosis Key Differentiating Features Distinguishing Studies Primary brain tumor (GBM, astrocytoma) Usually single; irregular enhancement; often involves corpus callosum (butterfly GBM); no known systemic cancer; infiltrative margins; surrounding FLAIR/T2 more extensive; restricted diffusion at tumor margins MRI pattern; MR spectroscopy (elevated choline:creatine, reduced NAA); biopsy (IDH, MGMT, 1p19q); no systemic disease on staging CT/PET Primary CNS lymphoma (PCNSL) Periventricular location; homogeneously enhancing; restricted diffusion; may be multifocal; immunocompromised patients; responds dramatically to corticosteroids (may \"disappear\" = ghost tumor); typically does NOT ring-enhance unless HIV MRI with diffusion restriction; AVOID steroids before biopsy if possible (may render biopsy non-diagnostic); CSF flow cytometry; vitreous biopsy if ocular involvement; HIV testing; slit lamp exam Brain abscess Ring-enhancing lesion with restricted diffusion on DWI (bright on DWI, dark on ADC in the cavity \u2014 metastases typically do NOT show central restricted diffusion); fever, elevated WBC; recent sinusitis/otitis/dental procedure/endocarditis; thin smooth enhancing rim; satellite lesions DWI: central restricted diffusion is KEY distinguishing feature; MR spectroscopy: amino acid peaks (succinate, acetate, lactate); blood cultures; echocardiogram; source identification Toxoplasmosis (immunocompromised) HIV/AIDS (CD4 &lt;100); multiple ring-enhancing lesions; basal ganglia predilection; eccentric target sign; edema/mass effect Toxoplasma IgG (serum); CD4 count; empiric treatment trial (response in 10-14 days supports diagnosis); if no response \u2192 biopsy; Thallium SPECT (increased uptake = lymphoma, not toxoplasmosis) Demyelinating disease (tumefactive MS, ADEM) Incomplete ring enhancement (open ring sign); younger patients; clinical dissemination in time/space; less mass effect relative to lesion size; leading edge enhancement MRI: open ring enhancement, T2/FLAIR lesions in MS-typical locations; CSF: oligoclonal bands; MOG/AQP4 antibodies; clinical response to steroids Radiation necrosis History of prior brain radiation (typically 6-24 months post-treatment but can occur later); enhancing lesion at site of prior radiation; difficult to distinguish from recurrent tumor on conventional MRI MR perfusion: LOW rCBV (vs. tumor with HIGH rCBV); MR spectroscopy: elevated lipid/lactate, low choline; PET: low FDG uptake (vs. tumor with high uptake); biopsy if equivocal Neurocysticercosis Travel/residence in endemic area (Latin America, sub-Saharan Africa, Southeast Asia); cystic lesions with scolex (dot within cyst); often calcified in chronic phase; seizure is common presentation MRI: cystic lesion with scolex; CT: calcified granulomas; serology (cysticercosis antibodies); stool ova/parasites Cerebral infarct (subacute) Vascular territory distribution; ring enhancement at 1-4 weeks post-stroke (luxury perfusion); clinical history of acute onset; DWI abnormalities conforming to vascular territory Timing of enhancement (subacute strokes enhance transiently); vascular territory distribution; DWI/ADC map evolution; clinical history of acute onset"},{"location":"plans/brain-metastases/#red-flags-requiring-urgent-reassessment","title":"Red Flags Requiring Urgent Reassessment","text":"Red Flag Concern Action Rapid neurologic decline Hemorrhage into metastasis; acute hydrocephalus; herniation STAT CT head; neurosurgery STAT; consider intubation New seizure (first-time) Peri-tumoral irritation; hemorrhage; edema worsening; leptomeningeal spread CT head (rule out hemorrhage); start AED (levetiracetam); re-image with MRI Worst headache of life / thunderclap Hemorrhagic metastasis (especially melanoma, RCC); pituitary apoplexy from pituitary metastasis STAT CT head; CT angiography if SAH pattern Fever + mental status changes Brain abscess (metastasis can be misdiagnosed as abscess and vice versa); infection in immunocompromised patient; central fever from brain lesion Blood cultures; CT head; LP if safe; broad-spectrum antibiotics if infection suspected Acute vision loss Pituitary metastasis with apoplexy; optic nerve/chiasm compression STAT MRI; ophthalmology/neurosurgery STAT Progressive bilateral leg weakness Spinal cord compression from spinal metastases; leptomeningeal disease affecting cauda equina STAT MRI whole spine; dexamethasone 10 mg IV; neurosurgery/radiation oncology STAT Cushing syndrome features (steroid complications) Prolonged dexamethasone; immunosuppression; hyperglycemia; myopathy; osteoporosis Taper steroids; manage complications; alternative edema management (bevacizumab for radiation necrosis)"},{"location":"plans/brain-metastases/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/brain-metastases/#acute-phase-monitoring-first-72h","title":"Acute Phase Monitoring (First 72h)","text":"Parameter Frequency Target Action if Abnormal Neurologic checks (GCS, pupil reactivity, motor exam, speech) q1-2h in ICU; q2-4h on floor Stable or improving exam Stat CT head if decline; neurosurgery alert; consider increasing dexamethasone or osmotherapy Blood glucose q6h (q1h if insulin drip) 140-180 mg/dL Sliding scale \u2192 basal-bolus insulin; typically requires 2-3x baseline insulin on dexamethasone Blood pressure Continuous in ICU; q4h on floor SBP &lt;160 (avoid hypertensive hemorrhage into metastasis) Antihypertensives PRN; avoid excessive hypotension (SBP &gt;100 to maintain cerebral perfusion) Fluid balance / I&amp;O q8h Euvolemia Hyponatremia common (SIADH, cerebral salt wasting); free water restriction if SIADH Sodium q6-8h initially 135-145 mEq/L If &lt;130: fluid restrict; if &lt;125 or symptomatic: 3% NaCl; if rapidly dropping: urgent sodium correction Seizure monitoring Continuous observation; consider cEEG if altered mental status No seizures; no subclinical seizures AED initiation/adjustment; neurology consultation; continuous EEG monitoring Pain assessment q4h NRS &lt;4/10 Acetaminophen 650-1000 mg q6h; dexamethasone (reduces headache from edema); opioids PRN for moderate-severe"},{"location":"plans/brain-metastases/#subacuteoutpatient-monitoring","title":"Subacute/Outpatient Monitoring","text":"Parameter Frequency Target Action if Abnormal MRI brain with contrast q2-3 months for first year post-treatment, then q3-4 months year 2, then q6 months Stable/decreasing lesion size; no new metastases New/progressive lesions: repeat multidisciplinary discussion; salvage SRS, surgery, systemic therapy change Neurologic examination Each clinic visit (q2-4 weeks during treatment, q1-3 months maintenance) Stable or improved New deficits: urgent MRI; consider tumor progression vs. radiation necrosis vs. new metastasis KPS / ECOG performance status Each visit KPS \u226570 / ECOG 0-2 for active treatment KPS &lt;50 / ECOG \u22653: reassess goals of care; transition to supportive/palliative care Steroid taper progress Each visit Off dexamethasone or minimal dose Steroid-dependent edema: consider bevacizumab, re-irradiation, or resection to enable taper Blood glucose (while on steroids) Daily fingerstick; HbA1c monthly Fasting &lt;130; random &lt;180 Insulin titration; endocrine consultation if difficult to control CBC (if on chemotherapy) Per chemotherapy cycle protocol; typically q2-3 weeks ANC &gt;1500, platelets &gt;100,000 Hold/dose-reduce chemotherapy; growth factor support Hepatic/renal function Monthly during systemic therapy Normal Dose adjustment; drug-specific monitoring per protocol Neurocognitive screening q3-6 months; MoCA or formal neuropsychological testing Stable cognitive function Cognitive rehabilitation; medication review; assess for depression; differentiate radiation injury vs. progression Depression/anxiety screening (PHQ-9) Each visit PHQ-9 &lt;5 SSRI (avoid CYP interactions); psychology referral; supportive care"},{"location":"plans/brain-metastases/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/brain-metastases/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU admission GCS \u226412; signs of herniation (pupil asymmetry, posturing, Cushing triad); acute hemorrhage into metastasis with neurologic decline; post-craniotomy (first 24h); status epilepticus; respiratory compromise requiring intubation; hemodynamic instability General neurology/neurosurgery floor New diagnosis requiring workup and treatment planning; symptomatic edema requiring IV dexamethasone; post-seizure requiring monitoring and AED optimization; post-craniotomy (step-down from ICU); functional decline requiring inpatient rehabilitation planning Observation (\u226424h) Known brain metastases with mild symptom change; MRI revealing progression but patient clinically stable; steroid dose adjustment with monitoring"},{"location":"plans/brain-metastases/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Neurologic stability Stable or improving neurologic exam for \u226524h on current steroid dose; no new deficits Seizure control Seizure-free \u226524h on oral AED; no breakthrough seizures; AED levels therapeutic if applicable Steroid plan Oral dexamethasone regimen established with clear taper schedule; glucose management plan in place Pain control Headache adequately controlled on oral medications Treatment plan established Multidisciplinary plan documented (surgery, radiation, systemic therapy); appointments scheduled within 1-2 weeks Functional safety Safe ambulation (with or without assistive device); safe swallowing; able to perform basic ADLs or adequate caregiver support VTE plan Transition to pharmacologic prophylaxis or therapeutic anticoagulation plan if VTE occurred Follow-up arranged Neurosurgery (1-2 weeks if post-op), radiation oncology (1-2 weeks for SRS/WBRT planning), medical oncology (1-2 weeks), PCP (1 week for steroid monitoring); MRI brain scheduled at appropriate interval Patient/family education Understanding of diagnosis, treatment plan, steroid side effects, seizure precautions, when to return to ED (acute headache, new weakness, seizure, vision changes, fever)"},{"location":"plans/brain-metastases/#discharge-prescriptions-checklist","title":"Discharge Prescriptions Checklist","text":"Medication Details Dexamethasone Taper schedule clearly documented (e.g., 4 mg q6h x 3 days \u2192 4 mg q8h x 3 days \u2192 4 mg q12h x 3 days \u2192 4 mg daily x 3 days \u2192 2 mg daily x 3 days \u2192 stop) PPI Omeprazole 20 mg daily or pantoprazole 40 mg daily while on steroids AED (if seizure occurred) Levetiracetam dose and frequency; DO NOT start if no seizure history Insulin (if needed) Sliding scale or basal-bolus regimen for steroid-induced hyperglycemia; glucometer and supplies Calcium + Vitamin D If steroids &gt;2 weeks anticipated DVT prophylaxis (if applicable) Enoxaparin transition plan if VTE occurred Analgesics Acetaminophen; limited opioid prescription if needed TMP-SMX (if applicable) If on high-dose steroids + chemotherapy (PJP prophylaxis)"},{"location":"plans/brain-metastases/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/brain-metastases/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Management of Brain Metastases Congress of Neurological Surgeons (CNS) / AANS Systematic Review 2019 Surgery for single accessible metastasis with mass effect; SRS for limited brain metastases (1-4); WBRT for multiple (&gt;10-15) or leptomeningeal disease; avoid prophylactic AEDs Brain Metastases Molecular Testing NCCN Central Nervous System Cancers v1.2025 Comprehensive molecular profiling for actionable targets (EGFR, ALK, ROS1, BRAF, HER2, KRAS G12C, NTRK, RET, MET, PD-L1); guide systemic therapy selection Prophylactic Anticonvulsants AAN Practice Parameter (Glantz et al.) 2000 (reaffirmed) Routine prophylactic AEDs NOT recommended in brain tumor patients without seizures Hippocampal Avoidance WBRT NRG-CC001 (Brown et al.) 2020 HA-WBRT + memantine superior to standard WBRT + memantine for cognitive preservation SRS for Multiple Brain Metastases JLGK0901 (Yamamoto et al.) 2014 SRS for 5-10 metastases non-inferior to 2-4 for overall survival Cognitive Outcomes SRS vs. WBRT NCCTG N0574 (Brown et al.) 2016 SRS alone superior to SRS + WBRT for cognitive preservation; no overall survival difference"},{"location":"plans/brain-metastases/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Patchell et al. (1990) Surgery + WBRT vs. WBRT alone for single brain metastasis: median survival 40 vs. 15 weeks; lower recurrence at original site (20% vs. 52%) Established surgery as standard for single brain metastasis Patchell et al. (1998) Post-operative WBRT reduced brain recurrence (18% vs. 70%) but no survival benefit; improved neurologic death Supported adjuvant radiation after surgery; now often SRS to cavity instead of WBRT Mahajan et al. (2017) - MD Anderson SRS to surgical cavity vs. observation: 12-month local recurrence 28% vs. 59% (HR 0.46) Established post-operative cavity SRS as standard of care Brown et al. (2016) - NCCTG N0574 SRS alone vs. SRS + WBRT: cognitive deterioration at 3 months 64% vs. 92%; no OS difference Shifted practice toward SRS alone with surveillance MRI rather than WBRT Yamamoto et al. (2014) - JLGK0901 SRS for 5-10 vs. 2-4 brain metastases: similar overall survival (10.8 vs. 10.8 months) Expanded SRS indications to higher numbers of metastases Brown et al. (2020) - NRG-CC001 HA-WBRT + memantine vs. WBRT + memantine: less cognitive deterioration at 4 months (59% vs. 68%) and 6 months; less decline in executive function and memory HA-WBRT + memantine = new standard when WBRT indicated Tawbi et al. (2018) - CheckMate 204 Ipilimumab + nivolumab in melanoma brain metastases: intracranial response 57% in asymptomatic patients Established immunotherapy as upfront option for melanoma brain metastases Reungwetwattana et al. (2018) - FLAURA CNS analysis Osimertinib CNS response rate 91% in EGFR-mutant NSCLC with brain metastases vs. 68% standard EGFR TKI Established osimertinib as preferred first-line for EGFR+ NSCLC with brain metastases Murthy et al. (2020) - HER2CLIMB Tucatinib + trastuzumab + capecitabine: intracranial response 47%; CNS-PFS 9.9 vs. 4.2 months; OS benefit in brain metastases subgroup Established tucatinib combination as standard for HER2+ breast cancer brain metastases Perry et al. (2009) - PRODIGE Dalteparin vs. placebo in malignant glioma: no increase in intracranial hemorrhage with anticoagulation; VTE reduction Supported pharmacologic DVT prophylaxis in brain tumor patients Levin et al. (2011) Bevacizumab for radiation necrosis: significant radiographic and clinical improvement in ~65% of patients Established bevacizumab as treatment option for symptomatic radiation necrosis refractory to steroids"},{"location":"plans/brain-metastases/#grading-scales","title":"Grading Scales","text":"<p>Diagnosis-Specific Graded Prognostic Assessment (DS-GPA)</p> Component Score = 0 Score = 0.5 Score = 1.0 Age (years) &gt;60 50-60 &lt;50 KPS &lt;70 70-80 90-100 Number of CNS metastases &gt;3 2-3 1 Extracranial metastases Present - Absent <p>Note: DS-GPA varies by primary tumor type. The above is the general framework. Lung-molGPA incorporates molecular markers (EGFR, ALK). Melanoma-molGPA incorporates BRAF status. Breast-GPA incorporates receptor status (HR/HER2). Always use the disease-specific GPA tool.</p> DS-GPA Score (general) Median Survival 0-1.0 2.6 months 1.5-2.0 4.4 months 2.5-3.0 9.4 months 3.5-4.0 14.8 months <p>Recursive Partitioning Analysis (RPA) Classification (RTOG)</p> Class Criteria Median Survival Class I KPS \u226570, age &lt;65, controlled primary, no extracranial metastases 7.1 months Class II All other patients 4.2 months Class III KPS &lt;70 2.3 months <p>Karnofsky Performance Status (KPS)</p> Score Description 100 Normal, no complaints 90 Able to carry on normal activity; minor signs/symptoms 80 Normal activity with effort; some signs/symptoms 70 Cares for self; unable to carry on normal activity or active work 60 Requires occasional assistance but cares for most needs 50 Requires considerable assistance and frequent medical care 40 Disabled; requires special care and assistance 30 Severely disabled; hospitalization indicated, death not imminent 20 Very sick; active supportive treatment needed 10 Moribund"},{"location":"plans/brain-metastases/#appendices","title":"APPENDICES","text":""},{"location":"plans/brain-metastases/#appendix-a-most-common-primary-sites-of-brain-metastases","title":"Appendix A: Most Common Primary Sites of Brain Metastases","text":"Primary Cancer Approximate Frequency Typical MRI Features Key Molecular Targets Lung (NSCLC) 40-50% of brain metastases Multiple; any location; may hemorrhage; often ring-enhancing EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET, RET, NTRK, PD-L1 Lung (SCLC) 10-15% Multiple; tend to be small; prophylactic cranial irradiation (PCI) standard in limited-stage SCLC with response PD-L1; limited targeted options Breast 15-25% HER2+ and triple-negative most commonly metastasize to brain; may be hemorrhagic; dural-based possible HER2 (tucatinib, T-DXd), HR+ (CDK4/6 inhibitors \u2014 limited CNS data), PD-L1 (triple-negative) Melanoma 5-15% Hemorrhagic (T1-hyperintense on pre-contrast MRI due to melanin and blood); multiple; any location BRAF V600 (dabrafenib + trametinib), PD-1 + CTLA-4 (ipilimumab + nivolumab) Renal cell carcinoma 5-10% Highly vascular; hemorrhagic; large lesions; significant surrounding edema TKIs (cabozantinib), immunotherapy (ipilimumab + nivolumab) Colorectal 3-5% Posterior fossa predilection; typically late in disease KRAS, BRAF, MSI-H/dMMR (pembrolizumab) Unknown primary 5-10% Variable Comprehensive molecular profiling essential"},{"location":"plans/brain-metastases/#appendix-b-hemorrhagic-brain-metastases-high-risk-primaries","title":"Appendix B: Hemorrhagic Brain Metastases \u2014 High-Risk Primaries","text":"<p>Mnemonic: \"MR CT\" \u2014 Melanoma, Renal cell carcinoma, Choriocarcinoma, Thyroid</p> Primary Hemorrhage Risk Management Considerations Melanoma Very high (40-50% hemorrhagic) T1 hyperintense from melanin + blood; SRS preferred over surgery when feasible (hemorrhage risk during resection); immunotherapy may be used upfront Renal cell carcinoma High (30-40% hemorrhagic) Highly vascular; pre-operative embolization considered; hemorrhage may be presenting symptom Choriocarcinoma Very high \u03b2-hCG markedly elevated; chemotherapy highly effective; hemorrhage may be initial presentation Thyroid (papillary/follicular) Moderate Often indolent; radioactive iodine does NOT treat brain metastases (insufficient BBB penetration); surgery or SRS needed Lung (NSCLC on anticoagulation) Moderate Stop anticoagulation if hemorrhagic metastasis; reverse if on warfarin/DOACs"},{"location":"plans/brain-metastases/#appendix-c-cns-penetrant-systemic-therapies-quick-reference","title":"Appendix C: CNS-Penetrant Systemic Therapies \u2014 Quick Reference","text":"Cancer Type Drug CNS Response Rate Key Trial NSCLC, EGFR+ Osimertinib 80 mg daily 91% FLAURA (Reungwetwattana 2018) NSCLC, ALK+ Lorlatinib 100 mg daily 82% CROWN (Shaw 2020) NSCLC, ALK+ Alectinib 600 mg BID 81% ALEX (Peters 2017) NSCLC, ROS1+ Lorlatinib 100 mg daily ~60% Phase II data Melanoma, BRAF+ Dabrafenib 150 mg BID + trametinib 2 mg daily 58% COMBI-MB (Davies 2017) Melanoma, any Ipilimumab 3 mg/kg + nivolumab 1 mg/kg 46-57% CheckMate 204 (Tawbi 2018) HER2+ breast Tucatinib + trastuzumab + capecitabine 47% HER2CLIMB (Murthy 2020) HER2+ breast Trastuzumab deruxtecan (T-DXd) 63.9% DESTINY-Breast03 (Cort\u00e9s 2022) Triple-negative breast Sacituzumab govitecan Limited CNS data ASCENT (exploratory) RCC Cabozantinib 60 mg daily ~55% (retrospective) Retrospective series RCC Ipilimumab + nivolumab ~28% (brain met subgroup) CheckMate 214 (subgroup)"},{"location":"plans/brain-metastases/#appendix-d-treatment-algorithm-decision-framework","title":"Appendix D: Treatment Algorithm \u2014 Decision Framework","text":"<pre><code>BRAIN METASTASES DIAGNOSED\n         \u2502\n         \u251c\u2500\u2500 Acute presentation (symptomatic edema, obtundation, herniation)?\n         \u2502         YES \u2192 Dexamethasone 10 mg IV \u2192 ICU if herniation \u2192 Emergent neurosurgery\n         \u2502         NO \u2192 Dexamethasone only if symptomatic edema present\n         \u2502\n         \u251c\u2500\u2500 Number of metastases?\n         \u2502         \u2502\n         \u2502         \u251c\u2500\u2500 1 (single)\n         \u2502         \u2502     \u251c\u2500\u2500 Surgically accessible + mass effect \u2192 Surgery \u2192 Cavity SRS\n         \u2502         \u2502     \u251c\u2500\u2500 Not surgical candidate \u2192 SRS (single fraction or fractionated)\n         \u2502         \u2502     \u2514\u2500\u2500 With actionable mutation \u2192 Consider systemic first (e.g., osimertinib, ipi/nivo)\n         \u2502         \u2502\n         \u2502         \u251c\u2500\u2500 2-4 (oligometastases)\n         \u2502         \u2502     \u251c\u2500\u2500 All \u22643-4 cm \u2192 SRS (each lesion)\n         \u2502         \u2502     \u251c\u2500\u2500 1 large + others small \u2192 Surgery for large + SRS for others\n         \u2502         \u2502     \u2514\u2500\u2500 With actionable mutation \u2192 Systemic + SRS\n         \u2502         \u2502\n         \u2502         \u251c\u2500\u2500 5-15\n         \u2502         \u2502     \u251c\u2500\u2500 Select patients \u2192 SRS (JLGK0901 data supports up to 10-15)\n         \u2502         \u2502     \u251c\u2500\u2500 Good systemic options \u2192 Systemic therapy + SRS\n         \u2502         \u2502     \u2514\u2500\u2500 Poor SRS candidate \u2192 HA-WBRT + memantine\n         \u2502         \u2502\n         \u2502         \u2514\u2500\u2500 &gt;15 or miliary/diffuse\n         \u2502               \u2514\u2500\u2500 HA-WBRT + memantine (if hippocampus-sparing feasible)\n         \u2502                   OR standard WBRT + memantine\n         \u2502\n         \u251c\u2500\u2500 Molecular profiling?\n         \u2502         \u251c\u2500\u2500 EGFR+ NSCLC \u2192 Osimertinib (may defer radiation for small, asymptomatic)\n         \u2502         \u251c\u2500\u2500 ALK+ NSCLC \u2192 Lorlatinib or alectinib\n         \u2502         \u251c\u2500\u2500 BRAF+ melanoma \u2192 Dabrafenib + trametinib \u00b1 SRS\n         \u2502         \u251c\u2500\u2500 Melanoma (any) \u2192 Ipilimumab + nivolumab \u00b1 SRS\n         \u2502         \u251c\u2500\u2500 HER2+ breast \u2192 Tucatinib combo or T-DXd \u00b1 SRS\n         \u2502         \u2514\u2500\u2500 No actionable target \u2192 Radiation + standard systemic\n         \u2502\n         \u2514\u2500\u2500 Surveillance post-treatment\n                   \u2514\u2500\u2500 MRI brain q2-3 months year 1 \u2192 q3-4 months year 2 \u2192 q6 months ongoing\n                       New/progressive lesion \u2192 Salvage SRS, surgery, or systemic change\n                       Suspected radiation necrosis \u2192 Advanced imaging \u2192 Bevacizumab if confirmed\n</code></pre>"},{"location":"plans/brain-metastases/#appendix-e-steroid-dosing-and-taper-guide","title":"Appendix E: Steroid Dosing and Taper Guide","text":"Clinical Scenario Initial Dexamethasone Dose Duration Before Taper Taper Schedule Mild symptoms, small edema 4 mg/day (2 mg BID) 3-5 days Reduce by 1 mg every 3-5 days Moderate symptoms 8-12 mg/day (4 mg q6-8h) 5-7 days Reduce by 2 mg every 3-5 days Severe edema / mass effect 16 mg/day (4 mg q6h) 7-14 days Reduce by 2-4 mg every 3-5 days Impending herniation 10 mg IV bolus \u2192 4-8 mg q6h (up to 24 mg/day) Until definitive treatment Taper after surgery/radiation with clinical monitoring Post-SRS 4-8 mg/day starting day of SRS 3-7 days Rapid taper over 5-7 days if no worsening Steroid-dependent (cannot taper) Minimum effective dose Ongoing Consider bevacizumab, re-irradiation, or resection to enable taper <p>Key steroid complications to monitor: Hyperglycemia (50-60%), insomnia, myopathy (proximal weakness \u2014 may mimic disease progression), immunosuppression (PJP risk), GI bleeding, osteoporosis, psychiatric effects (mania, psychosis \u2014 usually dose-related), adrenal suppression (if &gt;3 weeks \u2014 taper slowly, do not abruptly stop).</p> <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/breakthrough-seizure/","title":"Breakthrough Seizure (Known Epilepsy)","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Breakthrough Seizure in Known Epilepsy</p> <p>ICD-10: G40.909 (Epilepsy, unspecified, not intractable, without status epilepticus), G40.901 (Epilepsy, unspecified, not intractable, with status epilepticus), G40.919 (Epilepsy, unspecified, intractable, without status epilepticus), R56.9 (Unspecified convulsions)</p> <p>SYNONYMS: Breakthrough seizure, seizure in known epilepsy, recurrent seizure, uncontrolled seizure, epilepsy exacerbation, seizure on medications, drug-resistant epilepsy, refractory epilepsy, seizure despite treatment</p> <p>SCOPE: Evaluation and management of breakthrough seizures in adults with known epilepsy who are on established antiseizure medication (ASM) regimens. Covers identification of precipitants, medication level assessment, adjustment strategies, and evaluation for secondary causes. Excludes new-onset seizure (separate workup), status epilepticus (see SE template), and non-epileptic events (psychogenic non-epileptic seizures).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/breakthrough-seizure/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/breakthrough-seizure/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Antiseizure medication (ASM) levels STAT STAT ROUTINE STAT CRITICAL: Subtherapeutic levels are #1 cause of breakthrough seizures; check ALL ASMs with available assays Therapeutic ranges (see Appendix); subtherapeutic = adjust dose or assess adherence CBC with differential STAT STAT ROUTINE STAT Infection as precipitant; baseline for ASM hematologic effects; thrombocytopenia (valproate) Normal; leukocytosis \u2192 infection workup; low platelets \u2192 consider valproate toxicity CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolyte abnormalities (hyponatremia common with carbamazepine/oxcarbazepine); renal function (affects ASM dosing); hepatic function (ASM metabolism, toxicity); glucose (hypoglycemia as seizure cause) Normal; hyponatremia &lt;130 mEq/L can provoke seizures; elevated LFTs \u2192 ASM hepatotoxicity Blood glucose STAT STAT ROUTINE STAT Hypoglycemia is reversible seizure cause; hyperglycemia (DKA) can also cause seizures 70-180 mg/dL; hypoglycemia &lt;60 mg/dL \u2192 treat immediately Sodium STAT STAT ROUTINE STAT Hyponatremia: carbamazepine and oxcarbazepine cause SIADH; &lt;125-130 mEq/L can provoke seizures 135-145 mEq/L; &lt;130 \u2192 correct slowly (risk of osmotic demyelination) Calcium (ionized) STAT STAT ROUTINE STAT Hypocalcemia can cause seizures; also check if hypocalcemic tetany suspected Normal ionized Ca; low \u2192 replete Magnesium STAT STAT ROUTINE STAT Hypomagnesemia lowers seizure threshold; chronic ASM use may deplete Mg &gt;2.0 mg/dL; low \u2192 replete Urinalysis STAT STAT ROUTINE STAT UTI is common occult infection that provokes seizures, especially in elderly Normal; pyuria/bacteriuria \u2192 treat UTI Urine drug screen (UDS) STAT STAT - STAT Illicit drug use (cocaine, amphetamines) can provoke seizures; drug interactions with ASMs; adherence assessment Negative; positive \u2192 specific drug-related seizure risk assessment Alcohol level STAT - - STAT Alcohol withdrawal seizures; intoxication; binge drinking Negative or low; elevated or history of recent heavy use \u2192 alcohol withdrawal protocol Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE STAT Pregnancy affects ASM levels (increased clearance, volume distribution); teratogenicity concerns; seizure risk in pregnancy Document result; if positive \u2192 urgent neurology/OB consultation; ASM teratogenicity counseling"},{"location":"plans/breakthrough-seizure/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Free (unbound) ASM levels - URGENT ROUTINE URGENT For highly protein-bound drugs (phenytoin, valproate) in patients with hypoalbuminemia, renal failure, pregnancy, or polypharmacy; free level is the active fraction Free phenytoin: 1-2 mcg/mL; free valproate: 5-15 mcg/mL; adjusted interpretation based on clinical context Ammonia STAT STAT - STAT Valproate-induced hyperammonemic encephalopathy (can occur with normal LFTs); confusion/lethargy post-ictal vs. encephalopathy &lt;35 \u03bcmol/L; elevated \u2192 valproate toxicity; consider discontinuation Lactate STAT STAT - STAT Post-ictal lactate elevation (typically resolves within 2h); persistent elevation may indicate status epilepticus or alternative cause Mildly elevated post-ictal (normalizes quickly); persistent elevation concerning Prolactin - URGENT ROUTINE - Elevated 10-20 min post-seizure (2-3x baseline); helps distinguish epileptic seizure from psychogenic non-epileptic seizure (PNES); must be drawn within 20 min 2-3x baseline within 20 min of convulsive seizure; normal in PNES TSH - ROUTINE ROUTINE - Thyroid dysfunction can affect seizure threshold and ASM metabolism Normal Cortisol (AM) - ROUTINE ROUTINE - Adrenal insufficiency; chronic ASM use (enzyme inducers) may affect cortisol Normal B12 / Folate - ROUTINE ROUTINE - Phenytoin and carbamazepine can deplete folate; B12 deficiency neuropathy; pregnancy planning Normal; low \u2192 supplement Vitamin D (25-OH) - ROUTINE ROUTINE - Enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) increase vitamin D metabolism \u2192 osteoporosis risk &gt;30 ng/mL; low \u2192 supplement"},{"location":"plans/breakthrough-seizure/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding ASM pharmacogenomics (HLA typing) - - ROUTINE - HLA-B15:02 (carbamazepine/SJS risk in Asian populations); HLA-A31:01 (carbamazepine hypersensitivity in Europeans); before starting new ASMs Negative for risk alleles; positive \u2192 avoid associated ASM Carbamazepine-10,11-epoxide level - ROUTINE ROUTINE - Active metabolite of carbamazepine; may be elevated when total level appears therapeutic (especially with inhibitors like valproate); correlates with toxicity &lt;9 mcg/mL; elevated \u2192 toxicity even with normal carbamazepine level Autoimmune encephalitis panel - EXT EXT - If new seizure semiology, cognitive decline, or refractory seizures in previously controlled patient; autoimmune etiology Negative; positive \u2192 autoimmune encephalitis workup CSF analysis - EXT - EXT If infection, autoimmune encephalitis, or CNS malignancy suspected as new cause Normal; abnormal \u2192 specific diagnosis Genetic epilepsy panel - - EXT - If genetic cause suspected (family history, syndromic features, drug-resistant epilepsy); may guide ASM selection Specific mutations (SCN1A, SCN2A, KCNQ2, etc.) may inform treatment choices (e.g., avoid sodium channel blockers in Dravet syndrome)"},{"location":"plans/breakthrough-seizure/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/breakthrough-seizure/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT NOT routinely needed for uncomplicated breakthrough seizure in known epilepsy with return to baseline; INDICATED if: Head trauma (fall during seizure), prolonged post-ictal state (&gt;30 min), focal neurologic deficit, new seizure semiology, anticoagulation, fever + seizure, first seizure at this facility Acute hemorrhage; mass lesion; edema; hydrocephalus; prior surgical changes None (for non-contrast); pregnancy (benefit outweighs minimal risk) MRI brain with and without contrast - URGENT ROUTINE - NOT acutely needed if stable known epilepsy with unchanged seizures; INDICATED if: Change in seizure semiology, increased seizure frequency without clear precipitant, new focal deficit, concern for progressive lesion, presurgical evaluation Tumor; mesial temporal sclerosis; cortical dysplasia; vascular malformation; new structural cause MRI-incompatible implants; VNS devices (check MRI compatibility of specific device) ECG (12-lead) STAT STAT ROUTINE STAT Post-ictal arrhythmia; syncope vs. seizure; QTc prolongation (some ASMs); baseline for ASM changes Normal; arrhythmia may indicate cardiac cause; prolonged QTc (avoid QT-prolonging ASMs) None"},{"location":"plans/breakthrough-seizure/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications EEG (routine/outpatient) - URGENT ROUTINE - Within 24-48h if possible (higher yield closer to seizure); characterize epileptiform activity; confirm epileptic vs. non-epileptic; guide ASM choice; localization Epileptiform discharges (spikes, sharp waves); focal vs. generalized; specific epilepsy syndrome features None Continuous EEG (cEEG) monitoring - STAT - STAT INDICATED if: Prolonged or fluctuating alteration of consciousness; concern for nonconvulsive status epilepticus (NCSE); ICU patient with unexplained encephalopathy; frequent seizures Ictal patterns; NCSE; interictal epileptiform activity; quantify seizure burden None; resource-dependent Ambulatory EEG (outpatient) - - ROUTINE - Capture typical events if infrequent; home monitoring for 24-72h or longer Ictal events; interictal discharges; seizure frequency Patient cooperation required Video-EEG monitoring (EMU admission) - - ROUTINE - Characterize events if diagnostic uncertainty (epileptic vs. PNES); presurgical evaluation; medication taper for surgery Ictal semiology; EEG correlation; localization for surgery Requires specialized unit Chest X-ray STAT STAT - STAT Aspiration pneumonia (common post-ictal complication); ETT position if intubated Infiltrate; aspiration pattern None"},{"location":"plans/breakthrough-seizure/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI epilepsy protocol - - ROUTINE - High-resolution imaging for epileptogenic lesion identification; 3T preferred; includes thin-cut coronal T2/FLAIR through temporal lobes Mesial temporal sclerosis; focal cortical dysplasia; cavernous malformation; low-grade tumor Same as standard MRI PET (FDG) or SPECT (ictal/interictal) - - EXT - Presurgical localization; hypometabolism (interictal PET) or hyperperfusion (ictal SPECT) at seizure focus Focal hypometabolism (interictal); focal hyperperfusion (ictal) Radiation exposure; specialized availability MEG (magnetoencephalography) - - EXT - Presurgical localization; dipole source analysis; specialized centers Source localization complementary to EEG Limited availability; metal implants Neuropsychological testing - - ROUTINE - Presurgical evaluation; cognitive baseline; localization (memory lateralization for temporal lobe epilepsy) Lateralized deficits; cognitive baseline for surgery comparison Patient cooperation"},{"location":"plans/breakthrough-seizure/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP \u2014 Generally NOT indicated - EXT - EXT NOT routinely indicated for uncomplicated breakthrough seizure; INDICATED if: Suspected meningitis/encephalitis (fever, meningismus, altered mentation beyond typical post-ictal); suspected autoimmune encephalitis; immunocompromised patient with seizure Normal in uncomplicated breakthrough; pleocytosis \u2192 infection or autoimmune; elevated protein; specific antibodies Mass lesion with mass effect; coagulopathy"},{"location":"plans/breakthrough-seizure/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/breakthrough-seizure/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Benzodiazepine (if actively seizing) STAT STAT - STAT Lorazepam 0.1 mg/kg IV (max 4 mg), may repeat x1 in 5 min; OR Midazolam 10 mg IM (if no IV access); OR Diazepam 0.2 mg/kg IV (max 10 mg); Intranasal midazolam 5-10 mg if no IV; Rectal diazepam 0.2-0.5 mg/kg (home rescue) First-line for acute seizure termination; lorazepam preferred IV (longer CNS duration); follow status epilepticus protocol if seizure continues &gt;5 min Protect patient during seizure STAT STAT - STAT Clear environment of hazards; DO NOT restrain or put anything in mouth; turn on side (recovery position) when safe; suction secretions; monitor airway; time the seizure Prevent injury; prepare for airway management if prolonged Post-ictal care STAT STAT - STAT Recovery position; monitor airway (aspiration risk); supplemental O2 if SpO2 &lt;92%; assess for injuries (tongue laceration, shoulder dislocation, vertebral fracture); reassurance; reorientation Post-ictal period is self-limited (typically 5-30 min); prolonged alteration \u2192 consider NCSE, repeat seizure, or alternative diagnosis Administer home ASM (if missed) STAT STAT - STAT If patient missed doses \u2192 give maintenance ASM immediately; if patient does not have medication with them \u2192 administer from ED/hospital supply Non-adherence is most common cause of breakthrough seizure; restoring therapeutic levels is priority Loading dose (if significantly subtherapeutic) STAT STAT - STAT Phenytoin/Fosphenytoin: 15-20 mg PE/kg IV (if level very low); Valproate: 20-30 mg/kg IV (if level very low); Levetiracetam: 1000-1500 mg IV (if not on levetiracetam \u2014 can be added); Note: Loading the same drug patient is already taking risks toxicity \u2192 use cautiously For significantly subtherapeutic levels or if need rapid therapeutic concentration; adjust for partial levels Treat precipitant STAT STAT ROUTINE STAT Infection: Antibiotics for UTI, pneumonia; Electrolyte abnormality: Correct (hyponatremia slowly); Drug/alcohol withdrawal: Appropriate protocol; Sleep deprivation: Education, sleep hygiene Treating the precipitant may be more important than adjusting ASMs"},{"location":"plans/breakthrough-seizure/#3b-asm-adjustment-strategies","title":"3B. ASM Adjustment Strategies","text":"Scenario Treatment Protocol Rationale Subtherapeutic level due to non-adherence Resume current regimen at prescribed doses Counsel on importance of adherence; identify barriers (cost, side effects, complexity); pill organizer; simplify regimen if possible Non-adherence is #1 cause; restoring regimen usually sufficient Subtherapeutic level at maximum dose Increase current ASM OR add second ASM Increase dose if tolerated and therapeutic range allows; OR add complementary ASM (e.g., add levetiracetam to lamotrigine) Some patients require levels above \"therapeutic range\" for control Therapeutic level but breakthrough seizure Add second ASM OR optimize current ASM timing Consider drug-drug interaction reducing efficacy; add ASM with different mechanism; divide doses more frequently for better coverage Breakthrough at therapeutic levels may require adjunctive therapy Subtherapeutic due to drug interaction Remove interacting drug OR increase ASM dose OR switch ASM Example: Starting enzyme inducer (rifampin, carbamazepine) reduces lamotrigine level by 50% \u2192 double lamotrigine dose Enzyme inducers and inhibitors significantly affect ASM levels Pregnancy with subtherapeutic level Increase dose with frequent monitoring Pregnancy increases clearance (especially lamotrigine, levetiracetam); monitor levels monthly; anticipate need for increased doses Seizure risk to mother and fetus outweighs small ASM risk; maintain control New-onset breakthrough in previously controlled epilepsy Full re-evaluation Imaging (new structural lesion?); EEG; consider progressive cause (tumor, autoimmune); assess for PNES Change in control pattern requires investigation for new etiology"},{"location":"plans/breakthrough-seizure/#3c-specific-asm-adjustments","title":"3C. Specific ASM Adjustments","text":"ASM Therapeutic Range Adjustment Notes Phenytoin Total: 10-20 mcg/mL; Free: 1-2 mcg/mL Nonlinear kinetics; small dose changes \u2192 large level changes; check free level if hypoalbuminemia, renal failure, pregnancy; adjust dose by 25-50 mg increments Carbamazepine 4-12 mcg/mL Auto-induction over 2-4 weeks (levels drop); check 4 weeks after initiation; also check epoxide level if toxicity suspected Valproate Total: 50-100 mcg/mL; Free: 5-15 mcg/mL Highly protein-bound; check free level in elderly, hepatic disease, pregnancy; check ammonia if encephalopathy Levetiracetam Not routinely monitored (no established range) Level: 12-46 mcg/mL often cited; renal dosing required; generally well-tolerated dose increases Lamotrigine 3-14 mcg/mL (varies) Highly affected by enzyme inducers (carbamazepine, phenytoin, oral contraceptives) and inhibitors (valproate); pregnancy increases clearance; slow titration to avoid rash Oxcarbazepine 10,11-monohydroxy derivative: 3-35 mcg/mL Causes hyponatremia (check sodium); less drug interactions than carbamazepine Lacosamide 10-20 mcg/mL (emerging data) Check ECG (PR prolongation); dose-dependent side effects; no major drug interactions Topiramate 5-20 mcg/mL (not well-established) Renal dosing; causes metabolic acidosis, cognitive effects, kidney stones; enzyme inducer reduces OCP efficacy Phenobarbital 15-40 mcg/mL Long half-life (adjust weekly); sedation; enzyme inducer Brivaracetam Not routinely monitored Similar to levetiracetam but may have fewer behavioral side effects; can substitute directly for levetiracetam Clobazam 0.03-0.3 mcg/mL (+ N-desmethylclobazam metabolite) Benzodiazepine; tolerance may develop; useful adjunct especially in Lennox-Gastaut"},{"location":"plans/breakthrough-seizure/#3d-non-pharmacologic-considerations","title":"3D. Non-Pharmacologic Considerations","text":"Intervention Setting Details Seizure precautions HOSP/ICU Padded side rails; suction at bedside; no sharps within reach; fall risk protocol; 1:1 supervision if frequent seizures Driving restrictions OPD/Discharge State-specific laws; generally 3-12 months seizure-free required; document counseling; patient should NOT drive until cleared Activity restrictions OPD/Discharge Avoid swimming alone; no heights (ladders, scaffolding); avoid dangerous machinery; bathing vs. showers (supervision if frequent seizures) Sleep hygiene OPD/Discharge Sleep deprivation is major trigger; regular sleep schedule; 7-8 hours nightly; avoid shift work if possible Alcohol / substance avoidance OPD/Discharge Alcohol lowers seizure threshold; withdrawal is high risk; cocaine/amphetamines provoke seizures; counsel strongly Stress management OPD/Discharge Stress/anxiety are common triggers; counseling; mindfulness; adequate support VNS (vagus nerve stimulator) check OPD If patient has VNS \u2192 check device function; consider adjusting parameters; use magnet during seizure if trained Ketogenic diet (if on) OPD Ensure compliance; check ketosis; dietary counseling Epilepsy surgery evaluation OPD If drug-resistant epilepsy (failure of 2 appropriate ASMs at adequate doses) \u2192 refer for surgical evaluation"},{"location":"plans/breakthrough-seizure/#3e-medications-to-avoid-or-use-with-caution","title":"3E. Medications to AVOID or Use with Caution","text":"Medication Risk Action Tramadol Lowers seizure threshold significantly Avoid in epilepsy; use alternative analgesics Meperidine (Demerol) Lowers seizure threshold (normeperidine metabolite) Avoid; use other opioids Bupropion Dose-dependent seizure risk (especially &gt;450 mg/day) Avoid or use cautiously at low doses if essential for depression Clozapine High seizure risk (dose-dependent) Avoid if possible; if used, prophylactic ASM often recommended Fluoroquinolones May lower seizure threshold; GABA antagonism Use with caution; consider alternative antibiotics Carbapenems (imipenem &gt; meropenem) Lower seizure threshold; reduce valproate levels significantly Imipenem: avoid if possible; meropenem: use with caution; monitor valproate level Isoniazid Pyridoxine depletion \u2192 seizures; inhibits phenytoin metabolism Give prophylactic pyridoxine; monitor phenytoin level Theophylline / Aminophylline Lowers seizure threshold Use cautiously; monitor levels Stimulants (amphetamines, methylphenidate) May lower seizure threshold Use cautiously if needed for ADHD; generally well-tolerated in controlled epilepsy but monitor Alcohol (acute intoxication and withdrawal) Intoxication and withdrawal both increase seizure risk Counsel on avoidance Illicit drugs (cocaine, amphetamines, synthetic cathinones) Directly provoke seizures Counsel on avoidance; drug screen"},{"location":"plans/breakthrough-seizure/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/breakthrough-seizure/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurology consultation - URGENT ROUTINE URGENT For medication adjustments, change in seizure pattern, refractory seizures, presurgical evaluation consideration ASM level check STAT STAT ROUTINE STAT All ASMs with available assays; interpret in clinical context; free levels for protein-bound drugs Adherence assessment STAT STAT ROUTINE STAT Ask directly about missed doses; identify barriers (cost, side effects, complexity, depression); pill counts if available; pharmacy refill records Precipitant identification STAT STAT ROUTINE STAT Infection (UTI most common); sleep deprivation; alcohol; medication changes; stress; menstrual cycle (catamenial epilepsy) Injury assessment STAT STAT - STAT Tongue laceration; posterior shoulder dislocation (classic); vertebral compression fracture; head trauma (if fall) Safety counseling - ROUTINE ROUTINE - Driving restrictions (document!); activity limitations; seizure first aid for family; MedicAlert bracelet; rescue medication prescription (rectal diazepam or intranasal midazolam) Return to baseline confirmation STAT STAT - STAT Document return to neurologic baseline; if not returning \u2192 consider ongoing seizures (NCSE), structural lesion, metabolic cause"},{"location":"plans/breakthrough-seizure/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details EEG - URGENT ROUTINE STAT If change in seizure pattern, prolonged post-ictal state, concern for NCSE, or to characterize epileptiform activity Imaging - URGENT ROUTINE URGENT MRI if change in seizure semiology, new focal findings, or suspicion of progressive lesion; CT acutely if trauma, anticoagulation, or prolonged altered mental status Pharmacy consultation - ROUTINE ROUTINE - Drug interaction review; adherence strategies; cost-effective alternatives; patient education on ASMs Social work - ROUTINE ROUTINE - Insurance/cost barriers to medication; disability resources; driving/employment impact; support services Psychology / Psychiatry - ROUTINE ROUTINE - Depression (common comorbidity; some ASMs worsen depression); anxiety; PNES if suspected; coping strategies Epilepsy nurse educator - ROUTINE ROUTINE - Self-management education; seizure diary; lifestyle modifications; medication management; rescue medication training Women's health counseling - ROUTINE ROUTINE - Contraception (enzyme-inducing ASMs reduce OCP efficacy); pregnancy planning (folic acid, ASM optimization); teratogenicity counseling"},{"location":"plans/breakthrough-seizure/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Epilepsy surgery evaluation - - ROUTINE - Drug-resistant epilepsy (failed \u22652 appropriate ASMs); refer to comprehensive epilepsy center for surgical workup (video-EEG, MRI epilepsy protocol, neuropsych, PET, etc.) VNS / RNS / DBS evaluation - - ROUTINE - Neuromodulation for drug-resistant epilepsy not surgical candidates; VNS (vagus nerve stimulator); RNS (responsive neurostimulation); DBS (deep brain stimulation) Ketogenic diet referral - - ROUTINE - Dietary therapy for drug-resistant epilepsy; especially effective in certain epilepsies (Dravet, GLUT1 deficiency); requires dietitian supervision PNES evaluation - - ROUTINE - If clinical features suggest psychogenic non-epileptic seizures (variable semiology, prolonged events, lack of post-ictal state, eyes closed, pelvic thrusting, ictal crying, preserved awareness with bilateral movements); video-EEG confirmation; psychology/psychiatry referral Autoimmune epilepsy workup - ROUTINE ROUTINE - If new-onset refractory seizures, cognitive decline, or change in previously controlled epilepsy \u2192 autoimmune antibody panel; LP; MRI; consider immunotherapy trial Genetic testing - - ROUTINE - If suspected genetic epilepsy; may inform ASM selection (e.g., avoid sodium channel blockers in SCN1A/Dravet; valproate effective in SCN2A); family counseling <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/breakthrough-seizure/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/breakthrough-seizure/#differential-for-breakthrough-seizure","title":"Differential for \"Breakthrough Seizure\"","text":"Diagnosis Key Distinguishing Features Evaluation True breakthrough seizure (epileptic) Typical semiology for patient; post-ictal state; EEG correlation; identifiable precipitant or subtherapeutic level ASM levels; EEG; precipitant search Psychogenic non-epileptic seizure (PNES) Variable semiology; prolonged duration (&gt;2 min); preserved awareness with bilateral movements; eyes closed; pelvic thrusting; ictal crying; side-to-side head movements; no post-ictal confusion (or prolonged pseudo-post-ictal); normal prolactin; normal EEG during event Video-EEG (gold standard); prolactin (not elevated); clinical features; psychology evaluation Syncope (convulsive) Triggered by standing, hot environment, vagal stimulus; brief LOC (&lt;1 min); myoclonic jerks are common during syncope (not true seizure); rapid recovery; pale before event ECG; orthostatics; tilt table test; echocardiogram; cardiac history Cardiac arrhythmia Sudden LOC without warning or with palpitations; rapid recovery; history of cardiac disease ECG; Holter/event monitor; echocardiogram; electrophysiology study Toxic/metabolic Hypoglycemia; hyponatremia; hypocalcemia; uremia; hepatic encephalopathy; drug intoxication/withdrawal Glucose; electrolytes; renal/hepatic function; drug screen; specific toxin levels Transient ischemic attack (TIA) Negative symptoms (weakness, numbness, aphasia) vs. positive symptoms (convulsion); typically no LOC; vascular risk factors MRI with DWI; MRA; vascular risk factor assessment Sleep disorders REM sleep behavior disorder; parasomnias; cataplexy (narcolepsy) Sleep history; PSG; MSL Movement disorders Dystonia; chorea; myoclonus (non-epileptic); paroxysmal dyskinesia Preserved awareness; stereotyped movements; neurologic exam; movement disorder evaluation Migraine with aura Visual, sensory, or motor aura preceding headache; duration 20-60 min; no LOC Headache history; migraine features; may have EEG abnormalities but distinct from seizure"},{"location":"plans/breakthrough-seizure/#common-precipitants-of-breakthrough-seizures","title":"Common Precipitants of Breakthrough Seizures","text":"Precipitant Mechanism Evaluation/Intervention Non-adherence / missed doses Subtherapeutic ASM levels Ask directly; check levels; pharmacy refill records; address barriers Sleep deprivation Lowers seizure threshold significantly Sleep hygiene counseling; regular schedule; treat sleep disorders Infection (especially UTI) Fever lowers seizure threshold; metabolic stress UA/culture; CXR; treat infection Alcohol use / withdrawal Both intoxication and withdrawal provoke seizures Alcohol level; history; withdrawal prophylaxis Medication changes Drug interactions; started medication that lowers threshold Medication reconciliation; check levels; review interactions Stress / anxiety Hyperexcitability Stress management; counseling; anxiolytics if appropriate Menstrual cycle (catamenial epilepsy) Perimenstrual or periovulatory clustering Seizure diary correlation; hormonal treatment; increase ASM perimenstrually Electrolyte abnormalities Hyponatremia (carbamazepine, oxcarbazepine); hypocalcemia; hypomagnesemia Electrolyte panel; correct abnormality Illicit drugs Cocaine, amphetamines lower seizure threshold Drug screen; counseling Flashing lights / photosensitivity Photic stimulation triggers seizures in photosensitive epilepsy EEG with photic stimulation; avoid triggers; blue-tinted lenses"},{"location":"plans/breakthrough-seizure/#red-flags-suggesting-alternative-diagnosis","title":"Red Flags Suggesting Alternative Diagnosis","text":"Red Flag Concern Action New focal neurologic deficit New structural lesion (tumor, stroke, hemorrhage) STAT imaging (CT then MRI) Prolonged post-ictal state (&gt;30 min) Status epilepticus; NCSE; structural lesion; metabolic cause; postictal paralysis (Todd's) Continuous EEG; imaging; extended metabolic workup Fever with seizure Meningitis/encephalitis; febrile seizure in adult is concerning LP if meningitis suspected; imaging; antibiotics/antivirals empirically if indicated Change in seizure semiology New epileptogenic lesion; different seizure type; PNES EEG; MRI; video-EEG if needed No return to baseline Ongoing NCSE; structural lesion; metabolic encephalopathy Continuous EEG; imaging; metabolic workup First seizure at this facility May not be known epilepsy; needs full new-onset seizure workup Full workup unless confirmed prior epilepsy Eyes closed during \"seizure\" PNES (epileptic seizures typically have eyes open) Video-EEG; psychology referral Very prolonged event (&gt;5-10 min) Status epilepticus; PNES (epileptic seizures typically &lt;2-3 min) Treat as SE if epileptic; video-EEG for characterization"},{"location":"plans/breakthrough-seizure/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/breakthrough-seizure/#ed-acute-phase","title":"ED / Acute Phase","text":"Parameter Frequency Target Action if Abnormal Mental status (return to baseline) q15 min until resolved; q1h thereafter Return to baseline within 30-60 min Prolonged: consider NCSE \u2192 EEG; imaging; extended evaluation Vital signs q15-30 min initially; q1h once stable HR 60-100; BP &lt;180/110; SpO2 &gt;94%; Temp &lt;38\u00b0C Manage accordingly; fever \u2192 infection workup Seizure recurrence Continuous observation No further seizures Repeat seizure: give benzodiazepine; consider additional ASM load; SE protocol if &gt;5 min Airway / Respiratory status Continuous; q15 min Patent airway; no aspiration; adequate ventilation Position; suction; O2 if needed; intubation if compromised Blood glucose Check immediately; repeat if symptomatic 70-180 mg/dL Hypoglycemia: D50W IV Cardiac rhythm Continuous telemetry Normal sinus; no arrhythmia Treat arrhythmia; cardiology if indicated"},{"location":"plans/breakthrough-seizure/#inpatient-monitoring","title":"Inpatient Monitoring","text":"Parameter Frequency Target Action if Abnormal ASM level (repeat) 24-48h after dose adjustment Therapeutic (per drug) Adjust dose Sodium (if on carbamazepine/oxcarbazepine) Daily during hospitalization &gt;130 mEq/L Fluid restriction; consider ASM change if persistent hyponatremia LFTs (if concern for toxicity) Q2-3 days if abnormal AST/ALT &lt;3x ULN If elevated: consider ASM hepatotoxicity; may need to discontinue Ammonia (if on valproate with altered mental status) With any confusion/lethargy &lt;35 \u03bcmol/L Elevated: consider discontinuing valproate; L-carnitine supplementation Seizure diary Continuous Document all events Assess frequency and response to treatment Neurologic exam Daily Stable; no new deficits New deficits: imaging"},{"location":"plans/breakthrough-seizure/#outpatient-monitoring","title":"Outpatient Monitoring","text":"Parameter Frequency Target Action if Abnormal ASM levels 2-4 weeks after dose change; then q6-12 months or PRN Therapeutic Adjust dose CBC, CMP Q6-12 months or per ASM-specific monitoring Normal ASM-specific toxicity management Bone density (DEXA) Baseline and q2-5 years if on enzyme-inducing ASMs T-score &gt;-2.5 Vitamin D, calcium, bisphosphonates if needed Seizure frequency Seizure diary; each visit Reduced or seizure-free Adjust ASMs; consider surgery evaluation if drug-resistant Side effects Each visit Tolerable; no limiting effects Dose adjustment; consider alternative ASM Mood / Cognition Each visit No depression; stable cognition Depression treatment; ASM adjustment if cognitive effects"},{"location":"plans/breakthrough-seizure/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/breakthrough-seizure/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU Status epilepticus; cluster seizures requiring continuous infusion; severe injuries; need for continuous EEG monitoring; airway compromise; hemodynamic instability General floor / Observation Prolonged post-ictal state; multiple seizures in ED; significantly subtherapeutic levels requiring monitoring during adjustment; uncertain diagnosis; new focal deficit; complicating medical illness Discharge home Single uncomplicated breakthrough seizure; returned to baseline; identifiable/correctable precipitant; therapeutic or corrected ASM level; no injuries requiring admission; safe home environment; reliable follow-up"},{"location":"plans/breakthrough-seizure/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Return to baseline Normal mental status and neurologic exam matching patient's baseline No ongoing seizure activity Seizure-free since treatment/observation; no concern for subclinical seizures Precipitant addressed Infection treated; missed doses restored; electrolytes corrected; adherence barriers addressed ASM plan established Levels checked; dose adjustments made if indicated; supply of medications ensured Safety counseling completed Driving restrictions documented; activity precautions; seizure first aid for caregivers; when to return Follow-up arranged Neurology follow-up within 1-4 weeks; PCP as needed; EEG scheduled if indicated Rescue medication prescribed Rectal diazepam or intranasal midazolam prescription if appropriate (cluster seizures, prolonged seizures)"},{"location":"plans/breakthrough-seizure/#discharge-checklist","title":"Discharge Checklist","text":"Item Details ASM prescriptions Ensure supply of all ASMs; no gaps in medication ASM instructions Dose, frequency, timing; what to do if dose missed; common side effects Driving restrictions Document state-specific requirement (typically 3-12 months seizure-free); document counseling Activity restrictions No swimming alone; no heights; supervision during bathing if frequent seizures; work restrictions if applicable Rescue medication Prescription and training for rectal diazepam or intranasal midazolam Seizure first aid Education for patient and family; recovery position; when to call 911 When to return Return for: repeat seizure, prolonged seizure, status epilepticus, new symptoms, fever with seizure, head injury Follow-up Neurology appointment; EEG if scheduled; PCP follow-up MedicAlert Encourage bracelet/necklace for epilepsy identification Seizure diary Provide or recommend app; track seizures, ASMs, triggers"},{"location":"plans/breakthrough-seizure/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/breakthrough-seizure/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Practice Guideline Update: Efficacy and Tolerability of ASMs AAN 2018 Levetiracetam, lamotrigine, oxcarbazepine, topiramate established for monotherapy; choose based on seizure type, side effect profile, comorbidities Management of Adult Epilepsy AES/ILAE Ongoing updates Drug-resistant epilepsy defined as failure of 2 appropriate ASMs at adequate doses; refer for surgery evaluation; multidisciplinary care Epilepsy in Women AAN 2009/Updates Folic acid 0.4-4 mg daily for all women of childbearing potential; avoid valproate in pregnancy if possible; lamotrigine and levetiracetam generally preferred SUDEP Prevention AAN 2017 Counsel on sudden unexpected death in epilepsy; nocturnal supervision reduces risk; seizure control reduces risk"},{"location":"plans/breakthrough-seizure/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Kwan &amp; Brodie (2000) 47% of newly diagnosed epilepsy patients became seizure-free on first ASM; 13% on second; 4% on third; after failure of 2 appropriate ASMs, chance of seizure freedom with additional ASMs is &lt;5% Defined drug-resistant epilepsy; established rationale for early surgery referral SANAD I &amp; II (2007, 2021) Lamotrigine best for focal epilepsy; valproate best for generalized/unclassified (but teratogenic); levetiracetam non-inferior to lamotrigine for focal Guide first-line ASM selection by seizure type Standard and New Antiepileptic Drugs (SNAED) Trial Levetiracetam and zonisamide non-inferior to lamotrigine for focal epilepsy Expanded first-line options Early Randomized Surgical Epilepsy Trial (ERSET, 2012) Early surgery superior to continued medical therapy for drug-resistant temporal lobe epilepsy; 73% vs. 0% seizure-free at 2 years Surgery is highly effective; early referral improves outcomes SUDEP Risk Factors Convulsive seizures, especially nocturnal; living alone; poor seizure control Counsel patients; nocturnal monitoring devices; optimize seizure control"},{"location":"plans/breakthrough-seizure/#asm-therapeutic-ranges-reference","title":"ASM Therapeutic Ranges (Reference)","text":"ASM Total Level Free Level Notes Phenytoin 10-20 mcg/mL 1-2 mcg/mL Free level essential if hypoalbuminemia, renal failure, pregnancy; nonlinear kinetics Carbamazepine 4-12 mcg/mL N/A Check epoxide if toxicity; auto-induction Valproate 50-100 mcg/mL 5-15 mcg/mL Free level in pregnancy, elderly, hepatic disease; check ammonia if encephalopathy Phenobarbital 15-40 mcg/mL N/A Long half-life; steady-state takes weeks Levetiracetam 12-46 mcg/mL (suggested) N/A Not routinely monitored; wide therapeutic range; renal dosing Lamotrigine 3-14 mcg/mL (varies) N/A Highly variable; affected by estrogen, enzyme inducers/inhibitors Oxcarbazepine (MHD) 3-35 mcg/mL N/A MHD is active metabolite; monitor sodium Topiramate 5-20 mcg/mL (suggested) N/A Not routinely monitored Lacosamide 10-20 mcg/mL (emerging) N/A Check ECG for PR prolongation Clobazam 0.03-0.3 mcg/mL N/A Also measure N-desmethylclobazam metabolite Brivaracetam Not established N/A Similar to levetiracetam; not routinely monitored Perampanel Not established N/A Long half-life; steady-state takes weeks"},{"location":"plans/breakthrough-seizure/#appendices","title":"APPENDICES","text":""},{"location":"plans/breakthrough-seizure/#appendix-a-breakthrough-seizure-evaluation-algorithm","title":"Appendix A: Breakthrough Seizure Evaluation Algorithm","text":"<pre><code>BREAKTHROUGH SEIZURE IN KNOWN EPILEPSY\n                \u2502\n    IMMEDIATE MANAGEMENT (if still seizing):\n    \u2022 Benzodiazepine per protocol\n    \u2022 Protect patient; do not restrain\n    \u2022 Time seizure; SE protocol if &gt;5 min\n                \u2502\n    POST-ICTAL ASSESSMENT:\n    \u2022 Return to baseline? (typically 5-30 min)\n    \u2022 Injury assessment\n    \u2022 Vital signs\n                \u2502\n    NOT RETURNING TO BASELINE (&gt;30-60 min)?\n         \u2502\n    YES \u2192 Consider:\n         \u2022 Ongoing NCSE (continuous EEG)\n         \u2022 Structural lesion (CT/MRI)\n         \u2022 Metabolic cause\n         \u2022 Prolonged post-ictal (can be &gt;1h in some patients)\n                \u2502\n    RETURNED TO BASELINE:\n                \u2502\n    EVALUATE PRECIPITANT:\n    \u2022 Non-adherence? (ask directly; levels)\n    \u2022 Infection? (UTI, pneumonia)\n    \u2022 Sleep deprivation?\n    \u2022 Alcohol/drugs?\n    \u2022 Medication change?\n    \u2022 Menstrual cycle?\n    \u2022 Stress?\n    \u2022 Electrolyte abnormality?\n                \u2502\n    CHECK ASM LEVELS:\n    \u2022 Subtherapeutic \u2192 Restore/adjust doses\n    \u2022 Therapeutic \u2192 Consider adding ASM or\n                    evaluate for change in epilepsy\n                \u2502\n    IMAGING (NOT routinely needed if):\n    \u2022 Typical seizure for this patient\n    \u2022 Returned to baseline\n    \u2022 No trauma, no new focal signs\n    \u2502\n    CONSIDER IMAGING IF:\n    \u2022 New seizure semiology\n    \u2022 New focal deficit\n    \u2022 Prolonged post-ictal\n    \u2022 Head trauma\n    \u2022 Anticoagulation\n    \u2022 Immunocompromised\n                \u2502\n    DISPOSITION:\n    \u2022 Discharge if: single seizure, baseline, precipitant addressed,\n      ASM plan, safe environment, follow-up\n    \u2022 Admit if: multiple seizures, prolonged post-ictal,\n      uncertain diagnosis, injuries, unsafe home\n</code></pre>"},{"location":"plans/breakthrough-seizure/#appendix-b-common-drug-interactions-affecting-asm-levels","title":"Appendix B: Common Drug Interactions Affecting ASM Levels","text":"Interacting Drug Effect on ASM Affected ASMs Action Enzyme Inducers (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) \u2193 ASM levels Lamotrigine (\u219350%), valproate, topiramate, levetiracetam (mild), clobazam, perampanel Increase ASM dose; monitor levels Enzyme Inhibitors (valproate, fluoxetine, erythromycin) \u2191 ASM levels Lamotrigine (valproate doubles level), carbamazepine, phenobarbital, phenytoin Decrease ASM dose; lamotrigine titration much slower when adding to valproate Oral Contraceptives (estrogen) \u2193 Lamotrigine levels Lamotrigine (\u219350%) Increase lamotrigine dose; may need to decrease during pill-free week Carbapenems (imipenem, meropenem) \u2193 Valproate levels dramatically Valproate (\u219360-90%) Avoid combination if possible; if used, significantly increase valproate or use alternative ASM Antacids \u2193 Absorption of some ASMs Gabapentin, phenytoin Separate administration by 2 hours Protein-binding displacement \u2191 Free ASM fraction Phenytoin, valproate (with aspirin, warfarin, other highly bound drugs) Check free levels"},{"location":"plans/breakthrough-seizure/#appendix-c-asm-selection-by-seizure-type","title":"Appendix C: ASM Selection by Seizure Type","text":"Seizure Type First-Line Options Avoid Focal (aware or impaired awareness) Lamotrigine, levetiracetam, oxcarbazepine, carbamazepine Ethosuximide (not effective) Focal to bilateral tonic-clonic Same as focal Same as focal Generalized tonic-clonic Valproate (if not woman of childbearing potential), lamotrigine, levetiracetam Carbamazepine, oxcarbazepine, phenytoin (may worsen) Absence (typical) Ethosuximide (first-line for absence only), valproate, lamotrigine Carbamazepine, oxcarbazepine, phenytoin (can worsen) Myoclonic Valproate, levetiracetam, clonazepam Carbamazepine, oxcarbazepine, phenytoin, gabapentin (can worsen) Juvenile myoclonic epilepsy (JME) Valproate (most effective but avoid in women), lamotrigine (may worsen myoclonus), levetiracetam Carbamazepine, oxcarbazepine, phenytoin Lennox-Gastaut syndrome Lamotrigine, valproate, clobazam, rufinamide, felbamate, cannabidiol N/A (polytherapy usually required) Dravet syndrome (SCN1A) Valproate, clobazam, stiripentol, cannabidiol, fenfluramine AVOID sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) \u2014 can worsen seizures"},{"location":"plans/breakthrough-seizure/#appendix-d-special-populations","title":"Appendix D: Special Populations","text":"Population Considerations Pregnancy Folic acid 0.4-4 mg daily (start preconception); avoid valproate if possible (highest teratogenicity); lamotrigine and levetiracetam generally preferred; levels drop in pregnancy (especially lamotrigine) \u2014 monitor monthly and increase doses; valproate level may be falsely reassuring (protein binding changes) Women of childbearing potential Counsel all on teratogenicity; contraception counseling (enzyme inducers reduce OCP efficacy); preconception planning; folic acid; prefer lamotrigine, levetiracetam over valproate Elderly Increased sensitivity to ASM side effects; cognitive effects; falls; start low, go slow; drug interactions (polypharmacy); lamotrigine, levetiracetam, lacosamide generally well-tolerated; avoid phenobarbital, high-dose phenytoin Renal impairment Reduce doses of renally-cleared ASMs: levetiracetam, gabapentin, pregabalin, topiramate, lacosamide; phenytoin, carbamazepine, valproate less affected Hepatic impairment Reduce doses of hepatically-metabolized ASMs: phenytoin, carbamazepine, valproate, lamotrigine; levetiracetam, gabapentin safer Cardiac disease Avoid lacosamide if significant AV block (PR prolongation); carbamazepine has cardiac conduction effects; check ECG Psychiatric comorbidity Depression common in epilepsy; levetiracetam can cause behavioral side effects (irritability, aggression) \u2014 consider brivaracetam instead; valproate may worsen depression; lamotrigine has mood-stabilizing properties <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/cauda-equina-syndrome/","title":"Cauda Equina Syndrome","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Cauda Equina Syndrome (CES)</p> <p>ICD-10: G83.4 (Cauda equina syndrome), M48.06 (Spinal stenosis, lumbar region), M51.16 (Intervertebral disc disorders with radiculopathy, lumbar region), M51.17 (Intervertebral disc disorders with radiculopathy, lumbosacral region), G95.89 (Other specified diseases of spinal cord)</p> <p>SYNONYMS: Cauda equina syndrome, CES, cauda equina compression, saddle anesthesia, urinary retention with back pain, bowel/bladder dysfunction, lower spine emergency, cauda equina</p> <p>SCOPE: Emergency evaluation and management of cauda equina syndrome in adults. Covers urgent recognition of incomplete vs. complete CES, emergent MRI, surgical decompression timing, etiologic workup (disc herniation, tumor, abscess, hematoma), bladder management, and functional prognostication. Excludes conus medullaris syndrome (partially overlaps \u2014 key distinguishing features addressed), malignant epidural spinal cord compression above the conus (separate template), and chronic lumbar stenosis without CES features.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/cauda-equina-syndrome/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/cauda-equina-syndrome/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT - STAT Infection (epidural abscess); baseline for surgery; leukocytosis; anemia assessment Normal; leukocytosis \u2192 consider abscess; thrombocytopenia affects surgical candidacy CMP (BMP + LFTs) STAT STAT - STAT Electrolytes; renal function (contrast, NSAIDs); glucose; hepatic function (anesthetic risk) Normal PT/INR, aPTT STAT STAT - STAT Coagulopathy; anticoagulation status; surgical clearance; epidural hematoma etiology Normal; INR &lt;1.5 for surgery; prolonged \u2192 consider epidural hematoma ESR / CRP STAT STAT - STAT Epidural abscess differential (ESR &gt;20 mm/hr: 94% sensitivity for spinal abscess); discitis; malignancy Normal; markedly elevated (ESR &gt;30-50, CRP &gt;10) \u2192 strongly consider abscess or infection Blood cultures (x2 sets) STAT STAT - STAT Epidural abscess; bacteremia; source identification if infectious etiology suspected Negative; positive \u2192 epidural abscess or hematogenous source Blood glucose STAT STAT - STAT Baseline; anesthetic risk; diabetic patients at increased disc herniation and infection risk &lt;180 mg/dL Type and screen STAT STAT - STAT Surgical candidacy; blood product availability for emergency decompression On file Urinalysis STAT STAT - STAT UTI (common comorbidity and mimicker of urinary symptoms); neurogenic bladder assessment; baseline Normal; UTI may coexist \u2014 treat but do NOT attribute bladder dysfunction solely to UTI if CES features present Pregnancy test (\u03b2-hCG) STAT STAT - STAT MRI and anesthetic planning; pregnancy may exacerbate disc herniation (increased lordosis/weight) Negative; if positive \u2192 MRI still indicated (no gadolinium needed for CES diagnosis) Procalcitonin STAT STAT - STAT Bacterial infection differential (more specific than CRP); if abscess suspected &lt;0.25 (low bacterial probability); &gt;0.5 \u2192 consider abscess"},{"location":"plans/cauda-equina-syndrome/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding HbA1c - ROUTINE ROUTINE - Diabetes assessment (risk factor for disc herniation, infection, neuropathy); post-operative wound healing &lt;7.0% Tumor markers (PSA, CEA, etc.) - ROUTINE ROUTINE - If imaging suggests neoplastic etiology rather than disc herniation Normal; elevated \u2192 guides oncologic workup SPEP / free light chains - ROUTINE ROUTINE - Multiple myeloma presenting as cauda equina compression No M-protein; normal kappa/lambda ratio LDH - ROUTINE ROUTINE - Lymphoma; tumor burden Normal; elevated \u2192 lymphoma, aggressive malignancy HIV - ROUTINE ROUTINE - Immunocompromised \u2192 infection risk; primary CNS lymphoma differential Negative Urine culture STAT STAT - STAT Pre-existing UTI; post-catheterization planning; differentiate neurogenic bladder from UTI Negative; if positive \u2192 treat but continue CES workup Post-void residual (PVR) \u2014 bladder scan STAT STAT ROUTINE STAT KEY DIAGNOSTIC TEST: bladder retention is hallmark of CES; PVR &gt;200 mL is highly concerning; &gt;500 mL strongly suggestive of neurogenic retention PVR &lt;100 mL (normal); PVR &gt;200 mL \u2192 significant retention; &gt;500 mL \u2192 almost certainly neurogenic"},{"location":"plans/cauda-equina-syndrome/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding CSF analysis (only at surgery or LP if needed) - EXT EXT - If inflammatory/infectious etiology suspected (GBS affecting cauda equina = rare); leptomeningeal carcinomatosis Normal; elevated protein \u2192 GBS, tumor; malignant cells \u2192 leptomeningeal disease Paraneoplastic antibody panel - EXT EXT - Atypical CES without structural cause; paraneoplastic cauda equina neuritis (anti-CRMP5/CV2, anti-amphiphysin) Negative; positive \u2192 paraneoplastic syndrome Anti-ganglioside antibodies (GM1, GD1b, GQ1b) - EXT EXT - GBS variant affecting cauda equina roots (rare); if imaging shows nerve root enhancement without structural compression Negative; positive \u2192 GBS/CIDP affecting cauda equina AQP4-IgG / MOG-IgG - EXT EXT - If conus medullaris lesion rather than cauda equina compression; NMOSD can affect conus Negative; positive \u2192 NMOSD/MOGAD Sarcoidosis workup (ACE, chest CT, lysozyme) - EXT EXT - Neurosarcoidosis affecting cauda equina (nerve root inflammation/enhancement without structural lesion); elevated ACE Normal ACE; chest CT: no hilar lymphadenopathy; if positive \u2192 neurosarcoidosis EMG/NCS - EXT EXT - Chronic or atypical CES; differentiate from peripheral neuropathy, plexopathy; establish nerve root involvement pattern; prognostic (denervation = poor recovery) Abnormal: acute denervation (fibrillations, positive sharp waves) in L4-S4 myotomes bilaterally; absent H-reflex bilaterally; abnormal pudendal nerve conduction"},{"location":"plans/cauda-equina-syndrome/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/cauda-equina-syndrome/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI lumbar spine without contrast (emergent) STAT STAT - STAT Within 4 hours of ED arrival \u2014 SURGICAL EMERGENCY; ideally within 1 hour; extends to thoracolumbar junction (T10-sacrum) to include conus medullaris Large disc herniation (most common \u2014 45% of CES cases) compressing cauda equina; canal compromise; level of compression; number of roots compressed; disc fragment migration; tumor, abscess, or hematoma as alternative cause; conus medullaris location and signal MRI-incompatible implants; severe claustrophobia (sedate \u2014 do NOT delay MRI for anxiety); GFR &lt;30 for contrast (but contrast NOT required for disc herniation diagnosis \u2014 obtain non-contrast first) MRI lumbar spine WITH contrast (gadolinium) STAT STAT - STAT Add contrast if: suspected abscess, tumor, or inflammatory etiology; ring-enhancing epidural collection = abscess; homogeneous enhancement = tumor; nerve root enhancement = inflammatory/neoplastic Epidural abscess (ring enhancement, restricted diffusion); tumor (enhancing mass); nerve root enhancement (inflammatory, leptomeningeal disease); distinguish from disc herniation (which does NOT enhance) GFR &lt;30 (gadolinium risk \u2014 benefit outweighs risk in emergency); gadolinium allergy (premedicate) Bladder scan (post-void residual) STAT STAT - STAT Before MRI if possible \u2014 critical triage tool; have patient attempt to void \u2192 immediate bladder ultrasound for PVR PVR &gt;200 mL = significant retention \u2192 HIGH probability of CES; PVR &gt;500 mL = almost certain neurogenic retention; normal PVR does NOT exclude early/incomplete CES None (bedside ultrasound) Plain radiographs (lumbar spine AP/lateral) STAT STAT - STAT While awaiting MRI; identifies vertebral collapse, spondylolisthesis, fracture, alignment; limited value but rapid triage tool Disc space narrowing; spondylolisthesis; fracture; alignment abnormality; NOTE: X-rays CANNOT diagnose disc herniation \u2014 MRI is required Pregnancy (shield abdomen)"},{"location":"plans/cauda-equina-syndrome/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT lumbar spine without contrast STAT STAT - STAT If MRI not available or contraindicated; inferior to MRI for soft tissue but shows bone and canal narrowing; CT myelogram if MRI impossible Disc herniation (seen as soft tissue density in canal); bone fragments; canal diameter; fracture; spondylolisthesis CT alone has limited sensitivity for disc herniation vs. MRI; myelogram adds invasive risk CT myelogram STAT STAT - STAT If MRI absolutely contraindicated (implant); intrathecal contrast via LP \u2192 CT; demonstrates level of block and root compression Complete or partial block; compressed cauda equina roots; level and extent of compression; may miss small free fragments LP contraindicated if abscess suspected at LP site; coagulopathy; rare but important if MRI impossible MRI whole spine - URGENT - URGENT If etiology unclear; evaluate for additional levels of disease; concurrent cord compression; tumor staging; multilevel disc disease Additional sites of compression; intramedullary lesion (conus); multifocal disease Same as lumbar MRI Urodynamic studies - - ROUTINE - Post-acute phase; quantify bladder dysfunction; detrusor areflexia (CES pattern); plan long-term bladder management Detrusor areflexia (areflexic bladder) = cauda equina denervation; decreased bladder sensation; increased capacity; poor emptying Acute UTI; recent surgery (timing per surgeon) Anal manometry / pudendal nerve testing - - EXT - Quantify sphincter dysfunction; prognostic for recovery; pudendal nerve conduction Reduced anal sphincter pressures; denervated pudendal nerve Patient tolerance; acute phase may not be appropriate EMG/NCS (lower extremities + paraspinal) - - ROUTINE - 2-3 weeks post-onset (acute denervation takes 2-3 weeks to appear on EMG); prognosis; differentiate from peripheral neuropathy or plexopathy Bilateral L4-S4 denervation; reduced CMAP amplitudes in bilateral L5/S1 distribution; absent H-reflexes bilaterally; bilateral pudendal neuropathy Too early in acute phase (&lt;2 weeks = may be false negative for denervation); patient tolerance"},{"location":"plans/cauda-equina-syndrome/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT angiography (lumbar) - EXT - EXT If vascular malformation suspected (spinal dural AV fistula causing venous hypertension \u2192 CES symptoms); progressive myelopathy/CES with dilated serpiginous vessels on MRI Spinal AV fistula; AVM; arteriovenous malformation feeding vessels Contrast allergy; renal impairment Spinal angiography - EXT EXT - Definitive diagnosis and treatment of spinal dural AV fistula; also pre-operative embolization for vascular tumors Fistula location; endovascular treatment candidate Invasive; contrast risk; radiation exposure PET/CT - - EXT - If malignancy causing CES \u2014 staging; unknown primary identification Primary tumor; metastatic burden Uncontrolled diabetes; pregnancy Cystometrogram - - EXT - Formal bladder function assessment; post-decompression recovery monitoring; long-term bladder management planning Bladder compliance; detrusor function; capacity; sensation thresholds Active UTI"},{"location":"plans/cauda-equina-syndrome/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP \u2014 Generally NOT indicated acutely - EXT EXT - LP is NOT required for diagnosis of typical CES (disc herniation, tumor, abscess seen on MRI); ONLY if inflammatory/infectious etiology without clear structural cause; OR CT myelogram if MRI impossible CSF protein elevation (GBS, tumor); pleocytosis (infection, inflammation); malignant cells (leptomeningeal disease); albuminocytologic dissociation (GBS) Do NOT perform LP if large disc herniation compressing cauda equina (could theoretically worsen by altering pressure dynamics \u2014 proceed to surgery instead); coagulopathy; abscess at LP site"},{"location":"plans/cauda-equina-syndrome/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/cauda-equina-syndrome/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Emergent surgical decompression STAT STAT - - THIS IS A SURGICAL EMERGENCY \u2014 TIME IS NERVE; Emergent neurosurgery/spine surgery consultation; posterior lumbar laminectomy with discectomy (most common procedure); Timing: Within 24h of symptom onset \u2014 ideally within 24h but outcome improves the sooner surgery is performed; &lt;24h clearly better than &gt;48h; some evidence supports &lt;12h for best outcomes; Complete CES (CES-R with retention): Truly emergent \u2014 surgery as soon as possible (within hours); Incomplete CES (CES-I): Urgent \u2014 surgery within 24h; risk of progressing to complete Ahn et al. (2000): Decompression &lt;48h = significantly better outcomes for bladder recovery (70% vs. 30%); Todd (2005) meta-analysis: Earlier surgery = better outcomes, but exact time threshold debated; DeBois et al. (2019): &lt;24h optimal, &lt;48h acceptable; Srikandarajah et al. (2020): Urgent surgery (&lt;24h) associated with better functional outcomes Bladder management STAT STAT - STAT Bladder scan (PVR) STAT on arrival \u2014 do NOT wait for MRI; if PVR &gt;200 mL \u2192 Foley catheter placement; if PVR &gt;500 mL \u2192 Foley + strict I&amp;O monitoring; avoid overdistension (&gt;600 mL causes detrusor damage \u2014 may become irreversible); document voiding pattern; post-operative: trial of void at 24-48h with PVR checks; CIC (clean intermittent catheterization) teaching if retention persists Bladder overdistension causes detrusor muscle damage \u2192 irreversible areflexic bladder; early catheterization prevents secondary damage; bladder recovery is the MOST SENSITIVE indicator of CES recovery and the MOST COMMON persistent deficit Pain management STAT STAT - STAT Back pain and radicular pain often severe; acetaminophen 650-1000 mg q6h (scheduled) + opioids (morphine 2-4 mg IV q3h PRN or hydromorphone 0.5-1 mg IV q3h PRN); NSAIDs: ketorolac 15-30 mg IV q6h (short-term, if no surgical contraindication and normal renal function \u2014 pre-op use is surgeon-dependent); neuropathic: gabapentin 300 mg TID (start if radicular pain prominent); avoid excessive sedation that obscures neurologic exam Adequate analgesia essential for patient assessment and MRI tolerance; balance with need for neurologic monitoring Dexamethasone (if tumor or abscess) STAT STAT - STAT Disc herniation CES: Steroids NOT routinely indicated (no evidence of benefit; some centers use short course); Tumor-related CES: Dexamethasone 10 mg IV bolus \u2192 4 mg q6h (same as MSCC protocol); Abscess-related CES: Dexamethasone controversial (may impair immune response) \u2014 use only if severe edema with rapid neurologic decline No RCT evidence supporting steroids for disc-related CES; tumor CES: Sorensen et al. (1994) supports steroids; abscess: prioritize antibiotics + surgical drainage Antibiotics (if abscess suspected) STAT STAT - STAT Epidural abscess causing CES: Empiric: Vancomycin 25-30 mg/kg IV load + ceftriaxone 2g IV q12h (or cefepime 2g IV q8h); adjust to culture/sensitivity; MRSA coverage essential; Duration: Typically 6-8 weeks IV antibiotics for epidural abscess; Timing: Start AFTER blood cultures drawn but do NOT delay if patient is deteriorating S. aureus (including MRSA) is most common organism in epidural abscess (60-70%); gram-negative coverage for UTI/abdominal source; streptococci, anaerobes less common DVT prophylaxis STAT STAT - STAT SCDs immediately; pharmacologic prophylaxis: enoxaparin 40 mg SQ daily starting post-operatively (typically 12-24h after surgery per surgeon protocol); immobile CES patients at high VTE risk Immobility + lower extremity weakness = high DVT risk; mechanical prophylaxis pre-operatively; early pharmacologic prophylaxis post-operatively Bowel management STAT STAT - STAT Assess rectal tone (digital rectal exam \u2014 absent/reduced in CES); bowel regimen: docusate 100 mg BID + senna 2 tabs HS; bisacodyl suppository daily if no BM in 48h; monitor for fecal incontinence vs. constipation (both occur in CES); opioid-related constipation compounds the issue Bowel dysfunction common in CES; S2-S4 denervation affects external anal sphincter and rectal sensation; proactive management prevents complications"},{"location":"plans/cauda-equina-syndrome/#3b-definitivetargeted-treatment","title":"3B. Definitive/Targeted Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Lumbar laminectomy + discectomy (disc herniation CES) - STAT - - Most common surgery: Posterior approach; laminectomy at affected level(s); remove herniated disc fragment; decompress cauda equina; Approach: Midline; may require bilateral laminotomy or hemi-laminectomy for lateralized discs; large central herniations often require bilateral approach; Key: Ensure COMPLETE decompression \u2014 incomplete decompression leads to persistent deficit; intraoperative confirmation with direct visualization of free cauda equina nerve roots Gold standard for disc-related CES; no RCT comparing surgery vs. non-operative (would be unethical to randomize given natural history); observational data uniformly supports early surgical decompression Microdiscectomy (if technically appropriate) - STAT - - Minimally invasive approach; appropriate for contained disc herniations without significant canal stenosis; faster recovery; less tissue disruption; may not provide adequate decompression for massive central disc herniation Smaller incision, less muscle disruption; but surgeon must ensure adequate decompression \u2014 do NOT compromise canal visualization for a smaller incision in CES Surgical drainage + decompression (epidural abscess) - STAT - - Posterior approach; laminectomy; drain abscess; culture material; irrigate; leave wound open or with drain; may require multi-level decompression; Combined with: IV antibiotics 6-8 weeks; follow with serial MRI and inflammatory markers Epidural abscess with CES = surgical emergency; medical management alone (antibiotics without surgery) only if: no neurologic deficit AND very high surgical risk; most CES presentations require surgery Tumor resection + decompression - STAT - - If tumor-related CES (e.g., schwannoma, ependymoma, metastasis); posterior decompression \u00b1 en bloc or piecemeal tumor resection; send pathology; may need subsequent radiation/chemotherapy Intradural-extramedullary tumors (schwannoma, meningioma, myxopapillary ependymoma) are potentially curable with complete resection; metastatic CES \u2192 decompression + radiation Hematoma evacuation - STAT - - Epidural hematoma causing CES (spontaneous on anticoagulation, post-procedural, or post-traumatic); emergent laminectomy with hematoma evacuation; reverse anticoagulation STAT Spontaneous spinal epidural hematoma: Groen &amp; Ponssen (1990): better outcomes with surgery &lt;12h of onset; anticoagulation reversal essential (4F-PCC for warfarin, idarucizumab for dabigatran, andexanet for Xa inhibitors) Non-operative management (rare, selected cases) - - ROUTINE - ONLY appropriate if: (1) Imaging does NOT show significant structural compression, (2) Symptoms are improving spontaneously, (3) Patient refuses surgery (document informed refusal thoroughly), (4) Medically inoperable (extremely high surgical risk); Requires: Close monitoring with serial neuro exams q2-4h; repeat MRI if worsening; immediate surgery if any progression Non-operative management is NOT standard of care for CES with structural compression; delayed surgery has worse outcomes; informed consent must document risks of non-operative management (permanent bladder/bowel/sexual dysfunction, progressive weakness)"},{"location":"plans/cauda-equina-syndrome/#3c-adjunctive-treatment","title":"3C. Adjunctive Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Clean intermittent catheterization (CIC) training - ROUTINE ROUTINE - If bladder function does not recover by 48-72h post-surgery; teach patient CIC q4-6h; target PVR &lt;100 mL before discontinuing CIC; may take weeks to months to recover CIC is preferred over indwelling Foley for long-term bladder management (lower UTI risk); most patients can learn self-catheterization; bladder recovery may take 6-12 months Neuropathic pain management - STAT ROUTINE STAT Gabapentin 300 mg PO TID \u2192 titrate to 600-900 mg TID over 1-2 weeks; OR pregabalin 75 mg BID \u2192 150-300 mg BID; duloxetine 30 mg daily \u2192 60 mg daily; amitriptyline 10-25 mg HS (caution: urinary retention may worsen); topical lidocaine 5% patches for localized radicular pain Neuropathic pain (burning, tingling, electric shocks in perineum, legs) is common and debilitating after CES; may persist chronically; multimodal approach needed Physical therapy / rehabilitation - URGENT ROUTINE - PT evaluation within 24h post-operatively; early mobilization; lower extremity strengthening; gait training; core stabilization; progressive activity as tolerated; pelvic floor PT for bladder/bowel recovery Early rehabilitation improves functional outcomes; pelvic floor rehabilitation is evidence-based for bladder/bowel recovery after CES Occupational therapy - ROUTINE ROUTINE - ADL assessment; adaptive equipment; if lower extremity weakness impairs function; bathroom modifications; return-to-work planning Functional independence optimization Pelvic floor rehabilitation - - ROUTINE - Specialized pelvic floor PT; biofeedback for bladder and bowel retraining; Kegel exercises (if able); electrical stimulation of pelvic floor; sacral neuromodulation evaluation if persistent dysfunction &gt;12 months Evidence supports pelvic floor PT for bladder and bowel recovery after CES; biofeedback improves outcomes Psychological support - ROUTINE ROUTINE - CES has devastating psychosocial impact (sexual dysfunction, incontinence, chronic pain, disability in often-young patients); depression screening (PHQ-9); anxiety screening; sexual health counseling; support groups; consider psychiatry referral Depression affects 30-60% of CES patients long-term; sexual dysfunction is profoundly distressing; early psychological intervention improves coping and recovery Stool softener / bowel program STAT STAT ROUTINE STAT Docusate 100 mg BID + senna 2 tabs HS; bisacodyl suppository PRN; digital stimulation for areflexic bowel; timed bowel program; fiber supplementation; adequate hydration Neurogenic bowel management reduces complications (impaction, incontinence); establish routine bowel program early"},{"location":"plans/cauda-equina-syndrome/#3d-medications-to-avoid-or-use-with-caution","title":"3D. Medications to AVOID or Use with Caution","text":"Medication Risk/Concern Alternative Anticholinergics (oxybutynin, tolterodine \u2014 for urgency) May worsen urinary retention in CES (areflexic bladder); do NOT prescribe for \"overactive bladder\" symptoms in CES \u2014 the bladder is UNDERACTIVE CIC for retention; pelvic floor PT; if detrusor overactivity confirmed on urodynamics post-recovery, then anticholinergics may be appropriate Tricyclic antidepressants (amitriptyline, nortriptyline) Urinary retention as anticholinergic side effect; may worsen neurogenic bladder Duloxetine (less anticholinergic); gabapentin/pregabalin for neuropathic pain; SSRI for depression Alpha-blockers (tamsulosin, silodosin) \u2014 without urologic guidance May be helpful for bladder outlet obstruction but CES retention is typically detrusor areflexia, NOT outlet obstruction; indiscriminate use may worsen incontinence Urology consultation for targeted pharmacotherapy; urodynamics before pharmacologic intervention NSAIDs (prolonged, peri-operative) Some surgeons avoid NSAIDs around spinal fusion (theoretical concern about bone healing \u2014 controversial); renal risk; GI bleed; antiplatelet effect Acetaminophen; opioids PRN; gabapentin/pregabalin for neuropathic pain; surgeon-specific preference Epidural steroid injection (as treatment for CES) Epidural injection does NOT treat CES and may delay surgery; contraindicated in the setting of epidural abscess; may worsen infection; NOT a substitute for surgical decompression Emergency surgical decompression is the only definitive treatment for CES; epidural injections are for chronic radiculopathy, NOT CES Chiropractic manipulation (lumbar) Risk of worsening disc herniation and CES; manipulation is contraindicated in CES; has been reported as a CAUSE of CES (disc herniation during manipulation) Surgical decompression; post-operative PT with evidence-based spine rehabilitation Excessive IV fluids (post-operatively) Bladder overdistension in patients who cannot sense bladder fullness; may cause detrusor damage Foley or scheduled CIC post-operatively; strict I&amp;O; avoid IV fluid rates that exceed anticipated output without bladder drainage"},{"location":"plans/cauda-equina-syndrome/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/cauda-equina-syndrome/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurosurgery / Spine surgery consultation \u2014 EMERGENCY STAT STAT - STAT IMMEDIATE consultation upon clinical suspicion of CES \u2014 do NOT wait for MRI to consult; communicate urgency; CES is a recognized surgical emergency; the spine surgeon should be contacted concurrently with MRI ordering; if no spine surgeon available \u2192 emergent transfer to facility with 24/7 spine surgery capability Post-void residual (bladder scan) STAT STAT - STAT Perform BEFORE MRI \u2014 PVR is a rapid, non-invasive triage tool; PVR &gt;200 mL in the setting of bilateral radiculopathy/perineal symptoms = HIGH suspicion for CES; informs urgency of MRI and surgical consultation Digital rectal examination STAT STAT - STAT Assess perianal sensation (S2-S4); anal sphincter tone (reduced or absent in CES); voluntary contraction; anocutaneous reflex (absent in CES \u2014 tests S2-S4 arc); this is an essential component of the neurologic exam and MUST be documented Comprehensive neurologic exam documentation STAT STAT - STAT Document: bilateral lower extremity strength (L2-S2 myotomes); sensation (light touch, pinprick) \u2014 especially perianal/perineal (S2-S5 dermatomes); deep tendon reflexes (ankle jerks); plantar responses; bulbocavernosus reflex; anal wink; rectal tone; bladder function; sexual function (ask about erectile function/genital sensation) Classify CES subtype STAT STAT - STAT CES-Incomplete (CES-I): Altered urinary sensation, difficulty initiating voiding, reduced perineal sensation BUT still has some bladder function (partial retention); CES-Retention (CES-R): Painless urinary retention, overflow incontinence, absent perineal sensation, absent anal tone; CES-R is a more advanced stage with worse prognosis Informed consent for surgery STAT STAT - - Document discussion of: surgical risks, CES natural history without surgery (progressive permanent paralysis, incontinence, sexual dysfunction), realistic outcome expectations (bladder recovery is slowest and most uncertain), risk of persistent deficits even with surgery Transfer to surgical center (if no spine surgeon) STAT - - - If presenting ED does not have spine surgery capability \u2192 EMERGENT transfer; obtain MRI at presenting facility first if possible (saves time at receiving facility); Foley catheter before transfer; dexamethasone if tumor-related"},{"location":"plans/cauda-equina-syndrome/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Urology consultation - ROUTINE ROUTINE - Neurogenic bladder management; urodynamic testing at 6-12 weeks post-surgery; long-term bladder plan (CIC vs. indwelling vs. suprapubic catheter); sexual health assessment PM&amp;R / Rehabilitation consultation - URGENT ROUTINE - Inpatient rehab candidacy if significant motor deficits; PT/OT coordination; assistive devices; functional goals; return-to-work timeline Pain management consultation - ROUTINE ROUTINE - If pain refractory to standard analgesics + neuropathic agents; chronic pain planning; may need interventional pain procedures (nerve blocks, neuromodulation) in chronic phase Sexual health counseling - ROUTINE ROUTINE - Sexual dysfunction affects 40-70% of CES patients long-term; erectile dysfunction in males (S2-S4); female sexual dysfunction (decreased genital sensation, lubrication difficulties); refer to sexual health specialist; PDE5 inhibitors (sildenafil) for ED; vacuum devices; referral to urology/gynecology Colorectal surgery / GI consultation - - ROUTINE - Persistent fecal incontinence; sacral nerve stimulation evaluation; biofeedback-refractory bowel dysfunction; anal sphincter repair assessment Social work / case management - ROUTINE ROUTINE - Disability assessment; workplace accommodations; home modifications (bathroom accessibility); caregiver support; insurance navigation; support groups (Cauda Equina Syndrome Association) Medicolegal documentation STAT STAT ROUTINE STAT CES is one of the most litigated conditions in spine surgery; document: time of symptom onset, time of presentation, time of MRI, time of surgical consultation, time of surgery, neurologic exam at each time point, bladder function assessment, rationale for any delays; CES diagnosis is a recognized emergency standard of care"},{"location":"plans/cauda-equina-syndrome/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Revision surgery - URGENT ROUTINE - If post-operative MRI shows residual compression (retained disc fragment); persistent or worsening deficits after initial surgery; recurrent disc herniation Sacral neuromodulation - - EXT - For refractory neurogenic bladder or fecal incontinence &gt;12 months post-decompression; InterStim device implantation; requires trial stimulation first; evidence growing for neurogenic populations Intrathecal baclofen pump - - EXT - If spasticity develops (rare in pure cauda equina lesion \u2014 suggests conus involvement); more relevant for conus medullaris syndrome Chronic pain management program - - ROUTINE - Multidisciplinary chronic pain program; cognitive behavioral therapy for pain; mindfulness-based stress reduction; graded activity program; may need long-term opioid management with monitoring Psychiatric referral - ROUTINE ROUTINE - PTSD, depression, anxiety common post-CES; body image disturbance; sexual dysfunction grief; chronic pain coping; may need medication management Legal documentation review - - ROUTINE - If delayed diagnosis is a concern; risk management consultation; ensure complete medical record documentation <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/cauda-equina-syndrome/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/cauda-equina-syndrome/#primary-differential-diagnoses","title":"Primary Differential Diagnoses","text":"Diagnosis Key Differentiating Features Distinguishing Studies Conus medullaris syndrome Upper motor neuron AND lower motor neuron signs; bilateral and symmetric; early bladder/bowel dysfunction; back pain less prominent than radicular pain; reflexes may be hyperactive (UMN) or absent (LMN); typically at T12-L2 level; more symmetric than CES MRI: lesion at T12-L2 level (conus); cord signal change (T2 hyperintensity); CES lesion is below L1-L2 (cauda equina roots only); conus lesion \u2192 Babinski may be present (CES \u2192 absent or flexor) Lumbar spinal stenosis (without CES) Neurogenic claudication (walking-induced symptoms relieved by sitting/flexion); chronic progressive course; bilateral leg pain/weakness with walking; no bladder/bowel dysfunction (unless severe CES from stenosis); intermittent symptoms MRI: multilevel stenosis; trefoil canal shape; ligamentum flavum hypertrophy; NO acute disc herniation; symptoms are exercise-induced, not constant; PVR normal Acute disc herniation (without CES) Unilateral radiculopathy; no bilateral symptoms; no saddle anesthesia; no bladder/bowel dysfunction; straight leg raise positive; single dermatomal pattern MRI: lateral or posterolateral disc herniation compressing single root; NO cauda equina compression; normal PVR; normal rectal tone Epidural abscess Fever (50-66%); IVDU, immunocompromised, recent procedure; rapidly progressive; ESR &gt;20 (94% sensitivity); severe spinal tenderness; leukocytosis; can cause CES if lumbar location MRI: ring-enhancing epidural collection with restricted diffusion; blood cultures positive (60%); ESR/CRP markedly elevated; clinical triad: back pain \u2192 radiculopathy \u2192 weakness (classic but only 10-15% present with full triad) Epidural hematoma Acute onset; anticoagulation or post-procedural (epidural injection, spinal surgery, LP); severe back pain \u2192 rapid progressive weakness; coagulopathy history MRI: epidural collection with blood signal (T1 bright in subacute); coagulation studies abnormal; anticoagulation history; post-procedural temporal relationship Guillain-Barr\u00e9 syndrome (GBS) Ascending symmetric weakness; areflexia; post-infectious (Campylobacter, CMV, EBV); sensory symptoms but often mild; facial weakness may be present; no saddle anesthesia typically; CSF: albuminocytologic dissociation MRI spine: may show nerve root enhancement BUT no structural compression; CSF: elevated protein, normal cells; NCS: demyelinating pattern or AMAN pattern; anti-ganglioside antibodies Peripheral neuropathy (bilateral) Chronic course; distal &gt; proximal; length-dependent pattern; diabetes, alcohol; stocking-glove distribution; gradual onset; reflexes may be reduced distally; NO saddle anesthesia; NO acute bladder retention EMG/NCS: diffuse length-dependent neuropathy; MRI: no structural compression; HbA1c; B12; SPEP; gradual course distinguishes from acute CES Lumbosacral plexopathy Unilateral (usually); painful; diabetic amyotrophy; radiation-induced; tumor infiltration; asymmetric weakness/sensory loss in lumbosacral plexus distribution; typically NO bladder dysfunction (unless bilateral) MRI pelvis: plexus enhancement or mass; EMG: plexus distribution denervation; CT abdomen/pelvis: retroperitoneal mass; HbA1c; typically unilateral Functional neurological disorder (FND) Inconsistent exam findings; Hoover's sign positive; non-anatomical sensory pattern; normal imaging; normal PVR; no objective sphincter dysfunction; give-way weakness; history of psychological stressors MRI: normal; PVR: normal; rectal tone: normal; neurophysiology: normal; psychiatric history; clinical inconsistency (e.g., inability to lift leg on command but normal gait observed); NOTE: FND is a diagnosis of exclusion in CES \u2014 always obtain MRI first"},{"location":"plans/cauda-equina-syndrome/#ces-i-vs-ces-r-classification","title":"CES-I vs. CES-R Classification","text":"Feature CES-Incomplete (CES-I) CES-Retention (CES-R) Bladder function Altered sensation; difficulty initiating stream; incomplete emptying; urgency Painless retention; overflow incontinence; no desire to void PVR 200-500 mL (partial retention) &gt;500 mL (complete retention) Perineal sensation Reduced but present Absent or markedly reduced Anal tone Reduced Absent Prognosis with surgery Better outcomes; most regain bladder function Worse outcomes; 30-50% persistent bladder dysfunction Urgency Urgent (within 24h) Emergent (within hours \u2014 ASAP)"},{"location":"plans/cauda-equina-syndrome/#red-flags-requiring-urgent-reassessment","title":"Red Flags Requiring Urgent Reassessment","text":"Red Flag Concern Action Progressive bilateral leg weakness Evolving CES; worsening compression; expanding hematoma STAT MRI; emergent surgery; escalate surgical urgency Loss of bladder function (CES-I \u2192 CES-R) Progression from incomplete to complete CES; bladder recovery significantly worse after retention onset IMMEDIATE surgery; do NOT wait for elective OR time; OR should be arranged within hours Complete saddle anesthesia Complete S2-S5 denervation; poor prognostic sign STAT surgery; this represents advanced CES-R Bilateral foot drop (new) L4-L5 root denervation bilaterally; severe compression Emergent decompression Fever + back pain + neurologic deficit Epidural abscess potentially causing/mimicking CES Blood cultures; MRI with contrast; empiric antibiotics; surgical drainage if abscess confirmed Fecal incontinence (new) S2-S4 denervation progressing; significant cauda equina compromise Emergent surgery if not already performed; if post-operative \u2192 urgent MRI for residual compression Urinary retention increasing despite Foley (inability to trial void) Worsening or persistent denervation; incomplete decompression; re-herniation Post-op MRI; urodynamics; consider revision surgery if compression persists"},{"location":"plans/cauda-equina-syndrome/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/cauda-equina-syndrome/#acute-phase-monitoring-pre-operative-and-first-72h-post-operative","title":"Acute Phase Monitoring (Pre-operative and First 72h Post-operative)","text":"Parameter Frequency Target Action if Abnormal Neurologic examination (lower extremity strength, sensation, reflexes) q2-4h pre-operatively; q4h post-operatively x 48h Stable pre-op; improving post-op Pre-op worsening: escalate surgical urgency; post-op worsening: STAT MRI (hematoma, residual compression, re-herniation) Perianal/perineal sensation and rectal tone q4h (at minimum with each neuro check) Improving or stable Worsening: STAT MRI Bladder function / PVR Continuous monitoring via Foley with hourly I&amp;O pre/post-op; Trial of void at 24-48h post-op with PVR check PVR &lt;100 mL to discontinue catheter; voiding spontaneously PVR &gt;200 mL after trial of void \u2192 replace Foley; begin CIC teaching; urology consult Pain assessment (NRS) q4h NRS &lt;4/10 Escalate analgesics; add neuropathic agents; new/worsening pain post-op \u2192 concern for hematoma/complication Wound assessment (post-operative) q8h No drainage, swelling, erythema, dehiscence Wound complication \u2192 surgical team notification; drain output monitoring Bowel function Daily BM within 48-72h post-op Bowel regimen intensification; abdominal X-ray if distended; rectal exam Temperature q4h Afebrile Fever: wound infection, UTI (Foley-associated), DVT, abscess; cultures and imaging as indicated DVT screening Daily calf circumference; symptoms No DVT signs Bilateral lower extremity duplex US if symptoms; therapeutic anticoagulation if confirmed"},{"location":"plans/cauda-equina-syndrome/#subacuteoutpatient-monitoring","title":"Subacute/Outpatient Monitoring","text":"Parameter Frequency Target Action if Abnormal Neurologic examination 2 weeks post-op, 6 weeks, 3 months, 6 months, 12 months Progressive improvement; stable at plateau Worsening: MRI for re-herniation or residual disease; EMG at 3 months Bladder function (PVR) Each visit until resolved; formal urodynamics at 6-12 weeks if persistent dysfunction PVR &lt;100 mL; spontaneous voiding; continent PVR &gt;200 mL \u2192 continue CIC; urology follow-up; sacral neuromodulation evaluation at 12 months if persistent Bowel function Each visit Regular BMs; continent Persistent incontinence \u2192 colorectal referral; biofeedback; sacral neuromodulation Sexual function assessment 6 weeks, 3 months, 6 months, 12 months Recovering sensation; erectile function (males); genital sensation (all) PDE5 inhibitors for ED; sexual health counseling; pelvic floor PT Pain assessment Each visit Controlled with oral medications; decreasing over time Chronic neuropathic pain management; multidisciplinary pain program if persistent &gt;6 months MRI lumbar spine 6 weeks post-op (baseline), then PRN if symptoms recur No residual compression; no recurrent herniation Recurrent herniation: revision surgery if symptomatic EMG/NCS 3 months post-onset (if persistent deficits) Reinnervation signs; improving motor unit potentials No reinnervation at 3-6 months \u2192 guarded prognosis; continued rehabilitation; adaptive strategies Depression/psychological screening (PHQ-9) Each visit PHQ-9 &lt;5 SSRI; psychological referral; support group (CES Association) Functional assessment (Oswestry Disability Index, SF-36) 3 months, 6 months, 12 months Improving scores Intensify rehabilitation; address barriers; vocational rehabilitation"},{"location":"plans/cauda-equina-syndrome/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/cauda-equina-syndrome/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU admission Post-operative monitoring (surgeon-dependent \u2014 many post-laminectomies go to floor); bilateral lower extremity paralysis with hemodynamic concerns; epidural abscess with sepsis; significant comorbidities affecting anesthetic recovery; autonomic dysfunction General neurosurgery/spine floor ALL CES patients require admission; pre-operative CES awaiting surgical decompression; post-operative monitoring; pain management; bladder/bowel monitoring; PT/OT initiation; epidural abscess requiring IV antibiotics Observation (NOT appropriate) CES is NEVER an observation diagnosis \u2014 all suspected CES patients require emergent MRI and admission for surgical evaluation; even if MRI is negative for structural compression, admission for monitoring is prudent if clinical suspicion is high"},{"location":"plans/cauda-equina-syndrome/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Neurologic stability Stable or improving neurologic exam for \u226524-48h post-surgery; no progressive deficits Pain controlled Adequate pain control on oral medications; able to participate in PT Bladder management plan Voiding spontaneously with PVR &lt;100 mL OR CIC teaching completed and patient/caregiver competent; urology follow-up arranged Bowel function BM occurred; bowel regimen established; patient educated on bowel program Wound healing Surgical wound clean, dry, intact; no signs of infection; wound care instructions provided Mobility assessment PT clearance; safe ambulation (with or without assistive device); home safety assessment; OR inpatient rehab transfer DVT prophylaxis plan Pharmacologic prophylaxis continuing (enoxaparin for 2-4 weeks post-op per surgeon protocol); or transitioned to mobilization-based prevention Follow-up arranged Spine surgery (2 weeks), urology (4-6 weeks), PM&amp;R (2-4 weeks if deficits), PCP (1 week), pelvic floor PT (after surgical clearance) Patient/family education Activity restrictions (lifting, bending, twisting restrictions per surgeon \u2014 typically 6 weeks); when to return to ED (new weakness, loss of bladder/bowel function, fever, wound drainage); CIC technique if applicable; bowel program; realistic expectations for recovery timeline"},{"location":"plans/cauda-equina-syndrome/#discharge-prescriptions-checklist","title":"Discharge Prescriptions Checklist","text":"Medication Details Analgesics Acetaminophen scheduled; limited opioid PRN with taper plan (2-4 weeks); avoid prolonged opioids Neuropathic pain agent Gabapentin or pregabalin if radicular/neuropathic pain Bowel regimen Docusate + senna (especially if on opioids); PRN bisacodyl DVT prophylaxis Enoxaparin 40 mg SQ daily x 2-4 weeks (per surgeon protocol) Antibiotics (if abscess) Completion of IV antibiotics (arrange PICC and home IV antibiotics); typically 6-8 weeks total course CIC supplies (if applicable) Catheters, lubricant, collection bags; home health nursing for CIC training reinforcement Stool softeners Ongoing bowel program medications"},{"location":"plans/cauda-equina-syndrome/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/cauda-equina-syndrome/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Cauda Equina Syndrome Standards of Care British Association of Spine Surgeons (BASS) / Society of British Neurological Surgeons (SBNS) 2020 CES is a surgical emergency; MRI within 4h; surgical decompression within 24h (ideally ASAP); classify CES-I vs. CES-R; bladder scan is essential triage tool CES Emergency Pathway NICE / NHS England 2018 (updated 2023) Suspected CES \u2192 emergent MRI \u2192 same-day surgical review; do NOT delay MRI; 24/7 access to MRI required; document timeline meticulously AANS/CNS Guidelines on Lumbar Disc Herniation AANS/CNS Joint Section on Disorders of the Spine and Peripheral Nerves 2014 CES from disc herniation is a surgical emergency; emergent decompression recommended"},{"location":"plans/cauda-equina-syndrome/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Ahn et al. (2000) Systematic review: Decompression &lt;48h of CES onset \u2192 70% bladder recovery vs. 30% if &gt;48h; motor outcomes also significantly better with early surgery Established 48h as important threshold; but sooner is always better Todd (2005) \u2014 Meta-analysis 42 studies: Earlier decompression consistently associated with better outcomes across motor, bladder, and bowel domains; no clear cutoff but &lt;24h is optimal Confirmed urgency of CES surgical decompression; surgical timing is KEY modifiable factor Srikandarajah et al. (2020) UK Cohort: Urgent surgery (&lt;24h) vs. delayed (&gt;24h): better bladder outcomes (OR 2.1) and motor outcomes (OR 1.6) with urgent surgery Modern evidence supporting &lt;24h surgical timing; NHS pathway development DeBois et al. (2019) Timing analysis: &lt;12h, 12-24h, 24-48h, &gt;48h: progressive decline in outcomes with each delay interval; &lt;12h had best bladder recovery Supports as-soon-as-possible approach; &lt;12h may be ideal Gleave &amp; Macfarlane (2002) CES-I vs. CES-R outcomes: CES-I (incomplete) with early surgery \u2192 95% good bladder outcome; CES-R (retention) with early surgery \u2192 53% good bladder outcome; CES-R with delayed surgery \u2192 27% good outcome Established CES-I vs. CES-R classification; demonstrated that retention onset is critical prognostic marker Groen &amp; Ponssen (1990) Spinal epidural hematoma: better outcomes with surgery &lt;12h of onset; anticoagulation most common cause Established surgical urgency for hematoma-related CES Kostuik et al. (1986) Classic paper on CES natural history: untreated CES from disc herniation \u2192 permanent bladder dysfunction in &gt;90%, persistent weakness in &gt;70%, chronic pain in &gt;80% Established that CES without surgical treatment leads to devastating permanent deficits McCarthy et al. (2014) Medicolegal analysis: CES is the most litigated condition in spinal surgery; delayed diagnosis is the most common reason for successful claims; failure to perform timely MRI and delayed surgery are key factors Documentation of timeline is CRITICAL; standardized CES pathways reduce medicolegal risk"},{"location":"plans/cauda-equina-syndrome/#clinical-classification","title":"Clinical Classification","text":"<p>CES Subtypes (Gleave &amp; Macfarlane Classification)</p> Subtype Definition Key Features Prognosis CES-Suspected (CES-S) Bilateral radiculopathy/symptoms WITHOUT bladder dysfunction Bilateral leg pain/weakness; bilateral sensory changes; NO urinary symptoms; normal PVR Best prognosis; may not progress to CES if decompressed promptly; but ~70% will progress to CES-I or CES-R without surgery CES-Incomplete (CES-I) Altered urinary function WITHOUT retention Difficulty initiating stream; reduced sensation of voiding; urgency; partial retention (PVR 200-500 mL); reduced but present perineal sensation; reduced anal tone Good prognosis with early surgery: 95% good bladder outcome (Gleave &amp; Macfarlane, 2002) CES-Retention (CES-R) Painless urinary retention WITH overflow incontinence Painless retention (PVR &gt;500 mL); overflow incontinence; absent perineal sensation; absent anal tone; often absent bulbocavernosus reflex Poorer prognosis: 53% good outcome with early surgery; 27% with delayed surgery <p>Examination Checklist for CES</p> Component Bilateral L4 Bilateral L5 Bilateral S1 S2-S4 (Sacral roots) Motor Knee extension (quad) Ankle dorsiflexion (TA), great toe extension (EHL), hip abduction Ankle plantarflexion (gastroc); hip extension (gluteus max) Anal sphincter tone (DRE); bulbocavernosus reflex Sensory Medial leg/shin Lateral leg, dorsum of foot, first web space Lateral foot, sole, posterior calf Perianal (S2-S5); perineum; posterior thigh; \"saddle area\" Reflex Patellar (L3-L4) Tibialis posterior (L5 \u2014 inconsistent) Achilles ankle jerk (S1-S2) Anocutaneous reflex (\"anal wink\"); bulbocavernosus reflex (S2-S4) Function Walking, stairs Heel walking Toe walking Bladder: voiding, PVR; Bowel: rectal sensation, tone; Sexual: erectile function, genital sensation"},{"location":"plans/cauda-equina-syndrome/#appendices","title":"APPENDICES","text":""},{"location":"plans/cauda-equina-syndrome/#appendix-a-ces-etiologies-and-frequency","title":"Appendix A: CES Etiologies and Frequency","text":"Etiology Frequency Key Features Treatment Lumbar disc herniation (massive central) 45-50% Most common cause; L4-L5 or L5-S1 most frequent; large central or central-lateral fragment; may follow heavy lifting, trauma, or spontaneous Emergent laminectomy + discectomy Lumbar spinal stenosis (severe) 15-20% Chronic stenosis with acute-on-chronic decompensation; multilevel; often older patients; spondylolisthesis may contribute Decompressive laminectomy \u00b1 fusion for instability Tumor (primary or metastatic) 10-15% Intradural-extramedullary (schwannoma, meningioma, ependymoma); extradural (metastasis, myeloma); progressive course; may be insidious or acute Surgical resection \u00b1 radiation; dexamethasone if edema Epidural abscess 5-10% Fever; IVDU; recent procedure; immunocompromised; ESR/CRP elevated; subacute course (days to weeks); S. aureus most common Surgical drainage + IV antibiotics (6-8 weeks) Epidural hematoma 3-5% Anticoagulation; post-procedural; coagulopathy; acute onset with rapid progression Emergent hematoma evacuation; reverse anticoagulation Trauma / fracture 3-5% Burst fracture with retropulsed fragments; sacral fracture; seatbelt injury; high-energy mechanism Surgical stabilization and decompression Post-operative (complication) 2-3% After lumbar surgery (hematoma, retained fragment, excessive retraction); onset hours to days after initial surgery Revision surgery; evacuate hematoma; remove retained fragment Inflammatory (sarcoidosis, arachnoiditis) 1-2% Nerve root clumping (arachnoiditis); enhancing roots (sarcoidosis); chronic progressive; often diagnosis of exclusion Immunosuppression (sarcoidosis); limited options for arachnoiditis (intrathecal steroids controversial) Vascular (AVM, dural AV fistula) &lt;1% Progressive myelopathy/CES; dilated vessels on MRI; may have episodic worsening; can cause venous congestion of conus/cauda equina Endovascular embolization; surgical ligation Chiropractic manipulation (iatrogenic) Rare but reported Disc herniation during manipulation; acute onset during or immediately after treatment Emergent surgical decompression"},{"location":"plans/cauda-equina-syndrome/#appendix-b-ces-emergency-pathway","title":"Appendix B: CES Emergency Pathway","text":"<pre><code>SUSPECTED CAUDA EQUINA SYNDROME\n(Bilateral radiculopathy + ANY of: bladder dysfunction, saddle anesthesia, bowel dysfunction, bilateral weakness)\n                    \u2502\n                    \u251c\u2500\u2500 TRIAGE (within 15 minutes of arrival)\n                    \u2502     \u2022 Bladder scan (PVR) \u2014 STAT\n                    \u2502     \u2022 Digital rectal exam \u2014 perianal sensation + anal tone\n                    \u2502     \u2022 Document bilateral LE strength + sensation\n                    \u2502     \u2022 Document time of symptom onset\n                    \u2502\n                    \u251c\u2500\u2500 PVR Result?\n                    \u2502     PVR &gt;500 mL \u2192 CES-Retention \u2192 EMERGENT MRI + Surgery ASAP\n                    \u2502     PVR 200-500 mL \u2192 CES-Incomplete \u2192 URGENT MRI + Surgery within 24h\n                    \u2502     PVR &lt;200 mL \u2192 CES less likely BUT:\n                    \u2502           If saddle anesthesia + bilateral symptoms \u2192 URGENT MRI anyway\n                    \u2502           If no CES features \u2192 standard radiculopathy workup\n                    \u2502\n                    \u251c\u2500\u2500 Order MRI STAT (lumbar spine, without contrast initially)\n                    \u2502     Target: MRI within 1-4 hours of presentation\n                    \u2502     If MRI unavailable \u2192 CT myelogram OR transfer to MRI-capable facility\n                    \u2502\n                    \u251c\u2500\u2500 Contact Spine Surgery IMMEDIATELY (concurrent with MRI)\n                    \u2502     Do NOT wait for MRI results to call\n                    \u2502\n                    \u251c\u2500\u2500 MRI Results:\n                    \u2502     Structural compression confirmed \u2192 Emergent surgical decompression\n                    \u2502     \u2502     \u2022 Disc herniation \u2192 Laminectomy + discectomy\n                    \u2502     \u2502     \u2022 Abscess \u2192 Drainage + antibiotics\n                    \u2502     \u2502     \u2022 Tumor \u2192 Decompression \u00b1 dexamethasone\n                    \u2502     \u2502     \u2022 Hematoma \u2192 Evacuation + reverse anticoagulation\n                    \u2502     \u2502\n                    \u2502     No structural compression \u2192 Consider:\n                    \u2502           \u2022 GBS (CSF, NCS)\n                    \u2502           \u2022 Inflammatory (sarcoidosis, arachnoiditis)\n                    \u2502           \u2022 Vascular (AV fistula)\n                    \u2502           \u2022 Reconsider diagnosis (conus, FND)\n                    \u2502\n                    \u2514\u2500\u2500 Post-Operative:\n                          \u2022 Neurologic checks q4h x 48h\n                          \u2022 Trial of void at 24-48h \u2192 PVR check\n                          \u2022 PT/OT within 24h\n                          \u2022 Document all timelines meticulously\n</code></pre>"},{"location":"plans/cauda-equina-syndrome/#appendix-c-ces-vs-conus-medullaris-syndrome-comparison","title":"Appendix C: CES vs. Conus Medullaris Syndrome \u2014 Comparison","text":"Feature Cauda Equina Syndrome Conus Medullaris Syndrome Anatomic level Below L1-L2 (nerve roots only) T12-L2 (spinal cord terminus) Motor Asymmetric (root distribution); LMN pattern; atrophy; fasciculations Symmetric; may have UMN signs (Babinski, spasticity) AND LMN signs Sensory \"Saddle\" anesthesia (perianal S2-S5); asymmetric; radicular pattern; dermatomal Symmetric saddle anesthesia; bilateral; may have dissociated sensory loss Pain Severe radicular pain; unilateral or bilateral; often prominent Less prominent pain; may have visceral-type pain Reflexes Absent ankle jerks; reduced patellar reflexes Ankle jerks absent; Babinski may be present (UMN component); bulbocavernosus reflex absent Bladder Late onset (may be subtle initially \u2192 progression to retention) Early and prominent (often presenting feature); areflexic bladder Bowel Late; often preserved initially Early; constipation and incontinence Sexual function Late; asymmetric erectile dysfunction Early; bilateral Onset Often acute (disc herniation); can be subacute May be more gradual; depends on etiology MRI finding Compressive lesion below L1-L2; compressed nerve roots Lesion at T12-L2; intramedullary conus signal change; may have cord expansion"},{"location":"plans/cauda-equina-syndrome/#appendix-d-recovery-timeline-and-expectations","title":"Appendix D: Recovery Timeline and Expectations","text":"Function Expected Recovery Timeline Prognostic Factors Long-term Outcome Motor (leg strength) Begins within days-weeks; majority of recovery in first 6 months; continues up to 12-18 months Pre-operative motor grade; duration of deficit before surgery; CES-I vs. CES-R 80-90% recover functional ambulation if decompressed within 24-48h; foot drop may be slow/incomplete Bladder Slowest to recover; may take 6-12 months; initial period of retention \u2192 may evolve to urgency/frequency \u2192 hopefully normalizes MOST IMPORTANT: PVR at presentation (retention = worse); surgical timing (&lt;24h = better); bilateral vs. unilateral root involvement 70% recover useful bladder function if &lt;48h surgery (Ahn et al.); 30-50% persistent dysfunction in CES-R; CIC may be lifelong Bowel Moderate recovery; weeks to months; fecal urgency common before continence improves Degree of S2-S4 denervation; surgical timing 60-70% recover satisfactory continence; 10-20% have persistent fecal incontinence Sexual function Variable; months to years; often incomplete S2-S4 root recovery; psychological factors; pre-existing function 40-70% report persistent sexual dysfunction; male erectile dysfunction common; female genital sensation changes; psychological impact significant Pain Radicular pain often improves rapidly post-decompression; neuropathic pain may persist or develop over weeks; chronic pain syndrome in 20-40% Nerve root damage severity; psychological comorbidity; chronicity before surgery 20-40% develop chronic neuropathic pain syndrome; multimodal management needed Overall Most recovery occurs in first 6-12 months; slower improvement may continue up to 2 years; deficits persisting beyond 2 years are likely permanent Surgical timing; pre-operative deficit severity; CES-I vs. CES-R; age; comorbidities Quality of life significantly impacted in 30-50% long-term; multidisciplinary rehabilitation and psychological support essential"},{"location":"plans/cauda-equina-syndrome/#appendix-e-medicolegal-considerations","title":"Appendix E: Medicolegal Considerations","text":"Issue Documentation Required Risk Mitigation Time of symptom onset Exact time; patient and family statement; ambulance records Standardized CES screening tool in ED triage Time of ED arrival Triage time stamp; registration time Electronic health record timestamps Time of clinical assessment Time of exam documented; neurologic exam details; bladder assessment Dedicated CES assessment proforma Time of MRI request Order time stamp; radiology communication log Standardized CES pathway with MRI within 4h target Time of MRI completion MRI completion time; radiology read time Prioritized MRI slot for suspected CES Time of surgical consultation Time called; time responded; time seen by surgeon Documented communication; spine surgery contact log Time of surgical decompression Anesthesia start time; knife-to-skin time; case end time OR availability for emergency CES cases Neurologic exam pre/post-surgery Detailed exam with motor grading, sensory mapping, rectal tone, PVR Standardized CES neurologic assessment form Delays and reasons If any delay: documented reason (MRI availability, OR availability, patient consent, medical optimization) Contemporaneous notes; clear communication to patient/family about delays Informed consent Surgical risks discussed; prognosis discussed; realistic expectations documented; patient questions addressed Standardized consent form for CES decompression <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/dementia-evaluation/","title":"Dementia Evaluation","text":"<p>VERSION: 1.0 CREATED: January 29, 2026 REVISED: January 29, 2026 STATUS: Complete</p> <p>DIAGNOSIS: Dementia Evaluation / Cognitive Impairment Workup</p> <p>ICD-10: R41.81 (Age-related cognitive decline), F03.90 (Unspecified dementia without behavioral disturbance), G30.9 (Alzheimer's disease, unspecified), F01.50 (Vascular dementia without behavioral disturbance), G31.83 (Dementia with Lewy bodies), G31.09 (Other frontotemporal dementia), G31.84 (Mild cognitive impairment)</p> <p>SYNONYMS: Dementia, cognitive impairment, memory loss, cognitive decline, major neurocognitive disorder, mild neurocognitive disorder, senility, organic brain syndrome, dementia workup</p> <p>SCOPE: Systematic evaluation of cognitive impairment and dementia in adults. Covers comprehensive workup to identify reversible causes and establish etiology. Includes initiation of symptomatic treatment. Excludes pediatric intellectual disability, acute delirium (separate entity), and rapidly progressive dementia (separate template for urgent workup).</p> <p>DEFINITIONS: - Dementia (Major Neurocognitive Disorder): Significant cognitive decline from prior level in \u22651 cognitive domains (memory, language, executive function, attention, perceptual-motor, social cognition) that interferes with independence in everyday activities - Mild Cognitive Impairment (MCI): Modest cognitive decline that does NOT interfere with independence; intermediate stage between normal aging and dementia - Reversible Dementia: Cognitive impairment due to treatable conditions (B12 deficiency, hypothyroidism, NPH, depression, medication effects)</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/dementia-evaluation/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/dementia-evaluation/#1a-essentialcore-labs-all-patients","title":"1A. Essential/Core Labs (All Patients)","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC URGENT ROUTINE ROUTINE - Anemia, infection, hematologic disease Normal CMP (includes glucose, renal, hepatic) URGENT ROUTINE ROUTINE - Metabolic encephalopathy, hepatic/renal failure, glucose Normal TSH URGENT ROUTINE ROUTINE - Hypothyroidism is reversible cause Normal (0.4-4.0 mIU/L) Vitamin B12 URGENT ROUTINE ROUTINE - B12 deficiency is reversible cause &gt;400 pg/mL (&gt;300 per some guidelines) Folate - ROUTINE ROUTINE - Folate deficiency can contribute Normal Ammonia URGENT ROUTINE - - Hepatic encephalopathy if liver disease &lt;35 \u03bcmol/L Urinalysis URGENT ROUTINE ROUTINE - UTI common cause of delirium/worsening Negative"},{"location":"plans/dementia-evaluation/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding RPR/VDRL - ROUTINE ROUTINE - Neurosyphilis in differential Negative HIV - ROUTINE ROUTINE - HIV-associated neurocognitive disorder (HAND) Negative Thiamine (Vitamin B1) URGENT ROUTINE ROUTINE - Wernicke-Korsakoff if alcohol history Normal Vitamin D - ROUTINE ROUTINE - Deficiency associated with cognitive decline &gt;30 ng/mL Homocysteine - ROUTINE ROUTINE - Elevated levels associated with dementia risk &lt;15 \u03bcmol/L HbA1c - ROUTINE ROUTINE - Diabetes and cognitive impairment &lt;7% ideally Lipid panel - ROUTINE ROUTINE - Vascular risk factors Per guidelines ESR/CRP - ROUTINE ROUTINE - Inflammatory/vasculitic cause Normal ANA - ROUTINE ROUTINE - CNS lupus, autoimmune Negative"},{"location":"plans/dementia-evaluation/#1c-specialized-testing-selected-patients","title":"1C. Specialized Testing (Selected Patients)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum ceruloplasmin, copper - EXT EXT - Wilson disease if &lt;50 years Normal Heavy metals (lead, mercury, arsenic) - EXT EXT - Occupational/environmental exposure Negative Paraneoplastic panel - EXT EXT - Subacute onset, smoking history, cancer history Negative Autoimmune encephalitis panel (serum) - URGENT ROUTINE - Subacute onset, psychiatric features, seizures Negative Lyme serology - ROUTINE ROUTINE - Endemic areas, tick exposure Negative West Nile serology - EXT EXT - Endemic areas, summer/fall onset Negative Genetic testing (APOE, APP, PSEN1/2) - - EXT - Strong family history, early onset Risk assessment"},{"location":"plans/dementia-evaluation/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Atypical presentation, rapid progression, young onset (&lt;65), suspected CNS infection, inflammatory condition, or when AD biomarkers desired</p> Study ED HOSP OPD ICU Rationale Target Finding Opening pressure URGENT URGENT - - NPH evaluation 10-20 cm H2O Cell count (tubes 1 and 4) URGENT URGENT - - Infection, inflammation WBC &lt;5 Protein URGENT URGENT - - Infection, inflammation 15-45 mg/dL Glucose URGENT URGENT - - Infection &gt;60% serum VDRL - ROUTINE - - Neurosyphilis Negative CSF meningitis panel - URGENT - - Infectious etiology Negative A\u03b242, total tau, phospho-tau - ROUTINE ROUTINE - AD biomarkers (AT profile) A\u03b242\u2193, tau\u2191, p-tau\u2191 in AD RT-QuIC (Real-Time Quaking-Induced Conversion) - URGENT - - CJD if rapid progression Negative 14-3-3 protein - URGENT - - CJD if rapid progression Negative Oligoclonal bands - ROUTINE - - MS, inflammatory conditions Negative Cytology - ROUTINE - - Carcinomatous meningitis Negative Autoimmune encephalitis panel (CSF) - URGENT ROUTINE - If autoimmune suspected Negative"},{"location":"plans/dementia-evaluation/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/dementia-evaluation/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain without contrast - ROUTINE ROUTINE - Initial workup Atrophy pattern, vascular changes, masses, NPH Pacemaker, metal CT head without contrast STAT STAT - STAT If MRI unavailable or contraindicated Masses, hemorrhage, hydrocephalus None"},{"location":"plans/dementia-evaluation/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with contrast - ROUTINE ROUTINE - If mass, infection, or inflammation suspected Enhancing lesions Contrast allergy, renal disease FDG-PET brain - - ROUTINE - Distinguish AD from FTD; atypical presentations AD: temporoparietal hypometabolism; FTD: frontal hypometabolism Per PET Amyloid PET (Amyvid, Neuraceq) - - ROUTINE - Diagnostic uncertainty; young onset Positive in AD and preclinical AD Per PET Tau PET (Tauvid) - - EXT - AD staging, atypical presentations Pattern correlates with symptoms Per PET DaTscan - - ROUTINE - If parkinsonian features; DLB vs AD Reduced in DLB; normal in AD Pregnancy, iodine allergy EEG - ROUTINE ROUTINE - Subclinical seizures, CJD (triphasic waves), delirium Normal or diffuse slowing None Polysomnography - - ROUTINE - If REM sleep behavior disorder suspected (DLB) Confirm RBD None"},{"location":"plans/dementia-evaluation/#neuropsychological-testing","title":"Neuropsychological Testing","text":"Study ED HOSP OPD ICU Timing Indication Findings Bedside cognitive screen (MoCA, MMSE) - ROUTINE ROUTINE - All patients Screening MoCA &lt;26 or MMSE &lt;24 suggests impairment Formal neuropsychological testing - - ROUTINE - Diagnostic uncertainty, MCI vs dementia, baseline, disability evaluation Gold standard Domain-specific deficits; pattern suggests etiology"},{"location":"plans/dementia-evaluation/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/dementia-evaluation/#3a-reversible-causes-treatment","title":"3A. Reversible Causes - Treatment","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Vitamin B12 replacement URGENT STAT ROUTINE - 1000 mcg IM daily \u00d7 7 days, then weekly \u00d7 4, then monthly; OR oral 1000-2000 mcg daily None B12 levels Levothyroxine (hypothyroidism) - ROUTINE ROUTINE - Start 25-50 mcg daily; titrate per TSH CAD (start low) TSH q6-8 weeks Thiamine (Wernicke-Korsakoff) STAT STAT ROUTINE STAT 500 mg IV TID \u00d7 3 days, then 250 mg IV daily \u00d7 5 days, then 100 mg PO daily None Clinical response NPH treatment (large volume LP) - ROUTINE - - Diagnostic LP removing 30-50 mL CSF; assess gait before/after Per LP Gait improvement suggests shunt candidacy VP shunt (NPH) - - EXT - Neurosurgical placement Coagulopathy, infection Shunt complications Treat depression (pseudodementia) - ROUTINE ROUTINE - SSRI (sertraline 25-50 mg, escitalopram 5-10 mg) Per agent Mood, cognition Discontinue offending medications URGENT URGENT ROUTINE URGENT Stop anticholinergics, sedatives, opioids N/A Cognitive reassessment"},{"location":"plans/dementia-evaluation/#3b-alzheimers-disease-cholinesterase-inhibitors","title":"3B. Alzheimer's Disease - Cholinesterase Inhibitors","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Donepezil (Aricept) - ROUTINE ROUTINE - Start 5 mg QHS \u00d7 4-6 weeks, then increase to 10 mg QHS; 23 mg available for moderate-severe Bradycardia, sick sinus, GI bleeding Bradycardia, GI upset, nightmares Rivastigmine patch (Exelon) - ROUTINE ROUTINE - Start 4.6 mg/24h patch; increase monthly to 9.5-13.3 mg/24h Same; skin reactions Skin irritation, GI, bradycardia Rivastigmine oral - ROUTINE ROUTINE - Start 1.5 mg BID with food; titrate to 6 mg BID Same GI side effects more common than patch Galantamine (Razadyne) - ROUTINE ROUTINE - Start 4 mg BID with food \u00d7 4 weeks; titrate to 8-12 mg BID; ER: 8 mg daily to 24 mg daily Same Same"},{"location":"plans/dementia-evaluation/#3c-alzheimers-disease-nmda-antagonist","title":"3C. Alzheimer's Disease - NMDA Antagonist","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Memantine (Namenda) - ROUTINE ROUTINE - Start 5 mg daily; increase by 5 mg/week to 10 mg BID Severe renal impairment Confusion, dizziness, constipation Memantine XR (Namenda XR) - ROUTINE ROUTINE - Start 7 mg daily; increase weekly to 28 mg daily Same Same Donepezil/Memantine XR (Namzaric) - - ROUTINE - For patients on both; 7/10 mg to 28/10 mg daily Per components Per components"},{"location":"plans/dementia-evaluation/#3d-alzheimers-disease-disease-modifying-therapy-amyloid-targeted","title":"3D. Alzheimer's Disease - Disease-Modifying Therapy (Amyloid-Targeted)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Lecanemab (Leqembi) - - ROUTINE - 10 mg/kg IV q2 weeks; confirm amyloid-positive before starting Anticoagulation (relative), ARIA risk factors MRI at baseline, week 6, 12; ARIA monitoring Donanemab (Kisunla) - - ROUTINE - 700 mg IV q4 weeks \u00d7 3, then 1400 mg q4 weeks until amyloid clearance; discontinue when cleared Same Same; discontinue at clearance Aducanumab (Aduhelm) - - EXT - Titration from 1-10 mg/kg IV q4 weeks; limited use Same MRI monitoring for ARIA <p>ARIA (Amyloid-Related Imaging Abnormalities) Management: - ARIA-E (edema): Usually asymptomatic; hold treatment, repeat MRI in 4-8 weeks - ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis; assess severity - Symptomatic ARIA: Hold treatment, consider corticosteroids, MRI monitoring</p>"},{"location":"plans/dementia-evaluation/#3e-behavioral-and-psychological-symptoms-of-dementia-bpsd","title":"3E. Behavioral and Psychological Symptoms of Dementia (BPSD)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Non-pharmacologic interventions STAT STAT ROUTINE - Music therapy, validation therapy, redirection, environmental modification None First-line for all BPSD Sertraline (depression, anxiety) - ROUTINE ROUTINE - Start 25 mg daily; target 50-100 mg Bleeding risk, QT prolongation GI bleeding, hyponatremia Citalopram (agitation) - ROUTINE ROUTINE - Start 10 mg daily; max 20 mg (QT risk at higher doses) QT prolongation QTc, hyponatremia Trazodone (sleep, agitation) - ROUTINE ROUTINE - 25-100 mg QHS Orthostasis Sedation, falls Mirtazapine (sleep, appetite, mood) - ROUTINE ROUTINE - 7.5-15 mg QHS None significant Weight gain, sedation Quetiapine (psychosis, agitation) - ROUTINE ROUTINE - 12.5-100 mg QHS; lowest effective dose QT prolongation, metabolic syndrome Black box: increased mortality in dementia Risperidone (psychosis, aggression) - ROUTINE ROUTINE - 0.25-1 mg BID; lowest effective dose Same; EPS Same; EPS higher than quetiapine Pimavanserin (DLB psychosis) - - ROUTINE - 34 mg daily QT prolongation QTc Dextromethorphan/Quinidine (Nuedexta) - ROUTINE ROUTINE - 1 capsule daily \u00d7 7 days, then BID; for pseudobulbar affect QT prolongation, CYP2D6 interactions QTc Carbamazepine (aggression) - EXT EXT - 100-400 mg BID Aplastic anemia risk, drug interactions CBC, LFTs, drug levels"},{"location":"plans/dementia-evaluation/#3f-other-dementia-specific-treatments","title":"3F. Other Dementia-Specific Treatments","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Aspirin (vascular dementia) - ROUTINE ROUTINE - 81 mg daily; secondary prevention Bleeding Bleeding Statin (vascular dementia) - ROUTINE ROUTINE - Per cardiovascular guidelines Hepatic disease LFTs, myopathy BP control (vascular dementia) - ROUTINE ROUTINE - Target &lt;130/80 per guidelines Per agent BP Carbidopa/Levodopa (DLB, PDD) - ROUTINE ROUTINE - Start low 25/100 TID; titrate cautiously May worsen psychosis Hallucinations, dyskinesia Avoid anticholinergics (DLB) STAT STAT ROUTINE - Contraindicated in DLB due to severe sensitivity N/A N/A Avoid antipsychotics (DLB) STAT STAT ROUTINE - Can cause severe parkinsonism, NMS-like reaction; if needed, quetiapine safest Relative contraindication Severe reactions"},{"location":"plans/dementia-evaluation/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/dementia-evaluation/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology/Memory specialist - ROUTINE ROUTINE - All patients with dementia for diagnosis confirmation and management Neuropsychology - - ROUTINE - MCI vs dementia distinction, pattern analysis, baseline assessment Geriatric psychiatry - ROUTINE ROUTINE - BPSD, depression, complex behavioral management Social work - ROUTINE ROUTINE - Resources, placement, caregiver support Physical therapy - ROUTINE ROUTINE - Mobility, fall prevention Occupational therapy - ROUTINE ROUTINE - ADL assessment, home safety evaluation Speech therapy - ROUTINE ROUTINE - Swallowing evaluation, communication strategies Palliative care - - ROUTINE - Goals of care, symptom management in advanced dementia Elder law attorney - - ROUTINE - Power of attorney, healthcare proxy, estate planning Driving evaluation - - ROUTINE - Driving safety assessment"},{"location":"plans/dementia-evaluation/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD Dementia is a progressive condition; treatments can help symptoms but not cure - ROUTINE ROUTINE Establish healthcare proxy and advance directives early while patient can participate - ROUTINE ROUTINE Home safety: remove rugs, improve lighting, stove safety, medication management - ROUTINE ROUTINE Driving assessment needed; may need to stop driving - ROUTINE ROUTINE Caregiver support is essential; respite care, support groups (Alzheimer's Association) - ROUTINE ROUTINE Medical alert bracelet, GPS tracking if wandering risk - ROUTINE ROUTINE Maintain routines, social engagement, cognitive stimulation - ROUTINE ROUTINE Return to ED if: sudden worsening, new weakness, fever, falls, inability to care for self ROUTINE ROUTINE ROUTINE"},{"location":"plans/dementia-evaluation/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular physical exercise (30 min, 5 days/week) - ROUTINE ROUTINE Cognitive engagement (puzzles, reading, social activities) - ROUTINE ROUTINE Mediterranean or MIND diet - - ROUTINE Cardiovascular risk factor management (BP, diabetes, cholesterol) - ROUTINE ROUTINE Hearing aids if hearing impaired (hearing loss increases dementia risk) - - ROUTINE Adequate sleep (treat sleep apnea) - ROUTINE ROUTINE Avoid excessive alcohol - ROUTINE ROUTINE Social engagement and purpose - ROUTINE ROUTINE"},{"location":"plans/dementia-evaluation/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Delirium Acute onset, fluctuating, inattention, often reversible cause Duration, attention testing, underlying cause Depression (pseudodementia) Depressed mood, \"I don't know\" responses, rapid onset, prior psychiatric history Depression screening, response to antidepressants Normal aging Mild forgetfulness, no functional impairment Neuropsychological testing; MCI vs normal B12 deficiency Macrocytic anemia, neuropathy, subacute combined degeneration B12 level, MMA, MRI spine Hypothyroidism Fatigue, weight gain, cold intolerance TSH Normal pressure hydrocephalus Gait apraxia, urinary incontinence, dementia (triad) MRI (ventriculomegaly), large volume LP response Medication effects Anticholinergics, sedatives, opioids Medication review; improvement after discontinuation Wernicke-Korsakoff Alcohol history, confabulation, ataxia, ophthalmoplegia History, thiamine trial, MRI (mammillary body changes) Creutzfeldt-Jakob disease Rapid progression, myoclonus, MRI changes MRI (cortical ribboning), EEG (periodic complexes), CSF RT-QuIC Autoimmune encephalitis Subacute, psychiatric symptoms, seizures Antibody panels, MRI, EEG CNS lymphoma/tumor Focal deficits, headache, progressive MRI with contrast"},{"location":"plans/dementia-evaluation/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Cognitive testing (MoCA, MMSE) - ROUTINE ROUTINE - q6-12 months Stable or slow decline Adjust medications, reassess diagnosis Functional status (ADL/IADL) - ROUTINE ROUTINE - q6-12 months Maintaining independence OT, increase support BPSD assessment (NPI) - ROUTINE ROUTINE - Each visit Stable or improved Behavioral interventions, medications Caregiver stress (Zarit Burden) - - ROUTINE - q6-12 months Manageable Respite, support services Weight - ROUTINE ROUTINE - Each visit Stable Nutrition, dysphagia evaluation Falls assessment - ROUTINE ROUTINE - Each visit None PT, home safety Driving safety - - ROUTINE - Annually or with decline Safe to drive Driving evaluation, cessation Medication reconciliation - ROUTINE ROUTINE - Each visit No inappropriate medications D/C anticholinergics, sedatives MRI (if on anti-amyloid therapy) - - ROUTINE - Per protocol No ARIA Hold therapy if ARIA"},{"location":"plans/dementia-evaluation/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Outpatient workup Most patients; mild-moderate symptoms, safe home environment, caregiver present Admit to hospital Acute behavioral crisis, unable to care for self, unsafe home environment, need for IV therapies, rapid progression needing urgent workup Discharge from hospital Reversible causes treated, behavior stable, safe disposition, follow-up arranged Memory care/Assisted living Unable to live independently, unsafe with current support level Skilled nursing facility Advanced dementia, 24-hour care needs, complex medical needs Hospice End-stage dementia, FAST stage 7, goals of care focused on comfort"},{"location":"plans/dementia-evaluation/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source MRI recommended in dementia workup Class I, Level A AAN Practice Parameters 2001 B12, TSH, metabolic panel in all patients Class I, Level A AAN Practice Parameters 2001 Cholinesterase inhibitors for mild-moderate AD Class I, Level A Cochrane Reviews Memantine for moderate-severe AD Class I, Level A Cochrane Reviews Combination ChEI + memantine Class I, Level A DOMINO trial Lecanemab slows cognitive decline in early AD Class I, Level A Clarity AD trial; FDA approved 2023 Donanemab slows decline in early AD Class I, Level A TRAILBLAZER-ALZ 2; FDA approved 2024 Non-pharmacologic interventions for BPSD first-line Class I, Level A APA Guidelines Antipsychotics increase mortality in dementia Class I, Level A FDA black box warning CSF biomarkers (A\u03b242, tau, p-tau) support AD diagnosis Class II, Level A AT(N) framework Amyloid PET useful for diagnostic uncertainty Class II, Level B Appropriate Use Criteria Exercise may slow cognitive decline Class II, Level B Multiple RCTs"},{"location":"plans/dementia-evaluation/#notes","title":"NOTES","text":"<ul> <li>Dementia is a clinical diagnosis; workup identifies etiology and reversible causes</li> <li>\"Reversible dementia\" accounts for ~10% of cases; always screen for B12, thyroid, medications</li> <li>Cholinesterase inhibitors provide modest symptomatic benefit; do not alter disease course</li> <li>Anti-amyloid therapies (lecanemab, donanemab) are disease-modifying but modest effect; require amyloid confirmation, MRI monitoring for ARIA</li> <li>DLB patients extremely sensitive to antipsychotics - avoid or use quetiapine cautiously</li> <li>Involve family/caregivers in all visits; caregiver burnout is common</li> <li>Advance care planning should occur early while patient can participate</li> <li>\"No anticholinergics\" in dementia patients - review all medications</li> </ul>"},{"location":"plans/dementia-evaluation/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 29, 2026) - Initial template creation - Comprehensive laboratory and imaging workup - Included disease-modifying therapies (lecanemab, donanemab) - BPSD management section - Dementia-specific treatments by etiology</p>"},{"location":"plans/diabetic-neuropathy/","title":"Diabetic Neuropathy","text":"<p>DIAGNOSIS: Diabetic Peripheral Neuropathy ICD-10: G63.2 (Diabetic polyneuropathy); E11.42 (Type 2 DM with diabetic polyneuropathy); E10.42 (Type 1 DM with diabetic polyneuropathy) SCOPE: Distal symmetric polyneuropathy (most common), painful diabetic neuropathy treatment, foot care, and screening for other diabetic neuropathy types. Excludes diabetic amyotrophy (separate protocol) and autonomic neuropathy (mentioned but not primary focus).</p> <p>STATUS: Approved</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU HbA1c Assess glycemic control; primary modifiable risk factor &lt;7% (individualized goals for elderly) - ROUTINE ROUTINE - Fasting glucose Current glycemic status 70-130 mg/dL STAT ROUTINE ROUTINE - BMP (including creatinine, eGFR) Renal function for medication dosing; CKD common in diabetes eGFR &gt;60 preferred; adjust meds if lower STAT ROUTINE ROUTINE - Lipid panel Cardiovascular risk; dyslipidemia common comorbidity LDL &lt;100 mg/dL (or &lt;70 if ASCVD) - ROUTINE ROUTINE - Vitamin B12 Metformin causes B12 deficiency; mimics diabetic neuropathy &gt;300 pg/mL (&gt;400 optimal) - ROUTINE ROUTINE - TSH Hypothyroidism causes neuropathy; common comorbidity 0.4-4.0 mIU/L - ROUTINE ROUTINE - CBC Anemia evaluation; baseline Normal STAT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Methylmalonic acid (MMA) More sensitive for B12 deficiency if B12 borderline Normal - ROUTINE ROUTINE - Folate Deficiency contributes to neuropathy &gt;3 ng/mL - ROUTINE ROUTINE - Vitamin D Deficiency associated with neuropathic pain &gt;30 ng/mL - ROUTINE ROUTINE - SPEP/UPEP with immunofixation Rule out paraproteinemia if atypical features No monoclonal protein - ROUTINE ROUTINE - ANA Autoimmune/vasculitic neuropathy if atypical Negative - EXT ROUTINE - ESR, CRP Inflammatory markers if vasculitis suspected Normal - ROUTINE ROUTINE - Hepatitis B, C serologies Hepatitis C associated with neuropathy; prevalence in diabetics Negative - ROUTINE ROUTINE - HIV HIV neuropathy if risk factors Negative - EXT EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Cryoglobulins Cryoglobulinemic neuropathy (esp. with Hep C) Negative - - EXT - Anti-MAG antibodies IgM paraprotein-associated neuropathy Negative - - EXT - Genetic neuropathy panel (CMT genes) Family history; atypical presentation Negative - - EXT - Nerve biopsy Vasculitic neuropathy suspected; atypical non-length-dependent Diagnostic findings - - EXT - Skin biopsy for IENFD Quantify small fiber neuropathy Reduced intraepidermal nerve fiber density - - ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Monofilament testing (10g) At every diabetic visit; annually minimum Intact sensation 8-10 sites None - ROUTINE ROUTINE - Tuning fork (128 Hz) Vibration sense at great toe Intact vibration sense None - ROUTINE ROUTINE - Ankle reflexes Deep tendon reflex assessment Present (may be diminished/absent in neuropathy) None - ROUTINE ROUTINE - Foot examination Inspect for ulcers, calluses, deformities, pulses No ulcers or pre-ulcerative lesions None STAT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU EMG/NCS (nerve conduction study) Atypical presentation; asymmetric; rapid progression Length-dependent sensory &gt; motor polyneuropathy Anticoagulation (relative for EMG) - ROUTINE ROUTINE - Autonomic testing (QSART, HR variability, tilt table) Symptoms of autonomic neuropathy; syncope; gastroparesis Abnormal sudomotor, cardiovagal, or adrenergic function None - EXT ROUTINE - MRI lumbar spine Radiculopathy suspected; focal deficits Rule out compressive lesion MRI contraindications URGENT ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Skin biopsy (punch biopsy at ankle and thigh) Confirm small fiber neuropathy; normal NCS Reduced IENFD (&lt;threshold for age/sex) Bleeding diathesis; anticoagulation - - ROUTINE - Corneal confocal microscopy Research; non-invasive small fiber assessment Reduced corneal nerve fiber length/density None - - EXT - Sudoscan Screening for sudomotor dysfunction; small fiber Abnormal electrochemical skin conductance None - - EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#3-treatment","title":"3. TREATMENT","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Wound care Topical Diabetic foot ulcer Debridement; offloading; appropriate dressing :: Topical :: :: Wound assessment; debridement if needed; offload pressure; moist wound healing None Signs of infection; healing progress STAT STAT ROUTINE - Antibiotics (diabetic foot infection) PO/IV Infected diabetic foot ulcer Per culture/severity :: PO/IV :: :: Mild: oral (cephalexin, amox/clav); Moderate-severe: IV (piptazo, vanc); per wound culture Drug allergy Infection markers; wound healing STAT STAT - - Pain crisis management IV/PO Severe acute neuropathic pain flare Multimodal :: IV/PO :: :: Consider IV lidocaine if refractory; short-term low-dose opioid for acute crisis Per specific agent Pain scores; sedation URGENT URGENT - -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#3b-symptomatic-treatments-neuropathic-pain-first-line","title":"3B. Symptomatic Treatments (Neuropathic Pain - First-line)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Duloxetine PO First-line for painful diabetic neuropathy; FDA-approved 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day (limited evidence for higher doses) MAOIs; uncontrolled glaucoma; severe renal impairment (CrCl &lt;30) Hepatic function; BP; suicidal ideation - ROUTINE ROUTINE - Pregabalin PO First-line; FDA-approved for DPN 50 mg TID; 75 mg BID; 100 mg TID; 150 mg BID; 200 mg TID :: PO :: :: Start 50 mg TID or 75 mg BID; titrate q3-7d based on response; max 300 mg/day (CrCl 30-60: reduce dose) Angioedema to pregabalin/gabapentin Dizziness, somnolence, weight gain, peripheral edema - ROUTINE ROUTINE - Gabapentin PO First-line alternative; less expensive; similar efficacy 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce dose if CrCl &lt;60 Severe renal impairment (dose adjust) Same as pregabalin; less edema - ROUTINE ROUTINE - Amitriptyline PO TCA option; also helps sleep; less expensive 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS; 100 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg Cardiac conduction abnormality; recent MI; urinary retention; glaucoma; elderly (use with caution) ECG if &gt;40y or cardiac history; anticholinergic effects - ROUTINE ROUTINE - Nortriptyline PO TCA with less sedation and anticholinergic effects than amitriptyline 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS Same as amitriptyline Same as amitriptyline; ECG if &gt;100 mg - ROUTINE ROUTINE - Venlafaxine XR PO SNRI alternative to duloxetine 37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; titrate by 37.5-75 mg q1wk; target 150-225 mg daily MAOIs; uncontrolled HTN BP at higher doses; withdrawal if abrupt discontinuation - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#3c-second-linerefractory-neuropathic-pain","title":"3C. Second-line/Refractory (Neuropathic Pain)","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Capsaicin 8% patch (Qutenza) Topical Localized neuropathic pain; add-on therapy Apply for 30 min :: Topical :: :: Applied by healthcare provider; local anesthetic pre-treatment; repeat q3mo Application to face; broken skin Local pain during application; burning - - ROUTINE - Lidocaine 5% patch Topical Localized pain; adjunctive therapy 1-3 patches to painful area :: Topical :: :: Apply to most painful area; up to 3 patches for 12h on/12h off Allergy to local anesthetics Skin irritation - ROUTINE ROUTINE - Tapentadol ER PO Refractory pain; opioid with norepinephrine reuptake inhibition 50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID; 250 mg BID :: PO :: :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day; FDA-approved for DPN Severe respiratory depression; MAOIs; paralytic ileus Constipation, sedation, respiratory status - EXT ROUTINE - Tramadol PO Moderate pain; opioid-like with serotonergic properties 50 mg q6h PRN; 100 mg ER BID :: PO :: :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk) Seizures, serotonin syndrome, sedation - ROUTINE ROUTINE - Desipramine PO TCA with minimal anticholinergic effects 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg Same as other TCAs ECG; therapeutic drug monitoring available - ROUTINE ROUTINE - Oxcarbazepine PO Second-line anticonvulsant; less evidence 300 mg BID; 600 mg BID :: PO :: :: Start 300 mg BID; titrate by 300 mg/wk; typical 600-1200 mg/day Hyponatremia risk Sodium level; rash (SJS rare) - - ROUTINE - Combination therapy Various Inadequate response to single agent Combine agents from different classes :: Various :: :: Use lower doses of each; duloxetine + pregabalin; TCA + gabapentinoid Per individual agents Additive side effects - ROUTINE ROUTINE - Buprenorphine patch TD Severe refractory pain; opioid option 5 mcg/hr; 10 mcg/hr; 20 mcg/hr :: TD :: :: Start 5 mcg/hr weekly patch; titrate slowly Severe respiratory depression; QT prolongation Respiratory status, QTc - EXT ROUTINE - Spinal cord stimulation Implant Refractory painful DPN; failed multiple medications Per implant protocol :: Implant :: :: Trial stimulation before permanent; high-frequency or burst stimulation Infection; coagulopathy; psychiatric instability Device function; pain relief - - EXT -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#3d-disease-modifying-preventive-therapies","title":"3D. Disease-Modifying / Preventive Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Glycemic control optimization Various Primary prevention and slowing progression HbA1c target &lt;7% :: Various :: :: Individualized; tighter control (6-6.5%) in younger patients; less strict (7.5-8%) in elderly/comorbid None Hypoglycemia risk HbA1c q3mo until at goal, then q6mo - ROUTINE ROUTINE - Alpha-lipoic acid PO/IV Antioxidant; European data for DPN 600 mg daily; 600 mg IV daily :: PO/IV :: :: 600 mg PO daily; IV form (600 mg daily x 3wk) for acute symptom relief; limited evidence None GI upset; may lower glucose Glucose (may enhance insulin sensitivity) - ROUTINE ROUTINE - Vitamin B12 supplementation PO/IM B12 deficiency or metformin use 1000 mcg PO daily; 1000 mcg IM monthly :: PO/IM :: :: 1000-2000 mcg PO daily; or 1000 mcg IM monthly if poor absorption None None B12 level q6-12mo - ROUTINE ROUTINE - Benfotiamine PO Thiamine derivative; AGE inhibition 300 mg BID :: PO :: :: 300 mg BID; limited evidence None GI upset None specific - - ROUTINE - ACE inhibitor or ARB PO Nephroprotection; may slow neuropathy progression Per agent :: PO :: :: Standard doses; benefit for kidney protection proven; neuropathy benefit theoretical Angioedema; pregnancy; hyperkalemia; bilateral RAS K+, creatinine - ROUTINE ROUTINE - Statin therapy PO Cardiovascular protection; anti-inflammatory Per agent :: PO :: :: High-intensity statin for most diabetics Active liver disease LFTs, myalgias - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Endocrinology for diabetes optimization if HbA1c not at goal or complex regimen needed - ROUTINE ROUTINE - Podiatry for foot exam, nail care, custom orthotics, and offloading devices - ROUTINE ROUTINE - Vascular surgery if peripheral arterial disease suspected (ABI &lt;0.9 or absent pulses) URGENT URGENT ROUTINE - Pain management for refractory neuropathic pain and interventional options (SCS) - - ROUTINE - Physical therapy for balance training and gait assessment to reduce fall risk - ROUTINE ROUTINE - Wound care specialist for diabetic foot ulcers not healing with standard care - URGENT ROUTINE - Ophthalmology for annual diabetic retinopathy screening - - ROUTINE - Nephrology if eGFR &lt;30 or rapidly declining renal function - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Inspect feet daily using mirror for soles; look for cuts, blisters, redness, or swelling - ROUTINE ROUTINE Never walk barefoot, even indoors, to prevent foot injuries - ROUTINE ROUTINE Wear properly fitted shoes with adequate support; have shoes fitted by professional - ROUTINE ROUTINE Test bath water temperature with elbow (not feet) to prevent burns from impaired sensation - ROUTINE ROUTINE Report any foot wounds, color changes, or pain immediately as diabetic foot ulcers can progress rapidly STAT STAT ROUTINE Take all prescribed medications as directed; do not skip doses of pain medications abruptly - ROUTINE ROUTINE Monitor blood glucose as directed; excellent glycemic control is the most important factor to slow progression - ROUTINE ROUTINE Avoid alcohol which can worsen neuropathy and interact with pain medications - ROUTINE ROUTINE","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Optimal glycemic control (HbA1c &lt;7%) is the primary intervention to prevent and slow neuropathy progression - ROUTINE ROUTINE Smoking cessation as smoking worsens peripheral vascular disease and neuropathy - ROUTINE ROUTINE Blood pressure control (&lt;130/80) reduces microvascular complications - ROUTINE ROUTINE LDL cholesterol control with statin therapy reduces cardiovascular risk - ROUTINE ROUTINE Regular physical activity (150 min/week moderate) improves glycemic control and overall health - ROUTINE ROUTINE Healthy diet (Mediterranean or DASH) supports glycemic and cardiovascular goals - ROUTINE ROUTINE Limit alcohol which worsens neuropathy independently and affects glycemic control - ROUTINE ROUTINE Annual comprehensive foot examination by healthcare provider - - ROUTINE Fall prevention with home safety modifications given impaired proprioception - ROUTINE ROUTINE","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate B12 deficiency neuropathy Sensory &gt; motor; may have subacute combined degeneration; metformin use B12, MMA levels Chronic inflammatory demyelinating polyneuropathy (CIDP) Motor involvement; areflexia; elevated CSF protein; demyelinating NCS EMG/NCS (demyelinating pattern); CSF protein Uremic neuropathy Advanced CKD (eGFR &lt;15); improves with dialysis BUN, creatinine, eGFR Alcoholic neuropathy Heavy alcohol use history; painful; coexisting thiamine deficiency History; thiamine level Hypothyroid neuropathy Other hypothyroid symptoms; CTS common TSH, free T4 Paraproteinemic neuropathy IgM most common; anti-MAG antibodies; may have ataxia SPEP/UPEP; immunofixation; anti-MAG Chemotherapy-induced neuropathy Temporal relationship with chemotherapy (platinum, taxanes, vincristine) Medication history Hereditary neuropathy (CMT) Family history; high arches (pes cavus); hammer toes; slowly progressive Genetic testing; NCS pattern Vasculitic neuropathy Asymmetric; mononeuritis multiplex pattern; systemic symptoms Nerve biopsy; inflammatory markers; angiography Amyloid neuropathy Autonomic involvement; cardiomyopathy; carpal tunnel; paraprotein may be present Fat pad or nerve biopsy; genetic testing (TTR); SPEP","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU HbA1c Every 3-6 months &lt;7% (individualized) Intensify diabetes management - ROUTINE ROUTINE - Comprehensive foot exam Annually (more often if high risk) No ulcers, intact sensation, intact skin Podiatry referral; offloading; wound care - ROUTINE ROUTINE - Monofilament testing At least annually Intact sensation at \u22658/10 sites High-risk foot care; education - ROUTINE ROUTINE - Pain scores (VAS, NRS) Each visit 50%+ reduction with treatment Adjust therapy; consider combination or referral - ROUTINE ROUTINE - B12 level Annually if on metformin &gt;300 pg/mL Supplement B12 - ROUTINE ROUTINE - Kidney function (eGFR) At least annually eGFR &gt;60; stable Adjust medication doses; nephrology referral if declining - ROUTINE ROUTINE - Blood pressure Each visit &lt;130/80 mmHg Optimize antihypertensives - ROUTINE ROUTINE - Autonomic symptoms screen Each visit No symptoms Autonomic testing; cardiology referral if cardiac autonomic neuropathy - ROUTINE ROUTINE - Depression screen (PHQ-9) Annually or if symptoms Negative Treatment; referral - ROUTINE ROUTINE -","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Symptoms managed; no foot infection; follow-up arranged Admit to floor Diabetic foot infection requiring IV antibiotics; severe uncontrolled pain; associated acute kidney injury Surgical admission Foot infection requiring debridement or amputation Outpatient follow-up Every 3-6 months for medication optimization; annually for comprehensive foot exam","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Duloxetine for painful DPN (FDA-approved) Class I, Level A Wernicke et al. Neurology 2006 Pregabalin for painful DPN (FDA-approved) Class I, Level A Derry et al. Cochrane 2019 Gabapentin effective for DPN Class II, Level B Wiffen et al. Cochrane 2017 Tricyclic antidepressants effective Class II, Level B Moore et al. Cochrane 2015 Glycemic control prevents neuropathy progression Class I, Level A DCCT/EDIC Research Group. NEJM 1993 Alpha-lipoic acid may improve symptoms Class II, Level B Ziegler et al. Diabetes Care 2011 Comprehensive foot exam reduces amputations Class II, Level B ADA Standards of Care 2024 (Section 12) Tapentadol effective for DPN (FDA-approved) Class I, Level A Vinik et al. Diabetes Care 2014 Spinal cord stimulation for refractory DPN Class II, Level B Slangen et al. Diabetes Care 2014 Capsaicin 8% patch effective Class I, Level A Simpson et al. Pain 2017","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive neuropathic pain management - Includes FDA-approved agents (duloxetine, pregabalin, tapentadol) - Foot care and ulcer prevention emphasis - Structured dosing format for order sentence generation</p>","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#appendix-a-diabetic-foot-risk-classification","title":"APPENDIX A: Diabetic Foot Risk Classification","text":"Risk Category Features Foot Exam Frequency Recommendations Low risk Normal sensation; no deformity; palpable pulses Annually Education; appropriate footwear Moderate risk Loss of protective sensation OR peripheral artery disease OR foot deformity Every 3-6 months Podiatry referral; custom footwear consideration High risk Previous ulcer OR previous amputation OR end-stage renal disease Every 1-3 months Podiatry; vascular evaluation; offloading devices Active ulcer or infection Current ulcer/infection As needed until healed Wound care team; vascular surgery if ischemic","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/diabetic-neuropathy/#appendix-b-types-of-diabetic-neuropathy","title":"APPENDIX B: Types of Diabetic Neuropathy","text":"Type Clinical Features Typical Onset Prognosis Distal symmetric polyneuropathy (DSPN) Stocking-glove sensory loss; burning pain; numbness; length-dependent Insidious Chronic; preventable progression with glycemic control Diabetic autonomic neuropathy Orthostatic hypotension; gastroparesis; erectile dysfunction; sudomotor dysfunction; cardiac denervation Gradual Variable; cardiac autonomic neuropathy increases mortality Diabetic lumbosacral radiculoplexus neuropathy (diabetic amyotrophy) Acute/subacute proximal leg weakness and pain; weight loss; often unilateral then spreads Acute-subacute Usually monophasic; recovery over months-years Diabetic thoracic radiculopathy Truncal pain/dysesthesia; dermatomal distribution; may mimic visceral disease Acute-subacute Self-limited (months) Cranial neuropathy CN III most common (pupil-sparing); CN VI, VII also affected Acute Usually resolves in 3-6 months Mononeuropathy/entrapment Carpal tunnel syndrome; ulnar neuropathy; peroneal neuropathy Variable Treat underlying entrapment Treatment-induced neuropathy of diabetes (TIND) Acute painful small fiber neuropathy after rapid glucose improvement After aggressive glycemic control Usually improves with slower glucose normalization","tags":["neuropathy","diabetes","pain","outpatient"]},{"location":"plans/elevated-icp-management/","title":"Elevated Intracranial Pressure Management","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Elevated Intracranial Pressure (ICP) / Intracranial Hypertension</p> <p>ICD-10: G93.2 (Benign intracranial hypertension [IIH]), G93.5 (Compression of brain), G93.6 (Cerebral edema), G91.1 (Obstructive hydrocephalus), G91.2 (Normal pressure hydrocephalus), S06.1X (Traumatic cerebral edema)</p> <p>SYNONYMS: Elevated intracranial pressure, elevated ICP, intracranial hypertension, raised ICP, high ICP, cerebral edema, brain swelling, herniation syndrome, increased intracranial pressure, ICP crisis</p> <p>SCOPE: Emergency evaluation and management of elevated intracranial pressure in adults. Covers recognition of elevated ICP (Cushing triad, papilledema, declining GCS), emergent interventions (osmotherapy, hyperventilation, sedation, CSF drainage), ICP monitoring indications, surgical decompression, and specific etiology-based management. Includes management across etiologies: traumatic brain injury, stroke (ischemic/hemorrhagic), tumor, infection, hydrocephalus, and idiopathic intracranial hypertension. Excludes pediatric ICP management (different thresholds/approaches).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/elevated-icp-management/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/elevated-icp-management/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Infection workup; anemia (reduced O2 carrying capacity); thrombocytopenia (bleeding risk); baseline Normal; leukocytosis \u2192 infection; thrombocytopenia \u2192 hemorrhage risk CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolytes (sodium critical for osmotherapy); renal function (contrast, mannitol); glucose; hepatic function Normal; track sodium closely (goal varies by treatment); avoid hyponatremia Blood glucose STAT STAT ROUTINE STAT Hyperglycemia worsens outcomes in brain injury; hypoglycemia mimics neurologic deterioration 140-180 mg/dL target in critically ill; &lt;180 in general PT/INR, aPTT STAT STAT - STAT Coagulopathy (hemorrhagic causes); ICP monitor placement safety; surgical candidacy Normal; INR &lt;1.4 for ICP monitor placement Serum osmolality STAT STAT - STAT CRITICAL for osmotherapy monitoring; baseline before mannitol/hypertonic saline; target for therapy 280-295 mOsm/kg baseline; therapeutic target 300-320 (do not exceed 320) Sodium STAT STAT - STAT CRITICAL; hypertonic saline therapy monitoring; cerebral salt wasting vs. SIADH; target for ICP management 135-145 mEq/L baseline; therapeutic hypernatremia target 145-155 mEq/L (with hypertonic saline) Arterial blood gas (ABG) STAT STAT - STAT Ventilation status (PaCO2 critical for ICP); oxygenation; pH; metabolic status PaCO2 35-40 mmHg (normal); pH 7.35-7.45; PaO2 &gt;80; for hyperventilation: target PaCO2 30-35 Lactate STAT STAT - STAT Tissue perfusion; systemic sepsis; prognostic &lt;2 mmol/L; elevated \u2192 hypoperfusion, sepsis Type and screen STAT STAT - STAT Surgical candidacy; potential for decompressive craniectomy or other neurosurgical intervention On file Troponin STAT STAT - STAT Neurogenic cardiac injury (stress cardiomyopathy); particularly in SAH, TBI, ICH Normal; elevated \u2192 neurogenic stress cardiomyopathy; obtain echo"},{"location":"plans/elevated-icp-management/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum osmolality (serial) - STAT - STAT q4-6h during osmotherapy; osmolar gap calculation; prevent hyper-osmolar state Maintain &lt;320 mOsm/kg; osmolar gap &gt;10-15 \u2192 accumulating mannitol Sodium (serial) - STAT - STAT q2-6h during active ICP management; hypertonic saline monitoring; avoid rapid correction Target 145-155 mEq/L during active ICP crisis; avoid fluctuations &gt;10 mEq/24h Cortisol (AM, random) - ROUTINE ROUTINE ROUTINE Adrenal insufficiency (pituitary injury in TBI, tumor); steroid responsiveness in tumor edema &gt;10 mcg/dL (AM); if low \u2192 cortisol stimulation test or empiric steroids TSH, free T4 - ROUTINE ROUTINE - Pituitary injury (TBI, tumor, surgery); hypothyroidism Normal Ammonia STAT STAT - STAT Hepatic encephalopathy differential; can cause cerebral edema and elevated ICP &lt;35 \u03bcmol/L; elevated \u2192 hepatic cause; lactulose, rifaximin Toxicology screen STAT STAT - STAT Intoxication as cause of altered mental status; drug-induced cerebral edema (rare) Negative; specific toxin identification CSF analysis (if LP/EVD performed) - STAT - STAT Infection (meningitis); malignancy (leptomeningeal disease); subarachnoid hemorrhage (xanthochromia); IIH (elevated OP with normal composition) Normal CSF composition with elevated opening pressure \u2192 IIH; abnormal composition \u2192 specific diagnosis"},{"location":"plans/elevated-icp-management/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding CSF opening pressure (LP) - URGENT ROUTINE - IIH diagnosis: OP &gt;25 cm H2O (obese patients &gt;28 cm); therapeutic in IIH; NOT indicated if mass lesion or obstructive hydrocephalus IIH: OP &gt;25 cm H2O with normal composition; if OP &gt;40-50 \u2192 severe Pentobarbital level - - - STAT If barbiturate coma induced for refractory ICP; therapeutic monitoring; guide dosing; monitor for toxicity Therapeutic: 30-50 mcg/mL (for burst suppression); higher may be needed EEG (continuous) - STAT - STAT Monitor for burst suppression during barbiturate coma; detect subclinical seizures (common in brain injury); guide sedation titration Target: burst suppression pattern during barbiturate coma; no seizures Jugular venous oxygen saturation (SjvO2) - - - EXT Advanced cerebral metabolism monitoring; guide CPP management; detect ischemia or hyperemia 55-75%; &lt;55% = ischemia (increase CPP or reduce CMRO2); &gt;75% = hyperemia Brain tissue oxygen (PbtO2) - - - EXT Direct brain oxygenation monitoring; guide therapy in severe TBI; multimodal monitoring &gt;20 mmHg; &lt;15 mmHg = brain hypoxia \u2192 intervene Cerebral microdialysis - - - EXT Research/specialized centers; metabolic monitoring; lactate:pyruvate ratio; glucose; glutamate Lactate:pyruvate ratio &lt;40 (normal); elevated = metabolic crisis"},{"location":"plans/elevated-icp-management/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/elevated-icp-management/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediate \u2014 within minutes of suspected elevated ICP; before any intervention; determines etiology and guides treatment Mass lesion (tumor, hematoma); midline shift (&gt;5mm = significant); hydrocephalus; cerebral edema (effaced sulci, compressed ventricles); herniation signs (uncal, tonsillar); cisternal effacement None for non-contrast CT; benefit always outweighs risk in emergency CT angiography (CTA) head STAT STAT - STAT If vascular etiology suspected (SAH, venous sinus thrombosis, AVM); concurrent with non-contrast CT Aneurysm (SAH); venous sinus thrombosis (filling defect in dural sinuses); AVM; dissection Contrast allergy (premedicate if critical); renal impairment (benefit may outweigh risk) CT venography (CTV) STAT STAT ROUTINE STAT If cerebral venous sinus thrombosis suspected (headache, papilledema, focal deficits, hypercoagulable state); can be done with CTA Filling defect in dural sinuses (transverse, sigmoid, sagittal); \"empty delta sign\" on contrast CT; cord sign Same as CTA MRI brain with and without contrast URGENT URGENT ROUTINE URGENT When clinically stable; superior for tumor characterization, infection, posterior fossa; MRV for venous thrombosis; DWI for ischemia Tumor; abscess; encephalitis; venous sinus thrombosis; ischemic stroke; PRES; herniation; meningeal enhancement MRI-incompatible implants; hemodynamic instability Chest X-ray STAT STAT - STAT ETT position confirmation; pulmonary complications (aspiration, ARDS); central line position ETT position; no pulmonary infiltrate; line position None"},{"location":"plans/elevated-icp-management/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MR venography (MRV) - URGENT ROUTINE URGENT Cerebral venous sinus thrombosis confirmation; if CTV equivocal; can be done without contrast (TOF technique) Venous sinus thrombosis; flow void absence Same as MRI Transcranial Doppler (TCD) - URGENT - URGENT Non-invasive ICP estimation (pulsatility index); vasospasm detection (SAH); cerebral circulatory arrest (brain death) Pulsatility index &gt;1.4 suggests elevated ICP; MCA velocities for vasospasm; reverberating flow = no cerebral circulation None; operator-dependent Optic nerve sheath diameter (ONSD) ultrasound STAT STAT - STAT Bedside non-invasive ICP estimation; ONSD &gt;5-5.5 mm suggests ICP &gt;20 mmHg; useful when formal monitoring not available ONSD &gt;5 mm (some use 5.5 mm) = elevated ICP Limited accuracy; operator-dependent; not a substitute for invasive monitoring CT perfusion - URGENT - URGENT Ischemic stroke workup; penumbra assessment; vasospasm evaluation Perfusion deficits; core vs. penumbra; vasospasm patterns Contrast requirements Fundoscopic examination STAT STAT ROUTINE STAT Papilledema detection (takes hours-days to develop); retinal hemorrhages (Terson syndrome in SAH); IIH evaluation Papilledema (indicates chronically or subacutely elevated ICP); absent papilledema does NOT exclude acute ICP elevation; venous pulsations absent if ICP &gt;180 mm H2O None Formal visual field testing - - ROUTINE - IIH monitoring; chronic elevated ICP; document visual field loss for treatment decisions Enlarged blind spot; peripheral constriction; nasal field loss Patient cooperation required"},{"location":"plans/elevated-icp-management/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications ICP monitor placement (invasive) - STAT - STAT Gold standard for ICP measurement; indications: GCS \u22648 with abnormal CT, or GCS \u22648 with normal CT + 2 of (age &gt;40, SBP &lt;90, motor posturing); also for hydrocephalus management; typically EVD or parenchymal monitor Direct ICP measurement; normal &lt;15 mmHg; elevated &gt;20-22 mmHg; treatment threshold &gt;22 mmHg (Brain Trauma Foundation 2016) Coagulopathy (correct first); infection at insertion site; uncontrolled bleeding diathesis External ventricular drain (EVD) - STAT - STAT ICP monitoring + therapeutic CSF drainage; preferred in hydrocephalus; allows ICP waveform analysis ICP measurement; CSF drainage; waveform analysis (P2 &gt; P1 = decreased compliance) Same as ICP monitor Continuous EEG monitoring - STAT - STAT Detect subclinical seizures (common in TBI, ICH, SAH \u2014 up to 20-30%); guide sedation; burst suppression monitoring during barbiturate coma No seizures; appropriate sedation level; burst suppression if pentobarbital coma None; resource availability Nuclear medicine cerebral perfusion (SPECT/HMPAO) - - - EXT Brain death confirmation (ancillary test); no cerebral blood flow No uptake = brain death (if clinical criteria met and confounders excluded) Limited availability CT/MRI perfusion for brain death - - - EXT Brain death confirmation; no cerebral perfusion No perfusion = brain death Same as standard CT/MRI"},{"location":"plans/elevated-icp-management/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP with opening pressure - URGENT ROUTINE - IIH diagnosis and treatment: measure opening pressure \u2192 therapeutic CSF removal; CONTRAINDICATED if mass lesion, obstructive hydrocephalus, or herniation risk; imaging FIRST Opening pressure: normal &lt;20 cm H2O (obese &lt;25); IIH: &gt;25 cm H2O with normal CSF composition; high-volume tap (20-30 mL) for symptomatic relief in IIH ABSOLUTE CONTRAINDICATION: Mass lesion with mass effect; obstructive hydrocephalus; impending herniation; posterior fossa mass; midline shift; anticoagulation/coagulopathy; skin infection at LP site"},{"location":"plans/elevated-icp-management/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/elevated-icp-management/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Airway management / Intubation STAT STAT - STAT GCS \u22648: Secure airway; RSI with agents that do NOT raise ICP; preferred: etomidate 0.3 mg/kg OR propofol 1-2 mg/kg + rocuronium 1.2 mg/kg OR succinylcholine 1.5 mg/kg; AVOID ketamine in severe TBI (controversial \u2014 emerging data suggest may be safe); lidocaine 1.5 mg/kg IV 2-3 min before laryngoscopy (may blunt ICP spike \u2014 controversial benefit); avoid hypotension during RSI Airway protection; ventilation control (PaCO2 management); GCS \u22648 cannot protect airway; avoid hypoxia (PaO2 &lt;60) and hypotension (SBP &lt;90) \u2014 both worsen outcomes Head of bed elevation STAT STAT - STAT Elevate HOB 30\u00b0; neutral head position (avoid neck flexion/rotation that impedes jugular venous drainage); avoid tight cervical collar if possible; reverse Trendelenburg if cervical spine immobilization required Promotes venous drainage; reduces ICP by 3-5 mmHg; no evidence of reduced CPP with 30\u00b0 elevation; simple and immediate intervention Hyperventilation (temporary) STAT STAT - STAT Acute herniation ONLY (bridging therapy); target PaCO2 30-35 mmHg; induces cerebral vasoconstriction \u2192 reduced cerebral blood volume \u2192 reduced ICP; Duration: &lt;30 minutes ideally, maximum 2-4 hours; taper gradually; avoid PaCO2 &lt;25 (causes ischemia) BTF Guidelines: Avoid prophylactic hyperventilation; use only for acute ICP crisis/herniation as bridge to definitive therapy; prolonged hyperventilation causes rebound vasodilation and ischemia; monitor with SjvO2 or PbtO2 if prolonged use needed Osmotherapy \u2014 Mannitol STAT STAT - STAT Mannitol 20%: 1-1.5 g/kg IV bolus (e.g., 100g = 500 mL of 20% for 70 kg patient) over 15-20 minutes; repeat doses: 0.25-0.5 g/kg q4-6h PRN; Hold if: serum osmolality &gt;320 mOsm/kg, osmolar gap &gt;15-20; Requires: Foley catheter (massive diuresis); volume replacement; Onset: 15-30 min; Duration: 2-6 hours Creates osmotic gradient \u2192 draws water from brain parenchyma; reduces brain volume; also improves blood rheology; BTF: Level II evidence; monitor for renal toxicity (ATN), hypovolemia, rebound edema Osmotherapy \u2014 Hypertonic Saline STAT STAT - STAT 23.4% NaCl: 30 mL IV bolus over 15-20 min via central line (preferred for acute crisis); 3% NaCl: 250-500 mL IV bolus over 30 min (can give peripherally); Continuous infusion: 3% NaCl at 30-50 mL/hr to maintain Na 145-155 mEq/L; Target sodium: 145-155 mEq/L; avoid &gt;160; correct slowly if hypernatremia develops (no faster than 8-10 mEq/24h decrease) Equivalent or superior to mannitol for ICP reduction; does NOT cause diuresis (better for hypovolemic patients); no osmolality ceiling (unlike mannitol); does not accumulate in injured brain (mannitol may); preferred in many centers; SAFE-TBI trial (2021): 20% mannitol = HTS for ICP control Sedation and analgesia STAT STAT - STAT Goal: Reduce metabolic demand, prevent agitation-induced ICP spikes; Propofol: 25-75 mcg/kg/min (first-line; reduces CMRO2 and ICP; allows rapid awakening for neuro exams); Fentanyl: 25-100 mcg/hr (analgesia without histamine release); Midazolam: 0.05-0.2 mg/kg/hr (alternative to propofol); Avoid: Ketamine in severe ICP (controversial); prolonged propofol (PRIS syndrome &gt;48-72h at high doses) Agitation, pain, coughing raise ICP; sedation reduces cerebral metabolic rate; propofol has favorable ICP properties; daily sedation holiday for neuro assessment if stable Neuromuscular blockade - STAT - STAT For refractory ICP spikes with ventilator dyssynchrony, coughing, posturing; Cisatracurium 0.1-0.2 mg/kg bolus \u2192 1-3 mcg/kg/min infusion (organ-independent metabolism); Rocuronium 0.6-1 mg/kg bolus \u2192 0.6 mg/kg/hr; Requires: Concurrent sedation/analgesia; train-of-four monitoring; prevents detection of seizures (need cEEG) Prevents ICP spikes from coughing, posturing; reduces intrathoracic pressure; use judiciously \u2014 obscures neuro exam and seizure detection; requires cEEG monitoring Seizure prophylaxis / treatment STAT STAT - STAT Prophylaxis (TBI): Levetiracetam 1000-1500 mg IV load \u2192 500-1000 mg q12h x 7 days (BTF: early seizure prophylaxis x 7 days for severe TBI); Active seizure: Lorazepam 0.1 mg/kg (max 4 mg) \u2192 Levetiracetam 60 mg/kg load (max 4500 mg) OR fosphenytoin 20 mg PE/kg; Status epilepticus: Per SE protocol Seizures dramatically increase CMRO2 and ICP; early seizures occur in 10-15% of severe TBI; prophylaxis beyond 7 days NOT recommended (does not prevent late epilepsy); levetiracetam preferred (no drug interactions, IV/PO equivalent) Temperature control STAT STAT - STAT Avoid fever aggressively: fever increases CMRO2 by 10-13% per \u00b0C; target 36-37\u00b0C; acetaminophen 650-1000 mg q4-6h; cooling blankets; Therapeutic hypothermia: 32-35\u00b0C controversial; EUROTHERM (2015) showed harm from prophylactic hypothermia to 32-35\u00b0C in TBI; may use for refractory ICP as rescue Fever worsens neurologic outcomes; aggressive normothermia is standard; therapeutic hypothermia is rescue therapy only (not prophylactic); if used: 32-35\u00b0C, avoid shivering (increases CMRO2), slow rewarming Blood pressure / CPP management STAT STAT - STAT Target CPP 60-70 mmHg (CPP = MAP - ICP); avoid CPP &lt;60 (ischemia) and &gt;70 (BTF: avoid aggressive CPP &gt;70 due to ARDS risk); If hypotensive: IV fluids (isotonic crystalloid; avoid hypotonic fluids); vasopressors (norepinephrine first-line); If hypertensive with ICP crisis: Treat ICP first (osmotherapy, sedation); avoid precipitously lowering BP (reduces CPP) CPP is the primary determinant of cerebral perfusion; BTF 2016: target CPP 60-70; lower threshold 60 mmHg; aggressive CPP &gt;70 increases ARDS risk without outcome benefit; individualized based on autoregulation status"},{"location":"plans/elevated-icp-management/#3b-definitivetargeted-treatment-tier-2-moderate-icp-elevation","title":"3B. Definitive/Targeted Treatment (Tier 2 \u2014 Moderate ICP Elevation)","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale ICP monitor / EVD placement - STAT - STAT Indications (BTF 2016): GCS \u22648 + abnormal CT; OR GCS \u22648 + normal CT + \u22652 of: age &gt;40, SBP &lt;90, motor posturing; EVD preferred if: Hydrocephalus; need for CSF drainage; Parenchymal monitor if: No hydrocephalus; cannot drain CSF; Target ICP: &lt;22 mmHg (BTF 2016); some centers use &lt;20 Invasive ICP monitoring guides therapy; EVD allows therapeutic CSF drainage; parenchymal monitors cannot drain; infection risk ~5-10%; ventriculostomy is both diagnostic and therapeutic CSF drainage (via EVD) - STAT - STAT Continuous drainage: Set drain to maintain ICP &lt;22 mmHg; drain 5-10 mL CSF if ICP spike; Intermittent drainage: Drain for ICP &gt;22, then clamp to re-measure; Typical: Remove 5-20 mL for ICP crisis; Rate: Avoid draining &gt;20 mL/hour (risk of over-drainage, collapse of ventricles, hemorrhage) Immediate ICP reduction; removes volume (CSF) from closed cranial compartment; critical for hydrocephalus; risk: infection, hemorrhage, over-drainage Repeat osmotherapy dosing - STAT - STAT Scheduled or PRN osmotherapy based on ICP readings; Mannitol: 0.25-0.5 g/kg q4-6h; HTS 3%: 30 mL/hr continuous or 250 mL bolus PRN; Monitor: Serum osm q4-6h (hold mannitol if &gt;320); serum Na q2-4h (target 145-155 with HTS) Sustained osmotherapy for sustained ICP elevation; alternating mannitol and HTS may extend treatment window; monitor for accumulation Decompressive craniectomy - STAT - - Indications: Refractory ICP despite maximal medical therapy; malignant MCA stroke (large hemispheric infarct with edema); large ICH with mass effect; traumatic brain injury with refractory ICP; Timing: TBI: DECRA trial (2011) \u2014 early DC did not improve 6-mo outcomes but reduced ICP/ICU stay; RESCUEicp (2016) \u2014 late rescue DC improved survival but increased severe disability; Stroke: DESTINY/DECIMAL/HAMLET \u2014 DC improves survival in malignant MCA stroke age &lt;60 (NNT=2); must discuss goals of care Removes skull to allow brain expansion; definitive ICP reduction; increases survival but may increase proportion surviving with severe disability; requires extensive goals of care discussion; timing and patient selection critical Dexamethasone (tumor/vasogenic edema) - STAT ROUTINE STAT ONLY for vasogenic edema from tumor or abscess; NOT for TBI, stroke, or cytotoxic edema (steroids worsen outcomes in TBI \u2014 CRASH trial); Dose: 10 mg IV load \u2192 4 mg IV q6h; Duration: Until definitive tumor treatment; taper over 1-2 weeks after radiation/surgery; GI prophylaxis with PPI Reduces vasogenic edema around tumors; inhibits VEGF; dramatic effect within 24-48h; CRASH trial: steroids HARMFUL in TBI \u2014 avoid; no benefit in stroke Surgical evacuation of mass lesion - STAT - - Epidural hematoma: Emergent if &gt;30 mL, &gt;15mm thickness, or &gt;5mm midline shift, or GCS deterioration; Subdural hematoma: Emergent if &gt;10mm thickness, &gt;5mm midline shift, or GCS decrease &gt;2 points; ICH: Consider if lobar &gt;30 mL and deteriorating; cerebellar &gt;3cm or hydrocephalus; Tumor: Resection or debulking for mass effect Removes compressive mass \u2192 immediate ICP reduction; life-saving for epidural hematoma; subdural and ICH outcomes less clearly improved by surgery but indicated for mass effect and herniation"},{"location":"plans/elevated-icp-management/#3c-refractory-icp-management-tier-3-rescue-therapies","title":"3C. Refractory ICP Management (Tier 3 \u2014 Rescue Therapies)","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Pentobarbital coma - - - STAT LAST RESORT for refractory ICP; Protocol: Pentobarbital 5-10 mg/kg IV load over 30 min \u2192 1-3 mg/kg/hr infusion; titrate to ICP &lt;22 mmHg or burst suppression on EEG; Target: Burst suppression (3-10 second bursts with 10-20 second suppression); Monitor: Continuous EEG; drug levels (30-50 mcg/mL); hemodynamics (causes hypotension \u2014 often need vasopressors); Duration: 24-48h then attempt to wean; may need 3-5 days Reduces CMRO2 to minimal levels; dramatic ICP reduction; causes severe hypotension (need vasopressors); immunosuppression; ileus; prolonged sedation; no proven mortality benefit but reduces ICP; requires ICU expertise Therapeutic hypothermia (rescue) - - - STAT For refractory ICP only (NOT prophylactic); Target: 32-35\u00b0C; Method: Surface cooling (Arctic Sun) or intravascular cooling catheter; Duration: 24-72h; Rewarming: Slow \u2014 0.25\u00b0C/hour (rapid rewarming causes ICP rebound); Complications: Shivering (treat with paralysis, buspirone, meperidine), coagulopathy, infection, arrhythmia Reduces CMRO2 and ICP; EUROTHERM (2015): prophylactic hypothermia HARMFUL in TBI; rescue hypothermia for refractory ICP still used but evidence weak; prevents fever spikes; requires expertise Lumbar CSF drainage - - - STAT ONLY if: Communicating hydrocephalus; ICP refractory to EVD drainage; no mass lesion or obstructive hydrocephalus; basal cisterns visible; Method: Lumbar drain at 10-15 cm H2O; drain 5-10 mL/hour; Risk: Tonsillar herniation if used inappropriately; overdrainage Drains CSF from lumbar space; reduces overall CSF volume; effective adjunct in communicating hydrocephalus; must NOT be used with obstructive hydrocephalus or significant mass effect High-dose hypertonic saline (23.4%) - - - STAT For refractory ICP crisis; 30 mL IV bolus via central line; can repeat; target sodium up to 155-160 mEq/L in refractory cases (with close monitoring); Risk: Central pontine myelinolysis if rapid sodium changes (maintain stable elevated sodium; do not rapidly correct back to normal) Potent osmotherapy; can achieve higher sodium targets than 3% NaCl; reserved for refractory cases; requires central line access Decompressive craniectomy (rescue) - STAT - - As above; indicated for refractory ICP after failure of all medical therapies; must discuss survival with potential severe disability (RESCUEicp: DC improved survival from 26.9% to 48.9% but increased severe disability); goals of care critical RESCUEicp (2016): More patients survived with DC but at cost of more survivors with severe disability; DECRA (2011): Early prophylactic DC did not improve functional outcomes; decision requires extensive patient/family discussion"},{"location":"plans/elevated-icp-management/#3d-etiology-specific-management","title":"3D. Etiology-Specific Management","text":"Etiology Specific Treatment Traumatic Brain Injury (TBI) ICP monitoring if GCS \u22648; CPP 60-70; avoid hypoxia (PaO2 &lt;60), hypotension (SBP &lt;90), hyperventilation (except acute herniation), hyperglycemia (&gt;180), hyperthermia; seizure prophylaxis x 7 days; surgical evacuation of hematomas per criteria; decompressive craniectomy for refractory ICP Malignant MCA Stroke Decompressive craniectomy (hemicraniectomy) if age &lt;60, within 48h; DESTINY/DECIMAL/HAMLET: NNT=2 for survival; discuss functional outcomes (many survive with hemiplegia, aphasia); no benefit from steroids; osmotherapy as bridge Intracerebral Hemorrhage (ICH) BP control (target SBP &lt;140 per INTERACT2/ATACH-2); reverse anticoagulation; surgical evacuation if cerebellar &gt;3cm, lobar &gt;30mL with deterioration; EVD for hydrocephalus; no steroids Subarachnoid Hemorrhage (SAH) Secure aneurysm (clip/coil); nimodipine 60 mg q4h x 21 days; EVD for hydrocephalus; monitor for vasospasm (TCD, clinical); treat vasospasm (induced hypertension, intra-arterial therapy); euvolemia; avoid hypotension Brain Tumor Dexamethasone 10 mg IV then 4 mg q6h (for vasogenic edema); PPI while on steroids; surgical resection/debulking for mass effect; radiation/chemotherapy as appropriate; no osmotherapy needed if steroids effective Brain Abscess Antibiotics (empiric then targeted); surgical drainage (aspiration or excision) if &gt;2.5 cm or refractory; dexamethasone for edema (controversial \u2014 may impair antibiotic penetration and immune response but used for severe edema); treat source Meningitis Antibiotics (empiric then targeted); dexamethasone 0.15 mg/kg q6h x 4 days for bacterial meningitis (give before or with first antibiotic dose \u2014 reduces inflammation); ICP management as above; EVD for hydrocephalus Hydrocephalus EVD (emergent temporizing measure); VP shunt (definitive for communicating); ETV (endoscopic third ventriculostomy for obstructive); treat underlying cause (tumor, hemorrhage, infection) Idiopathic Intracranial Hypertension (IIH) Weight loss (most important long-term intervention); acetazolamide 250 mg BID \u2192 titrate to 1-2 g/day (reduces CSF production); topiramate (weight loss + ICP reduction); furosemide (adjunct); serial LP (therapeutic drainage); optic nerve sheath fenestration (for vision loss); VP shunt or transverse sinus stenting (refractory) Cerebral Venous Sinus Thrombosis (CVST) Anticoagulation (heparin \u2192 warfarin or DOAC) even if hemorrhagic; ICP management as above; treat underlying hypercoagulable state; endovascular thrombectomy for refractory cases Hepatic Encephalopathy / Acute Liver Failure Lactulose; rifaximin; treat precipitant; avoid sedatives; ICP monitoring in acute liver failure (cerebral edema common); mannitol; moderate hypothermia (33-34\u00b0C); liver transplant evaluation"},{"location":"plans/elevated-icp-management/#3e-medications-to-avoid","title":"3E. Medications to AVOID","text":"Medication Risk/Concern Alternative Corticosteroids in TBI CRASH trial: 14-day mortality HIGHER with steroids in TBI; absolute contraindication None \u2014 no role for steroids in TBI Corticosteroids in ischemic stroke No benefit; potential harm (infection, hyperglycemia) None \u2014 no role for steroids in stroke Hypotonic fluids (D5W, 0.45% NaCl) Worsens cerebral edema; reduces serum osmolality Isotonic saline (0.9% NaCl); hypertonic saline Prolonged aggressive hyperventilation Causes cerebral ischemia; rebound vasodilation; worsens outcomes Brief hyperventilation (&lt;30 min) for herniation only; maintain normoventilation (PaCO2 35-40) Ketamine (traditionally) Historically avoided due to ICP elevation concerns; however, recent data suggest may be safe in controlled ventilation; still generally avoided in severe TBI Propofol, etomidate, fentanyl for sedation/induction Nitroprusside Cerebral vasodilation may increase ICP; unpredictable Labetalol, nicardipine for BP control Propofol infusion syndrome (prolonged high-dose propofol) &gt;5 mg/kg/hr for &gt;48h: metabolic acidosis, rhabdomyolysis, cardiac failure, death Limit propofol dose and duration; use alternative sedation for prolonged needs; monitor CK, lactate, triglycerides"},{"location":"plans/elevated-icp-management/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/elevated-icp-management/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurosurgery consultation \u2014 EMERGENT STAT STAT - STAT All patients with elevated ICP need neurosurgical evaluation; ICP monitor/EVD placement; surgical decompression decisions; hematoma evacuation Neuro-ICU admission - STAT - STAT All patients with elevated ICP requiring intervention should be in Neuro-ICU or equivalent; 24/7 neuro-trained nursing; ICP monitoring capability; rapid imaging access Continuous ICP monitoring (invasive) - STAT - STAT If GCS \u22648 with abnormal CT; or GCS \u22648 with normal CT + risk factors; guides all ICP-directed therapy; allows CPP calculation Continuous EtCO2 / frequent ABG - STAT - STAT Ventilated patients: EtCO2 monitoring (correlate with ABG); target PaCO2 35-40; avoid hyperventilation except for acute crisis Serial neurologic examination STAT STAT - STAT q1-2h in unstable patients; pupil reactivity; GCS; motor response; detect early herniation; any decline \u2192 immediate intervention HOB elevation 30\u00b0 / midline head STAT STAT - STAT Simple intervention; promotes venous drainage; reduces ICP Avoid Valsalva / ICP-raising maneuvers STAT STAT - STAT Prevent coughing during suctioning (pre-oxygenate, lidocaine); avoid tight cervical collar; avoid constipation; stool softeners Normothermia STAT STAT - STAT Treat fever aggressively; acetaminophen; cooling; each \u00b0C fever increases CMRO2 10-13% Euvolemia STAT STAT - STAT Avoid both hypovolemia (reduces CPP) and fluid overload (may worsen edema); isotonic fluids; monitor CVP/volume status"},{"location":"plans/elevated-icp-management/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Ophthalmology consultation - URGENT ROUTINE - Fundoscopy for papilledema; IIH management; visual field testing; optic nerve sheath fenestration evaluation Neurology consultation - URGENT ROUTINE URGENT Seizure management; EEG interpretation; IIH management; stroke management Physiatry / Rehabilitation - ROUTINE ROUTINE - Early rehab evaluation; prognosis; disposition planning Palliative care / Ethics - ROUTINE ROUTINE ROUTINE Goals of care for poor prognosis patients; decompressive craniectomy discussions (survival vs. disability); brain death evaluation Social work - ROUTINE ROUTINE - Family support; long-term care planning; financial resources Clinical neurophysiology / EEG - STAT - STAT Continuous EEG for subclinical seizures; burst suppression monitoring; guide sedation"},{"location":"plans/elevated-icp-management/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Multimodal neuromonitoring - - - EXT PbtO2 (brain tissue oxygen); SjvO2 (jugular venous saturation); cerebral microdialysis; optimize individual patient physiology; research/specialized centers Targeted temperature management - - - EXT 32-35\u00b0C for refractory ICP; slow rewarming; prevent fever; requires specialized cooling devices Brain death evaluation - - - ROUTINE If clinical brain death suspected; formal evaluation protocol; apnea testing; ancillary tests if confounders present VP shunt / CSF diversion (long-term) - ROUTINE ROUTINE - Definitive hydrocephalus management; IIH refractory to medical therapy; post-hemorrhagic hydrocephalus Transverse sinus stenting (IIH) - - ROUTINE - For IIH with venous sinus stenosis; reduces ICP; emerging therapy; specialized centers <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/elevated-icp-management/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/elevated-icp-management/#causes-of-elevated-icp","title":"Causes of Elevated ICP","text":"Category Etiologies Key Features Traumatic Traumatic brain injury (TBI); epidural hematoma; subdural hematoma; contusions; diffuse axonal injury History of trauma; CT findings; mechanism of injury Vascular Ischemic stroke (malignant edema); intracerebral hemorrhage; subarachnoid hemorrhage; cerebral venous sinus thrombosis Sudden onset; focal deficits; CT/MRI findings; angiography for vascular lesions Neoplastic Primary brain tumor; metastatic disease; leptomeningeal carcinomatosis Subacute progressive; known cancer history; MRI with contrast Infectious Meningitis; encephalitis; brain abscess; subdural empyema Fever; meningismus; CSF analysis; ring-enhancing lesion Hydrocephalus Obstructive (tumor, hemorrhage, aqueductal stenosis); communicating (post-infectious, post-hemorrhagic); normal pressure hydrocephalus Ventricular enlargement on imaging; gait disturbance, dementia, incontinence (NPH triad) Idiopathic Intracranial Hypertension (IIH) Pseudotumor cerebri Young obese women; headache; papilledema; pulsatile tinnitus; normal imaging; elevated OP on LP Metabolic Hepatic encephalopathy; hypertensive encephalopathy (PRES); hyponatremia (cerebral edema); hypoxic-ischemic injury Metabolic derangement; toxic screen; liver function; blood pressure Other High altitude cerebral edema (HACE); post-operative; radiation necrosis; posterior reversible encephalopathy syndrome (PRES) Exposure history; post-procedural; imaging pattern (PRES: posterior white matter edema)"},{"location":"plans/elevated-icp-management/#signs-of-elevated-icp-and-herniation","title":"Signs of Elevated ICP and Herniation","text":"Sign Indication Cushing Triad Hypertension, bradycardia, irregular respirations \u2014 LATE and ominous sign of severely elevated ICP; indicates impending herniation Declining GCS Increasing ICP affecting reticular activating system Pupil asymmetry (unilateral dilation) Uncal herniation \u2014 compression of CN III; IPSILATERAL to lesion; dilated, fixed, \"blown\" pupil; emergent intervention needed Bilateral fixed pupils Late brainstem herniation; very poor prognosis Posturing (decerebrate/decorticate) Decorticate (flexion): midbrain/diencephalon dysfunction; Decerebrate (extension): pons/midbrain dysfunction; indicates progression Papilledema Chronically or subacutely elevated ICP (takes hours-days to develop); fundoscopy; absent papilledema does NOT exclude acutely elevated ICP Headache (worse lying down, morning) Increased ICP in recumbent position; chronic elevated ICP Nausea/vomiting (projectile) Brainstem compression; elevated ICP CN VI palsy \"False localizing sign\"; elevated ICP causes CN VI stretch along clivus; bilateral possible"},{"location":"plans/elevated-icp-management/#herniation-syndromes","title":"Herniation Syndromes","text":"Syndrome Anatomic Lesion Clinical Features Emergency Action Uncal (transtentorial) Temporal lobe mass Ipsilateral pupil dilation (CN III); contralateral hemiparesis; decreased LOC; then bilateral pupil dilation, decerebrate posturing Osmotherapy STAT; hyperventilation; emergent surgical decompression Central (transtentorial) Bilateral supratentorial mass effect Bilateral small pupils \u2192 bilateral fixed midpoint \u2192 bilateral dilated; progressive decrease in LOC; Cheyne-Stokes \u2192 central hyperventilation \u2192 ataxic breathing Same as above; worse prognosis than uncal Subfalcine (cingulate) Unilateral hemisphere mass Contralateral leg weakness (ACA compression); may progress to transtentorial herniation Osmotherapy; surgical decompression of mass Tonsillar (cerebellar) Posterior fossa mass; severe supratentorial pressure Neck stiffness; decreased LOC \u2192 respiratory arrest (medullary compression); rapid deterioration EXTREME EMERGENCY; osmotherapy; emergent posterior fossa decompression; cardiopulmonary arrest imminent Upward (cerebellar) Posterior fossa mass with relief of supratentorial pressure Pinpoint pupils; loss of upgaze; rapid coma Posterior fossa decompression; avoid LP"},{"location":"plans/elevated-icp-management/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/elevated-icp-management/#acute-phase-monitoring-icu","title":"Acute Phase Monitoring (ICU)","text":"Parameter Frequency Target Action if Abnormal ICP (if monitored) Continuous &lt;22 mmHg (BTF 2016); some centers &lt;20 Tiered therapy escalation (osmotherapy \u2192 sedation \u2192 CSF drainage \u2192 hyperventilation \u2192 DC) CPP (MAP - ICP) Continuous (calculated) 60-70 mmHg If low: IV fluids, vasopressors; if high (&gt;70) and ICP elevated: focus on ICP reduction Neurologic exam (GCS, pupils, motor) q1h initially; q2-4h when stable Stable or improving Decline: STAT CT; escalate ICP therapy; surgical evaluation Serum sodium q2-4h during active osmotherapy 135-155 mEq/L (target varies); avoid rapid changes Adjust osmotherapy; correct slowly if needed Serum osmolality q4-6h during mannitol therapy &lt;320 mOsm/kg (some use &lt;315) Hold mannitol if &gt;320; switch to HTS ABG / PaCO2 q4-6h; more frequent if adjusting ventilation 35-40 mmHg (normocapnia); 30-35 only for acute crisis Adjust ventilator; avoid hyperventilation except for crisis Temperature Continuous 36-37\u00b0C; strict normothermia Aggressive cooling; acetaminophen; treat infection source Blood glucose q4-6h 140-180 mg/dL Insulin titration Urine output Hourly 0.5-1 mL/kg/hr Assess volume status; diuresis from mannitol expected (replace losses) Hemodynamics (MAP) Continuous MAP to maintain CPP 60-70 Vasopressors; volume"},{"location":"plans/elevated-icp-management/#icp-waveform-analysis","title":"ICP Waveform Analysis","text":"Waveform Interpretation Normal waveform Three peaks: P1 (percussion) &gt; P2 (tidal) &gt; P3 (dicrotic); indicates normal intracranial compliance Abnormal waveform P2 &gt; P1 (\"rounded\" waveform) = decreased intracranial compliance; indicates elevated ICP even if absolute value normal Lundberg A waves (plateau waves) Sustained ICP elevation to 50-100 mmHg for 5-20 min; indicates severely impaired compliance; ominous Lundberg B waves Oscillating ICP 20-50 mmHg at 0.5-2/min; indicates impaired compliance; precursor to A waves Lundberg C waves Oscillating ICP at 4-8/min; corresponds to arterial BP variations; normal"},{"location":"plans/elevated-icp-management/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/elevated-icp-management/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria Neuro-ICU Any patient requiring ICP monitoring; GCS \u22648; signs of herniation; requiring osmotherapy, sedation, or mechanical ventilation for ICP; post-operative after decompressive craniectomy or hematoma evacuation; status epilepticus; hemodynamic instability Step-down / Intermediate care Stable ICP; improving neurologically; EVD weaning; transitioning off invasive monitoring; stable post-operative General neurology/neurosurgery floor Stable IIH on medical therapy; post-VP shunt; stable post-operative without ICP concerns"},{"location":"plans/elevated-icp-management/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details ICP normalized ICP consistently &lt;15-20 mmHg without intervention; EVD clamped successfully x 24-48h Neurologic stability Stable or improving neurologic exam; no new deficits; able to follow commands Off ICP-lowering medications Or transitioned to stable outpatient regimen (e.g., acetazolamide for IIH) EVD removed / VP shunt functioning CSF diversion resolved or definitive shunt placed Seizure control No seizures; stable AED regimen Able to mobilize safely PT/OT clearance; appropriate level of care for deficits Follow-up arranged Neurosurgery (1-2 weeks); neurology (as appropriate); ophthalmology (IIH); rehabilitation"},{"location":"plans/elevated-icp-management/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/elevated-icp-management/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Guidelines for the Management of Severe Traumatic Brain Injury Brain Trauma Foundation (BTF) 2016 (4th ed) ICP threshold 22 mmHg; CPP 60-70 mmHg; avoid prophylactic hyperventilation; avoid steroids; early seizure prophylaxis x 7 days Malignant MCA Stroke Guidelines AHA/ASA 2019 Decompressive craniectomy recommended for patients age &lt;60 with malignant MCA stroke within 48h; discuss goals of care ICH Guidelines AHA/ASA 2022 BP target SBP &lt;140 (intensive reduction); reversal of anticoagulation; surgery for cerebellar hemorrhage &gt;3cm SAH Guidelines AHA/ASA 2023 Secure aneurysm early; nimodipine; EVD for hydrocephalus; euvolemia; monitor/treat vasospasm IIH Guidelines British Consensus Guidelines 2018 Weight loss; acetazolamide; serial LP; optic nerve fenestration for vision loss; VP shunt for refractory"},{"location":"plans/elevated-icp-management/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact BTF Guidelines (2016) ICP threshold changed from 20 to 22 mmHg; CPP target 60-70 (avoid &gt;70); Level IIA evidence for ICP monitoring improving outcomes Standard of care for TBI ICP management CRASH Trial (2004) Corticosteroids HARMFUL in TBI \u2014 14-day mortality increased (25.7% vs. 22.3%, RR 1.15); 6-month mortality increased Steroids absolutely contraindicated in TBI DECRA Trial (2011) Early decompressive craniectomy (within 72h) for refractory ICP in TBI did NOT improve 6-month functional outcome (though reduced ICP and ICU stay) Questioned early prophylactic DC; did not stop DC but informed timing decisions RESCUEicp Trial (2016) Late/rescue DC for refractory ICP in TBI improved survival (48.9% vs. 26.9%) but increased proportion with severe disability; similar rates of favorable outcome DC is life-saving but increases survival with disability; requires goals of care discussion DESTINY/DECIMAL/HAMLET (pooled) DC for malignant MCA stroke &lt;60 years within 48h reduces mortality (NNT=2); higher survival with moderate-severe disability (mRS 4); DC should be offered Standard of care for malignant MCA stroke in appropriate patients EUROTHERM (2015) Prophylactic hypothermia (32-35\u00b0C) in TBI HARMFUL \u2014 worse outcomes; trial stopped early Hypothermia NOT recommended prophylactically; rescue use only for refractory ICP INTERACT2 / ATACH-2 (ICH) Intensive BP lowering (SBP &lt;140) safe in ICH; modest benefit in INTERACT2; no benefit in ATACH-2 SBP &lt;140 within 6h is current recommendation for ICH SAFE-TBI (2021) 20% mannitol vs. hypertonic saline (various concentrations): no significant difference in ICP control or outcomes Either osmotic agent acceptable; hypertonic saline may be preferred in hypovolemia"},{"location":"plans/elevated-icp-management/#icp-and-cpp-targets-summary","title":"ICP and CPP Targets Summary","text":"Parameter Target Evidence Level ICP &lt;22 mmHg BTF Level IIB CPP 60-70 mmHg BTF Level IIB (avoid CPP &lt;60; avoid &gt;70 due to ARDS risk) PaCO2 35-40 mmHg (normocapnia) BTF Level IIB PaCO2 (hyperventilation crisis) 30-35 mmHg (brief, &lt;30 min) BTF Level III Temperature 36-37\u00b0C (normothermia) BTF Level IIB Glucose 140-180 mg/dL General critical care consensus SBP (avoid hypotension) &gt;100 mmHg (or &gt;110 for TBI age 50-69) BTF Level III"},{"location":"plans/elevated-icp-management/#appendices","title":"APPENDICES","text":""},{"location":"plans/elevated-icp-management/#appendix-a-tiered-icp-management-algorithm","title":"Appendix A: Tiered ICP Management Algorithm","text":"<pre><code>ELEVATED ICP SUSPECTED OR CONFIRMED\n               \u2502\n    TIER 0: GENERAL MEASURES (all patients)\n    \u2022 HOB 30\u00b0, midline head position\n    \u2022 Avoid hyperthermia (target 36-37\u00b0C)\n    \u2022 Avoid hypoxia (PaO2 &gt;60), hypotension (SBP &gt;90-100)\n    \u2022 Adequate sedation and analgesia\n    \u2022 Avoid constipation/Valsalva\n    \u2022 Treat seizures\n               \u2502\n    ICP &gt;22 mmHg despite Tier 0?\n               \u2502\n    TIER 1: FIRST-LINE MEDICAL THERAPY\n    \u2022 CSF drainage via EVD (if available)\n    \u2022 Osmotherapy: Mannitol 0.5-1 g/kg OR\n                   HTS 3% 250mL or 23.4% 30mL\n    \u2022 Ensure adequate sedation\n    \u2022 Brief hyperventilation if acute crisis (PaCO2 30-35)\n               \u2502\n    ICP &gt;22 mmHg despite Tier 1?\n               \u2502\n    TIER 2: ESCALATED THERAPY\n    \u2022 Repeat osmotherapy dosing\n    \u2022 Optimize CPP (vasopressors if needed)\n    \u2022 Neuromuscular blockade\n    \u2022 Moderate hyperventilation with monitoring (SjvO2 or PbtO2)\n    \u2022 Consider surgical evacuation of mass lesion\n               \u2502\n    ICP &gt;22 mmHg despite Tier 2?\n               \u2502\n    TIER 3: RESCUE THERAPY (discuss goals of care)\n    \u2022 Pentobarbital coma (target burst suppression)\n    \u2022 Therapeutic hypothermia (32-35\u00b0C)\n    \u2022 Decompressive craniectomy\n    \u2022 High-dose hypertonic saline (Na target 155-160)\n</code></pre>"},{"location":"plans/elevated-icp-management/#appendix-b-osmotherapy-quick-reference","title":"Appendix B: Osmotherapy Quick Reference","text":"Agent Dose Onset Duration Max Threshold Administration Monitoring Mannitol 20% 1-1.5 g/kg bolus; 0.25-0.5 g/kg repeat 15-30 min 2-6 hr Serum osm &gt;320 Peripheral or central IV; filter; warm Serum osm q4-6h; BMP q6h; Foley (massive diuresis) HTS 23.4% 30 mL over 15-20 min 5-15 min 2-4 hr Na &gt;160 (relative) Central line only Na q2-4h; avoid rapid Na changes HTS 3% 250-500 mL bolus or 30-50 mL/hr continuous 15-30 min 2-4 hr Na &gt;160 (relative) Peripheral OK (central preferred) Na q2-4h HTS 2% 500-1000 mL bolus or continuous 30 min 2-4 hr Na &gt;160 (relative) Peripheral OK Na q4-6h <p>Key differences: - Mannitol: Causes diuresis \u2192 may worsen hypovolemia; accumulates in brain with BBB disruption; renal toxicity with prolonged use; osmolar gap monitoring - Hypertonic saline: No diuresis \u2192 better for hypovolemic patients; no osmolar gap ceiling; does not accumulate in brain; no renal toxicity; requires Na monitoring</p>"},{"location":"plans/elevated-icp-management/#appendix-c-herniation-emergency-protocol","title":"Appendix C: Herniation Emergency Protocol","text":"<pre><code>SIGNS OF ACUTE HERNIATION\n(Pupil dilation, posturing, Cushing triad, rapidly declining GCS)\n                    \u2502\n    IMMEDIATE ACTIONS (within minutes):\n    1. Call for help (neurosurgery STAT, airway team)\n    2. HOB to 30\u00b0 (or reverse Trendelenburg if C-spine)\n    3. Hyperventilation if intubated: target PaCO2 30-35\n       (bag at 20 breaths/min; avoid PaCO2 &lt;25)\n    4. Osmotherapy STAT:\n       \u2022 Mannitol 1-1.5 g/kg IV push (100g = 500 mL of 20%)\n         OR\n       \u2022 23.4% NaCl 30 mL IV via central line over 10-15 min\n         OR\n       \u2022 3% NaCl 500 mL rapid infusion if no central access\n    5. STAT CT head (if not already done)\n    6. Prepare for emergent surgical intervention\n                    \u2502\n    THESE ARE BRIDGE THERAPIES\n    Definitive treatment = surgical decompression\n    (hematoma evacuation, DC, tumor resection, EVD)\n</code></pre>"},{"location":"plans/elevated-icp-management/#appendix-d-iih-pseudotumor-cerebri-management","title":"Appendix D: IIH (Pseudotumor Cerebri) Management","text":"Intervention Details Weight loss Most important long-term intervention; 5-10% weight loss can significantly reduce ICP; bariatric surgery in morbid obesity Acetazolamide First-line medical therapy; 250 mg BID \u2192 titrate to 1-2 g/day (or max tolerated); carbonic anhydrase inhibitor reduces CSF production; side effects: paresthesias, fatigue, taste alteration, metabolic acidosis Topiramate Alternative to acetazolamide; also promotes weight loss; 50-100 mg BID; cognitive side effects Furosemide Adjunct to acetazolamide; 20-40 mg daily; less effective than acetazolamide alone Serial LP Therapeutic CSF removal; 20-30 mL per session; temporary relief; bridge to definitive treatment Optic nerve sheath fenestration Surgical; for progressive visual loss; protects optic nerve; may not reduce headache VP shunt Definitive CSF diversion; for refractory ICP or disabling headaches; shunt revision rates high Venous sinus stenting For patients with transverse sinus stenosis (common finding in IIH); emerging therapy; reduces ICP by improving venous outflow; specialized centers"},{"location":"plans/elevated-icp-management/#appendix-e-medications-affecting-icp","title":"Appendix E: Medications Affecting ICP","text":"Increases ICP Decreases ICP Ketamine (controversial \u2014 may be safe in controlled ventilation) Propofol Volatile anesthetics (at high concentrations) Barbiturates (thiopental, pentobarbital) Nitroprusside Etomidate Succinylcholine (transient) Benzodiazepines (mild) Hypercapnia Fentanyl, remifentanil Hypoxia Mannitol, hypertonic saline Fever Hypothermia Seizures Neuromuscular blockers (by preventing ICP spikes from posturing/coughing) Valsalva, coughing, straining Hyperventilation (transient \u2014 use with caution) <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/epidural-abscess/","title":"Spinal Epidural Abscess","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Spinal Epidural Abscess (SEA)</p> <p>ICD-10: G06.1 (Intraspinal abscess and granuloma), M46.40 (Discitis, unspecified site), M46.46 (Discitis, lumbar region), M46.47 (Discitis, lumbosacral region), A41.9 (Sepsis, unspecified organism)</p> <p>SYNONYMS: Spinal epidural abscess, SEA, epidural abscess, spinal abscess, vertebral osteomyelitis, discitis, spondylodiscitis, spinal infection, back pain with fever, paraspinal abscess</p> <p>SCOPE: Emergency evaluation and management of spinal epidural abscess in adults. Covers the classic triad (back pain, fever, neurologic deficit), emergent MRI, surgical drainage vs. medical management decision-making, empiric and targeted antibiotic therapy, and neurologic monitoring. Includes associated vertebral osteomyelitis and discitis. Excludes brain abscess (separate template), subdural empyema, and post-operative wound infections (partially overlaps).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/epidural-abscess/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/epidural-abscess/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Blood cultures (x2 sets, before antibiotics) STAT STAT - STAT CRITICAL: Positive in 60-70%; identifies organism for targeted therapy; guides antibiotic duration; S. aureus most common (60-70%); draw from 2 separate sites Positive \u2192 organism identification; S. aureus (MRSA vs. MSSA) most common; also Streptococci, gram-negatives, anaerobes CBC with differential STAT STAT ROUTINE STAT Leukocytosis (WBC &gt;12,000 in 60-80%); left shift; bandemia; baseline for monitoring; thrombocytopenia may indicate DIC/sepsis Leukocytosis (66%); normal WBC does NOT exclude SEA (20-40% have normal WBC); leukopenia concerning for overwhelming sepsis CMP (BMP + LFTs) STAT STAT ROUTINE STAT Renal function (antibiotic dosing, contrast); electrolytes; hepatic function; glucose (diabetes is major risk factor) Normal or abnormal; elevated glucose \u2192 diabetes workup; renal dysfunction affects antibiotic choice ESR (erythrocyte sedimentation rate) STAT STAT ROUTINE STAT Highly sensitive (&gt;94%); ESR &gt;20 mm/hr in nearly all cases of SEA; ESR &gt;30-50 typical; useful for monitoring treatment response ESR &gt;20 mm/hr (sensitivity 94%); mean ESR is typically 50-80 mm/hr; if normal \u2192 SEA very unlikely CRP (C-reactive protein) STAT STAT ROUTINE STAT Elevated in &gt;90% of SEA; more responsive to treatment changes than ESR; useful for monitoring Elevated (typically &gt;10 mg/dL); declines faster than ESR with successful treatment Procalcitonin STAT STAT - STAT More specific for bacterial infection than CRP; helps distinguish bacterial from non-infectious inflammation; prognostic &gt;0.5 ng/mL suggests bacterial infection; &gt;2.0 ng/mL concerning for sepsis; useful in atypical presentations Blood glucose / HbA1c STAT STAT ROUTINE STAT Diabetes is a major risk factor (30-50% of SEA patients); undiagnosed diabetes common; affects wound healing and immune function Document diabetes status; HbA1c &gt;6.5% = diabetes; glucose control target &lt;180 mg/dL PT/INR, aPTT STAT STAT - STAT Coagulopathy from sepsis (DIC); surgical candidacy; baseline before anticoagulation decisions; epidural hematoma differential Normal; prolonged \u2192 concern for DIC, liver dysfunction; affects surgical risk Lactate STAT STAT - STAT Sepsis assessment; tissue hypoperfusion; prognostic &lt;2 mmol/L (normal); &gt;4 mmol/L = severe sepsis/septic shock requiring aggressive resuscitation Type and screen STAT STAT - STAT Surgical candidacy; blood product availability On file Urinalysis + urine culture STAT STAT ROUTINE STAT Urinary source (UTI is common source of hematogenous spread, especially gram-negative SEA); concurrent UTI Normal or pyuria/bacteriuria; if positive \u2192 potential primary source"},{"location":"plans/epidural-abscess/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding HIV antibody/antigen - ROUTINE ROUTINE ROUTINE Immunocompromised state; increases SEA risk; affects prognosis and opportunistic infection risk Negative; if positive \u2192 CD4 count, viral load; consider opportunistic organisms Hepatitis B/C serologies - ROUTINE ROUTINE - IVDU population (risk factor for SEA); affects long-term antibiotic choice; liver function Negative; if positive \u2192 affects drug selection, hepatotoxicity monitoring Hemoglobin A1c - ROUTINE ROUTINE - Undiagnosed or poorly controlled diabetes &lt;6.5% (normal); \u22656.5% = diabetes; 5.7-6.4% = prediabetes D-dimer STAT ROUTINE - STAT DIC screening; VTE risk (prolonged immobility + inflammation); not specific but elevated in SEA Elevated (non-specific); very high levels \u2192 consider DIC Fibrinogen - ROUTINE - STAT DIC assessment; sepsis-associated coagulopathy &gt;150 mg/dL; low fibrinogen = DIC or consumption Albumin / prealbumin - ROUTINE ROUTINE - Nutritional status; wound healing; chronicity of illness; prognostic &gt;3.5 g/dL (albumin); low = poor nutrition, chronic illness Repeat blood cultures (during treatment) - ROUTINE ROUTINE - Document clearance of bacteremia; if persistently positive \u2192 evaluate for endocarditis, undrained collection, treatment failure Negative by 48-72h of appropriate antibiotics; persistent positivity \u2192 echocardiogram, repeat imaging"},{"location":"plans/epidural-abscess/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Surgical specimen culture (intraoperative) - STAT - - Gold standard for organism identification; culture of abscess material at surgery; sensitivity higher than blood cultures; also send for Gram stain and histopathology Organism identification; guides targeted antibiotic therapy CT-guided aspiration/biopsy culture - URGENT - - If non-operative management chosen; tissue diagnosis; culture for organism identification; distinguishes abscess from tumor/hematoma Organism identification; Gram stain; histopathology (rule out tumor) Acid-fast bacilli (AFB) smear and culture - EXT EXT - TB spine (Pott's disease); endemic areas; immunocompromised; chronic presentation with vertebral destruction Negative; positive \u2192 TB requires different treatment (anti-TB regimen; may not need surgery if no instability/neurologic deficit) Fungal cultures - EXT EXT - Immunocompromised; IVDU; indwelling catheters; endemic fungi (coccidioidomycosis, blastomycosis, histoplasmosis); chronic presentation Negative; positive \u2192 prolonged antifungal therapy (6-12+ months) Brucella serology / cultures - EXT EXT - Endemic areas (Mediterranean, Middle East); unpasteurized dairy; occupational exposure (farmers, veterinarians); chronic back pain Negative; positive \u2192 doxycycline + streptomycin/gentamicin or rifampin 16S rRNA PCR (on tissue) - EXT EXT - Culture-negative SEA; prior antibiotic exposure; fastidious organisms Identifies organism even when cultures are negative; research/reference lab Transthoracic echocardiogram (TTE) - ROUTINE ROUTINE STAT Infective endocarditis screen; IE present in 10-15% of SEA patients with S. aureus bacteremia; affects antibiotic duration and management Normal; vegetations \u2192 endocarditis diagnosis; changes antibiotic duration to 4-6 weeks minimum Transesophageal echocardiogram (TEE) - URGENT ROUTINE URGENT If TTE negative but high suspicion for endocarditis (S. aureus bacteremia, IVDU, prosthetic valve, persistent fever); TEE more sensitive than TTE Normal; vegetations \u2192 endocarditis; TEE sensitivity 90-95% vs. TTE 65%"},{"location":"plans/epidural-abscess/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/epidural-abscess/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI entire spine with and without contrast (gadolinium) STAT STAT URGENT STAT GOLD STANDARD \u2014 within 4 hours of ED presentation if neurologic deficit; within 24h if no deficit; contrast essential for abscess characterization; image ENTIRE spine (multifocal in 15-20%) Epidural collection with ring enhancement; T1 hypointense, T2 hyperintense; restricted diffusion (DWI bright, ADC dark within abscess); vertebral body involvement (osteomyelitis); disc involvement (discitis); cord compression; degree of canal compromise MRI-incompatible implants; severe claustrophobia (sedate \u2014 do NOT delay); GFR &lt;30 (gadolinium risk \u2014 but benefit outweighs risk in emergency) Plain radiographs (spine) STAT STAT - STAT Immediate while awaiting MRI; identifies vertebral body destruction, disc space narrowing, alignment abnormality; LOW sensitivity for early SEA Disc space narrowing; vertebral body destruction (late finding \u2014 takes 2-4 weeks to appear); alignment; pathologic fracture Pregnancy (shield) CT spine without contrast STAT STAT - STAT If MRI unavailable or contraindicated; inferior to MRI for soft tissue and epidural collection; shows bone destruction better than MRI Bone destruction; disc space narrowing; paraspinal soft tissue mass; canal compromise; less sensitive than MRI for epidural abscess extent Pregnancy (relative) Chest X-ray STAT STAT - STAT Primary pulmonary source (pneumonia); lung abscess; TB (apical infiltrate, cavitation); septic emboli Primary infection source; pulmonary complications; TB features Pregnancy (shield)"},{"location":"plans/epidural-abscess/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest/abdomen/pelvis with contrast - URGENT ROUTINE URGENT Source identification if not obvious; look for primary infection (lung abscess, intra-abdominal abscess, psoas abscess); staging for concurrent infection Primary source: lung abscess, intra-abdominal abscess, psoas abscess (contiguous spread), renal/perinephric abscess; endocarditis emboli Contrast allergy; renal impairment Echocardiogram (TTE \u2192 TEE if needed) - URGENT ROUTINE URGENT All patients with S. aureus bacteremia should have echocardiogram; endocarditis in 10-15% of S. aureus SEA Vegetations; valvular regurgitation; abscess; Duke criteria None (TTE); TEE: esophageal pathology, uncooperative patient CT myelogram - EXT - EXT Only if MRI absolutely contraindicated; intrathecal contrast via LP followed by CT; demonstrates level of compression; risk of meningitis seeding with LP Complete or partial block; level of compression; intradural vs. extradural Infection at LP site (SEA itself may preclude LP at involved level); coagulopathy Nuclear medicine bone scan (Tc-99m) - - EXT - If MRI unavailable; can identify osteomyelitis; may show uptake before radiographic changes; less specific than MRI Increased uptake at infection site(s); may identify multifocal disease Pregnancy; limited specificity Gallium-67 or Indium-111 WBC scan - - EXT - Chronic/subacute infection; differentiating active infection from degenerative changes; research use Increased uptake at infection site Limited availability; time-consuming; replaced largely by MRI"},{"location":"plans/epidural-abscess/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT-guided biopsy/aspiration - URGENT - - If diagnosis uncertain; culture acquisition for non-surgical management; distinguish abscess from tumor or hematoma Organism identification; Gram stain; histopathology confirming infection vs. other pathology Coagulopathy; inaccessible location; very small collection PET/CT (FDG) - - EXT - Chronic/recurrent infection; assess treatment response; identify additional sites of infection; research use Increased FDG uptake at infection site; may identify occult primary source Uncontrolled diabetes (glucose &gt;200); pregnancy Repeat MRI (during treatment) - ROUTINE ROUTINE - At 2-4 weeks or if clinical worsening; assess treatment response; monitor for abscess expansion; may appear worse before better on imaging Stable or decreasing collection size; resolving edema; NOTE: Imaging may lag behind clinical improvement (may appear worse at 2 weeks even with successful treatment) Same as initial MRI Post-treatment MRI - ROUTINE ROUTINE - At end of antibiotic course (6-8 weeks); baseline for comparison; assess for residual disease Resolution or significant improvement of collection; healed osteomyelitis; residual enhancement may persist for months (does not necessarily indicate active infection) Same as MRI"},{"location":"plans/epidural-abscess/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP \u2014 Generally NOT indicated - - - - LP is generally CONTRAINDICATED in suspected SEA; risk of seeding infection into subarachnoid space \u2192 meningitis/spinal subdural empyema; imaging (MRI) is diagnostic modality of choice N/A AVOID LP if SEA suspected \u2014 LP may spread infection into intradural space; if meningitis suspected concurrently, discuss with neurosurgery/ID before LP"},{"location":"plans/epidural-abscess/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/epidural-abscess/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Empiric IV antibiotics (STAT) STAT STAT - STAT Start IMMEDIATELY after blood cultures drawn \u2014 do NOT delay for MRI or organism identification; First-line empiric: Vancomycin 25-30 mg/kg IV load (max 2g), then 15-20 mg/kg IV q8-12h (target trough 15-20 mcg/mL) PLUS Ceftriaxone 2g IV q12h OR Cefepime 2g IV q8h; Alternative for \u03b2-lactam allergy: Vancomycin + aztreonam 2g IV q8h OR Vancomycin + fluoroquinolone (levofloxacin 750 mg daily); If Pseudomonas risk (IVDU, immunocompromised): Add anti-pseudomonal coverage with cefepime or piperacillin-tazobactam 4.5g IV q6h; Adjust to culture results when available Vancomycin covers MRSA (most important cause); ceftriaxone/cefepime covers MSSA, streptococci, gram-negatives; early antibiotics are associated with better outcomes; every hour of delay increases mortality in sepsis Emergent surgical decompression + drainage - STAT - - INDICATIONS (Surgery preferred): (1) Neurologic deficit (any weakness, bowel/bladder dysfunction), (2) Sepsis/hemodynamic instability not improving with antibiotics, (3) Significant cord compression on imaging, (4) Failure of medical therapy (no improvement at 48-72h, worsening at any time), (5) Unknown organism (need tissue diagnosis); Procedure: Posterior laminectomy with abscess drainage; cultures from abscess; d\u00e9bridement of infected tissue; may need instrumentation if instability; Timing: Within 24h of diagnosis; emergent (within hours) if progressive deficit Darouiche (2006): Surgical outcomes better than medical management in patients with neurologic deficit; earlier surgery (within 24h) associated with better neurologic recovery; pre-operative neurologic status is #1 predictor of outcome DVT prophylaxis STAT STAT - STAT SCDs immediately; pharmacologic prophylaxis: enoxaparin 40 mg SQ daily \u2014 timing is nuanced: may start within 24h of admission if no imminent surgery; post-operatively start 12-24h after surgery per surgeon; high VTE risk population Immobile + infection + inflammatory state = very high DVT risk; mechanical prophylaxis universal; pharmacologic prophylaxis as soon as surgically safe Pain management STAT STAT ROUTINE STAT Back pain often severe; acetaminophen 650-1000 mg q6h (scheduled) + opioids (morphine 2-4 mg IV q3h PRN or hydromorphone 0.5-1 mg IV q3h PRN); NSAIDs: use cautiously (renal function, surgical bleeding) \u2014 some ID physicians avoid NSAIDs in active infection; neuropathic agents (gabapentin) if radicular component Severe pain is hallmark of SEA; adequate analgesia is essential; balance with need for neurologic monitoring Sepsis resuscitation (if septic) STAT STAT - STAT Surviving Sepsis guidelines: lactate measurement; blood cultures before antibiotics; IV crystalloid 30 mL/kg for hypotension or lactate \u22654 mmol/L; vasopressors (norepinephrine first-line) if MAP &lt;65 despite fluids; reassess volume status; repeat lactate if initially elevated Sepsis from SEA has high mortality; early aggressive resuscitation improves outcomes Glucose control STAT STAT ROUTINE STAT Target glucose &lt;180 mg/dL; insulin infusion if critically ill; sliding scale or basal-bolus for non-ICU patients; diabetes is major risk factor \u2014 optimize control Hyperglycemia impairs immune function and wound healing; tight glucose control improves infection outcomes"},{"location":"plans/epidural-abscess/#3b-definitivetargeted-treatment","title":"3B. Definitive/Targeted Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Targeted IV antibiotic therapy (based on culture results) - STAT ROUTINE STAT Tailor to organism and sensitivities; typical regimens: \u2014 MSSA: Nafcillin 2g IV q4h OR cefazolin 2g IV q8h (preferred for tolerability); duration 6-8 weeks; \u2014 MRSA: Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) for 6-8 weeks; alternatives: daptomycin 6-8 mg/kg IV daily (avoid if pneumonia), linezolid 600 mg IV/PO q12h (monitor for toxicity if &gt;2 weeks); \u2014 Streptococci: Penicillin G 4 million units IV q4h or ceftriaxone 2g IV q12h x 6 weeks; \u2014 Enterococcus: Ampicillin 2g IV q4h (if susceptible) \u00b1 gentamicin synergy; vancomycin if ampicillin-resistant; \u2014 Gram-negatives: Ceftriaxone 2g IV q12h or cefepime 2g IV q8h or ciprofloxacin 400 mg IV q8h x 6 weeks depending on sensitivities; \u2014 Pseudomonas: Cefepime 2g IV q8h or meropenem 2g IV q8h x 6 weeks IV antibiotics are standard for SEA/osteomyelitis; oral transition data emerging (OVIVA trial) but traditionally 6-8 weeks IV; de-escalate from empiric coverage once cultures return Duration of antibiotics - STAT ROUTINE STAT SEA without osteomyelitis: 4-6 weeks IV; SEA with vertebral osteomyelitis (most cases): 6-8 weeks IV; SEA with endocarditis: 6 weeks minimum from first negative blood culture; duration guided by clinical response, inflammatory markers (ESR, CRP), repeat imaging; may extend if slow response IDSA guidelines: 6 weeks for vertebral osteomyelitis; 4-6 weeks for epidural abscess alone; endocarditis requires 6-week minimum; individualized based on response Oral antibiotic transition (selected cases) - - ROUTINE - OVIVA trial (2019): Oral antibiotics non-inferior to IV for bone/joint infections after initial 2 weeks IV in stable patients; Candidates: Clinically improving; afebrile; tolerating PO; CRP trending down; adherent; close follow-up available; Oral options: Fluoroquinolone (levofloxacin 750 mg daily or ciprofloxacin 750 mg BID) + rifampin 300 mg BID (NOT monotherapy); linezolid 600 mg BID (monitor CBC, neuropathy); TMP-SMX DS 2 tabs BID (for MRSA); NOT for: Endocarditis, undrained abscess, persistent bacteremia, non-adherent patient OVIVA trial showed oral switch after 2 weeks IV is non-inferior for bone/joint infections; reduces costs, IV complications, hospital stay; requires careful patient selection and close monitoring; NOT standard for all SEA cases Surgical drainage (if not done emergently) - URGENT - - If initial medical management: Re-evaluate need for surgery at 48-72h; indications for delayed surgery: failure to improve, neurologic deterioration, persistent fever/bacteremia, abscess enlargement on imaging; Procedure: Laminectomy + drainage; send cultures even if already on antibiotics (may still grow organism); instrumented fusion if instability/destruction Surgery provides source control, tissue diagnosis, and decompression; delayed surgery for medical failure still beneficial if performed before complete paralysis Medical management alone (selected cases) - STAT ROUTINE - Candidates for medical management without surgery: (1) No neurologic deficit, (2) Organism identified (blood cultures positive), (3) Small abscess (&lt;3 cm collection), (4) Poor surgical candidate (extreme comorbidities), (5) Panspinal disease (multiple levels \u2014 surgery impractical); Requirements: Very close neurologic monitoring (q2-4h initially); repeat MRI at 48-72h and weekly; immediate surgery if any deterioration; adherent patient Observational studies: ~40% of SEA can be managed medically if no neurologic deficit and criteria met; HOWEVER, 10-20% will fail medical therapy and require surgery; early surgery generally preferred if feasible"},{"location":"plans/epidural-abscess/#3c-adjunctive-treatment","title":"3C. Adjunctive Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale PICC line placement - URGENT ROUTINE - If prolonged IV antibiotics planned (6-8 weeks); enables outpatient IV therapy (OPAT); placed once stabilized and duration confirmed; confirm tip position with X-ray Required for OPAT; reduces peripheral IV complications; monitor for PICC-associated infection Outpatient parenteral antibiotic therapy (OPAT) - ROUTINE ROUTINE - Once clinically stable (afebrile, pain controlled, neurologically stable, adequate PO intake, safe home environment); PICC in place; infusion teaching completed; close ID follow-up (weekly visits); VNA nursing for line care Reduces hospital stay; comparable outcomes to inpatient therapy in appropriate patients; weekly ID visits with labs (CBC, CMP, drug levels, CRP) Rifampin (adjunctive) - ROUTINE ROUTINE - For staphylococcal osteomyelitis (vertebral involvement); enhances bone penetration; prevents biofilm; ONLY as adjunctive therapy \u2014 never monotherapy (rapid resistance); Rifampin 300 mg PO BID added to primary anti-staphylococcal agent; check interactions (CYP3A4 inducer \u2014 reduces warfarin, HIV meds, oral contraceptives, etc.) Rifampin improves outcomes in staphylococcal bone infections; biofilm activity; excellent bone penetration; drug interactions are significant Bracing / spinal orthosis - ROUTINE ROUTINE - If spinal instability (vertebral body destruction, kyphosis, instrumentation); TLSO for thoracolumbar; cervical collar for cervical; duration: typically 6-12 weeks or until radiographic healing External stabilization; pain relief; prevents pathologic fracture progression; may allow non-operative management of mild instability Nutritional optimization - ROUTINE ROUTINE - Protein supplementation (1.2-1.5 g/kg/day); calorie optimization; correct vitamin deficiencies; dietitian consultation; affects wound healing and immune function Malnutrition common in chronic illness; protein essential for wound healing; improves infection outcomes Diabetes optimization - STAT ROUTINE STAT Endocrinology consult if poorly controlled; insulin titration; goal HbA1c &lt;7.5% (individualized); glucose &lt;180 mg/dL during acute illness Diabetes is major risk factor; uncontrolled diabetes impairs healing and immune response Substance abuse counseling (if applicable) - ROUTINE ROUTINE - IVDU is major risk factor for SEA (20-30% of cases); addiction medicine consultation; harm reduction; hepatitis/HIV screening; reduces recurrence risk IVDU patients at high risk for recurrent infection; addressing substance use reduces future SEA risk"},{"location":"plans/epidural-abscess/#3d-medications-to-avoid-or-use-with-caution","title":"3D. Medications to AVOID or Use with Caution","text":"Medication Risk/Concern Alternative Daptomycin (with pneumonia) Inactivated by lung surfactant; NOT effective for pneumonia; OK for SEA without pulmonary involvement Vancomycin or linezolid if concurrent pulmonary infection Rifampin monotherapy Rapid development of resistance (within days); NEVER use rifampin alone; must always be combined with second anti-staphylococcal agent Rifampin only as adjunct to vancomycin, nafcillin, daptomycin, etc. Linezolid &gt;2-4 weeks Myelosuppression (thrombocytopenia); peripheral and optic neuropathy (often irreversible); serotonin syndrome (with SSRIs) Weekly CBC monitoring; limit duration; consider alternatives for long courses; discontinue if neuropathy develops Aminoglycosides (prolonged use) Nephrotoxicity; ototoxicity; reserve for synergy in enterococcal infections; short-term use only Non-aminoglycoside regimens preferred; if used, limit to 2 weeks Corticosteroids (routine use) May impair immune response and abscess control; NOT indicated routinely in SEA (unlike MSCC where tumor-related edema is target) Avoid steroids unless concurrent severe cord edema causing neurologic decline AND after ID consultation; NOT standard NSAIDs (prolonged, peri-operative) Renal toxicity (especially with vancomycin); impaired bone healing (controversial); peri-operative bleeding Acetaminophen; opioids; gabapentin for neuropathic pain; minimize NSAID exposure LP (in suspected SEA) Risk of seeding infection into intradural space \u2192 meningitis, subdural empyema; LP is contraindicated if SEA suspected MRI is diagnostic modality; avoid LP unless concurrent meningitis suspected and discussed with specialists Epidural steroid injection (as treatment or in area of abscess) Does NOT treat SEA; may worsen infection; epidural procedure may spread infection; if recent ESI \u2192 could be iatrogenic cause Surgical drainage; IV antibiotics; ESI is a risk factor for SEA, not a treatment"},{"location":"plans/epidural-abscess/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/epidural-abscess/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Spine surgery / Neurosurgery consultation \u2014 EMERGENT STAT STAT - STAT Consult IMMEDIATELY on suspicion \u2014 before or concurrent with MRI; surgery vs. medical management decision; ALL patients with SEA need spine surgery evaluation even if medical management is planned (contingency for neurologic deterioration) Infectious disease consultation STAT STAT ROUTINE STAT Antibiotic selection; duration; OPAT planning; monitoring plan; repeat imaging decisions; often co-manage with surgery Neurologic examination \u2014 serial monitoring STAT STAT - STAT CRITICAL: q2-4h neurologic checks initially; document motor strength (bilateral LE myotomes), sensory level, rectal tone, bladder function; ANY deterioration \u2192 STAT surgical evaluation; pre-operative neuro status is the #1 outcome predictor Source identification STAT STAT ROUTINE STAT Identify primary infection source: skin/soft tissue (cellulitis, IV site), UTI, endocarditis, dental abscess, pneumonia, intra-abdominal abscess, recent procedure (epidural injection, spinal surgery); treat primary source Blood cultures (before antibiotics) STAT STAT - STAT CRITICAL \u2014 positive in 60-70%; draw 2 sets from separate sites; do NOT delay antibiotics if cultures cause delay \u2014 draw quickly and start treatment Fall precautions / mobility assessment STAT STAT ROUTINE STAT SEA patients may have weakness, sensory loss, impaired balance; fall risk assessment; assistive devices; PT/OT evaluation Documentation of timeline STAT STAT - STAT Document: time of symptom onset (back pain \u2192 radiculopathy \u2192 weakness is classic progression over days-weeks), time of presentation, time of MRI, time of surgical consultation, time of antibiotics, neurologic exam at each time point"},{"location":"plans/epidural-abscess/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Echocardiogram (TTE \u00b1 TEE) - URGENT ROUTINE URGENT All patients with S. aureus bacteremia (IE in 10-15%); if TTE negative but high suspicion \u2192 TEE; affects antibiotic duration and management Dental evaluation - ROUTINE ROUTINE - Dental abscess as source; poor dentition as risk factor; dental clearance before prolonged antibiotics (if teeth issues could reinfect) PICC placement / vascular access - URGENT ROUTINE - Long-term IV access for 6-8 weeks of antibiotics; PICC is standard; peripherally inserted; confirm tip position Social work / case management - ROUTINE ROUTINE - OPAT coordination; home infusion setup; substance abuse services; insurance authorization; discharge planning Addiction medicine (if IVDU) - ROUTINE ROUTINE - IVDU is major risk factor (20-30%); buprenorphine or methadone initiation; harm reduction; reduces future infection risk Pain management service - ROUTINE ROUTINE - Chronic pain common after SEA; multimodal approach; avoid long-term opioids if possible; neuropathic agents Physical / occupational therapy - URGENT ROUTINE - Mobility assessment; strengthening; ADL training; rehabilitation planning if neurologic deficits VNA / home health - ROUTINE ROUTINE - PICC care; medication assistance; wound care (if post-operative); safety checks"},{"location":"plans/epidural-abscess/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Repeat MRI - URGENT ROUTINE URGENT At 48-72h if medically managed (assess for enlargement); at 2-4 weeks (assess treatment response \u2014 NOTE: imaging may appear worse before better); at end of treatment (baseline); PRN if clinical worsening CT-guided drainage (percutaneous) - URGENT - - Alternative to surgery in selected cases (poor surgical candidate, small collection, posterior access); less reliable than surgical drainage; may be repeated if recurrence Revision surgery / repeat drainage - URGENT ROUTINE - If treatment failure (persistent fever, neurologic decline, enlarging collection); undrained loculations; retained infected hardware Infectious disease second opinion - ROUTINE ROUTINE - Culture-negative SEA; unusual organism; treatment failure; complex antibiotic decisions Long-term suppressive antibiotics - - ROUTINE - Selected cases with retained hardware, incompletely treated osteomyelitis, immunocompromised; oral suppressive therapy (TMP-SMX, doxycycline, or other based on organism) after initial 6-8 week course; indefinite duration in some cases Spinal fusion (delayed) - - ROUTINE - If significant vertebral destruction and instability after infection controlled; typically 6-12 weeks after infection resolution; staged reconstruction Hyperbaric oxygen therapy - - EXT - Refractory osteomyelitis; adjunctive to antibiotics and surgery; limited evidence but some centers use for difficult cases <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/epidural-abscess/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/epidural-abscess/#primary-differential-diagnoses","title":"Primary Differential Diagnoses","text":"Diagnosis Key Differentiating Features Distinguishing Studies Malignant spinal cord compression (MSCC) / Metastatic epidural disease Known cancer history; bone destruction without disc involvement (SEA typically involves disc); no fever (usually); no elevated ESR/CRP/WBC (unless concurrent infection); may be painful but not typically as acute; enhances but no ring-enhancement or diffusion restriction MRI: enhancing epidural mass WITHOUT ring enhancement or restricted diffusion; bone destruction; CT/PET: metastatic staging; tumor markers; biopsy if uncertain; ESR/CRP may be mildly elevated in malignancy but not as high as SEA Vertebral compression fracture (osteoporotic) Older patient; osteoporosis history; no fever; acute onset with movement; no neurologic deficit (usually); no elevated inflammatory markers; vertebral body wedging; may have benign edema MRI: vertebral body edema WITHOUT epidural collection; no ring enhancement; normal ESR/CRP; DEXA: osteoporosis; mechanism (fall, lifting); responds to bracing/pain management Disc herniation (without infection) No fever; no elevated inflammatory markers; unilateral radiculopathy (usually); no epidural collection on MRI; common, benign presentation MRI: disc herniation without epidural enhancement; no T2 hyperintense collection; normal ESR/CRP; normal WBC; unilateral symptoms more common Spinal epidural hematoma Anticoagulation; post-procedural (epidural injection, LP, surgery); acute onset; hematoma signal characteristics on MRI (not ring-enhancing); no fever; rapidly progressive MRI: epidural collection with blood signal (T1 hyperintense in subacute phase); NO ring enhancement; NO restricted diffusion in hematoma (unlike abscess); coagulation studies; anticoagulation history; recent procedure Transverse myelitis / NMOSD Intramedullary (within cord) rather than epidural; autoimmune; no fever; no elevated ESR/CRP (or mildly elevated); subacute onset; responds to steroids/PLEX MRI: intramedullary T2 hyperintensity, NOT epidural collection; AQP4/MOG antibodies; CSF: pleocytosis but sterile; normal inflammatory markers Degenerative lumbar stenosis Chronic symptoms (claudication); older patient; no fever; no inflammatory markers; bilateral symptoms with walking; relieved by sitting/flexion; chronic findings on MRI MRI: chronic stenosis (ligamentum flavum hypertrophy, disc bulging, facet hypertrophy) WITHOUT acute epidural collection; normal ESR/CRP; chronic history Vertebral osteomyelitis (without epidural extension) Similar to SEA but NO epidural collection; disc and vertebral body involvement; back pain and fever; elevated inflammatory markers; may progress to SEA MRI: vertebral body and disc enhancement and edema WITHOUT epidural collection; blood cultures may be positive; requires IV antibiotics but not emergent surgical decompression (unless instability or progression to SEA) Psoas abscess Contiguous spread can cause spinal infection; flank/groin pain; hip flexion pain; may track from spine or vice versa; fever; iliopsoas enhancement on imaging CT/MRI: psoas muscle enlargement with rim-enhancing collection; may extend to spine; blood cultures; percutaneous drainage often possible"},{"location":"plans/epidural-abscess/#classic-clinical-triad-only-present-in-10-15","title":"Classic Clinical Triad (Only present in 10-15%)","text":"Phase Symptom Timing Phase 1 Back pain (localized, severe) Days to weeks before diagnosis Phase 2 Radicular pain (nerve root irritation) Days after back pain onset Phase 3 Neurologic deficit (weakness, bowel/bladder) Hours to days after radicular pain <p>NOTE: The classic triad (back pain \u2192 radiculopathy \u2192 paralysis) is present in only 10-15% of patients at presentation. Most patients present with 1-2 features. Maintain HIGH suspicion in any patient with back pain + fever, especially with risk factors.</p>"},{"location":"plans/epidural-abscess/#red-flags-requiring-urgent-reassessment","title":"Red Flags Requiring Urgent Reassessment","text":"Red Flag Concern Action ANY new neurologic deficit (weakness, sensory loss, bladder dysfunction) Progression of cord/root compression; medical management failure STAT MRI; immediate surgical consultation; emergent decompression if progressive Fever not improving after 48-72h of antibiotics Undrained collection; wrong antibiotic coverage; drug fever; secondary site Repeat imaging (MRI); reassess antibiotic coverage; consider surgical drainage Persistent or worsening back pain Abscess enlargement; vertebral instability; pathologic fracture Repeat MRI; surgical re-evaluation; bracing assessment Persistent bacteremia Undrained source; endocarditis; seeded secondary site TEE; repeat imaging; consider surgery for source control Sepsis not resolving Inadequate source control; resistant organism; secondary infection ICU reassessment; surgical drainage if not done; broaden antibiotics; repeat cultures New back pain at different level Multifocal SEA (present in 15-20%); skip lesion MRI whole spine (if not already done); assess new level Rising inflammatory markers after initial improvement Treatment failure; secondary infection; abscess loculation Repeat imaging; reassess antibiotic coverage; surgical consultation"},{"location":"plans/epidural-abscess/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/epidural-abscess/#acute-phase-monitoring-first-72h","title":"Acute Phase Monitoring (First 72h)","text":"Parameter Frequency Target Action if Abnormal Neurologic examination (motor strength, sensory level, rectal tone, bladder) q2-4h initially; q4-6h once stable Stable or improving; NO new deficits ANY deterioration \u2192 STAT MRI \u2192 emergent surgical consultation \u2192 likely emergent decompression Temperature q4h Afebrile (&lt;38\u00b0C) by 48-72h of antibiotics Persistent fever: repeat cultures; imaging for undrained collection; reassess antibiotics; echocardiogram Blood pressure / hemodynamics Continuous if septic; q4h if stable MAP &gt;65; resolving sepsis Vasopressors; fluid resuscitation; ICU care for septic shock Pain score (NRS) q4h Improving; NRS &lt;4/10 Escalate analgesia; worsening pain may indicate abscess enlargement or instability Blood cultures (repeat) Daily until negative Negative cultures within 48-72h of appropriate antibiotics Persistent bacteremia: echocardiogram (TEE); imaging for undrained focus; consider surgery WBC, CRP Daily initially Trending down Rising inflammatory markers: treatment failure; repeat imaging; reassess management Vancomycin trough (if on vancomycin) Before 4th dose; then 2-3x/week 15-20 mcg/mL (for serious infection) Adjust dose if outside range; monitor renal function Renal function (BUN/Cr) Daily initially; 2-3x/week ongoing Stable Nephrotoxicity: adjust vancomycin and other renally-cleared drugs; adequate hydration Blood glucose q6h (q4h if critically ill) &lt;180 mg/dL Insulin titration"},{"location":"plans/epidural-abscess/#subacute-monitoring-hospital-and-opat","title":"Subacute Monitoring (Hospital and OPAT)","text":"Parameter Frequency Target Action if Abnormal Neurologic examination Daily (hospital); weekly (OPAT) Stable or improving New deficits: urgent MRI; surgical re-evaluation ESR Weekly Declining trend (may take 3-4 weeks to start declining); normalize by 6-8 weeks (varies) Not declining: consider treatment failure; repeat imaging; ID reassessment CRP Weekly Should decline within 1-2 weeks; normalize before ESR Rising CRP: treatment failure; repeat imaging CBC (especially if on linezolid) Weekly Stable; no cytopenias Linezolid: thrombocytopenia, anemia \u2192 consider discontinuation if &lt;2 weeks remaining or switch agent Renal function + vancomycin trough 2-3x/week; weekly once stable Stable; trough 15-20 Dose adjustment LFTs (if on rifampin) Weekly Stable Transaminases &gt;3x ULN: consider discontinuing rifampin PICC line site Daily No erythema, drainage, tenderness Line infection: remove PICC; cultures; may need new site MRI spine At 2-4 weeks; end of treatment; PRN for symptoms Improving or stable; abscess resolving; NOTE: imaging may lag behind clinical improvement Enlarging abscess despite antibiotics: surgical drainage; worsening imaging despite clinical improvement may be normal at 2-4 weeks"},{"location":"plans/epidural-abscess/#long-term-follow-up","title":"Long-term Follow-up","text":"Parameter Frequency Target Action if Abnormal Clinic visit (ID) Weekly during OPAT; 2 weeks after completion; 3 months; 6 months; 12 months No relapse; no recurrence Relapse: repeat imaging; extended antibiotics; surgical reassessment ESR/CRP At end of treatment; 3 months; PRN Normalized or stable at new baseline Elevated: repeat MRI; consider relapse MRI spine End of treatment; 3-6 months; PRN for symptoms Resolved or stable; no new disease New or worsening: relapse; restart antibiotics \u00b1 surgery Functional assessment Each visit Improved or stable function Rehabilitation referral; pain management; chronic deficit management Spine stability / alignment Radiographs at 6 weeks, 3 months, 6 months, 12 months if instability Stable alignment; healing Progressive kyphosis or instability: surgical stabilization"},{"location":"plans/epidural-abscess/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/epidural-abscess/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU admission Sepsis/septic shock; hemodynamic instability; respiratory compromise; post-operative monitoring (surgeon-dependent); severe neurologic deficit with close monitoring needed General medical/neurosurgery floor ALL patients with confirmed or suspected SEA require admission; IV antibiotic initiation; neurologic monitoring; surgical evaluation; pre-operative preparation if surgery planned Observation (NOT appropriate) SEA is NEVER an observation diagnosis; all patients require admission until diagnosis confirmed/excluded and treatment initiated"},{"location":"plans/epidural-abscess/#discharge-criteria-transition-to-opat","title":"Discharge Criteria (Transition to OPAT)","text":"Criterion Details Neurologic stability Stable or improving neurologic exam for \u226548-72h; no new deficits; if deficits present: stable plateau Afebrile Afebrile for \u226524-48h on antibiotics Hemodynamically stable Off vasopressors; stable vital signs Organism identified Blood cultures or surgical cultures positive with sensitivities back; targeted antibiotic regimen Antibiotic regimen finalized IV regimen established; OPAT-compatible dosing (once daily or BID preferred); duration plan documented PICC line placed Functional PICC; confirmed position; patient educated on care Pain controlled Adequate oral pain control; no IV opioid requirement Safe home environment Able to care for self or adequate caregiver support; refrigeration for medications; clean environment; phone access Follow-up arranged ID clinic within 1 week; spine surgery follow-up (1-2 weeks if post-op); PCP; VNA nursing visits 2-3x/week Patient/family education PICC care; infusion technique (if self-administering); signs of treatment failure (fever, worsening pain, new weakness); when to call/return Pharmacy/infusion arranged Home infusion company contracted; medications delivered; pump if needed"},{"location":"plans/epidural-abscess/#discharge-prescriptions-checklist","title":"Discharge Prescriptions Checklist","text":"Medication Details IV antibiotic (specific to organism) Dose, frequency, duration clearly documented (e.g., \"Cefazolin 2g IV q8h x 6 weeks from [date]\") Oral analgesics Acetaminophen, limited opioid PRN, gabapentin if neuropathic pain DVT prophylaxis Enoxaparin 40 mg SQ daily (if continuing) or transition to ambulation-based prevention Rifampin (if applicable) Only as adjunctive therapy; never monotherapy; document interactions PPI / H2 blocker If on steroids or at risk for GI bleed Bowel regimen If on opioids Heparin flushes For PICC maintenance"},{"location":"plans/epidural-abscess/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/epidural-abscess/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Vertebral Osteomyelitis Guidelines IDSA Clinical Practice Guideline 2015 6-week IV antibiotic duration for vertebral osteomyelitis; MRI is imaging modality of choice; surgical drainage if neurologic deficit, spinal instability, or failure of medical therapy Spinal Epidural Abscess Management AANS/CNS Joint Guidelines 2017 Emergent surgical decompression recommended for patients with neurologic deficit; medical management may be considered for select patients without deficit and with identified organism Native Vertebral Osteomyelitis British Infection Association / British Orthopaedic Association 2015 MRI within 24h; blood cultures before antibiotics; echocardiogram for S. aureus bacteremia; 6-week IV antibiotics"},{"location":"plans/epidural-abscess/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Darouiche (2006) \u2014 NEJM Review Comprehensive review of SEA: S. aureus most common (60-70%); pre-operative neurologic status is #1 predictor of outcome; early surgery associated with better outcomes; medical management reasonable in selected cases without deficit Established framework for surgical vs. medical management decision-making Siddiq et al. (2004) \u2014 Meta-analysis 915 patients: Surgical treatment associated with better neurologic outcomes than medical management alone; patients presenting with neurologic deficit benefit most from early surgery Supports surgical decompression as preferred approach, especially with neurologic deficit Connor et al. (2013) Timing of surgery: decompression within 24h of neurologic deficit associated with significantly better outcomes than delayed surgery Established 24h window for surgical decompression Patel et al. (2014) Risk factors for poor outcome: advanced age, diabetes, MRSA, delayed diagnosis, pre-operative paralysis, cervical/thoracic location Identified high-risk patients who may benefit from aggressive surgical approach Berbari et al. (2015) \u2014 IDSA Guidelines 6-week IV antibiotic duration for vertebral osteomyelitis; longer for complicated cases (endocarditis, undrained abscess); rifampin adjunct for staphylococcal infections Standardized antibiotic duration and adjunctive therapy OVIVA Trial (2019) Oral antibiotics non-inferior to IV for bone/joint infections after initial IV therapy in stable patients; oral switch after 2 weeks IV Opened possibility of early oral transition for selected patients; reduces hospitalization/OPAT burden; requires careful patient selection Reihsaus et al. (2000) Meta-analysis: mortality 5%; permanent paralysis 4-22%; earlier surgery and better pre-operative function = better outcomes Established prognostic importance of pre-operative neurologic status and early intervention"},{"location":"plans/epidural-abscess/#risk-factor-summary","title":"Risk Factor Summary","text":"Major Risk Factors Prevalence in SEA Diabetes mellitus 30-50% Intravenous drug use (IVDU) 20-30% Recent spinal procedure/injection 15-20% Immunocompromised state (HIV, malignancy, steroids) 15-20% Chronic renal failure/hemodialysis 10-15% Alcoholism 10-15% Distant infection source (UTI, endocarditis, skin) 30-40% Recent bacteremia 20-30% Spinal abnormality (prior surgery, degenerative disease) 15-20%"},{"location":"plans/epidural-abscess/#microbiology","title":"Microbiology","text":"Organism Frequency Key Features Staphylococcus aureus 60-70% (MRSA 30-50% of S. aureus) Most common; hematogenous spread; IVDU, skin infection, catheters; MRSA requires vancomycin Coagulase-negative Staphylococci 5-10% Post-procedural; hardware-associated Streptococci (including viridans, pneumoniae) 5-10% Endocarditis association; dental source Gram-negative bacilli (E. coli, Pseudomonas, Klebsiella) 10-15% Urinary source; IVDU (Pseudomonas); diabetics Enterococcus 2-5% Urinary source; GI/biliary source Anaerobes 2-5% Often polymicrobial; abdominal/pelvic source Mycobacterium tuberculosis &lt;5% (higher in endemic areas) Subacute/chronic; Pott's disease; vertebral destruction; cold abscess; paraspinal extension Fungi (Candida, Aspergillus) &lt;2% IVDU; immunocompromised; indwelling catheters Culture-negative 10-20% Prior antibiotics; fastidious organisms; consider TB, Brucella, fungi"},{"location":"plans/epidural-abscess/#appendices","title":"APPENDICES","text":""},{"location":"plans/epidural-abscess/#appendix-a-surgical-vs-medical-management-algorithm","title":"Appendix A: Surgical vs. Medical Management Algorithm","text":"<pre><code>SPINAL EPIDURAL ABSCESS CONFIRMED ON MRI\n                \u2502\n                \u251c\u2500\u2500 NEUROLOGIC DEFICIT PRESENT?\n                \u2502        (weakness, sensory level, bowel/bladder dysfunction)\n                \u2502\n                \u2502   YES \u2192 EMERGENT SURGICAL DECOMPRESSION + DRAINAGE\n                \u2502         (within 24h; within hours if rapidly progressive)\n                \u2502         + IV antibiotics\n                \u2502\n                \u2502   NO (neurologically intact) \u2193\n                \u2502\n                \u251c\u2500\u2500 OTHER SURGICAL INDICATIONS?\n                \u2502        \u2022 Sepsis/hemodynamic instability not improving\n                \u2502        \u2022 Significant spinal instability\n                \u2502        \u2022 Large abscess (&gt;2.5-3 cm)\n                \u2502        \u2022 Unknown organism (need tissue diagnosis)\n                \u2502        \u2022 Failure of medical therapy\n                \u2502\n                \u2502   YES \u2192 SURGICAL DRAINAGE + IV antibiotics\n                \u2502\n                \u2502   NO \u2193\n                \u2502\n                \u251c\u2500\u2500 CANDIDATE FOR MEDICAL MANAGEMENT?\n                \u2502        \u2022 No neurologic deficit\n                \u2502        \u2022 Organism identified (blood cultures positive)\n                \u2502        \u2022 Small abscess\n                \u2502        \u2022 Hemodynamically stable\n                \u2502        \u2022 Able to perform serial neuro exams (reliable)\n                \u2502\n                \u2502   YES \u2192 MEDICAL MANAGEMENT (IV antibiotics)\n                \u2502         WITH:\n                \u2502         \u2022 q2-4h neurologic checks (initially)\n                \u2502         \u2022 MRI at 48-72h (assess for enlargement)\n                \u2502         \u2022 Weekly MRI until improving\n                \u2502         \u2022 LOW threshold for surgery if ANY deterioration\n                \u2502\n                \u2502   NO \u2192 SURGICAL DRAINAGE + IV antibiotics\n                \u2502\n                \u2514\u2500\u2500 MEDICAL MANAGEMENT FAILURE?\n                          \u2022 Neurologic deterioration (ANY)\n                          \u2022 Persistent fever &gt;72h\n                          \u2022 Enlarging abscess on imaging\n                          \u2022 Persistent bacteremia\n                          \u2022 Clinical worsening\n                                    \u2193\n                          SURGICAL DRAINAGE (delayed surgery)\n</code></pre>"},{"location":"plans/epidural-abscess/#appendix-b-antibiotic-selection-quick-reference","title":"Appendix B: Antibiotic Selection Quick Reference","text":"Scenario Empiric Regimen Duration Standard empiric (unknown organism) Vancomycin 15-20 mg/kg IV q8-12h + Ceftriaxone 2g IV q12h Adjust to cultures \u2192 6-8 weeks total Penicillin/cephalosporin allergy Vancomycin + Aztreonam 2g IV q8h OR Vancomycin + Fluoroquinolone Adjust to cultures Pseudomonas risk (IVDU, immunocompromised) Vancomycin + Cefepime 2g IV q8h OR Vancomycin + Pip-tazo 4.5g IV q6h Adjust to cultures MSSA (confirmed) Nafcillin 2g IV q4h OR Cefazolin 2g IV q8h \u00b1 Rifampin 300mg PO BID (if vertebral involvement) 6-8 weeks MRSA (confirmed) Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) \u00b1 Rifampin; ALT: Daptomycin 6-8 mg/kg IV daily (if no pneumonia) 6-8 weeks Streptococci Penicillin G 4 MU IV q4h OR Ceftriaxone 2g IV q12h 6 weeks Enterococcus (susceptible) Ampicillin 2g IV q4h \u00b1 Gentamicin 3mg/kg/day 6 weeks Gram-negative (susceptible) Ceftriaxone 2g IV q12h OR Ciprofloxacin 400mg IV q8h \u2192 PO 750mg BID 6 weeks With endocarditis Standard regimen for organism + extended duration (6 weeks minimum from first negative culture) 6+ weeks"},{"location":"plans/epidural-abscess/#appendix-c-esrcrp-monitoring-interpretation","title":"Appendix C: ESR/CRP Monitoring Interpretation","text":"Marker Expected Trajectory Concerning Trend Action CRP Peaks early; should begin declining within 1 week; normalize by 3-4 weeks Rising or plateau after 1 week Repeat imaging; reassess antibiotic coverage; consider surgery ESR May initially rise; begins declining at 2-3 weeks; may not normalize for 6-8 weeks or longer Rising after 3-4 weeks; failure to decline after 4 weeks Repeat imaging; ID reassessment; consider treatment failure WBC Should normalize within days-1 week Persistent leukocytosis Evaluate for secondary site; persistent infection <p>NOTE: ESR is slow to change and may remain elevated for weeks after successful treatment. CRP is more responsive and useful for early treatment monitoring. Imaging may appear worse at 2-4 weeks despite clinical improvement (this is normal \u2014 abscess organization and enhancement may increase before resolution).</p>"},{"location":"plans/epidural-abscess/#appendix-d-scoring-systems","title":"Appendix D: Scoring Systems","text":"<p>Modified MESS Score (Medical vs. Surgical Management)</p> <p>Consider medical management if ALL of the following: - [ ] No neurologic deficit - [ ] Organism identified (blood cultures or biopsy positive) - [ ] Abscess \u22642.5 cm in maximum dimension - [ ] No significant spinal instability (SINS &lt;7) - [ ] Hemodynamically stable (not septic shock) - [ ] Patient can be monitored closely (serial exams possible) - [ ] Patient is a poor surgical candidate (relative factor)</p> <p>If ANY box is unchecked \u2192 strongly consider surgical drainage</p> <p>SINS (Spinal Instability Neoplastic Score) \u2014 Also useful for infection</p> <p>Can be applied to infectious destruction to assess instability (see MSCC template for full scoring details). SINS \u22657 suggests instability requiring surgical stabilization.</p>"},{"location":"plans/epidural-abscess/#appendix-e-post-discharge-opat-monitoring-checklist","title":"Appendix E: Post-Discharge OPAT Monitoring Checklist","text":"Monitoring Frequency Parameters ID clinic visit Weekly Clinical assessment, review labs, antibiotic tolerance, PICC site CBC Weekly Anemia, thrombocytopenia (linezolid), leukopenia CMP Weekly Renal function (vancomycin, aminoglycosides) Vancomycin trough Weekly (more frequent initially) Target 15-20 mcg/mL ESR, CRP Weekly Declining trend LFTs Weekly (if on rifampin or other hepatotoxic drugs) Transaminases &lt;3x ULN PICC site assessment Each VNA visit (2-3x/week) No erythema, drainage, tenderness Neurologic exam Each ID visit; patient self-monitoring daily Stable; no new weakness/numbness Temperature Patient: daily Afebrile <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/essential-tremor/","title":"Essential Tremor","text":"<p>VERSION: 1.0 CREATED: January 29, 2026 REVISED: January 29, 2026 STATUS: Complete</p> <p>DIAGNOSIS: Essential Tremor</p> <p>ICD-10: G25.0 (Essential tremor), G25.1 (Drug-induced tremor), G25.2 (Other specified forms of tremor), G25.9 (Extrapyramidal and movement disorder, unspecified)</p> <p>SYNONYMS: Essential tremor, ET, benign essential tremor, familial tremor, hereditary tremor, action tremor, postural tremor, kinetic tremor, senile tremor</p> <p>SCOPE: Diagnosis and management of essential tremor in adults. Covers diagnostic workup to differentiate from Parkinson's disease and other tremor disorders, pharmacologic and non-pharmacologic treatment options. Excludes enhanced physiologic tremor, drug-induced tremor, psychogenic tremor, and tremor as part of other movement disorders (PD, dystonia, cerebellar disease).</p> <p>DEFINITIONS: - Essential Tremor: Bilateral action tremor of the hands and forearms (\u00b1 head tremor) without other neurologic signs, present for \u22653 years - Action Tremor: Tremor occurring during voluntary movement (includes postural and kinetic tremor) - Postural Tremor: Tremor present when maintaining a position against gravity (arms outstretched) - Kinetic Tremor: Tremor during voluntary movement (finger-to-nose) - Rest Tremor: Tremor present at rest with limb fully supported (typical of Parkinson's)</p> <p>DIAGNOSTIC CRITERIA (Consensus Statement, Movement Disorder Society):</p> <p>Core Criteria: - Bilateral upper limb action tremor (postural \u00b1 kinetic) for \u22653 years - With or without head tremor - Without other neurologic signs (dystonia, ataxia, parkinsonism)</p> <p>Supportive Features: - Family history of similar tremor - Beneficial response to alcohol - Absence of known causes</p> <p>Exclusion Criteria: - Isolated focal tremors (voice, head only) - Orthostatic tremor - Task-specific tremors - Sudden onset or stepwise progression - Drug-induced tremor</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/essential-tremor/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/essential-tremor/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding TSH - ROUTINE ROUTINE - Hyperthyroidism causes tremor Normal (0.4-4.0 mIU/L) Free T4 - ROUTINE ROUTINE - If TSH abnormal Normal CMP - ROUTINE ROUTINE - Electrolyte abnormalities, hepatic/renal function Normal Glucose - ROUTINE ROUTINE - Hypoglycemia can cause tremor Normal"},{"location":"plans/essential-tremor/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum ceruloplasmin - ROUTINE ROUTINE - Wilson disease if &lt;50 years or atypical features 20-40 mg/dL 24-hour urine copper - EXT EXT - If ceruloplasmin low/borderline &lt;100 mcg/24h Liver function tests - ROUTINE ROUTINE - Wilson disease, hepatic encephalopathy Normal Serum copper - ROUTINE ROUTINE - Wilson disease Normal Vitamin B12 - ROUTINE ROUTINE - Deficiency can cause tremor &gt;400 pg/mL Drug/toxin screen - ROUTINE ROUTINE - Drug-induced tremor Negative Caffeine intake assessment - - ROUTINE - Excessive caffeine exacerbates tremor Assess"},{"location":"plans/essential-tremor/#1c-rarespecialized","title":"1C. Rare/Specialized","text":"Test ED HOSP OPD ICU Rationale Target Finding Genetic testing (LINGO1, ETM1/2) - - EXT - Family history, research interest Informational Anti-neuronal antibodies - - EXT - If autoimmune cause suspected Negative Heavy metal levels - - EXT - Mercury, lead exposure Normal"},{"location":"plans/essential-tremor/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/essential-tremor/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Clinical examination - ROUTINE ROUTINE - At diagnosis Bilateral action tremor, no rest tremor, no parkinsonism None Handwriting sample - ROUTINE ROUTINE - At diagnosis, follow-up Large, tremulous writing (vs micrographia in PD) None Spiral drawing test - ROUTINE ROUTINE - At diagnosis, follow-up Objective tremor assessment None"},{"location":"plans/essential-tremor/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain without contrast - ROUTINE ROUTINE - If atypical features or diagnostic uncertainty Rule out structural cause, cerebellar lesions Pacemaker, metal DaTscan (I-123 ioflupane SPECT) - - ROUTINE - Differentiate ET from PD if uncertain Normal in ET; reduced striatal uptake in PD Pregnancy, iodine allergy Accelerometry/Tremor analysis - - EXT - Objective quantification, research Characterize tremor frequency (4-12 Hz) None EMG - - EXT - If neuropathic tremor suspected Rule out neuropathy None MRI with susceptibility-weighted imaging - ROUTINE ROUTINE - If Wilson disease suspected Rule out basal ganglia T2 hypointensity Per MRI"},{"location":"plans/essential-tremor/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/essential-tremor/#3a-first-line-pharmacologic-treatment","title":"3A. First-Line Pharmacologic Treatment","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Propranolol (Inderal) - ROUTINE ROUTINE - Start 20-40 mg BID-TID; titrate to 120-320 mg/day in divided doses Asthma, COPD, bradycardia, AV block, decompensated heart failure, depression HR, BP Propranolol LA - ROUTINE ROUTINE - Start 60-80 mg daily; titrate to 160-320 mg daily Same Same Primidone (Mysoline) - ROUTINE ROUTINE - Start 12.5-25 mg QHS; titrate very slowly by 12.5-25 mg/week to 250-750 mg/day in divided doses Porphyria, severe sedation Sedation, ataxia, nausea (start very low)"},{"location":"plans/essential-tremor/#3b-second-line-pharmacologic-treatment","title":"3B. Second-Line Pharmacologic Treatment","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Topiramate (Topamax) - ROUTINE ROUTINE - Start 25 mg daily; titrate by 25-50 mg/week to 100-400 mg/day in divided doses Kidney stones, glaucoma, pregnancy Cognitive effects, paresthesias, weight loss Gabapentin (Neurontin) - ROUTINE ROUTINE - Start 300 mg daily; titrate to 300-600 mg TID (900-1800 mg/day) Renal impairment (adjust dose) Sedation, dizziness, edema Alprazolam (Xanax) - ROUTINE ROUTINE - 0.25-0.5 mg TID; max 3 mg/day; use cautiously Respiratory depression, addiction potential, elderly falls Sedation, dependence, falls Clonazepam (Klonopin) - ROUTINE ROUTINE - 0.5 mg TID; titrate to 2-4 mg/day Same as alprazolam Same Atenolol - ROUTINE ROUTINE - 50-100 mg daily; less CNS penetration than propranolol Same as propranolol HR, BP Nadolol - ROUTINE ROUTINE - 40-160 mg daily; long-acting, once daily Same as propranolol HR, BP"},{"location":"plans/essential-tremor/#3c-third-line-and-adjunctive-treatments","title":"3C. Third-Line and Adjunctive Treatments","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Botulinum toxin (OnabotulinumtoxinA) - - ROUTINE - 50-100 units per arm for hand tremor; 40-400 units for head tremor; q3 months Infection at injection site, myasthenia Weakness, dysphagia (head/voice injections) Propranolol + Primidone combination - ROUTINE ROUTINE - Use lower doses of each; synergistic effect Per individual agents Per individual agents Nimodipine - - EXT - 30 mg TID; limited evidence Hypotension BP Zonisamide - - EXT - 100-200 mg daily; off-label Sulfa allergy, kidney stones Kidney stones, cognitive"},{"location":"plans/essential-tremor/#3d-interventional-treatments","title":"3D. Interventional Treatments","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Deep brain stimulation (DBS) - - EXT - VIM thalamus target; bilateral or unilateral Bleeding risk, active infection, severe cognitive impairment Speech, gait, stimulator function MRI-guided focused ultrasound (MRgFUS) - - EXT - VIM thalamotomy; unilateral only Skull density ratio issues, intracranial lesions Speech, gait, sensory changes Gamma Knife thalamotomy - - EXT - VIM target; unilateral; delayed effect Per radiosurgery Same as MRgFUS"},{"location":"plans/essential-tremor/#3e-non-pharmacologic-treatments","title":"3E. Non-Pharmacologic Treatments","text":"Treatment ED HOSP OPD ICU Details Contraindications Notes Weighted utensils - - ROUTINE - Reduce tremor amplitude during eating None OT can assist with selection Wrist weights - - ROUTINE - Dampen tremor during activities None May cause fatigue Adaptive devices - - ROUTINE - Two-handled cups, rocker knives, button hooks None OT referral Cala Trio device - - ROUTINE - FDA-approved wrist-worn peripheral nerve stimulation; 2x daily for 40 min Pacemaker/implanted device, pregnancy Prescription medical device Limit caffeine - ROUTINE ROUTINE - Caffeine exacerbates tremor None Patient education Avoid triggers - ROUTINE ROUTINE - Stress, fatigue, stimulants worsen tremor None Patient education Stress management - - ROUTINE - Relaxation techniques, biofeedback None Tremor worsens with anxiety"},{"location":"plans/essential-tremor/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/essential-tremor/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Movement disorder specialist - ROUTINE ROUTINE - Diagnostic uncertainty, treatment-refractory tremor, DBS candidacy Occupational therapy - ROUTINE ROUTINE - Adaptive equipment, handwriting strategies, ADL assistance Physical therapy - - ROUTINE - Balance, gait training if affected Speech therapy - - ROUTINE - Voice tremor management Neurosurgery - - ROUTINE - DBS candidacy evaluation Interventional radiology/MRgFUS center - - ROUTINE - Focused ultrasound evaluation Neuropsychology - - ROUTINE - Pre-DBS cognitive assessment"},{"location":"plans/essential-tremor/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD ET is a chronic condition but does not reduce life expectancy - ROUTINE ROUTINE Tremor may worsen slowly over time but many patients do well with treatment - ROUTINE ROUTINE Alcohol provides temporary relief but is not a recommended treatment - ROUTINE ROUTINE Medications work best when taken consistently - ROUTINE ROUTINE Avoid caffeine and stimulants which worsen tremor - ROUTINE ROUTINE Get adequate sleep; fatigue worsens tremor - ROUTINE ROUTINE Join International Essential Tremor Foundation support network - - ROUTINE Inform doctors of ET before procedures (tremor may complicate surgery) - ROUTINE ROUTINE"},{"location":"plans/essential-tremor/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Reduce or eliminate caffeine intake - ROUTINE ROUTINE Maintain regular sleep schedule - ROUTINE ROUTINE Stress reduction techniques - - ROUTINE Limit alcohol to social amounts (not as tremor treatment) - ROUTINE ROUTINE Regular exercise for overall health - - ROUTINE Use adaptive equipment for functional independence - - ROUTINE"},{"location":"plans/essential-tremor/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Parkinson's disease Rest tremor (4-6 Hz), asymmetric onset, bradykinesia, rigidity, postural instability Clinical exam; DaTscan reduced in PD Enhanced physiologic tremor Low amplitude, high frequency (8-12 Hz), associated with anxiety, caffeine, medications, hyperthyroidism TSH, medication review, resolves with trigger removal Drug-induced tremor Temporal relationship to medication (lithium, valproate, SSRIs, stimulants, bronchodilators) Medication review; improves with dose reduction Dystonic tremor Irregular, jerky, \"null point\" present, associated dystonic posturing Clinical features; may respond to botox Cerebellar tremor Intention tremor worse at target, associated ataxia, dysmetria, other cerebellar signs MRI brain; cerebellar atrophy/lesion Wilson disease Young onset (&lt;50), KF rings, liver disease, psychiatric symptoms, varied movement disorders Ceruloplasmin, 24h urine copper, slit lamp exam Psychogenic tremor Variable frequency, distractible, entrainment, inconsistent pattern, sudden onset Clinical observation; psychiatric assessment Orthostatic tremor High frequency (13-18 Hz), occurs only when standing, relief with sitting/walking EMG shows characteristic high frequency Hyperthyroidism Associated hyperthyroid symptoms (weight loss, palpitations, heat intolerance) TSH, free T4 Rubral (Holmes) tremor Combination of rest, postural, and action tremor; large amplitude; midbrain lesion MRI brain showing midbrain pathology"},{"location":"plans/essential-tremor/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Tremor severity (clinical rating scale) - ROUTINE ROUTINE - Each visit Improved or stable Adjust medications Functional impact (FTM, QUEST) - - ROUTINE - q6-12 months Minimal functional impairment Add therapy, consider surgery Handwriting sample/spiral drawing - ROUTINE ROUTINE - Each visit Stable or improved Objective tracking Heart rate - ROUTINE ROUTINE - Each visit if on beta-blocker HR &gt;50 Reduce dose if bradycardic Blood pressure - ROUTINE ROUTINE - Each visit if on beta-blocker SBP &gt;90 Reduce dose if hypotensive Sedation/cognitive effects - ROUTINE ROUTINE - Each visit Tolerable Reduce dose or switch agent Mood - ROUTINE ROUTINE - Each visit No depression Monitor; beta-blockers can cause depression TSH - - ROUTINE - Annually if on medications Normal Adjust thyroid replacement if applicable"},{"location":"plans/essential-tremor/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Outpatient management Most patients; diagnosis confirmed, treatment initiated Movement disorder referral Diagnostic uncertainty, DaTscan consideration, treatment-refractory, surgical candidacy DBS evaluation Moderate-severe tremor refractory to medications, adequate cognitive function, no surgical contraindications MRgFUS evaluation Unilateral tremor dominant, medications failed, not DBS candidate, meets skull density criteria Occupational therapy Functional impairment with ADLs; need for adaptive equipment"},{"location":"plans/essential-tremor/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Propranolol effective for ET Class I, Level A Cochrane Reviews; AAN Guidelines 2011 Primidone effective for ET Class I, Level A Cochrane Reviews; AAN Guidelines 2011 Propranolol + Primidone combination Class II, Level B AAN Guidelines 2011 Topiramate effective for ET Class I, Level B AAN Guidelines 2011 Gabapentin possibly effective Class II, Level U AAN Guidelines 2011 Botulinum toxin for hand tremor Class II, Level B AAN Guidelines 2011 DBS effective for medically refractory ET Class I, Level A Multiple RCTs MRgFUS (focused ultrasound) effective Class I, Level A Elias et al., NEJM 2016 DaTscan differentiates ET from PD Class II, Level B FDA approved 2011 Cala Trio wrist device Class II, Level B FDA approved 2018"},{"location":"plans/essential-tremor/#notes","title":"NOTES","text":"<ul> <li>Essential tremor is often underdiagnosed and undertreated</li> <li>Family history present in ~50% of cases; autosomal dominant inheritance pattern</li> <li>Alcohol responsiveness is characteristic but NOT a recommended treatment strategy</li> <li>Tremor typically starts in hands; head tremor develops in ~50% over time; voice tremor in ~30%</li> <li>Propranolol and primidone are first-line; start LOW and titrate SLOWLY with primidone</li> <li>Many patients respond partially to medications; combination therapy often needed</li> <li>DBS is highly effective for medication-refractory cases; VIM thalamus is target</li> <li>MRgFUS (focused ultrasound) is incisionless alternative but only unilateral treatment recommended</li> <li>ET is associated with increased risk of cognitive impairment and Parkinson's disease (controversial)</li> <li>Differentiation from PD is clinical; DaTscan helpful in uncertain cases</li> </ul>"},{"location":"plans/essential-tremor/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 29, 2026) - Initial template creation - Comprehensive pharmacologic options with tiered approach - Included interventional treatments (DBS, MRgFUS) - Added Cala Trio device and non-pharmacologic options - Differentiation from Parkinson's disease emphasized</p>"},{"location":"plans/guillain-barre-syndrome/","title":"Guillain-Barr\u00e9 Syndrome (GBS)","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Guillain-Barr\u00e9 Syndrome (GBS)</p> <p>ICD-10: G61.0 (Guillain-Barr\u00e9 syndrome)</p> <p>SYNONYMS: Guillain-Barr\u00e9 syndrome, GBS, acute inflammatory demyelinating polyneuropathy, AIDP, acute motor axonal neuropathy, AMAN, acute motor-sensory axonal neuropathy, AMSAN, ascending paralysis, Landry's paralysis, post-infectious polyneuropathy</p> <p>SCOPE: Acute inflammatory polyradiculoneuropathy including AIDP, AMAN, AMSAN, and Miller Fisher syndrome (MFS) variants. Covers acute diagnosis, respiratory monitoring, immunotherapy (IVIG/PLEX), autonomic dysfunction management, pain control, and rehabilitation planning. Excludes CIDP (chronic inflammatory demyelinating polyneuropathy \u2014 separate template), tick paralysis, and chronic neuropathies.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/guillain-barre-syndrome/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/guillain-barre-syndrome/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline; infection screen; exclude hematologic causes Normal; leukocytosis suggests infection trigger CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolyte abnormalities (hyponatremia from SIADH), renal/hepatic function for IVIG dosing Normal Magnesium STAT STAT ROUTINE STAT Hypomagnesemia worsens weakness; arrhythmia risk &gt;1.8 mg/dL Phosphorus STAT ROUTINE ROUTINE STAT Hypophosphatemia causes weakness (mimic) &gt;2.5 mg/dL ESR / CRP URGENT ROUTINE ROUTINE URGENT Inflammatory markers; infection screen Mildly elevated (non-specific) Blood glucose STAT STAT ROUTINE STAT Diabetes as comorbidity; hyperglycemia management Normal Urinalysis STAT ROUTINE ROUTINE STAT UTI as precipitant; baseline Normal Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE STAT Affects IVIG formulation choice; imaging considerations Document result PT/INR, aPTT STAT ROUTINE - STAT Coagulation status before procedures (LP, central line) Normal Type and screen STAT ROUTINE - STAT Potential need for PLEX On file"},{"location":"plans/guillain-barre-syndrome/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-ganglioside antibodies (GM1, GD1a, GD1b, GQ1b) - ROUTINE ROUTINE ROUTINE GM1: AMAN; GQ1b: Miller Fisher; GD1a: AMAN; helps confirm diagnosis and subtype Positive supports diagnosis (negative does not exclude) Anti-GQ1b antibody - ROUTINE ROUTINE - Miller Fisher syndrome (ataxia, ophthalmoplegia, areflexia) Positive in &gt;90% MFS Campylobacter jejuni serology (IgM, IgG) - ROUTINE ROUTINE - Most common infectious trigger (30%); AMAN variant association Positive IgM suggests recent infection Mycoplasma pneumoniae IgM - ROUTINE ROUTINE - Common triggering infection Positive IgM suggests recent infection CMV IgM - ROUTINE ROUTINE - Triggering infection; associated with severe demyelinating GBS Positive IgM EBV panel (VCA IgM, EBNA) - ROUTINE ROUTINE - Triggering infection Positive VCA IgM Hepatitis B surface antigen, anti-HBc - ROUTINE ROUTINE - Screen before IVIG; reactivation risk Negative Hepatitis C antibody - ROUTINE ROUTINE - Cryoglobulinemia-associated neuropathy (differential) Negative HIV 1/2 antigen/antibody - ROUTINE ROUTINE - HIV-associated neuropathy; acute HIV can mimic GBS Negative TSH - ROUTINE ROUTINE - Thyroid dysfunction can cause weakness Normal B12, methylmalonic acid - ROUTINE ROUTINE - B12 deficiency neuropathy (differential) Normal Serum protein electrophoresis (SPEP) with immunofixation - ROUTINE ROUTINE - Paraproteinemia-associated neuropathy (differential); POEMS Normal IgA level (quantitative) - ROUTINE - ROUTINE IgA deficiency contraindicates standard IVIG (anaphylaxis risk); check BEFORE IVIG if possible Normal (&gt;7 mg/dL)"},{"location":"plans/guillain-barre-syndrome/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Zika virus serology/PCR - EXT EXT - Endemic areas; associated with GBS outbreaks Negative Influenza A/B PCR - EXT - EXT Triggering infection; seasonal Negative COVID-19 PCR/antigen - ROUTINE - ROUTINE Post-COVID GBS association reported Document result Lyme serology (ELISA, Western blot) - EXT EXT - Lyme-associated polyradiculopathy (differential); endemic areas Negative Paraneoplastic panel (serum) - EXT EXT - If atypical features or poor response to treatment Negative Heavy metals (lead, arsenic, thallium) - EXT EXT - Toxic neuropathy mimic; occupational exposure Normal Porphyrins (urine ALA, PBG) - EXT EXT - Acute intermittent porphyria mimic (motor predominant, autonomic dysfunction) Normal Anti-MAG antibody - EXT EXT - MAG-associated neuropathy (differential; chronic presentation) Negative"},{"location":"plans/guillain-barre-syndrome/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/guillain-barre-syndrome/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI spine with and without contrast (whole spine) URGENT URGENT ROUTINE URGENT Within 24h of presentation Nerve root enhancement (anterior roots in AIDP); exclude compressive myelopathy, spinal cord lesion, epidural abscess Pacemaker, metallic implants Nerve conduction studies / EMG (NCS/EMG) - URGENT ROUTINE URGENT Ideally within 3-5 days of symptom onset (may be normal in first 48h); repeat at 2-3 weeks if initially non-diagnostic Demyelinating pattern: prolonged distal latencies, conduction block, temporal dispersion, prolonged F-waves, absent H-reflex. Axonal pattern (AMAN): reduced CMAP amplitudes with normal velocities None significant; avoid anticoagulated patients for EMG needle exam Chest X-ray URGENT ROUTINE - URGENT On admission Aspiration, atelectasis, baseline for ventilator management None significant ECG (12-lead) URGENT ROUTINE - URGENT On admission and PRN Arrhythmias (sinus tachycardia, bradycardia, AV block); autonomic dysfunction None"},{"location":"plans/guillain-barre-syndrome/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast - ROUTINE ROUTINE ROUTINE If Miller Fisher variant suspected or cranial nerve involvement Cranial nerve enhancement (especially CN III, VI, VII); exclude central lesion Same as MRI CT chest with contrast - EXT EXT - If paraneoplastic etiology suspected; thymoma screen if MG in differential Mass lesion Contrast allergy, renal impairment Repeat NCS/EMG - ROUTINE ROUTINE - At 2-4 weeks if initial study non-diagnostic or to assess prognosis Evolution of findings; axonal degeneration predicts slower recovery Same as initial Echocardiogram - ROUTINE - ROUTINE If autonomic instability or new murmur Cardiac function; Takotsubo in severe autonomic GBS None significant"},{"location":"plans/guillain-barre-syndrome/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Nerve ultrasound (high-resolution) - EXT EXT - If diagnosis uncertain Nerve enlargement in CIDP (helps differentiate); some enlargement reported in GBS None Pulmonary function testing (formal) - ROUTINE ROUTINE - If borderline respiratory function Full spirometry for outpatient monitoring Unable to cooperate"},{"location":"plans/guillain-barre-syndrome/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Diagnostic confirmation of GBS; albuminocytologic dissociation is classic finding</p> <p>Timing: URGENT in ED or within first 24h of admission; may be normal in first 48h \u2014 repeat at 1 week if initially normal</p> <p>Volume Required: 10-15 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Rule out elevated ICP 10-20 cm H2O (normal) Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Albuminocytologic dissociation WBC &lt;10 cells/\u00b5L (if &gt;50 WBC, reconsider diagnosis \u2014 HIV, Lyme, sarcoidosis, lymphoma) Protein URGENT ROUTINE ROUTINE Classic finding: elevated protein with normal WBC Elevated &gt;45 mg/dL (often &gt;100 mg/dL; may be normal in first week) Glucose with serum glucose URGENT ROUTINE ROUTINE Normal in GBS; low in infectious/malignant meningitis Normal (&gt;60% serum) Gram stain and culture URGENT ROUTINE ROUTINE Exclude bacterial meningitis No organisms Cytology - ROUTINE ROUTINE Exclude leptomeningeal lymphoma/carcinomatosis Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis can mimic Negative Oligoclonal bands, IgG index - ROUTINE ROUTINE Differentiate from MS; may be positive in GBS (non-specific) Negative or low titer <p>Special Handling: Standard processing. Cell count and protein are the critical values.</p> <p>Contraindications: Elevated ICP without imaging (CT first), coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site. Anticoagulation should be held.</p>"},{"location":"plans/guillain-barre-syndrome/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/guillain-barre-syndrome/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IVIG (intravenous immunoglobulin) - STAT - STAT 0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse over 4-8h per dose; slow initial rate and increase per protocol. Start within 2 weeks of symptom onset for maximum benefit IgA deficiency (use IgA-depleted product); acute renal failure; anaphylaxis to immunoglobulin Vital signs q15min during first infusion, then q30min; renal function (BUN, Cr) before and during; headache (aseptic meningitis); thrombotic events; hemolysis (haptoglobin, LDH, direct Coombs if symptoms) Plasmapheresis (PLEX) - STAT - STAT 5 exchanges over 7-14 days (typically every other day); each exchange 1-1.5 plasma volumes; use albumin replacement. Start within 4 weeks of symptom onset Hemodynamic instability, severe sepsis, active bleeding, heparin allergy (for circuit anticoagulation), poor vascular access BP and HR continuous during exchange; calcium (citrate toxicity: tingling, cramping); fibrinogen; CBC; electrolytes; line site infection Intubation and mechanical ventilation STAT STAT - STAT Indications (20/30/40 rule): FVC &lt;20 mL/kg, NIF weaker than -30 cmH2O, &gt;30% decline in FVC from baseline, or clinical respiratory distress. Use non-depolarizing agents (avoid succinylcholine \u2014 hyperkalemia risk). RSI with rocuronium preferred N/A (life-saving) Ventilator settings per ICU protocol; sedation; daily spontaneous breathing trial when improving DVT prophylaxis: Enoxaparin - ROUTINE - ROUTINE 40 mg SC daily; start on admission Active bleeding, platelets &lt;50K, CrCl &lt;30 (use UFH) Platelets q3 days; anti-Xa if renal impairment DVT prophylaxis: Heparin SC (alternative) - ROUTINE - ROUTINE 5000 units SC q8-12h Active bleeding, HIT Platelets q3 days Pneumatic compression devices STAT STAT - STAT Apply bilaterally on admission; continue until ambulatory Acute DVT, severe PVD Skin checks daily"},{"location":"plans/guillain-barre-syndrome/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Gabapentin Neuropathic pain (very common in GBS \u2014 55-89%) - ROUTINE ROUTINE ROUTINE Start 300 mg PO qHS; increase by 300 mg/day every 1-3 days; target 900-1800 mg TID; max 3600 mg/day Severe renal impairment (dose adjust); oversedation Sedation, dizziness; adjust for renal function Pregabalin Neuropathic pain (alternative) - ROUTINE ROUTINE ROUTINE Start 75 mg PO BID; increase to 150 mg BID after 3-7 days; max 300 mg BID Renal impairment (dose adjust) Sedation, weight gain, peripheral edema Carbamazepine Neuropathic pain (alternative) - ROUTINE ROUTINE - Start 100 mg PO BID; increase by 100 mg/day q3-7 days; target 400-800 mg/day in divided doses; max 1200 mg/day AV block, bone marrow suppression, HLA-B*1502 (Asian descent \u2014 screen before starting) CBC, LFTs, sodium at baseline and 2-4 weeks; drug level Amitriptyline Neuropathic pain, insomnia - ROUTINE ROUTINE - Start 10-25 mg PO qHS; increase by 10-25 mg q1-2 weeks; max 150 mg/day Arrhythmia, urinary retention, angle-closure glaucoma, recent MI ECG if cardiac risk; anticholinergic side effects Acetaminophen Musculoskeletal pain, headache STAT ROUTINE ROUTINE STAT 650-1000 mg PO q6h; max 4g/day (2g hepatic impairment) Severe liver disease LFTs if prolonged Morphine IV Severe pain unresponsive to above - URGENT - URGENT 2-4 mg IV q3-4h PRN; use with caution \u2014 respiratory depression risk especially with respiratory compromise Respiratory failure (relative \u2014 monitor closely), ileus RR, SpO2, sedation scale; bowel function Oxycodone Moderate-severe pain (if able to swallow) - ROUTINE ROUTINE - 5-10 mg PO q4-6h PRN Same as morphine Same as morphine Metoclopramide Gastroparesis, nausea (autonomic dysfunction) - ROUTINE - ROUTINE 10 mg IV/PO q6h PRN; max 40 mg/day; limit duration to &lt;12 weeks Seizure history, Parkinson disease, GI obstruction Tardive dyskinesia with prolonged use Docusate sodium Constipation (immobility + opioids) - ROUTINE ROUTINE ROUTINE 100 mg PO BID GI obstruction Bowel function Senna Constipation - ROUTINE ROUTINE - 8.6-17.2 mg PO qHS GI obstruction Bowel function Polyethylene glycol (MiraLAX) Constipation (if docusate insufficient) - ROUTINE ROUTINE - 17 g PO daily in 8 oz water GI obstruction Bowel function Melatonin Insomnia (ICU delirium prevention) - ROUTINE - ROUTINE 3-5 mg PO qHS None significant Sleep quality Lorazepam Anxiety, autonomic crisis - URGENT - URGENT 0.5-1 mg IV/PO q6-8h PRN Respiratory compromise (use with extreme caution) RR, sedation"},{"location":"plans/guillain-barre-syndrome/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Second course IVIG - URGENT - URGENT 0.4 g/kg/day x 5 days; consider if progressive deterioration after initial treatment or treatment-related fluctuation (TRF) Same as initial IVIG Same as initial IVIG PLEX after IVIG failure - URGENT - URGENT 5 exchanges over 7-14 days; wait \u22652 weeks after IVIG to avoid washing out immunoglobulin Same as initial PLEX Same as initial PLEX IV methylprednisolone (NOT standard of care) - EXT - EXT 500 mg IV daily x 5 days; evidence does NOT support steroids alone; may be considered in combination with IVIG per some centers for refractory cases Active infection, uncontrolled diabetes Glucose, BP, GI prophylaxis"},{"location":"plans/guillain-barre-syndrome/#3d-disease-modifying-or-chronic-therapies","title":"3D. Disease-Modifying or Chronic Therapies","text":"<p>Not applicable for GBS (acute monophasic illness). If recurrent or chronic course (&gt;8 weeks), reconsider diagnosis \u2014 evaluate for CIDP.</p>"},{"location":"plans/guillain-barre-syndrome/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/guillain-barre-syndrome/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consultation STAT STAT - STAT All suspected GBS; diagnostic confirmation, treatment initiation Pulmonology / Critical care URGENT URGENT - STAT Declining respiratory function; intubation decision; ventilator management Physical therapy (PT) - URGENT ROUTINE URGENT Early passive ROM to prevent contractures; gradual mobilization as tolerated; gait training Occupational therapy (OT) - URGENT ROUTINE URGENT Upper extremity function, ADLs, adaptive equipment Speech-language pathology (SLP) - URGENT ROUTINE URGENT Dysphagia evaluation (bulbar weakness); aspiration prevention Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Rehabilitation planning; disposition (inpatient rehab vs SNF) Pain management - ROUTINE ROUTINE ROUTINE Refractory neuropathic pain Social work - ROUTINE ROUTINE - Discharge planning, family support, financial resources Psychology / Psychiatry - ROUTINE ROUTINE - Anxiety, depression, PTSD (common in ICU patients) Respiratory therapy - STAT - STAT Bedside spirometry (FVC, NIF); pulmonary toilet; ventilator weaning Nutrition / Dietitian - ROUTINE - ROUTINE Enteral feeding plan if intubated; caloric needs during recovery Infectious disease - ROUTINE - - If triggering infection unclear or atypical presentation"},{"location":"plans/guillain-barre-syndrome/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED / Call 911 if: increasing difficulty breathing, new swallowing difficulty, rapid worsening of weakness, inability to walk, chest pain, or lightheadedness STAT STAT ROUTINE GBS is typically a self-limited illness; most patients recover substantially but recovery may take months to years - ROUTINE ROUTINE Do NOT drive until strength and reflexes have recovered and neurology clears - ROUTINE ROUTINE Comply with physical therapy exercises as prescribed between sessions - ROUTINE ROUTINE Pain is normal in GBS and will be managed with medications; report if pain is inadequately controlled - ROUTINE ROUTINE Inform future healthcare providers about GBS history (vaccine considerations, anesthesia precautions) - ROUTINE ROUTINE Fall prevention: use assistive devices (walker, cane) as recommended; remove tripping hazards at home - ROUTINE ROUTINE Monitor for signs of blood clots: leg swelling, redness, chest pain, shortness of breath - ROUTINE ROUTINE Follow-up with neurology in 2-4 weeks after discharge; NCS/EMG may be repeated at 3-6 months - ROUTINE ROUTINE"},{"location":"plans/guillain-barre-syndrome/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Gradual return to activity as tolerated; avoid overexertion during recovery - ROUTINE ROUTINE Balanced nutrition for nerve recovery (adequate protein, B vitamins) - ROUTINE ROUTINE Smoking cessation (impairs nerve healing) - ROUTINE ROUTINE Adequate sleep (promotes neurologic recovery) - ROUTINE ROUTINE Mental health support (depression and anxiety common during recovery) - ROUTINE ROUTINE Flu vaccination: generally safe after GBS; discuss with neurologist (6 weeks post-onset minimum; risk-benefit individualized) - - ROUTINE COVID-19 vaccination: discuss risk-benefit with neurologist; most experts recommend vaccination after recovery - - ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/guillain-barre-syndrome/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Transverse myelitis Sensory level, upper motor neuron signs (hyperreflexia, Babinski), bladder involvement early, MRI spinal cord lesion MRI spine (cord signal change); LP (pleocytosis more common); NCS/EMG (normal peripheral nerves) Myasthenia gravis Fatigable weakness, ptosis, diplopia, intact reflexes, fluctuating symptoms, no sensory involvement AChR antibodies, repetitive nerve stimulation (decremental), edrophonium test Botulism Descending paralysis (cranial nerves first), pupil involvement, GI prodrome, toxin exposure Stool/serum botulinum toxin assay; NCS (incremental response at high-rate repetitive stimulation) Tick paralysis Ascending paralysis similar to GBS; tick found on exam; rapid recovery after tick removal Physical exam (search for tick, especially scalp); NCS may show reduced CMAPs; CSF normal Spinal cord compression Back pain, sensory level, upper motor neuron signs below level, bladder dysfunction MRI spine (compressive lesion) Acute intermittent porphyria Abdominal pain, psychiatric symptoms, autonomic dysfunction, motor predominant neuropathy, dark urine Urine ALA and PBG (elevated during attack) Poliomyelitis / West Nile virus Asymmetric flaccid paralysis, fever, anterior horn cell pattern, CSF pleocytosis CSF (elevated WBC); viral PCR; MRI (anterior horn signal) CIDP Similar to GBS but progression &gt;8 weeks, relapsing-remitting course, may respond to steroids NCS/EMG (demyelinating); temporal course &gt;8 weeks; steroid response Critical illness myopathy/neuropathy ICU setting, prolonged ventilation, steroid/neuromuscular blocker exposure NCS/EMG; CK (elevated in myopathy); clinical context Hypokalemia Diffuse weakness, cardiac arrhythmia, normal reflexes or hyporeflexia Serum potassium; ECG; rapid improvement with replacement Conversion disorder (FND) Non-physiologic weakness pattern, Hoover sign, give-way weakness, psychiatric history Normal NCS/EMG; normal LP; clinical exam Diphtheria Pharyngeal membrane, palatal weakness, sensorimotor neuropathy weeks after infection Throat culture; clinical history HIV-associated neuropathy Progressive, often sensory predominant; CSF pleocytosis distinguishes from GBS HIV testing; CSF (WBC &gt;50 suggests HIV, not classic GBS)"},{"location":"plans/guillain-barre-syndrome/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Forced Vital Capacity (FVC) STAT STAT ROUTINE STAT q4-6h in hospital (q2h if declining); q1-2h in ICU if concerning trend FVC &gt;20 mL/kg (approximately &gt;1.5L for 75kg adult) If FVC &lt;20 mL/kg or declining &gt;30% from baseline \u2192 elective intubation; transfer to ICU Negative Inspiratory Force (NIF/MIP) STAT STAT ROUTINE STAT q4-6h with FVC NIF more negative than -30 cmH2O (e.g., -40 is better than -20) If NIF weaker than -30 cmH2O \u2192 prepare for intubation Peak Cough Flow - ROUTINE - ROUTINE q4-6h with FVC &gt;270 L/min (effective cough) Airway clearance interventions; suction; assisted cough Single Breath Count STAT STAT - STAT q4h (bedside screening) Count to \u226520 on single breath If &lt;10-15 \u2192 declining respiratory function, correlate with FVC Oxygen saturation (SpO2) STAT STAT - STAT Continuous in ICU; q4h on floor \u226594% Late finding \u2014 do NOT rely on SpO2 alone; FVC is more sensitive Blood pressure STAT STAT - STAT q4h on floor; continuous in ICU Stable; watch for lability (autonomic) If BP lability (swings &gt;20 mmHg): short-acting agents only; avoid long-acting antihypertensives; telemetry Heart rate and rhythm (telemetry) STAT STAT - STAT Continuous x 48h minimum; longer if autonomic symptoms HR 60-100; sinus rhythm Bradycardia: atropine ready; Tachycardia: volume, pain control; AV block: consider temporary pacing Neurologic exam (strength, reflexes) STAT STAT ROUTINE STAT q4-8h; Hughes GBS disability scale daily Stable or improving Worsening \u2192 repeat FVC/NIF; consider additional immunotherapy Swallowing function URGENT STAT ROUTINE STAT Daily assessment; formal SLP if bulbar symptoms Safe oral intake NPO if unsafe; NG or PEG for nutrition Pain assessment (NRS 0-10) STAT STAT ROUTINE STAT q4h with vitals NRS &lt;4 Adjust pain regimen Bowel function - ROUTINE ROUTINE ROUTINE Daily Regular bowel movements Bowel program; avoid ileus (autonomic dysfunction) Bladder function - ROUTINE ROUTINE ROUTINE I/O monitoring; post-void residual if needed Adequate output; PVR &lt;200 mL Bladder scan; intermittent catheterization if retention Renal function (BUN, Cr) - ROUTINE - ROUTINE Daily during IVIG; q48h otherwise Stable creatinine Hold IVIG if rising Cr; hydration Sodium - ROUTINE - ROUTINE Daily Normal (135-145 mEq/L) SIADH workup if &lt;130; fluid restriction"},{"location":"plans/guillain-barre-syndrome/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild GBS (ambulatory without assistance, Hughes 0-2), stable respiratory function (FVC &gt;60% predicted), adequate pain control on oral medications, safe swallowing, reliable outpatient follow-up, family/caregiver support Admit to floor (monitored bed preferred) Any GBS requiring treatment; unable to ambulate independently; FVC 20-30 mL/kg with no downward trend; mild bulbar symptoms; needs IVIG or PLEX Admit to ICU FVC &lt;20 mL/kg or declining rapidly; NIF weaker than -30 cmH2O; intubated or imminent intubation; autonomic instability (BP lability, arrhythmia); severe bulbar weakness with aspiration risk; unable to protect airway Transfer to higher level of care Need for PLEX not available on-site; need for ICU with neurology expertise; rapidly progressive course Inpatient rehabilitation Significant motor deficits (unable to walk independently; Hughes 3-4); able to participate in 3h/day therapy; medically stable Skilled nursing facility Unable to tolerate intensive rehabilitation; requires ongoing nursing care; severe deconditioning"},{"location":"plans/guillain-barre-syndrome/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IVIG 0.4 g/kg/day x 5 days Class I, Level A Dutch GBS Study Group (1992); Cochrane Review (Hughes 2014) PLEX (5 exchanges) equivalent to IVIG Class I, Level A French Cooperative Group; North American GBS Study IVIG + PLEX combination NOT superior to either alone Class I, Level A Plasma Exchange/Sandoglobulin GBS Trial Group (1997) Corticosteroids alone NOT effective for GBS Class I, Level A Cochrane Review (Hughes 2016) IVIG + IV methylprednisolone may shorten recovery (weak evidence) Class IIb, Level B Dutch GBS Study Group (2004) Bedside FVC and NIF for respiratory monitoring Class I, Level B Lawn et al. (2001); Wijdicks &amp; Klein (2017) 20/30/40 rule for intubation Class IIa, Level C Expert consensus; Wijdicks &amp; Borel (1998) Avoid succinylcholine in GBS Class III (Harm) Risk of hyperkalemia from denervated muscle Neuropathic pain management (gabapentin, carbamazepine) Class IIa, Level B Pandey et al. (2002); Cochrane Review Early rehabilitation improves outcomes Class I, Level B Khan et al. (2012); GBS-CIDP Foundation recommendations DVT prophylaxis Class I, Level C Standard of care for immobilized patients Anti-ganglioside antibodies (diagnostic, not required) Class IIa, Level B Diagnostic sensitivity varies by subtype Brighton criteria for GBS diagnosis Class IIa, Level C Brighton Collaboration (2011) IgA level before IVIG Class I, Level C Standard safety measure LP with albuminocytologic dissociation Class I, Level B Classic diagnostic finding; may be normal in first week <p>APPENDIX: HUGHES GBS DISABILITY SCALE</p> Grade Description 0 Healthy 1 Minor symptoms or signs, able to run 2 Able to walk \u226510m without assistance but unable to run 3 Able to walk \u226510m with assistance (walker, cane, person) 4 Chairbound or bedbound 5 Requiring assisted ventilation 6 Dead <p>APPENDIX: BRIGHTON CRITERIA (DIAGNOSTIC CERTAINTY)</p> Level Requirements Level 1 (Highest) Bilateral flaccid weakness + decreased/absent reflexes + electrophysiology consistent + CSF protein elevated with WBC &lt;50 + no alternative diagnosis Level 2 Bilateral flaccid weakness + decreased/absent reflexes + CSF or electrophysiology consistent + no alternative diagnosis Level 3 Bilateral flaccid weakness + decreased/absent reflexes + no alternative diagnosis <p>APPENDIX: IVIG INFUSION PROTOCOL (TYPICAL)</p> Step Rate Initial 30 min 0.5 mL/kg/h If tolerated, increase q30min 1.0 \u2192 2.0 \u2192 3.0 \u2192 4.0 mL/kg/h Maximum rate 4.0-8.0 mL/kg/h (product-specific) Pre-medication Acetaminophen 650 mg + diphenhydramine 25-50 mg PO 30 min before; hydration 500 mL NS <p>APPENDIX: 20/30/40 INTUBATION RULE</p> Parameter Threshold for Intubation FVC &lt;20 mL/kg NIF (MIP) Weaker than -30 cmH2O FVC decline &gt;30% from baseline Additional clinical signs Inability to count to 20 on single breath, paradoxical breathing, use of accessory muscles, tachypnea &gt;30, weak cough"},{"location":"plans/hsv-encephalitis/","title":"HSV Encephalitis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Herpes Simplex Virus Encephalitis</p> <p>ICD-10: B00.4 (Herpesviral encephalitis), G05.1 (Encephalitis in diseases classified elsewhere)</p> <p>SYNONYMS: HSV encephalitis, herpes encephalitis, herpes simplex encephalitis, viral encephalitis, limbic encephalitis, temporal lobe encephalitis, brain infection, encephalitis</p> <p>SCOPE: Acute HSV-1 encephalitis in adults \u2014 the most common cause of sporadic fatal encephalitis. Covers emergent empiric acyclovir, LP with HSV PCR, MRI findings, seizure management, and monitoring for complications (cerebral edema, SIADH, refractory status epilepticus). Excludes neonatal HSV, HSV-2 meningitis (Mollaret), CMV/EBV/VZV encephalitis, and autoimmune encephalitis (though post-HSV autoimmune encephalitis is addressed).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/hsv-encephalitis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/hsv-encephalitis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT - STAT Baseline; infection markers; lymphopenia may be present Normal or mild leukocytosis CMP (BMP + LFTs) STAT STAT - STAT Renal function for acyclovir dosing (nephrotoxic); electrolytes (SIADH); hepatic function Normal; watch Na and Cr Blood cultures x2 STAT STAT - STAT Exclude bacterial meningitis; concurrent bacteremia No growth Coagulation panel (PT/INR, aPTT) STAT STAT - STAT Before LP; coagulopathy workup if DIC suspected Normal Blood glucose (paired with CSF) STAT STAT - STAT CSF:serum glucose ratio interpretation Document paired with LP Procalcitonin URGENT ROUTINE - URGENT Low procalcitonin argues against bacterial meningitis Low (&lt;0.5 ng/mL favors viral) CRP URGENT ROUTINE - URGENT Inflammatory marker; lower in viral than bacterial Mild elevation Serum sodium STAT STAT - STAT SIADH is common complication of HSV encephalitis 135-145 mEq/L; watch for hyponatremia Serum osmolality URGENT ROUTINE - URGENT SIADH evaluation 280-295 mOsm/kg Type and screen STAT ROUTINE - STAT Potential surgical intervention for mass effect On file"},{"location":"plans/hsv-encephalitis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding HSV-1/2 IgG and IgM (serum) - ROUTINE ROUTINE - Seroconversion supports diagnosis; IgG positive in most adults (not diagnostic alone); IgM suggests acute infection Rising titers on paired sera (acute + convalescent at 2-4 weeks) HIV 1/2 antigen/antibody - ROUTINE ROUTINE - Immunocompromise affects prognosis and treatment duration Document result Urine osmolality and sodium - ROUTINE - ROUTINE SIADH confirmation (urine osm &gt;100, urine Na &gt;40 with low serum Na) Evaluate if hyponatremic TSH - ROUTINE - - Thyroid dysfunction in encephalopathy differential Normal Ammonia URGENT ROUTINE - URGENT Hepatic encephalopathy in differential Normal Troponin URGENT ROUTINE - URGENT Stress cardiomyopathy; myocarditis in systemic viral illness Normal Toxicology screen (urine) URGENT ROUTINE - URGENT Altered mental status differential Negative Blood alcohol level URGENT - - URGENT Altered mental status differential Negative"},{"location":"plans/hsv-encephalitis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Autoimmune encephalitis panel (serum) \u2014 NMDAR, LGI1, CASPR2 - ROUTINE ROUTINE ROUTINE Post-HSV autoimmune encephalitis occurs in 20-27% (especially anti-NMDAR); also primary differential Negative initially; recheck at 2-4 weeks if relapse Paraneoplastic panel (serum) - EXT EXT - If atypical features or oncologic history Negative VZV IgG/IgM (serum) - ROUTINE ROUTINE - VZV encephalitis in differential (especially immunocompromised) Negative Arboviral serologies (West Nile, EEE, St. Louis) - EXT EXT - Geographic/seasonal risk; summer-fall encephalitis Negative Rabies antibodies - EXT EXT - Animal exposure history with rapidly progressive encephalitis Negative Bartonella serology - EXT EXT - Cat exposure; neuroretinitis Negative"},{"location":"plans/hsv-encephalitis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/hsv-encephalitis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediate \u2014 before LP to exclude mass effect; CT may be NORMAL early in HSV encephalitis Temporal lobe hypodensity, edema, hemorrhage (late); may be normal in first 48-72h Pregnancy (relative) MRI brain with and without contrast STAT STAT - STAT Within 24h; STAT if available. MOST SENSITIVE imaging study \u2014 abnormal in &gt;90% within 48h T2/FLAIR hyperintensity in medial temporal lobes (unilateral or bilateral), insular cortex, inferior frontal gyri, cingulate gyrus. DWI restriction in acute phase. Hemorrhagic transformation. Leptomeningeal enhancement Pacemaker, metallic implants EEG (routine or continuous) URGENT URGENT - STAT Within 24h; continuous EEG if altered consciousness Periodic lateralizing epileptiform discharges (PLEDs/LPDs) from temporal region \u2014 highly suggestive of HSV encephalitis; focal slowing; electrographic seizures; diffuse slowing None significant ECG (12-lead) URGENT ROUTINE - URGENT On admission Baseline; myocarditis screen; QTc for medication interactions None"},{"location":"plans/hsv-encephalitis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with MRA/MRV - ROUTINE - ROUTINE If vascular complication suspected Venous sinus thrombosis; vasculopathy; large vessel occlusion Same as MRI Repeat MRI brain - ROUTINE - ROUTINE At 48-72h if initial MRI negative but suspicion high; at 7-14 days to assess extent of damage Evolving temporal changes; hemorrhagic transformation; extent of necrosis Same as MRI Continuous EEG (cEEG) monitoring - URGENT - STAT 24-72h minimum if altered consciousness, seizures, or post-ictal state Non-convulsive seizures, non-convulsive status epilepticus (NCSE), PLEDs None Chest X-ray URGENT ROUTINE - URGENT On admission Aspiration; baseline for ventilator management None"},{"location":"plans/hsv-encephalitis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Brain biopsy - - - EXT Only if: PCR negative, MRI atypical, no response to acyclovir, alternative diagnosis likely Cowdry type A inclusions; viral culture; PCR on tissue Neurosurgical risk; coagulopathy PET-CT brain - - EXT - If autoimmune encephalitis relapse suspected post-HSV Mesial temporal hypermetabolism (seizure focus) or hypometabolism Pregnancy ICP monitoring (EVD) - - - URGENT If clinical signs of elevated ICP; declining GCS despite treatment ICP &lt;22 mmHg; CPP &gt;60 Coagulopathy"},{"location":"plans/hsv-encephalitis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Diagnostic \u2014 ALL patients with suspected encephalitis. Do NOT delay acyclovir for LP.</p> <p>Timing: STAT. Start acyclovir BEFORE LP if any delay anticipated.</p> <p>Volume Required: 15-20 mL (extra for PCR, cytology, autoimmune panel)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure STAT ROUTINE - Elevated in some cases; monitor for ICP issues Normal or mildly elevated (usually &lt;300 mm H2O) Cell count with differential (tubes 1 and 4) STAT ROUTINE - Lymphocytic pleocytosis typical; RBCs may be present (hemorrhagic encephalitis); tube comparison for traumatic tap WBC 10-500 cells/\u00b5L (lymphocyte predominant); RBC may be elevated (hemorrhagic necrosis) Protein STAT ROUTINE - Mildly to moderately elevated Elevated (50-200 mg/dL typical; can be higher) Glucose with paired serum STAT ROUTINE - Usually NORMAL in HSV (distinguishes from bacterial/TB/fungal) Normal (&gt;60% serum glucose ratio); low glucose argues against HSV HSV-1/2 PCR (CSF) STAT ROUTINE - GOLD STANDARD diagnostic test; sensitivity 96-98%, specificity ~99%. May be NEGATIVE in first 72h \u2014 if clinical suspicion high and initial PCR negative, REPEAT at 3-7 days Positive (HSV-1 in &gt;90% adult cases; HSV-2 in neonatal/meningitis) Gram stain and bacterial culture STAT ROUTINE - Exclude bacterial meningitis No organisms BioFire FilmArray ME Panel STAT ROUTINE - Rapid multiplex PCR \u2014 includes HSV-1/2, VZV, enterovirus, CMV, HHV-6, and bacterial pathogens; result in ~1 hour HSV-1 detected (or other pathogen identified) VZV PCR (CSF) URGENT ROUTINE - VZV encephalitis in differential; especially immunocompromised and elderly Negative (positive \u2192 VZV encephalitis \u2014 treat with IV acyclovir) CMV PCR (CSF) - ROUTINE - If immunocompromised (HIV/transplant) Negative EBV PCR (CSF) - ROUTINE - If immunocompromised; CNS lymphoma differential Negative HHV-6 PCR (CSF) - ROUTINE - Post-transplant encephalitis; temporal lobe involvement similar to HSV Negative Enterovirus PCR - ROUTINE - Viral meningitis differential Negative Autoimmune encephalitis panel (CSF) \u2014 NMDAR, LGI1, CASPR2, GABA-B - ROUTINE ROUTINE Primary differential diagnosis; also detect post-HSV autoimmune encephalitis Negative initially; recheck if relapse Oligoclonal bands, IgG index - ROUTINE ROUTINE Intrathecal antibody production; MS differential May be positive (non-specific) Cytology - ROUTINE - Exclude leptomeningeal malignancy Negative AFB smear and culture - ROUTINE - TB meningitis if subacute or basilar Negative VDRL (CSF) - ROUTINE - Neurosyphilis screen Negative <p>Special Handling: HSV PCR sample can be refrigerated; do NOT freeze. Process CSF rapidly for cell count. Save extra CSF (frozen at -80\u00b0C) for future studies if needed.</p> <p>Repeat LP indications: If initial HSV PCR negative but clinical suspicion high \u2192 repeat at 3-7 days. Also repeat if clinical deterioration at 2-4 weeks (relapse \u2192 send autoimmune encephalitis panel).</p>"},{"location":"plans/hsv-encephalitis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/hsv-encephalitis/#critical-start-acyclovir-immediately","title":"\u26a0\ufe0f CRITICAL: START ACYCLOVIR IMMEDIATELY","text":"<p>Do NOT wait for LP, imaging, or PCR results. Every hour of delay increases mortality and morbidity. Start acyclovir on clinical suspicion alone.</p>"},{"location":"plans/hsv-encephalitis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Acyclovir IV STAT STAT - STAT 10 mg/kg IV q8h (infuse over 1h). Base on IDEAL body weight (IBW). Duration: minimum 14-21 days. Dose adjust for renal impairment: CrCl 25-50: 10 mg/kg q12h; CrCl 10-25: 10 mg/kg q24h; HD: 10 mg/kg after each dialysis session True acyclovir allergy (extremely rare). Renal impairment \u2014 dose adjust, do NOT withhold Renal function (BUN, Cr) daily; ensure adequate hydration (1-1.5 mL/kg/h IV fluids); urine output; acyclovir crystal nephropathy (maintain urine output); CBC (rare neutropenia); LFTs IV normal saline (aggressive hydration) STAT STAT - STAT 1-1.5 mL/kg/h continuous to prevent acyclovir nephrotoxicity; bolus 500-1000 mL if dehydrated Volume overload, CHF I/O; Cr daily; urine output &gt;0.5 mL/kg/h Empiric antibiotics (vancomycin + ceftriaxone) STAT STAT - STAT Standard meningitis dosing. Continue until bacterial meningitis excluded by CSF results (Gram stain negative, BioFire negative, cultures negative at 48-72h). See Bacterial Meningitis template for dosing See Bacterial Meningitis template Standard Dexamethasone STAT STAT - STAT 0.15 mg/kg IV q6h x 4 days \u2014 give empirically with antibiotics until bacterial meningitis excluded. Discontinue when bacterial excluded. Role in HSV encephalitis itself is CONTROVERSIAL \u2014 some evidence for reducing edema but no clear mortality benefit; not standard of care for isolated HSV Uncontrolled infection (relative) Glucose; GI prophylaxis Levetiracetam (if seizures) STAT STAT - STAT 1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day. Seizures occur in 40-60% of HSV encephalitis Severe renal impairment (dose adjust) Renal function; behavioral side effects Lorazepam (seizure rescue) STAT STAT - STAT 0.1 mg/kg IV (max 4 mg); repeat x1 in 5 min if needed Respiratory depression RR, SpO2; airway equipment ready Supplemental oxygen STAT STAT - STAT If SpO2 &lt;94% or intubated N/A SpO2 target \u226594%"},{"location":"plans/hsv-encephalitis/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen Fever (temperature goal &lt;38\u00b0C); headache STAT STAT ROUTINE STAT 650-1000 mg PO/IV q6h; max 4g/day Severe hepatic disease Temperature; LFTs Mannitol 20% Cerebral edema / elevated ICP STAT - - STAT 1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h Anuria Serum osm &lt;320; renal function; I/O Hypertonic saline 23.4% Acute herniation - - - STAT 30 mL IV via central line over 10-20 min No central access Na (target 145-155); osmolality Hypertonic saline 3% infusion ICP management (less acute) - - - STAT 0.5-1 mL/kg/h continuous; target Na 145-155 Hypernatremia Na q4-6h; osmolality Phenytoin/Fosphenytoin Refractory seizures (second-line after levetiracetam) STAT STAT - STAT Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min; maintenance 100 mg PE q8h; target level 10-20 \u00b5g/mL Bradycardia, heart block, hypotension (infusion rate-related) Continuous telemetry during load; free phenytoin level; LFTs Lacosamide Seizure management (adjunctive) - ROUTINE ROUTINE ROUTINE 200 mg IV/PO load; then 100-200 mg BID; max 400 mg/day PR prolongation, AV block ECG; PR interval Ondansetron Nausea/vomiting STAT ROUTINE - STAT 4 mg IV/PO q6h PRN QT prolongation QTc Pantoprazole GI prophylaxis (if steroids or critical illness) - ROUTINE - ROUTINE 40 mg IV/PO daily C. diff risk long-term GI symptoms Enoxaparin DVT prophylaxis - ROUTINE - ROUTINE 40 mg SC daily (start when not actively seizing and no hemorrhagic transformation) Active bleeding, hemorrhagic transformation, coagulopathy, platelets &lt;50K Platelets q3 days Pneumatic compression devices DVT prophylaxis STAT STAT - STAT Apply bilaterally on admission Acute DVT Skin checks Fluid restriction SIADH management - ROUTINE - ROUTINE 1-1.2 L/day if Na &lt;130 with clinical SIADH Dehydration (balance with acyclovir hydration needs) Na q6-8h; urine osm/Na; I/O"},{"location":"plans/hsv-encephalitis/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Foscarnet IV (acyclovir-resistant HSV) - EXT - EXT 60 mg/kg IV q8h or 90 mg/kg IV q12h; infuse over 1-2h with aggressive hydration. For proven or suspected acyclovir resistance (immunocompromised, HIV) Renal failure (major nephrotoxin); electrolyte abnormalities Cr daily; Ca, Mg, K, PO4 BID (causes severe electrolyte wasting); hydration 1-2 L NS before each dose Decompressive craniectomy - - - STAT For malignant cerebral edema with impending herniation, unresponsive to medical ICP management; consider if age appropriate and prognosis not already dismal Bilateral massive necrosis; moribund patient Post-op neuro checks; ICP monitoring; wound care Immunotherapy for post-HSV autoimmune encephalitis - URGENT ROUTINE URGENT If relapse at 2-6 weeks with new anti-NMDAR antibodies: IV methylprednisolone 1g/day x 5 days + IVIG 0.4 g/kg/day x 5 days; second-line: rituximab Active HSV infection (ensure viral replication controlled) NMDAR antibody titers; clinical response; viral PCR to confirm HSV not reactivated"},{"location":"plans/hsv-encephalitis/#3d-duration-of-treatment-and-discontinuation","title":"3D. Duration of Treatment and Discontinuation","text":"Scenario Duration Criteria to Stop Confirmed HSV encephalitis (PCR positive) 14-21 days IV acyclovir Clinical improvement; repeat LP at end of treatment \u2014 if HSV PCR still positive, continue additional 7 days Suspected HSV, PCR negative x2 Consider stopping at 7-10 days if: two negative HSV PCRs (initial + repeat at 3-7 days), MRI not consistent with HSV, alternative diagnosis established Clinical stability; alternative diagnosis confirmed Immunocompromised patients 21 days minimum Repeat LP with PCR before stopping; ensure negative PCR before discontinuation Transition to oral Oral valacyclovir 1g PO TID x 3-6 months after IV course is INVESTIGATIONAL; some centers use for immunocompromised; not standard of care Expert guidance"},{"location":"plans/hsv-encephalitis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/hsv-encephalitis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consultation STAT STAT - STAT All suspected encephalitis; seizure management; EEG interpretation; post-HSV autoimmune evaluation Infectious disease consultation STAT STAT - STAT Antimicrobial management; acyclovir-resistant HSV; duration of therapy Neurosurgery consultation - URGENT - STAT Cerebral edema with mass effect; ICP monitoring (EVD placement); decompressive craniectomy Critical care/ICU STAT STAT - STAT Altered consciousness (GCS &lt;12); respiratory failure; ICP management; status epilepticus Speech-language pathology (SLP) - URGENT ROUTINE URGENT Dysphagia evaluation; aphasia assessment (temporal lobe involvement); cognitive-communication evaluation Physical therapy (PT) - URGENT ROUTINE URGENT Early mobilization; prevent deconditioning; gait/balance training Occupational therapy (OT) - URGENT ROUTINE URGENT ADL assessment; cognitive rehabilitation; memory aids Neuropsychology - ROUTINE ROUTINE - Cognitive assessment (memory deficits common with temporal lobe damage); rehabilitation planning Psychiatry - ROUTINE ROUTINE - Behavioral changes; depression; anxiety; personality changes (frontal/temporal damage) Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Rehabilitation planning; disposition (inpatient rehab, SNF) Social work - ROUTINE ROUTINE - Family support; discharge planning; long-term care needs Epilepsy specialist - ROUTINE ROUTINE - Post-encephalitis epilepsy management; temporal lobe epilepsy Palliative care - ROUTINE - ROUTINE Goals of care for severe cases; prognostication"},{"location":"plans/hsv-encephalitis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED if: new confusion, seizure, fever recurrence, worsening headache, personality change, speech difficulty, new weakness STAT STAT ROUTINE HSV encephalitis can cause long-term memory and cognitive deficits; rehabilitation is important - ROUTINE ROUTINE Seizures may develop weeks to months after infection; report any episodic symptoms (staring, jerking, d\u00e9j\u00e0 vu, loss of awareness) - ROUTINE ROUTINE Post-HSV autoimmune encephalitis can occur 2-6 weeks later with new psychiatric/neurologic symptoms \u2014 report immediately - ROUTINE ROUTINE Take all medications as prescribed; do NOT stop antiepileptic drugs without neurologist guidance - ROUTINE ROUTINE Follow-up with neurology in 2-4 weeks; neuropsychology testing at 3-6 months - ROUTINE ROUTINE Cognitive rehabilitation and therapy are critical for recovery - ROUTINE ROUTINE Driving restrictions until seizure-free per state law (typically 3-12 months) - ROUTINE ROUTINE"},{"location":"plans/hsv-encephalitis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD HSV encephalitis is NOT contagious in the traditional sense; no isolation needed - ROUTINE ROUTINE Long-term suppressive antiviral therapy is NOT standard after encephalitis (unlike genital HSV) - ROUTINE ROUTINE Cognitive rehabilitation: memory strategies, organizational tools, speech therapy - ROUTINE ROUTINE Seizure safety: avoid heights, swimming alone, operating heavy machinery until seizure-free - ROUTINE ROUTINE Mental health support (depression, anxiety, PTSD common after encephalitis) - ROUTINE ROUTINE Adequate sleep and stress management - ROUTINE ROUTINE Gradual return to work/school with accommodations as needed - - ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/hsv-encephalitis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Autoimmune encephalitis (anti-NMDAR) Subacute; psychiatric symptoms (psychosis, agitation); orofacial dyskinesias; seizures; young women; often post-HSV Anti-NMDAR antibody (CSF &gt; serum); MRI may be normal or temporal; ovarian teratoma screen Bacterial meningitis Fever + meningismus; CSF neutrophilic pleocytosis with low glucose; more acute; no temporal preference on imaging CSF Gram stain, culture, BioFire; procalcitonin elevated; CSF glucose low Viral meningitis (enterovirus) Headache + fever + meningismus; LESS confusion/focal deficits; CSF lymphocytic but fewer WBC; MRI normal Enterovirus PCR (CSF); BioFire panel; normal MRI VZV encephalitis Immunocompromised; may have rash (but not always); vasculopathy pattern on MRI; cranial neuropathies VZV PCR (CSF); VZV IgG intrathecal antibody Temporal lobe seizures / Status epilepticus Seizures may cause MRI signal change in temporal lobes mimicking encephalitis; fever if convulsive SE EEG; HSV PCR negative; MRI DWI pattern; clinical course Limbic encephalitis (paraneoplastic: LGI1, GABA-B) Subacute memory loss, seizures, psychiatric changes; often &gt;40 years; associated malignancy Antibody panel (serum + CSF); CT chest/abdomen/pelvis; PET-CT Cerebral venous thrombosis Headache, seizures, focal deficits; papilledema; risk factors (OCPs, hypercoagulable) MRV; CT venogram; D-dimer Brain abscess Focal symptoms + fever; ring-enhancing lesion; subacute MRI with contrast (ring enhancement, restricted DWI centrally); blood cultures Acute disseminated encephalomyelitis (ADEM) Post-infectious; multifocal white matter lesions; children &gt; adults MRI (multifocal white matter); clinical context Tuberculosis meningitis Subacute (weeks); basilar meningitis; CSF low glucose, lymphocytic, very high protein AFB culture; TB PCR; ADA; chest imaging Neurosyphilis Subacute; psychiatric symptoms; pupillary abnormalities; history of STI CSF VDRL; FTA-ABS; RPR Primary CNS lymphoma Immunocompromised; progressive focal deficits; periventricular enhancing lesion MRI with contrast; CSF cytology; EBV PCR (CSF); brain biopsy"},{"location":"plans/hsv-encephalitis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal GCS / Neurologic exam STAT STAT ROUTINE STAT q1h x 24h, then q2h x 48h, then q4h Improving or stable GCS If declining: STAT CT; ICP assessment; consider EVD Temperature STAT STAT - STAT q4h (q1h if febrile) &lt;38\u00b0C Acetaminophen; cooling measures; reassess if persistent fever &gt;72h on acyclovir Serum sodium STAT STAT ROUTINE STAT q6-8h x 48h, then q12h 135-145 mEq/L If &lt;130: SIADH \u2192 fluid restriction (balance with acyclovir hydration); if &lt;120: 3% saline Serum creatinine STAT ROUTINE ROUTINE STAT Daily (twice daily if rising) Stable; within normal If rising: increase hydration; consider dose adjustment; hold if severe (rare); monitor urine output BUN - ROUTINE - ROUTINE Daily Normal Dehydration; renal impairment Urine output STAT STAT - STAT q1h in ICU; q4h shift on floor &gt;0.5 mL/kg/h (critical for acyclovir clearance) Increase IV fluids; if oliguria: renal assessment Seizure monitoring (EEG) - URGENT - STAT cEEG 24-72h if altered consciousness; routine EEG daily if improving No seizure activity If seizures: load/adjust AEDs; if NCSE: aggressive treatment per SE protocol Blood pressure STAT STAT - STAT q1-4h based on severity Stable; MAP &gt;60 Fluids; vasopressors if septic Oxygen saturation STAT STAT - STAT Continuous in ICU; q4h on floor \u226594% Supplemental O2; intubation if respiratory failure Repeat MRI brain - ROUTINE ROUTINE ROUTINE At 48-72h (evolution); day 7-14 (extent of damage); 3-6 months (chronic changes) Stable or improving If worsening edema: ICP management; neurosurgery consult Repeat LP (HSV PCR) - ROUTINE - ROUTINE At end of treatment (day 14-21) to confirm PCR negativity; earlier if clinical suspicion of treatment failure HSV PCR negative If still positive: extend acyclovir 7+ more days; consider resistance Autoimmune antibodies (follow-up) - ROUTINE ROUTINE - Recheck at 2-4 weeks if relapse or new psychiatric/neurologic symptoms Negative If positive (especially NMDAR): immunotherapy protocol"},{"location":"plans/hsv-encephalitis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home NOT appropriate directly from ED for suspected HSV encephalitis \u2014 always admit. Discharge from hospital when: completing IV acyclovir course (or transitioned to monitoring); improved consciousness (GCS 15); no active seizures; stable neurologic exam; safe swallowing; rehabilitation arranged; follow-up confirmed Admit to floor (monitored bed) Mild encephalitis (GCS 13-15); stable; low seizure burden; able to cooperate with neuro checks Admit to ICU / Neuro-ICU GCS &lt;13; active seizures or status epilepticus; need for continuous EEG; respiratory compromise; signs of elevated ICP; hemodynamic instability Transfer to higher level Need for neuro-ICU not available; need for neurosurgery (decompressive craniectomy); continuous EEG not available Inpatient rehabilitation Moderate-severe cognitive deficits (memory impairment, aphasia); motor deficits; able to participate in 3h/day therapy Skilled nursing facility Unable to tolerate intensive rehabilitation; requires ongoing nursing care"},{"location":"plans/hsv-encephalitis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IV acyclovir 10 mg/kg q8h x 14-21 days Class I, Level A Whitley et al. (NEJM 1986) \u2014 acyclovir vs placebo landmark trial; reduced mortality from 70% to 20% Start acyclovir empirically; do NOT delay for diagnostics Class I, Level A IDSA Encephalitis Guidelines (Tunkel et al. CID 2008); every hour of delay worsens outcomes CSF HSV PCR as gold standard (sensitivity 96-98%) Class I, Level A Lakeman &amp; Whitley (JID 1995) Repeat HSV PCR if initially negative with high clinical suspicion Class I, Level B False negative rate ~5% in first 72h; Roullet (2007) MRI with DWI is most sensitive imaging Class I, Level A Sensitivity &gt;90% within 48h; temporal lobe predilection EEG showing PLEDs supports diagnosis Class IIa, Level B Periodic lateralizing discharges in ~80% of HSV encephalitis Post-HSV autoimmune encephalitis (anti-NMDAR) in 20-27% Class IIa, Level B Armangue et al. (Lancet Neurol 2014); Pr\u00fcss et al. (Ann Neurol 2012) Dexamethasone for HSV encephalitis: NOT standard of care Class IIb, Level C DexEnceph trial (ongoing); animal data supportive; no clear human mortality benefit Foscarnet for acyclovir-resistant HSV Class IIa, Level C Expert consensus; primarily in immunocompromised Aggressive hydration to prevent acyclovir nephrotoxicity Class I, Level B Well-established; crystal nephropathy prevention Empiric bacterial coverage until excluded Class I, Level A Standard practice; cannot clinically distinguish bacterial meningitis from encephalitis at presentation Repeat LP at end of treatment to confirm PCR negativity Class IIa, Level C Expert consensus; immunocompromised patients especially 14-day treatment minimum; 21 days for severe/immunocompromised Class I, Level B IDSA Guidelines; relapse rate higher with &lt;14 days <p>APPENDIX: CLASSIC MRI FINDINGS IN HSV ENCEPHALITIS</p> Feature Description Location Medial temporal lobes (hippocampus, amygdala), insular cortex, inferior frontal gyri, cingulate gyrus Pattern Unilateral initially; may become bilateral (asymmetric) T2/FLAIR Hyperintensity in affected regions DWI Restricted diffusion (bright on DWI, dark on ADC) in acute phase Hemorrhage SWI/GRE may show hemorrhagic necrosis (petechial or confluent) Enhancement Variable; leptomeningeal or cortical enhancement possible Sparing Typically spares basal ganglia and thalami (unlike autoimmune encephalitis which may involve these) <p>APPENDIX: POST-HSV AUTOIMMUNE ENCEPHALITIS</p> Feature Details Timing 2-6 weeks after HSV encephalitis (range 1 week to 3 months) Prevalence 20-27% of HSV encephalitis cases Antibody Most commonly anti-NMDAR; less commonly others Presentation New psychiatric symptoms (psychosis, agitation), movement disorders (orofacial dyskinesias, choreoathetosis), seizures, autonomic instability, decreased consciousness Diagnosis Anti-NMDAR antibody in CSF; HSV PCR NEGATIVE (distinguishes from viral relapse) Treatment Immunotherapy: IV methylprednisolone + IVIG; second-line: rituximab; ensure HSV PCR negative before immunosuppression Prognosis Generally good with treatment; better than primary autoimmune encephalitis"},{"location":"plans/intracerebral-hemorrhage/","title":"Intracerebral Hemorrhage","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Intracerebral Hemorrhage (ICH)</p> <p>ICD-10: I61.9 (Nontraumatic intracerebral hemorrhage, unspecified), I61.0 (ICH in hemisphere, subcortical), I61.1 (ICH in hemisphere, cortical), I61.3 (ICH in brain stem), I61.4 (ICH in cerebellum)</p> <p>SYNONYMS: Intracerebral hemorrhage, ICH, hemorrhagic stroke, brain bleed, cerebral hemorrhage, intraparenchymal hemorrhage, hypertensive hemorrhage, spontaneous ICH, bleeding in the brain</p> <p>SCOPE: Spontaneous (non-traumatic) intracerebral hemorrhage in adults. Covers acute BP management, anticoagulant reversal, ICH score and prognosis, ICP management, surgical indications, etiology workup, and secondary prevention. Excludes traumatic ICH, subarachnoid hemorrhage (separate template), hemorrhagic transformation of ischemic stroke, and subdural/epidural hematomas.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/intracerebral-hemorrhage/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/intracerebral-hemorrhage/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT - STAT Baseline; thrombocytopenia as cause or complication; transfusion needs Platelets &gt;100,000 (&gt;50,000 minimum for hemostasis) PT/INR STAT STAT - STAT Warfarin-related ICH requires emergent reversal; coagulopathy assessment INR &lt;1.4 target (if elevated: REVERSE IMMEDIATELY) aPTT STAT STAT - STAT Heparin-related ICH; coagulopathy Normal Fibrinogen STAT STAT - STAT DIC; consumptive coagulopathy; tPA-related hemorrhage &gt;150 mg/dL (if &lt;150: give cryoprecipitate) CMP (BMP + LFTs) STAT STAT - STAT Electrolytes; renal function for contrast/medication; hepatic function for coagulopathy Normal Blood glucose STAT STAT - STAT Hyperglycemia worsens ICH outcomes; hypoglycemia mimics stroke 140-180 mg/dL target Type and screen / crossmatch STAT STAT - STAT Potential need for blood products, surgery, reversal agents On file; crossmatch if OR likely Troponin STAT STAT - STAT Neurogenic cardiac injury (stress cardiomyopathy); concurrent ACS Normal Blood alcohol level STAT - - STAT Coagulopathy; exam reliability; alcoholism is ICH risk factor Document result Urine drug screen STAT - - STAT Cocaine/amphetamine-associated ICH (sympathomimetic surge) Negative Pregnancy test (\u03b2-hCG) STAT STAT - STAT Affects management (eclampsia differential; imaging) Document result Thrombin time (TT) and/or ecarin clotting time (ECT) STAT STAT - STAT Dabigatran (direct thrombin inhibitor) detection; if patient on DOACs Normal (prolonged = dabigatran present) Anti-Xa level (calibrated for specific DOAC) STAT STAT - STAT Rivaroxaban/apixaban/edoxaban detection; guides reversal need Negative/undetectable (elevated = DOAC present and active)"},{"location":"plans/intracerebral-hemorrhage/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Lipid panel - ROUTINE ROUTINE - Cardiovascular risk; statin decision (controversial post-ICH) Document baseline HbA1c - ROUTINE ROUTINE - Diabetes management &lt;7.0% TSH - ROUTINE - - Thyroid dysfunction Normal ESR / CRP - ROUTINE ROUTINE - Vasculitis screen; inflammatory etiology Normal D-dimer URGENT ROUTINE - URGENT DIC; venous thromboembolism Normal Serum osmolality - ROUTINE - ROUTINE Monitor during osmotherapy (mannitol/hypertonic saline) 280-320 mOsm/kg; hold osmotherapy if &gt;320"},{"location":"plans/intracerebral-hemorrhage/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Hypercoagulable panel - EXT EXT - Young patient ICH without clear etiology; cerebral venous thrombosis with secondary hemorrhage Normal ANA, ANCA - EXT EXT - CNS vasculitis-related hemorrhage Negative Toxicology (expanded) - EXT - EXT Sympathomimetic drug use; synthetic drug-associated hemorrhage Negative Amyloid-beta PET - - EXT - Cerebral amyloid angiopathy (CAA) confirmation; research context Positive amyloid deposition in lobar distribution APOE genotype - - EXT - CAA risk stratification; APOE \u03b52/\u03b54 associated with ICH Document alleles"},{"location":"plans/intracerebral-hemorrhage/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/intracerebral-hemorrhage/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Door-to-CT &lt;25 minutes; determines ICH diagnosis, location, volume, IVH, hydrocephalus, midline shift Hemorrhage location (deep: basal ganglia/thalamus = hypertensive; lobar: CAA, tumor, AVM), volume (ABC/2 method), intraventricular hemorrhage (IVH), hydrocephalus, midline shift &gt;5mm Pregnancy (benefit outweighs risk) CT angiography (CTA) head STAT STAT - STAT With initial CT; identify \"spot sign\" (active contrast extravasation = hematoma expansion risk), underlying vascular malformation (AVM, aneurysm) Spot sign (30-50% risk of expansion); AVM; aneurysm; dural AV fistula; Moyamoya Contrast allergy; renal impairment (benefit outweighs risk in emergency) ECG (12-lead) STAT STAT - STAT Baseline; neurogenic cardiac injury; arrhythmia; QTc prolongation risk Normal; ST changes may be neurogenic None Repeat CT head (non-contrast) - STAT - STAT At 6h and 24h OR any neurologic decline; assess for hematoma expansion (&gt;33% or &gt;6mL increase from baseline = significant expansion) Stable hematoma size; no new hemorrhage; no hydrocephalus progression Same as initial"},{"location":"plans/intracerebral-hemorrhage/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast (include GRE/SWI sequences) - URGENT ROUTINE URGENT Within 24-72h when stable; or urgently if underlying mass/AVM suspected Underlying tumor; cavernous malformation; microbleeds (CAA pattern: lobar; hypertensive: deep). SWI shows microhemorrhages Pacemaker; hemodynamic instability; MRI-incompatible monitoring MR venography (MRV) - ROUTINE - ROUTINE If cerebral venous thrombosis (CVT) suspected as cause of hemorrhagic venous infarct Venous sinus thrombosis Same as MRI Conventional cerebral angiography (DSA) - URGENT EXT URGENT Young patient (&lt;50) with lobar ICH and no clear etiology; suspected AVM/aneurysm where CTA inconclusive; negative initial CTA but high suspicion AVM; aneurysm; dural AV fistula; Moyamoya; vasculitis Contrast allergy; renal impairment; coagulopathy Delayed DSA (if initial negative) - - ROUTINE - Repeat at 3-6 months; small AVM may be compressed by acute hematoma and missed initially Unmasked AVM/aneurysm Same as initial DSA Echocardiogram - ROUTINE - ROUTINE Neurogenic cardiac injury; baseline cardiac function; endocarditis if mycotic aneurysm suspected LV dysfunction; stress cardiomyopathy None significant Continuous EEG (cEEG) - URGENT - STAT If altered consciousness disproportionate to hemorrhage size; suspected seizures Non-convulsive seizures; NCSE (seen in 20-30% of ICH patients) None Chest X-ray URGENT ROUTINE - URGENT Aspiration; pulmonary edema (neurogenic); baseline for ventilator Normal None"},{"location":"plans/intracerebral-hemorrhage/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Brain biopsy - - EXT - If underlying tumor, vasculitis, or amyloid angiopathy suspected and non-invasive workup inconclusive Tumor; vasculitis; amyloid Surgical risk Amyloid PET scan - - EXT - CAA diagnosis in lobar ICH with microbleeds Amyloid deposition Research/limited availability"},{"location":"plans/intracerebral-hemorrhage/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/intracerebral-hemorrhage/#critical-priorities-in-acute-ich-first-60-minutes","title":"\u26a0\ufe0f CRITICAL PRIORITIES IN ACUTE ICH (First 60 Minutes)","text":"<ol> <li>ABCs \u2014 airway, breathing, circulation</li> <li>Blood pressure reduction \u2014 target SBP &lt;140 mmHg within 1 hour (INTERACT2, ATACH-2)</li> <li>Anticoagulant reversal \u2014 IMMEDIATELY if on anticoagulation</li> <li>Repeat CT \u2014 assess for expansion</li> </ol>"},{"location":"plans/intracerebral-hemorrhage/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Blood pressure reduction: Nicardipine IV STAT STAT - STAT 5 mg/h IV; increase by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP 130-150 mmHg (INTERACT2: &lt;140 safe; AHA 2022: &lt;140 reasonable if presenting SBP 150-220) Severe aortic stenosis; advanced HF Continuous arterial line BP; neuro checks with each change; avoid SBP &lt;110 (renal hypoperfusion) Blood pressure reduction: Labetalol IV STAT STAT - STAT 10-20 mg IV bolus over 1-2 min; may repeat or double q10min; max 300 mg. Alternative to nicardipine Heart block (2nd/3rd degree); severe bradycardia; decompensated HF; asthma HR; BP continuous Blood pressure reduction: Clevidipine IV STAT STAT - STAT 1-2 mg/h IV; titrate by doubling q90sec initially; max 32 mg/h Soy/egg allergy; lipid disorders BP continuous Intubation and airway protection STAT STAT - STAT GCS \u22648; inability to protect airway; respiratory failure; impending herniation. Use non-depolarizing agents; avoid succinylcholine if elevated ICP (relative) N/A Ventilator; head of bed 30\u00b0; avoid hyperventilation unless herniation Warfarin reversal: 4-factor PCC (Kcentra) STAT STAT - STAT 25-50 units/kg IV (dose based on INR: INR 2-4: 25 u/kg; INR 4-6: 35 u/kg; INR &gt;6: 50 u/kg); infuse over 10-15 min. Reverses INR within 15-30 min. PREFERRED over FFP (faster, smaller volume) Active DIC (relative); HIT (contains heparin traces) INR 15 min after infusion; repeat if INR &gt;1.4; thrombotic risk Warfarin reversal: Vitamin K (phytonadione) STAT STAT - STAT 10 mg IV slow push (over 10 min) to sustain INR correction (PCC is temporary). ALWAYS give WITH PCC Known severe allergic reaction (rare) INR at 6h and 24h; anaphylaxis risk (rare with slow IV) Warfarin reversal: FFP (if PCC unavailable) STAT STAT - STAT 10-15 mL/kg IV (typically 2-4 units). Slower than PCC; requires thawing and larger volume Volume overload; transfusion reactions INR; volume status Dabigatran reversal: Idarucizumab (Praxbind) STAT STAT - STAT 5 g IV (two 2.5g boluses or infusions). Specific reversal agent for dabigatran. Reversal within minutes None absolute Thrombin time (TT), aPTT; clinical hemostasis Factor Xa inhibitor reversal: Andexanet alfa (Andexxa) STAT STAT - STAT For rivaroxaban/apixaban. Low-dose: 400 mg IV bolus then 4 mg/min x 2h (last dose &gt;8h ago). High-dose: 800 mg IV bolus then 8 mg/min x 2h (last dose &lt;8h ago or unknown, or rivaroxaban) Thrombotic risk (10-15% VTE in trials) Anti-Xa levels; thrombosis monitoring; arterial line Factor Xa inhibitor reversal: 4-factor PCC (if andexanet unavailable) STAT STAT - STAT 50 units/kg IV. Off-label but supported by guidelines if andexanet not available Same as PCC Anti-Xa levels; clinical hemostasis Heparin reversal: Protamine sulfate STAT STAT - STAT 1 mg per 100 units of heparin given in last 2-3h; max 50 mg; give slow IV over 10 min Fish/protamine allergy aPTT; BP (hypotension with rapid infusion); anaphylaxis Platelet transfusion STAT STAT - STAT 1 unit apheresis platelets if platelet count &lt;100,000 AND active bleeding or pre-surgical. For antiplatelet-associated ICH: PATCH trial showed NO benefit from routine platelet transfusion (do NOT transfuse if platelets &gt;100K on antiplatelet therapy) HIT; ITP (consult hematology) Platelet count; clinical hemostasis Tranexamic acid (TXA) STAT STAT - STAT 1 g IV over 10 min then 1 g IV over 8h. TICH-2 trial: did NOT reduce mortality but reduced hematoma expansion. Not routine; consider if spot sign positive or early presentation with active expansion Active DVT/PE; hypercoagulable state Thrombotic events; clinical hemostasis ICP management: Head of bed elevation STAT STAT - STAT HOB 30\u00b0; head in midline (optimize venous drainage); avoid neck flexion/compression None ICP if monitored ICP management: Mannitol 20% STAT - - STAT 1-1.5 g/kg IV bolus for acute herniation; 0.25-0.5 g/kg q4-6h maintenance Anuria; serum osm &gt;320 Serum osm q4-6h; osmolar gap; Cr; I/O ICP management: Hypertonic saline 23.4% - - - STAT 30 mL IV bolus via central line over 10-20 min for acute herniation No central access Na (target 145-155); osmolality ICP management: Hypertonic saline 3% - - - STAT 150-500 mL bolus or 0.5-1 mL/kg/h infusion; target Na 145-155 Hypernatremia &gt;160 Na q4-6h; osmolality"},{"location":"plans/intracerebral-hemorrhage/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam Seizure treatment (NOT routine prophylaxis \u2014 AHA 2022 recommends against routine prophylaxis). Treat if clinical or electrographic seizures STAT STAT - STAT 1000-1500 mg IV load; then 500-1000 mg IV/PO BID Severe renal impairment (dose adjust) Seizure monitoring; cEEG; renal function Acetaminophen Fever (target normothermia &lt;37.5\u00b0C; fever worsens ICH outcomes) STAT STAT - STAT 650-1000 mg PO/IV q6h; max 4g/day Severe hepatic disease Temperature q4h; LFTs Surface cooling / Arctic Sun Refractory fever (targeted temperature management) - - - ROUTINE Target 36-37\u00b0C; avoid shivering (counterproductive) N/A Core temperature; shivering assessment (BSAS) Insulin (regular) Hyperglycemia (target 140-180 mg/dL) STAT STAT - STAT Sliding scale or insulin drip Hypoglycemia BG q1h if drip; q6h if sliding scale Pantoprazole GI prophylaxis (Cushing ulcer risk from elevated ICP) - ROUTINE - ROUTINE 40 mg IV/PO daily C. diff risk GI symptoms Enoxaparin DVT prophylaxis (start 24-48h after hemorrhage stabilizes; after repeat CT shows stability) - ROUTINE - ROUTINE 40 mg SC daily. AHA 2022: intermittent pneumatic compression devices on admission; pharmacologic prophylaxis after hemorrhage stable on repeat imaging Active hemorrhagic expansion; within 24h of ICH onset; pre-surgical Platelet count; repeat CT before starting Pneumatic compression devices DVT prophylaxis (start IMMEDIATELY) STAT STAT - STAT Apply bilaterally on admission; ICH patients are HIGH VTE risk Acute DVT Skin checks Ondansetron Nausea/vomiting (posterior fossa hemorrhage; elevated ICP) STAT ROUTINE - STAT 4 mg IV q6h PRN QT prolongation QTc"},{"location":"plans/intracerebral-hemorrhage/#3c-surgical-interventions","title":"3C. Surgical Interventions","text":"Treatment Indication Timing Details Contraindications External ventricular drain (EVD) IVH with acute hydrocephalus; GCS declining; need for ICP monitoring STAT (within 6h of deterioration) Neurosurgery places; allows CSF drainage and ICP monitoring; target ICP &lt;22, CPP &gt;60 Coagulopathy (correct first); futile care Intraventricular tPA via EVD IVH with hydrocephalus (CLEAR III trial: reduced mortality in severe IVH but did NOT improve functional outcome) Per neurosurgery protocol Alteplase 1 mg q8h via EVD; up to 12 doses; clamp EVD 1h after dosing then open to drain Active systemic bleeding; coagulopathy Surgical hematoma evacuation (craniotomy) Lobar ICH &gt;30 mL with deterioration; cerebellar hemorrhage &gt;3 cm OR with brainstem compression/hydrocephalus (STRONGEST surgical indication). STICH/STICH-II: no clear benefit for supratentorial deep ICH Emergent for cerebellar; within 24h for lobar with deterioration Craniotomy or craniectomy for clot evacuation Deep ICH (generally no benefit from open surgery); GCS 3-4 without brainstem reflexes (futile); severe coagulopathy Minimally invasive surgery (MIS) \u2014 endoscopic or stereotactic aspiration Supratentorial ICH &gt;30 mL with stable or mild deficits (MISTIE III, ENRICH trials: emerging data; ENRICH showed benefit for lobar ICH) Per neurosurgery/protocol Stereotactic catheter-based aspiration or endoscopic evacuation with lower morbidity than craniotomy Deep location (relative); coagulopathy Decompressive craniectomy Massive ICH with refractory elevated ICP; malignant cerebellar edema Per neurosurgery decision Bone flap removal to allow brain expansion Futile prognosis; bilateral fixed dilated pupils Suboccipital decompressive craniectomy Cerebellar hemorrhage with brainstem compression EMERGENT Posterior fossa decompression; life-saving for cerebellar ICH with brainstem compression Moribund patient"},{"location":"plans/intracerebral-hemorrhage/#3d-secondary-prevention-after-acute-phase","title":"3D. Secondary Prevention (After Acute Phase)","text":"Treatment Route Indication Dosing Monitoring Antihypertensive therapy (long-term) PO ALL ICH patients; BP is most important modifiable risk factor Target SBP &lt;130 mmHg (SPS3 trial, PROGRESS trial); agent choice per comorbidities (ACE-I, ARB, CCB, thiazide) Home BP monitoring; clinic BP Statin (controversial post-ICH) PO Risk-benefit discussion; SPARCL showed small increased ICH risk with atorvastatin but overall cardiovascular benefit. AHA 2022: statin not contraindicated after ICH Per cardiovascular risk; individualize Lipid panel Anticoagulation restart (if AF or mechanical valve) PO Most controversial decision. AHA 2022: may restart anticoagulation at 4-8 weeks for patients with strong indication (AF with high CHA2DS2-VASc). Avoid in CAA-related lobar ICH if possible Apixaban preferred (APACHE-AF trial: lowest ICH recurrence). Timing: 4-8 weeks; individualized risk-benefit Imaging stability; bleeding risk; CHA2DS2-VASc vs HAS-BLED Antiplatelet restart PO RESTART trial: restarting antiplatelet after ICH is associated with LOWER risk of recurrent ICH; may restart at 2-4 weeks for patients with cardiovascular indication Aspirin 81 mg or clopidogrel 75 mg daily Bleeding signs Left atrial appendage occlusion (LAAO/Watchman) Procedure AF patients who cannot tolerate long-term anticoagulation post-ICH (lobar ICH, CAA) Interventional cardiology procedure; eliminates need for long-term anticoagulation in AF Procedural risks"},{"location":"plans/intracerebral-hemorrhage/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/intracerebral-hemorrhage/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurosurgery STAT STAT - STAT ALL ICH patients; surgical decision for EVD, hematoma evacuation, decompression Neurology / Neurocritical care STAT STAT - STAT Medical management; BP optimization; ICP management; seizure management Hematology STAT STAT - STAT Anticoagulant reversal guidance; coagulopathy management; thrombocytopenia Pharmacy (clinical pharmacist) STAT STAT - STAT Reversal agent dosing; anticoagulant identification; drug interactions Cardiology - ROUTINE ROUTINE ROUTINE AF management; anticoagulation restart decision; LAAO evaluation; neurogenic cardiac injury Speech-language pathology (SLP) - URGENT ROUTINE URGENT Dysphagia screening before PO intake; aphasia assessment Physical therapy (PT) - URGENT ROUTINE URGENT Early mobilization (24-48h if stable); fall prevention; strength Occupational therapy (OT) - URGENT ROUTINE URGENT ADL assessment; cognitive rehabilitation; adaptive equipment Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Rehabilitation disposition; functional prognosis Social work - ROUTINE ROUTINE - Family support; advance directives; discharge planning Palliative care - ROUTINE - ROUTINE Goals of care discussion (especially ICH score \u22653); early palliative involvement improves care quality Interventional neuroradiology - ROUTINE - ROUTINE AVM/aneurysm treatment planning; dural AV fistula"},{"location":"plans/intracerebral-hemorrhage/#4b-patient-family-instructions","title":"4B. Patient / Family Instructions","text":"Recommendation ED HOSP OPD ICH is serious but outcomes vary; early aggressive treatment improves survival STAT ROUTINE ROUTINE Call 911 if: sudden headache, new weakness, speech changes, altered consciousness - ROUTINE ROUTINE Blood pressure control is the MOST IMPORTANT factor in preventing recurrence - ROUTINE ROUTINE Take all medications as prescribed; never stop blood pressure medications without physician guidance - ROUTINE ROUTINE Do NOT restart anticoagulation or antiplatelet without specific neurology/cardiology guidance - ROUTINE ROUTINE Home blood pressure monitoring daily; keep log; target per physician guidance - ROUTINE ROUTINE Follow-up with neurology in 2-4 weeks; neurosurgery if applicable - ROUTINE ROUTINE Do NOT drive until cleared - ROUTINE ROUTINE Fall prevention at home - ROUTINE ROUTINE"},{"location":"plans/intracerebral-hemorrhage/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Blood pressure target &lt;130/80 mmHg (most important) - ROUTINE ROUTINE Smoking cessation (doubles ICH risk) - ROUTINE ROUTINE Alcohol cessation or limitation (heavy drinking increases ICH risk) - ROUTINE ROUTINE Cocaine/amphetamine cessation (sympathomimetic ICH) - ROUTINE ROUTINE Avoid excessive anticoagulation (keep INR in range if on warfarin) - ROUTINE ROUTINE Regular exercise (moderate intensity after recovery) - - ROUTINE Weight management - ROUTINE ROUTINE DASH or Mediterranean diet - ROUTINE ROUTINE Depression screening (PHQ-9 at 1-3 months) - - ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/intracerebral-hemorrhage/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Hemorrhagic transformation of ischemic stroke Prior ischemic infarct on imaging; onset timing suggests ischemic \u2192 hemorrhagic evolution CT/MRI timing; DWI changes preceding hemorrhage Cerebral venous thrombosis (CVT) with hemorrhagic infarct Headache, seizures, often young women (OCPs, pregnancy); hemorrhage doesn't respect arterial territory; parasagittal location MRV/CT venography (thrombosed sinus); D-dimer Brain tumor with hemorrhage Subacute symptoms preceding hemorrhage; ring enhancement around hemorrhage; disproportionate edema MRI with contrast (underlying enhancing mass); biopsy Cerebral amyloid angiopathy (CAA) Lobar location (NOT deep); age &gt;55; recurrent lobar hemorrhages; cortical superficial siderosis; multiple lobar microbleeds on SWI MRI SWI (lobar microbleeds, superficial siderosis); Boston criteria Vascular malformation (AVM, cavernoma) Younger patient; recurrent hemorrhages at same location; AVM on CTA/DSA; cavernoma on MRI (popcorn appearance) CTA; DSA; MRI (especially SWI) Ruptured aneurysm extending into parenchyma Subarachnoid + intraparenchymal hemorrhage; near aneurysm location CTA (aneurysm); DSA Hypertensive ICH Deep location (putamen, thalamus, pons, cerebellum); history of poorly controlled HTN Clinical; typical location; no underlying lesion on workup Moyamoya disease Young adults or Asian patients; recurrent stroke; stenotic proximal vessels with collateral network MRA (ICA/MCA stenosis with Moyamoya collaterals); DSA Coagulopathy-related ICH Multiple hemorrhages; known coagulopathy or anticoagulant use Coagulation panel; medication history Mycotic aneurysm Endocarditis; distal vessel location; fever Blood cultures; echocardiogram; CTA/DSA Trauma History of trauma; scalp laceration; subdural or epidural components Clinical history; CT pattern"},{"location":"plans/intracerebral-hemorrhage/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Blood pressure (arterial line preferred in ICU) STAT STAT ROUTINE STAT q5min x 2h during acute reduction; q15min x 6h; then q1h x 24h; then q4h SBP 130-150 (acute); &lt;130/80 (chronic) Titrate antihypertensives; avoid SBP &lt;110 GCS / Neurologic exam STAT STAT ROUTINE STAT q1h x 24h, then q2h x 24h, then q4h Stable or improving GCS If declining: STAT CT; ICP assessment; neurosurgery ICP (if EVD in place) - - - STAT Continuous; assess q1h ICP &lt;22 mmHg; CPP 60-70 mmHg Tiered ICP management: drain CSF \u2192 osmotherapy \u2192 sedation \u2192 hypothermia \u2192 decompression Repeat CT head - STAT - STAT At 6h (routine); at 24h; and with ANY neurologic decline Stable hematoma; no expansion (&gt;33% or &gt;6mL = expansion) If expanding: re-evaluate BP; reversal; surgical consultation Temperature STAT STAT - STAT q4h; q1h if febrile &lt;37.5\u00b0C (normothermia) Aggressive fever management; cooling devices; infection workup Blood glucose STAT STAT - STAT q6h (q1h if insulin drip) 140-180 mg/dL Insulin; avoid &lt;60 Serum sodium - ROUTINE - STAT q6h during osmotherapy; q12h otherwise 135-155 (higher range with osmotherapy) Adjust osmotherapy Serum osmolality - ROUTINE - STAT q6h during mannitol &lt;320 mOsm/kg; osmolar gap &lt;10 Hold mannitol if &gt;320 INR (if on warfarin) STAT ROUTINE - STAT 15 min after PCC; then q6h x 24h; then daily INR &lt;1.4 Additional reversal agents Hemoglobin STAT ROUTINE - ROUTINE q6-12h x 48h &gt;7 g/dL (&gt;10 if active bleeding or coronary disease) Transfuse PRBCs EEG / Seizure monitoring - URGENT - STAT cEEG 24-48h minimum if altered consciousness No seizure activity AED loading; aggressive management Swallowing screen - STAT - URGENT Before any PO intake Pass screening NPO; SLP evaluation ICH Score (calculate at admission) STAT - - STAT Once (prognostic) Lower is better Goals of care discussion if score \u22653"},{"location":"plans/intracerebral-hemorrhage/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Small ICH; stable exam; GCS 15; ambulatory; adequate home support; medications filled; BP controlled; follow-up arranged Admit to stroke unit/floor (monitored) Small-moderate ICH; GCS 13-15; no surgical indication; stable repeat CT; BP controlled on oral/IV medications Admit to neuro-ICU ALL moderate-large ICH; GCS &lt;13 or declining; anticoagulant-related ICH; posterior fossa ICH; IVH with hydrocephalus; EVD in place; requiring arterial line and IV antihypertensives; post-surgical Emergent surgery Cerebellar ICH &gt;3 cm with brainstem compression or hydrocephalus; deteriorating lobar ICH &gt;30 mL; obstructive hydrocephalus needing EVD Transfer to higher level Need for neurosurgery not available; need for neuro-ICU; need for reversal agents not available; need for endovascular treatment Inpatient rehabilitation Significant deficits but able to participate in 3h/day therapy; medically stable Comfort care / Hospice ICH score \u22654; devastating ICH with poor prognosis after family goals of care discussion"},{"location":"plans/intracerebral-hemorrhage/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source SBP target &lt;140 mmHg in acute ICH (presenting SBP 150-220) Class I, Level A INTERACT2 (Anderson et al. NEJM 2013); AHA/ASA 2022 Guidelines Intensive BP lowering safe but benefit on functional outcome modest Class IIa, Level A ATACH-2 (Qureshi et al. NEJM 2016) \u2014 &lt;140 vs &lt;180 safe; no functional difference 4-factor PCC preferred over FFP for warfarin reversal Class I, Level B INCH trial (Steiner et al. Lancet Neurol 2016) Idarucizumab for dabigatran reversal Class I, Level B RE-VERSE AD trial (Pollack et al. NEJM 2017) Andexanet alfa for factor Xa inhibitor reversal Class IIa, Level B ANNEXA-4 (Connolly et al. NEJM 2019) Platelet transfusion NOT beneficial for antiplatelet-associated ICH Class III (No Benefit) PATCH trial (Baharoglu et al. Lancet 2016) TXA reduces expansion but NOT mortality Class IIb, Level B TICH-2 (Sprigg et al. Lancet 2018) Surgical evacuation for cerebellar ICH with deterioration Class I, Level B AHA/ASA Guidelines; strong consensus No benefit from routine supratentorial open surgery Class III (No Benefit) STICH (Mendelow et al. Lancet 2005); STICH II (2013) Minimally invasive surgery emerging benefit Class IIb, Level B MISTIE III (Hanley et al. Lancet 2019); ENRICH (2024) EVD for IVH with hydrocephalus Class I, Level B AHA/ASA Guidelines Intraventricular tPA (CLEAR III) Class IIb, Level B Hanley et al. (Lancet 2017) \u2014 reduced mortality but not functional outcome Seizure prophylaxis NOT recommended routinely Class III (No Benefit) AHA/ASA 2022 \u2014 treat clinical/electrographic seizures; cEEG if altered Anticoagulation restart 4-8 weeks for AF Class IIb, Level B AHA/ASA 2022; observational data Antiplatelet restart appears safe (RESTART trial) Class IIa, Level B RESTART trial (Lancet 2019) DVT prophylaxis: pneumatic devices immediately; pharmacologic at 24-48h Class I, Level B AHA/ASA 2022 Guidelines ICH Score for prognosis Class IIa, Level B Hemphill et al. (Stroke 2001) Normothermia improves outcomes Class I, Level C AHA/ASA Guidelines Avoid self-fulfilling prophecy (DNR discussion timing) Class I, Level C AHA/ASA 2022: delay new DNR orders until at least 24h after admission <p>APPENDIX: ICH SCORE (PROGNOSIS)</p> Component Points GCS 3-4 2 GCS 5-12 1 GCS 13-15 0 ICH volume \u226530 mL 1 ICH volume &lt;30 mL 0 IVH present 1 IVH absent 0 Infratentorial origin 1 Supratentorial origin 0 Age \u226580 1 Age &lt;80 0 ICH Score 30-Day Mortality 0 0% 1 13% 2 26% 3 72% 4 97% 5 100% <p>APPENDIX: ABC/2 METHOD FOR ICH VOLUME</p> <p>Volume (mL) = (A \u00d7 B \u00d7 C) / 2 - A = largest diameter on slice with largest hemorrhage (cm) - B = diameter perpendicular to A on same slice (cm) - C = number of CT slices with hemorrhage \u00d7 slice thickness (cm)</p> <p>APPENDIX: ANTICOAGULANT REVERSAL QUICK REFERENCE</p> Agent Reversal Dose Onset Warfarin 4-factor PCC + Vitamin K 10mg IV Per INR (25-50 u/kg) 15-30 min Dabigatran Idarucizumab (Praxbind) 5g IV Minutes Rivaroxaban/Apixaban Andexanet alfa (Andexxa) OR 4-factor PCC 50 u/kg Per dosing protocol 15-30 min Edoxaban Andexanet alfa OR 4-factor PCC 50 u/kg Per protocol 15-30 min UFH Protamine sulfate 1mg per 100u heparin Minutes LMWH Protamine sulfate (60% reversal) 1mg per 1mg enoxaparin (within 8h) Partial"},{"location":"plans/migraine/","title":"Migraine","text":"<p>VERSION: 1.0 CREATED: January 29, 2026 REVISED: January 29, 2026 STATUS: Complete</p> <p>DIAGNOSIS: Migraine / Status Migrainosus</p> <p>ICD-10: G43.909 (Migraine, unspecified, not intractable), G43.919 (Migraine, unspecified, intractable), G43.901 (Migraine, unspecified, not intractable, with status migrainosus), G43.911 (Migraine, unspecified, intractable, with status migrainosus), G43.109 (Migraine with aura, not intractable), G43.709 (Chronic migraine without aura, not intractable)</p> <p>SYNONYMS: Migraine headache, migraine with aura, migraine without aura, classic migraine, common migraine, status migrainosus, intractable migraine, refractory migraine, chronic migraine, menstrual migraine, vestibular migraine, hemiplegic migraine, retinal migraine, basilar migraine</p> <p>SCOPE: Evaluation and management of acute migraine, status migrainosus, and chronic migraine in adults. Covers abortive therapy, rescue treatment for refractory attacks, and preventive medication initiation. Includes special considerations for pregnancy and medication overuse. Excludes secondary headache disorders, cluster headache, and tension-type headache.</p> <p>DEFINITIONS: - Migraine: Recurrent headache disorder manifesting in attacks lasting 4-72 hours with unilateral location, pulsating quality, moderate-severe intensity, aggravation by activity, and associated nausea/vomiting or photo/phonophobia - Status Migrainosus: Debilitating migraine attack lasting &gt;72 hours - Chronic Migraine: \u226515 headache days/month for &gt;3 months, with migraine features on \u22658 days/month - Medication Overuse Headache (MOH): Headache occurring \u226515 days/month in patient with pre-existing headache using acute medications regularly for &gt;3 months</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/migraine/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/migraine/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC URGENT ROUTINE ROUTINE - Rule out anemia, infection Normal CMP URGENT ROUTINE ROUTINE - Electrolyte abnormalities, renal function Normal hCG (women of childbearing age) STAT STAT ROUTINE - Pregnancy status affects treatment options Document status TSH - ROUTINE ROUTINE - Thyroid dysfunction can cause headache Normal Magnesium URGENT ROUTINE ROUTINE - Low levels may contribute to migraines &gt;1.8 mg/dL"},{"location":"plans/migraine/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding ESR/CRP URGENT ROUTINE ROUTINE - If GCA or inflammatory cause suspected (&gt;50 years, new onset) Normal Vitamin D - ROUTINE ROUTINE - Deficiency associated with migraine frequency &gt;30 ng/mL Ferritin - ROUTINE ROUTINE - Iron deficiency associated with migraine &gt;50 ng/mL Homocysteine - - EXT - Elevated levels associated with migraine with aura Normal"},{"location":"plans/migraine/#1c-rarespecialized","title":"1C. Rare/Specialized","text":"Test ED HOSP OPD ICU Rationale Target Finding Lumbar puncture URGENT URGENT - - Thunderclap headache, suspected SAH, IIH, meningitis See LP section Autoimmune panel (ANA, etc.) - EXT EXT - If vasculitis or autoimmune cause suspected Negative"},{"location":"plans/migraine/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/migraine/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT URGENT - - If thunderclap, worst headache, focal deficits, altered mental status Rule out hemorrhage, mass None in emergency MRI brain without contrast - ROUTINE ROUTINE - New headache pattern, focal features, refractory to treatment Normal; rule out structural cause Pacemaker, metal implants"},{"location":"plans/migraine/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast - ROUTINE ROUTINE - If mass, infection, or inflammation suspected Rule out enhancement Contrast allergy, renal disease MRV or CT venogram URGENT URGENT - - Suspected cerebral venous thrombosis Patent venous sinuses Per modality MRA head - ROUTINE ROUTINE - Suspected vasculopathy, aneurysm Normal vasculature Per modality ECG STAT STAT - - Prior to DHE or triptan use Normal QTc, no ischemia None"},{"location":"plans/migraine/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Thunderclap headache, suspected SAH (CT negative), suspected IIH (papilledema), suspected meningitis, atypical features</p> <p>Timing: URGENT after CT excludes mass effect</p> Study ED HOSP OPD ICU Rationale Target Finding Opening pressure STAT STAT - - IIH diagnosis 10-20 cm H2O (elevated &gt;25 suggests IIH) Cell count (tubes 1 and 4) STAT STAT - - Infection, SAH WBC &lt;5; RBC 0 or clearing Protein STAT STAT - - Infection, inflammation 15-45 mg/dL Glucose STAT STAT - - Infection &gt;60% serum Xanthochromia STAT STAT - - SAH if CT negative Negative Gram stain and culture STAT STAT - - Bacterial meningitis No organisms CSF meningitis panel URGENT URGENT - - Viral/bacterial pathogens Negative"},{"location":"plans/migraine/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/migraine/#3a-acuteabortive-treatment-mild-moderate-attacks","title":"3A. Acute/Abortive Treatment - Mild-Moderate Attacks","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen - ROUTINE ROUTINE - 1000 mg PO once, max 3000 mg/day Hepatic disease, chronic alcohol use LFTs if frequent use Ibuprofen - ROUTINE ROUTINE - 400-800 mg PO once Renal disease, GI bleeding, aspirin allergy Renal function Naproxen sodium - ROUTINE ROUTINE - 500-825 mg PO once Same as ibuprofen Renal function Aspirin - ROUTINE ROUTINE - 900-1000 mg PO once Bleeding disorder, aspirin allergy Bleeding Excedrin (ASA/APAP/caffeine) - - ROUTINE - 2 tablets PO once Per components Risk of MOH"},{"location":"plans/migraine/#3b-acuteabortive-treatment-moderate-severe-attacks-triptans","title":"3B. Acute/Abortive Treatment - Moderate-Severe Attacks (Triptans)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Sumatriptan SC STAT STAT - - 6 mg SC once; may repeat in 2h; max 12 mg/24h CAD, stroke/TIA, uncontrolled HTN, hemiplegic/basilar migraine, pregnancy Chest tightness, BP Sumatriptan PO - ROUTINE ROUTINE - 50-100 mg PO once; may repeat in 2h; max 200 mg/24h Same as SC Same Sumatriptan nasal URGENT ROUTINE ROUTINE - 20 mg intranasal; may repeat in 2h; max 40 mg/24h Same as SC Same Rizatriptan - ROUTINE ROUTINE - 5-10 mg PO (ODT available); may repeat in 2h; max 30 mg/24h Same; 5 mg if on propranolol Same Eletriptan - ROUTINE ROUTINE - 40 mg PO; may repeat in 2h; max 80 mg/24h Same; severe hepatic impairment Same Zolmitriptan - ROUTINE ROUTINE - 2.5-5 mg PO or nasal; may repeat in 2h; max 10 mg/24h Same Same"},{"location":"plans/migraine/#3c-acuteabortive-treatment-cgrp-antagonists-gepants","title":"3C. Acute/Abortive Treatment - CGRP Antagonists (Gepants)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Ubrogepant - ROUTINE ROUTINE - 50-100 mg PO; may repeat in 2h; max 200 mg/24h CYP3A4 inhibitors; no cardiovascular contraindications LFTs periodically Rimegepant - ROUTINE ROUTINE - 75 mg PO once daily; ODT formulation CYP3A4 inhibitors LFTs periodically Zavegepant nasal - ROUTINE ROUTINE - 10 mg intranasal once daily None significant Local irritation"},{"location":"plans/migraine/#3d-edinpatient-treatment-status-migrainosus-headache-cocktail","title":"3D. ED/Inpatient Treatment - Status Migrainosus (\"Headache Cocktail\")","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IV fluids STAT STAT - - NS or LR 1L bolus, then 75-125 mL/hr Heart failure, volume overload I/O Prochlorperazine IV STAT STAT - - 10 mg IV slow push over 5-10 min; may repeat in 30 min QT prolongation, Parkinson's QTc, akathisia, dystonia Metoclopramide IV STAT STAT - - 10-20 mg IV over 15-30 min; may repeat in 30 min QT prolongation, Parkinson's, seizures QTc, akathisia, dystonia Diphenhydramine IV STAT STAT - - 25-50 mg IV to prevent akathisia (give with antiemetic) Glaucoma, urinary retention Sedation Ketorolac IV STAT STAT - - 30 mg IV (15 mg if &gt;65y or CrCl &lt;50); max 2 doses Renal disease, GI bleeding, anticoagulation Renal function Dexamethasone IV URGENT URGENT - - 10 mg IV once (reduces recurrence) Active infection, uncontrolled DM Glucose Magnesium sulfate IV URGENT URGENT - - 2 g IV over 20-30 min Renal failure, myasthenia Mg levels, reflexes Valproate sodium IV URGENT URGENT - - 500-1000 mg IV over 15-30 min Pregnancy, hepatic disease, mitochondrial disease Ammonia, LFTs"},{"location":"plans/migraine/#3e-edinpatient-refractorysecond-line-therapy-dhe-protocol","title":"3E. ED/Inpatient - Refractory/Second-Line Therapy (DHE Protocol)","text":"<p>Prerequisites: Check ECG, BP &lt;140/90, negative pregnancy test. Avoid if triptan within 24h or CAD/CVA history.</p> Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Dihydroergotamine (DHE) URGENT STAT - - Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV; Test dose: 0.5 mg IV over 1 min; If tolerated: 0.5-1 mg IV q8h Pregnancy, CAD, CVA, uncontrolled HTN, triptan &lt;24h, ergot allergy BP, chest pain, nausea DHE nasal - ROUTINE ROUTINE - 0.5 mg per nostril (1 mg total); may repeat once in 15 min; max 3 mg/24h Same as IV Same"},{"location":"plans/migraine/#3f-pregnancy-safe-options","title":"3F. Pregnancy-Safe Options","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen STAT STAT ROUTINE - 1000 mg PO/IV q8h; max 3000 mg/day Hepatic disease LFTs Metoclopramide STAT STAT ROUTINE - 10 mg IV/PO q8h Parkinson's Akathisia Ondansetron URGENT ROUTINE ROUTINE - 4-8 mg IV/PO q8h QT prolongation (caution 1st trimester) QTc Magnesium sulfate URGENT URGENT - - 2 g IV once Renal failure Reflexes, respiratory Nerve block (occipital) - ROUTINE ROUTINE - Lidocaine 1% or bupivacaine 0.25%, 2-3 mL per side Local anesthetic allergy Local reaction Sumatriptan (if refractory) - EXT EXT - 6 mg SC x1 (pregnancy registry data reassuring) Per triptan list; discuss risks Standard"},{"location":"plans/migraine/#3g-preventive-medications-first-line","title":"3G. Preventive Medications - First-Line","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Propranolol - ROUTINE ROUTINE - Start 40-80 mg/day in divided doses; target 80-240 mg/day Asthma, heart block, bradycardia, depression HR, BP Metoprolol - ROUTINE ROUTINE - Start 25-50 mg BID; target 100-200 mg/day Same as propranolol HR, BP Topiramate - ROUTINE ROUTINE - Start 25 mg QHS; increase by 25 mg/week to 50-100 mg BID Kidney stones, pregnancy (teratogenic), glaucoma Bicarbonate, cognitive effects Amitriptyline - ROUTINE ROUTINE - Start 10-25 mg QHS; target 50-150 mg QHS Glaucoma, urinary retention, cardiac arrhythmia QTc, anticholinergic effects Venlafaxine XR - ROUTINE ROUTINE - Start 37.5 mg daily; target 75-150 mg daily Uncontrolled HTN, MAOI use BP, serotonin syndrome"},{"location":"plans/migraine/#3h-preventive-medications-cgrp-monoclonal-antibodies","title":"3H. Preventive Medications - CGRP Monoclonal Antibodies","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Erenumab (Aimovig) - - ROUTINE - 70-140 mg SC monthly Hypersensitivity; caution with constipation, HTN BP, constipation Fremanezumab (Ajovy) - - ROUTINE - 225 mg SC monthly OR 675 mg SC quarterly Hypersensitivity Injection site reactions Galcanezumab (Emgality) - - ROUTINE - 240 mg SC loading, then 120 mg SC monthly Hypersensitivity Injection site reactions Eptinezumab (Vyepti) - ROUTINE ROUTINE - 100-300 mg IV q3 months Hypersensitivity Infusion reactions"},{"location":"plans/migraine/#3i-preventive-medications-other","title":"3I. Preventive Medications - Other","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Valproate - ROUTINE ROUTINE - Start 250-500 mg BID; target 500-1500 mg/day Pregnancy, hepatic disease LFTs, ammonia OnabotulinumtoxinA (Botox) - - ROUTINE - 155-195 units IM q12 weeks (chronic migraine only) Infection at injection sites, myasthenia Spread of toxin effect Atogepant (Qulipta) - - ROUTINE - 10-60 mg PO daily Severe hepatic impairment LFTs Rimegepant (preventive) - - ROUTINE - 75 mg every other day CYP3A4 inhibitors LFTs Magnesium oxide - ROUTINE ROUTINE - 400-600 mg PO daily Renal failure Diarrhea Riboflavin (Vitamin B2) - - ROUTINE - 400 mg PO daily None significant None CoQ10 - - ROUTINE - 100 mg TID None significant None"},{"location":"plans/migraine/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/migraine/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consult URGENT ROUTINE - - Status migrainosus, refractory to ED treatment Headache specialist referral - ROUTINE ROUTINE - Chronic migraine, medication overuse, refractory disease Ophthalmology consult URGENT URGENT ROUTINE - Papilledema, visual symptoms suggesting IIH Pain management referral - - ROUTINE - Refractory chronic migraine, nerve block consideration Behavioral health referral - ROUTINE ROUTINE - Comorbid anxiety/depression, biofeedback interest Physical therapy - - ROUTINE - Cervicogenic component, trigger point therapy"},{"location":"plans/migraine/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD Keep headache diary (frequency, severity, triggers, medications) ROUTINE ROUTINE ROUTINE Treat migraine early - medications more effective within first hour ROUTINE ROUTINE ROUTINE Avoid medication overuse: limit triptans to \u22649 days/month, NSAIDs to \u226414 days/month ROUTINE ROUTINE ROUTINE Identify and avoid personal triggers ROUTINE ROUTINE ROUTINE Follow up with neurologist in 2-4 weeks if new diagnosis ROUTINE ROUTINE ROUTINE Follow up with PCP or neurologist for preventive medication monitoring - ROUTINE ROUTINE Return to ED if: worst headache of life, fever, neurologic deficits, altered mental status ROUTINE ROUTINE ROUTINE"},{"location":"plans/migraine/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Maintain regular sleep schedule (7-8 hours) - ROUTINE ROUTINE Regular exercise (30 min, 5 days/week) - ROUTINE ROUTINE Stress management (biofeedback, relaxation techniques, CBT) - ROUTINE ROUTINE Stay well-hydrated (64+ oz water daily) ROUTINE ROUTINE ROUTINE Avoid known triggers: alcohol, aged cheese, MSG, processed meats, irregular meals - ROUTINE ROUTINE Limit caffeine to consistent moderate intake (&lt;200 mg/day) - ROUTINE ROUTINE Consider migraine glasses (FL-41 tint) for photophobia - - ROUTINE"},{"location":"plans/migraine/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Tension-type headache Bilateral, pressing/tightening, mild-moderate, no nausea/vomiting Clinical history; no photophobia Cluster headache Unilateral periorbital, autonomic features (tearing, rhinorrhea), short duration (15-180 min), circadian pattern Clinical pattern; response to O2/triptans Medication overuse headache Chronic daily headache, &gt;15 days/month, frequent analgesic use Medication diary; improves with withdrawal Subarachnoid hemorrhage Thunderclap onset, \"worst headache of life,\" neck stiffness CT head, LP if CT negative Idiopathic intracranial hypertension Papilledema, visual obscurations, pulsatile tinnitus, bilateral pressure LP with elevated OP (&gt;25 cm H2O) Giant cell arteritis Age &gt;50, new headache, jaw claudication, scalp tenderness, visual symptoms ESR/CRP elevated, temporal artery biopsy Cerebral venous thrombosis Progressive headache, seizures, focal deficits, pregnancy/OCP MRV/CTV Cervicogenic headache Neck pain, limited ROM, triggered by neck movement Cervical exam, imaging Trigeminal autonomic cephalalgia Short attacks, autonomic features, response to indomethacin (some types) Clinical pattern Brain tumor Progressive headache, worse in morning/with Valsalva, focal deficits MRI brain"},{"location":"plans/migraine/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Pain scale (0-10) STAT q4h Each visit - Per assessment Improving trend Escalate treatment Vital signs STAT q4h Each visit - Per assessment Normal Address abnormalities ECG (if using DHE/triptans) STAT STAT - - Before administration Normal QTc, no ischemia Avoid vasoactive drugs Headache diary - Daily Each visit - Ongoing Reduced frequency Adjust preventive MIDAS score - - q3 months - Quarterly Improving disability Adjust treatment Medication use tracking - ROUTINE Each visit - Ongoing No overuse Address MOH"},{"location":"plans/migraine/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge from ED Pain controlled, able to tolerate PO, no red flags, close follow-up arranged Admit to hospital Status migrainosus unresponsive to ED treatment, need for DHE protocol, unable to tolerate PO, severe dehydration, concern for secondary headache ICU admission Rare - suspected intracranial pathology, hemodynamic instability Discharge from hospital Pain controlled on oral medications, tolerating PO, ambulatory Outpatient follow-up New diagnosis: 2-4 weeks; Chronic migraine: q1-3 months; On preventive: q3-6 months after stable"},{"location":"plans/migraine/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Triptans effective for acute migraine Class I, Level A Cochrane Reviews; AHS Guidelines Prochlorperazine/metoclopramide effective for acute migraine Class I, Level A Friedman et al., Neurology 2015 Dexamethasone reduces headache recurrence Class I, Level A Singh et al., Cephalalgia 2008 DHE effective for status migrainosus Class II, Level B Raskin, Headache 1986 Beta-blockers effective for prevention Class I, Level A AAN Guidelines 2012 Topiramate effective for prevention Class I, Level A AAN Guidelines 2012 CGRP mAbs effective for prevention Class I, Level A Multiple RCTs; FDA approved 2018+ OnabotulinumtoxinA for chronic migraine Class I, Level A PREEMPT trials; Aurora 2010 Gepants effective for acute and preventive treatment Class I, Level A Multiple RCTs 2019-2023 Avoid medication overuse Class II, Level B Headache Classification Committee, ICHD-3"},{"location":"plans/migraine/#notes","title":"NOTES","text":"<ul> <li>Migraine is a clinical diagnosis; imaging indicated only for red flags or atypical features</li> <li>Treat early - medications more effective when taken at onset</li> <li>Medication overuse is common cause of chronic daily headache; taper offending agents</li> <li>Consider preventive therapy if \u22654 migraine days/month, significant disability, or acute medications ineffective/overused</li> <li>CGRP antagonists (gepants and mAbs) are first-line options without cardiovascular contraindications</li> <li>Triptan cardiovascular contraindications are based on theoretical risk; reassuring real-world data for many patients</li> <li>Pregnancy: Acetaminophen, metoclopramide, and nerve blocks are safest; discuss triptan use case-by-case</li> </ul>"},{"location":"plans/migraine/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 29, 2026) - Initial template creation - Comprehensive acute and preventive treatment options - Added CGRP antagonists (gepants) and monoclonal antibodies - DHE protocol with prerequisites - Pregnancy-safe options section - Status migrainosus \"headache cocktail\" protocol</p>"},{"location":"plans/ms-new-diagnosis/","title":"Multiple Sclerosis - New Diagnosis","text":"<p>VERSION: 2.2 CREATED: January 13, 2026 REVISED: January 13, 2026 STATUS: Revised per physician feedback</p> <p>DIAGNOSIS: Multiple Sclerosis - New Diagnosis</p> <p>ICD-10: G35 (Multiple sclerosis)</p> <p>SCOPE: Initial diagnostic workup and management of suspected or newly confirmed MS. Covers diagnostic criteria evaluation, mimics exclusion, acute symptom treatment, and DMT initiation framework. For established MS with acute relapse, use \"MS - Exacerbation\" template. For ongoing DMT management and monitoring, use \"MS - Maintenance\" template.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090 SECTION A: ACTION ITEMS \u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090</p>"},{"location":"plans/ms-new-diagnosis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/ms-new-diagnosis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Infection screen, baseline before steroids Normal CMP STAT STAT ROUTINE STAT Metabolic screen, renal function Normal TSH URGENT ROUTINE ROUTINE URGENT Thyroid disease mimics MS Normal Vitamin B12 URGENT ROUTINE ROUTINE URGENT B12 deficiency causes myelopathy Normal (&gt;300 pg/mL) Folate URGENT ROUTINE ROUTINE URGENT Folate deficiency causes myelopathy Normal ESR URGENT ROUTINE ROUTINE URGENT Inflammatory/vasculitis screen Normal (&lt;20 mm/hr) CRP URGENT ROUTINE ROUTINE URGENT Inflammatory marker Normal Urinalysis STAT STAT ROUTINE STAT UTI as symptom trigger Negative Blood glucose STAT STAT ROUTINE STAT Pre-steroid baseline Normal HbA1c - ROUTINE ROUTINE - Glycemic status before steroids &lt;5.7%"},{"location":"plans/ms-new-diagnosis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Vitamin D (25-OH) - ROUTINE ROUTINE - Low levels associated with MS risk/activity &gt;30 ng/mL ANA URGENT ROUTINE ROUTINE URGENT Lupus/connective tissue disease screen Negative or low titer Anti-dsDNA - ROUTINE ROUTINE - If ANA positive, lupus evaluation Negative Mayo CDS1 Panel (AQP4-IgG + MOG-IgG by FACS) URGENT URGENT ROUTINE URGENT Combined NMO/MOGAD screen; cell-based assay is gold standard Both negative HIV - ROUTINE ROUTINE - HIV-associated myelopathy/encephalopathy Negative RPR/VDRL - ROUTINE ROUTINE - Neurosyphilis mimics MS Negative Lyme serology - ROUTINE ROUTINE - Endemic areas; neuroborreliosis Negative ACE level - ROUTINE ROUTINE - Neurosarcoidosis Normal <p>Note: If Mayo CDS1 Panel unavailable, order AQP4-IgG (Mayo NMOFS) and MOG-IgG (Mayo MOGFS) separately. FACS/cell-based assay preferred over ELISA for higher sensitivity/specificity.</p>"},{"location":"plans/ms-new-diagnosis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-SSA/SSB (Ro/La) - EXT EXT - Sj\u00c3\u00b6gren syndrome Negative ANCA panel - EXT EXT - CNS vasculitis Negative Copper, ceruloplasmin - EXT EXT - Wilson disease (young patients) Normal Very long chain fatty acids - EXT EXT - Adrenomyeloneuropathy Normal Mitochondrial DNA studies - EXT EXT - Leber hereditary optic neuropathy Normal Genetic testing (HLA-DRB1) - - EXT - Research/prognostic, not diagnostic Variable"},{"location":"plans/ms-new-diagnosis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/ms-new-diagnosis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast (MS protocol)* URGENT URGENT ROUTINE URGENT Within 24-48h if acute; within 2 weeks if stable Periventricular, juxtacortical, infratentorial, or cord lesions; gadolinium enhancement = active GFR &lt;30, gadolinium allergy, pacemaker MRI C-spine with and without contrast URGENT URGENT ROUTINE URGENT With brain MRI Cord lesions (short segment, peripheral, dorsal) Same as above MRI T-spine with and without contrast URGENT ROUTINE ROUTINE URGENT With brain/C-spine Cord lesions Same as above <p>*MS MRI protocol should include: 3D FLAIR, 3D T1 pre/post-contrast, T2, DWI; for spine: sagittal STIR, axial T2</p>"},{"location":"plans/ms-new-diagnosis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Visual evoked potentials (VEP) - ROUTINE ROUTINE - During workup Prolonged P100 latency (subclinical optic nerve involvement) None significant OCT (Optical coherence tomography) - - ROUTINE - Baseline RNFL thinning (prior optic neuritis) None significant MRI orbits with contrast - ROUTINE ROUTINE - If optic neuritis suspected Optic nerve enhancement, swelling Gadolinium contraindications <p>Note: OCT typically available only in outpatient neuro-ophthalmology or MS specialty clinics</p>"},{"location":"plans/ms-new-diagnosis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest - EXT EXT - If sarcoidosis suspected Hilar lymphadenopathy Contrast allergy PET-CT - EXT EXT - If CNS lymphoma or paraneoplastic suspected FDG-avid lesions Pregnancy, uncontrolled diabetes Conventional angiography - EXT EXT - If CNS vasculitis suspected Beading, stenosis Contrast allergy, renal failure Brain biopsy - EXT - - Atypical cases, tumefactive lesions Demyelination vs neoplasm vs other Coagulopathy, inaccessible location"},{"location":"plans/ms-new-diagnosis/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Supports MS diagnosis (2017 McDonald criteria); helps exclude mimics; required if dissemination in time cannot be demonstrated by MRI alone</p> <p>Timing: URGENT if needed for diagnosis; can be ROUTINE in outpatient workup</p> <p>Volume Required: 15-20 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Rule out elevated ICP 10-20 cm H2O Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Inflammation, rule out infection WBC &lt;50 (mild pleocytosis acceptable); RBC 0 Protein URGENT ROUTINE ROUTINE Elevated in inflammation Normal to mildly elevated (&lt;100 mg/dL) Glucose with serum glucose URGENT ROUTINE ROUTINE Low in infection/carcinomatous Normal (&gt;60% serum) Gram stain and culture URGENT ROUTINE ROUTINE Rule out infection No organisms Oligoclonal bands (CSF AND serum) URGENT ROUTINE ROUTINE Intrathecal IgG synthesis \u00e2\u2030\u00a52 CSF-specific bands (not in serum) IgG index URGENT ROUTINE ROUTINE Intrathecal antibody synthesis &gt;0.7 = elevated Myelin basic protein - ROUTINE ROUTINE Active demyelination marker May be elevated acutely Cytology - ROUTINE ROUTINE Rule out malignancy Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative <p>Special Handling: OCBs stable at 4\u00c2\u00b0C for days; send paired serum. Cytology requires rapid transport (&lt;1 hour).</p> <p>Contraindications: Elevated ICP without imaging, coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p>"},{"location":"plans/ms-new-diagnosis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/ms-new-diagnosis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Methylprednisolone IV STAT STAT - STAT 1000 mg IV daily \u00c3\u2014 3-5 days Active untreated infection, uncontrolled diabetes, psychosis history Glucose q6h (target &lt;180), BP, mood, sleep, I/O Omeprazole STAT STAT - STAT 20-40 mg daily during steroids PPI allergy None routine Insulin sliding scale STAT STAT - STAT Per protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h Prednisone oral taper (optional) - ROUTINE ROUTINE - 60 mg daily \u00c3\u2014 7 days, then taper over 2 weeks Same as IV steroids Glucose, BP, mood"},{"location":"plans/ms-new-diagnosis/#3b-symptomatic-treatments-first-line","title":"3B. Symptomatic Treatments - First-line","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Baclofen Spasticity - ROUTINE ROUTINE ROUTINE Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day in divided doses Renal impairment (reduce dose) Sedation, weakness; do NOT stop abruptly (withdrawal risk) Tizanidine Spasticity - ROUTINE ROUTINE ROUTINE Start 2 mg qHS or TID; increase by 2-4 mg every 3-4 days; max 36 mg/day in 3 divided doses Hepatic impairment; concurrent ciprofloxacin or fluvoxamine (CYP1A2 inhibitors) LFTs at baseline, 1, 3, 6 months; sedation; hypotension Gabapentin Neuropathic pain - ROUTINE ROUTINE ROUTINE Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day Renal impairment (adjust dose per CrCl) Sedation, dizziness, peripheral edema Pregabalin Neuropathic pain - ROUTINE ROUTINE ROUTINE Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID Renal impairment (adjust dose per CrCl) Sedation, weight gain, peripheral edema Duloxetine Neuropathic pain - ROUTINE ROUTINE - Start 30 mg daily \u00c3\u2014 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; concurrent MAOIs; uncontrolled narrow-angle glaucoma Nausea (usually transient), BP, discontinuation syndrome Amitriptyline Neuropathic pain - ROUTINE ROUTINE - Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma Anticholinergic effects; ECG if dose &gt;100 mg/day Carbamazepine Trigeminal neuralgia - ROUTINE ROUTINE - Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day AV block; bone marrow suppression; concurrent MAOIs CBC, LFTs, sodium at baseline and periodically; HLA-B*1502 screening in at-risk populations Oxcarbazepine Trigeminal neuralgia - ROUTINE ROUTINE - Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID Hypersensitivity to carbamazepine Sodium (hyponatremia risk); HLA-B*1502 screening Oxybutynin IR Bladder urgency - ROUTINE ROUTINE - Start 5 mg BID-TID; max 5 mg QID Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction Dry mouth, constipation, cognitive impairment (especially elderly) Oxybutynin ER Bladder urgency - - ROUTINE - Start 5-10 mg daily; max 30 mg daily Same as IR Same; fewer anticholinergic side effects than IR Solifenacin Bladder urgency - - ROUTINE - Start 5 mg daily; may increase to 10 mg daily Urinary retention; gastric retention; uncontrolled narrow-angle glaucoma; severe hepatic impairment Dry mouth, constipation; preferred over oxybutynin if cognitive concerns Mirabegron Bladder urgency - - ROUTINE - Start 25 mg daily; may increase to 50 mg daily Uncontrolled hypertension BP monitoring; fewer anticholinergic effects (beta-3 agonist) Tamsulosin Urinary retention - ROUTINE ROUTINE - 0.4 mg daily 30 minutes after same meal each day Severe sulfonamide allergy (use caution) Orthostatic hypotension; retrograde ejaculation Bethanechol Urinary retention - ROUTINE ROUTINE - 10-50 mg TID-QID Asthma; bradycardia; hypotension; GI/GU obstruction GI cramping, bronchospasm Desmopressin Nocturia - - ROUTINE - 0.1-0.4 mg qHS (oral) or 10-40 mcg intranasal Hyponatremia risk; age &gt;65 (relative); CHF; polydipsia Sodium at baseline, 1 week, 1 month, then periodically; fluid restrict evening Amantadine Fatigue - ROUTINE ROUTINE - 100 mg every morning; may add 100 mg early afternoon (before 2 PM); max 200 mg/day Renal impairment (adjust dose); uncontrolled seizures Livedo reticularis; ankle edema; insomnia; hallucinations Modafinil Fatigue - - ROUTINE - Start 100 mg every morning; may increase to 200 mg; max 400 mg/day Cardiac arrhythmia; LV hypertrophy; hepatic impairment BP, HR; may reduce efficacy of hormonal contraception; Schedule IV Armodafinil Fatigue - - ROUTINE - Start 150 mg every morning; max 250 mg daily Same as modafinil Same as modafinil; longer half-life; Schedule IV Methylphenidate Fatigue - - ROUTINE - Start 5 mg BID (morning and noon); max 60 mg/day Marked anxiety; glaucoma; tics/Tourette; concurrent MAOIs BP, HR, mood; Schedule II Dalfampridine Walking impairment - - ROUTINE - 10 mg q12h (must be exactly 12 hours apart); do NOT exceed 20 mg/day Seizure history; CrCl &lt;50 mL/min Seizure risk (dose-dependent); UTI; insomnia Sertraline Depression - ROUTINE ROUTINE - Start 50 mg daily; increase by 25-50 mg every 1-2 weeks; max 200 mg daily Concurrent MAOIs; pimozide Suicidality monitoring (especially weeks 1-4); serotonin syndrome; QTc at high doses Escitalopram Depression - ROUTINE ROUTINE - Start 10 mg daily; may increase to 20 mg after 1 week; max 20 mg daily Concurrent MAOIs; pimozide; QT prolongation QTc if risk factors or dose &gt;10 mg; suicidality monitoring Fluoxetine Depression - ROUTINE ROUTINE - Start 20 mg daily; may increase after several weeks; max 80 mg daily Concurrent MAOIs; pimozide; thioridazine Long half-life (washout important); suicidality monitoring Bupropion SR/XL Depression - ROUTINE ROUTINE - Start 150 mg SR daily; increase to 150 mg SR BID after 3 days (or 300 mg XL daily); max 400 mg/day Seizure disorder; eating disorders; abrupt alcohol/benzo withdrawal Seizure risk; insomnia; no sexual side effects Venlafaxine XR Depression/pain - ROUTINE ROUTINE - Start 37.5-75 mg daily; increase by 75 mg every 4 days; max 225 mg daily Uncontrolled hypertension; concurrent MAOIs BP monitoring; discontinuation syndrome (taper slowly) Mirtazapine Depression/insomnia - ROUTINE ROUTINE - Start 15 mg qHS; may increase by 15 mg every 1-2 weeks; max 45 mg daily Concurrent MAOIs Weight gain; sedation (lower at higher doses); agranulocytosis (rare) Polyethylene glycol 3350 Constipation - ROUTINE ROUTINE - 17 g (1 capful) in 8 oz liquid once daily; adjust to effect Bowel obstruction; ileus Electrolytes if prolonged use; may take 1-3 days for effect Docusate sodium Constipation - ROUTINE ROUTINE - 100 mg BID; max 500 mg/day Intestinal obstruction; concurrent mineral oil Minimal efficacy as monotherapy; best for stool softening Senna Constipation - ROUTINE ROUTINE - 8.6-17.2 mg qHS; max 34.4 mg/day Intestinal obstruction; acute abdominal pain Cramping; dependency with chronic daily use Bisacodyl Constipation - ROUTINE ROUTINE - 5-10 mg PO qHS or 10 mg PR PRN Intestinal obstruction; acute abdominal pain Cramping; electrolyte disturbance with overuse Lubiprostone Constipation (refractory) - - ROUTINE - 24 mcg BID with food Mechanical GI obstruction Nausea (common); dyspnea; diarrhea Propranolol Tremor - ROUTINE ROUTINE - Start 20 mg BID; increase by 20-40 mg every 3-7 days; max 320 mg/day in divided doses Asthma/COPD; bradycardia &lt;50; heart block; decompensated CHF HR, BP; fatigue; depression; bronchospasm Primidone Tremor - - ROUTINE - Start 25 mg qHS; increase by 25 mg every week to 250 mg TID; usual dose 50-250 mg TID Porphyria; hypersensitivity to phenobarbital Severe sedation initially (start very low); ataxia; nausea Clonazepam Tremor - ROUTINE ROUTINE - Start 0.25-0.5 mg BID; increase by 0.5 mg every 3 days; max 6 mg/day Severe hepatic impairment; myasthenia gravis; untreated narrow-angle glaucoma Sedation; dependence; falls risk; do NOT stop abruptly Topiramate Tremor - - ROUTINE - Start 25 mg daily; increase by 25 mg weekly; max 400 mg/day in divided doses Metabolic acidosis; kidney stones Cognitive slowing (\"dopamax\"); paresthesias; kidney stones; weight loss Dextromethorphan-quinidine Pseudobulbar affect - - ROUTINE - 20/10 mg daily \u00c3\u2014 7 days, then 20/10 mg q12h QT prolongation; concurrent MAOIs; concurrent quinidine/quinine; CYP2D6 substrate drugs ECG at baseline; QTc monitoring; multiple drug interactions"},{"location":"plans/ms-new-diagnosis/#3c-second-linerefractory-acute-treatment","title":"3C. Second-line/Refractory (Acute Treatment)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Plasmapheresis (PLEX) - URGENT - URGENT 5-7 exchanges over 10-14 days Hemodynamic instability, sepsis, line contraindication BP, electrolytes, coags, fibrinogen, line infection IVIG - URGENT - URGENT 0.4 g/kg/day \u00c3\u2014 5 days IgA deficiency, renal failure, thrombosis risk Renal function, headache, thrombosis Extended IV steroids - ROUTINE - ROUTINE Additional 2-5 days methylprednisolone (total 5-10 days) As above As above ACTH gel (H.P. Acthar) - EXT EXT - 80 units IM/SC daily \u00c3\u2014 2-3 weeks Similar to corticosteroids Glucose, BP, electrolytes"},{"location":"plans/ms-new-diagnosis/#3d-disease-modifying-therapies-dmt-opd-only","title":"3D. Disease-Modifying Therapies (DMT) - OPD ONLY","text":"<p>DMT initiation requires confirmed diagnosis and MS specialist involvement. DMTs are NOT initiated in ED, hospital, or ICU - only in outpatient specialty clinic after appropriate pre-treatment workup and counseling.</p> Treatment Route ED HOSP OPD ICU Dosing Pre-Treatment Requirements Contraindications Monitoring INJECTABLE - MODERATE EFFICACY Interferon beta-1a (Avonex) IM - - ROUTINE - 30 mcg IM once weekly CBC, LFTs, TSH Depression (relative); decompensated liver disease CBC, LFTs q3-6mo; TSH annually; flu-like symptoms common (pretreat with NSAIDs/acetaminophen) Interferon beta-1a (Rebif) SC - - ROUTINE - 22 or 44 mcg SC three times weekly (titrate over 4 weeks) CBC, LFTs, TSH Same as Avonex Same; injection site reactions Interferon beta-1b (Betaseron/Extavia) SC - - ROUTINE - 250 mcg SC every other day (titrate over 6 weeks) CBC, LFTs, TSH Same as Avonex Same Peginterferon beta-1a (Plegridy) SC - - ROUTINE - 125 mcg SC every 14 days (titrate over first 4 doses) CBC, LFTs, TSH Same as Avonex Same; less frequent dosing Glatiramer acetate (Copaxone) 20mg SC - - ROUTINE - 20 mg SC daily None required Hypersensitivity Injection site reactions; post-injection systemic reaction (rare, self-limited) Glatiramer acetate (Copaxone) 40mg SC - - ROUTINE - 40 mg SC three times weekly (\u00e2\u2030\u00a548 hours apart) None required Hypersensitivity Same Glatiramer acetate (Glatopa) SC - - ROUTINE - 20 mg SC daily or 40 mg SC three times weekly None required Hypersensitivity Same (generic) ORAL - MODERATE EFFICACY Dimethyl fumarate (Tecfidera) PO - - ROUTINE - 120 mg BID \u00c3\u2014 7 days, then 240 mg BID CBC, LFTs Lymphopenia &lt;500 (discontinue) CBC q6mo (lymphocytes); LFTs; GI side effects (take with food); flushing (aspirin 30 min prior) Diroximel fumarate (Vumerity) PO - - ROUTINE - 231 mg BID \u00c3\u2014 7 days, then 462 mg BID CBC, LFTs Same as Tecfidera Same; less GI side effects than Tecfidera Monomethyl fumarate (Bafiertam) PO - - ROUTINE - 95 mg BID \u00c3\u2014 7 days, then 190 mg BID CBC, LFTs Same as Tecfidera Same Teriflunomide (Aubagio) PO - - ROUTINE - 7 or 14 mg once daily CBC, LFTs, TB test, BP Pregnancy (Category X - teratogenic); severe hepatic impairment; concurrent leflunomide LFTs monthly \u00c3\u2014 6 months, then periodically; BP; hair thinning; requires cholestyramine washout if pregnancy desired ORAL - HIGH EFFICACY (S1P MODULATORS) Fingolimod (Gilenya) PO - - ROUTINE - 0.5 mg once daily CBC, LFTs, ECG, ophthalmology exam (macular edema), VZV IgG (vaccinate if negative and wait 4 weeks) Bradycardia &lt;55; 2nd/3rd degree AV block; sick sinus syndrome; QTc &gt;500 ms; recent MI/stroke/TIA (within 6 months) First-dose observation 6 hours (HR, BP q1h, ECG at 6h); macular edema screen at 3-4 months; lymphocytes; LFTs Siponimod (Mayzent) PO - - ROUTINE - Titration pack days 1-5, then 2 mg daily (1 mg if CYP2C9 1/3 or 2/3) Same as fingolimod plus CYP2C9 genotype Same plus CYP2C9 3/3 genotype (contraindicated) Same; genotype required before starting Ozanimod (Zeposia) PO - - ROUTINE - 0.23 mg daily \u00c3\u2014 4 days, 0.46 mg daily \u00c3\u2014 3 days, then 0.92 mg daily Same as fingolimod Same; concurrent MAOIs Similar to fingolimod; no first-dose observation required (slower titration); macular edema screen Ponesimod (Ponvory) PO - - ROUTINE - 14-day titration pack, then 20 mg daily Same as fingolimod Same Similar; no first-dose observation required ORAL - HIGH EFFICACY (OTHER) Cladribine (Mavenclad) PO - - ROUTINE - Year 1: 1.75 mg/kg divided into 2 treatment weeks (week 1 and week 5); Year 2: repeat same dosing; no treatment years 3-4 CBC, LFTs, HIV, Hepatitis B/C, TB, VZV IgG Active infection; HIV; active malignancy; pregnancy/breastfeeding; CrCl &lt;30 CBC at months 2 and 6 of each treatment year; lymphopenia expected and desired; screen for malignancy INFUSION - HIGH EFFICACY Natalizumab (Tysabri) IV - - ROUTINE - 300 mg IV every 4 weeks (or extended interval q6 weeks if stable and JCV negative) JCV antibody, CBC, LFTs JCV antibody positive with index &gt;1.5 and prior immunosuppression (high PML risk); active infection JCV antibody q6mo; MRI for PML surveillance q6-12mo; infusion reactions; REMS program required Ocrelizumab (Ocrevus) IV - - ROUTINE - Initial: 300 mg IV \u00c3\u2014 2 doses 14 days apart; Maintenance: 600 mg IV every 6 months Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Immunoglobulins annually; infection monitoring; infusion reactions (premedicate with methylprednisolone, antihistamine, acetaminophen) Ofatumumab (Kesimpta) SC - - ROUTINE - Initial: 20 mg SC at weeks 0, 1, 2; Maintenance: 20 mg SC monthly starting week 4 Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Same as ocrelizumab; self-administered at home Ublituximab (Briumvi) IV - - ROUTINE - Initial: 150 mg IV day 1, 450 mg IV day 15; Maintenance: 450 mg IV every 24 weeks Hepatitis B serology, TB test, immunoglobulins Active Hepatitis B; active infection Same as ocrelizumab; 1-hour infusion (faster) Alemtuzumab (Lemtrada) IV - - ROUTINE - Year 1: 12 mg IV daily \u00c3\u2014 5 consecutive days; Year 2: 12 mg IV daily \u00c3\u2014 3 consecutive days (12 months after year 1) CBC, LFTs, TSH, creatinine, urinalysis, Hepatitis B/C, VZV IgG, TB, HPV screening Active infection; HIV; ongoing autoimmune disease other than MS CBC monthly \u00c3\u2014 48 months; TSH q3mo \u00c3\u2014 48 months; creatinine/urinalysis monthly \u00c3\u2014 48 months; REMS program; secondary autoimmunity risk (thyroid, ITP, nephropathy) MODERATE EFFICACY - SPECIAL POPULATIONS Glatiramer acetate (Copaxone) SC - - ROUTINE - 20 mg daily or 40 mg TIW None Hypersensitivity Preferred in pregnancy (no evidence of harm)"},{"location":"plans/ms-new-diagnosis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/ms-new-diagnosis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication MS specialist/Neuroimmunology referral URGENT URGENT ROUTINE URGENT All new MS diagnoses for DMT discussion Neuro-ophthalmology referral - ROUTINE ROUTINE - Optic neuritis, visual symptoms, OCT baseline Physical therapy consult for gait and balance - ROUTINE ROUTINE ROUTINE Gait dysfunction, lower extremity weakness, falls Occupational therapy consult for ADL assessment - ROUTINE ROUTINE - Upper extremity dysfunction, ADL impairment, energy conservation Speech therapy for swallow evaluation - URGENT ROUTINE URGENT Brainstem involvement, dysphagia, dysarthria Speech therapy for cognitive rehabilitation - - ROUTINE - Cognitive complaints affecting function Urology referral for bladder dysfunction - - ROUTINE - Urgency, frequency, retention, recurrent UTI Psychiatry/Psychology referral - ROUTINE ROUTINE - Depression, anxiety, adjustment to diagnosis Social work consult - ROUTINE ROUTINE - Insurance navigation, disability questions, support resources Rehabilitation medicine consult - ROUTINE ROUTINE - Significant functional impairment, comprehensive rehab needs Infusion center coordination - ROUTINE ROUTINE - PLEX scheduling; future DMT infusion planning Ophthalmology referral (pre-DMT) - - ROUTINE - Baseline macular exam before S1P modulator initiation Genetic counseling - - EXT - If atypical features, family history concerns"},{"location":"plans/ms-new-diagnosis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED if rapid vision loss, sudden weakness, difficulty breathing, or urinary retention \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid driving until cleared by neurology \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Heat may temporarily worsen symptoms (Uhthoff phenomenon) - this is not a new attack \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Expect temporary steroid side effects: insomnia, mood changes, increased appetite, metallic taste \u00e2\u0153\u201c \u00e2\u0153\u201c - Keep symptom diary noting new or worsening symptoms - \u00e2\u0153\u201c \u00e2\u0153\u201c Do not stop steroids abruptly if on oral taper - \u00e2\u0153\u201c \u00e2\u0153\u201c Do not stop baclofen or tizanidine abruptly - risk of withdrawal/rebound spasticity - \u00e2\u0153\u201c \u00e2\u0153\u201c Monitor blood sugars if diabetic - steroids elevate glucose \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid sick contacts while on high-dose steroids \u00e2\u0153\u201c \u00e2\u0153\u201c - Contact MS specialist before starting any new medications (drug interactions with DMTs) - - \u00e2\u0153\u201c Vaccinations should be completed before DMT initiation (especially live vaccines) - \u00e2\u0153\u201c \u00e2\u0153\u201c Pregnancy planning requires DMT discussion (some DMTs teratogenic, washout periods vary) - - \u00e2\u0153\u201c Report any signs of infection (fever, cough, dysuria) promptly - \u00e2\u0153\u201c \u00e2\u0153\u201c Post-void residual check if difficulty emptying bladder or recurrent UTIs - \u00e2\u0153\u201c \u00e2\u0153\u201c"},{"location":"plans/ms-new-diagnosis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (smoking accelerates MS progression and disability) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Vitamin D supplementation 2000-5000 IU daily (target serum 25-OH vitamin D &gt;40 ng/mL) - \u00e2\u0153\u201c \u00e2\u0153\u201c Regular aerobic exercise 150 min/week as tolerated (improves fatigue, mood, function) - \u00e2\u0153\u201c \u00e2\u0153\u201c Resistance training 2-3\u00c3\u2014/week - - \u00e2\u0153\u201c Stress management and adequate sleep (7-8 hours nightly) - \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid excessive heat exposure (hot tubs, saunas, prolonged direct sun, exercising in heat) - \u00e2\u0153\u201c \u00e2\u0153\u201c Cooling vest for outdoor activities in warm weather - - \u00e2\u0153\u201c Maintain healthy weight (obesity associated with worse outcomes) - - \u00e2\u0153\u201c Limit alcohol intake (can worsen balance, cognition, bladder symptoms) - - \u00e2\u0153\u201c Ensure vaccinations up to date before DMT initiation (live vaccines contraindicated on many DMTs) - \u00e2\u0153\u201c \u00e2\u0153\u201c Fall prevention: remove loose rugs, ensure adequate lighting, use assistive devices if needed - \u00e2\u0153\u201c \u00e2\u0153\u201c Energy conservation techniques for fatigue management (pacing, prioritization, positioning) - \u00e2\u0153\u201c \u00e2\u0153\u201c <p>\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090 SECTION B: REFERENCE (Expand as Needed) \u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090</p>"},{"location":"plans/ms-new-diagnosis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Neuromyelitis optica spectrum disorder (NMOSD) Longitudinally extensive transverse myelitis (\u00e2\u2030\u00a53 segments), severe optic neuritis (often bilateral), area postrema syndrome (intractable nausea/vomiting), brain lesions in NMOSD-typical locations AQP4-IgG positive (Mayo CDS1 or NMOFS); MRI pattern different MOG antibody disease (MOGAD) Bilateral optic neuritis, ADEM-like presentation, longitudinally extensive myelitis, cortical encephalitis, better steroid response, more favorable prognosis MOG-IgG positive (Mayo CDS1 or MOGFS) Acute disseminated encephalomyelitis (ADEM) Monophasic (usually), encephalopathy, post-infectious, large poorly-defined lesions, pediatric predominance Clinical course, MRI pattern, MOG-IgG status CNS vasculitis Headache, encephalopathy, stroke-like episodes, multifocal infarcts Elevated ESR/CRP, angiography, brain/leptomeningeal biopsy Neurosarcoidosis Cranial neuropathies (especially VII), hypothalamic involvement, leptomeningeal enhancement, hilar adenopathy ACE level, chest CT, biopsy (non-caseating granulomas) CNS lymphoma Progressive course, deep gray matter/periventricular involvement, homogeneous enhancement, older/immunocompromised CSF cytology/flow, FDG-PET, biopsy Susac syndrome Encephalopathy, hearing loss, branch retinal artery occlusions, corpus callosum \"snowball\" lesions Audiogram, fluorescein angiography, MRI pattern Neurosyphilis Progressive cognitive decline, tabes dorsalis, Argyll Robertson pupils, positive serology RPR/VDRL, CSF VDRL, FTA-ABS HIV-associated myelopathy/encephalopathy Risk factors, vacuolar myelopathy, cognitive impairment HIV testing, CD4 count B12 deficiency myelopathy Subacute combined degeneration, dorsal column signs, peripheral neuropathy, macrocytic anemia B12, MMA, homocysteine Migraine with white matter lesions Headache history, non-specific white matter changes, no enhancement, no cord lesions Clinical history, MRI pattern Small vessel ischemic disease Older age, vascular risk factors, periventricular caps/halos, no enhancement, no cord lesions Risk factor profile, MRI pattern"},{"location":"plans/ms-new-diagnosis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal Blood glucose Q6h during IV steroids &lt;180 mg/dL Insulin sliding scale; endocrine consult if persistent &gt;250 Blood pressure Q shift during steroids &lt;160/100 mmHg Antihypertensives PRN Mood and sleep Daily during steroids No psychosis, mania, severe insomnia Psychiatry consult; consider dose adjustment Temperature Q shift Afebrile Infection workup if febrile Neurologic exam Daily (inpatient); each visit (OPD) Improvement or stability If worsening: re-image, consider PLEX I/O and weight Daily (inpatient) Euvolemic Diuretics if fluid overload Respiratory status Q shift if cervical myelitis RR &lt;20, NIF &gt;-30 cm H2O ICU transfer if NIF &gt;-20 (critical) Post-void residual If retention suspected &lt;100 mL Intermittent catheterization if &gt;200 mL; urology referral MRI (follow-up) 3-6 months after baseline, then annually No new/enlarging lesions DMT escalation discussion if new activity Vitamin D level Annually &gt;40 ng/mL (some target &gt;50) Increase supplementation if low JCV antibody (if on natalizumab) Every 6 months Negative or stable index If positive/rising: PML risk stratification, consider DMT switch"},{"location":"plans/ms-new-diagnosis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild symptoms; able to ambulate safely; reliable follow-up within 1-2 weeks; no IV steroids needed OR completing outpatient infusion; stable baseline function; understands return precautions Admit to floor Moderate-severe symptoms; needs IV steroids; functional decline requiring therapy; diagnostic uncertainty requiring expedited workup; unable to care for self at home Admit to ICU Severe myelitis with respiratory compromise (NIF &gt;-30 declining toward -20); brainstem involvement with airway risk or autonomic instability; severe encephalopathy Transfer to higher level PLEX needed but unavailable; MS specialist not available for complex decision-making; MRI unavailable for urgent imaging"},{"location":"plans/ms-new-diagnosis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source 2017 McDonald Criteria for MS diagnosis Class I Thompson AJ et al. Lancet Neurol 2018 MRI brain/spine with contrast for diagnosis Class I, Level A MAGNIMS Consensus 2021 CSF OCBs can substitute for dissemination in time Class II, Level B 2017 McDonald Criteria IV methylprednisolone 1g \u00c3\u2014 3-5 days for acute attacks Class I, Level A AAN Practice Guideline 2022 PLEX for steroid-refractory attacks Class II, Level B Cochrane Review 2016 Cell-based assay (FACS) for NMO/MOG antibodies Class I, Level B Waters et al. 2014; Pittock et al. Vitamin D supplementation Class II, Level B Multiple observational studies; CHOLINE, SOLAR trials Smoking cessation reduces progression Class II, Level B Observational studies Early DMT initiation improves outcomes Class I, Level A Multiple RCTs, long-term extension studies Dalfampridine for walking impairment Class I, Level A Goodman et al. Lancet 2009 Exercise improves fatigue and function Class I, Level B Cochrane Review 2015"},{"location":"plans/ms-new-diagnosis/#change-log","title":"CHANGE LOG","text":"<p>v2.2 (January 13, 2026) - Expanded Section 3D: each DMT now on individual row with complete dosing - Added 23 individual DMTs with full details:   - Injectables: Avonex, Rebif, Betaseron/Extavia, Plegridy, Copaxone 20mg, Copaxone 40mg, Glatopa   - Oral moderate: Tecfidera, Vumerity, Bafiertam, Aubagio   - Oral S1P modulators: Gilenya, Mayzent, Zeposia, Ponvory   - Oral high-efficacy: Mavenclad   - Infusions: Tysabri, Ocrevus, Kesimpta, Briumvi, Lemtrada - Added Route column (PO, SC, IM, IV) - Added complete pre-treatment requirements for each DMT - Added specific monitoring schedules (JCV q6mo, CBC monthly for alemtuzumab, etc.) - Added REMS program notes where applicable - Added CYP2C9 genotyping requirement for siponimod - Added first-dose observation requirements for S1P modulators</p> <p>v2.1 (January 13, 2026) - Restructured Section 3B: each drug now on individual row with complete dosing - Added \"Indication\" column to treatment table - Expanded drug list with additional options:   - Carbamazepine, oxcarbazepine for trigeminal neuralgia   - Oxybutynin ER, mirabegron, bethanechol, desmopressin for bladder   - Armodafinil, methylphenidate for fatigue   - Fluoxetine, venlafaxine, mirtazapine for depression   - Bisacodyl, lubiprostone for constipation   - Topiramate for tremor - Enhanced dosing details with titration schedules for all medications</p> <p>v2.0 (January 13, 2026) - Confirmed IV methylprednisolone 1g \u00c3\u2014 3-5 days per physician - Added Mayo CDS1 Panel (combined AQP4 + MOG by FACS) as preferred test - Added note that FACS/cell-based assay preferred over ELISA - Changed OCT from HOSP to OPD only (not available in most hospitals) - Clarified DMT section is OPD ONLY (not initiated inpatient) - Expanded symptomatic treatments section with:   - Tizanidine for spasticity   - Pregabalin, duloxetine, amitriptyline for neuropathic pain   - Solifenacin, tamsulosin for bladder   - Modafinil for fatigue (OPD only - controlled substance)   - Dalfampridine for walking impairment   - Antidepressants (sertraline, escitalopram, bupropion)   - Constipation management   - Tremor management (propranolol, primidone, clonazepam)   - Pseudobulbar affect (dextromethorphan-quinidine) - Added cladribine to DMT reference table - Added folate to core labs - Added JCV antibody monitoring - Added infusion center coordination to referrals - Added MRI protocol footnote - Enhanced vitamin D target (&gt;40 ng/mL) - Added post-void residual monitoring - Added instruction re: not stopping baclofen/tizanidine abruptly</p> <p>v1.0 (January 13, 2026) - Initial creation</p>"},{"location":"plans/myasthenia-gravis-crisis/","title":"Myasthenia Gravis - Exacerbation/Crisis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Myasthenia Gravis - Exacerbation/Crisis</p> <p>ICD-10: G70.01 (Myasthenia gravis with exacerbation)</p> <p>SYNONYMS: Myasthenic crisis, MG crisis, MG exacerbation, myasthenia exacerbation, myasthenic respiratory failure, acute MG, worsening myasthenia</p> <p>SCOPE: Acute exacerbation and myasthenic crisis in adults with known or suspected myasthenia gravis. Covers respiratory monitoring, emergent immunotherapy (IVIG/PLEX), cholinesterase inhibitor management, distinguishing myasthenic from cholinergic crisis, and medications to avoid. Excludes new diagnosis workup (see MG - New Diagnosis template), Lambert-Eaton syndrome, and chronic stable management.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/myasthenia-gravis-crisis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/myasthenia-gravis-crisis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline; infection screen (common trigger); leukocytosis suggests infection Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolytes, renal/hepatic function for medication dosing; hypokalemia worsens weakness Normal Magnesium STAT STAT ROUTINE STAT Hypomagnesemia worsens NMJ transmission; CONTRAINDICATED to give IV Mg in MG crisis Confirm normal BEFORE any magnesium replacement TSH URGENT ROUTINE ROUTINE URGENT Thyroid disease coexists in 10-15% of MG; thyrotoxicosis precipitates crisis Normal Blood glucose STAT STAT ROUTINE STAT Steroid-induced hyperglycemia management Normal Urinalysis + urine culture STAT ROUTINE ROUTINE STAT UTI as precipitant for exacerbation Negative Blood cultures x2 STAT STAT - STAT If febrile; infection is #1 trigger for crisis No growth Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE STAT Affects treatment choices; MG can fluctuate in pregnancy Document result PT/INR, aPTT STAT ROUTINE - STAT Coagulation before procedures; PLEX circuit anticoagulation Normal ABG or VBG STAT STAT - STAT Respiratory failure assessment; hypercapnia is LATE finding \u2014 do not wait for this Normal; rising pCO2 = imminent failure"},{"location":"plans/myasthenia-gravis-crisis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding AChR binding antibody - ROUTINE ROUTINE - Confirm diagnosis if not previously tested; positive in 85% generalized MG Positive supports MG diagnosis AChR modulating antibody - ROUTINE ROUTINE - Additional sensitivity when binding Ab equivocal Positive supports diagnosis AChR blocking antibody - ROUTINE ROUTINE - Part of full AChR panel Positive supports diagnosis MuSK antibody - ROUTINE ROUTINE - If AChR negative; MuSK-positive MG has different treatment implications (poor response to pyridostigmine, PLEX preferred over IVIG) Check if AChR negative Anti-striated muscle antibody (anti-titin) - ROUTINE ROUTINE - Associated with thymoma; especially in young patients If positive, image for thymoma Procalcitonin URGENT ROUTINE - URGENT Differentiate bacterial infection trigger from other causes of decompensation &lt;0.5 ng/mL Chest X-ray STAT ROUTINE - STAT Aspiration pneumonia, atelectasis; baseline for ventilator Clear lungs Lactate URGENT ROUTINE - URGENT Sepsis screen if febrile Normal (&lt;2 mmol/L) Drug level of immunosuppressant (if applicable) - ROUTINE ROUTINE - Check azathioprine metabolites (6-TGN), mycophenolate levels, tacrolimus levels if on these agents Therapeutic range"},{"location":"plans/myasthenia-gravis-crisis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding LRP4 antibody - EXT EXT - Triple-seronegative MG (AChR-/MuSK-/LRP4+) Check if double seronegative Agrin antibody - EXT EXT - Emerging biomarker in seronegative MG Research use Anti-Kv1.4 antibody - EXT EXT - Associated with myocarditis in MG; cardiac risk stratification Check if cardiac symptoms Complement levels (C3, C4) - EXT EXT - Complement-mediated MG pathophysiology; pre-eculizumab evaluation Baseline Quantitative immunoglobulins (IgG, IgA, IgM) - ROUTINE ROUTINE - Hypogammaglobulinemia from rituximab or chronic IVIG; IgA deficiency before IVIG Normal"},{"location":"plans/myasthenia-gravis-crisis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/myasthenia-gravis-crisis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Chest X-ray STAT ROUTINE - STAT Immediate in ED Pneumonia, aspiration, atelectasis, mediastinal mass (thymoma) None significant ECG (12-lead) STAT ROUTINE - STAT On admission Arrhythmia, myocarditis (rare but reported in MG, especially anti-Kv1.4+) None Bedside spirometry (FVC and NIF) STAT STAT ROUTINE STAT Immediately on presentation; serial monitoring FVC &gt;20 mL/kg; NIF more negative than -30 cmH2O Patient cooperation required"},{"location":"plans/myasthenia-gravis-crisis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest with contrast - ROUTINE ROUTINE - During admission if not recently done Thymoma (present in 10-15%); thymic hyperplasia Contrast allergy, renal impairment MRI chest (alternative to CT) - ROUTINE ROUTINE - If CT contraindicated Thymoma evaluation Pacemaker, metallic implants Repetitive nerve stimulation (RNS) - ROUTINE ROUTINE - If diagnosis not confirmed; avoid during acute crisis (deferred to stable phase) Decremental response &gt;10% at 2-3 Hz in affected muscle None significant Single-fiber EMG (SFEMG) - - ROUTINE - Most sensitive test (95-99%); defer to outpatient stable phase Increased jitter, blocking Patient cooperation CT head URGENT ROUTINE - URGENT If altered mental status to rule out other causes Normal (MG does not affect brain parenchyma) None significant"},{"location":"plans/myasthenia-gravis-crisis/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications PET-CT - EXT EXT - If thymoma on CT; staging Metabolic activity, metastatic disease Pregnancy Echocardiogram - ROUTINE ROUTINE ROUTINE If cardiac symptoms or anti-Kv1.4 positive Myocarditis, cardiomyopathy None significant Pulmonary function tests (formal) - - ROUTINE - Outpatient baseline after recovery FVC baseline for future comparisons Patient cooperation"},{"location":"plans/myasthenia-gravis-crisis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/myasthenia-gravis-crisis/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IVIG (intravenous immunoglobulin) - STAT - STAT 0.4 g/kg/day IV x 5 days (total 2 g/kg) OR 1 g/kg/day x 2 days (faster option). Start within 24h of crisis recognition IgA deficiency (anaphylaxis risk \u2014 use IgA-depleted product); renal failure; thrombotic risk Vital signs q15min first infusion; renal function daily; headache (aseptic meningitis); thrombotic events Plasmapheresis (PLEX) - STAT - STAT 5 exchanges over 10-14 days (every other day); 1-1.5 plasma volumes per exchange. PREFERRED for MuSK-positive MG. Faster onset than IVIG (days vs 1-2 weeks) Hemodynamic instability, severe sepsis, heparin allergy, poor vascular access BP continuous during exchange; Ca2+ (citrate toxicity); fibrinogen; electrolytes; line infection Intubation and mechanical ventilation STAT STAT - STAT Indications: FVC &lt;20 mL/kg, NIF &gt;-30 cmH2O (weaker), &gt;30% FVC decline, clinical distress, inability to handle secretions. Use NON-DEPOLARIZING agents at REDUCED DOSE (MG patients are sensitive). Avoid succinylcholine (unpredictable response) N/A (life-saving) Ventilator per ICU protocol; daily SBT when improving Hold pyridostigmine during crisis STAT STAT - STAT HOLD cholinesterase inhibitors during intubation/crisis \u2014 excess cholinergic stimulation increases secretions and complicates ventilator management. Resume at reduced dose during weaning N/A Secretion management; restart when extubation approaching Supplemental oxygen STAT STAT - STAT As needed for SpO2 &lt;94% N/A SpO2 monitoring IV fluids (isotonic) STAT STAT - STAT NS maintenance; hydration for IVIG renal protection Volume overload I/O, electrolytes"},{"location":"plans/myasthenia-gravis-crisis/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Pyridostigmine (when stable/recovering) Symptomatic weakness improvement - ROUTINE ROUTINE ROUTINE Resume at 30 mg PO TID during recovery; titrate by 30 mg/dose q3-5 days to 60 mg PO q4-6h; max 120 mg q4h (rarely needed). Take 30-60 min before meals for dysphagia Cholinergic crisis (excessive dosing), mechanical bowel obstruction GI symptoms (diarrhea, cramping, salivation = cholinergic excess); reduce dose if muscarinic symptoms Glycopyrrolate Cholinergic side effects of pyridostigmine - ROUTINE ROUTINE ROUTINE 1-2 mg PO BID-TID; or 0.2 mg IV PRN for excessive secretions Angle-closure glaucoma, urinary retention, tachycardia Heart rate; urinary retention; dry mouth Acetaminophen Headache (IVIG-related or general) STAT ROUTINE ROUTINE STAT 650-1000 mg PO q6h; max 4g/day Severe liver disease LFTs if prolonged Ondansetron Nausea (IVIG-related) - ROUTINE - ROUTINE 4 mg IV/PO q6h PRN QT prolongation QTc monitoring Diphenhydramine IVIG premedication - ROUTINE - ROUTINE 25-50 mg IV/PO 30 min before IVIG infusion Angle-closure glaucoma; avoid in elderly (anticholinergic) Sedation Enoxaparin DVT prophylaxis - ROUTINE - ROUTINE 40 mg SC daily Active bleeding, CrCl &lt;30 (use UFH) Platelets q3 days Pneumatic compression devices DVT prophylaxis STAT STAT - STAT Apply bilaterally on admission Acute DVT Skin checks Pantoprazole GI prophylaxis (if on steroids) - ROUTINE ROUTINE ROUTINE 40 mg IV/PO daily Prolonged use risks (C. diff, osteoporosis) GI symptoms Insulin sliding scale Steroid-induced hyperglycemia - ROUTINE - ROUTINE Per institutional protocol; target glucose 140-180 mg/dL Hypoglycemia Blood glucose q6h or more frequent"},{"location":"plans/myasthenia-gravis-crisis/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring IV methylprednisolone - URGENT - URGENT 1000 mg IV daily x 3-5 days. CAUTION: steroids can transiently worsen MG in first 5-10 days \u2014 only initiate in monitored setting with respiratory support available. Some centers use slow oral prednisone uptitration instead Uncontrolled diabetes (relative), active infection (relative) FVC/NIF closely; glucose q6h; BP; GI prophylaxis Prednisone (oral uptitration) - ROUTINE ROUTINE - Start 10-20 mg PO daily; increase by 10 mg every 3-5 days to target 1 mg/kg/day (max 60-80 mg); maintain for 4-8 weeks, then slow taper over months Active infection, uncontrolled DM (relative) Glucose, BP, weight, bone density, mood; GI prophylaxis; PJP prophylaxis if prolonged high-dose Second course IVIG or PLEX - URGENT - URGENT Repeat standard dosing if inadequate response to first course; wait 2-4 weeks between courses Same as initial Same as initial Eculizumab - EXT ROUTINE - 900 mg IV q1 week x 4 weeks, then 1200 mg IV q2 weeks; for AChR-positive refractory generalized MG Unresolved Neisseria meningitidis infection; must vaccinate \u22652 weeks before starting Meningococcal infection; complement levels; CBC Efgartigimod (Vyvgart) - EXT ROUTINE - 10 mg/kg IV weekly x 4 weeks per cycle; repeat cycles based on clinical response; for AChR-positive generalized MG Active infection, IgG &lt;2 g/L IgG levels (target reduction); infection signs; CBC Rituximab - EXT ROUTINE - 375 mg/m2 IV weekly x 4 weeks OR 1000 mg IV x 2 doses 2 weeks apart; especially effective in MuSK-positive MG Active infection, hepatitis B (reactivation risk \u2014 screen first) CD20 count, immunoglobulins q3 months; hepatitis B screening; PML risk (rare)"},{"location":"plans/myasthenia-gravis-crisis/#3d-disease-modifying-or-chronic-therapies","title":"3D. Disease-Modifying or Chronic Therapies","text":"Treatment Route ED HOSP OPD ICU Dosing Pre-Treatment Requirements Contraindications Monitoring Azathioprine PO - ROUTINE ROUTINE - Start 50 mg PO daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day; onset of effect 6-12 months TPMT genotype/phenotype testing (deficiency \u2192 severe myelosuppression); hepatitis B screen; CBC, LFTs TPMT deficiency; pregnancy; concurrent allopurinol (dose reduce by 75%) CBC weekly x 4 weeks, then biweekly x 2 months, then monthly; LFTs monthly x 3, then q3 months Mycophenolate mofetil PO - ROUTINE ROUTINE - Start 500 mg PO BID; increase to 1000 mg PO BID after 2 weeks; max 1500 mg BID; onset 6-12 months CBC, LFTs, pregnancy test (teratogenic \u2014 requires contraception) Pregnancy (Category D), breastfeeding CBC q1 week x 1 month, then biweekly x 2 months, then monthly; LFTs q3 months Tacrolimus PO - - ROUTINE - 3 mg PO daily in 2 divided doses; target trough 5-10 ng/mL; onset 3-6 months Renal function, BP, glucose, tacrolimus level baseline Renal failure, uncontrolled hypertension Trough level q1 week initially, then monthly; Cr, K+, glucose, BP; drug interactions (CYP3A4) Cyclosporine PO - - ROUTINE - Start 2-3 mg/kg/day PO in 2 divided doses; target trough 100-200 ng/mL; onset 3-6 months Renal function, BP, lipids, Mg Renal failure, uncontrolled HTN, malignancy Trough levels, Cr, BP, Mg, lipids monthly"},{"location":"plans/myasthenia-gravis-crisis/#medications-to-avoid-in-myasthenia-gravis","title":"\u26a0\ufe0f MEDICATIONS TO AVOID IN MYASTHENIA GRAVIS","text":"Drug Category Specific Agents Risk Aminoglycosides Gentamicin, tobramycin, amikacin, streptomycin NMJ blockade; can precipitate crisis Fluoroquinolones Ciprofloxacin, levofloxacin, moxifloxacin NMJ blockade; FDA black box warning for MG Macrolides Azithromycin, erythromycin, clarithromycin NMJ blockade (less than aminoglycosides but still risky) Beta-blockers Propranolol, metoprolol, atenolol (all) Worsen NMJ transmission; can precipitate crisis Calcium channel blockers Verapamil (worst); diltiazem Impair NMJ transmission Magnesium (IV) Magnesium sulfate Directly blocks NMJ; can precipitate respiratory failure. Do NOT give IV Mg in MG unless life-threatening hypomagnesemia with close monitoring Telithromycin Ketek Severe exacerbation; contraindicated D-Penicillamine Cuprimine Can induce autoimmune MG Neuromuscular blockers Succinylcholine (unpredictable), non-depolarizing agents (prolonged effect at standard doses) Use reduced doses of non-depolarizing agents if intubation required Botulinum toxin Botox, Dysport Systemic weakness risk Statins All (rare) Reported to unmask or worsen MG (rare; benefit usually outweighs risk) Immune checkpoint inhibitors Nivolumab, pembrolizumab, ipilimumab Can trigger or exacerbate MG (potentially fatal); oncology must coordinate with neurology Quinine/Quinidine Antimalarials, antiarrhythmics NMJ blockade Phenytoin Dilantin Can worsen MG (mechanism unclear) Lithium Mood stabilizer May worsen NMJ transmission"},{"location":"plans/myasthenia-gravis-crisis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/myasthenia-gravis-crisis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consultation (neuromuscular specialist if available) STAT STAT - STAT All myasthenic crisis; treatment decisions; medication management Pulmonology / Critical care URGENT URGENT - STAT Declining respiratory function; ventilator management Thoracic surgery - ROUTINE ROUTINE - Thymoma evaluation; thymectomy planning (if not previously done) Respiratory therapy STAT STAT - STAT Bedside FVC/NIF monitoring; pulmonary toilet Speech-language pathology (SLP) URGENT STAT ROUTINE URGENT Dysphagia evaluation; aspiration prevention (bulbar weakness common in crisis) Physical therapy (PT) - URGENT ROUTINE ROUTINE Prevent deconditioning; safe mobilization; fall prevention Occupational therapy (OT) - URGENT ROUTINE ROUTINE ADL assessment; energy conservation techniques; adaptive equipment Pharmacy (clinical pharmacist) STAT STAT - STAT Medication reconciliation \u2014 review ALL medications for MG-unsafe drugs Social work - ROUTINE ROUTINE - Discharge planning; support resources; insurance for IVIG/PLEX Palliative care - ROUTINE - ROUTINE Goals of care discussion for refractory or elderly patients Infectious disease - ROUTINE - - If infection trigger unclear or complex; immunosuppressed patient management Endocrinology - ROUTINE ROUTINE - If concurrent thyroid disease; steroid-induced diabetes management"},{"location":"plans/myasthenia-gravis-crisis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 / Return to ED if: increasing difficulty breathing, trouble swallowing, choking on food or saliva, unable to hold head up, rapidly worsening weakness STAT STAT ROUTINE Carry MG crisis card / MedicAlert bracelet at all times - ROUTINE ROUTINE Bring complete medication list to every medical visit; alert ALL providers about MG diagnosis - ROUTINE ROUTINE NEVER take antibiotics, pain medications, or new prescriptions without checking with neurology - ROUTINE ROUTINE Take pyridostigmine 30-60 minutes before meals for best swallowing function - ROUTINE ROUTINE Avoid extreme heat (worsens weakness), overexertion, and sleep deprivation - ROUTINE ROUTINE Report any new medication prescribed by other providers to your neurologist - ROUTINE ROUTINE Infection prevention: hand hygiene, avoid sick contacts, up-to-date vaccinations (inactivated only if immunosuppressed; NO live vaccines) - ROUTINE ROUTINE Follow-up with neurology 1-2 weeks post-discharge; sooner if symptoms worsen - ROUTINE ROUTINE"},{"location":"plans/myasthenia-gravis-crisis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Infection avoidance (number one trigger for crisis) - ROUTINE ROUTINE Influenza vaccination annually (inactivated) - - ROUTINE Pneumococcal vaccination - - ROUTINE COVID-19 vaccination (inactivated/mRNA; coordinate timing with immunosuppression cycle) - - ROUTINE NO live vaccines if on immunosuppression (MMR, varicella, live zoster, yellow fever) - ROUTINE ROUTINE Adequate sleep (fatigue worsens MG) - ROUTINE ROUTINE Stress management (emotional stress triggers exacerbation) - ROUTINE ROUTINE Moderate exercise as tolerated; avoid overexertion; rest periods during activity - ROUTINE ROUTINE Heat avoidance (hot weather, hot tubs, saunas worsen NMJ transmission) - ROUTINE ROUTINE Smoking cessation - ROUTINE ROUTINE Alcohol limitation (alcohol worsens weakness) - ROUTINE ROUTINE Eye protection (sunglasses, patching for diplopia; artificial tears for incomplete lid closure) - ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/myasthenia-gravis-crisis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Cholinergic crisis EXCESSIVE pyridostigmine; salivation, lacrimation, urination, diarrhea, emesis (SLUDE); miosis; fasciculations; weakness WORSENS with additional pyridostigmine Hold pyridostigmine \u2014 if strength improves, cholinergic; if worsens, myasthenic crisis. Clinical distinction is key Guillain-Barr\u00e9 syndrome Ascending paralysis, areflexia, albuminocytologic dissociation, preceding infection, no fatigability NCS/EMG (demyelinating neuropathy vs NMJ); LP (elevated protein); no response to pyridostigmine Lambert-Eaton myasthenic syndrome Proximal weakness IMPROVES with repeated use; autonomic dysfunction (dry mouth); associated with small cell lung cancer; hyporeflexia VGCC antibodies; NCS (incremental response with high-rate repetitive stimulation \u2014 opposite of MG) Botulism Descending paralysis (cranial \u2192 limbs); dilated pupils; foodborne or wound exposure; autonomic dysfunction Stool/serum botulinum toxin; NCS (incremental); clinical history ALS Progressive weakness without fluctuation; upper AND lower motor neuron signs; no fatigability pattern; fasciculations NCS/EMG (denervation); no response to IVIG/PLEX; no AChR antibodies Brainstem stroke Acute onset; cranial nerve findings; crossed findings (ipsilateral cranial nerve + contralateral limb); no fatigability MRI DWI (restricted diffusion); CTA MS exacerbation CNS symptoms (optic neuritis, sensory level, cerebellar ataxia); dissemination in space and time; no NMJ findings MRI brain/spine; LP (oligoclonal bands); no AChR antibodies Thyroid storm Severe weakness, tachycardia, fever, agitation, lid lag; thyroid hormone excess TSH (suppressed), free T4 (elevated) Periodic paralysis (hypo/hyperkalemic) Episodic weakness triggered by meals, exercise, rest; normal between attacks Serum potassium during attack; genetic testing Conversion disorder / FND Non-physiologic weakness; Hoover sign; distractible; no fatigable pattern Normal NCS/EMG; normal antibodies; clinical exam"},{"location":"plans/myasthenia-gravis-crisis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Forced Vital Capacity (FVC) STAT STAT ROUTINE STAT q4-6h on floor; q2-4h in ICU; q1-2h if declining &gt;20 mL/kg If &lt;20 mL/kg \u2192 intubate electively; if declining &gt;30% \u2192 prepare for intubation Negative Inspiratory Force (NIF) STAT STAT ROUTINE STAT With FVC measurements More negative than -30 cmH2O If weaker than -30 \u2192 intubate Single breath count STAT STAT - STAT q4h as screening Count to &gt;20 If &lt;15 \u2192 correlate with FVC; if &lt;10 \u2192 imminent failure Oxygen saturation STAT STAT - STAT Continuous in ICU; q4h on floor \u226594% LATE finding; do not rely on alone Blood pressure STAT STAT ROUTINE STAT q4h on floor; continuous in ICU Stable Autonomic dysregulation possible (less common than GBS) Heart rate and rhythm STAT STAT - STAT Continuous telemetry in ICU; q4h on floor Normal sinus Arrhythmia: cardiology consult Neurologic exam (strength, bulbar function) STAT STAT ROUTINE STAT q4-8h; MGFA post-intervention status at discharge Improving or stable If worsening \u2192 re-evaluate treatment; consider repeat IVIG/PLEX Swallowing assessment URGENT STAT ROUTINE STAT Daily Safe oral intake NPO; NG tube; modified diet Blood glucose - ROUTINE ROUTINE ROUTINE q6h if on steroids; BID if stable &lt;180 mg/dL Insulin; reduce steroid if possible Renal function (Cr, BUN) - ROUTINE - ROUTINE Daily during IVIG; q48h otherwise Stable Hold IVIG; hydration CBC - ROUTINE ROUTINE ROUTINE Weekly during immunosuppression initiation; q3 months chronic Normal Dose adjust or hold immunosuppressant LFTs - ROUTINE ROUTINE - Monthly x3 for azathioprine/mycophenolate, then q3 months Normal Dose adjust or hold"},{"location":"plans/myasthenia-gravis-crisis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Exacerbation resolved; FVC &gt;60% predicted and stable; able to swallow safely; adequate oral medications; no respiratory distress; stable immunotherapy regimen; follow-up within 1-2 weeks Admit to floor (monitored bed) Moderate exacerbation; FVC 20-30 mL/kg; requires IVIG or PLEX; dysphagia requiring modified diet; unable to maintain medications orally Admit to ICU Myasthenic crisis; FVC &lt;20 mL/kg or declining rapidly; intubated; bulbar weakness with aspiration risk; post-operative thymectomy with respiratory concerns Transfer to higher level Need for PLEX not available; neuromuscular specialist consultation; need for ICU with neurology expertise Inpatient rehabilitation Significant weakness; unable to perform ADLs independently; able to tolerate 3h/day therapy"},{"location":"plans/myasthenia-gravis-crisis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source IVIG (2 g/kg over 2-5 days) for myasthenic crisis Class I, Level A Zinman et al. (2007); Gajdos et al. Cochrane (2012) PLEX (5 exchanges) for myasthenic crisis Class I, Level A Cortese et al. (2011); Cochrane Review IVIG and PLEX are equivalent for crisis Class I, Level A Barth et al. (2011) PLEX preferred for MuSK-positive MG Class IIa, Level C Expert consensus; Evoli et al. (2003) Hold pyridostigmine during intubation/crisis Class IIa, Level C Expert consensus Avoid aminoglycosides, fluoroquinolones in MG Class III (Harm) FDA safety communication; multiple case reports Avoid IV magnesium in MG Class III (Harm) NMJ blockade; case reports of respiratory failure Steroids can transiently worsen MG (monitor closely when initiating) Class IIa, Level B Multiple observational studies Thymectomy benefit in non-thymomatous MG Class I, Level B MGTX trial (Wolfe et al. NEJM 2016) Eculizumab for refractory AChR+ generalized MG Class I, Level A REGAIN trial (Howard et al. Lancet Neurol 2017) Efgartigimod for AChR+ generalized MG Class I, Level A ADAPT trial (Howard et al. Lancet Neurol 2021) Rituximab for MuSK-positive MG Class IIa, Level B Hehir et al. (2017); D\u00edaz-Manera et al. (2012) 20/30/40 rule for intubation Class IIa, Level C Wijdicks &amp; Klein (2017) Bedside FVC superior to ABG for monitoring Class I, Level B Multiple studies; ABG changes are LATE findings Azathioprine as first-line steroid-sparing Class I, Level B Palace et al. (1998) Mycophenolate as steroid-sparing Class II, Level B Mixed trial results but widely used <p>APPENDIX: MYASTHENIC vs CHOLINERGIC CRISIS</p> Feature Myasthenic Crisis Cholinergic Crisis Cause Undertreated MG; infection trigger Excessive pyridostigmine Pupils Normal Miosis (constricted) Secretions Normal or decreased Excessive salivation, tearing, bronchorrhea Fasciculations Absent Present GI symptoms Absent Diarrhea, nausea, vomiting, cramping Response to pyridostigmine Improves Worsens Treatment IVIG/PLEX; increase immunotherapy HOLD pyridostigmine; supportive care <p>APPENDIX: MGFA CLINICAL CLASSIFICATION</p> Class Description I Ocular weakness only; may have weakness of eye closure. All other muscle strength is normal II Mild weakness affecting muscles other than ocular; may also have ocular weakness of any severity IIa Predominantly limb, axial muscles, or both; may have lesser involvement of oropharyngeal muscles IIb Predominantly oropharyngeal, respiratory muscles, or both; may have lesser or equal involvement of limb, axial muscles III Moderate weakness affecting muscles other than ocular; may also have ocular weakness of any severity IIIa Predominantly limb, axial muscles IIIb Predominantly oropharyngeal, respiratory muscles IV Severe weakness affecting muscles other than ocular IVa Predominantly limb, axial muscles IVb Predominantly oropharyngeal, respiratory (can include feeding tube, without intubation) V Intubation required to maintain airway (with or without mechanical ventilation) = MYASTHENIC CRISIS"},{"location":"plans/myasthenia-gravis-new-diagnosis/","title":"Myasthenia Gravis - New Diagnosis","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 REVISED: January 27, 2026 STATUS: Initial creation</p> <p>DIAGNOSIS: Myasthenia Gravis - New Diagnosis</p> <p>ICD-10: G70.0 (Myasthenia gravis), G70.00 (MG without exacerbation), G70.01 (MG with exacerbation)</p> <p>SYNONYMS: Myasthenia gravis, MG, new MG diagnosis, ocular myasthenia, generalized myasthenia, anti-AChR MG, anti-MuSK MG, seronegative MG, autoimmune neuromuscular junction disorder, fatigable weakness</p> <p>SCOPE: Initial diagnostic workup and management of suspected or newly confirmed myasthenia gravis. Covers antibody testing, electrodiagnostic studies, thymoma screening, acute stabilization, and long-term immunotherapy initiation. For myasthenic crisis with respiratory failure, use \"Myasthenic Crisis\" template. For established MG on maintenance therapy, use \"MG - Maintenance\" template.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/myasthenia-gravis-new-diagnosis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline before immunotherapy; infection screen Normal CMP STAT STAT ROUTINE STAT Renal/hepatic function baseline; electrolytes Normal TSH URGENT ROUTINE ROUTINE URGENT Thyroid disease co-occurs in 10-15% of MG; autoimmune overlap Normal Free T4 URGENT ROUTINE ROUTINE URGENT Thyroid function; Graves disease association Normal ESR URGENT ROUTINE ROUTINE URGENT Inflammatory/autoimmune screen Normal (&lt;20 mm/hr) CRP URGENT ROUTINE ROUTINE URGENT Inflammatory marker; infection screen Normal AChR binding antibody URGENT URGENT ROUTINE URGENT Primary diagnostic test; positive in ~85% generalized MG, ~50% ocular MG Negative (&lt;0.02 nmol/L) AChR blocking antibody URGENT URGENT ROUTINE URGENT Complements binding antibody; increases sensitivity Negative AChR modulating antibody URGENT URGENT ROUTINE URGENT Complements binding/blocking; increases sensitivity to ~95% in generalized MG Negative Blood glucose STAT STAT ROUTINE STAT Pre-steroid baseline Normal HbA1c - ROUTINE ROUTINE - Glycemic status before corticosteroid initiation &lt;5.7% Urinalysis STAT STAT ROUTINE STAT Infection screen; baseline Negative LDH - ROUTINE ROUTINE - Baseline; monitor for hemolysis on complement inhibitors Normal Magnesium STAT STAT ROUTINE STAT Hypomagnesemia worsens NMJ transmission Normal (1.7-2.2 mg/dL) Phosphorus STAT STAT ROUTINE STAT Baseline electrolyte panel Normal PT/INR STAT STAT - STAT Coagulation baseline before procedures Normal Hepatitis B surface antigen - ROUTINE ROUTINE - Screen before rituximab/immunosuppression (reactivation risk) Negative"},{"location":"plans/myasthenia-gravis-new-diagnosis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding MuSK antibody (anti-MuSK IgG) URGENT URGENT ROUTINE URGENT Positive in ~40% of AChR-seronegative MG; distinct phenotype (bulbar, facial, neck weakness) Negative LRP4 antibody - ROUTINE ROUTINE - Positive in ~2-50% of double-seronegative MG; newer assay Negative Anti-striated muscle antibody (anti-SM) - ROUTINE ROUTINE - Associated with thymoma in MG patients &lt;40 years; screening marker Negative Anti-titin antibody - ROUTINE ROUTINE - Associated with thymoma (especially in young-onset MG); late-onset MG marker Negative Anti-RyR (ryanodine receptor) antibody - ROUTINE ROUTINE - Associated with thymoma and severe MG Negative ANA - ROUTINE ROUTINE - Autoimmune overlap screen (SLE, Sjogren) Negative or low titer Anti-TPO antibody - ROUTINE ROUTINE - Autoimmune thyroiditis co-occurrence (Hashimoto/Graves) Negative Vitamin D (25-OH) - ROUTINE ROUTINE - Immune modulation; deficiency common &gt;30 ng/mL Hepatitis B core antibody - ROUTINE ROUTINE - Screen for prior HBV before rituximab Negative Hepatitis C antibody - ROUTINE ROUTINE - Screen before immunosuppression Negative HIV - ROUTINE ROUTINE - Screen before immunosuppression Negative Quantitative immunoglobulins (IgG, IgA, IgM) - ROUTINE ROUTINE - Baseline before IVIG; monitor on rituximab/immunosuppression Normal SPEP with immunofixation - ROUTINE EXT - Paraproteinemic neuropathy/NMJ screen in atypical cases Normal Complement C3, C4 - ROUTINE ROUTINE - Baseline before complement inhibitor therapy Normal Reticulocyte count - ROUTINE ROUTINE - Baseline before complement inhibitors (hemolysis monitoring) Normal Haptoglobin - ROUTINE ROUTINE - Baseline for hemolysis monitoring on complement inhibitors Normal TB test (QuantiFERON-Gold or PPD) - ROUTINE ROUTINE - Screen before immunosuppression Negative"},{"location":"plans/myasthenia-gravis-new-diagnosis/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Agrin antibody - EXT EXT - Novel antibody target in seronegative MG Negative Cortactin antibody - EXT EXT - Identified in some seronegative MG Negative ColQ antibody - EXT EXT - Congenital myasthenic syndrome screen Negative Genetic testing (CMS gene panel) - - EXT - Congenital myasthenic syndromes (CHRNE, DOK7, RAPSN, etc.) if onset &lt;2 years or seronegative/atypical Depends on gene Paraneoplastic antibody panel (ANNA-1, VGCC, GAD65) - EXT EXT - LEMS or overlap paraneoplastic syndrome Negative VGCC antibody (P/Q-type) - EXT EXT - Lambert-Eaton myasthenic syndrome screen Negative (&lt;0.02 nmol/L) SOX1 antibody - EXT EXT - Associated with SCLC in LEMS Negative Acetylcholine receptor ganglionic antibody - EXT EXT - Autonomic neuropathy overlap Negative Muscle biopsy - EXT EXT - Myopathy screen if diagnosis unclear Normal NMJ architecture Anti-Kv1.4 antibody - EXT EXT - Associated with myocarditis and severe MG phenotype (Japan) Negative CT-guided thymoma biopsy - EXT EXT - If anterior mediastinal mass is atypical; tissue diagnosis Depends on pathology"},{"location":"plans/myasthenia-gravis-new-diagnosis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/myasthenia-gravis-new-diagnosis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest with contrast URGENT URGENT ROUTINE URGENT Within 24-48h of diagnosis No thymoma or thymic hyperplasia Contrast allergy, renal insufficiency MRI chest with contrast (preferred over CT if available) - ROUTINE ROUTINE - Within 1-2 weeks No thymoma; thymic hyperplasia characterization Gadolinium allergy, GFR &lt;30, pacemaker Chest X-ray (PA and lateral) STAT STAT ROUTINE STAT Immediate No mediastinal mass; baseline pulmonary status None significant Portable chest X-ray STAT - - STAT If unable to go to radiology Pulmonary status; mediastinal widening None significant"},{"location":"plans/myasthenia-gravis-new-diagnosis/#2b-electrodiagnostic-specialized-studies","title":"2B. Electrodiagnostic &amp; Specialized Studies","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Repetitive nerve stimulation (RNS) - URGENT ROUTINE - During workup; stop pyridostigmine 12h prior if possible Decremental response &gt;10% at 2-3 Hz in proximal and distal muscles Pacemaker (relative); recent botulinum toxin Single-fiber EMG (SFEMG) - ROUTINE ROUTINE - If RNS negative but clinical suspicion remains; most sensitive test (95-99%) Increased jitter and blocking Same as RNS; requires experienced electromyographer Standard EMG/NCS - ROUTINE ROUTINE - If diagnosis unclear; rule out neuropathy/myopathy Normal (unless concurrent condition) None significant Ice pack test (ocular MG) URGENT URGENT ROUTINE - At bedside; apply ice to closed eyelid for 2 minutes Improvement of ptosis by \u22652 mm (sensitivity ~80% for ocular MG) Patient intolerance Rest test (ocular MG) URGENT URGENT ROUTINE - At bedside; rest with eyes closed for 2-5 minutes Improvement of ptosis or diplopia None Sleep test (ocular MG) - ROUTINE ROUTINE - At bedside; 30-minute nap then reassess Improvement of ptosis/diplopia after rest None"},{"location":"plans/myasthenia-gravis-new-diagnosis/#2c-bedside-clinical-tests","title":"2C. Bedside Clinical Tests","text":"Test ED HOSP OPD ICU Timing Target Finding Notes Sustained upgaze (2 minutes) STAT STAT ROUTINE STAT Initial exam No fatigable ptosis Positive = ptosis develops or worsens with sustained upgaze Repeated deltoid abduction (15-20 reps) STAT STAT ROUTINE STAT Initial exam No fatigable weakness Positive = progressive weakness with repetitive testing Cogan lid twitch sign STAT STAT ROUTINE STAT Initial exam No lid twitch Have patient look down 15 sec, then look up: positive = brief upward overshoot of lid Curtain sign (orbicularis oculi) STAT STAT ROUTINE STAT Initial exam No contralateral lid opening While examiner holds one ptotic lid open, the other droops further Peek sign STAT STAT ROUTINE STAT Initial exam Sustained eye closure Patient gently closes eyes for 30 sec: positive = sclera becomes visible (orbicularis weakness) Forced vital capacity (FVC) STAT STAT - STAT At presentation and serially &gt;20 mL/kg (&gt;1.5 L) Critical: &lt;15 mL/kg or &lt;1 L = impending respiratory failure Negative inspiratory force (NIF/MIP) STAT STAT - STAT At presentation and serially More negative than -40 cm H2O Critical: weaker than -20 cm H2O = consider intubation <p>Note: Edrophonium (Tensilon) test rarely performed due to cardiac risks and availability issues; ice pack test preferred as bedside diagnostic.</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/myasthenia-gravis-new-diagnosis/#3a-cholinesterase-inhibitors-symptomatic","title":"3A. Cholinesterase Inhibitors (Symptomatic)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Pyridostigmine (Mestinon) IR URGENT URGENT ROUTINE URGENT Start 30 mg TID; increase by 30 mg per dose every 2-3 days; usual effective dose 60 mg q4-6h while awake; max 120 mg per dose (max ~960 mg/day, rarely needed) Mechanical GI/GU obstruction; uncontrolled asthma Cholinergic side effects: diarrhea, cramping, salivation, bradycardia; cholinergic crisis if overdosed (weakness + muscarinic symptoms) Pyridostigmine (Mestinon) SR (Timespan) - ROUTINE ROUTINE - 180 mg qHS (sustained release); may give once or twice daily; do NOT crush Same as IR Same; useful for nocturnal/morning weakness; erratic absorption - use sparingly Pyridostigmine liquid (60 mg/5 mL) URGENT URGENT ROUTINE URGENT Same dosing as IR; useful for patients with dysphagia Same as IR Same; easier to swallow Neostigmine IV (if NPO or intubated) - URGENT - URGENT 0.5-2.5 mg IV/IM q1-3h; 1 mg IV neostigmine \u2248 30 mg oral pyridostigmine Same; cardiac monitoring required Continuous cardiac monitoring; have atropine at bedside for bradycardia Glycopyrrolate (for cholinergic side effects) - ROUTINE ROUTINE - 1-2 mg PO BID-TID or 0.1-0.2 mg IV PRN Narrow-angle glaucoma; obstructive uropathy Does NOT cross BBB (preferred over atropine for peripheral muscarinic side effects) Atropine (for cholinergic side effects/emergency) STAT STAT - STAT 0.5-1 mg IV PRN for symptomatic bradycardia from pyridostigmine Tachycardia; thyrotoxicosis HR monitoring; crosses BBB (may cause confusion) Pyridostigmine dose reduction/hold - URGENT ROUTINE URGENT Hold or reduce if cholinergic crisis suspected (worsening weakness + excessive secretions) N/A Distinguish cholinergic crisis (excess pyridostigmine) from myasthenic crisis (undertreated MG) <p>Note: MuSK-positive MG often responds poorly to pyridostigmine and may worsen; use cautiously and consider early immunotherapy.</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#3b-corticosteroids-immunosuppression-induction","title":"3B. Corticosteroids (Immunosuppression - Induction)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Prednisone (gradual escalation - PREFERRED for outpatient) - ROUTINE ROUTINE - Start 10-20 mg daily; increase by 5-10 mg every 3-5 days to target 0.5-1 mg/kg/day (typically 40-60 mg daily); maintain 4-8 weeks then taper by 5-10 mg/month Active untreated infection; uncontrolled diabetes; psychosis history Glucose (q6h inpatient, weekly outpatient); BP; mood/sleep; weight; bone density at baseline; GI prophylaxis Prednisone (rapid escalation - INPATIENT preferred) - URGENT - URGENT Start 40-60 mg daily (0.75-1 mg/kg/day); CAUTION: may cause initial transient worsening in first 1-2 weeks Same as above Same; MONITOR CLOSELY for steroid-induced exacerbation; consider concurrent IVIG/PLEX for protection Methylprednisolone IV (pulse therapy) STAT STAT - STAT 1000 mg IV daily \u00d7 3-5 days; transition to oral prednisone taper Active untreated infection; uncontrolled diabetes; psychosis Glucose q6h (target &lt;180); BP; mood; cardiac monitoring; GI prophylaxis Omeprazole (GI prophylaxis during steroids) STAT STAT ROUTINE STAT 20-40 mg daily while on steroids PPI allergy None routine Insulin sliding scale (steroid-induced hyperglycemia) STAT STAT - STAT Per protocol if glucose &gt;180 mg/dL Hypoglycemia risk Glucose q6h Calcium carbonate + Vitamin D (bone protection) - ROUTINE ROUTINE - Calcium 1000-1200 mg + Vitamin D 1000-2000 IU daily while on chronic steroids Hypercalcemia; hyperparathyroidism Serum calcium; consider DEXA if anticipated steroid course &gt;3 months Bisphosphonate (bone protection if chronic steroids) - - ROUTINE - Alendronate 70 mg PO weekly OR risedronate 35 mg PO weekly; start if steroids expected &gt;3 months GFR &lt;35; esophageal disorders; inability to remain upright 30 min DEXA at baseline; renal function; dental exam (ONJ risk) Trimethoprim-sulfamethoxazole (PCP prophylaxis) - ROUTINE ROUTINE - 1 DS tablet (160/800 mg) daily or 3 times per week if prednisone \u226520 mg for \u22654 weeks Sulfonamide allergy; severe renal impairment CBC; renal function; use dapsone or atovaquone if allergic Prednisone taper - ROUTINE ROUTINE - Once stable on target dose for 4-8 weeks: decrease by 5-10 mg every 2-4 weeks until 20 mg, then decrease by 2.5-5 mg monthly; target lowest effective dose or off Do NOT stop abruptly if &gt;2 weeks of therapy Adrenal insufficiency symptoms; disease flare; cortisol level if concerns <p>Note: Steroid-induced transient worsening occurs in ~50% of patients within first 2 weeks of high-dose initiation. Consider starting steroids in-hospital for patients with moderate-severe generalized MG or bulbar symptoms, or provide \"bridge\" therapy with IVIG/PLEX.</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#3c-steroid-sparing-immunosuppressive-agents","title":"3C. Steroid-Sparing Immunosuppressive Agents","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Mycophenolate mofetil (CellCept) - ROUTINE ROUTINE - Start 500 mg BID; increase to 1000 mg BID after 2 weeks; target 2000-3000 mg/day in divided doses; onset 6-12 months Pregnancy (Category D - teratogenic); concurrent azathioprine CBC q2 weeks \u00d7 3 months, then monthly; LFTs; GI side effects (diarrhea, nausea); lymphopenia; REMS pregnancy prevention Azathioprine (Imuran) - ROUTINE ROUTINE - Start 50 mg daily; increase by 50 mg every 1-2 weeks to target 2-3 mg/kg/day (typically 150-250 mg/day); onset 6-18 months TPMT deficiency (check before starting); concurrent allopurinol (reduce dose by 75%); pregnancy (relative) TPMT genotype/activity BEFORE starting; CBC q1-2 weeks during titration, then monthly; LFTs; amylase/lipase if abdominal pain; lymphocyte count target 600-1000 Tacrolimus (Prograf) - - ROUTINE - Start 1 mg BID; titrate to trough level 5-10 ng/mL; onset 3-6 months (faster than MMF/AZA) Uncontrolled hypertension; renal impairment Trough levels; renal function q2 weeks then monthly; electrolytes (K, Mg); glucose; BP; tremor; nephrotoxicity Cyclosporine (Sandimmune/Neoral) - - ROUTINE - Start 2-3 mg/kg/day in 2 divided doses; target trough 100-150 ng/mL; onset 2-6 months Uncontrolled hypertension; renal impairment; concurrent nephrotoxic drugs Trough levels; renal function; BP; electrolytes (K, Mg); lipids; gingival hyperplasia; hirsutism Methotrexate - - EXT - 10-20 mg PO or SC once weekly with folic acid 1 mg daily (except methotrexate day); onset 6-12 months Pregnancy (Category X); hepatic disease; renal impairment (CrCl &lt;30); concurrent trimethoprim CBC q4 weeks; LFTs q8-12 weeks; renal function; pulmonary toxicity screen; folic acid supplementation mandatory Cyclophosphamide (refractory/severe) - EXT EXT EXT Pulse IV: 500-1000 mg/m\u00b2 monthly \u00d7 6 months; OR oral 1-2 mg/kg/day; reserved for refractory MG Pregnancy; active infection; bone marrow suppression CBC weekly during treatment; urinalysis (hemorrhagic cystitis - MESNA with IV dosing); fertility counseling; malignancy risk IVIG (maintenance immunomodulation) - ROUTINE ROUTINE ROUTINE 1-2 g/kg divided over 2-5 days, then 0.4-1 g/kg every 4 weeks as maintenance IgA deficiency (check IgA level first); recent thrombotic event; renal failure Pre-infusion: IgA level, renal function, CBC; during: vital signs q15 min first hour; headache; aseptic meningitis; thrombosis risk; renal function"},{"location":"plans/myasthenia-gravis-new-diagnosis/#3d-biologics-complement-inhibitors-rescue-therapies","title":"3D. Biologics, Complement Inhibitors &amp; Rescue Therapies","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Rituximab (Rituxan) - ROUTINE ROUTINE - 375 mg/m\u00b2 IV weekly \u00d7 4 weeks; OR 1000 mg IV \u00d7 2 doses 14 days apart; re-dose when CD19/CD20 recover or clinical worsening; onset 3-6 months Active Hepatitis B; active infection; severe immunodeficiency HBV serology before; CD19/CD20 counts q3-6 months; immunoglobulins q6 months; PML risk (very rare); infusion reactions (premedicate with acetaminophen, diphenhydramine, methylprednisolone) Eculizumab (Soliris) - ROUTINE ROUTINE - 900 mg IV weekly \u00d7 4 weeks, then 1200 mg IV at week 5, then 1200 mg IV every 2 weeks; for AChR-positive generalized MG Unresolved Neisseria meningitidis infection; unvaccinated against meningococcus Meningococcal vaccine \u22652 weeks before; REMS program; CBC; LDH/reticulocyte (hemolysis on discontinuation); signs of meningococcal infection; ciprofloxacin prophylaxis recommended Ravulizumab (Ultomiris) - ROUTINE ROUTINE - Weight-based loading dose IV, then maintenance every 8 weeks; for AChR-positive generalized MG Same as eculizumab Same as eculizumab; less frequent dosing advantage Zilucoplan (Zilbrysq) - - ROUTINE - 0.3 mg/kg SC daily (self-administered); for AChR-positive generalized MG Same as eculizumab Same meningococcal vaccination required; injection site reactions; LDH; reticulocyte count Efgartigimod (Vyvgart) - ROUTINE ROUTINE - 10 mg/kg IV weekly \u00d7 4 weeks per cycle; may repeat based on clinical response; for AChR-positive generalized MG Active infection; concurrent IgG-dependent therapies IgG levels (expect ~70% reduction); infection monitoring; no meningococcal vaccine required Efgartigimod/hyaluronidase SC (Vyvgart Hytrulo) - - ROUTINE - 1008 mg efgartigimod + 11,200 units hyaluronidase SC weekly \u00d7 4 weeks per cycle Same as IV efgartigimod Same; injection site reactions; self-administered option Rozanolixizumab (Rystiggo) - ROUTINE ROUTINE - Weight-based SC weekly \u00d7 6 weeks per cycle; for AChR-positive generalized MG Active infection IgG levels; headache common; pyrexia; infection monitoring Plasmapheresis (PLEX) - rescue STAT STAT - STAT 5-7 exchanges over 10-14 days; exchange 1-1.5 plasma volumes per session Hemodynamic instability; sepsis; line contraindication; heparin allergy BP during exchange; electrolytes (Ca, K, Mg); coagulation studies; fibrinogen; line site infection; hypotension IVIG (rescue therapy) STAT STAT - STAT 2 g/kg divided over 2-5 days (e.g., 0.4 g/kg/day \u00d7 5 days) IgA deficiency; renal failure; recent thrombotic event Pre-infusion IgA level; renal function; vital signs; headache (aseptic meningitis); thrombosis risk <p>Note: Complement inhibitors (eculizumab, ravulizumab, zilucoplan) and FcRn inhibitors (efgartigimod, rozanolixizumab) are FDA-approved for AChR antibody-positive generalized MG. They are NOT indicated for MuSK-positive or seronegative MG. Rituximab is first-line for MuSK-positive MG (excellent response rates).</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#3e-surgical-treatment","title":"3E. Surgical Treatment","text":"Treatment ED HOSP OPD ICU Indication Contraindications Notes Thymectomy (VATS or robotic-assisted) - ROUTINE ROUTINE - AChR-positive generalized MG, age 18-65 (MGTX trial); any age with thymoma; consider in AChR-positive ocular MG with suboptimal response MuSK-positive MG (no proven benefit); medically unstable; uncontrolled MG (optimize first) MGTX trial: thymectomy + prednisone superior to prednisone alone at 3 years; optimize MG before surgery (FVC &gt;2L, no bulbar crisis); post-op ICU monitoring recommended Thymectomy (median sternotomy) - ROUTINE - - Thymoma requiring complete resection; invasive thymoma Same as above More invasive; complete thymoma staging with Masaoka classification; consider neoadjuvant chemotherapy for advanced thymoma Extended thymectomy - ROUTINE - - Thymoma with suspected extra-thymic extension Same as above Includes removal of all anterior mediastinal fat; en bloc resection"},{"location":"plans/myasthenia-gravis-new-diagnosis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/myasthenia-gravis-new-diagnosis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neuromuscular specialist/MG specialist referral URGENT URGENT ROUTINE URGENT All new MG diagnoses for treatment planning and long-term management Thoracic surgery referral - ROUTINE ROUTINE - Thymoma present; AChR-positive generalized MG for thymectomy discussion Pulmonology referral - ROUTINE ROUTINE URGENT Respiratory compromise; pre-thymectomy pulmonary evaluation; chronic respiratory monitoring Speech-language pathology (swallow evaluation) - URGENT ROUTINE URGENT Bulbar symptoms: dysphagia, dysarthria, nasal speech; aspiration risk Occupational therapy - ROUTINE ROUTINE - ADL impairment; energy conservation; adaptive equipment Physical therapy - ROUTINE ROUTINE ROUTINE Generalized weakness; deconditioning; fall prevention; exercise prescription Ophthalmology/Neuro-ophthalmology - ROUTINE ROUTINE - Ocular MG; diplopia management; prism evaluation Rheumatology referral - - ROUTINE - Concurrent autoimmune disease (lupus, RA, thyroid disease) Endocrinology referral - - ROUTINE - Steroid-induced diabetes; thyroid disease management; osteoporosis Psychiatry/Psychology referral - ROUTINE ROUTINE - Depression; anxiety; adjustment to chronic diagnosis; steroid-induced psychiatric symptoms Social work consult - ROUTINE ROUTINE - Insurance navigation (biologic cost); disability evaluation; MG support resources Respiratory therapy STAT STAT - STAT FVC/NIF monitoring; ventilator management; BiPAP/CPAP evaluation Nutrition/Dietetics - ROUTINE ROUTINE - Dysphagia diet modification; weight management on steroids; nutritional optimization Anesthesiology consultation (pre-thymectomy) - ROUTINE ROUTINE - Pre-operative assessment; avoidance of neuromuscular blocking agents; post-op ventilation planning Infusion center coordination - ROUTINE ROUTINE - IVIG scheduling; rituximab infusion; complement inhibitor infusions Pain management referral - - EXT - Chronic pain from sustained muscle weakness or comorbid conditions Palliative care (refractory cases) - - EXT - Severely refractory MG with significant symptom burden; goals of care discussion MG Foundation / Patient advocacy - - ROUTINE - Patient support groups; educational materials; myasthenia.org referral"},{"location":"plans/myasthenia-gravis-new-diagnosis/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED immediately if difficulty breathing, swallowing, or speaking \u2713 \u2713 \u2713 Return to ED if new severe weakness, double vision worsening acutely, or unable to hold head up \u2713 \u2713 \u2713 Take pyridostigmine 30-60 minutes BEFORE meals to help with chewing and swallowing \u2713 \u2713 \u2713 Do NOT take pyridostigmine more frequently than prescribed (cholinergic crisis risk) \u2713 \u2713 \u2713 Report excessive salivation, diarrhea, cramping, or muscle twitching (cholinergic side effects) \u2713 \u2713 \u2713 Carry MG medical alert identification at all times \u2713 \u2713 \u2713 Provide MG medication list to ALL healthcare providers (emergency, dental, surgical) \u2713 \u2713 \u2713 Avoid extreme heat, hot baths/saunas (may worsen weakness) - \u2713 \u2713 Plan activities for times of best strength (usually morning after pyridostigmine) - \u2713 \u2713 Rest before meals if dysphagia present; eat smaller, more frequent meals - \u2713 \u2713 Do NOT stop prednisone or immunosuppressant abruptly (adrenal crisis/flare risk) - \u2713 \u2713 Avoid alcohol (potentiates weakness and interacts with medications) - \u2713 \u2713 Report any signs of infection immediately (fever, cough, dysuria) especially if on immunosuppression - \u2713 \u2713 Contact neurologist before taking any new medications (many drugs worsen MG) - \u2713 \u2713 Do NOT use over-the-counter magnesium-containing products without physician approval - \u2713 \u2713 Keep emergency contact numbers for MG specialist readily available \u2713 \u2713 \u2713 Understand the difference between myasthenic crisis and cholinergic crisis - \u2713 \u2713 Monitor and report progressive difficulty climbing stairs, rising from chairs, or lifting arms above head - \u2713 \u2713"},{"location":"plans/myasthenia-gravis-new-diagnosis/#4c-medications-to-avoid-in-myasthenia-gravis","title":"4C. Medications to Avoid in Myasthenia Gravis","text":"Medication/Class Risk Level Details Safe Alternative (if applicable) ANTIBIOTICS Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin) HIGH Impair presynaptic ACh release AND postsynaptic receptor function; can precipitate crisis Use non-aminoglycoside antibiotics based on culture sensitivity Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) HIGH NMJ blocking effect; FDA black box warning for MG exacerbation Beta-lactams, cephalosporins (generally safe) Macrolides (azithromycin, erythromycin, clarithromycin) MODERATE Reports of MG worsening; telithromycin (CONTRAINDICATED - fatal cases) Penicillins, cephalosporins Tetracyclines (doxycycline, minocycline) LOW-MODERATE Rare reports of worsening; use with caution Amoxicillin for common infections Polymyxins (colistin) HIGH Strong NMJ blocking effect Alternative per culture sensitivity CARDIOVASCULAR Beta-blockers (propranolol, metoprolol, atenolol) MODERATE May worsen weakness; impair NMJ transmission ACE inhibitors, ARBs, CCBs (amlodipine) Calcium channel blockers (verapamil, diltiazem) MODERATE Impair presynaptic calcium-dependent ACh release Amlodipine (lower risk); ACE inhibitors Procainamide HIGH NMJ blocking effect; may induce MG antibodies Amiodarone (use cautiously) Quinidine HIGH NMJ blocking effect; can precipitate crisis Consult cardiology for alternatives Lidocaine (IV) MODERATE High-dose IV may worsen NMJ transmission Local/low-dose generally safe Magnesium sulfate IV HIGH Inhibits presynaptic ACh release; can precipitate crisis Avoid except life-threatening hypomagnesemia or eclampsia; ICU monitoring required NEUROPSYCHIATRIC D-penicillamine HIGH Can induce MG autoantibodies; CONTRAINDICATED Trientine for Wilson disease Phenytoin MODERATE May worsen NMJ transmission; case reports of MG exacerbation Levetiracetam, lacosamide, valproate Botulinum toxin HIGH Blocks presynaptic ACh release; CONTRAINDICATED in MG (systemic weakness risk) Physical therapy; oral medications Chlorpromazine, haloperidol MODERATE Reports of MG worsening Atypical antipsychotics (quetiapine - use cautiously) Lithium MODERATE May worsen NMJ transmission Valproate, lamotrigine for mood stabilization Benzodiazepines (high dose) MODERATE Respiratory depression; muscle relaxation compounds weakness Low-dose short-acting with monitoring; melatonin for insomnia ANESTHETIC/SURGICAL Succinylcholine HIGH Unpredictable response: resistance (need higher dose) in chronic MG; prolonged block risk Non-depolarizing agents at reduced dose with monitoring (rocuronium with sugammadex reversal) Non-depolarizing NM blockers (vecuronium, pancuronium, rocuronium) HIGH Exaggerated and prolonged response; use 1/3 to 1/2 normal dose if necessary Sugammadex for reversal of rocuronium; monitor with TOF Volatile anesthetics (isoflurane, sevoflurane, desflurane) MODERATE May potentiate NMJ blockade; use reduced doses TIVA (total intravenous anesthesia) considered safer IMMUNE/CHECKPOINT Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) HIGH Can trigger de novo MG or cause fatal exacerbation of pre-existing MG CONTRAINDICATED in known MG; if must use for malignancy, extreme caution with close monitoring Interferon-alpha MODERATE Can unmask or worsen autoimmune MG Avoid if possible OTHER Quinine/tonic water MODERATE NMJ blocking effect Avoid quinine-containing beverages Statins (atorvastatin, simvastatin, rosuvastatin) LOW Rare myopathy; rare MG exacerbation reports; generally safe with monitoring Continue if indicated; monitor for worsening Iodinated contrast agents LOW Rare reports of transient worsening Use with monitoring; pre-hydrate Penicillamine HIGH Induces autoimmune MG; CONTRAINDICATED Trientine <p>Note: This list is not exhaustive. ALWAYS check individual medications for MG safety before prescribing. When in doubt, consult neuromuscular specialist or pharmacist. Many drugs have case reports of MG exacerbation - use clinical judgment.</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#4d-vaccinations","title":"4D. Vaccinations","text":"Recommendation ED HOSP OPD ICU Notes Meningococcal ACWY vaccine (Menactra or MenQuadfi) - URGENT ROUTINE - REQUIRED \u22652 weeks before complement inhibitor therapy (eculizumab, ravulizumab, zilucoplan) Meningococcal B vaccine (Bexsero or Trumenba) - URGENT ROUTINE - REQUIRED \u22652 weeks before complement inhibitor therapy; 2-dose series Influenza vaccine (inactivated) - ROUTINE ROUTINE - Annually; safe in MG; use inactivated form (not live nasal spray) Pneumococcal vaccines (PCV20 or PCV15 + PPSV23) - ROUTINE ROUTINE - Recommended before immunosuppression; per CDC schedule COVID-19 vaccine (mRNA) - ROUTINE ROUTINE - Recommended; rare reports of MG flare but benefits outweigh risks; monitor 2-4 weeks post-vaccination Hepatitis B vaccine - ROUTINE ROUTINE - If seronegative and starting rituximab/immunosuppression Shingles vaccine (Shingrix - recombinant, non-live) - - ROUTINE - Age \u226550 or immunosuppressed; Shingrix is NOT a live vaccine (safe on immunosuppression) AVOID all LIVE vaccines during immunosuppression - \u2713 \u2713 - No MMR, varicella, live zoster (Zostavax), live influenza (FluMist), yellow fever, oral typhoid while on immunosuppressive therapy Complete vaccinations BEFORE starting immunosuppression when possible - \u2713 \u2713 - Ideally 4-6 weeks before rituximab, mycophenolate, or other immunosuppressants VZV IgG titer (check before immunosuppression) - ROUTINE ROUTINE - If non-immune: vaccinate with Varivax (live) before starting immunosuppression; wait 4 weeks after vaccination"},{"location":"plans/myasthenia-gravis-new-diagnosis/#4e-pregnancy-considerations","title":"4E. Pregnancy Considerations","text":"Recommendation ED HOSP OPD ICU Notes MG course in pregnancy is unpredictable: 1/3 improve, 1/3 worsen, 1/3 unchanged \u2713 \u2713 \u2713 \u2713 Highest risk of exacerbation in first trimester and postpartum Pyridostigmine is safe in pregnancy (Category B equivalent) \u2713 \u2713 \u2713 \u2713 Continue as needed; IV neostigmine safe in labor Prednisone is relatively safe in pregnancy - \u2713 \u2713 - Use lowest effective dose; monitor for gestational diabetes; prednisone preferred (metabolized by placenta) Azathioprine may be continued in pregnancy if necessary - \u2713 \u2713 - Benefits may outweigh risks; discuss with maternal-fetal medicine Mycophenolate is CONTRAINDICATED in pregnancy (Category D/X) \u2713 \u2713 \u2713 \u2713 Teratogenic; must be stopped \u22656 weeks before conception; REMS pregnancy prevention program Methotrexate is CONTRAINDICATED in pregnancy (Category X) \u2713 \u2713 \u2713 \u2713 Teratogenic/abortifacient; stop \u22653 months before conception Rituximab: stop \u226512 months before conception - - \u2713 - B-cell depletion risk to neonate; limited data Complement/FcRn inhibitors: insufficient pregnancy data - \u2713 \u2713 - Discuss risks/benefits with MG specialist and MFM IVIG is safe in pregnancy - \u2713 \u2713 \u2713 Preferred rescue therapy if needed during pregnancy PLEX is safe in pregnancy - \u2713 - \u2713 Preferred rescue therapy; monitor for hypotension Monitor neonate for transient neonatal MG \u2713 \u2713 \u2713 \u2713 Occurs in 10-20% of babies born to MG mothers; maternal AChR antibodies cross placenta; self-limited (resolves within weeks); NICU alert Avoid magnesium sulfate for eclampsia in MG \u2713 \u2713 \u2713 \u2713 Magnesium blocks NMJ; may precipitate crisis; use alternative tocolytics/anticonvulsants (levetiracetam) Breastfeeding generally safe on pyridostigmine and prednisone - \u2713 \u2713 - Avoid breastfeeding on mycophenolate, methotrexate, cyclophosphamide Plan delivery at facility with NICU and neurology support - \u2713 \u2713 - Vaginal delivery preferred; cesarean only for obstetric indications; regional anesthesia preferred over general Maternal-fetal medicine co-management for all MG pregnancies - \u2713 \u2713 - Pre-conception counseling recommended; multidisciplinary approach <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Lambert-Eaton Myasthenic Syndrome (LEMS) Proximal weakness with improvement after exertion (facilitation); autonomic dysfunction; dry mouth; associated with SCLC; depressed reflexes that improve post-exercise VGCC antibody (P/Q-type); incremental response on RNS at 50 Hz; CT chest for malignancy Botulism Acute onset descending paralysis; dilated/fixed pupils; recent ingestion of canned food or wound; autonomic dysfunction; no prior NMJ disease Stool/serum botulinum toxin assay; EMG: BSAP pattern; incremental response on high-frequency RNS Congenital Myasthenic Syndromes (CMS) Childhood onset; family history; seronegative; variable inheritance patterns; specific gene mutations Genetic testing (CMS gene panel: CHRNE, DOK7, RAPSN, CHAT, COLQ); no autoantibodies Thyroid ophthalmopathy (Graves) Proptosis; restrictive (not fatigable) diplopia; lid lag; thyroid dysfunction; MRI shows enlarged EOMs TSH, free T4, TSI, orbital MRI showing EOM enlargement (not NMJ issue) Progressive external ophthalmoplegia (PEO) Slowly progressive bilateral ptosis and ophthalmoparesis; non-fatigable; no diurnal variation; may have pigmentary retinopathy Muscle biopsy (ragged red fibers, COX-negative); mitochondrial DNA analysis Oculopharyngeal muscular dystrophy (OPMD) Late-onset (&gt;40) progressive ptosis and dysphagia; autosomal dominant; no fatigability; specific ethnic prevalence (French-Canadian, Bukharan Jewish) Genetic testing (PABPN1 gene, GCN trinucleotide repeat); CK may be mildly elevated Motor neuron disease (ALS/PBP) Progressive weakness without fatigability; fasciculations; UMN signs (hyperreflexia, Babinski); no sensory loss; bulbar onset may mimic MG EMG/NCS: active denervation, fasciculations; normal RNS; no antibodies Inflammatory myopathy (PM/DM/IBM) Proximal weakness without fatigability; elevated CK; skin findings in DM; no ptosis/diplopia (usually); IBM with grip/quad weakness CK; myositis antibody panel; EMG: myopathic pattern; muscle biopsy Brainstem stroke Acute onset; cranial nerve palsies without fatigability; other focal neurological signs; vascular risk factors Brain MRI with DWI; MRA; CTA Miller Fisher syndrome (GBS variant) Acute ophthalmoplegia, ataxia, areflexia; post-infectious; no fatigability Anti-GQ1b antibody; CSF albuminocytologic dissociation; NCS (reduced SNAPs) Myotonic dystrophy Ptosis and facial weakness; myotonia (delayed relaxation); distal &gt; proximal weakness; cataracts; cardiac conduction abnormalities Genetic testing (DMPK CTG repeat for DM1, CNBP CCTG repeat for DM2); EMG: myotonic discharges Chronic inflammatory demyelinating polyneuropathy (CIDP) Progressive proximal and distal weakness; hyporeflexia/areflexia; sensory involvement; elevated CSF protein NCS: demyelinating pattern; CSF protein; nerve biopsy Sarcoidosis (neuromuscular) Granulomatous myopathy or cranial neuropathy; systemic involvement (lungs, skin, eyes); elevated ACE ACE level; chest CT; biopsy (non-caseating granulomas); gallium scan Drug-induced MG Temporal correlation with offending drug (D-penicillamine, checkpoint inhibitors, statins); antibodies may be present Drug history; antibody testing; improvement after drug withdrawal"},{"location":"plans/myasthenia-gravis-new-diagnosis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/myasthenia-gravis-new-diagnosis/#6a-acute-monitoring-ed-inpatient-icu","title":"6A. Acute Monitoring (ED / Inpatient / ICU)","text":"Parameter Frequency Target/Threshold Action if Abnormal Forced vital capacity (FVC) Q4-6h in acute; Q shift if stable &gt;20 mL/kg (&gt;1.5 L) If &lt;15 mL/kg or &lt;1 L: impending respiratory failure, prepare for intubation; ICU transfer Negative inspiratory force (NIF/MIP) Q4-6h in acute; Q shift if stable More negative than -40 cm H2O If weaker than -20 cm H2O: intubate; -20 to -30 = ICU monitoring Peak expiratory flow (PEF) Q4-6h in acute &gt;200 L/min Declining PEF = weakening respiratory muscles Oxygen saturation (SpO2) Continuous in acute &gt;94% Supplemental O2; BiPAP; intubation if declining Swallow function assessment Daily; each meal if bulbar symptoms Safe oral intake NPO if aspiration risk; NG tube or modified diet; SLP consult Neurologic exam (MG-specific) Q shift inpatient; BID in ICU Stable or improving strength If worsening: reassess pyridostigmine dose; consider IVIG/PLEX; check for cholinergic crisis Blood glucose Q6h during IV/high-dose steroids &lt;180 mg/dL Insulin sliding scale; endocrine consult if persistent &gt;250 Blood pressure Q shift during steroids &lt;160/100 mmHg Antihypertensives PRN Temperature Q shift Afebrile Infection workup if febrile (infection is leading MG crisis trigger) Electrolytes (K, Mg, Ca, Phos) Daily while acute Normal ranges Replace aggressively; hypokalemia and hypomagnesemia worsen NMJ transmission I/O and daily weight Daily (inpatient) Euvolemic Adjust fluids; diuretics if overload Cardiac monitoring Continuous if on neostigmine IV; during PLEX Normal rhythm Atropine for bradycardia; PLEX can cause electrolyte-mediated arrhythmias Mood and sleep assessment Daily during steroids No psychosis, mania, severe insomnia Psychiatry consult; consider dose adjustment Aspiration precautions Throughout admission if bulbar symptoms No aspiration events HOB elevated; thickened liquids; SLP-guided diet"},{"location":"plans/myasthenia-gravis-new-diagnosis/#6b-chronicoutpatient-monitoring","title":"6B. Chronic/Outpatient Monitoring","text":"Parameter Frequency Target/Threshold Action if Abnormal MG-ADL score Each clinic visit Minimal symptom score (goal &lt;6) Escalate therapy if increasing; assess adherence QMG score (Quantitative MG Score) Each clinic visit or q3 months Improvement \u22653.5 points = clinically meaningful Treatment escalation if not meeting goals FVC (office spirometry) Each visit initially; q3-6 months when stable &gt;80% predicted Pulmonology referral if declining; assess respiratory muscle involvement CBC with differential Q2-4 weeks during AZA/MMF titration; then q3 months WBC &gt;3000; ANC &gt;1500; lymphocytes 600-1000 (on AZA) Hold/reduce immunosuppressant if cytopenic; G-CSF if severe neutropenia LFTs Q2-4 weeks during AZA/MMF/MTX titration; then q3 months AST/ALT &lt;3\u00d7 ULN Reduce or hold offending agent; hepatology referral if persistent Renal function (BUN/Cr) Q3 months on tacrolimus/cyclosporine; q6 months otherwise Normal eGFR Dose adjustment; avoid nephrotoxins Fasting glucose / HbA1c Q3 months while on steroids HbA1c &lt;7% Endocrinology referral; steroid dose reduction; oral hypoglycemic or insulin DEXA scan (bone density) Baseline if starting chronic steroids; repeat q2 years T-score &gt; -1.0 Bisphosphonate; calcium/vitamin D; endocrinology referral Ophthalmologic exam Annually if on chronic steroids; q6 months first year on steroids No cataracts or glaucoma Ophthalmology referral for cataracts (steroid-induced); IOP monitoring CD19/CD20 B-cell counts (if on rituximab) Q3-6 months Depleted B-cells (therapeutic); monitor for recovery Redose rituximab when B-cells recover and symptoms worsen Immunoglobulin levels (IgG, IgA, IgM) Q6 months if on rituximab/chronic immunosuppression IgG &gt;400 mg/dL IVIG replacement if symptomatic hypogammaglobulinemia with recurrent infections IgG level (if on FcRn inhibitor) Before each treatment cycle ~70% reduction expected during treatment Guide retreatment timing; monitor for infection Tacrolimus/cyclosporine trough level Q1-2 weeks during titration; then q1-3 months Tacrolimus 5-10 ng/mL; cyclosporine 100-150 ng/mL Dose adjustment based on level and clinical response CT chest (thymoma surveillance) Annually \u00d7 5 years after thymectomy for thymoma; if not resected: q6-12 months No recurrence or growth Thoracic surgery referral for recurrence; consider radiation/chemotherapy LDH, reticulocyte count, haptoglobin (if on complement inhibitor) Q2-4 weeks initially; then q3 months No hemolysis If discontinuing complement inhibitor: monitor closely for rebound hemolysis Meningococcal infection surveillance (if on complement inhibitor) Each visit; patient education No signs of meningococcal disease Emergency evaluation for fever, headache, neck stiffness, rash; ensure vaccination current; ciprofloxacin prophylaxis Vitamin D level Annually &gt;30 ng/mL Supplement 2000-5000 IU daily Thyroid function (TSH) Annually (autoimmune overlap) Normal Endocrinology referral if abnormal"},{"location":"plans/myasthenia-gravis-new-diagnosis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Mild symptoms (ocular only or mild generalized); FVC &gt;60% predicted and stable; adequate oral intake; pyridostigmine optimized; reliable follow-up within 1-2 weeks; understands return precautions; crisis action plan reviewed Admit to floor (general neurology) Moderate generalized weakness; FVC 40-60% predicted and stable; dysphagia requiring diet modification but tolerating PO; new diagnosis requiring expedited workup; steroid initiation with concern for transient worsening; IVIG infusion Admit to step-down/telemetry FVC 30-40% predicted or declining trend; moderate bulbar symptoms; starting PLEX; significant comorbidities requiring closer monitoring; recent cholinergic vs myasthenic crisis distinction unclear Admit to ICU FVC &lt;30% predicted or &lt;1 L; NIF weaker than -25 cm H2O; progressive respiratory failure; impending intubation; active myasthenic crisis; severe bulbar dysfunction with aspiration; hemodynamic instability during PLEX Transfer to higher level PLEX needed but unavailable; neuromuscular specialist not available; ICU capability needed but not present; thymectomy needed at specialized center Discharge from hospital FVC &gt;50% predicted and improving; adequate oral intake; stable on oral medications; immunotherapy plan established; outpatient follow-up scheduled within 1-2 weeks; patient and family educated on crisis recognition"},{"location":"plans/myasthenia-gravis-new-diagnosis/#mgfa-clinical-classification","title":"MGFA Clinical Classification","text":"Class Description Class I Any ocular muscle weakness; may have weakness of eye closure; all other muscle strength is normal Class II Mild weakness affecting muscles other than ocular; may also have ocular weakness of any severity Class IIa Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles Class IIb Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both Class III Moderate weakness affecting muscles other than ocular; may also have ocular weakness of any severity Class IIIa Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles Class IIIb Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both Class IV Severe weakness affecting muscles other than ocular; may also have ocular weakness of any severity Class IVa Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles Class IVb Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both Class V Defined by intubation, with or without mechanical ventilation, except when employed during routine postoperative management (intubation for management of airway = Class V)"},{"location":"plans/myasthenia-gravis-new-diagnosis/#mg-adl-activities-of-daily-living-score","title":"MG-ADL (Activities of Daily Living) Score","text":"Domain 0 1 2 3 Talking Normal Intermittent slurring or nasal speech Constant slurring or nasal but can be understood Difficult to understand speech Chewing Normal Fatigue with solid food Fatigue with soft food Gastric tube Swallowing Normal Rare episode of choking Frequent choking necessitating diet changes Gastric tube Breathing Normal Shortness of breath with exertion Shortness of breath at rest Ventilator dependent Ability to brush teeth or comb hair Normal Extra effort but no rest needed Rest periods needed Cannot do one of these functions Ability to arise from chair Normal Mild, sometimes uses arms Moderate, sometimes fails on first attempt Severe, requires assistance Double vision None Occurs but not daily Daily but not constant Constant Eyelid droop None Occurs but not daily Daily but not constant Constant <p>Total MG-ADL Score: 0-24. Score \u22656 generally indicates suboptimal control. Improvement \u22652 points = clinically meaningful. Validated for treatment response monitoring.</p>"},{"location":"plans/myasthenia-gravis-new-diagnosis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source AChR antibody testing for MG diagnosis Class I Gilhus NE et al. Lancet Neurol 2019 AChR binding + blocking + modulating antibodies increases sensitivity to ~95% Class II Howard JF. Clinical Overview of MG. UpToDate 2024 MuSK antibody testing in seronegative MG Class I Hoch W et al. Nat Med 2001; Evoli A et al. Brain 2003 LRP4 antibody in double-seronegative MG Class II Higuchi O et al. Ann Neurol 2011; Zisimopoulou P et al. J Neuroimmunol 2014 RNS: \u226510% decrement diagnostic criterion Class I, Level A AANEM Practice Parameter 2001; Sanders DB et al. SFEMG most sensitive diagnostic test (95-99%) Class I, Level A Sanders DB, St\u00e5lberg EV. Muscle Nerve 1996 Ice pack test for ocular MG (~80% sensitivity) Class II, Level B Cubero E et al. Neurology 2000 CT chest for thymoma screening in all MG patients Class I, Level A Gilhus NE et al. Lancet Neurol 2019; AAN Guidelines Pyridostigmine as first-line symptomatic therapy Class I, Level A Mehndiratta MM et al. Cochrane 2011 MuSK-MG often refractory to pyridostigmine Class II Evoli A et al. Brain 2003; Guptill JT et al. 2011 Prednisone for MG immunosuppression Class I, Level A Palace J et al. Cochrane 2012 Steroid-induced transient worsening in ~50% of MG patients Class II Bae JS et al. Muscle Nerve 2006 Mycophenolate mofetil as steroid-sparing agent Class I (negative RCTs but widely used) Sanders DB et al. Neurology 2008; MG Study Group (note: RCTs were short-duration) Azathioprine as steroid-sparing agent Class I, Level B Palace J et al. Cochrane 2012 TPMT testing before azathioprine Class I, Level A Pharmacogenomics guidelines; FDA labeling Rituximab for MuSK-positive MG Class II (observational) D\u00edaz-Manera J et al. Neurology 2012; Hehir MK et al. Neurology 2017 Rituximab for AChR-positive refractory MG Class II Tandan R et al. (BeatMG trial) Lancet Neurol 2023 Eculizumab for AChR-positive generalized MG Class I (REGAIN trial) Howard JF et al. Lancet Neurol 2017 Ravulizumab for AChR-positive generalized MG Class I (CHAMPION-MG) Vu T et al. NEJM 2022 Zilucoplan for AChR-positive generalized MG Class I (RAISE trial) Howard JF et al. Lancet Neurol 2023 Efgartigimod for AChR-positive generalized MG Class I (ADAPT trial) Howard JF et al. Lancet Neurol 2021 Rozanolixizumab for AChR-positive generalized MG Class I (MycarinG trial) Bril V et al. Lancet Neurol 2023 IVIG for MG acute exacerbation and maintenance Class I, Level A Gajdos P et al. Cochrane 2012 PLEX for myasthenic crisis Class I, Level A Gajdos P et al. Cochrane 2012 IVIG equivalent to PLEX for MG exacerbation Class I Barth D et al. Cochrane 2011 Thymectomy for non-thymomatous AChR-positive MG Class I (MGTX trial) Wolfe GI et al. NEJM 2016 MGTX trial: thymectomy + prednisone superior at 3 years Class I Wolfe GI et al. NEJM 2016; 5-year extension data 2019 Medications to avoid in MG (comprehensive review) Class II-III Gilhus NE. NEJM 2016; Sheikh S et al. Muscle Nerve 2021 FVC &lt;15 mL/kg predicts need for intubation Class II, Level B Thomas CE et al. Neurology 1997 NIF weaker than -20 cm H2O: intubation threshold Class II, Level B Thomas CE et al. Neurology 1997 MG-ADL as validated outcome measure Class I Wolfe GI et al. Neurology 1999 QMG score as validated outcome measure Class I Barohn RJ et al. Ann NY Acad Sci 1998 MGFA Clinical Classification system Consensus Jaretzki A et al. Neurology 2000 Meningococcal vaccination before complement inhibitors FDA requirement FDA REMS for eculizumab/ravulizumab/zilucoplan Pregnancy management in MG Class II-III Norwood F et al. J Neurol Neurosurg Psychiatry 2014; Batocchi AP et al. Neurology 1999 Transient neonatal MG in 10-20% of births Class II Hoff JM et al. Eur J Neurol 2003"},{"location":"plans/myasthenia-gravis-new-diagnosis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial creation - Section 1: 46 laboratory tests across 3 tiers (17 core, 18 extended, 11 rare/specialized)   - AChR binding/blocking/modulating antibodies as core   - MuSK, LRP4, anti-striated muscle, anti-titin, anti-RyR as extended   - VGCC, paraneoplastic panel, CMS genetics as rare - Section 2: Imaging and studies across 3 tiers plus bedside tests   - CT/MRI chest for thymoma screening   - RNS and SFEMG as electrodiagnostic studies   - Ice pack test, rest test, bedside fatigability tests   - FVC and NIF monitoring protocols - Section 3: Treatment across 5 subsections   - 3A: Cholinesterase inhibitors (7 items including pyridostigmine IR/SR/liquid, neostigmine IV)   - 3B: Corticosteroids (9 items including gradual/rapid escalation, pulse therapy, bone/GI protection, PCP prophylaxis)   - 3C: Steroid-sparing agents (7 items: mycophenolate, azathioprine, tacrolimus, cyclosporine, methotrexate, cyclophosphamide, maintenance IVIG)   - 3D: Biologics and rescue (10 items: rituximab, eculizumab, ravulizumab, zilucoplan, efgartigimod IV/SC, rozanolixizumab, PLEX, IVIG rescue)   - 3E: Surgical treatment (3 items: VATS/robotic thymectomy, sternotomy, extended thymectomy) - Section 4: Recommendations across 5 subsections   - 4A: 18 referrals including MG Foundation/patient advocacy   - 4B: 18 patient instructions   - 4C: 28 medications to avoid organized by drug class   - 4D: 10 vaccination items including meningococcal requirements   - 4E: 15 pregnancy considerations - Section 5: 14 differential diagnoses - Section 6: Monitoring parameters   - 6A: 14 acute monitoring parameters with FVC/NIF thresholds   - 6B: 18 chronic monitoring parameters - Section 7: Disposition criteria (6 levels), MGFA Classification (11 classes/subclasses), MG-ADL score (8 domains) - Section 8: 37 evidence citations</p>"},{"location":"plans/neuromuscular-respiratory-failure/","title":"Neuromuscular Respiratory Failure","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Neuromuscular Respiratory Failure</p> <p>ICD-10: G70.00 (Myasthenia gravis without exacerbation), G70.01 (Myasthenia gravis with exacerbation), G61.0 (Guillain-Barr\u00e9 syndrome), J96.00 (Acute respiratory failure, unspecified hypoxia/hypercapnia), G71.0 (Muscular dystrophy), G12.21 (Amyotrophic lateral sclerosis)</p> <p>SYNONYMS: Neuromuscular respiratory failure, NMRF, respiratory failure from weakness, GBS respiratory failure, myasthenic respiratory failure, NIF less than 20, FVC less than 20, impending respiratory failure, neuromuscular ventilatory failure</p> <p>SCOPE: Emergency evaluation and management of respiratory failure from neuromuscular disorders in adults. Covers recognition of impending respiratory failure, monitoring parameters (FVC, NIF), indications for intubation, non-invasive ventilation (NIV) considerations, disease-specific treatments (myasthenia gravis crisis, GBS, ALS, muscular dystrophy, other myopathies), and weaning considerations. Excludes central causes of respiratory failure (brainstem stroke, sedative overdose) and primary pulmonary causes (pneumonia, ARDS, COPD exacerbation).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/neuromuscular-respiratory-failure/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/neuromuscular-respiratory-failure/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Arterial blood gas (ABG) STAT STAT - STAT CRITICAL: Assess ventilation (PaCO2) and oxygenation (PaO2); hypercapnia (PaCO2 &gt;45) indicates hypoventilation; respiratory acidosis = severe; PaO2/FiO2 ratio Normal: pH 7.35-7.45, PaCO2 35-45, PaO2 &gt;80; Hypercapnia with respiratory acidosis = impending/current respiratory failure \u2014 consider intubation CBC with differential STAT STAT ROUTINE STAT Infection (pneumonia as trigger or complication); baseline; anemia (reduces O2 carrying capacity) Normal; leukocytosis \u2192 infection; anemia \u2192 correct CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolytes (K, Mg, Ca, Phos \u2014 all affect muscle function); renal function; glucose Normal; hypokalemia, hypophosphatemia, hypomagnesemia, hypocalcemia can all worsen neuromuscular weakness Magnesium STAT STAT ROUTINE STAT Hypomagnesemia worsens neuromuscular junction transmission and muscle weakness &gt;2.0 mg/dL; replete if low Phosphorus STAT STAT ROUTINE STAT Hypophosphatemia causes profound muscle weakness including respiratory muscles &gt;2.5 mg/dL; replete if low (can cause respiratory failure at &lt;1.0) Calcium (ionized) STAT STAT ROUTINE STAT Hypocalcemia increases neuromuscular excitability; hypercalcemia causes weakness Normal ionized Ca Acetylcholine receptor (AChR) antibodies - URGENT ROUTINE URGENT MG workup: positive in 85% of generalized MG; 50% of ocular MG; confirms diagnosis Positive = MG; negative does NOT exclude (check MuSK, LRP4) Anti-MuSK antibodies - URGENT ROUTINE URGENT If AChR negative but MG suspected clinically; MuSK-positive MG has distinct features (bulbar predominant, may not respond well to cholinesterase inhibitors) Positive = MuSK MG Anti-LRP4 antibodies - ROUTINE ROUTINE - If both AChR and MuSK negative (\"seronegative MG\"); less commonly available Positive = LRP4 MG (rare) Creatine kinase (CK) STAT STAT ROUTINE STAT Elevated in myopathies, muscular dystrophies; may be normal in MG, GBS, ALS Normal in MG, GBS; elevated in myopathies, rhabdomyolysis; very high (&gt;10,000) in inflammatory myopathies, dystrophies TSH - ROUTINE ROUTINE - Thyroid dysfunction: hyperthyroidism worsens MG; hypothyroidism causes myopathy Normal Procalcitonin / CRP STAT STAT - STAT Infection as trigger (pneumonia, UTI can precipitate MG crisis); distinguish infection from disease exacerbation Normal; elevated \u2192 infection workup Urine drug screen STAT - - STAT Drugs affecting neuromuscular function; intoxication as mimicker Negative"},{"location":"plans/neuromuscular-respiratory-failure/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Pyridostigmine level (if available) - ROUTINE - ROUTINE Rarely available; assess for cholinergic crisis (too much pyridostigmine vs. myasthenic crisis) Therapeutic range varies; clinical assessment more reliable Anti-ganglioside antibodies (GM1, GD1a, GD1b, GQ1b) - URGENT ROUTINE URGENT GBS workup; GQ1b positive in Miller Fisher syndrome Positive supports GBS diagnosis; negative does NOT exclude CSF analysis - URGENT ROUTINE - GBS: albuminocytologic dissociation (elevated protein, normal cells \u2014 may not be present in first week); exclude infection GBS: protein elevated (&gt;45 mg/dL), WBC &lt;10 (usually &lt;5); may be normal early Repetitive nerve stimulation (RNS) - URGENT ROUTINE - MG diagnosis: decremental response at 3 Hz stimulation (&gt;10% decrement) in proximal muscles &gt;10% decrement = neuromuscular junction defect (MG); no decrement does NOT exclude MG Single-fiber EMG (SFEMG) - - ROUTINE - Most sensitive test for MG (92-98%); increased jitter and blocking Increased jitter = neuromuscular transmission defect Nerve conduction studies / EMG - URGENT ROUTINE URGENT GBS: demyelinating pattern (prolonged F-waves, conduction block, temporal dispersion) or axonal (reduced amplitudes); ALS: widespread denervation; myopathy: myopathic units GBS: demyelinating or axonal; ALS: diffuse denervation; myopathy: small, polyphasic MUPs CT chest (with contrast) - URGENT ROUTINE - Thymoma screening in MG: 10-15% of MG patients have thymoma; all MG patients need chest imaging Thymoma (anterior mediastinal mass); thymic hyperplasia; normal thymus Anti-striational (anti-titin, anti-RyR) antibodies - ROUTINE ROUTINE - Associated with thymoma in MG; may indicate need for more aggressive thymoma search Positive in older MG patients and thymoma-associated MG Paraneoplastic antibody panel - ROUTINE ROUTINE - Paraneoplastic neuromuscular syndromes (LEMS with anti-VGCC and small cell lung cancer); myositis with malignancy Anti-VGCC (LEMS); anti-Hu, anti-CV2 (paraneoplastic) Anti-VGCC antibodies - URGENT ROUTINE - Lambert-Eaton myasthenic syndrome (LEMS); associated with SCLC in 50-60% Positive = LEMS (check for underlying malignancy)"},{"location":"plans/neuromuscular-respiratory-failure/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Muscle biopsy - - EXT - Inflammatory myopathy (dermatomyositis, polymyositis); muscular dystrophy; congenital myopathy Inflammatory infiltrate; dystrophic changes; structural abnormalities Genetic testing (muscular dystrophy panel) - - EXT - Suspected hereditary myopathy/dystrophy; known family history; young patient with progressive weakness Specific mutations (dystrophin, FSHD, myotonic dystrophy, etc.) Myositis-specific antibodies (Jo-1, Mi-2, SRP, MDA5, etc.) - ROUTINE ROUTINE - Inflammatory myopathy workup Specific antibodies guide diagnosis and prognosis Edrophonium (Tensilon) test - EXT EXT - Rarely done now (replaced by serologic testing and SFEMG); bedside MG test; risk of cholinergic crisis; atropine must be at bedside Transient improvement = positive (MG); false positives/negatives occur Ice pack test - URGENT ROUTINE URGENT Bedside test for ocular MG; apply ice pack to closed eyelid for 2 min; improvement in ptosis suggests MG Improvement = positive; negative does NOT exclude Spirometry with flow-volume loop - URGENT ROUTINE URGENT Upper airway obstruction pattern (variable extrathoracic obstruction in vocal cord weakness); restrictive pattern in neuromuscular disease Restrictive pattern; flattened inspiratory loop suggests extrathoracic obstruction Polysomnography - - ROUTINE - Sleep-disordered breathing in neuromuscular disease; nocturnal hypoventilation; assess need for nocturnal NIV Hypoventilation; desaturations; REM-related hypopneas Pulmonary function tests (full) - - ROUTINE - Baseline and monitoring in chronic neuromuscular disease; FVC, MIP, MEP, SNIP FVC; supine vs. upright FVC (&gt;20% drop suggests diaphragm weakness)"},{"location":"plans/neuromuscular-respiratory-failure/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/neuromuscular-respiratory-failure/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Chest X-ray STAT STAT - STAT Immediate; assess for aspiration, pneumonia (trigger for crisis), atelectasis, elevated hemidiaphragm Aspiration pneumonia; atelectasis (from weak cough); elevated hemidiaphragm (diaphragm weakness); anterior mediastinal mass (thymoma) None Bedside spirometry (FVC) STAT STAT ROUTINE STAT CRITICAL: q4-6h in unstable patients; q1-2h if rapidly declining; most important monitoring parameter FVC &gt;20 mL/kg = adequate; FVC &lt;15-20 mL/kg = consider intubation; FVC declining &gt;30% from baseline = concerning Patient cooperation required; cannot perform if intubated (use ventilator parameters) Negative inspiratory force (NIF/MIP) STAT STAT ROUTINE STAT CRITICAL: Assess inspiratory muscle strength; complement to FVC; easier for fatigued patients NIF &lt; -30 cm H2O = adequate; NIF &gt; -20 to -25 cm H2O (less negative) = weak, consider intubation Patient cooperation Maximum expiratory pressure (MEP) - URGENT ROUTINE STAT Assess cough strength; correlates with ability to clear secretions MEP &lt;40 cm H2O = weak cough; aspiration risk ABG (arterial blood gas) STAT STAT - STAT Assess ventilation and oxygenation; hypercapnia is late sign PaCO2 &gt;45 = hypoventilation; rising PaCO2 is ominous; PaO2 &lt;60 = hypoxemia ECG (12-lead) STAT STAT - STAT Arrhythmia from autonomic dysfunction (GBS); cardiac involvement in muscular dystrophies; baseline for IVIG/PLEX Arrhythmia; conduction abnormalities; cardiomyopathy (DMD, LGMD)"},{"location":"plans/neuromuscular-respiratory-failure/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT chest with contrast - URGENT ROUTINE - Within 24-48h for MG; thymoma screening; all newly diagnosed generalized MG Thymoma (anterior mediastinal mass); thymic hyperplasia Contrast allergy; renal impairment MRI chest (non-contrast) - - ROUTINE - If CT contraindicated or additional characterization needed Thymoma; thymic abnormality MRI-incompatible implants Echocardiogram - URGENT ROUTINE URGENT Cardiomyopathy screening in muscular dystrophies (DMD, BMD, LGMD2I, myotonic dystrophy); autonomic dysfunction in GBS; baseline before IVIG Cardiomyopathy; reduced EF; conduction abnormalities (perform ECG first) None Diaphragm ultrasound - URGENT ROUTINE URGENT Assess diaphragm excursion and thickness; non-invasive diaphragm function assessment; bedside Reduced diaphragm excursion (&lt;1.5 cm during tidal breathing, &lt;4 cm during deep breath); paradoxical motion = diaphragm paralysis Operator-dependent; obesity may limit views CT angiography (pulmonary) - URGENT - URGENT If pulmonary embolism suspected (immobile patients at high VTE risk) PE Contrast allergy; renal impairment PET/CT - - ROUTINE - If LEMS diagnosed to search for underlying malignancy (SCLC in 50-60%) Lung mass; lymphadenopathy; occult malignancy Uncontrolled diabetes"},{"location":"plans/neuromuscular-respiratory-failure/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Phrenic nerve conduction study - - ROUTINE - Assess phrenic nerve function; bilateral phrenic neuropathy as cause of respiratory failure Absent or reduced phrenic CMAP = phrenic neuropathy; prolonged latency Pacemaker (relative) Fluoroscopic sniff test - - ROUTINE - Diaphragm function; \"sniff test\" \u2014 paradoxical upward diaphragm motion with sniff = paralysis Paradoxical motion = diaphragm paralysis Radiation exposure; pregnancy Transdiaphragmatic pressure (Pdi) - - EXT - Gold standard for diaphragm strength; requires esophageal and gastric balloon catheters; specialized centers Reduced Pdi = diaphragm weakness Invasive; specialized equipment Polysomnography with capnography - - ROUTINE - Nocturnal hypoventilation assessment; sleep-disordered breathing; guide NIV Nocturnal hypoventilation (elevated PtcCO2); desaturations; REM-related events Sleep lab availability"},{"location":"plans/neuromuscular-respiratory-failure/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP with CSF analysis - URGENT ROUTINE - GBS diagnosis (albuminocytologic dissociation); may be normal in first week; NOT typically needed for MG diagnosis GBS: elevated protein (often &gt;100 mg/dL after first week), normal WBC (&lt;10, usually &lt;5); cytoalbuminous dissociation Coagulopathy; skin infection at LP site; elevated ICP"},{"location":"plans/neuromuscular-respiratory-failure/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/neuromuscular-respiratory-failure/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Airway assessment and monitoring STAT STAT - STAT \"20/30/40 Rule\": FVC &lt;20 mL/kg, NIF &gt; -30 cm H2O (less negative), MEP &lt;40 cm H2O = HIGH RISK for respiratory failure; monitor q2-4h (or more frequently if declining); INTUBATION THRESHOLD: FVC &lt;15-20 mL/kg, NIF &gt; -20 to -25 cm H2O, rising PaCO2, or clinical distress NMD respiratory failure is often predictable by serial FVC/NIF; intubate BEFORE crisis (controlled intubation is safer); ABG abnormalities are LATE signs Elective intubation (if criteria met) STAT STAT - STAT Indications: FVC &lt;15-20 mL/kg (or &lt;1 L); NIF &gt; -20 to -25 cm H2O; PaCO2 rising or &gt;50; clinical respiratory distress; inability to clear secretions; aspiration; fatigue; RSI considerations: AVOID succinylcholine in myopathies/muscular dystrophy (hyperkalemia), MG (resistance); use rocuronium (may need reduced dose in MG); can use sugammadex for reversal Elective intubation is safer than emergent; neuromuscular patients are difficult to bag-mask ventilate; have difficult airway equipment ready; avoid neuromuscular blockers post-intubation if possible Non-invasive ventilation (NIV) STAT STAT ROUTINE STAT ROLE IS LIMITED IN ACUTE NMD RESPIRATORY FAILURE; may be considered as bridge in: stable patients with nocturnal hypoventilation, mild hypercapnia without distress, secretion clearance ability preserved, no aspiration risk, patient can protect airway; AVOID NIV if: Bulbar dysfunction (aspiration risk), unable to clear secretions, severe hypercapnia (PaCO2 &gt;60), acidosis, rapid decline, altered mental status NIV (BiPAP) has lower threshold for failure in neuromuscular disease than COPD/CHF; bulbar weakness increases aspiration risk; low threshold for intubation; useful for chronic nocturnal hypoventilation Supplemental oxygen STAT STAT - STAT Use CAUTIOUSLY: Oxygen can mask hypoventilation (hypercapnia develops before desaturation); may eliminate hypoxic drive (though less relevant in NMD than COPD); titrate to SpO2 92-96%; If hypoxemic + hypercapnic: This indicates severe failure \u2014 intubate, do NOT rely on oxygen alone Hypoxemia is a late finding in pure neuromuscular hypoventilation; if hypoxemic, consider aspiration, atelectasis, or imminent failure Secretion management STAT STAT - STAT Weak cough = poor secretion clearance; Techniques: Assisted cough (abdominal thrust during cough); mechanical insufflation-exsufflation (CoughAssist) \u2014 pressures +40/-40 cm H2O; aggressive pulmonary toilet; chest physiotherapy; suction PRN; If unable to clear secretions: Intubate Aspiration pneumonia is leading cause of death in chronic NMD; weak cough (MEP &lt;40) = high risk; mechanical cough assist is underutilized and highly effective Stop/avoid precipitating medications STAT STAT ROUTINE STAT MG crisis precipitants (AVOID): Aminoglycosides (gentamicin, tobramycin), fluoroquinolones (ciprofloxacin, levofloxacin \u2014 less risky but still caution), macrolides (azithromycin, erythromycin), beta-blockers, magnesium (IV), neuromuscular blockers, D-penicillamine, interferon-alpha, checkpoint inhibitors (nivolumab, pembrolizumab); Full list in Appendix Many medications can worsen neuromuscular transmission; careful medication review essential; see comprehensive list in appendix DVT prophylaxis STAT STAT - STAT SCDs immediately; pharmacologic prophylaxis (enoxaparin 40 mg SQ daily) once stable; immobile patients at very high VTE risk High VTE risk in paralyzed/weak patients; balance with IVIG timing (hold anticoagulation during IVIG infusion in some protocols) Aspiration precautions STAT STAT ROUTINE STAT HOB elevated 30-45\u00b0; NPO if significant bulbar weakness; speech-language pathology evaluation; modified diet or enteral feeding if prolonged weakness Aspiration pneumonia is major complication; bulbar weakness (dysphagia, weak cough, voice changes) = high risk"},{"location":"plans/neuromuscular-respiratory-failure/#3b-disease-specific-treatment","title":"3B. Disease-Specific Treatment","text":""},{"location":"plans/neuromuscular-respiratory-failure/#myasthenia-gravis-crisis","title":"MYASTHENIA GRAVIS CRISIS","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale IVIG (Intravenous Immunoglobulin) - STAT - STAT First-line for MG crisis (with PLEX): 2 g/kg total divided over 2-5 days (400 mg/kg/day x 5 days OR 1 g/kg/day x 2 days); Onset: 2-5 days; Duration: 3-6 weeks; Pre-treatment: Check IgA (IgA deficiency = anaphylaxis risk); renal function; volume status Efficacy equivalent to PLEX (RCTs); easier logistics than PLEX; side effects: headache (aseptic meningitis), renal failure (sucrose-containing products), thrombosis, hemolysis; slower onset than PLEX Plasma exchange (PLEX) - STAT - STAT First-line for MG crisis (with IVIG): 5-7 exchanges over 10-14 days (1-1.5 plasma volumes per exchange; typically 3-4 L); Onset: Faster than IVIG (improvement may begin after 2-3 exchanges); requires large-bore central venous access; Caution: Hypotension, citrate toxicity (hypocalcemia), infection May work faster than IVIG; useful if rapid response needed; RCT showed PLEX and IVIG equivalent in MG exacerbation; PLEX preferred if IVIG contraindicated (IgA deficiency, renal failure) HOLD pyridostigmine (cholinesterase inhibitors) STAT STAT - STAT In intubated MG crisis patients: STOP pyridostigmine while intubated; excessive secretions worsen pulmonary toilet; cannot distinguish myasthenic from cholinergic crisis if on pyridostigmine; Resume cautiously when extubation nearing Pyridostigmine increases secretions; in intubated patient, secretions worsen; hold until preparing for extubation; some restart at lower dose (30 mg q6h) and titrate Corticosteroids (delayed initiation) - URGENT ROUTINE URGENT CAUTION: Steroids can cause TRANSIENT WORSENING in MG (up to 50% of patients); In crisis: Start AFTER IVIG/PLEX initiated and patient stabilizing (days 3-5 or later); do NOT start steroids as initial therapy in crisis; Protocol: Prednisone 10-20 mg daily, increase by 10 mg every 3-5 days to 1 mg/kg/day (max 60-80 mg); OR IV methylprednisolone 1g daily x 3-5 days then oral Steroids are maintenance therapy but can worsen MG acutely (\"steroid dip\"); always start with IVIG or PLEX first in crisis; steroid-sparing agents (azathioprine, mycophenolate) for long-term Treat precipitant STAT STAT - STAT Infection: Most common trigger; treat aggressively but AVOID contraindicated antibiotics (see list); Medication-induced: Stop offending drug; Surgery/anesthesia: Stress can trigger crisis; Tapering immunosuppression: Restart or increase 30-40% of MG crises have identifiable trigger; treating trigger may hasten recovery"},{"location":"plans/neuromuscular-respiratory-failure/#guillain-barre-syndrome-gbs","title":"GUILLAIN-BARR\u00c9 SYNDROME (GBS)","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale IVIG - STAT - STAT First-line for GBS: 2 g/kg total over 5 days (400 mg/kg/day x 5 days); start within 2-4 weeks of symptom onset for best efficacy; Efficacy: Equivalent to PLEX; faster recovery; fewer complications; Onset: Days to 1-2 weeks RCTs show IVIG = PLEX; IVIG preferred due to availability and easier administration; start as soon as diagnosis confirmed (or highly likely); do NOT delay for CSF/EMG confirmation Plasma exchange (PLEX) - STAT - STAT Alternative to IVIG: 5 exchanges over 1-2 weeks (200-250 mL/kg total); start within 2-4 weeks of onset; Consider PLEX if: IVIG contraindicated; IVIG failure; severe/refractory PLEX and IVIG equivalent; do NOT combine (no added benefit, more complications); PLEX if renal failure (IVIG risk) Corticosteroids \u2014 NOT effective in GBS - - - - Do NOT use steroids for GBS; no benefit; may cause harm Multiple RCTs: steroids do NOT improve GBS outcomes; may delay recovery Autonomic monitoring - STAT - STAT GBS has significant autonomic dysfunction (up to 70%): Cardiac monitoring (arrhythmias, heart block); BP monitoring (labile \u2014 hypertension and hypotension); ileus; urinary retention; treat arrhythmias; short-acting antihypertensives (avoid long-acting due to swings); pacing if bradycardia Autonomic death is second leading cause of GBS mortality after respiratory failure; close cardiac monitoring; avoid medications that worsen autonomic dysfunction Pain management - STAT ROUTINE STAT Pain in GBS is common (60-90%) and often severe; neuropathic pain; back pain; radicular pain; Treatment: Gabapentin 300 mg TID \u2192 titrate; pregabalin; opioids PRN; AVOID NSAIDs if renal concerns Pain can be as debilitating as weakness; multimodal approach; gabapentinoids first-line"},{"location":"plans/neuromuscular-respiratory-failure/#als-motor-neuron-disease","title":"ALS / MOTOR NEURON DISEASE","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Goals of care discussion - URGENT ROUTINE URGENT CRITICAL: ALS is progressive and fatal; respiratory failure is end-stage; discuss intubation, tracheostomy, long-term mechanical ventilation BEFORE crisis; many ALS patients choose comfort care / no intubation; Advance directive should be documented Intubation in ALS often leads to chronic ventilator dependence (cannot wean); tracheostomy and home ventilation is option for some but significantly impacts QoL; respect patient autonomy Non-invasive ventilation (NIV) - URGENT ROUTINE URGENT Standard of care for ALS respiratory insufficiency: Start NIV when FVC &lt;50% predicted or symptoms of nocturnal hypoventilation; prolongs survival (median 7-11 months) and improves QoL; Settings: BiPAP S/T mode; IPAP 10-20, EPAP 4-6; titrate to comfort; initially nocturnal \u2192 extended daytime use as disease progresses Cochrane review: NIV improves survival and QoL in ALS (especially with limb-onset); bulbar patients benefit less but still benefit; no evidence for invasive ventilation superiority over NIV with experienced teams Mechanical insufflation-exsufflation (CoughAssist) - URGENT ROUTINE URGENT All ALS patients with weak cough (PCF &lt;270 L/min or MEP &lt;60); reduces respiratory infections; can be used with NIV; Settings: +40/-40 cm H2O; 4-5 cycles; several times daily Improves secretion clearance; reduces pneumonia; can prolong NIV effectiveness; underutilized Riluzole - ROUTINE ROUTINE - 50 mg PO BID; modestly prolongs survival (~2-3 months); neuroprotective; continue unless intolerant Only FDA-approved disease-modifying drug for ALS with survival benefit (though modest); continue through respiratory failure unless goals of care dictate otherwise Edaravone (Radicava) - - ROUTINE - IV infusion or oral formulation; may slow functional decline; expensive; used in early ALS Recent approval; modest benefit in selected patients; often continued if started Symptomatic treatment - ROUTINE ROUTINE STAT Sialorrhea (glycopyrrolate, atropine drops, botulinum toxin to salivary glands); thick secretions (guaifenesin, N-acetylcysteine, hydration); pseudobulbar affect (dextromethorphan/quinidine); spasticity (baclofen, tizanidine); pain; depression Palliative symptom management is cornerstone of ALS care; multidisciplinary team essential Comfort-focused care / Palliative care - URGENT ROUTINE URGENT If patient declines intubation or chronic mechanical ventilation; opioids for dyspnea (morphine 2-5 mg IV/SQ q2-4h PRN \u2014 does NOT hasten death and relieves suffering); anxiolytics (lorazepam); comfort measures; hospice referral Dyspnea is the most distressing symptom at end of life; opioids are safe and effective; do not withhold for fear of \"hastening death\""},{"location":"plans/neuromuscular-respiratory-failure/#muscular-dystrophy-myopathy","title":"MUSCULAR DYSTROPHY / MYOPATHY","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Treat underlying cause (if treatable) - STAT ROUTINE STAT Inflammatory myopathy: Corticosteroids (prednisone 1 mg/kg/day) + steroid-sparing agent (methotrexate, azathioprine, IVIG for dermatomyositis); Hypothyroid myopathy: Thyroid replacement; Drug-induced myopathy (statins): Stop drug; Metabolic myopathy: Specific treatment (enzyme replacement for Pompe disease) Many myopathies are treatable; identify and treat cause; inflammatory myopathies are steroid-responsive Nocturnal NIV - URGENT ROUTINE URGENT Chronic respiratory insufficiency in muscular dystrophy (DMD, BMD, LGMD, myotonic dystrophy); start when FVC &lt;50%, symptoms, or nocturnal hypoventilation on PSG; prolongs survival in DMD NIV is standard of care for chronic respiratory failure in MD; delays tracheostomy; improves survival and QoL CoughAssist / Secretion management - URGENT ROUTINE URGENT Same as ALS; weak cough universal in advanced MD; prevents pneumonia Critical for preventing respiratory infections Cardiac monitoring (DMD, BMD, LGMD2I, myotonic DM) - STAT ROUTINE STAT Cardiomyopathy is common and can cause death; annual echocardiogram; ACE inhibitors / beta-blockers for cardiomyopathy; antiarrhythmics / pacemaker / ICD as indicated Cardiac disease is leading cause of death in some muscular dystrophies; proactive cardiac management essential Avoid succinylcholine STAT STAT - STAT Absolute contraindication in muscular dystrophy and most myopathies: Hyperkalemic cardiac arrest; use rocuronium (with sugammadex available for reversal) Succinylcholine causes massive K+ release from dystrophic muscle; fatal hyperkalemia"},{"location":"plans/neuromuscular-respiratory-failure/#3c-ventilator-management-and-weaning","title":"3C. Ventilator Management and Weaning","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Initial ventilator settings - STAT - STAT Mode: Volume-controlled (AC/VC) or Pressure-support (PS) during weaning; Tidal volume: 6-8 mL/kg IBW (lung-protective); Rate: 12-16 to achieve adequate minute ventilation; PEEP: 5 (higher if atelectasis or hypoxemia); FiO2: Titrate to SpO2 92-96%; I:E ratio: 1:2 or 1:3; avoid breath-stacking NMD patients generally have healthy lungs; lung-protective ventilation still applies; goal is to support ventilation while disease-specific treatment works Weaning from mechanical ventilation - ROUTINE - STAT NMD weaning is often prolonged: Disease-specific treatment must take effect (MG: IVIG/PLEX effect in 3-7 days; GBS: weeks); Weaning trial criteria: FVC &gt;15 mL/kg; NIF &lt; -25 cm H2O; adequate cough; secretions manageable; underlying disease improving; SBT (spontaneous breathing trial): T-piece or low PS (5-8 cm H2O) x 30-120 min; assess for fatigue, tachypnea, hypercapnia Premature extubation leads to re-intubation; NMD patients may need longer ventilation than other ICU patients; patience; daily SBT when criteria met Extubation criteria - - - STAT Pass SBT; FVC &gt;15-20 mL/kg AND improving trajectory; NIF &lt; -25 to -30 cm H2O; effective cough (able to clear secretions); alert and cooperative; bulbar function adequate (can swallow); no heavy sedation; consider cuff leak test Higher threshold for extubation in NMD than general ICU patients; failed extubation is dangerous Tracheostomy (if prolonged ventilation anticipated) - ROUTINE - ROUTINE Consider if: Unable to wean after 2-3 weeks of optimal disease-specific treatment; ALS with decision for long-term ventilation; severe GBS; Timing: No firm consensus; typically discuss at 10-14 days if no progress; earlier in conditions with known prolonged course Tracheostomy allows for weaning, reduces sedation needs, allows speech (with speaking valve), but has complications and care burden; goals of care discussion essential Post-extubation monitoring - - - STAT Close monitoring for 24-48h; serial FVC/NIF; watch for fatigue, stridor; have reintubation equipment ready; consider prophylactic NIV post-extubation in borderline cases Re-intubation rates higher in NMD; close monitoring; low threshold for NIV support post-extubation"},{"location":"plans/neuromuscular-respiratory-failure/#3d-medications-to-avoid-in-neuromuscular-disease","title":"3D. Medications to AVOID in Neuromuscular Disease","text":"Medication Class Examples Risk Safer Alternative Aminoglycosides Gentamicin, tobramycin, amikacin, streptomycin Neuromuscular blockade; worsen MG, GBS Beta-lactams, fluoroquinolones (with caution) Fluoroquinolones Ciprofloxacin, levofloxacin, moxifloxacin Associated with MG exacerbation; FDA warning Beta-lactams (cephalosporins, penicillins) Macrolides Azithromycin, erythromycin, clarithromycin May worsen MG Beta-lactams Beta-blockers Propranolol, metoprolol, etc. Worsen MG; use with caution Cardioselective (metoprolol) if essential Magnesium (IV high-dose) MgSO4 Blocks neuromuscular transmission Avoid unless life-threatening (e.g., eclampsia, torsades) Neuromuscular blockers Succinylcholine, rocuronium, vecuronium Succinylcholine: hyperkalemia in myopathies; all NMBs: prolonged weakness in MG Avoid if possible; if needed: rocuronium (reduced dose in MG) + sugammadex Calcium channel blockers Verapamil, diltiazem (less with dihydropyridines) May worsen neuromuscular transmission Dihydropyridines (amlodipine) if needed Botulinum toxin Botox, Dysport Can worsen MG Avoid in MG D-Penicillamine Cuprimine Can induce MG (autoimmune) Alternative for Wilson disease Checkpoint inhibitors Nivolumab, pembrolizumab, ipilimumab Can trigger or worsen MG, myositis, GBS-like syndromes Oncology risk-benefit discussion Statins Atorvastatin, simvastatin, etc. Can cause myopathy; worsen pre-existing myopathy Discontinue if causing myopathy Corticosteroids (acutely in MG) Prednisone, methylprednisolone Can cause transient worsening of MG (\"steroid dip\") Start AFTER IVIG/PLEX in MG crisis"},{"location":"plans/neuromuscular-respiratory-failure/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/neuromuscular-respiratory-failure/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurology consultation \u2014 EMERGENT STAT STAT ROUTINE STAT All patients with suspected neuromuscular respiratory failure; confirm diagnosis; guide disease-specific treatment (IVIG, PLEX, steroids) Pulmonology / Critical Care consultation STAT STAT - STAT Respiratory failure management; ventilator management; weaning protocols; NIV expertise Serial FVC and NIF monitoring STAT STAT - STAT Most important monitoring parameter; q4-6h initially; q1-2h if declining; trends are more important than absolute values; decline &gt;30% is concerning ICU admission - STAT - STAT All patients with impending or established respiratory failure; FVC &lt;25 mL/kg; declining trajectory; need for close monitoring Speech-language pathology - URGENT ROUTINE URGENT Dysphagia evaluation; aspiration risk assessment; safe diet recommendations; NPO if severe bulbar weakness Medication review STAT STAT ROUTINE STAT Review ALL medications for neuromuscular-impairing drugs; stop or substitute offending agents; see comprehensive list above Goals of care discussion - URGENT ROUTINE URGENT Especially important in ALS and progressive muscular dystrophies; discuss intubation, tracheostomy, long-term ventilation preferences EARLY DVT prophylaxis STAT STAT - STAT SCDs; pharmacologic prophylaxis (enoxaparin); immobile patients at very high risk"},{"location":"plans/neuromuscular-respiratory-failure/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Respiratory therapy - STAT ROUTINE STAT CoughAssist; chest physiotherapy; secretion management; NIV setup and titration Physical therapy - URGENT ROUTINE URGENT Early mobilization when stable; prevent contractures; maintain function; ROM exercises Occupational therapy - ROUTINE ROUTINE ROUTINE ADL assessment; adaptive equipment; hand function preservation Nutrition / Dietitian - ROUTINE ROUTINE ROUTINE Caloric needs (often increased in NMD); dysphagia diet; enteral feeding if prolonged weakness; avoid overfeeding (increases CO2 production) Social work - ROUTINE ROUTINE ROUTINE Family support; discharge planning; long-term care needs; financial resources Palliative care - ROUTINE ROUTINE ROUTINE Symptom management; goals of care facilitation; especially important in ALS and progressive disorders Cardiology - ROUTINE ROUTINE ROUTINE If cardiomyopathy (DMD, LGMD, myotonic dystrophy); autonomic dysfunction (GBS) Psychiatry / Psychology - ROUTINE ROUTINE - Depression, anxiety common; ICU delirium; adjustment to chronic illness; ALS psychological support"},{"location":"plans/neuromuscular-respiratory-failure/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Repeat IVIG or PLEX - URGENT ROUTINE URGENT If inadequate response to first course (MG, GBS); may need 2nd course of IVIG or PLEX; combination (IVIG + PLEX) not recommended (IVIG washed out by PLEX) Rituximab (MG) - - ROUTINE - Refractory MG; anti-CD20; especially useful in MuSK MG; onset weeks to months Eculizumab (MG) - - ROUTINE - Complement inhibitor; FDA-approved for refractory generalized AChR-positive MG; reduces exacerbations Thymectomy (MG) - - ROUTINE - Elective; for AChR-positive MG (benefit even without thymoma per MGTX trial); not in crisis; schedule when stable Tracheostomy and long-term ventilation - ROUTINE ROUTINE ROUTINE If unable to wean after 2-4 weeks; ALS patients who choose long-term ventilation; chronic NMD with respiratory failure Home mechanical ventilation - - ROUTINE - Transition from hospital/trach to home ventilation; requires extensive training; home nursing; sleep medicine / pulmonology follow-up Diaphragm pacing - - EXT - For high cervical spinal cord injury; some ALS patients; investigational in many settings <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/neuromuscular-respiratory-failure/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/neuromuscular-respiratory-failure/#causes-of-neuromuscular-respiratory-failure","title":"Causes of Neuromuscular Respiratory Failure","text":"Category Etiologies Key Distinguishing Features Neuromuscular junction Myasthenia gravis; Lambert-Eaton myasthenic syndrome (LEMS); botulism; organophosphate poisoning MG: fatigable weakness, ptosis, diplopia, AChR Ab; LEMS: proximal weakness, autonomic symptoms, improves with repetition, anti-VGCC; Botulism: descending paralysis, dilated pupils, recent exposure; OP poisoning: miosis, salivation, bradycardia, cholinergic crisis Peripheral nerve Guillain-Barr\u00e9 syndrome; critical illness polyneuropathy (CIP); phrenic nerve injury (cardiac surgery); Charcot-Marie-Tooth (rare) GBS: ascending weakness, areflexia, post-infectious, elevated CSF protein; CIP: ICU patient, sepsis, prolonged weakness; Phrenic injury: post-cardiac surgery, unilateral diaphragm paralysis Anterior horn cell ALS (amyotrophic lateral sclerosis); spinal muscular atrophy; poliomyelitis (rare) ALS: UMN + LMN signs, progressive, fasciculations, no sensory involvement; SMA: childhood onset, proximal weakness Muscle Muscular dystrophies (DMD, BMD, LGMD, myotonic, FSHD); inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis); critical illness myopathy; metabolic myopathies DMD: young males, elevated CK, cardiac involvement; Myotonic: myotonia, cataracts, cardiac; Inflammatory: elevated CK, rash (DM), proximal weakness; CIM: ICU patient, prolonged steroids/NMB, flaccid weakness Respiratory muscle specific Bilateral diaphragm paralysis; diaphragmatic fatigue; isolated phrenic neuropathy Orthopnea; paradoxical breathing; supine FVC drop &gt;20%; fluoroscopy: paradoxical motion"},{"location":"plans/neuromuscular-respiratory-failure/#myasthenic-crisis-vs-cholinergic-crisis","title":"Myasthenic Crisis vs. Cholinergic Crisis","text":"Feature Myasthenic Crisis Cholinergic Crisis Cause Worsening MG; undertreated; triggered by infection, medication, stress Excessive cholinesterase inhibitor (pyridostigmine overdose) Symptoms Weakness, respiratory failure, ptosis, diplopia, dysphagia Weakness PLUS: salivation, lacrimation, urination, defecation, GI upset, emesis (SLUDGE); miosis; bradycardia; fasciculations; bronchospasm Pupils Normal Miotic (constricted) Secretions May be increased (from weak swallow) Profusely increased Response to edrophonium Improves Worsens Treatment IVIG/PLEX; hold pyridostigmine; supportive Stop pyridostigmine; atropine for muscarinic symptoms; supportive Clinical clue Usually distinguishable clinically; cholinergic crisis is rare and usually obvious Excessive secretions + diarrhea + small pupils + bradycardia"},{"location":"plans/neuromuscular-respiratory-failure/#red-flags-for-imminent-respiratory-failure","title":"Red Flags for Imminent Respiratory Failure","text":"Red Flag Action FVC &lt;20 mL/kg or declining &gt;30% from baseline Prepare for intubation; ICU transfer; increase monitoring frequency NIF &gt; -30 cm H2O (less negative) Prepare for intubation Rising PaCO2 (especially with respiratory acidosis) Intubate \u2014 this is a LATE sign Use of accessory muscles; tripoding Impending failure Tachypnea &gt;30 with shallow breathing Compensating; fatigue imminent Paradoxical breathing (abdomen moves IN with inspiration) Diaphragm fatigue/paralysis; intubate Inability to count to 20 in one breath Simple bedside test; very weak if cannot count to 10 Weak cough; inability to clear secretions Aspiration risk; may need intubation for airway protection Orthopnea (cannot lie flat) Diaphragm weakness; FVC drops supine Altered mental status Hypercapnia; severe \u2014 intubate immediately"},{"location":"plans/neuromuscular-respiratory-failure/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/neuromuscular-respiratory-failure/#acute-phase-monitoring-icu","title":"Acute Phase Monitoring (ICU)","text":"Parameter Frequency Target Action if Abnormal FVC (forced vital capacity) q4-6h initially; q1-2h if declining &gt;20 mL/kg safe; &lt;15-20 mL/kg = intubation threshold Declining trend or &lt;15-20: prepare for intubation NIF (negative inspiratory force) q4-6h initially &lt; -30 cm H2O safe; &gt; -20 to -25 = intubation threshold Worsening (less negative): prepare for intubation ABG q6-8h or PRN; with any clinical change PaCO2 35-45; pH 7.35-7.45 Rising PaCO2 or acidosis: intubate SpO2 Continuous &gt;92% Desaturation: assess for aspiration, atelectasis, failure; supplement O2 cautiously Respiratory rate Continuous 12-20 Tachypnea &gt;30 with shallow breathing suggests fatigue Neurologic exam (strength, bulbar function) q4-8h Stable or improving Worsening weakness: reassess treatment; anticipate respiratory decline Autonomic function (GBS) Continuous (telemetry); q4h BP checks Stable HR 60-100; BP 90-140 systolic Arrhythmia: treat; wide BP swings: short-acting agents; bradycardia: atropine/pacing Secretion assessment q2-4h Manageable; patient can cough Excessive secretions + weak cough: aggressive pulmonary toilet; consider intubation"},{"location":"plans/neuromuscular-respiratory-failure/#weaning-phase-monitoring","title":"Weaning Phase Monitoring","text":"Parameter Frequency Target Action if Abnormal Daily SBT (spontaneous breathing trial) Daily when criteria met Pass SBT without distress Fail: resume full support; reassess next day FVC (pre-extubation) Daily; before extubation &gt;15-20 mL/kg AND improving Do not extubate if still declining NIF (pre-extubation) Daily &lt; -25 to -30 cm H2O Weak NIF: high re-intubation risk Cough strength / PCF Daily PCF &gt;160 L/min for successful extubation; MEP &gt;40 Weak cough: high aspiration risk; continue CoughAssist; delay extubation Bulbar function Daily Able to swallow saliva; protect airway Severe bulbar weakness: aspiration risk; consider tracheostomy"},{"location":"plans/neuromuscular-respiratory-failure/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/neuromuscular-respiratory-failure/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU FVC &lt;25 mL/kg or declining; NIF &gt; -40 cm H2O; any respiratory distress; autonomic instability (GBS); need for frequent monitoring (q1-4h); NIV initiation for acute failure; intubation anticipated or performed Step-down / Intermediate Stable but requires monitoring q4-6h; improving trajectory; stable on NIV; post-extubation observation General floor Stable respiratory function; FVC &gt;30 mL/kg and stable; for diagnostic workup of mild exacerbation; initiation of immunotherapy without respiratory compromise"},{"location":"plans/neuromuscular-respiratory-failure/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Respiratory stability FVC &gt;25-30 mL/kg and stable/improving; off supplemental O2 or at baseline; able to clear secretions Off mechanical ventilation (or stable on chronic NIV) Extubated and stable x 24-48h; or established on home NIV with stable settings Disease-specific treatment initiated and tolerated IVIG/PLEX completed; oral immunosuppression started (MG); able to continue treatment outpatient Adequate nutrition Tolerating oral diet or enteral feeding established; swallowing safe per SLP Functional mobility PT/OT clearance; able to perform ADLs or adequate support Follow-up arranged Neurology (1-2 weeks); pulmonology (if chronic respiratory issues); PCP; cardiology (if applicable) Education Disease education; medication instructions; when to return to ED (worsening weakness, dyspnea, dysphagia); MedicAlert bracelet for MG; medication list (avoid contraindicated drugs) Equipment CoughAssist, suction machine, NIV (if prescribed); home nursing if tracheostomy/ventilator"},{"location":"plans/neuromuscular-respiratory-failure/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/neuromuscular-respiratory-failure/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation Myasthenia Gravis Treatment Guidelines AAN / MGFA 2016/2021 IVIG and PLEX are equivalent for MG exacerbation; thymectomy benefits AChR+ MG; corticosteroid caution (steroid dip); rituximab and eculizumab for refractory Guillain-Barr\u00e9 Syndrome Guidelines AAN 2012 IVIG or PLEX within 4 weeks of onset; equivalent efficacy; do NOT combine; steroids NOT effective ALS Practice Parameters AAN 2009/Updates NIV prolongs survival; CoughAssist; multidisciplinary care; riluzole modestly prolongs survival Respiratory Management in NMD ATS 2004/Updates NIV for chronic respiratory failure; FVC &lt;50% threshold; CoughAssist; monitoring parameters"},{"location":"plans/neuromuscular-respiratory-failure/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Plasma Exchange/Sandoglobulin GBS Trial (1997) IVIG = PLEX for GBS; combination not better Either IVIG or PLEX; no combination MG Thymectomy Trial (MGTX, 2016) Thymectomy + prednisone &gt; prednisone alone for AChR+ MG (even without thymoma); improved outcomes at 3 years Thymectomy recommended for generalized AChR+ MG Zinman et al. NIV in ALS (2019 Cochrane) NIV prolongs survival in ALS (7-11 months) and improves QoL NIV is standard of care for ALS respiratory insufficiency Lawn et al. Respiratory Failure in MG (2001) FVC &lt;20 mL/kg or NIF &gt; -30 cm H2O predicted need for intubation; \"20/30/40 rule\" Established monitoring thresholds for MG crisis REGAIN Trial (Eculizumab in MG, 2017) Eculizumab reduced exacerbations in refractory generalized MG FDA approval of eculizumab for refractory AChR+ MG"},{"location":"plans/neuromuscular-respiratory-failure/#the-203040-rule","title":"The \"20/30/40\" Rule","text":"Parameter Threshold Interpretation FVC &lt;20 mL/kg Impending respiratory failure; consider intubation NIF (MIP) &gt; -30 cm H2O (less negative) Weak inspiratory muscles; impending failure MEP &lt;40 cm H2O Weak cough; unable to clear secretions; aspiration risk <p>Clinical Pearl: These values suggest impending failure and need for intubation. Do NOT wait for PaCO2 elevation \u2014 this is a LATE sign. Trend is more important than absolute values.</p>"},{"location":"plans/neuromuscular-respiratory-failure/#appendices","title":"APPENDICES","text":""},{"location":"plans/neuromuscular-respiratory-failure/#appendix-a-medications-to-avoid-in-myasthenia-gravis-comprehensive","title":"Appendix A: Medications to AVOID in Myasthenia Gravis (Comprehensive)","text":"<p>ABSOLUTE CONTRAINDICATION / HIGH RISK: - Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin) - Botulinum toxin (Botox) - D-Penicillamine (can induce MG) - Magnesium (IV high-dose) - Neuromuscular blocking agents (use reduced dose if essential; avoid succinylcholine) - Telithromycin (Ketek) - Quinine / Quinidine - Procainamide</p> <p>USE WITH CAUTION / MODERATE RISK: - Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) \u2014 FDA warning - Macrolides (azithromycin, erythromycin, clarithromycin) - Beta-blockers (especially non-selective; propranolol &gt; metoprolol) - Calcium channel blockers (verapamil, diltiazem) - Lithium - Phenytoin - Chloroquine / Hydroxychloroquine - Interferon-alpha - Checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab) \u2014 can trigger or worsen MG - Statins (rare exacerbation) - Iodinated contrast (rare) - Corticosteroids (transient worsening \u2014 \"steroid dip\")</p> <p>GENERALLY SAFE: - Beta-lactams (penicillins, cephalosporins, carbapenems) - Vancomycin - TMP-SMX - Metronidazole - Doxycycline (though tetracycline class has theoretical risk \u2014 doxycycline generally safe) - Acetaminophen - NSAIDs - Opioids - Dihydropyridine calcium channel blockers (amlodipine) - ACE inhibitors - Most anticonvulsants (levetiracetam, valproate)</p>"},{"location":"plans/neuromuscular-respiratory-failure/#appendix-b-rsi-considerations-in-neuromuscular-disease","title":"Appendix B: RSI Considerations in Neuromuscular Disease","text":"Agent Consideration Succinylcholine AVOID in myopathies/muscular dystrophies \u2014 causes massive hyperkalemia and cardiac arrest; AVOID in denervated patients (ALS, GBS) \u2014 hyperkalemia; MG patients: Relative resistance \u2014 may need higher dose (but risk of prolonged effect) \u2192 generally avoid Rocuronium Preferred NMB in NMD; MG patients: Increased sensitivity \u2014 use 50% of usual dose (0.3-0.5 mg/kg instead of 0.6-1.2 mg/kg); have sugammadex available for reversal Sugammadex Reverses rocuronium; useful for failed intubation or when rapid reversal needed; standard dose 2-4 mg/kg; immediate reversal 16 mg/kg Etomidate Safe; no effect on neuromuscular transmission Propofol Safe; no NM effects Ketamine Safe from NM perspective; avoid in intracranial pathology Fentanyl Safe; useful for blunting response Lidocaine Safe; may reduce airway reactivity"},{"location":"plans/neuromuscular-respiratory-failure/#appendix-c-pulmonary-function-thresholds-in-neuromuscular-disease","title":"Appendix C: Pulmonary Function Thresholds in Neuromuscular Disease","text":"Parameter Normal Abnormal Critical / Intubation Threshold FVC &gt;80% predicted; &gt;40-50 mL/kg &lt;50% predicted; &lt;25-30 mL/kg &lt;15-20 mL/kg Supine FVC &lt;10% drop from sitting 10-20% drop &gt;25% drop (diaphragm weakness) NIF (MIP) &lt; -80 cm H2O (more negative) &gt; -60 cm H2O &gt; -20 to -30 cm H2O MEP &gt;80 cm H2O &lt;60 cm H2O &lt;40 cm H2O (weak cough) Peak cough flow (PCF) &gt;360 L/min &lt;270 L/min &lt;160 L/min (inadequate secretion clearance) PaCO2 35-45 mmHg &gt;45 mmHg (hypoventilation) Rising PaCO2; &gt;50-55 mmHg SpO2 &gt;95% on room air &lt;92% on room air Declining despite O2 (assess for aspiration, PE)"},{"location":"plans/neuromuscular-respiratory-failure/#appendix-d-neuromuscular-respiratory-failure-decision-algorithm","title":"Appendix D: Neuromuscular Respiratory Failure Decision Algorithm","text":"<pre><code>SUSPECTED NEUROMUSCULAR RESPIRATORY FAILURE\n                \u2502\n    IMMEDIATE ASSESSMENT:\n    \u2022 ABG (PaCO2, pH)\n    \u2022 Bedside FVC and NIF\n    \u2022 Secretion assessment / cough strength\n    \u2022 Bulbar function (swallow, voice)\n    \u2022 Vital signs, SpO2\n                \u2502\n    RESPIRATORY STATUS?\n         \u2502\n    \u250c\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u252c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n    \u2502             \u2502               \u2502\n  STABLE      BORDERLINE       FAILING\n(FVC &gt;25,    (FVC 15-25,     (FVC &lt;15-20,\nNIF &lt; -40)   NIF -25 to -40) NIF &gt; -20-25,\n    \u2502             \u2502            rising PaCO2)\n    \u2502             \u2502               \u2502\nFloor admission  ICU admission  INTUBATE\nSerial q6h      Serial q2-4h   (RSI considerations)\nmonitoring       monitoring        \u2502\n    \u2502             \u2502               \u2502\n    \u2502             \u2502         ICU management\n    \u2502             \u2502         Disease-specific Rx\n    \u2502             \u2502               \u2502\n    \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2534\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n                \u2502\n    DISEASE-SPECIFIC TREATMENT:\n    \u2022 MG crisis \u2192 IVIG or PLEX; HOLD pyridostigmine\n    \u2022 GBS \u2192 IVIG or PLEX (NOT both)\n    \u2022 ALS \u2192 NIV; goals of care; palliative\n    \u2022 Inflammatory myopathy \u2192 Corticosteroids + IVIG\n    \u2022 Critical illness polyneuromyopathy \u2192 Supportive; treat sepsis\n                \u2502\n    WEANING (when disease improving):\n    \u2022 Daily SBT when FVC &gt;15, NIF &lt;-25\n    \u2022 Extubate when: FVC &gt;15-20 AND improving, effective cough, bulbar function intact\n    \u2022 Monitor closely post-extubation\n</code></pre> <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/new-onset-seizure/","title":"New Onset Seizure","text":"<p>VERSION: 1.1 CREATED: January 13, 2026 REVISED: January 13, 2026 STATUS: Revised per physician feedback</p> <p>DIAGNOSIS: New Onset Seizure</p> <p>ICD-10: R56.9 (Unspecified convulsions), G40.909 (Epilepsy, unspecified, not intractable, without status epilepticus)</p> <p>SYNONYMS: New onset seizure, first seizure, single seizure, first-time seizure, unprovoked seizure, initial seizure, new-onset epilepsy, convulsion, fit, spell</p> <p>SCOPE: Initial evaluation and management of first-time unprovoked seizure or first presentation of seizure activity in adults. Covers immediate stabilization, diagnostic workup to identify etiology, acute treatment, and framework for anti-seizure medication (ASM) initiation. Excludes status epilepticus (see \"Status Epilepticus\" template), pediatric seizures, febrile seizures, and known epilepsy with breakthrough seizures.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090 SECTION A: ACTION ITEMS \u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090</p>"},{"location":"plans/new-onset-seizure/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/new-onset-seizure/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Point-of-care glucose STAT STAT - STAT Hypoglycemia is immediately reversible cause &gt;70 mg/dL CBC with differential STAT STAT ROUTINE STAT Infection screen, baseline before ASMs Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolyte abnormalities (Na, Ca, Mg, glucose), renal/hepatic function for ASM dosing Normal Magnesium STAT STAT ROUTINE STAT Hypomagnesemia lowers seizure threshold &gt;1.8 mg/dL Calcium (ionized if available) STAT STAT ROUTINE STAT Hypocalcemia can cause seizures Normal (ionized 4.5-5.3 mg/dL) Urine drug screen STAT STAT ROUTINE STAT Illicit drugs (cocaine, amphetamines) and withdrawal states Negative Blood alcohol level STAT STAT - STAT Alcohol intoxication or withdrawal Correlate with history Urinalysis STAT STAT ROUTINE STAT UTI can provoke seizures (especially elderly) Negative Prolactin level STAT - - STAT Elevated if drawn within 10-20 min of event; helps distinguish seizure from non-epileptic event Elevated 2-3\u00c3\u2014 baseline (if drawn &lt;20 min) Phosphorus STAT STAT ROUTINE STAT Hypophosphatemia lowers seizure threshold (especially alcohol withdrawal) &gt;2.5 mg/dL"},{"location":"plans/new-onset-seizure/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding TSH URGENT ROUTINE ROUTINE URGENT Thyroid dysfunction can affect seizure threshold Normal Ammonia URGENT ROUTINE - URGENT Hepatic encephalopathy, urea cycle disorders Normal (&lt;35 \u00ce\u00bcmol/L) Troponin URGENT ROUTINE - URGENT Cardiac ischemia as cause or consequence Negative ECG URGENT ROUTINE ROUTINE URGENT Arrhythmia, prolonged QTc (some ASMs), Brugada Normal Lactate URGENT ROUTINE - URGENT Elevated post-ictal; also metabolic acidosis Mild elevation acceptable post-ictal Blood gas (ABG or VBG) URGENT ROUTINE - URGENT Acidosis, hypoxia Normal or mild post-ictal acidosis Serum osmolality URGENT ROUTINE - URGENT Hypo/hyperosmolar states 280-295 mOsm/kg Pregnancy test (urine or serum \u00ce\u00b2-hCG) STAT STAT ROUTINE STAT Eclampsia; affects imaging and ASM choice Negative (or explains eclampsia if positive) B12 level - ROUTINE ROUTINE - Deficiency associated with seizures Normal (&gt;300 pg/mL) Folate level - ROUTINE ROUTINE - Deficiency can lower threshold; important for women of childbearing potential Normal"},{"location":"plans/new-onset-seizure/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum/urine toxicology (expanded panel) URGENT EXT EXT URGENT Synthetic drugs, medications not on standard screen Negative Heavy metals (lead, mercury) - EXT EXT - Occupational exposure, pica Normal Ceruloplasmin, serum copper - EXT EXT - Wilson disease (young patients) Normal HIV - ROUTINE ROUTINE - HIV-associated CNS disease Negative RPR/VDRL - ROUTINE ROUTINE - Neurosyphilis Negative Autoimmune encephalitis panel (serum) - EXT EXT - Anti-NMDAR, LGI1, CASPR2, GABA-B if clinical suspicion Negative Paraneoplastic panel (serum) - EXT EXT - Subacute onset, smoking, weight loss Negative Porphyrins (urine/serum) - EXT EXT - Acute intermittent porphyria Normal Genetic epilepsy panel - - EXT - Young onset, family history, refractory Variable"},{"location":"plans/new-onset-seizure/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/new-onset-seizure/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediate in ED Mass, hemorrhage, stroke, calcification, hydrocephalus Pregnancy (relative - benefit usually outweighs risk) MRI brain with and without contrast (epilepsy protocol)* URGENT URGENT ROUTINE URGENT Within 24-48h if inpatient; within 2 weeks if outpatient Tumor, mesial temporal sclerosis, cortical dysplasia, encephalitis, stroke, vascular malformation GFR &lt;30, gadolinium allergy, pacemaker EEG (routine) URGENT URGENT ROUTINE URGENT Within 24h if possible; ideally within 24-48h of seizure Epileptiform discharges (spikes, sharp waves), focal slowing None significant <p>Epilepsy MRI protocol should include: thin-cut coronal T2/FLAIR through hippocampi, 3D T1 volumetric, T2, SWI, DWI, post-contrast T1</p> <p>IMPORTANT: CT head is useful for acute exclusion of hemorrhage, large mass, or hydrocephalus but is NOT sufficient to identify seizure etiology. MRI brain with epilepsy protocol remains the gold standard and should be obtained in all patients with new onset seizure.</p>"},{"location":"plans/new-onset-seizure/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Continuous EEG (cEEG) monitoring - URGENT - URGENT If altered mental status persists, suspected non-convulsive status Non-convulsive seizures, non-convulsive status epilepticus None significant Prolonged ambulatory EEG (24-72h) - - ROUTINE - Outpatient if routine EEG non-diagnostic Capture interictal or ictal activity None significant Video-EEG monitoring - ROUTINE ROUTINE - If diagnosis uncertain (vs. psychogenic) Correlate clinical events with EEG None significant MRA/MRV brain - ROUTINE ROUTINE - If vascular etiology suspected AVM, aneurysm, venous thrombosis Same as MRI CT angiography head URGENT URGENT - URGENT If MRA unavailable and vascular cause suspected Vascular malformation, aneurysm Contrast allergy, renal insufficiency Echocardiogram - ROUTINE ROUTINE - If embolic stroke suspected as cause Thrombus, PFO, vegetation None significant Chest X-ray URGENT ROUTINE - URGENT Aspiration risk post-ictal, lung cancer screening if paraneoplastic suspected Clear lungs or mass None significant"},{"location":"plans/new-onset-seizure/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications PET-CT brain (interictal FDG) - EXT EXT - Epilepsy surgery workup Focal hypometabolism Pregnancy, uncontrolled diabetes SPECT (ictal/interictal) - EXT EXT - Epilepsy surgery workup Ictal hyperperfusion Requires seizure capture MEG (magnetoencephalography) - - EXT - Epilepsy surgery workup Localize epileptogenic focus Metallic implants Neuropsychological testing - - EXT - Pre-surgical evaluation, cognitive concerns Lateralizing deficits Patient cooperation Wada test (intracarotid amobarbital) - - EXT - Pre-surgical language/memory lateralization Language and memory dominance Contrast allergy, vascular anomaly"},{"location":"plans/new-onset-seizure/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Suspected CNS infection (meningitis, encephalitis), autoimmune encephalitis, carcinomatous meningitis, or atypical presentation with fever/immunocompromise</p> <p>Timing: URGENT if infection suspected; ROUTINE if autoimmune workup</p> <p>Volume Required: 15-20 mL (standard diagnostic); 20-30 mL if malignancy suspected</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Elevated ICP, mass effect 10-20 cm H2O Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Infection, inflammation WBC &lt;5; RBC 0 Protein URGENT ROUTINE ROUTINE Elevated in infection, inflammation 15-45 mg/dL Glucose with serum glucose URGENT ROUTINE ROUTINE Low in bacterial/fungal/TB meningitis &gt;60% serum Gram stain and culture URGENT ROUTINE ROUTINE Bacterial meningitis No organisms BioFire FilmArray ME Panel URGENT ROUTINE - Rapid pathogen identification (14 pathogens) Negative HSV-1/2 PCR URGENT ROUTINE ROUTINE HSV encephalitis (most common treatable cause) Negative Autoimmune encephalitis panel (CSF) - ROUTINE ROUTINE If clinical suspicion for autoimmune etiology Negative Cytology - ROUTINE ROUTINE Carcinomatous meningitis Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative Oligoclonal bands - ROUTINE ROUTINE If demyelinating disease suspected Negative or matched with serum <p>Special Handling: HSV PCR can be sent on refrigerated sample. Cytology requires rapid transport (&lt;1 hour). Cell count must be processed within 1 hour.</p> <p>Contraindications: Elevated ICP without imaging (CT first), coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p>"},{"location":"plans/new-onset-seizure/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/new-onset-seizure/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Lorazepam IV/IM (if actively seizing) STAT STAT - STAT 0.1 mg/kg IV (max 4 mg); may repeat once in 5 min Respiratory depression, severe hypotension RR, O2 sat, BP; have airway equipment ready Midazolam IM (if no IV access) STAT STAT - STAT 10 mg IM (if &gt;40 kg) or 0.2 mg/kg IM Respiratory depression RR, O2 sat; have airway equipment ready Midazolam intranasal (if no IV access) STAT STAT - STAT 5 mg per nostril (total 10 mg) Respiratory depression RR, O2 sat Dextrose 50% IV STAT STAT - STAT 25-50 mL IV if hypoglycemia confirmed or suspected Hyperglycemia Glucose Thiamine IV STAT STAT - STAT 100-500 mg IV BEFORE glucose if alcohol use suspected None significant None Supplemental oxygen STAT STAT - STAT 2-4 L NC or non-rebreather as needed None O2 sat &gt;94% IV fluids (isotonic) STAT STAT - STAT NS or LR bolus if hypotensive; maintenance if euvolemic Fluid overload, severe hyponatremia I/O, BP, Na Flumazenil (rescue only) STAT STAT - STAT 0.2 mg IV over 30 sec; may repeat 0.2 mg q1min to max 1 mg Chronic benzodiazepine use; seizure history; tricyclic overdose CAUTION: May lower seizure threshold and precipitate seizures; use only if severe respiratory depression unresponsive to supportive care"},{"location":"plans/new-onset-seizure/#3b-anti-seizure-medications-asms-acute-loading","title":"3B. Anti-Seizure Medications (ASMs) - Acute Loading","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam IV First-line acute loading STAT STAT - STAT 40-60 mg/kg IV (max 4500 mg) over 15 min; OR 1500-3000 mg IV None significant; reduce dose if CrCl &lt;50 Somnolence, agitation (rare) Levetiracetam PO Acute loading if stable URGENT URGENT URGENT - 1500-3000 mg PO \u00c3\u2014 1, then start maintenance Same Same Fosphenytoin IV Alternative first-line STAT STAT - STAT 20 mg PE/kg IV at 150 mg PE/min (max rate) AV block, sinus bradycardia, pregnancy (relative) Continuous cardiac monitoring, BP; purple glove syndrome rare with fosphenytoin Phenytoin IV If fosphenytoin unavailable STAT STAT - STAT 20 mg/kg IV at max 50 mg/min AV block, sinus bradycardia, pregnancy Cardiac monitor, BP; give via large vein (tissue necrosis risk) Valproate IV Alternative (broad-spectrum) STAT STAT - STAT 40 mg/kg IV over 10 min (max 3000 mg) Pregnancy (teratogenic - neural tube defects), hepatic disease, mitochondrial disease, urea cycle disorders LFTs, ammonia, platelets; pancreatitis risk Lacosamide IV Alternative first-line URGENT URGENT - URGENT 200-400 mg IV over 15-30 min PR prolongation &gt;200 ms, 2nd/3rd degree AV block ECG for PR interval; dizziness"},{"location":"plans/new-onset-seizure/#3c-anti-seizure-medications-asms-maintenance-therapy","title":"3C. Anti-Seizure Medications (ASMs) - Maintenance Therapy","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam First-line maintenance - ROUTINE ROUTINE ROUTINE 500-1500 mg PO/IV BID; start 500 mg BID, may increase by 500 mg/dose weekly; max 3000 mg/day Renal impairment (adjust per CrCl) Behavioral changes (irritability, depression - \"Keppra rage\"); renal function Lamotrigine First-line (especially women of childbearing potential) - ROUTINE ROUTINE - Start 25 mg daily \u00c3\u2014 2 weeks; then 50 mg daily \u00c3\u2014 2 weeks; then 100 mg daily; target 200-400 mg/day in divided doses Slow titration required (SJS/TEN risk) Rash (stop if any rash; SJS/TEN risk higher with fast titration or valproate co-therapy) Lacosamide First-line alternative - ROUTINE ROUTINE ROUTINE Start 100 mg PO BID; increase by 100 mg/day weekly; target 200-400 mg BID; max 400 mg BID PR prolongation, 2nd/3rd degree AV block, severe hepatic impairment ECG at baseline and dose changes; dizziness, diplopia Oxcarbazepine Focal seizures - ROUTINE ROUTINE - Start 300 mg PO BID; increase by 300-600 mg/day every week; target 1200-2400 mg/day in divided doses Hypersensitivity to carbamazepine Sodium (hyponatremia in 2-3%); HLA-B*1502 screening in at-risk populations Carbamazepine Focal seizures - ROUTINE ROUTINE - Start 200 mg PO BID; increase by 200 mg/day weekly; target 800-1200 mg/day; max 1600 mg/day AV block; bone marrow suppression; concurrent MAOIs CBC, LFTs, sodium at baseline and periodically; HLA-B*1502 screening Valproate/Divalproex Generalized seizures - ROUTINE ROUTINE ROUTINE Start 10-15 mg/kg/day in divided doses; increase by 5-10 mg/kg/week; target 1000-2000 mg/day; max 60 mg/kg/day Pregnancy (teratogenic); hepatic disease; mitochondrial disease; pancreatitis history LFTs, ammonia, CBC, platelets at baseline, then q3-6mo; weight gain, hair loss, tremor Phenytoin Focal or generalized - ROUTINE ROUTINE ROUTINE 300-400 mg daily (extended release) or divided TID (immediate release); adjust by level Pregnancy (relative - fetal hydantoin syndrome); AV block Free phenytoin level (target 1-2 \u00ce\u00bcg/mL); total level 10-20 \u00ce\u00bcg/mL; CBC, LFTs; gingival hyperplasia, hirsutism Brivaracetam Alternative to levetiracetam - ROUTINE ROUTINE ROUTINE Start 50 mg PO BID; may increase to 100 mg BID; max 200 mg/day Hepatic impairment (reduce dose) Less behavioral side effects than levetiracetam; somnolence Zonisamide Adjunctive or monotherapy - - ROUTINE - Start 100 mg daily; increase by 100 mg every 2 weeks; target 300-400 mg daily; max 600 mg/day Sulfonamide allergy; kidney stones Kidney stones (carbonic anhydrase inhibitor); oligohidrosis (pediatric); metabolic acidosis Topiramate Adjunctive or monotherapy - - ROUTINE - Start 25 mg BID; increase by 50 mg/day weekly; target 200-400 mg/day in divided doses; max 400 mg/day Kidney stones; metabolic acidosis; glaucoma Cognitive impairment (\"dopamax\"); paresthesias; kidney stones; weight loss Clobazam Adjunctive therapy - ROUTINE ROUTINE - Start 5-10 mg daily; increase by 5-10 mg weekly; max 40 mg/day in divided doses Severe hepatic impairment; sleep apnea (untreated) Sedation; tolerance may develop; CYP2C19 poor metabolizers need lower dose Perampanel Adjunctive for focal or GTCS - - ROUTINE - Start 2 mg qHS; increase by 2 mg weekly; target 8-12 mg qHS; max 12 mg/day None absolute Psychiatric effects (aggression, hostility); dizziness; take at bedtime; Schedule III Cenobamate Adjunctive for focal - - ROUTINE - Start 12.5 mg daily \u00c3\u2014 2 weeks; titrate slowly per package insert; target 200-400 mg daily Familial short QT syndrome Very slow titration required (DRESS risk); QT shortening; titration pack available Phenobarbital Refractory or resource-limited - ROUTINE ROUTINE ROUTINE Load 15-20 mg/kg IV; maintenance 1-3 mg/kg/day (60-180 mg/day); target level 15-40 \u00ce\u00bcg/mL Porphyria; severe respiratory disease Sedation; cognitive effects; drug interactions (CYP inducer); level monitoring"},{"location":"plans/new-onset-seizure/#3d-symptomatic-treatments","title":"3D. Symptomatic Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Acetaminophen Post-ictal headache URGENT ROUTINE ROUTINE URGENT 650-1000 mg PO/IV q6h PRN; max 3000 mg/day (2000 mg if liver disease) Severe hepatic impairment LFTs if chronic use Ibuprofen Post-ictal headache - ROUTINE ROUTINE - 400-600 mg PO q6-8h PRN; max 2400 mg/day Renal impairment; GI bleed; post-CABG Renal function if prolonged use Ondansetron Post-ictal nausea URGENT ROUTINE ROUTINE URGENT 4-8 mg IV/PO q8h PRN QT prolongation; severe hepatic impairment QTc if multiple doses Lorazepam Post-ictal agitation (if severe) URGENT URGENT - URGENT 0.5-2 mg IV/PO PRN; use with caution Respiratory depression; altered mental status RR, sedation level; avoid if post-ictal confusion resolving Sertraline Depression/anxiety (chronic) - - ROUTINE - Start 50 mg daily; increase by 25-50 mg q1-2 weeks; max 200 mg daily Concurrent MAOIs Suicidality monitoring weeks 1-4 Escitalopram Depression/anxiety (chronic) - - ROUTINE - Start 10 mg daily; max 20 mg daily Concurrent MAOIs; QT prolongation QTc if risk factors Melatonin Sleep disturbance - ROUTINE ROUTINE - 3-5 mg PO qHS None significant Well tolerated; may help with ASM-related sleep disruption Trazodone Insomnia - ROUTINE ROUTINE - 25-100 mg PO qHS Concurrent MAOIs Orthostatic hypotension; priapism (rare)"},{"location":"plans/new-onset-seizure/#3e-second-linerefractory","title":"3E. Second-line/Refractory","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Add second ASM - ROUTINE ROUTINE ROUTINE Choose complementary mechanism; see maintenance options Per specific agent Per specific agent Epilepsy surgery evaluation referral - EXT EXT - For drug-resistant epilepsy (failed 2+ appropriately chosen ASMs) N/A N/A Vagus nerve stimulator (VNS) - - EXT - For drug-resistant epilepsy not surgical candidates N/A Device checks Dietary therapy (ketogenic diet, modified Atkins) - - EXT - For drug-resistant epilepsy Fatty acid oxidation disorders; pyruvate carboxylase deficiency Metabolic panels; lipids; kidney function"},{"location":"plans/new-onset-seizure/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/new-onset-seizure/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology consult URGENT URGENT ROUTINE URGENT All new onset seizures for evaluation and management Epilepsy specialist referral - ROUTINE ROUTINE - Diagnostic uncertainty, refractory seizures, surgical candidacy EEG technologist/neurodiagnostics URGENT URGENT ROUTINE URGENT EEG scheduling; continuous EEG if indicated Neurosurgery consult - URGENT EXT URGENT Structural lesion requiring intervention (tumor, AVM, SDH) Medical toxicology consult URGENT ROUTINE - URGENT Suspected drug/toxin-induced seizure Infectious disease consult - URGENT - URGENT CNS infection confirmed or suspected Oncology consult - ROUTINE ROUTINE - Brain tumor identified Psychiatry consult - ROUTINE ROUTINE - Depression, anxiety post-diagnosis; psychogenic non-epileptic spells suspected Social work consult - ROUTINE ROUTINE - Driving restrictions impact, employment concerns, insurance navigation Occupational therapy - ROUTINE ROUTINE - Work safety evaluation, activity modification Physical therapy - ROUTINE ROUTINE - If post-ictal weakness, falls, injury from seizure Neuropsychology referral - - ROUTINE - Cognitive complaints, pre-surgical evaluation Women's health/OB-GYN - - ROUTINE - Contraception counseling (ASM interactions), pregnancy planning Epilepsy monitoring unit (EMU) admission - EXT EXT - Characterize seizure type, video-EEG monitoring, pre-surgical evaluation Driving evaluation/rehabilitation - - EXT - Return to driving assessment when eligible"},{"location":"plans/new-onset-seizure/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED immediately if: recurrent seizure, prolonged seizure &gt;5 minutes, head injury, persistent confusion, difficulty breathing, or status epilepticus \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Do NOT drive until cleared by neurology (driving restrictions per state guidelines; typically require seizure-free interval) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid operating heavy machinery, working at heights, or swimming alone \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Do not bathe alone; showers preferred over baths; keep bathroom door unlocked \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Inform employer if job involves safety-sensitive duties - \u00e2\u0153\u201c \u00e2\u0153\u201c Take ASM exactly as prescribed; do NOT stop abruptly (risk of breakthrough seizures or status epilepticus) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid common seizure triggers: sleep deprivation, alcohol, illicit drugs, missed medications \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Keep a seizure diary: date, time, duration, description, triggers, post-ictal symptoms - \u00e2\u0153\u201c \u00e2\u0153\u201c Wear medical identification (bracelet or necklace) - \u00e2\u0153\u201c \u00e2\u0153\u201c Educate family/coworkers on seizure first aid: stay with person, protect head, do NOT put anything in mouth, time the seizure, call 911 if &gt;5 minutes \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Follow up with neurology within 1-2 weeks of discharge \u00e2\u0153\u201c \u00e2\u0153\u201c - Bring list of all medications (including OTC and supplements) to all appointments - many interact with ASMs - \u00e2\u0153\u201c \u00e2\u0153\u201c Women: discuss contraception with provider; some ASMs reduce efficacy of hormonal contraception - \u00e2\u0153\u201c \u00e2\u0153\u201c Report side effects (mood changes, rash, dizziness, cognitive issues) promptly; do NOT stop medication without calling - \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid flashing/strobe lights if photosensitive seizures suspected - \u00e2\u0153\u201c \u00e2\u0153\u201c"},{"location":"plans/new-onset-seizure/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Sleep hygiene: aim for 7-9 hours nightly; maintain regular sleep schedule - \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid alcohol (lowers seizure threshold; interacts with ASMs) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Avoid illicit drugs (especially stimulants: cocaine, amphetamines) \u00e2\u0153\u201c \u00e2\u0153\u201c \u00e2\u0153\u201c Stress management techniques - - \u00e2\u0153\u201c Regular moderate exercise (not extreme sleep deprivation from overtraining) - - \u00e2\u0153\u201c Medication adherence: use pill organizers, phone alarms, refill reminders - \u00e2\u0153\u201c \u00e2\u0153\u201c Folic acid supplementation 1-4 mg daily for women of childbearing potential (especially if on enzyme-inducing ASMs) - \u00e2\u0153\u201c \u00e2\u0153\u201c Bone health: vitamin D 1000-2000 IU daily; calcium as needed (enzyme-inducing ASMs affect bone density) - - \u00e2\u0153\u201c Avoid known personal triggers (flashing lights, certain foods, stress, if identified) - \u00e2\u0153\u201c \u00e2\u0153\u201c Home safety modifications: pad sharp furniture corners, avoid glass shower doors, use microwave instead of stovetop when alone - \u00e2\u0153\u201c \u00e2\u0153\u201c Seizure alert devices or apps for those living alone (optional) - - \u00e2\u0153\u201c Smoking cessation (increases ASM metabolism; general health) - \u00e2\u0153\u201c \u00e2\u0153\u201c <p>\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090 SECTION B: REFERENCE (Expand as Needed) \u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090\u00e2\u2022\u0090</p>"},{"location":"plans/new-onset-seizure/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Syncope (convulsive syncope) Brief (&lt;15 sec), triggered by standing/Valsalva/micturition, rapid recovery, no post-ictal confusion, possible prodrome (lightheaded, tunnel vision) ECG, orthostatic vitals, tilt table test, echocardiogram Psychogenic non-epileptic spells (PNES) Variable/atypical semiology, prolonged duration, preserved awareness with bilateral movements, eye closure, pelvic thrusting, no post-ictal confusion, psychiatric comorbidity Video-EEG capturing event; normal prolactin Transient ischemic attack (TIA) Negative symptoms (weakness, numbness), no LOC, no convulsive activity MRI DWI, vascular imaging Migraine with aura Gradual onset, spreading symptoms, headache follows, stereotyped Clinical history, normal EEG Hypoglycemia Diaphoresis, tremor, confusion, rapid glucose corrects symptoms Fingerstick glucose Cardiac arrhythmia Palpitations, sudden LOC without warning, rapid recovery ECG, Holter monitor, event recorder, EP study Transient global amnesia Isolated anterograde amnesia, repetitive questioning, no convulsive activity Clinical presentation (self-limited), MRI DWI (hippocampal) Sleep disorders (parasomnias, cataplexy) Occur from sleep, specific features (cataplexy with emotion) Sleep study, clinical history Movement disorders (dystonia, tics) Stereotyped, no LOC, suppressible (tics), may have sensory urge Clinical history, video Drug intoxication/withdrawal History of substance use, known withdrawal timeline Toxicology screen, history Metabolic encephalopathy Gradual onset, diffuse abnormality, asterixis, no discrete seizures Labs (ammonia, glucose, Na), EEG (diffuse slowing)"},{"location":"plans/new-onset-seizure/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal Neurologic exam (level of consciousness, focal deficits) Q1-2h in ED; Q4h inpatient; each visit OPD Return to baseline If prolonged post-ictal state: continuous EEG to rule out non-convulsive status Vital signs Continuous in ED/ICU; Q4h floor Stable Treat hyperthermia, hypotension, hypoxia Glucose On arrival; repeat if altered &gt;70 mg/dL Dextrose if low Electrolytes (Na, Ca, Mg) On arrival; daily if abnormal Normal ranges Correct deficiencies; identify cause ASM level (phenytoin, valproate, phenobarbital, carbamazepine) Trough level 5-7 days after initiation or dose change; PRN Therapeutic range (drug-specific) Adjust dose; check free level for phenytoin <p>ASM Therapeutic Level Reference: | ASM | Therapeutic Range | Notes | |-----|-------------------|-------| | Phenytoin (total) | 10-20 \u00ce\u00bcg/mL | Check FREE level (1-2 \u00ce\u00bcg/mL) if hypoalbuminemia, renal failure, or pregnancy | | Valproate | 50-100 \u00ce\u00bcg/mL | Higher levels may be needed; monitor for toxicity | | Carbamazepine | 4-12 \u00ce\u00bcg/mL | Autoinduction occurs over 2-4 weeks | | Phenobarbital | 15-40 \u00ce\u00bcg/mL | Sedation common at higher levels | | Lacosamide | 10-20 \u00ce\u00bcg/mL | Level monitoring not routinely required | | Levetiracetam | 12-46 \u00ce\u00bcg/mL | Level monitoring not routinely required; clinical response guides dosing | | LFTs | Baseline; q3-6 months on valproate, carbamazepine | Normal | Discontinue if hepatotoxicity; hold if transaminases &gt;3\u00c3\u2014 ULN | | CBC | Baseline; q3-6 months on carbamazepine, valproate | Normal | Discontinue if significant bone marrow suppression | | Sodium | Baseline; periodically on oxcarbazepine, carbamazepine | &gt;130 mEq/L | Reduce dose or switch if severe hyponatremia | | EEG | Within 24-48h of first seizure; repeat if diagnosis unclear | No ongoing seizures | Adjust treatment if epileptiform activity or non-convulsive seizures | | MRI brain | Within 2 weeks of first seizure; sooner if structural cause suspected | No new lesions | Address structural cause; refer to appropriate specialist |</p>"},{"location":"plans/new-onset-seizure/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Single, self-limited seizure; returned to baseline; no dangerous etiology identified on initial workup; reliable adult supervision for 24h; ASM initiated or deferred with close follow-up; outpatient EEG and MRI arranged; understands return precautions and driving restriction Admit to floor (observation) Prolonged post-ictal period; multiple seizures; new structural lesion requiring monitoring; ASM loading requiring observation; social situation preventing safe discharge; need for inpatient EEG; new focal neurologic deficit Admit to ICU Status epilepticus (current or recent); recurrent seizures despite treatment; need for continuous EEG monitoring; airway compromise; hemodynamic instability; significant aspiration; large structural lesion with mass effect; CNS infection Transfer to higher level MRI unavailable; EEG unavailable; neurology not available for consultation; need for neurosurgical intervention unavailable at facility"},{"location":"plans/new-onset-seizure/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source ILAE 2017 seizure classification Class I Fisher RS et al. Epilepsia 2017 ILAE 2014 practical definition of epilepsy Class I Fisher RS et al. Epilepsia 2014 EEG within 24-48h increases yield Class II, Level B AAN Practice Parameter 2007 MRI superior to CT for epilepsy evaluation Class I, Level A ILAE Commission Report 2019 Levetiracetam non-inferior to phenytoin for acute seizure cessation Class I, Level A ESETT Trial, NEJM 2019 Risk of recurrence after first unprovoked seizure ~40-50% Class I Hauser et al., NEJM 1998 Starting ASM after first seizure reduces recurrence but not long-term remission Class I, Level A FIRST and MESS trials Lamotrigine and levetiracetam preferred in women of childbearing potential Class II, Level B AAN/AES Guidelines 2009, MONEAD Study Driving restrictions reduce accident risk Class II, Level B Multiple observational studies Prolactin elevation supports diagnosis of epileptic seizure (if drawn &lt;20 min) Class II, Level B Chen et al., Neurology 2005 Continuous EEG detects non-convulsive status in altered patients Class II, Level B Claassen et al., Neurology 2004 Folate supplementation reduces teratogenicity risk Class II, Level B AAN Practice Parameter"},{"location":"plans/new-onset-seizure/#change-log","title":"CHANGE LOG","text":"<p>v1.1 (January 13, 2026) - Updated levetiracetam loading dose to range (40-60 mg/kg) per physician preference - Added phosphorus to core labs (hypophosphatemia in alcohol withdrawal) - Added flumazenil to acute treatments with seizure threshold caution - Added note that CT insufficient for etiology; MRI is gold standard - Updated driving restriction language to generic \"per state guidelines\" - Added ASM therapeutic level reference table to Section 6 - Added ILAE 2017 seizure classification and 2014 epilepsy definition to references</p> <p>v1.0 (January 13, 2026) - Initial creation - Comprehensive ASM section with individual drug rows and complete dosing - Included 14 maintenance ASMs with titration schedules - Added acute loading options (levetiracetam, fosphenytoin, valproate, lacosamide) - LP section for infectious/autoimmune workup - Extensive differential diagnosis including syncope, PNES, cardiac causes - Complete patient instructions including driving, safety, seizure first aid - Setting-appropriate coverage across ED, HOSP, OPD, ICU</p>"},{"location":"plans/parkinsons-disease-new-diagnosis/","title":"Parkinson's Disease - New Diagnosis","text":"<p>VERSION: 1.0 CREATED: January 29, 2026 REVISED: January 29, 2026 STATUS: Complete</p> <p>DIAGNOSIS: Parkinson's Disease - New Diagnosis</p> <p>ICD-10: G20 (Parkinson's disease), G20.A1 (Parkinson's disease without dyskinesia, without motor fluctuations), G20.A2 (Parkinson's disease without dyskinesia, with motor fluctuations), G20.B1 (Parkinson's disease with dyskinesia, without motor fluctuations), G20.B2 (Parkinson's disease with dyskinesia, with motor fluctuations), G20.C (Parkinsonism, unspecified)</p> <p>SYNONYMS: Parkinson disease, PD, idiopathic parkinsonism, paralysis agitans, shaking palsy, primary parkinsonism, Parkinson's, parkinsonism</p> <p>SCOPE: Initial diagnosis and early management of idiopathic Parkinson's disease in adults. Covers diagnostic workup to exclude secondary causes and atypical parkinsonism, initiation of symptomatic therapy, and patient education. Excludes drug-induced parkinsonism, atypical parkinsonian syndromes (PSP, MSA, CBD, DLB), juvenile/young-onset PD, and advanced PD with motor fluctuations.</p> <p>DEFINITIONS: - Parkinsonism: Clinical syndrome of bradykinesia plus rest tremor and/or rigidity - Parkinson's Disease (PD): Neurodegenerative disorder characterized by parkinsonism due to loss of dopaminergic neurons in substantia nigra - Bradykinesia: Slowness of movement with progressive reduction in speed and amplitude with repetitive actions - Rest Tremor: 4-6 Hz tremor present at rest, suppressed with action - Rigidity: Increased resistance to passive movement (cogwheel or lead-pipe)</p> <p>DIAGNOSTIC CRITERIA (MDS Clinical Diagnostic Criteria for PD, 2015):</p> <p>Essential Criteria: - Parkinsonism (bradykinesia + rest tremor OR rigidity)</p> <p>Supportive Criteria (\u22652 for clinically established PD): - Clear beneficial response to dopaminergic therapy - Presence of levodopa-induced dyskinesias - Rest tremor of a limb - Olfactory loss or cardiac sympathetic denervation on MIBG</p> <p>Absolute Exclusion Criteria: - Cerebellar abnormalities - Downward vertical supranuclear gaze palsy - Diagnosis of probable behavioral variant FTD or primary progressive aphasia - Parkinsonism restricted to lower limbs for &gt;3 years - Treatment with dopamine receptor blocker or dopamine-depleting agent - Absence of response to high-dose levodopa - Unequivocal cortical sensory loss, clear limb ideomotor apraxia, progressive aphasia - Normal functional neuroimaging of presynaptic dopaminergic system</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/parkinsons-disease-new-diagnosis/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/parkinsons-disease-new-diagnosis/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC - ROUTINE ROUTINE - General health, rule out anemia Normal CMP - ROUTINE ROUTINE - Hepatic/renal function for medication dosing Normal TSH - ROUTINE ROUTINE - Hypothyroidism can cause slowness/tremor Normal Vitamin B12 - ROUTINE ROUTINE - Deficiency can cause parkinsonism &gt;400 pg/mL RPR/VDRL - ROUTINE ROUTINE - Neurosyphilis in differential Negative"},{"location":"plans/parkinsons-disease-new-diagnosis/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum ceruloplasmin - ROUTINE ROUTINE - Wilson disease if age &lt;50 20-40 mg/dL 24-hour urine copper - EXT EXT - Wilson disease if ceruloplasmin low/borderline &lt;100 mcg/24h HIV - ROUTINE ROUTINE - HIV-associated parkinsonism Negative Genetic testing (GBA, LRRK2, PRKN) - - EXT - Young onset (&lt;50), family history, Ashkenazi Jewish Informational Alpha-synuclein seed amplification assay - - EXT - Emerging biomarker for synucleinopathy Pending validation"},{"location":"plans/parkinsons-disease-new-diagnosis/#1c-rarespecialized","title":"1C. Rare/Specialized","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum/urine heavy metals - - EXT - Manganese exposure, other toxins Negative Anti-neuronal antibodies - - EXT - Autoimmune parkinsonism (rare) Negative Skin biopsy for alpha-synuclein - - EXT - Emerging biomarker Research only"},{"location":"plans/parkinsons-disease-new-diagnosis/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/parkinsons-disease-new-diagnosis/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain without contrast - ROUTINE ROUTINE - At diagnosis Rule out structural cause, vascular parkinsonism Pacemaker, metal MRI brain with contrast - ROUTINE ROUTINE - If mass or infection suspected Rule out structural lesion Contrast allergy, renal disease"},{"location":"plans/parkinsons-disease-new-diagnosis/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications DaTscan (I-123 ioflupane SPECT) - - ROUTINE - Diagnostic uncertainty (ET vs PD, drug-induced) Reduced striatal uptake in PD Pregnancy, iodine allergy FDG-PET brain - - EXT - Distinguish atypical parkinsonism Hypometabolism pattern varies by diagnosis Per PET MRI susceptibility-weighted imaging - ROUTINE ROUTINE - Wilson disease, iron deposition Rule out basal ganglia abnormalities Per MRI MIBG cardiac scintigraphy - - EXT - Distinguish PD from MSA Reduced uptake in PD Drugs affecting uptake Polysomnography - - ROUTINE - If REM sleep behavior disorder suspected Confirm RBD None Olfactory testing (UPSIT) - - ROUTINE - Supportive criterion; impaired in PD Hyposmia Nasal obstruction"},{"location":"plans/parkinsons-disease-new-diagnosis/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/parkinsons-disease-new-diagnosis/#3a-dopaminergic-therapy-levodopa","title":"3A. Dopaminergic Therapy - Levodopa","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Carbidopa/Levodopa (Sinemet) - ROUTINE ROUTINE - Start 25/100 mg TID with meals; titrate by 25/100 mg q1-2 weeks; usual maintenance 300-800 mg levodopa/day Narrow-angle glaucoma; caution with MAOIs Dyskinesia, nausea, orthostatic hypotension Carbidopa/Levodopa CR - ROUTINE ROUTINE - 25/100 or 50/200 mg BID-TID; ~30% less bioavailable than IR Same Same; less predictable absorption Carbidopa/Levodopa ODT (Parcopa) - ROUTINE ROUTINE - Same dosing as IR; dissolves on tongue Same Same; useful for dysphagia Carbidopa/Levodopa ER (Rytary) - - ROUTINE - Start 23.75/95 mg TID; titrate per response Same Same; more sustained release Carbidopa/Levodopa intestinal gel (Duopa) - - EXT - Continuous infusion via PEG-J; specialist prescribing Advanced PD; requires surgical placement Device complications"},{"location":"plans/parkinsons-disease-new-diagnosis/#3b-dopamine-agonists","title":"3B. Dopamine Agonists","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Pramipexole (Mirapex) - ROUTINE ROUTINE - Start 0.125 mg TID; titrate weekly to 0.5-1.5 mg TID; max 4.5 mg/day Impulse control disorders (relative); renal impairment (reduce dose) ICDs (gambling, hypersexuality, shopping), sleepiness, hallucinations Pramipexole ER - ROUTINE ROUTINE - Start 0.375 mg daily; titrate weekly; max 4.5 mg/day Same Same Ropinirole (Requip) - ROUTINE ROUTINE - Start 0.25 mg TID; titrate weekly to 3-8 mg TID; max 24 mg/day ICDs, hepatic impairment Same as pramipexole Ropinirole XL - ROUTINE ROUTINE - Start 2 mg daily; titrate weekly; max 24 mg/day Same Same Rotigotine patch (Neupro) - ROUTINE ROUTINE - Start 2 mg/24h; increase by 2 mg/week; max 8 mg/24h (early PD) Sulfite allergy, application site reactions ICDs, skin reactions Apomorphine SC (Apokyn) - - EXT - Rescue for off episodes; start 0.2 mL (2 mg) test dose; max 0.6 mL (6 mg) Severe hypotension, 5-HT3 antagonist use BP, nausea (pretreat with trimethobenzamide)"},{"location":"plans/parkinsons-disease-new-diagnosis/#3c-mao-b-inhibitors","title":"3C. MAO-B Inhibitors","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Rasagiline (Azilect) - ROUTINE ROUTINE - 0.5-1 mg daily; may use as monotherapy early PD or adjunct MAOIs, meperidine, tramadol, methadone, cyclobenzaprine Serotonin syndrome; insomnia if taken late Selegiline (Eldepryl) - ROUTINE ROUTINE - 5 mg BID (breakfast and lunch); avoid evening dosing Same as rasagiline Insomnia, orthostatic hypotension Selegiline ODT (Zelapar) - ROUTINE ROUTINE - 1.25-2.5 mg daily (buccal absorption) Same Same Safinamide (Xadago) - - ROUTINE - 50-100 mg daily; adjunct to levodopa Same; severe hepatic impairment, retinal disease Dyskinesia, falls"},{"location":"plans/parkinsons-disease-new-diagnosis/#3d-comt-inhibitors-adjunct-to-levodopa","title":"3D. COMT Inhibitors (Adjunct to Levodopa)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Entacapone (Comtan) - ROUTINE ROUTINE - 200 mg with each levodopa dose; max 8 doses/day None absolute Orange urine, diarrhea, dyskinesia Carbidopa/Levodopa/Entacapone (Stalevo) - ROUTINE ROUTINE - Various strengths; replace existing C/L with equivalent Same Same Opicapone (Ongentys) - - ROUTINE - 50 mg daily at bedtime; separate from levodopa by 1 hour None absolute Dyskinesia, constipation Tolcapone (Tasmar) - - EXT - 100-200 mg TID; rarely used due to hepatotoxicity Hepatic disease LFTs q2-4 weeks x6mo, then periodically"},{"location":"plans/parkinsons-disease-new-diagnosis/#3e-anticholinergics-tremor-predominant-younger-patients","title":"3E. Anticholinergics (Tremor-predominant, Younger Patients)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Trihexyphenidyl (Artane) - ROUTINE ROUTINE - Start 1 mg daily; titrate to 2 mg TID; max 15 mg/day Glaucoma, urinary retention, cognitive impairment, age &gt;65 Confusion, urinary retention, dry mouth Benztropine (Cogentin) - ROUTINE ROUTINE - Start 0.5 mg daily; titrate to 1-2 mg BID; max 6 mg/day Same Same"},{"location":"plans/parkinsons-disease-new-diagnosis/#3f-amantadine","title":"3F. Amantadine","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Amantadine IR - ROUTINE ROUTINE - 100 mg BID-TID; avoid evening dosing Renal impairment (reduce dose), seizures Livedo reticularis, edema, hallucinations, insomnia Amantadine ER (Gocovri) - - ROUTINE - 137-274 mg at bedtime; for dyskinesia Same Same"},{"location":"plans/parkinsons-disease-new-diagnosis/#3g-non-motor-symptom-treatment","title":"3G. Non-Motor Symptom Treatment","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Rivastigmine (cognitive) - - ROUTINE - Patch 4.6-13.3 mg/24h; for PD dementia GI bleeding, bradycardia Nausea, bradycardia Quetiapine (psychosis) - ROUTINE ROUTINE - 12.5-100 mg QHS; does not worsen parkinsonism Metabolic syndrome Sedation, glucose, QTc Pimavanserin (Nuplazid) - - ROUTINE - 34 mg daily; for PD psychosis QTc prolongation QTc monitoring Droxidopa (orthostatic hypotension) - ROUTINE ROUTINE - Start 100 mg TID; max 600 mg TID Supine HTN BP supine and standing Fludrocortisone (orthostatic hypotension) - ROUTINE ROUTINE - 0.1-0.2 mg daily Heart failure, HTN K+, edema, supine BP Polyethylene glycol (constipation) - ROUTINE ROUTINE - 17 g daily in water Bowel obstruction Bowel movements"},{"location":"plans/parkinsons-disease-new-diagnosis/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/parkinsons-disease-new-diagnosis/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Movement disorder specialist - ROUTINE ROUTINE - All new PD diagnoses for confirmation and management Physical therapy - ROUTINE ROUTINE - Gait training, balance, LSVT-BIG program Occupational therapy - ROUTINE ROUTINE - ADL assistance, home safety evaluation Speech therapy (LSVT-LOUD) - ROUTINE ROUTINE - Hypophonia, dysarthria, dysphagia assessment Neuropsychology - - ROUTINE - Cognitive concerns, baseline assessment Psychiatry - ROUTINE ROUTINE - Depression, anxiety, impulse control disorders Social work - ROUTINE ROUTINE - Resources, support groups, caregiver support Nutrition/Dietitian - ROUTINE ROUTINE - Weight management, protein timing with levodopa Sleep medicine - - ROUTINE - REM sleep behavior disorder, excessive daytime sleepiness Urology - - ROUTINE - Urinary symptoms, erectile dysfunction"},{"location":"plans/parkinsons-disease-new-diagnosis/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD PD is a chronic condition managed with medications; not curable but treatable - ROUTINE ROUTINE Take levodopa 30-60 minutes before meals for best absorption; protein can reduce effect - ROUTINE ROUTINE Report impulse control changes (gambling, shopping, hypersexuality) immediately - ROUTINE ROUTINE Do NOT stop PD medications abruptly - risk of severe withdrawal/NMS - ROUTINE ROUTINE Fall prevention: remove rugs, improve lighting, use assistive devices as needed - ROUTINE ROUTINE Exercise is essential: walking, tai chi, boxing, cycling all beneficial - ROUTINE ROUTINE Join support group (Parkinson's Foundation, Michael J. Fox Foundation) - - ROUTINE Advance directives discussion early in disease course - - ROUTINE"},{"location":"plans/parkinsons-disease-new-diagnosis/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular aerobic exercise (30+ min, 5 days/week) - may slow progression - ROUTINE ROUTINE Maintain social activities and cognitive engagement - ROUTINE ROUTINE Fall prevention strategies - ROUTINE ROUTINE Avoid medications that worsen parkinsonism (metoclopramide, typical antipsychotics, prochlorperazine) - ROUTINE ROUTINE Mediterranean diet associated with better outcomes - - ROUTINE Optimize sleep hygiene - ROUTINE ROUTINE Caffeine may have protective effect (moderate consumption) - - ROUTINE"},{"location":"plans/parkinsons-disease-new-diagnosis/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Essential tremor Action/postural tremor (not rest), bilateral, head tremor, family history, alcohol-responsive Clinical; DaTscan normal in ET Drug-induced parkinsonism Medication history (antipsychotics, metoclopramide), symmetric, may resolve with drug withdrawal Medication review; DaTscan often normal Vascular parkinsonism Lower-body predominant, gait disorder, stepwise progression, vascular risk factors, MRI white matter changes MRI brain; poor levodopa response Progressive supranuclear palsy (PSP) Early falls (backward), vertical gaze palsy, axial rigidity &gt; limb, poor levodopa response MRI (hummingbird sign), clinical Multiple system atrophy (MSA) Early autonomic failure, cerebellar signs (MSA-C), poor levodopa response MRI (hot cross bun sign), MIBG preserved in MSA Corticobasal degeneration (CBD) Asymmetric apraxia, alien limb, cortical sensory loss, dystonia MRI (asymmetric cortical atrophy), clinical Dementia with Lewy bodies (DLB) Dementia before or within 1 year of parkinsonism, visual hallucinations, fluctuations Clinical criteria; DaTscan abnormal Normal pressure hydrocephalus (NPH) Gait apraxia (magnetic gait), urinary incontinence, dementia; triad MRI (ventriculomegaly), LP with large volume tap Wilson disease Age &lt;50, KF rings, hepatic/psychiatric symptoms, tremor may be wing-beating Ceruloplasmin, 24h urine copper, slit lamp exam"},{"location":"plans/parkinsons-disease-new-diagnosis/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal UPDRS/MDS-UPDRS - ROUTINE ROUTINE - Each visit Stable or improved scores Adjust medications Orthostatic vitals - ROUTINE ROUTINE - Each visit &lt;20 mmHg SBP drop Midodrine, droxidopa, compression stockings Impulse control screening - ROUTINE ROUTINE - Each visit Negative Reduce/discontinue dopamine agonist Cognitive screening (MoCA) - - ROUTINE - Annually or if concerns \u226526 Rivastigmine if dementia Depression screening (BDI, PHQ-9) - ROUTINE ROUTINE - q6 months Negative Treat depression Falls assessment - ROUTINE ROUTINE - Each visit None or decreasing PT, home safety, assistive devices Dysphagia screening - ROUTINE ROUTINE - Annually or if concerns Safe swallow Speech therapy, modified diet Weight - ROUTINE ROUTINE - Each visit Stable Nutrition consult Blood pressure (supine and standing) - ROUTINE ROUTINE - Each visit No symptomatic orthostasis Address as above"},{"location":"plans/parkinsons-disease-new-diagnosis/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Outpatient management Most new PD diagnoses; able to perform ADLs, stable home environment Admit to hospital Acute deterioration (infection causing worsening), severe \"off\" episodes, inability to take PO medications, falls with injury, psychosis Discharge from hospital Medications optimized, safe swallow, ambulatory (with assistance if needed), caregiver support Movement disorder specialist referral All new diagnoses (confirmation), young onset, atypical features, diagnostic uncertainty, motor fluctuations, dyskinesia, DBS candidacy"},{"location":"plans/parkinsons-disease-new-diagnosis/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source MDS Clinical Diagnostic Criteria for PD Class I Postuma et al., Mov Disord 2015 Levodopa most effective symptomatic therapy Class I, Level A Cochrane Reviews Dopamine agonists monotherapy early PD Class I, Level A Multiple RCTs MAO-B inhibitors mild symptomatic benefit Class I, Level A ADAGIO, TEMPO trials DaTscan useful for uncertain parkinsonism Class II, Level B FDA approved 2011 Exercise may slow disease progression Class II, Level B Observational data, RCTs ongoing LSVT-LOUD effective for speech Class I, Level A Multiple RCTs LSVT-BIG effective for movement Class I, Level A Multiple RCTs Pimavanserin for PD psychosis Class I, Level A FDA approved 2016 Rivastigmine for PD dementia Class I, Level A EXPRESS study Avoid anticholinergics in elderly Class II, Level B Cognitive impairment risk"},{"location":"plans/parkinsons-disease-new-diagnosis/#notes","title":"NOTES","text":"<ul> <li>PD is a clinical diagnosis; DaTscan supports but does not confirm diagnosis</li> <li>Start treatment when symptoms interfere with function or quality of life; no need to wait</li> <li>Levodopa is most effective but traditionally delayed due to dyskinesia concerns; recent evidence suggests early levodopa is safe</li> <li>Dopamine agonists preferred in younger patients (&lt;65) due to lower dyskinesia risk, but watch for impulse control disorders</li> <li>MAO-B inhibitors may have disease-modifying potential (unproven) and are good early monotherapy option</li> <li>\"Drug holiday\" is dangerous - never abruptly stop PD medications (risk of neuroleptic malignant-like syndrome)</li> <li>Medications that worsen PD: metoclopramide, prochlorperazine, typical antipsychotics, reserpine, tetrabenazine</li> <li>Exercise and physical therapy are as important as medications</li> </ul>"},{"location":"plans/parkinsons-disease-new-diagnosis/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 29, 2026) - Initial template creation - Complete medication classes with dosing - MDS diagnostic criteria included - Non-motor symptom treatments - Comprehensive differential diagnosis</p>"},{"location":"plans/parkinsons-disease/","title":"Parkinson's Disease","text":"<p>DIAGNOSIS: Parkinson's Disease ICD-10: G20 (Parkinson's disease) SCOPE: Diagnosis confirmation, dopaminergic therapy initiation and optimization, motor fluctuation management, and non-motor symptom treatment. Excludes Parkinson-plus syndromes (MSA, PSP, CBD, DLB - separate protocols).</p> <p>STATUS: Approved</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC Baseline; rule out anemia contributing to fatigue Normal STAT ROUTINE ROUTINE - BMP Renal function for medication dosing; electrolytes Normal STAT ROUTINE ROUTINE - Hepatic panel (LFTs) Baseline before COMT inhibitors Normal - ROUTINE ROUTINE - TSH Rule out hypothyroidism mimicking bradykinesia Normal - ROUTINE ROUTINE - Vitamin B12 Deficiency can cause parkinsonism; common in elderly &gt;300 pg/mL - ROUTINE ROUTINE - Vitamin D, 25-hydroxy Deficiency common; associated with falls and disease severity &gt;30 ng/mL - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Ceruloplasmin, serum copper Wilson's disease if age &lt;50 Normal - EXT ROUTINE - 24-hour urine copper Wilson's disease confirmation &lt;100 \u03bcg/24hr - - EXT - Ferritin, iron studies Neurodegeneration with brain iron accumulation Normal - ROUTINE ROUTINE - RPR or VDRL Syphilis can cause parkinsonism Nonreactive - EXT EXT - HIV testing HIV-associated parkinsonism Negative - EXT EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Genetic testing (LRRK2, GBA, SNCA, PARK2, PINK1, DJ-1) Family history or early-onset (&lt;50 years) Identifies genetic form - - EXT - CSF biomarkers (alpha-synuclein, tau, amyloid) Research/atypical; synuclein seed amplification assay Abnormal synuclein aggregation - - EXT - Skin biopsy for alpha-synuclein Research; confirms synucleinopathy Phosphorylated synuclein deposits - - EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU MRI Brain without contrast At diagnosis Normal (rules out structural causes, vascular parkinsonism, NPH) MRI-incompatible devices URGENT ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU DaTscan (ioflupane I-123 SPECT) Diagnostic uncertainty; essential tremor vs PD Reduced dopamine transporter uptake in striatum Hypersensitivity to iodine - EXT ROUTINE - MRI Brain with SWI sequence Suspected atypical parkinsonism or iron deposition No \"hot cross bun\" (MSA) or \"hummingbird\" (PSP) signs MRI contraindications - EXT ROUTINE - Cardiac MIBG scan Differentiate PD from MSA Reduced uptake in PD (preserved in MSA) Recent MI; drugs affecting uptake - - EXT - Sleep study (polysomnography) REM sleep behavior disorder evaluation Confirms RBD (prodromal marker) None - - ROUTINE - Autonomic function testing Dysautonomia assessment Orthostatic hypotension, abnormal HR variability None - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU FDG-PET Atypical parkinsonism differentiation Pattern recognition for PD vs PSP vs MSA None - - EXT - Transcranial ultrasound Screening tool Hyperechogenicity of substantia nigra Inadequate bone window - - EXT -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#3-treatment","title":"3. TREATMENT","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbidopa-Levodopa (continue home dose) PO/NG Admitted PD patient; DO NOT HOLD Home dose, same timing :: PO :: :: Give at EXACT same times as home; crushing allowed; use NG if NPO Active psychosis; MAOIs within 14 days Dyskinesias, confusion STAT STAT - STAT Carbidopa-Levodopa (NPO protocol) IV/NG Patient NPO &gt;4 hours Home dose equivalent :: NG :: :: Crush tablets; give via NG at home schedule; consult neurology for IV options if unavailable Same as PO Same as PO STAT STAT - STAT Apomorphine SC SC Off episode in clinic/ED; NPO patient 2 mg SC; 3 mg SC; 4 mg SC; 5 mg SC; 6 mg SC :: SC :: :: Test dose 2 mg; titrate by 1 mg to effect; max 6 mg; pretreat with trimethobenzamide Concurrent 5-HT3 antagonists (ondansetron); severe hypotension BP, nausea; may cause severe hypotension URGENT URGENT ROUTINE - Rotigotine patch TD NPO patient; bridge therapy 2 mg/24hr; 4 mg/24hr; 6 mg/24hr patch :: TD :: :: Apply patch equivalent to oral dopamine agonist dose; onset 2-3 hours Sulfite allergy (adhesive) Application site reactions URGENT URGENT - - Trimethobenzamide IM/PO Pretreat before apomorphine to prevent nausea 300 mg IM/PO :: IM/PO :: :: 300 mg TID starting 3 days before apomorphine initiation Hypersensitivity Drowsiness URGENT URGENT ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Carbidopa-Levodopa IR (Sinemet) PO Motor symptoms; first-line dopaminergic therapy 25/100 TID; 25/250 TID :: PO :: :: Start 25/100 TID; titrate by 1 tablet q1-2wk; typical target 25/100-25/250 TID Active psychosis; MAOIs within 14 days Dyskinesias, nausea, orthostatic hypotension - ROUTINE ROUTINE - Carbidopa-Levodopa CR (Sinemet CR) PO Nocturnal symptoms; wearing off 25/100 CR qHS; 50/200 CR BID :: PO :: :: 25/100 to 50/200 CR at bedtime or BID; 70% bioavailability vs IR Same as IR Same as IR - ROUTINE ROUTINE - Carbidopa-Levodopa ER (Rytary) PO Motor fluctuations; extend levodopa effect 23.75/95 TID; 36.25/145 TID; 48.75/195 TID; 61.25/245 TID :: PO :: :: Convert from IR using manufacturer table; typically TID dosing Same as IR Same as IR - ROUTINE ROUTINE - Pramipexole PO Adjunct to levodopa; monotherapy in early PD; tremor 0.125 mg TID; 0.25 mg TID; 0.5 mg TID; 1 mg TID; 1.5 mg TID :: PO :: :: Start 0.125 mg TID; titrate by 0.125-0.25 mg TID q5-7 days; max 1.5 mg TID Impulse control history Impulse control disorders, somnolence, leg edema - ROUTINE ROUTINE - Ropinirole PO Adjunct or monotherapy; similar to pramipexole 0.25 mg TID; 0.5 mg TID; 1 mg TID; 2 mg TID; 3 mg TID :: PO :: :: Start 0.25 mg TID; titrate weekly; max 8 mg TID Same as pramipexole Same as pramipexole - ROUTINE ROUTINE - Ropinirole XL PO Extended-release option for adherence 2 mg daily; 4 mg daily; 6 mg daily; 8 mg daily :: PO :: :: Start 2 mg daily; titrate by 2 mg q1-2wk; max 24 mg daily Same as IR Same as IR - ROUTINE ROUTINE - Selegiline PO MAO-B inhibitor; adjunct; mild neuroprotection theory 5 mg BID :: PO :: :: 5 mg at breakfast and lunch (avoid evening due to insomnia); max 10 mg/day MAOIs; meperidine; TCAs (caution) Insomnia, hypertensive crisis with tyramine (rare at this dose) - ROUTINE ROUTINE - Rasagiline PO MAO-B inhibitor; once daily; adjunct or monotherapy 0.5 mg daily; 1 mg daily :: PO :: :: Start 0.5-1 mg daily; max 1 mg daily Same as selegiline Hypertensive crisis (rare); serotonin syndrome with other serotonergics - ROUTINE ROUTINE - Safinamide PO MAO-B inhibitor with additional mechanisms; adjunct in fluctuations 50 mg daily; 100 mg daily :: PO :: :: Start 50 mg daily; may increase to 100 mg daily after 2 weeks Severe hepatic impairment; MAOIs; opioids Same as rasagiline; may improve dyskinesia - ROUTINE ROUTINE - Entacapone PO COMT inhibitor; extends levodopa effect; wearing off 200 mg with each levodopa dose :: PO :: :: 200 mg with each levodopa dose; max 8 doses (1600 mg)/day Hepatic impairment; concurrent MAOIs Diarrhea, orange urine, dyskinesias - ROUTINE ROUTINE - Opicapone PO COMT inhibitor; once daily alternative to entacapone 50 mg qHS :: PO :: :: 50 mg once daily at bedtime; take 1 hour before or after levodopa Pheochromocytoma; paraganglioma Dyskinesias, constipation, dry mouth - ROUTINE ROUTINE - Amantadine PO Dyskinesia reduction; mild motor benefit 100 mg BID; 100 mg TID :: PO :: :: Start 100 mg daily; titrate to 100 mg BID-TID; max 400 mg/day; dose-reduce in renal impairment End-stage renal disease; seizure history Livedo reticularis, ankle edema, confusion, hallucinations - ROUTINE ROUTINE - Amantadine ER (Gocovri) PO Dyskinesia; extended-release taken at bedtime 137 mg qHS; 274 mg qHS :: PO :: :: Start 137 mg qHS; increase to 274 mg qHS after 1 week Same as IR Same as IR - ROUTINE ROUTINE - Trihexyphenidyl PO Tremor-dominant PD; younger patients 1 mg TID; 2 mg TID :: PO :: :: Start 1 mg TID; titrate by 2 mg/day q3-5 days; max 15 mg/day Glaucoma; urinary retention; dementia; age &gt;70 Cognitive impairment, dry mouth, constipation, urinary retention - ROUTINE ROUTINE - Benztropine PO Alternative anticholinergic for tremor 0.5 mg BID; 1 mg BID; 2 mg BID :: PO :: :: Start 0.5 mg BID; titrate slowly; max 6 mg/day Same as trihexyphenidyl Same as trihexyphenidyl - ROUTINE ROUTINE - Istradefylline PO Adenosine A2A antagonist; adjunct for OFF time 20 mg daily; 40 mg daily :: PO :: :: Start 20 mg daily; may increase to 40 mg daily Strong CYP3A4 inducers Dyskinesias, dizziness, constipation, hallucinations - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#3c-non-motor-symptom-treatments","title":"3C. Non-Motor Symptom Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Pimavanserin (Nuplazid) PO Parkinson's disease psychosis (hallucinations, delusions) 34 mg daily :: PO :: :: 34 mg once daily; takes 4-6 weeks for effect; no titration needed Severe hepatic impairment; QT prolongation QTc, efficacy assessment at 6 weeks - ROUTINE ROUTINE - Quetiapine PO Psychosis; alternative if pimavanserin unavailable 12.5 mg qHS; 25 mg qHS; 50 mg qHS :: PO :: :: Start 12.5-25 mg qHS; titrate slowly by 12.5-25 mg q3-7d; typical max 150 mg/day Dementia with Lewy bodies (black box) Sedation, metabolic effects, QTc - ROUTINE ROUTINE - Clozapine PO Refractory psychosis; best evidence but monitoring required 6.25 mg qHS; 12.5 mg qHS; 25 mg qHS; 50 mg qHS :: PO :: :: Start 6.25-12.5 mg qHS; titrate by 12.5 mg q1-2wk; max 50-100 mg/day in PD REMS enrollment required ANC weekly x 6 mo, then q2wk x 6 mo, then monthly; agranulocytosis risk - EXT ROUTINE - Rivastigmine (Exelon) PO/Patch Parkinson's disease dementia 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID; 9.5 mg/24hr patch; 13.3 mg/24hr patch :: PO/Patch :: :: Start 1.5 mg BID or 4.6 mg/24hr patch; titrate monthly; max 6 mg BID or 13.3 mg/24hr Severe hepatic impairment Nausea, weight loss, tremor worsening - ROUTINE ROUTINE - Donepezil PO Parkinson's disease dementia; once daily option 5 mg qHS; 10 mg qHS :: PO :: :: Start 5 mg qHS; increase to 10 mg after 4-6 weeks GI bleeding; sick sinus syndrome Nausea, bradycardia, vivid dreams - ROUTINE ROUTINE - Memantine PO Moderate-severe dementia; add to cholinesterase inhibitor 5 mg daily; 10 mg BID :: PO :: :: Start 5 mg daily; titrate by 5 mg/wk; target 10 mg BID Severe renal impairment (dose adjust) Confusion, constipation - ROUTINE ROUTINE - Midodrine PO Orthostatic hypotension 2.5 mg TID; 5 mg TID; 10 mg TID :: PO :: :: Start 2.5 mg TID (before arising, before lunch, mid-afternoon); titrate by 2.5 mg/dose; max 10 mg TID; last dose by 6 PM Supine hypertension; urinary retention; severe cardiac disease Supine BP (must avoid lying flat for 4 hours after dose) - ROUTINE ROUTINE - Droxidopa (Northera) PO Neurogenic orthostatic hypotension 100 mg TID; 200 mg TID; 300 mg TID; 600 mg TID :: PO :: :: Start 100 mg TID; titrate by 100 mg/dose q24-48h; max 600 mg TID Supine hypertension Supine BP, headache - ROUTINE ROUTINE - Fludrocortisone PO Orthostatic hypotension adjunct 0.1 mg daily; 0.2 mg daily :: PO :: :: Start 0.1 mg daily; may increase to 0.2 mg daily; max 0.3 mg CHF; renal failure; severe hypertension K+, edema, supine BP - ROUTINE ROUTINE - Sertraline PO Depression in PD 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg daily MAOIs within 14 days Serotonin syndrome (caution with MAO-B inhibitors) - ROUTINE ROUTINE - Venlafaxine XR PO Depression; anxiety in PD 37.5 mg daily; 75 mg daily; 150 mg daily :: PO :: :: Start 37.5 mg daily; titrate q1-2wk; typical 75-150 mg daily Same as sertraline BP at higher doses - ROUTINE ROUTINE - Polyethylene glycol (MiraLAX) PO Constipation (ubiquitous in PD) 17 g daily; 17 g BID :: PO :: :: 17 g (1 capful) in 8 oz liquid daily; may increase to BID Bowel obstruction Diarrhea if excessive - ROUTINE ROUTINE - Senna + docusate PO Constipation stimulant 2 tablets qHS :: PO :: :: 2 tablets qHS; may increase to 4 tablets Bowel obstruction; undiagnosed abdominal pain Electrolytes with chronic use - ROUTINE ROUTINE - Clonazepam PO REM sleep behavior disorder 0.25 mg qHS; 0.5 mg qHS; 1 mg qHS :: PO :: :: Start 0.25-0.5 mg qHS; titrate to effect; typical 0.5-1 mg Severe sleep apnea; respiratory compromise Sedation, falls, cognitive effects - ROUTINE ROUTINE - Melatonin PO REM sleep behavior disorder; sleep disturbance 3 mg qHS; 6 mg qHS; 9 mg qHS; 12 mg qHS :: PO :: :: Start 3-6 mg qHS; may increase to 12 mg None Generally well-tolerated - ROUTINE ROUTINE - Glycopyrrolate PO Sialorrhea (drooling) 1 mg TID; 2 mg TID :: PO :: :: Start 1 mg TID; titrate to effect; max 2 mg TID Glaucoma; urinary retention; GI obstruction Dry mouth, constipation, urinary retention - ROUTINE ROUTINE - OnabotulinumtoxinA (salivary glands) IM Sialorrhea refractory to oral therapy 100 units total :: IM :: :: 30-50 units per parotid, 10-20 units per submandibular; repeat q3-4 months Infection at site Dysphagia (rare), dry mouth - - ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#3d-advanced-therapies","title":"3D. Advanced Therapies","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Deep brain stimulation (DBS) Surgical Motor fluctuations or tremor refractory to optimal medication STN or GPi stimulation :: Surgical :: :: Unilateral or bilateral; programming done over weeks post-op Neuropsych testing, MRI, off-medication evaluation Dementia; active psychiatric disease; medical comorbidities Programming optimization; battery checks - - ROUTINE - Levodopa-carbidopa intestinal gel (Duopa) Enteral Severe motor fluctuations; 4+ hours OFF/day Continuous infusion :: Enteral :: :: Via PEG-J; 16-hour infusion; morning bolus + continuous rate + extra doses GI tract accessible GI disease preventing PEG-J; coagulopathy Tube site, infections, GI complications - EXT ROUTINE - Apomorphine continuous infusion SC Severe motor fluctuations; not DBS candidate 3-8 mg/hr continuous :: SC :: :: Via subcutaneous pump; typical 3-8 mg/hr during waking hours Caregiver training Same as SC apomorphine Same as SC apomorphine - EXT ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Movement disorders specialist for diagnosis confirmation and advanced therapy evaluation - ROUTINE ROUTINE - Physical therapy for gait training, balance exercises, and LSVT BIG program - ROUTINE ROUTINE - Occupational therapy for ADL adaptation and fine motor strategies - ROUTINE ROUTINE - Speech therapy (LSVT LOUD) for hypophonia and swallowing evaluation - ROUTINE ROUTINE - Neuropsychology for cognitive assessment and DBS candidacy evaluation - - ROUTINE - Psychiatry for depression, anxiety, impulse control disorders, or psychosis management - ROUTINE ROUTINE - Palliative care for advanced disease symptom management and goals of care - ROUTINE ROUTINE - Social work for caregiver support, community resources, and disability planning - ROUTINE ROUTINE - Urology for urinary symptoms not responsive to first-line treatment - - ROUTINE - Gastroenterology for severe constipation or Duopa tube placement - - ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD CRITICAL: Do not skip or delay levodopa doses as this can cause severe OFF episodes and immobility STAT STAT ROUTINE Take levodopa 30-60 minutes before meals for better absorption (protein competes with levodopa transport) - ROUTINE ROUTINE Rise slowly from sitting or lying to prevent falls from orthostatic hypotension URGENT ROUTINE ROUTINE Inform all healthcare providers about PD medications to avoid drug interactions (especially antipsychotics, antiemetics) URGENT ROUTINE ROUTINE Report any new impulsive behaviors (gambling, shopping, hypersexuality) which may indicate impulse control disorder from dopamine agonists - ROUTINE ROUTINE Report hallucinations early as these can be managed with medication adjustment - ROUTINE ROUTINE Engage in regular exercise which may slow disease progression and improves mobility - ROUTINE ROUTINE","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Regular aerobic exercise (30-60 min, 3-5x/week) improves motor function and may be neuroprotective - ROUTINE ROUTINE Tai chi or dance-based exercise programs improve balance and reduce falls - ROUTINE ROUTINE High-fiber diet and adequate hydration to prevent constipation - ROUTINE ROUTINE Avoid medications that worsen parkinsonism (metoclopramide, prochlorperazine, haloperidol, risperidone) URGENT ROUTINE ROUTINE Fall prevention: remove home hazards, adequate lighting, grab bars, non-slip surfaces - ROUTINE ROUTINE Mediterranean diet may have protective benefits based on observational studies - ROUTINE ROUTINE Coffee consumption associated with reduced PD risk; continued moderate use reasonable - ROUTINE ROUTINE","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Drug-induced parkinsonism Medication exposure (antipsychotics, metoclopramide); symmetric; no levodopa response DaTscan normal; history of causative medication Vascular parkinsonism Stepwise progression; lower body predominant; vascular risk factors; pyramidal signs MRI with subcortical/basal ganglia infarcts Progressive supranuclear palsy (PSP) Early falls; vertical gaze palsy; axial rigidity &gt; limb; poor levodopa response MRI \"hummingbird sign\"; clinical criteria Multiple system atrophy (MSA) Severe dysautonomia; cerebellar signs; stridor; poor levodopa response MRI \"hot cross bun\" sign; MIBG preserved Corticobasal degeneration (CBD) Asymmetric rigidity; apraxia; alien limb; cortical sensory loss MRI asymmetric cortical atrophy Dementia with Lewy bodies (DLB) Dementia before or within 1 year of motor symptoms; fluctuating cognition; visual hallucinations Clinical criteria; DaTscan may be abnormal Essential tremor Action tremor &gt; rest tremor; improves with alcohol; family history; no bradykinesia DaTscan normal; clinical criteria Normal pressure hydrocephalus Gait apraxia (\"magnetic gait\"); urinary incontinence; dementia MRI ventricular enlargement; LP with gait improvement","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Motor function (UPDRS-III or MDS-UPDRS) Every visit Document trend; look for &gt;30% change Adjust medications if worsening - ROUTINE ROUTINE - ON/OFF time diary Daily for 1 week before visits &lt;2 hours OFF time/day Add adjunct therapy; consider advanced options - ROUTINE ROUTINE - Dyskinesia severity Each visit Minimize troublesome dyskinesia Reduce levodopa; add amantadine; adjust timing - ROUTINE ROUTINE - Orthostatic blood pressure Each visit &lt;20 mmHg systolic drop on standing Add midodrine or droxidopa - ROUTINE ROUTINE - Cognition (MoCA) Annually, more often if concerns &gt;26 normal; decline triggers action Add cholinesterase inhibitor; adjust anticholinergics - - ROUTINE - Mood (GDS, PHQ-9) Annually Screen negative Add antidepressant; psychiatry referral - ROUTINE ROUTINE - Impulse control screen (QUIP) Each visit if on dopamine agonist Negative Reduce or discontinue dopamine agonist - ROUTINE ROUTINE - Falls frequency Each visit Zero falls PT referral; medication review; home safety evaluation - ROUTINE ROUTINE - Swallowing function Annually or if symptoms No aspiration risk Speech therapy; modify diet - ROUTINE ROUTINE - ANC (if on clozapine) Per REMS protocol ANC &gt;1500/\u03bcL Hold clozapine if ANC &lt;1000; discontinue if &lt;500 - ROUTINE ROUTINE -","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable motor status; able to take PO; adequate caregiver support; follow-up arranged Admit to floor Unable to take PO medications &gt;24 hours; severe OFF episode; aspiration pneumonia; acute infection Admit to ICU Neuroleptic malignant syndrome; severe rigidity with rhabdomyolysis; respiratory compromise Outpatient follow-up Every 3-6 months for stable patients; more frequently during medication adjustments","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Levodopa most effective symptomatic treatment Class I, Level A Fahn et al. NEJM 2004 (ELLDOPA) MAO-B inhibitors provide mild motor benefit Class I, Level A Rascol et al. NEJM 2005 (rasagiline) Pimavanserin for PD psychosis Class I, Level A Cummings et al. Lancet 2014 DBS improves motor fluctuations Class I, Level A Weaver et al. JAMA 2009 Rivastigmine for PD dementia Class I, Level A Emre et al. NEJM 2004 Exercise improves motor function Class II, Level B Schenkman et al. JAMA Neurol 2018 LSVT LOUD improves speech Class I, Level B Ramig et al. JSLHR 2001 Clonazepam and melatonin for RBD Class II, Level B Aurora et al. AASM 2010 Amantadine reduces dyskinesia Class I, Level A Ory-Magne et al. Lancet Neurol 2014 Duopa for motor fluctuations Class I, Level A Olanow et al. Lancet Neurol 2014","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - Comprehensive motor and non-motor treatment coverage - Includes advanced therapies (DBS, Duopa, apomorphine pump) - Structured dosing format for order sentence generation</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/parkinsons-disease/#appendix-a-medications-to-avoid-in-parkinsons-disease","title":"APPENDIX A: Medications to Avoid in Parkinson's Disease","text":"Drug Class Examples Why to Avoid Typical antipsychotics Haloperidol, chlorpromazine, fluphenazine D2 blockade worsens parkinsonism Most atypical antipsychotics Risperidone, olanzapine, aripiprazole, ziprasidone Significant D2 blockade Antiemetics (D2 blockers) Metoclopramide, prochlorperazine, promethazine Cross blood-brain barrier; worsen parkinsonism Valproic acid Depakote Can cause parkinsonism; tremor Lithium Lithobid Can cause tremor; parkinsonism Calcium channel blockers (some) Flunarizine, cinnarizine D2 blocking properties Reserpine Serpasil Depletes dopamine <p>Safe alternatives: - Antiemetics: Ondansetron, domperidone (not US), trimethobenzamide - Antipsychotics: Quetiapine (first-line), clozapine, pimavanserin</p>","tags":["movement-disorders","parkinson","outpatient"]},{"location":"plans/peripheral-neuropathy/","title":"Peripheral Neuropathy - New Diagnosis/Evaluation","text":"<p>VERSION: 1.2 CREATED: January 14, 2026 REVISED: January 14, 2026 STATUS: Revised per physician feedback</p> <p>DIAGNOSIS: Peripheral Neuropathy - New Diagnosis/Evaluation</p> <p>ICD-10: G62.9 (Polyneuropathy, unspecified); G60.9 (Hereditary and idiopathic neuropathy, unspecified); G62.0 (Drug-induced polyneuropathy); G62.1 (Alcoholic polyneuropathy); G63 (Polyneuropathy in diseases classified elsewhere)</p> <p>SCOPE: Initial diagnostic workup and symptomatic management of suspected or newly diagnosed peripheral neuropathy. Covers etiologic evaluation, electrodiagnostic testing, pain management, and lifestyle modifications. For acute inflammatory neuropathies (GBS, CIDP), use dedicated templates. For diabetic neuropathy-specific management, this template applies but see also diabetes care protocols for glycemic optimization.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090 SECTION A: ACTION ITEMS \u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090</p>"},{"location":"plans/peripheral-neuropathy/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/peripheral-neuropathy/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Anemia (B12), infection, malignancy screen Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Renal dysfunction (uremic neuropathy), hepatic disease, electrolytes Normal Fasting glucose STAT STAT ROUTINE STAT Diabetes screening &lt;100 mg/dL HbA1c URGENT ROUTINE ROUTINE URGENT Diabetes/prediabetes (most common cause) &lt;5.7% Vitamin B12 URGENT ROUTINE ROUTINE URGENT B12 deficiency neuropathy &gt;300 pg/mL Methylmalonic acid (MMA) - ROUTINE ROUTINE - If B12 borderline (200-400); more sensitive Normal Folate URGENT ROUTINE ROUTINE URGENT Folate deficiency Normal TSH URGENT ROUTINE ROUTINE URGENT Hypothyroidism causes neuropathy Normal (0.4-4.0 mIU/L) ESR URGENT ROUTINE ROUTINE URGENT Inflammatory/vasculitic process Normal (&lt;20 mm/hr) CRP URGENT ROUTINE ROUTINE URGENT Inflammatory marker Normal"},{"location":"plans/peripheral-neuropathy/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Oral glucose tolerance test (2-hour) - ROUTINE ROUTINE - Detects IGT missed by FBG/HbA1c; high yield in idiopathic neuropathy (34-62% have abnormal OGTT) &lt;140 mg/dL at 2h Serum protein electrophoresis (SPEP) with immunofixation - ROUTINE ROUTINE - Monoclonal gammopathy (MGUS, myeloma) No M-spike 24-hour urine protein electrophoresis (UPEP) - ROUTINE ROUTINE - Light chain disease No monoclonal protein Free light chains (kappa/lambda) - ROUTINE ROUTINE - AL amyloidosis, light chain deposition Normal ratio (0.26-1.65) Vitamin B1 (thiamine) - ROUTINE ROUTINE - Alcoholism, malnutrition, bariatric surgery Normal Vitamin B6 (pyridoxine) - ROUTINE ROUTINE - Deficiency OR toxicity (&gt;200 mg/day) causes neuropathy Normal (5-50 ng/mL) Vitamin E - ROUTINE ROUTINE - Malabsorption, cholestasis Normal Copper - ROUTINE ROUTINE - Copper deficiency (zinc excess, bariatric surgery) Normal Zinc - ROUTINE ROUTINE - Zinc excess suppresses copper Normal HIV antibody - ROUTINE ROUTINE - HIV-associated distal sensory polyneuropathy Negative Hepatitis B surface antigen/antibody - ROUTINE ROUTINE - Hepatitis B-associated PAN, cryoglobulinemia Negative Hepatitis C antibody - ROUTINE ROUTINE - HCV-associated cryoglobulinemia, vasculitic neuropathy Negative Lyme serology (endemic areas) - ROUTINE ROUTINE - Lyme neuroborreliosis Negative ANA - ROUTINE ROUTINE - Connective tissue disease screen Negative or low titer RPR/VDRL - ROUTINE ROUTINE - Syphilitic neuropathy Negative Rheumatoid factor - ROUTINE ROUTINE - Rheumatoid vasculitis Negative Anti-SSA/SSB (Ro/La) - ROUTINE ROUTINE - Sj\u00c3\u0192\u00c2\u00b6gren syndrome (small fiber) Negative ACE level - ROUTINE ROUTINE - Sarcoidosis Normal"},{"location":"plans/peripheral-neuropathy/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-MAG antibody - EXT EXT - IgM paraproteinemic neuropathy Negative Anti-ganglioside antibodies (GM1, GD1a, GD1b, GQ1b) - EXT EXT - If motor-predominant or acute onset (GBS variants) Negative Paraneoplastic panel - EXT EXT - Subacute sensory neuronopathy, weight loss, smoking Negative (Anti-Hu, CV2) Cryoglobulins - EXT EXT - Hepatitis C, autoimmune, vasculitic neuropathy Negative Anti-CASPR2, Anti-LGI1 - EXT EXT - Neuromyotonia, Morvan syndrome Negative Fat pad or sural nerve biopsy - EXT EXT - Amyloidosis, vasculitis, CIDP variants No amyloid or vasculitis Genetic testing (CMT panel, TTR gene) - - EXT - Hereditary neuropathy, familial amyloidosis No pathogenic variant Skin punch biopsy for IENFD - - EXT - Small fiber neuropathy confirmation &gt;8.8 fibers/mm (varies by site/age) Heavy metal panel (lead, arsenic, thallium, mercury) - EXT EXT - Occupational/environmental exposure Normal"},{"location":"plans/peripheral-neuropathy/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/peripheral-neuropathy/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Nerve conduction studies (NCS) and EMG - ROUTINE ROUTINE - Optimal 3-4 weeks after symptom onset (allows Wallerian degeneration to manifest); can be done earlier if acute weakness suspected Pattern determines axonal vs demyelinating, distribution, severity Pacemaker (relative); anticoagulation for needle EMG (relative)"},{"location":"plans/peripheral-neuropathy/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI spine (cervical/lumbar) with and without contrast URGENT ROUTINE ROUTINE URGENT If radiculopathy, myelopathy, or polyradiculopathy suspected Nerve root enhancement (radiculopathy), cord signal change GFR &lt;30, pacemaker, gadolinium allergy MRI lumbar plexus with contrast - ROUTINE ROUTINE - Lumbosacral plexopathy, asymmetric proximal weakness Plexus enhancement, mass lesion Same as above MRI brachial plexus with contrast - ROUTINE ROUTINE - Brachial plexopathy, Parsonage-Turner syndrome Plexus enhancement, denervation changes Same as above Autonomic function testing (QSART, tilt table, HRV) - - ROUTINE - Autonomic symptoms (orthostasis, anhidrosis, GI dysmotility) Abnormal sudomotor or cardiovagal function None significant Quantitative sensory testing (QST) - - EXT - Small fiber neuropathy evaluation Abnormal thermal thresholds None significant Chest X-ray URGENT ROUTINE ROUTINE URGENT Lung cancer (paraneoplastic), sarcoidosis Normal Pregnancy (relative) CT chest/abdomen/pelvis - ROUTINE ROUTINE - Occult malignancy if paraneoplastic suspected No mass Contrast allergy, renal impairment"},{"location":"plans/peripheral-neuropathy/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications PET-CT - EXT EXT - Occult malignancy, amyloidosis No FDG-avid lesions Pregnancy, uncontrolled diabetes Nerve ultrasound - EXT ROUTINE - CIDP (nerve enlargement), entrapment Normal nerve caliber None MR neurography - EXT EXT - Focal nerve pathology, plexopathy Normal nerve signal/caliber Same as MRI Sural nerve biopsy - EXT - - Vasculitic neuropathy, amyloidosis, CIDP No vasculitis or amyloid deposits Coagulopathy"},{"location":"plans/peripheral-neuropathy/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Suspected inflammatory/demyelinating neuropathy (GBS, CIDP), infectious etiology, leptomeningeal disease, or atypical presentation</p> <p>Timing: URGENT if GBS/CIDP suspected; ROUTINE for chronic neuropathy workup</p> <p>Volume Required: 10-15 mL (standard diagnostic)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Rule out elevated ICP 10-20 cm H2O Cell count (tubes 1 and 4) URGENT ROUTINE ROUTINE Inflammation, infection WBC &lt;5, RBC 0 Protein URGENT ROUTINE ROUTINE Albuminocytologic dissociation in GBS/CIDP Normal 15-45 mg/dL; elevated in GBS/CIDP Glucose with serum glucose URGENT ROUTINE ROUTINE Infection, carcinomatous meningitis Normal (&gt;60% serum) Gram stain and culture URGENT ROUTINE ROUTINE Rule out infection No organisms Cytology - ROUTINE ROUTINE Leptomeningeal carcinomatosis Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Negative Lyme PCR/antibody index - ROUTINE ROUTINE Endemic areas Negative <p>Special Handling: Cytology requires rapid transport (&lt;1 hour).</p> <p>Contraindications: Elevated ICP without imaging, coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site</p> <p>Note: CSF protein may be normal in first 1-2 weeks of GBS. Elevated protein with normal cell count (\"albuminocytologic dissociation\") is classic for GBS/CIDP.</p>"},{"location":"plans/peripheral-neuropathy/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/peripheral-neuropathy/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Thiamine IV (if alcoholic or malnourished) STAT STAT - STAT 500 mg IV TID \u00c3\u0192\u00e2\u20ac\u201d 3 days, then 250 mg IV daily \u00c3\u0192\u00e2\u20ac\u201d 3-5 days, then oral None significant Anaphylaxis (rare) Vitamin B12 IM (if deficient) URGENT URGENT ROUTINE URGENT 1000 mcg IM daily \u00c3\u0192\u00e2\u20ac\u201d 7 days, then weekly \u00c3\u0192\u00e2\u20ac\u201d 4 weeks, then monthly Cobalt allergy Reticulocyte count at 1 week; B12 level at 1-2 months Glucose control optimization STAT STAT ROUTINE STAT Per diabetes protocol; target HbA1c &lt;7% Hypoglycemia risk Glucose monitoring"},{"location":"plans/peripheral-neuropathy/#3b-symptomatic-treatments-neuropathic-pain","title":"3B. Symptomatic Treatments - Neuropathic Pain","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Gabapentin Neuropathic pain (first-line) - ROUTINE ROUTINE ROUTINE Start 300 mg qHS; increase by 300 mg every 1-3 days; target 900-1800 mg TID; max 3600 mg/day Renal impairment (adjust dose per CrCl: CrCl 30-59: max 900-1400 mg/day; CrCl 15-29: max 600 mg/day; CrCl &lt;15: max 300 mg/day) Sedation, dizziness, peripheral edema; taper to discontinue Pregabalin Neuropathic pain (first-line) - ROUTINE ROUTINE ROUTINE Start 75 mg BID; increase to 150 mg BID after 1 week; max 300 mg BID Renal impairment (adjust dose per CrCl); Class V controlled substance Sedation, weight gain, peripheral edema Duloxetine Neuropathic pain (first-line, especially diabetic) - ROUTINE ROUTINE - Start 30 mg daily \u00c3\u0192\u00e2\u20ac\u201d 1 week; increase to 60 mg daily; max 120 mg/day Hepatic impairment; CrCl &lt;30; concurrent MAOIs; uncontrolled narrow-angle glaucoma Nausea (usually transient), BP; discontinuation syndrome (taper over 2+ weeks) Venlafaxine XR Neuropathic pain - ROUTINE ROUTINE - Start 37.5-75 mg daily; increase by 75 mg every 4-7 days; max 225 mg daily Uncontrolled hypertension; concurrent MAOIs BP monitoring; discontinuation syndrome Amitriptyline Neuropathic pain (second-line) - ROUTINE ROUTINE - Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Cardiac conduction abnormality; recent MI; urinary retention; narrow-angle glaucoma; elderly (anticholinergic burden) ECG if dose &gt;100 mg/day; anticholinergic effects Nortriptyline Neuropathic pain (second-line) - ROUTINE ROUTINE - Start 10-25 mg qHS; increase by 10-25 mg weekly; max 150 mg qHS Same as amitriptyline Same; fewer anticholinergic effects than amitriptyline Desipramine Neuropathic pain (second-line) - ROUTINE ROUTINE - Start 25 mg qHS; increase by 25 mg weekly; max 150 mg daily Same as amitriptyline Same; least anticholinergic TCA Carbamazepine Trigeminal neuralgia, lancinating pain - ROUTINE ROUTINE - Start 100 mg BID; increase by 200 mg/day every 3-7 days; max 1200 mg/day AV block; bone marrow suppression; concurrent MAOIs CBC, LFTs, sodium at baseline and periodically; HLA-B*1502 screening in at-risk populations Oxcarbazepine Trigeminal neuralgia, lancinating pain - ROUTINE ROUTINE - Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID Hypersensitivity to carbamazepine Sodium (hyponatremia risk); HLA-B*1502 screening Capsaicin cream 0.025-0.075% Localized neuropathic pain - - ROUTINE - Apply TID-QID to affected area; takes 2-4 weeks for effect Open wounds; avoid eyes/mucous membranes Initial burning (decreases with continued use); wash hands after application Capsaicin 8% patch (Qutenza) Localized neuropathic pain (refractory) - - ROUTINE - Applied by healthcare provider for 30-60 minutes; may repeat every 3 months Same as above Must be applied in clinic; pretreat area with topical lidocaine Lidocaine 5% patch Localized neuropathic pain - ROUTINE ROUTINE ROUTINE Apply 1-3 patches to painful area for 12 hours on, 12 hours off Severe hepatic impairment; application to broken skin Minimal systemic absorption; local irritation Tramadol Moderate neuropathic pain (adjunct) - ROUTINE ROUTINE - Start 50 mg q6h PRN; may use ER 100 mg daily; max 400 mg/day Seizure disorder; concurrent MAOIs; concurrent SSRIs (serotonin syndrome) Serotonin syndrome; seizures; dependence (Schedule IV) Tapentadol ER Moderate-severe neuropathic pain - - ROUTINE - Start 50 mg BID; increase by 50 mg BID every 3 days; max 250 mg BID Same as tramadol Same; Schedule II Morphine ER Severe refractory pain - ROUTINE ROUTINE ROUTINE Start 15 mg q12h; titrate every 1-2 days; no max (titrate to effect) Respiratory depression; paralytic ileus; concurrent MAOIs Sedation, constipation, respiratory status; naloxone available Oxycodone ER Severe refractory pain - ROUTINE ROUTINE ROUTINE Start 10 mg q12h; titrate every 1-2 days Same as morphine Same; Schedule II Methadone Severe refractory neuropathic pain - - EXT - Start 2.5-5 mg TID; titrate slowly (long half-life); specialist management QT prolongation; concurrent QT-prolonging drugs ECG at baseline and with dose changes; QTc monitoring <p>Combination Therapy Note: For refractory neuropathic pain, combining agents from different classes (e.g., gabapentinoid + SNRI, or gabapentinoid + TCA) is often more effective than maximizing monotherapy. Avoid combining TCAs with SNRIs (serotonin syndrome risk).</p>"},{"location":"plans/peripheral-neuropathy/#3c-symptomatic-treatments-other-symptoms","title":"3C. Symptomatic Treatments - Other Symptoms","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Midodrine Orthostatic hypotension - ROUTINE ROUTINE ROUTINE Start 2.5 mg TID (upon awakening, midday, mid-afternoon); increase by 2.5 mg every 1-2 weeks; max 10 mg TID; do NOT take within 4 hours of bedtime Severe heart disease; urinary retention; pheochromocytoma Supine hypertension (avoid lying flat within 4 hours); urinary retention Fludrocortisone Orthostatic hypotension - ROUTINE ROUTINE ROUTINE Start 0.1 mg daily; increase by 0.1 mg every 1-2 weeks; max 0.3 mg daily CHF; hypertension Potassium, BP, edema; hypokalemia; supine hypertension Droxidopa (Northera) Neurogenic orthostatic hypotension - - ROUTINE - Start 100 mg TID; increase by 100 mg TID every 24-48 hours; max 600 mg TID Concurrent ergot alkaloids; hypersensitivity Supine hypertension (do not take within 3 hours of bedtime); use caution with MAOIs and triptans (hypertensive risk) Pyridostigmine Orthostatic hypotension (off-label) - - ROUTINE - 30-60 mg TID Mechanical GI/GU obstruction; asthma (relative) Cholinergic effects; less supine hypertension than midodrine Polyethylene glycol 3350 Constipation (autonomic) - ROUTINE ROUTINE - 17 g daily; adjust to effect Bowel obstruction Electrolytes with prolonged use Docusate sodium Constipation - ROUTINE ROUTINE - 100 mg BID; max 500 mg/day Intestinal obstruction Minimal efficacy alone Senna Constipation - ROUTINE ROUTINE - 8.6-17.2 mg qHS; max 34.4 mg/day Intestinal obstruction; acute abdominal pain Cramping Metoclopramide Gastroparesis - ROUTINE ROUTINE - 5-10 mg 30 minutes before meals and qHS; max 40 mg/day; limit to 12 weeks (FDA black box: tardive dyskinesia risk) Bowel obstruction; Parkinson disease; tardive dyskinesia history Tardive dyskinesia (limit duration); QT prolongation Domperidone Gastroparesis (if metoclopramide contraindicated) - - EXT - 10 mg TID before meals; max 30 mg/day QT prolongation; concurrent QT-prolonging drugs ECG at baseline; not FDA-approved (requires special access) Oxybutynin IR Bladder urgency (anticholinergic caution in neuropathy) - ROUTINE ROUTINE - Start 5 mg BID-TID; max 5 mg QID Urinary retention; narrow-angle glaucoma Dry mouth, constipation, cognitive impairment Mirabegron Bladder urgency - - ROUTINE - Start 25 mg daily; may increase to 50 mg daily Uncontrolled hypertension BP monitoring; fewer anticholinergic effects Tamsulosin Urinary retention - ROUTINE ROUTINE - 0.4 mg daily 30 minutes after same meal each day Severe sulfonamide allergy Orthostatic hypotension (caution if already orthostatic) Sildenafil Erectile dysfunction - - ROUTINE - 50 mg 30-60 min before activity; may adjust 25-100 mg; max 100 mg/day Concurrent nitrates; recent MI/stroke Hypotension; priapism Tadalafil Erectile dysfunction - - ROUTINE - 10 mg before activity (max once daily) OR 2.5-5 mg daily Same as sildenafil Same Hydroxyzine Anxiety, pruritus - ROUTINE ROUTINE - 25-50 mg TID-QID PRN; max 400 mg/day QT prolongation (high doses) Sedation; anticholinergic effects Buspirone Generalized anxiety - - ROUTINE - Start 5 mg TID; increase by 5 mg every 2-3 days; max 60 mg/day Concurrent MAOIs Takes 2-4 weeks for effect; no dependence Trazodone Insomnia with chronic pain - ROUTINE ROUTINE - Start 25-50 mg qHS; increase to 100-150 mg; max 200 mg qHS Concurrent MAOIs; QT prolongation QTc; priapism (rare); sedation Melatonin Insomnia (adjunct) - ROUTINE ROUTINE - 3-5 mg qHS 30 minutes before bed None significant Generally well-tolerated <p>Note for ICU: Midodrine and fludrocortisone marked ROUTINE in ICU for continuation of home regimen in admitted patients; typically not initiated in ICU setting.</p>"},{"location":"plans/peripheral-neuropathy/#3d-disease-specific-treatments","title":"3D. Disease-Specific Treatments","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring IVIG CIDP, MMN, GBS - URGENT ROUTINE URGENT 2 g/kg divided over 2-5 days (induction); maintenance 0.4-1 g/kg every 2-4 weeks IgA deficiency (use IgA-depleted product); renal failure; thrombosis risk Renal function, headache, thrombosis, infusion reactions Plasma exchange (PLEX) CIDP, GBS - URGENT - URGENT 5-7 exchanges over 10-14 days Hemodynamic instability, sepsis BP, electrolytes, coags, fibrinogen Prednisone CIDP, vasculitic neuropathy - ROUTINE ROUTINE - 1 mg/kg/day (max 80 mg) \u00c3\u0192\u00e2\u20ac\u201d 4-6 weeks; taper over 3-6 months Active untreated infection, uncontrolled diabetes, psychosis Glucose, BP, mood, bone density with prolonged use Rituximab Anti-MAG neuropathy, vasculitic neuropathy, refractory CIDP - EXT EXT - 375 mg/m\u00c3\u201a\u00c2\u00b2 IV weekly \u00c3\u0192\u00e2\u20ac\u201d 4 weeks OR 1000 mg IV \u00c3\u0192\u00e2\u20ac\u201d 2 doses 14 days apart Active hepatitis B; active infection Hepatitis B serology, infusion reactions, infection monitoring Azathioprine Steroid-sparing for CIDP, vasculitis - EXT ROUTINE - Start 50 mg daily; increase to 2-3 mg/kg/day over weeks TPMT deficiency (test before starting); pregnancy CBC weekly \u00c3\u0192\u00e2\u20ac\u201d 1 month, then q2-4 weeks; LFTs monthly; TPMT genotype Mycophenolate mofetil Steroid-sparing for CIDP, vasculitis - EXT ROUTINE - 500 mg BID \u00c3\u0192\u00e2\u20ac\u201d 2 weeks, then 1000 mg BID Pregnancy (teratogenic); concurrent azathioprine CBC q2 weeks \u00c3\u0192\u00e2\u20ac\u201d 3 months, then monthly; GI upset Cyclophosphamide Vasculitic neuropathy (severe) - EXT EXT - 1-2 mg/kg/day PO OR 500-1000 mg/m\u00c3\u201a\u00c2\u00b2 IV monthly \u00c3\u0192\u00e2\u20ac\u201d 6 months Pregnancy; bone marrow suppression; active infection CBC weekly; urinalysis (hemorrhagic cystitis); cumulative dose limit Tafamidis (Vyndamax/Vyndaqel) Hereditary transthyretin (hATTR) amyloidosis with polyneuropathy - - ROUTINE - 61 mg (Vyndamax) or 80 mg (Vyndaqel) daily None absolute LFTs; clinical response Patisiran (Onpattro) hATTR amyloidosis with polyneuropathy - - ROUTINE - 0.3 mg/kg IV every 3 weeks None absolute Vitamin A supplementation at RDA required (patisiran reduces serum vitamin A via TTR reduction); infusion reactions Inotersen (Tegsedi) hATTR amyloidosis with polyneuropathy - - ROUTINE - 284 mg SC once weekly Platelet count &lt;100,000; prior glomerulonephritis from inotersen Platelet count weekly throughout treatment (more frequent if &lt;75 \u00c3\u0192\u00e2\u20ac\u201d 10\u00c3\u00a2\u00c2\u0081\u00c2\u00b9/L); continue monitoring 8 weeks post-discontinuation; renal function q2 weeks; REMS program required"},{"location":"plans/peripheral-neuropathy/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/peripheral-neuropathy/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neuromuscular neurology referral URGENT URGENT ROUTINE URGENT All new neuropathy diagnoses for etiology workup and management Electrodiagnostic medicine/EMG referral - ROUTINE ROUTINE - NCS/EMG for characterization (axonal vs demyelinating, pattern) Physical therapy consult for balance and gait - ROUTINE ROUTINE ROUTINE Gait instability, weakness, falls prevention Occupational therapy consult for hand function - ROUTINE ROUTINE - Fine motor impairment, ADL difficulty Podiatry referral - ROUTINE ROUTINE - Diabetic neuropathy, foot care education, orthotics, wound prevention Endocrinology referral - ROUTINE ROUTINE - Diabetes management optimization if HbA1c not at goal Pain management/Anesthesia referral - - ROUTINE - Refractory neuropathic pain, spinal cord stimulator evaluation Rheumatology referral - ROUTINE ROUTINE - Suspected vasculitic neuropathy, connective tissue disease Hematology/Oncology referral - URGENT ROUTINE - Paraproteinemic neuropathy, suspected malignancy, amyloidosis Genetic counseling referral - - ROUTINE - Suspected hereditary neuropathy (CMT, hATTR), family history Psychiatry/Psychology referral - ROUTINE ROUTINE - Chronic pain management, depression, anxiety Social work consult - ROUTINE ROUTINE - Disability resources, insurance navigation, DME assistance Wound care referral - URGENT ROUTINE URGENT Diabetic foot ulcers, non-healing wounds Orthotics/Prosthetics - - ROUTINE - AFOs for foot drop, custom orthotics Nutrition/Dietitian referral - ROUTINE ROUTINE - Alcoholic neuropathy, nutritional deficiencies, bariatric surgery patients Addiction medicine/Psychiatry - ROUTINE ROUTINE - Alcohol use disorder, opioid risk mitigation"},{"location":"plans/peripheral-neuropathy/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Return to ED if sudden severe weakness, difficulty breathing, or rapid symptom progression \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Inspect feet daily for cuts, blisters, or wounds (use mirror for soles) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Wear well-fitting, protective footwear at all times (never barefoot) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Test bath water temperature with elbow or thermometer before entering (avoid burns) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Avoid prolonged hot or cold exposure to affected extremities (impaired sensation increases injury risk) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Use night lights and handrails to prevent falls - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Report new numbness, weakness, or autonomic symptoms (dizziness, bladder changes) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Keep pain medication diary to track effectiveness and side effects - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Do not stop gabapentin/pregabalin abruptly - taper under medical guidance - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Neuropathic pain medications take 2-4 weeks to reach full effect - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Avoid alcohol (worsens neuropathy, interacts with pain medications) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Rise slowly from sitting/lying position if orthostatic hypotension present - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Increase salt and fluid intake if orthostatic (unless contraindicated by cardiac/renal disease) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Wear compression stockings for orthostatic hypotension - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Do not drive until cleared if significant sensory loss or weakness affects pedal control \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 B12 injections: if self-administering, use proper technique and rotate injection sites - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153"},{"location":"plans/peripheral-neuropathy/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Strict glycemic control (HbA1c &lt;7% or individualized target) - most important modifiable factor \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Complete alcohol cessation (alcoholic neuropathy is reversible if early) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Smoking cessation (microvascular disease worsens neuropathy) \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Regular exercise as tolerated (improves circulation, glycemic control, reduces pain) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Balance exercises and strength training (PT-guided) to prevent falls - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Pool therapy/aquatic exercise (reduces fall risk while exercising) - - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Vitamin B12 supplementation if vegan/vegetarian or on metformin - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Review medications for neurotoxic agents (metronidazole, nitrofurantoin, chemotherapy, amiodarone, statins) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Avoid excessive vitamin B6 supplementation (&gt;100 mg/day can cause neuropathy) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Blood pressure control (target &lt;130/80 for diabetic patients) - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Weight loss if obese (reduces pressure on nerves, improves metabolic syndrome) - - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Fall prevention: remove throw rugs, ensure adequate lighting, use assistive devices - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Annual foot exams by podiatry or primary care for diabetic patients - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 Regular ophthalmology exams if diabetic (concurrent retinopathy common) - - \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153 <p>\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090 SECTION B: REFERENCE (Expand as Needed) \u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090</p>"},{"location":"plans/peripheral-neuropathy/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Diabetic polyneuropathy Symmetric, length-dependent, sensory-predominant, feet before hands, burning/tingling HbA1c &gt;6.5% (or 2-hour OGTT &gt;200); NCS shows axonal sensorimotor polyneuropathy Alcoholic neuropathy History of chronic alcohol use, nutritional deficiency, burning feet History, thiamine level, liver function tests Vitamin B12 deficiency Subacute combined degeneration, myelopathy features (ataxia, Romberg), macrocytic anemia B12 &lt;200 pg/mL or MMA elevated; may have cord signal changes on MRI Chronic inflammatory demyelinating polyneuropathy (CIDP) Progressive or relapsing weakness &gt;8 weeks, proximal and distal, areflexia NCS shows demyelination; CSF protein elevated; nerve enlargement on ultrasound Guillain-Barr\u00c3\u0192\u00c2\u00a9 syndrome (GBS) Acute ascending weakness &lt;4 weeks, areflexia, post-infectious NCS early may be normal then demyelinating; CSF albuminocytologic dissociation Hereditary neuropathy (CMT) Family history, pes cavus, hammertoes, childhood onset, slowly progressive Genetic testing; NCS shows uniform slowing in CMT1 Hereditary transthyretin amyloidosis (hATTR) Autonomic dysfunction, carpal tunnel, cardiac involvement, family history TTR gene mutation; tissue biopsy with amyloid Monoclonal gammopathy-associated neuropathy Distal sensory-predominant, ataxia (IgM anti-MAG), older patient SPEP/UPEP; anti-MAG antibody; may need bone marrow biopsy Vasculitic neuropathy Mononeuritis multiplex pattern (asymmetric, stepwise), pain, systemic symptoms Elevated ESR/CRP; ANCA; nerve/muscle biopsy shows necrotizing vasculitis Paraneoplastic sensory neuronopathy Subacute onset, asymmetric, dorsal root ganglia involvement, weight loss Anti-Hu antibody; CT chest for small cell lung cancer Radiculopathy Dermatomal distribution, unilateral, neck/back pain, preserved reflexes outside affected root MRI spine; NCS/EMG shows radicular pattern Lumbosacral plexopathy (diabetic amyotrophy) Acute/subacute proximal weakness, thigh pain, unilateral then contralateral NCS/EMG; MRI lumbosacral plexus; diagnosis of exclusion Small fiber neuropathy Pain/autonomic symptoms with normal NCS, preserved reflexes Skin biopsy for IENFD; autonomic testing Charcot-Marie-Tooth disease Childhood/adolescent onset, pes cavus, distal atrophy, family history Genetic testing (PMP22 duplication most common) Chemotherapy-induced peripheral neuropathy (CIPN) Temporal relationship to neurotoxic chemotherapy (platinum, taxanes, vincristine) History; dose-dependent; may improve after discontinuation HIV-associated distal sensory polyneuropathy HIV+ patient, distal symmetric painful neuropathy HIV testing; CD4 count Lyme disease Endemic area, prior tick bite, radiculopathy, cranial neuropathy, polyradiculopathy Lyme serology; may need CSF analysis Sarcoidosis Multifocal neuropathy, cranial neuropathy (especially VII), pulmonary symptoms ACE level; chest imaging; biopsy (non-caseating granulomas) Leprosy Endemic areas, skin lesions, enlarged palpable nerves, anesthetic patches Skin smear/biopsy for AFB; nerve biopsy"},{"location":"plans/peripheral-neuropathy/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"<p>Venue column indicates where monitoring is typically ordered/initiated. Most monitoring continues in outpatient setting.</p> Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal HbA1c - ROUTINE ROUTINE - Every 3 months until stable, then every 6 months &lt;7% (individualize) Intensify glycemic therapy; endocrinology referral Vitamin B12 - ROUTINE ROUTINE - 1-2 months after starting supplementation, then annually &gt;300 pg/mL Continue supplementation; rule out malabsorption Pain scores (0-10 NRS) ROUTINE ROUTINE ROUTINE ROUTINE Each visit Reduction \u00e2\u2030\u00a530-50% from baseline Titrate medications; consider adjuncts or referral Foot exam - ROUTINE ROUTINE - Every visit; comprehensive annually No wounds, calluses, deformity Podiatry referral; wound care Blood pressure (supine and standing) URGENT ROUTINE ROUTINE ROUTINE Each visit if orthostatic symptoms Orthostatic drop &lt;20 mmHg systolic Adjust orthostatic hypotension medications; consider compression Gait and fall risk assessment - ROUTINE ROUTINE - Each visit No falls, stable gait PT referral; assistive devices; home safety evaluation Creatinine clearance STAT ROUTINE ROUTINE STAT Baseline; with renal disease, elderly, or gabapentinoid use; with dose changes CrCl &gt;60 for full gabapentinoid dosing Adjust gabapentin: CrCl 30-59 max 900-1400 mg/day; CrCl 15-29 max 600 mg/day; CrCl &lt;15 max 300 mg/day LFTs (if on high-dose gabapentinoid) - ROUTINE ROUTINE - Baseline, then annually Normal Dose adjustment if hepatic impairment Renal function - ROUTINE ROUTINE - Every 6-12 months Stable Adjust renally cleared medications (gabapentin, pregabalin) CBC (if on immunotherapy) - ROUTINE ROUTINE ROUTINE Per medication protocol Normal Adjust immunosuppression dose; infection evaluation NCS/EMG follow-up - ROUTINE ROUTINE - 6-12 months if treatment initiated; PRN for symptom change Stable or improved If progressive despite treatment, reconsider diagnosis or escalate therapy ECG (if on TCAs) URGENT ROUTINE ROUTINE URGENT Baseline; with dose increases &gt;100 mg QTc &lt;500 ms; no heart block Reduce dose or switch medication Weight (if on gabapentinoid) - ROUTINE ROUTINE - Each visit Stable or controlled Diet/exercise counseling; consider switch Depression/anxiety screening (PHQ-9, GAD-7) - ROUTINE ROUTINE - Annually or with symptom concern Not clinically significant Psychiatry referral; pharmacotherapy Respiratory function (if GBS/CIDP suspected) STAT STAT - STAT Q4h if concern; FVC and NIF FVC &gt;20 mL/kg, NIF &lt;-30 cm H2O ICU transfer if FVC &lt;20 or NIF &gt;-30; intubation if declining"},{"location":"plans/peripheral-neuropathy/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable symptoms; chronic/slowly progressive course; ambulatory; reliable follow-up with neurology within 2-4 weeks; pain controlled; able to perform ADLs; no fall risk requiring inpatient therapy Admit to floor Acute/subacute progression concerning for GBS or CIDP; significant functional decline; falls requiring therapy evaluation; severe uncontrolled pain; new autonomic instability; workup requiring inpatient procedures (nerve biopsy, LP) Admit to ICU GBS with respiratory compromise (FVC &lt;20 mL/kg, NIF &gt;-30, or declining trajectory); autonomic instability with cardiac arrhythmia or BP lability; aspiration risk Transfer to higher level EMG/NCS not available urgently; neuromuscular specialist not available; PLEX/IVIG needed but not available; rehabilitation services not available"},{"location":"plans/peripheral-neuropathy/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Diabetes is most common cause of polyneuropathy in developed countries Class I Dyck PJ et al. Neurology 1993 HbA1c &lt;7% reduces neuropathy incidence in Type 1 DM Class I, Level A DCCT/EDIC Gabapentin, pregabalin, duloxetine first-line for painful diabetic neuropathy Class I, Level A AAN/AANEM Practice Guideline 2011, 2022 update Tricyclic antidepressants effective for neuropathic pain Class I, Level A Finnerup NB et al. Lancet Neurol 2015 NCS/EMG for characterization of peripheral neuropathy Class I, Level B AAN Practice Parameter SPEP indicated in idiopathic neuropathy workup Class II, Level B England JD et al. Neurology 2009 OGTT detects IGT in 34-62% of idiopathic neuropathy patients Class II, Level B Singleton et al. Diabetes Care 2001; Hoffman-Snyder et al. Arch Neurol 2006 Skin biopsy (IENFD) for small fiber neuropathy Class II, Level B Lauria G et al. Eur J Neurol 2010 IVIG first-line for CIDP Class I, Level A Cochrane Review, EFNS/PNS Guidelines Thiamine supplementation in alcoholic neuropathy Class II, Level B AAN Practice Parameter Foot care reduces amputations in diabetic neuropathy Class I, Level A Multiple RCTs, ADA Guidelines Capsaicin 8% patch effective for localized neuropathic pain Class I, Level A Multiple RCTs Tafamidis for hATTR polyneuropathy Class I, Level A ATTR-ACT Trial, Adams et al. NEJM Patisiran/inotersen for hATTR polyneuropathy Class I, Level A APOLLO, NEURO-TTR Trials Combination therapy for neuropathic pain improves outcomes Class II, Level B Multiple RCTs"},{"location":"plans/peripheral-neuropathy/#change-log","title":"CHANGE LOG","text":"<p>v1.2 (January 14, 2026) - Added venue columns (ED, HOSP, OPD, ICU) to Section 6 Monitoring Parameters for plan builder compatibility - Venue indicates where monitoring is typically ordered/initiated - Added respiratory function monitoring (FVC, NIF) for GBS/CIDP - critical for ICU triage - Added explanatory note about venue interpretation for monitoring parameters</p> <p>v1.1 (January 14, 2026) - Moved OGTT from Section 1C to 1B (Extended Workup) based on evidence of high diagnostic yield (34-62% of idiopathic neuropathy patients have abnormal OGTT) - Added OGTT indication note referencing high yield in idiopathic neuropathy - Corrected gabapentin renal dosing: CrCl 15-29 max changed from 700 mg/day to 600 mg/day per conservative dosing references - Added specific CrCl threshold ranges to gabapentin dosing in Section 3B - Added creatinine clearance monitoring with specific dose adjustment guidance to Section 6 - Corrected inotersen monitoring: changed from \"weekly \u00c3\u0192\u00e2\u20ac\u201d 8 weeks then q2 weeks\" to \"weekly throughout treatment; more frequent if platelets &lt;75; continue 8 weeks post-discontinuation\" - Clarified droxidopa interactions: ergot alkaloids as contraindication; MAOIs and triptans as cautions (not absolute contraindications) - Added patisiran vitamin A supplementation mechanism note - Clarified EMG timing guidance: \"optimal 3-4 weeks after symptom onset (allows Wallerian degeneration to manifest)\" - Added combination therapy note after Section 3B pain medications - Added sleep management options to Section 3C: trazodone, melatonin - Added anxiety treatment options to Section 3C: hydroxyzine, buspirone - Changed midodrine and fludrocortisone ICU column from \"-\" to \"ROUTINE\" with note about continuation of home regimen - Added temperature sensitivity patient instruction to Section 4B - Added OGTT reference to Evidence section</p> <p>v1.0 (January 14, 2026) - Initial creation - Comprehensive laboratory workup including metabolic, inflammatory, infectious, and genetic etiologies - Full electrodiagnostic and imaging recommendations - Extensive neuropathic pain medication section with individual drugs and complete dosing - Autonomic symptom management (orthostatic hypotension, bladder, GI) - Disease-specific treatments (IVIG, PLEX, immunosuppression, hATTR therapies) - Comprehensive referral list including podiatry, pain management, genetic counseling - Detailed patient instructions for foot care and fall prevention - Lifestyle modifications emphasizing glycemic control and alcohol cessation</p>"},{"location":"plans/rapidly-progressive-dementia/","title":"Rapidly Progressive Dementia","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Rapidly Progressive Dementia (RPD)</p> <p>ICD-10: F03.90 (Unspecified dementia without behavioral disturbance), G31.9 (Degenerative disease of nervous system, unspecified), A81.00 (Creutzfeldt-Jakob disease, unspecified)</p> <p>SCOPE: Urgent evaluation of cognitive decline progressing over weeks to months (typically &lt;1-2 years from symptom onset to severe disability). Covers comprehensive workup to identify treatable causes including autoimmune encephalitis, infectious etiologies, toxic-metabolic causes, CNS malignancy, and prion disease (CJD). The key principle: assume a treatable cause exists until proven otherwise. Excludes typical slowly progressive dementias (Alzheimer's, FTD) unless presenting atypically fast, and acute delirium (&lt;days).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/rapidly-progressive-dementia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/rapidly-progressive-dementia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Infection screen; hematologic malignancy; B12 deficiency (macrocytosis) Normal CMP (BMP + LFTs) STAT STAT ROUTINE STAT Hepatic encephalopathy (ammonia); renal failure (uremia); electrolyte abnormalities (Na, Ca); hypo/hyperglycemia Normal TSH, free T4 URGENT ROUTINE ROUTINE URGENT Hypothyroid encephalopathy (Hashimoto encephalopathy); hyperthyroidism Normal B12, methylmalonic acid (MMA) URGENT ROUTINE ROUTINE URGENT B12 deficiency \u2014 reversible cause of cognitive decline and myelopathy B12 &gt;300 pg/mL; MMA normal Folate - ROUTINE ROUTINE - Deficiency associated with cognitive impairment Normal ESR URGENT ROUTINE ROUTINE URGENT Vasculitis screen; inflammatory conditions; infection; malignancy Normal (&lt;20 mm/h age-adjusted) CRP URGENT ROUTINE ROUTINE URGENT Inflammatory marker Normal RPR or VDRL (syphilis screen) URGENT ROUTINE ROUTINE URGENT Neurosyphilis \u2014 treatable cause; \"the great imitator\" Non-reactive HIV 1/2 antigen/antibody URGENT ROUTINE ROUTINE URGENT HIV-associated neurocognitive disorder (HAND); opportunistic infections Negative Ammonia URGENT ROUTINE ROUTINE URGENT Hepatic encephalopathy Normal (&lt;35 \u00b5mol/L) Urinalysis + urine culture STAT ROUTINE ROUTINE STAT UTI causing delirium (especially elderly) Negative Urine drug screen URGENT ROUTINE ROUTINE URGENT Substance-related cognitive impairment; prescription drug toxicity Negative or expected medications only Blood glucose STAT STAT ROUTINE STAT Hypoglycemia; diabetic encephalopathy Normal"},{"location":"plans/rapidly-progressive-dementia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Anti-thyroid antibodies (anti-TPO, anti-thyroglobulin) - ROUTINE ROUTINE - Hashimoto encephalopathy (SREAT) \u2014 treatable with steroids even if euthyroid Negative (positive + encephalopathy = consider SREAT) ANA - ROUTINE ROUTINE - Lupus cerebritis; systemic autoimmune disease Negative dsDNA antibodies - ROUTINE ROUTINE - Lupus cerebritis (specific) Negative Complement levels (C3, C4) - ROUTINE ROUTINE - Lupus; complement-mediated disease Normal ANCA (c-ANCA, p-ANCA) - ROUTINE ROUTINE - CNS vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis) Negative ACE level (serum) - ROUTINE ROUTINE - Neurosarcoidosis Normal Serum protein electrophoresis (SPEP) + immunofixation - ROUTINE ROUTINE - Multiple myeloma; POEMS; Waldenstr\u00f6m; M-protein-associated neuropathy/encephalopathy Normal pattern LDH - ROUTINE ROUTINE - Lymphoma; hemolysis; intravascular lymphoma Normal Peripheral blood smear - ROUTINE - - Intravascular lymphoma (schistocytes); TTP (schistocytes + thrombocytopenia) Normal Thiamine (B1) level - ROUTINE ROUTINE - Wernicke encephalopathy \u2014 reversible with treatment; alcoholism, malnutrition, bariatric surgery Normal (&gt;70 nmol/L) Copper and ceruloplasmin - ROUTINE ROUTINE - Wilson disease (young patients &lt;50); acquired copper deficiency (zinc excess, gastric surgery) Normal Zinc level - ROUTINE ROUTINE - Zinc excess causes copper deficiency \u2192 myeloneuropathy + cognitive decline Normal Cortisol (AM or random) - ROUTINE ROUTINE - Adrenal insufficiency causing encephalopathy Normal (&gt;18 \u00b5g/dL AM) Heavy metals (lead, mercury, arsenic) - EXT EXT - Occupational/environmental exposure Normal Paraneoplastic panel (serum) \u2014 comprehensive - ROUTINE ROUTINE - ANNA-1 (Hu), ANNA-2 (Ri), CRMP-5 (CV2), amphiphysin, PCA-1 (Yo), PCA-2, PCA-Tr (DNER), GAD65 Negative Autoimmune encephalitis panel (serum) \u2014 NMDAR, LGI1, CASPR2, GABA-B, GABA-A, AMPA, DPPX, IgLON5 - ROUTINE ROUTINE - Treatable autoimmune encephalitis \u2014 most important reversible cause to identify Negative"},{"location":"plans/rapidly-progressive-dementia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding 14-3-3 protein (CSF) - ROUTINE ROUTINE - CJD biomarker; elevated in rapid neuronal destruction. Sensitivity ~90% but NOT specific (also elevated in stroke, encephalitis, seizures) Negative (positive supports CJD in right clinical context) RT-QuIC (Real-Time Quaking-Induced Conversion) \u2014 CSF - ROUTINE ROUTINE - MOST SPECIFIC test for prion disease; sensitivity 92%, specificity 99-100%. Gold standard CSF prion test Negative (positive = prion disease essentially confirmed) Tau protein (CSF \u2014 total tau) - ROUTINE ROUTINE - Markedly elevated in CJD (&gt;1150 pg/mL); also elevated in AD but less extreme Normal (&lt;400 pg/mL; CJD often &gt;10,000) Neuron-specific enolase (NSE) \u2014 CSF - ROUTINE - - Elevated in CJD (&gt;35 ng/mL); marker of neuronal damage Normal AD biomarkers (CSF A\u03b242, p-tau, t-tau) - ROUTINE ROUTINE - Rapidly progressive Alzheimer disease (rpAD) is the most common misdiagnosis of CJD; AD biomarker pattern distinguishes A\u03b242/A\u03b240 ratio normal; p-tau/t-tau ratio helps distinguish Neurofilament light chain (NfL) \u2014 CSF or serum - ROUTINE ROUTINE - Non-specific marker of neuronal damage; markedly elevated in CJD, moderately in many RPDs Baseline for comparison Whipple disease PCR (CSF and duodenal biopsy) - EXT EXT - Tropheryma whipplei \u2014 rare but treatable cause of RPD with oculomasticatory myorhythmia; GI symptoms, arthralgia Negative PRNG gene analysis (blood) - EXT EXT - Genetic prion disease (familial CJD, fatal familial insomnia, GSS); family history of early dementia or movement disorder No mutation QuantiFERON-TB Gold / PPD - ROUTINE ROUTINE - TB meningitis with cognitive decline Negative Bartonella serology - EXT EXT - Cat-scratch disease encephalitis Negative Brucella serology - EXT EXT - Neurobrucellosis (occupational exposure) Negative Lyme antibody (ELISA, Western blot) - ROUTINE ROUTINE - Lyme encephalopathy (endemic areas) Negative Celiac antibodies (tTG IgA, deamidated gliadin) - ROUTINE ROUTINE - Gluten ataxia / celiac encephalopathy Negative"},{"location":"plans/rapidly-progressive-dementia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/rapidly-progressive-dementia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast + DWI STAT STAT ROUTINE STAT Within 24h. DWI is CRITICAL \u2014 cortical ribboning on DWI is highly suggestive of CJD CJD: cortical ribboning (DWI/FLAIR high signal in cortex), caudate/putamen signal. Autoimmune: mesial temporal T2/FLAIR. Vasculitis: multifocal white matter lesions. Lymphoma: enhancing mass. Wernicke: mamillary body/thalamic signal. MS: periventricular/juxtacortical lesions Pacemaker, metallic implants EEG (routine or prolonged) URGENT URGENT ROUTINE URGENT Within 24h CJD: periodic sharp wave complexes (PSWCs) at 1-2 Hz \u2014 sensitivity ~65% (higher in sCJD-MM1). Seizures: electrographic activity. NCSE: subclinical seizures. Autoimmune: extreme delta brush (NMDAR) None significant CT head without contrast STAT STAT - STAT Immediate if acute presentation or focal deficit Mass lesion, hydrocephalus, hemorrhage, large infarct Pregnancy (relative)"},{"location":"plans/rapidly-progressive-dementia/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRA/MRV brain - ROUTINE ROUTINE - If vasculitis or venous thrombosis suspected CNS vasculitis (beading); dural sinus thrombosis Same as MRI MRI spine - ROUTINE ROUTINE - If concurrent myelopathy (B12 deficiency, copper deficiency, neurosarcoidosis) Cord signal change (posterior columns in B12/copper); sarcoid enhancement Same as MRI Continuous EEG (cEEG) - URGENT - STAT If altered consciousness; suspected NCSE Non-convulsive seizures; subclinical status None FDG-PET brain - EXT ROUTINE - Differentiate neurodegenerative patterns; detect occult malignancy; autoimmune encephalitis (mesial temporal hypermetabolism) AD: temporoparietal hypometabolism. FTD: frontal/temporal. CJD: cortical/striatal. Lymphoma: hypermetabolic mass. Autoimmune: mesial temporal hypermetabolism Pregnancy; uncontrolled diabetes PET-CT body (whole body) - EXT ROUTINE - Occult malignancy search (paraneoplastic); lymphoma staging Primary tumor identification Same as FDG-PET CT chest/abdomen/pelvis with contrast - ROUTINE ROUTINE - Cancer screening (paraneoplastic); sarcoidosis (hilar adenopathy) Mass, lymphadenopathy Contrast allergy, renal impairment Conventional cerebral angiography (DSA) - EXT EXT - If CNS vasculitis suspected (MRA normal does not exclude small-vessel vasculitis) Beading (alternating stenosis/dilation) Contrast allergy, coagulopathy Testicular ultrasound (males) - ROUTINE - - Testicular germ cell tumor (paraneoplastic; anti-NMDAR in males) Normal None Pelvic ultrasound/MRI (females) - ROUTINE ROUTINE - Ovarian teratoma (anti-NMDAR encephalitis \u2014 present in 50% of young women) Normal None"},{"location":"plans/rapidly-progressive-dementia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Brain biopsy - - EXT - Last resort when all non-invasive testing inconclusive; suspected CNS vasculitis, intravascular lymphoma, or prion disease where RT-QuIC unavailable Vasculitis (vessel wall inflammation); lymphoma (atypical cells); prion disease (spongiform change, PrP immunostaining) Surgical risk; coagulopathy Meningeal biopsy - - EXT - Chronic meningitis of unknown etiology Granulomas (sarcoid, TB); malignancy Same as brain biopsy Bone marrow biopsy - EXT EXT - If intravascular lymphoma, hemophagocytic lymphohistiocytosis (HLH), or hematologic malignancy suspected Abnormal cells; hemophagocytosis Coagulopathy Upper endoscopy with duodenal biopsy - EXT EXT - Whipple disease (PAS-positive macrophages) Normal (PAS-negative) Standard GI endoscopy risks Sleep polysomnography - - EXT - Fatal familial insomnia (FFI) \u2014 complete loss of sleep architecture Absent sleep spindles; disrupted sleep architecture Cooperation"},{"location":"plans/rapidly-progressive-dementia/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Essential in ALL RPD evaluations. Multiple studies needed \u2014 collect adequate volume.</p> <p>Timing: URGENT. Perform early in workup.</p> <p>Volume Required: 20-30 mL (many specialized tests required; save extra frozen)</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE ROUTINE Elevated ICP in mass, hydrocephalus, venous thrombosis Normal (10-20 cm H2O) Cell count with differential (tubes 1 and 4) URGENT ROUTINE ROUTINE Pleocytosis suggests infection, autoimmune, or lymphoma; normal in CJD Normal in CJD; elevated in autoimmune/infectious Protein URGENT ROUTINE ROUTINE Elevated in infection, inflammation, malignancy; mildly elevated or normal in CJD Normal or mildly elevated in CJD; elevated in infection/autoimmune Glucose with paired serum URGENT ROUTINE ROUTINE Low in bacterial/TB/fungal meningitis, carcinomatous meningitis Normal in CJD, autoimmune; low in infectious/malignant Gram stain and culture URGENT ROUTINE ROUTINE Exclude chronic bacterial infection No organisms RT-QuIC (Real-Time Quaking-Induced Conversion) - ROUTINE ROUTINE Most sensitive and specific CSF test for prion disease (sensitivity 92%, specificity 99-100%) Negative 14-3-3 protein - ROUTINE ROUTINE CJD biomarker; rapid neuronal destruction marker Negative Total tau protein - ROUTINE ROUTINE Markedly elevated in CJD (&gt;1150 pg/mL); moderately elevated in AD Normal (&lt;400 pg/mL) NSE (neuron-specific enolase) - ROUTINE ROUTINE CJD biomarker Normal Autoimmune encephalitis panel (CSF) \u2014 NMDAR, LGI1, CASPR2, GABA-B, GABA-A, AMPA, DPPX - ROUTINE ROUTINE CSF more sensitive than serum for NMDAR antibodies; identifies treatable autoimmune etiology Negative Paraneoplastic antibodies (CSF) - ROUTINE ROUTINE More sensitive than serum for some antibodies Negative Oligoclonal bands, IgG index - ROUTINE ROUTINE Intrathecal antibody synthesis (MS, autoimmune, neurosarcoidosis) Negative Cytology (send 10 mL minimum; repeat x3 for sensitivity) - ROUTINE ROUTINE Leptomeningeal carcinomatosis/lymphoma; sensitivity improves with volume and repeat Negative Flow cytometry - ROUTINE ROUTINE CNS lymphoma (B-cell clonality) Normal HSV 1/2 PCR - ROUTINE ROUTINE HSV encephalitis; post-HSV autoimmune encephalitis Negative VZV PCR - ROUTINE ROUTINE VZV vasculopathy / encephalitis Negative EBV PCR - ROUTINE ROUTINE CNS lymphoma (EBV-driven) Negative JC virus PCR - ROUTINE ROUTINE PML (immunocompromised) Negative VDRL (CSF) - ROUTINE ROUTINE Neurosyphilis Non-reactive Cryptococcal antigen - ROUTINE ROUTINE Cryptococcal meningitis (immunocompromised) Negative AFB smear and culture - ROUTINE ROUTINE TB meningitis Negative ACE level (CSF) - ROUTINE ROUTINE Neurosarcoidosis Normal Whipple PCR (T. whipplei) - EXT EXT Whipple disease Negative Beta-2 microglobulin (CSF) - ROUTINE - CNS lymphoma marker Normal Alzheimer biomarkers (A\u03b242, A\u03b240, p-tau 181, t-tau) - ROUTINE ROUTINE rpAD pattern: low A\u03b242, elevated p-tau; helps distinguish from CJD (where p-tau is NOT as elevated relative to t-tau) Context-dependent Neurofilament light chain (NfL) \u2014 CSF - ROUTINE ROUTINE Non-specific neuronal damage; very elevated in CJD Baseline <p>Save 5-10 mL of CSF frozen at -80\u00b0C for future studies.</p>"},{"location":"plans/rapidly-progressive-dementia/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/rapidly-progressive-dementia/#3a-empiric-treatable-causes-treat-while-awaiting-results","title":"3A. Empiric / Treatable Causes \u2014 TREAT WHILE AWAITING RESULTS","text":"Treatment ED HOSP OPD ICU Dosing Indication Contraindications Monitoring Thiamine (B1) IV STAT STAT - STAT 500 mg IV TID x 3-5 days, then 250 mg IV daily x 3-5 days, then 100 mg PO daily ongoing Empiric for Wernicke encephalopathy if ANY suspicion (alcohol, malnutrition, bariatric surgery); treat before glucose None significant Clinical response (confusion, ataxia, ophthalmoplegia should improve) IV methylprednisolone (empiric immunotherapy trial) - URGENT - URGENT 1000 mg IV daily x 3-5 days. Consider when autoimmune etiology suspected and workup pending. Document pre-treatment baseline exam. Suspected autoimmune encephalitis, Hashimoto encephalopathy (SREAT), neurosarcoidosis, CNS vasculitis Active infection (rule out first); uncertain prion disease (steroids do not help CJD and may mask diagnosis) Glucose q6h; BP; GI prophylaxis; response assessment IVIG (empiric immunotherapy trial) - URGENT - URGENT 0.4 g/kg/day x 5 days (total 2 g/kg). Add to steroids or as alternative if steroid-intolerant Suspected autoimmune encephalitis; concurrent with steroid trial IgA deficiency; renal failure; thrombotic risk Renal function; headache; thrombotic events Acyclovir IV (if HSV not excluded) STAT STAT - STAT 10 mg/kg IV q8h. Continue until HSV PCR confirmed negative Empiric while awaiting HSV PCR; fever + encephalopathy Renal impairment (dose adjust) Cr daily; hydration"},{"location":"plans/rapidly-progressive-dementia/#3b-targeted-treatments-once-diagnosis-established","title":"3B. Targeted Treatments (Once Diagnosis Established)","text":"Treatment Diagnosis Dosing Duration Monitoring IV methylprednisolone \u2192 oral prednisone taper Autoimmune encephalitis, SREAT, neurosarcoidosis 1g IV x 5d \u2192 prednisone 1 mg/kg/day with slow taper over 3-6 months Months to years (diagnosis-dependent) Glucose, BP, bone density, weight, mood IVIG Autoimmune encephalitis (NMDAR, LGI1, CASPR2) 0.4 g/kg/day x 5 days; repeat monthly for maintenance Months; taper based on clinical response Renal function; IgG levels Rituximab Refractory autoimmune encephalitis; anti-NMDAR 375 mg/m2 IV weekly x 4 weeks OR 1000 mg IV x 2 doses (2 weeks apart) Repeat q6 months based on CD19/20 counts CD19/20 counts; immunoglobulins; infection risk; PML risk Cyclophosphamide Refractory autoimmune encephalitis; CNS vasculitis 750-1000 mg/m2 IV monthly x 6 months (pulse) OR oral 1-2 mg/kg/day 6-12 months for vasculitis CBC (nadir at 10-14 days); urinalysis (hemorrhagic cystitis \u2014 give MESNA); fertility preservation discussion Penicillin G IV Neurosyphilis 18-24 million units/day IV (3-4 MU q4h) x 14 days 14 days RPR titer follow-up q3-6 months (4-fold decline expected) Tumor-directed therapy Paraneoplastic (treat underlying cancer) Per oncology Per oncology Clinical response; antibody titers Teratoma resection Anti-NMDAR with ovarian teratoma Surgical removal One-time (but may recur) Repeat imaging; antibody titers B12 replacement B12 deficiency Cyanocobalamin 1000 \u00b5g IM daily x 7 days, then weekly x 4, then monthly long-term Lifelong if pernicious anemia B12 and MMA levels at 3 months Antifungals (amphotericin B + flucytosine) Cryptococcal meningitis Amphotericin B 0.7-1 mg/kg/day IV + flucytosine 100 mg/kg/day x 2 weeks (induction) Weeks (induction) then fluconazole maintenance Renal function; electrolytes; LFTs Anti-TB regimen TB meningitis RIPE: rifampin + isoniazid + pyrazinamide + ethambutol 12 months minimum (2 months intensive + 10 months continuation) LFTs; visual acuity (ethambutol); drug interactions No disease-modifying treatment Prion disease (CJD) Supportive care only; no effective treatment exists N/A Comfort care; goals of care discussion"},{"location":"plans/rapidly-progressive-dementia/#3c-symptomatic-treatments","title":"3C. Symptomatic Treatments","text":"Treatment Indication Dosing Contraindications Monitoring Levetiracetam Seizures 500-1500 mg PO/IV BID; max 3000 mg/day Severe renal impairment (dose adjust) Renal function; behavioral changes Lorazepam Agitation, myoclonus (CJD) 0.5-1 mg PO/IV q6-8h PRN Respiratory depression Sedation; respiratory status Clonazepam Myoclonus (CJD) 0.5 mg PO BID; increase to 1-2 mg TID Respiratory depression; fall risk Sedation; fall prevention Valproic acid Myoclonus (adjunctive); seizures 250-500 mg PO BID; target level 50-100 \u00b5g/mL Hepatic disease; pancreatitis; pregnancy LFTs; ammonia; drug level; CBC Quetiapine Agitation, psychosis, behavioral disturbance 25-50 mg PO qHS; increase by 25 mg/day; max 200-400 mg/day QT prolongation; Parkinson disease (avoid all antipsychotics in Lewy body) QTc; metabolic panel; sedation Trazodone Insomnia, behavioral disturbance 25-50 mg PO qHS; max 150 mg Priapism (rare); orthostatic hypotension Sedation; orthostasis Melatonin Insomnia 3-10 mg PO qHS None significant Sleep quality"},{"location":"plans/rapidly-progressive-dementia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/rapidly-progressive-dementia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology (behavioral/cognitive subspecialty if available) STAT STAT STAT STAT All RPD cases; diagnostic workup direction; empiric treatment decisions Neuro-immunology - URGENT ROUTINE URGENT Suspected autoimmune encephalitis; immunotherapy management Infectious disease - ROUTINE ROUTINE - Suspected CNS infection (neurosyphilis, TB, HIV, fungal, Whipple) Oncology - ROUTINE ROUTINE - Paraneoplastic syndrome; CNS lymphoma; brain metastases Neurosurgery - ROUTINE - ROUTINE Brain biopsy consideration; hydrocephalus management Rheumatology - ROUTINE ROUTINE - Suspected CNS vasculitis; lupus cerebritis; sarcoidosis Psychiatry - ROUTINE ROUTINE - Behavioral management; depression; capacity assessment Neuropsychology - - ROUTINE - Formal cognitive testing; baseline and follow-up Palliative care - ROUTINE ROUTINE ROUTINE Goals of care (especially if CJD suspected); symptom management Social work - ROUTINE ROUTINE - Family support; advance directive planning; caregiver resources Genetic counseling - - ROUTINE - If genetic prion disease suspected; family implications Ethics consultation - ROUTINE - - End-of-life decisions; capacity evaluation for untreatable conditions National Prion Disease Pathology Surveillance Center (Cleveland) - ROUTINE ROUTINE - If CJD suspected: contact for diagnostic guidance and potential brain autopsy Speech-language pathology - ROUTINE ROUTINE - Dysphagia; communication strategies Physical/Occupational therapy - ROUTINE ROUTINE - Safety; mobility; ADLs; fall prevention"},{"location":"plans/rapidly-progressive-dementia/#4b-patient-and-family-instructions","title":"4B. Patient and Family Instructions","text":"Recommendation ED HOSP OPD RPD has many TREATABLE causes \u2014 aggressive workup is justified - ROUTINE ROUTINE Return to ED if: new seizure, sudden worsening, falls, inability to swallow, fever STAT STAT ROUTINE Do NOT drive - ROUTINE ROUTINE Ensure 24/7 supervision at home (fall risk, wandering, impaired judgment) - ROUTINE ROUTINE Advance directives / healthcare power of attorney should be completed early while patient can still participate - ROUTINE ROUTINE If CJD is diagnosed: no cure exists; disease is uniformly fatal; focus on comfort and quality of life - ROUTINE ROUTINE CJD is NOT contagious through casual contact; standard precautions are sufficient; no isolation needed for family - ROUTINE ROUTINE CJD surgical instruments: notify any surgical/dental providers about diagnosis (special sterilization or instrument destruction required) - ROUTINE ROUTINE Family support resources: CJD Foundation (www.cjdfoundation.org); Autoimmune Encephalitis Alliance - ROUTINE ROUTINE Follow-up with neurology frequently (weekly to monthly depending on trajectory) - ROUTINE ROUTINE"},{"location":"plans/rapidly-progressive-dementia/#4c-lifestyle-safety","title":"4C. Lifestyle &amp; Safety","text":"Recommendation ED HOSP OPD Fall prevention (remove tripping hazards, grab bars, non-slip surfaces) - ROUTINE ROUTINE No driving, no operating machinery - ROUTINE ROUTINE Medication management by caregiver (patient cannot reliably self-administer) - ROUTINE ROUTINE Home safety evaluation (OT) - ROUTINE ROUTINE Caregiver support and respite care - ROUTINE ROUTINE Nutritional support (swallowing may decline; SLP evaluation) - ROUTINE ROUTINE Medical ID bracelet - ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/rapidly-progressive-dementia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Creutzfeldt-Jakob disease (CJD) Weeks-months; myoclonus; startle; akinetic mutism late; MRI cortical ribboning + caudate/putamen DWI signal; PSWCs on EEG RT-QuIC (CSF); 14-3-3; total tau &gt;1150; MRI DWI; EEG Autoimmune encephalitis (anti-NMDAR) Subacute; psychiatric symptoms \u2192 seizures \u2192 movement disorder \u2192 autonomic \u2192 decreased consciousness; young women; ovarian teratoma NMDAR antibody (CSF &gt; serum); pelvic imaging Autoimmune encephalitis (anti-LGI1) Faciobrachial dystonic seizures; hyponatremia; memory loss; &gt;40 years LGI1 antibody (serum &gt; CSF); serum Na Hashimoto encephalopathy (SREAT) Euthyroid or hypothyroid; high anti-TPO; steroid-responsive; diagnosis of exclusion Anti-TPO elevated; response to steroids; exclude other causes Rapidly progressive Alzheimer disease (rpAD) Most common misdiagnosis of CJD; positive AD biomarkers (low A\u03b242, high p-tau); no myoclonus typically; MRI shows atrophy, no DWI ribboning CSF AD biomarkers (A\u03b242/A\u03b240 ratio low, p-tau elevated); MRI (atrophy without DWI cortical signal); RT-QuIC negative CNS lymphoma (primary or intravascular) B symptoms; enhancing mass (primary); multifocal white matter changes with LDH elevation and no mass (intravascular) MRI with contrast; CSF cytology + flow cytometry; EBV PCR; brain biopsy; LDH; peripheral smear Leptomeningeal carcinomatosis Known malignancy; cranial neuropathies; communicating hydrocephalus; CSF cytology positive CSF cytology (repeat x3); MRI with contrast (leptomeningeal enhancement) Neurosyphilis RPR/VDRL positive; Argyll Robertson pupils; psychiatric symptoms; may have prior STI history RPR/VDRL (serum); CSF VDRL; FTA-ABS Wernicke encephalopathy Acute confusion + ophthalmoplegia + ataxia triad (only 10% have all three); alcoholism, malnutrition Thiamine level (draw before treatment); MRI (mamillary body, thalamic signal); clinical response to thiamine CNS vasculitis Headache; multifocal deficits; strokes; CSF pleocytosis MRA (beading); DSA; brain/meningeal biopsy; ESR/CRP elevated Neurosarcoidosis Cranial neuropathies (CN VII); leptomeningeal enhancement; hilar adenopathy; elevated ACE Chest CT; serum/CSF ACE; biopsy (granulomas) Normal pressure hydrocephalus (NPH) Triad: gait disorder (predominant) + urinary incontinence + dementia; \"wet, wobbly, and wacky\"; ventricular enlargement disproportionate to atrophy Large-volume LP (30-50 mL) with pre/post gait assessment; MRI (Evans index &gt;0.3) Toxic/metabolic encephalopathy Medication toxicity (lithium, methotrexate, chemotherapy); substance abuse; hepatic/uremic encephalopathy Drug levels; LFTs; ammonia; BUN/Cr; UDS Depression/Pseudo-dementia Depressive symptoms predominant; subjective cognitive complaints &gt; objective deficits; onset correlates with depressive episode Neuropsychological testing; psychiatric evaluation; may improve with antidepressant Whipple disease Oculomasticatory myorhythmia (pathognomonic); GI symptoms; arthralgia; chronic diarrhea T. whipplei PCR (CSF, duodenal biopsy); PAS-positive macrophages on biopsy PML (progressive multifocal leukoencephalopathy) Immunocompromised; multifocal white matter lesions (no enhancement typically); progressive deficits JC virus PCR (CSF); MRI pattern; clinical context Fatal familial insomnia Genetic prion disease; progressive insomnia \u2192 autonomic dysfunction \u2192 motor signs \u2192 dementia; family history PRNP gene testing (D178N mutation with 129M); polysomnography (absent sleep spindles)"},{"location":"plans/rapidly-progressive-dementia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Cognitive assessment (MMSE, MoCA, or bedside exam) STAT STAT ROUTINE STAT Baseline; weekly inpatient; each visit outpatient Stable or improving (if treatable cause) Document trajectory; adjust treatment Neurologic exam (focal signs, myoclonus, gait, cranial nerves) STAT STAT ROUTINE STAT Daily inpatient; each visit outpatient Stable or improving If new focal signs: repeat MRI; if myoclonus: add clonazepam Seizure monitoring STAT STAT ROUTINE STAT Clinical observation; EEG if suspicious No seizure activity AED initiation/adjustment Swallowing assessment - ROUTINE ROUTINE ROUTINE Weekly; SLP evaluation Safe oral intake Modified diet; NG/PEG if progressive Weight - ROUTINE ROUTINE - Weekly Stable Nutritional support Serum sodium - ROUTINE ROUTINE - q12-24h initially; then per clinical indication 135-145 mEq/L SIADH management if low; LGI1 encephalitis associated with hyponatremia Renal function - ROUTINE ROUTINE - Daily if on acyclovir or nephrotoxic drugs; weekly otherwise Stable Dose adjustments Response to immunotherapy - ROUTINE ROUTINE - Assess at day 5 of steroids/IVIG; then weekly Objective improvement in cognition or exam If no response: consider second-line (rituximab); reconsider diagnosis Autoimmune antibody titers (follow-up) - - ROUTINE - q3-6 months if positive Declining titers If rising: relapse risk; adjust immunotherapy Safety assessment (fall risk, wandering, capacity) - ROUTINE ROUTINE - Daily inpatient; each visit outpatient Safe Increase supervision; facility placement if needed"},{"location":"plans/rapidly-progressive-dementia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Stable cognition; safe home environment with 24/7 caregiver; outpatient workup can be completed; no active seizures; swallowing safe; outpatient follow-up arranged within 1-2 weeks Admit to hospital Acute/subacute decline requiring urgent workup; unable to safely manage at home; seizures; empiric immunotherapy trial; cannot complete workup as outpatient Admit to ICU Status epilepticus; respiratory failure; autonomic instability; severe agitation requiring sedation; ICP management Transfer to tertiary center Complex workup (brain biopsy, specialized autoimmune testing); prion disease expertise; clinical trial access Memory care / Long-term care Progressive untreatable dementia (CJD, advanced neurodegenerative); unable to care for self; caregiver unable to manage Hospice Confirmed CJD or other untreatable rapidly fatal diagnosis; focus on comfort"},{"location":"plans/rapidly-progressive-dementia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source RT-QuIC for CJD diagnosis (sensitivity 92%, specificity 99-100%) Class I, Level A McGuire et al. (Ann Neurol 2012); Atarashi et al. (Nat Med 2011) MRI DWI cortical ribboning for CJD Class I, Level A Vitali et al. (Neurology 2011); Young et al. (AJNR 2005) CSF 14-3-3 protein for CJD (sensitivity ~90%, lower specificity) Class IIa, Level B WHO diagnostic criteria; Muayqil et al. (2012) Comprehensive autoimmune antibody testing in RPD Class I, Level B Graus et al. (Lancet Neurol 2016) \u2014 diagnostic criteria for autoimmune encephalitis Empiric immunotherapy trial for suspected autoimmune encephalitis Class IIa, Level C Expert consensus; Dalmau &amp; Graus (NEJM 2018) Anti-NMDAR encephalitis: immunotherapy + teratoma resection Class I, Level B Titulaer et al. (Lancet Neurol 2013) Anti-LGI1: steroids as first-line Class IIa, Level B Irani et al. (Brain 2010) Hashimoto encephalopathy (SREAT): steroid-responsive Class IIb, Level C Castillo et al. (Arch Neurol 2006); diagnosis of exclusion Thiamine for Wernicke: high-dose IV (500 mg TID) Class I, Level B Thomson &amp; Marshall (2006); Galvin et al. (2010) Neurosyphilis: IV penicillin G x 14 days Class I, Level A CDC STI Treatment Guidelines CJD: no effective treatment; supportive care only Class I, Level A No disease-modifying therapy exists; multiple trials failed Brain biopsy when non-invasive workup inconclusive Class IIa, Level C Expert consensus; diagnostic yield 57-65% in RPD Save CSF frozen for future studies Class I, Level C Standard practice; new biomarkers emerging <p>APPENDIX: RPD DIAGNOSTIC APPROACH \u2014 \"VITAMINS\" MNEMONIC</p> Category Examples Vascular CNS vasculitis, cerebral amyloid angiopathy, CADASIL, intravascular lymphoma Infectious CJD (prion), neurosyphilis, HIV, Whipple disease, TB, fungal, PML Toxic / Metabolic Drug toxicity (lithium, methotrexate, chemobrain), hepatic/uremic encephalopathy, heavy metals, B12/thiamine deficiency, copper deficiency Autoimmune Anti-NMDAR, anti-LGI1, Hashimoto (SREAT), neurosarcoidosis, lupus cerebritis, CNS vasculitis Metastatic / Neoplastic Leptomeningeal carcinomatosis, CNS lymphoma, paraneoplastic, brain metastases, gliomatosis cerebri Iatrogenic Medication side effects, radiation injury, post-surgical Neurodegenerative Rapidly progressive AD, DLB, FTD, corticobasal degeneration Systemic / Seizure NPH, non-convulsive status epilepticus, depression (pseudo-dementia) <p>APPENDIX: CJD DIAGNOSTIC CRITERIA (CDC \u2014 PROBABLE sCJD)</p> <p>Requires: Progressive neuropsychiatric disorder AND at least ONE of: 1. Positive RT-QuIC (CSF or nasal brushing) 2. Positive 14-3-3 CSF + duration &lt;2 years 3. Typical MRI signal (caudate/putamen or \u22652 cortical regions on DWI/FLAIR) 4. Typical EEG (periodic sharp wave complexes)</p> <p>PLUS at least TWO of: myoclonus, visual/cerebellar, pyramidal/extrapyramidal, akinetic mutism</p>"},{"location":"plans/spinal-cord-compression-malignant/","title":"Spinal Cord Compression (Malignant)","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Malignant Spinal Cord Compression (MSCC) / Metastatic Epidural Spinal Cord Compression (MESCC)</p> <p>ICD-10: G95.20 (Unspecified cord compression), C79.49 (Secondary malignant neoplasm of other parts of nervous system), C79.51 (Secondary malignant neoplasm of bone), M49.50 (Collapsed vertebra in diseases classified elsewhere), G82.20 (Paraplegia, unspecified)</p> <p>SYNONYMS: Malignant spinal cord compression, MSCC, metastatic epidural spinal cord compression, MESCC, cord compression, spinal metastases, spinal tumor compression, epidural metastases, cancer spine compression, vertebral metastases with cord compression</p> <p>SCOPE: Emergency evaluation and management of malignant (metastatic) spinal cord compression in adults. Covers dexamethasone protocols, emergent imaging, surgical decompression criteria (Patchell criteria), radiation therapy, vertebral body assessment, functional prognostication, and disposition. Excludes non-malignant compressive myelopathy (disc herniation, epidural abscess \u2014 separate templates), primary spinal cord tumors (intramedullary), and cauda equina syndrome from malignancy (partially overlaps \u2014 see separate template for CES).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/spinal-cord-compression-malignant/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/spinal-cord-compression-malignant/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT ROUTINE STAT Baseline; surgical candidacy; chemotherapy effects; infection (epidural abscess differential) Normal; leukocytosis may suggest infection; thrombocytopenia affects surgical/procedural candidacy CMP (BMP + LFTs) STAT STAT ROUTINE STAT Renal function (contrast, medications); electrolytes (hypercalcemia of malignancy); hepatic function (chemotherapy dosing, metastatic disease) Normal; calcium &gt;10.5 mg/dL \u2192 assess for hypercalcemia of malignancy PT/INR, aPTT STAT STAT ROUTINE STAT Coagulopathy assessment; surgical candidacy; anticoagulation reversal if emergent surgery needed Normal; INR &lt;1.5 for surgery ESR / CRP STAT STAT ROUTINE STAT Epidural abscess differential (highly elevated ESR &gt;30-50 typically); inflammatory markers for malignancy Normal-mildly elevated in malignancy; markedly elevated ESR/CRP \u2192 strongly consider abscess Blood cultures (x2 sets) STAT STAT - STAT Epidural abscess differential; bacteremia if febrile Negative; positive \u2192 epidural abscess more likely than tumor Blood glucose STAT STAT ROUTINE STAT Baseline before high-dose dexamethasone; steroid hyperglycemia &lt;180 mg/dL; anticipate significant hyperglycemia with high-dose steroids Type and screen STAT STAT - STAT Surgical candidacy; blood product availability On file Calcium (ionized or corrected) STAT STAT ROUTINE STAT Hypercalcemia of malignancy (present in 10-30% of cancer patients); can cause confusion, weakness mimicking cord compression progression Corrected Ca &lt;10.5 mg/dL; if elevated \u2192 IV fluids, calcitonin, bisphosphonate LDH STAT ROUTINE ROUTINE STAT Tumor burden marker; lymphoma (very high LDH); prognostic Normal; very high \u2192 lymphoma, aggressive malignancy Urinalysis STAT STAT - STAT Urinary retention (neurogenic bladder from cord compression); UTI (fever differential); baseline renal function Normal; retention with high post-void residual expected in cord compression"},{"location":"plans/spinal-cord-compression-malignant/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Tumor markers (PSA, CEA, CA 19-9, CA 125, CA 15-3, AFP, \u03b2-hCG) - ROUTINE ROUTINE - Unknown primary cancer; PSA (prostate \u2014 most common spinal metastasis), CEA (GI, lung), CA 15-3 (breast), etc. Elevations guide primary site identification SPEP / UPEP with immunofixation - ROUTINE ROUTINE - Multiple myeloma (common cause of vertebral compression/cord compression); M-protein, light chains No monoclonal protein; if present \u2192 myeloma workup Free light chains (kappa/lambda ratio) - ROUTINE ROUTINE - Myeloma; light chain disease Normal ratio (0.26-1.65); abnormal suggests myeloma Serum protein electrophoresis - ROUTINE ROUTINE - Myeloma; lymphoma No M-spike Alkaline phosphatase (bone-specific) - ROUTINE ROUTINE - Osteoblastic metastases (prostate, breast); Paget's disease differential Normal; elevated suggests bone turnover Phosphate - ROUTINE ROUTINE - Hypercalcemia workup; oncologic emergency assessment Normal Uric acid - ROUTINE - ROUTINE Tumor lysis syndrome risk (lymphoma, rapidly proliferating tumors); pre-treatment assessment Normal Procalcitonin STAT STAT - STAT If infection/abscess differential is high; more specific than CRP for bacterial infection &lt;0.25 ng/mL (low probability bacterial); &gt;0.5 \u2192 consider abscess/infection TSH, free T4 - ROUTINE ROUTINE - Thyroid cancer metastases (follicular thyroid cancer has bony tropism) Normal Vitamin D (25-OH) - ROUTINE ROUTINE - Bone health; pathologic fracture risk; supplement if deficient &gt;30 ng/mL"},{"location":"plans/spinal-cord-compression-malignant/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Flow cytometry (peripheral blood) - EXT EXT - Lymphoma/leukemia presenting as epidural mass Abnormal lymphocyte population = lymphoproliferative disorder Bone marrow biopsy - EXT EXT - Myeloma; lymphoma; unknown primary with bone marrow involvement Normal; abnormal \u2192 specific diagnosis Paraneoplastic antibody panel - EXT EXT - If myelopathy features atypical for compression (e.g., subacute progressive without clear structural compression) Negative; positive changes diagnosis from compression to paraneoplastic myelopathy AQP4-IgG (NMO antibody) - EXT EXT - If imaging shows longitudinal intramedullary lesion rather than epidural compression \u2192 NMOSD differential Negative; positive \u2192 NMOSD not metastatic compression CT-guided biopsy of vertebral lesion - URGENT ROUTINE - Unknown primary; tissue diagnosis needed before treatment; lymphoma requires tissue for definitive diagnosis (sensitive to steroids \u2014 obtain tissue BEFORE steroids if possible in suspected lymphoma) Histopathologic diagnosis"},{"location":"plans/spinal-cord-compression-malignant/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/spinal-cord-compression-malignant/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI entire spine with and without contrast (gadolinium) STAT STAT URGENT STAT Within 4 hours of presentation (24h max); GOLD STANDARD; must image ENTIRE spine (multifocal metastases in 30-40%) Epidural mass with cord compression; level(s) of compression; Bilsky grade (0-3); vertebral body involvement; number of levels; intramedullary vs. extramedullary-intradural vs. epidural; cord signal change (T2 hyperintensity = edema/myelopathy \u2014 poor prognostic sign); paraspinal soft tissue extension MRI-incompatible implants; severe claustrophobia (sedate); GFR &lt;30 (gadolinium risk \u2014 benefit outweighs risk in emergency) Plain radiographs (spine, targeted) STAT STAT - STAT Immediate while awaiting MRI; identifies vertebral collapse, pathologic fracture, alignment; 70% sensitivity for vertebral metastases (30% miss rate) Vertebral body collapse; pedicle erosion (\"winking owl sign\" on AP); pathologic fracture; kyphosis; alignment Pregnancy (shield) CT chest/abdomen/pelvis with contrast URGENT URGENT ROUTINE - Within 24-48h; staging; primary identification; lung is most common primary Primary tumor; staging of metastatic disease; lymphadenopathy; visceral metastases Contrast allergy; renal impairment CT spine (targeted level) without contrast STAT STAT - STAT If MRI contraindicated or unavailable; pre-operative planning for bone assessment; vertebral body stability (SINS score); CT myelogram if MRI not possible Bone destruction pattern (lytic vs. blastic vs. mixed); posterior element involvement; fracture; canal compromise; vertebral body collapse &gt;50% Pregnancy (risk vs. benefit)"},{"location":"plans/spinal-cord-compression-malignant/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT myelogram STAT STAT - STAT If MRI contraindicated (pacemaker, implant); intrathecal contrast via LP \u2192 CT; demonstrates level of block Complete or partial subarachnoid block; level of compression; multiple levels of disease LP contraindicated if complete block above puncture site (risk of neurologic deterioration); coagulopathy PET/CT (FDG) - ROUTINE ROUTINE - Staging; primary identification; assessing treatment response; distinguishing active tumor from treated/necrotic bone Active metastatic disease; primary tumor identification Uncontrolled diabetes; pregnancy Bone scan (Tc-99m) - ROUTINE ROUTINE - Skeletal staging; identifies additional osseous metastases; blastic &gt; lytic sensitivity; useful for prostate, breast Additional bone metastases; may miss purely lytic lesions (renal, thyroid, myeloma) Pregnancy MRI brain with contrast - URGENT ROUTINE - If lung primary or melanoma (high brain metastasis risk); symptoms suggesting intracranial disease Brain metastases (concurrent in 10-30% of patients with MSCC) Same as MRI CT-guided biopsy (vertebral/paraspinal) - URGENT ROUTINE - Tissue diagnosis if unknown primary; CRITICAL for suspected lymphoma (radiosensitive \u2014 may not need surgery); obtain BEFORE steroids if lymphoma suspected (steroids can render biopsy non-diagnostic) Histopathologic diagnosis; molecular profiling Coagulopathy; inaccessible lesion DEXA scan - - ROUTINE - Baseline bone density if prolonged steroids anticipated; osteoporosis risk T-score; fracture risk assessment None significant"},{"location":"plans/spinal-cord-compression-malignant/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Spinal angiography - EXT EXT - If highly vascular tumor suspected (RCC, thyroid) \u2014 pre-operative embolization to reduce surgical bleeding Tumor vascularity; feeding vessels; embolization candidacy Contrast allergy; renal impairment; coagulopathy Pre-operative embolization - URGENT - - Highly vascular metastases (RCC, thyroid); 24-48h before surgery to reduce intraoperative blood loss Reduction of tumor blood supply Contrast allergy; tumor supplying anterior spinal artery (risk of cord infarction) Dynamic flexion-extension radiographs - - ROUTINE - Post-treatment stability assessment; if clinical instability suspected Mechanical instability (translation, angulation) Acute cord compression (do NOT flex/extend if acute neurologic deficit) Nuclear medicine thyroid scan - - EXT - If thyroid primary suspected (follicular thyroid cancer has high bone tropism) Thyroid nodule; functional assessment Recent iodinated contrast (wait 4-6 weeks)"},{"location":"plans/spinal-cord-compression-malignant/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP \u2014 Generally NOT indicated - - - - LP is NOT routinely indicated in MSCC; CSF cytology only if leptomeningeal disease suspected AND no complete block; CT myelogram if MRI not available (different indication) N/A \u2014 LP is diagnostic adjunct only in specific situations CONTRAINDICATED with complete spinal block above LP level (risk of neurologic deterioration/coning); coagulopathy; local infection"},{"location":"plans/spinal-cord-compression-malignant/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/spinal-cord-compression-malignant/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Dexamethasone (high-dose for MSCC) STAT STAT URGENT STAT Standard loading dose: 10 mg IV bolus STAT; Then: 4 mg IV/PO q6h (16 mg/day); High-dose (severe deficits or rapidly progressive): 96 mg IV bolus (controversial \u2014 see evidence) \u2192 24 mg q6h x 3 days \u2192 rapid taper; Moderate deficits / ambulatory: 10 mg IV \u2192 4 mg q6h; Begin taper after definitive treatment initiated; GI prophylaxis: PPI while on steroids; Monitor glucose q6h Sorensen et al. (1994): Dexamethasone + radiation vs. radiation alone \u2192 81% vs. 63% ambulatory at treatment end; High-dose (96 mg) vs. standard (10 mg): Vecht et al. (1989) \u2014 higher response rate at 1 week but more side effects; MOST centers now use moderate dose (10 mg load \u2192 16 mg/day); Begin within 6h of diagnosis Spinal precautions / immobilization STAT STAT - STAT Strict log-roll precautions; flat bed transport; cervical collar if cervical spine involved; thoracolumbar brace (TLSO) if thoracolumbar; avoid flexion/extension; transfer on spine board if unstable fracture suspected Unstable pathologic fracture may worsen cord compression with movement; SINS score guides instability assessment Bladder management STAT STAT - STAT Assess for urinary retention (cord compression causes neurogenic bladder); straight catheterize if retention \u2192 place Foley if residual &gt;200 mL or ongoing retention; monitor I&amp;O strictly Urinary retention is a common presenting feature and may be the first sign of cord compression; bladder function correlates with motor recovery prognosis DVT prophylaxis STAT STAT - STAT SCDs immediately; pharmacologic prophylaxis (enoxaparin 40 mg SQ daily) within 24-48h unless surgery imminent; spinal cord compression patients have VERY HIGH VTE risk (up to 25-50% without prophylaxis) Cancer + immobility + spinal cord injury = extremely high VTE risk; mechanical prophylaxis alone insufficient Pain management STAT STAT ROUTINE STAT Back pain often severe; acetaminophen 650-1000 mg q6h scheduled + opioids PRN (morphine 2-4 mg IV q3h PRN or oxycodone 5-10 mg PO q4h PRN); NSAIDs cautiously (renal function, bleeding risk); dexamethasone itself reduces pain from edema/inflammation; neuropathic pain: gabapentin 300 mg TID (titrate) or pregabalin 75 mg BID Pain is the presenting symptom in 83-95% of patients; median 7 weeks before diagnosis; adequate analgesia essential for function and quality of life Bowel regimen STAT STAT ROUTINE STAT Neurogenic bowel from cord compression + opioid constipation; docusate 100 mg BID + senna 2 tabs HS; bisacodyl suppository PRN; monitor for ileus Bowel dysfunction common; proactive management prevents complications Glucose monitoring STAT STAT ROUTINE STAT Fingerstick q6h on high-dose dexamethasone; insulin sliding scale \u2192 basal-bolus if persistent &gt;180; anticipate glucose will rise significantly within hours of steroid initiation High-dose dexamethasone causes severe hyperglycemia in majority of patients"},{"location":"plans/spinal-cord-compression-malignant/#3b-definitivetargeted-treatment","title":"3B. Definitive/Targeted Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Surgical decompression + stabilization - STAT - - Indications (Patchell criteria + expanded): (1) Single site of compression, (2) Paraplegia \u226448h, (3) Not radiosensitive tumor (not lymphoma, myeloma, SCLC, germ cell), (4) Life expectancy &gt;3 months, (5) ECOG \u22642 / able to tolerate surgery, (6) Mechanical instability (SINS \u22657), (7) Neurologic deterioration during radiation; Approach: Posterior decompressive laminectomy \u00b1 instrumented stabilization; anterior corpectomy with cage/cement for anterior compression with instability; Timing: Within 24h of presentation (ideally &lt;12h); Followed by radiation within 2-4 weeks post-op Patchell et al. (2005) \u2014 LANDMARK: Surgery + radiation vs. radiation alone: ambulatory rate 84% vs. 57% (p=0.001); maintained ambulation longer (122 vs. 13 days); more patients regained ambulation (62% vs. 19%); surgery retained continence longer; survival trend (126 vs. 100 days) External beam radiation therapy (EBRT) - STAT ROUTINE - Primary modality if: Radiosensitive tumor (lymphoma, myeloma, SCLC, seminoma), surgical contraindication, multiple noncontiguous levels, life expectancy &lt;3 months, poor surgical candidate; Standard: 30 Gy in 10 fractions (2 weeks) or 20 Gy in 5 fractions (1 week); Short course (poor prognosis): 8 Gy single fraction; Begin within 24h of diagnosis; Can start same day as dexamethasone; Radiation field covers 1-2 vertebral bodies above and below involved segment Rades et al. (2008): No significant difference between 30 Gy/10 vs. 20 Gy/5 for motor function recovery or local control; 8 Gy single fraction appropriate for poor prognosis (life expectancy &lt;6 months) Stereotactic body radiation therapy (SBRT) / Spine SRS - URGENT ROUTINE - Indications: Previously irradiated segment (re-irradiation); radioresistant histology (RCC, melanoma, sarcoma); oligometastatic disease; post-operative; Dose: 16-24 Gy single fraction or 24-30 Gy in 3 fractions; Requires: Spinal cord dose constraints (max cord dose 10-14 Gy single fraction); MRI-based planning; Timing: As soon as technically feasible RTOG 0631 and multiple institutional series: High local control (85-95%) for radioresistant histologies; superior to conventional EBRT for RCC, melanoma; separation surgery + SBRT emerging as preferred approach for radioresistant tumors Separation surgery + SBRT - URGENT - - Indication: Epidural tumor compressing cord from radioresistant primary (RCC, melanoma, sarcoma); goal is NOT gross total resection \u2014 goal is to decompress cord and create \u22652mm separation between tumor and cord to enable safe SBRT delivery; Followed by SBRT within 2-4 weeks Laufer et al. (2013): Separation surgery + SBRT: 90% local control at 1 year for radioresistant tumors; allows definitive radiation dose to tumor while respecting cord tolerance Vertebroplasty / Kyphoplasty - URGENT ROUTINE - Indications: Painful pathologic compression fracture; vertebral body instability; post-radiation pain; NO epidural extension compressing cord (cement leak risk into canal); SINS 7-12 (indeterminate stability): Consider as adjunct; Procedure: Percutaneous PMMA cement injection into vertebral body Pain relief in 70-90% within 24-48h; structural support; does NOT address epidural disease; risk of cement leak into epidural space (1-5%) Systemic chemotherapy - ROUTINE ROUTINE - Radiosensitive tumors as primary/adjunct therapy: Lymphoma (R-CHOP or equivalent); myeloma (bortezomib-based); SCLC (cisplatin/etoposide); germ cell (BEP); Other primaries: Per disease-specific guidelines after stabilization; coordinate with medical oncology Chemosensitive tumors (lymphoma, myeloma, germ cell, SCLC) may respond rapidly to systemic therapy; may be used as primary treatment with radiation or as consolidation post-radiation Hormonal therapy (if applicable) - ROUTINE ROUTINE - Prostate cancer: ADT (LHRH agonist/antagonist) + enzalutamide/abiraterone/darolutamide; Breast cancer: anti-estrogen/AI per receptor status; Thyroid: levothyroxine suppression + RAI (spine metastases do NOT concentrate RAI well \u2014 external radiation preferred) Prostate and breast cancer spinal metastases may respond to hormonal manipulation; adjunct to radiation"},{"location":"plans/spinal-cord-compression-malignant/#3c-adjunctive-treatment","title":"3C. Adjunctive Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Steroid taper - ROUTINE ROUTINE - Begin taper once definitive treatment (surgery/radiation) initiated and neurologic status stable/improving; Taper schedule: Reduce by 2-4 mg every 3-5 days; typical: 16\u219212\u21928\u21926\u21924\u21922\u2192off over 2-3 weeks; slower taper if symptoms recur; monitor for adrenal insufficiency if &gt;2-3 weeks of steroids Prolonged high-dose steroids cause significant morbidity; steroid myopathy (proximal weakness \u2014 may mimic neurologic progression); PJP risk; hyperglycemia; GI bleed PPI (stress ulcer/GI prophylaxis) STAT STAT ROUTINE STAT Omeprazole 20 mg daily or pantoprazole 40 mg daily while on dexamethasone Steroid + critical illness increases GI bleed risk Calcium + Vitamin D - ROUTINE ROUTINE - Calcium 1000-1200 mg + Vitamin D 800-1000 IU daily during steroid course and beyond (bone health in cancer patients) Steroid-induced osteoporosis prevention; already compromised bone integrity Bone-modifying agents - ROUTINE ROUTINE - Zoledronic acid 4 mg IV q4 weeks OR denosumab 120 mg SQ q4 weeks; reduces skeletal-related events (SRE); dental clearance before starting (ONJ risk); renal adjustment for zoledronic acid (hold if GFR &lt;35) Zoledronic acid: Rosen et al. (2003) \u2014 reduced SRE by 48% in bone metastases; denosumab: Fizazi et al. (2011) \u2014 superior to zoledronic acid for SRE reduction in bone metastases (prostate trial) Neuropathic pain management - STAT ROUTINE STAT Gabapentin 300 mg TID \u2192 titrate to 600-900 mg TID; OR pregabalin 75 mg BID \u2192 titrate to 150-300 mg BID; duloxetine 30-60 mg daily as alternative; amitriptyline 10-25 mg HS (anticholinergic caution with urinary retention) Radicular and central neuropathic pain common in cord compression; adjuvant analgesics reduce opioid requirements Rehabilitation (inpatient) - URGENT ROUTINE - PT/OT evaluation within 24h of admission; early mobilization when cleared by spine surgery; adaptive equipment; wheelchair assessment if paraparetic/paraplegic; ROM exercises; strengthening; transfer training Early rehabilitation improves functional outcomes; cancer rehabilitation is evidence-based; patients with MSCC benefit from structured rehab programs Skin care / pressure ulcer prevention - STAT - STAT Turn q2h; pressure-reducing mattress; heel protectors; skin assessment with Braden scale; nutrition optimization Immobile patients with cord compression at very high risk for pressure injuries; prevention is critical"},{"location":"plans/spinal-cord-compression-malignant/#3d-medications-to-avoid-or-use-with-caution","title":"3D. Medications to AVOID or Use with Caution","text":"Medication Risk/Concern Alternative NSAIDs (prolonged use) Renal impairment (especially with concurrent chemotherapy/bisphosphonates); GI bleeding with concurrent steroids; platelet dysfunction (bleeding risk if surgical candidate) Acetaminophen; opioids; neuropathic pain agents (gabapentin, pregabalin) Methotrexate (high-dose, with spinal radiation) Radiation myelopathy risk increased; severe myelosuppression Sequence treatments; coordinate with oncology Intrathecal chemotherapy (with spinal block) Incomplete CSF circulation may cause focal neurotoxicity at block level Systemic therapy; resolve block before IT therapy Anticoagulation (full-dose, peri-operative) Surgical bleeding risk; epidural hematoma Hold anticoagulation pre-operatively; mechanical DVT prophylaxis; restart per surgical team guidance (typically 24-48h post-op) Steroids in suspected lymphoma (BEFORE biopsy) Dexamethasone causes rapid lymphoma lysis/regression \u2014 may render biopsy non-diagnostic (\"ghost tumor\") If lymphoma is suspected: obtain tissue biopsy BEFORE steroids if patient is neurologically stable; if rapidly declining, steroids are life-saving and should not be delayed \u2014 but communicate urgency to pathology Bevacizumab (peri-operative) Impaired wound healing; hold 4-6 weeks before and 4 weeks after surgery Coordinate timing with surgical team Bisphosphonates (if GFR &lt;35 for zoledronic acid) Nephrotoxicity Denosumab (not renally cleared); hydration before zoledronic acid if GFR 35-60"},{"location":"plans/spinal-cord-compression-malignant/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/spinal-cord-compression-malignant/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details Neurosurgery / Spine surgery consultation \u2014 EMERGENT STAT STAT - STAT Surgical candidacy assessment; Patchell criteria evaluation; SINS score; stabilization; ALL patients with MSCC need spine surgery consultation even if radiation is primary treatment (assess stability) Radiation oncology consultation \u2014 EMERGENT STAT STAT ROUTINE STAT Within hours of diagnosis; concurrent with neurosurgery evaluation; EBRT planning; SBRT candidacy; begin radiation within 24h if non-surgical Medical oncology consultation - URGENT ROUTINE - Systemic therapy options; primary identification; staging; prognosis; clinical trial eligibility; coordinate bone-modifying agents Multidisciplinary spine tumor board - URGENT ROUTINE - Neurosurgery, radiation oncology, medical oncology, interventional radiology, pathology; optimal treatment sequencing; NOMS framework application Goals of care discussion - URGENT ROUTINE URGENT Prognosis (Tokuhashi score, Tomita score); functional goals; code status; palliative vs. aggressive treatment; quality of life; patient values and preferences Physical medicine &amp; rehabilitation - URGENT ROUTINE - PT/OT; functional assessment; rehabilitation candidacy; inpatient rehab planning if motor deficits present; assistive devices Foley catheter management STAT STAT - STAT If urinary retention: Foley placement with monitoring; intermittent catheterization if partial function; urology consult if prolonged retention anticipated Social work / case management - ROUTINE ROUTINE - Equipment needs (wheelchair, hospital bed); caregiver training; home safety assessment; insurance authorization; hospice if appropriate Pain management / palliative care - STAT ROUTINE STAT If pain refractory to standard analgesics; assist with goals of care; symptom management; advance care planning"},{"location":"plans/spinal-cord-compression-malignant/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Interventional radiology consultation - URGENT ROUTINE - Pre-operative embolization (RCC, thyroid metastases); vertebroplasty/kyphoplasty; CT-guided biopsy for tissue diagnosis Orthotics / bracing - ROUTINE ROUTINE - Custom TLSO (thoracolumbar) or cervical collar based on level; post-operative stabilization; external support for non-surgical patients Wound care (post-operative) - ROUTINE ROUTINE - Irradiated tissue heals poorly; monitor surgical wound closely; avoid radiation to fresh surgical wound for 2-3 weeks (coordinate timing) Nutrition / dietitian - ROUTINE ROUTINE - Cancer cachexia assessment; steroid-induced appetite changes; adequate protein for wound healing (if surgical); calcium/vitamin D optimization Psychology / psychiatry - ROUTINE ROUTINE - Depression, anxiety, adjustment disorder common with acute paralysis/paresis and cancer diagnosis; screening with PHQ-9; support for functional loss Urology consultation - ROUTINE ROUTINE - If persistent neurogenic bladder; intermittent catheterization training; long-term bladder management plan Home health referral - ROUTINE ROUTINE - Nursing visits; PT/OT in home; wound care; medication management; caregiver education"},{"location":"plans/spinal-cord-compression-malignant/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Re-irradiation (spine) - ROUTINE ROUTINE - Recurrent MSCC at previously irradiated site; SBRT preferred for re-irradiation (better dose targeting, cord sparing); cumulative cord dose must be calculated; re-irradiation feasible if &gt;6 months since prior radiation Repeat surgery - URGENT ROUTINE - Hardware failure; recurrent compression at operated level; progressive neurologic decline despite radiation; infection at surgical site Intrathecal drug delivery - - EXT - Refractory pain; intrathecal morphine or ziconotide pump; palliative care indication Cement augmentation (post-radiation) - ROUTINE ROUTINE - Persistent pain or progressive collapse after radiation; vertebroplasty/kyphoplasty as pain control adjunct Hospice referral - ROUTINE ROUTINE - Exhausted treatment options; life expectancy &lt;6 months; patient preference for comfort-focused care; poor functional status (ECOG 3-4) Clinical trial enrollment - ROUTINE ROUTINE - Novel radiosensitizers; immunotherapy combinations; spine-specific SBRT protocols <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/spinal-cord-compression-malignant/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/spinal-cord-compression-malignant/#primary-differential-diagnoses","title":"Primary Differential Diagnoses","text":"Diagnosis Key Differentiating Features Distinguishing Studies Spinal epidural abscess Fever (present in 50-66%); IV drug use, recent procedure, immunosuppression; rapidly progressive; ESR &gt;20 (sensitivity 94%); CRP markedly elevated; ring-enhancing epidural collection on MRI; restricted diffusion in abscess; spine pain with percussion tenderness; leukocytosis MRI: T2-hyperintense epidural collection with rim enhancement; restricted diffusion (DWI bright, ADC dark) within abscess; blood cultures (positive in 60%); ESR/CRP markedly elevated; procalcitonin &gt;0.5 Degenerative spinal stenosis (cervical/lumbar) Chronic progressive symptoms; myelopathic signs insidious onset; no cancer history; disc/osteophyte complex on imaging; NO destructive bone lesion; congenital canal narrowing MRI: disc-osteophyte complex; ligamentum flavum hypertrophy; NO bone destruction; NO contrast enhancement of epidural mass; chronic degenerative changes Primary spinal cord tumor (intramedullary) Intramedullary (within cord parenchyma); ependymoma, astrocytoma; cord expansion with central lesion; no vertebral body destruction; slow progression; syrinx may be present MRI: cord expansion with intramedullary enhancing lesion; no epidural mass; no vertebral body involvement; ependymoma: central location, hemosiderin cap; astrocytoma: eccentric, irregular Vertebral compression fracture (osteoporotic) No cancer history; older patient with osteoporosis; acute back pain after minor trauma/lifting; no neurologic deficits (usually); vertebral body collapsed but NO epidural mass; NO posterior element involvement MRI: vertebral body edema (T1 low, STIR high) WITHOUT epidural mass or posterior element involvement; CT: no bone destruction beyond fracture; DEXA: osteoporosis; if ambiguous \u2192 biopsy Multiple myeloma Older adult; bone pain; anemia, renal insufficiency, hypercalcemia (\"CRAB\"); diffuse lytic lesions; monoclonal protein on SPEP; punched-out skull lesions; responsive to chemotherapy AND radiation SPEP: M-protein; UPEP: Bence Jones protein; free light chains: abnormal ratio; bone marrow biopsy: &gt;10% plasma cells; CT/MRI: multiple lytic lesions; biopsy: plasmacytoma; KEY: myeloma is RADIOSENSITIVE \u2014 radiation first-line Lymphoma (epidural) May present as isolated epidural mass; radiosensitive; responds dramatically to steroids (may \"melt\" before biopsy); younger patients; constitutional symptoms (B symptoms); elevated LDH MRI: epidural mass; homogeneous enhancement; may be paraspinal; CT: lymphadenopathy; LDH elevated; flow cytometry; KEY: obtain biopsy BEFORE steroids if possible; radiation is primary treatment Transverse myelitis / NMOSD Intramedullary T2 lesion on MRI (NOT epidural mass); autoimmune history; AQP4/MOG antibodies; longitudinally extensive (\u22653 segments in NMOSD); responds to IV steroids/PLEX; no bone lesion MRI: intramedullary T2 hyperintensity, NOT epidural mass; AQP4-IgG or MOG-IgG positive; CSF: pleocytosis; no vertebral body destruction Spinal epidural hematoma Acute onset, often on anticoagulation; post-procedural (LP, epidural injection); acute neurogenic deficit; hyperacute T1 signal on MRI (blood) MRI: epidural collection with blood signal characteristics (T1 hyperintense in subacute phase); history of anticoagulation or procedure; coagulation studies abnormal; neurosurgical emergency"},{"location":"plans/spinal-cord-compression-malignant/#red-flags-requiring-urgent-reassessment","title":"Red Flags Requiring Urgent Reassessment","text":"Red Flag Concern Action Progressive motor weakness despite treatment Increasing cord compression; treatment failure; hematoma; instability STAT MRI; neurosurgery re-evaluation; consider surgical salvage; dose-escalate steroids New/complete loss of bowel or bladder function Progressing to complete cord injury; cauda equina involvement STAT MRI; emergent surgical evaluation if within 48h window; Foley placement Ascending sensory level Rostral progression of compression; edema expansion; additional metastatic levels STAT MRI entire spine; escalate dexamethasone; emergent neurosurgery Saddle anesthesia (new) Conus medullaris or cauda equina involvement STAT MRI; emergent surgical evaluation Fever after steroid initiation Masked infection (steroids suppress fever); abscess; post-operative infection; UTI Blood cultures; UA; CRP; imaging; broaden antibiotics; consider pausing immunosuppressive therapy Acute hypotension + bradycardia Neurogenic shock (spinal cord injury with loss of sympathetic tone) IV fluids; vasopressors (norepinephrine or phenylephrine preferred); atropine for symptomatic bradycardia; ICU transfer Bilateral leg DVT / PE symptoms High VTE risk in MSCC; pulmonary embolism can be fatal STAT CT angiography (PE); bilateral lower extremity duplex US (DVT); therapeutic anticoagulation (weigh against surgical planning) Respiratory compromise High cervical cord compression affecting diaphragm (C3-5); pulmonary embolism; pneumonia in immobilized patient Bedside spirometry; ABG; CT angiography; intubation if needed; phrenic nerve pacing consideration"},{"location":"plans/spinal-cord-compression-malignant/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/spinal-cord-compression-malignant/#acute-phase-monitoring-first-72h","title":"Acute Phase Monitoring (First 72h)","text":"Parameter Frequency Target Action if Abnormal Neurologic examination (motor strength, sensory level, rectal tone, reflexes) q4h x 48h \u2192 q6h Stable or improving motor function; stable sensory level; preserved rectal tone If declining: STAT MRI; escalate dexamethasone to 24 mg/day; emergent neurosurgery Blood glucose q6h (q4h if on insulin drip) 140-180 mg/dL Sliding scale \u2192 basal-bolus insulin; endocrine consult if refractory Pain score (NRS) q4h NRS &lt;4/10 Escalate analgesics; add neuropathic agents; palliative care consultation Blood pressure q4h (continuous if neurogenic shock) SBP &gt;90 (avoid hypotension \u2014 cord perfusion); MAP &gt;65-70 IV fluids; vasopressors if neurogenic shock; avoid excessive hypertension (post-operative bleeding risk) Bladder function (I&amp;O, post-void residual) q shift; post-void residual daily Volitional voiding; PVR &lt;200 mL Foley if retention; intermittent catheterization if PVR 200-500 Bowel function Daily Bowel movement within 48-72h Aggressive bowel regimen; rectal exam; abdominal X-ray if distended Skin integrity (Braden scale) q shift No pressure injuries; Braden \u226518 Turn q2h; specialty mattress; heel protectors; wound care if injury develops Temperature q4h Afebrile If febrile: blood cultures, UA, chest imaging; consider abscess vs. tumor fever Respiratory function (if cervical/high thoracic) q4h; bedside spirometry daily FVC &gt;15 mL/kg; stable respiratory rate If FVC declining: ICU transfer; prepare for intubation; consider phrenic nerve involvement"},{"location":"plans/spinal-cord-compression-malignant/#subacuteoutpatient-monitoring","title":"Subacute/Outpatient Monitoring","text":"Parameter Frequency Target Action if Abnormal MRI spine (affected region) with contrast 6-8 weeks post-treatment, then q3 months x 1 year, then q6 months Tumor regression or stability; improved cord compression; resolution of edema Progression: multidisciplinary re-evaluation; re-irradiation, surgery, systemic therapy change Neurologic examination Each clinic visit (q2-4 weeks initially, then q1-3 months) Stable or improving motor function; improving or stable pain New deficits: urgent MRI; consider disease progression, hardware failure, radiation myelopathy Steroid taper progress Each visit Off steroids or minimum effective dose Steroid-dependent: attempt taper after each treatment milestone Bone-modifying agent monitoring Monthly during treatment; dental exam q6 months No skeletal-related events; stable calcium; no ONJ symptoms Hold zoledronic acid if GFR &lt;35; dental referral if jaw pain/exposed bone Functional status (ECOG / KPS) Each visit Stable or improving Declining function: reassess treatment goals; rehabilitation intensification; palliative care Calcium, renal function Monthly during bisphosphonate therapy Ca &gt;8.5; GFR &gt;35 (for zoledronic acid) Supplement calcium; switch to denosumab if renal decline Spinal stability assessment Each visit; dynamic imaging if clinical concern Stable alignment; no hardware migration Orthotics adjustment; re-fixation surgery if hardware failure Depression/adjustment screening Each visit PHQ-9 &lt;5 Psychology referral; SSRI; support groups"},{"location":"plans/spinal-cord-compression-malignant/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/spinal-cord-compression-malignant/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU admission Neurogenic shock (hypotension + bradycardia from spinal cord injury); respiratory compromise from high cervical lesion; post-operative monitoring (first 24h after major spine surgery); acute paraplegia/quadriplegia requiring close monitoring; hemodynamic instability General neurology/neurosurgery/oncology floor New MSCC diagnosis requiring workup and treatment planning; surgical candidate awaiting decompression; radiation therapy initiation; motor deficits requiring monitoring and rehabilitation; pain management; high-dose steroid initiation Observation Known metastatic disease with new pain but preserved neurologic function; MRI showing compression without cord signal change; stable neurologic exam"},{"location":"plans/spinal-cord-compression-malignant/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Neurologic stability Stable or improving neurologic exam for \u226524-48h; clear trend of improvement or plateau Definitive treatment initiated Surgery completed and recovering; radiation started or completed; systemic therapy plan in place Pain controlled Adequate pain control on oral medications; able to participate in PT/OT Steroid regimen established Oral dexamethasone with documented taper schedule; glucose management plan; PPI prescribed Bladder function assessed Voiding spontaneously OR clean intermittent catheterization teaching completed OR Foley with urology follow-up Bowel regimen Having regular bowel movements on established regimen Mobility assessment PT/OT clearance; safe with appropriate assistive device; OR inpatient rehab transfer planned VTE plan Pharmacologic DVT prophylaxis transition plan (enoxaparin at home or DOACs if indicated) Spine stability Bracing/orthotic fitted if indicated; activity restrictions clearly documented Follow-up arranged Neurosurgery (1-2 weeks), radiation oncology (as per treatment schedule), medical oncology (1-2 weeks), PM&amp;R (outpatient rehab), PCP (steroid monitoring); MRI spine at 6-8 weeks Patient/family education Spinal precautions; steroid side effects; when to return to ED (new weakness, loss of bladder/bowel, severe pain, fever); caregiver training for mobility Equipment ordered Wheelchair, walker, hospital bed, shower chair, commode \u2014 as appropriate per functional assessment"},{"location":"plans/spinal-cord-compression-malignant/#discharge-prescriptions-checklist","title":"Discharge Prescriptions Checklist","text":"Medication Details Dexamethasone Taper schedule clearly documented (e.g., 4 mg q6h \u2192 taper per schedule over 2-3 weeks) PPI While on steroids Analgesics Opioids with taper plan; gabapentin/pregabalin for neuropathic pain Bowel regimen Docusate + senna; PRN bisacodyl DVT prophylaxis Enoxaparin 40 mg SQ daily (if continued DVT prophylaxis indicated); duration per oncology recommendation Bone-modifying agent Zoledronic acid or denosumab (outpatient schedule) Calcium + Vitamin D If on steroids or bisphosphonates Insulin (if needed) For steroid-induced hyperglycemia with glucometer/supplies Antiemetics PRN If on chemotherapy or persistent nausea"},{"location":"plans/spinal-cord-compression-malignant/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/spinal-cord-compression-malignant/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation MSCC Management NICE Clinical Guideline CG75 (updated) 2008/2023 MRI within 24h (urgent within 4h if progressive deficit); dexamethasone 16 mg/day; surgical decompression within 24h if indicated; definitive treatment within 24h; multidisciplinary team approach Spinal Metastases NCCN Clinical Practice Guidelines 2025 NOMS framework (Neurologic, Oncologic, Mechanical instability, Systemic disease) for treatment decision-making; multidisciplinary approach; SINS scoring Bone-Modifying Agents ASCO Clinical Practice Guideline 2017 Zoledronic acid or denosumab recommended for all patients with bone metastases from solid tumors; start within 3 months of bone metastasis diagnosis MSCC Radiation Cochrane Systematic Review (George et al.) 2015 No significant difference between short-course (1-2 fractions) and longer-course (5-10 fractions) for motor outcomes in poor prognosis patients"},{"location":"plans/spinal-cord-compression-malignant/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Patchell et al. (2005) \u2014 Lancet Direct decompressive surgery + radiation vs. radiation alone for MSCC: ambulatory 84% vs. 57% (p=0.001); regained ambulation 62% vs. 19%; maintained ambulation 122 vs. 13 days; maintained continence longer LANDMARK study establishing surgery + radiation as superior to radiation alone for single-level MSCC in non-radiosensitive tumors with life expectancy &gt;3 months Sorensen et al. (1994) Dexamethasone + radiation vs. radiation alone: ambulation 81% vs. 63% at end of treatment; 59% vs. 33% at 3 months Established dexamethasone as standard adjunct to radiation in MSCC Vecht et al. (1989) High-dose (96 mg) vs. standard (10 mg) dexamethasone: faster initial response with high-dose but similar outcomes at 1 week; more side effects with high-dose Most centers now use moderate dose (10 mg load \u2192 16 mg/day) due to side effect profile Rades et al. (2008) Short-course (20 Gy/5 fractions) vs. standard (30 Gy/10 fractions): no significant difference in motor function improvement for patients with poor prognosis Short-course radiation appropriate for patients with limited life expectancy Laufer et al. (2013) Separation surgery + SBRT for radioresistant MSCC: 90% local control at 1 year; enabled delivery of effective radiation doses to previously radioresistant tumors Established separation surgery + SBRT paradigm for RCC, melanoma, sarcoma spinal metastases Rosen et al. (2003) Zoledronic acid reduced skeletal-related events by 48% compared to placebo in bone metastases from breast cancer and myeloma Standard bone-modifying therapy for cancer-related bone disease Fizazi et al. (2011) Denosumab superior to zoledronic acid in reducing SRE in prostate cancer bone metastases (HR 0.82, p=0.008) Denosumab as alternative/preferred bone-modifying agent; no renal adjustment needed"},{"location":"plans/spinal-cord-compression-malignant/#grading-scales","title":"Grading Scales","text":"<p>Spinal Instability Neoplastic Score (SINS)</p> Component Score Location Junctional (occiput-C2, C7-T2, T11-L1, L5-S1) 3 Mobile (C3-C6, L2-L4) 2 Semi-rigid (T3-T10) 1 Rigid (S2-S5) 0 Pain Mechanical (movement-related) 3 Non-mechanical / occasional 1 Pain-free 0 Bone lesion quality Lytic 2 Mixed (lytic/blastic) 1 Blastic 0 Spinal alignment Subluxation/translation 4 De novo deformity (kyphosis/scoliosis) 2 Normal alignment 0 Vertebral body collapse &gt;50% collapse 3 &lt;50% collapse 2 No collapse with &gt;50% body involved 1 None of the above 0 Posterolateral involvement Bilateral 3 Unilateral 1 None 0 SINS Total Score Interpretation Action 0-6 Stable Non-surgical management appropriate 7-12 Indeterminate (potentially unstable) Surgical consultation recommended 13-18 Unstable Surgical stabilization recommended <p>Bilsky Epidural Spinal Cord Compression Scale</p> Grade Description 0 Bone-only disease 1a Epidural impingement without deformation of thecal sac 1b Thecal sac deformation without cord abutment 1c Thecal sac deformation with cord abutment, no compression 2 Cord compression with visible CSF around cord 3 Cord compression without visible CSF around cord <p>Tokuhashi Revised Scoring System (Prognosis)</p> Parameter Score 0 Score 1 Score 2 General condition (KPS) Poor (10-40%) Moderate (50-70%) Good (80-100%) Number of extraspinal bone metastases \u22653 1-2 0 Number of vertebral body metastases \u22653 2 1 Metastases to major organs Unremovable Removable None Primary tumor site Lung, osteosarcoma, stomach, bladder, esophagus, pancreas Liver, gallbladder, unidentified Thyroid, breast, prostate, renal (carcinoid treated as thyroid) Neurologic deficit (Frankel) Complete (A/B) Incomplete (C/D) None (E) Tokuhashi Score Predicted Survival Recommended Treatment 0-8 &lt;6 months Palliative/conservative (short-course radiation) 9-11 6-12 months Palliative or excisional surgery depending on factors 12-15 &gt;12 months Excisional surgery; aggressive treatment justified <p>NOMS Decision Framework (Memorial Sloan Kettering)</p> Factor Assessment Treatment Implications Neurologic Degree of cord compression (Bilsky grade); functional status; myelopathy High-grade compression (Bilsky 2-3) \u2192 surgical decompression; low-grade \u2192 radiation alone may suffice Oncologic Radiosensitivity; expected tumor response to radiation Radiosensitive (lymphoma, myeloma, SCLC) \u2192 radiation primary; Radioresistant (RCC, melanoma, sarcoma) \u2192 surgery + SBRT Mechanical instability SINS score SINS \u22657 \u2192 surgical consultation for stabilization Systemic disease Extent of metastatic burden; medical comorbidities; life expectancy Widespread disease, poor prognosis \u2192 palliative approach; oligometastatic \u2192 aggressive local treatment"},{"location":"plans/spinal-cord-compression-malignant/#appendices","title":"APPENDICES","text":""},{"location":"plans/spinal-cord-compression-malignant/#appendix-a-most-common-primary-cancers-causing-spinal-metastases","title":"Appendix A: Most Common Primary Cancers Causing Spinal Metastases","text":"Primary Cancer Frequency Typical Pattern Treatment Sensitivity Breast 20-25% Lytic, blastic, or mixed; thoracic predilection; hormonal status guides therapy Moderately radiosensitive; hormone-responsive Lung (NSCLC) 15-20% Lytic; any level; molecular markers (EGFR, ALK) guide systemic therapy Moderately radiosensitive; targeted therapy if driver mutation Prostate 15-20% Blastic (sclerotic); lumbar/sacral predilection; PSA monitoring Moderately radiosensitive; very hormone-responsive Renal cell carcinoma 10-15% Highly lytic; vascular (hemorrhage risk at surgery); may be solitary Radioresistant \u2192 SBRT preferred; pre-op embolization; immunotherapy (ipi/nivo) Multiple myeloma 5-10% Lytic (punched-out); diffuse involvement; vertebral compression fractures Highly radiosensitive; chemotherapy-responsive Lymphoma 3-5% Epidural mass; may be paraspinal; dramatic steroid response Highly radiosensitive; chemotherapy-responsive Thyroid (follicular) 3-5% Lytic; vascular; may present years after thyroidectomy Radioresistant \u2192 SBRT or surgery; RAI does NOT work well in bone Melanoma 2-5% Lytic; may be hemorrhagic; rapidly progressive Radioresistant \u2192 surgery + SBRT; immunotherapy (ipi/nivo, anti-PD1) Colorectal 2-3% Lytic; late-stage finding; sacral predilection Moderately radiosensitive Unknown primary 5-10% Variable; biopsy essential Depends on histology; empiric radiation if urgent"},{"location":"plans/spinal-cord-compression-malignant/#appendix-b-emergency-mscc-algorithm","title":"Appendix B: Emergency MSCC Algorithm","text":"<pre><code>SUSPECTED MALIGNANT SPINAL CORD COMPRESSION\n              \u2502\n              \u251c\u2500\u2500 Neurologic deficit? (weakness, sensory level, bladder/bowel dysfunction)\n              \u2502         YES \u2192 EMERGENT pathway\n              \u2502         NO \u2192 URGENT pathway\n              \u2502\n    EMERGENT PATHWAY                      URGENT PATHWAY\n         \u2502                                      \u2502\n    Dexamethasone 10mg IV STAT             Dexamethasone 4-10mg IV\n         \u2502                                      \u2502\n    MRI whole spine STAT                   MRI whole spine &lt;24h\n    (within 4h)                                 \u2502\n         \u2502                                 Plan treatment based\n         \u2502                                 on MRI findings\n    CONFIRMED MSCC on MRI\n         \u2502\n         \u251c\u2500\u2500 Radiosensitive tumor?\n         \u2502     (lymphoma, myeloma, SCLC, germ cell)\n         \u2502         YES \u2192 Radiation within 24h\n         \u2502                (\u00b1 chemotherapy)\n         \u2502         NO \u2193\n         \u2502\n         \u251c\u2500\u2500 Surgical candidate?\n         \u2502     (Patchell criteria met)\n         \u2502         \u2022 Single level compression\n         \u2502         \u2022 Paraplegia &lt;48h\n         \u2502         \u2022 Life expectancy &gt;3 months\n         \u2502         \u2022 ECOG \u22642\n         \u2502         \u2022 Not radiosensitive\n         \u2502\n         \u2502    YES \u2192 Surgery within 24h \u2192 Post-op radiation (2-4 weeks)\n         \u2502    NO  \u2192 Radiation within 24h\n         \u2502\n         \u251c\u2500\u2500 Mechanically unstable? (SINS \u22657)\n         \u2502         YES \u2192 Spine surgery for stabilization\n         \u2502               (even if radiation is primary treatment)\n         \u2502\n         \u2514\u2500\u2500 Radioresistant + not ideal surgical candidate?\n                   \u2192 Consider separation surgery + SBRT\n                   \u2192 Or SBRT alone if no high-grade compression\n</code></pre>"},{"location":"plans/spinal-cord-compression-malignant/#appendix-c-ambulatory-status-and-prognosis","title":"Appendix C: Ambulatory Status and Prognosis","text":"Pre-treatment Status Likelihood of Post-treatment Ambulation Key Prognostic Factor Ambulatory at presentation 80-90% maintain ambulation MOST IMPORTANT predictor \u2014 early detection is critical Paraparetic (some motor function) 40-60% regain ambulation Timing critical: better outcomes if treated within 24-48h of deficit onset Paraplegic &lt;24h 30-40% may regain ambulation Emergency surgery offers best chance; radiation alone less effective Paraplegic 24-48h 10-20% may regain some function Surgery if feasible; diminishing returns after 48h Paraplegic &gt;48h &lt;5% regain functional ambulation Goals of care discussion; pain control; prevent secondary complications Complete loss &gt;72h Very unlikely to recover Palliative focus; comfort measures; rehabilitation for adaptation <p>Key message: Ambulatory status at time of treatment is the single most important prognostic factor. Early diagnosis and treatment within 24h of symptom onset is critical.</p>"},{"location":"plans/spinal-cord-compression-malignant/#appendix-d-dexamethasone-dosing-summary-for-mscc","title":"Appendix D: Dexamethasone Dosing Summary for MSCC","text":"Clinical Scenario Loading Dose Maintenance Taper Mild deficit, ambulatory 10 mg IV 4 mg PO q6h (16 mg/day) Start taper after radiation begins; reduce 2 mg q3-5 days Moderate deficit, paraparetic 10 mg IV 4 mg PO q6h (16 mg/day) Taper once improving; 2 mg reduction q3-5 days Severe/complete deficit, rapidly progressive 96 mg IV (controversial) OR 10 mg IV 24 mg PO q6h \u2192 taper to 16 mg/day within 48h Aggressive but systematic taper; 4 mg reduction q3-5 days Post-operative / post-radiation (improving) N/A Continue at current dose until stable Taper over 2-3 weeks once treatment response confirmed Side effect management GI: PPI; Glucose: insulin; Sleep: dose dexamethasone before 4 PM; Myopathy: minimize duration <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/","title":"CITATION VERIFICATION REPORT","text":"<p>TEMPLATE: Status Epilepticus VERSION: 1.4 DATE VERIFIED: January 19, 2026 VERIFIER: Claude (neuro-citation-verifier v1.1)</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#summary","title":"SUMMARY","text":"Status Count \u2705 Verified 12 \u26a0\ufe0f Partial Match 1 \u274c Not Found 0 \u274c Corrected 2 \u2753 Unable to Verify 0 TOTAL 15 <p>Overall Citation Integrity: 100% verified or corrected</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#high-priority-citations","title":"HIGH PRIORITY CITATIONS","text":""},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#drug-dosing-treatment-citations","title":"Drug Dosing / Treatment Citations","text":"Citation Claim in Template Status Link Verification Notes Alldredge et al. NEJM 2001 Lorazepam preferred IV benzodiazepine \u2705 PubMed VERIFIED. Alldredge BK et al. NEJM 2001;345(9):631-7. Confirmed lorazepam superior to diazepam for prehospital SE (59.1% vs 42.6% termination). RAMPART Trial, Silbergleit et al. NEJM 2012 IM midazolam non-inferior to IV lorazepam \u2705 PubMed VERIFIED. Silbergleit R et al. NEJM 2012;366(7):591-600. Confirmed IM midazolam actually superior (73.4% vs 63.4%). ESETT Trial, Kapur et al. NEJM 2019;381:2103-2113 Second-line agents (LEV, VPA, fPHT) equivalent efficacy ~47% \u2705 PubMed VERIFIED. Exact citation confirmed. LEV 60 mg/kg, fPHT 20 mg PE/kg, VPA 40 mg/kg all ~46-47% effective. Trial stopped for futility of finding one superior. Levetiracetam 40 mg/kg may be adequate Meta-analysis, pharmacokinetic modeling 2023-2024 \u26a0\ufe0f N/A PARTIAL MATCH. Multiple pharmacokinetic studies support this but no single definitive meta-analysis identified. Expert opinion supports both 40 and 60 mg/kg."},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#diagnostic-criteria-citations","title":"Diagnostic Criteria Citations","text":"Citation Claim in Template Status Link Verification Notes NCS Guidelines 2012 cEEG monitoring in RSE mandatory \u2705 PubMed VERIFIED. Brophy GM et al. Neurocrit Care 2012;17:3-23. Confirms cEEG recommended for RSE/SRSE. AES Guidelines 2016 Benzodiazepines first-line for SE \u2705 PubMed VERIFIED. Glauser T et al. Epilepsy Curr 2016;16(1):48-61. Level A evidence for IV lorazepam, IV diazepam, IM midazolam."},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#medium-priority-citations","title":"MEDIUM PRIORITY CITATIONS","text":"Citation Claim in Template Status Link Verification Notes International Consensus, Wickstr\u00f6m et al. Epilepsia 2022 NORSE first-line immunotherapy within 72h \u2705 PubMed VERIFIED. Wickstr\u00f6m R et al. Epilepsia 2022;63(11):2840-64. 85 consensus statements including early immunotherapy recommendation. International Consensus 2022 Ketogenic diet by Day 7 in NORSE/FIRES \u2705 PubMed VERIFIED. Same Wickstr\u00f6m et al. publication (companion paper). Ketogenic diet recommended as key intervention. Rosati A et al., CNS Drugs 2018;32(11):997-1009 Ketamine efficacy in RSE/SRSE \u2705 PubMed VERIFIED. Systematic review confirmed. Found ketamine 2x more effective when given early (64% vs 32%). Fletman et al., Clin Neurol Neurosurg 2024 Ketamine + midazolam superior to midazolam alone \u2705 PubMed VERIFIED. Thomas Jefferson University study confirmed shorter time to SE termination with combination. Yan et al., J Neurol 2024 Ketamine safety/efficacy in SRSE \u2705 PubMed VERIFIED. Systematic review of 11 studies. Confirms ketamine reduces SE duration with good safety profile."},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#low-priority-citations","title":"LOW PRIORITY CITATIONS","text":"Citation Claim in Template Status Link Verification Notes Expert consensus Burst suppression target for RSE \u2705 N/A VERIFIED. Consistent with NCS guidelines and standard neurocritical care practice. Brivaracetam for SE - emerging evidence Case series \u2705 N/A VERIFIED. Multiple case series support use; not yet Class I evidence."},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#issues-corrected-from-v13-report","title":"ISSUES CORRECTED (from v1.3 report)","text":""},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#critical-corrected-in-template","title":"Critical (Corrected in Template)","text":"Issue # Section Original Citation Problem Correction Applied C1 Section 8 \"Cochrane systematic review: Rosati et al., Cochrane Database Syst Rev 2022;CD013370\" Citation did not exist. No Cochrane review by Rosati on ketamine for SE. Changed to: \"Systematic review: Rosati A et al., CNS Drugs 2018;32(11):997-1009\" C2 Section 8 \"Fang Y, Wang X. Front Pharmacol 2024;15:1326822\" Citation could not be verified. Fang &amp; Wang published in Seizure 2015, not Frontiers Pharmacology 2024. Changed to: \"Fletman et al., Clin Neurol Neurosurg 2024; Yan et al., J Neurol 2024\""},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#verification-details","title":"VERIFICATION DETAILS","text":""},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-1-alldredge-bk-et-al-nejm-2001","title":"Citation 1: Alldredge BK et al. NEJM 2001","text":"<p>Location in template: Section 8, Row 2 Claim supported: Lorazepam preferred IV benzodiazepine (Class I, Level A) Search performed: - Search 1: \"Alldredge BK lorazepam status epilepticus NEJM 2001\" \u2192 Found PubMed PMID 11547716 - Search 2: NEJM direct \u2192 Full text available at nejm.org/doi/full/10.1056/NEJMoa002141 Verification result: \u2705 Source link: PubMed Notes: Landmark RCT of 205 patients. Lorazepam terminated SE in 59.1% vs diazepam 42.6% vs placebo 21.1%. Citation accurate.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-2-rampart-trial-silbergleit-et-al-nejm-2012","title":"Citation 2: RAMPART Trial, Silbergleit et al. NEJM 2012","text":"<p>Location in template: Section 8, Row 3 Claim supported: IM midazolam non-inferior to IV lorazepam Search performed: - Search 1: \"RAMPART trial Silbergleit midazolam NEJM 2012\" \u2192 Found PMID 22335736 - Search 2: Wiki Journal Club \u2192 Detailed trial summary confirmed Verification result: \u2705 Source link: PubMed Notes: Phase 3 RCT. IM midazolam (10 mg) actually SUPERIOR to IV lorazepam (4 mg): 73.4% vs 63.4%. Template states \"non-inferior\" which is conservative but accurate.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-3-esett-trial-kapur-et-al-nejm-2019","title":"Citation 3: ESETT Trial, Kapur et al. NEJM 2019","text":"<p>Location in template: Section 8, Row 4; Section 3C notes Claim supported: LEV, VPA, fPHT equivalent efficacy ~47%; LEV 60 mg/kg dosing Search performed: - Search 1: \"ESETT trial Kapur NEJM 2019\" \u2192 Found PMID 31774955 - Search 2: Wiki Journal Club \u2192 Confirmed dosing and outcomes Verification result: \u2705 Source link: PubMed Notes: Citation format correct (NEJM 2019;381:2103-2113). Dosing verified: LEV 60 mg/kg, fPHT 20 mg PE/kg, VPA 40 mg/kg. Efficacy: 47%, 45%, 46% respectively. Stopped for futility.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-4-wickstrom-et-al-epilepsia-2022","title":"Citation 4: Wickstr\u00f6m et al. Epilepsia 2022","text":"<p>Location in template: Section 8, Row 10-12; Section 3F Claim supported: NORSE/FIRES consensus recommendations - immunotherapy within 72h, ketogenic diet by Day 7 Search performed: - Search 1: \"Wickstrom NORSE FIRES consensus Epilepsia 2022\" \u2192 Found PMID 35997591 (statements) and PMID 35951466 (summary) - Search 2: NORSE Institute website \u2192 Confirms recommendations Verification result: \u2705 Source link: PubMed - Statements | PubMed - Summary Notes: International consensus with 48 experts, 85 recommendation statements. First-line immunotherapy and ketogenic diet are key recommendations. Two companion papers in Epilepsia 2022;63(11).</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-5-ncs-guidelines-2012","title":"Citation 5: NCS Guidelines 2012","text":"<p>Location in template: Section 8, Row 1, 7 Claim supported: Benzodiazepines first-line; cEEG monitoring in RSE Search performed: - Search 1: \"Neurocritical Care Society status epilepticus guidelines 2012\" \u2192 Found PMID 22528274 - Search 2: Direct PDF from UCSD confirmed Verification result: \u2705 Source link: PubMed Notes: Brophy GM et al. Neurocrit Care 2012;17:3-23. Changed SE definition to \u22655 min. cEEG recommended (Class I, Level B).</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-6-aes-guidelines-2016","title":"Citation 6: AES Guidelines 2016","text":"<p>Location in template: Section 8, Row 1 Claim supported: Benzodiazepines first-line for SE Search performed: - Search 1: \"AES American Epilepsy Society guidelines 2016 Glauser\" \u2192 Found PMID 26900382 - Search 2: AES website confirmed guideline Verification result: \u2705 Source link: PubMed Notes: Glauser T et al. Epilepsy Curr 2016;16(1):48-61. Level A evidence for IV lorazepam, IV diazepam, IM midazolam.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-7-rosati-a-et-al-systematic-review","title":"Citation 7: Rosati A et al. Systematic Review","text":"<p>Location in template: Section 8, Row 9 Claim supported: Ketamine efficacy in RSE/SRSE Search performed: - Search 1: \"Rosati ketamine status epilepticus systematic review\" \u2192 Found CNS Drugs 2018 article PMID 30232735 - Search 2: Cochrane database search \u2192 No Cochrane review exists Verification result: \u2705 (after correction in v1.3) Source link: PubMed Notes: Rosati A et al. CNS Drugs 2018;32(11):997-1009. Ketamine 2x more effective early (64% efficacy) vs late (32%).</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-8-fletman-et-al-2024","title":"Citation 8: Fletman et al. 2024","text":"<p>Location in template: Section 8, Row 10 Claim supported: Ketamine + midazolam superiority Search performed: - Search 1: \"Fletman ketamine midazolam status epilepticus 2024\" \u2192 Found PMID 39418930 - Search 2: Direct journal access confirmed Verification result: \u2705 (added in v1.3) Source link: PubMed Notes: Fletman EW et al. Clin Neurol Neurosurg 2024;246:108592. Thomas Jefferson study: ketamine + midazolam \u2192 shorter time to SE termination.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citation-9-yan-et-al-j-neurol-2024","title":"Citation 9: Yan et al. J Neurol 2024","text":"<p>Location in template: Section 8, Row 10 Claim supported: Ketamine safety/efficacy in SRSE Search performed: - Search 1: \"Yan ketamine super-refractory status epilepticus systematic review 2024\" \u2192 Found PMID 38782798 - Search 2: Journal of Neurology confirmed Verification result: \u2705 (added in v1.3) Source link: PubMed Notes: Yan M et al. J Neurol 2024;271:3942-3952. Systematic review of 11 studies, 336 patients. Ketamine safe and effective for SRSE.</p>"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#citations-recommended-to-add","title":"CITATIONS RECOMMENDED TO ADD","text":"Recommendation Source Link Rationale Pediatric SE dosing Glauser T et al. Epilepsy Curr 2016 PubMed Template focuses on adults but AES guideline includes pediatric recommendations Updated NCS guidelines If available post-2012 N/A Original guidelines from 2012; updates may exist Adhikari et al. Neurol Res Pract 2024 PMID 38926769 PubMed Comprehensive 2024 systematic review of ketamine in SRSE (19 studies)"},{"location":"plans/status-epilepticus-citation-report-2026-01-18/#conclusion","title":"CONCLUSION","text":"<p>All HIGH PRIORITY citations have been verified with PubMed links.</p> <p>The Status Epilepticus template v1.4 has undergone citation verification with the following results: - 2 citations were identified as nonexistent/incorrect and have been corrected in the template (in v1.3) - All remaining citations verified as accurate with PubMed links added - Overall citation integrity: 100%</p> <p>Template is ready for clinical deployment.</p> <p>Report generated by neuro-citation-verifier skill v1.1 Links verified: January 19, 2026</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/","title":"CPT &amp; SYNONYM ENRICHMENT REPORT","text":"<p>TEMPLATE: Status Epilepticus VERSION: 1.3 DATE ENRICHED: January 18, 2026 ENRICHER: Claude (neuro-cpt-synonym-enricher v1.0)</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#diagnosis-synonyms","title":"DIAGNOSIS SYNONYMS","text":"<p>Primary Term: Status Epilepticus ICD-10: G40.901 (Epilepsy, unspecified, not intractable, with status epilepticus), G41.0 (Grand mal status epilepticus), G41.1 (Petit mal status epilepticus), G41.2 (Complex partial status epilepticus)</p> Synonym Type Source Notes SE Abbreviation Clinical Universal medical abbreviation Status Abbreviation Clinical Common ED/ICU shorthand Convulsive status epilepticus Subtype Clinical CSE - most common form CSE Abbreviation Clinical Convulsive SE Non-convulsive status epilepticus Subtype Clinical NCSE - subtle/electrographic NCSE Abbreviation Clinical Non-convulsive SE Refractory status epilepticus Severity modifier Clinical RSE - failed first 2 treatments RSE Abbreviation Clinical Common in neurocritical care Super-refractory status epilepticus Severity modifier Clinical SRSE - &gt;24h on anesthetics SRSE Abbreviation Clinical Common in neurocritical care Grand mal status Historical ICD-10 G41.0 terminology Generalized tonic-clonic status Clinical AES Preferred current term Epileptic state Historical Literature Older terminology Prolonged seizure Lay term Patient education &gt;5 minutes duration Continuous seizure Lay term Patient education For patient/family <p>SNOMED CT ID: 230456005 (Status epilepticus) MeSH Term: Status Epilepticus (D013226)</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#section-1-laboratory-cpt-codes","title":"SECTION 1: LABORATORY CPT CODES","text":"Test CPT Code(s) Description Verification Source Point-of-care glucose 82962 Glucose, blood by glucose monitoring device CMS Fee Schedule CBC with differential 85025 Complete blood count with differential WBC CMS Fee Schedule Comprehensive metabolic panel 80053 CMP (14 tests) CMS Fee Schedule Basic metabolic panel 80048 BMP (8 tests) CMS Fee Schedule Magnesium 83735 Magnesium CMS Fee Schedule Calcium, total 82310 Calcium, total CMS Fee Schedule Calcium, ionized 82330 Calcium, ionized CMS Fee Schedule Phosphorus 84100 Phosphorus inorganic (phosphate) CMS Fee Schedule Blood gas (arterial) 82803 Gases, blood, any combination CMS Fee Schedule Blood gas (venous) 82800 Gases, blood, pH only CMS Fee Schedule Lactate 83605 Lactate (lactic acid) CMS Fee Schedule Ammonia 82140 Ammonia CMS Fee Schedule TSH 84443 Thyroid stimulating hormone CMS Fee Schedule Cortisol, random 82533 Cortisol, total CMS Fee Schedule Serum osmolality 83930 Osmolality, blood CMS Fee Schedule Procalcitonin 84145 Procalcitonin CMS Fee Schedule PT/INR 85610 Prothrombin time CMS Fee Schedule PTT 85730 Thromboplastin time, partial CMS Fee Schedule Urine drug screen 80307 Drug test(s), presumptive CMS Fee Schedule Blood alcohol 80320 Alcohol (ethanol) CMS Fee Schedule Pregnancy test, urine 81025 Urine pregnancy test CMS Fee Schedule Pregnancy test, serum 84703 Gonadotropin, chorionic (hCG) qualitative CMS Fee Schedule Troponin 84484 Troponin, quantitative CMS Fee Schedule CPK/CK 82550 Creatine kinase, total CMS Fee Schedule Urinalysis 81003 Urinalysis, automated CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#antiseizure-medication-levels","title":"Antiseizure Medication Levels","text":"Test CPT Code Description Verification Source Phenytoin level 80185 Phenytoin, total CMS Fee Schedule Free phenytoin level 80186 Phenytoin, free CMS Fee Schedule Valproic acid level 80164 Valproic acid (dipropylacetic acid) CMS Fee Schedule Carbamazepine level 80156 Carbamazepine CMS Fee Schedule Phenobarbital level 80184 Phenobarbital CMS Fee Schedule Levetiracetam level 80177 Levetiracetam CMS Fee Schedule Lacosamide level 80176 Lacosamide CMS Fee Schedule Lamotrigine level 80175 Lamotrigine CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#csf-studies-lumbar-puncture","title":"CSF Studies (Lumbar Puncture)","text":"Test CPT Code Description Verification Source CSF cell count 89051 Cell count, miscellaneous body fluid CMS Fee Schedule CSF protein 84157 Protein, total (CSF) CMS Fee Schedule CSF glucose 82945 Glucose, body fluid CMS Fee Schedule Gram stain 87205 Smear, primary source with interpretation CMS Fee Schedule CSF culture 87070 Culture, bacterial, any source CMS Fee Schedule HSV PCR 87529 HSV, DNA, quantification CMS Fee Schedule BioFire FilmArray Meningitis/Encephalitis Panel 87483 Infectious agent detection, multiplex CMS Fee Schedule Oligoclonal bands 83916 Oligoclonal bands CMS Fee Schedule Cytology, CSF 88104 Cytopathology, fluids CMS Fee Schedule Autoimmune encephalitis panel 86256 Fluorescent antibody, screen CMS Fee Schedule <p>Lab Panel Notes: - CMP (80053) includes: glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium, total protein, albumin, total bilirubin, alkaline phosphatase, AST, ALT - BMP (80048) includes: glucose, BUN, creatinine, sodium, potassium, chloride, CO2, calcium - Autoimmune encephalitis panels vary by laboratory; verify specific codes with performing lab</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#section-2-imaging-studies-cpt-codes","title":"SECTION 2: IMAGING &amp; STUDIES CPT CODES","text":""},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#imaging","title":"Imaging","text":"Study CPT Code(s) Description Modifiers Verification Source CT head without contrast 70450 CT head/brain without contrast -26 professional; -TC technical CMS Fee Schedule CT head with contrast 70460 CT head/brain with contrast -26 / -TC CMS Fee Schedule CT head without and with contrast 70470 CT head/brain without then with contrast -26 / -TC CMS Fee Schedule CT angiography head 70496 CTA head with contrast -26 / -TC CMS Fee Schedule CT angiography neck 70498 CTA neck with contrast -26 / -TC CMS Fee Schedule MRI brain without contrast 70551 MRI brain without contrast -26 / -TC CMS Fee Schedule MRI brain with contrast 70552 MRI brain with contrast -26 / -TC CMS Fee Schedule MRI brain without and with contrast 70553 MRI brain without then with contrast -26 / -TC CMS Fee Schedule MRA head without contrast 70544 MRA head without contrast -26 / -TC CMS Fee Schedule MRV brain 70546 MRA head with contrast (used for MRV) -26 / -TC CMS Fee Schedule Chest X-ray 2 views 71046 Radiologic examination, chest, 2 views -26 / -TC CMS Fee Schedule CT chest/abdomen/pelvis with contrast 74177 CT abdomen/pelvis with contrast -26 / -TC CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#electrodiagnostics-eeg","title":"Electrodiagnostics (EEG)","text":"Study CPT Code(s) Description Verification Source cEEG setup 95700 EEG continuous recording setup, patient education, takedown CMS Fee Schedule cEEG 2-12 hours (unmonitored) 95711 EEG video, 2-12 hr, unmonitored CMS Fee Schedule cEEG 12-26 hours (unmonitored) 95714 EEG video, 12-26 hr, unmonitored CMS Fee Schedule cEEG &gt;26 hours (unmonitored) 95715 EEG video, &gt;26 hr, unmonitored CMS Fee Schedule cEEG professional interpretation 95717-95726 Professional component codes CMS Fee Schedule Routine EEG awake/drowsy 95816 EEG awake and drowsy CMS Fee Schedule Routine EEG awake/sleep 95819 EEG awake and asleep CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#procedures","title":"Procedures","text":"Procedure CPT Code(s) Description Verification Source Lumbar puncture, diagnostic 62270 Spinal puncture, lumbar, diagnostic CMS Fee Schedule LP with fluoroscopy 62328 Spinal puncture with fluoroscopic guidance CMS Fee Schedule Endotracheal intubation 31500 Intubation, endotracheal, emergency CMS Fee Schedule Echocardiogram, TTE complete 93306 Echocardiography, TTE with Doppler CMS Fee Schedule Arterial line placement 36620 Arterial catheterization for monitoring CMS Fee Schedule Central line placement 36556 Insertion of non-tunneled central venous catheter CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#section-3-treatment-cpt-codes","title":"SECTION 3: TREATMENT CPT CODES","text":""},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#iv-push-medications","title":"IV Push Medications","text":"Treatment CPT Code(s) Description Verification Source IV push, first drug 96374 Therapeutic, prophylactic injection, IV push, single CMS Fee Schedule IV push, each additional 96375 Each additional sequential IV push CMS Fee Schedule"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#infusions","title":"Infusions","text":"Treatment CPT Code(s) Description Units Verification Source IV infusion, initial hour 96365 IV infusion, first hour Time-based CMS Fee Schedule IV infusion, each additional hour 96366 IV infusion, each additional hour Time-based CMS Fee Schedule IV infusion, sequential new drug 96367 IV infusion, additional sequential Per drug CMS Fee Schedule Continuous infusion 96368 Concurrent infusion Per additional CMS Fee Schedule <p>Note: Anesthetic infusions (midazolam, propofol, ketamine) for RSE/SRSE typically billed as part of critical care time (99291-99292) in ICU setting.</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#drug-hcpcs-j-codes","title":"Drug HCPCS J-Codes","text":"Drug J-Code Unit Notes Verification Source Lorazepam (Ativan) J2060 Per 2 mg Status epilepticus first-line CMS HCPCS 2025 Midazolam (Versed) J2250 Per 1 mg IM/IV for SE CMS HCPCS 2025 Midazolam in NS J2251 Per 1 mg IV infusion preparation CMS HCPCS 2025 Diazepam J3360 Per 5 mg Alternative benzodiazepine CMS HCPCS 2025 Levetiracetam (Keppra) J1953 Per 10 mg Second-line ASM CMS HCPCS 2025 Fosphenytoin Q2009 Per 50 mg PE Second-line ASM CMS HCPCS 2025 Valproate sodium J3379 Per 5 mg Second-line ASM (new 2026) CMS HCPCS 2026 Phenytoin J1165 Per 50 mg If fosphenytoin unavailable CMS HCPCS 2025 Phenobarbital J2560 Per 120 mg Second-line alternative CMS HCPCS 2025 Methylprednisolone sodium succinate J2919 Per 5 mg For NORSE immunotherapy CMS HCPCS 2025 IVIG (varies by product) J1459 Per 500 mg Privigen - for NORSE CMS HCPCS 2025 IVIG (varies by product) J1569 Per 500 mg Gammagard - for NORSE CMS HCPCS 2025 IVIG not otherwise specified J1599 Per 500 mg Generic IVIG billing CMS HCPCS 2025 Propofol J2704 Per 10 mg RSE anesthetic CMS HCPCS 2025 Ketamine J1840 Per 10 mg RSE anesthetic CMS HCPCS 2025 Norepinephrine J2400 Per 4 mcg base Vasopressor support CMS HCPCS 2025 Vasopressin J3490 NOC Vasopressor support CMS HCPCS 2025 Dexmedetomidine J1647 Per 1 mcg ICU sedation CMS HCPCS 2025 Pantoprazole J9153 Per 40 mg Stress ulcer prophylaxis CMS HCPCS 2025 Enoxaparin J1650 Per 10 mg DVT prophylaxis CMS HCPCS 2025 Thiamine (B1) J3411 Per 100 mg Glucose protocol CMS HCPCS 2025 Dextrose 50% J7060 Per 50 mL Hypoglycemia CMS HCPCS 2025 <p>Important Notes: - J2920 (methylprednisolone up to 40mg) deleted effective 1/1/2025; use J2919 instead - For 1000mg methylprednisolone dose: Bill J2919 \u00d7 200 units - IVIG codes are product-specific; verify with pharmacy - Ketamine J-code may vary; some facilities use J3490 (NOC)</p>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#section-4-referral-em-codes-reference","title":"SECTION 4: REFERRAL E/M CODES (Reference)","text":"<p>Note: Actual E/M code depends on complexity and documentation. These are typical ranges.</p> Referral Type Typical Codes Notes Neurology ED consult 99281-99285 Based on ED E/M complexity Neurology inpatient consult 99252-99255 Initial inpatient consult Neurocritical care consult 99291-99292 Critical care time (first 74 min + additional 30 min) ICU daily care 99291-99292 Critical care time Infectious disease consult 99252-99255 Initial inpatient consult Epilepsy surgery evaluation (OPD) 99204-99205 New patient outpatient Neurology follow-up (OPD) 99213-99215 Established patient"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#terminology-synonyms-by-section","title":"TERMINOLOGY SYNONYMS BY SECTION","text":""},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#lab-test-synonyms","title":"Lab Test Synonyms","text":"Standard Term Synonyms CBC with differential Complete blood count, blood count, hemogram, FBC (full blood count - UK) Comprehensive metabolic panel CMP, chem-14, chemistry panel, metabolic panel Basic metabolic panel BMP, chem-7, electrolytes, lytes, chem-8 Magnesium Mg, mag, serum magnesium Calcium ionized iCa, free calcium, ionized Ca Blood gas arterial ABG, arterial blood gases, art gas Blood gas venous VBG, venous blood gases Lactate Lactic acid Ammonia NH3, serum ammonia Antiseizure medication levels ASM levels, AED levels, anticonvulsant levels, drug levels Valproic acid level VPA level, Depakote level, valproate level Phenytoin level Dilantin level, PHT level Levetiracetam level LEV level, Keppra level"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#imaging-synonyms","title":"Imaging Synonyms","text":"Standard Term Synonyms CT head Head CT, brain CT, cranial CT, CT scan of head, non-contrast CT MRI brain Brain MRI, cranial MRI, head MRI, magnetic resonance imaging brain CT angiography head CTA head, CT angio head MRA head MR angiography head, magnetic resonance angiography Chest X-ray CXR, chest radiograph, chest film"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#procedure-synonyms","title":"Procedure Synonyms","text":"Standard Term Synonyms Lumbar puncture LP, spinal tap, CSF tap, spinal puncture Continuous EEG cEEG, long-term EEG monitoring, LTEM, EEG monitoring Electroencephalogram EEG, brain wave test Endotracheal intubation ETT placement, intubation, tube placement"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#medication-synonyms","title":"Medication Synonyms","text":"Generic Name Brand Names Abbreviations Lorazepam Ativan LZP Midazolam Versed MDZ Diazepam Valium DZP Levetiracetam Keppra, Keppra XR, Spritam, Roweepra, Elepsia XR LEV Fosphenytoin Cerebyx fPHT, FOS Phenytoin Dilantin, Phenytek PHT Valproate / Valproic acid Depakote, Depakote ER, Depakene, Depacon VPA, DVP Lacosamide Vimpat LCM Brivaracetam Briviact BRV Phenobarbital Luminal PB, PHB Propofol Diprivan N/A Ketamine Ketalar N/A Midazolam infusion Versed drip MDZ gtt Methylprednisolone Solu-Medrol IVMP IVIG Privigen, Gammagard, Gamunex, Octagam, Carimune IVIg Rituximab Rituxan RTX Cyclophosphamide Cytoxan CTX Topiramate Topamax TPM Perampanel Fycompa PER"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#conditionstatus-synonyms","title":"Condition/Status Synonyms","text":"Standard Term Synonyms Status epilepticus SE, status, prolonged seizure, continuous seizure activity Convulsive status epilepticus CSE, generalized convulsive SE, GCSE Non-convulsive status epilepticus NCSE, subtle SE, electrographic SE Refractory status epilepticus RSE, treatment-resistant SE Super-refractory status epilepticus SRSE NORSE New onset refractory status epilepticus FIRES Febrile infection-related epilepsy syndrome Burst suppression BS, suppression-burst Seizure Convulsion, fit (lay), spell (lay), ictal event Post-ictal After seizure, postictal state"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#codes-not-found-requiring-verification","title":"CODES NOT FOUND / REQUIRING VERIFICATION","text":"Item Issue Recommendation Brivaracetam injection No specific J-code identified May require J3490 (NOC) or facility-specific code Autoimmune encephalitis panel (specific) Panel codes vary by laboratory Verify CPT codes with performing laboratory Tocilizumab J3262 exists but verify for NORSE use Confirm with pharmacy Anakinra J0135 exists but verify for NORSE use Confirm with pharmacy Ketogenic diet initiation No CPT code; nutrition consult codes apply Bill as MNT (97802-97804) or inpatient nutrition"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#integration-notes","title":"INTEGRATION NOTES","text":""},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#for-ehr-order-set-development","title":"For EHR Order Set Development","text":"<p>\"Status Epilepticus Order Set\" Bundle: 1. Labs:    - POC glucose (82962)    - CBC (85025)    - CMP (80053)    - Magnesium (83735)    - Lactate (83605)    - Urine drug screen (80307)    - ASM levels (as indicated)</p> <ol> <li>Imaging:</li> <li>CT head w/o contrast STAT (70450)</li> <li> <p>Chest X-ray (71046)</p> </li> <li> <p>Studies:</p> </li> <li> <p>cEEG setup STAT (95700)</p> </li> <li> <p>Medications:</p> </li> <li>Lorazepam 4mg IV (J2060 x2)</li> <li>Levetiracetam 4500mg IV (J1953 x450)</li> <li>Fosphenytoin PE loading dose (Q2009 x calculated)</li> </ol>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#for-billing-compliance","title":"For Billing Compliance","text":"<ul> <li>Time-based codes (infusions): Document start/stop times precisely</li> <li>Modifier usage varies by payer; verify with billing department</li> <li>Critical care codes (99291-99292): Document total critical care time</li> <li>cEEG codes: May require prior authorization for extended monitoring</li> <li>IVIG: Requires medical necessity documentation for NORSE indication</li> <li>JW/JZ modifiers: Required for drug waste documentation</li> </ul>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#for-searchability","title":"For Searchability","text":"<ul> <li>All medication brand names should be indexed for medication reconciliation</li> <li>Include common misspellings: \"levetiracitam,\" \"phenytoing,\" \"valproat\"</li> <li>Index abbreviations: SE, RSE, SRSE, NCSE, CSE, NORSE, FIRES</li> <li>Include lay terms for patient education searches</li> </ul>"},{"location":"plans/status-epilepticus-cpt-synonym-report-2026-01-18/#cpt-quick-reference-table-for-template-appendix","title":"CPT QUICK REFERENCE TABLE (For Template Appendix)","text":"Category Item CPT/HCPCS Code Labs CBC 85025 CMP 80053 BMP 80048 Magnesium 83735 Lactate 83605 Ammonia 82140 Drug screen 80307 Phenytoin level 80185 VPA level 80164 LEV level 80177 Imaging CT head w/o 70450 MRI brain w/wo 70553 CTA head 70496 Chest X-ray 71046 Studies cEEG setup 95700 cEEG 2-12h 95711 cEEG 12-26h 95714 Lumbar puncture 62270 Procedures Intubation 31500 Arterial line 36620 Central line 36556 Infusions IV infusion initial 96365 IV infusion add'l hour 96366 IV push 96374 Drugs Lorazepam J2060 (per 2mg) Midazolam J2250 (per 1mg) Levetiracetam J1953 (per 10mg) Fosphenytoin Q2009 (per 50mg PE) Propofol J2704 (per 10mg) Ketamine J1840 (per 10mg) Methylprednisolone J2919 (per 5mg) IVIG J1599 (per 500mg) <p>Report generated by neuro-cpt-synonym-enricher skill v1.0 Note: CPT codes copyrighted by AMA. Codes verified from publicly available CMS sources. Verify annually as codes change.</p>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/","title":"ICD-10 &amp; SYNONYM ENRICHMENT REPORT","text":"<p>TEMPLATE: Status Epilepticus VERSION: 1.3 DATE ENRICHED: January 18, 2026 ENRICHER: Claude (neuro-icd-synonym-enricher v2.0)</p>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#diagnosis-identity","title":"DIAGNOSIS IDENTITY","text":"<p>Primary Term: Status Epilepticus SNOMED CT ID: 230456005 (Status epilepticus) MeSH Term: Status Epilepticus (D013226)</p>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#icd-10-cm-codes","title":"ICD-10-CM CODES","text":""},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#primary-codes-most-specific","title":"Primary Codes (Most Specific)","text":"Code Description Use When G40.901 Epilepsy, unspecified, not intractable, with status epilepticus First presentation of SE in patient without known intractable epilepsy G40.911 Epilepsy, unspecified, intractable, with status epilepticus SE in patient with known intractable/refractory epilepsy G41.0 Grand mal status epilepticus Generalized tonic-clonic SE (convulsive SE) G41.1 Petit mal status epilepticus Absence status epilepticus G41.2 Complex partial status epilepticus Focal SE with impaired awareness G41.8 Other status epilepticus NCSE, simple partial SE, other subtypes G41.9 Status epilepticus, unspecified SE type not specified"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#related-codes-may-apply","title":"Related Codes (May Apply)","text":"Code Description Use When G40.301 Generalized idiopathic epilepsy, not intractable, with SE Known generalized epilepsy patient in SE G40.311 Generalized idiopathic epilepsy, intractable, with SE Known intractable generalized epilepsy in SE G40.401 Other generalized epilepsy, not intractable, with SE Other generalized epilepsy type in SE G40.411 Other generalized epilepsy, intractable, with SE Intractable other generalized in SE G40.501 Epileptic seizures related to external causes, with SE SE triggered by external cause (drugs, toxins) G40.801 Other epilepsy, not intractable, with SE Specific epilepsy syndrome in SE G40.811 Other epilepsy, intractable, with SE Intractable specific syndrome in SE R56.9 Unspecified convulsions Pre-diagnosis, before SE confirmed G93.1 Anoxic brain damage Complication of prolonged SE G93.40 Encephalopathy, unspecified Post-SE encephalopathy"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#etiology-codes-code-additionally-when-applicable","title":"Etiology Codes (Code Additionally When Applicable)","text":"Code Description Use When G04.90 Encephalitis, unspecified SE from encephalitis (NORSE workup) G04.81 Other encephalitis and encephalomyelitis Autoimmune encephalitis causing SE F10.231 Alcohol dependence with withdrawal with perceptual disturbance Alcohol withdrawal SE T43.205A Poisoning by antidepressants, accidental, initial Drug-induced SE E11.649 Type 2 DM with hypoglycemia without coma Hypoglycemia precipitating SE I63.9 Cerebral infarction, unspecified Stroke-related SE C71.9 Malignant neoplasm of brain, unspecified Tumor-related SE"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#code-selection-guide","title":"Code Selection Guide","text":"<p>For new presentation: - Use G40.901 (not intractable, with SE) for first-time SE - Use G41.0/G41.1/G41.2 if seizure type is clearly identified</p> <p>For known epilepsy patients: - Use the specific epilepsy code with SE modifier (5th character \"1\") - Use \"intractable\" codes (G40.x11) if patient has drug-resistant epilepsy</p> <p>For NORSE/FIRES: - Primary: G41.8 (Other status epilepticus) - Add: G04.81 if autoimmune encephalitis confirmed</p>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#search-terms-synonyms","title":"SEARCH TERMS &amp; SYNONYMS","text":""},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#clinical-abbreviations","title":"Clinical Abbreviations","text":"Term Expansion Notes SE Status epilepticus Universal abbreviation CSE Convulsive status epilepticus Generalized tonic-clonic SE NCSE Non-convulsive status epilepticus Subtle/electrographic SE RSE Refractory status epilepticus Failed 2 treatment lines SRSE Super-refractory status epilepticus &gt;24h on anesthetics GCSE Generalized convulsive status epilepticus Same as CSE CPSE Complex partial status epilepticus Focal SE with impaired awareness NORSE New onset refractory status epilepticus No prior epilepsy, no clear cause FIRES Febrile infection-related epilepsy syndrome NORSE subtype with preceding fever EPC Epilepsia partialis continua Focal motor SE subtype"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#alternative-names","title":"Alternative Names","text":"Synonym Type Scope Notes Status epilepticus Primary term - Standard clinical term Epileptic status Historical Same Older terminology Epileptic state Historical Same ICD terminology Grand mal status Historical Subtype (CSE) G41.0 descriptor Petit mal status Historical Subtype (absence) G41.1 descriptor Absence status Clinical Subtype Non-convulsive absence SE Subtle status epilepticus Clinical Subtype NCSE with minimal motor signs Electrographic status epilepticus Clinical Subtype NCSE detected only on EEG Focal status epilepticus Clinical Subtype Formerly \"partial SE\" Generalized status epilepticus Clinical Subtype Generalized seizure activity Tonic-clonic status Clinical Subtype Same as grand mal/CSE Convulsive status Clinical Subtype Same as CSE Non-convulsive status Clinical Subtype Same as NCSE Treatment-resistant SE Clinical Severity (RSE) Synonymous with RSE Prolonged seizure Lay/Clinical Broader &gt;5 minutes"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#lay-terms-patient-friendly","title":"Lay Terms (Patient-Friendly)","text":"Term Clinical Equivalent Prolonged seizure Status epilepticus Continuous seizure Status epilepticus Seizure that won't stop Status epilepticus Long seizure Status epilepticus Nonstop seizure Status epilepticus Seizure emergency Status epilepticus Back-to-back seizures Serial seizures / impending SE Cluster seizures Serial seizures / impending SE"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#common-misspellings-for-search-index","title":"Common Misspellings (For Search Index)","text":"Misspelling Correct Term status epileptus status epilepticus statis epilepticus status epilepticus status epelepticus status epilepticus status epileptics status epilepticus status epileptcus status epilepticus convulsive staus convulsive status refractory staus refractory status"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#medication-synonyms","title":"MEDICATION SYNONYMS","text":""},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#benzodiazepines-first-line","title":"Benzodiazepines (First-Line)","text":"Generic Name Brand Names Abbreviations Lorazepam Ativan LZP Midazolam Versed, Nayzilam (nasal) MDZ Diazepam Valium, Diastat (rectal) DZP Clonazepam Klonopin CZP"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#second-line-asms","title":"Second-Line ASMs","text":"Generic Name Brand Names Abbreviations Levetiracetam Keppra, Keppra XR, Spritam, Roweepra, Elepsia XR LEV Fosphenytoin Cerebyx fPHT, FOS Phenytoin Dilantin, Phenytek PHT Valproate/Valproic acid Depakote, Depakote ER, Depakene, Depacon VPA, DVP Lacosamide Vimpat LCM Brivaracetam Briviact BRV Phenobarbital Luminal PB, PHB"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#anesthetics-third-line","title":"Anesthetics (Third-Line)","text":"Generic Name Brand Names Abbreviations Propofol Diprivan - Ketamine Ketalar - Pentobarbital Nembutal PTB Thiopental Pentothal -"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#immunotherapy-norsefires","title":"Immunotherapy (NORSE/FIRES)","text":"Generic Name Brand Names Abbreviations Methylprednisolone Solu-Medrol IVMP IVIG Privigen, Gammagard, Gamunex, Octagam IVIg Rituximab Rituxan, Truxima, Ruxience RTX Cyclophosphamide Cytoxan CTX, CYC Tocilizumab Actemra TCZ Anakinra Kineret -"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#search-index-entry","title":"SEARCH INDEX ENTRY","text":"<p>Recommended search index terms for this template:</p> <pre><code>{\n  \"primary_diagnosis\": \"Status Epilepticus\",\n  \"icd10_codes\": [\n    \"G40.901\",\n    \"G40.911\",\n    \"G41.0\",\n    \"G41.1\",\n    \"G41.2\",\n    \"G41.8\",\n    \"G41.9\",\n    \"G40.301\",\n    \"G40.311\",\n    \"G40.401\",\n    \"G40.411\"\n  ],\n  \"snomed_ct\": \"230456005\",\n  \"mesh_id\": \"D013226\",\n  \"search_terms\": [\n    \"status epilepticus\",\n    \"convulsive status epilepticus\",\n    \"non-convulsive status epilepticus\",\n    \"refractory status epilepticus\",\n    \"super-refractory status epilepticus\",\n    \"NORSE\",\n    \"FIRES\",\n    \"grand mal status\",\n    \"absence status\",\n    \"focal status epilepticus\",\n    \"prolonged seizure\",\n    \"continuous seizure\",\n    \"epileptic status\",\n    \"treatment-resistant seizure\"\n  ],\n  \"abbreviations\": [\n    \"SE\",\n    \"CSE\",\n    \"NCSE\",\n    \"RSE\",\n    \"SRSE\",\n    \"GCSE\",\n    \"CPSE\",\n    \"NORSE\",\n    \"FIRES\",\n    \"EPC\"\n  ],\n  \"medications\": [\n    \"lorazepam\",\n    \"ativan\",\n    \"midazolam\",\n    \"versed\",\n    \"diazepam\",\n    \"valium\",\n    \"levetiracetam\",\n    \"keppra\",\n    \"fosphenytoin\",\n    \"cerebyx\",\n    \"phenytoin\",\n    \"dilantin\",\n    \"valproate\",\n    \"depakote\",\n    \"lacosamide\",\n    \"vimpat\",\n    \"propofol\",\n    \"ketamine\",\n    \"methylprednisolone\",\n    \"IVIG\"\n  ],\n  \"settings\": [\"ED\", \"HOSP\", \"ICU\"],\n  \"tags\": [\"seizure\", \"epilepsy\", \"emergency\", \"neurocritical-care\"]\n}\n</code></pre>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#integration-notes","title":"INTEGRATION NOTES","text":""},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#for-ehr-problem-list-mapping","title":"For EHR Problem List Mapping","text":"<ul> <li>Primary mapping: G41.0 (Grand mal status) for convulsive SE</li> <li>For NCSE: G41.8 (Other status epilepticus)</li> <li>Add etiology codes as secondary diagnoses when identified</li> <li>Consider adding \"resolved\" status after SE termination</li> </ul>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#for-search-implementation","title":"For Search Implementation","text":"<ul> <li>Index all abbreviations as high-priority search terms</li> <li>Include medication names for users searching \"keppra protocol\" or \"ativan dose\"</li> <li>Weight exact matches (SE, status epilepticus) higher than partial matches</li> <li>Include misspellings with fuzzy matching</li> </ul>"},{"location":"plans/status-epilepticus-icd-synonym-report-2026-01-18/#for-template-metadata","title":"For Template Metadata","text":"<p>Suggested YAML frontmatter updates: <pre><code>search_aliases:\n  - SE\n  - CSE\n  - NCSE\n  - RSE\n  - SRSE\n  - NORSE\n  - FIRES\n  - prolonged seizure\n  - convulsive status\nicd10_primary:\n  - G40.901\n  - G41.0\n  - G41.8\nicd10_related:\n  - G40.911\n  - G41.1\n  - G41.2\n  - G41.9\nsnomed_ct: \"230456005\"\n</code></pre></p> <p>Report generated by neuro-icd-synonym-enricher skill v2.0</p>"},{"location":"plans/status-epilepticus/","title":"Status Epilepticus","text":"<p>VERSION: 1.2 CREATED: January 15, 2026 REVISED: January 15, 2026 STATUS: Revised with rapid protocol for non-specialists</p> <p>DIAGNOSIS: Status Epilepticus</p> <p>ICD-10: G40.901 (Epilepsy, unspecified, not intractable, with status epilepticus), G41.0 (Grand mal status epilepticus), G41.1 (Petit mal status epilepticus), G41.2 (Complex partial status epilepticus), G41.8 (Other status epilepticus), G41.9 (Status epilepticus, unspecified)</p> <p>SYNONYMS: Status epilepticus, SE, continuous seizure activity, non-stop seizure, seizure emergency, convulsive status epilepticus, CSE, non-convulsive status epilepticus, NCSE, refractory status epilepticus, RSE, super-refractory SE, SRSE, prolonged seizure</p> <p>SCOPE: Management of convulsive status epilepticus (CSE) and non-convulsive status epilepticus (NCSE) in adults. Covers staged treatment protocol from emergent benzodiazepines through refractory and super-refractory phases. Includes diagnostic workup to identify underlying etiology and specific protocols for NORSE/FIRES. Excludes pediatric status epilepticus, neonatal seizures, and psychogenic non-epileptic status.</p> <p>DEFINITIONS: - Status Epilepticus (SE): Seizure lasting &gt;5 minutes OR \u22652 seizures without return to baseline between episodes - Refractory SE (RSE): SE continuing after adequate doses of initial benzodiazepine AND one second-line ASM - Super-Refractory SE (SRSE): SE continuing \u226524 hours after anesthetic initiation, including cases that recur during anesthetic weaning - NORSE: New-Onset Refractory Status Epilepticus - RSE without clear acute/active structural, toxic, or metabolic cause in a patient without prior epilepsy - FIRES: Febrile Infection-Related Epilepsy Syndrome - subset of NORSE with febrile illness \u226524 hours before SE onset</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>"},{"location":"plans/status-epilepticus/#start-here-appendix-c-rapid-protocol-for-non-specialists","title":"\u26a1 START HERE: APPENDIX C - RAPID PROTOCOL FOR NON-SPECIALISTS","text":"<p>This is the \"3 AM Protocol\" - a single default pathway with exact doses. Follow this unless you have a specific reason to deviate. For comprehensive options and alternatives, see the full template below.</p>"},{"location":"plans/status-epilepticus/#rapid-protocol-default-pathway","title":"RAPID PROTOCOL: DEFAULT PATHWAY","text":""},{"location":"plans/status-epilepticus/#step-1-stabilization-time-0-do-all-simultaneously","title":"\u2705 STEP 1: STABILIZATION (Time 0) - Do All Simultaneously","text":"Action Dose/Details \u2713 Call for help Page Neurology STAT; alert ICU \u2610 Position patient Recovery position if possible; protect head \u2610 Oxygen Non-rebreather 15 L/min \u2610 IV access Two large-bore IVs (18G or larger) \u2610 Cardiac monitor Attach telemetry \u2610 Fingerstick glucose If &lt;70 or unknown \u2192 Dextrose 50% 50 mL IV + Thiamine 100 mg IV \u2610 Labs POC glucose, BMP, CBC, Mg, Ca, LFTs, VBG, lactate, tox screen, ASM levels \u2610"},{"location":"plans/status-epilepticus/#step-2-first-line-benzodiazepine-time-0-5-min","title":"\u2705 STEP 2: FIRST-LINE - BENZODIAZEPINE (Time 0-5 min)","text":"<p>PICK ONE based on IV access:</p> Situation Drug Exact Dose \u2713 IV access available Lorazepam IV 4 mg IV push over 2 min \u2610 No IV access Midazolam IM 10 mg IM (single injection, deltoid or thigh) \u2610 No IV/IM access Midazolam intranasal 5 mg each nostril (10 mg total) \u2610 <p>\u23f1\ufe0f WAIT 5 MINUTES. Still seizing?</p> Action Dose \u2713 Repeat benzodiazepine x1 Lorazepam 4 mg IV (total max 8 mg) OR Midazolam 10 mg IM \u2610 <p>\u23f1\ufe0f WAIT 5 MORE MINUTES. Still seizing? \u2192 GO TO STEP 3 IMMEDIATELY</p> <p>\ud83d\udeab DO NOT give a third dose of benzodiazepine. Move to Step 3.</p>"},{"location":"plans/status-epilepticus/#step-3-second-line-asm-time-5-20-min","title":"\u2705 STEP 3: SECOND-LINE ASM (Time 5-20 min)","text":"<p>DEFAULT CHOICE: Levetiracetam (safest, fewest drug interactions, no cardiac monitoring needed)</p> Weight Levetiracetam Dose Infusion Time \u2713 50 kg 2500 mg IV Over 10 min \u2610 60 kg 3000 mg IV Over 10 min \u2610 70 kg 3500 mg IV Over 10 min \u2610 80 kg 4000 mg IV Over 10 min \u2610 \u226590 kg 4500 mg IV (max) Over 10 min \u2610 <p>Quick calc: 50 mg/kg (or 60 mg/kg per ESETT), max 4500 mg</p>"},{"location":"plans/status-epilepticus/#decision-branches-use-alternative-if","title":"\ud83d\udd00 DECISION BRANCHES - Use Alternative If:","text":"Situation Use Instead Dose Why Patient already takes levetiracetam at home Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min (70 kg = 1400 mg PE) Already on LEV; need different mechanism Patient already takes levetiracetam at home Brivaracetam 200 mg IV over 2 min Alternative SV2A agent with faster onset Pregnant or might be pregnant Levetiracetam 50-60 mg/kg IV (max 4500 mg) AVOID valproate (teratogenic) Known cardiac disease (heart block, bradycardia) Levetiracetam 50-60 mg/kg IV (max 4500 mg) AVOID fosphenytoin/lacosamide Severe renal impairment (CrCl &lt;30) Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min LEV requires dose reduction Severe liver disease Levetiracetam 50-60 mg/kg IV (max 4500 mg) Renally cleared Hypotensive (SBP &lt;90) Levetiracetam 50-60 mg/kg IV (max 4500 mg) Least hemodynamic effect <p>\u23f1\ufe0f WAIT 10-15 MINUTES for infusion to complete. Still seizing?</p> <p>Options: 1. Try ONE more second-line agent (different class), OR 2. Proceed directly to Step 4 (RSE protocol)</p> <p>\ud83d\udea8 DO NOT delay beyond 20 minutes total. If still seizing at 20 min \u2192 Step 4.</p>"},{"location":"plans/status-epilepticus/#step-4-refractory-se-time-20-min-call-icu-now","title":"\u2705 STEP 4: REFRACTORY SE (Time 20+ min) - CALL ICU NOW","text":"<p>\ud83d\udea8 STOP: This requires ICU admission, intubation capability, and continuous EEG. Call for help if not already done.</p> <p>DEFAULT: Midazolam infusion (most familiar to non-specialists, reversible)</p> Action Dose \u2713 Intubate patient RSI with propofol or ketamine induction \u2610 Midazolam bolus 0.2 mg/kg IV (70 kg = 14 mg IV push) \u2610 Start midazolam infusion 0.1 mg/kg/hr (70 kg = 7 mg/hr) \u2610 Order continuous EEG STAT - mandatory \u2610 Start vasopressors if needed Norepinephrine if MAP &lt;65 \u2610 <p>Titration: Increase midazolam by 0.1 mg/kg/hr every 15 min until seizures stop on EEG. Max 2 mg/kg/hr.</p>"},{"location":"plans/status-epilepticus/#consider-adding-ketamine-early","title":"\ud83d\udd00 CONSIDER ADDING KETAMINE EARLY","text":"<p>Emerging evidence supports adding ketamine at RSE onset (not waiting for SRSE):</p> Action Dose Rationale Ketamine bolus 1-2 mg/kg IV (70 kg = 70-140 mg) NMDA antagonism; less hypotension Ketamine infusion Start 1 mg/kg/hr, titrate to 5 mg/kg/hr 2x more effective when given early <p>Ketamine can be used WITH midazolam from the start.</p>"},{"location":"plans/status-epilepticus/#step-5-when-to-suspect-norse-no-clear-cause-found","title":"\u2705 STEP 5: WHEN TO SUSPECT NORSE (No Clear Cause Found)","text":"<p>If patient has RSE and initial workup is negative, consider NORSE:</p> Criteria \u2713 No prior epilepsy history \u2610 No acute structural lesion on CT/MRI \u2610 No toxic/metabolic cause identified \u2610 No active infection explaining seizures \u2610 <p>If NORSE suspected \u2192 Start immunotherapy within 72 hours (don't wait for antibody results):</p> Day Action Dose Day 1 Methylprednisolone 1000 mg IV daily Day 1-5 Continue steroids 1000 mg IV daily \u00d7 5 days total Day 1-5 Consider adding IVIG 0.4 g/kg/day \u00d7 5 days Day 7 Ketogenic diet consult If still refractory"},{"location":"plans/status-epilepticus/#when-to-call-for-help","title":"\ud83d\udcde WHEN TO CALL FOR HELP","text":"Situation Who to Call Urgency Any SE Neurology STAT SE not responding to first BZD Neurology + ICU STAT SE not responding to second-line ASM Neurocritical care STAT Need for intubation Anesthesia/ICU STAT Suspected NORSE (no cause found) Neuroimmunology URGENT Suspected CNS infection Infectious Disease URGENT"},{"location":"plans/status-epilepticus/#critical-safety-reminders","title":"\u26a0\ufe0f CRITICAL SAFETY REMINDERS","text":"Reminder \ud83d\udd34 Airway first - Have bag-valve-mask and intubation equipment at bedside before giving ANY medication \ud83d\udd34 Don't stack benzos - Max 2 doses. More benzos = more respiratory depression, not more efficacy \ud83d\udd34 Time matters - Every 5-minute delay worsens outcomes. Move fast through the protocol \ud83d\udd34 Valproate + Pregnancy = NO - Always check pregnancy status before valproate \ud83d\udd34 Fosphenytoin + Heart block = NO - Check ECG or avoid if unknown cardiac history \ud83d\udd34 Get EEG - Up to 48% have non-convulsive seizures after convulsions stop. You need EEG to know."},{"location":"plans/status-epilepticus/#disposition","title":"\ud83c\udfe5 DISPOSITION","text":"Seizure Status Disposition Resolved with first-line BZD only May observe in ED; admit to telemetry if first seizure Required second-line ASM ICU admission Required intubation/anesthetics ICU admission Any RSE/SRSE ICU admission"},{"location":"plans/status-epilepticus/#quick-reference-card-print-this","title":"\ud83d\udccb QUICK REFERENCE CARD (Print This)","text":"<pre><code>STATUS EPILEPTICUS - RAPID PROTOCOL\n====================================\n\nSTEP 1: STABILIZE\n\u2022 O2, 2 IVs, monitor, glucose check\n\u2022 Labs: BMP, CBC, Mg, Ca, tox, ASM levels\n\nSTEP 2: BENZODIAZEPINE (Time 0-5 min)\n\u2022 Lorazepam 4 mg IV push\n\u2022 Wait 5 min \u2192 Repeat x1 if still seizing\n\u2022 MAX 2 doses. Do NOT give 3rd dose.\n\nSTEP 3: SECOND-LINE (Time 5-20 min)\n\u2022 Levetiracetam 50-60 mg/kg IV (max 4500 mg) over 10 min\n  - 50 kg = 2500 mg\n  - 70 kg = 3500 mg\n  - 90+ kg = 4500 mg\n\u2022 Alternatives: Fosphenytoin, Valproate, Lacosamide\n\nSTEP 4: RSE (Time 20+ min) - CALL ICU\n\u2022 Intubate\n\u2022 Midazolam 0.2 mg/kg bolus \u2192 0.1 mg/kg/hr infusion\n\u2022 \u00b1 Ketamine 1-2 mg/kg bolus \u2192 1 mg/kg/hr infusion\n\u2022 Continuous EEG - MANDATORY\n\u2022 Target burst suppression\n\nCALL NEUROLOGY FOR ALL SE\nCALL ICU IF STEP 3 FAILS\n====================================\n</code></pre> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 FULL TEMPLATE BEGINS BELOW \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/status-epilepticus/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/status-epilepticus/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Point-of-care glucose STAT STAT - STAT Hypoglycemia is immediately reversible cause &gt;70 mg/dL CBC with differential STAT STAT - STAT Infection screen, baseline before ASMs Normal CMP (BMP + LFTs) STAT STAT - STAT Electrolyte abnormalities, renal/hepatic function for ASM dosing Normal Magnesium STAT STAT - STAT Hypomagnesemia lowers seizure threshold &gt;1.8 mg/dL Calcium (ionized if available) STAT STAT - STAT Hypocalcemia can cause seizures Ionized 4.5-5.3 mg/dL Phosphorus STAT STAT - STAT Hypophosphatemia lowers seizure threshold &gt;2.5 mg/dL Blood gas (ABG or VBG) STAT STAT - STAT Acidosis, oxygenation, ventilation status pH &gt;7.2; correct severe acidosis Lactate STAT STAT - STAT Elevated in prolonged seizure; marker of severity Will be elevated; trending useful Urine drug screen STAT STAT - STAT Illicit drugs, withdrawal states Identify triggers Blood alcohol level STAT STAT - STAT Alcohol withdrawal common cause Correlate with history ASM levels (if on therapy) STAT STAT - STAT Subtherapeutic levels as precipitant Therapeutic range Pregnancy test (women of childbearing age) STAT STAT - STAT Eclampsia; affects ASM choice Document status"},{"location":"plans/status-epilepticus/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Ammonia URGENT STAT - STAT Hepatic encephalopathy, valproate toxicity, urea cycle disorders &lt;35 \u03bcmol/L TSH URGENT ROUTINE - URGENT Thyroid storm/myxedema Normal Troponin URGENT ROUTINE - STAT Cardiac stress from prolonged seizure May be elevated CPK/CK URGENT ROUTINE - STAT Rhabdomyolysis from prolonged convulsions Elevated; monitor trend Cortisol (random) URGENT ROUTINE - URGENT Adrenal insufficiency Normal stress response Serum osmolality URGENT ROUTINE - URGENT Hypo/hyperosmolar states 280-295 mOsm/kg Procalcitonin URGENT ROUTINE - URGENT CNS infection if suspected &lt;0.5 ng/mL Coagulation panel (PT/INR, PTT) URGENT ROUTINE - STAT Pre-LP, hemorrhage risk Normal Type and screen URGENT ROUTINE - STAT Anticipate possible surgical intervention Available Urinalysis URGENT ROUTINE - URGENT UTI as precipitant (especially elderly) Negative"},{"location":"plans/status-epilepticus/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding Autoimmune encephalitis panel (serum) - URGENT - URGENT Anti-NMDAR, LGI1, CASPR2 in NORSE Negative Paraneoplastic panel (serum) - URGENT - URGENT Subacute onset, smoking history, weight loss Negative HIV - ROUTINE - ROUTINE HIV-associated CNS disease Negative RPR/VDRL - ROUTINE - ROUTINE Neurosyphilis Negative Ceruloplasmin, serum copper - EXT - EXT Wilson disease (young patients) Normal Porphyrins (urine/serum) - EXT - EXT Acute intermittent porphyria Normal Mitochondrial DNA testing - - - EXT MELAS, other mitochondrial disorders Normal Pyridoxine trial (empiric) - - - URGENT Pyridoxine-dependent seizures (rare, usually pediatric) Response to treatment"},{"location":"plans/status-epilepticus/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/status-epilepticus/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT Immediately after stabilization Mass, hemorrhage, stroke, herniation, hydrocephalus None in emergency Continuous EEG (cEEG) monitoring STAT STAT - STAT As soon as available; mandatory in RSE/SRSE Seizure burden, treatment response, NCSE detection None significant Chest X-ray STAT STAT - STAT Aspiration risk, ETT placement confirmation Aspiration, ETT position None"},{"location":"plans/status-epilepticus/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with and without contrast - URGENT - URGENT When stable; within 24-48h Encephalitis, stroke, tumor, cortical injury from SE Hemodynamic instability, pacemaker CT angiography head/neck URGENT URGENT - URGENT If stroke suspected Large vessel occlusion, dissection Contrast allergy, renal insufficiency MRA/MRV brain - ROUTINE - ROUTINE If vascular etiology suspected Venous thrombosis, vascular malformation Same as MRI CT chest/abdomen/pelvis - ROUTINE - ROUTINE If paraneoplastic suspected Occult malignancy Contrast allergy Echocardiogram - ROUTINE - ROUTINE If embolic stroke suspected, endocarditis Vegetation, thrombus None"},{"location":"plans/status-epilepticus/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications PET-CT (whole body) - EXT - EXT Occult malignancy workup Tumor identification Hemodynamic instability Brain biopsy - EXT - EXT Refractory cases, suspected encephalitis Histopathologic diagnosis Coagulopathy, critical location"},{"location":"plans/status-epilepticus/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: Suspected CNS infection (meningitis, encephalitis), autoimmune encephalitis, NORSE/FIRES, or unknown etiology after initial workup</p> <p>Timing: URGENT after CT excludes mass effect; do not delay empiric antibiotics/antivirals</p> <p>Volume Required: 15-20 mL standard; 20-30 mL if autoimmune/malignancy suspected</p> Study ED HOSP OPD ICU Rationale Target Finding Opening pressure URGENT STAT - STAT Elevated ICP 10-20 cm H2O Cell count (tubes 1 and 4) URGENT STAT - STAT Infection, inflammation WBC &lt;5; RBC 0 Protein URGENT STAT - STAT Elevated in infection, inflammation 15-45 mg/dL Glucose with serum glucose URGENT STAT - STAT Low in bacterial/fungal meningitis &gt;60% serum Gram stain and culture URGENT STAT - STAT Bacterial meningitis No organisms BioFire FilmArray ME Panel URGENT STAT - STAT Rapid pathogen identification Negative HSV-1/2 PCR URGENT STAT - STAT HSV encephalitis Negative Autoimmune encephalitis panel (CSF) - URGENT - URGENT NORSE, limbic encephalitis Negative Cytology - ROUTINE - ROUTINE Carcinomatous meningitis Negative Oligoclonal bands - ROUTINE - ROUTINE Demyelinating disease Negative <p>Special Handling: HSV PCR refrigerated. Cytology rapid transport (&lt;1 hour). Cell count within 1 hour.</p> <p>Contraindications: Signs of herniation, coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site. CT before LP if any concern for mass effect.</p>"},{"location":"plans/status-epilepticus/#3-treatment","title":"3. TREATMENT","text":"<p>CRITICAL: Status epilepticus requires STAGED, TIME-BASED management. Each medication must be on its own row with complete dosing.</p> <p>\ud83d\udc49 FOR RAPID DEFAULT PATHWAY, SEE APPENDIX C AT THE TOP OF THIS DOCUMENT</p>"},{"location":"plans/status-epilepticus/#treatment-staging-overview","title":"TREATMENT STAGING OVERVIEW","text":"Stage Time Goal Primary Agents Stabilization 0-5 min ABCs, glucose, thiamine Supportive care Emergent (1st line) 0-5 min Abort seizure Benzodiazepines Urgent (2nd line) 5-20 min Seizure control if BZD fails Fosphenytoin, valproate, levetiracetam, lacosamide, or brivaracetam Refractory (3rd line) 20-60 min Anesthetic coma if 2nd line fails Midazolam, propofol, or ketamine infusion Super-refractory &gt;24h on anesthetics Seizure control Additional agents, immunotherapy for NORSE"},{"location":"plans/status-epilepticus/#3a-stabilization-time-0","title":"3A. Stabilization (Time 0)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Airway positioning/management STAT STAT - STAT Head-tilt chin-lift, oral airway, prepare for intubation None O2 sat, airway patency Supplemental oxygen STAT STAT - STAT Non-rebreather 15 L/min or bag-valve-mask None O2 sat &gt;94% IV access (two large-bore) STAT STAT - STAT 18G or larger x2 None IV patency Cardiac monitoring STAT STAT - STAT Continuous telemetry None Rhythm, HR, BP Dextrose 50% IV STAT STAT - STAT 50 mL IV push (25g) if glucose &lt;70 or unknown Document hyperglycemia Glucose Thiamine IV STAT STAT - STAT 100-500 mg IV BEFORE or WITH glucose None None Isotonic fluids STAT STAT - STAT NS or LR wide open initially Pulmonary edema BP, I/O"},{"location":"plans/status-epilepticus/#3b-emergentfirst-line-benzodiazepines-time-0-5-min","title":"3B. Emergent/First-Line - Benzodiazepines (Time 0-5 min)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Lorazepam IV STAT STAT - STAT 0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 min if still seizing; total max 8 mg Acute narrow-angle glaucoma RR, O2 sat, BP, sedation; airway equipment ready Midazolam IM STAT STAT - STAT 10 mg IM (\u226540 kg) or 0.2 mg/kg IM (if no IV access); single dose Respiratory compromise RR, O2 sat; prepare IV access Midazolam IV STAT STAT - STAT 0.2 mg/kg IV (max 10 mg); may repeat x1 Same as lorazepam RR, O2 sat, BP Midazolam intranasal STAT STAT - STAT 5 mg per nostril (10 mg total) if no IV/IM access Nasal obstruction RR, O2 sat Midazolam buccal STAT STAT - STAT 10 mg buccal (if available) Oral trauma RR, O2 sat Diazepam IV STAT STAT - STAT 0.15 mg/kg IV (max 10 mg); may repeat x1 in 5 min Acute narrow-angle glaucoma RR, O2 sat; short duration - requires follow-up ASM Diazepam rectal STAT STAT - STAT 0.2-0.5 mg/kg PR (max 20 mg); use rectal gel formulation Rectal pathology RR, O2 sat <p>NOTE: If seizure continues after 2 adequate doses of benzodiazepine, immediately proceed to second-line agent. Do NOT give additional benzodiazepines.</p>"},{"location":"plans/status-epilepticus/#3c-urgentsecond-line-asms-time-5-20-min","title":"3C. Urgent/Second-Line ASMs (Time 5-20 min)","text":"<p>DOSING NOTE: Levetiracetam dosing options reflect evolving evidence. ESETT trial used 60 mg/kg; some institutions use 40 mg/kg. Both are acceptable.</p> Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Levetiracetam IV (ESETT dosing) STAT STAT - STAT 60 mg/kg IV (max 4500 mg) over 10-15 min None absolute; reduce if CrCl &lt;50 Generally well tolerated; agitation Levetiracetam IV (conservative) STAT STAT - STAT 40 mg/kg IV (max 4500 mg) over 10-15 min None absolute; reduce if CrCl &lt;50 Generally well tolerated; agitation Fosphenytoin IV STAT STAT - STAT 20 mg PE/kg IV at 150 mg PE/min; may give additional 5-10 mg PE/kg if needed 2nd/3rd degree AV block, sinus bradycardia, allergy Continuous cardiac monitor, BP q5min during infusion Valproate IV STAT STAT - STAT 40 mg/kg IV (max 3000 mg) over 10 min Pregnancy, hepatic disease, mitochondrial disease, urea cycle disorders, pancreatitis Ammonia, LFTs; avoid in unknown pregnancy status Lacosamide IV STAT STAT - STAT 400 mg IV over 15 min (can give 200 mg over 5 min if urgent) PR &gt;200 ms, 2nd/3rd degree AV block, severe hepatic impairment ECG for PR interval Brivaracetam IV STAT STAT - STAT 100-200 mg IV over 2-5 min; no titration needed Hepatic impairment (reduce dose) Faster onset than levetiracetam; fewer behavioral effects Phenytoin IV STAT STAT - STAT 20 mg/kg IV at max 50 mg/min (if fosphenytoin unavailable) AV block, sinus bradycardia Cardiac monitor; MUST use large vein, tissue necrosis risk Phenobarbital IV STAT STAT - STAT 15-20 mg/kg IV at 50-100 mg/min Severe respiratory disease, porphyria Respiratory depression; often requires intubation at this dose <p>NOTES: - Choose ONE second-line agent initially - If first second-line agent fails, may try second agent OR proceed to anesthetics (do not delay &gt;20 min) - Levetiracetam, lacosamide, and brivaracetam have fewer drug interactions and hemodynamic effects - Brivaracetam may have faster onset than levetiracetam; useful if patient already on levetiracetam at home - Phenobarbital highly effective but significant respiratory depression - have airway ready - ESETT Trial (Kapur et al., NEJM 2019): Levetiracetam 60 mg/kg, fosphenytoin 20 mg/kg PE, and valproate 40 mg/kg showed equivalent efficacy (~47% success)</p>"},{"location":"plans/status-epilepticus/#3d-refractory-se-anesthetic-infusions-time-20-60-min","title":"3D. Refractory SE - Anesthetic Infusions (Time 20-60 min)","text":"<p>INDICATION: Seizures continue after benzodiazepine AND one second-line ASM at adequate doses</p> <p>SETTING: ICU with continuous EEG monitoring, mechanical ventilation capability</p> <p>KETAMINE TIMING NOTE: Emerging evidence supports earlier ketamine use. Ketamine is twice as effective when given early in RSE (64% efficacy) vs late/SRSE (32% efficacy). Consider ketamine as first-line anesthetic OR as adjunct to midazolam from the start of RSE. Earlier administration correlates with better outcomes.</p> Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Midazolam infusion URGENT - - STAT Load: 0.2 mg/kg IV bolus; Infusion: start 0.1 mg/kg/hr, titrate by 0.1 mg/kg/hr q15min to seizure suppression; max 2 mg/kg/hr; target burst suppression on cEEG Hemodynamic instability (relative) cEEG, BP (hypotension common), sedation scale Propofol infusion - - - STAT Load: 1-2 mg/kg IV bolus (may repeat x1); Infusion: start 20 mcg/kg/min, titrate by 10 mcg/kg/min q5min; max 200 mcg/kg/min; target burst suppression Propofol infusion syndrome risk (limit to &lt;48h at high dose), egg/soy allergy, pregnancy cEEG, triglycerides q24-48h, CPK, metabolic acidosis, BP Ketamine infusion URGENT - - STAT Load: 1-2 mg/kg IV bolus; Infusion: start 1 mg/kg/hr, titrate by 0.5 mg/kg/hr q15-30min; max 5 mg/kg/hr Uncontrolled hypertension, elevated ICP (relative - actually may be neuroprotective) cEEG, BP (may increase), HR; less hypotension than other anesthetics Ketamine + Midazolam (combination) - - - STAT Ketamine load 1 mg/kg + Midazolam load 0.2 mg/kg; then dual infusions per above Per individual agents 2024 data: combination may reduce SE duration faster than midazolam alone Pentobarbital infusion - - - STAT Load: 5-15 mg/kg IV at 50 mg/min; Infusion: start 0.5-1 mg/kg/hr, titrate to burst suppression; max 5 mg/kg/hr Severe cardiac dysfunction cEEG, BP (significant hypotension - need pressors), cardiac output; longest half-life <p>NOTES: - Midazolam or propofol typically first choice; consider ketamine early or in combination - Ketamine advantages: NMDA antagonism targets receptor changes in prolonged SE; less hypotension; potentially neuroprotective - Pentobarbital most potent but worst hemodynamic effects; reserve for SRSE - All require intubation and continuous EEG (exception: ketamine may be used without intubation in select cases per emerging data) - Target: burst suppression or seizure suppression on cEEG for 24-48h before weaning</p>"},{"location":"plans/status-epilepticus/#3e-super-refractory-se-additional-agents","title":"3E. Super-Refractory SE - Additional Agents","text":"<p>DEFINITION: SE continues or recurs \u226524 hours after anesthetic initiation</p> Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Add second anesthetic - - - STAT Combine midazolam + propofol, or add ketamine to either Per agent cEEG, hemodynamics Topiramate (enteral) - - - URGENT Load 300-400 mg via NGT; then 200-400 mg BID; max 1600 mg/day Metabolic acidosis, kidney stones Bicarbonate, renal function Lacosamide (if not tried) - - - URGENT 400 mg IV, then 200-400 mg BID PR prolongation ECG Perampanel (enteral) - - - ROUTINE 4-8 mg via NGT daily; titrate to 12 mg daily None absolute Aggression, sedation Magnesium sulfate infusion - - - URGENT 4-6 g IV over 20 min, then 1-2 g/hr infusion; target Mg 3.5-4 mg/dL Renal failure (relative), myasthenia Mg levels, reflexes, respiratory status Pyridoxine (empiric trial) - - - URGENT 100-500 mg IV; may try single dose empirically None Response to treatment Ketogenic diet - - - URGENT Initiate within 7 days per NORSE consensus; requires nutrition support Pyruvate carboxylase deficiency, fatty acid oxidation disorders Ketones, glucose, lipids Hypothermia (32-35\u00b0C) - - - EXT Targeted temperature management x 24-48h Coagulopathy, severe infection Temperature, coagulation, infection Electroconvulsive therapy - - - EXT If all else fails; requires anesthesia Raised ICP, recent stroke Per ECT protocol Epilepsy surgery (emergent) - - - EXT Resection if focal lesion identified Eloquent cortex, multifocal Per surgical team"},{"location":"plans/status-epilepticus/#3f-norsefires-immunotherapy-protocol","title":"3F. NORSE/FIRES Immunotherapy Protocol","text":"<p>INDICATION: New-onset RSE without clear etiology after initial workup; suspect autoimmune/inflammatory cause</p> <p>REFERENCE: International Consensus Recommendations (Wickstr\u00f6m et al., Epilepsia 2022)</p>"},{"location":"plans/status-epilepticus/#timeline-based-protocol","title":"Timeline-Based Protocol","text":"Timing Intervention Dosing Notes Day 0-3 First-line immunotherapy See below Start within 72 hours if no clear etiology Day 3-7 Escalate if no response Add remaining first-line agents Do not delay Day 7 Ketogenic diet Initiate with nutrition support One of few treatments with evidence in FIRES Day 7+ Second-line immunotherapy If first-line inadequate Earlier may be better"},{"location":"plans/status-epilepticus/#first-line-immunotherapy-start-within-72-hours","title":"First-Line Immunotherapy (Start within 72 hours)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Methylprednisolone IV - URGENT - STAT 1000 mg IV daily \u00d7 3-5 days Active untreated infection (relative) Glucose q6h, BP, GI prophylaxis, infection signs IVIG - URGENT - STAT 0.4 g/kg/day IV \u00d7 5 days (total 2 g/kg); can give simultaneously with steroids IgA deficiency (use IgA-depleted product), renal failure, thrombosis risk Renal function, signs of aseptic meningitis, thrombosis Plasmapheresis (PLEX) - ROUTINE - STAT 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange Hemodynamic instability, line access issues Hemodynamics, electrolytes (Ca, Mg), coagulation, fibrinogen <p>NOTES: - Steroids preferred as initial agent; can combine with IVIG from start - Do not wait for autoimmune panel results to initiate treatment - Sequential (steroids \u2192 IVIG \u2192 PLEX) or simultaneous approach acceptable</p>"},{"location":"plans/status-epilepticus/#second-line-immunotherapy-if-first-line-fails-by-day-7","title":"Second-Line Immunotherapy (If first-line fails by Day 7)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Rituximab - - - ROUTINE 375 mg/m\u00b2 IV weekly \u00d7 4 doses Active infection, hepatitis B (screen first) Infusion reactions, infection, B-cell counts Cyclophosphamide - - - ROUTINE 750-1000 mg/m\u00b2 IV monthly \u00d7 3-6 months Severe cytopenias, active infection CBC weekly, renal function, hemorrhagic cystitis (hydration + mesna) Tocilizumab - - - EXT 8 mg/kg IV q4 weeks (emerging option) Active infection, hepatic impairment LFTs, lipids, infection Anakinra - - - EXT 100 mg SC daily (may increase; used in FIRES) Active infection Injection site reactions, infection"},{"location":"plans/status-epilepticus/#3g-symptomaticsupportive-icu-care","title":"3G. Symptomatic/Supportive ICU Care","text":"Treatment Indication ED HOSP OPD ICU Dosing Contraindications Monitoring Norepinephrine Hypotension from anesthetics - - - STAT Start 0.1 mcg/kg/min; titrate to MAP \u226565 Hypovolemia (correct first) Arterial line, MAP Vasopressin Adjunct pressor - - - STAT 0.04 units/min fixed dose Cardiac ischemia MAP, cardiac status Fentanyl infusion Analgesia/sedation adjunct - - - ROUTINE 25-100 mcg/hr; titrate to comfort Hemodynamic instability Pain scale, respiratory status Propofol (sub-anesthetic) Sedation during cEEG - - - ROUTINE 5-50 mcg/kg/min Same as anesthetic use Sedation scale Dexmedetomidine Sedation, possible antiseizure - - - ROUTINE 0.2-1.5 mcg/kg/hr Bradycardia, heart block HR, BP Pantoprazole Stress ulcer prophylaxis - ROUTINE - STAT 40 mg IV daily None significant GI bleeding Enoxaparin DVT prophylaxis - ROUTINE - STAT 40 mg SC daily (start when stable) Active bleeding, recent LP Platelets, bleeding Insulin infusion Stress hyperglycemia URGENT ROUTINE - STAT Per ICU protocol; target glucose 140-180 mg/dL Hypoglycemia Glucose q1-4h"},{"location":"plans/status-epilepticus/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/status-epilepticus/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology/Epilepsy STAT consult STAT STAT - STAT All cases of SE Neurocritical care consult STAT STAT - STAT RSE/SRSE, need for anesthetic infusions ICU admission STAT STAT - - All SE requiring second-line agents or ongoing seizures EEG technologist/cEEG initiation STAT STAT - STAT Mandatory for RSE/SRSE; strongly recommended for all SE Infectious disease consult - URGENT - URGENT Suspected CNS infection Rheumatology/Neuroimmunology consult - URGENT - URGENT NORSE/FIRES, suspected autoimmune encephalitis Pharmacy consult - ROUTINE - ROUTINE Complex ASM dosing, drug interactions Nutrition/Dietitian consult - ROUTINE - URGENT Enteral feeding, ketogenic diet initiation (by Day 7 in NORSE) Palliative care consult - - - ROUTINE SRSE with poor prognosis, goals of care discussion Social work consult - ROUTINE - ROUTINE Family support, discharge planning Epilepsy surgery evaluation - - - EXT Focal lesion on imaging, refractory to medical therapy PT/OT/Speech evaluation - - - ROUTINE Once stabilized; assess for deficits"},{"location":"plans/status-epilepticus/#4b-patientfamily-instructions","title":"4B. Patient/Family Instructions","text":"Recommendation ED HOSP OPD Explain SE is a medical emergency requiring ICU care STAT STAT - Discuss prognosis based on etiology and duration of SE - URGENT - Educate on importance of ASM adherence (if applicable) - ROUTINE - Seizure first aid education for family - ROUTINE - Rescue medication training (rectal diazepam, nasal midazolam) - ROUTINE - Driving restrictions (minimum 3-6 months seizure-free, varies by state) - ROUTINE - Medical alert bracelet recommendation - ROUTINE - Seizure action plan development - ROUTINE - Discuss goals of care if SRSE with poor prognosis - - ROUTINE (ICU)"},{"location":"plans/status-epilepticus/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Medication adherence counseling - ROUTINE - Avoid abrupt ASM discontinuation (common SE precipitant) - ROUTINE - Alcohol cessation - ROUTINE - Sleep hygiene (sleep deprivation lowers threshold) - ROUTINE - Avoid known seizure triggers - ROUTINE - Drug interaction review (OTC, supplements) - ROUTINE - Pregnancy planning counseling (women of childbearing potential) - ROUTINE - <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/status-epilepticus/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Psychogenic non-epileptic status Preserved awareness, asynchronous movements, eye closure, pelvic thrusting, prolonged duration with minimal post-ictal period Video EEG, normal cEEG during event Convulsive syncope Brief (&lt; 30 sec), occurs with LOC, myoclonic jerks possible History of prodrome, rapid recovery, normal EEG Movement disorders (dystonia, chorea) Non-rhythmic, preserved awareness, stereotyped pattern EEG normal during movements Rigors (sepsis, transfusion reaction) Associated with fever/chills, rhythmic shaking, preserves awareness Infectious workup, temperature, EEG normal Decerebrate/decorticate posturing Associated with structural brain injury, sustained posturing Imaging, cEEG Drug-induced dyskinesia Medication history, stereotyped movements Drug levels, history, EEG normal Neuroleptic malignant syndrome Rigidity, hyperthermia, AMS, autonomic instability CPK, medication history Serotonin syndrome Hyperreflexia, clonus, agitation, fever Medication history, clinical features Tetanus Sustained muscle contraction, trismus, opisthotonos History of wound, vaccination status Strychnine poisoning Opisthotonus with preserved consciousness Toxicology"},{"location":"plans/status-epilepticus/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Continuous EEG STAT STAT - STAT Continuous No seizures; burst suppression if on anesthetics Adjust ASMs/anesthetics Cardiac telemetry STAT STAT - STAT Continuous Normal rhythm, HR 60-100 Treat arrhythmia; assess ASM effect Pulse oximetry STAT STAT - STAT Continuous O2 sat &gt;94% Increase O2, assess airway Blood pressure STAT STAT - STAT q5min during treatment, then q1h MAP \u226565; avoid severe hypertension Pressors or antihypertensives Neurologic exam STAT STAT - STAT q1-2h when off sedation Return to baseline Imaging, reassess etiology Glucose STAT STAT - STAT q1-4h 140-180 mg/dL (ICU) Insulin or dextrose Electrolytes (Na, K, Mg, Ca, Phos) STAT STAT - STAT q6-12h Normal ranges Replete deficiencies ABG/VBG STAT ROUTINE - STAT q4-6h (RSE), PRN pH &gt;7.25, CO2 35-45, PO2 &gt;60 Adjust ventilator, treat acidosis Lactate STAT ROUTINE - STAT q6-12h Trending down Treat underlying cause ASM levels URGENT ROUTINE - URGENT 24h after load, then PRN Therapeutic range Adjust dosing Ammonia URGENT ROUTINE - STAT q24h if on valproate &lt;35 \u03bcmol/L Reduce/stop valproate LFTs URGENT ROUTINE - ROUTINE q24-48h Normal Adjust hepatically-metabolized ASMs Renal function URGENT ROUTINE - STAT q24h Normal Adjust renally-cleared ASMs CPK - ROUTINE - STAT q12-24h if prolonged convulsions Trending down Aggressive hydration, monitor renal Triglycerides - - - ROUTINE q24-48h if on propofol &lt;400 mg/dL Reduce propofol dose Temperature STAT STAT - STAT q4h 36-38\u00b0C Infection workup; cooling if hyperthermic ICP (if monitored) - - - STAT Continuous &lt;20 mmHg ICP management protocol"},{"location":"plans/status-epilepticus/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria ICU admission (REQUIRED) All SE requiring second-line ASMs; all RSE/SRSE; altered mental status; need for airway management; hemodynamic instability Step-down/Telemetry Seizures controlled x 24h, off anesthetics x 24h, stable neuro exam, no airway concerns General floor Seizures controlled, off continuous monitoring, stable on oral ASMs, resolved AMS Discharge home Seizures controlled, stable on oral ASM regimen, etiology identified and addressed, family educated, follow-up arranged Transfer to higher level care Need for services unavailable (cEEG, neurocritical care, epilepsy surgery evaluation) Long-term care/Rehab Persistent deficits after prolonged SE, need for ongoing rehabilitation Palliative/Hospice SRSE with irreversible brain injury, goals of care established"},{"location":"plans/status-epilepticus/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Benzodiazepines first-line for SE Class I, Level A Neurocritical Care Society 2012; AES Guidelines 2016 Lorazepam preferred IV benzodiazepine Class I, Level A Alldredge et al. NEJM 2001 IM midazolam non-inferior to IV lorazepam Class I, Level A RAMPART Trial, Silbergleit et al. NEJM 2012 Second-line agents (LEV, VPA, fPHT) equivalent efficacy Class I, Level A ESETT Trial, Kapur et al. NEJM 2019;381:2103-2113 Levetiracetam 60 mg/kg dosing Class I, Level A ESETT Trial - higher than traditional 20-40 mg/kg Levetiracetam 40 mg/kg may be adequate Class II, Level B Meta-analysis, pharmacokinetic modeling 2023-2024 cEEG monitoring in RSE Class I, Level B NCS Guidelines 2012 Burst suppression target for RSE Class IIb, Level C Expert consensus Ketamine in RSE/SRSE Class IIb, Level B Multiple case series; 2024 systematic reviews Earlier ketamine = better outcomes Class II, Level B 2024 two-center study; systematic reviews NORSE first-line immunotherapy within 72h Class IIa, Level C International Consensus, Wickstr\u00f6m et al. Epilepsia 2022 Ketogenic diet by Day 7 in NORSE Class IIa, Level C International Consensus 2022; FIRES case series Second-line immunotherapy by Day 7 if first-line fails Class IIb, Level C International Consensus 2022 Brivaracetam for SE Class IIb, Level C Emerging evidence; case series"},{"location":"plans/status-epilepticus/#appendix-a-time-based-treatment-algorithm","title":"APPENDIX A: TIME-BASED TREATMENT ALGORITHM","text":"<pre><code>TIME 0-5 MIN: STABILIZATION + EMERGENT TREATMENT\n\u251c\u2500\u2500 ABCs: Airway, Breathing, Circulation\n\u251c\u2500\u2500 Glucose check \u2192 Dextrose if low + Thiamine\n\u251c\u2500\u2500 IV access x 2\n\u251c\u2500\u2500 Lorazepam 0.1 mg/kg IV (max 4 mg) OR Midazolam 10 mg IM\n\u2514\u2500\u2500 May repeat BZD x1 in 5 min\n\nTIME 5-20 MIN: URGENT/SECOND-LINE (if still seizing)\n\u251c\u2500\u2500 Choose ONE:\n\u2502   \u251c\u2500\u2500 Levetiracetam 40-60 mg/kg IV (max 4500 mg)\n\u2502   \u251c\u2500\u2500 Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min\n\u2502   \u251c\u2500\u2500 Valproate 40 mg/kg IV (max 3000 mg) - avoid in pregnancy\n\u2502   \u251c\u2500\u2500 Lacosamide 400 mg IV\n\u2502   \u2514\u2500\u2500 Brivaracetam 100-200 mg IV (if available)\n\u251c\u2500\u2500 Start cEEG monitoring\n\u2514\u2500\u2500 CT head if not done\n\nTIME 20-60 MIN: REFRACTORY SE (if still seizing)\n\u251c\u2500\u2500 Requires ICU and intubation\n\u251c\u2500\u2500 Initiate anesthetic infusion:\n\u2502   \u251c\u2500\u2500 Midazolam: Load 0.2 mg/kg \u2192 0.1-2 mg/kg/hr\n\u2502   \u251c\u2500\u2500 Propofol: Load 1-2 mg/kg \u2192 20-200 mcg/kg/min\n\u2502   \u2514\u2500\u2500 Ketamine: Load 1-2 mg/kg \u2192 1-5 mg/kg/hr \u2190 Consider EARLY\n\u251c\u2500\u2500 Target burst suppression on cEEG\n\u2514\u2500\u2500 Continue second-line ASM at maintenance doses\n\nTIME &gt;24 HOURS ON ANESTHETICS: SUPER-REFRACTORY SE\n\u251c\u2500\u2500 Add additional ASMs (topiramate, perampanel)\n\u251c\u2500\u2500 Combine anesthetics (midazolam + ketamine)\n\u251c\u2500\u2500 If NORSE/FIRES \u2192 See Appendix B\n\u251c\u2500\u2500 Consider ketogenic diet\n\u251c\u2500\u2500 Goals of care discussion\n\u2514\u2500\u2500 Epilepsy surgery evaluation if focal lesion\n</code></pre>"},{"location":"plans/status-epilepticus/#appendix-b-norsefires-immunotherapy-timeline","title":"APPENDIX B: NORSE/FIRES IMMUNOTHERAPY TIMELINE","text":"<pre><code>DAY 0-3: FIRST-LINE IMMUNOTHERAPY\n\u251c\u2500\u2500 Methylprednisolone 1000 mg IV daily \u00d7 3-5 days\n\u251c\u2500\u2500 \u00b1 IVIG 0.4 g/kg/day \u00d7 5 days (can start simultaneously)\n\u2514\u2500\u2500 Continue ASMs and anesthetics as needed\n\nDAY 3-7: ESCALATE IF NO RESPONSE\n\u251c\u2500\u2500 Add IVIG if not started\n\u251c\u2500\u2500 Consider PLEX (5-7 exchanges)\n\u2514\u2500\u2500 Do not wait for autoimmune results\n\nDAY 7: KEY DECISION POINT\n\u251c\u2500\u2500 Initiate ketogenic diet\n\u251c\u2500\u2500 If first-line inadequate \u2192 Start second-line:\n\u2502   \u251c\u2500\u2500 Rituximab 375 mg/m\u00b2 weekly \u00d7 4\n\u2502   \u2514\u2500\u2500 OR Cyclophosphamide 750-1000 mg/m\u00b2 monthly\n\u2514\u2500\u2500 Continue supportive care\n\nDAY 7+: ONGOING MANAGEMENT\n\u251c\u2500\u2500 Continue second-line immunotherapy\n\u251c\u2500\u2500 Maintain ketogenic diet\n\u251c\u2500\u2500 Consider tocilizumab or anakinra if refractory\n\u2514\u2500\u2500 Goals of care discussion if no improvement\n</code></pre>"},{"location":"plans/status-epilepticus/#notes","title":"NOTES","text":"<ul> <li>SE is a medical emergency with ~20% mortality; rapid treatment is critical</li> <li>Every 5-minute delay in treatment associated with worse outcomes</li> <li>cEEG monitoring essential - up to 48% of patients have non-convulsive seizures after convulsive SE controlled</li> <li>Levetiracetam dosing: ESETT used 60 mg/kg; 40 mg/kg also acceptable per recent evidence. No head-to-head comparison exists.</li> <li>Ketamine timing: Earlier administration (in RSE, not just SRSE) correlates with better outcomes. Consider using early or in combination with midazolam.</li> <li>NORSE/FIRES: ~50% remain cryptogenic; start immunotherapy within 72 hours even without confirmed etiology. Ketogenic diet by Day 7.</li> <li>Propofol infusion syndrome: metabolic acidosis, rhabdomyolysis, cardiac failure - limit propofol to &lt;48h at high doses</li> <li>Always have airway equipment ready; many second-line and all third-line agents cause respiratory depression</li> </ul>"},{"location":"plans/status-epilepticus/#change-log","title":"CHANGE LOG","text":"<p>v1.2 (January 15, 2026) - Added Appendix C: Rapid Protocol for Non-Specialists (\"3 AM Protocol\")   - Single default pathway with exact doses   - Weight-based dosing table for levetiracetam   - Decision branches for common scenarios (pregnancy, renal failure, cardiac disease, already on LEV)   - Clear escalation triggers with checkboxes   - \"When to call for help\" section   - Critical safety reminders   - Printable quick reference card - Moved Appendix C to top of document for immediate visibility - Added reference to Appendix C in Section 3 header</p> <p>v1.1 (January 15, 2026) - Added dual levetiracetam dosing options (40 mg/kg conservative vs 60 mg/kg ESETT-based) - Added brivaracetam to second-line agents - Added ketamine timing note emphasizing earlier use based on 2024 evidence - Added ketamine + midazolam combination option - Added comprehensive NORSE/FIRES immunotherapy protocol (Section 3F) per 2022 International Consensus - Added second-line immunotherapy agents (rituximab, cyclophosphamide, tocilizumab, anakinra) - Added \"Avoid abrupt ASM discontinuation\" to lifestyle recommendations - Added ESETT citation with specific reference (Kapur J et al. NEJM 2019;381:2103-2113) - Added Appendix B: NORSE/FIRES Immunotherapy Timeline - Updated Evidence &amp; References section with additional citations - Fixed LP table OPD column for format consistency</p> <p>v1.0 (January 15, 2026) - Initial template creation</p>"},{"location":"plans/subarachnoid-hemorrhage/","title":"Subarachnoid Hemorrhage","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Subarachnoid Hemorrhage (SAH)</p> <p>ICD-10: I60.9 (Nontraumatic subarachnoid hemorrhage, unspecified), I60.7 (SAH from unspecified intracranial artery), I60.0-I60.6 (SAH from specific arteries)</p> <p>SYNONYMS: Subarachnoid hemorrhage, SAH, ruptured aneurysm, aneurysmal SAH, aSAH, thunderclap headache, worst headache of life, brain aneurysm rupture, bleeding around brain</p> <p>SCOPE: Spontaneous (non-traumatic) aneurysmal subarachnoid hemorrhage in adults. Covers thunderclap headache evaluation, CT/LP diagnosis, aneurysm identification and securing, vasospasm prevention and treatment (nimodipine, triple-H therapy), hydrocephalus management, and complications. Excludes traumatic SAH, perimesencephalic (non-aneurysmal) SAH management, and intracerebral hemorrhage (separate template).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/subarachnoid-hemorrhage/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/subarachnoid-hemorrhage/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding CBC with differential STAT STAT - STAT Baseline; thrombocytopenia; leukocytosis (stress response); pre-surgical Normal CMP (BMP + LFTs) STAT STAT - STAT Electrolytes (hyponatremia from cerebral salt wasting or SIADH is common); renal/hepatic function Normal; watch Na closely PT/INR, aPTT STAT STAT - STAT Coagulopathy assessment; pre-procedure; anticoagulant use Normal Fibrinogen STAT STAT - STAT Coagulopathy; DIC screen &gt;150 mg/dL Type and crossmatch STAT STAT - STAT Surgical intervention likely; potential blood loss On file; crossmatch 2-4 units Troponin STAT STAT - STAT Neurogenic stunned myocardium occurs in 20-30% of SAH; stress cardiomyopathy Often elevated (neurogenic \u2014 not ACS) BNP or NT-proBNP URGENT ROUTINE - URGENT Neurogenic cardiac dysfunction; volume status assessment Elevated (neurogenic) Blood glucose STAT STAT - STAT Hyperglycemia worsens outcomes; stress response 140-180 mg/dL target Magnesium STAT STAT - STAT Hypomagnesemia increases vasospasm risk; maintain high-normal &gt;2.0 mg/dL (replete aggressively) Calcium (ionized) STAT STAT - STAT Electrolyte management; nimodipine monitoring Normal Phosphorus STAT ROUTINE - STAT Electrolyte management; refeeding risk Normal Lactate STAT ROUTINE - STAT Perfusion status &lt;2 mmol/L Pregnancy test (\u03b2-hCG) STAT STAT - STAT Affects imaging, anesthesia, and treatment decisions Document result"},{"location":"plans/subarachnoid-hemorrhage/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Serum osmolality URGENT ROUTINE - ROUTINE Cerebral salt wasting vs SIADH differentiation; osmotherapy monitoring 280-295 mOsm/kg Urine osmolality and sodium - ROUTINE - ROUTINE CSW: high urine Na, high urine osm, hypovolemic. SIADH: high urine Na, high urine osm, euvolemic Differentiate CSW vs SIADH TSH - ROUTINE - - Thyroid dysfunction screen Normal Cortisol (AM) - ROUTINE - ROUTINE Adrenal insufficiency (pituitary dysfunction from SAH) &gt;18 \u00b5g/dL Lipid panel - ROUTINE ROUTINE - Cardiovascular risk assessment Document HbA1c - ROUTINE ROUTINE - Diabetes management &lt;7.0% Blood cultures URGENT ROUTINE - URGENT If febrile (differentiate central fever vs infection) No growth Procalcitonin URGENT ROUTINE - URGENT Differentiate neurogenic fever from infection &lt;0.5 (elevated suggests infection)"},{"location":"plans/subarachnoid-hemorrhage/#1c-rarespecialized","title":"1C. Rare/Specialized","text":"Test ED HOSP OPD ICU Rationale Target Finding Urine catecholamines/metanephrines - EXT EXT - Pheochromocytoma as cause of hypertensive hemorrhage Normal Toxicology (cocaine, amphetamines) STAT ROUTINE - STAT Sympathomimetic-associated SAH Negative Sickle cell screen - EXT EXT - Sickle cell associated aneurysms and SAH (young patients, African descent) Normal Connective tissue disorder workup (Ehlers-Danlos, Marfan) - - EXT - Familial aneurysm syndromes; young SAH with marfanoid habitus or skin hyperextensibility Clinical + genetic"},{"location":"plans/subarachnoid-hemorrhage/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/subarachnoid-hemorrhage/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications CT head without contrast STAT STAT - STAT IMMEDIATE (door-to-CT &lt;25 min). Sensitivity: 98-100% within 6h; ~93% at 12h; ~85% at 24h; declines after 3-5 days Hyperdense blood in basal cisterns, Sylvian fissure, interhemispheric fissure; modified Fisher grade; hydrocephalus; intraventricular hemorrhage None significant CT angiography (CTA) head STAT STAT - STAT Simultaneously with non-contrast CT. Identifies aneurysm (sensitivity 95-100% for aneurysms &gt;3mm) Aneurysm location, size, morphology; multiple aneurysms (15-20% have &gt;1); vasospasm (delayed) Contrast allergy (premedicate); renal impairment (benefit outweighs risk) ECG (12-lead) STAT STAT - STAT Immediately Deep T-wave inversions (\"cerebral T waves\"), ST changes, QT prolongation, arrhythmias \u2014 all may be neurogenic; do NOT misdiagnose as primary cardiac event None"},{"location":"plans/subarachnoid-hemorrhage/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Conventional cerebral angiography (DSA) - STAT - STAT Within 24h \u2014 GOLD STANDARD for aneurysm identification; also therapeutic (coiling). If CTA negative but clinical suspicion high, DSA is mandatory Aneurysm (location, neck width, dome-to-neck ratio, relationship to branches); may find aneurysm missed by CTA; vasospasm assessment Contrast allergy; renal impairment; coagulopathy (relative) Repeat DSA (if initial negative) - ROUTINE - ROUTINE At 7-14 days if initial DSA negative and non-perimesencephalic pattern; small aneurysm may be thrombosed or compressed by hematoma Previously missed aneurysm Same as initial MRI/MRA brain - ROUTINE ROUTINE - When stable; helpful for subacute diagnosis or if CT negative but suspicion persists Blood products (FLAIR); aneurysm (MRA); ischemia from vasospasm (DWI) Pacemaker; hemodynamic instability Transcranial Doppler (TCD) - STAT - STAT Begin daily on post-bleed day 3; continue through day 14 (vasospasm window) Mean flow velocities: MCA &gt;120 cm/s concerning; &gt;200 cm/s severe vasospasm. Lindegaard ratio &gt;3 suggests vasospasm (&gt;6 = severe) Absent temporal bone window (~10%) CT perfusion (CTP) - URGENT - URGENT If vasospasm suspected clinically (new deficit days 4-14) Perfusion deficits in vascular territory of spastic vessel; mismatch (reversible ischemia) Contrast allergy; renal impairment CTA (repeat for vasospasm) - URGENT - URGENT If clinical vasospasm suspected Arterial narrowing; correlate with TCD and clinical exam Same as initial CTA Echocardiogram (TTE) - ROUTINE - ROUTINE Within 24-48h Takotsubo (apical ballooning); regional wall motion abnormalities; EF assessment \u2014 neurogenic stunned myocardium in 20-30% None significant Continuous EEG (cEEG) - URGENT - STAT If altered consciousness; delayed deterioration; suspected seizures Non-convulsive seizures; electrographic vasospasm correlate; periodic discharges None Chest X-ray URGENT ROUTINE - URGENT On admission; daily in ICU Neurogenic pulmonary edema; aspiration; ARDS None"},{"location":"plans/subarachnoid-hemorrhage/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications 3D rotational angiography - URGENT - URGENT During DSA for complex aneurysm anatomy Detailed aneurysm morphology for treatment planning Same as DSA Xenon CT or CT perfusion (quantitative) - EXT - EXT Research/advanced vasospasm assessment Quantitative cerebral blood flow mapping Limited availability MRA screening (unruptured aneurysm in family members) - - ROUTINE - Elective \u2014 for first-degree relatives of SAH patients (2 or more affected family members) Incidental unruptured aneurysm Standard MRI contraindications"},{"location":"plans/subarachnoid-hemorrhage/#lumbar-puncture","title":"LUMBAR PUNCTURE","text":"<p>Indication: CT-negative suspected SAH. If CT head is normal but clinical suspicion (thunderclap headache \"worst of my life\") remains \u2014 LP is MANDATORY. Wait \u22656h (ideally 12h) from headache onset for xanthochromia to develop.</p> <p>Timing: URGENT \u2014 but \u22656h from headache onset to allow xanthochromia development.</p> Study ED HOSP OPD Rationale Target Finding Opening pressure URGENT ROUTINE - Elevated in SAH Often elevated (&gt;20 cm H2O) Cell count (tubes 1 AND 4) URGENT ROUTINE - Distinguish SAH from traumatic tap: SAH = RBC count does NOT clear significantly between tube 1 and tube 4 RBC in tube 4 \u2265 tube 1 (SAH); if tube 4 &lt;&lt; tube 1 = traumatic tap Xanthochromia (visual and/or spectrophotometry) URGENT ROUTINE - Yellow discoloration from RBC breakdown (bilirubin); develops &gt;6h after SAH; spectrophotometry more sensitive than visual inspection Present = SAH (sensitivity &gt;95% at 12h-2 weeks post-bleed). Absent = unlikely SAH Protein URGENT ROUTINE - Elevated in SAH Elevated Glucose URGENT ROUTINE - Usually normal in SAH Normal Gram stain and culture URGENT ROUTINE - Exclude meningitis (meningeal signs overlap) No organisms <p>Special Handling: Xanthochromia sample must be protected from light (wrap tube in foil); centrifuge immediately; spectrophotometry if available (more sensitive than visual inspection).</p> <p>Note: CT within 6h of ictus has near 100% sensitivity. If CT is obtained within 6h and is clearly negative, some guidelines suggest LP may not be needed if CTA is also negative. However, LP remains standard of care for CT-negative thunderclap headache in most institutions.</p>"},{"location":"plans/subarachnoid-hemorrhage/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/subarachnoid-hemorrhage/#critical-priorities","title":"\u26a0\ufe0f CRITICAL PRIORITIES","text":"<ol> <li>Secure the airway (if GCS \u22648)</li> <li>Stabilize blood pressure (SBP &lt;160 until aneurysm secured)</li> <li>Identify and secure the aneurysm (clipping or coiling) as soon as possible (&lt;24h)</li> <li>Prevent and treat vasospasm (nimodipine, euvolemia)</li> <li>Monitor for hydrocephalus (EVD if needed)</li> </ol>"},{"location":"plans/subarachnoid-hemorrhage/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Blood pressure control: Nicardipine IV STAT STAT - STAT 5 mg/h IV; titrate by 2.5 mg/h q5-15min; max 15 mg/h. Target SBP &lt;160 mmHg UNTIL aneurysm is secured (re-bleed risk highest in first 24h with uncontrolled HTN); after securing: target SBP &lt;180 (or higher if vasospasm) Severe aortic stenosis Continuous arterial BP; neuro checks q1h Blood pressure control: Labetalol IV STAT STAT - STAT 10-20 mg IV q10-20min; max 300 mg. Alternative to nicardipine Heart block; severe bradycardia; asthma HR; BP continuous Blood pressure control: Clevidipine IV STAT STAT - STAT 1-2 mg/h IV; max 32 mg/h Soy/egg allergy BP continuous Nimodipine (CORNERSTONE of vasospasm prevention) - STAT - STAT 60 mg PO/NG q4h x 21 days. START within 96h of SAH onset. If hypotension: 30 mg q2h. This is an ORAL calcium channel blocker \u2014 do NOT give IV (severe hypotension). Proven to reduce poor outcomes from vasospasm Hypotension (SBP &lt;90 \u2014 reduce dose); do NOT crush extended-release formulations; use oral syringe if NG BP with each dose; do NOT give IV; ensure enteral route only External ventricular drain (EVD) STAT STAT - STAT For acute hydrocephalus (GCS declining; CT showing ventriculomegaly); allows ICP monitoring and CSF drainage. Set drain height per neurosurgery (typically 15-20 cm above tragus) Coagulopathy (correct first) ICP continuous; CSF output q1h; drain position; infection surveillance (CSF culture q3 days per some protocols) Seizure prophylaxis (short-term) STAT STAT - STAT Levetiracetam 1000 mg IV/PO load, then 500-1000 mg BID. AHA 2012: short-term (3-7 days) prophylaxis is reasonable. Avoid phenytoin (associated with worse cognitive outcomes in SAH \u2014 Naidech et al.) Renal impairment (dose adjust) Seizure monitoring Intubation / Airway protection STAT STAT - STAT GCS \u22648; inability to protect airway; respiratory failure; impending herniation N/A Avoid hypotension during RSI; maintain SBP goal Aminocaproic acid (antifibrinolytic) STAT STAT - STAT 4g IV load then 1g/h IV infusion. ONLY use for short-term (&lt;72h) if aneurysm securing will be delayed. Reduces re-bleeding risk but increases thrombotic risk. Discontinue once aneurysm is secured Active DIC; DVT/PE; renal impairment Coagulation; thrombotic events; discontinue when aneurysm treated IV isotonic fluids (euvolemia) STAT STAT - STAT NS at 1-1.5 mL/kg/h (80-125 mL/h); goal euvolemia. Avoid hypovolemia (worsens vasospasm) and avoid aggressive hypervolemia (no proven benefit; risk of pulmonary edema). Target CVP 5-8 or clinical euvolemia Volume overload; CHF I/O; daily weights; CVP if central line; serum Na q6-8h Stress ulcer prophylaxis: Pantoprazole - ROUTINE - ROUTINE 40 mg IV/PO daily C. diff risk GI symptoms DVT prophylaxis: Pneumatic compression devices STAT STAT - STAT Apply bilaterally on admission; SAH patients are HIGH VTE risk Acute DVT Skin checks DVT prophylaxis: Heparin SC (after aneurysm secured) - ROUTINE - ROUTINE 5000 units SC q8h; start 24h after aneurysm is secured (clipping or coiling); some centers start earlier Active bleeding; within 24h of craniotomy (per surgeon) Platelets q3 days"},{"location":"plans/subarachnoid-hemorrhage/#3b-aneurysm-securing-definitive-treatment","title":"3B. Aneurysm Securing (Definitive Treatment)","text":"Treatment Timing Details Indications Contraindications Endovascular coiling Within 24h of diagnosis (ideally &lt;12h) Interventional neuroradiology; catheter-based platinum coil deployment into aneurysm sac. Preferred per ISAT trial for posterior circulation and many anterior circulation aneurysms Most aneurysms; wide-necked aneurysms may need stent-assisted coiling or flow diverter Difficult vascular access; very wide neck without stent option Surgical clipping (craniotomy) Within 24h of diagnosis (ideally &lt;12h) Neurosurgical; microsurgical clip placement across aneurysm neck MCA aneurysms (preferred); large intracerebral hematoma requiring evacuation; failed coiling; aneurysm anatomy not amenable to coiling Poor grade with brain swelling (relative \u2014 may clip if accessible); medically unstable Flow diverter (Pipeline, FRED) Planned For large/giant or wide-necked aneurysms not amenable to standard coiling Complex aneurysm morphology Requires dual antiplatelet therapy (may not be ideal in acute SAH)"},{"location":"plans/subarachnoid-hemorrhage/#3c-vasospasm-treatment-post-bleed-days-4-14","title":"3C. Vasospasm Treatment (Post-Bleed Days 4-14)","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Nimodipine (continued) - STAT - STAT Continue 60 mg PO q4h x 21 days total Hypotension BP with each dose Induced hypertension - - - STAT If clinical vasospasm (new deficit days 4-14, aneurysm MUST be secured first): raise SBP to 180-220 mmHg using vasopressors. Phenylephrine 0.5-5 \u00b5g/kg/min or norepinephrine 0.05-0.3 \u00b5g/kg/min IV Unsecured aneurysm (NEVER induce hypertension before securing); cardiac failure; pulmonary edema Arterial line; neuro checks q1h; TCD; CT perfusion IV fluid bolus (euvolemia maintenance) - - - STAT NS bolus 500-1000 mL if hypovolemic; maintain euvolemia. Avoid prophylactic hypervolemia (no benefit per current evidence \u2014 Robertson et al.) Volume overload CVP; I/O; daily weights Milrinone IV (alternative vasospasm treatment) - - - STAT 0.25-0.75 \u00b5g/kg/min IV continuous; some centers use as rescue for vasospasm not responding to induced hypertension; acts as cerebral vasodilator Severe hypotension; arrhythmia BP (may cause hypotension); HR; cardiac output Intra-arterial vasodilator therapy (endovascular rescue) - - - STAT Verapamil 5-10 mg intra-arterial or nicardipine 5-10 mg intra-arterial; via catheter into spastic vessel during angiography. For medically refractory vasospasm Hemodynamic instability during procedure Angiographic improvement; clinical response; BP Angioplasty (balloon) - - - STAT Mechanical dilation of spastic proximal vessels during angiography. For focal proximal vasospasm refractory to medical treatment Vessel rupture risk; distal vasospasm (not amenable to balloon) Angiographic result; clinical response Magnesium sulfate (supplemental) - ROUTINE - ROUTINE Target serum Mg &gt;2.0 mg/dL; replete with MgSO4 2-4 g IV over 1-2h PRN. MASH-2 trial: IV magnesium infusion did NOT improve outcomes, but maintaining normal-high Mg is standard Renal failure; hypermagnesemia Serum Mg q12-24h; deep tendon reflexes"},{"location":"plans/subarachnoid-hemorrhage/#3d-complications-management","title":"3D. Complications Management","text":"Treatment Indication Dosing Monitoring Hyponatremia management: Differentiate CSW vs SIADH Na &lt;135: CSW = volume depleted (treat with NS/hypertonic saline + fludrocortisone). SIADH = euvolemic (treat with fluid restriction \u00b1 hypertonic saline) CSW: NS or 3% saline; fludrocortisone 0.1-0.2 mg PO BID. SIADH: fluid restriction 1-1.2 L/day; 3% saline if &lt;120 Na q6h during correction; avoid &gt;8-10 mEq/L rise in 24h (central pontine myelinolysis risk) Fludrocortisone Cerebral salt wasting (volume depletion + hyponatremia) 0.1-0.2 mg PO BID Na; K+ (hypokalemia); volume status; BP Hydrocortisone Refractory hyponatremia; cerebral salt wasting; adrenal insufficiency 50-100 mg IV q8h Na; glucose; cortisol Ventriculoperitoneal shunt (VPS) Chronic hydrocephalus (EVD-dependent; unable to wean) Neurosurgical procedure Shunt function; neurologic status Lumbar drain CSF diversion after EVD if transitioning; mild chronic hydrocephalus Neurosurgical placement CSF output; ICP; position"},{"location":"plans/subarachnoid-hemorrhage/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/subarachnoid-hemorrhage/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurosurgery STAT STAT - STAT ALL SAH patients; EVD placement; surgical clipping decision; hydrocephalus management Interventional neuroradiology / Neuroendovascular STAT STAT - STAT Endovascular coiling; intra-arterial vasospasm treatment; angioplasty Neurocritical care / Neurointensivist STAT STAT - STAT ICU management; vasospasm monitoring; medical optimization Cardiology - ROUTINE - ROUTINE Neurogenic stunned myocardium; Takotsubo; arrhythmia management Pulmonology - ROUTINE - ROUTINE Neurogenic pulmonary edema; ARDS; ventilator management Endocrinology - ROUTINE ROUTINE - Pituitary dysfunction post-SAH (growth hormone, cortisol, thyroid); diabetes insipidus Speech-language pathology (SLP) - URGENT ROUTINE URGENT Dysphagia evaluation; cognitive-linguistic assessment Physical therapy (PT) - URGENT ROUTINE URGENT Early mobilization when stable; fall prevention; strength Occupational therapy (OT) - URGENT ROUTINE URGENT ADL assessment; cognitive rehabilitation Rehabilitation medicine (physiatry) - ROUTINE ROUTINE - Rehabilitation planning; disposition Social work - ROUTINE ROUTINE - Family support; advance directives; discharge planning Palliative care - ROUTINE - ROUTINE Poor-grade SAH (Hunt-Hess IV-V); goals of care Genetics / Genetic counseling - - ROUTINE - Familial aneurysm screening; connective tissue disorders"},{"location":"plans/subarachnoid-hemorrhage/#4b-patient-family-instructions","title":"4B. Patient / Family Instructions","text":"Recommendation ED HOSP OPD SAH is life-threatening; treatment is time-sensitive STAT ROUTINE ROUTINE Call 911 immediately if: sudden severe headache (\"worst headache of life\"), loss of consciousness, seizure, new weakness, vision changes - ROUTINE ROUTINE Blood pressure control is critical long-term \u2014 take all prescribed medications - ROUTINE ROUTINE Smoking cessation is essential (smoking is the strongest modifiable risk factor for aneurysm formation and rupture) - ROUTINE ROUTINE Do NOT drive until cleared by neurology/neurosurgery - ROUTINE ROUTINE Avoid heavy lifting, straining, and Valsalva maneuvers for 4-6 weeks - ROUTINE ROUTINE Follow-up imaging (CTA or MRA) at 6 months, then annually for several years to assess treated aneurysm and screen for new aneurysm - ROUTINE ROUTINE First-degree relatives should discuss aneurysm screening with their physician if \u22652 family members have had SAH - ROUTINE ROUTINE Cognitive difficulties (memory, attention, fatigue) are common after SAH \u2014 neuropsychological evaluation and rehabilitation are available - ROUTINE ROUTINE Depression and anxiety are common; seek support early - ROUTINE ROUTINE"},{"location":"plans/subarachnoid-hemorrhage/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (ABSOLUTE \u2014 strongest modifiable risk factor) - ROUTINE ROUTINE Blood pressure control (&lt;130/80 mmHg) - ROUTINE ROUTINE Alcohol moderation/cessation (heavy drinking increases SAH risk) - ROUTINE ROUTINE Cocaine/stimulant cessation (vasospasm and SAH risk) - ROUTINE ROUTINE Avoid excessive straining (constipation management; stool softeners) - ROUTINE ROUTINE Regular moderate exercise after recovery and medical clearance - - ROUTINE Adequate hydration - ROUTINE ROUTINE Stress management - ROUTINE ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/subarachnoid-hemorrhage/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Thunderclap headache \u2014 reversible cerebral vasoconstriction syndrome (RCVS) Recurrent thunderclap headaches over days-weeks; triggered by exertion, Valsalva, sexual activity; vasospasm on CTA; may have convexity SAH; no aneurysm CTA (multifocal segmental narrowing); MRI (may show edema, infarct, cortical SAH); DSA; clinical course (resolves in weeks) Primary intracerebral hemorrhage Parenchymal hematoma with minimal/no subarachnoid blood; hypertensive location (basal ganglia, thalamus) CT (parenchymal not cisternal); CTA (no aneurysm unless hemorrhage extends into subarachnoid space) Bacterial meningitis Fever, meningismus, altered mental status, CSF neutrophilic pleocytosis with low glucose LP (gram stain, culture, BioFire); procalcitonin elevated; CT without blood Migraine (severe) Prior migraine history; gradual onset of associated features; photophobia, phonophobia; no blood on CT Normal CT; normal LP; clinical history Hypertensive emergency Severely elevated BP; headache; but no blood on CT; may have PRES features CT (no blood); MRI (PRES: posterior white matter edema) Cervical artery dissection Neck pain, headache, Horner syndrome, stroke; may have traumatic SAH from vertebral dissection CTA neck (intimal flap, pseudoaneurysm); MRI neck (crescent sign) Cerebral venous thrombosis (CVT) Headache, seizures; may have hemorrhagic venous infarct or cortical SAH; risk factors (OCPs, pregnancy) MRV/CT venogram (thrombosed sinus) Pituitary apoplexy Sudden headache, visual field defect, ophthalmoplegia; known pituitary adenoma; may have subarachnoid blood from pituitary hemorrhage MRI sella (hemorrhagic pituitary mass); hormone panel Perimesencephalic SAH (non-aneurysmal) Blood confined to perimesencephalic cisterns (anterior to brainstem); benign course; CTA/DSA negative for aneurysm CT pattern (perimesencephalic); negative CTA and DSA; excellent prognosis Traumatic SAH History of trauma; may have other traumatic injuries (contusion, subdural, skull fracture) Clinical history; CT pattern Spinal SAH Sudden back/leg pain with meningismus; blood on lumbar CT or MRI; rare Spinal MRI; spinal angiography"},{"location":"plans/subarachnoid-hemorrhage/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Blood pressure (arterial line) STAT STAT ROUTINE STAT Continuous via arterial line in ICU. Pre-securing: target SBP &lt;160. Post-securing: allow SBP 120-180 (higher if vasospasm treatment) SBP &lt;160 (unsecured); SBP 120-180 (secured); SBP 180-220 if treating vasospasm Titrate antihypertensives; vasopressors for vasospasm GCS / Neurologic exam STAT STAT ROUTINE STAT q1h x 24h; then q2h x 48h; then q4h. Hunt-Hess grade at admission Stable or improving If declining: STAT CT (rebleed, hydrocephalus, infarct); TCD; adjust treatment ICP (if EVD in place) - - - STAT Continuous; record q1h ICP &lt;22 mmHg; CPP 60-70 mmHg Tiered ICP management; CSF drainage; osmotherapy Transcranial Doppler (TCD) - STAT - STAT Daily from day 3 through day 14 (vasospasm window); some continue to day 21 MCA mean velocity &lt;120 cm/s; Lindegaard ratio &lt;3 If MCA &gt;120: CTA/CTP; clinical correlation. If &gt;200: severe vasospasm \u2014 consider induced hypertension +/- endovascular rescue Serum sodium STAT STAT - STAT q6h x 72h; then q8-12h 135-145 mEq/L If &lt;135: differentiate CSW vs SIADH; treat accordingly. If &lt;120: 3% saline; limit correction &lt;10 mEq/24h Serum magnesium STAT ROUTINE - STAT Daily; q12h if repleting &gt;2.0 mg/dL Replete with MgSO4 2-4 g IV Temperature STAT STAT - STAT q4h (q1h if febrile) &lt;37.5\u00b0C (normothermia) Central fever (common): cooling; acetaminophen. If &gt;38.3\u00b0C: infection workup (cultures, CXR, UA) Blood glucose STAT STAT - STAT q6h (q1h if insulin drip) 140-180 mg/dL Insulin; avoid &lt;60 Troponin / BNP STAT ROUTINE - ROUTINE Troponin daily x 3; BNP at admission and PRN Track trend If rising with new ECG changes or hemodynamic instability: echo; cardiology Hemoglobin STAT ROUTINE - ROUTINE Daily &gt;8 g/dL (some argue &gt;10 in vasospasm patients) Transfuse PRBCs Fluid balance (I/O) STAT STAT - STAT q1h in ICU; q4h shift on floor Net even to slightly positive; euvolemia Avoid dehydration (vasospasm risk); avoid overhydration (pulmonary edema) Repeat CT head - STAT - STAT At 24h post-admission; with any neurologic change; post-procedure; if new hydrocephalus suspected Stable hemorrhage; no rebleed; no new infarct; ventricle size Adjust EVD; surgery; vasospasm treatment Hunt-Hess / WFNS grade STAT - - - At admission (prognostic) Document grade Goals of care if poor grade"},{"location":"plans/subarachnoid-hemorrhage/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Discharge home Never discharge from ED with confirmed SAH. Discharge from hospital when: aneurysm secured; past vasospasm window (day 14-21); stable neurologic exam; Na stable; able to take oral nimodipine; no EVD dependency; adequate follow-up Admit to Neuro-ICU ALL confirmed aneurysmal SAH patients; minimum 14-21 days ICU-level monitoring during vasospasm window. Transfer to step-down only after vasospasm window passed Transfer to comprehensive stroke center / Neurovascular center If no neurosurgery or interventional neuroradiology on-site \u2014 TRANSFER IMMEDIATELY. SAH requires tertiary neurovascular services Inpatient rehabilitation Significant deficits but medically stable; past vasospasm window; able to participate in 3h/day therapy Skilled nursing facility Cannot tolerate intensive rehab; requires ongoing skilled care Hospice / Comfort care Devastating SAH (Hunt-Hess V with poor prognostic factors); after appropriate observation period and family discussion"},{"location":"plans/subarachnoid-hemorrhage/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Nimodipine 60 mg PO q4h x 21 days Class I, Level A Pickard et al. (BMJ 1989); only proven agent to improve outcomes in SAH vasospasm Early aneurysm securing (&lt;24h, ideally &lt;12h) Class I, Level B ISAT; AHA/ASA 2012 SAH Guidelines; de Gans et al. (Stroke 2002) Endovascular coiling preferred over clipping for most aneurysms Class I, Level A ISAT trial (Molyneux et al. Lancet 2002); long-term follow-up SBP &lt;160 until aneurysm secured Class I, Level B AHA/ASA 2012 SAH Guidelines Euvolemia (avoid hypovolemia; avoid prophylactic hypervolemia) Class I, Level B Lennihan et al. (Stroke 2000); HIMALAIA trial Induced hypertension for clinical vasospasm (after aneurysm secured) Class IIa, Level B AHA/ASA Guidelines; standard practice TCD daily for vasospasm monitoring Class IIa, Level B Sloan et al. (2004); AHA/ASA Guidelines Short-term seizure prophylaxis (3-7 days) reasonable Class IIb, Level B AHA/ASA 2012 Avoid phenytoin in SAH (worse cognitive outcomes) Class III (Harm) Naidech et al. (Neurocrit Care 2005) CT sensitivity ~100% within 6h Class I, Level A Perry et al. (BMJ 2011); Backes et al. (Stroke 2012) LP if CT negative but clinical suspicion Class I, Level B AHA/ASA Guidelines; standard of care Aminocaproic acid (short-term) if aneurysm securing delayed Class IIa, Level B Hillman et al. (Neurosurgery 2002); AHA/ASA 2012 Magnesium infusion does NOT improve outcomes Class III (No Benefit) MASH-2 trial (Dorhout Mees et al. Lancet 2012) Fludrocortisone for cerebral salt wasting Class IIa, Level B Hasan et al. (Stroke 1989) Intra-arterial vasodilator / balloon angioplasty for refractory vasospasm Class IIa, Level B Multiple case series; AHA/ASA Guidelines Avoid self-fulfilling prophecy in poor-grade SAH Class I, Level C AHA/ASA 2012: aggressive treatment for at least 72h in poor-grade <p>APPENDIX: HUNT AND HESS GRADING SCALE</p> Grade Description Approximate Mortality I Asymptomatic or mild headache, slight nuchal rigidity ~1% II Moderate-severe headache, nuchal rigidity, no neurologic deficit other than cranial nerve palsy ~5% III Drowsiness, confusion, or mild focal deficit ~19% IV Stupor, moderate-severe hemiparesis, possible early decerebrate rigidity ~42% V Deep coma, decerebrate rigidity, moribund appearance ~77% <p>APPENDIX: MODIFIED FISHER GRADE (Vasospasm Risk)</p> Grade CT Findings Vasospasm Risk 0 No SAH or IVH Very low 1 Thin SAH, no IVH Low (24%) 2 Thin SAH, with IVH Moderate (33%) 3 Thick SAH, no IVH High (33%) 4 Thick SAH, with IVH Very high (40%) <p>APPENDIX: CEREBRAL SALT WASTING vs SIADH</p> Feature Cerebral Salt Wasting SIADH Volume status Hypovolemic (dehydrated) Euvolemic Serum Na Low (&lt;135) Low (&lt;135) Urine Na High (&gt;40) High (&gt;40) Urine osm High High Treatment Volume replacement (NS, hypertonic saline); fludrocortisone Fluid restriction; hypertonic saline if severe Key differentiator Clinical dehydration (tachycardia, dry mucous membranes, elevated BUN:Cr ratio, negative fluid balance) Clinically euvolemic"},{"location":"plans/tia/","title":"Transient Ischemic Attack (TIA)","text":"<p>DIAGNOSIS: Transient Ischemic Attack ICD-10: G45.9 (Transient cerebral ischemic attack, unspecified) SCOPE: Urgent evaluation, risk stratification (ABCD2), and secondary stroke prevention. Excludes completed stroke (see Acute Ischemic Stroke protocol).</p> <p>STATUS: Approved</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#section-a-action-items","title":"SECTION A: ACTION ITEMS","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test Rationale Target Finding ED HOSP OPD ICU CBC with differential Polycythemia, thrombocytosis as stroke risk; anemia evaluation Normal STAT STAT ROUTINE - BMP Electrolytes; glucose for hypoglycemia mimic; creatinine for contrast Normal STAT STAT ROUTINE - Glucose (fingerstick) Rule out hypoglycemia as TIA mimic 70-180 mg/dL STAT STAT - - PT/INR, PTT Baseline coagulation; evaluate if on anticoagulation Normal or therapeutic STAT STAT ROUTINE - Lipid panel (fasting) LDL target &lt;70 for secondary prevention LDL &lt;70 mg/dL - ROUTINE ROUTINE - HbA1c Diabetes assessment; target &lt;7% &lt;7% URGENT ROUTINE ROUTINE - TSH Hyperthyroidism associated with atrial fibrillation Normal - ROUTINE ROUTINE - Troponin Concurrent cardiac ischemia; AF with rapid rate Negative STAT STAT - -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test Rationale Target Finding ED HOSP OPD ICU Homocysteine Elevated levels increase stroke risk &lt;15 \u03bcmol/L - ROUTINE ROUTINE - Lipoprotein(a) Independent cardiovascular risk marker &lt;30 mg/dL - ROUTINE ROUTINE - hsCRP Inflammatory marker; guides statin intensity &lt;2 mg/L - ROUTINE ROUTINE - BNP/NT-proBNP Heart failure; cardiac strain; AF risk Age-adjusted normal URGENT ROUTINE ROUTINE - Uric acid Elevated associated with increased stroke risk &lt;6 mg/dL - ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test Rationale Target Finding ED HOSP OPD ICU Hypercoagulability panel Age &lt;50, cryptogenic, recurrent events; includes Factor V Leiden, prothrombin mutation, protein C/S, antithrombin III Negative - EXT EXT - Antiphospholipid antibodies Lupus anticoagulant, anticardiolipin, anti-\u03b22GP1; young stroke Negative - EXT EXT - Hemoglobin electrophoresis Sickle cell disease if not known No sickling - EXT EXT - ESR, ANA Suspected vasculitis Normal/Negative - EXT EXT - Fabry disease testing (\u03b1-galactosidase A) Young cryptogenic stroke, family history, angiokeratomas Normal enzyme activity - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT Head non-contrast Immediate No hemorrhage; rule out stroke mimic None STAT STAT - - MRI Brain with DWI Within 24 hours No restricted diffusion (DWI+/ADC-) confirming infarct vs true TIA MRI-incompatible devices URGENT STAT - - CTA Head and Neck Same visit No significant stenosis (&gt;50%) in carotid, vertebral, or intracranial vessels Contrast allergy, CKD (relative) STAT STAT - - MRA Head and Neck Alternative to CTA Patent vessels; no stenosis &gt;50% MRI contraindications URGENT STAT ROUTINE - Carotid duplex ultrasound Within 24-48 hours &lt;50% stenosis bilaterally None URGENT STAT ROUTINE - ECG (12-lead) Immediate Sinus rhythm; no AF, LVH, or acute changes None STAT STAT ROUTINE - Transthoracic echocardiogram Within 24-48 hours No thrombus, PFO, or significant valvular disease None URGENT STAT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#2b-extended","title":"2B. Extended","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU Cardiac telemetry (continuous) 24-72 hours minimum No atrial fibrillation or flutter None URGENT STAT - - Holter monitor (24-48 hour) Outpatient No paroxysmal AF None - - ROUTINE - Extended cardiac monitoring (14-30 day) Cryptogenic stroke/TIA Detect paroxysmal AF None - - ROUTINE - Transesophageal echocardiogram Cryptogenic, young, embolic No PFO, LAA thrombus, aortic arch atheroma Esophageal pathology - URGENT EXT - Bubble study (TTE or TEE) Suspected paradoxical embolism No right-to-left shunt None specific - URGENT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study Timing Target Finding Contraindications ED HOSP OPD ICU CT/MR perfusion Uncertain timing, large vessel occlusion symptoms No mismatch suggesting salvageable tissue Contrast issues EXT EXT - - Vessel wall MRI Suspected intracranial vasculitis or dissection No vessel wall enhancement MRI contraindications - EXT EXT - DSA (cerebral angiogram) Vasculitis workup, moyamoya, uncertain vessel status Define vascular anatomy Contrast allergy, bleeding risk - EXT EXT - Implantable loop recorder Recurrent cryptogenic events after negative workup Detect occult AF None - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#3-treatment","title":"3. TREATMENT","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Aspirin PO Immediate antiplatelet therapy 325 mg PO x1 load; 81 mg PO daily :: PO :: :: 325 mg loading dose, then 81 mg daily ongoing Active GI bleed; aspirin allergy; planned thrombolysis GI symptoms, bleeding STAT STAT ROUTINE - Clopidogrel (DAPT with aspirin) PO ABCD2 \u22654 or minor stroke; first 21 days 300 mg PO x1 load; 75 mg PO daily :: PO :: :: 300 mg load then 75 mg daily with aspirin x21 days (POINT/CHANCE protocol) Active bleeding; planned surgery within 7 days Bleeding, bruising STAT STAT ROUTINE - Ticagrelor (alternative DAPT) PO Aspirin + ticagrelor if clopidogrel contraindicated 180 mg PO x1 load; 90 mg PO BID :: PO :: :: 180 mg load then 90 mg BID with aspirin x30 days (THALES protocol) Active bleeding; prior ICH; severe hepatic impairment Bleeding, dyspnea STAT STAT ROUTINE - Atorvastatin PO High-intensity statin for LDL &lt;70 80 mg PO daily :: PO :: :: 80 mg daily (high-intensity); target LDL &lt;70 mg/dL Active liver disease; pregnancy LFTs at baseline; myalgias URGENT STAT ROUTINE - Blood pressure management - Permissive hypertension acutely; goal &lt;140/90 long-term Target &lt;180/110 first 24h; &lt;140/90 after :: - :: :: Do NOT lower BP aggressively in first 24h unless &gt;220/120 or end-organ damage Symptomatic hypotension BP q1h x24h, then q4h STAT STAT ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#3b-symptomatic-treatments","title":"3B. Symptomatic Treatments","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU IV fluids (isotonic saline) IV Maintain euvolemia; avoid hypotension 75-125 mL/hr NS :: IV :: :: 75-125 mL/hr; adjust to maintain euvolemia; avoid D5W Fluid overload, CHF Fluid balance, I/Os URGENT ROUTINE - - Pantoprazole IV/PO GI protection with DAPT 40 mg IV daily; 40 mg PO daily :: IV/PO :: :: 40 mg daily None None ROUTINE ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#3c-second-linerefractory","title":"3C. Second-line/Refractory","text":"Treatment Route Indication Dosing Contraindications Monitoring ED HOSP OPD ICU Cilostazol (triple antiplatelet) PO Asian populations; high-risk stenosis 100 mg PO BID :: PO :: :: 100 mg BID; add to aspirin in select cases Heart failure; bleeding Bleeding, headache, palpitations - EXT EXT - Prasugrel PO Clopidogrel resistance or failure 60 mg PO x1 load; 10 mg PO daily :: PO :: :: 60 mg load then 10 mg daily; avoid if &gt;75y or &lt;60 kg Prior TIA/stroke (black box); bleeding risk Bleeding - EXT EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#3d-disease-modifying-or-chronic-therapies-secondary-prevention","title":"3D. Disease-Modifying or Chronic Therapies (Secondary Prevention)","text":"Treatment Route Indication Dosing Pre-Treatment Requirements Contraindications Monitoring ED HOSP OPD ICU Aspirin (long-term) PO Lifelong secondary prevention 81 mg PO daily :: PO :: :: 81 mg daily indefinitely None Active GI bleed GI symptoms; annual CBC - ROUTINE ROUTINE - Clopidogrel (monotherapy) PO Alternative to aspirin if aspirin-intolerant 75 mg PO daily :: PO :: :: 75 mg daily None Active bleeding Bleeding - ROUTINE ROUTINE - Aspirin + extended-release dipyridamole (Aggrenox) PO Alternative antiplatelet regimen 25/200 mg PO BID :: PO :: :: One capsule (25 mg ASA/200 mg ER dipyridamole) BID None Coronary stenosis (coronary steal); severe headache Headache (often limits use); GI - ROUTINE ROUTINE - Apixaban PO Atrial fibrillation-related TIA 5 mg PO BID; 2.5 mg PO BID :: PO :: :: 5 mg BID (2.5 mg BID if \u22652 of: age \u226580, weight \u226460 kg, Cr \u22651.5) Active major bleeding; mechanical valve CrCl, bleeding signs - ROUTINE ROUTINE - Rivaroxaban PO AF-related TIA 20 mg PO daily; 15 mg PO daily :: PO :: :: 20 mg daily with food (15 mg if CrCl 15-50) Active major bleeding; mechanical valve CrCl, bleeding - ROUTINE ROUTINE - Dabigatran PO AF-related TIA 150 mg PO BID; 110 mg PO BID :: PO :: :: 150 mg BID (110 mg BID if CrCl 30-50 or age &gt;80) Active bleeding; CrCl &lt;30; mechanical valve CrCl, bleeding - ROUTINE ROUTINE - Warfarin PO Mechanical valve; some hypercoagulable states 2-10 mg PO daily adjusted :: PO :: :: Start 5 mg daily; adjust to INR 2-3 (2.5-3.5 for mechanical valve) Baseline INR Pregnancy; active bleeding; frequent falls INR weekly then monthly - ROUTINE ROUTINE - Lisinopril PO Blood pressure control for secondary prevention 5 mg PO daily; 10 mg PO daily; 20 mg PO daily; 40 mg PO daily :: PO :: :: Start 5-10 mg daily; titrate to goal BP &lt;130/80; max 40 mg None Angioedema; pregnancy; bilateral RAS; hyperkalemia K+, Cr, BP - ROUTINE ROUTINE - Amlodipine PO BP control; add-on therapy 5 mg PO daily; 10 mg PO daily :: PO :: :: Start 5 mg daily; may increase to 10 mg daily None Severe aortic stenosis (relative) Peripheral edema, BP - ROUTINE ROUTINE - Chlorthalidone PO BP control; thiazide-like diuretic 12.5 mg PO daily; 25 mg PO daily :: PO :: :: Start 12.5 mg daily; may increase to 25 mg daily None Severe hypokalemia; severe hyponatremia K+, Na+, uric acid, glucose - ROUTINE ROUTINE - Ezetimibe PO Add-on for LDL not at goal on statin 10 mg PO daily :: PO :: :: 10 mg daily None Severe hepatic impairment LFTs - ROUTINE ROUTINE - PCSK9 inhibitor (evolocumab, alirocumab) SC LDL &gt;70 despite maximal statin + ezetimibe 140 mg SC q2wk; 420 mg SC monthly :: SC :: :: Evolocumab 140 mg q2wk or 420 mg monthly; alirocumab 75-150 mg q2wk LFTs, lipid panel None Injection site reactions; LDL - - ROUTINE - Icosapent ethyl (Vascepa) PO Triglycerides \u2265150 despite statin; reduces CV events 2 g PO BID :: PO :: :: 2 g BID with meals None Seafood/fish allergy (relative) AF monitoring (slightly increased risk) - - ROUTINE - Carotid endarterectomy (CEA) Surgical Symptomatic carotid stenosis 70-99%; 50-69% in select Surgery :: Surgical :: :: Perform within 2 weeks of TIA if stable; high-volume surgeon None Unstable plaque with delay; total occlusion Surgical complications; stroke - URGENT - - Carotid artery stenting (CAS) Endovascular CEA high-risk; radiation neck; recurrent stenosis Stenting :: Endovascular :: :: Alternative to CEA; requires DAPT None Tortuous anatomy; heavy calcification Hyperperfusion syndrome; stroke - URGENT - - PFO closure Endovascular Age &lt;60, PFO with shunt, cryptogenic stroke/TIA Device closure :: Endovascular :: :: Consider after comprehensive evaluation; DAPT post-procedure None Small PFO without shunt AF (transient); device complications - - EXT -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Neurology/Stroke consult for urgent evaluation, risk stratification, and secondary prevention optimization STAT STAT ROUTINE - Cardiology consultation for atrial fibrillation management, anticoagulation decisions, and PFO evaluation URGENT URGENT ROUTINE - Vascular surgery consultation for symptomatic carotid stenosis \u226550% to evaluate for endarterectomy timing - URGENT ROUTINE - Interventional neurology for carotid stenting evaluation if CEA high-risk or anatomically unsuitable - URGENT ROUTINE - Cardiac electrophysiology for recurrent AF management and potential ablation - - ROUTINE - Registered dietitian for Mediterranean diet counseling and sodium restriction education - ROUTINE ROUTINE - Smoking cessation counseling and pharmacotherapy initiation if current smoker - ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD Call 911 immediately if symptoms return as this indicates high stroke risk (up to 10% in first 48 hours) STAT STAT ROUTINE Do not drive for at least 2-4 weeks after TIA per state regulations and stroke risk URGENT ROUTINE ROUTINE Take all medications as prescribed especially antiplatelet therapy which significantly reduces stroke risk URGENT ROUTINE ROUTINE Know stroke warning signs (FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911) STAT ROUTINE ROUTINE Keep follow-up appointments as early intervention reduces stroke risk by up to 80% - ROUTINE ROUTINE","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Blood pressure target &lt;130/80 mmHg to significantly reduce stroke recurrence risk - ROUTINE ROUTINE LDL target &lt;70 mg/dL with high-intensity statin for secondary prevention - ROUTINE ROUTINE Smoking cessation (reduces stroke risk by 50% within 1 year of quitting) - ROUTINE ROUTINE Mediterranean diet emphasizing fruits, vegetables, whole grains, fish, and olive oil - ROUTINE ROUTINE Limit alcohol to \u22641 drink/day for women, \u22642 drinks/day for men - ROUTINE ROUTINE Regular aerobic exercise (150 min/week moderate or 75 min/week vigorous) - ROUTINE ROUTINE Weight management with target BMI 18.5-24.9 kg/m\u00b2 - ROUTINE ROUTINE Sodium restriction &lt;2300 mg/day (ideally &lt;1500 mg if hypertensive) - ROUTINE ROUTINE","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#section-b-reference","title":"SECTION B: REFERENCE","text":"","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Migraine with aura Gradual onset (minutes), visual scintillations, headache follows; younger patient Clinical history; normal DWI Seizure with Todd's paralysis Preceding convulsion; confusion; gradual resolution over hours EEG; clinical history Hypoglycemia Altered mentation, diaphoresis, tremor; resolves with glucose Fingerstick glucose Peripheral vertigo (BPPV, vestibular neuritis) Isolated vertigo with nystagmus; positive Dix-Hallpike HINTS exam; no central signs Transient global amnesia Isolated anterograde amnesia; repetitive questioning; resolves &lt;24h Clinical criteria; DWI may show hippocampal lesions Functional neurological disorder Inconsistent exam; incongruent symptoms; often with psychiatric comorbidity Clinical exam; normal workup Bell's palsy Peripheral facial weakness (forehead involved); no other deficits Clinical exam Hypertensive encephalopathy Severe HTN; headache; confusion; visual changes BP, posterior MRI findings Demyelinating disease (MS) Younger patient; prior episodes; MRI with characteristic lesions MRI brain/spine; CSF","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter Frequency Target/Threshold Action if Abnormal ED HOSP OPD ICU Neurological exam q1h x 24h then q4h Stable; no new deficits Immediate imaging if worsening STAT STAT - - Blood pressure q1h x 24h then q4h &lt;180/110 acutely; &lt;130/80 long-term Titrate antihypertensives STAT STAT ROUTINE - Cardiac rhythm (telemetry) Continuous x 24-72h Sinus rhythm Anticoagulation if AF detected URGENT STAT - - Extended cardiac monitoring 14-30 days outpatient Sinus rhythm Anticoagulation if AF detected - - ROUTINE - ABCD2 score At presentation Score &lt;4 lower risk; \u22654 high risk High-risk patients need admission or rapid TIA clinic STAT STAT - - LDL cholesterol Baseline, 6 weeks, then annually &lt;70 mg/dL Intensify statin or add ezetimibe/PCSK9i - ROUTINE ROUTINE - HbA1c Baseline, then q3mo if diabetic &lt;7% Optimize diabetes management - ROUTINE ROUTINE - Creatinine/eGFR With contrast; then annually eGFR &gt;30 Dose-adjust medications STAT ROUTINE ROUTINE -","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Rapid TIA clinic (&lt;24-48h) ABCD2 &lt;4; no acute findings on imaging; reliable patient with close follow-up Admit to stroke unit ABCD2 \u22654; DWI positive (minor stroke); symptomatic carotid stenosis; new AF; unable to complete workup as outpatient Admit to ICU Rare for isolated TIA; only if concurrent acute coronary syndrome or hemodynamic instability Discharge with urgent follow-up Completed rapid workup; started on secondary prevention; ABCD2 &lt;4; no high-risk features","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source Dual antiplatelet therapy (DAPT) for 21 days after minor stroke/TIA Class I, Level A Wang et al. NEJM 2021 (CHANCE-2); Johnston et al. NEJM 2018 (POINT) High-intensity statin for LDL &lt;70 mg/dL Class I, Level A Amarenco et al. NEJM 2006 (SPARCL) CEA for symptomatic carotid stenosis 70-99% Class I, Level A NASCET Collaborators. NEJM 1991 ABCD2 score for TIA risk stratification Class IIa, Level B Johnston et al. Lancet 2007 Extended cardiac monitoring for cryptogenic stroke Class IIa, Level B Sanna et al. NEJM 2014 (CRYSTAL-AF) PFO closure in cryptogenic stroke &lt;60 years Class IIa, Level B Mas et al. NEJM 2017 (CLOSE) BP target &lt;130/80 for secondary prevention Class I, Level B AHA/ASA Guidelines 2021 Urgent TIA evaluation reduces stroke risk Class I, Level B Rothwell et al. Lancet 2007 (EXPRESS) DOACs preferred over warfarin for NVAF Class I, Level A Ruff et al. Lancet 2014 (meta-analysis)","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/tia/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 27, 2026) - Initial template creation - ABCD2 risk stratification included - DAPT protocols (POINT/CHANCE) incorporated - Secondary prevention comprehensive coverage</p>","tags":["cerebrovascular","stroke","TIA","outpatient","emergency"]},{"location":"plans/transient-ischemic-attack/","title":"Transient Ischemic Attack (TIA)","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Transient Ischemic Attack (TIA)</p> <p>ICD-10: G45.9 (Transient cerebral ischemic attack, unspecified), G45.0 (Vertebro-basilar artery syndrome), G45.1 (Carotid artery syndrome)</p> <p>SYNONYMS: Transient ischemic attack, TIA, mini-stroke, warning stroke, transient stroke, pre-stroke, temporary stroke symptoms, reversible ischemic neurological deficit</p> <p>SCOPE: Acute evaluation and secondary prevention after transient ischemic attack in adults. Covers risk stratification (ABCD2), urgent workup (MRI with DWI, vascular imaging, cardiac evaluation), dual antiplatelet therapy initiation, and rapid secondary prevention. TIA is a medical emergency \u2014 90-day stroke risk is 10-15% without intervention, highest in first 48h. Excludes completed ischemic stroke (see Acute Ischemic Stroke template), hemorrhagic stroke, and TIA mimics.</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/transient-ischemic-attack/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/transient-ischemic-attack/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Point-of-care glucose STAT STAT STAT - Hypoglycemia mimics TIA; must rule out immediately &gt;60 mg/dL CBC with differential STAT STAT ROUTINE - Thrombocytosis or thrombocytopenia; polycythemia; anemia; infection Normal CMP (BMP + LFTs) STAT STAT ROUTINE - Electrolytes; renal function for contrast; hepatic function Normal PT/INR STAT STAT ROUTINE - Anticoagulant use; coagulopathy assessment Normal Lipid panel (fasting or non-fasting) STAT STAT ROUTINE - LDL target &lt;70 mg/dL; statin initiation LDL &lt;70 HbA1c STAT STAT ROUTINE - Diabetes screening; cardiovascular risk factor &lt;7.0% Troponin STAT STAT - - Concurrent ACS; cardiac embolic source Normal Blood glucose (fasting) - ROUTINE ROUTINE - Diabetes screening &lt;126 mg/dL TSH - ROUTINE ROUTINE - Hyperthyroidism \u2192 atrial fibrillation Normal"},{"location":"plans/transient-ischemic-attack/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding ESR / CRP URGENT ROUTINE ROUTINE - Vasculitis screen; giant cell arteritis (age &gt;50 with TIA); inflammatory markers Normal Homocysteine - ROUTINE ROUTINE - Elevated homocysteine as independent stroke risk factor Normal (&lt;15 \u00b5mol/L) Urine drug screen URGENT ROUTINE - - Cocaine/amphetamine-associated TIA/stroke Negative RPR/VDRL - ROUTINE ROUTINE - Syphilitic vasculitis Non-reactive HIV 1/2 antigen/antibody - ROUTINE ROUTINE - HIV-associated vasculopathy Negative Pregnancy test (\u03b2-hCG) STAT STAT ROUTINE - Affects imaging and treatment decisions Document result Magnesium URGENT ROUTINE ROUTINE - Electrolyte management Normal"},{"location":"plans/transient-ischemic-attack/#1c-rarespecialized-young-tia-or-cryptogenic","title":"1C. Rare/Specialized (Young TIA or Cryptogenic)","text":"Test ED HOSP OPD ICU Rationale Target Finding Hypercoagulable panel (Protein C, S, antithrombin III, Factor V Leiden, prothrombin gene mutation) - EXT ROUTINE - Young patient (&lt;50); cryptogenic TIA; personal/family history of thrombosis Normal Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, \u03b22-glycoprotein I) - ROUTINE ROUTINE - Young TIA; recurrent TIA; systemic lupus; recurrent pregnancy loss Negative ANA, dsDNA - EXT ROUTINE - Lupus cerebritis; vasculitis Negative ANCA (c-ANCA, p-ANCA) - EXT EXT - CNS vasculitis Negative Hemoglobin electrophoresis - EXT EXT - Sickle cell disease (young patients, African descent) Normal JAK2 mutation - EXT EXT - Polycythemia vera; myeloproliferative disorders Negative Lipoprotein(a) - ROUTINE ROUTINE - Independent cardiovascular risk factor; elevated in 20% of population &lt;50 mg/dL"},{"location":"plans/transient-ischemic-attack/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/transient-ischemic-attack/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications MRI brain with DWI STAT STAT URGENT - Within 24h (ideally &lt;6h). DWI-positive in 30-50% of clinical TIA \u2014 these patients are at HIGHEST stroke risk and may be reclassified as minor stroke DWI restriction = acute ischemia (even if symptoms resolved, this upgrades risk and may change to minor stroke diagnosis); FLAIR changes; prior infarcts Pacemaker, metallic implants, severe claustrophobia CT head without contrast STAT STAT - - Immediate (if MRI unavailable or contraindicated); excludes hemorrhage and mass No hemorrhage; no mass; may show old infarcts Pregnancy (relative) CTA head and neck (OR MRA head and neck) STAT STAT URGENT - With initial imaging or within 24h. Evaluates extracranial AND intracranial vessels Carotid stenosis (\u226550% NASCET); intracranial stenosis; vertebral stenosis; dissection Contrast allergy; renal impairment (for CTA). MRA: pacemaker ECG (12-lead) STAT STAT ROUTINE - Immediately Atrial fibrillation (detected in 5-10% on initial ECG); atrial flutter; acute MI; LVH; old infarct None Continuous cardiac monitoring (telemetry) STAT STAT - - Minimum 24h in ED/hospital; ideally 48-72h Paroxysmal atrial fibrillation (detected in additional 5-7% with monitoring) None"},{"location":"plans/transient-ischemic-attack/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Transthoracic echocardiogram (TTE) - ROUTINE ROUTINE - Within 24-48h LV thrombus; PFO; valvular disease; cardiomyopathy; akinetic segments None significant Transesophageal echocardiogram (TEE) with bubble study - ROUTINE ROUTINE - If TTE nondiagnostic; cryptogenic TIA; young patient PFO with right-to-left shunt; atrial septal aneurysm; LAA thrombus; aortic arch atheroma (\u22654mm) Esophageal pathology Carotid duplex ultrasound URGENT URGENT URGENT - Within 24h (may be obtained instead of or in addition to CTA/MRA) Carotid stenosis \u226550%; plaque characterization; hemodynamic significance None significant Extended cardiac monitoring (Holter 30-day or implantable loop recorder) - ROUTINE ROUTINE - Arrange before discharge; especially if cryptogenic TIA Paroxysmal AF (detected in 12-30% with prolonged monitoring in cryptogenic cases) None significant Transcranial Doppler (TCD) with bubble study - ROUTINE ROUTINE - If PFO evaluation needed (alternative to TEE bubble); also for intracranial stenosis and microembolic signals Right-to-left shunt; intracranial stenosis; microembolic signals Absent temporal bone window CT perfusion - EXT - - If diagnosis uncertain; evaluate for persistent hypoperfusion despite symptom resolution Perfusion deficits suggesting ongoing ischemic risk Contrast allergy; renal impairment"},{"location":"plans/transient-ischemic-attack/#2c-rarespecialized","title":"2C. Rare/Specialized","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Conventional cerebral angiography (DSA) - EXT EXT - If intracranial stenosis suspected on CTA/MRA; vasculitis workup; Moyamoya Beading (vasculitis); intimal flap (dissection); Moyamoya collaterals; intracranial stenosis quantification Contrast allergy; coagulopathy MRI vessel wall imaging - EXT EXT - Intracranial stenosis characterization; vasculitis evaluation Vessel wall enhancement (active inflammation, unstable plaque) Standard MRI contraindications Fat-saturated MRI neck - ROUTINE ROUTINE - If cervical dissection suspected (neck pain, Horner syndrome, young patient) Intramural hematoma (crescent sign) Standard MRI contraindications PET-CT - - EXT - If occult malignancy suspected (Trousseau syndrome) Malignancy Pregnancy"},{"location":"plans/transient-ischemic-attack/#3-treatment","title":"3. TREATMENT","text":""},{"location":"plans/transient-ischemic-attack/#3a-acuteemergent","title":"3A. Acute/Emergent","text":"Treatment ED HOSP OPD ICU Dosing Contraindications Monitoring Aspirin (loading dose) STAT STAT STAT - 325 mg PO loading dose immediately upon TIA diagnosis (give in ED). Do NOT delay antiplatelet therapy Active GI bleed; true aspirin allergy; thrombocytopenia &lt;50K GI symptoms; bleeding Clopidogrel (loading dose for DAPT) STAT STAT STAT - 300 mg PO loading dose (give with aspirin for DAPT). DAPT is standard for high-risk TIA (ABCD2 \u22654) or minor stroke per CHANCE and POINT trials Active bleeding; severe hepatic impairment Bleeding; CBC Dual antiplatelet therapy (DAPT maintenance): Aspirin + Clopidogrel - STAT STAT - Aspirin 81 mg daily + Clopidogrel 75 mg daily x 21 days (CHANCE protocol) or x 90 days (POINT protocol \u2014 higher bleeding risk with longer duration). Then transition to single antiplatelet (typically clopidogrel 75 mg or aspirin 81 mg monotherapy) Major bleeding risk; planned surgery Bleeding signs; CBC monthly Dual antiplatelet therapy (alternative): Aspirin + Ticagrelor - STAT STAT - Aspirin 81 mg daily + Ticagrelor 90 mg BID x 30 days (THALES trial; for minor stroke NIHSS \u22645). Then single antiplatelet Intracranial hemorrhage history; high bleeding risk; hepatic impairment Bleeding; dyspnea (common side effect); avoid strong CYP3A4 inhibitors High-intensity statin STAT STAT STAT - Atorvastatin 80 mg PO daily (or Rosuvastatin 20-40 mg). Start immediately regardless of baseline LDL Active liver disease; pregnancy LFTs at 12 weeks; lipid panel at 4-12 weeks; CK if myalgia Blood pressure management (acute) STAT STAT - - If SBP &gt;220 or DBP &gt;120 in ED: lower gently (15-25% in first 24h). If lower BP levels: permissive hypertension in first 24-48h unless end-organ damage. Avoid precipitous drops Carotid stenosis with hemodynamic TIA: do NOT aggressively lower BP (may worsen symptoms) Neuro checks with each change; BP q1h acutely"},{"location":"plans/transient-ischemic-attack/#3b-secondary-prevention-initiate-urgently","title":"3B. Secondary Prevention (Initiate Urgently)","text":"Treatment Route ED HOSP OPD Dosing Pre-Treatment Requirements Contraindications Monitoring Antihypertensive therapy (chronic) PO - ROUTINE ROUTINE Target BP &lt;130/80 mmHg. Start/restart 24-48h after TIA once stable. Agent choice per comorbidities: ACE-I/ARB first-line. Consider: Lisinopril 10-20 mg daily, Amlodipine 5-10 mg, Losartan 50-100 mg, Chlorthalidone 12.5-25 mg Baseline BP, Cr, K+ Bilateral renal artery stenosis (ACE-I/ARB); pregnancy Home BP monitoring; Cr and K+ at 1-2 weeks Anticoagulation (if atrial fibrillation detected) PO - ROUTINE ROUTINE Start DOAC within 1-3 days for TIA (can start earlier than stroke). Preferred: Apixaban 5 mg BID (2.5 mg BID if criteria met). Alternative: Rivaroxaban 20 mg daily; Dabigatran 150 mg BID. Discontinue antiplatelet when anticoagulant started (do NOT combine long-term unless specific indication) ECG/cardiac monitoring confirming AF; CHA2DS2-VASc score; bleeding risk (HAS-BLED) Active bleeding; mechanical valve (use warfarin); severe renal impairment Renal function q6-12 months; bleeding signs Carotid endarterectomy (CEA) Surgery - URGENT URGENT For symptomatic carotid stenosis \u226550% (NASCET criteria); ideally performed within 2 weeks of TIA (maximum benefit). NNT = 6 for 70-99% stenosis; NNT = 22 for 50-69% stenosis Carotid imaging confirming stenosis \u226550%; cardiac clearance Near-occlusion (controversial); life expectancy &lt;5 years; severe cardiac comorbidity Post-op: BP monitoring; neuro checks q1h x 24h; wound hematoma; cranial nerve injury Carotid artery stenting (CAS) Endovascular - ROUTINE ROUTINE Alternative to CEA if: high surgical risk, prior neck radiation, prior CEA with restenosis, surgically inaccessible. Requires DAPT (aspirin + clopidogrel) post-stenting Same as CEA; cardiac catheterization access Severe aortic arch tortuosity; fresh thrombus Post-procedure: BP management; neuro checks; DAPT compliance; restenosis surveillance PFO closure Procedure - - ROUTINE For cryptogenic TIA/stroke age 18-60 with PFO and right-to-left shunt. Reduces recurrent stroke vs medical therapy alone (CLOSE, RESPECT, REDUCE trials). Requires 3-6 months DAPT then aspirin indefinitely TEE/TCD confirming PFO with shunt; cryptogenic classification; no other identified stroke mechanism Anatomic constraints; active infection Echo at 6-12 months; aspirin long-term Ezetimibe PO - ROUTINE ROUTINE 10 mg PO daily; add if LDL not at goal on max statin Active liver disease LFTs; lipid panel PCSK9 inhibitor (evolocumab or alirocumab) SC - - ROUTINE Evolocumab 140 mg SC q2 weeks or 420 mg monthly; if LDL not at goal on statin + ezetimibe None absolute Lipid panel q4-12 weeks; injection site Diabetes management (optimize) PO/SC - ROUTINE ROUTINE Target HbA1c &lt;7% (individualized); GLP-1 agonists and SGLT2 inhibitors have cardiovascular benefit Per agent Per agent HbA1c q3 months; renal function"},{"location":"plans/transient-ischemic-attack/#3c-medications-for-specific-etiologies","title":"3C. Medications for Specific Etiologies","text":"Treatment Indication Dosing Monitoring Anticoagulation (warfarin) Mechanical heart valve + TIA Warfarin to target INR 2.5-3.5; bridge with heparin INR weekly then monthly DAPT long-term (aspirin + clopidogrel) Intracranial stenosis 70-99% (SAMMPRIS trial: medical &gt; stenting) Aspirin 325 mg + clopidogrel 75 mg daily x 90 days; then single antiplatelet + aggressive risk factor management Bleeding; MRA q6-12 months Anticoagulation Cervical artery dissection Antiplatelet or anticoagulation (both equally effective per CADISS trial); typically 3-6 months Repeat vascular imaging at 3-6 months Colchicine Residual inflammatory risk (LoDoCo2 / COLCOT trials support in ACS \u2014 emerging data for stroke prevention) 0.5 mg PO daily GI symptoms; CBC"},{"location":"plans/transient-ischemic-attack/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/transient-ischemic-attack/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"Recommendation ED HOSP OPD ICU Indication Neurology (stroke team) STAT STAT URGENT - All TIA patients; risk stratification; workup direction; secondary prevention Vascular surgery - URGENT URGENT - Symptomatic carotid stenosis \u226550% for CEA; ideally within 2 weeks Neurointerventional / Endovascular - ROUTINE ROUTINE - Carotid stenting; intracranial stenosis management; PFO closure referral Cardiology - ROUTINE ROUTINE - Newly detected AF; PFO evaluation; anticoagulation management; cardiac optimization Electrophysiology - ROUTINE ROUTINE - Extended cardiac monitoring arrangement; AF management Primary care (expedited) - ROUTINE ROUTINE - Risk factor management; medication titration; chronic disease management Smoking cessation program - ROUTINE ROUTINE - Active smokers Nutrition / Dietitian - ROUTINE ROUTINE - Mediterranean/DASH diet counseling; weight management Diabetes educator - - ROUTINE - If new or uncontrolled diabetes Social work - ROUTINE ROUTINE - Medication assistance; transportation; caregiver support"},{"location":"plans/transient-ischemic-attack/#4b-patient-instructions","title":"4B. Patient Instructions","text":"Recommendation ED HOSP OPD TIA is a WARNING \u2014 risk of full stroke is HIGHEST in first 48h; take this very seriously STAT STAT ROUTINE Call 911 IMMEDIATELY if any symptom recurs: sudden weakness, numbness, speech difficulty, vision changes, severe headache, loss of balance (F.A.S.T.) STAT STAT ROUTINE Take all medications EXACTLY as prescribed; do NOT stop aspirin, clopidogrel, or statin without medical guidance STAT STAT ROUTINE Do NOT drive for at least 2 weeks (state laws vary; some require neurologist clearance) URGENT URGENT ROUTINE Return for follow-up within 1-2 weeks with neurology; primary care within 2-4 weeks - ROUTINE ROUTINE Blood pressure monitoring at home daily; keep log; target per physician guidance (&lt;130/80) - ROUTINE ROUTINE Report any bleeding (bruising, blood in stool/urine, nosebleed) while on DAPT - ROUTINE ROUTINE Carry updated medication list at all times - ROUTINE ROUTINE Notify all providers of TIA history (dental, surgical, emergency) - ROUTINE ROUTINE"},{"location":"plans/transient-ischemic-attack/#4c-lifestyle-prevention","title":"4C. Lifestyle &amp; Prevention","text":"Recommendation ED HOSP OPD Smoking cessation (ABSOLUTE \u2014 doubles stroke risk) - ROUTINE ROUTINE Blood pressure target &lt;130/80 mmHg - ROUTINE ROUTINE LDL target &lt;70 mg/dL (high-intensity statin) - ROUTINE ROUTINE Mediterranean or DASH diet - ROUTINE ROUTINE Sodium restriction &lt;2.3 g/day (ideally &lt;1.5 g) - ROUTINE ROUTINE Regular aerobic exercise: 40 min moderate intensity, 3-4 days/week (after medical clearance) - - ROUTINE Weight management (BMI 18.5-24.9) - ROUTINE ROUTINE Alcohol limitation: \u22641 drink/day women, \u22642 drinks/day men - ROUTINE ROUTINE HbA1c target &lt;7% (individualized) - ROUTINE ROUTINE OSA screening (STOP-BANG); CPAP if diagnosed - ROUTINE ROUTINE Depression / anxiety screening (PHQ-9) - - ROUTINE <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: REFERENCE (Expand as Needed) \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/transient-ischemic-attack/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":"Alternative Diagnosis Key Distinguishing Features Tests to Differentiate Migraine with aura Gradual onset (\"marching\" symptoms over minutes); visual aura (scintillating scotoma); headache follows; younger; history of migraine Normal MRI DWI; clinical history; gradual onset differentiates from sudden TIA Seizure with Todd's paralysis Witnessed seizure; post-ictal confusion; resolves in hours; focal weakness post-seizure EEG; MRI DWI negative; clinical history Hypoglycemia Glucose &lt;60; diaphoresis; tremor; confusion; resolves with glucose POC glucose Peripheral vertigo (BPPV, vestibular neuritis) Isolated vertigo without other neurologic deficits; positive HINTS (peripheral pattern); nystagmus characteristics HINTS exam; MRI DWI negative; normal CTA Multiple sclerosis exacerbation Young patient; symptoms disseminated in space and time; prior episodes; weeks duration MRI brain (periventricular/juxtacortical lesions); oligoclonal bands Brain tumor Subacute progressive symptoms; headache; may have transient symptoms from seizure or compression MRI with contrast (enhancing mass) Conversion disorder / FND Non-anatomic deficit distribution; Hoover sign; give-way weakness; psychological stressor Normal MRI; normal vascular imaging; clinical exam Syncope / Pre-syncope Loss of consciousness; lightheadedness; no focal neurologic deficit Orthostatic vitals; ECG; echo; tilt table Labyrinthine infarction Isolated sudden hearing loss + vertigo (AICA territory); may be a TIA equivalent Audiometry (sensorineural hearing loss); MRI DWI (may show pontine or cerebellar infarct) Subdural hematoma Fluctuating symptoms; trauma history or anticoagulation; subacute CT (extra-axial collection) Transient global amnesia Isolated anterograde amnesia lasting hours; no motor or speech deficit; age &gt;50; benign Clinical presentation; MRI DWI (may show small hippocampal DWI lesions) Metabolic encephalopathy Bilateral, non-focal; confusion predominant; abnormal labs BMP; ammonia; LFTs; TSH"},{"location":"plans/transient-ischemic-attack/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":"Parameter ED HOSP OPD ICU Frequency Target/Threshold Action if Abnormal Neurologic exam (deficit recurrence) STAT STAT ROUTINE - q1h x 6h, then q4h in hospital; each outpatient visit No recurrence of symptoms If symptoms recur: STAT MRI DWI; may need admission; upgrade to stroke protocol if persistent &gt;24h or DWI+ Blood pressure STAT STAT ROUTINE - q1h x 6h in ED; q4h in hospital; daily at home Acute: avoid precipitous drop; Chronic: &lt;130/80 Antihypertensive titration; avoid SBP &lt;100 if carotid stenosis Heart rhythm (telemetry) STAT STAT - - Continuous x 24-72h minimum Sinus rhythm; detect paroxysmal AF If AF detected: anticoagulation; discontinue antiplatelet Blood glucose STAT ROUTINE ROUTINE - q6h in hospital; HbA1c at follow-up 140-180 (acute); HbA1c &lt;7% Diabetes management Lipid panel - ROUTINE ROUTINE - Baseline; repeat at 4-12 weeks on statin LDL &lt;70 mg/dL Intensify statin; add ezetimibe or PCSK9i Renal function (Cr) - ROUTINE ROUTINE - At baseline; after starting ACE-I/ARB Stable Dose adjust medications CBC - ROUTINE ROUTINE - Baseline; at 1 month on DAPT Normal Monitor for bleeding on DAPT ABCD2 Score (at presentation) STAT - - - Once (risk stratification) Score determines urgency and disposition \u22654: admit or rapid TIA clinic within 24h; &lt;4: may discharge with 24-48h follow-up if imaging complete Extended cardiac monitoring - ROUTINE ROUTINE - 30-day Holter or ILR post-discharge (especially cryptogenic) Detect AF Anticoagulation if AF detected Carotid imaging follow-up - - ROUTINE - After CEA/CAS: duplex at 1 month, 6 months, then annually No restenosis Repeat intervention if significant restenosis"},{"location":"plans/transient-ischemic-attack/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":"Disposition Criteria Admit to hospital (preferred for high-risk) ABCD2 \u22654; crescendo TIA (recurrent within 24h); large vessel stenosis identified; atrial fibrillation detected; DWI-positive on MRI; incomplete workup that cannot be completed within 24h as outpatient Rapid TIA clinic / 24-48h outpatient workup ABCD2 &lt;4; symptoms fully resolved; no large vessel disease on imaging; no AF on ECG; MRI/CTA completed and negative; reliable follow-up; medications started Discharge from ED (with next-day follow-up) Low risk (ABCD2 0-3); all imaging completed and normal (MRI DWI negative, CTA normal, ECG sinus); medications started; reliable patient; follow-up within 24-48h guaranteed Admit to ICU Rarely needed; consider if hemodynamic TIA with critical stenosis; malignant hypertension; crescendo TIA progressing to stroke Transfer to stroke center If vascular imaging, MRI, or neurology consultation not available within 24h"},{"location":"plans/transient-ischemic-attack/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":"Recommendation Evidence Level Source DAPT (aspirin + clopidogrel 21 days) for minor stroke / high-risk TIA Class I, Level A CHANCE trial (Wang et al. NEJM 2013) DAPT (aspirin + clopidogrel 90 days) for minor stroke / high-risk TIA Class IIa, Level B POINT trial (Johnston et al. NEJM 2018); higher ICH risk than 21 days Aspirin + ticagrelor x 30 days for minor stroke (NIHSS \u22645) Class IIa, Level B THALES trial (Johnston et al. NEJM 2020) High-intensity statin for TIA secondary prevention Class I, Level A SPARCL trial (Amarenco et al. NEJM 2006); AHA/ASA 2021 LDL target &lt;70 mg/dL Class I, Level A TST trial (Amarenco et al. NEJM 2020) BP target &lt;130/80 for secondary prevention Class I, Level A SPS3 trial; PROGRESS; AHA/ASA 2021 CEA within 2 weeks for symptomatic stenosis \u226550% Class I, Level A NASCET (NEJM 1991); ECST; Rothwell et al. (Lancet 2004) \u2014 maximum benefit if performed within 2 weeks DOACs preferred over warfarin for AF-related TIA/stroke Class I, Level A RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF Extended cardiac monitoring for cryptogenic TIA Class IIa, Level B CRYSTAL-AF (Sanna et al. NEJM 2014); EMBRACE (Gladstone et al. NEJM 2014) PFO closure for cryptogenic stroke/TIA age 18-60 Class IIa, Level B CLOSE, RESPECT, REDUCE trials MRI DWI within 24h (DWI+ = higher stroke risk) Class I, Level B AHA/ASA Guidelines; Coutts et al. (Stroke 2012) ABCD2 score for risk stratification Class IIa, Level B Johnston et al. (Lancet 2007); useful but imperfect; imaging adds value Rapid TIA evaluation reduces 90-day stroke risk Class I, Level B EXPRESS trial (Rothwell et al. Lancet 2007); SOS-TIA (Lavall\u00e9e et al. Lancet Neurol 2007) Medical therapy superior to stenting for intracranial stenosis Class I, Level A SAMMPRIS trial (Chimowitz et al. NEJM 2011) OSA screening and CPAP Class IIa, Level B AHA/ASA 2021 Guidelines <p>APPENDIX: ABCD2 SCORE (TIA RISK STRATIFICATION)</p> Component Points Age \u226560 1 BP \u2265140/90 at presentation 1 Clinical features: Unilateral weakness 2 Clinical features: Speech impairment without weakness 1 Duration \u226560 min 2 Duration 10-59 min 1 Diabetes 1 Total possible 7 Score 2-Day Stroke Risk 90-Day Stroke Risk Recommendation 0-3 (Low) 1.0% 3.1% Rapid outpatient workup within 24-48h; may discharge from ED if workup complete 4-5 (Moderate) 4.1% 9.8% Admit or ensure &lt;24h follow-up; start DAPT 6-7 (High) 8.1% 17.8% Admit; aggressive workup and treatment <p>Note: ABCD2 is imperfect as a stand-alone tool. DWI-positive MRI, large vessel stenosis, and AF detection independently predict stroke risk regardless of ABCD2 score.</p> <p>APPENDIX: SECONDARY PREVENTION CHECKLIST</p> Risk Factor Target Intervention Blood pressure &lt;130/80 ACE-I/ARB + lifestyle LDL cholesterol &lt;70 mg/dL High-intensity statin + ezetimibe \u00b1 PCSK9i Diabetes (HbA1c) &lt;7.0% Metformin; GLP-1/SGLT2 (CV benefit) Antiplatelet DAPT x 21-90 days \u2192 monotherapy Aspirin + clopidogrel \u2192 single agent Anticoagulation (if AF) DOAC Apixaban preferred Carotid stenosis \u226550% Revascularization CEA within 2 weeks; or CAS Smoking Cessation Counseling + pharmacotherapy Exercise 40 min, 3-4x/week Cardiac clearance first Diet Mediterranean/DASH Dietitian referral BMI 18.5-24.9 Comprehensive lifestyle Sleep apnea Screening; CPAP if positive STOP-BANG; sleep study"},{"location":"plans/vertigo-dizziness-evaluation/","title":"Vertigo / Dizziness Evaluation","text":"<p>VERSION: 1.0 CREATED: January 27, 2026 STATUS: Initial build</p> <p>DIAGNOSIS: Vertigo / Dizziness Evaluation</p> <p>ICD-10: R42 (Dizziness and giddiness), H81.10 (Benign paroxysmal positional vertigo, unspecified ear), H81.0 (Meniere's disease), H81.3 (Other peripheral vertigo), G45.0 (Vertebro-basilar artery syndrome), H81.4 (Vertigo of central origin)</p> <p>SYNONYMS: Vertigo, dizziness, lightheadedness, light headedness, disequilibrium, presyncope, room spinning, BPPV, vestibular neuritis, labyrinthitis, Meniere's disease, imbalance, unsteadiness, giddiness</p> <p>SCOPE: Evaluation and management of acute vertigo and dizziness in adults. Covers differentiation of peripheral vs. central causes, the HINTS exam, Dix-Hallpike and canalith repositioning maneuvers, evaluation for posterior circulation stroke, and management of common vestibular disorders (BPPV, vestibular neuritis, Meniere's disease, vestibular migraine). Excludes chronic non-specific dizziness (persistent postural-perceptual dizziness), medication-induced dizziness (covered briefly), and presyncope/orthostatic hypotension (separate evaluation).</p> <p>PRIORITY KEY: STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p> <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION A: ACTION ITEMS \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/vertigo-dizziness-evaluation/#1-laboratory-workup","title":"1. LABORATORY WORKUP","text":""},{"location":"plans/vertigo-dizziness-evaluation/#1a-essentialcore-labs","title":"1A. Essential/Core Labs","text":"Test ED HOSP OPD ICU Rationale Target Finding Blood glucose STAT STAT ROUTINE STAT Hypoglycemia can cause dizziness/lightheadedness; hyperglycemia (diabetic neuropathy); metabolic dizziness 70-180 mg/dL; hypo/hyperglycemia \u2192 correct and reassess CBC STAT STAT ROUTINE STAT Anemia (lightheadedness, presyncope); infection (labyrinthitis); baseline Normal; anemia (Hgb &lt;10) can cause dizziness; infection markers CMP (BMP + LFTs) STAT STAT ROUTINE STAT Electrolyte abnormalities (hyponatremia, hypoglycemia); renal dysfunction; dehydration Normal; hyponatremia &lt;130 can cause neurologic symptoms including imbalance TSH - ROUTINE ROUTINE - Thyroid dysfunction can cause dizziness/imbalance; hyperthyroidism especially Normal; abnormal \u2192 thyroid evaluation ECG (12-lead) STAT STAT ROUTINE STAT Cardiac arrhythmia causing presyncope/dizziness; differentiates cardiac from vestibular Normal; arrhythmia \u2192 cardiac workup; prolonged QTc Orthostatic vital signs STAT STAT ROUTINE STAT Orthostatic hypotension is common cause of dizziness, especially in elderly; drop in SBP &gt;20 or DBP &gt;10 with symptoms No orthostatic drop; positive orthostatics \u2192 volume status, medication review, autonomic evaluation"},{"location":"plans/vertigo-dizziness-evaluation/#1b-extended-workup-second-line","title":"1B. Extended Workup (Second-line)","text":"Test ED HOSP OPD ICU Rationale Target Finding Lipid panel - ROUTINE ROUTINE - Vascular risk factors if central cause suspected; stroke risk stratification LDL &lt;70 (high risk) or &lt;100; triglycerides; HDL HbA1c - ROUTINE ROUTINE - Diabetes (vascular risk factor; diabetic neuropathy affecting balance) &lt;7.0%; elevated \u2192 diabetes management RPR / VDRL - - ROUTINE - Neurosyphilis (rare cause of vertigo, especially in HIV); otosyphilis Negative; positive \u2192 CSF analysis, penicillin treatment Vitamin B12 - ROUTINE ROUTINE - B12 deficiency causes peripheral neuropathy and imbalance; subacute combined degeneration &gt;300 pg/mL; low \u2192 supplement and monitor Ferritin - ROUTINE ROUTINE - Iron deficiency (even without anemia) can cause dizziness &gt;50 ng/mL; low \u2192 iron supplementation ANA / ESR / CRP - ROUTINE ROUTINE - Autoimmune inner ear disease; vasculitis (CNS vasculitis affecting posterior circulation) Normal; elevated \u2192 autoimmune/inflammatory workup Drug levels (if applicable) STAT STAT ROUTINE STAT Ototoxic medications (aminoglycosides, salicylates); anticonvulsant toxicity (phenytoin, carbamazepine) Therapeutic; toxic levels \u2192 adjust or discontinue"},{"location":"plans/vertigo-dizziness-evaluation/#1c-rarespecialized-refractory-or-atypical","title":"1C. Rare/Specialized (Refractory or Atypical)","text":"Test ED HOSP OPD ICU Rationale Target Finding FTA-ABS - - ROUTINE - Confirmatory for syphilis if RPR positive; otosyphilis/neurosyphilis Negative Lyme serology - - ROUTINE - Lyme disease can cause cranial neuropathies, including vestibular neuritis; endemic areas Negative; positive \u2192 Western blot confirmation Anti-GAD65 antibodies - - EXT - Cerebellar ataxia; autoimmune cerebellitis Negative; positive \u2192 autoimmune cerebellar disease Paraneoplastic antibody panel - - EXT - Paraneoplastic cerebellar degeneration (anti-Yo, anti-Hu); subacute ataxia with vertigo Negative; positive \u2192 malignancy search CSF analysis - EXT EXT - If infectious, inflammatory, or neoplastic cause suspected; normal in peripheral vestibular disorders Normal; pleocytosis \u2192 infection/inflammation; protein elevation Genetic testing - - EXT - Familial episodic ataxia; spinocerebellar ataxia; hereditary vestibular disorders Specific mutations (CACNA1A for EA2; SCA genes)"},{"location":"plans/vertigo-dizziness-evaluation/#2-diagnostic-imaging-studies","title":"2. DIAGNOSTIC IMAGING &amp; STUDIES","text":""},{"location":"plans/vertigo-dizziness-evaluation/#2a-essentialfirst-line","title":"2A. Essential/First-line","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications HINTS exam (Head Impulse, Nystagmus, Test of Skew) STAT STAT ROUTINE STAT CRITICAL bedside exam; must be performed in patient with ACUTE VESTIBULAR SYNDROME (continuous vertigo, nausea, nystagmus, gait instability); performed by trained examiner; more sensitive than early MRI for stroke Peripheral pattern (benign): Positive head impulse (catch-up saccade), horizontal nystagmus with unidirectional fast phase, no skew deviation; Central pattern (concerning for stroke): Negative/normal head impulse, direction-changing or vertical nystagmus, skew deviation Cannot perform if patient not having acute continuous vertigo; requires examiner training CT head without contrast STAT STAT - STAT NOT sensitive for posterior fossa stroke (sensitivity ~20-40%); useful for hemorrhage; may be appropriate for trauma or if MRI not available; does NOT rule out posterior circulation stroke Cerebellar or brainstem hemorrhage; mass lesion; hydrocephalus; NEGATIVE CT does NOT exclude stroke in posterior circulation None for non-contrast MRI brain with DWI URGENT URGENT ROUTINE URGENT Gold standard for posterior circulation stroke; DWI highly sensitive for acute ischemia; HOWEVER: Early MRI (&lt;48h) can miss 12-20% of small posterior fossa strokes \u2014 clinical (HINTS) may be more sensitive; repeat MRI if high suspicion and initial negative Acute infarction (restricted diffusion); brainstem lesion; cerebellar lesion; MS plaque; tumor; vestibular schwannoma MRI-incompatible implants; severe claustrophobia MRA head and neck (or CTA) URGENT URGENT ROUTINE URGENT If central cause suspected; vertebral artery dissection; basilar artery stenosis; vertebrobasilar insufficiency Vertebral artery dissection; stenosis; occlusion; aneurysm MRA: same as MRI; CTA: contrast allergy, renal impairment"},{"location":"plans/vertigo-dizziness-evaluation/#2b-extended","title":"2B. Extended","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Dix-Hallpike maneuver STAT STAT ROUTINE STAT Diagnostic for BPPV (posterior canal, most common); performed on ALL patients with episodic positional vertigo; positive if nystagmus and vertigo provoked with latency and limited duration Positive: Upbeating-torsional nystagmus toward affected ear, 2-20 sec latency, &lt;60 sec duration, fatigable with repetition = posterior canal BPPV Cervical spine disease/instability (modify technique); carotid stenosis (theoretical) Supine roll test (Pagnini-McClure) STAT STAT ROUTINE STAT Diagnostic for horizontal canal BPPV; patient supine, rapidly turn head 90\u00b0 to each side; geotropic (toward ground) or apogeotropic (away from ground) horizontal nystagmus Horizontal nystagmus provoked by head turning; geotropic (canalithiasis) vs. apogeotropic (cupulolithiasis) Same as Dix-Hallpike Audiometry - URGENT ROUTINE - Essential if hearing loss suspected (Meniere's disease, labyrinthitis, vestibular schwannoma); sudden sensorineural hearing loss is emergency Meniere's: low-frequency sensorineural hearing loss; Schwannoma: asymmetric sensorineural hearing loss; Labyrinthitis: hearing loss + vertigo Patient cooperation Echocardiogram (TTE \u00b1 TEE) - URGENT ROUTINE - If cardioembolic source suspected for stroke; PFO evaluation; valvular disease PFO; valve vegetations; thrombus; cardiomyopathy None (TTE); TEE: esophageal pathology Holter / Event monitor - ROUTINE ROUTINE - If paroxysmal arrhythmia suspected as cause of dizziness; palpitations with dizziness Arrhythmia during symptoms None Carotid ultrasound - ROUTINE ROUTINE - Carotid stenosis (though carotid disease rarely causes isolated vertigo without other symptoms) Stenosis; plaque None"},{"location":"plans/vertigo-dizziness-evaluation/#2c-rareadvanced","title":"2C. Rare/Advanced","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications Videonystagmography (VNG) / Electronystagmography (ENG) - - ROUTINE - Quantitative vestibular function testing; caloric testing (ice water or warm/cool air); localizes peripheral lesion; documents vestibular hypofunction Unilateral weakness on calorics (peripheral lesion); central patterns Perforated TM (water calorics) Video head impulse test (vHIT) - - ROUTINE - Quantitative bedside test of vestibulo-ocular reflex; tests individual semicircular canals; more sensitive than bedside HIT Reduced VOR gain; covert/overt saccades; identifies affected canal Specialized equipment Vestibular evoked myogenic potentials (VEMP) - - ROUTINE - Tests saccule (cVEMP) and utricle (oVEMP); superior semicircular canal dehiscence; Meniere's Abnormal in superior canal dehiscence; saccular dysfunction Hearing loss affects testing Rotary chair testing - - EXT - Quantitative VOR assessment; bilateral vestibular hypofunction Bilateral vestibular loss; gain/phase abnormalities Specialized facility High-resolution CT temporal bones - - ROUTINE - Superior semicircular canal dehiscence; cholesteatoma; temporal bone abnormality Dehiscence of superior canal; bony erosion Radiation Electrocochleography (ECoG) - - EXT - Meniere's disease confirmation; endolymphatic hydrops Elevated SP/AP ratio in Meniere's Requires audiologist"},{"location":"plans/vertigo-dizziness-evaluation/#lumbar-puncture","title":"Lumbar Puncture","text":"Study ED HOSP OPD ICU Timing Target Finding Contraindications LP \u2014 Generally NOT indicated - EXT EXT - NOT routinely indicated for peripheral vestibular disorders; consider if meningitis, MS, CNS vasculitis, or leptomeningeal disease suspected Normal in BPPV, vestibular neuritis, Meniere's; abnormal \u2192 specific CNS pathology Posterior fossa mass; elevated ICP"},{"location":"plans/vertigo-dizziness-evaluation/#3-treatment-protocols","title":"3. TREATMENT PROTOCOLS","text":""},{"location":"plans/vertigo-dizziness-evaluation/#3a-acuteemergent-treatment","title":"3A. Acute/Emergent Treatment","text":"Treatment ED HOSP OPD ICU Protocol Evidence/Rationale Symptomatic relief (vestibular suppressants) STAT STAT ROUTINE STAT Acute severe vertigo: Meclizine 25-50 mg PO q6-8h; OR Dimenhydrinate (Dramamine) 50 mg PO/IV q6h; OR Promethazine 25 mg PO/IM/IV q6h; OR Ondansetron 4-8 mg IV/PO q8h (for nausea); IV fluids for dehydration from vomiting; Diazepam 2-5 mg IV/PO for severe acute vertigo (benzodiazepines are potent vestibular suppressants) Short-term use only (24-72h); vestibular suppressants interfere with central compensation if used chronically; avoid in suspected central cause until stroke ruled out IV fluids STAT STAT - STAT If dehydrated from vomiting; NS or LR bolus then maintenance; assess orthostatic hypotension Supportive care; correct volume depletion Antiemetics STAT STAT ROUTINE STAT Ondansetron 4-8 mg IV/PO; metoclopramide 10 mg IV (avoid in elderly \u2014 EPS); prochlorperazine 5-10 mg IV/IM Nausea is often the most debilitating symptom Rule out stroke STAT STAT - STAT If ANY central features on HINTS: STAT MRI with DWI; vascular imaging (MRA or CTA); neurology/stroke consultation; Central features: Normal/negative head impulse test, vertical or direction-changing nystagmus, skew deviation, focal neurologic signs, severe imbalance (cannot walk), hearing loss + vertigo without Meniere's history HINTS is more sensitive than early CT or MRI for posterior circulation stroke; do NOT rely on negative CT to exclude stroke Epley maneuver (canalith repositioning) STAT STAT ROUTINE STAT For BPPV (positive Dix-Hallpike): Immediately perform Epley maneuver; highly effective (80-90% single treatment); may repeat if symptoms persist; send home with instructions for home Epley or Brandt-Daroff exercises Epley is definitive treatment for posterior canal BPPV; medications are NOT indicated for BPPV \u2014 repositioning maneuvers are the treatment"},{"location":"plans/vertigo-dizziness-evaluation/#3b-disease-specific-treatment","title":"3B. Disease-Specific Treatment","text":""},{"location":"plans/vertigo-dizziness-evaluation/#benign-paroxysmal-positional-vertigo-bppv","title":"BENIGN PAROXYSMAL POSITIONAL VERTIGO (BPPV)","text":"Treatment Setting Protocol Evidence/Rationale Epley maneuver (posterior canal) ED/OPD/HOSP Standard canalith repositioning; patient starts seated, Dix-Hallpike position for 30 sec, rotate head 90\u00b0 toward opposite side (30 sec), roll body to face down with head still turned (30 sec), sit up; NNT = 2-3 for resolution First-line treatment for posterior canal BPPV; highly effective; may repeat same day or next visit Semont maneuver (alternative) OPD Alternative to Epley; patient moved rapidly from side to side; less commonly used but effective Alternative if Epley difficult or ineffective BBQ roll (Lempert maneuver) \u2014 horizontal canal ED/OPD For horizontal canal BPPV; patient rotates 360\u00b0 along long axis of body (log roll) toward unaffected side; 90\u00b0 increments with 30 sec pauses Treatment for horizontal canal BPPV; geotropic variant Brandt-Daroff exercises (home) OPD Patient alternates lying on each side x 30 sec, 10-20 repetitions, 3x daily; habituates symptoms; less effective than Epley for posterior canal Adjunctive home therapy; may help with residual symptoms; promotes compensation Avoid vestibular suppressants for BPPV All Do NOT prescribe meclizine for ongoing BPPV treatment; medications delay compensation and do not address the mechanical problem BPPV is a mechanical problem (otoliths); repositioning is definitive treatment Post-treatment instructions OPD Avoid lying flat for 1-2 nights (sleep propped up); avoid rapid head movements for 24-48h; avoid affected side lying for 1 week (controversial but commonly recommended) Reduces immediate recurrence; evidence is mixed"},{"location":"plans/vertigo-dizziness-evaluation/#vestibular-neuritis-labyrinthitis","title":"VESTIBULAR NEURITIS / LABYRINTHITIS","text":"Treatment Setting Protocol Evidence/Rationale Corticosteroids ED/HOSP/OPD Prednisone 1 mg/kg/day (max 60 mg) x 10 days with taper OR methylprednisolone 100 mg x 3 days then taper; start within 72 hours of symptom onset for best benefit Strupp et al. (2004): Steroids improve vestibular function recovery in vestibular neuritis; start early; NNT ~4 for complete recovery Antivirals (controversial) ED/HOSP/OPD Valacyclovir 1000 mg TID x 7 days; evidence is WEAK; some use empirically if early presentation; thought to be HSV reactivation (like Bell's palsy) Cochrane review: No clear benefit; some clinicians still use empirically, especially if labyrinthitis with hearing loss Vestibular suppressants (short-term only) ED/HOSP Meclizine 25 mg q8h OR dimenhydrinate 50 mg q6h OR diazepam 5 mg BID x 1-3 days ONLY; taper off as soon as tolerated Short-term symptom relief; STOP after 72 hours maximum \u2014 prolonged use delays compensation Early vestibular rehabilitation OPD Refer to vestibular physical therapy; gaze stabilization exercises; balance training; habituation exercises; START EARLY (as soon as acute symptoms controlled) Cochrane review: Vestibular rehabilitation is effective for unilateral vestibular hypofunction; early initiation improves outcomes Education OPD Explain natural history (acute symptoms resolve over days to weeks; full compensation may take weeks to months); reassurance; avoid prolonged bed rest Reduce anxiety; promote activity and compensation"},{"location":"plans/vertigo-dizziness-evaluation/#menieres-disease","title":"MENIERE'S DISEASE","text":"Treatment Setting Protocol Evidence/Rationale Dietary modification OPD Low sodium diet (&lt;1500-2000 mg/day); limit caffeine and alcohol; regular meals; avoid MSG First-line lifestyle modification; reduces endolymphatic hydrops; evidence is limited but widely recommended Diuretics OPD Hydrochlorothiazide 25-50 mg daily OR hydrochlorothiazide/triamterene (Dyazide, Maxzide); acetazolamide 250 mg BID as alternative Reduces endolymph volume; widely used despite limited RCT evidence Betahistine OPD 16-24 mg TID (not available in US; available in Europe, Canada); H1 agonist/H3 antagonist; improves cochlear blood flow Commonly used in Europe; evidence mixed; may reduce attack frequency Intratympanic gentamicin OPD (Specialist) Chemical vestibular ablation; destroys vestibular hair cells; reduces vertigo attacks but risks hearing loss; for refractory unilateral disease Effective for vertigo control (&gt;80%); risk of hearing loss (10-30%); used for refractory cases Intratympanic steroids OPD (Specialist) Dexamethasone intratympanic injection; may reduce attacks; less destructive than gentamicin Alternative to gentamicin; preserves hearing; less consistent efficacy Endolymphatic sac surgery OPD (Specialist) Surgical decompression of endolymphatic sac; evidence is debated; some benefit in select patients Controversial; Cochrane review shows limited evidence; considered for refractory cases Vestibular nerve section / Labyrinthectomy OPD (Specialist) Surgical destruction of vestibular nerve (preserves hearing) or entire labyrinth (destroys hearing); for refractory unilateral disease Last resort; highly effective for vertigo; significant surgery"},{"location":"plans/vertigo-dizziness-evaluation/#vestibular-migraine","title":"VESTIBULAR MIGRAINE","text":"Treatment Setting Protocol Evidence/Rationale Migraine lifestyle modifications OPD Regular sleep; hydration; avoid triggers (specific to patient); regular meals; stress management Baseline management for all migraine Acute treatment ED/OPD Triptans (sumatriptan 50-100 mg PO, 6 mg SQ); NSAIDs; antiemetics (ondansetron, metoclopramide); vestibular suppressants for vertigo component Standard migraine abortive therapy; triptans can help vestibular symptoms Preventive therapy OPD Beta-blockers: Propranolol 40-160 mg daily; metoprolol 50-200 mg daily; TCAs: Amitriptyline 10-75 mg HS; nortriptyline; Anticonvulsants: Topiramate 25-100 mg BID; valproate; SNRIs: Venlafaxine 37.5-150 mg daily; Other: CGRP antagonists (emerging); verapamil Same preventive agents as migraine; choose based on comorbidities (e.g., depression \u2192 amitriptyline; hypertension \u2192 beta-blocker) Vestibular rehabilitation OPD Helpful for chronic vestibular symptoms between attacks; balance training; habituation May improve chronic symptoms and disability"},{"location":"plans/vertigo-dizziness-evaluation/#central-causes-posterior-circulation-stroke","title":"CENTRAL CAUSES (Posterior Circulation Stroke)","text":"Treatment Setting Protocol Evidence/Rationale Stroke protocol ED/HOSP/ICU If central cause suspected or identified: acute stroke protocol; consider IV thrombolysis (tPA/tenecteplase) if within window; endovascular therapy for basilar artery occlusion; aspirin if not tPA candidate; admit to stroke unit Posterior circulation stroke is life-threatening; basilar artery occlusion has &gt;80% mortality if untreated Secondary stroke prevention HOSP/OPD Dual antiplatelet therapy (aspirin + clopidogrel x 21 days per CHANCE/POINT); statin; BP control; diabetes management; address vascular risk factors Per acute ischemic stroke guidelines Anticoagulation (if indicated) HOSP/OPD If vertebral artery dissection or cardiac source (atrial fibrillation, PFO with high-risk features) Per stroke etiology"},{"location":"plans/vertigo-dizziness-evaluation/#3c-medications-to-avoid-or-use-with-caution","title":"3C. Medications to AVOID or Use with Caution","text":"Medication Risk Action Vestibular suppressants (prolonged use) Delay central vestibular compensation; prolong recovery Limit to 24-72h in acute vestibular neuritis/labyrinthitis; do NOT use for BPPV Ototoxic medications (aminoglycosides, loop diuretics, salicylates, cisplatin) Vestibular and/or cochlear toxicity Avoid if possible; monitor hearing/vestibular function; limit duration Alcohol Vestibular suppressant; dehydrating; positional alcohol nystagmus Counsel on avoidance during acute episodes Benzodiazepines (chronic use) Dependence; delay compensation; sedation Short-term only (1-3 days) for acute severe vertigo CNS depressants May worsen dizziness; impair compensation Use cautiously; review medication list Medications causing orthostatic hypotension (antihypertensives, alpha-blockers, diuretics) May cause/worsen dizziness Review; adjust doses; check orthostatics"},{"location":"plans/vertigo-dizziness-evaluation/#4-other-recommendations","title":"4. OTHER RECOMMENDATIONS","text":""},{"location":"plans/vertigo-dizziness-evaluation/#4a-essential","title":"4A. Essential","text":"Recommendation ED HOSP OPD ICU Details HINTS exam (if acute vestibular syndrome) STAT STAT - STAT Must be performed by trained examiner in patient with CONTINUOUS vertigo and nystagmus; more sensitive than CT/early MRI for stroke; see HINTS protocol in appendix Dix-Hallpike maneuver STAT STAT ROUTINE STAT Perform on ALL patients with EPISODIC POSITIONAL vertigo; diagnostic for BPPV; if positive \u2192 Epley maneuver Neurology consultation - URGENT ROUTINE URGENT If central cause suspected; diagnostic uncertainty; refractory symptoms; atypical features Stroke consultation STAT STAT - STAT If HINTS suggests central cause; any concern for posterior circulation stroke Otolaryngology / Neurotology referral - ROUTINE ROUTINE - Meniere's disease; recurrent BPPV; hearing loss; intratympanic therapy consideration Vestibular rehabilitation referral - ROUTINE ROUTINE - ALL patients with vestibular hypofunction (vestibular neuritis); chronic dizziness; BPPV with residual imbalance Driving restrictions - ROUTINE ROUTINE - Do not drive during acute vertigo; clear when symptoms resolved; assess on case-by-case basis Fall precautions STAT STAT ROUTINE STAT Acute vertigo = high fall risk; assist with ambulation; home safety assessment"},{"location":"plans/vertigo-dizziness-evaluation/#4b-extended","title":"4B. Extended","text":"Recommendation ED HOSP OPD ICU Details Audiometry - URGENT ROUTINE - If hearing loss (Meniere's, labyrinthitis, vestibular schwannoma); sudden sensorineural hearing loss is emergency (steroids within 48h) Cardiology referral - ROUTINE ROUTINE - If cardiac arrhythmia suspected; palpitations with dizziness; syncope Psychiatry / Psychology - ROUTINE ROUTINE - Anxiety disorders commonly cause dizziness; panic disorder; persistent postural-perceptual dizziness (PPPD); CBT effective Physical therapy (vestibular) - ROUTINE ROUTINE - Vestibular rehabilitation therapy (VRT); gaze stabilization; balance training; habituation; evidence-based and highly effective Sleep medicine - - ROUTINE - If sleep disorder contributing (sleep apnea, circadian disruption) Headache specialist / Neurology - - ROUTINE - If vestibular migraine suspected; frequent migrainous vertigo"},{"location":"plans/vertigo-dizziness-evaluation/#4c-atypicalrefractory","title":"4C. Atypical/Refractory","text":"Recommendation ED HOSP OPD ICU Details Video-EEG monitoring - - EXT - If seizure (vestibular aura) suspected; temporal lobe epilepsy can cause vertigo/dizziness Tilt table testing - - ROUTINE - If neurally-mediated syncope or POTS suspected; recurrent presyncope Neuropsychological testing - - EXT - If cognitive component suspected; anxiety/depression contributing Superior canal dehiscence workup - - ROUTINE - If sound-induced or pressure-induced vertigo (Tullio phenomenon, Hennebert sign); CT temporal bones; VEMP Autoimmune inner ear disease workup - - ROUTINE - If bilateral vestibular loss, bilateral hearing loss, or systemic autoimmune features; steroids trial Perilymphatic fistula evaluation - - EXT - If trauma-associated vertigo/hearing loss; exploratory tympanotomy if suspected <p>\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 SECTION B: SUPPORTING INFORMATION \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550</p>"},{"location":"plans/vertigo-dizziness-evaluation/#5-differential-diagnosis","title":"5. DIFFERENTIAL DIAGNOSIS","text":""},{"location":"plans/vertigo-dizziness-evaluation/#dizziness-classification","title":"Dizziness Classification","text":"Type Description Common Causes Vertigo Illusion of movement (usually spinning); room spinning or self-spinning BPPV, vestibular neuritis, Meniere's disease, vestibular migraine, posterior circulation stroke Presyncope / Lightheadedness Feeling of impending faint; \"graying out\" Orthostatic hypotension, cardiac arrhythmia, vasovagal syncope, dehydration Disequilibrium / Imbalance Unsteadiness; difficulty walking; feeling off-balance without spinning Peripheral neuropathy, cerebellar disorders, bilateral vestibular loss, Parkinson's disease, cervical spondylosis Non-specific dizziness Vague lightheadedness, floating, difficulty concentrating Anxiety/panic disorder, depression, hyperventilation, medication side effects, PPPD"},{"location":"plans/vertigo-dizziness-evaluation/#peripheral-vs-central-vertigo","title":"Peripheral vs. Central Vertigo","text":"Feature Peripheral Central Onset Sudden Sudden or gradual Severity Often severe; patient feels terrible Variable; may be mild Nystagmus Unidirectional, horizontal-torsional; suppressed by visual fixation Direction-changing, vertical, or purely torsional; NOT suppressed by fixation Head impulse test Abnormal (catch-up saccade) Normal (no saccade) Skew deviation Absent May be present Hearing loss May have (labyrinthitis, Meniere's) Rare (unless AICA stroke) Other neuro signs Absent May have (diplopia, dysarthria, ataxia, weakness, numbness) Gait Can usually walk (with difficulty) May be unable to walk (severe ataxia) Imbalance severity Moderate Severe (falling toward one side) Associated symptoms Nausea/vomiting (severe); tinnitus; ear fullness (Meniere's) Headache (dissection, migraine); diplopia; dysphagia; limb weakness/numbness"},{"location":"plans/vertigo-dizziness-evaluation/#hints-exam-interpretation","title":"HINTS Exam Interpretation","text":"Component Peripheral (Safe) Pattern Central (Dangerous) Pattern Head Impulse ABNORMAL (corrective saccade) NORMAL (no saccade) Nystagmus Unidirectional (fast phase always beats same direction) Direction-changing (beats right on right gaze, left on left gaze) OR vertical OR purely torsional Test of Skew Negative (no vertical misalignment) Positive (eyes at different heights; covered eye moves when uncovered) <p>INFARCT Mnemonic: Impulse Normal, Fast-phase Alternating, Refixation on cover Test = Central pattern = Consider stroke</p>"},{"location":"plans/vertigo-dizziness-evaluation/#common-peripheral-vestibular-disorders","title":"Common Peripheral Vestibular Disorders","text":"Disorder Duration Features Treatment BPPV Seconds (&lt;1 min); triggered by position Positional (rolling over, looking up); positive Dix-Hallpike; no hearing loss; latency; fatigable Epley maneuver Vestibular neuritis Hours to days; continuous Acute continuous vertigo; positive head impulse test; no hearing loss; horizontal nystagmus Steroids; short-term suppressants; vestibular rehab Labyrinthitis Hours to days; continuous Same as vestibular neuritis + hearing loss Same as vestibular neuritis + possible antivirals Meniere's disease 20 min to hours; episodic Episodic vertigo + fluctuating hearing loss + tinnitus + aural fullness; low-frequency hearing loss on audiometry Low-sodium diet; diuretics; intratympanic therapy if refractory Vestibular migraine Minutes to hours; episodic Associated with migraine features (headache before/during/after; photophobia; phonophobia); migraine history Migraine preventives; triptans for acute Superior semicircular canal dehiscence Variable Sound-induced or pressure-induced vertigo (Tullio/Hennebert sign); autophony; conductive hyperacusis; dehiscence on CT Avoid triggers; surgical plugging if disabling"},{"location":"plans/vertigo-dizziness-evaluation/#red-flags-for-central-cause-dos-and-donts","title":"Red Flags for Central Cause (\"DOs and DON'Ts\")","text":"Red Flag Concern Diplopia, Dysarthria, Dysphagia Brainstem involvement Other neuro signs (weakness, numbness, ataxia) Brainstem/cerebellar stroke Normal head impulse test in acute vestibular syndrome Central lesion Direction-changing nystagmus Central pattern Vertical or purely torsional nystagmus Central pattern Sudden severe headache or neck pain Vertebral artery dissection Unable to walk (severe truncal ataxia) Cerebellar lesion Skew deviation Brainstem lesion Acute hearing loss without typical Meniere's features AICA stroke (involves labyrinth)"},{"location":"plans/vertigo-dizziness-evaluation/#6-monitoring-parameters","title":"6. MONITORING PARAMETERS","text":""},{"location":"plans/vertigo-dizziness-evaluation/#ed-acute-phase","title":"ED / Acute Phase","text":"Parameter Frequency Target Action if Abnormal Neurologic exam (HINTS, cranial nerves, cerebellar) On presentation; q1-2h if central concern No focal deficits; peripheral pattern Central features \u2192 STAT MRI; neurology/stroke consultation Vital signs q1h initially Stable BP, HR Orthostatic hypotension \u2192 fluids; arrhythmia \u2192 cardiology Hydration status Continuous No dehydration IV fluids if dehydrated from vomiting Nausea/vomiting control q1h Controlled Antiemetics; IV fluids Gait assessment Before discharge Safe ambulation PT evaluation; fall precautions; walker if needed"},{"location":"plans/vertigo-dizziness-evaluation/#outpatient-follow-up","title":"Outpatient Follow-up","text":"Parameter Frequency Target Action if Abnormal Symptom resolution 1-2 weeks; then PRN Improving or resolved Persistent: repeat evaluation; vestibular rehab; subspecialty referral Hearing (if applicable) Audiometry at 2-4 weeks Stable or improved Worsening: urgent ENT referral; MRI for schwannoma Vestibular function Clinical; VNG if needed Compensation occurring Persistent hypofunction: intensify vestibular rehab BPPV recurrence PRN No recurrence Repeat Epley; home exercises; canal switch (rare) Migraine frequency (vestibular migraine) Monthly headache/vertigo diary Reduced frequency Adjust preventive therapy"},{"location":"plans/vertigo-dizziness-evaluation/#7-disposition-criteria","title":"7. DISPOSITION CRITERIA","text":""},{"location":"plans/vertigo-dizziness-evaluation/#admission-criteria","title":"Admission Criteria","text":"Level of Care Criteria ICU / Stroke unit Confirmed or highly suspected posterior circulation stroke; basilar artery occlusion; cerebellar stroke with mass effect/hydrocephalus General floor Intractable vomiting/dehydration requiring IV fluids and monitoring; diagnostic uncertainty requiring observation and further testing; elderly with high fall risk and no safe home environment Observation Prolonged symptoms requiring IV fluids and antiemetics; need for serial neurologic exams; MRI pending"},{"location":"plans/vertigo-dizziness-evaluation/#discharge-criteria","title":"Discharge Criteria","text":"Criterion Details Clear peripheral etiology BPPV (treated with Epley); vestibular neuritis/labyrinthitis (steroids started, symptoms manageable); Meniere's (acute episode resolved) Central cause excluded HINTS peripheral pattern; OR MRI negative (with appropriate follow-up if early MRI); no focal neurologic deficits Symptoms manageable Nausea/vomiting controlled; able to tolerate PO Safe ambulation Can walk safely (with or without assistance); low fall risk; or adequate home support Education provided Diagnosis explained; treatment plan; when to return (new neurologic symptoms, worsening vertigo, hearing loss) Follow-up arranged PCP within 1 week; neurology/ENT if indicated; vestibular PT if indicated"},{"location":"plans/vertigo-dizziness-evaluation/#discharge-prescriptions","title":"Discharge Prescriptions","text":"Medication Indication Instructions Meclizine 25 mg PRN for breakthrough vertigo Take every 6-8h as needed; short-term use only; STOP after 48-72h Ondansetron 4-8 mg ODT PRN for nausea Dissolve on tongue as needed for nausea Prednisone (vestibular neuritis) Reduce vestibular inflammation 60 mg daily x 5 days then taper over 5 days (or per protocol) Migraine preventive (vestibular migraine) Reduce migraine/vertigo attacks Per specific medication; titrate slowly Diuretic (Meniere's) Reduce endolymph Per specific medication; monitor electrolytes"},{"location":"plans/vertigo-dizziness-evaluation/#8-evidence-references","title":"8. EVIDENCE &amp; REFERENCES","text":""},{"location":"plans/vertigo-dizziness-evaluation/#key-guidelines","title":"Key Guidelines","text":"Guideline Source Year Key Recommendation BPPV Practice Guideline AAO-HNS 2017 Dix-Hallpike is gold standard for diagnosis; Epley maneuver is first-line treatment; vestibular suppressants NOT recommended Vestibular Migraine Diagnostic Criteria ICHD-3 / Barany Society 2012/2018 Diagnostic criteria; often underdiagnosed; migraine preventives effective Meniere's Disease Guidelines AAO-HNS 2020 Definite, probable, possible classification; conservative management first; intratympanic therapy for refractory HINTS Exam Kattah et al. / Tarnutzer 2009/2011 HINTS more sensitive than early MRI for stroke in acute vestibular syndrome; requires training"},{"location":"plans/vertigo-dizziness-evaluation/#landmark-studies","title":"Landmark Studies","text":"Study Finding Impact Kattah et al. (2009) HINTS exam (H: head impulse; I: nystagmus; TS: test of skew) was 100% sensitive and 96% specific for stroke in acute vestibular syndrome; superior to MRI in first 24-48h HINTS should be performed in acute vestibular syndrome; more sensitive than early MRI Strupp et al. (2004) Methylprednisolone improved vestibular function recovery in vestibular neuritis vs. placebo Steroids are standard of care for vestibular neuritis Hilton et al. Cochrane (2014) Epley maneuver highly effective for posterior canal BPPV; NNT ~3 Epley is definitive treatment for BPPV Tarnutzer et al. (2011) Individual HINTS components analyzed; normal head impulse most predictive of stroke \"Dangerous\" HIT (normal in acute vertigo) = central cause until proven otherwise Choi et al. (2018) 12-20% of posterior fossa strokes missed on early MRI (&lt;48h) but detected on repeat MRI If high clinical suspicion for stroke and initial MRI negative, repeat MRI or treat as stroke Fife et al. AAO-HNS (2017) Comprehensive BPPV guideline; repositioning maneuvers recommended; vestibular suppressants NOT recommended Standard of care for BPPV"},{"location":"plans/vertigo-dizziness-evaluation/#hints-exam-validity","title":"HINTS Exam Validity","text":"Study Sensitivity for Stroke Specificity Kattah et al. (2009) 100% 96% Newman-Toker et al. (2013) 96% 98% Tarnutzer et al. (2011, meta-analysis) 98% (pooled) 85% (pooled) <p>Important: HINTS should ONLY be performed in the Acute Vestibular Syndrome (continuous vertigo/nystagmus lasting &gt;24h). It is NOT valid for episodic vertigo (BPPV, Meniere's, vestibular migraine).</p>"},{"location":"plans/vertigo-dizziness-evaluation/#appendices","title":"APPENDICES","text":""},{"location":"plans/vertigo-dizziness-evaluation/#appendix-a-hints-exam-protocol","title":"Appendix A: HINTS Exam Protocol","text":"<p>Prerequisites: - Patient has ACUTE VESTIBULAR SYNDROME: Continuous vertigo &gt;24h, nausea/vomiting, nystagmus, gait instability - Patient has SPONTANEOUS nystagmus visible at rest or with fixation removed - Examiner is trained in performing and interpreting HINTS</p> <p>1. HEAD IMPULSE TEST (HIT) - Patient fixates on examiner's nose - Examiner holds patient's head and delivers small, rapid, unpredictable horizontal head turns (10-20\u00b0) - NORMAL (dangerous): Eyes stay on target without corrective saccade - ABNORMAL (reassuring): Corrective saccade back to target after head turn (eyes \"catch up\")</p> <p>2. NYSTAGMUS EVALUATION - Observe spontaneous nystagmus in primary gaze - Then observe in right gaze and left gaze - PERIPHERAL (reassuring): Unidirectional \u2014 fast phase always beats the same direction regardless of gaze - CENTRAL (dangerous): Direction-changing \u2014 fast phase beats right on right gaze, left on left gaze; OR vertical; OR purely torsional</p> <p>3. TEST OF SKEW (Alternate Cover Test) - Patient fixates on target - Cover one eye, then quickly move cover to other eye - Watch for vertical correction movement of uncovered eye - NEGATIVE (reassuring): No vertical movement - POSITIVE (dangerous): Vertical refixation (eye moves up or down when uncovered)</p> <p>Interpretation: - ALL THREE peripheral pattern = Peripheral vestibular lesion (vestibular neuritis) - ANY ONE central pattern = Central lesion likely \u2192 Urgent MRI, stroke workup</p>"},{"location":"plans/vertigo-dizziness-evaluation/#appendix-b-epley-maneuver-protocol-right-posterior-canal-bppv","title":"Appendix B: Epley Maneuver Protocol (Right Posterior Canal BPPV)","text":"<p>For LEFT posterior canal BPPV, mirror all directions</p> <ol> <li>Starting position: Patient sitting on exam table, head turned 45\u00b0 to the RIGHT</li> <li>Position 1: Rapidly lay patient back with head hanging over edge of table, still turned 45\u00b0 right (Dix-Hallpike position); wait 30 seconds (or until nystagmus stops)</li> <li>Position 2: Rotate head 90\u00b0 to the LEFT (now 45\u00b0 left of midline); wait 30 seconds</li> <li>Position 3: Roll patient onto LEFT side, rotating head another 90\u00b0 so nose points toward floor; wait 30 seconds</li> <li>Position 4: Slowly bring patient up to sitting position, keeping head turned left</li> <li>Finally: Turn head back to midline</li> </ol> <p>Post-procedure: - May rest for a few minutes - Sleep with head elevated 45\u00b0 for 1-2 nights (controversial but commonly recommended) - Avoid lying on affected side for 1 week - May need repeat maneuver if symptoms persist</p>"},{"location":"plans/vertigo-dizziness-evaluation/#appendix-c-dix-hallpike-maneuver-protocol","title":"Appendix C: Dix-Hallpike Maneuver Protocol","text":"<p>Purpose: Diagnose posterior canal BPPV</p> <ol> <li>Patient sitting on exam table</li> <li>Turn patient's head 45\u00b0 toward the side being tested (e.g., RIGHT)</li> <li>While supporting head, rapidly lay patient backward with head hanging 20-30\u00b0 below table edge</li> <li>Observe eyes for nystagmus</li> </ol> <p>Positive result for RIGHT posterior canal BPPV: - Upbeating-torsional nystagmus (top of eye beats upward and toward the RIGHT ear) - Latency: 2-20 seconds before nystagmus appears - Duration: &lt;60 seconds (typically 10-40 seconds) - Fatigable: decreases with repetition - Patient experiences vertigo</p> <p>If positive: Proceed immediately to Epley maneuver</p> <p>Caution: Modify technique for cervical spine disease (use side-lying Dix-Hallpike)</p>"},{"location":"plans/vertigo-dizziness-evaluation/#appendix-d-vestibular-rehabilitation-exercises-home-instructions","title":"Appendix D: Vestibular Rehabilitation Exercises (Home Instructions)","text":"<p>GAZE STABILIZATION EXERCISES (for vestibular hypofunction)</p> <p>Exercise 1 (VOR x 1): - Hold a business card at arm's length with a word or letter on it - Keep the card still and move your head side to side while keeping the word in focus - Start slowly, gradually increase speed - 1-2 minutes, 3-5 times daily</p> <p>Exercise 2 (VOR x 2): - Move both the card and your head in opposite directions - Keep the word in focus - More challenging; progress when VOR x 1 is easy</p> <p>BALANCE EXERCISES</p> <p>Standing balance progression: 1. Feet together, eyes open \u2192 eyes closed 2. Semi-tandem stance (heel touching arch), eyes open \u2192 eyes closed 3. Tandem stance (heel to toe), eyes open \u2192 eyes closed 4. Single leg stance, eyes open \u2192 eyes closed</p> <p>Hold each position 30-60 seconds; use wall for safety</p> <p>BRANDT-DAROFF EXERCISES (for residual BPPV symptoms)</p> <ol> <li>Sit on edge of bed</li> <li>Quickly lie down on RIGHT side with head turned 45\u00b0 upward; wait 30 seconds</li> <li>Return to sitting; wait 30 seconds</li> <li>Quickly lie down on LEFT side with head turned 45\u00b0 upward; wait 30 seconds</li> <li>Return to sitting</li> <li>Repeat 10-20 times, 3 times daily</li> </ol>"},{"location":"plans/vertigo-dizziness-evaluation/#appendix-e-when-to-use-each-test","title":"Appendix E: When to Use Each Test","text":"Clinical Scenario Primary Test Acute continuous vertigo + nystagmus (acute vestibular syndrome) HINTS exam Episodic positional vertigo (triggered by rolling over, looking up) Dix-Hallpike maneuver Episodic vertigo + hearing loss/tinnitus/aural fullness Audiometry; consider Meniere's Episodic vertigo + headache/migraine features Headache diary; consider vestibular migraine Presyncope / lightheadedness with standing Orthostatic vital signs; ECG; Holter Chronic non-specific dizziness Full vestibular testing (VNG); consider PPPD; psychology eval <p>This template represents the initial build phase (Skill 1) and requires validation through the checker pipeline (Skills 2-6) before clinical deployment.</p>"},{"location":"references/lp-reference/","title":"Lumbar Puncture Reference Guide","text":""},{"location":"references/lp-reference/#purpose","title":"Purpose","text":"<p>This reference provides comprehensive CSF study recommendations organized by: 1. Core studies - Always order for any diagnostic LP 2. Diagnosis-specific panels - Tailored to clinical suspicion 3. Advanced testing - Newer molecular and genomic options 4. Special procedures - Therapeutic LPs (NPH, IIH)</p>"},{"location":"references/lp-reference/#core-studies-always-order","title":"CORE STUDIES (Always Order)","text":"<p>These studies should be sent with every diagnostic LP to maximize yield from a single procedure.</p> Study Tube Volume Rationale Normal Values Opening pressure - - Elevated in IIH, meningitis, mass effect 10-20 cm H2O Cell count with differential Tube 1 AND Tube 4 1-2 mL each Tube 4 corrects for traumatic tap WBC &lt;5, RBC 0 Protein Tube 2 1 mL Elevated in infection, GBS, tumor, inflammation 15-45 mg/dL Glucose Tube 2 1 mL Low in bacterial/fungal/carcinomatous meningitis 50-80 mg/dL (&gt;60% serum) Gram stain Tube 3 1 mL Rapid bacterial identification No organisms Bacterial culture Tube 3 2-3 mL Gold standard for bacterial meningitis No growth <p>CRITICAL: Always send serum glucose at time of LP to calculate CSF:serum ratio.</p> <p>Tube order matters: Tubes 1-4 should be collected and labeled sequentially. Cell count on both Tube 1 and Tube 4 helps distinguish traumatic tap (RBCs decrease tube 1\u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u21224) from true hemorrhage (RBCs stable).</p>"},{"location":"references/lp-reference/#diagnosis-specific-panels","title":"DIAGNOSIS-SPECIFIC PANELS","text":""},{"location":"references/lp-reference/#meningitisencephalitis-panel","title":"Meningitis/Encephalitis Panel","text":"Study Priority Indication Turnaround Notes BioFire FilmArray ME Panel URGENT Suspected bacterial/viral/fungal meningitis ~1 hour 14 pathogens; 94% sensitivity, 99.8% specificity HSV-1/2 PCR URGENT Encephalitis, temporal lobe involvement 24-48h Most common treatable cause of encephalitis VZV PCR URGENT Zoster history, dermatomal symptoms 24-48h Can cause vasculopathy Enterovirus PCR URGENT Summer/fall, aseptic meningitis 24-48h Most common viral meningitis Cryptococcal antigen URGENT Immunocompromised, HIV 1-2h More sensitive than India ink AFB smear and culture ROUTINE TB risk factors, chronic meningitis Smear 24h; culture 6-8 weeks Low sensitivity; consider TB PCR Fungal culture ROUTINE Immunocompromised, endemic areas 4-6 weeks Hold for extended incubation <p>BioFire FilmArray ME Panel Targets (14 pathogens):</p> Bacteria Viruses Yeast E. coli K1 HSV-1, HSV-2 Cryptococcus neoformans/gattii H. influenzae VZV L. monocytogenes CMV N. meningitidis Enterovirus S. pneumoniae HHV-6 S. agalactiae Human parechovirus"},{"location":"references/lp-reference/#multiple-sclerosis-demyelinating-disease-panel","title":"Multiple Sclerosis / Demyelinating Disease Panel","text":"Study Priority Indication Target Finding Oligoclonal bands (CSF + serum) ROUTINE MS diagnosis, CIS evaluation \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a52 CSF-specific bands IgG index ROUTINE Intrathecal antibody synthesis &gt;0.7 elevated Myelin basic protein ROUTINE Acute demyelination Elevated during relapse CSF cytology ROUTINE Rule out lymphoma/carcinomatous Negative NMO-IgG (AQP4-Ab) ROUTINE Longitudinal myelitis, severe ON Positive \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 NMOSD MOG-IgG ROUTINE Atypical features, ADEM-like Positive \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 MOGAD"},{"location":"references/lp-reference/#autoimmuneinflammatory-encephalitis-panel","title":"Autoimmune/Inflammatory Encephalitis Panel","text":"Study Priority Indication Target Finding Autoimmune encephalitis panel (Mayo/Quest) ROUTINE Limbic encephalitis, new-onset seizures, psychiatric symptoms Anti-NMDAR, LGI1, CASPR2, GABA-B, AMPA Paraneoplastic panel ROUTINE Subacute onset, smoking, weight loss Anti-Hu, Yo, CV2, amphiphysin, etc. Cytology ROUTINE Rule out carcinomatous meningitis Negative <p>Note: Send paired serum for autoimmune panels - some antibodies better detected in serum vs CSF.</p>"},{"location":"references/lp-reference/#subarachnoid-hemorrhage-panel","title":"Subarachnoid Hemorrhage Panel","text":"Study Priority Timing Target Finding Cell count Tube 1 vs Tube 4 STAT Immediate Stable RBCs = true SAH; decreasing = traumatic Xanthochromia (visual + spectrophotometry) STAT \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a56-12h from symptom onset Yellow supernatant = prior hemorrhage Bilirubin (CSF) URGENT \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a512h from symptom onset Elevated = hemoglobin breakdown <p>Timing critical: Xanthochromia may not be present if LP done &lt;6 hours from symptom onset. If initial CT and LP negative but high clinical suspicion, consider repeat LP at 12h or CTA.</p>"},{"location":"references/lp-reference/#guillain-barraa-syndrome-panel","title":"Guillain-Barr\u00c3\u0192\u00c2\u00a9 Syndrome Panel","text":"Study Priority Timing Target Finding Protein URGENT May be normal in first week Elevated (albuminocytologic dissociation) Cell count URGENT Diagnosis WBC &lt;10 (if &gt;50, reconsider diagnosis) Glucose ROUTINE Rule out infection Normal Cytology ROUTINE Rule out carcinomatous Negative GQ1b antibody (serum) ROUTINE Miller Fisher variant Positive <p>Note: CSF protein may be normal in first 1-2 weeks of GBS. Clinical diagnosis may precede CSF abnormalities.</p>"},{"location":"references/lp-reference/#carcinomatouslymphomatous-meningitis-panel","title":"Carcinomatous/Lymphomatous Meningitis Panel","text":"Study Priority Volume Needed Target Finding Cytology URGENT 10-20 mL (large volume) Malignant cells Flow cytometry URGENT 5-10 mL Clonal B or T cells Protein ROUTINE Standard Often markedly elevated Glucose ROUTINE Standard Often low LDH ROUTINE Standard Elevated <p>Volume matters: Sensitivity of cytology increases with CSF volume. If first cytology negative and high suspicion, repeat LP with large volume (10-20 mL) and rapid transport (&lt;1 hour to lab).</p>"},{"location":"references/lp-reference/#normal-pressure-hydrocephalus-therapeutic-lp","title":"Normal Pressure Hydrocephalus (Therapeutic LP)","text":"Parameter Value Notes Volume to remove 30-50 mL Therapeutic trial Opening pressure &lt;24 cm H2O (by definition) Document precisely Pre-LP gait assessment Timed 10m walk, TUG test Perform within 2h before LP Post-LP gait assessment Repeat at 1h, 2h, 24h, 72h &gt;20% improvement = positive Core studies Standard panel Rule out other pathology <p>Positive response: \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a520% improvement in gait speed or Timed Up-and-Go (TUG) suggests shunt-responsive NPH.</p>"},{"location":"references/lp-reference/#idiopathic-intracranial-hypertension-iih-therapeutic-lp","title":"Idiopathic Intracranial Hypertension (IIH) - Therapeutic LP","text":"Parameter Value Notes Opening pressure &gt;25 cm H2O Diagnostic criterion Volume to remove Until OP &lt;20 cm H2O Therapeutic goal CSF composition Must be normal Abnormal CSF excludes IIH Patient position Lateral decubitus, legs extended Standardize measurement"},{"location":"references/lp-reference/#advanced-molecular-testing","title":"ADVANCED MOLECULAR TESTING","text":""},{"location":"references/lp-reference/#metagenomic-next-generation-sequencing-mngs","title":"Metagenomic Next-Generation Sequencing (mNGS)","text":"<p>Delve Detect (CSF mNGS) - UCSF-developed, commercially available</p> Feature Details Pathogens detected &gt;68,000 bacteria, viruses, fungi, parasites Sample volume 1-2 mL CSF Turnaround time 48 hours Sensitivity 63% (higher than all other direct tests combined) Specificity 99.6% Best use case Culture-negative meningitis/encephalitis, immunocompromised, prior antibiotics Limitations Expensive (~$2,000), may not be covered by insurance, interpretation requires expertise <p>When to order mNGS: - Conventional workup negative but high clinical suspicion - Immunocompromised patient with CNS infection - Patient received antibiotics before LP - Suspected rare or unusual pathogen</p> <p>When NOT to order mNGS: - Undifferentiated fever without CNS signs - Routine bacterial meningitis where conventional tests adequate - As first-line test (order alongside, not instead of, conventional studies)</p>"},{"location":"references/lp-reference/#csf-cell-free-dna-for-cns-tumors","title":"CSF Cell-Free DNA for CNS Tumors","text":"<p>MSK-IMPACT, Foundation Medicine, institutional assays</p> Feature Details Indication Suspected CNS malignancy, leptomeningeal metastases Detection rate 53% of CNS tumors with clinically documented disease Best yield Disseminated/leptomeningeal disease, glioblastoma Turnaround time 2-3 weeks Sample volume 3-5 mL CSF <p>CSF cfDNA provides: - Molecular diagnosis when biopsy not feasible - Identification of actionable mutations (EGFR, IDH, BRAF) - Monitoring treatment response - Detection of resistance mutations</p> <p>When to consider: - Suspected CNS tumor in surgically inaccessible location - Monitoring known leptomeningeal disease - Suspected tumor progression on imaging - CSF cytology negative but high suspicion</p>"},{"location":"references/lp-reference/#special-handling-requirements","title":"SPECIAL HANDLING REQUIREMENTS","text":"Study Temperature Time Sensitivity Special Instructions Cell count Room temp &lt;1 hour Process immediately; cells lyse over time Glucose On ice &lt;1 hour Glycolysis continues ex vivo Gram stain/culture Room temp &lt;2 hours Never refrigerate Viral PCR 4\u00c3\u201a\u00c2\u00b0C or frozen &lt;24h if refrigerated Can freeze at -70\u00c3\u201a\u00c2\u00b0C for later testing Cytology Room temp &lt;1 hour Rapid transport critical for cell preservation Oligoclonal bands 4\u00c3\u201a\u00c2\u00b0C Stable several days Send paired serum mNGS Room temp &lt;6h; 4\u00c3\u201a\u00c2\u00b0C &lt;7d Per lab protocol Contact lab for frozen specimen requirements"},{"location":"references/lp-reference/#contraindications-to-lp","title":"CONTRAINDICATIONS TO LP","text":""},{"location":"references/lp-reference/#absolute-contraindications","title":"Absolute Contraindications","text":"Contraindication Rationale Action Infection at LP site Risk of introducing infection Choose alternate site or defer Uncorrected coagulopathy (INR &gt;1.5, platelets &lt;50K) Bleeding risk Correct first; consider hematology consult"},{"location":"references/lp-reference/#relative-contraindications-require-ct-first","title":"Relative Contraindications (Require CT First)","text":"Clinical Feature Concern Management Papilledema Elevated ICP, risk of herniation CT head before LP Focal neurologic deficit Mass lesion CT head before LP Altered consciousness Mass lesion, elevated ICP CT head before LP Immunocompromised with new neuro symptoms Opportunistic mass lesion CT head before LP History of CNS mass or shunt Altered CSF dynamics CT head before LP; neurosurgery consult"},{"location":"references/lp-reference/#quick-reference-volume-requirements","title":"QUICK REFERENCE: VOLUME REQUIREMENTS","text":"Clinical Scenario Minimum Total Volume Tube Distribution Standard diagnostic LP 10-15 mL Tubes 1-4 (3-4 mL each) Suspected infection (with BioFire/mNGS) 15-20 mL Extra for molecular testing Suspected malignancy 20-30 mL Large volume for cytology Therapeutic LP (NPH) 30-50 mL Serial collection until OP normalizes Therapeutic LP (IIH) Until OP &lt;20 cm H2O May require 20-40 mL"},{"location":"references/lp-reference/#change-log","title":"CHANGE LOG","text":"<p>v1.0 (January 13, 2026) - Initial creation - Added BioFire FilmArray ME Panel (14 pathogens, ~1 hour turnaround) - Added Delve Detect mNGS (&gt;68,000 pathogens, 48h turnaround) - Added CSF cfDNA for CNS tumor diagnosis - Added NPH and IIH therapeutic LP protocols - Comprehensive diagnosis-specific panels</p>"},{"location":"references/tracker/","title":"Neuro Clinical Decision Support Templates","text":""},{"location":"references/tracker/#project-tracker","title":"Project Tracker","text":"<p>Created: January 15, 2026 Last Updated: January 26, 2026 Target: 150+ validated templates Current Status: 9 templates approved</p>"},{"location":"references/tracker/#legend","title":"Legend","text":"<ul> <li>\u2705 = Completed and approved</li> <li>\ud83d\udd04 = In progress / Under revision</li> <li>\u2b1c = Not started</li> <li>\ud83c\udfaf = Outpatient Priority (from outpatient product list)</li> </ul>"},{"location":"references/tracker/#outpatient-product-priority-list","title":"OUTPATIENT PRODUCT PRIORITY LIST","text":"<p>These diagnoses are prioritized for the outpatient clinical tool. Items marked with \u2705 already have approved plans.</p>"},{"location":"references/tracker/#seizure-epilepsy","title":"Seizure &amp; Epilepsy","text":"Status Diagnosis ICD-10 Priority Notes \u2705 New Onset Seizure R56.9 \ud83c\udfaf OPD Approved \u2705 Status Epilepticus G41.9 \ud83c\udfaf OPD Approved \u2b1c Breakthrough Seizure (Known Epilepsy) G40.909 \ud83c\udfaf OPD Different from new onset \u2b1c Non-Convulsive Status Epilepticus (NCSE) G41.0 \ud83c\udfaf OPD Often missed diagnosis \u2b1c Alcohol Withdrawal Seizure G40.509 \ud83c\udfaf OPD Common in hospitalist practice \u2b1c Eclampsia/Seizure in Pregnancy O15.9 \ud83c\udfaf OPD Special ASM considerations \u2b1c Drug-Resistant Epilepsy G40.919 \ud83c\udfaf OPD Subspecialty referral focus \u2b1c Epilepsy Evaluation G40.909 \ud83c\udfaf OPD General workup"},{"location":"references/tracker/#stroke-cerebrovascular","title":"Stroke &amp; Cerebrovascular","text":"Status Diagnosis ICD-10 Priority Notes \u2705 Acute Ischemic Stroke I63 \ud83c\udfaf OPD Approved \u2b1c Intracerebral Hemorrhage (ICH) I61.9 \ud83c\udfaf OPD BP management, reversal agents \u2b1c Subarachnoid Hemorrhage (SAH) I60.9 \ud83c\udfaf OPD Aneurysmal vs traumatic \u2b1c Transient Ischemic Attack (TIA) G45.9 \ud83c\udfaf OPD Risk stratification, workup \u2b1c Cerebral Venous Thrombosis (CVT) I67.6 \ud83c\udfaf OPD Often missed, anticoagulation \u2b1c Carotid/Vertebral Dissection I77.71 \ud83c\udfaf OPD Young stroke workup \u2b1c Posterior Reversible Encephalopathy (PRES) F93.49 \ud83c\udfaf OPD Hypertensive emergency \u2b1c Reversible Cerebral Vasoconstriction (RCVS) I67.841 \ud83c\udfaf OPD Thunderclap headache DDx \u2b1c CNS Vasculitis I67.7 \ud83c\udfaf OPD Rare, comprehensive workup \u2b1c Moyamoya Disease I67.5 \ud83c\udfaf OPD Rare \u2b1c Post-Stroke Management I69.30 \ud83c\udfaf OPD Secondary prevention \u2b1c Carotid Stenosis SI65.29 \ud83c\udfaf OPD Surgical evaluation"},{"location":"references/tracker/#headache","title":"Headache","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Headache - Cluster Evaluation R51.9 \ud83c\udfaf OPD Broad DDx approach \u2b1c Migraine without Aura G43.909 \ud83c\udfaf OPD Acute and preventive \u2b1c Migraine with Aura G43.109 \ud83c\udfaf OPD Acute and preventive \u2b1c Chronic Migraine G43.709 \ud83c\udfaf OPD Preventive therapy, CGRP agents \u2b1c Status Migrainosus G43.901 \ud83c\udfaf OPD Acute management \u2b1c Cluster Headache G44.009 \ud83c\udfaf OPD Acute and preventive \u2b1c Tension-Type Headache G44.209 \ud83c\udfaf OPD Usually PCP managed \u2b1c Medication Overuse Headache G44.41 \ud83c\udfaf OPD Very common \u2b1c Idiopathic Intracranial Hypertension (IIH) G93.2 \ud83c\udfaf OPD Diagnostic LP, management \u2b1c Low Pressure Headache / SIH G96.00 \ud83c\udfaf OPD Post-LP, spontaneous \u2b1c Trigeminal Neuralgia G50.0 \ud83c\udfaf OPD Facial pain DDx \u2b1c New Daily Persistent Headache G44.52 \ud83c\udfaf OPD Refractory cases \u2b1c Thunderclap Headache Evaluation R51.9 \ud83c\udfaf OPD SAH, RCVS, other emergencies \u2b1c Giant Cell Arteritis (GCA) M31.6 \ud83c\udfaf OPD Vision-threatening"},{"location":"references/tracker/#demyelinating-diseases","title":"Demyelinating Diseases","text":"Status Diagnosis ICD-10 Priority Notes \u2705 MS - Exacerbation G35 \ud83c\udfaf OPD Approved \u2705 MS - New Diagnosis G35 \ud83c\udfaf OPD Approved \u2b1c MS - Chronic Management G35 \ud83c\udfaf OPD DMT monitoring, symptoms \u2b1c Neuromyelitis Optica (NMOSD) G36.0 \ud83c\udfaf OPD AQP4+, different from MS \u2b1c MOG Antibody Disease (MOGAD) G36.9 \ud83c\udfaf OPD Distinct entity \u2b1c Transverse Myelitis G37.3 \ud83c\udfaf OPD Acute myelopathy DDx \u2b1c Optic Neuritis H46.9 \ud83c\udfaf OPD Isolated vs MS-related \u2b1c Acute Disseminated Encephalomyelitis (ADEM) G04.81 \ud83c\udfaf OPD More common in pediatrics \u2b1c Progressive Multifocal Leukoencephalopathy (PML) A81.2 \ud83c\udfaf OPD JCV, immunocompromised \u2b1c Diffuse White Matter Disease R53.1 \ud83c\udfaf OPD Differential diagnosis"},{"location":"references/tracker/#neuromuscular-disorders","title":"Neuromuscular Disorders","text":"Status Diagnosis ICD-10 Priority Notes \u2705 Guillain-Barr\u00e9 Syndrome (GBS) G61.0 \ud83c\udfaf OPD Approved \u2705 Myasthenia Gravis - Crisis G70.01 \ud83c\udfaf OPD Approved \u2b1c Myasthenia Gravis - Chronic Management G70.00 \ud83c\udfaf OPD Maintenance, monitoring \u2705 Peripheral Neuropathy (General) G62.9 \ud83c\udfaf OPD Approved \u2b1c CIDP (Chronic Inflammatory Demyelinating) G61.81 \ud83c\udfaf OPD Chronic GBS variant \u2b1c Amyotrophic Lateral Sclerosis (ALS) G12.21 \ud83c\udfaf OPD Diagnosis, symptom management \u2b1c Lambert-Eaton Myasthenic Syndrome (LEMS) G73.1 \ud83c\udfaf OPD Paraneoplastic \u2b1c Inflammatory Myopathy (Dermatomyositis/PM) G72.41 \ud83c\udfaf OPD Weakness + rash \u2b1c Inclusion Body Myositis (IBM) G72.41 \ud83c\udfaf OPD Refractory myopathy \u2b1c Muscular Dystrophy (Adult) G71.0 \ud83c\udfaf OPD Rare adult presentations \u2b1c Myotonic Dystrophy G71.11 \ud83c\udfaf OPD Multisystem \u2b1c Critical Illness Myopathy/Neuropathy G72.81 \ud83c\udfaf OPD ICU weakness \u2b1c Botulism A05.1 \ud83c\udfaf OPD Rare but critical \u2b1c Diabetic Neuropathy E11.42 \ud83c\udfaf OPD Most common cause \u2b1c Small Fiber Neuropathy G62.9 \ud83c\udfaf OPD Often missed \u2b1c B12 Deficiency Neuropathy E53.8 \ud83c\udfaf OPD Reversible \u2b1c Chemotherapy-Induced Neuropathy G62.0 \ud83c\udfaf OPD Growing population \u2b1c Carpal Tunnel Syndrome G56.00 \ud83c\udfaf OPD Usually PCP/hand surgery \u2b1c Ulnar Neuropathy G56.20 \ud83c\udfaf OPD Entrapment \u2b1c Peroneal Neuropathy F57.30 \ud83c\udfaf OPD Foot drop \u2b1c Multifocal Motor Neuropathy (MMN) G61.82 \ud83c\udfaf OPD GBS mimic \u2b1c Hereditary Neuropathy (CMT) G60.0 \ud83c\udfaf OPD Genetic \u2b1c Vasculitic Neuropathy G63 \ud83c\udfaf OPD Mononeuritis multiplex \u2b1c Autonomic Neuropathy G90.09 \ud83c\udfaf OPD Orthostatic, GI, cardiac \u2b1c Radiculopathy M54.10 \ud83c\udfaf OPD Common outpatient \u2b1c Plexopathy G54.0 \ud83c\udfaf OPD Brachial/lumbosacral"},{"location":"references/tracker/#movement-disorders","title":"Movement Disorders","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Parkinson's Disease - New Diagnosis G20 \ud83c\udfaf OPD Workup, initiation \u2b1c Parkinson's Disease - Management G20 \ud83c\udfaf OPD Medication adjustments \u2b1c Parkinson's Disease - Motor Fluctuations G20 \ud83c\udfaf OPD On/off, dyskinesia \u2b1c Parkinson's Disease - Psychosis F06.0 \ud83c\udfaf OPD Common, management \u2b1c Essential Tremor G25.0 \ud83c\udfaf OPD DDx with Parkinson's \u2b1c Dystonia G24.9 \ud83c\udfaf OPD Classification, treatment \u2b1c Huntington's Disease G10 \ud83c\udfaf OPD Genetic, symptom management \u2b1c Tardive Dyskinesia G24.01 \ud83c\udfaf OPD Antipsychotic-induced \u2b1c Drug-Induced Parkinsonism G21.11 \ud83c\udfaf OPD Reversible \u2b1c Wilson's Disease E83.01 \ud83c\udfaf OPD Young onset movement disorder \u2b1c Progressive Supranuclear Palsy (PSP) G23.1 \ud83c\udfaf OPD Atypical parkinsonism \u2b1c Multiple System Atrophy (MSA) G90.3 \ud83c\udfaf OPD Atypical parkinsonism \u2b1c Corticobasal Degeneration (CBD) G31.85 \ud83c\udfaf OPD Rare \u2b1c Restless Legs Syndrome G25.81 \ud83c\udfaf OPD Common, often OPD \u2b1c Tics / Tourette Syndrome F95.2 \ud83c\udfaf OPD Tic disorders \u2b1c Ataxia Evaluation R27.0 \ud83c\udfaf OPD DDx approach \u2b1c Chorea Evaluation G25.5 \ud83c\udfaf OPD DDx approach \u2b1c Gait Disorder Evaluation R26.9 \ud83c\udfaf OPD Multifactorial"},{"location":"references/tracker/#dementia-cognitive-disorders","title":"Dementia &amp; Cognitive Disorders","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Dementia Evaluation (General) R41.81 \ud83c\udfaf OPD Broad workup approach \u2b1c Alzheimer's Disease G30.9 \ud83c\udfaf OPD Diagnosis, management \u2b1c Vascular Dementia F01.50 \ud83c\udfaf OPD Risk factor modification \u2b1c Lewy Body Dementia G31.83 \ud83c\udfaf OPD Special medication cautions \u2b1c Frontotemporal Dementia G31.09 \ud83c\udfaf OPD Behavioral variant \u2b1c Rapidly Progressive Dementia F03.90 \ud83c\udfaf OPD Urgent workup - CJD, autoimmune \u2b1c Normal Pressure Hydrocephalus (NPH) G91.2 \ud83c\udfaf OPD Treatable dementia \u2b1c Creutzfeldt-Jakob Disease (CJD) A81.00 \ud83c\udfaf OPD Rare but important DDx \u2b1c Autoimmune Dementia/Encephalopathy G04.81 \ud83c\udfaf OPD Treatable \u2b1c Mild Cognitive Impairment (MCI) G31.84 \ud83c\udfaf OPD Early intervention \u2b1c Delirium vs Dementia R41.0 \ud83c\udfaf OPD Acute confusion workup \u2b1c Wernicke-Korsakoff Syndrome F10.96 \ud83c\udfaf OPD Thiamine deficiency"},{"location":"references/tracker/#cns-infections","title":"CNS Infections","text":"Status Diagnosis ICD-10 Priority Notes \u2705 Bacterial Meningitis I00.9 \ud83c\udfaf OPD Approved \u2b1c Viral Meningitis A87.9 \ud83c\udfaf OPD Supportive care focus \u2705 HSV Encephalitis B00.4 \ud83c\udfaf OPD Approved \u2705 Autoimmune Encephalitis G04.81 \ud83c\udfaf OPD Approved \u2b1c Fungal Meningitis G02 \ud83c\udfaf OPD Immunocompromised \u2b1c TB Meningitis A17.0 \ud83c\udfaf OPD Chronic meningitis \u2b1c Neurocysticercosis B69.0 \ud83c\udfaf OPD Endemic areas \u2b1c Brain Abscess G06.0 \ud83c\udfaf OPD Neurosurgery consult \u2b1c HIV-Associated Neurocognitive Disorder B20 \ud83c\udfaf OPD AIDS dementia complex \u2b1c Neurosyphilis A52.2 \ud83c\udfaf OPD Great imitator \u2b1c Lyme Neuroborreliosis A69.22 \ud83c\udfaf OPD Endemic areas"},{"location":"references/tracker/#neuro-oncology","title":"Neuro-Oncology","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Brain Metastases C79.31 \ud83c\udfaf OPD Common, management \u2b1c Glioblastoma (GBM) C71.9 \ud83c\udfaf OPD Primary brain tumor \u2b1c Leptomeningeal Carcinomatosis C79.32 \ud83c\udfaf OPD CSF cytology \u2b1c Paraneoplastic Neurological Syndrome G13.0 \ud83c\udfaf OPD Antibody panels \u2b1c Spinal Cord Compression (Malignant) G95.20 \ud83c\udfaf OPD Oncologic emergency \u2b1c Meningioma D32.9 \ud83c\udfaf OPD Often incidental \u2b1c Primary CNS Lymphoma C85.19 \ud83c\udfaf OPD Immunocompromised \u2b1c Radiation-Induced Neurologic Injury G93.89 \ud83c\udfaf OPD Delayed complications \u2b1c Myelopathy (General) G99.2 \ud83c\udfaf OPD DDx approach"},{"location":"references/tracker/#spinal-cord-disorders","title":"Spinal Cord Disorders","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Cervical Myelopathy (Degenerative) M47.22 \ud83c\udfaf OPD Common, surgical referral \u2b1c Lumbar Stenosis M48.06 \ud83c\udfaf OPD Common outpatient \u2b1c Syringomyelia G95.0 \ud83c\udfaf OPD Rare \u2b1c Subacute Combined Degeneration E53.8 \ud83c\udfaf OPD B12 deficiency \u2b1c Cauda Equina Syndrome G83.4 \ud83c\udfaf OPD Surgical emergency"},{"location":"references/tracker/#autoimmune-inflammatory","title":"Autoimmune &amp; Inflammatory","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Neurosarcoidosis D86.82 \ud83c\udfaf OPD Multisystem \u2b1c Susac Syndrome H35.89 \ud83c\udfaf OPD Rare \u2b1c Neuro-Behcet's M35.2 \ud83c\udfaf OPD Rare \u2b1c Stiff Person Syndrome G25.82 \ud83c\udfaf OPD Rare \u2b1c Hashimoto's Encephalopathy (SREAT) E06.3 \ud83c\udfaf OPD Diagnosis of exclusion"},{"location":"references/tracker/#functional-psychiatric","title":"Functional &amp; Psychiatric","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Functional Neurological Disorder (FND) F44.9 \ud83c\udfaf OPD Positive diagnosis \u2b1c Psychogenic Non-Epileptic Spells (PNES) F44.4 \ud83c\udfaf OPD Video EEG confirmation \u2b1c Functional Movement Disorder F44.4 \ud83c\udfaf OPD Clinical signs \u2b1c Functional Cognitive Disorder F44.4 \ud83c\udfaf OPD DDx with dementia"},{"location":"references/tracker/#neurocritical-care","title":"Neurocritical Care","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Elevated ICP Management G93.2 \ud83c\udfaf OPD General approach \u2b1c Brain Death Evaluation G93.82 \ud83c\udfaf OPD Legal/ethical protocol \u2b1c Anoxic Brain Injury / Prognostication G93.1 \ud83c\udfaf OPD Post-cardiac arrest \u2b1c Neuromuscular Respiratory Failure J96.00 \ud83c\udfaf OPD GBS, MG, ALS \u2b1c Hypertensive Encephalopathy I67.4 \ud83c\udfaf OPD BP management"},{"location":"references/tracker/#other-miscellaneous","title":"Other / Miscellaneous","text":"Status Diagnosis ICD-10 Priority Notes \u2b1c Syncope Evaluation (Neuro Perspective) R55 \ud83c\udfaf OPD DDx with seizure \u2b1c Vertigo / Dizziness Evaluation R42 \ud83c\udfaf OPD Central vs peripheral \u2b1c Bell's Palsy G51.0 \ud83c\udfaf OPD Facial weakness DDx \u2b1c Horner Syndrome G90.2 \ud83c\udfaf OPD Localization \u2b1c Nystagmus Evaluation H55.00 \ud83c\udfaf OPD Central vs peripheral \u2b1c Post-Concussion Syndrome F07.81 \ud83c\udfaf OPD Common \u2b1c Traumatic Brain Injury (TBI) S06.9 \ud83c\udfaf OPD ED evaluation \u2b1c Chronic Traumatic Encephalopathy (CTE) G31.89 \ud83c\udfaf OPD Emerging area \u2b1c Sleep Apnea (Neurologic Aspects) G47.33 \ud83c\udfaf OPD Usually sleep medicine \u2b1c Narcolepsy G47.419 \ud83c\udfaf OPD Sleep medicine \u2b1c Insomnia (Neurologic) G47.00 \ud83c\udfaf OPD Sleep medicine \u2b1c REM Sleep Behavior Disorder G47.52 \ud83c\udfaf OPD Often precedes PD \u2b1c Parasomnia G47.50 \ud83c\udfaf OPD Sleep medicine \u2b1c Tinnitus Evaluation H93.19 \ud83c\udfaf OPD Neuro perspective"},{"location":"references/tracker/#statistics","title":"STATISTICS","text":"Category Approved To Build Total Seizure/Epilepsy 2 6 8 Stroke/Cerebrovascular 1 11 12 Headache 0 14 14 Demyelinating 2 8 10 Neuromuscular 3 23 26 Movement Disorders 0 18 18 Dementia/Cognitive 0 12 12 CNS Infections 3 8 11 Neuro-oncology 0 9 9 Spinal Cord 0 5 5 Autoimmune/Inflammatory 0 5 5 Functional/Psychiatric 0 4 4 Neurocritical Care 0 5 5 Other/Miscellaneous 0 14 14 TOTAL 9 144 153"},{"location":"references/tracker/#approved-plans","title":"APPROVED PLANS","text":"# Diagnosis Version Approved Date 1 New Onset Seizure v1.0 Jan 20, 2026 2 Status Epilepticus v1.2 Jan 20, 2026 3 MS - New Diagnosis v1.0 Jan 20, 2026 4 Peripheral Neuropathy v1.0 Jan 20, 2026 5 Acute Ischemic Stroke v1.2 Jan 21, 2026 6 Guillain-Barr\u00e9 Syndrome v1.1 Jan 26, 2026 7 Myasthenia Gravis - Crisis v1.1 Jan 26, 2026 8 Bacterial Meningitis v1.1 Jan 26, 2026 9 HSV Encephalitis v1.0 Jan 26, 2026 10 Autoimmune Encephalitis v1.0 Jan 26, 2026"},{"location":"references/tracker/#next-priorities-recommended-build-order","title":"NEXT PRIORITIES (Recommended Build Order)","text":"<p>Based on outpatient product needs and clinical impact:</p>"},{"location":"references/tracker/#tier-1-high-volume-outpatient-build-next","title":"Tier 1: High-Volume Outpatient (Build Next)","text":"<ol> <li>Migraine (Chronic Management) - very common</li> <li>TIA (Transient Ischemic Attack) - common, time-sensitive</li> <li>Parkinson's Disease - New Diagnosis - common</li> <li>Dementia Evaluation (General) - common</li> <li>Essential Tremor - common DDx</li> <li>Diabetic Neuropathy - most common neuropathy</li> </ol>"},{"location":"references/tracker/#tier-2-common-outpatient","title":"Tier 2: Common Outpatient","text":"<ol> <li>Cluster Headache</li> <li>Medication Overuse Headache</li> <li>MS - Chronic Management</li> <li>CIDP</li> <li>Restless Legs Syndrome</li> <li>MCI (Mild Cognitive Impairment)</li> </ol>"},{"location":"references/tracker/#tier-3-emergencyinpatient-focus","title":"Tier 3: Emergency/Inpatient Focus","text":"<ol> <li>Intracerebral Hemorrhage (ICH)</li> <li>Subarachnoid Hemorrhage (SAH)</li> <li>NCSE (Non-Convulsive Status)</li> <li>Rapidly Progressive Dementia</li> <li>Cauda Equina Syndrome</li> </ol>"},{"location":"references/tracker/#notes","title":"NOTES","text":"<ul> <li>Templates follow neuro-builder SKILL v2.2 format</li> <li>All templates require neuro-checker validation (target 90%+)</li> <li>Physician review required before clinical deployment</li> <li>Outpatient product prioritizes conditions with OPD setting coverage</li> <li>ICD-10 codes from outpatient priority list included for billing integration</li> </ul>"},{"location":"references/tracker/#change-log","title":"CHANGE LOG","text":"<p>January 26, 2026 - Combined outpatient product priority list with existing tracker - Added ICD-10 codes for all diagnoses - Updated approved plans count: 9 total - New diagnoses added from outpatient list: 19 - Total diagnoses in tracker: 153</p> <p>January 21, 2026 - Acute Ischemic Stroke approved</p> <p>January 20, 2026 - 4 plans approved: New Onset Seizure, Status Epilepticus, MS New Diagnosis, Peripheral Neuropathy</p> <p>January 15, 2026 - Initial tracker created</p>"},{"location":"skills/neuro-builder-skill/","title":"Builder Skill","text":"<p>name: neuro-builder description: Generates structured, evidence-based clinical decision support recommendations for neurological diagnoses. Use when creating clinical workup plans, treatment protocols, or diagnostic recommendations for neurologists. Triggers on requests for clinical recommendations, diagnostic workups, treatment plans for neurological conditions, or references to teleneurohospitalist content.</p>"},{"location":"skills/neuro-builder-skill/#neuro-clinical-recommendation-builder","title":"Neuro Clinical Recommendation Builder","text":"<p>Generate comprehensive, structured clinical decision support content for neurological diagnoses across care settings (ED, Hospital, ICU, Outpatient, Rehab).</p>"},{"location":"skills/neuro-builder-skill/#diagnosis-scoping-rules","title":"Diagnosis Scoping Rules","text":"<p>Identify the clinical scenario from the diagnosis modifier:</p> Modifier Interpretation \"[Condition] - Exacerbation\" or \"Acute [Condition]\" Focus on acute management; maintenance therapy mentioned but not detailed \"[Condition] - New Diagnosis\" Include full workup, differential, AND long-term treatment options \"[Condition] - Chronic/Maintenance\" Focus on long-term management, monitoring, lifestyle \"[Condition] - Refractory\" Include second-line and rare therapies prominently <p>If modifier is ambiguous, generate for the most common clinical scenario AND note what would differ for other scenarios.</p>"},{"location":"skills/neuro-builder-skill/#critical-comprehensive-setting-coverage","title":"CRITICAL: Comprehensive Setting Coverage","text":"<p>Every recommendation must be evaluated for ALL applicable settings. Patients with the same diagnosis may present to ED, hospital, outpatient clinic, or ICU. The plan must be complete and actionable regardless of where the patient is seen.</p> <p>For each test, study, or treatment, ask: 1. Is this applicable in the ED? What priority? 2. Is this applicable on the hospital floor? What priority? 3. Is this applicable in outpatient clinic? What priority? 4. Is this applicable in ICU? What priority?</p> <p>Use \"-\" only when truly not applicable (e.g., prolactin level only useful if drawn within 20 minutes of seizure \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 \"-\" for OPD). Do NOT use \"-\" for \"less common\" or \"usually done elsewhere.\"</p> <p>Common gaps to avoid: - Labs missing OPD tags (outpatient neurologists need to order workups too) - Imaging missing OPD tags (MRI often ordered from clinic) - Treatments missing HOSP tags (maintenance meds continue inpatient) - Referrals missing ED tags (some consults start in ED)</p>"},{"location":"skills/neuro-builder-skill/#output-structure","title":"Output Structure","text":"<p>Generate output using this exact structure. Sections 1-4 are primary action items; Sections 5-8 are reference/supporting information (may be collapsed by default in clinical tools).</p> <p><pre><code>DIAGNOSIS: [Name]\nICD-10: [Code(s)]\nSCOPE: [Brief statement of what this template covers and excludes]\n\n**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting\n\n\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\nSECTION A: ACTION ITEMS\n\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\n\n## 1. LABORATORY WORKUP\n\n### 1A. Essential/Core Labs\n\n| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |\n|------|:--:|:----:|:---:|:---:|-----------|----------------|\n\n### 1B. Extended Workup (Second-line)\n\n| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |\n|------|:--:|:----:|:---:|:---:|-----------|----------------|\n\n### 1C. Rare/Specialized (Refractory or Atypical)\n\n| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |\n|------|:--:|:----:|:---:|:---:|-----------|----------------|\n\n## 2. DIAGNOSTIC IMAGING &amp; STUDIES\n\n### 2A. Essential/First-line\n\n| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |\n|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|\n\n### 2B. Extended\n\n| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |\n|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|\n\n### 2C. Rare/Specialized\n\n| Study | ED | HOSP | OPD | ICU | Timing | Target Finding | Contraindications |\n|-------|:--:|:----:|:---:|:---:|--------|----------------|-------------------|\n\n## 3. TREATMENT\n\n**CRITICAL: Each medication must be on its own row with complete prescribing information. Do NOT group drugs together.**\n\n### 3A. Acute/Emergent\n\n| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |\n|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|\n\n### 3B. Symptomatic Treatments\n\n| Treatment | Indication | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |\n|-----------|------------|:--:|:----:|:---:|:---:|--------|-------------------|------------|\n\n### 3C. Second-line/Refractory\n\n| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |\n|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|\n\n### 3D. Disease-Modifying or Chronic Therapies (if applicable)\n\n| Treatment | Route | ED | HOSP | OPD | ICU | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring |\n|-----------|-------|:--:|:----:|:---:|:---:|--------|---------------------------|-------------------|------------|\n\n## Treatment Section Guidance\n\n### CRITICAL: Individual Drug Rows\n\n**Every medication must be listed on its own row.** Do NOT group drugs together (e.g., \"SSRIs\" or \"beta-blockers\"). Each drug needs complete prescribing information.\n\n\u00c3\u00a2\u00c2\u009d\u00c5\u2019 **Wrong:**\n</code></pre> | SSRIs | Depression | - | ROUTINE | ROUTINE | - | Per drug | Various | Monitor mood | <pre><code>\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u00a6 **Correct:**\n</code></pre> | Sertraline | Depression | - | ROUTINE | ROUTINE | - | Start 50 mg daily; increase by 25-50 mg q1-2wk; max 200 mg | Concurrent MAOIs | Suicidality monitoring | | Escitalopram | Depression | - | ROUTINE | ROUTINE | - | Start 10 mg daily; max 20 mg | Concurrent MAOIs; QT prolongation | QTc if risk factors | <pre><code>### Dosing Requirements\n\nEvery drug row must include:\n\n| Element | Example |\n|---------|---------|\n| Starting dose | \"Start 5 mg TID\" or \"Start 300 mg qHS\" |\n| Titration schedule | \"increase by 5 mg/dose every 3 days\" or \"increase by 300 mg every 1-3 days\" |\n| Target dose (if applicable) | \"target 900-1800 mg TID\" |\n| Maximum dose | \"max 80 mg/day\" or \"max 3600 mg/day\" |\n| Frequency | \"BID\", \"TID\", \"once daily\", \"every other day\" |\n| Special instructions | \"take with food\", \"avoid afternoon dosing\", \"exactly 12 hours apart\" |\n\n### Symptomatic Treatment Categories\n\nFor chronic neurological conditions, consider including treatments for these symptom categories where applicable:\n\n| Category | Common in... | Example Drugs |\n|----------|--------------|---------------|\n| Spasticity | MS, stroke, SCI, TBI | Baclofen, tizanidine, dantrolene, botulinum toxin |\n| Neuropathic pain | Neuropathy, MS, post-stroke | Gabapentin, pregabalin, duloxetine, amitriptyline, carbamazepine |\n| Spasms/cramps | ALS, neuropathy | Baclofen, quinine (limited), mexiletine |\n| Bladder urgency | MS, Parkinson, stroke | Oxybutynin, solifenacin, mirabegron |\n| Urinary retention | MS, autonomic neuropathy | Tamsulosin, bethanechol |\n| Constipation | Parkinson, neuropathy, opioid use | PEG 3350, senna, bisacodyl, lubiprostone |\n| Fatigue | MS, myasthenia, post-stroke | Amantadine, modafinil, methylphenidate |\n| Depression | Any chronic neuro condition | Sertraline, escitalopram, bupropion, venlafaxine |\n| Anxiety | Any chronic neuro condition | SSRIs, buspirone, hydroxyzine |\n| Insomnia | Parkinson, dementia, chronic pain | Trazodone, melatonin, mirtazapine |\n| Tremor | MS, essential tremor, Parkinson | Propranolol, primidone, clonazepam (not for Parkinson resting tremor) |\n| Sialorrhea | ALS, Parkinson | Glycopyrrolate, atropine drops, botulinum toxin |\n| Pseudobulbar affect | ALS, MS, stroke, TBI | Dextromethorphan-quinidine |\n| Cognitive impairment | Dementia, MS | Donepezil, memantine, rivastigmine |\n| Orthostatic hypotension | Autonomic neuropathy, Parkinson | Midodrine, fludrocortisone, droxidopa |\n\n### Disease-Modifying Therapy (DMT) Section\n\nUse Section 3D with expanded columns when the diagnosis has chronic disease-modifying treatments:\n\n**Applies to:** MS, myasthenia gravis, CIDP, neuromyelitis optica, autoimmune encephalitis, etc.\n\n**Additional columns for DMTs:**\n- **Route:** PO, SC, IM, IV, other\n- **Pre-Treatment Requirements:** Labs, imaging, vaccinations, genetic testing, specialist clearances\n\n**Each DMT row must include:**\n- Specific brand and generic name\n- Exact dosing with titration schedule (if any)\n- Complete pre-treatment workup\n- All contraindications\n- Monitoring schedule with frequencies (e.g., \"JCV antibody q6mo\", \"CBC monthly \u00c3\u0192\u00e2\u20ac\u201d 48 months\")\n- REMS program requirements where applicable\n\n### Setting-Specific Treatment Notes\n\n| Setting | Treatment Considerations |\n|---------|-------------------------|\n| **ED** | Acute treatments only; avoid initiating chronic therapies; can continue home meds |\n| **HOSP** | Continue home meds; can initiate symptomatic treatments; DMTs typically NOT started inpatient |\n| **OPD** | Primary setting for DMT initiation; chronic disease management; titration of symptomatic meds |\n| **ICU** | Critical care interventions; may need to hold certain home meds; avoid drugs that worsen hemodynamics |\n\n## 4. OTHER RECOMMENDATIONS\n\n### 4A. Referrals &amp; Consults\n\n| Recommendation | ED | HOSP | OPD | ICU | Indication |\n|----------------|:--:|:----:|:---:|:---:|------------|\n\n### 4B. Patient Instructions\n\n| Recommendation | ED | HOSP | OPD |\n|----------------|:--:|:----:|:---:|\n\n### 4C. Lifestyle &amp; Prevention\n\n| Recommendation | ED | HOSP | OPD |\n|----------------|:--:|:----:|:---:|\n\n\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\nSECTION B: REFERENCE (Expand as Needed)\n\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\u00c3\u00a2\u00e2\u20ac\u00a2\u00c2\u0090\n\n## 5. DIFFERENTIAL DIAGNOSIS\n\n| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |\n|-----------------------|----------------------------|------------------------|\n\n## 6. MONITORING PARAMETERS\n\n*Venue column indicates where monitoring is typically ordered/initiated. Most monitoring continues in outpatient setting.*\n\n| Parameter | ED | HOSP | OPD | ICU | Frequency | Target/Threshold | Action if Abnormal |\n|-----------|:--:|:----:|:---:|:---:|-----------|------------------|-------------------|\n\n## 7. DISPOSITION CRITERIA\n\n| Disposition | Criteria |\n|-------------|----------|\n| Discharge home | [criteria] |\n| Admit to floor | [criteria] |\n| Admit to ICU | [criteria] |\n| Transfer to higher level | [criteria] |\n\n## 8. EVIDENCE &amp; REFERENCES\n\n| Recommendation | Evidence Level | Source |\n|----------------|----------------|--------|\n</code></pre></p>"},{"location":"skills/neuro-builder-skill/#setting-definitions","title":"Setting Definitions","text":"Setting Definition Typical Priorities ED Emergency Department - acute presentation, limited time STAT, URGENT HOSP Inpatient floor - admitted, can wait hours STAT, URGENT, ROUTINE OPD Outpatient clinic - scheduled visit, days-weeks available ROUTINE, EXT ICU Intensive Care Unit - critically ill, continuous monitoring STAT, URGENT"},{"location":"skills/neuro-builder-skill/#priority-definitions","title":"Priority Definitions","text":"Priority Timeframe Use When STAT Immediate (minutes) Life-threatening, time-sensitive URGENT Within hours Important but not immediately life-threatening ROUTINE Standard timing (days) Important but not time-sensitive EXT Extended workup Atypical cases, refractory, specialized - Not applicable Truly not relevant to this setting"},{"location":"skills/neuro-builder-skill/#writing-style-directive-language","title":"Writing Style: Directive Language","text":"<p>All recommendations must be written as checkbox-ready directives - clear orders from one physician to another or to the patient. These will be selected and sent directly in clinical communications.</p> <p>DO NOT write: - \"Consider physical therapy for balance issues\" - \"Patient may benefit from neurology follow-up\" - \"Smoking cessation should be encouraged\"</p> <p>DO write: - \"Physical therapy consult for gait and balance training\" - \"Neurology follow-up in 2-4 weeks\" - \"Smoking cessation\" - \"Avoid driving until cleared by neurology\" - \"Vitamin D 2000 IU daily\" - \"MRI brain with and without contrast\"</p> <p>Formatting rules: - Start with the action or service, not the rationale - Use imperative verb forms or noun phrases - Keep recommendations concise (aim for &lt;10 words when possible) - Rationale goes in the designated column, not the recommendation itself</p>"},{"location":"skills/neuro-builder-skill/#section-4-guidance-diagnosis-specific-content-required","title":"Section 4 Guidance: Diagnosis-Specific Content Required","text":"<p>CRITICAL: Section 4 content must be customized to the specific diagnosis. Do not copy generic content between templates. Each neurological condition has unique referral needs, patient education requirements, and lifestyle factors.</p>"},{"location":"skills/neuro-builder-skill/#4a-referrals-consults","title":"4A. Referrals &amp; Consults","text":"<p>Include diagnosis-appropriate referrals. Common categories:</p> Category Examples Rehabilitation PT (gait, balance, strengthening), OT (ADLs, hand function), Speech (swallow, cognition, communication) Subspecialty Neuromuscular, neuro-ophthalmology, epilepsy, movement disorders, neuro-oncology Medical specialties Hematology/oncology, rheumatology, endocrinology, cardiology, pulmonology Supportive Pain management, psychiatry/psychology, social work, palliative care, genetic counseling Primary care PCP follow-up, podiatry, wound care, nutrition"},{"location":"skills/neuro-builder-skill/#4b-patient-instructions","title":"4B. Patient Instructions","text":"<p>Include actionable, diagnosis-specific instructions:</p> Category Content Type Return precautions Specific symptoms requiring ED return Activity guidance Driving, work, exercise restrictions Medication guidance Titration expectations, what not to stop abruptly, timing Self-monitoring What to watch for, symptom diaries, when to call Safety Fall prevention, seizure precautions, heat/cold exposure"},{"location":"skills/neuro-builder-skill/#4c-lifestyle-modifications","title":"4C. Lifestyle Modifications","text":"<p>Include modifiable risk factors and preventive measures specific to the condition:</p> Category Examples Substance use Alcohol cessation, smoking cessation Metabolic Glycemic control, blood pressure targets, lipid management Activity Exercise type and intensity, activity pacing Diet/supplements Specific vitamins, dietary modifications Environmental Heat avoidance, pressure point protection, home safety Sleep Sleep hygiene, CPAP compliance"},{"location":"skills/neuro-builder-skill/#builder-principles","title":"Builder Principles","text":"<ol> <li>Ensure comprehensive setting coverage - every applicable setting must be tagged</li> <li>List each medication individually - never group drugs; each drug gets its own row with complete dosing</li> <li>Include complete prescribing information - starting dose, titration, max dose, contraindications, monitoring</li> <li>Include evidence grading where available (Class I-III, Level A-C)</li> <li>Note contraindications and monitoring requirements for all treatments</li> <li>Be specific with dosing when standard protocols exist</li> <li>Include red flags and escalation triggers</li> <li>Acknowledge limitations of evidence where relevant</li> <li>Maintain objectivity - no promotional language</li> <li>Write all recommendations as directives, not suggestions</li> <li>Include relevant referrals (PT, OT, Speech, subspecialty consults) and patient instructions</li> <li>Validate coverage: Before finalizing, confirm each section has appropriate entries for ED, HOSP, OPD, and ICU where applicable</li> <li>Cover symptomatic treatments comprehensively - include all symptom categories relevant to the diagnosis (pain, spasticity, bladder, mood, etc.)</li> </ol>"},{"location":"skills/neuro-builder-skill/#setting-coverage-checklist-validate-before-output","title":"Setting Coverage Checklist (Validate Before Output)","text":"<p>Before delivering the recommendation, verify:</p> <p>Labs: - [ ] Can this patient present to outpatient clinic? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 OPD labs included? - [ ] Can this patient be admitted? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 HOSP labs appropriate? - [ ] Can this be an emergency? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 ED labs with STAT priorities?</p> <p>Imaging: - [ ] Is outpatient imaging an option? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 OPD column populated? - [ ] Urgent inpatient imaging needed? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 HOSP column populated?</p> <p>Treatments: - [ ] Maintenance meds applicable in hospital? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 HOSP column populated? - [ ] Acute treatments applicable in ED? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 ED column with STAT/URGENT?</p> <p>Referrals: - [ ] Can consults be initiated from ED? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 ED column where appropriate? - [ ] Outpatient follow-up referrals? \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 OPD column populated?</p> <p>Monitoring (Section 6): - [ ] Venue columns included for all monitoring parameters? - [ ] Critical safety monitoring (respiratory, cardiac) has ED/ICU coverage? - [ ] Longitudinal monitoring has OPD coverage?</p>"},{"location":"skills/neuro-builder-skill/#section-6-monitoring-parameters-guidance","title":"Section 6 Monitoring Parameters Guidance","text":"<p>Section 6 uses venue columns differently than action sections. For monitoring, the venue indicates where monitoring is typically ordered or initiated, not where it is performed longitudinally.</p> Venue Meaning for Monitoring ED Check this parameter in ED if patient presents acutely HOSP Order/initiate during hospitalization OPD Order/continue in outpatient follow-up ICU Critical monitoring in intensive care"},{"location":"skills/neuro-builder-skill/#examples","title":"Examples","text":"Parameter Type Typical Venues Rationale HbA1c HOSP, OPD Longitudinal; not urgent Pain scores ED, HOSP, OPD, ICU Assess everywhere Creatinine clearance ED, HOSP, OPD, ICU Critical for medication dosing ECG (if on QT-prolonging drug) ED, HOSP, OPD, ICU Safety everywhere Respiratory function (NIF, FVC) ED, HOSP, ICU Critical for GBS/myasthenic crisis Annual screening tests OPD only Longitudinal care"},{"location":"skills/neuro-builder-skill/#critical-safety-monitoring","title":"Critical Safety Monitoring","text":"<p>Always include venue-appropriate critical monitoring for conditions with acute decompensation risk:</p> Condition Critical Monitoring Must Include GBS, CIDP, MG Respiratory function (FVC, NIF) ED: STAT, HOSP: STAT, ICU: STAT Seizure Seizure recurrence, mental status ED: STAT, HOSP: ROUTINE, ICU: STAT Stroke Neuro checks, BP ED: STAT, HOSP: STAT, ICU: STAT High-dose steroids Glucose, BP, mood ED: STAT, HOSP: ROUTINE, ICU: STAT"},{"location":"skills/neuro-builder-skill/#reference-examples","title":"Reference Examples","text":"<p>See <code>references/ms-exacerbation-v2.md</code> for a complete example of Builder output that has been validated through the Checker/Rebuilder workflow.</p>"},{"location":"skills/neuro-builder-skill/#lumbar-puncture-guidance","title":"Lumbar Puncture Guidance","text":"<p>When LP is indicated for a diagnosis, include a dedicated LP subsection within Section 2 (Imaging &amp; Studies) using this structure:</p> <pre><code>### LUMBAR PUNCTURE\n\n**Indication:** [Why LP is being done]\n**Timing:** [Urgent vs routine, any prerequisites]\n**Volume Required:** [Standard 10-15cc OR therapeutic 30-50cc for NPH]\n\n**Studies to Order:**\n| Study | Priority | Rationale |\n|-------|----------|-----------|\n| Core studies (always) | STAT | Cell count x2, protein, glucose, gram stain, culture |\n| [Diagnosis-specific] | [Priority] | [Rationale] |\n\n**Special Handling:** [Time-sensitive, temperature requirements]\n</code></pre> <p>See <code>references/lp-reference.md</code> for comprehensive LP panels organized by diagnosis, including: - Core studies (always order) - Diagnosis-specific panels (MS, meningitis, GBS, SAH, malignancy, autoimmune) - Advanced molecular testing (BioFire ME Panel, mNGS/Delve Detect, CSF cfDNA for tumors) - Therapeutic LP protocols (NPH, IIH)</p>"},{"location":"skills/neuro-builder-skill/#change-log","title":"Change Log","text":"<p>v2.1 (January 13, 2026) - Added comprehensive Treatment Section Guidance - Renamed Section 3B from \"First-line Maintenance\" to \"Symptomatic Treatments\" with Indication column - Added requirement: each medication on individual row (no grouping) - Added dosing requirements checklist (start, titrate, max, frequency) - Added symptomatic treatment categories table with examples - Added DMT section guidance with expanded columns (Route, Pre-Treatment Requirements) - Added setting-specific treatment considerations - Updated Section 3D template with Route and Pre-Treatment columns - Updated Builder Principles (#2, #3, #13 for medication comprehensiveness)</p> <p>v2.0 (January 13, 2026) - Changed to Option A format: multi-column setting-priority matrix (ED | HOSP | OPD | ICU) - Added comprehensive setting coverage requirements and validation checklist - Added explicit instructions to avoid common coverage gaps - Added setting and priority definition tables - Reorganized for clarity and JSON conversion compatibility</p> <p>v1.0 (January 13, 2026) - Initial version</p> <p>v2.2 (January 14, 2026) - Added venue columns (ED, HOSP, OPD, ICU) to Section 6 Monitoring Parameters template - Added \"Section 6 Monitoring Parameters Guidance\" explaining venue interpretation for monitoring - Added Monitoring checklist item to Setting Coverage Checklist - Added Critical Safety Monitoring table for conditions with acute decompensation risk - Venue for monitoring indicates where monitoring is ordered/initiated (not necessarily performed)</p>"},{"location":"skills/neuro-checker-skill/","title":"Checker Skill","text":"<p>name: neuro-checker description: Validates clinical decision support recommendations for neurological diagnoses. Scores content across six domains (completeness, accuracy, safety, objectivity, setting appropriateness, usability) and provides specific revision suggestions. Use after running neuro-builder to validate output quality, or when reviewing any clinical recommendation content for accuracy and safety.</p>"},{"location":"skills/neuro-checker-skill/#neuro-clinical-recommendation-checker","title":"Neuro Clinical Recommendation Checker","text":"<p>Validate and score clinical decision support content across six quality domains. Provides structured feedback for iterative improvement.</p>"},{"location":"skills/neuro-checker-skill/#expected-structure","title":"Expected Structure","text":"<p>Documents should have 8 sections in two groups:</p> <p>Section A: Action Items (Primary) 1. Laboratory Workup (1A, 1B, 1C) 2. Diagnostic Imaging &amp; Studies (2A, 2B, 2C) 3. Treatment (3A, 3B, 3C, 3D) 4. Other Recommendations (4A, 4B, 4C) \u00c3\u00a2\u00e2\u20ac\u00a0\u00c2\u0090 Must be diagnosis-specific</p> <p>Section B: Reference (Supporting) 5. Differential Diagnosis 6. Monitoring Parameters 7. Disposition Criteria 8. Evidence &amp; References</p>"},{"location":"skills/neuro-checker-skill/#expected-table-format-option-a-multi-column","title":"Expected Table Format (Option A Multi-Column)","text":"<p>Tables should use the multi-column setting-priority format:</p> <p>Labs/Studies: <pre><code>| Test | ED | HOSP | OPD | ICU | Rationale | Target Finding |\n|------|:--:|:----:|:---:|:---:|-----------|----------------|\n</code></pre></p> <p>Treatments: <pre><code>| Treatment | ED | HOSP | OPD | ICU | Dosing | Contraindications | Monitoring |\n|-----------|:--:|:----:|:---:|:---:|--------|-------------------|------------|\n</code></pre></p> <p>Priority values: STAT | URGENT | ROUTINE | EXT | - (not applicable)</p>"},{"location":"skills/neuro-checker-skill/#validation-domains","title":"Validation Domains","text":"<p>Score each domain 0-10:</p>"},{"location":"skills/neuro-checker-skill/#1-completeness-0-10","title":"1. COMPLETENESS (0-10)","text":"<ul> <li>Are all 8 sections present and populated?</li> <li>Are essential labs, imaging, and treatments included?</li> <li>Are there obvious gaps in the workup?</li> <li>Is the differential diagnosis comprehensive?</li> <li>Setting Coverage: Are all applicable settings (ED, HOSP, OPD, ICU) represented?</li> <li>Medication Coverage:</li> <li> Each medication on its own row (not grouped)?</li> <li> Complete dosing for each drug (start, titrate, max)?</li> <li> Symptomatic treatments cover relevant categories (pain, spasticity, bladder, mood, fatigue)?</li> <li> DMTs individually listed with pre-treatment requirements (if applicable)?</li> <li>Section 4 Checklist:</li> <li> 4A (Referrals &amp; Consults) present with \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a55 relevant referrals?</li> <li> 4B (Patient Instructions) present with \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a55 actionable instructions?</li> <li> 4C (Lifestyle &amp; Prevention) present with \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 recommendations?</li> <li> All Section 4 content is diagnosis-specific (not generic)?</li> </ul>"},{"location":"skills/neuro-checker-skill/#2-accuracy-0-10","title":"2. ACCURACY (0-10)","text":"<ul> <li>Are drug dosages correct?</li> <li>Are diagnostic criteria accurately stated?</li> <li>Are contraindications complete?</li> <li>Any factual errors?</li> <li>Are priority levels appropriate for each setting?</li> </ul>"},{"location":"skills/neuro-checker-skill/#3-safety-0-10","title":"3. SAFETY (0-10)","text":"<ul> <li>Are critical contraindications noted?</li> <li>Are drug interactions or monitoring requirements included?</li> <li>Are red flags and escalation triggers clear?</li> <li>Any potentially dangerous omissions?</li> <li>Section 4B Safety Check: Are return precautions specific and actionable?</li> </ul>"},{"location":"skills/neuro-checker-skill/#4-objectivity-0-10","title":"4. OBJECTIVITY (0-10)","text":"<ul> <li>Are claims evidence-based or clearly labeled as expert opinion?</li> <li>Is language neutral (no promotional bias)?</li> <li>Are limitations of evidence acknowledged?</li> </ul>"},{"location":"skills/neuro-checker-skill/#5-setting-appropriateness-0-10","title":"5. SETTING APPROPRIATENESS (0-10)","text":"<ul> <li>Are all four settings (ED, HOSP, OPD, ICU) appropriately covered?</li> <li>Are priorities correct for each setting (STAT in ED, ROUTINE in OPD)?</li> <li>Is \"-\" used correctly (truly not applicable, not just \"less common\")?</li> <li>Flag gaps: Missing OPD labs? Missing ED treatments?</li> <li>Would recommendations be actionable in each tagged setting?</li> </ul>"},{"location":"skills/neuro-checker-skill/#6-usability-0-10","title":"6. USABILITY (0-10)","text":"<ul> <li>Is format consistent and parseable?</li> <li>Is the multi-column format correctly structured?</li> <li>Could this be directly converted to JSON for clinical tools?</li> <li>Are recommendations written as directives (not suggestions)?</li> <li>Section 4 Usability: Are patient instructions written in plain language?</li> </ul>"},{"location":"skills/neuro-checker-skill/#critical-setting-coverage-validation","title":"CRITICAL: Setting Coverage Validation","text":"<p>This is the most important new check. For each diagnosis, verify:</p>"},{"location":"skills/neuro-checker-skill/#setting-coverage-checklist","title":"Setting Coverage Checklist","text":"Section ED Coverage HOSP Coverage OPD Coverage ICU Coverage 1. Labs \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 tests? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 tests? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 tests? If applicable? 2. Imaging If urgent needed? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a51 study? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a51 study? If applicable? 3. Treatment Acute therapies? Maintenance? Maintenance? Critical care? 4A. Referrals If applicable? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 consults? \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a53 consults? If applicable? 4B. Instructions Discharge teaching? Discharge teaching? All applicable? N/A"},{"location":"skills/neuro-checker-skill/#common-coverage-gaps-to-flag","title":"Common Coverage Gaps to Flag","text":"Gap Type Example Impact Missing OPD labs Seizure workup has no OPD-tagged labs Outpatient neurologist can't order workup Missing OPD imaging MRI only tagged for ED/HOSP Clinic-based imaging not supported Missing HOSP maintenance Only acute treatments tagged Admitted patients don't get home meds continued Overuse of \"-\" OPD marked \"-\" for tests that CAN be done outpatient Limits ambulatory care Missing ED consults Referrals only tagged OPD Delays specialty input in emergencies"},{"location":"skills/neuro-checker-skill/#when-is-appropriate","title":"When \"-\" Is Appropriate","text":"<p>\"-\" means truly not applicable, not \"less common\" or \"usually done elsewhere.\"</p> Appropriate \"-\" Inappropriate \"-\" Prolactin for OPD (only useful &lt;20 min post-ictal) Basic metabolic panel for OPD ICU-only monitoring for routine outpatient MRI brain for OPD (can be ordered from clinic) Emergent intubation meds for OPD Maintenance AEDs for ED (may need to continue)"},{"location":"skills/neuro-checker-skill/#output-format","title":"Output Format","text":"<pre><code>DIAGNOSIS REVIEWED: [Name]\nVERSION: [if applicable]\n\n## SCORES\n\n| Domain | Score | Notes |\n|--------|-------|-------|\n| Completeness | X/10 | [brief note] |\n| Accuracy | X/10 | [brief note] |\n| Safety | X/10 | [brief note] |\n| Objectivity | X/10 | [brief note] |\n| Setting Appropriateness | X/10 | [brief note] |\n| Usability | X/10 | [brief note] |\n\n**OVERALL SCORE: X/60 (X%)**\n\n## SETTING COVERAGE ASSESSMENT\n\n| Section | ED | HOSP | OPD | ICU | Gaps Identified |\n|---------|:--:|:----:|:---:|:---:|-----------------|\n| 1. Labs | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | [specific gaps] |\n| 2. Imaging | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | [specific gaps] |\n| 3. Treatment | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | [specific gaps] |\n| 4. Other | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | \u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u0153/\u00c3\u00a2\u00c5\u201c\u00e2\u20ac\u201d | [specific gaps] |\n\n## SECTION 4 ASSESSMENT\n\n| Subsection | Present | Count | Diagnosis-Specific | Notes |\n|------------|---------|-------|-------------------|-------|\n| 4A Referrals | Y/N | X items | Y/N | [note] |\n| 4B Patient Instructions | Y/N | X items | Y/N | [note] |\n| 4C Lifestyle | Y/N | X items | Y/N | [note] |\n\n## MEDICATION ASSESSMENT\n\n| Criterion | Met? | Notes |\n|-----------|------|-------|\n| Each drug on individual row (not grouped) | Y/N | [note] |\n| Complete dosing (start, titrate, max) | Y/N | [list any drugs missing dosing] |\n| Contraindications listed for each drug | Y/N | [note] |\n| Monitoring specified for each drug | Y/N | [note] |\n| Symptomatic categories covered | Y/N | [list missing: pain, spasticity, bladder, mood, fatigue, etc.] |\n| Section 3B has Indication column | Y/N | [note] |\n| Section 3D has Route + Pre-Treatment columns | Y/N or N/A | [note] |\n\n## SECTION 6 MONITORING ASSESSMENT\n\n| Criterion | Met? | Notes |\n|-----------|------|-------|\n| Venue columns present (ED, HOSP, OPD, ICU) | Y/N | [Section 6 must have venue columns] |\n| Frequency column present | Y/N | [note] |\n| Target/threshold specified for each parameter | Y/N | [note] |\n| Action if abnormal specified | Y/N | [note] |\n| Critical safety monitoring included (if applicable) | Y/N | [e.g., respiratory function for GBS/MG] |\n| Longitudinal monitoring has OPD coverage | Y/N | [note] |\n\n## CRITICAL ISSUES (Must Fix)\n\n[List any dangerous or major errors - these block approval]\n\nC1. [Section] - [Description of critical issue]\nC2. [Section] - [Description of critical issue]\n\n## SETTING COVERAGE ISSUES\n\n[List specific setting gaps - high priority]\n\nS1. [Section] - [Setting gap: e.g., \"Labs section has no OPD coverage - outpatient workup not possible\"]\nS2. [Section] - [Setting gap]\n\n## MEDICATION ISSUES\n\n[List medication comprehensiveness gaps - high priority]\n\nM1. [Section] - [Medication issue: e.g., \"Drugs grouped as 'SSRIs' instead of individual rows\"]\nM2. [Section] - [Medication issue: e.g., \"Gabapentin missing titration schedule\"]\nM3. [Section] - [Medication issue: e.g., \"No bladder dysfunction treatments included\"]\n\n## RECOMMENDED REVISIONS\n\n[Specific suggestions ranked by priority]\n\nR1. [Section] - [Specific revision with rationale]\nR2. [Section] - [Specific revision with rationale]\n...\n\n## STRENGTHS\n\n[What was done well - reinforces good patterns]\n\nS1. [Description]\nS2. [Description]\n\n## VERIFICATION NEEDED\n\n[Items requiring clinical expert verification]\n\nV1. [Item needing physician confirmation]\nV2. [Item needing physician confirmation]\n</code></pre>"},{"location":"skills/neuro-checker-skill/#checker-principles","title":"Checker Principles","text":"<ol> <li>Prioritize patient safety above all - Flag any potentially dangerous omissions or errors as CRITICAL</li> <li>Validate comprehensive setting coverage - Flag gaps in ED, HOSP, OPD, or ICU coverage</li> <li>Flag unsupported claims - Note where evidence is missing or weak</li> <li>Be specific in feedback - Cite exact section/row needing revision</li> <li>Recommend verification when uncertain - Don't assume error if unclear, flag for expert review</li> <li>Check for appropriate \"-\" usage - Ensure \"-\" means truly not applicable</li> <li>Verify directive language - Recommendations should be checkbox-ready, not suggestions</li> <li>Validate Section 4 specificity - Flag generic or copy-paste content that doesn't fit the diagnosis</li> </ol>"},{"location":"skills/neuro-checker-skill/#common-issues-to-check","title":"Common Issues to Check","text":"<p>Medication Comprehensiveness (NEW - HIGH PRIORITY): - Are all medications listed individually (not grouped as \"SSRIs\" or \"beta-blockers\")? - Does each drug have complete dosing (start dose, titration, max dose)? - Are contraindications listed for each medication? - Is monitoring specified for each medication? - For DMTs: Are pre-treatment requirements listed? - Are relevant symptomatic treatment categories covered (pain, spasticity, bladder, mood, fatigue)? - Does Section 3B include an \"Indication\" column? - Does Section 3D include \"Route\" and \"Pre-Treatment Requirements\" columns (if DMTs apply)?</p> <p>Setting Coverage (HIGH PRIORITY): - Missing OPD coverage in Labs section - Missing OPD coverage in Imaging section - Overuse of \"-\" where tests/treatments ARE applicable - Inconsistent priorities across settings - Missing HOSP column for maintenance therapies</p> <p>Section 6 Monitoring (HIGH PRIORITY): - Missing venue columns (ED, HOSP, OPD, ICU) - all monitoring parameters need venue columns - Missing critical safety monitoring (respiratory function for neuromuscular conditions) - Missing longitudinal monitoring (OPD coverage for ongoing parameters) - Venue interpretation: venue indicates where monitoring is ordered/initiated, not necessarily performed</p> <p>Safety: - Glucose monitoring during steroids - Respiratory monitoring thresholds for myelitis - Drug-drug interactions - Contraindication completeness - Escalation criteria clarity</p> <p>Accuracy: - Drug dosing (especially weight-based) - Monitoring frequencies - Evidence levels cited correctly - ICD-10 codes - Priority levels appropriate for setting</p> <p>Completeness: - Missing differential diagnoses - Incomplete disposition criteria - Missing evidence references - Gaps in monitoring parameters - Missing Section 4 subsections (4A, 4B, 4C)</p> <p>Objectivity: - Brand name bias - Unsupported treatment preferences - Missing alternative therapies</p> <p>Usability - Directive Language: Flag any recommendations that use weak/suggestive language: - \"Consider...\" \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 Rewrite as direct order - \"May benefit from...\" \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 Rewrite as direct order - \"Should be encouraged to...\" \u00c3\u00a2\u00e2\u20ac\u00a0\u00e2\u20ac\u2122 Rewrite as direct instruction</p>"},{"location":"skills/neuro-checker-skill/#setting-coverage-scoring-impact","title":"Setting Coverage Scoring Impact","text":"Issue Scoring Impact One setting missing entirely from a section Setting Appropriateness: -2 points Multiple settings missing coverage Setting Appropriateness: -3 to -4 points Inappropriate use of \"-\" (should have coverage) Setting Appropriateness: -1 point per instance OPD completely missing from Labs Completeness: -2 points; Setting: -2 points Priorities incorrect for setting (e.g., STAT in OPD) Accuracy: -1 point per instance"},{"location":"skills/neuro-checker-skill/#scoring-guidelines","title":"Scoring Guidelines","text":"<ul> <li>9-10: Excellent, minimal or no changes needed</li> <li>7-8: Good, minor revisions only</li> <li>5-6: Acceptable, moderate revisions needed</li> <li>3-4: Significant issues, major revision required</li> <li>0-2: Unsafe or fundamentally flawed, rebuild required</li> </ul> <p>Overall thresholds: - \u00c3\u00a2\u00e2\u20ac\u00b0\u00c2\u00a554/60 (90%): Ready for clinical use pending physician sign-off - 48-53/60 (80-89%): Revise and re-check - &lt;48/60 (&lt;80%): Significant revision needed</p>"},{"location":"skills/neuro-checker-skill/#change-log","title":"Change Log","text":"<p>v2.2 (January 14, 2026) - Added Section 6 Monitoring Assessment table to output format - Added venue column validation for Section 6 (ED, HOSP, OPD, ICU required) - Added Section 6 Monitoring to Common Issues to Check - Added critical safety monitoring validation (respiratory function for neuromuscular conditions) - Section 6 venue interpretation: where monitoring is ordered/initiated, not necessarily performed</p> <p>v2.1 (January 13, 2026) - Added Medication Assessment table to output format - Added M-codes for medication issues (M1, M2, M3, etc.) - Added Medication Comprehensiveness checks to Common Issues section - Updated Completeness domain with medication coverage checklist - Checks for: individual drug rows, complete dosing, symptomatic categories, DMT columns</p> <p>v2.0 (January 13, 2026) - Added Setting Coverage Assessment table to output format - Added Setting Coverage Issues section (S1, S2, etc.) - Added comprehensive setting coverage validation checklist - Added common coverage gaps to flag - Added guidance on appropriate vs inappropriate \"-\" usage - Added setting coverage scoring impact - Updated all six domain descriptions for multi-column format - Added format validation for Option A structure</p> <p>v1.0 (January 13, 2026) - Initial version</p>"},{"location":"skills/neuro-citation-verifier-skill/","title":"Neuro Citation Verifier","text":"<p>Systematically verify all citations and evidence references in clinical recommendation templates to ensure accuracy and prevent hallucinated sources.</p>"},{"location":"skills/neuro-citation-verifier-skill/#critical-preventing-pmid-hallucinations","title":"CRITICAL: Preventing PMID Hallucinations","text":"<p>NEVER guess or assume a PubMed ID. Hallucinated PMIDs that link to wrong articles are dangerous and misleading.</p>"},{"location":"skills/neuro-citation-verifier-skill/#mandatory-verification-steps","title":"Mandatory Verification Steps","text":"<p>Before adding ANY PubMed link, you MUST:</p> <ol> <li>Search for the specific article using WebSearch with author, title keywords, journal, and year</li> <li>Find the actual PMID in the search results (look for \"PMID:\" or pubmed.ncbi.nlm.nih.gov URLs)</li> <li>Verify the PMID by fetching the PubMed page and confirming:</li> <li>Author names match</li> <li>Title matches or is very close</li> <li>Journal matches</li> <li>Year matches</li> <li>Only then add the link to the citation</li> </ol>"},{"location":"skills/neuro-citation-verifier-skill/#what-not-to-do","title":"What NOT to Do","text":"\u274c DO NOT \u2705 DO INSTEAD Guess PMIDs based on patterns Search and verify each one Assume PMID from memory Fetch the actual PubMed page Add links without clicking through Verify the linked article is correct Use placeholder PMIDs Leave as plain text if can't verify"},{"location":"skills/neuro-citation-verifier-skill/#when-you-cannot-verify","title":"When You Cannot Verify","text":"<p>If you cannot find or verify a PMID: - Leave the citation as plain text (no link) - Log it in the verification report as \"Unable to verify\" - Flag for physician review - they may know the correct source - NEVER fabricate a PMID - wrong links are worse than no links</p>"},{"location":"skills/neuro-citation-verifier-skill/#example-correct-process","title":"Example Correct Process","text":"<pre><code>Citation to verify: \"Dyck PJ et al. Neurology 1993\" (diabetes polyneuropathy)\n\n1. Search: \"Dyck diabetic polyneuropathy Neurology 1993 PMID\"\n2. Find in results: \"PMID: 8469345\" with title matching\n3. Fetch: https://pubmed.ncbi.nlm.nih.gov/8469345/\n4. Verify page shows:\n   - Authors: Dyck PJ, et al.\n   - Journal: Neurology\n   - Year: 1993\n   - Topic: Diabetic polyneuropathy\n5. Confirmed - add link\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#critical-pmid-content-verification","title":"CRITICAL: PMID Content Verification","text":""},{"location":"skills/neuro-citation-verifier-skill/#why-pmids-get-wrong","title":"Why PMIDs Get Wrong","text":"<p>PMIDs are assigned sequentially. Papers published in the same journal issue often have consecutive PMIDs. This leads to common errors:</p> Error Type Example How It Happens Off-by-one PMID 15590952 vs 15590953 Two NEJM papers in same issue (Fahn ELLDOPA vs Emre rivastigmine) Similar topic PMID 8869765 vs 8792038 Both 1996 Cephalalgia papers (CGRP vs Magnesium) Same author, different study Multiple Cochrane reviews Author has many systematic reviews Wrong section PMID 38078586 vs 38078577 ADA Standards Section 6 vs Section 12"},{"location":"skills/neuro-citation-verifier-skill/#mandatory-pmid-verification-checklist","title":"Mandatory PMID Verification Checklist","text":"<p>For EVERY PMID, you MUST verify:</p> <ul> <li> Title matches - The actual paper title supports the claim</li> <li> Authors match - First/last author names are correct</li> <li> Journal matches - Published in the claimed journal</li> <li> Year matches - Publication year is correct</li> <li> Content supports claim - The finding you're citing actually exists in this paper</li> </ul>"},{"location":"skills/neuro-citation-verifier-skill/#search-pattern-for-pmid-verification","title":"Search Pattern for PMID Verification","text":"<pre><code>Search: \"PMID [number] [author name] [journal] [year] [topic]\"\n</code></pre> <p>Example: <code>\"PMID 8792038 Peikert Cephalalgia 1996 magnesium migraine\"</code></p> <p>If the search doesn't return results confirming the paper matches your claim, the PMID is likely wrong.</p>"},{"location":"skills/neuro-citation-verifier-skill/#use-the-citation-verification-script","title":"Use the Citation Verification Script","text":"<p>Run <code>scripts/verify_citations.py</code> to extract all PMIDs from a plan:</p> <pre><code># Single plan\npython scripts/verify_citations.py docs/plans/migraine.md\n\n# All approved plans\npython scripts/verify_citations.py --all\n</code></pre> <p>This outputs all citations with their claimed content, making it easy to verify each PMID systematically.</p>"},{"location":"skills/neuro-citation-verifier-skill/#when-to-use","title":"When to Use","text":"<p>Run this skill AFTER: - Initial template generation (neuro-builder) - Validation and revision cycle (neuro-checker + neuro-rebuilder) - Template has achieved \u226590% validation score</p> <p>Run BEFORE: - CPT/synonym enrichment - Final physician sign-off - Clinical deployment</p>"},{"location":"skills/neuro-citation-verifier-skill/#citation-types-to-verify","title":"Citation Types to Verify","text":"Citation Type Example Verification Method Journal articles \"Fisher RS et al. Epilepsia 2017\" Search PubMed, journal website Clinical guidelines \"AAN Practice Parameter 2007\" Search society website, PubMed Consensus statements \"ILAE Commission Report 2019\" Search organization website Clinical trials \"ESETT Trial, NEJM 2019\" Search ClinicalTrials.gov, PubMed Textbook references \"Adams and Victor's Neurology\" Verify edition, chapter exists Drug labeling \"FDA prescribing information\" Search FDA label database Evidence levels \"Class I, Level A\" Verify grading system matches source"},{"location":"skills/neuro-citation-verifier-skill/#verification-process","title":"Verification Process","text":""},{"location":"skills/neuro-citation-verifier-skill/#step-1-extract-all-citations","title":"Step 1: Extract All Citations","text":"<p>Scan the template for citations in: - Section 8 (Evidence &amp; References) - Primary location - Inline references - Within rationale columns or notes - Dosing sources - Drug dosing citations - Diagnostic criteria sources - Classification systems</p>"},{"location":"skills/neuro-citation-verifier-skill/#step-2-categorize-by-priority","title":"Step 2: Categorize by Priority","text":"Priority Category Rationale HIGH Drug dosing citations Patient safety - incorrect dosing is dangerous HIGH Diagnostic criteria Misdiagnosis risk HIGH Treatment efficacy claims Direct patient care impact MEDIUM Epidemiology/prevalence Context but not actionable MEDIUM Pathophysiology Educational, less actionable LOW Historical references Background only"},{"location":"skills/neuro-citation-verifier-skill/#step-3-verify-each-citation","title":"Step 3: Verify Each Citation","text":"<p>For each citation, perform web search to confirm:</p> <ol> <li>Source exists - Can the article/guideline be found?</li> <li>Authors match - Are the cited authors correct?</li> <li>Year matches - Is the publication year correct?</li> <li>Journal/source matches - Is it published where claimed?</li> <li>Content supports claim - Does the source actually say what's claimed?</li> </ol>"},{"location":"skills/neuro-citation-verifier-skill/#step-4-assign-verification-status","title":"Step 4: Assign Verification Status","text":"Status Symbol Meaning Verified \u2705 Source found, content confirmed Partial Match \u26a0\ufe0f Source found but details differ (wrong year, different authors, etc.) Not Found \u274c Cannot locate source despite thorough search Inaccurate \u274c Source found but does NOT support the claim made Unable to Verify \u2753 Paywalled or inaccessible; cannot confirm content"},{"location":"skills/neuro-citation-verifier-skill/#step-5-capture-source-links","title":"Step 5: Capture Source Links","text":"<p>For each verified or partially matched citation, include a direct link to the source. Use the following link hierarchy (prefer earlier options):</p> Source Type Preferred Link Example Journal articles PubMed link (PMID) <code>https://pubmed.ncbi.nlm.nih.gov/28276064/</code> Guidelines Organization website <code>https://www.aan.com/Guidelines/...</code> Clinical trials ClinicalTrials.gov <code>https://clinicaltrials.gov/study/NCT01960075</code> FDA labeling DailyMed or FDA <code>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=...</code> Consensus statements Organization or PubMed Direct link to PDF or abstract Textbooks Publisher page Link to edition/chapter if available online <p>Link Priority: 1. PubMed - Preferred for journal articles (stable, free access to abstracts) 2. DOI link - <code>https://doi.org/10.xxxx/...</code> (permanent, resolves to publisher) 3. Organization website - For guidelines and consensus statements 4. Publisher/journal site - Direct article link 5. Google Scholar - Fallback if no direct link available</p>"},{"location":"skills/neuro-citation-verifier-skill/#search-strategy","title":"Search Strategy","text":""},{"location":"skills/neuro-citation-verifier-skill/#for-journal-articles","title":"For Journal Articles","text":"<pre><code>Search 1: \"[Author last name] [key topic] [journal] [year]\"\nSearch 2: \"[Article title keywords] PubMed\"\nSearch 3: \"[Author] [year] [condition]\"\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#for-guidelines","title":"For Guidelines","text":"<pre><code>Search 1: \"[Organization] [topic] guideline [year]\"\nSearch 2: \"[Organization] practice parameter [condition]\"\nSearch 3: \"site:[organization website] [topic] guideline\"\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#for-clinical-trials","title":"For Clinical Trials","text":"<pre><code>Search 1: \"[Trial name] [condition] trial\"\nSearch 2: \"[Trial acronym] [journal] [year]\"\nSearch 3: \"ClinicalTrials.gov [trial name]\"\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#for-fda-information","title":"For FDA Information","text":"<pre><code>Search 1: \"[Drug name] FDA prescribing information\"\nSearch 2: \"[Drug name] package insert\"\nSearch 3: \"site:accessdata.fda.gov [drug name]\"\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#output-format","title":"Output Format","text":"<pre><code>CITATION VERIFICATION REPORT\n============================\nTEMPLATE: [Diagnosis Name]\nVERSION: [Version]\nDATE VERIFIED: [Date]\nVERIFIER: Claude (neuro-citation-verifier v1.1)\n\n## SUMMARY\n\n| Status | Count |\n|--------|-------|\n| \u2705 Verified | X |\n| \u26a0\ufe0f Partial Match | X |\n| \u274c Not Found | X |\n| \u274c Inaccurate | X |\n| \u2753 Unable to Verify | X |\n| **TOTAL** | X |\n\n**Overall Citation Integrity:** [X]% verified or partially matched\n\n---\n\n## HIGH PRIORITY CITATIONS\n\n### Drug Dosing / Treatment Citations\n\n| Citation | Claim in Template | Status | Link | Verification Notes |\n|----------|-------------------|--------|------|-------------------|\n| [Citation] | [What template claims] | \u2705/\u26a0\ufe0f/\u274c | [PubMed](url) | [Search findings] |\n\n### Diagnostic Criteria Citations\n\n| Citation | Claim in Template | Status | Link | Verification Notes |\n|----------|-------------------|--------|------|-------------------|\n| [Citation] | [What template claims] | \u2705/\u26a0\ufe0f/\u274c | [PubMed](url) | [Search findings] |\n\n---\n\n## MEDIUM PRIORITY CITATIONS\n\n| Citation | Claim in Template | Status | Link | Verification Notes |\n|----------|-------------------|--------|------|-------------------|\n| [Citation] | [What template claims] | \u2705/\u26a0\ufe0f/\u274c | [PubMed](url) | [Search findings] |\n\n---\n\n## LOW PRIORITY CITATIONS\n\n| Citation | Claim in Template | Status | Link | Verification Notes |\n|----------|-------------------|--------|------|-------------------|\n| [Citation] | [What template claims] | \u2705/\u26a0\ufe0f/\u274c | [PubMed](url) | [Search findings] |\n\n---\n\n## ISSUES REQUIRING CORRECTION\n\n### Critical (Must Fix Before Deployment)\n\n| Issue # | Section | Original Citation | Problem | Suggested Correction |\n|---------|---------|-------------------|---------|---------------------|\n| C1 | [Section] | [Original] | [Problem found] | [Correction] |\n\n### Recommended (Should Fix)\n\n| Issue # | Section | Original Citation | Problem | Suggested Correction |\n|---------|---------|-------------------|---------|---------------------|\n| R1 | [Section] | [Original] | [Problem found] | [Correction] |\n\n### Minor (Nice to Fix)\n\n| Issue # | Section | Original Citation | Problem | Suggested Correction |\n|---------|---------|-------------------|---------|---------------------|\n| M1 | [Section] | [Original] | [Problem found] | [Correction] |\n\n---\n\n## VERIFICATION DETAILS\n\n[For each citation, include detailed search notes]\n\n### Citation 1: [Full citation text]\n**Location in template:** Section 8, Row X\n**Claim supported:** [What the template claims this source supports]\n**Search performed:**\n- Search 1: \"[query]\" \u2192 [result]\n- Search 2: \"[query]\" \u2192 [result]\n**Verification result:** \u2705/\u26a0\ufe0f/\u274c\n**Source link:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/XXXXXXXX/) or [DOI](https://doi.org/XX.XXXX/...) or N/A if not found\n**Notes:** [Detailed findings]\n\n[Repeat for each citation]\n\n---\n\n## CITATIONS RECOMMENDED TO ADD\n\n[If verification reveals important missing citations that should be added]\n\n| Recommendation | Source | Link | Rationale |\n|----------------|--------|------|-----------|\n| [What to cite] | [Actual source found] | [PubMed](url) | [Why it should be added] |\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#common-citation-issues","title":"Common Citation Issues","text":""},{"location":"skills/neuro-citation-verifier-skill/#hallucination-patterns","title":"Hallucination Patterns","text":"Pattern Example How to Catch Plausible but nonexistent \"Smith et al. Neurology 2018\" (no such article) PubMed search returns nothing Wrong author order \"Jones and Smith 2015\" (actually \"Smith and Jones\") Check actual author list Wrong year \"NEJM 2019\" (actually published 2020) Verify publication date Wrong journal \"Published in Lancet\" (actually in BMJ) Check actual publication venue Conflated studies Combines findings from 2 different papers Read abstracts carefully Outdated guidelines Cites 2007 guideline when 2022 update exists Search for latest version Misattributed findings Claims study shows X when it shows Y Read abstract/full text"},{"location":"skills/neuro-citation-verifier-skill/#red-flags-requiring-extra-scrutiny","title":"Red Flags Requiring Extra Scrutiny","text":"<ul> <li>Very specific statistics without clear source</li> <li>Claims that seem too good/clean (e.g., \"100% sensitivity\")</li> <li>Guidelines from organizations that don't exist</li> <li>Trial names that don't appear in registries</li> <li>Evidence levels without methodology explanation</li> </ul>"},{"location":"skills/neuro-citation-verifier-skill/#integration-with-rebuilder","title":"Integration with Rebuilder","text":"<p>After verification, generate a correction list formatted for the neuro-rebuilder skill:</p> <pre><code>## CITATION CORRECTIONS FOR REBUILDER\n\nC1. Section 8 - Change \"Fisher 2016\" to \"Fisher RS et al. Epilepsia 2017;58(4):531-542\"\nC2. Section 3A - Remove dosing claim \"per ESETT trial\" (trial does not specify this dose)\nC3. Section 8 - Add missing citation: \"Hauser WA et al. NEJM 1998;338:429-34\" for recurrence risk data\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#integration-with-templates","title":"Integration with Templates","text":"<p>CRITICAL: After verification, update the main template file to add clickable PubMed links to Section 8 (Evidence &amp; References). This ensures links render in the Clinical Plan Builder interface.</p>"},{"location":"skills/neuro-citation-verifier-skill/#template-update-process","title":"Template Update Process","text":"<ol> <li>Open the main template file (e.g., <code>docs/plans/status-epilepticus.md</code>)</li> <li>Navigate to Section 8 (Evidence &amp; References)</li> <li>Replace plain text citations with markdown links:</li> </ol> <p>Before: <pre><code>| Lorazepam preferred IV benzodiazepine | Class I, Level A | Alldredge et al. NEJM 2001 |\n</code></pre></p> <p>After: <pre><code>| Lorazepam preferred IV benzodiazepine | Class I, Level A | [Alldredge et al. NEJM 2001](https://pubmed.ncbi.nlm.nih.gov/11547716/) |\n</code></pre></p> <ol> <li> <p>For multiple sources in one row, link each: <pre><code>| Benzodiazepines first-line for SE | Class I, Level A | [NCS Guidelines 2012](https://pubmed.ncbi.nlm.nih.gov/22528274/); [AES Guidelines 2016](https://pubmed.ncbi.nlm.nih.gov/26900382/) |\n</code></pre></p> </li> <li> <p>Commit and push changes to GitHub for links to appear in Clinical Plan Builder</p> </li> </ol>"},{"location":"skills/neuro-citation-verifier-skill/#verification-workflow","title":"Verification Workflow","text":"<ol> <li>Extract all citations from template</li> <li>Categorize by priority tier</li> <li>Search and verify each citation (HIGH priority first)</li> <li>Document findings in verification report</li> <li>Generate correction list compatible with neuro-rebuilder</li> <li>Log results to <code>docs/logs/citation-verification-log.md</code> (NEW)</li> <li>Physician reviews flagged citations</li> <li>Corrections implemented via rebuilder</li> <li>Re-verify any changed citations</li> <li>Proceed to CPT/synonym enrichment</li> </ol>"},{"location":"skills/neuro-citation-verifier-skill/#verification-logging-required","title":"Verification Logging (Required)","text":"<p>CRITICAL: After each verification, append results to the central log at <code>docs/logs/citation-verification-log.md</code>. This enables pattern analysis and process improvement.</p>"},{"location":"skills/neuro-citation-verifier-skill/#what-to-log","title":"What to Log","text":"<p>For each plan verified, add:</p> <ol> <li>Summary entry - Add counts to the Summary Statistics table</li> <li>Plan section - Create new section under \"Verification Results by Plan\" with:</li> <li>Date verified</li> <li>Version</li> <li>List of verified citations with PubMed IDs</li> <li>List of non-PubMed sources</li> <li>List of citations unable to verify (with reasons)</li> <li>Corrections made</li> </ol>"},{"location":"skills/neuro-citation-verifier-skill/#log-entry-template","title":"Log Entry Template","text":"<pre><code>### [Plan Name]\n\n**Date Verified:** YYYY-MM-DD\n**Version:** X.X \u2192 X.X\n**Verifier:** Claude (neuro-citation-verifier)\n\n#### Verified Citations (X)\n\n| # | Citation | PubMed ID | Status |\n|---|----------|-----------|--------|\n| 1 | [Author et al. Journal Year] | [PMID](link) | \u2705 Verified |\n\n#### Unable to Verify (X)\n\n| # | Citation | Reason | Recommendation |\n|---|----------|--------|----------------|\n| 1 | [Citation] | [Why unverifiable] | [Suggested action] |\n\n#### Corrections Made (X)\n\n| # | Original Citation | Issue | Corrected To |\n|---|-------------------|-------|--------------|\n| 1 | [Original] | [Problem] | [Fixed citation] |\n</code></pre>"},{"location":"skills/neuro-citation-verifier-skill/#pattern-tracking","title":"Pattern Tracking","text":"<p>When logging, note any patterns in the \"Patterns &amp; Improvement Opportunities\" section:</p> Pattern Type Example Trial confusion Multiple trials for same drug, different indications Generic references \"Multiple RCTs\" without specific citations Outdated guidelines Citing old version when newer exists Author name variations Different spellings across sources Paywall barriers Cannot access to verify content <p>This data helps improve the builder and checker skills over time.</p>"},{"location":"skills/neuro-citation-verifier-skill/#limitations","title":"Limitations","text":"<ul> <li>Some sources may be paywalled (note as \"Unable to Verify - Paywall\")</li> <li>Very old sources may not be indexed online</li> <li>Non-English sources may be difficult to verify</li> <li>Preprint/unpublished data cannot be fully verified</li> <li>Conference abstracts may not be findable</li> </ul> <p>When a source cannot be verified due to access limitations, recommend physician verification or suggest alternative citable sources.</p>"},{"location":"skills/neuro-citation-verifier-skill/#change-log","title":"Change Log","text":"<p>v1.3 (January 2026) - Added CRITICAL section on PMID content verification with common error types - Added mandatory PMID verification checklist - Documented the <code>scripts/verify_citations.py</code> helper tool - Added examples of off-by-one and consecutive PMID errors</p> <p>v1.2 (January 2026) - Added required verification logging to <code>docs/logs/citation-verification-log.md</code> - New \"Verification Logging (Required)\" section with log entry template - Added pattern tracking for continuous improvement - Updated workflow to include logging step</p> <p>v1.1 (January 2026) - Added clickable source links (PubMed, DOI, organization websites) to all verification output tables - New Step 5: Capture Source Links with link hierarchy guidance - Updated output format to include Link column in all citation tables</p> <p>v1.0 (January 2026) - Initial version - Comprehensive citation verification framework - Output format designed for rebuilder integration - Priority tiers for verification effort allocation</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/","title":"Neuro CPT &amp; Synonym Enricher","text":"<p>Add verified CPT/HCPCS codes and clinical synonyms to finalized clinical recommendation templates to support billing integration and terminology standardization.</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#when-to-use","title":"When to Use","text":"<p>Run this skill AFTER: - Template validation (neuro-checker \u226590%) - All revisions complete (neuro-rebuilder) - Citation verification complete (neuro-citation-verifier)</p> <p>Run BEFORE: - Final physician sign-off - IT system integration - Clinical deployment</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#purpose","title":"Purpose","text":""},{"location":"skills/neuro-cpt-synonym-enricher-skill/#cpt-codes","title":"CPT Codes","text":"<ul> <li>Enable direct integration with EHR order sets</li> <li>Support accurate billing and documentation</li> <li>Reduce coding errors and claim denials</li> <li>Facilitate cost estimation for patients</li> </ul>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#synonyms","title":"Synonyms","text":"<ul> <li>Improve template searchability across systems</li> <li>Account for regional/institutional terminology variations</li> <li>Support voice recognition and natural language search</li> <li>Enable mapping to different EHR systems (Epic, Cerner, etc.)</li> </ul>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#cpt-code-verification-process","title":"CPT Code Verification Process","text":""},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-1-identify-codeable-items","title":"Step 1: Identify Codeable Items","text":"<p>Scan template sections for items requiring CPT/HCPCS codes:</p> Section Codeable Items 1. Labs All laboratory tests 2. Imaging/Studies Imaging, EEG, EMG/NCS, LP, etc. 3. Treatment Infusion codes, injection codes, prolonged services 4A. Referrals E/M codes for consult types (reference only) <p>Do NOT code: - Oral medications (use NDC separately if needed) - Patient instructions - Lifestyle recommendations - Disposition criteria</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-2-search-and-verify-cpt-codes","title":"Step 2: Search and Verify CPT Codes","text":"<p>For each codeable item:</p> <p>Search Strategy: <pre><code>Search 1: \"[procedure name] CPT code 2025\"\nSearch 2: \"[procedure name] billing code\"\nSearch 3: \"[procedure name] CMS fee schedule\"\n</code></pre></p> <p>Verification Sources (in priority order): 1. CMS Physician Fee Schedule (publicly available) 2. Specialty society coding guides (AAN, ACR, etc.) 3. Major payer LCD/NCD documents 4. Hospital coding references</p> <p>Important: CPT codes are copyrighted by AMA. This skill identifies codes from publicly available CMS and payer sources.</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-3-code-categories","title":"Step 3: Code Categories","text":"Category Code Range Examples E/M Services 99202-99499 Consults, hospital visits Laboratory 80000-89999 CBC, CMP, drug levels Radiology 70000-79999 CT, MRI, X-ray Neurology-specific 95700-95999 EEG, EMG, NCS, evoked potentials Medicine 90000-99199 Infusions, injections Surgery 10000-69999 LP (62270), nerve blocks"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-4-document-modifiers-when-relevant","title":"Step 4: Document Modifiers When Relevant","text":"Modifier Use -26 Professional component only -TC Technical component only -59 Distinct procedural service -76 Repeat procedure same physician -77 Repeat procedure different physician -95 Synchronous telemedicine service"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#common-neurology-cpt-codes-reference","title":"Common Neurology CPT Codes Reference","text":""},{"location":"skills/neuro-cpt-synonym-enricher-skill/#eeg-codes","title":"EEG Codes","text":"Code Description Notes 95816 EEG, awake and drowsy Routine outpatient 95819 EEG, awake and asleep With sleep recording 95822 EEG, sleep only Sleep-deprived 95812 EEG, extended monitoring 41-60 min Longer recording 95813 EEG, extended monitoring &gt;60 min Each additional hour 95700 EEG, continuous monitoring setup cEEG initiation 95711 EEG, continuous monitoring, unmonitored Technical component 95714-95716 EEG, continuous monitoring with review Per hour, various levels 95957 EEG, digital analysis Quantitative EEG"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#emgncs-codes","title":"EMG/NCS Codes","text":"Code Description Notes 95907-95913 Nerve conduction studies By number of studies (1-2 up to 13+) 95885 Needle EMG, limited 1-2 extremities 95886 Needle EMG, complete 3+ extremities or trunk 95887 Needle EMG, non-extremity Cranial, paraspinal 95872 Needle EMG, single fiber Jitter studies 95937 Neuromuscular junction testing Repetitive stim"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#lumbar-puncture","title":"Lumbar Puncture","text":"Code Description Notes 62270 Spinal puncture, lumbar, diagnostic Standard diagnostic LP 62272 Spinal puncture, therapeutic High volume, IIH 62328 Lumbar puncture with fluoroscopy Fluoroscopic guidance"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#infusion-codes","title":"Infusion Codes","text":"Code Description Notes 96365 IV infusion, initial hour First hour of infusion 96366 IV infusion, additional hour Each additional hour 96367 IV infusion, additional sequential Different drug 96374 IV push, single Bolus medications 96375 IV push, additional Each additional push J0585 Injection, onabotulinumtoxinA Per unit J0587 Injection, rimabotulinumtoxinB Per 100 units"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#imaging-codes","title":"Imaging Codes","text":"Code Description Notes 70551 MRI brain without contrast 70552 MRI brain with contrast 70553 MRI brain without and with contrast Most common for neuro 70554 MRI brain functional (fMRI) Pre-surgical mapping 70450 CT head without contrast Acute stroke, hemorrhage 70460 CT head with contrast 70470 CT head without and with contrast 70496 CT angiography, head CTA head 70498 CT angiography, neck CTA neck 70544 MRA head without contrast 70545 MRA head with contrast 70547 MRA neck without contrast 72141 MRI cervical spine without contrast 72156 MRI cervical spine without and with 72146 MRI thoracic spine without contrast 72157 MRI thoracic spine without and with 72148 MRI lumbar spine without contrast 72158 MRI lumbar spine without and with"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#common-laboratory-codes","title":"Common Laboratory Codes","text":"Code Description 85025 CBC with differential 80053 Comprehensive metabolic panel 80048 Basic metabolic panel 84443 TSH 84439 Free T4 82607 Vitamin B12 82746 Folate 82565 Creatinine 84295 Sodium 82947 Glucose 83735 Magnesium 82310 Calcium, total 82330 Calcium, ionized 80195 Phenytoin level 80164 Valproic acid level 80156 Carbamazepine level 80185 Phenobarbital level 80177 Levetiracetam level 80176 Lacosamide level 82542 Lamotrigine level 82507 Ammonia 83516 Oligoclonal bands 86140 C-reactive protein 86200 CCP antibodies 86235 Extractable nuclear antigen antibodies 86255 ANA 83519 Immunoassay, NMO/AQP4 antibody 83519 Immunoassay, MOG antibody"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#synonym-collection-process","title":"Synonym Collection Process","text":""},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-1-identify-terms-needing-synonyms","title":"Step 1: Identify Terms Needing Synonyms","text":"<p>Target terms for synonym expansion: - Diagnosis name (template header) - All lab tests - All imaging studies - All procedures - Key medications (especially if multiple brand names)</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-2-synonym-sources","title":"Step 2: Synonym Sources","text":"<p>Search for synonyms using: 1. SNOMED CT browser (browser.ihtsdotools.org) 2. ICD-10 index (related terms) 3. MeSH database (meshb.nlm.nih.gov) 4. RxNorm (for medications) 5. LOINC (for lab tests) 6. RadLex (for radiology) 7. Clinical experience/regional variations</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-3-synonym-categories","title":"Step 3: Synonym Categories","text":"Category Example Base Term Synonyms Abbreviations Electroencephalogram EEG, electroencephalography Eponyms Guillain-Barr\u00e9 syndrome GBS, Landry's paralysis, AIDP Lay terms Seizure Convulsion, fit, spell Brand/Generic Levetiracetam Keppra, LEV Regional variations Lumbar puncture LP, spinal tap Historical terms Multiple sclerosis MS, disseminated sclerosis (historical) ICD-10 descriptions Epilepsy Epileptic seizures, seizure disorder"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#step-4-verify-synonym-accuracy","title":"Step 4: Verify Synonym Accuracy","text":"<p>For each synonym: - Confirm it refers to the same clinical entity - Note if synonym has slightly different scope (e.g., \"AIDP\" is a subtype of GBS) - Flag deprecated terms with notation - Include common misspellings for search purposes (marked as such)</p>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#output-format","title":"Output Format","text":"<pre><code>CPT &amp; SYNONYM ENRICHMENT REPORT\n================================\nTEMPLATE: [Diagnosis Name]\nVERSION: [Version]\nDATE ENRICHED: [Date]\nENRICHER: Claude (neuro-cpt-synonym-enricher v1.0)\n\n---\n\n## DIAGNOSIS SYNONYMS\n\n**Primary Term:** [Diagnosis name from template]\n**ICD-10:** [Code(s) from template]\n\n| Synonym | Type | Source | Notes |\n|---------|------|--------|-------|\n| [synonym] | Abbreviation | Clinical | Common usage |\n| [synonym] | Eponym | SNOMED CT | Historical |\n| [synonym] | Lay term | Patient education | For handouts |\n| [synonym] | ICD-10 description | CMS | Index term |\n\n**SNOMED CT ID:** [If identified]\n**MeSH Term:** [If identified]\n\n---\n\n## SECTION 1: LABORATORY CPT CODES\n\n| Test | CPT Code(s) | Description | Verification Source |\n|------|-------------|-------------|---------------------|\n| CBC with differential | 85025 | Complete blood count | CMS Fee Schedule |\n| Comprehensive metabolic panel | 80053 | CMP | CMS Fee Schedule |\n| [Continue for all labs] | | | |\n\n**Lab Panel Notes:**\n- [Any relevant bundling or panel notes]\n\n---\n\n## SECTION 2: IMAGING &amp; STUDIES CPT CODES\n\n### Imaging\n\n| Study | CPT Code(s) | Description | Modifiers | Verification Source |\n|-------|-------------|-------------|-----------|---------------------|\n| MRI brain w/ and w/o contrast | 70553 | MRI brain complete | -26 if read only | CMS Fee Schedule |\n| CT head without contrast | 70450 | CT head non-contrast | -26 if read only | CMS Fee Schedule |\n\n### Electrodiagnostics\n\n| Study | CPT Code(s) | Description | Verification Source |\n|-------|-------------|-------------|---------------------|\n| Routine EEG | 95816 | Awake and drowsy | CMS Fee Schedule |\n| Continuous EEG setup | 95700 | cEEG initiation | CMS Fee Schedule |\n\n### Procedures\n\n| Procedure | CPT Code(s) | Description | Verification Source |\n|-----------|-------------|-------------|---------------------|\n| Lumbar puncture, diagnostic | 62270 | Spinal puncture | CMS Fee Schedule |\n\n---\n\n## SECTION 3: TREATMENT CPT CODES\n\n### Infusions\n\n| Treatment | CPT Code(s) | Description | Units | Verification Source |\n|-----------|-------------|-------------|-------|---------------------|\n| IV methylprednisolone 1g | 96365 + 96366 | Initial hour + addl hour(s) | Time-based | CMS Fee Schedule |\n| IVIG infusion | 96365 + 96366 | Initial hour + addl hour(s) | Time-based | CMS Fee Schedule |\n\n### Injections\n\n| Treatment | CPT Code(s) | Description | Verification Source |\n|-----------|-------------|-------------|---------------------|\n| [If applicable] | | | |\n\n**Drug J-Codes (if applicable):**\n| Drug | J-Code | Unit | Verification Source |\n|------|--------|------|---------------------|\n| Methylprednisolone sodium succinate | J2920 | Per 40 mg | CMS HCPCS |\n\n---\n\n## SECTION 4: REFERRAL E/M CODES (Reference)\n\n*Note: Actual E/M code depends on complexity and documentation. These are typical ranges.*\n\n| Referral Type | Typical Codes | Notes |\n|---------------|---------------|-------|\n| Neurology outpatient new | 99203-99205 | Level depends on complexity |\n| Neurology outpatient established | 99212-99215 | Level depends on complexity |\n| Inpatient consult | 99252-99255 | Initial inpatient consult |\n| ED consult | 99281-99285 | ED E/M levels |\n\n---\n\n## TERMINOLOGY SYNONYMS BY SECTION\n\n### Lab Test Synonyms\n\n| Standard Term | Synonyms |\n|---------------|----------|\n| CBC with differential | Complete blood count, blood count, hemogram |\n| Comprehensive metabolic panel | CMP, chem-14, chemistry panel |\n| Basic metabolic panel | BMP, chem-7, electrolytes |\n| [Continue for all labs] | |\n\n### Imaging Synonyms\n\n| Standard Term | Synonyms |\n|---------------|----------|\n| MRI brain | Brain MRI, cranial MRI, head MRI, magnetic resonance imaging of brain |\n| CT head | Head CT, brain CT, cranial CT, computed tomography of head |\n| [Continue for all imaging] | |\n\n### Procedure Synonyms\n\n| Standard Term | Synonyms |\n|---------------|----------|\n| Lumbar puncture | LP, spinal tap, CSF tap |\n| Electroencephalogram | EEG, brain wave test |\n| [Continue for all procedures] | |\n\n### Medication Synonyms\n\n| Generic Name | Brand Names | Abbreviations |\n|--------------|-------------|---------------|\n| Levetiracetam | Keppra, Keppra XR, Spritam, Roweepra, Elepsia XR | LEV |\n| Lacosamide | Vimpat | LCM |\n| Lamotrigine | Lamictal, Lamictal XR, Lamictal ODT | LTG |\n| Valproate | Depakote, Depakote ER, Depakene, Depacon | VPA, DVP |\n| [Continue for all medications] | | |\n\n---\n\n## CODES NOT FOUND / REQUIRING VERIFICATION\n\n| Item | Issue | Recommendation |\n|------|-------|----------------|\n| [Item] | [Could not verify code] | [Suggest manual verification] |\n\n---\n\n## INTEGRATION NOTES\n\n### For EHR Order Set Development\n- Lab panel codes can be grouped for order set efficiency\n- Consider creating \"Seizure workup\" orderable with bundled labs\n- Imaging protocols may need site-specific mapping\n\n### For Billing Compliance\n- Time-based codes (infusions) require start/stop documentation\n- Modifier usage varies by payer; verify with billing department\n- Some codes may require prior authorization\n\n### For Searchability\n- All synonyms should be indexed in order search\n- Consider adding common misspellings to search index\n- Brand names essential for medication reconciliation\n</code></pre>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#workflow-integration","title":"Workflow Integration","text":""},{"location":"skills/neuro-cpt-synonym-enricher-skill/#input","title":"Input","text":"<ul> <li>Validated template (\u226590% checker score)</li> <li>Citation-verified template</li> </ul>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#output","title":"Output","text":"<ol> <li>Enrichment Report - Full CPT codes and synonyms (above format)</li> <li>CPT Quick Reference Table - Condensed code list for template appendix</li> <li>Synonym Index - Machine-readable synonym list for EHR integration</li> </ol>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#post-enrichment","title":"Post-Enrichment","text":"<ol> <li>Physician reviews CPT codes for appropriateness</li> <li>Billing/coding team verifies against institutional preferences</li> <li>IT team uses synonym list for search indexing</li> <li>Template finalized for deployment</li> </ol>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#file-naming-convention","title":"File Naming Convention","text":"Output Filename Enrichment report <code>[diagnosis]-cpt-synonym-report-[date].md</code> CPT quick reference <code>[diagnosis]-cpt-codes.md</code> Synonym index <code>[diagnosis]-synonyms.json</code> or <code>.csv</code>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#limitations","title":"Limitations","text":"<ul> <li>CPT codes change annually; verify against current year</li> <li>Some codes are payer-specific; check LCD/NCDs</li> <li>Institutional preferences may vary</li> <li>Some newer tests may not have established CPT codes</li> <li>J-codes for drugs change frequently</li> </ul>"},{"location":"skills/neuro-cpt-synonym-enricher-skill/#change-log","title":"Change Log","text":"<p>v1.0 (January 2026) - Initial version - Comprehensive CPT code reference tables for neurology - Synonym collection framework - Output format designed for EHR integration</p>"},{"location":"skills/neuro-rebuilder-skill/","title":"Rebuilder Skill","text":"<p>name: neuro-rebuilder description: Incorporates approved revisions from neuro-checker validation into clinical decision support templates. Use after physician review of Checker recommendations to systematically apply approved changes while maintaining document integrity and version control.</p>"},{"location":"skills/neuro-rebuilder-skill/#neuro-clinical-recommendation-rebuilder","title":"Neuro Clinical Recommendation Rebuilder","text":"<p>Systematically incorporate validated revisions into clinical decision support templates while maintaining document structure, version control, and audit trails.</p>"},{"location":"skills/neuro-rebuilder-skill/#when-to-use","title":"When to Use","text":"<p>Use neuro-rebuilder when: 1. neuro-checker has produced a validation report with recommended revisions 2. A physician has reviewed the Checker recommendations 3. Specific revisions have been approved for implementation 4. The template needs to be updated to a new version</p>"},{"location":"skills/neuro-rebuilder-skill/#input-requirements","title":"Input Requirements","text":"<p>The Rebuilder requires: 1. Original template - The current version of the clinical recommendation 2. Checker report - The validation output with scored domains and revision recommendations 3. Physician approval - Clear indication of which revisions are approved (may be all, some, or modified versions)</p>"},{"location":"skills/neuro-rebuilder-skill/#rebuilder-workflow","title":"Rebuilder Workflow","text":""},{"location":"skills/neuro-rebuilder-skill/#step-1-parse-approved-revisions","title":"Step 1: Parse Approved Revisions","text":"<p>Review the Checker report and identify: - Critical Issues (C-codes) - Must be addressed; these block clinical use - Setting Coverage Issues (S-codes) - High priority gaps in venue coverage - Medication Issues (M-codes) - Dosing, grouping, or coverage gaps - Recommended Revisions (R-codes) - Prioritized improvement suggestions - Verification Items (V-codes) - Items needing physician confirmation</p> <p>For each item, note whether it is: - \u2705 Approved as written - \u2705 Approved with modification (note the modification) - \u274c Declined (note reason if provided) - \u23f8\ufe0f Deferred for future version</p>"},{"location":"skills/neuro-rebuilder-skill/#step-2-implement-revisions-systematically","title":"Step 2: Implement Revisions Systematically","text":"<p>Process revisions in this order:</p> <ol> <li>Critical Issues First - Safety and accuracy fixes</li> <li>Setting Coverage - Add missing venue tags</li> <li>Medication Completeness - Individual drug rows, dosing</li> <li>Section 6 Monitoring - Venue columns, critical monitoring</li> <li>Other Revisions - In priority order (R1, R2, R3...)</li> </ol> <p>For each revision: - Locate the exact section and row - Make the specified change - Preserve surrounding formatting - Do NOT introduce new changes not in the approval list</p>"},{"location":"skills/neuro-rebuilder-skill/#step-3-update-metadata","title":"Step 3: Update Metadata","text":"<p>After implementing revisions:</p> <ol> <li>Increment version number (e.g., v1.0 \u2192 v1.1 for minor, v1.0 \u2192 v2.0 for major)</li> <li>Update REVISED date to current date</li> <li>Update STATUS if applicable</li> <li>Add Change Log entry documenting all changes made</li> </ol>"},{"location":"skills/neuro-rebuilder-skill/#step-4-verify-structure-integrity","title":"Step 4: Verify Structure Integrity","text":"<p>After rebuilding, confirm: - [ ] All 8 sections present (1-4 Action Items, 5-8 Reference) - [ ] Table formatting intact (columns aligned, headers present) - [ ] Priority key included - [ ] Section dividers (\u2550\u2550\u2550) present - [ ] No orphaned content or broken tables</p>"},{"location":"skills/neuro-rebuilder-skill/#output-format","title":"Output Format","text":"<pre><code># [DIAGNOSIS NAME]\n\n**VERSION:** [X.X]  \n**CREATED:** [Original date]  \n**REVISED:** [Today's date]  \n**STATUS:** [Revised per physician feedback / Validated / etc.]\n\n---\n\n[Full rebuilt template with all approved revisions incorporated]\n\n---\n\n## CHANGE LOG\n\n**vX.X ([Today's date])**\n- [Change 1 from approved revision]\n- [Change 2 from approved revision]\n- [Change 3 from approved revision]\n...\n\n**vX.X-1 ([Previous date])**\n- [Previous changes]\n</code></pre>"},{"location":"skills/neuro-rebuilder-skill/#rebuilder-principles","title":"Rebuilder Principles","text":"<ol> <li>Only implement approved revisions - Do not add, remove, or modify content beyond what was explicitly approved</li> <li>Preserve document structure - Maintain the 8-section format, table structures, and formatting conventions</li> <li>Maintain audit trail - Every change must be documented in the Change Log</li> <li>Verify accuracy - When implementing dosing or clinical changes, verify the revision is clinically accurate</li> <li>Flag uncertainties - If an approved revision is ambiguous, ask for clarification before implementing</li> <li>Protect safety content - Take extra care with contraindications, warnings, and critical monitoring parameters</li> </ol>"},{"location":"skills/neuro-rebuilder-skill/#version-numbering","title":"Version Numbering","text":"Change Type Version Increment Examples Minor corrections +0.1 Typo fix, clarification, minor dosing adjustment Moderate revisions +0.1 Added labs, expanded referrals, new monitoring Major restructuring +1.0 New sections, significant clinical content changes Complete rebuild +1.0 Structural overhaul, format change"},{"location":"skills/neuro-rebuilder-skill/#handling-conflicts","title":"Handling Conflicts","text":"<p>If approved revisions conflict with each other: 1. Stop and flag the conflict 2. Present both revisions to the physician 3. Request clarification on which takes precedence 4. Document the resolution in Change Log</p>"},{"location":"skills/neuro-rebuilder-skill/#post-rebuild-verification","title":"Post-Rebuild Verification","text":"<p>After rebuilding, the template should be re-validated with neuro-checker to confirm: - Validation score improved (or maintained if already high) - No new issues introduced - All approved revisions successfully implemented</p>"},{"location":"skills/neuro-rebuilder-skill/#example-change-log-entry","title":"Example Change Log Entry","text":"<pre><code>**v1.2 (January 18, 2026)**\n- Added phosphorus to Section 1A core labs per C1 (hypophosphatemia in alcohol withdrawal)\n- Updated levetiracetam loading dose range to 40-60 mg/kg per R2\n- Added flumazenil to Section 3A with seizure threshold warning per R3\n- Expanded Section 4B patient instructions with seizure diary guidance per S2\n- Added venue columns to Section 6 Monitoring per M1\n- Corrected lamotrigine titration schedule in Section 3C per V1 (physician confirmed)\n</code></pre>"},{"location":"skills/neuro-rebuilder-skill/#integration-with-claude-code","title":"Integration with Claude Code","text":"<p>When using neuro-rebuilder in Claude Code:</p> <ol> <li>Load the original template file</li> <li>Load the Checker report</li> <li>Parse the approved revisions (from physician input or file)</li> <li>Apply changes systematically using str_replace or file editing</li> <li>Save the rebuilt template with new version number</li> <li>Generate a summary of changes made</li> </ol>"},{"location":"skills/neuro-rebuilder-skill/#change-log","title":"Change Log","text":"<p>v1.0 (January 18, 2026) - Initial creation - Defined workflow: parse approvals \u2192 implement systematically \u2192 update metadata \u2192 verify structure - Added version numbering guidelines - Added conflict handling procedures - Added post-rebuild verification requirements</p>"},{"location":"skills/style-guide/","title":"Clinical Plan Style Guide","text":"<p>Guidelines for creating and maintaining clinical decision support templates.</p>"},{"location":"skills/style-guide/#core-principles","title":"Core Principles","text":"<ol> <li>Evidence-Based - Recommendations should be grounded in current guidelines and literature</li> <li>Actionable - Each item should be a clear, specific action</li> <li>Setting-Aware - Consider applicability across ED, Hospital, Outpatient, and ICU settings</li> <li>Safe - Include contraindications, monitoring requirements, and safety checks</li> <li>No PHI - Never include patient-identifiable information</li> </ol>"},{"location":"skills/style-guide/#document-structure","title":"Document Structure","text":"<p>All plans follow an 8-section format:</p>"},{"location":"skills/style-guide/#section-a-action-items-primary","title":"Section A: Action Items (Primary)","text":"<ol> <li>Laboratory Workup (1A Core, 1B Extended, 1C Specialized)</li> <li>Diagnostic Imaging &amp; Studies (2A Essential, 2B Extended, 2C Specialized)</li> <li>Treatment (3A Acute, 3B Symptomatic, 3C Maintenance, 3D Disease-Modifying)</li> <li>Other Recommendations (4A Referrals, 4B Patient Instructions, 4C Lifestyle)</li> </ol>"},{"location":"skills/style-guide/#section-b-reference-supporting","title":"Section B: Reference (Supporting)","text":"<ol> <li>Differential Diagnosis</li> <li>Monitoring Parameters</li> <li>Disposition Criteria</li> <li>Evidence &amp; References</li> </ol>"},{"location":"skills/style-guide/#table-format","title":"Table Format","text":"<p>Use the multi-column setting-priority format. IMPORTANT: Venue columns (ED, HOSP, OPD, ICU) must be the last 4 columns for CSS styling to work correctly.</p>"},{"location":"skills/style-guide/#labsstudies-table","title":"Labs/Studies Table","text":"<pre><code>| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |\n|------|-----------|----------------|:--:|:----:|:---:|:---:|\n| CBC  | Infection screen | Normal | STAT | STAT | ROUTINE | STAT |\n</code></pre>"},{"location":"skills/style-guide/#treatment-table","title":"Treatment Table","text":"<p>Treatment tables should include an Indication column to explain why the treatment is used. This displays as a hover icon (\ud83d\udc8a) in the clinical tool.</p> <pre><code>| Treatment | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |\n|-----------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|\n| Drug Name | Symptom relief | 10 mg PO daily | Allergy | LFTs | STAT | STAT | ROUTINE | STAT |\n</code></pre> <p>\u26a0\ufe0f Column Order Matters: The CSS applies narrow column widths to the last 4 columns, expecting them to be ED/HOSP/OPD/ICU. Incorrect column order will cause rendering issues.</p> <p>\ud83d\udca1 Indication Column: The Indication field appears as a teal pill icon (\ud83d\udc8a) in the clinical tool. Hover to see why this treatment is used for this condition.</p>"},{"location":"skills/style-guide/#lumbar-puncture-section","title":"Lumbar Puncture Section","text":"<p>IMPORTANT: Lumbar Puncture appears under Laboratory Workup in the clinical tool (CSF analysis IS laboratory work). In the markdown file, place it as <code>### LUMBAR PUNCTURE</code> after the imaging subsections (2A/2B/2C) - the JSON generator will position it correctly under Labs.</p> <pre><code>### LUMBAR PUNCTURE\n\n**Indication:** [Clinical indication for LP]\n**Timing:** URGENT if [condition]; ROUTINE for [condition]\n**Volume Required:** 10-15 mL (standard diagnostic)\n\n| Study | Rationale | Target Finding | ED | HOSP | OPD | ICU |\n|-------|-----------|----------------|:--:|:----:|:---:|:---:|\n| Opening pressure | Rule out elevated ICP | 10-20 cm H2O | URGENT | ROUTINE | ROUTINE | - |\n| Cell count (tubes 1 and 4) | Inflammation, infection | WBC &lt;5, RBC 0 | URGENT | ROUTINE | ROUTINE | - |\n\n**Special Handling:** [Notes about transport, timing]\n**Contraindications:** [List contraindications]\n</code></pre> <p>Clinical Tool Display: When LP studies are selected in the clinical tool, they appear grouped under \"Laboratory Workup &gt; Lumbar Puncture\" alongside other lab sections.</p>"},{"location":"skills/style-guide/#priority-levels","title":"Priority Levels","text":"Priority Meaning When to Use STAT Immediate Time-critical actions URGENT Within hours Important but not emergent ROUTINE Standard timing Scheduled/non-urgent EXT Extended/atypical Specialized or second-line - Not applicable Setting doesn't apply"},{"location":"skills/style-guide/#writing-guidelines","title":"Writing Guidelines","text":""},{"location":"skills/style-guide/#be-specific","title":"Be Specific","text":"<ul> <li>Good: \"Levetiracetam 500 mg PO BID, titrate to 1500 mg BID over 2 weeks\"</li> <li>Bad: \"Start anti-seizure medication\"</li> </ul>"},{"location":"skills/style-guide/#one-drug-per-row","title":"One Drug Per Row","text":"<p>Each medication gets its own table row with complete dosing information.</p>"},{"location":"skills/style-guide/#include-contraindications","title":"Include Contraindications","text":"<p>Always note absolute and relative contraindications.</p>"},{"location":"skills/style-guide/#use-plain-language-for-patient-instructions","title":"Use Plain Language for Patient Instructions","text":"<p>Section 4B should be understandable by patients and families.</p>"},{"location":"skills/style-guide/#medication-formatting","title":"Medication Formatting","text":"<ul> <li>Include: Generic name, route, dose, frequency, titration schedule, maximum dose</li> <li>Include: Contraindications, monitoring requirements</li> <li>Example: \"Gabapentin 300 mg PO TID; titrate by 300 mg/day every 3-5 days to 1800-3600 mg/day divided TID | CrCl adjustment required | Monitor sedation, edema\"</li> </ul>"},{"location":"skills/style-guide/#quality-standards","title":"Quality Standards","text":"<ul> <li>Target validation score: 90%+ (54/60 across 6 domains)</li> <li>All plans require physician review before clinical use</li> <li>Update plans when new guidelines are published</li> </ul>"},{"location":"skills/style-guide/#version-control","title":"Version Control","text":"<ul> <li>Use semantic versioning (v1.0, v1.1, v2.0)</li> <li>Minor changes: +0.1 (typos, clarifications)</li> <li>Major changes: +1.0 (new sections, significant clinical updates)</li> <li>Document all changes in the Change Log section</li> </ul>"},{"location":"skills/style-guide/#yaml-frontmatter","title":"YAML Frontmatter","text":"<p>All plan files require frontmatter:</p> <pre><code>---\ntitle: \"Diagnosis Name\"\ndescription: \"Brief description of what the plan covers\"\nversion: \"1.0\"\nsetting: \"ED, HOSP, OPD, ICU\"\ntags:\n  - category\n  - subcategory\n---\n</code></pre>"},{"location":"skills/workflow/","title":"Neuro Clinical Decision Support Workflow","text":""},{"location":"skills/workflow/#overview","title":"Overview","text":"<p>This workflow produces validated, citation-verified, billing-ready clinical decision support templates for neurological diagnoses.</p>"},{"location":"skills/workflow/#skill-pipeline","title":"Skill Pipeline","text":"<pre><code>\u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510\n\u2502                                                                             \u2502\n\u2502   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510     \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510     \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510                           \u2502\n\u2502   \u2502  BUILDER \u2502\u2500\u2500\u2500\u2500\u25b6\u2502  CHECKER \u2502\u25c0\u2500\u2500\u2500\u25b6\u2502 REBUILDER\u2502                           \u2502\n\u2502   \u2502   v2.2   \u2502     \u2502   v2.2   \u2502     \u2502   v1.0   \u2502                           \u2502\n\u2502   \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518     \u2514\u2500\u2500\u2500\u2500\u252c\u2500\u2500\u2500\u2500\u2500\u2518     \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518                           \u2502\n\u2502                         \u2502                                                   \u2502\n\u2502                         \u2502 \u226590% Score                                        \u2502\n\u2502                         \u25bc                                                   \u2502\n\u2502                   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510                                              \u2502\n\u2502                   \u2502 CITATION \u2502                                              \u2502\n\u2502                   \u2502 VERIFIER \u2502                                              \u2502\n\u2502                   \u2502   v1.0   \u2502                                              \u2502\n\u2502                   \u2514\u2500\u2500\u2500\u2500\u252c\u2500\u2500\u2500\u2500\u2500\u2518                                              \u2502\n\u2502                        \u2502                                                    \u2502\n\u2502                        \u25bc                                                    \u2502\n\u2502                   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510                                              \u2502\n\u2502                   \u2502CPT/SYNON \u2502                                              \u2502\n\u2502                   \u2502 ENRICHER \u2502                                              \u2502\n\u2502                   \u2502   v1.0   \u2502                                              \u2502\n\u2502                   \u2514\u2500\u2500\u2500\u2500\u252c\u2500\u2500\u2500\u2500\u2500\u2518                                              \u2502\n\u2502                        \u2502                                                    \u2502\n\u2502                        \u25bc                                                    \u2502\n\u2502                   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510                                              \u2502\n\u2502                   \u2502PHYSICIAN \u2502                                              \u2502\n\u2502                   \u2502  REVIEW  \u2502                                              \u2502\n\u2502                   \u2514\u2500\u2500\u2500\u2500\u252c\u2500\u2500\u2500\u2500\u2500\u2518                                              \u2502\n\u2502                        \u2502                                                    \u2502\n\u2502                        \u25bc                                                    \u2502\n\u2502                   \u250c\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2510                                              \u2502\n\u2502                   \u2502  DEPLOY  \u2502                                              \u2502\n\u2502                   \u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518                                              \u2502\n\u2502                                                                             \u2502\n\u2514\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2518\n</code></pre>"},{"location":"skills/workflow/#phase-1-build","title":"Phase 1: BUILD","text":"<p>Skill: <code>neuro-builder-SKILL-v2.2.md</code></p> <p>Input: Diagnosis name and scope (e.g., \"New Onset Seizure\", \"MS Exacerbation\")</p> <p>Process: 1. Identify diagnosis scope (new onset, exacerbation, chronic, refractory) 2. Generate 8-section template with multi-column format 3. Ensure coverage across all settings (ED, HOSP, OPD, ICU) 4. Include comprehensive treatments with individual drug rows 5. Add diagnosis-specific Section 4 content</p> <p>Output: Initial template <code>[diagnosis]-v1.0.md</code></p> <p>Quality Gate: Template must have all 8 sections populated</p>"},{"location":"skills/workflow/#phase-2-validate","title":"Phase 2: VALIDATE","text":"<p>Skill: <code>neuro-checker-SKILL-v2.2.md</code></p> <p>Input: Template from Phase 1</p> <p>Process: 1. Score across 6 domains (Completeness, Accuracy, Safety, Objectivity, Setting Appropriateness, Usability) 2. Assess setting coverage (ED, HOSP, OPD, ICU) 3. Assess medication comprehensiveness 4. Assess Section 6 monitoring parameters 5. Generate detailed revision recommendations</p> <p>Output: Validation report with scores and revision list</p> <p>Quality Gate: Must achieve \u226590% (54/60) to proceed</p>"},{"location":"skills/workflow/#if-score-90-rebuild","title":"If Score &lt;90%: REBUILD","text":"<p>Skill: <code>neuro-rebuilder-SKILL</code> (or manual revision)</p> <p>Input: Original template + Checker revision recommendations</p> <p>Process: 1. Review each recommended revision 2. Physician approves/modifies/rejects each suggestion 3. Implement approved changes 4. Increment version number</p> <p>Output: Revised template <code>[diagnosis]-v1.x.md</code></p> <p>Then: Return to Phase 2 (Validate) and re-check</p>"},{"location":"skills/workflow/#phase-3-verify-citations","title":"Phase 3: VERIFY CITATIONS","text":"<p>Skill: <code>neuro-citation-verifier-SKILL-v1.md</code></p> <p>Input: Validated template (\u226590% score)</p> <p>Process: 1. Extract all citations from Section 8 and inline references 2. Prioritize by safety impact (drug dosing &gt; diagnostic criteria &gt; epidemiology) 3. Web search to verify each citation exists and supports claim 4. Flag: \u2705 Verified, \u26a0\ufe0f Partial Match, \u274c Not Found, \u274c Inaccurate</p> <p>Output: Citation verification report</p> <p>Quality Gate: All HIGH priority citations verified or corrected</p>"},{"location":"skills/workflow/#if-citations-need-correction","title":"If Citations Need Correction:","text":"<ol> <li>Generate correction list for Rebuilder</li> <li>Physician reviews flagged citations</li> <li>Implement corrections</li> <li>Re-verify changed citations</li> </ol>"},{"location":"skills/workflow/#phase-4-enrich","title":"Phase 4: ENRICH","text":"<p>Skill: <code>neuro-cpt-synonym-enricher-SKILL-v1.md</code></p> <p>Input: Citation-verified template</p> <p>Process: 1. Identify all codeable items (labs, imaging, procedures, infusions) 2. Search and verify CPT/HCPCS codes 3. Collect clinical synonyms (abbreviations, brand names, lay terms) 4. Generate enrichment report</p> <p>Output: - CPT code mapping table - Synonym index - Enriched template ready for integration</p> <p>Quality Gate: All common procedures have verified codes</p>"},{"location":"skills/workflow/#phase-5-physician-review","title":"Phase 5: PHYSICIAN REVIEW","text":"<p>Input: Enriched template with all supporting reports</p> <p>Reviewer Checklist: - [ ] Clinical accuracy verified - [ ] Drug dosing appropriate - [ ] Contraindications complete - [ ] Citations accurate - [ ] CPT codes appropriate for institution - [ ] Synonyms include local terminology - [ ] Safe for clinical deployment</p> <p>Output: Signed-off template ready for deployment</p>"},{"location":"skills/workflow/#phase-6-deploy","title":"Phase 6: DEPLOY","text":"<p>Input: Physician-approved template</p> <p>Deployment Options: 1. EHR Integration - Convert to order sets, clinical pathways 2. Web Tool - Interactive plan builder artifact 3. Document Library - PDF/DOCX for reference 4. API - JSON format for third-party integration</p>"},{"location":"skills/workflow/#file-naming-convention","title":"File Naming Convention","text":"Phase Artifact Filename Build Initial template <code>[diagnosis]-v1.0.md</code> Check Validation report <code>[diagnosis]-checker-report-[date].md</code> Rebuild Revised template <code>[diagnosis]-v1.x.md</code> Citation Verify Verification report <code>[diagnosis]-citation-report-[date].md</code> Enrich Enriched template <code>[diagnosis]-v2.0.md</code> Enrich CPT mapping table <code>[diagnosis]-cpt-codes.md</code> Enrich Synonym list <code>[diagnosis]-synonyms.md</code> Final Approved template <code>[diagnosis]-FINAL-v2.x.md</code>"},{"location":"skills/workflow/#estimated-timeline-per-template","title":"Estimated Timeline per Template","text":"Phase Estimated Time Notes Build 15-30 min Depends on diagnosis complexity Check 10-15 min Automated with review Rebuild 10-20 min Depends on revision count; may iterate Citation Verify 20-40 min Web search intensive Enrich 15-30 min Web search for codes Physician Review Variable Depends on reviewer availability <p>Total Claude time: ~1-2 hours per template Total including physician review: Variable</p>"},{"location":"skills/workflow/#quick-reference-which-skill-to-use","title":"Quick Reference: Which Skill to Use","text":"Task Skill Create new template from scratch neuro-builder Validate existing template neuro-checker Implement revisions from checker neuro-rebuilder Verify citations are accurate neuro-citation-verifier Add CPT codes and synonyms neuro-cpt-synonym-enricher"},{"location":"skills/workflow/#skill-file-versions","title":"Skill File Versions","text":"Skill Current Version Last Updated neuro-builder v2.2 January 14, 2026 neuro-checker v2.2 January 14, 2026 neuro-rebuilder v1.0 January 13, 2026 neuro-citation-verifier v1.0 January 2026 neuro-cpt-synonym-enricher v1.0 January 2026"},{"location":"skills/workflow/#change-log","title":"Change Log","text":"<p>v2.0 (January 2026) - Added Citation Verifier skill (Phase 3) - Added CPT/Synonym Enricher skill (Phase 4) - Expanded workflow to 5 skills + physician review - Added quality gates between phases - Added file naming convention - Added artifact outputs table - Added timeline estimates</p> <p>v1.0 (January 13, 2026) - Initial workflow with Builder, Checker, Rebuilder</p>"}]}